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technology transfer professionals, licensing executives, and scientists, this Handbook
offers up-to-date information and strategies for utilizing the power of both intellectual
property and the public domain.
Eschewing ideological debates and general proclamations, the authors always keep
their eye on the practical side of IP management. The Handbook provides substantive
discussions and analyses of the opportunities awaiting anyone in the field who wants
to put intellectual property to work.

“This Handbook is timely. [It] is a valuable guide in helping to navigate the complex—
but rewarding—world of an increasingly global innovation system.”
—From the Foreword of Norman Borlaug, Nobel Peace Prize Laureate

“For all who believe, as I believe, that developing countries can—and should—participate in
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and Chairperson of the WHO Advisory Committee on Health Research

“This Handbook—which really transcends the category of handbooks altogether—
is a must read for anyone who deals with intellectual property.”
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“Intellectual property (IP) has become a much richer field of endeavor as it has moved from
isolationism in the world of policy to a position of engagement … [This Handbook] will serve
as an invaluable resource in this challenging new environment.”

Intellectual Property Management
in Health and Agricultural Innovation

—Ariel Pablos-Méndez,
Managing Director,
Rockefeller Foundation

Prepared by and for policy-makers, leaders of public sector research establishments,

a handbook of best practices

“At the dawn of the 21st
century the world created
an unprecedented wave of
public–private partnerships.
For such investments to
bear fruit as public goods
it is paramount to manage
intellectual property with the
public interest in mind. This
Handbook provides expert
guidance to do just that
and will assist in developing
new capabilities in low- and
middle-income countries.”
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“[This] Handbook is an important step towards transnational networks … involving multiple
partners in both North and South—donors and doers alike—who believe in the power of
innovation to address the needs of the poor.”
—From the Foreword of Sir Gordon Conway, KCMG DL FRS, Chief Scientific Adviser, DFID UK
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President

Over the last decade, the world has been paying increasing attention to the
agricultural, health, and economic disparities between industrialized and
developing countries. The Rockefeller Foundation is proud to have helped develop
and launch some of the numerous initiatives to address these issues—initiatives
such as the African Agricultural Technology Foundation, the Alliance for a Green
Revolution in Africa, the International AIDS Vaccine Initiative, the Global Alliance
for TB Drug Development, and others.
We believe, however, that launching the success of these and other similar
initiatives requires that we both engage directly with research universities in the
industrialized world and encourage the growing innovation capacity of developing
countries. The Public Intellectual Property Resource for Agriculture (PIPRA) and
the Centre for the Management of Intellectual Property in Health Research and
Development (MIHR) were created for precisely these reasons. Their mission
is to enhance the power of publicly funded research institutions to harness new
technologies and to ensure that the benefits of globalization are shared more
equitably. This Handbook and the companion Executive Guide and online version
are a natural outcome of their efforts to contribute new solutions to this two-fold
challenge. A follow-on interactive electronic version will reach an even wider
audience and, we hope, provide even greater benefits.
The Rockefeller Foundation is delighted to have supported the creation of this
unique resource. It holds lessons that are valuable (in many senses of the word)
for policy-makers, leaders of research institutions, researchers, and technology
managers alike—in both industrialized and developing countries. Indeed, this
Handbook and Executive Guide, a testament to the committed, excellent work of
MIHR and PIPRA, might be the most thorough primer on intellectual property
management for the public interest ever assembled. As such, it will be an
indispensable tool for both planners and practitioners for years to come.
With best wishes,
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New York, New York
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president@rockfound.org
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Foreword by Norman E. Borlaug
This Handbook is timely for several reasons. Whether we like it or not, when it comes to
technology transfer, global integration has created a complex system of intellectual property
management. This system includes public sector research institutions in developing coun
tries that need guidance on how to negotiate the new and changing terrain. The Handbook
aims to provide these institutions with such guidance in the form of a reference resource.
But the Handbook is more than that. It not only explains the intellectual property system,
but shows how both public sector research institutions and developed countries can use
intellectual property to achieve their humanitarian and socio-economic objectives.
The past 50 years make up the most productive period in history, in terms of ag
riculture. Innovations in agricultural science and technology made possible the Green
Revolution, which is reputed to have spared one billion people the pain of hunger and
starvation. New health innovations have helped control the scourges of polio, leprosy, and
smallpox. Although we have seen the greatest reductions in hunger in history, it has not
been enough. And despite the enormous potential of modern medicine, its reach is still too
short for the hundreds of millions most in need of its preventative and curative powers.
Several billion people around the globe require access to new agricultural technologies
that could feed families while protecting the environment, as well as new health innova
tions to combat HIV/AIDS, malaria, tuberculosis, dengue, and a host of other diseases that
typically afflict the poor in developing countries. New science and technology—including
biotechnology—have the potential to satisfy these needs.
Today, the world food supply is nearly six billion gross metric tons and three billion
net metric tons of edible dry matter. It includes cereals, roots and tubers, legumes, fruits
and vegetables, livestock and fish. Within the next 50 years, the world’s population is likely
to increase 60%–80%, requiring global food production to nearly double. We will have to
achieve this increase on a shrinking agricultural land base, with most of the increased pro
duction to occur in the countries that will consume it. Compounding the problem is the
fact that more than half of the world’s 800 million hungry people are small-scale farmers
who cultivate environmentally sensitive marginal lands in developing countries. Bringing
the power of science and technology to bear on the protection of these fragile environments
is one of the greatest challenges of the 21st century.
Borlaug NE. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
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Despite these serious and daunting challenges, there is reason for hope. With the new
biotechnology tools, we are poised for another period of rapid agricultural innovation. New
science has the power to increase yields, address agroclimatic extremes, and mitigate a range
of environmental and biological problems. Private industry has invested billions of dollars in
research to make astonishing new discoveries and products, such as genetically modified crops.
Unfortunately, with the notable exception of insect resistant Bt cotton in China and India,
relatively few of the new crops developed by private industry are reaching smallholder farmers
in the developing world. This situation must be corrected as soon as possible.
The world of scientific innovation works differently today than it did 50, or even 20, years
ago. Developing countries can no longer rely primarily on innovations from the public sector,
because the private sector has taken the lead in inventing new technologies. Even those innova
tions developed by public sector research institutions are inextricably part of a global IP regime
since they normally build on inventions made by both public and private entities.
As part of a global system, scientific institutions in developing countries need to un
derstand how the IP system works to be able to capitalize on new opportunities. Moreover,
global public sector research no longer marches to its own beat; to move forward, it must
now work in tandem with the private sector. The promise offered by the new system is
enormous; developing countries need to know how to negotiate access and how to build
partnerships based on mutual value exchange.
This Handbook is a valuable guide to navigating the complex—but bountiful—world
of an increasingly global innovation system. The reader will find relevant case studies, con
crete observations, and practical suggestions. The Handbook should be most useful to gov
ernment policy-makers, senior managers of public research institutions, technology trans
fer officers, and scientists in developing and developed countries. It is a resource that can
help governments and other institutions move forward to meet the agricultural and health
challenges of tomorrow. ■
December 2006
El Batán, Mexico

NORMAN E. BORLAUG, CIMMYT, Apdo. Postal 6-641, 06600 Mexico, D.F., Mexico. N.Borlaug@cgiar.org
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Foreword by R. A. Mashelkar
Intellectual property (IP) is no longer seen as a self-contained domain in which specialists
alone work and dwell. It is viewed as an integral part of innovation-driven socio-economic
development across the globe and is increasingly becoming an effective policy instrument
with respect to a range of technological, socio-economic, and political concerns. This
Handbook of best practices in intellectual property management, with its novel and useful
Executive Guide is, therefore, an extraordinary contribution that has arrived at precisely the
right time.
The issues of generation, valuation, protection, and valorization of intellectual
property are growing in complexity. There is increasing demand for new forms of IP
protection. Economies are changing, with a new knowledge-based economy replacing
“bricks-and-mortar” based economies. Scientific knowledge is growing exponentially.
A new “geography of science” exists with innovative developing countries, such as
India, China, and Brazil, having emerged as major contributors to science and technol
ogy. Policy-makers, researchers, and entrepreneurs have begun to appreciate the vast
resource of traditional knowledge in the developing world and to recognize the com
plex issues connected with intellectual property therein. Not long ago, IP experts had
only to deal with inanimate objects. Today, IP involving plants and animals, including
humans, raises new complex issues and perplexing questions. Therefore, a book dealing
with guidance on these issues with authority and clarity was sorely needed. The timely
issuance of the Handbook and Executive Guide fulfills that need. The book is authorita
tive, comprising contributions by many of the leading practitioners and thought lead
ers in the field of IP management. The book has clarity. Its best practices and strategies
have been explained in a way that is very easy to assimilate.
Books on intellectual property that were published in the past, while in many ways
valuable, dealt only with enterprises and institutions in developed countries. This Handbook
represents the first major effort to deal with issues of concern within the developing world.
Furthermore, the role of public sector research institutions in fulfilling the socio-econom
ic goals and objectives of developing nations, by contributing immensely to the public
good as well as to the private good, had never before been written about extensively. This
Handbook fills this void admirably.
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In the past, issues of emerging global innovation networks related only to North–North
partnerships. But today North–South partnerships as well as South–South partnerships
are emerging. As “technonationalism” finds a new equilibrium with “technoglobalism,”
IP management issues are becoming ever more complex. New forms of knowledge in the
private domain as well as the public domain are being created. It is no longer Linux versus
Windows—it is Linux with Windows! In general, how do we create a new nexus between
the public and the private? The Handbook has taken up this new challenge head-on.
Drafting, interpreting, and analyzing the techno-legal and business information con
tained in IP documents requires specialized skills. Monitoring, through online databases,
the wealth of information in patents and other forms of intellectual property in order to
ward off threats to national IP portfolios is becoming critical. Analyzing such information,
for market intelligence, to identify strategic alliances, and to exploit potential niche areas
for the innovative use of intellectual property will, itself, give rise to new knowledge-based
businesses. This Handbook is invaluable from this perspective, as well.
Today, start-up companies and spinouts reach beyond Stanford, M.I.T., Cambridge,
and Oxford. Leadership in China reports that Chinese universities have set up several hun
dred high-tech start-ups. India is introducing a Bayh-Dole-type law for Indian universities
and research institutions. In short, the phenomenon of wealth creation through the knowl
edge generated at universities is spreading across the world. The Handbook offers valuable
guidance to university inventors and administrators with regard to licensing, negotiating
agreements, technology transfer, dispute resolution, and so on.
One of the most fascinating sections presents institutional case studies, providing in
sights from Stanford, M.I.T., Cambridge, and other leading public sector research institu
tions. The case studies will be most revealing for institutions in emerging economies setting
up their own technology transfer systems and wishing to emulate those universities.
When a patenting culture starts in an institution, issues of how to read and write
patent applications, how to document inventions, as well as how to prepare laboratory
notebooks and invention disclosures become crucial. In India, there was nothing to guide
us when our own “patent literacy movement” began. We learned the hard way. How much
easier and productive our work would have been had the Handbook and Executive Guide
been available to us then!
The issues of IP management in low- and middle-income countries are vastly complex.
In particular, lifesaving innovations in health and livelihood-generating innovations in ag
riculture directly affect those countries’ socio-economic development. Special attention has
been given in the Handbook to address these issues.
I do hope this Handbook will not only help in providing guiding principles and best
practices in IP management, but will become a lighthouse that will show the way toward
a more equitable and inclusive world. After all, making intellectual property work for the
poor, whether it is owned by the public or by private entities, can be the only way to create
an innovation-led inclusive growth movement.
March 2007
Pune, India

R. A. MAshELkAR, Bhatnagar Fellow, National Chemical Laboratory, Pune 411 008, India. ram@ncl.res.in.
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Foreword by Francis Gurry
Intellectual property (IP) has become a much richer field of endeavor as it has moved from
isolationism in the world of policy to a position of engagement. From a one-dimensional
technical specialization, intellectual property has become a multidimensional complex of
policies. The transition has not, however, been without cost, in this case in the form of
greater complexity. The range of policy fora in which intellectual property is discussed has
expanded, seemingly without limit, to encompass most international organizations, as each
of the policy domains for which these organizations are responsible confronts the implica
tions of IP rights in the new environment of the knowledge economy. These policy inter
sections recur at each of the regional, bilateral, and national levels. And the cast of actors
involved in the drama contains a much wider and more diverse range of characters, per
forming a more demanding repertoire than would have been imaginable two decades ago.
Nowhere is this development more striking than in the life sciences, especially related to in
novation for public health and agriculture, where the promises of new technology that may
serve the most fundamental of human needs vie with complex concerns over the impact of
technologies, ethical issues, and claims over fundamental justice and human rights.
Intellectual Property Management in Health and Agricultural Innovation: A Handbook
of Best Practices will serve as an invaluable resource in this challenging new environment.
The Handbook is based on a number of orientations that contribute in highly positive ways
to an understanding of the utility, value, and limitations of IP rights as a system of law, a
mechanism for policy development, and a policy instrument.
The Handbook’s first positive orientation is the practical approach embraced by it and by
the companion Executive Guide. The increased attention that intellectual property has, quite un
derstandably, attracted has brought with it a certain tendency to conflate IP issues with some of
the grandes idées that permeate the reflections of contemporary society, such as globalization, the
ethical limits of scientific endeavor, and distributional equity. This tendency has had an adverse
effect on IP management because it has redirected the focus of intellectual property away from
practical issues; intellectual property is not necessarily neutral with respect to any of these grand
movements of thought. But we would do well to remember that policies involving intellectual
property are operational policies, the effects of which depend heavily on how the intellectual
property is deployed and used. Solid practical guidance and experience are precious resources
and they are to be found in abundance in the Handbook.
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Practical approaches and solutions offer a welcome contrast to the notion that every
thing has a legislative solution. Legislation, whether national or international, is of limited
value and is always without meaning unless given life through practical action or imple
mentation. We have experienced an explosion of IP legislation at the international level in
the past 15 years, with ten new multilateral treaties being concluded between 1989 and
2000. Experience of the practical management of IP rights provides a rich knowledge base
for evaluating and harnessing the benefits of this legislative landscape and for assessing the
full range of options open to public- and private-sector actors to deliver, in practice, the
ostensible benefits of this intense phase of legislative activity.
A second very positive orientation of the Handbook is through the espousal of a meth
odology of best practices. In the complex world of international negotiations, solutions
are often based on the identification of the lowest common denominator of the varied
positions and underlying interests of the countries involved. Such an approach is often
necessary for finding agreement in a world with, as yet, a still underdeveloped sense of the
common sphere. Few examples are to be found of agreements based on the identification
of best practices, as a positive expression of the common interest, and agreement on the
aspiration of striving toward such best practices. While the world awaits more widespread
acceptance of the methodology of best practices with regard to the international legislative
process, the Handbook makes a major contribution, by providing a description of the use
of that methodology, with respect to practical choices for the management of intellectual
property within the current legislative environment.
An understanding of best practices is essential for the Handbook’s strategic orienta
tion—a strategic approach to the management of intellectual property. The complexity of
the environment of intellectual property demands the use of effective strategies for navi
gating the sophisticated institutional architecture and for utilizing the potential that intel
lectual property offers for the generation, deployment, and diffusion of new knowledge in
the commercial, scientific, and public sectors. The patent system has developed the most
comprehensive, systematic, and accessible record of humanity’s technology. Fifteen years
ago, this treasure of knowledge was known only to a small group of experts who had access
to the paper collections in which the record was stored. Digital technology has combined
with the accessibility of the Internet to make this record available, free of charge, to the
whole world. When mined intelligently, this wealth of raw data can provide the techno
logical and policy information that enables the public and private sectors to have a more
strategic approach to the identification of research opportunities, freedom to operate, and
business strategies.
The Centre for the Management of Intellectual Property in Health Research and
Development (MIHR) and the Public Intellectual Property Resource for Agriculture
(PIPRA) are to be commended for the development and publication of the Handbook,
which will advance the understanding and practice of intellectual property in a construc
tive, pragmatic, and highly effective manner.
March 2007
Geneva, Switzerland

FRANcis GURRy, Deputy Director-General, World Intellectual Property Organization (WIPO), 34, chemin des
Colombettes, 1211 Geneva 20, Switzerland. francis.gurry@wipo.int
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Foreword by Howard A. Zucker
The past 25 years have witnessed major challenges and successes in the field of public health.
Carefully planned and implemented measures for prevention and control have shown their
worth in battling formidable infectious scourges: smallpox was eradicated in 1979, and
the public health menace measles has been contained. New drugs have been developed for
HIV infection, dramatically improving the prognosis of those who receive antiretroviral
therapy. Even with new menaces, such as avian influenza, and setbacks to such programs as
polio eradication, the control of communicable diseases is technically feasible.
What is technically possible, however, has not always been accessible by developing
countries. Indeed, access to appropriate treatments for diseases and conditions that dispro
portionately affect developing countries is still a big stumbling block. Part of the problem
stems from inadequate health-services coverage: one-third of the world’s population lacks
regular access to essential modern medicine (up to one-half, in certain parts of Africa and
Asia). Direct financial constraints contribute to the problem. Drug discovery and develop
ment is a complex, lengthy, and costly process. As recently reviewed in the World Health
Organization Report of the Commission on Intellectual Property Rights, Innovation and
Public Health (see pages 17 and 76 of that report*), even moderate estimates of the cost of
R&D for some drugs put the total between US$115 million and US$240 million.
Socio-cultural inequalities also have a profound affect on distribution. The majority of
potential patients live in the poorer parts of the world, whereas the majority of drug and
vaccine producers—and purchasers—are found in affluent countries. Although developing
countries have more than 80 percent of the world’s population, they account for only about
10% of drug sales. Major pharmaceutical producers—however great their desire to benefit
all—are answerable to market forces and to the wishes of shareholders.
For health products, both demand and supply are out of balance. Many public-health
policy experts have pointed to the concept of IP (intellectual property) rights—the protec
tion of intellectual and financial investments in new drugs and vaccines—as contributing
to this imbalance and inequity. As part of the ongoing international debate about the wider
aspects of the relationship between IP rights, innovation, and public health, the World
Health Assembly under the auspices of the World Health Organization decided to establish
an independent Commission to analyze the issue. The Commission’s report, released in
Zucker HA. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A
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2006, states that governments around the world have recognized moral and legal issues
with respect to ensuring general access to existing drugs (see pages 8 and 9 of that report).
This access is essential for sustaining government efforts in developing countries and else
where to control disease.
As a follow-up to the Commission’s report, a working group comprising government
officials and other key stakeholders in public health, innovation, and intellectual prop
erty is developing a global strategy and plan of action. The goal is to secure an enhanced
and sustainable basis for need-driven health research and development aimed at curing or
treating diseases that disproportionately affect developing countries. The strategy being
discussed includes “making intellectual property work for health” as one of three major chal
lenges. Among eight elements of the proposed plan of action for implementing the strategy
is the management of intellectual property, including such aspects as legislation, incentives,
documentation, training, and regulation.
In deliberations of the intergovernmental working group, Member States have identi
fied IP management as a key element of progress in the fight against diseases, an element
that poses complex and sensitive problems in the realms of ethics, economics, and health
policies. This Handbook of Best Practices is both timely and highly relevant. It is hoped that
the Handbook will help build capacity in decision making at the national level by assisting
academics, researchers, and policy-makers—especially in the developing world—to clarify
many of the issues that currently influence the relationship between generalized access to
drugs and the protection of IP rights.
March 2007
Geneva, Switzerland

* http://www.who.int/intellectualproperty/report/en/index.html
hOwARd A. ZUckER, Assistant Director-General, Health Technology and Pharmaceuticals, Representative of
the Director-General on Intellectual Property, Innovation and Public Health, World Health Organization, 20
Avenue Appia, CH-1211 Geneva 27, Switzerland. zuckerh@who.int
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Foreword by Sir Gordon Conway
From 1998 to 2004, I served as president of the Rockefeller Foundation. During that time,
it’s fair to say there was no universally accepted understanding of the exact relationship be
tween intellectual property (IP) and affordable essential goods for the poor. The foundation
chose to approach this issue in a variety of ways, including support for the creation of the
Centre for the Management of Intellectual Property in Health Research and Development
(MIHR) and the Public Intellectual Property Resource for Agriculture (PIPRA). Until now,
these organizations have worked independently. But although they differ in many respects,
they share a common goal: to develop and disseminate best practices for the management
of IP for the public good. Now, for the first time, the organizations have joined forces to
weave together the common threads of their respective fields in order to create this unique
and comprehensive book titled IP Management in Health and Agricultural Innovation: A
Handbook of Best Practices.
I would like to reflect a bit on the founding principles of these complementary orga
nizations. Both PIPRA and MIHR were developed to promote the ethical stewardship of
new technologies in their respective fields, based on the idea that publicly owned IP can be
a currency to improve access to health and agricultural products and know-how. Yet the idea
for each organization arose independently within The Rockefeller Foundation, following
separate consultations with the agricultural and health communities. During the time that
the foundation’s rice biotechnology program was operational, food security officers were
keenly aware that many proprietary technologies developed in public institutions were
then locked up in large corporations, a problem that was becoming evident to experts at
U.S. universities as well. The “health equity” theme encountered similar problems as the
foundation was working to establish global public–private partnerships for the develop
ment of affordable drugs and vaccines.
How had this situation developed? In many cases, research institutions in developed
countries simply hadn’t considered the impact of their technology-licensing practices on
developing countries. Public institutions in both developed and developing countries
lacked sound policies that were specifically designed to maximize the benefits of global
public goods resulting from their own public–private partnerships in R&D. To address
these problems, local technology managers would need to become better informed and
empowered to think globally, while public research institutions would need sound instiConway G. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, California, U.S.A. Available online at www.ipHandbook.org.
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tutional policies to ensure that public investment would lead to affordable essential goods
for the poor.
So far, MIHR’s efforts have focused on capacity building, working to build a cadre
of technology management professionals in developing countries and to raise the stature
of these professionals. MIHR has also worked to develop and promote a “tool kit” of best
practices for technology managers in both developed and developing countries to encour
age licensing practices that would benefit global health.
PIPRA, in contrast to MIHR, is a consortium made up of more than 40 major
American research universities and not-for-profit research institutions in the United States
and abroad. The consortium was established to enhance global access to agricultural tech
nologies that are developed by its member institutions. PIPRA promotes research collabo
ration and collective management of IP among its members for public benefit.
The PIPRA consortium is creating a broad patent/license database that will make it
possible to determine readily both the range of technologies available from its member
institutions and the manners in which these technologies will be made available to allow
for specific applications. Where freedom to operate is clear, PIPRA is developing strategies
that will promote the use of technologies by scientists to address the agricultural needs of
poor farmers in developing countries. PIPRA is also creating public sector tools for use of
improved subsistence crops for developing countries and of specialty crops to be grown in
the United States.
The PIPRA business plan envisioned future work in the building of agricultural tech
nology–management capacity in developing countries—an effort that has been central to
the mission of MIHR. At the same time, MIHR’s business plan envisioned the creation
of a patent-and-licensing database for health technologies, and MIHR is currently explor
ing the creation of a PIPRA-like consortium of university technology-management offices
based in developed countries. In biotechnology, the similarities between agriculture and
health range from the reagents used in the laboratory to their national regulatory and
industrial policies. The potential for collaboration between PIPRA and MIHR on a wide
range of issues is obvious. This publication is an exciting first step in that direction.
I believe the global community must do more to promote the ethical stewardship of
new technologies arising from public funding in developed countries to benefit agricul
ture and health in the developing world. At the same time, we must begin to recognize
that developing countries themselves are increasingly capable of contributing solutions
to their own food shortages and public health challenges. This Handbook advances these
goals. It is an important step toward both building upon and transcending the work of
MIHR and PIPRA, by creating new transnational networks that involve multiple part
ners—donors and doers alike—who believe that the power of innovation can address the
needs of the poor. ■
December 2006
London, U.K.

siR GORdON cONwAy kcMG dL FRs, Chief Scientific Adviser, Department for International Development
(DFID), 1 Palace Street, London, SW1E 5HE, U.K. g-conway@dfid.gov.uk
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Message from the Editorial Board:
From Best Principles to Best Practice
As members of the Editorial Board, we represent not only a diversity of professional back
grounds, institutions, and geographic regions, but also a diversity of viewpoints about in
tellectual property (IP). We agree on many things and we share a common goal: to broaden
and accelerate access—especially in developing countries—to life-saving and poverty-al
leviating innovations in health and agriculture. A fundamental vision of a more equitable
world—represented in the points that follow—binds us together in this endeavor.
• Intellectual property is a tool to foster innovation. Intellectual property is
here. And here to stay. Whether viewed as a legal concept, a social construct, a
business asset, or an instrument to achieve humanitarian objectives, the value
of intellectual property cannot be disputed. The notion that inventions can
become property and can therefore be owned and sold, has encouraged scien
tists and researchers to invent, and entrepreneurs and companies to invest in
innovation, by allowing them to profit from the resulting technologies. But
by permitting entrepreneurs to exclude competitors and set higher prices, IP
protection may also prevent some individuals, or populations, from being able
to access products. There are many ways, however, that intellectual property
can be utilized and distributed. Through the publishing of this Handbook, the
companion Executive Guide, and the online version, we intend to help put
intellectual property to work for the public sector and the public interest. We
agree that intellectual property should be neither feared, nor blindly embraced;
rather, it should be managed to maximize the benefits of innovation for all of
society, especially the poor.
• IP rights are a compromise and an imperfect solution. They represent the
search for balance between making all knowledge freely available within the
public domain and granting ownership of valuable discoveries to the inven
tors. Historically, we have seen that this balance encourages investment—and
reinvestment—in innovation, although this innovation too infrequently is di
rected toward the needs of the poor. Reaching an appropriate balance requires
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP
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continuous, sound IP management, and our desire to encourage this was a ma
jor impetus for compiling this Handbook and for writing the Executive Guide.
Fortunately, as numerous case studies have shown, the public sector can craft
effective solutions that can achieve, or at least approach, a suitable balance. This
can be accomplished by using the existing IP system, especially as it addresses
situations in which companies agree to donate or otherwise share their intel
lectual property.
• Genius can flourish anywhere, and the emerging global systems of innovation
in health and agriculture open up new prospects for innovation everywhere.
This notion has profound implications for the management of innovation,
technology transfer, market competition, and economic development in every
country, regardless of its economic status. Provided with opportunities and re
sources, scientists and scholars from any locale can create promising inventions
with the potential to become valuable technology. And whether inventions are
home grown or come from outside, authoritative IP management will play a
crucial role in enabling and preserving access to the resulting innovations.
• Policies to promote the creation and management of intellectual property by
public sector institutions should give first priority to advancing the mission
of those institutions. In most countries, the mission of universities is edu
cation, research, and public service. Universities are not revenue generators.
Technology transfer should support the larger mission, and not merely the
budgets, of those institutions.
• The historical trend has been for intellectual property to benefit mostly the
affluent. This is due, in part, to the fact that insufficient attention has been
paid by the public sector to managing intellectual property. This lack of fo
cused attention must be corrected. Public sector IP management is a rather
young discipline, and there have been enormous changes in the public sector’s
involvement in health research since the 1970s and in agri-biotechnology since
the 1990s. The public sector is only now beginning to appreciate how it can
use its own intellectual property—and leverage that of others—to help meet its
social mission, including its responsibilities to the poor. We believe that there
is growing interest, within both the public and private sectors, in using intel
lectual property for public benefit but, also, a lack of knowledge and capacity.
This Handbook is designed to help address these needs.
We hope this Handbook and Executive Guide will encourage all parties to take greater
advantage of the unprecedented opportunity to benefit from the strategic management of
intellectual property aimed at promoting the public welfare—especially those people who
have, until now, been unable to partake in technology’s benefits—and that this will con
tribute to building a healthier and more equitable world. ■
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Prelude
The many voices in this Handbook make up an expert chorus in the field of intellectual
property (IP) management. Motivated by their passion for a better world, these virtuosos
volunteered to share their experiences as part of a broader effort to bring innovation to the
poor and improve the lives of millions of people. These selfless, ground-breaking experts
bring to mind another revolutionary, Ludwig van Beethoven, who declared, “I have never
thought of writing for reputation and honor. What I have in my heart must come out;
that is the reason why I compose.” The compositions here are obviously less sublime than
Beethoven’s, but their potential to inspire is nonetheless comparable: they are always writ
ten from the heart.
The creativity in these chapters reflects the fact that IP management is an emerging
discipline, one best described not as science but as art. This is why the title pages of ev
ery chapter announce that this Handbook is “Sharing the Art of IP Management.” These
chapters offer lucid, cogent analyses of the role of intellectual property in many practical
contexts and give free play to the imagination, inspiring readers to try new strategies, risk
improvisation, and embrace new motifs. Such creativity is a necessary response to the in
creasing complexity and importance of the nexus of intellectual property and the public
good.
Given that intellectual property is a critical institutional management and global pol
icy issue, it can no longer be ignored by public sector-research institutions or left to the
legal establishment. Policy-makers, leaders of scientific institutions, licensing experts, and
scientists everywhere all need to act in concert to make the most of their work. But protect
ing intellectual property is just the beginning. The real challenge is to use one’s intellectual
property and to leverage that of others. This approach is at least as important for the public
sector as it is for the private sector, given its humanitarian and socio-economic mandate.
This concerto grosso gathers the experiences of IP professionals from North, South,
East, and West, and offers innovative knowledge and strategies that can be applied to many
institutional settings. Because increasing numbers of developing countries are seeking to
optimize the economic, social, and cultural value of their IP assets and resources, I believe
this Handbook will find a ready audience. The suite of chapters, composed by nearly 200
authors, offers pragmatic suggestions and reference resources that will pave the way to
greater access to health solutions and agricultural innovations. The authors write about
Krattiger A. 2007. Prelude. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
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the topics from various perspectives, an approach that inevitably led to some overlap. This
overlap allows the reader to see a topic from several perspectives. The authors have distinc
tive voices, and, as with Beethoven’s famous counterpoint, the distinctive parts are precisely
what make the whole so compelling.
Driven by rapid advances in science and technology and by the dawn of a worldwide,
networked society, the increasing economic and humanitarian centrality of intellectual
property will lead to more sophisticated and complex institutional infrastructures. The
process is happening even as you read this Prelude. This is no time, therefore, to remain in
complacent isolation. It is time to join your voices—and aggregate your values and your ac
tions—to form a network of effective partnerships. A solo performance will lack the power
of a full orchestra, and solo efforts at innovation will be stymied without collaboration.
The strength of this Handbook is the depth and breadth of its information. But just
as notes only become music when the bow meets the viola string and the timpani sounds,
so these chapters will matter only when the reader translates them into action. My high
est hope is that this Handbook will incite a passionate, rousing performance, one that will
touch the lives of others and reverberate far beyond these pages.
Anatole Krattiger
Editor-in-Chief

ANAtOLE kRAttiGER, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDe
velopments-International Institute; and Adjunct Professor, Cornell University. PO Box 26, Interlaken, NY,
14847, U.S.A. afk3@cornell.edu

xlii | HANDBOOK OF BEST PRACTICES

Acknowledgments
Like the progress of any invention from bench to bedside (to use a health-related meta
phor), or from sowing to harvesting (to borrow from agriculture), the road leading to the
creation of this Handbook, and its companion Executive Guide and online version, has
required a great deal of effort and more than a little good fortune. As editor-in-chief, I have
discovered that compiling a book composed of 158 chapters and prefatory comments,
written by nearly 200 authors, presents many unique challenges but offers many more
unique rewards.
The authors, first and foremost, deserve special thanks for their willingness to share
their experiences and insights, their cooperation in meeting sometimes rather tight dead
lines, and for their readiness to volunteer their valuable time (thanks are also due to their
employers for allowing the authors to take the time to write). The hard work of these au
thors is the good fortune of any reader of this Handbook.
Special thanks go to the Rockefeller Foundation, particularly Ariel Pablos-Méndez
and Charles Gardner, in health; Gary Toenniessen and Deborah Delmer, in agriculture;
and Jacob Werksman (now at the World Resources Institute). Under their leadership, the
Centre for the Management of Intellectual Property in Health Research and Development
(MIHR) and the Public Intellectual Property Resource for Agriculture (PIPRA) were estab
lished several years ago. Their inspired vision and determination, along with the foresight
of Judith Rodin, president of the Rockefeller Foundation, has enabled us to bring you this
Handbook. On behalf of all the users of the Handbook, the Editorial Board, and MIHR
and PIPRA, I would like to offer my sincere appreciation to the Rockefeller Foundation
for its commitment to and primary funding of this venture. Funding from the Ewing
Marion Kauffman Foundation is also gratefully acknowledged. Lesa Mitchell’s interest in
the Executive Guide was particularly welcome. Their combined sponsorship of these two
foundations made the preparation of this Handbook possible. We would like to emphasize,
however, that all of the policy, content, and editorial decisions were the sole purview of
the Editorial Board. Naturally, as editor-in-chief, I take full responsibility for any errors or
omissions.
We are grateful for the generosity of our Distribution Supporters. After the Handbook
content had been prepared, a number of organizations were provided copies of sample
chapters which prompted some to come forward to purchase copies for wide distribution
in low- and middle-income countries. It is particularly noteworthy that the Distribution
Supporters include several institutions from developing economies, in addition to aca
demic and public-sector research institutions, philanthropic foundations, and companies.
The impact of this Handbook will be greatly enhanced by the support of the Distribution
Supporters–including those that we hope will come forward in the future.
HANDBOOK OF BEST PRACTICES | xliii

The Editorial Board would like to express its gratitude to all the members of the Board
of Patrons for their generous endorsement of the Handbook. Their wise counsel is much
valued.
The Editorial Board also wishes to thank the Association of University Technology
Managers (AUTM) for allowing us to choose, update, and edit selected papers from the
AUTM Technology Transfer Practice Manual, which appear as chapters in this Handbook, as
well as for giving us permission to reproduce case studies from the association’s Better World
Project and Reports from the Field (which appear in the Executive Guide). These contribu
tions add much breadth and depth to the Handbook’s content. Mark Crowell, John Fraser,
Stu Gordon, Vicki Loise, and Lisa Richter were all especially helpful. The Editorial Board
would also like to thank the Public Interest Intellectual Property Advisors, Inc. (PIIPA),
especially Michael Gollin and Steven Price, for assistance in enlisting the help of the law
firms within its network; members of those law firms contributed many important chap
ters. The individuals proved their commitment to PIIPA’s ideals by responding so promptly
to our request and willingly contributing their ideas and experiences to the Handbook.
The University Companies Association of the United Kingdom (UNICO) deserves ap
preciation for sharing a valuable UNICO Practical Guide. My sincere gratitude also goes
to the Guide’s main author, Mark Anderson, of Anderson & Company, for his coopera
tion during the editing phase. I extend my gratitude to Intellectual Asset Magazine (IAM,
published by Globe White Page, Ltd.) and particularly its editor, Joff Wild, for allowing
the Handbook’s editors to edit and update an important chapter that previously appeared
as an article in IAM. Thanks go also to Les Nouvelles, published by the Licensing Executives
Society, for allowing us to revise two of its articles for inclusion in the Handbook.
Particular thanks go to the Whitehead Institute for Biomedical Research, which,
through the good offices of Amina Hamzaoui, granted us a license to its valuable, pro
prietary patent- and agreements-management system, WIIPS™ (the Whitehead Institute
Intellectual Property System), and granted us the right to sublicense the system to technol
ogy transfer offices through the online version of the Handbook.
The members of the Editorial Board are most grateful to the colleagues at MIHR in
Oxford, U.K. First, the Editorial Board would like to thank Robert Eiss, CEO, for his
resourcefulness in facilitating progress on the Handbook. Thanks are due also to Junko
Chapman for coordinating, most diligently and always with characteristic Japanese cour
teousness, all of the authors’ biographies, deeds, and photographs (the latter appear in the
online version of the Handbook). Rachelle Harris deserves special appreciation for her in
dustrious help—and always enthusiastic support—on many different crucial fronts. Thanks
to the administrative staff at MIHR who always went the extra mile to get things done.
Sincere thanks go to the entire Board of Trustees of MIHR, particularly the chair, Pramilla
Senanayake, for their foresight in establishing a Board subcommittee for the Handbook.
That committee, composed of Lita Nelsen, Richard T. Mahoney, and Jerry Keusch, was
astonishingly effective. I thank them for their pragmatism and encouragement.
This endeavor has truly been a collaborative effort between MIHR and PIPRA—an
essential partnership that made this Handbook possible. Members of PIPRA’s staff, led by
Alan Bennett and Greg Graff (both members of the Editorial Board), Sara Boettiger, and
Cecilia Chi-Ham, were always a pleasure to work with. Their efforts, always indispensable,
were executed with PIPRA’s characteristic professionalism and efficiency.
Without its skillful and effective editorial and production team, this Handbook could
not have taken shape nor reached its high level of readability and quality. My personal and
most sincere thanks go to David Alvarez, for his unstinting help and commitment. He
xliv | HANDBOOK OF BEST PRACTICES

worked with me throughout this project and his good humor made crunch times more
bearable. Thanks also to his most able and enthusiastic manuscript editors, Jacqueline
Stuhmiller and Katy Dixon. I am most grateful also to Paula Douglass for her diligent,
sharp, and sensitive editing of the manuscripts and her exacting standards. I wish to espe
cially acknowledge the efforts of the contributing editors, Stan Kowalski and Greg Graff,
for their perseverance. Their ability to organize and process complex and diverse material
proved indispensable.
The elegant design work by Linette Lao will be evident to anyone holding this
Handbook. She is truly a pleasure to work with, and I am grateful to her staff—Mary Penn,
Julie Morelli, and Kristin Schrader—who sometimes worked around the clock on the lay
out and design of this book. On behalf of all of the Handbook’s readers, I thank eagle-eyed
Barry Hall who performed the final copyediting of each and every chapter.
Stan, David, Jacqueline, Paula, Greg, Linette, Mary, and Barry deserve special mention
for extraordinary dedication, which allowed us to go to press in a timely manner.
It is a particular pleasure to acknowledge the creativity and superb work of the staff of
Dynamic Diagrams, Inc.—Lisa Agustin and her team of Timothy Roy, Fred Toth, Matt
DeMeis, and Henry Woodbury—for their excellent work in developing the online version
of this Handbook. Their enthusiasm and focus have taken the online version further than
we could ever have imagined. Jacob Werksman’s foresight proved particularly valuable.
A special word of appreciation goes to Charles Arntzen at the Biodesign Institute at
Arizona State University for having recognized the importance of this Handbook and for
his thoughtful support. Michael Crow, president of Arizona State University, with his vi
sion and enthusiasm, encouraged me both directly and indirectly. I am indebted to John
Dodds of Dodds & Associates for having taught me a great deal about the ins and outs of
intellectual property management. His advice on legal matters during the chapter review
process was extremely helpful.
I have been most fortunate, as editor-in-chief, to have had the assistance and support
of an outstanding Editorial Board. The hard work, deep commitment, expert guidance,
and collective experience of these dedicated and talented Board members have inspired
and motivated me, personally and professionally, and have kept this project on course. I am
grateful for having had the opportunity to lead this worthwhile and far-reaching endeavor
with these fine individuals.
Finally, on behalf of the Editorial Board, I would specifically like to thank Richard
T. Mahoney, co-editor-in-chief of this Handbook and sole editor of an earlier and more
concise version. Richard’s book—and life work—inspired me throughout the work on this
Handbook. His enthusiastic support and creativity and generous investment of time and
energy over the last two years were always delivered allegro maestoso. His good humor and
pragmatism—which helped keep everything in perspective—have contributed in immea
surable ways to creating this Handbook and making it available to you. ■
Anatole Krattiger
Editor-in-Chief

HANDBOOK OF BEST PRACTICES | xlv

About MIHR
Centre for the Management of Intellectual Property
in Health Research and Development
To contribute to a world in which the thoughtful stewardship and creative
management of intellectual property leads to better health for the poorest.

Over successive generations, innovations result
ing from research have dramatically improved
life expectancy and quality of life. However, the
benefits of these innovations are not reaching the
populations with the greatest need. Stark dis
parities persist with regard to health status both
among and within populations. Today there is
an urgent need to identify practical mechanisms
that translate R&D investments more effectively
into affordable interventions for diseases of the
poor. Central to resolving the issue is the need to
develop and promote forms of IP management
and technology transfer practices that enable and
empower local public–private technology part
nerships, that direct them toward public health
priorities, and that follow licensing practices that
ensure access for the poor.
MIHR was established in 2002 with funds
from The Rockefeller Foundation, to advance
the goal of improving availability of health
products needed by the poorest in develop
ing countries. MIHR is a not-for-profit global
organization headquartered in Oxford, U.K.
Its foundational tenet is that improved man
agement of innovation and intellectual prop
erty (IP) by the public sector is a key means to
achieve that goal.
The organization works to improve the
processes of innovation management in the
biomedical arena by building skills, know-how,
and awareness in developing countries and by
contributing to the understanding of sustain
able innovation and IP policies that affect global
health research.

MIHR also works to ensure that holders and
managers of technology worldwide are aware of
the need for and potential applicability of their in
ventions for improving health in developing coun
tries. The Centre accomplishes this by facilitating
local development of appropriate, affordable, and
innovative biomedical technologies for poor pop
ulations. MIHR contributes to economic devel
opment by enhancing essential linkages between
sectors, institutions, and disciplines involved in
biomedical innovation and by enhancing the ca
pabilities relevant to technology transfer that con
tribute to economic and social welfare.
MIHR’s core objectives are:
• to create a broad and sustained program
of capacity building in IP and technology
management to promote global health equi
ty through North–South and South–South
institutional partnerships and networks
• to help ensure that access considerations for
global health are pursued in parallel with
product development, so that successfully
developed products become available and
affordable to populations in need
• to develop technology and IP management
approaches that create incentives for re
search cooperation in global health by sup
porting analysis and new models
MIHR achieves its goals by working through
and with other institutions. It functions with
a small core operational staff, a Committee of
Interested Parties, and a Board of Trustees. ■
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A public sector collaboration for agricultural IP management:
Enabling access to intellectual property for the development of improved crops
Patenting of agricultural biotechnologies has ex
panded dramatically over the last 25 years, and
today a lack of access to patented technologies
represents a significant barrier to new crop devel
opment. Companies are addressing the develop
ment of major crops and large market opportuni
ties, yet most crops in developing countries and
specialty crops in developed countries are being
neglected. Developing countries are not receiving
research investment or opportunties to benefit
from the many promising technologies developed
and patented by both public and private sector
researchers.
The public sector and publicly supported
research continues to play a major role, as it has
historically, in agricultural innovation. This is par
ticularly true in developing countries where the
public sector and publicly supported research in
stitutions are virtually the only innovative forces.
In spite of this and the now well-established im
portance of intellectual property (IP) in agricul
tural innovation, public sector institutions have
not developed the skill base and infrastructure
needed to actively manage intellectual property.
Consequently, these institutions find that their
research programs may be blocked at the point of
application or that they are unable to effectively
transfer their own technology for private sector
development.
The primary objective of the Public
Intellectual Property Resource for Agriculture
(PIPRA) is to promote access to agricultural tech
nologies developed in public and/or private non
profit research institutions for both humanitar
ian and neglected commercial purposes. PIPRA

was created as a result of lengthy consultations
involving two philanthropic foundations, the
Rockefeller and McKnight foundations, and ap
proximately 12 public and/or private nonprofit
agricultural research institutions. The consulta
tions identified many of the IP issues and barriers
that were affecting the ability of public institu
tions to address their historic mission of deploy
ing new agricultural technologies.
In response, PIPRA has established a strategy
and a series of programs that promote broad ac
cess to agricultural technologies. The strategy is
based on bringing together a strong membership
base of the major public or nonprofit agricultural
technology developers of the world. PIPRA is
seeking, through its membership base, to build a
framework of open and collaborative communi
cation and principles for IP management and to
begin to coordinate the highly fragmented port
folio of agricultural intellectual property owned
by its member institutions.
PIPRA does not subscribe to a single phi
losophy or approach to addressing IP issues.
Instead, PIPRA believes in employing a wide
range of available IP management tactics. These
include defensive publishing, trademarks, bail
ment, open source, patenting, and careful licens
ing. In each case PIPRA chooses the best tools
available to achieve the goals of a specific project.
This approach is practical in that it recognizes
that technologies may need to be sourced from a
wide range of public and private technology de
velopers who have their own objectives and their
own IP strategies. PIPRA has developed sufficient
internal capability to work flexibly in navigating
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a path to enable agricultural projects that meet
the complementary objectives of a community of
public/nonprofit technology developers.
PIPRA’s services, its broad membership base,
its extensive knowledge of public sector agricul
ture, its legal network, and its capacity for legal
research, work to reduce the IP hurdles that exist
along the path from research, through develop
ment, to distribution. This work enables the
strategic use of IP rights to further the goals of
public sector research and reduces the diversion
of individual institutional resources into the legal
issues of technology access and IP rights.
PIPRA’s primary strategies to improve access
to technologies are to:
• provide an IP clearinghouse for access to
public-sector patented technologies
• provide a resource for the analysis of pat
ented technologies for implementation of
specific projects
• develop gene transfer and gene-based-trait
technologies that have maximum legal free
dom to operate
• manage pools of public sector technologies
to promote availability and reduce transac
tion costs associated with the transfer of
rights to patented technologies
• support the development of IP manage
ment best practices and capacity enhance
ment in developing countries. ■
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Disclaimer
The publishers, editors, and authors have given their best efforts in preparing this publica
tion, and, while we believe the Handbook (including the Executive Guide and the online
version) will all be useful resources relating to intellectual property and the management
thereof, the Handbook is not intended to serve as the sole source of information on the top
ic. Readers are advised to seek independent legal counsel and/or other professional advice
for all intellectual property and contractual matters with regard to appropriate practices for
specific situations and countries. No warranties or representations of any kind are made as
to the accuracy, usefulness, or completeness of any suggestions or information provided in
the Handbook. Neither MIHR, PIPRA, nor any of the contributors to the Handbook, nor
the editors, funding agencies, or sponsors will be liable for any loss or damage arising out of
the use of any information or suggestions in the Handbook. This comprehensive limitation
of liability applies to all damages of any kind, including (without limitation) compensa
tory, direct, or consequential damages; loss of data, income, or profit; loss of or damage
to property; and claims of third parties. All Web pages have last been accessed between 15
February and 18 March 2007.
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SECTION

1

Innovation and IP Management:
A Contextual Overview

CHAPTER 1.1

The Role of IP Management
in Health and Agricultural Innovation
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative,

International Vaccine Institute, Republic of Korea

anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;
Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

Recent national and international changes in intellectual
property (IP) legislative frameworks are likely to have
profound effects on the ways in which health and agri
cultural innovations reach the poor and on how public
and private research and development institutions pursue
their work. Whereas IP rights are sometimes viewed as
creating barriers to access to innovations in health and ag
riculture, we argue that it is not intellectual property, per
se, that raises barriers, but rather how intellectual prop
erty is used and managed, particularly by public sector
institutions. Above all, we argue that intellectual property
is only one of six components of innovation. It is rarely
the most important component.
The chapter reviews recent dramatic developments
in institutional aspects of intellectual property, as well
as global policy shifts and international studies that,
among other outcomes, affected the environment for the
creation of MIHR and PIPRA. In the field of health,
changes have been particularly pronounced with the
founding of a new form of institution for innovation:
product-development partnerships (PDPs). As a result,
we make the case for a fundamental shift in the way in
which IP management in health and agricultural innova
tion is viewed and conducted. In addition, we argue that
IP management should be seen as an important element
in developing countries’ strategies to become more in
novative in addressing diseases of poverty, the alleviation
of poverty, and malnutrition. The public sector can em
ploy new ways to achieve its goals within the evolving IP
framework. These new ways can help it better mobilize
the resources to take a product through the process of
innovation. These new ways should include, a) creative
licensing practices that ensure global access and affordability, b) improved institutional IP management capa
bilities, c) the formulation of comprehensive national IP

policies, and d) the strengthening of IP court systems
and patent offices.
These are what best practices in IP management are all
about, and what this Handbook seeks to help bring about
and promote.

1. InTRoduCTIon
Changes in both national and international legis
lative frameworks have profoundly affected how
innovation reaches the poor and how public and
private research and development institutions
pursue their work. In this regard, the experience
of the United States with the Bayh-Dole Act of
1980, which harmonized the numerous IP own
ership policies of U.S. government agencies, is
quite instructive.1 The act significantly changed
how academic institutions manage intellectual
property. Universities had to adapt to an increas
ingly knowledge-based economy, a trend that is
continuing and even intensifying. And because of
the increasing interaction between developed and
developing economies and the increased number
and complexity of relationships between the pub
lic and private sectors, the need for understand
ing these partnerships and how they can best op
erate is becoming compelling. Some of the major
changes in this environment of the last decade in
health, agriculture, and intellectual property itself
are shown in Box 1.
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In addition, the last several years have been
marked both by big changes in institutional IP
infrastructures and by dramatic developments
in the world of non-governmental organizations
(NGOs), public sector research institutions, and
public–private partnerships (see Box 2 for a dis
cussion on agricultural biotechnology-related as
pects). These developments promise to reshape
the global IP environment, especially for devel
oping countries. Some of the more significant of
these events include:2
• 2003: The founding of the African
Agricultural Technology Foundation
(AATF)
• 2003: The founding of the Centre for
the Management of Intellectual Property
in Health Research and Development
(MIHR)

• 2003: The creation, within AUTM, of the
Technology Managers for Global Health
(TMGH) group
• 2004: The founding of the Public Intellectual
Property Resource for Agriculture (PIPRA)
In the field of health, the changes have been
no less dramatic. A number of product-develop
ment partnerships (PDPs), concerned with most
of the high priority diseases in developing coun
tries, emerged during the 1990s and 2000s. PDPs
must deal daily with IP management issues, and
the lessons they are learning about the role of in
tellectual property are of great interest. MIHR
has convened two meetings to analyze IP man
agement in PDPs, both of which took place at the
Aeras Global TB Vaccine Foundation, the first in
December 2004 and the second in July 2006.3
In fact, MIHR’s founding and development in

Box 1: Major Recent Events in the Global IP system
Concerning IP in General

• 2002: Report of the Commission on Intellectual Property Rights of the United Kingdom4
• 2005: Entry of many low- and middle-income countries into TRIPS on January 1
Primarily Health-Related

• 2001: Meeting of the 4th Ministerial Conference of the World Trade Organization (WTO),
which adopted the Doha Declaration concerning the TRIPS Agreement and Public Health5
• 2005:Approval of the amendment to the TRIPS Agreement providing for the supply of drugs
manufactured under compulsory licenses for developing countries without manufacturing
capability
• 2006: Report of the WHO Commission on Intellectual Property Rights, Innovation and
Public Health6
Primarily Agriculture-Related

• 2001: Creation of the World Intellectual Property Organization (WIPO) Intergovernmental
Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and
Folklore7
• 2001: Creation of the International Treaty on Plant Genetic Resources for Food and
Agriculture, under the Food and Agriculture Organization of the United Nations (FAO)
• 2002: Establishment of the Global Crop Diversity Trust, by FAO and the World Bank
• 2002: Adoption of the Bonn Guidelines on Access to Genetic Resources and Fair and
Equitable Sharing of Benefits Arising out of Their Utilization, under the Convention on
Biological Diversity
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Box 2: Putting Public-Sector Agricultural Intellectual Property to Work
During the 1990s, the field of agricultural biotechnology was consolidated. A few large companies
owned important elements of the enabling technology platforms. That ownership, coupled
with strong R&D capability, existing marketing and distribution networks, and substantial cash
flows from agro-chemicals and seeds, gave the companies incentives to invest heavily in the
development of agricultural biotechnology products. With these increased R&D investments,
the companies became the dominant providers of new crop genetics and genetically modified
crops.8 During the same period, biosafety regulatory requirements led to greatly increased R&D
costs that slowed public sector developments of agri-biotechnology crops, especially public
sector crop breeding programs.9 Research on minor crops and on traits of low economic value
in developing country agriculture also decreased, even though these crops and traits have high
social, humanitarian, and environmental value.10
A significant turning point in the relationship between the public sector and intellectual property
in agriculture occurred when a freedom-to-operate (FTO) review, commissioned by the Rockefeller
Foundation, led by one of us (AK), of pro-Vitamin A-containing Golden Rice showed that around
70 patents and patent applications were applicable to the improved rice.11 Fortunately, all of these
constraints were resolved in a few months by a straightforward IP management strategy (grant
back of rights to a single entity that could use the rights for the benefit of developing countries).
The rapid resolution of these obstacles demonstrated, first of all, how effective IP management,
coupled with strong collaborations between the public and private sectors, can help achieve
humanitarian goals. The IP constraints did not delay the development of the product, and their
resolution did not cost much, especially when compared to the overall R&D costs.The FTO review,
moreover, served as a wake-up call to the public sector to pay more attention to IP management
as a powerful tool.
Concern about potential constraints on public sector research and innovation in agriculture
spurred the public sector’s interest in intellectual property. One important response was work
that led to the formation of the Public Intellectual Property Resource for Agriculture (PIPRA).12
Supported by the Rockefeller and McKnight foundations, among others, PIPRA is a public sector
initiative that recognizes that continuing and enhancing relationships with the private sector are
critical components of successfully utilizing intellectual property to meet public sector goals.
As part of its initial work, PIPRA began a study of the structure of IP ownership in agricultural
biotechnology. In the words of the study’s authors, Richard C. Atkinson and colleagues:
This study found that roughly one-fourth of the patented inventions were made by public-sector
researchers, which is substantially larger than the IP portfolio held by any single agricultural
biotechnology company. It is, however, highly fragmented across institutions and across technology
categories. And much of this IP has been licensed, often under terms that are confidential but which
have likely resulted in greatly restricted access to the underlying technologies. This study suggested
that, apart from a few important exceptions, public-sector scientists have invented many of the
types of technologies that are necessary to conduct basic biological research and develop new
transgenic plant varieties. For instance, they have developed technologies to transfer genes into
plant cells; have characterized specific DNA elements that drive unique patterns of gene expression;
and have identified many genes that confer important plant traits. Such discoveries underscore
the fact that public-sector research institutions have been significant sources of technological
innovation … .13
We believe that these innovations can be put to work more directly to help the poor with more
focused public sector IP management.
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many ways reflect, and perhaps have helped to in
fluence, the changing environment of IP manage
ment. We summarize here the story of MIHR’s
founding to help understand the major changes
that have occurred and are underway.
We believe that the events of the last decade
have led the international development commu
nity in health and agriculture to fundamentally
reconceptualize the role of intellectual property
in health and agricultural innovation, especially
in relation to the needs of the poor. In the 1980s
and 1990s, many individuals argued that intel
lectual property and patents were bad for people’s
health and innovative biotechnology products
bad for their food. According to this argument,
intellectual property was controlled by large
pharmaceutical and agricultural companies that
used the power of IP rights to capture markets,
limit consumer choice in both health and agri
culture, and, above all, raise prices. This not only
priced the poor out of the market, but also dis
couraged further innovation of products needed
by the poor.14
The claims of these arguments hold, howev
er, only when the public sector responds passively
to the global IP system. Like everyone else, the
public sector needs to adapt to the changes in this
system so that it can seize new opportunities and
take advantage of previously unavailable options.
Indeed, by neglecting to utilize the IP system ef
fectively, the public sector not only neglects its
own interests but the interests of those it serves.
Without effective IP management, the public sec
tor risks squandering the new powers that the re
vised IP system provides. Intellectual property is
a tool, and the impact of a tool depends on who
uses it, how it is used, and for what purpose.
This perspective has led to new efforts, in
cluding the founding of MIHR (see below) and
of PIPRA (see Box 3), to make IP management a
powerful tool for the benefit of the public sector.

2. THE RoAd LEAdInG To MIHR
Toward the end of the 1990s, staff of the Health
Equity program at the Rockefeller Foundation
became concerned about the possible impact of
patents and other intellectual property on the
 | HANDBOOK OF BEST PRACTICES

development and availability of new health tech
nologies that addressed diseases affecting people
in developing countries. In the 1990s, the staff
had observed a significant amount of agricultural
intellectual property captured by multinational
companies, a situation that made it difficult to
conduct certain kinds of agricultural research for
the benefit of poor countries. The Rockefeller
Foundation staff sought to ensure that a similar
situation did not occur vis-à-vis health technol
ogy development. The Foundation therefore
commissioned a group of individuals, led by one
of us (RTM), to assess in detail the needs and op
portunities in intellectual property and health.
The results of this assessment eventually led to the
founding of MIHR.
The study was launched in April 2001. At
the time there was a lot of confusion about the
role and impact of patents and other intellectual
property. It was feared that crucial intellectual
property would be controlled by private entities,
and that this control would make it impossible
to conduct product research and development.
With respect to existing products, there was con
cern that patents provided virtual monopolies
for companies—monopolies that the companies
would use to extract high rents on the market
place, making it difficult, if not impossible, for
the poor to access the technologies that could
benefit them.
The Rockefeller Foundation study immedi
ately faced a practical difficulty: little research had
been done on needs and opportunities in intel
lectual property and health. Only a small body
of published literature addressed issues of interest
to the foundation. Moreover, few scholars were
studying these issues. The study team therefore
decided to carry out its work by interviewing a
wide array of individuals in the public and private
sectors and in developed and developing coun
tries. Nearly 200 individuals were interviewed,
sometimes in groups but most often one-on-one.
The following highlights some of the study’s sig
nificant findings.
The study began by contextualizing the prob
lem. In market economies, the private sector is
driven by the desire to maximize returns on in
vestment. Modern economic theory holds that
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maximizing such returns spurs economic growth.
Because selling highly profitable health products
to the well-to-do leads to the highest maximiza
tion of return on investment, the private sector
accords priority to products for these individuals.
Conversely, the private sector does not and can
not be expected to accord priority to the needs of
the very poor.
The public sector, on the other hand, is driv
en, in democracies, by its search to maximize hu
man well-being. Modern social theory holds that
all humans, regardless of citizenship, economic
status, or other demographic variables, should
be given the chance to maximize their well-be
ing. Because the poor suffer the lowest quality
of health, and because they often cannot afford
to buy needed pharmaceuticals, the public sec
tor has the responsibility of according priority to
these individuals.

Within this political and economic frame
work, which is certain to be with us for the fore
seeable future, intellectual property has grown
increasingly important. Capitalist companies
energetically seek and avidly protect intellectual
property to obtain adequate returns on invest
ment. Indeed, it is widely accepted that intel
lectual property is essential for the private sector.
But what about the public sector? Does or can
intellectual property help achieve important pub
lic sector goals?

. THE SoCIAL And EConoMIC
IMpERATIvES of pRoduCT
dEvELopMEnT And ACCESS
On the most pragmatic level, intellectual prop
erty is important to the public sector because it
is important to the private sector. If public sector

Box 3: The Public Intellectual Property Resource for Agriculture (PIPRA)
PIPRA is an international initiative undertaken by universities, foundations, and nonprofit research institutions to make agricultural technologies more easily available for the
development and distribution of subsistence crops in the developing world and specialty
crops in the developed world.
With the introduction of biotechnology in agriculture, researchers have a unique opportunity
to contribute to the development of improved staple and specialty crop varieties. However,
developing new crop varieties with biotechnology depends on access to multiple technologies,
which are often patented or otherwise protected by IP rights. Ownership of these rights is
fragmented across many institutions in the public and private sector, a situation that makes it
difficult to identify who holds what rights to what technologies, and in which countries. Such
information is necessary, however, to establish whether or not a new crop variety is at risk of
infringing those rights. The current situation thus creates barriers to commercializing new
staple and specialty crop varieties. PIPRA members believe that if public-sector institutions
collaborated in gathering information about and in the use of agricultural IP rights, it would
be easier for them to speed up the creation and commercialization of improved staple and
specialty crops and thereby fulfill part of their public missions. Specifically, PIPRA focuses on
the following principal activities:
• Reviewing public sector licensing practices
• Implementing a collective public IP asset database
• Developing shared technology packages
• Providing information, engaging other organizations, and stimulating discussions
• Engaging private sector organizations
Source: Adapted from PIPRA.15
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organizations, such as PDPs, want to collaborate
with the private sector to develop new, valuable
health technologies, they must address IP issues.
Many, if not all, of the PDPs have recognized
this. In fact, their experiences have led many of
them to reassess the role that intellectual property
plays in making health and agricultural products
available to the poor. Before PDPs, critics con
tended that intellectual property allowed private
pharmaceutical companies to dominate markets,
perpetuating high prices and excluding the poor.
The experience of PDPs, however, shows not only
that intellectual property can be utilized to serve
the needs of the poor, but also that its misuse or
waste slows the development of new technologies
for developing countries.
But how can the public sector best use the
IP system? Should it seek to minimize the prob
lems that emerge from patents and other forms
of intellectual property? Or should it take a more
active role and seek to take advantage of some of
the powers provided by intellectual property? To
answer these questions, one must be able to see
what capabilities and what benefits might accrue
from the exercise of these powers.
The study ultimately concluded that there is
a very important reason for public sector support
of intellectual property: it is an essential tool for
achieving safe and effective health technologies.
Why? The answer is found in a combination of
government actions and economic imperatives.
During the latter half of the 20th century, de
veloped countries created whole new systems
of drug regulation. Of these, the Center for
Biologics Evaluation and Research of the Food
and Drug Administration (FDA) in the United
States is one of the more influential. One of the
motivations for its founding was the death of
several children from polio vaccinations; the
vaccine turned out to contain live poliovirus.16
Rules and regulations, therefore, were estab
lished to produce and distribute vaccines and
drugs that are safe and effective. Over the years,
these rules and regulations have become steadily
more rigorous, making it increasingly expensive
to develop new, safe, and effective pharmaceuti
cals. As the costs of developing drugs rose, the
pharmaceutical industry had to raise greater
 | HANDBOOK OF BEST PRACTICES

amounts of capital in order to pay for them. The
investors who put up such huge sums naturally
sought high returns on their risky investments,
and such high returns could not be achieved
without IP protection. In fact, the existence of
intellectual property allowed the private sector
to mobilize the funds necessary to develop safe
and effective pharmaceuticals. The public sec
tor could not (or at least did not) provide these
funds, nor was it capable of developing the new
products that were needed.
The study therefore concluded that the IP
regime plays an essential role in achieving an im
portant public sector goal: the development of
safe and effective pharmaceuticals. Accordingly,
its next question was whether or not intellectual
property had some additional practical benefits
for the public sector. The study consequently
identified a number of licensing practices that
public sector organizations have used for the
public’s benefit. If the public sector owned valu
able intellectual property, it could license that
intellectual property to private sector companies
with conditions that benefited the public sector.
For example, the licensing terms could require fa
vorable pricing to the public sector. Moreover, by
licensing to more than one company, the public
sector could foster competition that could lead
to lower prices for consumers. And finally, the
public sector could require that the product be
made available to both the lucrative private sector
market and to the public sector.
In addition, the emergence of Innovative
Developing Countries (IDCs),17 such as Brazil,
China, and India, is changing the face of global
health and agricultural innovation. These coun
tries and others like them will certainly contrib
ute significantly to biomedical R&D in the near
future. A major unresolved question, however, is
whether their innovations will benefit the poor
within their own borders and in other less well-off
countries. It is important to identify innovation
strategies and IP management policies and prac
tices that will help ensure that the investments of
IDCs in R&D benefit the poor.
The study also concluded that the public sec
tor, especially in developing countries, had very
little capability—in terms of staff, policies, and
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practices—to extract the benefits that could be
obtained were they to implement enlightened li
censing practices. The study therefore proposed
programs to document best licensing practices
and capacity-building initiatives. These are two of
MIHR’s major programs, and this Handbook ad
dresses both of these goals: it seeks to document
best practices and to be a teaching and capacitybuilding resource.
As noted above, one of the concerns the study
addressed was the extent to which the existence
of patents and other intellectual property might
inhibit or prevent the development of products
needed by the poor in developing countries. The
study, like that of Golden Rice (see Box 2 above),
concluded that intellectual property rarely, if ever,
blocks product development. This conclusion
was supported by interviews with individuals in
both the public and private sectors. They noted
that there were several ways that companies or
product developers could address “blocking pat
ents.” First, one could seek a license from the pat
ent owner. If this attempt was unsuccessful, other
courses of action could be taken. For example, if
an expert opinion determined that the blocking
patents might not withstand legal challenge, then
one could proceed without a license. In addition,
Europe has a general research exemption that al
lows one to undertake research using a patented
technology without having to obtain a license for
that technology. In the United States, however,
“safe harbor” provisions18 greatly facilitated the
development of a vigorous generic drug industry
through a research exemption of the patent laws
allowing them to make and use (but not to sell) a
drug during its period of patent protection. This
exclusion was critical to developing data neces
sary for regulatory approval once the patents had
expired. A third option is to “invent around”
intellectual property: in other words, to create
a similar technology that does not infringe on
any existing patents. For vaccines, this is a com
mon practice because it is often difficult to secure
one or more dominating patents (that is, patents
that would make it nearly impossible to invent
around). Yet another strategy is to develop and
market the products in countries where patents
have not yet been filed.19 This was the strategy

used by several Korean manufacturers that jointly
developed a hepatitis B vaccine.20
The study’s analysis concluded that intellec
tual property is almost never the most important
factor affecting the development and availabil
ity of pharmaceuticals and vaccines. Instead, the
most important factor seems to be the existence
or absence of a market for those pharmaceuticals.
Hepatitis B again presents a cogent case study.
From a price of greater than $18 a dose, hepatitis
B vaccine cost fell to less than $0.30 a dose once
the public sector “made a market,” i.e. started
buying tens of millions of doses per year.21 This
finding about the relative lack of importance of
IP led Rockefeller Foundation staff to study all
of the major issues affecting the development
and availability of pharmaceuticals. Briefly, the
analysis revealed that the other factors were: sup
port for research and development, the existence
of domestic markets (including national health
systems), the existence of international trade in
the products (including procurement by inter
national public-sector procurement agencies),
the operation of capable regulatory systems, and
the ability to manufacture products to high stan
dards. Intellectual property was only one of six
factors—and rarely the most important. These
six factors are referred to as the “components of
innovation.”
We believe that placing intellectual prop
erty in a broader product-development context
is necessary to improve the development and
availability of health technologies for the poor.
Conversely, any strategy that focuses only on IP
issues is bound to fail and may be counterpro
ductive. Thus, efforts to promote compulsory
licensing to get low prices for pharmaceuticals
in developing countries must overcome not only
IP difficulties but also the obstacles presented by
other components of innovation: the existence
of capable manufacturing facilities that meet
international standards, the availability of funds
to procure the products for both domestic and
international distribution, and the cost of ob
taining regulatory approval for products manu
factured under compulsory licenses. These are all
significant, costly hurdles; any one of them could
prevent a compulsory license from being useful
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or cost effective, i.e. the cost of production un
der a compulsory license may be greater than the
cost that could have been obtained through direct
procurement of bulk quantities either individu
ally by nations or through mechanisms such as
the GAVI Alliance. (The Global Fund to Fight
AIDS, TB and Malaria is [as of mid-2007] recon
sidering it procurement policies. Rather than al
lowing each country to do its own procurement,
the Fund is considering doing bulk procurement
to ensure getting the best prices.)

. InnovATIon And Ip MAnAGEMEnT
In A poST-TRIpS WoRLd
Shortly after the MIHR study began, the Doha
Declaration was approved. It called for accord
ing higher priority to public health than to trade
concerns, and it emphasized that countries were
free to use the “flexibilities” of TRIPS to protect
public health. A few years after MIHR was estab
lished, the Doha Declaration was approved as an
amendment to the TRIPS agreement. In the in
terval between the Doha meeting and the approv
al of the amendment, there were vigorous debates
about the potential impact of TRIPS on access
to medicines in developing countries. Some felt
that TRIPS would be disastrous for developing
countries. There were fears that it would suppress
R&D, cause generics to disappear, and rapidly
raise drug prices. Others felt that TRIPS would
create a surge of support in developing coun
tries for R&D, encourage joint ventures between
pharmaceutical companies in developed and de
veloping countries, and have little if any impact
on the availability and prices of generics.
In January 2005, India and many other devel
oping countries came under the rules of TRIPS. In
December 2005, MIHR and the Indian Council
of Medical Research convened an international
symposium to examine the impact of TRIPS. The
full report of the symposium has since been pub
lished.22 In short, the meeting’s conclusions tend
to support the positive predictions mentioned
above. Of perhaps greater importance, however,
the meeting emphasized the need for developing
countries to increase their capacities to manage
intellectual property in ways that meet their own
10 | HANDBOOK OF BEST PRACTICES

needs. The meeting also concluded that innova
tion is such a complex process—of which intel
lectual property is only one component—that it
would be very difficult to document the impact
of TRIPS on innovation; conversely, any impacts
will be the result of a combination of factors, and
will never be due to intellectual property alone.
Toward the end of the MIHR study that
began in 2001, but before the establishment of
MIHR, the UK Commission on Intellectual
Property Rights (CIPR) issued its report,23 which
was read with great interest by the MIHR study
team. A core conclusion of the CIPR report was
that a one-size-fits-all approach to intellectual
property was undesirable. Each country should
have some freedom to adopt and implement laws
and regulations that fit its own needs. Most re
cently, the WHO Commission on Intellectual
Property Rights, Innovation, and Public Health
(CIPIH) report has emerged. It takes an even
broader view of intellectual property and innova
tion than the CIPR report. Both reports come to
the following conclusions:
• Innovation takes place in a complex en
vironment in which intellectual property
is only one factor, and rarely is the most
important.
• Developing countries need to determine
what kinds of rules and regulations best ad
dress their particular needs.
• IP management capabilities in developing
countries need to be rapidly improved in
order to ensure that intellectual property is
used to improve health.
An analysis of IP management and innova
tion by Morel and colleagues24 found that donors
have already marshaled significant resources and
created organizational structures that accelerate
the development of new health products and that
procure and distribute drugs and vaccines for the
poor. Their analysis concluded with a proposal
for complementary strategies to improve health
equity: national governments should support
product-development efforts, and the public and
private sectors need a coherent strategy to address
each of the six interrelated components of inno
vation, also called determinants.25
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. ConCLuSIonS
The Rockefeller Foundation launched in-depth
evaluations of the role of intellectual property in
innovation of health and agricultural technologies
that benefit the poor, especially those in develop
ing countries. Its efforts and those of the many
individuals and organizations that have worked
in this space to date have helped to reconceptual
ize the relationship between the global intellectu
al property system and developing countries. This
reconceptualization has the following elements:
• The dominant political/social framework
of capitalism, markets, and democracy ac
cords high priority to the protection of in
tellectual property. This framework is going
to be with us for the foreseeable future, and
so the public sector needs to find ways to
achieve its goals within this framework.
• Intellectual property is important to the
private sector because it helps investors
achieve high returns on their investments.
• Intellectual property is also of importance
to the public sector because:
− It mobilizes the resources that are needed
to take a product through the process of
research and development (especially
those steps that are designed to ensure
the product’s safety and efficacy).
− It can help the poor. Creative licensing
practices, for example, can help ensure
global access and affordability.
• IP management capabilities need to be im
proved, particularly in developing coun
tries, so that intellectual property can be
managed for the benefit of the poor.
• Intellectual property is only one of six
components of innovation and is rarely the
most important. Efforts to meet the needs
of the poor must also:
- Support R&D
- Develop national health programs and
agricultural extension systems that are
sustaining domestic markets, including
distribution systems in both the public
and private sectors
- Be conducive to facilitating trade in
health and agricultural technologies and
products (both input and output)

- Encourage high-quality manufacturing
of drugs and vaccines and investments
in high-quality seed production and that
of other agricultural inputs
- Adopt policies and develop safe and ef
fective regulatory systems (for drug and
vaccine registration; biosafety and food
safety for applications of biotechnology
in food, feed, and fiber; and seed quality
certifications)
• Each country needs to take advantage of the
freedoms granted by TRIPS and formulate
and implement policies and practices that
best meet its own needs. Short-cut solu
tions to technology needs in medicine and
health, such as compulsory licenses, are un
likely to be as effective or sustainable as are
collaborative efforts between the public and
private sectors. Countries would benefit
substantially from developing their internal
IP management capabilities, strengthening
their IP court systems and patent offices,
and according priority to meeting the needs
of the poor.
When it comes to increasing developing
countries’ access to fundamental innovations in
health and agriculture, success requires knowl
edge, capacity, and active engagement. These
are what best practices in IP management are all
about and what this Handbook seeks to help cre
ate and promote. n
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Building Product Innovation Capability in Health
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative,

International Vaccine Institute, Republic of Korea

ABSTRACT

This chapter presents a theoretical framework to explain
the role of intellectual property (IP) in innovation and ap
plies the framework to the growth of the pharmaceutical
industry. Developing countries progress through stages of
capability to reach the status of Innovative Developing
Country (IDC). To reach the status of an IDC, coun
tries need to give concerted attention to six components
of product innovation: R&D in the public and private
sectors, regulatory mechanisms for drugs and vaccines to
achieve safety and efficacy, the ability to manufacture to
high standards new health technology products, national
distribution systems in both the public and private sec
tors, international distribution systems (including supply
of drugs and vaccines through international organizations
such as UNICEF, the operation of global funds, and trade
among countries), and systems for managing IP.
An analysis of pharmaceutical innovation in Korea’s
vaccine industry concludes that its success in develop
ing its impressive capabilities was achieved by paying
close attention to all six components of innovation.
Yet unknown is the extent to which the Agreement on
Trade-Related Aspects of Intellectual Property will stimu
late or thwart progress in the other innovation compo
nents when IP is quickly moved to an advanced stage.

1. InTRoduCTIon
Several developing countries, including Brazil,
China, India, and South Africa, are rapidly in
creasing funding for biotechnology. These
countries and others are improving their drug

regulatory agencies and are adopting modern
laws and regulations for IP management, as well.
Some of the pharmaceutical companies in those
countries have entered the international market
with both generics and self-developed products.
Rapid economic development is leading to ex
panded domestic markets. This expansion is in
creasing demand for products that address domes
tic diseases. Countries that are developing in the
ways mentioned here are referred to as Innovative
Developing Countries (IDCs).1 Because diseases
of the poor disproportionately affect these and
other developing countries, IDCs may become
a major source of health product innovation for
diseases of the poor.
The changes in IP management taking place
in IDCs need to be assessed so that the interna
tional development community can understand
how IDCs can best participate in and, in some
instances, actually lead efforts to develop new
health technologies for the poor in developing
countries. Such an assessment should consider
changes in biotechnology manufacture, local de
mand for these products, potential for export,
the nature and extent of public and private sec
tor support for biotechnology research, and the
changing environment of IP, drug, and vaccine
regulations. This chapter describes a framework
for analyzing these factors.
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2. A fRAMEWoRk foR AnALyzInG THE
pHARMACEuTICAL InduSTRy
2.1 The six components

The framework allows us to analyze the develop
ment of the pharmaceutical industry in develop
ing countries through six components:
1. R&D in the public and private sectors
2. Ability to manufacture to high standards
new health technology products
3. National distribution systems in both the
public and private sectors
4. International distribution systems, includ
ing supply through international organiza
tions such as UNICEF, the operation of
global funds, and trade between countries
5. Systems to manage IP
6. Systems for drug and vaccine regulation to
achieve safety and efficacy
The components of the framework are linked
dynamically. Progress in one requires progress in
most—if not all—of the other components. It is
difficult to improve R&D capability without first
increasing manufacturing capability or having a
national or international export market (requiring
a distribution system) to generate resources for
investment in production facilities. It is likewise
difficult to enter markets in developed countries
without good IP or regulatory systems. And while
developing countries can access new technologies
by entering into joint ventures with sophisticated
firms in developed countries, these foreign firms
will decide to form joint ventures based on the
value of the domestic market in the developing
country, the capability of local R&D centers, and
IP protection levels. The interconnectedness of
the six components is clearly very strong. And IP
is an important aspect in all of them.
2.2 From knowledge access to the role of IP

IP policy-making in developing countries seems
to be driven by conflicting goals. One goal is to
encourage the influx of foreign technology. This
can be achieved by providing enough protection
for IP rights to enable foreign IP owners to pursue
profits through licensing, marketing, and invest
ment in the recipient country. This protection is
1 | HANDBOOK OF BEST PRACTICES

needed especially when domestic R&D is focused
on imitating or modifying foreign technology.
On the other hand, developing countries have
been able to access foreign technology cheaply
and build manufacturing capability more quickly
when unfettered by IP rights. This has worked to
keep IP protection levels low, especially since few
domestic innovators are harmed by such a regime.
Instead of viewing the goals of foreign IP owners
and domestic innovators as simply opposed, how
ever, a closer analysis leads to a dynamic perspec
tive. In the early stage of development, conflicts
with foreign IP holders are minimal, typically,
because domestic capability is poor and few for
eign firms are interested in bringing technologies
to the country. As the country’s technological ca
pability improves, poor protection of foreign IP
rights is likely to conflict with the further growth
of domestic capability. In the last stage, when lo
cal firms are able to generate their own IP, local
demand for greater IP protection increases, re
ducing conflicts with foreign IP holders.2
2. The special role of drug and
vaccine regulation

One key difference between the pharmaceutical
industry and most other industries is the role of
the stringency of the regulatory system for drugs
and vaccines. As a country develops, the IP sys
tem and the regulatory system often progress in
tandem.3 In the early stage, there is little need
for a well-developed national regulatory system.
Most drugs and vaccines are imported from other
countries, and it is assumed that the regulatory
agencies of the producing countries have ensured
their safety and efficacy. Any local production is
contracted by foreign companies, which ensure
quality control in order to meet regulatory stan
dards in their home country or other countries
where the products will be sold.
However, as the local production of copied
products intended for the domestic market be
comes important, the need for local regulation
emerges. The government now has an interest
in ensuring quality products. Initially, its main
activities are to check composition and review
the production facilities. Later, domestic compa
nies demand a much more developed regulatory
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capability. They want greater regulation and a
capable regulatory agency for two reasons: to es
tablish an approval process for newly developed
products and to support the development and
sustenance of export markets.

. Ip And THE GRoWTH of
BIoTECHnoLoGy In koREA
.1 A dynamic version of the framework

The growth of biotechnology in developing coun
tries is illustrated in Figure 1, which shows the
patenting trends in Korea and the United States
by Korean vaccine inventors. Korea is a good
example for purposes of this chapter because of
its rapid development in biotechnology. Korean
vaccine biotechnology evolved rapidly, especially
beginning in the mid-1990s.

The growth of the biotechnology industry
in Korea can be interpreted in terms of the six
framework components illustrated in Table 1.
Showing the varying levels of capability with re
spect to each of the components of innovation
at each stage, the table illustrates how developing
countries can progress through four stages of capa
bility in pharmaceuticals. The table distinguishes
between national and international distribution
and breaks out support for R&D into public and
private sectors. The table illustrates that there are
different systems of IP management at different
stages of development. The table assists our think
ing about one of the challenges brought about
by the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS Agreement),
namely that all developing countries that are sig
natories of the Agreement will have to move im
mediately to Stage 3. Several countries, such as

Figure 1: Vaccine-Related Patents Obtained by Koreans
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Importation of finished
goods or assembly
of parts into finished
products

Production on license or
by copy

Manufacture of
domestically developed,
high technology
products

Highest capabilities to
produce high technology
drugs and vaccines

Stage 1.
Establishing
the
foundation

Stage 2.
Capacity
Building

Stage 3.
Maturation
IDCs

Stage 4.
The MostDeveloped
Countries,
with a drug
or Vaccine
Industry

Development of
Manufacturing

Highly profitable market
in both the public and
private sectors, generating
profits to support, in part,
advanced research

Rapidly growing domestic
market of interest to
foreign companies

Growing local market
of increasing interest to
foreign companies; import
substitution

Small domestic market

Global companies

Increasing exports
that account for a
growing share of GNP

Growing companies
learning how to
establish export
markets

Very little, except as
toll manufacturer

Development of Distribution Systems
National
International

Vast acceleration
of funding for R&D;
development of major
research centers;
linking with private
sector

Development of
university and
independent research
centers; capacity
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Very little

Generous support for health research from basic
to applied; large research investment by private
companies, including large pharmaceutical
manufacturers and biotechnology companies

Small-scale, advanced
R&D effort capable of
creating new products
for domestic and export
market

R&D to understand
technology either to
produce on license or
to copy

Very little

Development of R&D Capability
Private Sector
Public Sector

Table 1: The Four Stages in the Development of Biotechnology

Sophisticated system
of IP management
operating according to
the requirements of the
TRIPS Agreement

Advanced IP system
but with certain
limitations such as lack
of enforcement

Interest growing among
foreign inventors; local
inventors starting to file
more patents

Initial development
allowing patents for local
inventors; no interest
from foreign inventors

IP Systems

Sophisticated agency
overseeing regulatory
approvals of drugs and
vaccines; government
oversees clinical trials and
production facilities and
enforces regulations

Advanced capabilities
but not at highest
level because of lack of
enforcement capabilities

Limited services but
without enforcement
capabilities

Very limited

Drug and Vaccine
Regulation
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Brazil, China, and India, have achieved this goal.
Others are in the process. The major unresolved
issue is whether the immediate move to Stage 3
IP systems will provide a pull effect on the other
components of innovation or whether it will lead
to imbalances that will adversely affect access to
pharmaceutical products.
.2 Development of IP systems in Korea

Korea provides a useful case study of a coun
try that developed economically and, for the
most part, independently enhanced IP protec
tion without the requirements of TRIPS. Now
in Stage 3, Korea was able to develop a vaccine
industry very rapidly because it addressed each
of the framework components stage-by-stage. It
passed through the first two stages of the frame
work in roughly ten-year steps during the 1980s
and 1990s. Having joined the World Intellectual
Property Organization (WIPO) in 1979, Korea
acceded to the Paris Convention in 1980 and the
Patent Cooperation Treaty (PCT) in 1984. The
country revised its laws in 1987 to allow product
patents. By the end of the 1980s, Korean laws and
policies largely conformed to the requirements
that TRIPS would eventually impose.
As with the development of biotechnology
R&D capability, Korea completed Stage 1 of its
IP system in about 1990. It acceded to the TRIPS
Agreement in 1995 and further revised its IP
laws in 1997–98 to reach full compliance with
TRIPS. The World Trade Organization (WTO)
conducted a trade policy review of Korea in 2000
and concluded that “protection of [intellectual
property] rights has been strengthened by the signing
of the new treaties, increased international coopera
tion, and stricter enforcement.”5
Unlike the United States, universities and
research institutes in Korea were not major
sources of technology for the country’s industry
during the 1980s and most of the 1990s. Most
companies wishing to obtain new technology
had to look outside the country. In the United
States, on the other hand, the Bayh-Dole legisla
tion had gone into effect in 1980, and universi
ties invested heavily in efforts to manage new IP
that they developed. This included not only the
out-licensing of patents for inventions made by

research scientists, but also the creation of spinouts, in which a professor set up a company for
the specific purpose of developing an invention
into a commercial product. Beginning in the
late 1990s, Korea followed suit, revolutionizing
its laws and regulations concerning IP manage
ment by public institutions. Public universities
were allowed to retain ownership of new IP and
were encouraged to set up technology transfer of
fices. The Technology Transfer Facilitation Law
was passed, mandating the establishment of tech
nology transfer offices and setting guidelines for
sharing licensing income with a specific allotment
for the inventors.
Based in part on the patent data in Table 1,
Korea seems to have completed Stage 2 of its IP
system in about 2000, again in tandem with its
progress in biotechnology R&D capability. Thus,
the country was able to develop its IP system in
tandem with the growth of capability in the five
other components of innovation. It will be in
teresting to see what happens in other develop
ing countries that, under the TRIPS Agreement,
must move immediately to Stage 3 in IP systems.
A broader survey of the development of IP sys
tems in Korea is available in Lee, et al.6 While we
lack sufficient data to make any unequivocal con
clusions, it is worth noting that Korea was able
to move forward by addressing all six innovation
components.

. ConCLuSIon
The framework shows that IP is an important
component of innovation in pharmaceutical de
velopment, but it is only one of six. As the analy
sis of biotechnology shows, the regulatory system
is also a very important component. Above all,
however, the above analysis demonstrates that
developing countries will pass through the four
stages of development as they increase their capa
bilities in biotechnology innovation. Such prog
ress is possible only by attending to each of the six
components of innovation. A key question that
the framework highlights is what impact the im
mediate movement of IP systems to Stage 3 will
have on countries that are still in Stage 1 or 2 of
pharmaceutical innovative capability. Will it hinHANDBOOK OF BEST PRACTICES | 1
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der or help their progress? We lack the data need
ed to assess the impact of this TRIPS requirement
for moving from Stage 1 to Stage 3. But the case
study of Korea shows that it was able to under
take a wide range of initiatives that helped it to
advance in biotechnology. The country addressed
all six components of innovation. In particular,
it made its IP systems compatible with those of
more developed countries and thus compatible
with TRIPS. At least with respect to vaccines,
Korea has experienced considerable success in
biotechnology. We conclude that TRIPS should
not inhibit efforts to enhance biotechnological
capabilities. It may actually promote such efforts.
Conversely, arguments that TRIPS is inimical to
the interests of developing countries seem prema
ture at best. At worst, they are counterproductive
because they may lead countries to seek higher
levels of biotechnology capability ineffectively:
They will not be able to participate in interna
tional trade (other than as importers) because
their products will not be accepted in markets
that observe IP rights. n
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IP Management and Deal Making for Global Health
Outcomes: The New “Return on Imagination” (ROI)
JOHN FRASER, 2006 President of AUTM and Executive Director,
Office of IP Development & Commercialization, Florida State University, U.S.A.

ABSTRACT

The benefits of technology transfer are everywhere ap
parent, and perhaps the best news—as this Handbook’s
compilation of case studies demonstrates—is that these
benefits are already reaching developing countries. Build
ing on the success of the U.S. Bayh-Dole Act, countries
everywhere are seeking to better utilize the research ca
pacities of their universities and public research institu
tions. The growth of such technology transfer initiatives
is inspiring, as are the innovative varieties of partnerships
that have developed to ensure that the world’s poor ben
efit from the global intellectual property system.

1. INTRODuCTION
Technology transfer works. Evidence of its suc
cess is everywhere and even unavoidable. We ben
efit from it when we get into a car and buckle up,
when we sweeten our coffee with saccharin, and
when we search the Internet using Google™. And
we all enjoy better health because of the success
of technology transfer: Allegra®; Taxol®, Trusopt®,
pap smears, hepatitus B vaccine, the carcinoem
bryonic antigen immunoassay for colon cancer,
insulin, the Rheo-Knee (the high-tech replace
ment knee), a nontoxic drug therapy for Chagas
disease, and the nicotine patch are just a few of
the health care innovations based on early inven
tions in university laboratories.
In addition to educating the next generation
and creating new knowledge, universities are con
tributing to saving lives, enhancing the quality of

life, and increasing productivity in the economy.
This innovation explosion began in the United
States with the passage of the Bayh-Dole Act,
which allowed universities and public research in
stitutions to patent inventions based on publicly
funded research and then license the inventions to
the private sector. The goal was to move inventions
from the laboratory onto store shelves by attracting
the private investments needed for commercializa
tion. In the words of one of its authors in the U.S.
Senate, “The Bayh-Dole Act more than fulfilled our
hopes and dreams. Many, many lives are the better for
the success our universities, small businesses and non
profit organizations have had as a result of this law. It
simply works.” Indeed, it is no accident that the rest
of the world is copying the Bayh-Dole model. The
European Union, Japan, China, India, and many
other countries hope to tap their own cutting-edge
university research to develop new products. And,
as the following case studies demonstrate, the ris
ing tide of innovation has the capacity to improve
the quality of life for people in both developed and
developing countries.

2. TECHNOlOGy TRANSFER
By THE NuMBERS
One way to look at how technology transfer is
changing the world is to consider the statistics
(culled from the AUTM Licensing Survey™ which
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regularly surveys U.S. and Canadian members).
In fiscal year 2004, U.S. institutions:1
• spent US$40 billion in research and develop
ment
• issued 4,783 licenses
• managed 27,322 active licenses
• facilitated 462 new spinout companies,
bringing the total since 1980 to 4,543
Each of the 27,322 licenses reflects a one
to-one relationship between a U.S. academic
center and a company focused on a product
development project. While reflecting the fact
that such innovations are increasingly an en
gine of the “knowledge economy,” what is re
ally impressive about these numbers is the myr
iad ways academic technology transfer impacts
people—through new products that save lives,
enhance quality of life, and increase economic
productivity.
Those of us who are involved in technology
transfer have some idea of how far-reaching and
valuable this work is, but even we cannot fully
realize the scope of the impact of technology
transfer. As technology transfer expands inside
developing countries, creative mechanisms are
emerging to further its impact and bring it to
bear on global health outcomes. The Association
of University Technology Managers (AUTM)
has increased its efforts to spotlight some of
the products that have originated at universi
ties around the world. The Better World Proj
ect (BWR) is an ongoing series of publications
and an online database.2 With two publications
showcasing 125 products, BWR includes an
electronic database of stories that document
the outcomes of academic technology transfer
in human terms (new editions are due out in
March each year).

3. THE ASSOCIATION OF uNIVERSITy
TECHNOlOGy MANAGERS
Another conspicuous sign of the growth of tech
nology transfer is the continued growth of AUTM.
Currently, the organization brings together more
than 3,500 technology transfer professionals, in
more than 30 countries, to define, develop, and
20 | HANDBOOK OF BEST PRACTICES

promote leadership excellence in academic tech
nology transfer.
More specifically, among AUTM members:
• 65% are based in academic technology
transfer offices (TTOs)
• 35% work outside of academia, in corpo
rate and service sectors
• 80% reside and work in the United States
• 9% live in Canada
• 11% live in other parts of the world
It is evident that, though relatively small in
number, this varied global network of profession
als is effecting change throughout the world.

4. THE TECHNOlOGy TRANSFER SPINOuT
Rather than asking existing companies to de
velop university-based products, universities and
their faculties are increasingly turning to a new
mechanism—the spinout company. This is a new
company typically created to produce and market
intellectual property developed at a university by
one of its employees. In fiscal year 2004, AUTM
reported 462 new U.S. companies had been
formed in this way. More than 4,443 spinout
companies have been reported since 1980. These
companies seek public and private funding (from
venture capital companies) to grow and put prod
ucts in the marketplace.
.1 Social responsibility: public–private
partnerships for product development

Product development partnerships (PDPs) are a
relatively recent phenomenon. They are similar to
spinout companies in that they are tightly focused
organizations created to develop products for ne
glected diseases in developing countries with the
aim of reducing the disease burden and improv
ing health. Several PDPs have licensed university
innovations to include the technologies in their
product development efforts. PDPs were set up as
virtual product-development companies for such
infectious diseases as tuberculosis, HIV, and malar
ia. The companies are supported by philanthropic
funds, employ corporate expertise, are structured
to reduce costs, and are driven by the urgent
need to make an impact. As the following cases
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studies involving PDPs reveal, they are marked by
creativity, a trait that will be invaluable as these
organizations move through clinical trials, address
manufacturing products, and face the critical issue
of distribution and patient compliance.
.2 Creativity for diseases in the developing
world: Venture Philanthropy

Venture Philanthropy was developed over the same
period as were PDPs. The mission of Venture Phi
lanthropy is to align good science with good busi
ness for developing new and improved drugs. In
several cases, individual serial entrepreneurs whose
families have been stricken by disease have created
disease-specific foundations, raised foundation
philanthropic and individual donations, and ap
plied the entrepreneurial business model approach
to disease research. For example, the Milken Insti
tute3 has been instrumental in educating people
and in highlighting best practices. Its recently
published report4 offers innovative financial solu
tions offered to help solve the serious decline in
funding for early-stage biomedical research.

5. CAuSE FOR ENTHuSIASM: THE BIG
NEWS ABOuT THE BIG PICTuRE
While some voices continue to raise objections
about the fairness of the global IP system, oth
ers are seizing new opportunities provided by the
system to improve the lives of the poor in the
developing world. The evidence is clear: creative
work is raising our expectations and allowing
us to pursue hopes that seemed like unattain
able utopian dreams before technology transfer
released the power of human imagination. The
University has always been the site of such vi
sionary imaginations, and it is fitting that a new
age of potentially greater global equity has been
envisioned in its classrooms and laboratories. In
deed, the age of technology transfer is changing
the perception and importance of these univer
sity-connected activities. Measures of the success
of academic technology transfer have broadened
beyond economics to include numbers of lives
saved, reductions in the disease burden, im
provements in the quality of life, and increases
in productivity.

Our understanding of what we do as technol
ogy transfer officers is changing. Traditionally, the
mission of the TTO was to bring university-gener
ated intellectual property into public use as rapidly
as possible. The TTO did this through corporate
partnerships that protected academic freedoms
and, in many cases, generated a financial return to
the university, inventors, and their departments.
TTOs still serve these functions. But over the
years, academic technology transfer has evolved to
serve a broader purpose: to enhance the reputation
of academic institutions and to help them achieve
their missions of education, research and commu
nity outreach by facilitating research relationships
with the private sector for the benefit of all.
Anyone who reads subsequent pages of this
Handbook, case studies that document the success
of technology transfer, will feel the same enthusi
asm and hope for the future that technology trans
fer officers feel. Today, problems can be tackled
that yesterday appeared intractable. And let me
say to my fellow technology transfer officers: we
should hold our heads high when we talk about
our work and our mission. When someone asks
you “What do you do?” be ready to tell them, “As
a technology transfer professional, I help make the
world a better place.” If they ask what financial re
turn on investment (ROI) you hope to make, tell
them, “Oh, ROI—you mean ‘Return on Imagi
nation.’ Let me show you what is possible.”
Then give them a copy of this Handbook, and
point to the successes in these case studies! ■
JOHN FRASER, 2006 President of AUTM and Executive

Director, Office of IP Development & Commercialization,
Florida State University, Suite 109, Westcott Building, Co
peland Avenue, Tallahassee, FL, 32306, U.S.A. jfraser@
research.fsu.edu
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CHAPTER 1.4

Ensuring Developing-Country Access to
New Inventions: The Role of Patents and the Power
of Public Sector Research Institutions
liTa nelsen, Director, M.I.T. Technology Licensing Office, U.S.A.
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;

Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

If universities adopt sound licensing practices, the univer
sities will not only help stimulate investment in research
on diseases that primarily afflict the poor in developing
countries, but also ensure that the products of the re
search are affordable and widely available in those coun
tries. Ensuring global access is one of the central goals of
intellectual property management. But universities con
front two main obstacles in their efforts to achieve the
goal. First, university administrators, technology transfer
officers, and business people are too often unaware of
both the need to ensure access to new health technologies
in developing countries and the manner in which patent
ing and licensing practices can be an integral component
of global access strategies. Second, there is only a short
history of experience in incorporating such concerns in
negotiating licenses, so no best practices have yet evolved.
This chapter offers a few possible approaches to ensuring
broad access to university inventions while preserving in
centives to development, including patenting inventions
in a select list of developing countries. The chapter con
cludes by urging all of the players in this field to build
upon their own experience and to take creative risks in
the pursuit of new solutions.

1. InTRoduCTIon
From a humanitarian point of view, a patent sys
tem presents a paradox. How can a system de
signed to restrict access to technologies, including
medical technologies, also be used to maximize
availability of needed medicines and vaccines at
affordable prices? One way of looking at that

paradox is to consider an extreme case: if all the
medicines and vaccines needed for diseases in
developing countries existed today, the patent
system might be unnecessary. The absence of
patents, some experts suggest, would presumably
allow for maximum competition, driving prices
down and thereby maximizing affordability and
availability.
But for many of the diseases of developing
countries, few drugs or preventatives exist; in
some cases none exists. Patent protection can
provide the necessary incentive to encourage in
dustry to use its skills and resources to discover,
develop, test, ensure quality control of, manufac
ture, and distribute new drugs and vaccines. Few
companies—if any—would embark on the long
trail of new-drug discovery and development,
if they could not be protected by patents from
competitors.
Thus, patents are neither inherently bad
nor inherently good with regard to this purpose,
but—like all tools—must be used wisely.
Research institutions, such as universities,
medical schools, and other nonprofit institutions
engaged in biological and medical research (col
lectively referred to as “universities” in this chap
ter), have a special role to play regarding the use
of patents for developing and distributing drugs
and vaccines for developing countries. These

Nelsen L and A Krattiger. 2007. Ensuring Developing-Country Access to New Inventions: The Role of Patents and the Power
of Public Sector Research Institutions. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available
online at www.ipHandbook.org.
© 2007. L Nelsen and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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institutions are often the source of the core tech
nology and, occasionally, lead compounds that
could be developed into drugs and vaccines.
Despite the avowed public purpose of their
technology transfer activities, universities have
recently come under criticism for using patents
in a way that could inhibit (and in very few
cases, has inhibited), the distribution of medi
cines at accessible costs to developing countries.
Critics argue that by granting exclusive licenses
to developed-country pharmaceutical compa
nies, the universities are allowing the pharma
ceutical companies, sometimes, to prevent local
companies from producing and selling drugs,
potentially at affordable prices—thus effectively
denying life-saving drugs to poor people in these
countries.
Although nonprofit research institutions
are not often involved in these issues, (in part
because the fraction of medically related patents
owned by these institutions is small), their vis
ibility, coupled with the universities’ public re
sponsibility, is causing university technology
transfer offices to modify their licensing practices
for patents relevant to healthcare in developing
countries.
Some thinkers have suggested that the best
thing universities can do to ensure access is to
cease patenting medically related inventions and
place everything in the public domain. But doing
so would be both unrealistic and counterproduc
tive. Patents have been shown to be a powerful
tool for directing investment into the develop
ment of technologies that would otherwise lie
fallow. University inventions are usually at such
an early stage (embryonic is a term commonly
used to describe them) that investment in de
velopment involves substantial risk. Neither the
technical practicality nor the market acceptabil
ity of the invention is proven. And many more
inventions fail to reach than do reach the mar
ket—particularly in the medical field. Patents
are an essential way for companies to manage the
risk, and the use of patents is even more impor
tant for medicines and vaccines, where the costs
of development and particularly of clinical tri
als require much larger investments and much
greater risk.
2 | HANDBOOK OF BEST PRACTICES

Universities and research institutions hope
for some financial return from their patents, but
contrary to widely held beliefs, this return is sel
dom large. On average, U.S. universities receive
licensing royalties equivalent to only 2%–4% of
their research budgets. Most universities believe
that the primary purpose of their technology
transfer activities is either (1) to induce invest
ment in developing technologies to bring prod
ucts to public use, (2) to aid local economic de
velopment through spinout companies based on
licenses to their technology, or (3) both.
Given their commitment to encouraging the
development of new technologies via patenting,
universities need sophisticated policies and pro
cedures in licensing to ensure that the poor will
have access to medicines based on the universi
ties’ technologies. Potentially, the access policies
developed by universities may—if the policies
are practical, properly implemented, and publi
cized—become “norms” that will be more widely
adopted by the private sector.
Awareness about these issues is new; tech
niques for addressing the problem are only just
emerging, and there is no consensus yet on best
practices. The remainder of this chapter addresses
some potential solutions.

2. RAISInG AWAREnESS
The first task in encouraging effective licens
ing policies and practices is to raise awareness of
the issues (discussed in section 1 above) in the
research institution community. Technology
transfer officers need to become aware of devel
oping country health-care needs and the univer
sities’ responsibilities with respect to those needs.
Given the general commitment of universities to
transfer technology to promote public welfare,
this awareness alone will go a long way toward
preventing the inadvertent granting of licenses
that lack consideration for the health needs of
developing countries. Senior administrators and
researchers also need to become more aware of
the issues involved so that these professionals
will acknowledge the broader value of licensing
terms that may be somewhat less profitable from
an economic standpoint, but that may address
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urgent medical problems in poor parts of the
world. Finally, consistent university policies on
these issues will raise awareness inside the com
panies universities work with, making such com
panies more readily accepting of licensing terms
that address these issues.
Awareness is already growing. In the United
States, the Association of University Technology
Managers (AUTM) began to publicize this issue
to its members in 2003. This organization is hav
ing a substantial impact on the understanding of
technology transfer professionals with respect to
these concerns: more than 90% of technology
transfer professionals from nonprofit research
institutions in the United States and Canada
belong to AUTM, along with several hundred
professionals from other countries. An AUTM
Special Interest Group, formed in 2003, has
evolved into the Technology Managers for Global
Health (TMGH),1 which is partially supported
by MIHR (the Centre for the Management of IP
in Health Research and Development). TMGH’s
purpose is to raise awareness about global health
issues and, with AUTM, to compile a collection
of best-practice policies and licensing terms that
can be distributed to AUTM members and oth
ers. The interest shown on the part of the greater
AUTM membership is especially encourag
ing. At its 2006 annual meeting, the opening
plenary session of AUTM was on “Innovative
Policies and Practices in Technology Transfer: A
Global Health Perspective.” The meeting agenda
included a program of education with several
workshops on global-health technology transfer
issues.
Through its guidelines on the patenting and
licensing of research tools, the National Institutes
of Health (NIH) have helped alert universities
to the need for thoughtful policies in exclusive
licensing.2 The NIH wants to make certain that
researchers in the health arena have access to re
search materials without undue hindrance by
patents, and so NIH has issued guidelines for
patenting and licensing research tools. The two
objectives—fostering access to medicines and
making research materials widely available—of
ten merge in the minds of technology transfer
professionals, making them more aware of the

need to exercise care when licensing university
technology.

. SuGGESTEd AppRoACHES
.1 Considering where to file patents

When a research institution patents and licenses
out a technology, usually the institution can—if
it insists—continue to own the patent after li
censing. (This is the practice in most U.S. univer
sities.) The institution can then control, by con
tract with the licensee, which countries the patent
will be filed in. Determining a strategy of where
to file, however, is not easy.
.1.1

Prohibition-of-filing strategy

Where a drug or vaccine in question has a large
developed-country market, one possible strategy
is to prohibit the patent from being filed in de
veloping countries. Most of the licensee’s profits
would presumably come from markets in de
veloped countries—with or without developing
country patents. The loss of potential revenue
from developing countries (which in any case
could not afford to purchase large quantities of
the medicines at developed country prices) would
be negligible, and the licensee mostly likely
would not be substantially disadvantaged by this
approach. The absence of patents in the develop
ing world, however, could allow “generic” com
petitors to produce the drugs in those countries
at low prices.
This strategy will be effective only if:
• The developed country market for the
medicine is large. If the developed country
market is only a specialty “travelers’ market”
and the primary demand for the medicine
is in developing countries (malaria vaccines
are a good example), this strategy may not
be acceptable to the licensee company.
• The drug or vaccine is relatively easy to
manufacture and does not rely on special
know-how possessed only by the licensee
company (including valuable regulator
dossiers). This is more likely with simple
chemical drugs than with biological drugs
(including vaccines), whose techniques for
HANDBOOK OF BEST PRACTICES | 2

NElSEN & KRATTIGER

production and purification may be beyond
the capabilities of most developing country
manufactures. Also, if the drug is easy to
manufacture, then safeguards must be in
place to avoid parallel imports.3
• The research institution owns the core pat
ent for the drug or vaccine, while other “sec
ondary” patents, owned by the licensee, are
not critical to developing and manufactur
ing the medicine. If secondary patents are
critical and the licensee chooses to file them
in developing countries, then attempts by
the university to provide its own technol
ogy free of charge may be moot. The only
benefit would be to shelter the university
from criticism. Theoretically, it is also pos
sible for the university to demand in its
licensing agreement that the licensee not
file such secondary patents in developing
countries, but it is doubtful that the uni
versity would have the negotiating power
to make that demand—particularly if the
university’s invention, at the time it is li
censed, is still far from a product.
.1.2

When patent filing in developing
countries may be beneficial for access

When the demand for a drug or vaccine is pri
marily (or exclusively) in developing countries
and there are no alternative products, the prima
ry problem is to develop a sufficiently profitable
market to provide an incentive for the private sec
tor to invest in R&D. The only other alternative
is for governments or nongovernmental organiza
tions (NGOs) to fund all of the research, devel
opment, clinical testing costs, and manufacture.
But having a public sector entity develop a com
mercially viable product is usually impossible.
Patents may provide an incentive to the pri
vate sector to invest by aggregating the develop
ing world market into a single, larger market. To
be successful, this strategy relies on:
• sufficient available resources for buying the
product once it is developed (Governments
and NGOs may have to step in to supply
money to the public sector of low-income
developing countries so that the product
2 | HANDBOOK OF BEST PRACTICES

can be purchased—particularly if there is
no private travelers’ market that can sup
port higher prices.)
• adequate systems for quality control and
regulatory approval to ensure consistent,
high-quality products in the absence of de
veloped country regulatory controls
• a belief that the legal systems in the nonmanufacturing countries will be strong and
consistent enough to allow the supplier to
enforce its patent rights and to maintain its
monopoly for a reasonable period of time
• a willingness of governments and NGOs to
accept prices that are high enough for sup
pliers to recoup research and development
costs
.1.

Licensing strategies

Research institutions have the most control over
optimizing the use of their inventions at the time
of licensing. It is before the invention is licensed
that the university can best ensure that the in
vention will be used to advance—or at least not
hinder—solutions to developing country health
needs.
The first decision is whether to grant (1) a
fully exclusive license, (2) an exclusive license
limited by product type, (3) an exclusive license
limited by geographical territory, or (4) a nonex
clusive license.4 Considering two extreme cases is
illuminating:
• Where the invention is a tool for discovery
that is useful to many without significant
development, then nonexclusive licensing
is probably most appropriate for developed
country use. Patents in developing coun
tries will essentially be unnecessary. (Many
universities will also require that the patents
not be asserted against nonprofit research
institutions in any country, thus allowing
free access by such institutions.)
• Where the patent covers the core invention
of a potential new drug or a vaccine that re
quire many years and tens, if not hundreds,
of million dollars of investment, an exclu
sive license may be the best strategy. In such
a case, patenting in selected developing
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countries may be an important element in
a strategy to ensure global access.
Exclusive licensing places a large responsibil
ity on the university to negotiate license clauses
that ensure both development of the product
and rapid distribution to developing countries
at affordable prices. Not every member of the
university technology transfer community is yet
conscious of this requirement. Best practices have
not yet been established for such negotiations,
and so strategies need to be based on evolving ex
perience. A few situations, we know in retrospect,
were clearly mistakes—experiences we can now
learn from. Some better, but still experimental
strategies include:
• development of milestones. As a condi
tion for a company maintaining a license,
the university requires that the company
devote at least a certain reasonable mini
mum of resources (money or staff time) to
developing the technology. The university
may also require certain success milestones
(for example, first clinical trials by a certain
date, product on the market by a certain
later date, and so forth).5 However, success
milestones are particularly difficult to nego
tiate for very early-stage technology.
• requirement of delivery of product for
developing countries. The university may
require the company to begin testing and
distributing the product for developing
countries simultaneously, or nearly simulta
neously, with its introduction to developed
countries. This is particularly important
for vaccines, for which the trickle-down
theory6 has sometimes deprived developing
countries of suitable product for decades.
• control over pricing in developing coun
tries. This is usually set at a small percentage
over cost (so-called cost-plus pricing). This
may be particularly relevant where there is a
large—and presumably profitable—market
as in the developed world.
• sublicensing. If the company cannot deliver
the product or deliver it at acceptable prices,
then the university may require the compa
ny to sublicense the patent to others. When

manufacturing the product is simple, this
strategy may work, but when the product
requires substantial company know-how
and background technology, the “victory”
in forcing a sublicense of the patent alone
may be a hollow one. This is particularly
true for complex biological drugs and many
vaccines. The university should therefore
negotiate clauses that make sublicensing as
attractive as possible, so that the company
will cooperate fully in the venture. A paper
by Friedman and colleagues7 describes such
a strategy by the Pharmacia Company. The
company enthusiastically sublicenses the
patent along with its know-how and exerts
some control over the quality of the prod
uct. The benefits to the company are pri
marily to its reputation, with a justifiable
pride in the good that is done, but allow
ing sublicensing also protects the company
from the criticism of not meeting the needs
of the poor in developing countries.

. ConCLuSIon
University technology transfer professionals are
becoming more aware of their obligations to en
sure that the poor have access to medicines based
on university technologies. To a large extent,
universities are embracing this obligation in the
hope that well-crafted patent and licensing poli
cies can be powerful tools to provide such access.
But there are no clear-cut mechanisms, nor many
precedents to guide professionals in this endeavor.
This chapter presented just a few of the strategies
that research institutions can pursue in their quest
to provide developing countries with access to
new medicines. Each of these strategies has been
tried, but they are all relatively new and will need
further refinements. This can only be achieved,
however, in actual negotiations between research
institutions and companies. New approaches will
also certainly develop in the future. None of these
efforts will be effective unless both research insti
tutions and companies first become more aware
of their obligations to the poor in developing
countries. Awareness is only the first step, how
ever, for none of these strategies will thrive unless
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they meet the needs of both the research institu
tions and the companies that are developing new
technologies to improve human health. Building
upon the knowledge and successes we already
possess, we must not only strive for novel, cre
ative solutions but also take reasonable risks in
the pursuit of these much-needed solutions. n
liTa nelsen, Director, M.I.T. Technology Licensing Office,
Massachusetts Institute of Technology, Five Cambridge
Center, Kendall Square, Room NE25-230, Cambridge,
MA, 02142-1493, U.S.A. lita@mit.edu
anaTole KRaTTigeR, Research Professor, the Biodesign

Institute at Arizona State University; Chair, bioDevel
opments-International Institute, and Adjunct Professor,
Cornell University. PO Box 26, Interlaken, NY, 14847,
U.S.A. afk3@cornell.edu
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Genomics, Ethics, and Intellectual Property
gaRy e. MaRchanT, Professor, Sandra Day O’Connor College of Law, Arizona State University, U.S.A.

ABSTRACT

Ethical concerns and controversies about patenting are
playing an increasingly prominent role in the develop
ment and applications of the biosciences. Despite the
growing importance of ethical issues, there is currently no
consensus or clarity on the ethical principles that should
guide patenting of human, animal, and plant genes and
cells. The three major areas of contention are: (1) whether
some or all patents on genes and cells are unethical per
se, based on concerns such as commodification, dignity,
and similar concepts; (2) how tissue samples are col
lected, particularly in reference to the principles of prior
informed consent and benefit sharing; and (3) how pat
ents are used to restrict access to medical and agricultural
use of biotechnology innovations. Given the lack of any
agreed guiding principles for navigating these issues, pol
icy-makers, decision-makers, scientists, and users of bio
technology have no choice but to address these contested
ethical concerns using a case-by-case approach.

1. InTRoduCTIon
Over the past three decades, much ink has been
spilt about the ethics of patenting in the life sci
ences. Unfortunately, these dialogues and debates
have produced very little clarity and consensus
on the ethical principles and practices that should
apply to patenting of biological materials. Policy
makers, decision-makers, companies, scientists,
and product end users therefore must navigate
through a complex web of unsettled legal prin
ciples, moral arguments, social norms, and po
litical influences that collectively represent the
ethical landscape for patents in this field. Failure

to adequately consider and conform to these in
fluences can result in an eruption of controversy,
disruption, and opposition. At the same time, ex
cessive caution and hewing to the most extreme
views and positions has the potential to impede
the scientific, economic, and developmental ben
efits of life-science research and innovation.
This chapter does not attempt to fully expli
cate or resolve the many ethical issues relating to
life-science patents. Rather, its more modest goal
is to briefly describe the various ethical contro
versies and landmines related to the patenting of
genes and other biological materials, and to dis
cuss how such issues are being resolved or man
aged in practice. The major controversies can be
grouped into the following three categories: (1)
whether some or all biotechnology patents are
unethical per se; (2) the manner in which the
patented invention was obtained or discovered;
and (3) how the patent is used.

2. ETHICS of pATEnTS
A threshold question is whether biological patents
are per se unethical. Some individuals, groups,
cultures, and nations adhere to a position that
any patenting of human, animal, or plant genes
and tissues is unethical. Various ethical argu
ments have been advanced against any patenting
of genetic or related biomedical innovations. One

Marchant GE. 2007. Genomics, Ethics, and Intellectual Property. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org.
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of the most common arguments is that patent
ing commodifies life-forms. A related critique
is that living materials are naturally occurring,
and thus isolation and description of “nature’s
handiwork” should not qualify as patentable
subject matter.1 Other ethical concerns include
fears that patenting will facilitate and accelerate
applications and commercialization of biotech
nology that are themselves viewed to be unethi
cal by some, that patenting will lead to greater
animal suffering, and that patenting undermines
the dignity of humans and other species by mak
ing their genes and cells subject to ownership by
others.2
A prominent expression of this deontologi
cal opposition to biotechnology patents was a
statement, issued by almost 200 religious lead
ers in 1995 opposing any patents of human or
genetically engineered animal tissues, that as
serted that “[w]e believe that humans and ani
mals are creations of God, not humans, and as such
should not be patented as human interventions.”3
Another much-publicized denunciation of gene
patenting was the 2000 statement of the French
Justice Minister, Elisabeth Guigou, that human
gene patents are contrary to the ethical norms of
France. The Council for Responsible Genetics
issued a Genetic Bill of Rights, which contends
that “all people have the right to a world in which
living organisms cannot be patented, including
human beings, animals, plants, and all of their
parts.”4
While some organizations and individuals
denounce patenting of living materials on some
or all of the grounds identified above, others de
fend the patentability of genes and other living
materials on ethical grounds.5, 6, 7 For example,
the United Nations Educational, Scientific, and
Cultural Organization (UNESCO) International
Bioethics Committee concluded that the “law
on intellectual property serves useful purposes, has a
foundation in ethical principles and universal hu
man rights, and often contributes to the benefit of
humanity.”8 Moreover, religious leaders are not
unified in their opposition to patents for genes
and other living tissues, with many prominent
religious organizations and individuals expressly
or implicitly supporting such patents.9
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Others argue that while there may indeed be
important ethical and policy concerns with some
biotechnological inventions, the patent office is
not the appropriate forum to address those con
cerns, if only because patent examiners have no
specialized training in ethics and policy. Yet an
other argument is that eliminating patent protec
tions from biotechnology inventions would make
those innovations less rather than more ethical,
in part by making new technologies less trans
parent as companies rely more on trade secrets in
place of patents and their requirement for public
disclosure.10
A blanket prohibition on any patents of
genes or other biological materials is inconsistent
with the Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS), which
requires countries to provide IP protection for
most biotechnology products. Thus, any exist
ing and prospective nation-state member of the
World Trade Organization (WTO) is unlikely to
try to adopt or enforce a generic prohibition on
biological patents. While advocates against any
patenting may advance the political and ethical
arguments summarized above against all patent
ing, such arguments will have little or no legal
force and relevance.
More relevant will often be arguments that
specific patents or types of patents are unethical.
For example, the TRIPS agreement allows WTO
countries to exclude bioengineered animals from
patentability. Thus, each nation must individu
ally decide whether it will extend its patent laws
to animals, and these debates generally focus on
ethical arguments about animal rights and commodification of life.
More generally, the TRIPS agreement specif
ically provides that nations may elect to include
a provision in their patent laws that deny patents
for specific innovations and inventions that are
not ethical. For example, the European Union has
an ordre public, or public morality clause that de
nies patent protections to inventions that are con
trary to public morality. Other nations, includ
ing the United States, have declined to include
such a morality clause, and the U.S. Patent and
Trademark Office claims that it does not have the
authority to deny otherwise valid patents based
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on the morality or ethical characteristics of the
underlying invention.
The U.S. courts have also disavowed any
role in reviewing the ethical or policy aspects of
patents. In approving the first patent of a living
organism in the United States, the U.S. Supreme
Court stated:
[W]e are without competence to entertain these
arguments… The choice we are urged to make is a
matter of high policy for resolution within the leg
islative process after the kind of investigation, ex
amination, and study that legislative bodies can
provide and courts cannot. That process involves the
balancing of competing values and interests, which
in our democratic system is the business of elected
representatives. Whatever their validity, the conten
tions now pressed on us should be addressed to the
political branches of the Government, the Congress
and the Executive, and not to the courts.11
In jurisdictions that recognize a morality ex
ception to patents, controversial patents are sub
ject to challenge under such clauses, both during
initial application, and in subsequent post-is
suance challenges. For example, challenges to
European patents for the BRCA1/2 breast cancer
genes and the oncogene mouse have been chal
lenged under the ordre public clause several years
after the original patents issued, which resulted
in the patents being narrowed but not rescind
ed.12 The European Union’s ordre public clause
also prohibits patents related to human cloning,
modifying human germ lines, using human em
bryos for commercial purposes, and genetically
engineering animals in ways that cause suffering
without a substantial medical benefit to humans.
In other cases, challenges under the ordre pub
lic clause to biotechnology patents have failed.13
One criticism of the ordre public provision is that
the European Patent Office has failed to articulate
a clear definition and criteria for the provision’s
application, resulting in case-by-case analyses that
do not always use consistent approaches.14
No issue has generated more outrage and
concern than attempts to patent products and
processes based on traditional knowledge. The
1992 Convention on Biological Diversity encour
ages nations to respect and protect traditional

knowledge. Any attempts to patent products
based on traditional knowledge is likely to gen
erate considerable controversy, as demonstrated
by the disputes that erupted over patents issued
for basmati rice, neem, and tumeric, all of which
were subsequently abandoned or revoked in re
sponse to a chorus of objections.15 The bottom
line is that any attempt to patent products that
are derived from traditional knowledge are likely
to generate considerable opposition and contro
versy, which may only be avoided if the biological
material is collected consistent with the principles
of prior informed consent and benefit-sharing
discussed in the next section.

. oBTAInInG BIoLoGICAL SAMpLES
Another area of ethical controversy over some bio
technology patents relates to the manner in which
the biological samples used for the patentable dis
covery were collected. In most human genetic re
search, the prevailing scientific norm is that donors
of tissue for research retain no property or other
rights in their cells or genes.16 This means tissue
donors receive no financial compensation for their
samples (other than reimbursement of their out-of
pocket expenses), are given no share of any profits
or revenues that may result from any commercial
products developed using the donated tissues, and
have no patent rights to any patentable discoveries
that may result from research using their tissues.
The legal and property rights of local populations
and national governments with regard to animal
and plant specimens collected within their terri
tory and used for a patented discovery are uncer
tain and often disputed. At the international level,
some of the most inflamed controversies have in
volved claims of biopiracy in which scientists from
an industrialized nation seek patents based on
human, animal, or plant materials collected from
other, less-developed nations. Two specific issues
that have been at the forefront of these ethical de
bates about the collection of biological samples are
prior consent and benefit sharing.
.1 Prior consent

Prior consent refers to the procurement of ad
vance approval from the relevant entities before
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taking biological samples. One issue relating to
prior consent is who must provide such consent.
The consent may need to be given by the specific
individuals from whom the tissue is taken (in the
case of human samples), from the local commu
nity, tribe, or local government in the region from
which the samples would be taken, and from the
national governmental authorities. Controversies
have arisen when only some but not all of these
three levels (individual, local, and national) of de
cision-makers have provided prior consent. For
example, the U.S. National Institutes of Health
(NIH) sought a patent in 1991 for a cell line de
rived from a member of the Hagahai, an isolated
tribe in Papua New Guinea, that had a high fre
quency of a gene related to leukemia. The focus
of the ensuing international controversy over this
patent application, which was subsequently aban
doned in response to the pressure, was whether
the NIH was required to obtain informed con
sent separately from the individual donor, the
Hagahai tribe, and the Papua New Guinea gov
ernment.17, 18
Another example of an international contro
versy over the alleged lack of appropriate prior
informed consent relates to the Guaymi Indians,
the largest indigenous tribe in Panama.19, 20
Thousands of Guaymi tribal members are in
fected with an HIV-like virus known as the
Human T-Lymphotropic Virus Type 2 (HTVL
II). The U.S. Centers for Disease Control and
Prevention (CDC) undertook a research project
to investigate infection in the early 1990s, and
subsequently the U.S. Department of Commerce
applied for a patent claiming a cell line isolated
from blood taken from a 26-year old Guaymi
woman being treated for leukemia in Panama.
The United States claimed that the woman gave
oral consent in the hospital (although the woman
was reportedly illiterate, unschooled, and quite
sick, which raises questions about the effective
ness of the informed consent). However, the fo
cus of the ensuing controversy was that the tribe
was never informed of, nor asked to consent to,
the removal of the blood sample to the United
States, the establishment of cell lines using those
samples, or the patent application. The presi
dent of the Guaymi General Congress strongly
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criticized the patent application as “immoral, con
trary to the Guaymi view of nature, and our place
in it.” The United States subsequently dropped
the patent application in response to the contro
versy. The lesson from these examples is that any
patent application based on tissues from identifi
able populations, such as indigenous tribes, may
be subject to significant controversy if prior in
formed consent is not obtained from the person
or persons providing the tissue samples as well as
the tribal authorities and, perhaps also, the na
tional government.
The content and form of the information
provided in the prior consent has also been con
troversial. In particular, must the consent process
include disclosure that the collected material may
be used to secure a patent? According to one critic
of current consent procedures, “over the past thirty
years, blood, tissue, and other bodily fluid samples
have been collected from individuals and used in ge
netic research without the person’s consent or knowl
edge. If a lucrative gene was found, it was patented.
Once a gene is identified and patented, its availabil
ity is often severely restricted, even to the people who
provided tissue samples and funding for the genetic
research.”21
The European Union’s Group of Advisers on
the Ethical Implications of Biotechnology has en
dorsed the need for prior consent before using a
donor’s tissue to develop a patentable invention:
The ethical principle of informed and free con
sent of the person from whom retrievals are per
formed must be respected. This principle includes
that the information of this person is complete and
specific, in particular on the potential patent appli
cation on the invention which could be made from
the use of this element. An invention based on the
use of elements of human origin, having been re
trieved without respecting the principle of consent,
will not fulfil the ethical requirements.22
In its directive on patenting of biotechnology
inventions, the European Union carried forward
this recommendation in Recital 26, which pro
vides “Whereas if an invention is based on biologi
cal material of human origin or if it uses such mate
rial, where a patent application is filed, the person
from whose body the material is taken must have
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had an opportunity of expressing free and informed
consent thereto, in accordance with national law”23
However, because this statement is in the recitals
of the directive, it is not legally binding but only
hortatory. There are also practical problems with
a requirement for prior consent in this context—
the original researchers, or subsequent research
ers who may have access to the tissue, may not
have the intent or knowledge at the time of tissue
collection that they will be pursuing a patent ap
plication based on that tissue. In addition, except
for rare cases (including in Moore v. The Regents
of the University of California discussed below),
most patentable inventions resulting from hu
man tissue are based on findings using large num
bers of samples, complicating and attenuating the
requirement for prior consent on future patents
from each individual tissue donor.
The most famous—some would say infa
mous—court case on this issue is Moore v. The
Regents of the University of California decided by
the California Supreme Court in 1991.24 Moore
had his spleen removed by doctors at the UCLA
Medical Center as part of his treatment for can
cer, but unbeknownst to him, his doctors used
the removed tissue to create a potentially lucrative
patented cell line. The doctors did not disclose
their intentions to Moore that they would pat
ent his cells without sharing any of the proceeds,
nor did they request his permission to do so.
Even more egregiously, they affirmatively misled
Moore into returning to the hospital on several
subsequent occasions to collect additional tissue.
The California Supreme Court rejected Moore’s
argument that he continued to own his cells after
they were removed from his body, but the court
refused to dismiss Moore’s claim that his doctors
failed to provide adequate informed consent by
not disclosing their potential financial interest in
Moore’s cells.
A more recent U.S. case raised similar issues,
but this time in the research context rather than
the clinical setting. Parents of children with the
inherited Canavan disease convinced a medi
cal researcher to attempt to isolate the gene re
sponsible for the disease, and provided tissue
samples from affected children and their families
and helped to raise funds for the research.25 The

researcher successfully identified the gene, but,
without informing the parents who had donated
tissue samples to the research, the researcher’s em
ployer (Miami Children’s Hospital) patented the
gene, and the genetic test based on the gene, and
began charging a modest licensing fee to clinics
that had starting using the newly discovered ge
netic test. The families and various support orga
nizations were outraged by these actions and sued
the hospital alleging various legal claims includ
ing conversion, failure to provide informed con
sent, unjust enrichment, and breach of fiduciary
duty. The federal district court dismissed most of
the families’ claims, but concluded that the un
just-enrichment claim was sufficiently viable to
go forward, and the case subsequently settled.26
This case, like the Moore case before it, demon
strates that a physician or researcher may have a
legal duty to inform tissue donors of their intent
to pursue patents using the donor’s tissue, but
even if such disclosure is not legally mandated,
the failure to obtain prior informed consent from
tissue donors runs the risk of provoking ethical
controversies that can result in bad publicity and
expensive, time-consuming litigation.
The ethical duty of informed consent is less
established in the context of plant and animal
samples compared to human tissue collection,
but there has been considerable momentum to
ward recognizing such a duty in recent years.
The 1992 Convention on Biological Diversity re
quires informed consent from the appropriate na
tional authorities as a condition of access to plant
or animal genetic resources. Several nations have
adopted their own laws requiring prior informed
consent to the collection of plant and animal re
sources.27 Several recent international studies and
proposals have been published on this subject in
recent years, but the legal and ethical status of
informed consent requirements for nonhuman
biological materials continues to be hotly debated
and uncertain.
.2 Benefit Sharing

A second major issue is whether entities that col
lect tissue samples that are used to patent a prod
uct are ethically obliged to share the economic
benefits of their discoveries with the individuals
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or population from whom the samples were tak
en. The Human Genome Organization (HUGO)
adopted a Statement on Benefit Sharing with re
gard to human genetic research in 2000, which
states: “in the interest of justice, the last decade
has witnessed an emerging international consensus
that groups participating in research should, at a
minimum, receive some benefit.”28 The statement
suggests that profit-making research institutions
“should dedicate 1-3% of their after-tax net prof
its to healthcare infrastructure and/or humanitar
ian efforts to benefit communities donating genetic
samples.” For nonprofit institutions, “immediate
health benefits as determined by community needs
could be provided.” Similarly, Article 19 of the
International Declaration on Human Genetic
Data provides that: “Benefits resulting from the use
of human genetic data, human proteomic data or
biological samples collected for medical and scientific
research should be shared with society as a whole and
the international community.”29
An important precedent for benefit sharing
in human genetic research is the ill-fated Human
Genome Diversity Project (HGDP), which sought
to collect genetic samples from as many human
populations as possible on the planet. Although
the project was never implemented, largely be
cause of ethical critiques and controversies about
the project,30 it did adopt precedent-setting ethi
cal guidelines that recognized an ethical duty for
benefit sharing. 31 The guidelines specify that “a
fair share of the financial rewards shall return to the
sampled populations” when the research results in
commercial products. The suggested mechanisms
for returning such payments to the donors in
clude (1) paying “a set percentage royalty … for the
benefit of the sampled populations” or (2) negotiat
ing “a reasonable financial payment with a trustee
for the sampled populations, with the proceeds for
the population’s benefit.”
With regard to food and agricultural prod
ucts, the 1992 Convention on Biological Diversity
clearly recognized that sovereign states have the
authority to regulate the collection and use of ge
netic resources within their territory by provid
ing in Article 15 that “the authority to determine
access to genetic resources rests with the national
government and is subject to national legislation.”32
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The Convention also recognizes in Article 1 the
principle of “fair and equitable sharing of the ben
efits” of biodiversity. The Treaty on Plant Genetic
Resources for Food and Agriculture, negotiated
under the Food and Agriculture Organization
(FAO) of the United Nations and concluded in
2001, goes further and establishes the principles
of “facilitated access” and “sharing of benefits” for
the commercial or scientific uses of the nation’s
resources by out-of-country entities.33 Of course,
these treaty obligations are only mandatory for
nations that have ratified the treaty, and many
prominent nations including the United States
and some European nations have yet to ratify the
2001 treaty. In addition, many individual nations
have adopted their own laws restricting access
to biological materials within their borders that
usually require some form of benefit sharing and
prior consent. By one recent count, more than 40
nations have enacted such laws since 1993.34
Despite the endorsement of benefit sharing
in the various statements and international agree
ments described above, benefit sharing remains a
controversial and uncertain principle. One prac
tical problem is that many scientific researchers
are not provided funds in their research grants for
providing economic compensation to individu
als or populations providing the tissue samples.
Another problem is that there is uncertainty in
many cases in identifying who should decide how
the benefits are allocated within populations.
When the samples are taken from a discrete com
munity or tribe with a recognized governance
structure, the allocation of the benefits is usually
not problematic in that the existing local govern
ment can take responsibility for using and dis
tributing the benefits, but when the population
is more dispersed or more difficult to clearly de
fine, the distribution of benefits becomes more
difficult. Finally, there is an ethical objection that
paying significant financial benefits to individual
tissue donors may unduly induce some individu
als to participate in research.
In sum, while some legal rules and precedents
address the issues of prior consent and benefit
sharing in certain limited contexts, these issues
are primarily ethical issues at the present time,
in the absence of applicable laws. At their core,
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the largely unresolved ethical debates on these
issues represent a concern with the fairness and
distributional aspects of biotechnology research
and commercialization, and are important factors
that should be considered in the context of any
research project or program involving the collec
tion of biological samples from plants, animals,
or human populations.

. uSE of pATEnTS
The final major area of controversy associated with
patents of biological materials is the use (or mis
use) of such patents after they have issued. Perhaps
the most common concern is that the availability
of the patented invention is unduly restricted or
costly due to high licensing fees, exclusive licens
ing, or similar access-limiting strategies by the
patent owner.35 Such practices may inhibit access
to the benefits associated with the patented tech
nology by entities with limited funding, includ
ing public research institutes, patients, farmers,
some healthcare providers, university researchers,
and similar entities. This restricted availability
could adversely affect, in particular, subsistence
agriculture, medical research, and health care.
For example, critics allege that Myriad
Genetic’s patents on the BRCA1 and BRCA2
breast-cancer genes, and the nearly US$3000
licensing fee per use it charges, adversely affects
scientific research and health care.36 This high
licensing fee and monopoly prevent some non
profit and other clinical-care units from offering
a genetic test for these mutations, particularly for
patients without health insurance or the means to
pay for such tests, and may also burden or restrict
scientific research related to hereditary breast can
cer, although the company provides a substantial
discount in the license fee to university and non
profit researchers.37
A 2003 survey of 132 directors of diagnostic
laboratories found that 25 percent had stopped
performing a medical test because of a patent or
license and 53% stopped research efforts because
of a patent or license.38 The practice of exclusive
licensing also limits access to important scien
tific tools, materials, and procedures. A survey
in the late 1990s found that out of 27 disease

gene patents studied, 14 had been licensed, and
all the licenses were exclusive.39 The American
College of Medical Genetics has adopted a po
sition statement advocating broad licensing of
patents on genes with clinical implications and
that “[l]icensing agreements should not limit access
through excessive royalties and other unreasonable
terms.”40
Other commentators are concerned that the
“upstream” patenting of research tools and genes
will create a “tragedy of the anticommons” that
will result in excessive and overlapping proprie
tary hurdles that will impede scientific research.41
A recent survey of 1,240 university geneticists
found that patenting and commercialization of
research may be impeding the scientific ideals of
openness and sharing, with 73% of respondents
claiming that withholding of data by colleagues is
slowing progress in their field.42
Yet another argument is that some biotech
nology patent holders are exploiting their patent
rights to provide greater market power and profits,
to the detriment of patients, farmers, and other
potential end users of the patented technologies.
For example, some farmers and public interest
groups have alleged that Monsanto’s patents on
genetically modified crops such as the herbicide
tolerant Roundup Ready® technology are being
used to promote sales of Monsanto’s Roundup
herbicide through license agreements that re
quires farmers who buy Roundup Ready® seeds
to also use Monsanto’s Roundup® rather than
competing brands of the herbicide glyphosate.
In several cases, lawsuits have been filed against
Monsanto for “patent misuse,” but to date these
legal claims have been unsuccessful,43 leaving the
issue to be debated in the ethical realm.
As with all other ethical issues relating to bio
technology patenting, the alleged harmful effects
of patenting on scientific research and healthcare
are not uncontroverted. Many biotechnology and
pharmaceutical companies consider their patents
to be the lifeblood of their business, without which
they could not raise and invest the substantial
amounts of money needed to develop innovative
products that can enhance human health. Some
independent analyses have concluded, contrary
to some of the arguments summarized above, that
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the benefits of patenting outweigh the costs in
the context of both scientific research and health
care,44 or that the problems feared from biological
patents have largely not manifested.45
Some commentators have suggested that
companies and other patent holders can take
steps to minimize these consequentialist argu
ments against patenting, including not enforcing
patents against university researchers and charg
ing reduced licensing fees for clinical testing by
nonprofit clinics and hospitals.46 Other policy ap
proaches that have been suggested for addressing
these concerns include requirements for compul
sory licensing, prohibition of exclusive licensing,
liability exemptions for clinical uses of patented
materials and tests, an expanded experimental-use
exemption, the development of patent pools, and
open-source approaches to biomedical research.
A related and relatively new issue is the use of
patent rights to promote certain ethical or political
objectives. For example, Myriad Genetics, which
has the exclusive patent rights to the BRCA1/2
breast-cancer genes in the United States and some
other jurisdictions, refuses to allow the patent to
be licensed for prenatal testing for these genetic
markers.47 This is an example of the patent right
being used to achieve a policy outcome—that is,
preventing prenatal testing (and presumably fol
low-up abortion in some cases) for cancer-suscep
tibility traits.
One group of researchers has suggested that
patent licensing could be used as a “moral toll
booth” to ensure the ethical use of biotechnol
ogy technologies.48 Under this proposal, patent
holders could be held liable for the unethical use
of genetic inventions. The authors suggest “that
a patent holder could be expected to ensure that a
licensee of that invention be required to meet emerg
ing legal and ethical norms associated with the use
of the technology, such as the requirement to provide
fully informed consent or genetic counseling where
appropriate.”49

. ConCLuSIon
Ethical issues and controversies about biotechnol
ogy patents are a significant, and growing, factor
in the development and implementation of
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biomedical and agricultural technologies. In a
few limited contexts, ethical concerns have been
translated into legal rules that specify a clear
course of conduct, but those situations are the
exception. In most cases, ethical concerns about
gene patents have not been incorporated into
laws, and the ethical issues remain largely unre
solved and hotly debated. The lack of clear ethical
principles and guidelines creates a problem for ac
tors in this field. As the U.S. Office of Technology
Assessment recognized many years ago:
Uncertainty about how courts will resolve dis
putes between specimen sources and specimen users
could be detrimental to both academic researchers
and the infant biotechnology industry… [R]egardless
of the merit of claims by the different interested par
ties, resolving the current uncertainty may be more
important to the future of biotechnology than resolv
ing it in any particular way.50
In the absence of greater ethical consensus
and clarity, decision-makers must navigate the
ethical minefields of biotechnology patents on a
case-by-case basis, seeking to avoid the ethical hot
spots that will likely trigger controversy, disrup
tion, and opposition, while avoiding being para
lyzed into inaction by the matrix of conflicting
ethical viewpoints and positions that exist. n
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2

Specific Strategies and Mechanisms
for Facilitating Access to Innovation

CHAPTER 2.1

Reservation of Rights for Humanitarian Uses
ALAN B. BENNETT, Associate Vice Chancellor, Office of Research, University of California, Davis;

and Executive Director, PIPRA, U.S.A.

ABSTRACT

An explicit reservation of rights in a commercial tech
nology license can ensure that the licensor’s institutional
objectives to support humanitarian applications of its
technology are not inadvertently blocked or sidetracked
by overly broad terms in the commercial license. Many
universities routinely use a reservation of rights to guaran
tee continued use of licensed technologies within the on
going research or educational programs of the university.
Clauses included in license agreements to reserve rights for
humanitarian use of technology are still rare, but aware
ness is increasing of the utility and importance of such
clauses, particularly as philanthropic-research sponsors be
gin to require grantees to ensure that results and discover
ies will be made available for humanitarian purposes. The
structure of a clause to reserve rights for humanitarian use
ideally both expresses the philosophical intent of the li
censee and clearly defines the boundaries of humanitarian
use, particularly in relation to commercial use.

1. INTRODuCTION
The reservation of certain rights in commercial
license agreements is a means for the technol
ogy provider (the licensor) to declare its explicit
intent to reserve or retain certain rights over the
technology—to not grant those rights under the
license—in order to help ensure that the terms
of the license will not block other specific goals
that the licensor may have. Such goals are typi
cally noncommercial and therefore do not di
rectly impair the licensee’s ability to commercial
ize the technology, but they may be important

to ensure that the licensor can continue to meet
other institutional objectives such as education,
research, and public service. In the case of uni
versity research, this typically includes the goal
of ensuring that future noncommercial research
is not blocked and, increasingly, that humanitar
ian uses and applications of the technology are
not blocked.1 This chapter will briefly address a
single issue—that of creating an explicit reserva
tion of rights in a commercial technology license
to ensure that institutional objectives to support
humanitarian applications of its technology are
not inadvertently sidetracked by an overly broad
commercial license. Furthermore, the regular use
of this type of reservation-of-rights clause provides
a means to regularly articulate an institution’s
commitment to manage technologies for the
broadest public benefit.

2. RESERVATION-OF-RIGHTS ClAuSE
License agreements broadly define the terms un
der which a technology provider (licensor) will
transfer intellectual property and/or tangible
property to a technology user or developer (li
censee), usually for commercial development. In
many cases, the license agreement is nonexclu
sive or it carefully defines the use of the technol
ogy for a specific field or a specific geography.
In such cases, the licensee does not grant—but

Bennett AB. 2007. Reservation of Rights for Humanitarian Uses. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org.
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instead retains—rights to the technology in all
areas other than those defined within the scope
of the license, and therefore a specific reserva
tion of rights may not be necessary. However,
for some technologies and in some technol
ogy sectors—including biotechnology—broad
exclusive licenses are often required to induce
follow-on investment in research and develop
ment. In these cases it can be important for the
licensee to explicitly reserve rights to ensure that
its noncommercial institutional objectives are
not blocked by the exclusive terms of the com
mercial license.
For example, universities frequently incorpo
rate a clause that reserves rights to carry on re
search using licensed patents and/or technology.
This has become increasingly important since the
Madey v. Duke University2 ruling effectively nar
rowed, beyond any practical use, the research ex
emption codified in U.S. patent law for university
research.3 This lack of a research exemption in the
United States has created the unusual situation
where a university invention, if licensed exclusive
ly, may be unavailable for ongoing research even
in the very laboratory where the invention itself
was made. To address this situation, many univer
sities in their exclusive license agreements now re
serve rights for the use of inventions within their
own institution or, even more broadly, within all
academic or nonprofit research institutions.
The University of California and Stanford
University routinely incorporate clauses into their
exclusive license agreements (Box 1). This type of

reservation-of-rights clause is perhaps the most
common type used in university license agree
ments, although even this straightforward and
reasonable term still is not used by many univer
sities in their exclusive license agreements.
Clauses in university license agreements that
reserve rights for humanitarian use of the tech
nology are an exception, rather than a rule, but
awareness of the utility and potential importance
of such clauses is increasing. Today there are
examples of research sponsors and programs—
such as philanthropic foundations—that require
grantees to ensure that research results and dis
coveries will be made available for humanitar
ian purposes. Based on this type of sponsor re
quirement, grantees who execute a commercial
license to any technology developed under the
research agreement would thus be required to
include a clause that acknowledged this existing
obligation and reserved rights for humanitarian
purposes.

3. THE STRuCTuRE OF A
RESERVATION OF RIGHTS
A reservation of rights for humanitarian uses can
be a very simple statement expressing the philo
sophical intent of the licensee. For example, at
the Donald Danforth Plant Science Center all re
search and license agreements include a statement
that the “Company and Danforth Center shall dil
igently and in good faith negotiate the terms of a
worldwide license, making provision for preserving

Box 1: Sample Reservation of Rights in Exclusive licensing Agreements
The university of California
Nothing in this Agreement will be deemed to limit the right of The Regents (the University)… to
make and use the Invention … and associated technology and allow other educational and nonprofit
institutions to do so for educational and research purposes.
Stanford university
Stanford retains the right, on behalf of itself and all other nonprofit academic research institutions,
to practice the Licensed Patent and Technology for any purpose, including sponsored research and
collaborations. Licensee agrees that, notwithstanding any other provision of this Agreement, it has
no right to enforce the Licensed Patent against any such institution.
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the availability of the intellectual property (IP) for
meeting the needs of developing countries.”4 While
this has the advantages of being simple and en
suring that the licensee is on notice with regard
to the intention of the licensor, the statement
may not provide sufficient definition of “meeting
the needs of developing countries” for the licensor
to assess the extent to which this statement may
affect its commercial markets. As a consequence,
more elaborate clauses have been crafted in ef
forts to clearly define the boundaries of humani
tarian uses, particularly in relation to commercial
uses.

desired geographies. Such a definition should
have flexibility to allow the expansion of the geo
graphical list. In addition, if such a geographical
definition of humanitarian uses is used, then the
issue of use and sales outside of this defined ter
ritory should be explicitly addressed.
Commercial purposes. Because the reserva
tion of rights for humanitarian uses is designed
to be used in the context of a commercial license
and, specifically, to segment the markets for a
technology between commercial and humanitar
ian uses, it may be important to define the scope
of commercial uses as well.

.1 Definitions

.2 Reservation of rights

The definitions are the most critical component
of a reservation of humanitarian use rights. The
key definitions are:
Humanitarian purposes. There are several
approaches used to define humanitarian purpos
es: by income level, by uses (subsistence or com
mercial), and by geography. Each approach has
its own set of limitations. Using a definition that
equates humanitarian uses with subsistence uses has
been adopted for some agricultural applications
but will probably not be applicable in the health
sector, since few technology applications can be
achieved without significant investment by a
commercial partner (this is becoming increas
ingly true in agricultural innovations as well).
Where subsistence uses are part of the definition,
it may be important to define income levels of
the subsistence “users.” This criterion has been
applied in the case of the humanitarian license for
Golden Rice5 but could raise difficult practical is
sues for compliance or monitoring. Alternatively,
humanitarian uses can be defined geographically
by specifying all uses of the technology within de
veloping countries.
Developing countries. If humanitarian uses
is defined geographically then an explicit defini
tion of developing countries is needed. For exam
ple, developing countries can be defined as those
listed by the World Bank or other international
agencies. While this definition can effectively
segment the commercial and humanitarian uses
of a technology, the current lists of develop
ing countries may not capture the entire set of

The reservation of rights is the operative paragraph
of the clause, and its structure will rely upon and
follow the above definitions. The reservation of
rights needs to clearly articulate what rights are
being reserved and should leave no doubt that the
reserved rights may be granted to other appropri
ate companies or organizations that can fulfill the
humanitarian objectives. This may be a topic of
discussion in license negotiations, largely because
it is likely to be an unfamiliar term to a commer
cial licensee.

4. STANDARD ClAuSES
There are relatively few examples of standard
ized reservation-of-rights clauses, because they
are likely to be crafted individually to meet spe
cific situations. However, as an object lesson, here
are two examples, one developed for agricultural
technology licenses and one developed for health
technology licenses.
The Public Intellectual Property Resource of
Agriculture (PIPRA) has crafted a standard res
ervation of humanitarian-use-rights clause that
encourages its members to include in commercial
licenses for agricultural technologies, particularly
in exclusive licenses. The clause (Box 2) may serve
as a model or starting point for similar license
clauses that seek similar objectives.
The Office of Technology Licensing at the
University of California, Davis crafted a reserva
tion-of-rights clause intended for a commercial
license of a health technology (Box 3). Likewise,
HANDBOOK OF BEST PRACTICES | 
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Box 2: PIPRA’s Reservation of Rights for Humanitarian uses
Definitions.
“Humanitarian Purposes” means (a) the use of Invention/Germplasm for research and
development purposes by any not-for-profit organization anywhere in the World that has the
express purpose of developing plant materials and varieties for use in a Developing Country, and
(b) the use of Invention/Germplasm for Commercial Purposes, including the use and production
of Germplasm, seed, propagation materials and crops for human or animal consumption, in a
Developing Country.
“Commercial Purposes” means to make, have made, propagate, have propagated, use, have used,
import, or export a product, good or service for the purpose of selling or offering to sell such
product, good or service.
“Developing Country”means any one of those countries identified as low-income or lower-middleincome economies by the World Bank Group at the time of the effective date of this agreement
and all other countries mutually agreed to by Licensor and Licensee (the current list of countries
is typically given in an appendix to the agreement).6
Reservation of rights.
Notwithstanding other provision of rights granted under this agreement, University hereby
reserves an irrevocable, nonexclusive right in the Invention/Germplasm for Humanitarian
Purposes. Such Humanitarian Purposes shall expressly exclude the right for the not-for-profit
organization and/or the Developing Country, or any individual or organization therein, to export
or sell the Germplasm, seed, propagation materials or crops from the Developing Country into a
market outside of the Developing Country where a commercial licensee has introduced or will
introduce a product embodying the Invention/Germplasm. For avoidance of doubt, not-for-profit
organization and/or the Developing Country, or any individual or organization therein, may export
the Germplasm, seed, propagation materials or crops from the Developing Country of origin to
other Developing Countries and all other countries mutually agreed to by Licensor and Licensee.

Box 3: Reservation of Rights for Humanitarian use:
university of California, Davis
1.40 “Humanitarian Purposes” means (a) the use of Licensed Products covered under Compound
Patent Rights (“Compound Products”) for research and development purposes by any
organization or other third party, anywhere in the world that has the express purpose of
developing the Compound Products for use in an Economically Disadvantaged Country,
and (b) the use of the Compound Products by any organization or other third party for
Commercial Purposes in an Economically Disadvantaged Country.
1.41 “Commercial Purposes” means to make, have made, use, have used, import, or export a
product, good, method, or service for the purpose of selling or offering to sell such product,
good, method, or service.
1.42 “Economically Disadvantaged Country” (“EDC”) means all countries listed on the United
Nations Conference on Trade and Development list of “Least Developed Countries” in effect
as of the Effective Date of this Agreement which are set forth on Appendix I hereto.
2.14 In any license to the Licensee, Licensee’s commercial use of the Compound Patent Rights to
make, use, sell, offer for sale and import Compound Products in EDCs will be royalty free and
the Licensee will be required to give away the Compound Products for free or at cost.
(Continued on Next Page)

 | HANDBOOK OF BEST PRACTICES

CHAPTER 2.1

it may serve as a model or starting point for simi
lar license clauses that seek such an objective.

5. CONCluSIONS
It has recently been suggested that national pub
lic policy guidance is needed to support measures
that require that publicly funded research results
be managed in a way that preserves the oppor
tunity to mobilize new technologies to meet hu
manitarian needs of the world’s poorest people in
addition to meeting the commercial needs of the
developed world.7 In the absence of such national
policies, voluntary measures can still be taken to
ensure that research results, new discoveries, and
patented inventions are not unnecessarily blocked
from serving humanitarian purposes and meet
ing the needs of the world’s poor. For public re
search institutions, a reservation of humanitarian
rights in commercial technology licenses is one
mechanism to help it meet its mission to serve
the public benefit through both commercial and
humanitarian channels. n

1

The broader topic of humanitarian access to health and
agricultural innovations and a discussion of strategies
to ensure broader access are also addressed in this
Handbook in various chapters, most notably chapter
2.2 by AL Brewster, SA Hansen and AR Chapman. For
specific aspects of the topic, see in this Handbook,
chapter 12.1 by RT Mahoney.

2
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3

Ludwig SP and JC Chumney. 2003. No Room for
Experiment: The Federal Circuit’s Narrow Construction
of the Experimental Use Defense. Nature Biotechnology
21:453.

4

Beachy R. 2003. IP Policies and Serving the Public.
Science 299:473. See also in this Handbook, chapter
17.10 by K Schubert.

5

Brewster AL, AR Chapman and SA Hansen. 2005.
Facilitating Humanitarian Access to Pharmaceutical
and Agricultural Innovation. Innovation Strategy Today
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Box 3 (continued)

2.15 Notwithstanding other provision of rights granted under this Agreement, The Regents
[the university] hereby reserves the right to license the Compound Patent Rights to any
third parties for solely Humanitarian Purposes. Such licenses for Humanitarian Purposes
will expressly exclude the right of the third party licensee to export or sell the Compound
Products from an EDC into a market outside of the EDC where Licensee has introduced or
will introduce a Compound Product and where Patent Rights exist. In any such license, the
third party licensee’s commercial use of the Compound Patent Rights to make, use, sell,
offer for sale and import Compound Products in EDCs will be royalty free and the third
party licensee will be required to give away the Compound Products for free or at cost.
For avoidance of doubt, the third party licensee may be permitted to export Compound
Products from the EDC of origin to other EDCs and all other countries mutually agreed to
by The Regents and Licensee.
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ABSTRACT

Because certain patenting and licensing strategies can in
hibit the development and dissemination of products for
developing countries, intellectual property management
strategies need to be developed that can help remove some
of these obstacles. It is equally important to apply creative
patent management strategies that actively promote access
to needed products in developing countries. Care must be
taken, however, to ensure that patents on research inputs do
not discourage or unreasonably increase the cost for prod
uct development that targets needs in small or unprofitable
markets. The American Association for the Advancement of
Science project on Science and Intellectual Property in the
Public Interest convened a working group to explore these
issues in 2004. This chapter draws upon the expertise of
that group to identify licensing strategies that are effective
in promoting humanitarian access to health and agricul
tural product innovations and expanding their use among
poor and disadvantaged groups, particularly in low-income
countries. The chapter encourages more public sector IP
managers to understand and employ strategies that will
achieve these goals and seeks to help private sector licensees
to understand the rationale behind and potential benefits
of such strategies. Indeed, humanitarian licensing strategies
should more and more become the norm by contributing to
the development and dissemination of essential medicines
and agricultural technologies for developing countries.

1. INTRODuCTION
1.1

Patents and neglected markets

Intellectual property (IP) rights play an increasingly
important role in the development, manufacture,

and distribution of products in agriculture and
health. During the past 25 years, there has been
an unprecedented increase in the scope, level, role,
and geographic and subject-matter coverage of IP
protection.1 Strong patent protection is intended
to contribute to increased research investments and
a favorable climate for technology transfer. But it
may not always produce these effects. In fact, IP li
censing practices may inhibit access to IP-protected
knowledge, research tools, and products.
The unmet medical and agricultural needs
of developing countries are vast. Reflecting the
technological and financial disparity between de
veloped and developing countries, low- and mid
dle-income countries account for less than 10%
of worldwide research and development expendi
tures.2 And despite increasing levels of investment
in pharmaceutical R&D during the past 30 years,
only 1% of new compounds marketed have been
for developing-world diseases.3 Recent research
has identified some increase in innovative activ
ity related to diseases specific to poor countries,
though this activity “remains extremely low rela
tive to pharmaceutical research overall,”4 and has
resulted, in large part, from increased public R&D
funding for global health.4, 5 Similarly, private sec
tor agricultural research is more likely to focus on
specialty crops of interest to developed countries
than on staple crops that are important to resource-poor farmers in developing countries.6

Brewster AL, SA Hansen and AR Chapman. 2007. Facilitating Humanitarian Access to Pharmaceutical and Agricultural Innovation. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. AL Brewster, SA Hansen and AR Chapman. Sharing the Art of IP Management: Photocopying and distribution
through the Internet for noncommercial purposes is permitted and encouraged.
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1.2 Background and related initiatives

Our discussion of strategies builds on the initia
tives, experience, and proposals of other organi
zations for the management of IP. The United
Nations Millennium Project Task Force on
Science, Technology, and Innovation recom
mended expanding mechanisms for inventors
to make their ideas available royalty free for uses
that meet the needs of poor countries, noting in
its final report that “only a handful of mecha
nisms are designed to promote such activities.”7
However, beginning in the 1980s, and expand
ing through the 1990s and the early years of the
21st century, an increasing number of organi
zations have been using IP management prac
tices to promote the health and food security
of underserved populations. These include the
Program for Appropriate Technologies in Health
(PATH) and the Population Council, as well as
various other public and public/private partner
ships, such as the International AIDS Vaccine
Initiative, the Global Alliance for TB Drug
Development, the Global Vaccine Initiative, the
Diseases of the Most Impoverished Program
of the International Vaccine Institute, and the
Centre for the Management of Intellectual
Property in Health Research and Development
(MIHR). International entities (for example,
the World Health Organization [WHO]) have
undertaken humanitarian licensing, as have na
tional entities such as the U.S. National Institutes
of Health (NIH), which now includes humani
tarian clauses in its licensing agreements as ap
propriate. Several governmental organizations
in developing countries, such as the Council for
Scientific and Industrial Research of India, are
beginning to undertake humanitarian licensing.
Agricultural organizations with relevant experi
ence include the African Agricultural Technology
Foundation8 (AATF), the International Service
for the Acquisition of Agri-biotech Applications
(ISAAA), and the institutes of the Consultative
Group on International Agricultural Research
(CGIAR).
One of the most noted examples of hu
manitarian IP management involves vitaminA-enriched Golden Rice. Although developed
mainly with public sector funding and research,
48 | HANDBOOK OF BEST PRACTICES

around 45 patents associated with Golden Rice
are owned by approximately 30 companies and
public institutions in the United States, and only
a few patents are held in developing countries.9
The inventors of Golden Rice licensed their in
ventions related to golden gice to Greenovation, a
biotech spinout company from the University of
Freiburg, which is owned by the inventors them
selves. Greenovation then exclusively licensed its
Golden-Rice-related patents to AstraZeneca, PLC
(now Syngenta). Subsequently, Syngenta entered
into a license agreement with the inventors that
allowed them, and Syngenta, to license Golden
Rice technologies to developing countries. Other
companies holding Golden-Rice-related pat
ents also agreed to the same arrangement. That
arrangement allows both Syngenta and the in
ventors to grant licenses—with the right to sub
license—to any bona fide research organization
for the development of Golden Rice. The rice can
be used royalty free and allows farmers to earn
as much as US$10,000 per year from its sale.
Higher sales would require farmers to acquire a
commercial license from Syngenta.10 The example
of Golden Rice illustrates that it is possible to
make IP available for research and commercial
ization in developing countries.
Yale University offers another example of hu
manitarian IP management. It holds a key patent
on stavudine (d4T), a widely used HIV/AIDS
antiretroviral drug. Yale renegotiated its exclusive
license with Bristol-Myers Squibb Co. to incor
porate renegotiated humanitarian terms, allowing
the drug to be subsequently licensed for generic
production in South Africa. The university also
negotiated a price cut, immediately reducing the
price of d4T in Africa to 1/30th of the price in the
United States. When the generic product came
on the market, it further reduced the price by as
much as 40%.
Other examples of humanitarian IP manage
ment include Cornell University’s transfer of ring
spot-virus-resistant papaya to Thailand, as well
as several projects brokered by the International
Service for the Acquisition of Agri-biotech
Applications (ISAAA). The latter include local
varieties of potato transferred from Monsanto
Co. to Mexico, as well as ring-spot-virus-resistant
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and delayed-ripening papayas transferred from
Monsanto and Syngenta, respectively, to Southeast
Asia.11 Finally, a recent agreement between Gilead
Sciences and the South African drugmaker Aspen
Pharmacare is another example of humanitarian
IP management for health products. Gilead will
allow Aspen to produce generic versions of the
HIV/AIDS antiretrovirals Truvada® and Viread®,
and university inventors who own foundation
al patents for both drugs have agreed to waive
royalties in the developing countries served by
Aspen.12
1.3 Intended audience

This paper is written primarily for licensors, par
ticularly university-based technology transfer
managers and public sector intellectual property
managers and, secondarily, for the staff of intel
lectual property departments in corporations with
which these entities may enter into agreements or
who may themselves decide to adopt some of the
following strategies. Foundations or agencies that
fund research and that may wish to encourage or
require their grantees to engage in humanitarian
IP management are another important audience.
1.3.1

Public sector

Universities and public sector institutions play
key roles in the development of medicines and
agricultural products. Their roles are generally
early in the process, and because university-based
research is most often upstream, final products
based on their research often involve significant
development by others. The manner in which
public sector researchers make their “upstream”
technologies and research tools available can
influence whether populations in developing
countries have access to the end products of this
research.13
In recent years a number of nonprofit public/private partnerships (PPPs) have formed with
the mission of developing health and agricultural
products for markets that are neglected by tradi
tional for-profit R&D companies. These PPPs are
typically funded by foundations or public sources
and may receive in-kind support, or in some cases
direct funding, from private companies.

Like typical drug companies, health-focused
PPPs often develop a portfolio of candidate
products, hoping that a few will be safe and ef
fective enough to treat their focal condition.
Examples of PPPs that develop pharmaceuticals
are listed in Box 1.
If a university has already licensed IP to a
company, renegotiating to provide access for a
PPP can be costly and difficult—even if the PPP
seeks to develop the invention into a noncom
peting product. However, the university can take
steps at the beginning of the technology transfer
process to facilitate the use of its invention for
developing products that serve the poor. If a tech
nology does not interest commercial licensees,
university IP managers can seek PPPs or other
nontraditional license partners to develop it for
neglected markets. To be able to take advantage
of these opportunities, it is very important for
universities to establish policies and guidelines to
manage university-generated IP for humanitarian
use and applications.
Why should universities and public sector in
stitutions take advantage of these opportunities to
promote humanitarian use? Most universities and
public sector research institutions seek to contrib
ute to the wellbeing of humankind through their
patenting and licensing activities. For example,
each of the top four university recipients of U.S
patents in 200416 states public benefit as an ex
plicit goal in its patent policy:
• University of California (424 patents).
“It is the intent of the President of the
University of California, in administering
intellectual property rights for the public
benefit, to encourage and assist members of
the faculty, staff, and others associated with
the University in the use of the patent system
with respect to their discoveries and inven
tions in a manner that is equitable to all
parties involved.”17
• California Institute of Technology (135
patents). “It is the policy of the Institute that
such patents be used for the public benefit. If
there are innovations or discoveries that result
in the filing of patent applications and the
acquisition of patents, the Institute intends to
serve the public interest by prudent and apHANDBOOK OF BEST PRACTICES | 49
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Box 1: PPPs That Develop Pharmaceuticals
Aeras (Aeras Global TB Vaccine Foundation)
www.aeras.org
Children’s Vaccine Programme at PATH
www.childrensvaccine.org
CONRAD
www.conrad.org
DNDi (Drugs for Neglected Diseases Initiative)
www.dndi.org
FIND (Foundation for Innovative New Diagnostics)
www.finddiagnostics.org
Gates Foundation/University of North Carolina Partnership for the Development of New Drugs
www.ippph.org/index.cfm?page=/ippph/partnerships/name&thechoice=show&id=85&typobj
=0
Global Microbicide Project
www.gmp.org
Global Vaccines Inc.
www.globalvaccines.org
Human Hookworm Vaccine Initiative at Sabin Vaccine Institute
www.sabin.org/hookworm_slides.htm
IAVI: International AIDS Vaccine Initiative
www.iavi.org
Infectious Disease Research Institute
www.idri.org
iOWH (Institute for OneWorld Health)
www.oneworldhealth.org
IPM (International Partnership for Microbicides)
www.ipm-microbicides.org
MMV (Medicines for Malaria Venture)
www.mmv.org
MVI (Malaria Vaccine Initiative)
www.malariavaccine.org
PATH (Program for Appropriate Technology in Health)
www.path.org
PDVI (Pediatric Dengue Vaccine Initiative)
www.pdvi.org
PneumoADIP (Pneumococcal Vaccines Accelerated Development and Introduction Plan)
www.pneumoADIP.org
TB Alliance (Global Alliance for TB Drug Development)
www.tballiance.org
Source: Compiled from Gardner and Garner14 and Merz.15
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propriate efforts to transfer the technology to
those who will facilitate public use.”18
• Massachusetts Institute of Technology (132
patents): “It has long been acknowledged that
the primary functions of a university are edu
cation, research, and public service. It is in the
context of public service that M.I.T. supports
efforts directed toward bringing the fruits of
M.I.T. research to public use and benefit.”19
• University of Texas (101 patents): “It is the
objective of this policy to encourage the devel
opment of inventions and other intellectual
creations for the best interest of the public, the
creator, and the research sponsor, if any, and
to permit the timely protection and disclosure
of such intellectual property by development,
commercialization after securing available
protection for the creation, by publication, or
both.”20

Public funding agencies also seek to promote
public benefit. The mission of NIH, for exam
ple, is to support biomedical research to extend
healthy life by reducing illness worldwide. NIH
therefore seeks to understand and overcome the
obstacles hindering the public availability of inventions made by NIH scientists. To this end,
NIH engages in a variety of forms of humanitarian licensing and humanitarian-use agreements.21
Many other public sector actors and universities
are also interested in “doing the right thing” in
terms of promoting access, but they often do not
know how to proceed.22
We anticipate that at least some types of
humanitarian IP strategies will have little or no
impact on licensing revenues for the technol
ogy creators. Whether that will be the case may
depend on whether humanitarian licensing be
comes commonly practiced and accepted. It may
be important for a university or research insti
tute’s administration to commit to humanitarian

Box 2: Developing a low-Cost Malaria Treatment
Strategy employed: Agreeing on IP management conditions in advance
A research group sponsored by the Medicines for Malaria Venture (MMV) has developed a
promising, low-cost malaria treatment known as OZ277 /RBx11160. MMV supported collaboration
between scientists at the University of Nebraska, Swiss Tropical Research Institute, Monash
University, and the F. Hoffman-La Roche, Ltd. to develop OZ. The drug incorporates some chemical
features of the plant-derived antimalarial artemesin, but can be produced through synthetic
chemical processes, making it significantly cheaper. Patents covering OZ have been assigned to
MMV, and MMV has engaged the Indian drug manufacturer Ranbaxy to further develop it. Upon
regulatory approval, Ranbaxy Laboratories, Ltd. will distribute OZ at low cost in malaria endemic
countries. MMV facilitated arrangements for patent, royalty, and pricing structures to benefit
those in need by establishing an IP management plan with its collaborators in advance. Below
are excerpts from the Statement of MMV Collaborative Principles:
MMV’s central objective is to ensure the sustainable and continuous generation of appropriate
new malaria medicines that are accessible to all of those in need in developing countries at the
lowest prices practicable.

MMV requires intellectual property rights on a royalty-free basis to the relevant intellectual
property, in the field of malaria, and developed through the collaboration.

MMV will seek the right to the relevant background intellectual property necessary to achieve
the objectives identified herein.

MMV would not normally have a desire to retain any interest in relevant intellectual property
rights for use outside the field of malaria or to constrain such use by its collaborators.
Source: MMV and JC CraftMedicines for Malaria Ventures. Statement of MMV
Collaboration Principles. Personal communication, J. Carl Craft, Chief Scientific Officer, MMV.23
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IP management as an extension of the institu
tion’s public mission (Box 2). This might enable
technology licensing officers to risk sacrificing
small amounts of licensing revenue when there is
an opportunity to enhance product development
initiatives for the poor. In addition, institutional
administrations can foster approaches among
technology licensing officers that would enhance
such product development initiatives when fi
nancial promise is low.
1.3.2 Private Sector

Why address intellectual property managers in
the commercial sector? Most technologies devel
oped by universities and public sector institutions
are at early stages of development and require pri
vate companies to invest more in research and
development to create practical applications.
Universities generally license these early-stage
technologies to the private sector. The success
of humanitarian licensing therefore depends on
the willingness of private sector actors to accept
certain conditions and requirements that would
increase access later in the product development
and marketing stages.
We think there are two reasons that commer
cial licensees may support humanitarian licensing.
First, commercial entities usually expect major fi
nancial returns in developed world markets, but
developing country markets are often considered
unprofitable. Hence, many types of humanitarian
licensing may not harm the financial interest of
the commercial licensee. Moreover, a corporation
may advance its reputation for social responsibil
ity and win greater esteem from the public by ac
cepting humanitarian licensing.
Multinational companies have already
shown a willingness to segment their markets
and offer concessionary terms to facilitate ac
cess to their products in poor countries. A num
ber of examples have been highlighted already,
including AstraZeneca, Bristol-Myers, Gilead,
Monsanto, and Syngenta. Activities by Chiron
Corp., GlaxoSmithKline, Pioneer International,
Inc. (affiliate of E. I. du Pont de Nemours and
Company), and Roche are mentioned later.
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2. HuMANITARIAN lICENSING STRATEGIES
In this section we discuss some successful strat
egies and some new proposals for managing IP
to facilitate humanitarian use and applications.
These include case studies in which IP owners
have used nontraditional IP management tech
niques to promote the development of products
for neglected markets. In this section, we describe
general approaches to licensing and some specific
license features that a patent owner can use when
transferring technology to a commercial entity.
2.1 Identifying the intended beneficiaries

Rights reserved or obligations set out to facilitate
access in developing countries will need to specify
the intended beneficiaries. In the end, all human
itarian licensing efforts should strive to benefit
underserved people in developing countries by
providing greater access to needed technologies.
However, defining this population or identifying
the institutions that could serve this population
with the licensed technology may require dif
ferent approaches, depending on the particular
technology and requirements of the primary li
censee. Below are some options for defining the
beneficiaries of humanitarian license terms.
A developing country can be defined in a
number of ways, for example, by reference to
the United Nations list of least developed coun
tries, by locale, or by reference to lists provided
by the Organisation for Economic Co-operation
and Development (OECD) countries, the World
Bank, or the Food and Agriculture Organization
(FAO). Beneficiary countries may also be mu
tually agreed to by the contracting parties, who
may also need to decide whether the agreement
will cover middle-income as well as low-income
countries.
In addition to or in place of defining a list
of countries covered by the reservations and/or
exemptions in a humanitarian license, negotia
tors may wish to further define the population
in those countries that would be covered. The
intended population might be “the poor,” “those
in need,” subsistence farmers, populations in geo
graphically underserved regions, or a particular
market segment.
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A market segmentation, or dual market, ap
proach is often used to target intended benefi
ciaries and is involved in many of the strategies
discussed in this paper. With this approach, an
exclusive license might give a private sector en
tity the sole right to use a technology in profitable
markets, while allowing others to use the technol
ogy at no cost or reduced royalties to serve market
segments that do not interest the private sector.
In the licensing arrangements for Golden
Rice, a humanitarian-use clause was used to seg
ment access to an agricultural technology, com
mitting the owners of key proprietary compo
nents to donating their technology to the poor.
Negotiations over how exactly to define and make
operational such “donations” are ongoing. These
negotiations focus on defining the humanitarianuse market and ultimately on the precise wording
of the humanitarian-use clause. This humanitar
ian-use clause will determine who qualifies as a
beneficiary of royalty-free access to Golden Rice
and exactly how they would benefit.24
Although market segmentation strategies
have been employed successfully,25 certain chal
lenges remain, namely the containment of the IP
within the targeted markets. In addition to the
humanitarian transfer of products to the intend
ed populations, many developing countries may
also have emerging private markets for the same
goods. Markets that would not be attractive to
large companies may nevertheless present niche
opportunities for smaller companies. Market seg
mentation might be most successful where non
commercial markets can be sharply delineated by
region, which makes it easier to exclude spillovers
to nontargeted markets.26 In addition, market
segmentation often requires intense negotiation,
the development of trust between partners, and
the capacity to enforce agreements.
2.2 Nonexclusive licensing

In nonexclusive licensing, in addition to the pri
mary license agreement, the licensor retains the
freedom to license the technology to other par
ties. Some institutions (for example, NIH) seek
to use nonexclusive licensing or to license to mul
tiple companies whenever possible. If a university
can accomplish technology transfer to a company

using nonexclusive licensing, it is free to subse
quently license the technology for humanitarian
applications. Sometimes a commercial licensee
insists upon an exclusive license, in which case
public sector licensors may limit the exclusive
license to developed-country markets (as dis
cussed later) or for specific product applications.
2.3 Transferring technology to
public-private partnerships (PPPs)

When it is clear that a technology could benefit
neglected markets (for example, a low-cost HIV
diagnostic or an agricultural trait important for
subsistence agriculture), university technology
managers may be able to transfer the technology
to a nonprofit corporation for product devel
opment either on an exclusive or nonexclusive
basis. The business models of PPPs vary. Some
conduct in-house product development; others
manage collaborative development by public
and private sector labs (Box 3). The transfer of
technology could take forms ranging from di
rect licensing or donation of a patented inven
tion to contributions of know-how or scientific
expertise.
Another possible model is an arrangement in
which a commercial licensee focused on markets
in affluent countries makes the technology avail
able to a PPP on concessionary terms for market
ing or development for poor countries. In order
to minimize transaction costs for the PPP, it is
highly preferable for the university to engage with
the nonprofit developer before completing nego
tiations with the commercial licensee.
University technology managers can also fa
cilitate nonprofit product-development efforts
by offering PPPs ownership of patents that the
university no longer wishes to maintain. Even
when a technology does not appear to have a
clear application for developing regions, it may
prove useful for some aspect of the PPP’s work to
develop products for these regions.
2.4 Transferring technology to
companies in developing countries

Technology managers may seek commercial part
ners in low- or middle-income countries to devel
op technologies that address conditions specific to
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those regions. These companies are likely to have
greater interest in developing products that meet
the needs of these countries than commercial
entities in wealthier countries. They may also be
able to develop, produce, and distribute products
at much lower cost than typical partners in the
United States or other industrialized countries.
2.5 Out-licensing

Out-licensing is primarily executed by drug com
panies that are already producing name-brand
versions of a patented drug, but universities could
negotiate with corporate licensees to ensure that
out-licensing to generic companies takes place.
Under the out-licensing approach, drug patent
holders award nonexclusive licenses to generics
manufacturers, allowing them to produce cheap
copies of drugs for sale exclusively in designated
poor countries. The generic makers are prohibited
from selling products in the patent holder’s devel
oped country markets, and they may be required
to modify their packaging so as to discourage reimportation by making the generic versions easier
for customs officials to identify. Generic produc
ers pay a royalty to the patent holder, and are
encouraged to compete on price. An advantage
of this semicooperative approach is that generic
makers in developing countries can get more in
formation from the patent holder than just the

patented technology itself, such as manufactur
ing expertise and regulatory data. In the rare case
that a university holds IP that needs little addi
tional development, it could essentially make the
out-licensing arrangement itself by licensing the
patent to a name-brand pharmaceutical company
(as opposed to a company specializing in the pro
duction and marketing of generics) for wealthy
markets and to generic manufacturers for pro
duction in developing countries. It may be more
difficult, though not impossible, to encourage the
sharing of manufacturing expertise and regula
tory information.
2.6 Conditions in funding agreements

Foundations, government agencies, and other
organizations can require that funded work be
licensed under humanitarian terms by inserting
conditions into funding agreements. Establishing
humanitarian IP management conditions in
advance can simplify later negotiations, help
researchers and IP managers plan ahead, and
increase the prospects of success (Box 4). The
Rockefeller Foundation has crafted language to
include in research agreements for this purpose,
offering a model for ways that funders can increase
humanitarian access to the research supported by
their grants. The Rockefeller Foundation requires
grantees, whether or not they claim or obtain

Box 3: CDA Malaria Treatment
Strategy employed:
PPP-sponsored product development and preferential pricing requirement
The WHO Tropical Disease Research program, the Medicines for Malaria Venture (MMV), and
GlaxoSmithKline have formed a partnership to build upon the two-drug antimalarial LapDap™
by adding artesunate to the combination. The new therapy will be called CDA, for its ingredients
chloroproguanil, dapsone, and artesunate. The original LapDap was conceived by scientists
from the Wellcome Trust Laboratory in Nairobi and the University of Liverpool, then brought to
market by a public/private partnership involving MMV, British universities, the Wellcome Trust,
GlaxoSmithKline, and the U.K. Department for International Development. It was approved by
the U.K. Medicines and Healthcare Products Regulatory Agency in 2003. Under the agreement for
developing the new triple-drug combination, it will be made available at preferential prices to the
public sector in malaria endemic countries.
Source: TDR News.27
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patents or other proprietary rights in their dis
coveries, “to license or otherwise make available
the Discoveries to third parties in the commercial
and public sectors (to the extent permitted under the
MTAs) for the purpose of furthering the creation,
reproduction, modification, and/or sale of the im
proved end product.”
2.7 Humanitarian conditionality
in licensing agreements

Licensing conditions may require the licensee to
do specific good things to benefit disadvantaged
populations. These conditions are sometimes re
ferred to as white knight clauses. These may in
clude marketing a product in developing nations
at a reduced royalty or price, donating materials
for clinical trials, or cooperating with a humani
tarian licensee in a specified way (for example, by
providing clinical or field trial results). A licensor
could also insert language requiring the licensee
to make products developed from improvements
to the technology available in low- and middleincome countries at a reduced cost.
NIH often uses these clauses in its agree
ments to ensure that the licensee undertakes
specific actions to benefit the public sector (for
example, mandating the supply-back of licensed
products or services, health education programs,
indigent access programs, reduced royalties for
developing countries, biodiversity compliance for
natural products, and other means of ensuring
developing country access for licensed products).
NIH also requires licensees to create a worldwide

development and marketing plan to facilitate de
veloping country access to licensed products, the
implementation of which it monitors through
agreed-upon benchmarks.29
2.8 Performance milestones

A milestone is a performance requirement on the
part of the licensee. Milestones are often used in
public/private partnerships and sponsored re
search agreements to measure a project’s progress
and success. An example of a humanitarian licens
ing milestone might be a requirement that on or
before the date of the first phase of a clinical trial
for a new drug, the licensee will have identified a
generic manufacturer in a middle-income country
to produce the licensed technology at a reason
able price for developing countries. Subsequently,
if this milestone is not met, other provisions and
reservations in the agreement would be activated,
for example, loss of exclusivity, sublicensing, ex
ercise of march-in rights, and even termination of
the agreement.
2.9 Ensuring accessibility through pricing

To help ensure access to products, the licensor
may require that any product developed and
brought to the market be distributed at a rea
sonable price. Despite the inherent difficulties
in defining what is reasonable, price is a readily
measurable condition that is easier to monitor
than more broadly defined requirements con
cerning access.30 This model could be expanded,
whereby licenses to companies include an appro-

Box 4: Developing a Portable HIV Diagnostic
Strategy employed: Condition in funding agreement
When technology transfer officers at Massachusetts General Hospital and the University of Texas
were licensing a prototype HIV diagnostic device to a start-up company, the requirements of the
foundation funders allowed the foundations to grant additional licenses to entities capable of
meeting charitable objectives in LDCs. Since it is a portable device, the technology could provide
an inexpensive, practical means of diagnosing HIV in resource-poor settings.
Source: Foskett, Menapace and Basu.28
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priate balance of incentives to the licensee and
market access for the poor. Licensees might be
required to meet certain milestones, such as gov
ernment procurement targets in defined coun
tries, and at prices that are deemed appropriate
for that market. Here, an appropriate price may
be defined as the cost of production plus a small
profit, usually in the 5%–10% range prior to
being allowed to commercialize the product in
more lucrative markets.31 To ensure that an ap
propriate price is reached and maintained, the
licensor may include contractual language that
mandates the submission of manufacturing cost
reports and product cost calculation details on a
regular basis.32
2.10 Reserving rights in license agreements

It is important to think through how the hu
manitarian-purpose licensee will actually use the
technology and to reserve an appropriate set of
rights and exemptions. For example, the negotia
tors will certainly want to consider the scope of
research rights and, depending on the particular
technology and application, the scope of inter
national trade rights. The humanitarian licensee
might need the right to carry out research or
manufacture within the commercial licensee’s
territory, so long as the research is done only for
developing nation needs or the manufacture for
export to developing nations. The commercial
licensee may then wish to be protected against
re-export into its primary commercial market.
As noted earlier, the humanitarian licensee may

also need rights for commercial use in low- and
middle-income regions. Although the reserva
tion may be defined as humanitarian use, licen
sors may wish to consider additional, more spe
cific reservations as described below.
2.11 Research exemption

One of the several goals of humanitarian IP
management is to encourage research to de
velop products appropriate to the needs of the
developing world. To this end, licensors could
opt to insert into licensing agreements a re
search exemption clause that exempts specified
categories and types of research from patent
infringement in using its proprietary technolo
gies, (for example, to develop products that
broadly benefit the public or the population of
poor countries). The University of California
technology transfer office has begun to insert
such research exemption clauses into licensing
agreements.33 Other universities already re
serve research rights for academic institutions
in their standard exclusive licensing agreements
(for example, Stanford, whose standard license
language is reproduced in Box 5). Such a clause
could facilitate humanitarian use of the tech
nology if it also reserved rights for nonprofit re
search institutions developing products for use
in developing countries.
2.12 Sublicenses for developing countries

Unless provided for in the agreement, a licens
ee generally does not have sublicensing rights.

Box 5: Stanford Reservation of Academic
Research Rights in Standard license Agreement
Strategy employed: Reservation of research rights
3.4 Retained Rights. Stanford retains the right, on behalf of itself and all other nonprofit academic
research institutions, to practice the Licensed Patent and use Technology for any purpose,
including sponsored research and collaborations. Licensee agrees that, notwithstanding any
other provision of this Agreement, it has no right to enforce the Licensed Patent against any such
institution. Stanford and any such other institution have the right to publish any information
included in the Technology or a Licensed Patent.
Source: Stanford Office of Technology Licensing.34
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Should the parties agree to allow sublicensing,
the main agreement should specify the rights
and obligations of the licensee with respect to
the sublicensee(s). In allowing for sublicenses,
consideration should be given to the possibility
of the original licensee entering into sublicenses
inconsistent with the humanitarian goals of the
agreement. This should be restricted. It is gen
eral practice for the licensor to hold the licensee
responsible for assuring that the sublicensee ful
fills all the requirements of the principal license.
The best way to ensure that the sublicensee has
obligations comparable to the licensee’s is for
the licensor to draft the sublicense terms. The
licensor can thus be certain that all the humani
tarian requirements within the primary agree
ment are included.
2.13 March-in rights

A licensor may wish to reserve march-in rights if
the humanitarian purposes or milestones embod
ied in the agreement are not met (for example,
revoking a license or sublicensing to third parties
in order to ensure access).
2.14 Treatment of future rights
in license agreements
2.14.1

Reach-through clauses

Reach-through clauses attempt to reach beyond
the licensed technology and to ensure that the
licensee treats new technologies, developed
through use of the licensed technology or un
der a cooperative agreement, honoring the same
kinds of development obligations covered by the
original license. This type of clause is often used
by public–private partnerships to encourage the
development of specific technologies that benefit
developing nations while allowing the private
sector partner to benefit in the developed world.
Licensors can also help make inventions more
available to populations in need by insisting on cer
tain terms when licensing inventions to commercial
partners. Opportunities to transfer technologies to
be developed by public–private partnerships or by
other organizations can also be pursued.
2.14.2

Grant-back clauses

If it is likely that the commercial licensee will
develop improvements to the technology, it
would be wise to require that the licensee grant
back nonexclusive rights to those improvements.
This would ensure that they would be available
later for a humanitarian purpose licensee. The
same might go for access to test results or regu
latory data. If either party is concerned about
liability issues, there might be, for example, re
quirements for any humanitarian licensee to be
adequately insured or to be operating in com
pliance with relevant regulations.
2.14.3

Amending existing agreements

While the goal of this document is to promote
humanitarian licensing from the outset, when
agreements already exist they can be amended
or revised to meet humanitarian needs. There
are several examples of successful renegotia
tions. For example, the humanitarian license
mentioned earlier between Yale University and
Bristol-Myers Squibb was actually the result of
a renegotiation of their license for the AIDS
drug d4T, which permitted generic d4T to be
made and used in South Africa. There are also
examples from the agricultural sector in which
parties successfully addressed barriers posed by
a worldwide exclusive license between a uni
versity and a company. In one case, a compa
ny insisted that no license was required to use
the licensed technology in a certain country. It
stated this in a letter that permitted the univer
sity to transfer a gene construct directly to the
country. In general, renegotiating license terms
is not desirable because it increases transaction
costs, delays projects, and may not always suc
ceed. However, while there are clear benefits to
addressing these issues up front wherever possi
ble, the fact that an agreement has already been
concluded should not discourage participants
from revisiting the agreement when an unfore
seen need arises.

3. PROPOSAlS FOR NEW APPROACHES
FOR HuMANITARIAN lICENSING OF IP
Two new proposals conclude our discussion of
specific strategies for humanitarian licensing: (1)
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considering a shorter length for an exclusive li
cense and (2) equitable access licensing.
3.1 Shorter lengths of license exclusivity

Instead of granting exclusive licenses that match the
term of the patent, the licensor can grant licenses
for shorter periods, allowing access by multiple
licensors over the life of the patent. There may
be practical complications to this approach, since
universities often receive patent-cost reimburse
ments from licensees, which in turn require ex
clusivity until expiration of the patent term.
Granting short-term exclusive licenses would
likely require the university to bear all the costs
related to maintaining and enforcing the patent,
which it could only afford to do if the patent itself
was bringing in significant licensing revenues. In
that case, the university may be reluctant to end
its licensing relationship with the high-revenue
licensor.35
3.2 Equitable access licensing

Universities can also make use of an equitable
access license to create enabling conditions for
competition in low- and middle-income coun
tries. An equitable access license (1) ensures free
dom to operate for any party that manufactures
and distributes the licensed technology and any
derivative products in low- and middle-income
countries and (2) minimizes administrative
overhead and political contingency by initiat
ing a self-enforcing open licensing regime. In
such a license, a university and licensee agree
that any licensed technology, as well as licensee
improvements (including improvement patents
and registration data), to be sold in low- or mid
dle-income countries will be openly licensed to
any company that meets Good Manufacturing
Practice standards.36 This arrangement allows
multiple producers (including producers in
high-income countries) to compete to produce
low-price products for sale only in low- and
middle-income countries simply after notifying
the parties to the license.
The Equitable Access License developed
by Universities Allied for Essential Medicines
(UAEM) includes a humanitarian research clause
to encourage research on neglected diseases. It
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provides that any party may pursue research
anywhere in the world using the university tech
nology and licensee improvements without pay
ing a royalty, if the research targets a neglected
disease.37

4. NExT STEPS FOR AAAS HuMANITARIAN
IP MANAGEMENT INITIATIVE
This document emphasizes the importance of
managing public sector IP to facilitate humani
tarian use and applications. It seeks to raise
awareness about some of the techniques that have
been pursued so far, and we are optimistic that
additional approaches will emerge as more insti
tutions undertake IP management with humani
tarian use and applications in mind. We certainly
do not mean to preclude other options.
Even if technology managers adopt humani
tarian IP management strategies in the construc
tion, negotiation, and formalization of legal
agreements, they will also need to connect with
development partners who can utilize the pro
tected technologies to serve unmet needs in de
veloping countries. In some cases, these partners
may not yet exist. But when they do, it will be
important to establish simple, efficient ways for
them to identify technologies that public sector
institutions are willing to share.
We believe that the number and variety of
technologies being managed with humanitar
ian goals in mind will continue to increase, and
so the Science and Intellectual Property in the
Public Interest (SIPPI) project plans to explore
ways to increase the transparency of license terms
covering these technologies, thus making this
information more widely available to potential
beneficiaries.
In continuing its work on humanitarian li
censing, the SIPPI project will identify ways to
encourage the use of humanitarian licensing
practices and increase the transparency of license
terms covering technologies in health and agricul
tural innovation, thus making that information
more widely available to potential beneficiaries.
It is pursuing the following interrelated activities
as a means to advance the use of humanitarian
licensing strategies.
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Promoting the use of humanitarian licens
ing practices. In collaboration with the Centre
for the Management of Intellectual Property in
Health Research and Development (MIHR),
SIPPI plans to identify and develop approaches
for encouraging technology managers to adopt
humanitarian licensing models. That will be
accomplished through a wide range of outreach
activities that will include holding workshops
to coincide with meetings of the Association
of University Technology Managers and the
Association of American Universities, and host
ing a series of meetings on this topic at the AAAS
headquarters in Washington, D.C., as well as at
SIPPI’s annual meeting.
Developing a Web-based clearinghouse. We
will develop and implement a Web-based clear
inghouse of technologies that are available for
humanitarian licensing for product development.
The clearinghouse will be designed as an openly
accessible database listing technologies available
for humanitarian use. It will identify the owner of
the technology and provide information as to the
specific licensing terms for each listed technology,
including type of license, field of use, and the in
tended beneficiaries for the use of the technology.
In addition to facilitating access to technologies,
the clearinghouse will allow technology transfer
managers to submit detailed information about
new technologies and, similar to the creative com
mons model, will supply online tools to build spe
cific humanitarian licenses for those technologies.
This model will allow the clearinghouse to con
tinue serving its intended purpose over the long
term. n
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ABSTRACT

In the last decade, product development partnerships
(PDPs) have become significant components of efforts to
develop and disseminate therapies for diseases in the de
veloping world. PDPs seek to fill a gap left by the private
sector—a gap that leaves 90% of the world’s disease burden
with only 10% of the world’s research money—through
innovative, comprehensive partnership strategies that tap
into the strengths of both the private and public sectors.
This chapter, based on the proceedings of a conference titled
Ensuring Global Access through Effective Management
of Intellectual Property in 2006, provides an overview of
the history and approaches of numerous PDPs. The chap
ter is anchored by reports from eight different PDPs and
aims toward explaining what potential problems to guard
against, what does not work, and—above all what does
work—when the public sector plugs into the dynamism of
the private sector to try to meet the health and agricultural
needs of developing countries. Recognizing that there is no
single business model, PDPs employ a common toolbox to
manage intellectual property for global health outcomes. It
includes defining a discrete territorial market; establishing
distinct structures for public sector and private sector mar
kets; determining field of use in a strategic manner; estab
lishing royalty rates to optimize incentives; and providing
for access to the developed technology in the event that
the research/industry partner abandons the project. Other
key areas of discussion, where parallels between PDPs exist,
include global-access strategies, pricing issues, the impor
tance of market segmentation, production capacity, stra
tegic early-stage licensing, the IP landscape, and systemic
challenges. Collectively, PDPs have broadened the creative
understanding of practical ways to resolve the public-policy
dilemma of balancing private incentives to generate needed
R&D investment with the goal of access to those in need.

1. InTRoduCTIon
Infectious diseases such as HIV/AIDS, tuberculo
sis (TB), and malaria are among the world’s lead
ing killers, affecting the poorest people in the most
impoverished countries. Yet affordable and acces
sible interventions are frequently unavailable to
them. Moreover, neglected diseases such as leish
maniasis and Chagas’ disease kill or disable mil
lions of people in the developing world every year.
Treatment options for these diseases are either in
adequate or nonexistent because of a lack of public
funds and private sector incentive to research and
develop new drugs and vaccines. This lack of R&D
has created what some call the 10/90 gap; less than
10% of global health R&D spending worldwide is
focused on diseases or conditions that account for
90% of the world’s disease burden.1
Focusing science and technology innova
tion on tackling these diseases is a necessary, but
not sufficient, condition for progress. Improving
global health will also require concerted efforts
by academic and industrial scientists, technology
developers, IP (intellectual property) experts, in
vestors, government officials, policy-makers, and
public-health officials. Partnerships are needed,
not only to develop the products and strate
gies for delivering interventions to populations
most in need, but also to forge IP and technol
ogy transfer agreements that will protect private
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interests while simultaneously promoting public
health. Mahoney and Morel have named this new
era, “the Era of Partnerships.”2 They argue for an
innovation framework having six components:
1. Development and expansion of national
health delivery systems, including an at
tractive, domestic, private-sector market
for health products
2. Development of manufacturing capability
for health products
3. Development of a drug and vaccine regula
tory system
4. Development of an IP regulatory system
5. Development of R&D capability by the
public and private sectors
6. Development of international trade sys
tems for health products, including global
procurement funds
The authors note that the components are
comprehensive in that they cover all the areas nec
essary to innovate successfully.3 All of the compo
nents are dynamically linked and attention to all
is required, since the failure of one component
will almost certainly guarantee failure for the
whole effort. Thus, though the IP system is only
one component of innovation, it is a necessary
component. Product development partnerships
(PDPs) must therefore attend to all the compo
nents of innovation, including intellectual prop
erty, in the quest to ensure global access.4
The emergence of PDPs over the past decade
has provided a unique mechanism, a hybrid public/private approach, by which to generate new
products for the neglected diseases of poverty.
PDPs employ a variety of strategies to achieve
goals (for example, creating new technologies
and ensuring that the developed technology is
available and affordable to as many beneficiaries
as possible in the developing world). The most
basic challenge is to provide access to needed
technologies and pay close attention to how the
technology is to be distributed or marketed, while
simultaneously offering appropriate incentives to
private sector partners to encourage the commit
ment of research, development, and manufactur
ing resources. To do this, PDPs are both chart
ing new territory and employing management
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models that borrow frequently from the private
sector. Moreover, in some cases PDPs have re
invented R&D approaches for preventing and
treating human diseases. Unlike traditional R&D
agreements, PDPs must make deals that extend
well beyond the scope of traditional commercial
agreements, stipulating access conditions to en
sure that the product reaches the target popula
tion. These terms and conditions frequently focus
on the strategic use of intellectual property and
often have to address such issues as market seg
mentation, pricing, and distribution.
The experiences of PDPs have shown that
several factors are driving some companies to
work collaboratively and to share disease-related
intellectual property. These factors include cor
porate social responsibility and strategic consid
erations, such as positioning in emerging mar
kets. An additional incentive is the potential that
R&D projects with PDPs may have relevance for
commercial compounds. For example, MMV
carries out joint studies on malaria tetracycline
resistance with industrial partners, which benefits
their commercial anti-bacterial research.
PDPs are an increasing and innovative group
of organizations. The diverse experiences of PDPs
can help inform the makeup and negotiation of
R&D partnerships and lead to better agreements
dealing with the various forms of IP. Several PDPs
are reaching a new mature phase, with products in
clinical development for poverty-related diseases.
These PDPs have designed workable solutions to
ensure access and affordability, from planning
production that will meet the size of demand, to
addressing issues of end-user acceptability. PDPs
are pioneering a new form of social contract to
promote the development of health products
where commercial incentive is lacking.
To promote and facilitate discussion among
those who have embarked on or are developing
plans for PDPs, the Centre for the Management
of Intellectual Property in Health Research and
Development (MIHR) and the Aeras Global
TB Vaccine Foundation, in partnership with the
Bill and Melinda Gates Foundation, convened a
meeting titled Ensuring Global Access through
Effective Management of Intellectual Property
in 2006.5 It built on a similar joint meeting held
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in 2004, also involving around 50 participants
including senior management, legal counsel,
program officers, and business development pro
fessionals from institutions and organizations in
volved with PDPs.6
This chapter summarizes presentations made
at the meeting by representative PDPs. Their sto
ries illustrate the diversity of approaches used in
making R&D agreements and managing intellec
tual property in the context of global health. The
structure of these agreements defines and is influ
enced by the relationships among the partners. As
Oehler noted:
By the nature of their business model, the
commercial interests of private sector companies
are, on the whole, oriented toward maximizing
profitability. It is not justified to expect that pri
vate sector business will automatically ensure best
services to the public sector and focus the genera
tion and use of intellectual property toward maxi
mized public-sector benefits.
To prepare for a situation where the original
targets of a license agreement are delayed or are
not achieved, and to avoid the situation where pro
jected public-sector benefits are delayed or are not
realized, it is good practice to establish contractual
milestones that regulate target achievement under
the license and to set incentives to keep to timelines
and performance accordingly. This allows licensor
and licensee(s) to focus resources on their efforts to
perform as was agreed upon in the first place.7

2. pdpS In ACTIon
2.1 Collaborative research with
centralized IP management: DNDi

Nicoletta Dentico noted that several PDPs fo
cus on creating R&D partnerships to achieve
outcomes that would otherwise be impossible.
For example, in 2003, seven organizations from
around the world joined forces to establish the
Drugs for Neglected Diseases initiative (DNDi).8
Among the seven were five public-sector institu
tions, one humanitarian organization, and one
international research organization.
DNDi was created in response to the fact
that of all the new drugs developed over the past

30 years, drugs for tropical diseases and TB ac
count for only 1.3%. The organization itself does
not conduct research and scientific work to devel
op drugs. Instead, it capitalizes on existing, frag
mented R&D capacity, especially in the develop
ing world, and complements it with additional
expertise as needed. According to Dentico, the
DNDi policy advisor, this integrative approach
helps cut costs.
The group builds its portfolio by identifying
medical needs and R&D opportunities and then
seeking letters of interest to conduct R&D proj
ects. Current projects by academic and industrial
laboratories are focused on identifying new drug
candidates for tropical diseases, such as trypano
somiasis, which afflicts over 66 million people
in 36 countries of Sub-Saharan Africa. Other
projects involve developing products that sim
plify and reduce the length of malaria treatments.
Participating partners provide funding, phar
maceutical development, in vitro and molecular
studies, development of analytical models, ani
mal toxicity testing, and clinical trials, all under
DNDi coordination and management. This col
laborative mode of operation blends centralized
management, which gives a clear project-specific
focus, and decentralized operations, which mimic
modern drug companies.
DNDi has also built regional networks of
scientists actively involved in the research of new
drugs for neglected diseases in Asia, Africa, and
Latin America. These regional networks, coordi
nated by DNDi regional liaison officers, are vital
to the success of DNDi. They are able to collect
data on available regional expertise, capacity, and
patients’ needs, and they actively advocate for
DNDi by encouraging scientists to submit pro
posals to DNDi.
DNDi negotiates intellectual property and
knowledge dissemination agreements to obtain
the best possible conditions for patients and to
ensure that the fruits of DNDi-sponsored re
search will be readily available and affordable in
developing countries. Exclusive rights, titles, and
interest in the results of a given research project
are retained by DNDi, including but not limited
to any resulting patents on any inventions. DNDi
decides on the best way to make the results of a
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research project available to the public, including
by putting the results in the public domain with
no limitations.
In addition, DNDi may choose a number
of IP management options: (1) apply for pat
ent protection to protect some or all of the out
puts of a research project, (2) keep such outputs
confidential, or (3) take any other measures that
would promote DNDi’s mission (such as publicly
disclosing the results). To ensure that DNDi can
make full use of the results of a research project,
DNDi asks partners to grant a nonexclusive,
worldwide, royalty-free, irrevocable license to use
any background IP rights that may be needed to
develop and commercialize a compound devel
oped during the course of a research project.
According to the experience of DNDi, forg
ing agreements with North American universities
is often a lengthy process: the average negotiating
time with academic entities in the United States
and Canada is eight months, whereas the aver
age negotiating time in Europe is four months.
Dentico added that PDPs could provide useful
collaborative R&D models to borrow from and to
create precedents for improving the current R&D
environment. This is especially the case for filling
needs not adequately addressed by government in
vestment, which often focuses on the earliest stages
of research. Unlike some other PDPs, DNDi fo
cuses much of its efforts at the public sector level.
In addition, DNDi wages public information cam
paigns that urge citizens to advocate governments
to fund research on diseases of the poor.
2.2 Bridging academe and industry through
social entrepreneurship: iOWH

Often characterized as the first nonprofit phar
maceutical company in the United States, the
Institute for OneWorld Health (iOWH) is an
other example of a PDP focused on finding
new drug candidates for the developing world.
Katherine Woo, director of scientific affairs at
iOWH, pointed out that the focus of the com
pany is to remove the profit element from the
business plan and to build a global organization
with core competencies in R&D and regulatory
approval for new drugs. A defining feature of
iOWH is its social entrepreneurial component,
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which aims to deliver medicines to the world’s
neediest populations.
According to Katherine Woo, the strategy is
to assemble an experienced team of pharmaceuti
cal scientists to identify the most promising drug
and vaccine candidates—often, the most prom
ising drug candidates are those that have been
discarded for lack of a viable market. Once such
candidates are identified, iOWH focuses on de
veloping them into safe, effective, and affordable
medicines. The group then partners with compa
nies, nonprofit hospitals, and organizations in the
developing world to complete the requisite ani
mal studies, conduct clinical trials, secure qual
ity manufacturing in disease endemic countries,
obtain regulatory approval, and distribute newly
approved therapies.
The group’s strategy, according to Woo, is
based on the assumption that pharmaceutical
R&D to create the new medicines for the develop
ing world need not involve huge costs. By partner
ing and collaborating with industry and research
ers, securing donated intellectual property, and
relying on and using the scientific and manufac
turing capacity of the developing world, needed
vaccines and drugs can be delivered affordably and
effectively. The PDP’s goal is to provide the bridge
between novel bench science and its conversion
into applications for the developing world. For ex
ample, industrial scientists are brought together to
assist university scientists on late-stage processes,
such as high-throughput screening and lead opti
mization of potential new drugs.
Carrying basic scientific research forward
through product development requires the par
ticipation of many groups; however, one partner
ultimately must take responsibility and be held
accountable if new drug development is to be
successful. In many cases iOWH serves as that
global development partner. It takes responsibil
ity for markets in the least developed countries
(dual market opportunities) and obtains resourc
es from private foundations and governments to
fund the development costs of taking a new drug
through to market in the developing world. In
addition, iOWH provides international regula
tory expertise to increase the number of countries
in which important new drugs are marketed.
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The company interprets global access as af
fordable prices, a sustainable supply, and en
gaged distributors. It directly controls pricing as
much as possible and attempts to maintain maxi
mum flexibility to engage downstream partners
(for example, by offering royalty-free licenses).
Negotiations on geographic coverage for market
ing, public sector price and exclusivity consider
ations can be complex and protracted.
As a nonprofit corporation, OneWorld
Health provides a tax deduction for the project
ed future value of donated intellectual property.
However, iOWH seeks exclusive licensing to pro
tect investment by philanthropy. Woo emphasized
that iOWH tries to avoid being surprised in its
IP management strategy and that they are always
on the lookout for intellectual property that has
the potential to discourage important research in
developing countries. When the IP requirements
of a partner become too burdensome or onerous,
the group sometimes walks away from the deal
and searches for another partner.
2. Managing intellectual property
in a research consortium: IAVI

Some PDPs serve as enabling bodies to create
incentive systems, modes of operation, and ne
gotiators for IP management. The International
AIDS Vaccine Initiative (IAVI) focuses on spur
ring R&D for the development of safe, effective,
and accessible preventive AIDS vaccines for use
throughout the world. Labeeb Abboud observed
that, in addition, IAVI is involved in advocacy
work, seeking to secure and sustain global, na
tional, and local community involvement and
commitment for the development of an AIDS
vaccine. Efforts focus on the developing world,
where the epidemic is most severe.
IAVI is supporting research into several key,
unresolved questions of vaccine development.
Among other projects and lines of investigation,
their effort involves a consortium of academic and
industrial research laboratories focusing on HIVneutralizing antibodies, mechanisms of protec
tion, and vector design. The consortium currently
has 16 members located in the United States and
Europe. IAVI negotiates the joint work plan and
provides a governance structure. The members of

the research consortium have agreed to common
provisions relating to IP management and owner
ship, including access provisions. IAVI is provided
with license rights to program intellectual proper
ty, and certain background intellectual property,
and is responsible for diligently pursuing further
development. Future licensing revenues are to be
shared among all members, with the expectation
that no royalties will be received from develop
ing country sales. Key to the effective functioning
of the consortium are the close working relation
ships among its members.
IAVI also has had several vaccine development
programs; it is currently conducting human clini
cal trials of three vaccine candidates in the United
States, Europe, Africa, and India. Although con
sistency in IP management is sought, flexibility
in the approach to IP ownership, management,
and licensing is also important. Ownership may
be determined by inventorship, by ownership of
background intellectual property, or by funding.
License rights to program intellectual property
may be exclusive or nonexclusive, and they may be
worldwide or restricted to certain geographic sec
tors. With respect to partnerships in which IAVI’s
partners control the intellectual property or license
rights, and thus are responsible for manufacturing
and distributing a future vaccine, IAVI’s contracts
require that the partners make access commit
ments for the developing world (relating to price,
quantity, and availability) and provide IAVI with
remedies, such as march-in rights, to ensure that
products developed through the consortium are
made available to people in need.
There are a number of challenges that arise in
the contracting process, as well as in the manage
ment of the ongoing relationships with partners.
Some of the greatest challenges are in the IP area,
with regard to due diligence, management (when
to file and where), meeting the requirements of
donors (including audits), and establishing termi
nation rights.
2. Tailoring IP provisions for each
agreement: Aeras Foundation

The Aeras Global TB Vaccine Foundation, found
ed in 1997, is an international nonprofit PDP
working toward developing a vaccine against TB,
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both at Aeras facilities and in collaboration with
academic/industrial partners. Rita Khanna, the
foundation’s legal counsel, explained that Aeras
actively pursues and helps fund joint-develop
ment activities with leading TB vaccine develop
ers around the world. It also develops candidate
vaccines in its own laboratory. Aeras’s partners
with other groups in order to develop vaccine
candidates and field sites for clinical development
and to ensure vaccine supply. Aeras’ partners in
clude companies in nine countries, academic lab
oratories in eight countries, and five foundation
or government partners. It is the goal of Aeras to
develop, test, characterize, license, manufacture,
and distribute at least one new TB vaccine within
10 years.
Aeras takes promising research and early-de
velopment candidates through preclinical regula
tory requirements; clinical phase one, two, and
three studies; process development; manufactur
ing; and release. The overarching scientific strat
egy is to improve the current, widely used bacille
Calmette-Guérin (BCG) vaccine—which has
limited efficacy—and boost the current BCG vac
cine with either a recombinant TB protein plus
adjuvant or a recombinant viral vector making
TB antigens. Prime-boost regimens of this sort
have proven to be the most powerful inducers of
immune responses and protection against TB in
animal models.
The focus of Aeras’s IP management strategy,
according to Khanna, is to ensure global access
to any resulting vaccine. Aeras has executed nu
merous research collaborations, licensing, and
other agreements with commercial and academic
partners. In one joint development collaboration,
the partner owns the background intellectual
property, while the ownership of new intellectual
property is determined by inventorship. Aeras
has a royalty-free, sublicensable exclusive license
to distribute and sell in developing countries and
public markets in emerging economy countries
(EECs), and the partner has a royalty-free, sublicensable exclusive license to commercialize in
developed countries and private markets in EECs.
The partner has the first right to negotiate—and
right of first refusal—to an exclusive manufac
turing contract to supply Aeras with vaccine for
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sale in developing countries and public markets
in EECs. If the partner is not able to meet the
demand of vaccine for distribution by Aeras, then
the partner must transfer the rights to Aeras or
to a mutually acceptable third party. Should the
partner breach the contract, Aeras would nego
tiate a license to continue commercialization for
developing countries and EECs.
A second type of agreement has many of the
same provisions, except Aeras and the partner
have a royalty-free, coexclusive license to distrib
ute and sell in developing countries with a right to
grant one sublicense. In this scenario, the collabo
rator has the exclusive right to commercialize in
developed countries and EECs. In addition, Aeras
has a royalty-free license for EECs if the partner
has not pursued regulatory approval within three
years of regulatory approval in an industrialized
country. The partner has manufacturing rights for
the first five years only. Should the partner breach
this contract, Aeras has a nonexclusive license to
continue development in the licensed territories
or the right to select an alternative manufacturer.
In similar agreements, Aeras has negotiated
terms in which the collaborator may use a “rea
sonable commercial effort” to manufacture and
supply the product. In addition, the collaborator
may provide the vaccine at two-tier differential
pricing in public and private markets. In this sce
nario, no IP rights are granted to Aeras.
Other agreements focus on license rights:
Aeras has a nonexclusive license in EECs in one
case and an exclusive, worldwide license in anoth
er case. In these types of agreements, Aeras owns
improvements and pays license fees, patent pros
ecution costs (past and future), minimum annual
royalties, milestone payments, and royalty on net
sales. These agreements typically include royaltystacking terms.
In a clinical trial agreement, Aeras retains
rights in intellectual property relating to clinical
trials, although there is joint ownership of intel
lectual property resulting from epidemiologi
cal studies. In a sponsored-research agreement,
Aeras provides funding for the research and has
an exclusive, first right to negotiate an exclusive
or nonexclusive, royalty-bearing license to make,
use, and sell any patentable inventions conceived
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and reduced to practice during the term of and
in the performance of the research supported by
Aeras. In another sponsored-research agreement,
Aeras owns all rights, title, and interest in and to
any intellectual property, material, data, and re
cords derived from performance of research sup
ported by Aeras.
Many of these agreements contain other key
provisions related to confidentiality, publishing
rights, patent enforcement and infringement,
indemnification, liability and insurance, law and
jurisdiction, dispute resolution and arbitration,
and termination.
2. Ensuring access to new drugs: from
aspiration to operation at MMV

Richard Wilder noted that while many PDPs
focus on early-stage efforts to discover and de
liver new drugs for neglected diseases, few have
reached the point of delivery. Indeed, planning
for the access and delivery of new drugs in dis
ease-endemic countries cannot be accomplished
by one PDP working alone.
The efforts of Medicines for Malaria Venture
(MMV) are focused on both delivery and R&D.
Formed in 1999, MMV is a nonprofit organiza
tion created to discover, develop, and deliver new
antimalarial drugs through effective public–pri
vate partnerships. MMV brings together global
public health organizations, the pharmaceutical
industry, government ministries, research institu
tions, and foundations to combine their expertise
and resources to ensure the needed research, de
velopment, and release of antimalarial drugs.
Currently, MMV is managing more than 20
projects that are in various stages of drug R&D,
and several in Phase Three clinical trials, with
reports that good progress is being made. The
group’s goal is to register at least one new antima
larial drug before 2010 and to maintain a sustain
able pipeline of antimalarials that can meet the
needs of the more than 2.4 billion people at risk.
These goals are bolstered by MMV’s ground
breaking collaboration with nearly 40 public
and private institutions around the world. In
particular, MMV entered into discussions with
pharmaceutical companies conducting antican
cer therapy research that led to the development

of compounds that are highly active against the
malaria parasite.
Because much of MMV’s focus is on laterstage issues, it already is discussing with collabo
rators provisions for pricing agreements, negotiat
ing third-party rights, and ensuring that sufficient
quantities of the drug are available once devel
oped. Provisions for handoff are discussed and
negotiated well in advance. All parties must un
derstand the goals, the need for speed, and a clear
view of the regulatory pathway in each country
where drugs are being tested. MMV negotiates
time limits for late-stage clinical trials and filings.
Products are registered and launched immedi
ately following regulatory approval. In addition,
deals with collaborators include requirements for
quality assurance.
MMV manages the ownership and licensing
of intellectual property so that the partners’ in
terests are reflected in the terms of agreements.
Depending on the situation, MMV might own
the intellectual property outright, retain licenses
to the intellectual property, or place conditions
in its agreements that, if not met, will transfer IP
rights back to MMV. Sometimes MMV’s owner
ship of IP rights is unnecessary because the group
is working with a company to both discover and
develop a promising compound as an antima
larial. In those cases, the company might retain
ownership of the IP rights for use in meeting
their obligations to MMV to develop and bring
an antimalarial to market.
MMV’s agreements specify the conditions
that have to be met, including price specifica
tions and access requirements (for example, ac
cess milestones). The experience of MMV sug
gests that setting access milestones should not be
done too late in the process, when time pressures
are heightened. Pricing agreements, moreover, are
particularly challenging because of the division of
markets in many countries where MMV is work
ing. And difficulties can arise if the price issues
are driven too far in advance. An advance com
mitment to a set price ceiling can, for example,
deter investment. If a partner company cannot or
will not meet the conditions of the agreement,
MMV requires that IP rights be returned so it can
seek another partner. However, the focus of deals
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is not on IP rights per se, but rather on the ability
of MMV to ensure that new antimalarial drugs
under development are brought to market and
made affordable and accessible to those who need
them in the developing world. From MMV’s per
spective, IP rights are merely a tool to help bring
partners together toward a common goal.
2. Securing candidate products
through creative licensing: IPM

The International Partnership for Microbicides
(IPM) is a nonprofit PDP established in 2002
to prevent HIV transmission by accelerating the
development and availability of safe and effec
tive microbicides for use by women in develop
ing countries. Paul Model explained that IPM’s
basic strategy involves the licensing of active
compounds from commercial pharmaceutical
companies for development as microbicides. IPM
already has announced compound licenses with
Johnson & Johnson/Tibotec, Merck, and Bristol
Myers-Squibb. IPM has found that larger phar
maceutical companies are more likely to grant
licenses on a no profit/no loss basis.
IPM promotes the rapid development and
delivery of safe and effective microbicide prod
ucts by pioneering best-practices approaches to:
• screen compounds and design optimal
formulations
• develop clinical trial sites and conduct clin
ical trials
• identify appropriate regulatory pathways
for microbicide products
• establish manufacturing and distribution
capacity to ensure rapid access to a micro
bicide as soon as it becomes available
IPM also funds, co-funds, or leverages re
sources to support the drug development projects
of other entities. In some cases, however, the most
efficient approach is for IPM to take the lead in
developing, testing, and conducting clinical tri
als of promising microbicide compounds. In this
role, IPM is the technology developer and receives
a nonexclusive license from the owner of the com
pound that is royalty free and permits distribution
on an affordable basis in resource-poor countries.
Rules and procedures are, however, imposed on
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access to the compound for research purposes.
Importantly, the compounds in development re
main proprietary. Thus, a grant-back license to
the owner of a compound typically is required
for modifications to the compound. Grant-back
licenses of products or formulations are subject to
negotiation.
According to Model, one of the more impor
tant aspects of negotiations involves defining what
constitutes a resource-poor country. In his experi
ence, each partner has its own list of countries;
there is often disagreement over whether certain
countries, such as China, India, and Brazil, qual
ify as resource-poor. However, so far IPM and its
partners have succeeded in reaching agreement
on this issue. In some cases, IPM has obtained
worldwide rights, recognizing that compounds
are still proprietary and ensuring that products
will be made available on an “affordable basis.”
Other important issues involve territory and
access. Some granting organizations are particu
larly concerned about access to results of funded
research. IPM has encountered complex “public
sector pricing regimes” in grant agreements that
are similar to those proposed to several other or
ganizations. These may present inconsistencies
with the structure of the licenses that IPM has
been able to negotiate with commercial pharma
ceutical companies. IPM strives in all cases to
reach agreement on affordable-basis criteria in all
agreements. These criteria include no compen
sation for intellectual property or development
costs, manufacture at lowest reasonable cost con
sistent with quality, and recognition that IPM’s
rights under its licenses are limited. Although
some collaborators are initially resistant to these
or other terms, peer pressure and the desire to do
the right thing are frequently the motivating fac
tors in closing a deal.
2. Deal making with a marketed
product: TB Alliance

Two billion people—one-third of the global pop
ulation—are infected with Mycobacterium tuber
culosis. More than eight million people develop
active diseases every year and two million people
die from the disease. Existing drugs are 40 years
old and impose a daily regimen that is long and
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cumbersome, which slows the control of the dis
ease and promotes the rise of drug-resistance. In
addition, TB/HIV co-infections are fueling each
other, and multidrug-resistant TB (MDR-TB)
and extremely drug resistant TB (XDR-TB) cases
are on the rise.
Gerald Siuta explained that the Global
Alliance for TB Drug Development (TB Alliance)
is a not-for-profit, product-development partner
ship that aims to accelerate the discovery and/or
development of affordable, new TB drugs. It is
hoped that such drugs will shorten treatment and
be easier to take, be more effective against drugresistant strains, be appropriate for patients with
HIV-TB co-infection, and be capable of improv
ing the treatment of latent infection.
In its first five years, the TB Alliance has
built the most robust TB drug pipeline in his
tory, helping to fill a gap left by the private sector.
Any new drug regimen must be more than just
highly effective and easy to use; it must also be
universally affordable, adopted, and accessible.
According to Siuta, this “AAA” goal guides all de
cisions on project selection and development, as
well as concurrent work to influence the policy
and regulatory environments to foster appropri
ate pricing in developing countries, ensure that
new drugs are incorporated into existing treat
ment programs, and facilitate procurement and
distribution to those patients who most need the
drugs.
One of two TB Alliance’s projects now in the
clinical phase is the testing of moxifloxacin for the
treatment of TB. Moxifloxacin is a fluroquino
lone antibiotic already approved in 104 countries
to treat respiratory and skin infections. It is novel
in that it kills mycobacterium TB through DNA
inhibition. Moxifloxacin has been shown to re
duce treatment time by two months when substi
tuted for isoniazid. Moreover, it is safe when used
in combination with antiretrovirals.
In October 2005, the TB Alliance and Bayer
Healthcare announced a partnership to coordinate
a global clinical trial program to study the poten
tial of moxifloxacin to shorten the standard sixmonth treatment of TB. Clinical trials will assess
the efficacy and safety of moxifloxacin as a frontline agent for the treatment of TB. If successful,

the partnership will register moxifloxacin for a
TB indication. Both parties are committed to
making the product affordable and accessible to
patients in the developing world. Nearly 2,500
TB patients are being enrolled in trials in Brazil,
Canada, South Africa, Spain, Tanzania, Uganda,
the United States, and Zambia.
Bayer has committed to donating moxi
floxacin to each clinical trial site, covering the
costs of regulatory filing, and providing moxi
floxacin at an affordable price for patients with
TB in the developing world. The TB Alliance
has committed to coordinate and help cover the
costs of the clinical trials, ensure coordination
of information and results for registration goals,
and leverage substantial support from the U.S.
Centers for Disease Control and Prevention, the
Orphan Products Development Center of the
U.S. Food and Drug Administration, and the
European and Developing Countries Clinical
Trials Partnership.
A crucial aspect of the deal was ensuring that
Bayer’s market for moxifloxacin was protected.
At the same time, if a TB indication is approved,
there is a potential for dual markets in which
there would be separate pricing and distribution
plans.
2. A focus on diagnostics: FIND

Herbert Clemens discussed The Foundation for
Innovative New Diagnostics (FIND), launched
in 2003 at the World Health Assembly in Geneva.
FIND is a nonprofit organization based in
Switzerland and dedicated to the development of
rapid, accurate, and affordable diagnostic tests for
poverty-related diseases in the developing world.
FIND aims to provide a bridge that can ef
fectively link academic research and the diagnos
tic industry to the specific needs of developing
countries. The agency provides this bridge by le
veraging the strengths of its diverse partners to
develop technological platforms for diagnosing
poverty-related diseases in the public, as well as
the private, health sector. Working in close collab
oration with the Special Programme for Research
and Training in Tropical Diseases (TDR) of the
United Nations Children’s Fund, the United
Nations Development Program (UNDP), the
HANDBOOK OF BEST PRACTICES | 1

EISS, HANNA & MAHONEY

World Bank and the World Health Organization
(WHO), the diagnostics industry, and other orga
nizations, the Foundation develops and validates
affordable, novel diagnostic tests for diseases in
high-burden countries. It is leveraging new tech
nologies that have revolutionized the simplicity,
speed, and accuracy of diagnostic tools for identi
fying diseases in the developed world.
FIND conducts its business essentially as
a spinout venture and has project portfolios in
the areas of malaria, TB, and sleeping sickness.
Although it is involved in project management
at all levels—financial, administration, strategic
planning, business development, communica
tions, information technology, and legal services—FIND focuses on the middle spectrum of
product development. FIND leverages its invest
ments to secure affordable pricing in developing
countries, thus helping to ensure equitable access
to diagnostic products for those most in need of
them.
Clemens noted that although FIND has IP
expectations for each project, there is a high de
gree of good faith among collaborators. IP own
ership generally rests with the partner. At the
end of a project, FIND negotiates with the col
laborator on how to dispose of the intellectual
property.
One of the most challenging issues is dealing
with market segmentation. Of the 193 countries
in the world, only 25% are developed, and many
have dual markets, so FIND must arrive at pric
ing agreements that satisfy both the market re
quirements of a sponsor (unit product cost plus
mark up) and FIND’s own access requirements
2. Biotechnology investment
in global health: BVGH

Christopher Earl observed that biotechnology
companies lead the world in developing new
health care products, often for “orphan dis
eases,” conditions for which the development
of drugs in not commercially viable or that are
rare. However, few companies have focused on
developing treatments for neglected diseases.
While many biotechnology industry leaders are
dedicated to contributing to advances in global
health, their companies often perceive market,
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financial, and information barriers that limit
their involvement.
BIO Ventures for Global Health (BVGH)
combines expertise in industry, in investing, and
in policy to bridge biotechnology and global
health. It operates on the assumption that be
cause technology platforms are already built and
“money is already sunk,” there is good reason to
take advantage of the existing infrastructure for
creating medicine for diseases of the developing
world.
BVGH was spun out of the Biotechnology
Industry Organization (BIO) and is supported
by the Bill and Melinda Gates Foundation and
The Rockefeller Foundation, as well as by leading
biotechnology companies. Earl noted that with
more than 4,000 companies and 270 approved
products on the market, the biotechnology in
dustry has created an extraordinarily diverse set
of high-technology platforms for drug discovery,
and thus is well situated to take on the challenges
of global health.
BVGH’s approach is market based: it seeks to
create or facilitate economic incentives and mar
ket mechanisms. Its approaches include: (1) iden
tifying targets for the development of new drugs,
vaccines, and diagnostics; (2) identifying market
opportunities for neglected diseases through a se
ries of disease-specific business cases; (3) working
with companies to build global health strategies
that optimally employ their core capabilities; and
(4) expanding access to information and resourc
es, providing opportunities to exchange informa
tion, facilitating new partnerships, and securing
financing for the most persuasive projects.
According to Earl, the biotechnology indus
try is made up of three tiers. Top-tier companies
are the largest and “act like pharmaceutical com
panies.” These companies are in the process of
building social responsibility models within their
organizations. Second-tier companies are insti
tutionally backed. They are “preprofitable,” their
investors are “tough,” and company strategies
are still focused very much on opportunity costs
and avoiding potential loss of focus. The third
tier consist of very small companies, essentially
“mom and pop” operations. The second tier com
panies are often the best targets for BVGH efforts
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because they have the infrastructure in place, have
financial backing, and yet are not committed to
a binding, long-term R&D plan. Moreover, if
a PDP already has pathways for production or
manufacturing, it reduces the opportunity costs
for such companies in that they can transfer their
technology directly to the effort without high
costs.
In brokering deals between PDPs and bio
technology companies, the innovation should be
in the product, not in the deal. Anytime one can
use existing agreements as models for moving for
ward, time and costs will be minimized, both of
which are at a premium for PDPs and midsize
biotechnology companies.
2.10 An agricultural model for cooperative
IP management: PIPRA

The Public Intellectual Property Resource for
Agriculture (PIPRA) is not a PDP, but rather an
initiative by universities, foundations, and non
profit research institutions to make agricultural
technologies more easily available for the devel
opment and distribution of subsistence crops for
humanitarian purposes in the developing world
and for specialty crops in the developed world.
Alan Bennett explained that although the IP
stakes are low in agriculture, the social and hu
man health stakes are quite high. Traditionally,
discoveries in public research institutions and ag
ricultural universities were seen as “public goods”
that flowed directly down the chain of public in
stitutions to farmers and businesses. This system
formed the basis for crop improvements and a
robust seed industry in developed countries while
significantly increasing food production in several
developing countries.
In the past few decades, however, changes in
U.S. patent law and university technology trans
fer programs have resulted in an increasing use of
the patent system to protect agricultural innova
tions. In many cases, dominant patents held by
the public sector were licensed for private use.
Companies then adopted and often improved
discoveries from public sector institutions and
turned them into crop varieties for commercial
markets. However, because of the many public
institutions conducting agricultural research, the

overall portfolio of public sector technologies is
highly fragmented across multiple institutions
and technology categories. Information about
existing technologies and where rights are held
is difficult to find. In addition, more intellectual
property has been licensed to the private sector,
sometimes under terms that are confidential and
often that provide exclusive rights to the licensee.
Since applied research and crop genetic improve
ment is a derivative process based on preexisting
plant material, each incremental improvement
that involves biotechnology can bring with it a
number of intellectual property and germplasm
constraints, which accumulate in the plant mate
rial. As a result, it has become more difficult for
public sector researchers to access technologies to
fulfill their missions, especially with regard to de
veloping sustainable agriculture for the develop
ing world.
The development of vitamin A-enhanced
rice, or “Golden Rice,” illustrates the conse
quences of the complex IP ownership of agri
cultural biotechnology. Golden Rice provides
dietary vitamin A when consumed. Thus, it offers
direct health benefits to millions of poor children
in developing countries, where vitamin-A de
ficiency causes 500,000 cases of blindness each
year, and is a contributing factor in over two mil
lion premature deaths each year. However, when
the time came to prepare this product, many of
the techniques used by the researchers were pat
ented in some countries, and some of the ma
terials had been used informally, or under legal
agreements that restricted further dissemination.
There were 70 proprietary technologies involved,
including 40 issued patents in the United States
and more than a dozen material transfer agree
ments (MTAs). Although these issues have now
been largely resolved through the cooperation of
the private and public sector, much effort was ex
pended to overcome these barriers.
As a result of this and other cases, PIPRA was
formed to help public sector agricultural-research
institutions achieve their public missions by en
suring access to the intellectual property they
need to develop and distribute improved crops.
Two PIPRA programs of relevance are focused on
IP best practices and management. One program
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is exploring and clarifying the implications of
public sector IP licensing practices and is seek
ing a series of best practices that will encourage
the commercial development of publicly funded
research innovations. At the same time, PIPRA
will also retain rights that public research institu
tions need to fulfill their mission of research for
the broader public benefit.
Another PIPRA program involves building
an IP database. Currently, the database contains
over 6,600 patents and patent applications from
39 different countries. Using the database, these
patents are searchable with respect to various
parameters, including licensing status. The data
represents the agricultural portfolios of 27 par
ticipating universities and nonprofit research in
stitutions. The goal of the database is to inform
public sector researchers about their freedom
to operate (that is, clear all IP barriers to bring
ing a new product to market). The software also
finds ways to invalidate patents and minimize the
chances of patent blocking. Use of the database
and PIPRA’s analytical services are free for aca
demic research and humanitarian purposes.

. kEy LESSonS
Many different models exist for identifying can
didate drugs, vaccines, and technologies, from
owning inventions to finding new uses or mar
kets for already-marketed products or abandoned
product lines. After patents have been issued, the
IP issues and liability concerns become simpler to
manage, since there will be an increasing amount
of safety data available. Partners owning the in
tellectual property are able to provide the back
ground technology and expertise, setting condi
tions for licensing and access.
There is no single business model that PDPs
ought to pursue. PDPs vary from virtual organi
zations that contract all aspects of product devel
opment, to universities and firms, to PDPs that
have developed considerable international capac
ities and expertise in product management and
regulatory affairs. Regardless of the type, all PDPs
negotiate diverse ranges of agreements, including,
sponsored-research contracts, know-how and pat
ent licenses, and distributorship agreements.
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Although their business models vary, PDPs
employ a common set of strategies to manage
intellectual property for global health outcomes,
usefully summarized by Antony Taubman of the
World Intellectual Property Organization. These
include:
• defining a discrete territorial market (sepa
rating industrialized markets from develop
ing countries, or focusing on target mar
kets), allowing investments and earnings
from Organisation for Economic Co-op
eration and Development markets to sub
sidize product availability in developing
countries
• establishing distinct structures for public
sector marketing, social marketing, and
private markets (for example, more open
licensing for the public sector balanced by
exclusivity over lucrative markets)
• determining field of use in a manner that
enables the covered technology or prod
uct to extend to indications for conditions
of prevalence in industrialized countries,
where feasible, as an investment incentive
• establishing royalty rates in a manner that
benefits the party requiring the greatest
incentive
• providing for access to the developed tech
nology in the event that the research/indus
try partner abandons the project or does
not service a particular sector, including
background and foreground intellectual
property, product development know-how,
and regulatory approval data
If the industrial partner bears some of the
risk, because of early-stage involvement either
through investment or conduct of R&D, then
IP issues, such as agreements about royalties,
licenses, and access, must be resolved early on.
These issues can be quite complex. The differ
ent levels and forms of contribution by the part
ner will influence the extent of and flexibility
of the terms. If multiple partners are involved,
each with background intellectual property and
expectations for foreground intellectual prop
erty, then royalty-stacking provisions may be
required.
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.1 Preparing for access

As PDPs plan for access, they face a series of prac
tical and conceptual challenges to ensure supply,
an affordable price, and effective delivery once
the product is successfully developed. An analysis
prepared for WHO’s Commission on Intellectual
Property Rights, Innovation and Public Health
by Jon Merz, indicates that many PDP R&D
contracts defer downstream issues related to man
ufacturing and distribution to future resolution.
Operational challenges face PDPs with regard to
pricing to the public sector, market segmenta
tion, market sizing, ensuring the lowest sustain
able cost of production, and quality control, as
well post-launch issues, such as pharmacovigi
lance and product liability.
Specifying requirements and strategies for ac
cess early on is critical so that unsurmountable
hurdles or costly delays are not encountered once
the product is developed. Indeed, experience
demonstrates that even where certain products
have been developed for distribution in develop
ing countries, uptake has been sluggish or stalled
due to a variety of downstream constraints. This
has been the case, for example, with the combina
tion antimalarial Coartem; praziquantel, for the
treatment of schistosomiasis; and the slow uptake
of hepatitis B vaccines. Some PDPs, especially
those that face inadequate delivery systems in tar
get countries (regarding deployment of microbi
cides or HIV vaccines, for example), have identi
fied preparation for access as a core aspect of their
mission and have begun to document their needs.
Moreover, the GAVI Accelerated Development
and Introduction Plans are forging approaches for
the phased introduction of selected vaccines.9 In
some cases, PDPs also may be able to work with
access public–private partnerships in fields where
they exist (e.g., Roll Back Malaria Partnership),
especially with regard to pricing and financ
ing mechanisms and delivery networks in target
countries.
An important tool in intellectual property
management is the detailed development of
contractual milestones in licensing intellectual
property from public to private sector, including
provisions for performance review and modifi
cations, when required. Key milestones include

pricing to the public sector, territory and exclu
sivity; regulatory work and time to market; royal
ties and terms; and termination of the licensing
agreement.
.2 Pricing issues

A key consideration in access negotiations is tar
get pricing. PDPs typically require the product
to be made available at affordable or reasonable
pricing, which may lead to complex negotiations
about how to calculate price, or consideration
of available price discriminate models. Price set
ting requires both parties to know in advance
the technical details of production, marketing,
and distributions costs. A clear framework to
compute manufacturing cost is required. Since
many PDPs enter negotiations based on earlystage discoveries, stipulating price in a contrac
tual arrangement could be a risky or impractical
proposition. In most instances, the cost of the
final product is the cost of production plus a
reasonably negotiated mark-up. Assessments on
what constitutes an affordable price are complex,
since they take into account the epidemiology of
the disease, purchasing power of those affected,
and government financing schemes, among oth
er factors. In comparison to drugs, where one
can project costs once a compound is identified,
pricing is more difficult with vaccines because
one does not know in advance what the accept
able price will be or what a government might
support. There was general agreement that pric
ing done too far in advance can deter industry
partners and discourage extended R&D com
mitments. Approaches to calculating price are a
priority topic for focused exchange among PDPs
and relevant experts.
. Market segmentation

Market segmentation has emerged as a common
issue in negotiation. Although there are com
mon sources for differentiating countries (for
example, World Bank income data), challenges
emerge with the division of rights in so-called
mixed-payer markets, such as Brazil and India. As
more agreements are pursued, it would be useful
to generate descriptive case studies on price tier
ing and its effectiveness at segmenting domestic
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markets. A correlative need is to prevent arbitrage
or leakage between public and private markets.
. Production and capacity issues

Production also must be addressed. PDPs pose a
new business model with new challenges, (for ex
ample, convincing a party to build a factory with
uptake, rights, and options for manufacturing and
operations that are uncertain). Identifying exist
ing facilities is a strength for some PDPs. Those
working in vaccines, however, have a greater chal
lenge in that for regulatory reasons, they must
find a purpose-built factory for every vaccine.
While excess capacity can typically be absorbed
for drug manufacturing plants, the same is there
fore not the case for vaccines. Thus, the price of
a vaccine is linked to the cost of production and
investment in the manufacturing plant.
Another critical issue is projecting and assur
ing capacity commitments as products approach
the large-scale processing stage. Some therefore
suggest that in some cases there should be public
ly dedicated capacity for manufacturing and that
PDPs should enter into deals with that expecta
tion in mind.
. Early-stage licensing

In negotiations with universities, several PDPs
note challenges with in-licensing the needed tech
nologies from academic institutions. Universities
may overvalue inventions or lack flexibility.
However, through the efforts of organizations
such as MIHR and PIPRA, many universities
are becoming increasingly able to use IP tools
to promote access in developing countries, such
as through the use of humanitarian licensing
provisions.
There are several constructive actions that
could assist the PDPs, including the establish
ment of inventories of IP rights held and a sur
vey of the licensing status in key global health
fields. A prototype database is being developed
at the U.S. National Institutes of Health (NIH),
based on the U.S. Federal Interagency Edison da
tabase of invention reports. At the institutional
level, there is growing interest among technology
transfer offices to operate against performance
expectations aligned with both economic and
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social goals. AUTM is considering new initiatives
in performance metrics, which potentially could
facilitate academic licensing to PDPs, if measure
ments incorporate global health or global access
considerations.
In some instances, negotiations with small
biotechnology firms are comparably difficult.
Such firms are sometimes concerned that sharing
platform technologies for use in the development
of noncommercial products may weaken com
mercial positions. The types of outreach initiatives
undertaken with universities may equally benefit
small biotechnology companies (for example,
through dissemination of case studies). A key
challenge is to demonstrate creditable demand to
encourage risk taking by corporate partners. In
several areas (HIV, pneumococcal, and rotavirus
vaccines), useful modeling work is being pursued
to assess demand and its implications for financ
ing mechanisms.
. Negotiating the IP landscape

PDPs practice due diligence and, where needed,
engage in IP mapping exercises to ensure freedom
to operate. IP assembly issues are becoming more
challenging, due to the increasing need for pro
prietary tools. This is especially the case for broad
umbrella or vaccine component patents, where a
variety of technologies may be required to express
or purify an antigen, bolster immunity, or devise
a delivery system. Related problems include roy
alty stacking and lack of ownership of intellectual
property to cross license.
Responses to patent thickets include li
cense mapping and exploring creative licensing
schemes. There is an emerging range of IP man
agement tools that can be applied, depending on
the particular needs of the scientific challenge.
However, more systematic efforts are needed to
identify where and when current or emerging IP
management strategies might best be considered
and to facilitate their application. The challenge
may be to identify the specific technology plat
forms around where public and private sector
product development interests strongly coincide.
It is also important to identify the key institutions
to bring together to discuss such a consortiumbased approach. Negotiating the patent landscape
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and access to research tools is a general challenge
for the scientific community. However, creative
models in the health sciences may find the most
fertile ground in the context of global health
products, since they represent noncommercial, or
“low margin,” R&D.
. Systemic challenges

The workshop emphasized the broader systemic
needs of the PDPs, including distribution chal
lenges within countries with poor infrastructures.
Reducing the time gap between development and
implementation also will require the continued
development of an international clinical trials
system that engages local investigators, commu
nities, ethical review committees, and regulatory
bodies in low- and middle-income countries. It
will require adequate systems for quality con
trol and regulatory approval to assure consistent,
high-quality products in the absence of first-world
regulatory control, and legal systems within man
ufacturing countries that enable the supplier to
effectively support its patent rights. To reach their
goal, PDPs will need greater engagement of the
scientific community and funding agencies in op
erational and health-services research, including
mode and cost of delivery, patient acceptability
and compliance, dosage and toxicity, and meth
ods to adapt interventions to local conditions and
integrate them into existing services.

. ConCLuSIonS
Workshop presenters broadly endorsed the use
fulness of bringing together diverse groups of
practitioners to address the challenges of IP man
agement for global health outcomes. The value
of such a platform increases as the numbers of
practitioners and institutions associated with
PDPs expand. There is value in continuing broad
discussion, as well as in more focused discussion
with respect to specific issues, such as calculat
ing price. From discussions at the workshop ideas
emerged in regard to a number of actions that
could both contribute to a wider understanding
of issues surrounding intellectual property:
• developing best practice standards and dis
seminating these widely

• developing and disseminating case studies
of various IP approaches related to market
segmentation, tiered pricing, and royalties
• pursuing focused workshops on common
issues such as pricing, product liability, ear
ly-stage licensing, and sponsored-research
agreements with academe, or IP assembly
and freedom to operate
• organizing inventories of IP rights held and
the licensing status of these IP rights in key
global health fields
• encouraging academic licensing practices
that make products more accessible to
impoverished populations and provisions
within research sponsorship agreements
that are responsive to the special require
ments of PDPs
• supporting IP mapping and/or IP-land
scape analysis for products of particular
priority, or disseminating such landscapes
where available
• instituting training programs and personnel
exchanges to build research and technology
management competencies and partner
ships in low- and middle-income countries
• encouraging needed market analysis, such
as estimates of need, to engage corporate
interest
It is clear that many PDPs have matured
over the past few years, progressing along the
continuum from R&D to dissemination. Many
have secured funding and negotiated successful
deals, sometimes with numerous partners. Most,
however, are still in the early stage of product de
velopment, and few have reached the threshold
of product completion and distribution. Thus,
there are no real outcomes to measure at this
time. Moreover, deals are highly contextual. Still,
although best practices will continue to emerge
and be refined, a set of best principles or working
tenets for ensuring product access and availability
has clearly been established. In all cases, the role
of intellectual property in PDP agreements is to
provide incentives for private investment in pub
lic health and to structure and define the nature of
the relationship among the partners with regard
to how rights will be shared or exercised. There
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is nothing particularly novel about the terms of
agreements reached by PDPs; rather, it is their
totality as a public/private hybrid that sets them
apart. Collectively, the PDPs are broadening our
creative understanding of practical ways to resolve
the public-policy dilemma of balancing private
incentives to generate needed R&D investment
with the goal of access to those in need. n

5

25 and 26 July 2006 at the Aeras facility in Rockville,
Maryland, U.S.A. The meeting included representatives
of PDPs, industry, and academe, who shared their
perspectives on IP issues, partnership strategies, and
value propositions or incentives in deal making. The
involvement of corporate and academic partners
helped facilitate discussions about the dynamics
that shape and direct successful public-private
partnerships. For example, there is a strong interest
on the part of the PDPs in building knowledge
among university technology managers of the special
needs and requirements of the PDPs as nonprofit
enterprises. Correspondingly, PDPs can learn from
university technology offices how to more effectively
negotiate sponsored research or early-stage licensing
agreements with universities, given the requirements
and needs of academic environments.

6

To view the 2004 MIHR report, see: www.
globalforumhealth.org/filesupld/ippph/dealmaking.
pdf. The 2006 meeting, like its predecessor, provided
a platform for exchanging emerging best practices
in structuring and negotiating product development
agreements for technologies needed in developing
countries. Presentations centered on case studies
of several PDPs to illustrate terms, conditions, and
strategies that may be employed to help ensure
product availability and access. Topics included:
segmentation of markets, pricing, negotiating with
universities, liability issues, ownership and use of
clinical trial and regulatory data, partnerships with
emerging suppliers, and technical assistance needs to
ensure technology transfer. Discussions were focused
on best practices for deal making in various contexts,
from understanding complementarities of missions to
negotiating contract language.
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See, also in this Handbook, chapter 2.7 by J
Oehler. See also Kaplan W. 2005. www.who.int/
intellectualproperty/studies/W.Kaplan2.pdf.
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See, also in this Handbook, chapter 17.9 by J Banerji and
B Pecoul.
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www.gavialliance.org.
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CHAPTER 2.4

Patenting and Licensing Research Tools
CHARLES CLIFT, London, U.K.

ABSTRACT

Research tools encompass a wide range of resources, in
cluding genes/gene fragments, cell lines, monoclonal an
tibodies, reagents, animal models, growth factors, combi
natorial chemistry and DNA libraries, clones and cloning
tools such as polymerase chain reaction, methods, labo
ratory equipment and machines, databases and computer
software. Access to research tools is integral to advancing
progress in biotechnological R&D, in both the biomedical
and agricultural sciences. However, a complex web of re
search tool patents has arisen as a result of the revolution in
molecular biology and coincident changes in public policy
and patent law. These patents can pose a potential block
to accessing research tools. For developing countries, sev
eral approaches can be formulated and then implemented
in order to overcome potential problems associated with
research tools. These include changes in patenting poli
cies, research exemptions in patent law to reduce the risk
of infringement in R&D, compulsory licensing to allow
access to upstream technologies, and institutional adapta
tions to facilitate access to needed technologies, such as
guidelines intended to promote more appropriate behav
ior by participants in the system. With carefully formu
lated, multitiered approaches, research tool patenting and
licensing (and its possible impact on innovation in health
and agricultural research) may be effectively managed.

1. INTRODuCTION
Research tools are difficult to define precisely.
They may be described, broadly, as any tangible
or informational input required in the pro
cess of discovering a drug, a medical therapy,

a diagnostic method, or a new crop variety. In
short, anything that a researcher needs to use or
access in the course of research—such as an as
say, a genomic database, an animal model, crop
germplasm and so on—may be classified as a
research tool.1 Research tools are defined by
the U.S. National Institutes of Health (NIH)
as the full range of resources that scientists use
in the laboratory, including “cell lines, monoclo
nal antibodies, reagents, animal models, growth
factors, combinatorial chemistry libraries, drugs
and drug targets, clones and cloning tools (such
as PCR), methods, laboratory equipment and ma
chines, databases and computer software.” 2 To
this definition, one should add genes and gene
fragments.
The classic statement on the possible con
sequences of protection by intellectual property
(IP) rights of research tools in biomedical re
search was made by Heller and Eisenberg:
… the recent proliferation of intellectual prop
erty rights in biomedical research suggests a dif
ferent tragedy, an “anticommons” in which people
underuse scarce resources because too many owners
can block each other. Privatization of biomedical
research must be more carefully deployed to sustain
both upstream research and downstream product
development. Otherwise, more intellectual prop
erty rights may lead paradoxically to fewer useful
products for improving human health.3

Clift C. 2007. Patenting and Licensing Research Tools. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org.
© 2007. C Clift. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial
purposes is permitted and encouraged.
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Similar concerns have been expressed about
agricultural research, for example by Boettiger
and Bennett.4

2. RESEARCH TOOlS: KEy EVENTS
There are three key events of relevance to the global
debate on the pros and cons of patenting research
tools, all of which date from 1980, or thereabouts.
2.1 Event one: the revolution in
molecular biology

The revolution in molecular biology has fostered
the development of wholly new branches of sci
entific investigation, such as proteomics (the sci
ence of proteins expressed by genes), which has
transformed the way research is conducted, as
well as widened, enormously, the potential for
scientific advances to address fundamental hu
man problems in health and agriculture. Many
of the immediate products of such research are
intermediate or platform technologies of use to
other researchers, but not (with certain exceptions
such as diagnostic tests) final products capable of
application by medical practitioners or farmers.
2.2 Event two: the Chakrabarty case

The landmark 1980 U.S. Supreme Court deci
sion, Diamond v. Chakrabarty,5 established that
genetic inventions (in this case a genetically en
gineered bacterium capable of breaking down
crude oil) were patentable subject matter under
U.S. law. The application of the patent system in
this way facilitated the development of a viable
business model for the biotechnology industry.
With the development of potentially revenueearning products, often a long way off for many
companies, they could nevertheless raise money,
or realize value (for example, via licensing, assign
ment, or other forms of acquisition) through the
patents taken out on research tools or other up
stream genetic technologies.6
2. Event three: the Bayh-Dole Act

The 1980 Bayh-Dole Act amended the patent
code in the United States, granting universities
permission to patent inventions resulting from
government-funded (federal) research, subject
0 | HANDBOOK OF BEST PRACTICES

to government march-in rights. This was based
on the premise that implementation of the BayhDole Act would hasten innovation, facilitate the
commercialization of research, and thereby move
new and innovative products into the marketplace
more quickly. As a result universities themselves
have become key players in the development
and patenting of new biotechnology inventions,
most of which are in the nature of research tools
rather than final products. Increasingly universi
ties have developed extensive patent portfolios in
both agricultural and biomedical technologies.
Subsequently, most of the developed world has
pursued similar policies to the United States in
promoting the commercialization of the products
of university research.

3. RESEARCH TOOlS: IMPlICATIONS
AND CHAllENGES
The more technologically advanced developing
countries, including Brazil, India and China, have
in recent years pursued essentially similar policies
to the United States in promoting the commer
cialization of the products of university research.
But developing countries, even those with a rela
tively well-developed scientific and medical infra
structure, face very different circumstances from
those in the United States and other developed
countries. Although most developed countries
have tried to emulate Bayh-Dole policies in differ
ent ways, the success of such policies in the United
States owes much to institutional arrangements
specific to the United States and is based on its
unique higher education system and history of in
teractions between universities and businesses.7
An emphasis on patenting and licensing by
universities as the chief means by which technol
ogy transfer occurs, as compared to publication
and open knowledge sharing, may have negative
implications for research in the area of public
health or agriculture, as well as other areas. Since
revenue prospects will be greater for products
that would have a market in a developed coun
try, this promise may further distort the alloca
tion of research funding away from the specific
public health problems of developing countries.
Therefore, care must be taken to ensure that
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research priorities, particularly those that could
directly benefit poor people, are not distorted by
the quest for larger licensing income.
Concerns about access to research tools ap
ply both to the public and private sectors. In the
public sector, for example, one university may wish
to access the patented technology of another for
research. Universities may wish to access private
sector technologies, and vice versa. Private sector
companies may experience difficulties in access
ing each others’ technologies.
Some see one university paying another to
license a technology as perverse when most re
search in universities is publicly funded, even
if the university is privately funded. But this is
a logical consequence of introducing patenting
into the university arena. In the United States,
in the Supreme Court case Madey v. Duke,8 the
Court found that, since the “business” of Duke
University was research and teaching, there was
no exemption from patent infringement in its
research, as the use of the patented invention
was in furtherance of that business. The profit or
nonprofit status of the user was not a critical fac
tor for the court. Although not part of the court’s
judgment, the implication was that as universities
were now enthusiastic users of patents and licens
es, and litigated to enforce their patent rights, it
would therefore be inconsistent for universities to
seek exemptions for the use of third-party patent
ed inventions for R&D in their own programs.

4. THE REAlITy OF RESEARCH TOOlS
.1 Biomedical research

In developed countries the evidence to date, which
mainly comes from the United States, suggests
that researchers in both the public and private sec
tor have found various ways of coping with the
new environment of patented research tools.
In biomedical research, working solutions
include licensing, inventing around patents, in
fringement (often informally invoking a research
exemption), developing and using public tools,
and challenging patents in court. Changes in the
institutional environment, such as the tightening
of gene patenting rules introduced by the U.S.

Patent and Trademark Office, and guidelines pro
duced by NIH to encourage good patenting and
licensing practices, appear to have further reduced
the threat of breakdown and access restrictions,
although the environment remains uncertain. It
is clear, however, that these various working so
lutions involve costs in terms of either time or
money or both.9
Furthermore, a recent study in the U.S. of re
searchers in academia, government and nonprofit
organizations, and industry suggests that difficul
ties in gaining access to materials (for example, data
or cell lines) through Material Transfer Agreements
(MTAs) may have more significant implications
for the conduct of research than patenting itself.10
A critical finding is that industry researchers
experience significantly greater delays and diffi
culties in accessing proprietary technologies than
academic researchers. In large part this is because
industry researchers work, self-evidently, in a
more commercial environment, are more patent
aware than academics, and more liable to respect
the patent rights of others and to assert their own
rights with respect to their own proprietary tech
nologies (including research tools). By contrast,
while commercial activity and pressures have be
come much more widespread in academic circles,
and patenting is common, researchers are less
aware of patent issues, more likely not to check
whether the technologies they use are protected,
and less likely to assert their own rights against
other academic researchers.
Another recent report from the Committee on
IP Rights in Genomic and Protein Research and
Innovation reached the following conclusion:
…the number of projects abandoned or delayed
as a result of difficulties in technology access is re
ported to be small, as is the number of occasions in
which investigators revise their protocols to avoid in
tellectual property issues or in which they pay high
costs to obtain intellectual property. Thus, for the
time being, it appears that access to patented inven
tions or information inputs into biomedical research
rarely imposes a significant burden for biomedical
researchers. For a number of reasons, however, the
committee concluded that the patent landscape,
which already is becoming complicated in areas such
as gene expression and protein-protein interactions,
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could become considerably more complex and bur
densome over time.11
Accordingly the committee made recommen
dations that addressed “an increasingly problematic
environment for research in genomics and proteomics
as more knowledge is created, more patent applica
tions are filed, and more restrictions are placed on
the availability of and access to information and
resources.”
A special case is that of genetic diagnostic
tests, which may be used either clinically or in
the course of follow-on research. They, therefore,
have a dual nature, both as a final product, and
as a discovery tool. A survey of over 100 labora
tories in the United States concluded that patent
ing and licensing practices in this field had had a
negative impact on clinical use and the develop
ment of further genetic tests.12
These survey results relate to mainstream re
search of potential commercial value. Furthermore,
it is likely that transaction costs could weigh more
heavily on those working with limited resources on
projects focusing on specific diseases particularly
affecting developing countries. On the other hand,
some public–private partnerships (for example, the
Global Alliance for TB Drug Development) say
that their philanthropic mandates can be useful
in encouraging companies to license their IP more
easily, and more cheaply, than would be likely in a
wholly commercial exchange. It is, therefore, dif
ficult to draw valid, general conclusions from the
evidence currently available.
There is also very little empirical evidence of
the impact of research tool patents in the biomedi
cal field in developing countries themselves. More
experience and empirical research are needed. The
impact of such patents may be more significant in
developing countries than in developed countries,
as research institutions or companies in developing
countries generally lack the legal and negotiating
capacity to engage in complex negotiations and
lack the organizational flexibility and funds to pay
license fees, if required by patent holders.
.2 Agricultural research

The institutional context for agricultural re
search, by which in this context we mainly mean
2 | HANDBOOK OF BEST PRACTICES

crop research, differs from biomedical research.
The size of the sector, and of the potential com
mercial market, is much smaller than in medi
cine. There is also a tradition of public sector
institutes taking research right through to the
point of commercialization (at least in tradi
tional breeding programs), whereas in medicine
commercialization is overwhelmingly a private
sector activity.
The advent of biotechnology and the spread
of gene patenting is one reason why the private
sector in agricultural research has come to be
dominated by a few large companies. In particu
lar, the existence of a large number of overlapping
patents for relatively important technologies has
been a powerful incentive for merger and acquisi
tions, as well as strategic alliances. For example,
patents on the Bt gene which can confer insect
resistance on a wide range of different crops are
strategically important for the whole industry.
Controlling or denying access to strategic tech
nologies is both commercially important to their
owners and, correspondingly, liable to adversely
affect research on crops where the commercial
market is small (for example, subsistence crops in
developing countries).
With respect to IP, research tools and agri
cultural research, a recent survey concluded that
evidence:
…suggests that the effects on research of lack of
access to needed technology have been more serious
on average for biotechnologists working on agricul
ture than for those focused on human health. This
might reflect the smaller set of promising technologies
in agriculture and the lower level of resources avail
able to help scientists surmount or invent around
roadblocks. 13
It also seems to be the case that patented ge
netic crop material (such as the Bt gene) is viewed
as having more commercial value than many of
the research tools used in biomedical research.
Thus, whereas patent holders may disregard in
fringements in upstream biomedical research, or
think it not cost effective to sue for infringement,
in the case of more downstream agricultural re
search this may not be so.
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5. ADDRESSING THE RESEARCH
TOOlS CHAllENGE
Developing countries have a number of possible
options, at the level of policy and practice, to
address the possibility that proprietary restric
tions will unduly limit the use of research tools.
Possible approaches used or considered to address
this issue include the following:
• changes in patenting policies
• research exemptions in patent law to reduce
the risk of infringement in R&D
• compulsory licensing to allow access to up
stream technologies
• institutional adaptations to facilitate access
to needed technologies, such as guidelines
intended to promote more appropriate be
havior by participants in the system
.1

Patenting policies

Countries may adopt different approaches to
patenting. On the one hand, the Agreement on
Trade-Related Aspects of Intellectual Property
Rights (TRIPS) in Article 27 (1) obliges coun
tries to grant patents across all fields of technology
provided that the technology is new, involves an
inventive step (or is nonobvious,) and is capable of
industrial application (or is useful). On the other
hand, the agreement allows various exclusions
from patentability, such as discoveries of natural
phenomena (which could include genes) that do
not meet the patentability criteria.
Governments may choose whether or not to
allow the patenting of genetic material. Plants and
animals may be excluded from patentability, ex
cept for microorganisms, and nonbiological and
microbiological processes. The TRIPS agreement
does not specify how countries should define what
an “invention” is, or how the criteria of patentability should be interpreted. Nor does it actually
refer to genes, or genetic material, at any point.
The desirability of restricting patentability
of genetic discoveries in this way will need to be
assessed according to the circumstances of each
country. For instance, countries that are mainly
users of research tools patented abroad might
promote the use of such tools by limiting their
patentability. Other countries, with more ad
vanced capacities in genomics, might favor a

less-stringent interpretation of patentability but
would need to be mindful of the possibility of
restrictions on their widespread use.
If patents are granted, they can limit the
scope of the claims to what has actually been in
vented. Patenting policy in biotechnology should
aim to facilitate R&D of healthcare products and
new agricultural crops. Unlike some other coun
tries, France and Germany have introduced rules
that limit the scope of patent protection for hu
man gene sequences to the specific use disclosed
in the patent application, thus excluding protec
tion for future, as yet undiscovered, uses.14 These
rules were introduced because broad protection
may disadvantage those wishing to build on the
invention, while narrower claims may facilitate
their downstream use.
.2 Research exemptions

The TRIPS agreement allows the use of limited ex
emptions under Article 30, which has a possible ap
plication to the research tool issue as well as others:
Members may provide limited exceptions to the
exclusive rights conferred by a patent, provided that
such exceptions do not unreasonably conflict with a
normal exploitation of the patent and do not unrea
sonably prejudice the legitimate interests of the pat
ent owner, taking account of the legitimate interests
of third parties.
In most of Europe, exemptions exist for acts
performed privately, for purposes that are noncom
mercial, and for experimentation on the subject mat
ter of the invention, even for commercial purposes.
In the United States, by contrast, there are no
equivalent statutory exemptions, even for non
commercial or research uses. In the past, however,
the courts have generally recognized some scope
for “making or using of a patented invention merely
for experimental purposes, without any intent to de
rive profits or practical advantage… .” In 2002, as
noted above, the case of Madey v. Duke essentially
ended this informal research exemption.15
There is an active debate in several coun
tries about the appropriate scope of any re
search exemption. In 2004, the U.S. National
Academies of Science (NAS) published a report
on the U.S. patent system recommending that
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the introduction of a formal research exemption
for noncommercial purposes.16 This recommen
dation was repeated in the subsequent report on
genomic and proteomic research.17
Thus, there is a broad spectrum of ways in
which the research exemptions allowed under
the TRIPS agreement are implemented in dif
ferent countries, and how these are interpreted
by courts. The essential point, in this context, is
how to ensure that follow-on research that may
be important to innovation in the fields of health
and agriculture is not inhibited. The appropriate
scope of the research exemption must be consid
ered in this light.
. Compulsory licensing

In most countries, the law allows governments
to issue compulsory licenses on a number of
grounds, including in circumstances where the
development of a research field of importance to
public health or agriculture could be inhibited by
the actions of particular patentees. For example,
in the United Kingdom there are extensive pow
ers in the Patent Act that, although rarely used,
can remedy such situations. Section 48A (1) of
the act, for instance, covers:
refusal of the proprietor of the patent to grant
a licence or licences on reasonable terms … the ex
ploitation … of any other patented invention which
involves an important technical advance of consider
able economic significance in relation to the inven
tion for which the patent concerned was granted is
prevented or hindered.
Similar provisions exist in many other coun
tries. In the United States, the Patent Act does
not provide for compulsory licensing as such, but
there are similar march-in rights, as part of the
Bayh-Dole amendments, only where federal fund
ing of an invention is involved (Section 203).
In the European Union, the 1998
Biotechnology Directive, which has been imple
mented in national law by many member states,
contains provisions that allow for compulsory li
censing of patents or plant variety rights if prior
negotiations with the owner are unsuccessful,
provided that the resultant invention constitutes
significant technical progress of considerable
 | HANDBOOK OF BEST PRACTICES

economic interest compared to the original inven
tion claimed in the patent or plant variety right.
. Institutional adaptations

Various initiatives have been considered or imple
mented to adapt or modify institutional practices
around patenting and licensing.
One example of adaptation to the changing
technical environment was the announcement in
2001 by the U.S. Patent Office of new guide
lines on expressed sequence tags (short pieces
of DNA that help to identify when particular
genes are being expressed in cells). These guide
lines tighten the specifications regarding what
constitutes “utility,” and provide guidance to
patent examiners about how to apply the util
ity criterion to biotechnological inventions. In
such cases, patentability can be established only
if the patent application discloses a specific, sub
stantial and credible utility.18 It was intended that
this new standard would prevent patents being
granted on inventions for which only a specula
tive application is disclosed. The introduction of
these tighter criteria may be one reason, among
others, why patent applications in this area have
declined recently.
Countries may also consider guidelines or oth
er means to encourage or mandate patenting and
licensing policies that promote innovation. In the
United States, NIH, as the principal funder of aca
demic biomedical research, took the lead in pub
lishing in 1999 principles and guidelines on sharing
biomedical research resources. These sought to pro
mote the widest possible dissemination of research
tools developed with NIH funds, in the interests
of accelerating scientific discovery and facilitating
product development. At the same time NIH con
sidered that “reasonable restrictions on the dissemina
tion of research tools are sometimes necessary to protect
legitimate proprietary interests and to preserve incen
tives for commercial development.” 19
In 2005, NIH introduced voluntary guide
lines (“best practices”) on the patenting and li
censing of genetic inventions funded by NIH
grants. On patenting, the guidelines said it should
be considered whether:
…significant further research and develop
ment by the private sector is required to bring the
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invention to practical and commercial application.
Intellectual property protection should be sought
when it is clear that private sector investment will be
necessary to develop and make the invention widely
available. By contrast, when significant further re
search and development investment is not required,
such as with many research material and research
tool technologies, best practices dictate that patent
protection rarely should be sought.
On licensing, the guidelines provided a
more extensive set of principles that support
nonexclusive licensing as a general rule. Where
exclusive licensing might be necessary to promote
further development, the guidelines suggest that
care should be taken to license only in the spe
cific area where the licensee is working, to avoid
blocking off other areas of research that may use
the same technology. In addition, they said con
sideration should be given to including specific
provisions to protect further research and public
health. For instance, a license could reserve the
right for the invention to be used in nonprofit
research organizations for either research or edu
cational uses.20 Boettiger and Bennett argue that
since the NIH guidelines appear to be working
well, they should be applied across the board
where federal funding is involved, keeping in
mind, specifically, the situation in agricultural
biotechnology.21
Guidelines on the licensing of genetic inven
tions have also been produced by the Organisation
for Economic Co-operation and Development
(OECD).22 Apart from the text of the guidelines,
an appendix contains a useful list of Web links to
model agreements on various aspects of licensing
and material transfers.
The international network of agricultural re
search centers, that is, the Consultative Group on
International Agricultural Research (CGIAR),
has a policy on IP, with the underlying principle
to “take every possible measure to facilitate access
to research products for the public benefit, in par
ticular in developing countries,” while recognizing
also that there will be exceptional circumstanc
es when taking out patents may be necessary
for the various centers to pursue their specific
objectives.23

Some U.S. universities are indeed experi
menting with new licensing arrangements. For
instance, Stanford University proposes wording,
along the following lines, as a standard means of
establishing freedom for universities, public sec
tor research organizations or, indeed, organiza
tions such as public–private partnerships to be
able to use particular technologies that it licenses
exclusively to a third party:
Stanford retains the right, on behalf of itself and
all other nonprofit academic research institutions, to
practice the Licensed Patent and use Technology for
any purpose, including sponsored research and col
laborations. Licensee agrees that, notwithstanding
any other provision of this Agreement, it has no right
to enforce the Licensed Patent against any such insti
tution. Stanford and any such other institution has
the right to publish any information included in the
Technology or a Licensed Patent.24
The organization Universities Allied for
Essential Medicines has been set up in the United
States to explore how universities can help ensure
that biomedical end products, such as drugs, are
made more accessible in poor countries, and to
increase the amount of research conducted on ne
glected diseases, or those diseases predominantly
affecting people who are too poor to constitute a
market attractive to private sector R&D invest
ment. The organization recognizes that university
scientists are major contributors in the drug-de
velopment pipeline and that universities have an
avowed commitment to advancing the public
good.25 The organization has developed a model
equitable access license to further these aims.26
A body of technology managers called the
Technology Managers for Global Health has
been formed, as a subgroup within the influential
Association of University Technology Managers
in the United States, to press for similar sorts
of arrangements to those promulgated by the
Universities Allied for Essential Medicines and
others. In conjunction with the Centre for the
Management of Intellectual Property in Health
Research and Development (MIHR), a co-spon
sor of this Handbook, the Technology Managers
for Global Health has published a booklet provid
ing case studies of academic licensing to product
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development partnerships for treatments for dis
eases affecting developing countries particularly.27
Another initiative seeks to draw on the suc
cess of the Open Source Initiative (OSI) which
has developed a more or less proven research
model, based on a general public license that
makes modifications of a software program freely
available to others to use or develop further. The
important aspect of this approach is that it mobi
lizes innovative effort from a range of developers
at little cost.
CAMBIA, a nonprofit organization based in
Australia, both undertakes research in molecu
lar biology in agriculture directed at the needs
of developing countries and also seeks to over
come the problems of fragmented technologies
by developing patent and technology databases
and innovative licensing techniques that draw on
the experience of OSI. CAMBIA has prepared a
model license28 that has the objective of creating
a common pool within which improvements can
be freely shared. On the other hand, the terms of
this license may conflict with the existing licens
ing terms of other technologies, which should
form part of the common pool.
The Public Intellectual Property Resource
for Agriculture (PIPRA), the other co-sponsor
of this Handbook, is an organization comprising
universities, foundations, and nonprofit research
institutions, which aims to make agricultural tech
nologies more easily available for the development
and distribution of subsistence crops for humani
tarian purposes in the developing world. PIPRA
seeks, through a variety of activities, including the
compilation of patent and licensing databases, to
mitigate problems arising from the fragmentation
of proprietary technologies and materials among
different institutions. It has also proposed a draft
license to facilitate research relevant to developing
countries.29
Another institutional approach is the poten
tial use of patent pools. In 2000, a report by the
U.S. Patent Office on patent pools and biotech
nology patents concluded that the “use of pat
ent pools in the biotechnology field could serve the
interests of both the public and private industry, a
win-win situation.”30 Among the benefits cited
for this approach to licensing were: efficiency in
 | HANDBOOK OF BEST PRACTICES

obtaining rights to patented technology through
one-stop licensing mechanisms; the distribution
of risks associated with research and develop
ment; and the elimination of blocking patents or
stacking licenses, and the consequent encourage
ment of cooperative efforts. Patent pools, there
fore, could be most useful for technologies par
ticularly relevant to developing countries, because
the lack of strong market incentives may enable
agreements that would otherwise be more dif
ficult to engineer. Low-margin research directed
toward problems of poor people might be pro
moted. Patent pools have also been proposed for
the development of vaccines, which is appropri
ate given the large number of products owned by
different entities and, consequently, the
complexity of identifying, tracking, and obtain
ing licenses for patented technologies.
Patent pools have been established in the con
sumer electronics industry, specifically in relation
to the broad adoption of industry standards. The
biotechnology industry, however, is very different
from the electronics industry. An OECD report
noted:
…the pharmaceutical biotechnology industry
may be fundamentally different from the electron
ics sector. It is not an industry in which defining
standards is important, and assuring interoperabil
ity of technologies is not very important, especially
not in the development of therapeutics. A company’s
worth is tightly tied to its intellectual property and
fosters a “bunker mentality.” There are likely to be
disagreements among partners over the value of the
different patents in a pool, and dominant players
may not have a strong incentive to join the pool. If
a limited field of application and essential patents
can be defined, the patent pool model is worthy of
consideration in biotechnology…31
The suitability of the patent pool for biotech
nology patents certainly requires further study, as
does the role of government in promoting them.
For these reasons, and others, patent pools in
biotechnology have not developed as a response
to fragmented patent ownership. In agricultural
biotechnology in particular, cross-licensing and,
ultimately, mergers and acquisitions are the
common response.
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6. CONCluSIONS
While no specific guidance or conclusions can
cover the specific circumstances of policy-mak
ers, researchers, universities, research institu
tions, foundations or other organizations in given
developed or developing countries, the sev
eral guidelines, enumerated below, might
help to conceptualize a starting point within a
broader framework:
• Developing countries need to consider im
plementing patent legislation, consistent
with TRIPS, that meets their objectives, in
particular with respect to genetic discoveries.
• Countries need to consider in their own
legislation what form of research exemption
might be appropriate, in their own circum
stances, to foster research and innovation in
health and agriculture.
• Countries should consider providing in
their legislation powers to use compulsory
licensing, in accordance with the TRIPS
agreement, where this power might be use
ful as one of the means available to promote,
inter alia, research that is directly relevant
to the health and agriculture problems of
developing countries.
• Countries should seek through patent
ing and licensing policies to maximize the
availability of innovations, including re
search tools and platform technologies, for
the development of products for human
health and agriculture.
• Public funding bodies should introduce policies
for sensible patenting and licensing practices,
for technologies arising from their funding,
to promote downstream innovation.
• Public research institutions and universi
ties in developed countries should seriously
consider initiatives designed to ensure that
access to R&D outputs relevant to the
health concerns of developing countries,
and to products derived therefrom, are
facilitated through appropriate licensing
policies and practices. n
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CHAPTER 2.5

Valuation and Licensing in Global Health
ashley J. sTevens, Associate Director, Institute for Technology Entrepreneurship and Commercialization,

School of Management, and Director, Office of Technology Transfer, Boston University, U.S.A.

ABSTRACT

Since 1999, two trends have transformed the landscape of
treating endemic diseases in the developing world: (1) the
establishment of highly effective drug development pub
lic private partnerships, which have secured substantial
amounts of philanthropic funding to develop new drugs
for developing countries and (2) the emergence of tiered
pricing for drugs that are under patent protection and
that treat diseases in both the developed and the develop
ing world. As a result, the options have increased for both
academic institutions and companies for developing new
therapies for low- and middle-income countries. This
also means that traditional bilateral licensing arrange
ments will be replaced by multimember networks that
bring together the necessary skills for R&D, regulatory
work, intellectual property (IP) management, produc
tion, and distribution and marketing. New licensing ap
proaches will be needed to ensure that IP issues facilitate,
rather than hinder, such collaborations and transactions.
This chapter presents evidence that suggests that all par
ties to such transactions should strive for a no profit–no
loss financial model in order to maximize humanitarian
benefits.

1. TWo pHARMACEuTICAL InduSTRIES:
TWo pRICInG pHILoSopHIES
In developed countries, the pharmaceutical in
dustry consists of two quite separate and largely
nonoverlapping sectors:1
• In the research-driven sector, new drugs are
developed and tested through clinical trials.
Typically, a new drug application (NDA)
is filed with the FDA; when the NDA is

approved, the drugs are sold at legal, patentprotected, monopoly prices based on the
benefits the drugs provide to patients.
• In the generic sector, drugs that are nearing
the end of their patent protection term are
prepared for market and, when patents ex
pire, sold competitively at commodity prices
based on the cost of production.
According to the Generic Pharmaceutical
Association, using IMS health data, generics ac
counted for 56% of all prescriptions dispensed in the
United States in 2005, but less than 13.1% of every
dollar spent on prescription drugs. Generics cost, on
average, 30% to 80% less than their branded coun
terparts.2 Prices for generic drugs are typically 10%
to 20% of their prepatent expiration price and are
cost based (that is, the price is based on a mark up
over the cost of production).3 Analysis of the finan
cial results of publicly traded generic-drug companies
shows that these companies typically operate with a
gross margin—the amount by which sales exceed the
cost of goods sold—of around 50%.4 This margin
covers the companies’ general and administrative
costs, marketing and selling costs, and profits.

2. dRuG pRICES In dEvELopEd CounTRIES
The United States has had a love–hate rela
tionship with the research-driven sector of the
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pharmaceutical industry almost from its incep
tion. Consumers love the new life-saving medica
tions that the industry has been able to discover,
but they hate the prices resulting from the patentprotected monopoly.
The issue first emerged in the late 1940s,
with the launch of the tetracycline family of anti
biotics.5 This was the first family of antibiotics to
be discovered by the U.S. pharmaceutical indus
try itself. The first antibiotics—penicillin, strep
tomycin, and neomycin—had been discovered
in academic laboratories (penicillin at St. Mary’s
Hospital in London, U.K. and Oxford University
with the critical process scale-up under war
time conditions led by the U.S. Department of
Agriculture6 and streptomycin, and neomycin at
Rutgers University7). All were licensed non-exclu
sively and the resulting competition caused prices
to fall rapidly.
By contrast, thanks to the patent protection
they enjoyed, prices for tetracyclines remained
high. However, eventually competition came
from overseas. At that time, Italy was the “rogue
state” of pharmaceutical patents, and through
bids by an Italian company for a U.S. military
procurement of tetracyclines, the government
became aware of the high profit margins on the
patented drugs. This discovery led to hearings fo
cused on the pharmaceutical industry led by U.S.
Senator Estes Kefauver, Chairman of the Senate
Antitrust and Monopoly Subcommittee, from
1959 to 1963. Kefauver correctly identified that
the pharmaceutical industry was making enor
mous profits on the new generation of antibiot
ics. Disclosures of price markups of thousands of
percents led to sensational headlines across the
country and to widespread public outrage. He
identified a number of other problems in the in
dustry, notably the lack of any requirement for
systematic testing for the safety and efficacy of
new drugs and the industry’s freedom to advertise
new drugs with the flimsiest of scientific support
for their claims.
Kefauver drafted a law to increase regula
tion of the industry. The report included re
quirements for demonstration of safety and ef
ficacy and for compulsory licensing of patents
three years after product launch. His colleague,
0 | HANDBOOK OF BEST PRACTICES

U.S. Representative Oren Harris, introduced
companion legislation in the U.S. House of
Representatives, and the combined bill became
known as the Kefauver-Harris Amendments to
the Antitrust Act. Hearings went on for seven
months, in the face of strong opposition from
the Pharmaceutical Manufacturers Association
and the American Medical Association, and the
legislation may well have died were it not for the
thalidomide catastrophe, which demonstrated
the critical need for a much more rigorous review
of new drugs. The Kefauver-Harris Amendment
passed, though without the compulsory licens
ing provision. And while it started the process of
FDA reform, no action was taken at that time to
control pricing.
The only substantive action the United
States has taken to control drug prices has
been the Drug Price Competition and Patent
Term Restoration Act of 1984, more common
ly known as the Hatch-Waxman Act. This leg
islation greatly facilitated the development of
a vigorous generic drug industry. Companies
received an exemption—the Section 271(e) re
search exemption of the patent laws—allowing
them to make and use (but not to sell) a drug
during its period of patent protection, for pur
poses of developing data to prove that a new
version of the drug was equivalent to the pat
ented version. The company could then file an
Abbreviated New Drug Application (ANDA)
with the FDA and be ready to put its gener
ic version of the drug on sale as soon as pat
ents expired. Absent this research exemption,
a drug company would enjoy a de facto year
or two of additional exclusivity, since generic
producers would not be able to make and use
the drug for testing until the patent had actu
ally expired.
Despite these legislative changes, drug pric
es remain a major issue in the United States. The
problem was exacerbated when the products of
the biotechnology industry were introduced in
the mid-1980s. These had substantially high
er production costs than those of traditional
(small-molecule or simple chemical) drugs,
resulting in prices of thousands of dollars per
year per patient, an order of magnitude higher
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than traditional drugs, already perceived to be
high priced. More recently, orphan drugs such as
Genzyme’s Ceredase® for Gaucher’s disease and
some cancer treatments are even more costly,
costing as much as US$300,000 per patient per
year.
A combination of third-party payers for the
insured and compassionate-access programs for
the uninsured has allowed the generally highpriced drug market to persist in the United
States. In Canada, Europe, and Japan, however,
a combination of single purchaser systems and
legislative activities have led to lower prices
than those in the United States, although prices
for drugs in these countries are still well above
the costs of production. The opportunity for
American citizens to purchase the same patent
ed drugs in Canada or online at low cost has ag
gravated the concern of patients over high drug
prices in the United States. This has made an
impression on the Congress and local govern
ment officials.

. THE dEvELopInG WoRLd And
TWo-TIER pRICInG
In the developing world, situations have var
ied widely. Countries such as India, Argentina,
and Brazil encouraged the development of the
generic-drug industry by recognizing only phar
maceutical process patents. Thus, drugs whose
composition of matter was patent-protected
in the United States and Europe could legally
be produced in these countries by a company
that could develop a novel production process.
However, countries without their own genericdrug industries could afford only to import
drugs whose patents had expired and were sub
ject to generic competition.
The second issue for developing countries is
that the diseases that afflict them tend to be very
different from those that afflict the developed
world, although more recently it has become ap
parent that the “diseases of the poor are not the only
diseases of the poor.”8 While Western drug compa
nies have set out to discover and develop drugs to
treat the diseases of the developed world, through
which they are able to earn an attractive return,

these companies have, for the most part, ignored
tropical diseases. One study showed that of the
1,339 new drugs introduced between 1975 and
1999, only 13 addressed tropical diseases, and
only three addressed tuberculosis, which still
takes an enormous human toll in the developing
world. A later study identified that even these 13
drugs were poorly suited to the needs of the de
veloping world.9
Fortunately, serendipity has sometimes
worked to help the developing world. For in
stance in the early 1980s, the animal health
division of Merck (now Merial, Inc.) devel
oped an antiparasitic called ivermectin (Ivomec
Plus Cattle Injection®), to treat gastrointestinal
roundworms, lungworms, sucking lice, mange
mites, cattle grubs, and adult liver flukes in
cattle. Ivermectin also had a large market for
use in treating lungworm infection in dogs and
cats. In addition, the drug was found to effec
tively treat two human parasitic diseases in subSaharan Africa:
• Onchocerciasis, commonly known as river
blindness, is a nematode infection trans
mitted through the bite of black flies. The
disease causes intense itching, disfiguring
dermatitis, eye lesions, and, over time,
blindness.
• Lymphatic filariasis, commonly referred to
as elephantiasis, coexists with river blind
ness in a number of African countries and
also occurs in a small number of Latin
American countries.
Merck developed ivermectin under the tradename Mectizan® for registration to treat humans
for these conditions, but it was the UNICEF
UNDP-World Bank-WHO10 Special Programme
for Research and Training in Tropical Diseases
that subsequently conducted the extensive trials
needed to establish the safety of mass adminis
tered Mectizan® for eradication or control pur
poses. Merck then created a donation program
that has donated enough Mectizan® to treat over
40 million patients a year since 1987.
GlaxoSmithKline (GSK) donates a treat
ment for parasitic worms, albendazole, which
is co-administered with Mectizan®.11 These
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programs have had a major impact on rates of
infection for these diseases.

. AIdS
.1. AIDS in the developed world

The uneasy status quo in the pharmaceutical indus
try fell apart with the AIDS crisis and the political
activism that emerged from it. The crisis created a
demand for access to effective, new drugs.
The response to the emergence of HIV/AIDS
represents a triumph for basic scientific research
in the U.S. and Europe, largely funded by gov
ernment, and its integration with the pharma
ceutical and biotechnology industries. While it
now appears that the first person to die of AIDS
was an inhabitant of the Democratic Republic of
the Congo who died in 195912 and that the HIV
virus was slowly spreading and infecting people
during the 1970s, (a U.S. teen who died in 1969
and a Norwegian sailor who died around 1976
have also subsequently been shown to have been
infected with HIV13) it was not until 1981 that
physicians in San Francisco and New York started
noticing an unusual incidence of a rare cancer,
Karposi’s sarcoma, and of a rare form of pneu
monia, pneumocystis carinii pneumonia, or PCP,
in the gay community. It was only then that it
became clear that a new disease was emerging.14
Although a new Republican administration
took office in early 1981 that was unsympathetic
to the gay community, investigators at the U.S.
National Institutes of Health (NIH) quickly re
alized the risk posed by HIV. Scientists at NIH
recognized the virus’ unique ability to infect and
destroy the human immune system. As a result,
NIH quickly devoted substantial resources to
fighting HIV and, together with the Centers for
Disease Control and Prevention (CDC), included
funds for investigating its epidemiology in Africa.
Progress in fighting the disease was rapid:
• In 1983, Luc Montagnier of the Pasteur
Institute in Paris identified a putative in
fectious agent, which he called lymphade
nopathy-associated virus or LAV.
• In 1984, Robert Gallo of the National
Cancer Institute in Washington, D.C.,
2 | HANDBOOK OF BEST PRACTICES

•
•
•

•

confirmed that LAV and a virus he had
identified and called human T-cell lympho
tropic virus III or HTLV-III were identi
cal and that it was the etiologic agent of
AIDS.15
In 1985, a diagnostic test was developed, li
censed, and put into routine use for screen
ing blood donations.
In 1987, Retrovir (AZT), the first drug that
was effective against HIV, received FDA
approval.
In 1992, a second antiretroviral drug,
Hivid (ddC, discovered by NIH scientists
and marketed by Roche), was approved and
combination therapy was started.
In 1996, Invirase (saquinavir; marketed
by Roche) the first drug of a second class
of drugs, the protease inhibitors, was ap
proved and “triple therapy” was launched.

With triple therapy, HIV infection was trans
formed from a delayed death sentence, to the ex
tent that opportunistic infections or Kaposi’s sar
coma could be treated, into a chronic condition
whose victims could enjoy a reasonable quality of
life for longer and longer periods as the drug regi
men improved. HIV was only the second viral
disease for which an effective treatment (as op
posed to a prophylactic vaccine) had been discov
ered, the first having been the use of Acyclovir to
treat herpes simplex in 1982.
.2. The impact of AIDS on the developing world

The incidence and impact of AIDS in the de
veloping world, particularly sub-Saharan Africa,
dwarfs anything seen in the developed world. In
some countries today, a third or more of the adult
population is infected with HIV. While preva
lence in some Asian countries remains low, the
sheer size of the population of India or China
means that there are an enormous number of in
fected people in these countries, official denials
notwithstanding.
As AIDS began to be well-controlled in de
veloped countries thanks to highly active antiret
roviral therapy (the “triple cocktail” or HAART)
in the mid- to late-1990s, the developing world
started to demand the same access to these life-
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saving medications. But there was a critical dif
ference between AIDS and other diseases. There
simply were no older, patent-expired drugs avail
able from generic manufacturers to provide to the
developing world. The disease was new, and the
drugs to treat it even newer, so the drugs were
all still under patent protection and would be for
years to come. AZT’s patent would be the first to
expire, in 2005.
Brazil invoked public-health-crisis measures
included in the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS),
which allowed it to override international patents
and make AIDS drugs in its state-owned phar
maceutical factories and make them available to
HIV-infected Brazilians under a free-drug pro
gram. Between 1997 and 2002, the cost of treat
ing an AIDS patient in Brazil fell from US$6,500
to US$1,500 per year,16 and the number of deaths
from AIDS was reduced to half.
Conditions in Africa were desperate. There
was no capacity to do what Brazil had done, and
the cost of importing AIDS drugs at developedworld prices, at an annual per patient cost that was
many multiples of average per capita GDP, meant
very few people were able to receive treatment. In
2001, 25 million people in Africa were infected
with HIV, but only 25,000—just 0.1% of the in
fected population—were receiving HAART.17
In December 1997, the Mandela govern
ment passed amendments to the South African
Medicines Act to break patents and to allow the
manufacture or importation of generic versions.
In 1999, the World Health Organization (WHO)
raised the issue of patents in the pricing of AIDS
medications in developing countries.
In response, six major pharmaceutical com
panies—Merck, Bristol-Myers, GSK, Pfizer,18 and
Boehringer-Ingelheim—approached WHO in
2000 with an offer to lower prices on AIDS drugs
in Africa. The initiative was called Accelerating
Access. In return, the companies asked that
WHO help distribute the drugs. Discussions be
gan and progressed slowly. Individual companies
started various philanthropic initiatives, primarily
focused on education, research, and community
outreach, but critics were not assuaged and con
tinued to demand lower prices for drugs.

A year after the launch of the initiative,
only three countries—Senegal, Uganda, and
Rwanda—had reached specific agreements with
WHO. Antiretroviral therapy cost US$1,000
to US$1,500 per patient per year through this
initiative, which is around 10% of U.S. prices.
Then Medecins Sans Frontiéres (MSF) entered
the debate. Everything changed in February 2001,
when the Indian generics manufacturer Cipla
offered to supply MSF with triple cocktail pills
for US$350 per patient. Cipla offered to supply
African governments with the pills for US$600 per
patient per year, US$400 below the Accelerating
Access price. Cipla’s initiative demonstrated that
most pharmaceutical companies only applied for
patents in South Africa. Only GSK, BoehringerIngelheim, and Agouron tended to apply for
patents throughout Africa.
In 2001, 39 pharmaceutical companies filed
suit against the South African government to en
force their IP rights and prevent Medecins Sans
Frontiéres from buying Cipla’s products.
. Yale University and Zerit

A pivotal catalyst for change was Amy Kapczynski, a
first-year student at Yale Law School in early 2001.
A seemingly innocuous decision made at
Yale in 1987—one that most academic institu
tions would make without hesitation even today
without thinking twice about it—backfired and
became a major issue in the debate about global
health and fair access to medicines. Yale’s fateful
decision was to allow the licensee of one of their
drugs to decide in which countries to apply for
patent protection.
The story began in the early 1960s at the
Detroit Institute of Cancer Research (now the
Barbara Ann Karmanos Cancer Institute), where
Jerome Horowitz, working on the then-prevalent
theory that cancer was caused by viruses, synthe
sized a number of compounds that would inhibit
DNA replication in the expectation that they
would be effective against cancer. Some of the
compounds Horowitz synthesized included:
• AZT
• ddC
• ddI
• d4T
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The theory was incorrect for the overwhelm
ing majority of types of cancer, so the compounds
were not effective and were shelved.
When the HIV epidemic emerged, Horowitz’
work resurfaced. Several of his compounds were
evaluated against HIV and found to be effective.
AZT (Burroughs Wellcome), ddC and ddI ( both
discovered by the NIH) were all discovered by
evaluating the efficacy of Horowitz compounds
against HIV
Tai-Shun Lin and William Prusoff of Yale
University worked with another Horowitz com
pound, d4T (stavudine), with funding from
NIH and Bristol-Myers Squibb (BMS), to eval
uate d4T’s effectiveness against HIV. BMS re
ceived an exclusive option to exclusive license to
any patents that emerged from the work. Prusoff
and Lin found d4T to be effective, and Yale filed
for a method-of-treating patent on December
17, 1986 (U.S. patent No. 4,978,655 was even
tually issued on December 18, 1990). BristolMyers Squibb exercised its option and signed a
license January 12, 1988. As is normal in aca
demic licenses, Yale gave BMS the right to file
in foreign countries, with Yale identified as the
assignee, and the company filed corresponding
applications in major western countries, such as
Europe, Japan, and Canada. Critically, the com
pany decided to include South Africa, Mexico,
and Egypt in its filings.
BMS commenced clinical development of
stavudine and received FDA approval on June
24, 1994. The product was trademarked Zerit®.
In 2001, 13 years after the license had been
signed, the South African patent made Zerit
too expensive for most South African AIDS
patients, particularly those living in the poor
est areas (typically the townships). Because
South Africa is the commercial gateway to SubSaharan Africa, Zerit was similarly unavailable
everywhere else on the continent.
Zerit was on the list of essential medicines
compiled by Toby Kasper, the head of the Access
to Essential Medicines Program for MSF. He had
met Amy Kapczynski at an AIDS conference in
Durban in July 2000 and immediately realized
that Amy could help put pressure on Yale for a
better license deal from within.19 Kapczynski’s
 | HANDBOOK OF BEST PRACTICES

first recruit to this cause was possibly one of the
most embarrassing to Yale—William Prusoff,
the inventor of Zerit. Then Kaczynski turned to
Michael Merson, Dean of Yale’s School of Public
Health, who formerly headed the AIDS program
of WHO.
On February 14, 2001, MSF wrote to Yale
and asked if it “would consider the importation
of generic versions of stavudine for use in provid
ing treatment free of charge to people with HIV/
AIDS unable to afford treatment an infringement
of your intellectual property rights,” and if not, if
Yale would “issue a voluntary license to allow the
importation and use of generic stavudine in South
Africa.”
On February 28, 2001: Yale replied, deny
ing the request on legal grounds, because it had
granted an exclusive license to BMS. Kapczynski
then put reporters at the Yale Daily News on the
trail of the story. The student paper published
its first story on the subject on March 2, 2001,
which served to mobilize opinion on campus.
A group of students in the graduate student
union—which had already been campaigning
against Yale’s relationship with corporate spon
sors—circulated a petition calling on the school
to ease its patent. The group collected 600 sig
natures from students, professors, and researchers
on campus. The students also assailed Yale for its
close ties with BMS—the company had donated
US$250,000 to the school in 1999. Kapczynski
carried out legal research on campus and tried,
unsuccessfully, to get a copy of the license agree
ment. She provided the information she discov
ered to MSF.
On March 9, 2001, MSF responded to Yale
suggesting that Yale’s own policy stated that a key
objective of their technology transfer program
was intended to be “the benefit of society in general”
and pointing out that d4T was not reaching those
who needed it in South Africa. Finally, MSF also
suggested that Yale had the ultimate power over
their patent and could breach their contract with
BMS if need be.
Two days later, The New York Times ran a
story “Yale Pressed to Help Cut Drug Costs in
Africa.” The impact was almost immediate. On
March 14, 2001, BMS issued a statement that
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“The Company will ensure that its patents do not
prevent inexpensive HIV/AIDS therapy in Africa.
The patent for Zerit, rights to which are owned by
Yale University and Bristol-Myers Squibb, will be
made available at no cost to treat AIDS in South
Africa under an agreement the Company has re
cently concluded with Yale.” In June 2001 BristolMyers signed an “agreement not to sue” with
Aspen Pharmacare, South Africa’s leading generic
manufacturer.
So, in less than two years, the world pharma
ceutical paradigm had been turned upside down.
“Two tier” pricing, whereby drugs could in the
future be sold at generic prices in developing
countries during the period of patent protected
exclusivity had been established. There is some
evidence that the pharmaceutical industry, or at
least its vaccine sector, has started to accept the
concept of tiered or segmented pricing according
to ability to pay.20

. THE AppRopRIATE LICEnSInG
AppRoACH?
The Yale lesson discussed above shows that every
license to a drug or vaccine candidate with the
remotest potential for treating developing world
needs must include fair-access licensing provi
sions from the outset. This is because after the
license is executed, the university cedes to the li
censee control of both the development strategy
and the patenting strategy.21
The objectives of a licensing program for
drugs with the potential to treat developing coun
try diseases should be:
• to maximize the possibilities that the drug
will be developed
• to structure the arrangements so that tiered
pricing will result, with the poorest coun
tries having access to drugs at the lowest
prices
An excellent review of potential licens
ing approaches and structures was published
by the open-access online journal Innovation
Strategy Today in a special issue jointly pub
lished with the American Association for the
Advancement of Science.22 However, the article

does not propose any model languages or stan
dard approaches.
Others, however, have put forward such
suggestions. With its considerable experience in
both developing and licensing neglected disease
treatments,23 the NIH has developed a set of white
knight-model licensing provisions (see Box 1).
A set of provisions has also been developed
at Boston University (BU) (see Box 2). They are
meant for use as a starting point to discuss prod
ucts that have markets in both the developed
and the developing world. The provisions utilize
a nonassert approach to manufacture for sale in
developing countries.
If the products envisioned by a partner
ship would only have relevance in the develop
ing world, then the role of IP protection may
only be to provide an incentive for a develop
ing country manufacturer to obtain a license to
develop the product, and a second source ap
proach may provide sufficient safeguards. BU’s
model provisions for these approaches are given
in Boxes 2 and 3.
These licensing principles remain valid, even
though traditional one-to-one licensing models
are not adequate for the complex networks that
have evolved over the past five to seven years
and have transformed the prospects for effec
tive and affordable therapies for the develop
ing world. The emergence of drug development
public-private-partnerships (PPPs), which have
secured large amounts of philanthropic funding
from the Bill and Melinda Gates Foundation,
The Rockefeller Foundation, and so forth, have
transformed drug development for neglected
diseases:24
• Large companies have been motivated
to contribute their drug-discovery skills
and resources because they are secure in
the knowledge that others would be re
sponsible for funding late-stage clinical
development.
• Small companies have secured funding to
develop technologies with dual-market
uses, with the PPPs securing license rights
for developing countries at zero or low roy
alty rates, and the small company retaining
rights for use in developed countries.
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• Academic institutions have had a new
channel to advance their neglected disease
discoveries.
• Developing country pharmaceutical com
panies have found their production and
distribution skills in demand.
In addition, the PPPs have had the financial
clout to insist on affordability conditions as part
of the transactions they have negotiated.

. LICEnSE TERMS foR dEvELopInG
CounTRy MARkETS
As has been discussed in many forums, it is pos
sible to obtain copies of a substantial number of
license agreements from public filings with the
Securities and Exchange Commission (SEC).25
However, only development-stage companies
that are publicly traded, or that have filed reg
istration statements to become publicly traded,

need to make such filings, and only for material
agreements—those affecting 10% of company
sales or 5% of company assets.
These restrictions mean that the transactions
discussed here are unavailable from SEC sources;
the examples that follow are all based on volun
tary disclosures. Because the underlying agree
ments are unavailable and because the examples
are based on third-party accounts, these thirdparty accounts are reported here generally verba
tim from the cited sources (sections 6.2 through
6.12 of this chapter).
In the course of researching this article, the
author was surprised at the lack of transparency in
what was expected to be the most transparent sec
tor of licensing. PPPs, companies, and academic
institutions that were approached to discuss trans
actions they had publicly announced having en
tered into all expressed an unwillingness to reveal
details, even when it was made clear that the infor
mation would be used to create a guide for others.

Box 1: National Institutes of Health: Excerpts of White Knight Provisions
Within six (6) months of New Drug Application/Biologic License Application approval in the United
States or its equivalent in Europe, Licensee shall send a written report to the Public Health Service
detailing the potential Public Sector market to fulfill the public health need for the approved drug or
vaccine in Developing Countries, including the impact of any approved competing drug or vaccine.
The report shall also include Licensee’s proposed amendment to the Commercial Development
Plan, Appendix E [not included here], and the Benchmarks and Performance, Appendix D [not
included here] to address the needs for Licensed Products in Developing Countries. Licensee will
diligently consider if it is possible from a commercial and technical point of view, to satisfy said
potential Public Sector market, either directly with Licensee’s own resources and/or through
joint ventures with third parties. Acceptance of this report and amendment is required by PHS in
writing; such acceptance will not be unreasonably denied.
“Public Sector” means the government of a Developing Country, or any entity empowered by the
government of a Developing Country to act for said government in matters applicable to this
Agreement, organizations within the United Nations system including the World Health Global
Organization and UNICEF, and other nonprofit agencies which may purchase drugs or vaccines for
delivery, manufacture and/or sale in Developing Countries.
“Developing Country” means countries eligible for support from the Global Fund for Children’s
Vaccines (GAVI) or successor organization, which at the effective date of this Agreement are those
countries with a Gross National Product of less than US$1,000 per capita per year, and at the
effective date of this Agreement include the countries listed in Appendix G [not included here].
Source: Stephen Ferguson, NIH, personal communication.
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Box 2: Boston university’s Nonassert Approach
1. Include in the “WHEREAS” clauses:

WHEREAS, University and Licensee acknowledge that it may serve the public good to make
certain drugs available at affordable prices to Non-Market Countries in certain circumstances,
with appropriate safeguards to Licensee’s economic interests in other markets.

2. Include in the “definitions”:

Market Countries shall mean:
(a) All current and future member countries of the Organisation for Economic Cooperation
and Development (OECD), presently consisting of Australia, Austria, Belgium, Canada,
Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy,
Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal,
Spain, Sweden, Switzerland, Turkey, the United Kingdom, and the United States; and
(b) All current and future members of the European Union; and

(c) Russian Federation, Republic of China (Chinese Taipei), Korea, Malaysia and Singapore.
Amend the definition of Net Sales to exclude sales of products made pursuant to the Non-Suit
provision of Section [XX; not given here] from the calculation of Net Sales
Non-Market Countries shall mean all countries other than Market Countries.
Public Sector shall include:

(a) The sovereign government of a country;

(b) Agencies of the United Nations, the World Health Organization, and the World Bank;

(c) Organizations which are members of the International Committee of the Red Cross
and Red Crescent;

(d) International charitable agencies (also known as Non-Governmental Organizations or
NGOs), including but not limited to Oxfam, Medecins Sans Frontiéres, and so forth;
(e) Organizations substantially supported by philanthropic organizations including but
not limited to the Bill and Melinda Gates Foundation, the Rockefeller Foundation, and so
forth, specifically including global product development and distribution public-private
partnerships.

Trade Dress shall mean the physical appearance of Product as sold in any Market Country by
Licensee, including but not limited to such characteristics as shape, color, flavor, tradename,
trademark, service mark, etc.
3. Include in the “Grant” clauses:

Non-suit: University and Licensee on behalf of themselves and any successors-in-interest to the
Intellectual Property covenant that they will not, before or after the date of this Agreement,
assert any claim of infringement (including direct infringement, contributory infringement,
and inducing infringement) of the Intellectual Property against any person or entity that sells
or offers to sell the Licensed Product to Public Sector entities for use in Non-Market countries, or
any entity that manufactures or otherwise makes the Licensed Product for sale to Public Sector
entities for use in Non-Market countries, or any person or entity that uses the Licensed Product
in a Non-Market country, to the extent such claims relate to or arise out of such manufacture,
sale or offer to sell.
Notwithstanding any other provision herein, this non-suit provision shall not apply to Products
that bear any element of the Trade Dress used by Licensee in any of the Market Countries, or
to Products that have not gained regulatory approval from either the U.S. Food and Drug
Administration (FDA), the European Agency for the Evaluation of Medicinal Products (EMEA) or
been pre-qualified by the World Health Organization pre-qualification scheme.
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.1 Compulsory licensing models

Several approaches to establishing fair license
terms (and, as will be discussed in Section 6.2
below licensing structures themselves) for devel
oping country markets have looked to compulsory
licensing principles for guidance. Such approach
es, authorized under the TRIPS Agreement, talk
about “adequate remuneration” to the patent
holder but without offering specific guidelines.26
A comprehensive review of the issues of compen
sation in compulsory licensing has been under
taken by Scherer.27
For much of the 1970s and 1980s, Canada
had an extensive compulsory pharmaceutical li
censing policy. In general, Canada required the
recipient of a compulsory license to pay the pat
ent holder a 4% royalty on the licensee’s sales price.
After the Doha Round of WTO, Canada was
the first country to implement the TRIPS com
pulsory licensing principles to supply countries
that could not produce drugs for their own use.
Canada has continued to use a 4% royalty rate,
adjusted for the gross domestic product (GDP)
of the country, so that in the poorest countries, a
royalty rate of 0.2% would apply.28, 29
.2 Equitable access license

Universities Allied for Essential Medicines, which
grew out of Amy Kapczynski ‘s student col
leagues (see section 4.3 above), has endorsed an
Equitable Access and Neglected Disease License30
(EAL) created by a working group at Yale. The
EAL proposes a US$50,000 fee plus a 5% roy
alty for licenses to sell in countries defined by the
World Bank as “middle-income countries” and
a US$5,000 fee and a 2% royalty on sales in the
World Bank’s “low-income countries. These fees
would be split 50:50 with the primary licensee.

However, the license terms require the licensee to
share with the university all of the know-how nec
essary to make, use, and sell the licensed products
in developing countries, so that the university
can, in turn, transfer that know-how to the devel
oping country licensees. The developing country
licensees will, likewise, share any know-how they
develop with the university. Universities Allied
for Essential Medicines formalized this approach
as the Philadelphia Consensus Statement at their
annual meeting in Philadelphia in October 2006
and provided a mechanism for individuals and
organizations to sign on.
The structure the EAL would establish pro
vides the ideal mechanism for providing low-cost
drugs to developing countries, but it is a utopian
standard that will likely create a strong disincen
tive to large companies to take out licenses to
develop academic technologies. A 1% or 2.5%
royalty on sales in developing countries in which
the target per patient cost is in cents rather than
dollars is unlikely to provide a sufficient incen
tive for them to provide all of their production
know-how to the licensing university. Spinouts
are probably equally likely to resist these terms
because of their potential to scare away poten
tial downstream partners. In addition, the EAL
would put a considerable administrative bur
den on the university’s technology transfer of
fice managing these various flows of confidential
know-how. The EAL would therefore likely vio
late the first of Hippocrates’ maxims as applied
to academic licensing: First Do No Harm.
As of this writing (February 2007), a signifi
cant number of individuals and not-for-profits
operating in the global health arena have signed
on to the Philadelphia Consensus Statement.
Noticeably, no universities have signed on as

Box 3: Boston university Second Source Approach
1. Include in the “Grant” clauses:
Second Source: University may, at any time after the first anniversary of Licensee’s receipt of the
first regulatory approval to sell Licensed Products, start to qualify a supplier for up to one third of
annual requirements of Licensed Products.
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corporate entities, and only one person with cur
rent, and one person with prior executive author
ity for academic licensing were listed as initial
signatories.
. Global Alliance for TB Drug
Development—Chiron

In one of the first drug development deals
between a drugmaker and a nonprofit orga
nization, the Global Alliance for TB Drug
Development announced that it had licensed
PA-824, a compound effective against M. tuber
culosis, from Chiron Corp.31 PA-824 was discov
ered and protected by PathoGenesis Inc., which
was subsequently acquired by Chiron. Chiron
has provided a worldwide exclusive license to
the TB Alliance for PA-824 and all its analogs,
in return for a modest, one-time licensing fee
(modest, that is, compared to the industry av
erage of US$1 million to US$3 million)32 and
yearly threshold R&D investments by the al
liance to ensure rapid progress. All preclinical
R&D on PA-824 is subcontracted to commer
cial clinical research organizations (CROs; paid
by the TB Alliance), and project management
(paid by the NIH) is conducted by the Research
Triangle Institute, a not-for-profit that conducts
contract research for the NIH and others. If and
when development is successful, Chiron has the
option of buying back the OECD rights by re
imbursing the TB alliance for all development
costs. The TB alliance would retain rights in all
developing country markets. The deal includes
“an expansive commitment” to affordable pric
ing. The agreement has a grant-back clause that
allows Chiron to reenter the TB drug develop
ment process, within a specific time period, in
wealthy countries. The deal also includes manu
facturing options for the company.
Though it has not proceeded beyond the
laboratory, the compound, called PA-824, has
been shown to be effective against drug-resis
tant strains of M. tuberculosis in tests carried
out in vitro. Researchers believe PA-824 may
be powerful enough to considerably shorten
the current short-course-treatment time of six
months, which would enable more people to
complete treatment.

. Institute for OneWorld Health—
Celera Genomics

The Institute for OneWorld Health (iOWH)
is a not-for-profit drug company founded by
Victoria Hale, a former employee of Genentech
and winner of a McArthur Foundation Genius
Award in 2006. The company sources drug
candidates for the treatment of diseases in
developing countries from universities and
drug companies and then seeks philanthropic
donations to fund clinical development.
In 2002, iOWH licensed Celera Genomics’
CRA-3316 as a potential new treatment for
Chagas’ disease. CRA-3316, formerly known
as APC-3116, is a cysteine protease inhibitor.
Development has been started in collabora
tion with NIH.33 Celera licensed CRA 3316
to iOWH royalty free because, according to
Wayne Montgomery, who heads intellectual
property at Celera, “the drug would have gath
ered dust otherwise.”34
. Institute for OneWorld Health—University
of California Berkeley—Amyris
Biotechnologies35

In December 2004, the Bill and Melinda Gates
Foundation awarded a five-year product de
velopment grant to iOWH to create a threeway partnership between iOWH, a university
(University of California, Berkeley), and a forprofit company (Amyris Biotechnologies, Inc.).
Using synthetic biology, industrial fermentation,
and chemical synthesis, the goal of this project
is to significantly reduce the cost of artemisinin,
a key precursor in the production of artemis
inin combination therapies (ACT) for malaria.
Artemisinin is chemically converted to one of
several derivatives that are then combined with
other drugs to make an ACT.
Artemisinin is currently extracted from
wormwood plant, which is supplied by farmers
in Vietnam and China (and more recently from
Africa). Seasonality and availability of the plant
contribute to the drug’s high price. The project,
funded by the Gates foundation, hopes to elimi
nate the need for plant extraction by utilizing
a platform technology of “synthetic biology”
developed by Jay Keasling at UC Berkeley. The
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goal is to lower the cost of artemisinin-contain
ing drugs ten-fold by producing a consistent,
reliable, high-quality supply of artemisinin in
microbes.
The US$42.6 million grant was divided
among the three parties: US$8 million to UC
Berkeley for continued basic research; US$12 mil
lion to Amyris for applied research on the fermen
tation and chemical processes; and US$22.6 mil
lion to iOWH to perform the required regulatory
work and lead the implementation of the product
development strategy for the developing world.
UC Berkeley’s role focuses on the engineering of
drug-precursor-producing microbe. Amyris’s ef
forts span the engineering of the production mi
crobe to optimizing the semi-synthesis of the drug
through fermentation and novel downstream
synthetic chemistry. The role of iOWHs includes
developing a commercialization strategy based on
a thorough understanding of worldwide regula
tory requirements and an analysis of the current
ACT manufacturing supply-chain and distribu
tion models. This one grant enables activities in all
three areas of development. It creates an integrat
ed team of partners, each applying its expertise to
streamline translation from bench to bedside. The
financial terms of the partnership are as follows:
License Grant(s)

• The arrangement is governed by a threeparty collaboration agreement and two
license agreements (from UC Berkeley to
each of Amyris and iOWH).
• UC Berkeley granted iOWH a royalty-free
license for the manufacture of artemisinin
based malaria treatments used in the de
veloping world. UC Berkeley further shall
grant royalty-free licenses to iOWH for
intellectual property developed under the
three-party collaboration agreement for use
in manufacturing artemisinin-based malar
ia treatments used in the developing world,
and iOWH is to establish partnerships for
ACT manufacture and distribution.
• UC Berkeley granted Amyris licenses to
develop the manufacturing process for the
developing world malaria market. Amyris
also has licenses for the developed world
malaria market, nonmalaria indications
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of artemisinin, and alternative uses of the
platform worldwide. UC Berkeley further
shall grant similar licenses to Amyris for
intellectual property developed under the
three-part collaboration agreement.
• Amyris shall grant iOWH a royalty-free
license for intellectual property developed
under the three-part collaboration agree
ment for the manufacture of artemisinin
based malaria treatments used in the devel
oping world.
Royalties

• The license from UC Berkeley to iOWH is
royalty free.
• The license from UC Berkeley to Amyris is
royalty free for the developing world ma
laria market (development for iOWH), and
royalty bearing for the developed world and
nonmalaria indications in the developing
world.
Patents

• Patent costs for UC Berkeley’s preexisting
patents are shared between iOWH and
Amyris.
• UC Berkeley patents on intellectual prop
erty arising from the collaborative research
may be filed by UC Berkeley and licensed
to iOWH and/or Amyris under the prear
ranged terms mentioned above. Costs are
shared by the licensee on a pro rata basis.
UC Berkeley has no obligation to file an
application if it does not have a commit
ment by a licensee to pay patent costs.
• Patents that are the sole property of Amyris
and/or iOWH may be filed by Amyris
and/or iOWH as the case may be, at their
own expense.
• Logistics of filing and payment of costs on
jointly owned intellectual property will be
negotiated in good faith by the joint own
ers when such joint intellectual property
arises. If the joint owners cannot agree,
and if iOWH has an ownership interest
in a joint property, then iOWH may file
and prosecute on behalf of the owners at its
own expense.
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. Aeras Global TB Vaccine Foundation—
Vanderbilt University36

On May 4, 2006, Aeras and Vanderbilt University
announced an exclusive license agreement for a
TB vaccine based on technology developed at
Vanderbilt. The technology enhances the abil
ity of the Bacille Calmette-Guérin (BCG) vac
cine to trigger immune-system responses. Under
the agreement, Aeras will use the technology to
modify the BCG vaccine and will guide the new
vaccine through clinical trials. The license agree
ment grants Aeras exclusive rights for developing
a TB vaccine. If a successful vaccine results from
the use of this technology, then Aeras will manu
facture the new vaccine at its facility in Rockville,
Maryland. Vanderbilt retains rights to the tech
nology as a delivery system for other uses. This
could potentially include new vaccines or immu
notherapies against other diseases from HIV and
malaria to cancer.
The Vanderbilt technology, called proapop
totic BCG, is designed to weaken the BCG
bacterium. It is a version of BCG with genetic
modifications designed to inhibit the bacterium’s
ability to stop the programmed cell death of a
patient’s immune cells. These modifications are
likely to result in a vaccine that provides better,
longer-lasting protection against TB and may
prevent progression to active TB among people
with compromised immune systems. The finan
cial terms are as follows:
• Grant: Aeras obtained an exclusive license
in its field of use.
• Field of Use: Aeras has an exclusive license
to the TB field; Vanderbilt retains rights in
other fields.
• Payments/Royalties: The license is royalty
bearing (including stacking terms) along
with milestone payments.
• Patents: Patent costs paid by Aeras.
. Global Alliance for TB Drug Development—
Bayer Healthcare AG37

Moxifloxacin is an antibiotic first approved in
1999 and currently used in 104 countries to treat
certain bacterial respiratory, skin, and intraab
dominal infections. It has been used by more than
47 million patients worldwide. Moxifloxacin is

generally well tolerated, but treatment may result
in certain usually mild side effects, including nau
sea, diarrhea, and dizziness. In vitro and in vivo
studies have demonstrated moxifloxacin activity
against Mycobacterium tuberculosis. Investigators
at Johns Hopkins discovered that substitution of
moxifloxacin for isoniazid in the reduced treat
ment time (two months shorter in mice) of the
TB treatment regimen. The treatment regimen
included rifampin, pyrazinamide, and either
moxifloxacin or isoniazid.
In October 2005, the TB Alliance and Bayer
Healthcare AG announced a partnership to co
ordinate a global clinical development program
to study the potential of moxifloxacin to shorten
the standard six-month treatment of TB by two
to three months. The trials will evaluate whether
the substitution of moxifloxacin for one of the
standard TB drugs (ethambutol or isoniazid)
eliminates TB infection faster than the current
standard therapy. If successful and approved by
the respective regulatory agencies, a new, shorter
regimen could be available in the next five years.
The Phase II/III clinical trial program spans
four continents and will enroll close to 2,500
patients with TB. The trials will take place in
Brazil, Canada, South Africa, Spain, Tanzania,
Uganda, the United States, and Zambia. If the
trials are successful, the partnership aims to reg
ister moxifloxacin for a TB indication. Upon
regulatory approval, the partnership is com
mitted to making it affordable and accessible in
developing countries where TB patients need it
most.
For this project, Bayer will donate moxifloxa
cin for each trial site and will cover the costs of reg
ulatory filings; the TB Alliance will coordinate and
help cover the costs of the trials, seeking to leverage
support from the U.S. Centers for Disease Control
and Prevention (CDC), the Orphan Products
Development Center of the U.S. Food and Drug
Administration, and the European and Developing
Countries Clinical Trials Partnership. In May 2006,
the TB Alliance received a US$104 million grant
from the Bill and Melinda Gates Foundation. The
grant will be used, in part, to fund Phase II and III
trials of moxifloxacin with the goal of showing the
efficacy of moxifloxacin in reducing TB treatment
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times by two months by 2010. The financial terms
for this development project are:
• Field of Use: Tuberculosis drugs.
• Payments/Royalties: Products will be made
available in developing countries at cost,
for use against tuberculosis.
• Patent strategy: Patents previously issued.
6.8 International AIDS Vaccine Initiative—
Neutralizing Antibody Consortium

The mission of the International AIDS Vaccine
Initiative (IAVI) is to ensure the development
of safe, effective, accessible, preventive HIV/
AIDS vaccines for use throughout the world.
Central to IAVI’s mission is to improve access
to a vaccine for the developing world,38 which
requires speed of development, as well as avail
ability and affordable pricing. IAVI uses a large
portion of its resources to conduct R&D to
design, manufacture, and test promising HIV/
AIDS vaccine candidates.
In July 2002, IAVI announced the forma
tion of the Neutralizing Antibody Consortium
(NAC), a five-year, multimillion dollar research
program to develop a preventative HIV/AIDS
vaccine that fills a critical gap not addressed by
most HIV/AIDS vaccines undergoing clinical tri
als. The original NAC consisted of four founding
institutions. Today, the NAC includes an interna
tional group of 15 laboratories, funded by IAVI,
representing academia, government, and not-for
profit research organizations. The financial terms
for the NAC are:
• IAVI funds individual research work plans
for NAC principal scientists; in some cases
restricted grant monies are used for select
ed research projects. These carry special
compliance terms that apply specifically
to that project.
• IAVI manages intellectual property
on behalf of the NAC. IAVI rights include:
- option for exclusive license to program
intellectual property in the field
- option for nonexclusive license to back
ground intellectual property
• IAVI pays for certain patent costs related
to program inventions and background
inventions.
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• Predetermined sharing of revenues among
all collaborators.
• Other provisions include diligence, gover
nance, publications, patent management,
and process for adding new members.
. Medicines for Malaria Venture (MMV)—
GlaxoSmithKline (GSK)

At the 2003, World Economic Forum’s Africa
Economic Summit in Durban, South Africa,
Medicines for Malaria Venture (MMV) and GSK
announced a joint portfolio of projects:
• Fab I—Fatty acid biosynthesis I
• Falcipains—Cysteine protease inhibition
• 4(1H)-pyridones—backups
• PDF—Peptide deformylase inhibitor [ter
minated in March 2005]
The main objective is to subsidize the so
cio-economic and public health benefit for the
developing world. Any successful medicines dis
covered as a result of this initiative will be made
available in endemic areas on a not-for-profit
basis. Research work will take place at the GSK
drug discovery unit in Tres Cantos, Spain, which
GSK has dedicated to research on diseases of the
developing world. The center has a team of 50
permanent staff with particular expertise in drug
discovery. The Tres Cantos Center is fully inte
grated into the GSK R&D organization, which
provides expertise and infrastructure for all as
pects of drug discovery and development. GSK
will contribute funding, staff with drug discovery
expertise in malaria, and state-of-the-art facilities.
MMV contributes funding for malaria drug dis
covery projects by subsidizing the employment of
additional scientists to join the existing staff at
Tres Cantos and expertise from its expert scien
tific advisory committee (ESAC).
.10 Harvard University—Medicine in Need

In November 2006, Harvard announced that
it would license a new aerosolized tuberculosis
vaccine invented by Professor David Edwards
to Medicine in Need (MEND), a Cambridge
nonprofit founded by the inventor.39 Sales to de
veloping countries will be royalty free, while sales
to developed countries will be royalty bearing,
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but Harvard will return a large proportion of
the royalties back to MEND. Edward’s work
was funded by a US$7.6 million grant from
the Bill and Melinda Gates Foundation, which
stipulated as part of the grant that Harvard
would have to license the technology to MEND
and that Harvard could not take royalties from
MEND’s sales to the developing world. The
Gates Foundation has also used this strategy in
its Grand Challenge Grants.
.11 Coley Pharmaceutical Group, Inc.—
Gates Foundation

Coley Pharmaceuticals Group, a publicly trad
ed biotechnology company based in Wellesley,
Massachusetts, has agreed to license VaxImmune
to the Bill and Melinda Gates Foundation for use
in conjunction with a vaccine for postinfection
malaria. VaxImmune is a TLR9-agonist designed
to enhance both antibody levels and potent killer
T-cell immune response to infection or tumors.
The agreement is a no-profit/no-loss arrangement,
in which all clinical development is performed by
the Institute for Tropical Diseases Research, funded
by the Gates foundation, while Coley receives no
royalties or other payments. Coley has partnered
VaxImmune with GSK for cancer and infectious
disease vaccines and with Novartis Vaccines and
Diagnostics for infectious-disease applications. It
will receive royalties on any commercial applica
tions of the technology that emerge from the Gates
foundation collaborations.40
.12 Unattributed transactions

Various sources41 quote royalty rates of no more
than 3%–5% of sales for those companies that
do insist on obtaining a financial return on sales
of drugs to the poorest of the poor. Procurement
costs for finished products are described as typi
cally being at cost of production or cost of pro
duction plus 3%–5%, with agreements having
not been reached when a margin of 15% over
cost was demanded. However, what was not clear
was how overhead, corporate costs, and cost of
capital were allocated. At some point, there will
need to be some incentive provided if private cap
ital is to be utilized and for-profit entities are to
become dependable suppliers, or alternatively the

PPPs will need to provide the necessary invest
ments for the construction of dedicated produc
tion facilities.

. CONCluSIONS: ToWARd AppRopRIATE
vALuATIon STRuCTuRES
The comparisons above clearly show that the right
valuation formula is to ask for the licensee(s) in
developing countries to take over responsibility
for future patent costs and to ask for no upfront
fees, no milestone payments, and no running
royalties. Any financial return to the university
will be derived from opportunities in developed
countries. Indeed, if a university’s objective tru
ly is to get drugs that have been discovered at
rich universities in developed countries, using
“other people’s money,” whether governmental
or philanthropic, to the worlds’ neediest people
as cheaply as possible, then true leadership re
quires that those same universities not start off
the process by putting their hands out and say
ing, “We have to charge a royalty.”
Universities are under no obligation, under
Bayh-Dole or any other law or regulation, to
charge a royalty. The message communicated by
asking for a royalty—even the modest rates sug
gested by the analysis above—would be inappro
priate and inconsistent with the public mission
of the university. Doing so would cost the moral
high ground and weaken universities’ ability to
lead in this humanitarian endeavor.
Clearly, internal consensus between the
research community, academic leadership, and
technology transfer offices within the university
is needed. The researchers who put their time
and effort into developing a drug or vaccine to
treat developing country diseases will certainly
be happy with this approach, as Yale’s experi
ence with William Prusoff shows. The dean of
the school of public health is a suitable avenue
to the administration, if one is needed, as Amy
Kapczynski also found at Yale. The develop
ment and public relations offices should be in
volved to ensure that the institution’s objectives
are properly portrayed and that the institution
receives the appropriate recognition for its hu
manitarian efforts.
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The technology transfer professional’s nego
tiating skills will be called into play when nego
tiating for the rights and financial terms for any
potential uses of the technology in developed
countries and for spinout technologies. If there
are none, it should be a simple negotiation, with
indemnification provisions likely to be the most
contentious issue. n
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Open Source Licensing
JaneT hope, Project Director, Co-operative Intellectual Property Management, Centre for Governance of Knowledge

and Development, Research School of Social Sciences, Australian National University, Australia

ABSTRACT

This chapter provides an introduction to open source
software licensing. The chapter seeks to demystify the
concept of open source so that intellectual property (IP)
owners and managers can decide whether an open source
approach is worth pursuing. The chapter explains the
principles of free and open source software licensing and
outlines the decisions that an innovator must make when
deciding which strategy to use for developing a new in
novation. Also explained are the differences between open
source and public domain, and between the uses of the
terms copyleft and academic to describe open source li
censes, as well as the incentives (financial and otherwise)
for open source licensing. Finally, the author identifies
important considerations regarding the possibilities for
open source licensing in fields other than software de
velopment, particularly biomedicine and agricultural
biotechnology.

1. InTRoduCTIon
Open source software has had remarkable tech
nological and commercial success. Since the late
1990s, many people have been interested in ap
plying the principles of open source to other
fields, including biomedicine and agriculture.
The term open source is sometimes used very
broadly to mean any approach to intellectual asset
management that entails a higher level of trans
parency, or greater access to information, than is
usual in a proprietary setting. This broad use of
the term is of little value to IP managers because
it is too imprecise.

In fact, the only context in which the term
open source has a generally accepted definition is
in software development.1 This chapter uses the
term in as far as possible the same sense as it is
used in the software context but suggests that the
underlying IP management approach could be
applied in other contexts.
Conventional software development is some
times termed cathedral building because it pro
ceeds according to the hierarchical directions of
one or more software architects (the word archi
tect is derived from words meaning “chief build
er”). Conventional software is usually protected
through IP rights, as a strategy to exclude some or
all prospective users of the technology.
By contrast, open source software develop
ment projects, such as those that produced Linux,
Apache, and BIND, are decentralized and self-or
ganized. Open source software development is an
evolutionary process: the contributions of self-se
lected project participants are subjected to trial
and-error testing in diverse use environments,
and the resulting information influences further
development. This mode of production has been
termed “the bazaar” and is also known as collective
or commons-based peer production.2
In order for open source software develop
ment to work, would-be users and developers
must be authorized to access the source code. In
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the conventional “proprietary” approach to soft
ware development, source code is not freely avail
able for two reasons: (1) source code is treated
as a trade secret and (2) the original expression
contained in a program’s source code is subject
to copyright protection. To enable open source
development, therefore, the software owner must
(1) refrain from keeping the source code secret
and (2) grant an IP license to others so that they
have the legal right to access and manipulate
copyright-protected aspects of the code.
Open source licensing should not, in theory,
pose any antitrust problem (at least in jurisdic
tions where the relevant test takes into account
substantive effects on competition), because its
effects are fundamentally pro-competitive.3

2. WHAT IS OPEN SOURCE?
2.1 The open source definition (OSD)

An open source software license is one that con
forms to the latest version of the open source defi
nition (OSD), published on the Web site of the
Open Source Initiative (OSI), a nonprofit cor
poration established in 1998 by a small group of
programmers who wanted to promote the wider
adoption of open source licenses.4 Licenses that
conform to the OSD are permitted to carry a reg
istered certification mark.
A summary of the requirements of the OSD
is that in order for a software license to be open
source, licensees must be free 1) to use the soft
ware for any purpose whatsoever; 2) to make cop
ies and distribute them without paying royalties
to the licensor; 3) to prepare derivative works and
distribute them, also without payment of royal
ties; 4) to access and use the source code; and 5)
to use the open source software in combination
with other software, including proprietary (that
is, non-open source) software.5 An open source
license may not restrict the number of products
a licensee is allowed to distribute, the identity or
geographic location of the recipients, or the price
the licensee asks them to pay. Optionally, these
same guidelines may be stipulated to apply to cer
tain improvements or other downstream uses of
the original software.
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The OSD’s definition could be summed up even
more concisely: in open source software licens
ing, anyone, anywhere, and for any purpose must
be allowed to copy, modify, and distribute the
software (either for free or for a fee) and, there
fore, must be allowed full access to the software’s
source code.6
2.2 The free software definition (FSD)

The OSI is not the only de facto standard-setting
body in the field of free and open source soft
ware licensing. Others include the Free Software
Foundation (FSF)7 and the Debian Linux
community8.
According to the FSF’s Free Software
Definition (FSD), software “freedom” is the
freedom to use, copy, study, modify and redis
tribute both modified and unmodified copies
of software programs, all without having to pay
for or otherwise obtain specific permission. To
give practical effect to this freedom the licensor
must allow users access to the software’s source
code.9
Clearly, the FSD is very similar to the OSD.
There are ongoing debates about the differences
between what constitutes free software and open
source software, but in fact the two are virtually
identical: with very few exceptions, free software
conforms to the OSD, and open source software
conforms to the FSD.10

. THE pRoCESS of dEvELopInG
A LICEnSInG STRATEGy
Open source licensing is just one kind of IP
strategy. Figure 1 depicts the process of choosing
which licensing strategies (if any) to use.
The first thing to do when formulating an
appropriate strategy for exploiting new technol
ogy is to make a careful cost-benefit analysis of all
the possible avenues for development.
This analysis will require certain
considerations:
• The first decision. If the technology is to
be disseminated rather than kept in-house,
resources must be committed to market
ing the technology, demonstrating and
improving its usefulness, and establishing it
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within extended research and development
networks.11
• The second decision. If an innovator de
cides to disseminate the technology, it is
not always advantageous for him or her to
restrict public access to it. Sometimes, an in
novation can be freely offered to the public
and still generate at least as much economic
advantage for the innovator as would a pro
prietary strategy. Nonproprietary strategies
can be more advantageous to the research
community, society as a whole, and the in
novator. Open source licensing generally
creates fewer transaction costs and is inher
ently more transparent than a proprietary
licensing strategy. The decision to follow a
nonproprietary strategy does not have to be

born out of altruism or ideology: it can in
stead be born out of healthy self-interest.
• The third decision. If an innovator decides
on a nonproprietary strategy, the innova
tion can be licensed on an open source basis
or placed in the public domain: that is, the
innovator can refrain from obtaining any
IP or other property rights at all. Licensing
an innovation is costly and time-consum
ing and should be considered only if there
is good reason to obtain or retain owner
ship of the technology.
• The fourth decision. After choosing an
open source approach, an innovator must
choose between an academic open source
license and a copyleft-style license (both
terms are defined in a later section). If the

Figure 1: Decision Tree to Determine the Type of license
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Keep in-house

Non-proprietary

Proprietary
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Open source
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main objective is to encourage widespread
adoption of the technology in its current
state, the more permissive academic license
is likely to be preferable. If the main objec
tive is to guarantee access for the innova
tor or others to improved versions of the
technology, or to other innovations built
upon it, a copyleft-style license is worth
considering.
• The fifth decision. If the innovator de
cides on a copyleft-style license, the final
decision must be how broad or narrow
the copyright obligation is to be. The nar
rowness or broadness of a copyright ob
ligation may be thought of as the reach
of the copyleft “hook.” Although the dia
gram depicts this decision as a binary one,
in fact, possible formulations of copyleft
obligations form a spectrum. The reach of
the copyright hook should be dictated by
the licensor’s assessment of prospective li
censees’ incentives to contribute to ongo
ing development.
This remainder of this chapter will explore
the nonproprietary options that are available to
the innovator, with a special emphasis on the var
ious types of open source licensing.

. opEn SouRCE vERSuS puBLIC doMAIn
Once an innovator has decided to disseminate his
or her technology in a nonproprietary fashion, he
or she must decide between open source licensing
and placing the innovation in the public domain
(also known as straightforward publication): that
is, foregoing IP protection altogether.
.1 The advantages of public
domain over open source

The primary advantage of straightforward pub
lication or dissemination of a new technology
over an open source approach is that it does not
require the innovator to obtain or maintain IP
protection. Depending on the type of IP right,
protecting IP can be costly in terms of time and
resources. It also has the disadvantage of contrib
uting to the proliferation of IP rights.
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In some contexts, claiming ownership over an
innovation may also create a negative effect with
respect to ongoing collaborations. It may create
ill will among prospective users and decrease the
chances that a technology will be widely adopted
or improved. Such negative effects are especially
likely when the ownership claim is particularly
broad (as in the case of the non-coding DNA se
quence patents or junk DNA)12 or when user-de
velopers have a strong belief that the technology
ought to be in the public domain (as in the case
of human genome project sequence data).13
.2 The advantages of open
source over public domain

There are several circumstances in which an open
source strategy might have advantages over a pub
lic domain approach as a way of encouraging the
widespread adoption and ongoing development
of an innovation.
One situation in which an open source ap
proach may be useful is where inventors have au
tomatic ownership rights over some part of the
relevant technology. Some biological innovations
incorporate tangible material components (such
as cell lines or germplasm) that are owned by the
inventor regardless of whether active efforts are
made to protect the innovation. Similarly, soft
ware programs, data, or written protocols that are
incorporated into biological innovations are au
tomatically subject to copyright protection pro
vided they meet statutory criteria. In such cases,
a license may help to reduce the transaction costs
of transferring the technology to other prospec
tive users because the license clarifies the owner’s
intention to make the technology available on
open source terms. (This is analogous to Creative
Commons’ objective of facilitating the dissemi
nation of cultural material by helping copyright
owners to specify which rights are reserved.)14
A second situation in which an open source
license may be preferable to straightforward pub
lication from the perspective of the innovator is
a situation in which there is a proliferation of
overlapping IP rights or the field of innovation is
especially competitive or litigious. While even an
open source license has the drawback of adding
to the complexity of the IP landscape, failure to
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assert ownership over a technology before making
it available for public use sometimes means that
someone else can patent the technology and pur
sue a proprietary exploitation strategy to the det
riment of the innovator and other potential users.
In this case, patenting followed by open source
licensing of an innovation is a form of defensive
disclosure that may be more reliable than other
defensive disclosure mechanisms as a means of
protecting against subsequent patent claims.
Third, IP ownership gives an innovator the
right to set terms of use and exclude anyone who
will not abide by those terms. For example, in a
copyleft-style arrangement, follow-on innova
tors must make some improvements available
to others on the same liberal terms as the initial
innovation was made available to them. Another
example is the litigation deterrent clause found
in many licenses (both open source and propri
etary), which terminates the licensee’s rights if he
or she sues the licensor (for example, for infringe
ment of one of the licensee’s patents).
Finally, IP rights may facilitate certain path
ways to development even if they are licensed on
open source terms. The existence of IP protection
signals to potential investors that the innovator is
disciplined and has financial backing and that the
innovation is worth supporting.
. Combining proprietary licensing, open
source, and public domain

There is nothing to stop an open source licensor
from offering a technology under both propri
etary and open source licenses. This approach,
known as dual licensing, generates a surprising
amount of income for many open source software
programmers, some of whose customers prefer,
and are willing to pay for, a more conventional
licensing arrangement. Thus, the commercial
application of an open source license does leave
some room for recovery of the costs of protecting
the relevant IP.
It is possible to adopt a nonproprietary strat
egy at a relatively late stage in an innovation’s
life cycle, perhaps when the amount of propri
etary licensing revenue the innovation generates
begins to decline. In this case, granting an open
source license to the innovation may be a sensible

alternative to abandoning the patent altogether.
In such circumstances the full cost of obtaining
and maintaining IP protection has little bear
ing on the decision to go open source, because
the majority of these costs have already been
incurred.

. InCEnTIvES foR opEn
SouRCE dEvELopMEnT
Why would any rational, self-interested IP owner
decide to adopt an open source license? Many
people think of open source licensing as an al
truistic exercise, or alternatively, as a strategy pur
sued for the sake of purely personal rewards, such
as fun or a sense of belonging to a community.
This is an unnecessarily limited view.
.1

Direct financial incentives

An open source license must permit the shar
ing and distribution of the technology without
charging any royalty. In this context, a royalty is
any ongoing payment that is linked to the use
of the technology (for example, a percentage of
profits on products generated using a technology,
or a regular payment whose amount depends on
the number of people who are given access to the
technology), not a one-time payment. Therefore,
although open source licensors cannot charge
royalties, they can charge a one-time fee that is as
high as the market will bear.15
Of course, the fact that an open source soft
ware license must guarantee its licensees’ freedom
to make copies of the licensed software and dis
tribute them to others without having to make
additional payments to the licensor means that
the price of the technology tends to be driven
down to the marginal cost of reproduction and
distribution—for software, close to zero. Keep
in mind that while the inexpensiveness of open
source software production relative to convention
al proprietary production is an inherent feature
of the open source model, the low price of open
source software to consumers (and hence the low
rate of return to licensors in the form of license
fees) is a consequence of market forces that may
not exist with respect to other types of technol
ogy. For example, because the marginal cost of
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reproduction and distribution may be quite high
for technologies that are less highly codified than
software or are embedded in tangible objects the
production costs of which are sensitive to econo
mies of scale, fewer distributors may come for
ward to compete with the original licensor, and
licensees may be more willing to pay the licensor
for extra “copies” of the technology than is the
case in the software context.16 This means that
there may be more opportunities for a licensor to
profit directly from the sale of non-software open
source technologies.
.2 Indirect financial incentives

Most of the incentives for open source licens
ing are indirect rather than direct. Sections 4.3
and 4.4 describe incentives relating to cost sav
ings, productivity gains, and reputational capital.
However, one of the most important effects of
open source licensing is to expand the user base
for a technology, thereby expanding the market
for complementary goods and services.
There are several reasons why an open source
license tends to increase user numbers. In the first
place, a technology that is distributed according
to open source terms is often more attractive to
users because it is more affordable and available
than its proprietary counterparts and because its
availability is not dependent on any particular
supply chain.
Next, open source technology is malleable.
Licensees can make modifications to the tech
nology and access the means for doing so. The
malleable nature of the technology creates mar
kets not just for the technology itself, but also for
associated maintenance services, upgrades, and
adjustments.
These market-expanding effects are especially
pronounced for technologies with strong network
effects (that is, technologies that become more
valuable as more people adopt them, which in
turn increases their popularity): this includes not
only information and communication technolo
gies but also many biomedical and agricultural
technologies. For example, a microarray reader
that displays data in a particular format becomes
more useful if a number of scientists use the same
reader: the uniformity of data output makes it
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easier to compare and verify data that originated
in many different laboratories.
As the market expands, revenues from sales,
one-off licenses, and dual licensing may be
enough to offset the opportunity cost of adopting
a nonproprietary licensing strategy. At the same
time, the demand will increase for complemen
tary products and services, including technology
training, technical support, customization ser
vices, hardware or wetware supplies, proprietary
data-analysis software, and so on. Many successful
commercial open source software ventures turn a
profit by providing complementary products and
services. Perhaps the most striking example is that
of IBM: a substantial investment in open source
software production provides IBM with access to
a better operating system that makes its primary
commercial offering, server hardware, more valu
able to consumers.
. Non-financial incentives for
individual researchers

Computer programmers are often motivated
to contribute to open source software develop
ment by incentives that are not strictly monetary
(though they can be translated into monetary re
wards in the employment market): the possibility
of enhanced personal reputation and the oppor
tunity to learn new skills.17
At first glance, such nonmonetary benefits
may seem irrelevant to the biomedical or agri
culture fields, where decisions about research
investments are commonly made at an institu
tional rather than an individual level. However,
individual researchers in both of these fields can
decide, to some extent, how and where they will
direct their own or their laboratory’s resources.
Such self-determination is common for academic
researchers, but is also evident in biotechnology
and pharmaceutical companies, many of which
allow staff to spend some designated fraction of
their time on personal research projects in order
to encourage creativity, increase job satisfaction,
and, it is hoped, generate new commercial op
portunities for the company.18 Researchers with
some creative freedom might decide to partici
pate in open source development under appro
priate funding and employment conditions. The
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same is true for the many open source software
developers who are not hobbyists but, instead,
professionals whose contributions form part of
their employment.19
. Institutional incentives
..1

Intrainstitutional incentives

It is to an organization’s advantage to build a
reputation for cutting-edge technological innova
tion, and to keep its researchers sharp by allow
ing them to participate in a range of projects,
regardless of their projected commercial value.
Furthermore, open source development encour
ages the development of a productive, collabora
tive environment.
..2 Interinstitutional incentives

In both biomedicine and agriculture, the locus of
innovation is often not the individual company
or university but the network of diverse collabora
tions among organizations.20 Open source licens
ing offers a way of sharing the costs and risk of
technology development among many prospec
tive users: in other words, open source develop
ment can be a form of precompetitive collabo
ration. As users and developers collaborate on a
project, technological applications multiply and
diversify, and robust and reliable tools are created.
Bruce Perens, author of the OSD, points out that
the same groups of companies often have a low
rate of success of proprietary consortium software
development but a high rate of success with large
open source projects; he suggests that the inher
ent fairness of open source licensing encourages
effective collaboration between parties with dif
ferent interests.21
Open source licensing is not primarily a
means of dealing with existing “anticommons
tragedies,” that is, bargaining failures among own
ers of multiple complementary IP assets.22 Unless
the technology in question is a killer app—a
software term for any tool that renders obsolete
all others in its class—the terms on which it is
licensed, whether open source or otherwise, can
have little impact on existing reach throughs,
royalty-stacking provisions, and other restrictive
licensing terms. Rather, open source is a means

of pre-empting such tragedies by establishing a
robust commons for basic or fundamental tech
nologies whose value is likely to be enhanced by
cumulative innovation. In situations where an
anticommons problem already exists, nonpro
prietary strategies can have a beneficial tipping
effect, because the greater the number of nonpro
prietary tools in any given tool kit, the greater the
incentive of everyone in the field to invest in de
veloping substitutes for the remaining proprietary
technologies for the sake of achieving freedom to
operate with the tool kit as a whole.

. dIffEREnT TypES of
opEn SouRCE LICEnSES
.1 Copyleft licenses

A copyleft, or reciprocal, license allows the user to
modify and redistribute a software program at
will. The licensee’s obligation under a copyleft
license is to make relevant downstream technolo
gies available to all comers (including the original
licensor) under the same terms as provided by the
original license. No one (including the original li
censor and his or her licensees) obtains any special
privilege regarding any next-generation technol
ogy, such as a right to preview any improvements
or exclusive sublicensing rights to any improve
ments. The point of a copyleft license is to create
an ever-growing pool of downstream innovations
that remain freely accessible to all comers.23
However, a copyleft license is not always the
best way for innovators to guarantee themselves
access to future improvements in the technology.
Instead, prospective licensors should carefully
consider how they can best encourage licensees to
contribute to a technology commons.
When deciding whether or not to use a
copyleft license, the innovator should take into
account the attitudes, needs, and constraints of
prospective users, as well as the other tools that
they are likely to use in conjunction with the
technology. For example, if licensees use tools
that are subject to proprietary intellectual prop
erty licenses, the conditions imposed by owners
of that intellectual property may conflict with
the copyleft obligation to make downstream
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innovations freely available. Furthermore, it is
possible to trigger a cycle of cumulative innova
tion even if users do not perfectly comply with
the copyleft ideal, provided there is a critical mass
of user-developers who do.
A copyleft-style obligation is probably neces
sary only if potential contributors are likely to be
seriously put off by the existence of free riders,
those who let others put in the time and mon
ey for research and development and then help
themselves to the results. Even then, an innovator
should take care to explain to his or her licens
ees why such an obligation is necessary. Under
no circumstances should an open source license
restrict licensees’ freedom to take development in
new directions, with or without the licensor’s ap
proval. The strength of open source is, after all,
its ability to harness the creativity of diverse usercontributors who are allowed to work in relative
freedom.
If it is decided to adopt a copyleft license,
the licensor has two main ways of tailoring the
license terms to maximize the incentives of pro
spective contributors. Not every modification,
improvement, or new application of a technology
that has been licensed on copyleft terms must be
made available on those same terms. In the first
place, only derivative works that are externally
deployed—that is, sold or otherwise distributed
outside the boundaries of the licensee’s organiza
tion—are subject to the reciprocal obligation un
der a copyleft license.
Second, even if a downstream innovation is
externally deployed, it still may not fall within
the definition of improvements in a particular
copyleft license, because different licenses have
broader or narrower definitions. The only real
check on the licensor’s discretion with respect
to the breadth of this definition, apart from the
willingness of other contributors to accept the
license terms, is the scope of the licensed intel
lectual property. A licensor who seeks to control
that which he or she does not own may run afoul
of competition laws.
In this connection, a trap for would-be
copyleft-style licensors to be aware of is that an open
source license must grant the licensee the freedom
to create a new collaborative-development project
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based on previous contributions (a phenomenon
known in the software industry as a code fork),
for any reason at all.24 The possibility of forking
means that technologies can still be improved even
if their initial innovators have lost interest in the
technologies or have lost the capability to develop
them. In practice, forking is rare, largely because
it is difficult to persuade others to abandon the
old project in order to start on a new one. It is
often easier for dissenters to continue working on
the original project and then invest some of their
own resources adapting its output to their specific
needs rather than abandon the original project al
together. However, in formulating the definition
of improvements in a copyleft license, the licen
sor (or his or her agent) must avoid restricting the
freedom to fork development.
Thus, the two most important aspects of a
copyleft-style license are: (1) the definition of
“improvements” (or an equivalent term) which
determines which follow-on innovations must be
licensed on the same terms as the initial licensed
innovation; and (2) the definition of “external
deployment” (or equivalent), which determines
under which circumstances the aforementioned
obligation must be fulfilled. These may be ad
justed by the licensor to create a copyleft license
that strikes the appropriate balance of incentives
to contribute to any given project.
.2 Academic licenses

Another type of open source license is the aca
demic or BSD-style license (named after the
Berkeley software distribution license, the old
est license in the OSI’s list of approved licenses).
These licenses do not require users to make ex
ternally deployed improvements available to the
licensor on the same terms as the original tech
nology; in some cases, the downstream user’s
only obligation is that he or she must give the
innovator credit for the innovation. According to
Larry Rosen, the difference between copyleft and
academic open source licenses is that the former
are employed by generous sharers of IP freedoms,
whereas the latter are employed by generous do
nors of IP freedoms.25
An academic license can achieve some of the
goals of open source as effectively as can a copyleft
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license. Indeed, where the licensor’s primary goal
is to encourage widespread adoption of the ini
tial innovation, an academic-style license may be
more effective because a copyleft license could
deter potential licensees who want to be able to
commercialize their own improvements on a pro
prietary basis.

. opEn SouRCE In fIELdS
oTHER THAn SofTWARE
Although most of the examples given here come
from the software industry, the principles of open
source can be applied to other fields as well. Open
source technology could be especially useful in
niche markets that are too small to be profitable
for companies that make off-the-shelf, proprietary
technologies. Importantly, open source technolo
gies can be tailored to serve small agricultural and
pharmaceutical markets in developing countries
(where small may refer either to the numbers of
potential users or the amount that potential users
can afford to pay).
.1

Biological innovations

Open source can have a place even in fields domi
nated by proprietary strategies, such as the life
sciences. Open source tools are important—and
growing ever more important—to life sciences re
search and development. Many of the most valu
able and widely used enabling technologies in the
field are bioinformatics software programs, li
censed on terms that are open source in the strict
est sense. A good starting point for readers inter
ested in exploring the possibilities of open source
software for biomedical and agricultural applica
tions is the Web site of the Open Bioinformatics
Foundation.26
What about open source licensing for nonsoftware biotechnologies? Starting as early as 1999,
a variety of life-sciences initiatives have conscious
ly adopted one or more open source principles
in attempts to overcome some of the challenges
posed by an increasingly complex IP landscape.
These initiatives include a Canadian proposal for
a General Public License for plant germplasm,27 a
draft license (never adopted) for human genome
project sequence data,28 the data access policy of

the international haplotype mapping (HapMap)
project,29 the Biobricks Foundation,30 Tropical
Diseases Initiative (TDI),31 Science Commons,32
and Biological Innovation for Open Society
(BIOS).33
Many open source software licenses are
drafted as generically as possible so that as many
people as possible can use them, as templates, for
as little cost as possible. It would be helpful, of
course, if the life sciences had open source prec
edents or template licenses—or, for that matter,
a voluntary licensing standard, equivalent to the
OSD, or a set of best-practice guidelines. Such
tools would not only help prospective licensees
decide whether a biomedical or agricultural tech
nology license is genuinely “open source”(thereby
helping them judge whether it is likely to achieve
the positive collaborative outcomes for which
open source licensing is valued) but would also
help prospective licensors set universally benefi
cial terms for technology transfer.
These tools, however, do not yet exist. In
developing such tools, the biomedical and agri
cultural research and development communities
could learn a lot from the experiences of software
developers. However, it may turn out that bio
technology—which is a far more technologically
diverse field than computer programming, and
which relies on expensive, time-consuming, and
complicated patents rather than automatic nocost copyrights—simply does not lend itself to
the use of template licenses.
Therefore, for the present, at least, IP manag
ers should be wary of uncritically imitating ex
isting attempts to formulate open source licenses
for non-software technologies, both because these
licenses are not generic enough to be appropriate
in all contexts and because some may not truly
embody the principles that make open source
work. Instead, prospective licensors and their ad
visors should develop tailored strategies.
.2 Examples of open source in
molecular diagnostics

The following examples reveal how open source
licensing could be advantageous in both the pub
lic and the private sector even outside the soft
ware context.
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Case #1: A nonprofit setting

Suppose that a clinical scientist working in a notfor-profit setting (a university or hospital labora
tory) discovers a genetic mutation that seems to
correspond with the occurrence of an inherited
disease in one of his or her patients’ families.
Using standard molecular biology tools, the sci
entist creates a diagnostic test and confirms the
discovery. Imagine that the diagnostic test is pat
entable, but, because there are probably tens or
hundreds of mutations associated with the dis
ease, the new test will detect only a fraction of
these mutations. As a result, the test has limited
value.
Clearly, the utility of this diagnostic test—
and hence the utility of the service the scientist’s
lab provides to patients, their families, and the
community as a whole—would be enhanced if
the new test could be combined with previously
existing tests for other mutations associated with
the same disease. The utility of the new test would
also be enhanced by increased use: the more peo
ple who use the test, the more likely that systemic
errors would be detected and corrected, and the
greater would be the cost-effectiveness, for regula
tors, of enforcing best-practice standards for the
test.
In this case, a copyleft-style open source li
cense might be the most sensible way to protect
the new genetic test. Such an approach would
ensure that users do not have to pay license fees
to subsequent developers in order to gain ac
cess to the most comprehensive version of the
test.
.2.2 Case #2: A for-profit setting

Suppose now that our hypothetical scientist works
for a small company that operates on a mixed-rev
enue business model. Some of the company’s rev
enue comes from the development and marketing
of diagnostic tests for use in hospitals, physicians’
offices, and in the home. More revenue comes
from data analysis and contract research services.
The rest of the revenue comes from licensing its
collection of gene patents.
The inventor’s company also conducts broadranging R&D activities that are economically
important to the company in two ways. First, by
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developing and patenting new technologies, the
company generates more revenue through patent
licensing. Second, the company’s research agenda
enhances the company’s reputation as a high-tech
organization, which in turn attracts new cus
tomers. Because of its small size, the company’s
stand-alone research capacity is limited, so it
makes a point of pooling resources with other
research organizations. However, competition is
fierce among small companies that want to forge
alliances with the most desirable partners from
industry and the nonprofit sector, so our imagi
nary company is always looking for ways to en
hance its capacity for cutting-edge research and
to advertise its excellent track record of scientific
collaborations.
If the genetic test mentioned above were to
be licensed under a copyleft-style license, the
company would gain access to any new versions
of the test—which are likely to be more reliable,
easier to perform, and more comprehensive than
the old ones—without having to pay exorbitant
fees to other developers or having to deal with
restrictive licensing terms. The better the test be
comes and the cheaper it is for people to use, the
larger the market will be for associated products
and services (for example, test kits and genetic
counseling). If the company is known as the pro
ducer of a cheap, effective test, the company’s
reputation will improve; the enhanced reputa
tion, in turn, will lead to greater demand for
its contract research services and, perhaps also,
greater demand for access to the company’s gene
patents. Further, a better standing in the indus
try will make it easier for the company to attract
and keep excellent employees and research part
ners. Meanwhile, the experience of leading an
open source project would give the company a
chance to acquire, and demonstrate, experience
in collaborative research.
Note that although open source develop
ment makes sense for the two hypothetical cases
outlined here, open source may not always be
appropriate. There are no hard-and-fast rules
about whether or not the benefits of an open
source approach will outweigh the costs, so each
situation must be evaluated on a case-by-case
basis.

CHAPTER 2.

. ConCLuSIonS
Much work remains to be done before open
source licensing is fully integrated into the bio
medical and agricultural spheres, and this chapter
has done no more than scratch the surface of the
topic. Ideally, those who are interested in explor
ing nonproprietary exploitation strategies in the
life sciences will continue discussions that will
eventually lead to the creation of open source
standards and open source license templates.
Until then, prospective licensors in the life scienc
es must be prepared to independently interpret
the lessons of open source software licensing. n
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Using Milestones in Healthcare Product Licensing
Deals to Ensure Access in Developing Countries
JoachiM oehleR, Chief Executive Officer, Concept Foundation, Thailand

ABSTRACT

When public–sector organizations and public–private
product development partnerships (PDPs) manage intel
lectual property (IP), they need to balance the commercial
interests of private–sector manufacturers with the public
sector’s mission to obtain access to products at the lowest
possible cost. An important tool for achieving this bal
ance is the detailed definition of contractual milestones,
which should clearly specify the terms for pricing to the
public sector, territory and exclusivity, regulatory work,
and time to market. Milestones should not, however, be
cast in stone. Based on detailed analyses of market condi
tions, milestones need to remain adjustable throughout
the life of the contract. When well defined, milestones
can be used to ensure the availability of the most modern
healthcare products to the developing world. After all, for
the public sector, successful IP management is defined by
how many poor people a product will reach, how easily
it will be available to them, and who and how many will
be able to afford the product. Accordingly, out-licensing
intellectual property from public–sector-based organiza
tions to private–sector partners requires the licensor to
actively guard public–sector interests.

1. InTRoduCTIon
When public–sector organizations and public–private product development partnerships
(PDPs) manage intellectual property, they need
to balance the commercial interests of pri
vate–sector manufacturers with the mission of
the public–sector to provide access to products
at the lowest possible cost. Many of the impor
tant inventions oriented toward public needs in

healthcare and biotechnology result from R&D
in public–sector research centers and interna
tional organizations. By adequately managing
the resulting IP, the public–sector can benefit
from its R&D investments by making the most
modern healthcare products available to the de
veloping world, eliminating significant barriers
to access.
1.1

The importance of contracts
and milestones

For parties entering into agreements of any
kind, the primary assumption of contractual re
lationships is that the principal subject of their
deal will be realized successfully. Obviously, this
is not always a safe assumption, and when un
foreseen events prevent the partners from reach
ing their goals, contracts differ considerably in
the quality and substance of the remedies they
provide. Too many contractual relations go sour
because partners rush into agreements without
carefully thinking about contingencies.
Without an early elaboration of contin
gency plans and crisis management, this honey
moon trap is why many contractual agreements
contain unclear, foggy language and omit defini
tive, detailed, and enforceable conditions. Such
conditions should address not only the con
tractual rights but also the obligations of each
partner and the specific countermeasures to be

Oehler J. 2007. Using Milestones in Healthcare Product Licensing Deals to Ensure Access in Developing Countries. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT
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taken should one party run into difficulties in
fulfilling its part of the deal. Instead, “best ef
forts clauses” or provisions for consultations to
solve problems case by case are used, so as not to
spoil the initial enthusiasm of making the deal.
When unforseen events occur, that can be a sure
recipe for disaster, especially if the mechanisms
to settle disputes over differing opinions about
contractual performance are unclear.
A typical contract specifies the subject mat
ter, the duration and terms, and the rights and
obligations of each party under the agreement.
Licensing agreements between two organiza
tions identify, among many issues, the nature
and scope of the intellectual property or prod
uct that is being licensed, the territorial grant to
the licensee where the licensed product would
be made available, and the financial obligations
of the licensee.
A practical example is the use of technical
know-how, or the results of scientific research,
that represents the particular intellectual prop
erty of a licensor and is to be licensed out to a
commercial company able to create a product
from the intellectual property and distribute it
to consumers and users. The interests of both
parties in the arrangement are straightforward
and mutually advantageous—it is a win-win
situation. This ordinary, idealistic assump
tion prevails at the beginning of any licensing
deal. All too often, however, reality thwarts the
goals of the initial agreement. Planned goals are
missed, or forecasts wrong, and the contractual
partners are left with only a subset of the origi
nal targets.
Too often, the public sector forgets that the
commercial interests of private-sector companies
are oriented toward maximizing profitability.
Accordingly, it should not be expected that pri
vate-sector businesses will automatically provide
the best services to the public sector or that they
will focus on the generation and use of intellec
tual property to maximize public–sector benefits.
To prepare for situations when the original tar
gets of a license agreement are delayed or not
achieved, and to avoid situations when projected
public–sector benefits are delayed or unrealized, it
is good practice to establish contractual milestones.
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These govern the goals of the license contract and
set incentives for keeping to timelines and perfor
mance targets. They encourage both the licensor
and licensee(s) to focus resources on their efforts
to perform as initially agreed.
But milestones should not be fixed or inflex
ible. They need to remain adjustable through
out the lifetime of a license contract because of
potential changes in project development, the
market environment, and other factors that
cannot be completely anticipated. When it
comes to the detailed specifications of individu
al milestones, it does not really matter if one is
choosing an absolute or a relative goal, or which
definition is finally settled upon. What matters
is to get the commitment of the private–sector
company to recognize public–sector targets. To
do this, a working set of adequate milestones
should be put in place, and periods for perfor
mance assessment of the private–sector contract
partner should be defined. And when new, solid
evidence requires a change of rules to keep both
the product and the public sector’s goals alive,
both parties should be open to revisions. Such
results-oriented milestones require intensive
preparations, detailed knowledge of the pro
cesses related to developing and marketing the
product, realistic forecasting of product poten
tial, persistence in quantitative forecasting and
establishing a master plan for the entire product
roll-out, and a mission-driven mindset to estab
lish optimum goals for the public sector.
Additionally, it is useful to spell out the level
and conditions of fines (monetary or otherwise)
to be paid when a partner does not fulfill its ob
ligations. This should include a mechanism to
prevent prolonged periods of quarreling over
differing opinions and disagreements over per
formance. Otherwise, product development or
marketing efforts could cease, which would ulti
mately hurt the public sector.
Most milestones cover:
• pricing to the public sector
• territory and exclusivity
• regulatory work and time-to-market
• royalties
• terms and termination of the license
agreement
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1.2 Public–private partnerships: closing
the medicines access gap in developing
countries

The role of public–private partnerships (PPPs),
or, in the context of health, more and more
frequently public-private product development
partnerships (PDPs), as an innovative approach
to the discovery, development, and distribu
tion of health products, drugs, and vaccines
for developing countries has been emphasized
repeatedly in various publications. In fact, more
than 90 PPPs have been established worldwide.1
However, the accomplishments of PPPs/PDPs
are rarely publicized, partly because most of
these entities are relatively young. Half of these
partnerships have been established since 1999.
Since normal times to market range from no less
than ten to around 12–15 years, on average, in
a pharmaceutical R&D or healthcare environ
ment, the time in existense of these partner
ships has been relatively short. It is still possible
to begin to gauge, however, the success of these
ventures.
One example of a PDP is the Concept
Foundation,2 established in 1989 through the
initiative and funding of the World Health
Organization’s Special Programme of Research,
Development, and Research Training in Human
Reproduction (WHO/HRP), the World Bank,
and United Nations Population Fund (UNFPA),
PATH/PIACT,3 and The Rockefeller Foundation.
The mission is “to provide access to top quality re
productive-health products for developing countries
at lowest possible prices in order to realize maximum
public-sector benefits through the management of
intellectual property and technology transfer for
contraceptives and pharmaceuticals that otherwise
would not be available to the public sector with
the intended quality and prices.” The Concept
Foundation has accumulated extensive experi
ence managing health technologies develop
ment and technology transfer in the pursuit of
rolling out new technologies in the developing
world.
Successful PPPs/PDPs are built on value
propositions, from the public sector to the pri
vate sector, that take advantage of the inherent
capabilities of the former. The public-sector IP

manager should identify the capabilities that are
relevant to a particular public–private partner
ship and turn these capabilities into specific val
ue propositions that will help the private–sector
partner realize its commercial goals. No poten
tial benefit to the public sector, however, should
be sacrificed. In this context, it is especially im
portant to overcome the common phenomenon
of further marginalizing the poor in the small
and smallest countries of the developing world.
Market attractiveness governs priorities in a
commercial environment, but in a public–sec
tor context, the poor in the smallest countries
have the highest needs for accessing affordable
products. As the experiences of the Concept
Foundation reveal, the public sector successfully
manages its intellectual property when it bridges
these ostensibly opposing interests.
The R&D process for developing new drugs,
vaccines, and diagnostics for diseases that afflict
the poor is a crucial step toward ultimately erad
icating these diseases. Many PPPs/PDPs con
centrate their efforts on product development,
and the largest product-development PPPs/
PDPs have successfully raised (in combined fig
ures) more than half a billion U.S. dollars in re
cent years to fund their R&D efforts. However,
product delivery is an equally important, if not
more decisive, factor for access to medicines,
and most product-development PPPs/PDPs are
not working to ensure that their products can
be delivered to the local healthcare infrastruc
ture. Indeed, product-development PPPs/PDPs
have little experience with the downstream
issues involved in bringing products to such
markets.
But PPPs/PDPs face numerous downstream
concerns associated with handling and financ
ing the introduction and launch of new products
including:
• adequacy of healthcare infrastructure
• disease surveillance
• compliance monitoring
• education and training of health workers
and medical staff
• improving healthcare facilities
• physical distribution networks
• satisfactory supply volumes
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• adequate volume forecasting
• minimizing product waste at the point of
treatment
As is well known from experiences in the
pharmaceutical industry, successful marketing
and distribution of a new medicine is a significant,
decisive part of its cost structure. While nobody
would expect the need to create market demand
(in other words, investing marketing dollars) for
products to fight diseases of poverty (these mar
kets exist!), huge investments are needed to com
pensate for the inability of the poorest regions to
pay for both modern, effective products and for
all downstream tasks related to effectively sup
plying and distributing these medicines. In ad
dition, costs for surveillance programs to guaran
tee successful outreach to all who need treatment
must be included. Product development public–private partnerships lack the experiences to
address these downstream issues.
These efforts must include achieving the
lowest possible manufacturing costs so that pref
erential pricing can be provided to public health
services, establishing sustainable manufacturing
with a continuous system for monitoring qual
ity, and creating a business model that is finan
cially attractive to private pharmaceutical com
panies thereby overcoming the expected poor
returns of operating in public sector markets.
The PPP/PDP business model of the Concept
Foundation has helped to realize these goals. It
takes into account the downstream issues sur
rounding product delivery and successfully uti
lizes contractual milestones to achieve the prin
cipal goal of closing the medical-product access
gap in developing countries.

2. THE GREAT DIVIDE IN BuSINESS
MODElS: INDuSTRy AND
THE PuBlIC SECTOR
No matter how well public sector players think
they understand industry, the discussion between
the public sector and industry is a cross-cultural
event. In such a cross-cultural environment,
there is nothing more dangerous and conducive
to misunderstandings than to assume the obvious,
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since what is obvious for a person with a public
sector background may be different for a poten
tial partner. Do not leave obligations and con
tractual performance to best efforts and com
mon sense! It is much better for both partners to
specify in writing exactly what the public sector
wants to achieve with a commercial partner. The
document should detail exactly when and how
the objective will be achieved and specify penal
ties for failure to meet objectives. If the agree
ment specifies only best efforts and unspecified
performance, disaster threatens!
To manage intellectual property for maxi
mized benefits to the public sector, the expec
tations of the public sector to obtain products
at the lowest possible prices, with excellent
quality, and in sufficient quantities must be
balanced with the expectations of private sec
tor companies to generate a satisfactory rate of
return.
Important value propositions for pharma
ceutical companies are:
• Save time to market. An earlier market
entry means higher market share oppor
tunities for the company and, ultimately,
more sales. Example: Pharmaceutical or
clinical research, using an existing net
work of public sector institutions in paral
lel speeds the generation of results needed
for drug regulatory approval by saving the
lead time required to approach new, unfa
miliar trial sites and train in GCP (good
clinical practices).
• Save resources. Reduced need for inter
nal company resources means a lower cost
burden for the licensee and improves the
bottom line. On the other hand, when
investment levels are maintained, more
parallel activities are possible with the
same amount of resources, helping to in
crease the company’s commercial output.
Example: Existing public sector distribu
tion networks, formal or informal, allow a
product to reach a large public sector mar
ket very quickly without the costly build
up of a supply chain.
• Save investments. A reduced need for
investments means better cash flow
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utilization within the company, which is
very important for investors.
Any plan for a value proposition must deal
specifically with the nature of the partnership,
and a successful proposal must present an au
thentic and actual value to a potential partner.
These authentic, actual values must be based on
the set of capabilities that the public sector orga
nization can offer—this is precisely the platform
for the creation of value—and based on what
private sector partner needs could be met by the
public sector. Such genuine values include the
examples above: save time to market, save re
sources, and save investments. As these demon
strate, one must look behind the immediate and
apparent face value of individual capabilities
in the public sector to be able to identify and
compose the true value of such contributions.
Indeed, an authentic value proposition is more
often composed of several contributions from
various capabilities than a single value factor.
Understanding all the specific values when
just beginning to approach potential licensing
partners is essential—especially those values that
drive an industry and are particularly important
for the potential licensee. A detailed analysis of
these values and their alignment with existing
public sector capabilities helps to identify the
value propositions that public sector organiza
tions can offer their private sector partners.

. THE MoST IMpoRTAnT MILESTonES
Maximizing public sector benefits through IP
management has three key aspects:
1 definition of the geographic coverage for
marketing the product (that is, territory)
2 the claim for product exclusivity by the
private sector licensee
3 the definition of the preferred public sec
tor price or other public sector benefit
These may seem very straightforward. It is
easy to imagine that the partners in a license
arrangement would agree on a set price for the
product for public sector distribution, agree on
the countries in which the product could be

sold and that, as a result, the private sector com
pany, as licensee, obtains the exclusive rights to
marketing and sales of the product in this ter
ritory. However, in real life, this does not nec
essarily mean that public sector benefits have
been maximized. Some key questions need to be
answered:
• How well will we reach smaller countries
with our product?
• How well will we reach rural populations
in developing countries that normally re
main underserved?
• Who will benefit from obtaining the prod
uct at a special public sector price?
• How can we ensure that we will obtain the
product at prices affordable to public sec
tor agencies?
The principal way to address these issues is
to set contractual milestones that prevent the
marginalization of the poor in smaller coun
tries, regulate public sector access, and set the
geographic coverage for all countries in a terri
tory (even in countries and regions that are not
interesting enough to generate sizeable returns
on investments and would therefore normally
not be served). Finally, there must be a clear
framework for computing manufacturing costs,
and this cost calculation must be available to the
public sector partner.
Due to commercial pressures, putting the
private sector and its commercial interests be
fore those of the public sector is an inherent
danger. Such prioritizing usually reflects at
tempts to simplify the private sector partner’s
participation because of fears about failing to
make a deal. While simplifying agreements is
good practice, establishing specific contractual
milestones and clarifying them under the terms
of an agreement are not necessarily complica
tions. Success requires focusing on which areas
to target and which issues to exclude. A tight
focus will guarantee the simplicity of the provi
sions and regulations without overburdening an
agreement.
When it comes to public sector benefits,
simply making a product available at market
prices or quickly placing it on the market does
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not indicate progress. Success is instead defined
by how many poor people the product will
reach, how easily it will be available to them,
and who and how many will be able to afford
the product. The goal is to reduce morbidity
and mortality. For the public sector, this is the
ultimate aim of product development. The nec
essary achievements for obtaining this outcome
need to be clearly specified as milestones in an
agreement. We will next take a closer look at ter
ritory, exclusivity, and pricing.
.1 Territory and field-of-use

A typical license agreement will specify the grant
of the license. Language such as: “LICENSOR
grants COMPANY the rights to manufacture
and sell the PRODUCT into the PRIVATE
SECTOR and PUBLIC SECTOR markets of
the TERRITORY” is commonly used. The
terms LICENSOR, COMPANY, PRODUCT,
PRIVATE SECTOR, PUBLIC SECTOR, and
TERRITORY are used according to the defini
tions in the introductory “Whereas” chapter to
the agreement.4
Under this wording, the license grant is es
tablished as a right of the licensee to the prod
uct. However, the license grant does not specify
the obligation to sell into the territory. This is
a very important issue of practical IP manage
ment for public sector benefits. While it is rea
sonable to assume in the case of a one-product,
home market manufacturer that the licensee will
introduce the product into this (single) market,
it is not necessarily true that a licensee will in
troduce the product into all markets of a mul
ticountry territory, especially the public sector.
This failure to reach all the desired markets may
result from various factors that were not known
or were underestimated when the license agree
ment was established.
Between the signing of a license agreement
and the commercial roll-out of the product, a
considerable period of time may be needed for
product development, manufacturing scaleup, and regulatory approval. Depending on
the capabilities of the licensee, this time peri
od may well extend over several years. During
this time, the company’s business and the
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business environment may change significantly,
and resources that originally were available for
dealing with the product may have been partial
ly redirected to other, possibly more profitable,
products and projects. Markets that initially
seemed attractive may have lost their appeal
compared to other opportunities since recog
nized by the company.
Changes in the business environment and the
focus of the business may affect the licensee’s com
mitment to serve the public sector as originally
envisioned for the entire area. To ensure availabil
ity and access to the product in the public sector’s
territory, it is only prudent to use the license grant
to obligate the licensee to sell the product in that
area—not just as a right of the licensee. This can
be accomplished in various ways:
• By separating the grant of the rights to
manufacture the product from the obliga
tion to sell the product into all countries of
the territory (Emphasis here should be on
all countries in the territory.)
• By attaching milestones to the execution
of the sales rights for the product (Only
after showing defined success according
to the milestones would the licensee be
granted additional sales rights for other
countries.)
• The rights of the public and private sec
tor to sell the product could be dealt with
in separate regulations that prioritize the
public sector organization’s goal of intro
ducing the product into the public sector
at a satisfactory level (to be defined by an
adequate milestone) in one country, be
fore additional rights to markets—public
and private—in other countries would be
granted. The license grant could specify,
for example, the rights of a Brazilian man
ufacturer to produce and sell the product
in Brazil, the home market, and the rights
to sell it in other Latin American coun
tries, once certain conditions are met. A
wide range of options for these conditions
are available and could be specified in the
license agreement, such as:
- Market share. licensee will gain the
rights to sell into other countries after
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establishing a market share of 20% in
the specific market segment, as reported
by IMS.5
- Market position. licensee will gain the
rights to sell into other countries after
positioning the product among the topthree products within its category in the
Brazilian market, as measured by ana
lyst reports.
- Sales volume. licensee will gain the
rights to sell into other countries after
an annual sales volume of five million
units is realized in the Brazilian market,
as measured by cumulative sales reports
from distribution agents.
- Public sector penetration. licensee will
gain the rights to sell into other coun
tries after the total output/annual out
put into the public sector in Brazil has
reached ten million units, as measured
by procurement orders from public sec
tor agencies.
In addition to the milestones for gaining
the rights to sell in additional countries, the re
maining countries in the licensed territory could
be prioritized in order of importance for the li
censee, and eventually the licensor as well. Each
country on the list would then be characterized
by individual milestones that the company must
reach before it could sell in an additional coun
try. These country priorities and milestone defi
nitions should be set when signing the license
agreement, with the option to revise the priori
ties and milestones after a certain period.
It is unwise to leave country priorities or
milestone definitions open and uncovered for
the sake of higher flexibility (for example, set
ting the next country priority shortly before
reaching the last defined milestone in the actual
country of activity or a similarly flexible model
that postpones decision-making). Reaching
consensus about country priorities and mile
stone definitions might become more and more
difficult for the licensor and licensee, especially
the closer the country of choice is to the bottom
of the priority list. The licensee might then no
longer desire to sell in a particular country, and

especially to the public sector, due to various,
possibly hidden, reasons. The company could
walk away from its responsibilities to serve a
particular country. In this case, the private sec
tor company would not be violating the license
agreement, since the milestones had not already
been mutually defined and negotiations about
new milestones had failed.
On the other hand, priorities and milestone
definitions may change over time in a fast-mov
ing business environment. Indeed, they might
not be considered valid after several years into
the lifetime of a license agreement. This is a
common concern when it comes to defining
priorities and milestones, especially among ad
vocates of real-time implementation. Given the
need to eventually define priorities and mile
stones, to protect public sector access to the
product everywhere as far as possible, and to
avoid the inherent dangers of leaving important
parts of an agreement initially undefined pend
ing a later mutual understanding, it is close to
irresponsible to skip over these definitions and
omit them from the initial version of the signed
license agreement. One can provide for a regular
update of the details of these conditions, when a
changed environment requires them, for exam
ple, by calls for revisions. At that time, however,
it would be up to the licensee to demonstrate
the need for changes and to prepare a detailed
proposal of what to change and how to change
it. Unless the proposed changes bring up com
pelling reasons for the licensor, original priori
ties and milestones would prevail. The originally
defined public sector goals would remain in
force without alteration and the licensee would
still be required to honor these goals.
Initially defining contractual priorities and
detailed milestones is, of course, a painstaking
process that requires intensive preparations to
ensure that essential aspects of the public sec
tor’s objectives are not overlooked. This desk
research and information collection is essential
for adequately preparing license agreements that
serve public sector interests. For initial negotia
tions between parties, the terms of a licensing
agreement should be rolled-out in all related
details, even though it may be difficult and
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resource-intensive to formulate all of them. The
tendency to postpone detailing specifications,
or calls from the contract partner to omit the
necessary detail in order to simplify and quickly
reach an agreement is a trap. It does not allow
the parties to establish the necessary framework
for an efficient and effective public sector-ori
ented licensing arrangement. If it is impossible
to reach an agreement on staggered priorities
with detailed milestones in the beginning of the
contract relationship, how can these differences
be ironed out later?
.2 Exclusivity

One of the first things that companies ask for is
exclusivity. It is important to link such requests
with specific milestones, such as:
• volume of sales reached in certain markets
after a certain time period from launch or
from the signing of the agreement
• level of market share reached against
competition
• level of market share established in a new
market segment, measured against the to
tal product potential
• level of coverage of different regions in a
large market or across different countries
of a region
• latest product launch date into a market
that will secure product/technology ex
clusivity for the company, in general, for
a selected territory
Specifying penalties and fines for the licens
ee if these milestones are not reached is just as
important as setting the specific milestones. The
penalties could be:
• temporary increase of royalties on private
sector sales until the milestone condition
has been reached
• loss of exclusivity for the product or tech
nology and conversion to a nonexclusive
license, in general, or for a specific region
• loss of exclusivity and territory to a
competitor
• payment of a fine, in a predefined amount,
for failure to introduce a product into a
country under exclusivity for the licensee.
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It is good practice to evaluate the request
for exclusivity with respect to the public sector
benefits that a potential licensee could deliver.
Again, it is unreasonable to expect that a private
sector company would concentrate major re
sources on serving the public sector when there
are no specific obligations in the license agree
ment or milestones are inadequate or undefined.
Since the request for exclusivity is made to pro
tect the commercial potential of a market place,
the public-sector partner has the right in a quid
pro quo to ensure the protection of public-sec
tor needs. It is especially important for the pub
lic sector partner to understand what kind of re
sources—in terms of quality and quantity—the
private sector company will make available and
mobilize for the public sector segment of the ex
clusive territory. This understanding should be
clearly stated in the license agreement.
. Pricing for the public sector

A key issue for the public sector in develop
ing countries is product affordability. Prices
must ensure the widest possible availability.
Prices, however, are calculated differently in
the pharmaceutical industry than in the public
sector.
Pharmaceutical companies commonly use a
retrograde calculation scheme. They base prod
uct prices on the perceived purchasing power of
the target segment in a market. Manufacturing
costs are not a major factor for the price calcu
lation. Overhead and marketing costs are usu
ally higher than production costs and need to be
well offset by product pricing. To a large extent,
adequate product positioning into affluent mar
kets determines achievable margins and operat
ing profitability.
In contrast, the public sector mostly uses
the cost-plus model for price determination.
Manufacturing and organizational infrastruc
ture contribute significantly to costs. Sales and
marketing costs are kept at the lowest possible
levels so as not to increase the product’s price.
A reasonable, but small, rate of operating profit
is added on top of these costs to determine the
product price. With the purchasing power of the
public sector under severe limitations, a price
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determination along the lines of a cost-plus
model is the method of choice.
An effective license agreement needs to em
ploy a detailed cost-calculation model. Its aim
should be to understand all directly and indi
rectly attributed product costs that contribute to
final cost. By applying the model and marking
up the ex-factory product price with a mutually
accepted profit margin for sales into the pub
lic sector, a reasonable platform for determin
ing the lowest possible public sector price can
be achieved. For indirect costs, it is necessary
to find out if the cost burden on the product
is fairly allocated. In the end, of course, private
sector pricing of the product is entirely up to the
discretion of the manufacturer and not a public
sector concern.
It is good practice to mandate the an
nual submission of manufacturing cost reports
andproductcost-calculationdetails.Furthermore,
the licensor should reserve the right to have these
cost reports independently audited.
Should a manufacturer be unable to match
expected price levels for the public sector when
the company begins manufacturing, a definite
timeline should be set to reach those levels.
Adequate penalties should be in place to cover
such cases. While a license agreement cannot be
a tool to force a manufacturer to sell a product
below cost, a detailed agreement based on the
manufacturing cost-calculation model and the
overall pricing structure for the product will
eliminate related concerns.
The licensor should define which public sec
tor organizations could obtain the product at the
preferred price. For pharmaceutical products, it
should be clearly defined whether these pub
lic sector organizations can be only ministries
of health, government purchase organizations,
public sector hospitals, and similar institutions
or if nongovernmental agencies with charitable
functions, social marketing organizations in a
country, international organizations with a hu
manitarian mission, and other institutions are
also potential beneficiaries. The license should
define how these agencies and organizations
would be informed about the availability of a
preferred public sector price for the product.

. Regulatory work and time-to-market

Pharmaceuticals are subject to drug regulatory
approval by health authorities, and the time
required for the regulatory approval process in
creases the time it takes for a product to reach
a market. It is good practice to stipulate in the
license agreement when the licensee must bring
the product forward to registration. It is also
best to specify within what time period after
signing the license agreement the licensee has to
forward a complete registration filing to the rel
evant authorities. For a multicountry territory,
specifying the sequence of registration filings in
the various countries and the maximum time al
lowed between individual filings is vital.
It is also advantageous to specify how much
time may pass between registration approval and
the product launch in the public sector. This
prevents the unusual, but realistic, scenario in
which a licensee sits on its rights and doesn’t uti
lize them for the benefit of the public sector.
. Avoiding the marginalization
of the poor in small countries

For commercial companies, large markets domi
nate priorities and occupy the top spots of ter
ritorial ranking, while small countries regularly
occupy the bottom. This is because market at
tractiveness rules priorities in a commercial
environment. The needs of the poor and of
public sector agencies in small countries are not
normally attractive markets for companies that
are expecting to generate sizeable commercial
returns from their manufacturing and market
ing efforts. A licensor must ensure that product
access is not limited just to larger markets and
that small countries will be covered in order to
avoid further marginalizing the poor.
When it comes to the territorial grant of a
license agreement aimed at maximizing public
sector benefits, the licensor must thoroughly
consider this particular issue. The prospect of
substantial profits from product sales in the
private markets of any territory is an important
issue for deciding to award the licensee com
mercial advantages under the license agreement.
However, the territorial grant must cover not
only large countries and their sizeable private
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markets—as main incentive that the public sec
tor would be reached as well—but also small
countries and their public sector markets that
the private sector partner would not normally
cover. An effective territorial grant must contain
a mix of large and small markets to balance the
commercial potentials for the licensee against
the humanitarian needs of the public sector.
Only the licensor can guard these public sector
interests.
It is good practice, therefore, not to grant
sales rights in large countries to a single licensee
without including an obligation to serve the
public sector and markets in the smallest coun
tries. If a single licensee cannot cover all of a
region’s markets, the entire region should be
appropriately segmented to ensure that two or
more licensees each get a profitable share and
that the public sector in the smallest countries
will be served. As outlined above, this goal
needs to be adequately supported by specific
milestones.
The up-front definition of territorial mile
stones is often skipped, or neglected, to the
public sector’s disadvantage. One very common
reason for this is that the primary needs of the
public sector are spread over a wide territorial
area and/or over a variety of minority groups in
dire need of services. Satisfactory coverage re
quires detailing a multitude of distinctive pri
orities and characteristic milestone definitions,
a burden squarely placed on the initial license
partners—especially the licensor.
One strategy for expanding territories is for
the licensor to generate sales to public sector
agencies in countries that are not covered by the
initial territory grant but that need the product
very much. This approach has the following ad
vantage: the licensee can focus on the obligations
and related milestones under the license agree
ment without facing multiple targets, while the
licensor serves public sector agencies outside the
territory and potentially establishes other useful
partnerships. If desired, this additional market
may be assumed by the licensee.
Setting a quantitative goal for public sector
sales needs special consideration. The licensor
could use absolute or relative target figures. The
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market share percentage reached after a certain
time from product launch is one good target
figure. Other possibilities would be to 1) define
the sales growth reached in the first years on the
market or 2) to use the sales volume after one,
three, or five years on the market to characterize
the expected—and initially agreed upon—suc
cess rate. The licensor could specify, for example,
that the product should be among the top-three
products within the specific market segment in
its third year of introduction.
In the private sector, competitiveness is an
important factor for measuring the success of
any product. Licensees need to achieve the high
est levels of competitiveness in private sector
markets in order to be able to reach their com
mercial objectives. This in turn would support a
very competitive manufacturing cost structure,
which ultimately would provide the public sec
tor with the lowest possible cost. Measuring pri
vate market targets is therefore, also an adequate
way to express public sector goals.
Another way to set milestones for perfor
mance in the public sector is to set sales volumes
in the private and public sectors in relation to
each other. A powerful milestone definition, for
example, specifies that public sector sales reach
40% (or any other agreed upon ratio) of the
sales volume for the private market within three
years after product launch.
With respect to the availability of the prod
uct in the public sectors, it is essential to spec
ify expected launch dates for the product. For
example, the license agreement could stipulate
that the product be made available in the public
sector not later than two years after the signing
of the agreement. Should a product require ini
tial sales in the private market for any reason,
an adequate requirement for public sector intro
duction could be “not later than X years after pri
vate-sector launch.” For multicountry territories,
specific requirements for each country would
need to be established and defined.
Remedies for unmet milestones need to
be part of the license agreement. One effective
remedy is to significantly increase royalties on
private market sales when a milestone has not
been reached.

CHAPTER 2.

. ConCLuSIonS: TouGH MILESTonES
foR A TouGH InduSTRy
Finally, some thoughts about milestones for the
cautious few who feel uncomfortable with the
idea of setting tough milestones in a tough in
dustry. In a process-oriented sense, milestones
represent and define the outcome of standard
operating procedures (SOPs) for organizations
that have voluntarily subjected themselves to cer
tification procedures, such as ISO. Why should
the public sector not also define such SOPs and
specific outcomes for the important targets of a
license agreement?
However, one of the underlying assump
tions for everything outlined above is that mile
stones are not cast in stone. Milestones should
be and need to remain adjustable throughout
the lifetime of a license agreement to respond
to changes in the project, changes in the mar
ket environment, and other factors that cannot
be anticipated. When it comes to the detailed
specifications of individual milestones, it does
not really matter if one is choosing an absolute
or a relative goal, or which definitions are finally
selected. What matters is getting a private sec
tor company to commit to accepting public sec
tor targets. To accomplish this, it is important
to have a working set of adequate milestones in
place, to define review periods for performance
assessment by the contract partner, and to be
ready to be open to, and to accept, milestone
revisions when new, solid evidence requires a
change of rules to keep the product and public
sector goals alive.
Such result-oriented milestones require:
• intensive preparation
• detailed knowledge of processes related to
product development and marketing

• detailed knowledge of markets
• realistic anticipation and forecasting of
product potential
• persistence in quantitative forecasting and
in establishing a master plan for the entire
product roll-out
• a mission-driven mindset to establish the
optimum public sector goals and to pre
vent the public sector from losing out to
commercial thinking
Finally, it is crucial to recognize that public–private partnerships are not a magic solution
per se for tasks that have not been well specified!
In this sense, public–private partnerships are a
poor substitute for specific, well-defined targets.
In fact, successful public–private partnerships
are built upon specific, well-defined targets. n
JoachiM oehleR, Chief Executive Officer, Concept
Foundation, Thailand Science Park, Klong 1, Klong
Luang, Pathumthani 12120, Thailand. joehler@concept
foundation.org
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See www.ippph.org for a complete list.
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www.ConceptFoundation.org.
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PIACT, the Program for the Introduction and
Adaptation of Contraceptive Technology, is a
predecessor of PATH.
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For a broader discussion on field-of-use licensing, see
the chapter 10.3, also in this Handbook, by SL Shotwell.
Also, the chapter by M Olson, also in this Handbook.
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IMS is an international company that publishes
reports on pharmaceutical sales by conducting
pharmacy audits and other means.
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ABSTRACT

This chapter reviews different forms of IP (intellectual
property) “assembly” mechanisms (royalty-collection
agencies, information clearinghouses, technology clear
inghouses, open-source innovation clearinghouses, honest
brokers, and other forms of facilitators, IP management
services, IP commercialization agents, the services of mer
chant banks and venture capital enterprises, and patent
pools). Emphasis is placed on patent pools, which are vol
untary agreements between two or more patent owners to
license one or more of their patents to one another or to
third parties. Although there are many forms of patent
pools, such arrangements fundamentally consist of the
interchange (cross-licensing) of rights to essential patents
by a number of entities, as well as an agreed framework
for out-licensing the pooled intellectual property to each
other and/or to third parties, including an agreed-pricing
and royalty-sharing scheme.
There are both benefits and risks associated with pat
ent pools. Benefits include greater ease with respect to
resolving patent conflicts, making assembled patents in
the pool available to others, and resolving disputes over
blocking patents. Risks include antitrust liability. Under
certain circumstances, patent pools have application in
the area of humanitarian licensing as instruments of as
sembly of intellectual property.

1. InTRoduCTIon
The importance of IP (intellectual property)
“assembly” is becoming increasingly evident as
the biotechnological components, both meth
ods and materials, that are used in the R&D of

agricultural and health innovations become more
and more complex. The use of patent pools can
be one way to achieve IP assembly. However, pat
ent-pool formation is complex and often costly;
it requires special economic, business, and legal
considerations, and it is but one option to facili
tate assembly and access.
One aspect of IP management is obtaining
freedom to operate (FTO) for a given product in
a given market.1 Assembling intellectual property
is therefore an essential step in innovation man
agement. But having FTO alone does not bring a
product to market, much less provide the product
to the poor in developing countries. In this con
text, the value of patent pools must be carefully
considered on a case-by-case basis, and, hence,
the appropriateness of a patent pool for any giv
en technological innovation will require careful
analysis and consideration. This analysis will nec
essarily include legal, business, operational, and
strategic considerations. Furthermore, it is im
portant to remember that a patent pool simplifies
the assembly of intellectual property, but does not
in itself do much or necessarily lead to technology
transfer or market access and distribution.
Before discussing patent pools in detail, the
chapter will provide a brief overview of IP assem
bly options and mechanisms. This broader per
spective will therefore place patent pools within

Krattiger A and SP Kowalski. 2007. Facilitating Assembly of and Access to Intellectual Property: Focus on Patent Pools and
a Review of Other Mechanisms. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of
Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
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a context of available IP assembly tactics and ex
plain the advantages and disadvantages of each.

2. Ip ASSEMBLy: MECHAnISMS And
opTIonS In pERSpECTIvE
A complex mix of factors drives technologi
cal innovation, but they essentially boil down
to national policies, international agreements,
and market dynamics. Innovation is the starting
point for making inventions commercially and
socially useful, but innovation alone will not lead
to technological products that can produce goods
or services. An invention must be assembled by
putting together the patents and other forms of
intellectual property from third parties. In-licens
ing is the best-known mechanism for intellectual
property assembly, and patent pools are a com
plex form of licensing. But other mechanisms are
also standard corporate approaches, including:
• mergers and acquisitions (M&As)
• strategic alliances (collaborations, joint
ventures, corporate partnerships)
• licensing (principally IP bundles compris
ing an entire range of inventions required
to practice, also called freedom to operate)
By itself, however, the assembly of IP will not
make an invention commercially useful; many
other steps are required, ranging from regula
tory to the access of know-how. From a broader
perspective, assembly and licensing can be fa
cilitated through a range of mechanisms. These
are summarized in Table 1. In the context of
this Handbook, the range of mechanisms listed
also include capacity-building services that more
broadly deal with technology transfer.
2.1 Royalty collection agencies

In its simplest form, a license collection agency
is a mechanism whereby one entity collects roy
alties on behalf of its members for a small fee.
In this situation, the members make deals and
set royalty rates, either bilaterally or multilater
ally. The multilateral system is best known in the
music business. Many restaurants and bars, for
example, have jukeboxes with hundreds of CDs
where customers insert money and select songs
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from individual CDs. Each time a song is played,
a percentage of the revenue goes to the publisher
of the CD and to the artist. In the United States,
the American Society of Composers, Authors, and
Publishers (ASCAP), composed of over 170,000
artists and publishers of every kind of music, pro
tects the rights of its members by licensing and
distributing royalties for the nondramatic pub
lic performances of their copyrighted works.3
ASCAP makes giving and obtaining permission
to perform music simple for both creators and us
ers of music, and its licensees encompass all who
want to perform copyrighted music publicly.
2.2 Information clearinghouses

The term clearinghouse derives from banking in
stitutions and refers to the mechanism by which
checks and bills are exchanged among member
banks so that only the net balances need to be
transferred in cash. Today, the term has much
broader meaning and includes any mechanism
whereby providers of goods, services, or infor
mation are matched. The CBD (Convention on
Biological Diversity) clearinghouse4 for biodiver
sity aims to promote and facilitate technical and
scientific cooperation, develop a global mecha
nism for exchanging and integrating information
on biodiversity, and develop the necessary human
and technological network. Information clearing
houses also provide entry to a country’s biotech
nology (for example, Finland5), as do training
clearinghouses that offer training for biotechnol
ogy technicians (for example, BioLink6), and in
dustry links, updates, news, and job markets (for
example, BioPortfolio7).
2. Technology clearinghouses

A comprehensive Web-based clearinghouse can
lower the transaction costs and increase partici
pation. In practice, however, such gains have not
been realized with IP exchanges. This is because
the applications specified in patents are highly
heterogeneous, often difficult to define, and
can only be valued after considerable experi
mentation and refinement has taken place and
then only within the technological application.8
However, IP exchanges are not very common.
Few of them are complete enough to allow a

CHAPTER 2.

Table 1: Summary of IP Assembly Mechanisms and Options
Type of Mechanism or Service

Characteristics

Examples

Royalty collection agencies:
Collection of royalties for a small
fee by one entity on behalf of its
members

Useful if licensing industries
are already established; can be
created by industry itself

American Society of
Composers, Authors,
and Publishers;
British Society of
Plant Breeders

Information clearinghouses:
Broad term denoting a
mechanism matching providers
of goods, services, or info.

Useful for the exchange of
specific information related to
an activity or industry; does not
facilitate tech transfer per se

BioBin,BINAS; portals
to countries or
industries biotech,
training programs

Technology clearinghouses:

Appropriate for general
purpose technologies, platform
technologies, bundles; limited
ability to spread tech transfer
further

Virtual trading floors,
patent auctions

2. Public-sector initiatives
dealing with training, good
practices, and the bundling of
technologies

Appropriate for development;
furthers tech transfer

Public Intellectual
Property Resource for
Agriculture (PIPRA)

open-source innovation
clearinghouses:
Web sites on which anyone can
post ideas or inventions, and
anyone is allowed to turn the
ideas into products

Potentially appropriate for opensource licensing and diffusion of
tangible research materials

Barry Nalebuff and
Ian Ayres “Why Not?”
or HalfBakery

Brokers and other forms
of facilitators:
Typically focused on creating
public–private partnerships,
providing “managed” tech
transfer

Appropriate for charting new
territory and bringing public and
private actors closer

African Agricultural
Technology
Foundation (AATF);
Global Alliance
for Vaccines and
Immunization (GAVI)

1. Web-based IP auctions and
licensing, including businessto-business

(Continued on Next Page)
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Table 1 (continued)

Type of Mechanism or Service

Characteristics

Examples

Ip management services:
Comprises a wide range of
entities, both public and
private, assisting institutions in
managing their IP assets

Good for addressing systemic
issues; establishes new modes of
interaction

Law firms,
management
consultants, global
nonprofit entities
(for example, MIHR),
and academic
training

Ip commercialization agents:

Highly effective business model;
1. Commercial entities dedicated useful to learn from their
to commercialization of third- experiences and adapt to serve
nascent private sectors.
party intellectual property

BTG Ltd.; certain
specialized law firms

2. Mixed commercial and public- Useful to learn from their
good objectives
experiences and adapt the model
to other biotech sectors

Concept Foundation,
for example

Integrated commercial services:
A range of services for M&As,
spinouts, including IP audits,
business valuation, due diligence

There could be a need for a
nonprofit merchant-bank-type
institution to provide services to
small/medium size enterprises

Merchant Banks;
venture capital
investment services

patent pools:
A voluntary agreement between
two or more patent owners to
license one or more of their
patents to one another or third
parties

Pooling unlikely to change the
underlying structural barriers to
technology transfer; difficult to
establish because industry players
have divergent strategic interests;
in partial/modified form, effective
for tech transfer

Internal, companyspecific pools;
portfolio pooling,
cooperative
pooling, third-party
aggregations, forced
pooling

other public technology transfer
and financing mechanisms

Range from education and training institutions, to
consortia in health, and to certain specialized UN
programs (including South–South transfers)

Company-to-company
arrangements:
collaborations, joint ventures,
strategic partnerships, and
corporate partnering

Some of the most ubiquitous and efficient systems
of technology transfer, rarely requiring public sector
assistance; different government policies either
encourage or thwart them

Source: Krattiger.2
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prospective licensee to assemble all the needed
licenses to obtain freedom to operate (FTO). In
addition, actually negotiating with a company
often not only allows for cross-licensing but also
for the transfer of know-how or trade secrets.
And finally, IP owners typically use their patent
portfolios as a strategic tool, a practice not con
ducive to wide licensing. Merely clicking on a
Web link, downloading a standard license, and
wiring money is rarely sufficient for technology
transfer to occur.
The Public Intellectual Property Resource
for Agriculture (PIPRA),9 on the other hand, as a
managed IP exchange initiative involving univer
sities, foundations, and nonprofit research insti
tutions, seeks to make agricultural technologies
more easily available so that subsistence crops for
humanitarian purposes in the developing world
and specialty crops in the developed world can
be more rapidly developed and distributed. The
rationale for PIPRA is that intellectual property
is often unwillingly encumbered. Universities,
for example, typically grant worldwide exclusive
licenses. Changing these licensing policies and
retaining the rights for humanitarian uses in the
developing world would make it much easier to
transfer intellectual property and tangible prop
erty (TP) from universities to the developing
world.
PIPRA brings together public sector institu
tions to collaborate and bundle their licensed and
unlicensed technologies, as “shared technology
packages,” making the technologies more readily
available to member institutions for commercial
licensing or for designated humanitarian or spe
cial use. As part of this effort, a database of pat
ented agricultural technologies is being developed
to inform researchers about FTO, allowing them
to modify their research plan to include more li
censable technologies (IP and TP) or public ones.
PIPRA is also currently exploring the creation of
a patent pool.
2. Open-source innovation clearinghouses

One special category of clearing houses is worth
mentioning, the open-source innovation clear
inghouse. Consider a Web site initiated by two
Harvard Business School professors, economist

Barry Nalebuff and law professor Ian Ayres,
to prove that innovation is a skill that can be
taught. One hotly debated idea at the site in re
cent months is the so-called “reverse 900 num
ber”—where telemarketers pay people to accept
calls. Their system of innovation is growing on
the Web10 and deploys economics, game theory,
psychology, and contract law to argue that inno
vation can be routinized and institutionalized.
Another Web initiative, called HalfBakery,11
allows anyone to post ideas for innovative prod
ucts and services. Anyone can turn the ideas into
marketable products if they wish, without the
need for licenses. The service quickly gained in
ternational fame when what may have appeared
as “half baked ideas” were turned into commer
cially successful products, though none, as yet, in
the area of health and agriculture.
This mechanism should not be confused with
open-source licensing.12 With software, opensource licensing is essentially the licensing of in
ventions without patent protection—the only
requirement is that any licensee must agree to
make available to others any improvements in the
invention or technology. Applying this established
mechanism of open source from software to bio
technology, where source code has no real equiva
lent, has not worked as yet. New terminology
might be appropriate, such as distributed, inter
net-based collaboration or “non-proprietary peerproduction of information-embedding goods.”13
One attempt to implement open source is the
Biological Innovation for Open Society (BiOS).14
Essentially, BiOS is a specific form of a patent li
cense. It is really another way to describe a pat
ent license with some novel terms. To what extent
BiOS will foster innovation remains to be seen.
2. Honest brokers and other
forms of facilitators

Honest broker is a term often used in peace negoti
ations but it has also been used by nonprofit orga
nizations engaged in public–private partnership
building. One institution that had its foundation
as an honest broker is the International Service
for the Acquisition of Agri-biotech Applications
(ISAAA).15 During the 1990s, it operated primar
ily as a facilitator, matching available technologies
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to meet identified needs, brokering technologies,
and building capacity by transferring knowledge
and know-how between companies in developed
countries and the public sector in developing
countries. ISAAA addressed other constraints in
biotechnology transfer, such as regulatory issues.
In the last few years, the organization has shifted
its strategy toward knowledge sharing.
A similar, more-recent institutional mecha
nism is the African Agricultural Technology
Foundation (AATF).16 Like PIPRA, AATF is
emerging from a Rockefeller Foundation initia
tive. AATF recognizes that new and unique public–private partnerships are needed to remove
many of the barriers that have prevented smallholder farmers in Africa from gaining access to
existing agricultural technologies. Focusing on
the creation of these public–private partnerships,
it seeks to dramatically improve access to agricul
tural technologies, materials, and know-how, at
the same time promoting efforts to create sustain
able markets.
A similar organization in human health bio
technology is the Global Alliance for Vaccines
and Immunization (GAVI).17 Created in 1999, it
functions as a broker for private and public sec
tor entities committed to expanding the use of
vaccines in the developing world. International
organizations, governments, vaccine industry,
research institutions, and major philanthropists
collectively form a dedicated partnership serving
the shared GAVI objectives. It includes as a sub
sidiary, or financial arm, the Vaccine Fund, which
sponsors GAVI’s objectives in poorer countries.
The alliance also has programs to stimulate the
vaccine industry to develop and supply vaccines
that are vital to low-income countries. GAVI acts
more at the product transfer level, whereas ISAAA
and AATF function somewhat further upstream.
ISAAA initially also aimed at charting new terri
tory and creating models (which are more time
consuming) rather than transferring large quanti
ties of technologies.
2. IP management services

The best-known IP management services are law
firms that specialize in patenting and licensing
and management consultants, such as KPMG,
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the Boston Consulting Group, and Ernst &
Young. These commercially oriented entities are
discussed in the next section, but let us first focus
on the nonprofit players in this field. A new orga
nization headquartered in the United Kingdom,
the Centre for the Management of IP in Health
R&D (MIHR),18 essentially acts as a service to
public sector organizations in developing coun
tries (and some private ones) to manage their
intellectual property (in-house–generated, in-li
censed, and to-be in-licensed) more authorita
tively. It assumes that health programs that man
age intellectual property well are more effective at
mobilizing resources, technologies, and partners
to deliver improved health care to the poor.
2. IP commercialization agents

Many types of “consulting” services fall broadly
within this category, but only one institution is
solely dedicated to the profitable commercializa
tion of third-party intellectual property in the
fields of health, medicine, and other biotechnolo
gies: BTG Ltd.,19 formerly known as the British
Technology Group. Perhaps the world leader in
commercializing novel technologies, BTG op
erates globally with a focus on Europe, North
America, and Japan. The firm combines a strong
commercial focus with a deep understanding of
how to develop innovation, enhance intellectual
property, and achieve critical development mile
stones. Clients include public research centers
and global technology companies, from start
ups to multinational companies. It functions as
a retainer for technology innovators, charging
fees and sharing in revenues generated from its
services.
In addition to services in several areas, the
company seeks licenses for the technologies they
manage. This includes assistance in seeking ven
ture capital, the management of startups around
platform technologies, and R&D funding to
ensure that the technologies in BTG’s portfo
lio become commercially viable. To accomplish
this, BTG acquires or in-licenses promising
technologies, assists in patent protection of in
ventions, forms alliances to advance inventions
through an R&D phase, and develops technol
ogy marketing strategies. In effect, BTG pools
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necessary technologies centered on the core in
novations it manages, in order to increase the
value of its portfolio. On the development side,
the most prominent enterprise is the Concept
Foundation,20 headquartered in Thailand, which
provides a mechanism to turn intellectual prop
erty, developed or owned by international or
ganizations, into competitive and cost-effective
products to be distributed at the lowest possible
cost, especially into the public sector healthcare
channels of developing countries. This intellec
tual property is typically owned in the form of
data from medical research and clinical trials,
data from pharmacological studies, manufactur
ing instructions, and so on. In some cases, the in
tellectual property owned by international orga
nizations such as the World Health Organization
(WHO) is enhanced through IP donations from
pharmaceutical manufacturers earmarked for
public sector healthcare services in the develop
ing world. The licenses are negotiated by highly
experienced foundation staff led by a former se
nior executive in pharmaceuticals.
2. Merchant banks

The term merchant bank was developed hundreds
of years ago to describe well-financed organiza
tions that sought high returns on their invest
ments in return for predictable risk (which was
also the original idea of a limited-liability com
pany). Today’s investment bank services include
IP audits, business valuation, due diligence, and
fairness opinions,21 acting as a confidential advi
sor in preparing divestiture, managing the entire
process of initial public offerings (IPOs), market
ing divestitures, finding acquisition targets, struc
turing transactions, providing financing, facilitat
ing financing, and refinancing existing debt.
Merchant Banks are essentially full-service
centers for M&As, financial management, agree
ments, required government filings, antitrust is
sues, valuations, due diligence, and so on. Their
services are crucial for any type of business, large
or small.
2. Other technology transfer mechanisms

It would be negligent to fail to mention other
types of technology transfer facilitators, ranging

from education and training institutions (for ex
ample, universities across the world), to interna
tional agricultural research centers (for example,
the CGIAR), to health consortia (for example, the
Program for Appropriate Technology in Health
[PATH]), or the many specialized UN programs.
Company-to-company arrangements (including
collaborations, joint ventures, strategic partner
ships, and corporate partnering) are some of the
most ubiquitous and efficient systems of technol
ogy transfer.

. foCuS on pATEnT pooLS
A patent pool is “an interchange of patent rights by
several companies. Either one or more of the patent
owners, or some separate entity, has the right to li
cense others under the pooled patents.”22 In essence,
a patent pool is a voluntary agreement between
two or more patent owners to license one or more
of their patents to one another or to third par
ties. In other words, they are “the aggregation of
intellectual property rights which are the subject of
cross-licensing, whether they are transferred directly
by patentee to licensee or through some medium, such
as a joint venture, set up specifically to administer
the patent pool.”23 And further, “The rationale for
patent pools is simple: by reducing the number of nec
essary transactions and by simplifying patent land
scapes, they can reduce transaction costs and facilitate
technology transfers. Patent pools have the obvious
but important advantage of considerably reducing
the number of licences that need to be negotiated.”24
Although there are many forms of patent
pools, such an arrangement fundamentally con
sists of the interchange (cross-licensing) of rights
to essential patents by a number of companies,
as well as an agreed framework for out-licensing
the pooled intellectual property to third parties,
including an agreed-pricing and royalty-sharing
scheme. Patentees can provide licenses directly to
licensees, or licenses can be provided indirectly
via a licensing entity that is specifically authorized
to administer the patent pool.25 “A key difference
between a patent pool and a cross-licensing agree
ment is that, in the former, the patent owners agree
to license to third parties that do not themselves con
tribute patents to the pool.”26
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.1 The main pros and cons

Patent pools are “competitively beneficial in that
they may help resolve patent conflicts, make assem
bled patents in the pool available to others, or resolve
disputes over blocking patents. On the other hand,
a patent pool is a horizontal agreement among com
petitors and carries the potential for abuse and as
a cover for an anticompetitive cartel.”27 Hence, a
patent pool, depending on how it is organized
and implemented, represents a potential doubleedged legal sword: able to cut through patentthicket blockages to facilitate access to critical
technological innovations, yet also potentially
honed in such a way that antitrust issues arise. In
other words, patent pools can facilitate access by
overcoming IP obstacles via assembly of patents
or can inhibit access via monopolization of in
tellectual property (complete with inequitable re
munerations) and shielding of invalid patents.28
In addition, from a practical perspective, it
is important to know what patent pools can, and
cannot, facilitate. For example, patent pools serve
the assembly of intellectual property, not the
transfer of technologies per se. Although the U.S.
Department of Justice (DOJ) along with the U.S.
Federal Trade Commission (FTC) have observed
that “by promoting the dissemination of technol
ogy, cross-licensing and pooling arrangement are
often procompetitive,” it is critical to understand
that, in the context of technology transfer and
collaboration with developing country partners,
patent pools would mainly assist with licensing in
tellectual property. That is, such developing coun
tries would not necessarily benefit equally from
sharing know-how, show-how, and trade secrets.
Hence, patent pools can serve certain purposes
and confer benefits, but they are not an IP man
agement panacea.
Still, a patent pool can have advantages: in
tellectual property can be licensed through an
efficient one-stop shop, stacking licenses can
be eliminated, patent litigation can be averted,
and institutionalized exchanges of otherwise
proprietary know-how (trade secrets) can be fa
cilitated.29 Significant research and administra
tive costs would decrease dramatically. Speed and
efficiency would be greatly increased. A patent
pool is an IP management tactic that can have a
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significant positive affect on facilitating access to
innovations, yet, it is important to recognize that
a pool may not be the only way to achieve these
objectives, and that, in the overall context of best
practices in IP management, there may be other
equally effective approaches.
Patent pooling has been more focused in
the realm of DVD technologies, where it makes
sense to generate revenue through sales and not
licensing. Such patent pools help to clear block
ing positions. But with regard to patent pools for
public-health initiatives, it appears that there is
less likelihood that companies will give up their
exclusive IP rights, depending, of course, on the
technologies under consideration. This is because
pools tend to arise organically because the own
ers of intellectual property are mutually stymied;
this, for example, has not yet happened for vac
cines. The technology is not at the same level of
maturity as in the DVD industry. Patent pools
are especially useful for developing industry stan
dards. Hence, although patent pools have been
successfully implemented in various industries
(notably electronics), their application to health
and agriculture may still be, relatively speaking,
premature. The pros and cons are summarized
in Table 2.
.2 Organization and establishment

Organizing and establishing a patent pool is not
a simple matter.30 It is a long, complex, multistep
process, with many technical, legal, and business
challenges. It therefore requires the interdisciplin
ary coordination of efforts by attorneys, scientists,
business professionals, and other experts. Setting
up a successful patent pool therefore requires or
ganization and planning, based on sound infor
mation and solid analysis. These conditions hav
ing been met, the operational, business and legal
aspects of the pool can be effectively managed
and successfully executed.
A ten-step checklist for setting up a patent
pool would include the following considerations:
1. Determining the validity of the patents to
be pooled
2. Determining the essentiality of the patents
being considered for inclusion in the pool
3. Patent analysis by an independent expert
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4. Nonexclusive licenses to the pool
5. Licensees must be free to develop and use
alternative technologies
6. Grant-back licensing provisions, from li
censees to licensors, on improvements to
essential patents and with reasonable terms,
should be available on a nonexclusive basis
7. Royalties should be distributed among the
licensors according to a formula set forth
in the patent pool agreement
8. Royalties paid to the pool by licens
ees should be fair, reasonable, and
nondiscriminatory
9. Sensitive business information must be
safeguarded
10. Appropriate dispute resolutions, prefer
ably, independent and neutral, should be
part of the patent-pool agreement
A ten-step procedure for setting up a patent
pool would include the following activities:
1. Observation of a potential patent thicket
that could be overcome by an appropri
ately structured patent pool

2. Patent and scientific experts identify essen
tial technologies
3. Patent experts identify patents and
patentees
4. Working group set up by counsel
5. Initial agreement among patentees to move
forward with pool development
6. Further evaluation of patents by both sci
entists and patent experts
7. Agreement on patent-pool conditions
8. Signing of patent-pool consortium
agreement
9. Antitrust analysis and evaluation as per
the jurisdictions under consideration (for
example, the United States, Europe, and
Japan)
10. Execution of patent-pool agreement
Patent pools are set up by the patent holders,
who function both as shareholders of the pool
and also as financiers of the designated licensing
authority (if the patentees themselves do not func
tion as the actual licensors). The patent holders,

Table 2: Summary and the Pros and Cons of Patent Pools
Pros

Cons

Integrates complementary
technologies

Difficult to agree on the value of
individual patents contributed to a pool

Reduces transaction costs

Complex to set up and avoid antitrust
problems (collusion and price fixing)

Clears blocking positions
Avoids costly infringement
litigation
Promotes the dissemination of
technology
Levels the playing field

May inflate licensing costs through
nonblocking or unnecessary patents
Complex when many patents are
under litigation, as is the case with
biotechnology
May shield invalid patents and thus
prevent much technology from entering
the public domain
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therefore, establish and retain authority over the
licensing provisions.31
. Examples of pools

One of the first such patent pools was created for
the manufacturing of sewing machines in the mid
19th century.32 Other examples of early patent pools
include aircraft manufacturing, glass manufactur
ing, and radio technology. In each case, the pool
contributed significantly to industry standards (for
example, radio waves). More recently, patent pools
were created to enable standard settings in DVDs,
video games, and MPEG2 video-compression
technology. Interestingly, private and public sector
participants formed the latter in 1997: Columbia
University, Fujitsu, General Instrument, Lucent,
Matshushita, Mitsubishi, Philips, and Sony.
Typically, however, patent pools are consti
tuted by members who each contribute patents
in their respective fields. Whether or not devel
oping country institutions will qualify to become
members of patent pools will, naturally, depend
on their respective potential contributions.
The following types of patent pools exist
today:
• internal, company specific. For example,
DuPont combining technologies through
internal development or Syngenta comple
menting its internal portfolio with outside
technology through licensing and M&As;
critical challenge is to keep internal innova
tion ongoing and tightly managed
• portfolio pooling. Internal technology sup
plemented with third-party technologies,
for example, Microsoft; critical challenge is
to have a dynamic team handling in-licens
ing and aligning strategies closely with the
overall corporate strategy
• cooperative pooling. Companies agree to
combine their technologies and allow them
to be managed by a separate entity, typi
cally for standard-setting purposes; critical
challenge is to avoid antitrust issues
• third-party aggregations. For example,
strategy practiced by BTG Ltd.; critical
challenge is to work around antistacking
provisions that are very common in bio
technology licenses
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• forced pooling. For example, rarely en
forced compulsory licensing and the pool
ing forced by the U.S. government shortly
after the radio was invented
. Patent pools in biotechnology

In biotechnology, unlike in much of the electron
ics industry, standard setting is not really an issue,
which may explain why patent pools have not
been necessary for the biotechnology industry to
commercialize products (for example, in the de
velopment of drugs and vaccines). Nonetheless,
as the biotechnology industry continues to grow
and mature, and with specific sectors becoming
commercially focused, there may be fundamen
tal challenges that can be effectively addressed via
patent pooling.
For example, the issue of “research tools” in
the life sciences has led to a call for patent pooling
in the U.S. companies, and institutions involved
in biotechnology research are encountering wide
spread delays due to the near-universal patent
ing of research techniques that were traditionally
available in the public domain. Uncertainty over
the prospective costs of licenses, royalty stacking
that creates uncompetitive costs, delays in obtain
ing licenses, and the differing definitions of pure
research versus product development across differ
ent territories are all inhibiting biotechnology
R&D in many areas.
Similarly, one of the biggest public concerns
voiced against the PTO for its practice of granting
of patents for inventions in biotechnology, par
ticularly in genomics, is the difficulty of accessing
patented inventions for basic biological research
and R&D. One solution to this constraint is to
form patent pools, a mechanism successfully im
plemented by other industries.
In a rapidly changing field such as biotech
nology, patent pools can have significant procompetitive effects and may improve an indus
try’s ability to survive. For developing countries,
patent pools may eventually become even more
important because companies can easily obtain
the licenses required to practice a particular tech
nology, which reduces transaction costs and facili
tates the rapid deployment of new applications in
health and agriculture. Hence, there is no reason

CHAPTER 2.

that a novel type of patent pool, centered on pref
erential licensing terms to developing countries,
could not be established.
Still, when considered from the perspective
of the overall biotechnology industry, while pat
ent pools may be very useful for assembling IP re
lated to platform technologies that need to estab
lish industry-wide standards (for example, DVD,
MP3), the value of patent pooling is much less
when industry interests are not aligned (still ma
turing industries), which, indeed, is the general
case with biotechnology. Hence, in the context of
R&D in many biotechnological applications, for
example, with respect to vaccines—an evolving
field with no platform and with no technology
clearly in the lead—industry interests can hardly
be considered aligned. Indeed, if a technology has
not matured to the stage where industry standards
can even be contemplated, then a patent pool
would likely not be the favored option. At these
earlier stages in the R&D of innovative technolo
gies, few companies will have an interest in giving
their rivals preferential access to their technolo
gies. Companies also typically become cautious
about antitrust issues when a patent pool is sug
gested, which might also hinder participation.
As an illustrative example of the current situ
ation with (at least most of ) the biotechnology
industry and the potential for using patent pools,
Gaulé draws our attention to the recent SARS
outbreak:
Shortly after the severe acute respiratory syn
drome (SARS) outbreak in February 2003, patent
applications covering sequences of the genome of
the SARS coronavirus were filed by several research
teams around the globe. Some have argued that this
may result in a complex, uncertain IP situation that
could delay the development of SARS vaccines and
diagnostic tools. As a result, the four parties known
to own key patent applications (CDC) have ex
pressed their willingness to form a patent pool and
enable wide access to the SARS genome. But con
sider the differences between the SARS patent pool
and the consumer electronics pools. The SARS patent
pool will not be in an industry characterized by allimportant network effects or be closely linked to a
standard. For the moment, the licensors are not ver
tically integrated firms but universities and public

institutions, and so there will be far fewer licensees.
Most importantly, however, the commercial products
in which the licensed technology will be embedded
do not yet exist and will be developed by the licensees
after extensive R&D efforts. Therefore, the licensing
policy of the SARS patent pool might be quite differ
ent from other modern patent pools.33
However, the use of patent pools in biotech
nology will likely increase as sectors of the indus
try mature into focused, identifiable technologies
and products/services (as has been the case in the
electronics industry). One area where this ap
pears to be the case is diagnostic genetics, that
is, disease-specific (for example, breast cancer and
cystic fibrosis) diagnostics. This indeed appears to
be an example of a rapidly emerging area of the
biotechnology industry where patent pools might
be applicable and advantageous. Unlike the gen
eral area of genomics, which is broadly diverse,
diagnostic genetics is commercially focused on
identified diseases with clear industry standards
(mutations for analysis), and the players in the
field share common goals. Hence, patent pools,
narrowly constructed to address the diagnosis of
specific polymutational diseases (for example,
cystic fibrosis), could have great utility in over
coming IP thickets that inhibit access to advances
in genetic diagnostics.34
Those who advocate patent pools as a solution
to a general problem with assembling intellectual
property related to biotechnological advances in
health and agriculture should keep in mind that
they embody many challenges; for example, in ad
dition to the presence, or lack thereof, of industry
standards, patent pools are expensive to establish
and maintain. Hence, unless a given technology
reaches a certain economic threshold, there is no
financial incentive to establish a patent pool. The
economic feasibility of a pool is determined by:
• number of pool participants
• number of patents held by each pool
participant
• likelihood of a patent being useful for a
given platform
• number of patents required to assemble a
viable platform
• market value of the assembled platform
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• cost to assemble and maintain the pool
As the biotechnology industry continues
to grow and mature, the applicability of patent
pools will also likely increase.
. Legal concerns

One reason why patent pools are often ap
proached with caution is because U.S. antitrust
law has the reputation for precariously situating
patent pools on the borderline between allowed
monopolies and antitrust violations. Although the
legalities of forming patent pools exceed the scope
of this chapter, it is worth noting that the U.S.
Department of Justice (DOJ) along with the U.S.
Federal Trade Commission (FTC) have published
guidelines for patent pool applications and require
an opportunity to review applications for them.35
The PTO has summarized the DOJ/FTC
patent pooling antitrust guidelines, and this
serves as a concise template for understanding the
potential antitrust implications of patent pools.36
When making antitrust determinations, courts
consider these guidelines as part of a multifactor
weighing “rule of reason” analysis.37 What follows
is a brief excerpt from the PTO paper.
Since 1979, the FTC has had a similar proce
dure, in which businesses may seek FTC advisory
opinions concerning proposed business practices.
These procedures led to Justice Department and
FTC policies in the IP licensing area, and in 1995,
these agencies issued Antitrust Guidelines for the
Licensing of Intellectual Property, “IP Guidelines,”
which sets forth their enforcement policies in this
area. The IP Guidelines specifically address pooling
arrangements involving IP owners and their rights.
In particular, the IP Guidelines state that IP
pooling is procompetitive when it:
• integrates complementary technologies
• reduces transaction costs
• clears blocking positions
• avoids costly infringement litigation
• promotes the dissemination of technology
The IP Guidelines also discuss that excluding
firms from an IP pool may be anticompetitive in
these circumstances:
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• The excluded firms cannot effectively com
pete in the relevant market for the good in
corporating the licensed technologies.
• The pool participants collectively possess
market power in the relevant market.
• The limitations on participation are not
reasonably related to the efficient devel
opment and exploitation of the pooled
technologies.
Anticompetitive effects may also occur if the
pooling arrangement deters or discourages par
ticipants from engaging in research and develop
ment that is more likely when the arrangement
includes a large fraction of the potential research
and development in an innovation market.
The DOJ has applied these guidelines in
considering and approving three proposed patent
pools. Its first review set forth the following ad
ditional guidelines:
• The patents in the pool must be valid and
not expired.
• These can be no aggregation of competitive
technologies and setting a single price for
them.
• An independent expert should be used to
determine whether a patent is essential to
complement technologies in the pool.
• The pool agreement must not disadvan
tage competitors in downstream product
markets.
• The pool participants must not collude on
prices outside the scope of the pool, for ex
ample, on downstream products.
Currently, the guidelines have been “collapsed”
into the following two overarching questions:
1. Whether the proposed licensing program is
likely to integrate complementary patent rights
And if so:
2. Whether the resulting competitive benefits
are likely to be outweighed by competitive
harm posed by other aspects of the program

. ConCLuSIonS
Patent pools have received much attention in
recent years as a possible solution to the patent
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thicket. This review shows that patent pools are
indeed one possible option, but others should
also be considered. Organizing and establishing
a patent pool is not a simple matter. It is a long,
complex, multistep process, with many techni
cal, legal, and business challenges involving the
interdisciplinary coordination of efforts by attor
neys, scientists, business professionals, and other
experts. Setting up a successful patent pool there
fore requires organization and planning, based on
sound information and solid analysis.
As procompetitive arrangements, patent pools
are aimed at IP assembly. They seek to resolve pat
ent conflicts (reducing litigation), to settle dis
putes over blocking patents (accelerating product
development and FTO), and to facilitate arrange
ments for licensing patents in the pool to outside
members (accelerating the setting of standards and
reducing licensing transaction costs). They exploit
economies of scale by integrating the technical
complementarities of the pool members.
From a legal perspective, pools require care
ful antitrust considerations to avoid potential,
perceived, or real anticompetitive behavior by
pool members or, more importantly, by the pool
itself. From an operational perspective, only es
sential patents can be included in a pool. And fi
nally, from a business perspective, the interests of
the various IP holders need to be aligned in order
to bring them to the table (pools are invariably
voluntary arrangements). n
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CHAPTER 3.1

The Courts and Innovation
pauline newMan, Judge, U.S. Court of Appeals for the Federal Circuit, U.S.A.

ABSTRACT

Established and enforceable rules of law can provide just
and expeditious resolution of the disputes that are inevi
table in vigorous commerce. But in the rapidly evolving
subject matter of biotechnology, this science can bring to
court issues for which there is no precedent and about
which there is no consensus. The rule of law, however, is
vibrant, adapting to the evolving contexts of science and
technology. In today’s era of rapid technological change,
jurisprudence provides the stability of the law, while re
flecting the social implications of the science. But the
scientific and technologic issues of today, such as arise in
IP disputes, must also be correctly decided to promote a
uniform and predictable application of the law that pro
motes commercial stability adequate to support industrial
innovation and the national interest.

1. InTRoduCTIon
The role of courts in technology development,
protection, transfer, and commercialization, in
biotechnology as in all fields, is a combination of
the traditional role of courts in dispute resolution
and the common-law role of courts in the evolu
tion of law. In a national and world economy that
is increasingly technology based and yet governed
by jurisprudence reflecting cultural norms, new
fields of science and technology propel the courts
into proceedings and decisions of economic and
societal impact.
With respect to commerce and trade, legal
systems have been described as having three mis
sions. The first is to establish the rights and rules

of property ownership, including intellectual
property (IP). The second is to protect property
rights from illegal disposition by guarding against
civil wrongs and crimes. The third is to provide
and enforce the rules of exchanges and transfers
of property: the laws of contracts and sales and
competition. In addition, legal systems establish
rules for entering and leaving commercial activity,
such as corporate law and bankruptcy law, and
rules that promote competition and innovation,
such as antitrust and IP law. In the development,
management, and transfer of technology, effective
legal systems provide stability and predictability
of national and international force. This concept
is globally applicable: strengthening the rule of
law has broad-ranging implications for every
country and organization. In regard to IP laws,
which partake of so many interrelated policies,
understanding how the courts balance conflicting
policies can provide useful guidance to business,
technology managers, and scientists.
Litigation in the fields of today’s biological
advances takes us to the edge, not only of science,
but also of conflicting policies—often at the limit
of judicial experience. Justice Holmes said, “The
life of the law has not been logic: it has been ex
perience.” Human experience absorbed science
and technology into the common law and its
basic concepts of property, human responsibility,
and fairness. But litigation of disputes concerning
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science and technology is bringing new challenges
to the search for justice through truth—the foun
dation of judicial systems.
Judges do not create national policy or in
dustrial policy; such policy finds its origins in the
cultures of nations, and its sustenance in the laws
of nations. Yet policy comprehension is essential
to judicial decisions. When technology and biol
ogy are involved, then the jurisprudential over
view (as well as the decision of individual cases)
can affect the nation’s economy and the public
interest. It will additionally have an even broader
global impact. This Handbook arises from the
premise that developing the products of science
and technology is of profound public benefit, a
benefit that requires both scientific and industrial
participation. This is a many-faceted concept, yet
today we exist in an era of such pervasive scien
tific and technological advance that the develop
ment of these benefits, and their movement into
commerce and among nations, warrant our most
concerned efforts.

2. THE CouRTS And
TECHnoLoGIC AdvAnCE
The courts implement the rules by which society
chooses to be governed. A reliable mechanism of
dispute resolution eases the path to sustainable
technologic advance, economic growth, and en
suing public benefit. Established and enforceable
rules of law can provide just and expeditious reso
lution of the disputes that are inevitable in vig
orous commerce. In the rapidly evolving subject
matter of biotechnology, this science can bring to
court issues for which there is no precedent and
about which there is no consensus. In such areas,
legal issues arising from developments in science
and technology often reach the courts for primary
resolution, and the decision can affect both eco
nomic and technologic advance.
An example is seen in the U.S. Supreme Court’s
decision in the Chakrabarty case in 1980,1 when
despite predictions of the dire consequences of au
thorizing patents on life forms, the Court opened
the nation’s economy to industrial biotechnology,
enabling commercialization of this nascent field,
to the human benefit that is today bearing fruit.
1 | HANDBOOK OF BEST PRACTICES

The growth of the biotech industry is a testament
to judicial vision, for the U.S. Patent Office had
refused to patent Dr. Chakrabarty’s modified bac
terium that was designed to digest oil spills. It was
the Court of Customs and Patent Appeals and the
Supreme Court that held otherwise.
Another example is seen in the U.S. Court
of Appeals for the Federal Circuit, created for the
purpose of revitalizing technologic innovation in
a faltering economy. The industrial and scientific
communities had recognized that national policy,
as implemented in the courts, was inadequately
supporting industrial innovation, a failure attrib
uted to an inadequate understanding of the re
lationships among scientific research, technologic
advance, and commercial investment. The ad
verse effects included a negative balance of trade,
retrenchments in industrial R&D, mass layoffs of
scientists and engineers, sparse capital formation,
stagnation in productivity, and loss of interna
tional competitiveness.
Judicial misunderstanding of the system of
patents and its purposes and processes was a pri
mary problem. As a result, patents were not viewed
as reliable support for commercial investment, for
they could be litigated in circuit after circuit until
they fell. And the Justice Department’s “nine no
no’s” of patent licensing were a further disincen
tive to technology transfer. During the economic
recession of the late 1970s, the retrenchment of
investment in new technologies was so severe that
dramatic remedies were accepted—including the
first major change in the federal judicial structure
in a hundred years.2
Thus the federal judicial system was restruc
tured to provide a national appellate court that
would receive all patent appeals throughout the
nation, whether from the district courts, the
International Trade Commission, or the Patent
Office.3 The hope was that a single appellate court
would better understand, and correct, the policy
misperceptions that had led to a judge-made re
duction of the patent incentive for investment in
technologic advance. The goal was a uniform and
predictable application of the law that would pro
mote commercial stability adequate to support in
dustrial innovation. The change was not without
vigorous controversy, but it was implemented
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with the congressional leadership of Wisconsin
Representative Robert W. Kastenmeier and sena
tors Robert Dole and Patrick Leahy. It was an ex
traordinary and creative action to change the na
tion’s court system as an incentive to technologic
advance. And the effect of this juridical change
was dramatic, as entrepreneurial business as well
as established industry returned to developing
new and improved technological products.
The change in industrial activity based on a
strengthened patent incentive surpassed the most
optimistic expectations. One rarely sees so direct a
relationship between judicial structure and com
mercial vigor.

. THE EvoLvInG pATEnT JuRISpRudEnCE
The legal framework of technology movement
into public availability through market forces
partakes primarily of the law governing all com
merce. As for all laws, the overarching consid
eration is the national interest. Patent law is
designed to serve as an incentive to promote
technologic research and industrial commercial
ization, not only to bring to the public the ben
efits and conveniences of new technologies, but
also to achieve a vigorous combination of indus
trial products and employment and trade. These
societal and economic policies undergird the laws
of intellectual property.
Starting about two decades ago, the U.S.
Court of Appeals for the Federal Circuit methodi
cally undertook to restore the patent law to the
legal mainstream. In decisions applying across all
areas of technology, the court implemented the
patent statute and revived dormant legal princi
ples. Some examples are the rulings that
• summary judgment is as available in patent
cases as in any other
• consent judgments and settlement agree
ments in patent cases are not contrary to
public policy
• an assignor can be estopped from challeng
ing the validity of an assigned patent, as
others are estopped who transfer property
for value
• infringement is a wrong and subject to rem
edy like other torts

• the measure of damages is to make the in
jured party whole, as for other torts
• patents are presumed valid, as the statute
requires
• proof of inequitable conduct in patent
prosecution requires both materiality and
deceptive intent
• preliminary injunctions in patent cases are
decided on the same criteria as in other
fields (as recently clarified by the Supreme
Court4)
The court, in its first years, developed ob
jective standards for determination of obvious
ness (this topic is at present under review by the
Supreme Court), applied the same law to the
Patent Office and to the courts, eliminated appel
late forum shopping, and generally restored the
effectiveness of the patent system as support for
industrial innovation. Much media attention was
given to the “new strength” of patents.
Subsequent decisions of the Federal Circuit
and the Supreme Court were geared toward refin
ing the law and adding precision, for many deci
sions depend more on the science and technology
than on the letter of the law. To this end, the court
adjusted the roles of judge and jury in interpret
ing patents. The Markman5 case, assigning the in
terpretation of patent claims to the judge instead
of the jury, has affected trial procedures as well
as the content and interpretation of patents. This
decision and its implementation are still not free
of controversy. Another controversial decision,
Festo,6 reduced the patentee’s access to unclaimed
technological equivalents, generally limiting pat
entees to what they actually described. The main
emphasis of these decisions is the enhancement of
predictability of patent scope, an emphasis that
has led to requiring more technical description by
the inventor and often more development of the
inventive subject matter. The balance between a
rigorous-notice function of patent claims and the
cost of protecting the innovator against imitators
who use the inventive concept but manage to skirt
the claims warrants an objective evaluation of the
benefits and obstacles presented by this direction
of the law, as the interested communities seek the
optimum policy and its legal implementation.
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New issues of law are constantly arising, for
developments in biological science and their ap
plication present factual situations that do not
easily fit into precedent, such as questions of pat
entable subject matter, or the nature and conduct
of scientific research. Such questions reach the
courts when disputes arise; as, depending on the
facts of the case, the courts try to implement the
law in line with statute, precedent, and a judicial
balance of practical economics, research incen
tive, and fairness. With each judicial decision,
precedent adds its weight to one or another com
peting policy, for there are many facets to the legal
and economic theory of intellectual property. For
example, some theorists see patents primarily as
an economic tool; some as founded on principles
of natural right and fairness. Some are concerned
lest the patent law impede the flow of ideas and
knowledge; others suggest that without patents,
fewer ideas and less knowledge would be gener
ated, and even less used for public benefit. Much
of the controversy concerning the role of patents
arises, I believe, from vested interests that em
phasize one or another of the purposes and uses
of patent systems, as the courts apply a one-law
fits-all structure to service the public and national
interests.

. AdJudICATInG ISSuES of
SCIEnCE And TECHnoLoGy
Judicial interpretation and application of every
aspect of IP law is challenged by the complexity
of science and technology. In Thomas Jefferson’s
day, an educated person could understand every
known technological aspect of life. Today we liti
gate questions whose scientific framework strains
even persons within the corresponding discipline.
These include the classical areas of technological
applications of law, such as medical causation and
product liability, as well as environmental issues
and patent infringement; these questions also in
clude new issues of constitutional and personal
and commercial rights that flow from new scien
tific knowledge and its applications.
The scientific issues in litigation are rarely
straightforward, and they tend to fall in incom
pletely explored areas and are often intermingled
10 | HANDBOOK OF BEST PRACTICES

with policy concerns. The ongoing scientific ad
vances in biology and genetics come to court in
many guises: there are issues of criminal behavior,
employment, insurance, and medical and product
liability, as well as intellectual property. No matter
how finely tuned a judge’s judicial intuition, no
matter how wise and benevolent, cases that turn
on findings of science or technology cannot al
ways be decided using the judge’s traditional tools
of reasoned analysis, an instinct for credibility,
and worldly experience.
How then can the truths of science and tech
nology be found in the courtroom? The just reso
lution of issues that turn on such findings presents
a profound challenge to the administration of jus
tice. Despite this concern, most judges prefer not
to depart from the procedures of the adversary
system—not as a matter of principle but of expe
rience. Judges learn that not all scientific questions
have clear answers; we have learned that scientific
truth is often a matter of the honest but divergent
viewpoints of scientist witnesses and that many
of the questions of science and technology that
come to court do not have a firm answer. Scientific
facts are not like the traditional facts of lawsuits,
based on the human components of recollection
and credibility. In traditional judicial fact finding
there are gradations of truth or falsity, questions
of weight and value of evidence. What judges call
“facts” are matters on which there is a difference
of opinion, while scientific facts are supposed to
be objective and absolute. The problem is that for
issues in litigation the scientific answer is often
unknown at the time of the lawsuit. By requiring
the judge to decide questions that the scientists
have not decided—and perhaps cannot decide—
on the present state of knowledge, the side with
the burden of proof simply is penalized.
Yet there is a natural partnership between
jurisprudence and science, for both enhance our
understanding of natural law. Both the law, and
the science it deals with, progress along irregular
pathways, via incremental steps in diverse direc
tions, sometimes with false starts and often en
countering dead ends, building on the past until
the present presents a coherent and stable body
of knowledge. Justice Felix Frankfurter called
the decision-making process the “correlation of
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imponderables,” a term never more apt than in
the evolving fields of biotechnology.
The rule of law is vibrant, adapting to the evolv
ing contexts of science and technology. In today’s
era of rapid technological change, jurisprudence
provides the stability of the law, while reflecting the
social implications of the science. But the scientific
and technologic issues of today, such as arise in IP
disputes, must also be correctly decided.
For determining the reliability of scientific
and technologic evidence, the Supreme Court
has exhorted judges to apply the same standards
as the scientific community. That is not easy, for
although judges can readily understand the meth
odology of science, it is the science itself that is
daunting. Habits of logical thinking, precision of
reasoning, are common to science and law, each
an elegant intellectual blend of theory and testing
that leads the mind through complexity. Although
as judges we do not test our theories in the labo
ratory, we do test them against the accumulated
knowledge and wisdom of the past. This is the
tradition and strength of the common law, as it
continually adapts and is usefully and effectively
applied to the new biology.

. WHAT ABouT THE fuTuRE?
A major problem in judicial decision-making is
how to achieve practical justice for the high-tech,
science-based issues of today’s disputes. The prob
lem goes beyond the laws of intellectual property,
for many issues that reach the courts (for example,
in environmental law, communications technol
ogy, product liability, forensics and other criminal
issues) turn on questions of science and technol
ogy of a complexity that did not exist even a few
years ago. These issues require full access to the
rule of law, with its protection of the public inter
est and private rights, its safeguards to litigants,
its concern for legislative intent, its openness, its
checks and balances. Its justice.
The rule of law contemplates a living law,
adapting to changing contexts while benefiting
from the experience of the past. Judges must un
derstand the social and economic fabric of the
statutes and precedent that we apply. It is essential
to preserve a stable jurisprudence, lest we build

uncertainty into areas whose strengths lie in their
reliability. Yet new questions are constantly aris
ing, or old questions in new contexts, such as the
question of whether there is, or should be, a re
search exception to the use of another’s patented
invention. No one really worried about that ques
tion until science, particularly biological science,
reached the stage where the boundary between
basic and applied research was blurred or lost.
For the new biology, in general the law has
lagged the science. Law usually lags social change.
The evolution may be too slow for the enlarging
issues of biology and genetics, as well as the devel
oping issues of biodiversity and agri-biotechnol
ogy. As we ponder the legal and policy aspects of
these new sciences (for example, with respect to
advances in genetic science), constitutional prin
ciples arise. Is the preservation of human diversity—including the sick, or the ugly, or the mo
ronic—a constitutional question? Justice Holmes
is still criticized for ruling that “three generations
of imbeciles is enough.”7 Would he be criticized
for ordering remedy in the womb—or for deny
ing such remedy? The cases in court often inspire
thinking about the foundations of the law, as well
as the historical and social and economic policies
of the law.
Disputes arising in the biological sciences are
likely to encounter the uncertainties of this juris
prudence, for the new biology raises new issues in
the context of commerce and the interaction of
public and private interests. I encourage you who
are engaged in the creation and dissemination of
these sciences to think about what the law should
be, so that together we may seek the optimum
legal framework for today’s and tomorrow’s scien
tific and technologic advances. n
pauline newMan, Judge, U.S. Court of Appeals for the
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Global Health: Lessons from Bayh-Dole
RACHEL A. NUgENT, Senior Health Program Associate, Center for Global Development, U.S.A.
gERALd T. kEUSCH, Provost and Dean for Global Health, Boston University Medical Center

and School of Public Health, U.S.A.

ABSTRACT

Public sector institutions help deliver public health goods.
By extension, universities that receive public research
funds must deliver a benefit to the public that goes be
yond licensing a discovery to the private sector for devel
opment. In the United States, 25 years of experience with
the Bayh-Dole Act, which governs the use of intellectual
property (IP) derived from public research, offers both
lessons and warnings for developing countries currently
establishing their own IP systems. Bayh-Dole successfully
created a large body of IP from publicly funded research.
Absent a strong profit motive for the private sector, how
ever, the Act has been much less successful at producing
public goods for health. Current practice undervalues
the “public benefit” aspect of the mandate, especially for
the poor. Possible ways to address this mandate would be
for public sector entities (and their academic partners in
the biomedical sciences) to invest some of their earnings
from licensing publicly funded discoveries into programs
for neglected diseases of the poor. IP rights from public
funded research could also be leveraged in negotiating
licensing agreements with the private sector to address
these neglected diseases. IP laws and institutions should
be designed to encourage such sharing. The public and
academic research sectors should also seek a new compact
with the private sector aimed at reducing the burden of
disease affecting the poor.

1. INTRODuCTION
In the past 50 years, the intensity of research
and the pace of discovery in the biomedical and
health fields have accelerated dramatically in the
United States, in both the public and private sec
tors. As a result, the number of safe and effective

drugs, vaccines, and medical devices for a broad
range of illnesses and conditions has skyrocketed.
But current laws and practices may mismeasure
the benefits of publicly funded health research by
relying too closely on a private sector yardstick.
Furthermore, in an increasingly global world—
where the risk of disease and the benefits of re
search can come from any corner—the society
that benefits from public sector health investment
should be the global society. The “public benefit”
aspect of U.S. federal research investments should
thus include the poor in societies inside as well
as outside of the United States, and IP laws and
practices should be changed to enhance the ben
efit of our investments.
Out of an estimated US$106 billion in
health R&D expenditures globally, about 50%
is estimated to come from public sources.1 In the
United States, most public funding of biomedical
and behavioral research is through the National
Institutes of Health (NIH), whose spending
on research is approximately US$28 billion in
2006. Those numbers dwarf the amount of pub
lic research funding in developing countries,
but developing country R&D investment will
continue to grow, along with IP derived from
it. As IP systems evolve in developing countries,
they should avoid or reduce barriers to the de
velopment of health and medical products for
the poor.
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Only in the past decade has global atten
tion focused on the health needs of poor and
marginalized populations in developing coun
tries.2 This new attention has opened to public
view the system of protections for IP and trade
embodied in national rules and in the global
Trade-Related Aspects of Intellectual Property
Rights (TRIPS) Agreement. Moreover, recent de
bates over access to drugs for low-income popu
lations in developing countries have highlighted
the controversies found in the often arcane details
of the patent system and IP laws.3 The media of
ten portray these debates as a struggle between
rich and poor countries, big drug companies and
sick people, or insensitive bureaucracies and car
ing relief organizations. While such portrayals
may gain the attention of the public and of poli
cy-makers, they at best oversimplify and at worst
obscure the true nature of the problems, and thus
create further barriers to finding solutions.
The economic, legal, and policy arrange
ments that move innovation from research labs
to consumers are the same ones that erect barriers
between those same labs and the poor. The main
economic barrier is the high cost of developing
a product from a basic discovery. The main legal
barrier is a complex ownership system, one that
goes too far in protecting the interests of those
who invest in research and development. Finally,
there is a policy barrier: the inability to balance
the competing interests of the scientific com
munity, consumers, and industrial development,
all of which vie for advantage in the increasingly
lucrative world of health care products. As IP sys
tems evolve in developing countries, they should
avoid repeating mistakes and act to reduce barri
ers to development of health and medical prod
ucts for the poor.
This chapter outlines several ways that public
and university decision makers can reorient their
IP strategies to remove these barriers. It first con
siders the rationale for government investment
in biomedical research, and then explains what
kind of public benefits should be expected from
that investment. The chapter then examines the
key U.S. laws governing technology transfer from
federally funded research and provides a synopsis
of the legislative context of their passage. Some
1 | HANDBOOK OF BEST PRACTICES

creative options for extending the benefits of
biomedical research to poor countries or global
beneficiaries are then proposed for the public sec
tor and universities. A few of these options could
also be adopted by developing-country research
funders and universities.
Indeed, there are several ways for public in
stitutions to increase the resources and tools de
voted to public health needs in the developing
world. At the upstream end, public institutions
could direct funds toward research in developing
countries and their diseases; they could also part
ner with private and nonprofit entities wishing
to do the same. At the downstream end public
institutions could directly render assistance to de
veloping country institutions in building research
capacity, provide products to users in poor coun
tries, reduce barriers to the transfer of technology,
or partner with industry and academia to expe
dite the development of products from research.
Most of these steps also apply to fields outside of
health and medicine.

2. PuBlIC SECTOR INVESTMENT
IN HEAlTH RESEARCH
It is generally acknowledged that publicly sup
ported basic research invaluably contributes to
the development of new medical technologies.
Creating such benefits is part of the mission of
the U.S. National Institutes of Health (NIH).
Moreover, the U.S. Congress and the NIH lead
ership recognize the direct connection between
global health improvement and the health and
well being of U.S. citizens. Public research agen
cies, such as the NIH, have a clear commitment
from Congress to provide global benefits from
their research. NIH has therefore allocated some
of its resources for research and research train
ing related to specific developing country health
needs (for example, HIV/AIDS, tuberculosis,
malaria, tobacco-related illness, cognitive devel
opment, and others). It has also advanced such
efforts through technology transfer negotiations
with private companies developing the discover
ies of NIH laboratories.
It is worth emphasizing that about 90% of
NIH research funds support extramural research,
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the vast majority in universities. Control of tech
nology from that research was placed in the hands
of universities by the Bayh-Dole Act of 1980.
Therefore, by far the greatest impact of any in
novation in intellectual property (IP) manage
ment comes from decisions made by university
presidents and their technology transfer officials.
They determine how IP derived from publicly
supported research is used. Most of the following
suggestions are meant for their special consider
ation. Similar arrangements, of course, could be
adapted in developing countries.
2.1 Rationale for public sector investment
in biomedical research

Several arguments have been put forth to jus
tify the government’s role in funding research.
Although this discussion mostly focuses on bio
medical research, the same arguments apply to
other sectors. First, funding basic research is a
classic example of the role of the government to
provide public goods, as applications for health
are built on the foundation of fundamental
knowledge. Because the market typically underinvests in fundamental knowledge creation and
utilization, government support of basic bio
medical and health research is an efficient use of
society’s resources. Furthermore, it is important
that the public sector continues to invest lest
the increasing expenditures of the private sector
unduly control access to basic knowledge. The
fruits of publicly funded research—whether in
genomics, developmental biology, aging, emerg
ing infectious diseases, molecular virology, can
cer, or other fields of science—benefit the public
in many ways. These benefits are delivered, not
only in the form of new medical technologies,
but also in ways unspecified and unforeseen. An
example of the latter is the NIH’s investment in
basic retrovirology, which paved the way for an
early understanding of the nature of HIV.
Second, public funding of research ensures
that data is available to scientists at the earliest
possible time. Academic research careers depend
on research productivity, often expressed as the
“publish or perish” dictum. Publicly funded re
search discoveries are often placed immediately
in the public domain through presentations,

publication, and professional networks. Privately
funded researchers, however, are under no obli
gation to make their findings available to other
researchers or to the public and indeed may in
some instances be prevented from doing so by
company policies.4 This difference is illustrated
in the approaches of the publicly funded hu
man genome project and the privately funded
sequencing research. The former placed the data
in the public realm in real time via the Internet,
whereas the latter did not—though the private
sector could still benefit from the publicly funded
program’s findings.
Third, publicly supported research can fill
knowledge gaps not addressed by private industry.
Because the public sector is based on incentives
other than the profit motive, government research
can set priorities based on society’s needs, scientific
promise, and other factors that—when no market
for a product exists—are not of paramount con
cern to the private sector. Therefore, the choice
of whether to develop new ideas into products is
largely left up to the private sector. The implication
of this is that technology development from pub
lic research by and large gets rationed according to
the priorities of the private sector, typically from
a “return on investment” perspective. Admittedly,
there are tensions across these public and private
sector interests. However, in the United States
these divergent paradigms are sorted out through
a multi-agent lobbying and vetting process that
occasionally produces disagreement but is gener
ally accessible and transparent.
One important consequence of this third
point is that publicly funded research can address
fundamental questions without undo concern
for the immediacy of its application. When pat
ents are derived from federally supported science
they are in fact generally for early-stage technol
ogy—often processes and materials to be used by
other researchers.5 Rarely does a discovery occur
in federal labs that does not require years of ad
ditional funding to enter into the market. This is
why public and private investments in biomedical
research are mutually dependent: a public sector
invention is usually brought to market by private
sector product development. Still, inherent in
this relationship is the reservation of the choice of
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whether to develop new ideas into products being
largely left up to the private sector. The implica
tion of this is that technology development from
public research gets rationed according to the pri
orities of the private sector.
2.2 Balancing public and private
research investment

The synergistic relationship between the public
and private sectors is generally highly efficient
and productive; however, the potential of this ar
rangement to create public goods from the invest
ment of the public sector is by no means certain.
In principle, the case can be made that beyond
the support for the research itself, public agencies
have a role to ensure that the benefits of basic re
search get delivered to the public. How it can best
carry out this role, however, is not obvious. Under
current arrangements, the public sector has lim
ited capacity and experience in the downstream
steps of developing and delivering products to
consumer markets. These steps are not only costly
but are also not aligned with the public sector’s
comparative advantage.
The public sector, therefore, requires two
kinds of investment: one enhances private sector
investment by supporting basic research that will
eventually lead to private sector product develop
ment; the other augments the private sector by
investing in those areas that are unattractive for
private sector investment. Both avenues are essen
tial for the public sector to pursue, and shifting
public health needs require the frequent rebalanc
ing of priorities.
The conundrum for public research agencies
is that however large their public funding may
appear, their resources are still limited relative to
scientific opportunity. They must prioritize re
search investments and are often unable to take
a technology far enough to determine how much
public benefit might be derived from the full,
vigorous exploration of its potential. The cost of
fully developing a new technology is great, and
the rate of attrition—explorations that end with
out a product or a profit—is very high.6
This underlies the crucial concern that
some explorations end prematurely because the
estimated market is too small to justify the needed
1 | HANDBOOK OF BEST PRACTICES

up-front investments. In the health sciences, this
may be particularly true of research for products
that target diseases of the poor or of developing
nations (for example, tropical and parasitic dis
eases) or that are more appropriate for delivery
and application in developing country health sys
tems. One hopeful note in the past five years has
been the substantial expansion in R&D invest
ment in neglected diseases of the poor via public/
private partnerships (PPPs): between 2000 and
2004, R&D expenditures from public/industry
nonprofit partnerships grew from US$23 million
to US$44 million per year.7
To help balance the above interests, the NIH
has created guidelines for sharing research tools.8
It is also tracking inventions produced from NIH
investments that result in therapeutic drugs or
vaccines. FDA-approved therapeutic drugs and
vaccines developed with technologies from the
intramural research programs at NIH are report
ed on the NIH Web site.9 Eventually this system
will document the public health outcomes of any
commercial technology developed with NIH
support. These steps may be worth emulating as
developing countries establish their own systems
for tracking the results of their research invest
ments. But while this system will produce valu
able information about the benefits of research
investments, it is still an a posteriori exercise.

3. IP lAWS AND PuBlIC
RESEARCH INVESTMENT
A successful research endeavor creates IP, but when
does this ownership enhance the public good?
The status and ownership of IP derived from gov
ernment-funded research in the United States is
framed by a series of public laws that establish
the current principles and procedures used by
the U.S. government and its private partners. For
purposes of this discussion, the most important
laws date from a quarter-century ago, although
the laws have been amended and enhanced in
minor ways since then. These are the StevensonWydler Technology Innovation Act (P.L. 96-480)
pertaining to intramural research in government
laboratories, and the Bayh-Dole Act (officially
Amendments to the Patent and Trademark Act,
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P.L. 96-517), pertaining to extramural research
outside of government laboratories.10 Both Acts
were passed in 1980 to stimulate greater use of
technologies developed through government
support. Their legislative history is instructive for
understanding the public benefit the laws were
designed to create.
.1 History of Bayh-Dole and
Stevenson-Wydler acts

In the mid-1970s, Congress became concerned
about the failure to use federally owned patents to
encourage product development stemming from
federally funded R&D. At the time, only 5% of
the 28,000 patents retained by the U.S. govern
ment had been licensed for use, whereas 25%–
30% of industry patents were being applied.11
These circumstances prompted Congress to in
quire into how federal research was transformed
into usable technology. Congress concluded that
the barriers were too great and the incentives too
small for academia or the private sector to develop
technology from the patents produced with gov
ernment research support. At the time, there was
no discussion about public sector involvement in
downstream activities.
The main barrier to the use of federally pat
ented technology was believed to rest with the
unwillingness of the responsible agencies to grant
exclusive licenses for companies to use the pat
ented technology and invest in product devel
opment. An exclusive license would allow one
company to have a monopoly in the invention
produced with government funds as an incen
tive to develop and test the product. Companies
complained also that even the attempt to obtain
nonexclusive licensing was an excruciatingly slow
process. Federal agencies imposed many paper
work requirements and other burdens on their
licensees in an apparent effort to protect the pub
lic’s interest in the invention. It became clear to
Congress that private companies would not ac
cept the risk and expense of developing technol
ogy for the marketplace without some exclusive
rights and without a more streamlined way to
obtain patent rights across agencies.12
The Bayh-Dole and Stevenson-Wydler acts
were intended to rectify this situation. They did

this by creating a uniform licensing system for
all federal agencies, reducing the steps needed
to grant licenses, and providing incentives for
industry to invest risk capital in product com
mercialization from federal patents. Most impor
tantly, Bayh-Dole allowed universities and smallbusiness government contractors to receive title
to inventions derived from government support,
rather than the prior arrangement in which gov
ernment was the sole holder of the patent. It also
allowed the grantees and contractors to license
the technology developed under these patents for
use by small business and private industry.13 The
Stevenson-Wydler Act effectively allowed federal
labs conducting intramural research to exercise
the same privileges.
The effect of these new statutes was to trans
fer the ownership of IP and the benefits derived
from it. They allowed companies to license and
develop products based on the discoveries of fed
erally funded university research with full legal
protection from competition. According to the
Congressional Research Service, “Proponents of
this approach contend that these benefits are more
important than the initial cost of the technology to
the government or any potential unfair advantage
one company may have over another in their deal
ings with the federal departments and agencies.”14
Interestingly, the Bayh-Dole legislation ini
tially proposed a formula for repayment to the
taxpayers of the government investment when a
patent yielded commercialized technology. This
provision was dropped in the final stages of pas
sage because of disagreements over technical as
pects of the repayment mechanisms.15 While the
legislative history demonstrates that there was
widespread acceptance of the principle of a right
ful return to the public from private sector use
of publicly funded technology, it was the details
of implementation that ultimately defeated its in
clusion in the bill.16
Nonetheless, the legislation was passed with
several clauses intended to ensure that the mo
nopoly powers granted to patent holders and li
censees would not be abused. These clauses have
been the subject of much debate among IP spe
cialists and are a cause of anxiety for the private
sector, which is concerned about when and with
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what justification they would be invoked by the
government. The legislation expressed Congress’s
view that the use of discoveries from federal re
search to improve health was clearly in the public
interest, even if it must be carried out by govern
ment action.
The Bayh-Dole law states the intention “to
ensure that the Government obtains sufficient rights
in federally-supported inventions to meet the needs
of the Government and protect the public against
nonuse or unreasonable use of inventions…”17 The
means to achieve that goal were codified in the
following provisions that reserve certain rights for
the government:
• The right to a nonexclusive, nontransfer
able, irrevocable, paid-up license to prac
tice for or on behalf of the United States
throughout the world.18
• “March-in” rights that enable the gov
ernment to require the licensee or pat
ent holder to grant use rights to another
user with due compensation under special
circumstances. The special circumstances
envisioned in this clause refer to lack of
use within an agreed-upon time frame
or special health or safety needs that are
not being met by the licensee or patent
holder.19

to invoke the government-use clause in pursuit of
its mission.
The second clause, the so-called march-in
right of government, has attracted greater at
tention and has been more extensively explored.
It has been formally tested just once, in a case
in which the NIH declined to initiate march-in
proceedings, thereby disallowing the petitioner
use of the technology.21 This test case provided
the opportunity for both the government and
affected parties (who were primarily third-party
recipients of government research funds or pro
spective licensees) to indicate their views on how
restrictive the march-in rights should be.22 The
debate centered on questions of what constitut
ed timely delivery and how critical the public
health or safety need had to be to in order to
warrant government action. The voluminous
record produced for this petition demonstrated
that universities and industry were extremely
concerned that the march-in provision would
undermine licensing rights under Bayh-Dole.
It also demonstrated that petitions for march
in would prompt a full-blown legal procedure,
imposing both time and financial costs on any
potential petitioner.

The first clause, allowing government use
of the technology, has been narrowly interpret
ed to refer only to a true government purpose.
This interpretation has not been fully litigated
and therefore it is likely that private pharmaceu
tical companies remain concerned that changes
in its interpretation could expand to threaten
their economic interests. This provision could
theoretically allow the government to practice
the technology—or contract with a third party
to have the technology practiced—for authorized
government purposes. Because the mission of the
NIH is “to secure, develop and maintain, distribute
and support the development and maintenance of
resources needed for research,” some have suggested
that there appears to be a limited scope for NIH
action in this regard.20 However, the Department
of Health and Human Services might, due to its
public health mission, have a clearer justification

The laws that govern the disposition and use of
technology derived from U.S. government invest
ment in health R&D must be judged first and
foremost by how well they have met their original
legislative intent. Assessments of the impacts of
the Bayh-Dole Act and related legislation suggest
that the laws performed as Congress intended.23
Most independent analyses have concluded that
the acts greatly increased technology transfer from
researchers to private industry in the biomedical
sciences, improved the governmental patenting
and licensing process, and made available to the
public products that improve their health and
well being.24 Thus, the goal of greater private sec
tor utilization of the research output by federally
funded scientists seems to have been achieved.25
Simultaneously, research universities expe
rienced significant upheavals as agendas and re
searcher time focused more and more on revenue
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.2 Twenty-five years after Bayh-Dole
and Stevenson-Wydler
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opportunities. In the two and a half decades since
passage of the Bayh-Dole Act, the major U.S.
research universities have developed highly pro
ficient offices of technology transfer, staffed by
professionals who deal with patents and licens
ing. Through this infrastructure, these universi
ties have come to expect financial rewards from
their research efforts in the form of royalties and
fees from patents and licenses. In the eyes of some
university officials, this income flow is justified as
partial compensation for the costs incurred dur
ing the conduct of federally supported research—
an enterprise most universities believe costs them
more than the infrastructure support provided
with federal grants.
Yet there is no guarantee of financial returns
from research, and most universities have long
operated without this extra income. They still do,
albeit there are consequences on investments in
expansions of faculty and facilities. The intent
of Bayh-Dole was not to produce supplemental
revenue streams to universities. Rather, it was to
engender innovation and increase the use of tech
nology for economic development. Universities
do accept their responsibilities to contribute to
the public good, but these have generally focused
first on university, state, and national health is
sues, in that order. Most universities have either
not addressed or achieved a balance between en
trepreneurship and the generation, use, and dis
semination of knowledge for the public good.
Recent analysis concludes that, although more
university technology transfer operations have be
come profitable over time, many universities do
not earn profits from licensing the results of re
search.26 The occasional blockbuster technology
has produced large royalties for a few universities
holding patent rights, and some others generate
a few million dollars annually. Most universities,
however, are still barely in the technology devel
opment business. Out of almost 1,500 licenses
executed during 2004, only 1.5% (67) generated
more than US$1 million in revenues. In 2004,
US$1.4 billion in earnings from licenses and
US$1.2 billion in royalties was reported by the
196 U.S. institutions that responded to an annual
survey of university research technology offices.
The survey respondents reported about US$41

billion in research expenditures for the same year,
and over 10,000 new patent applications filed.27
Much has changed in the 25 years since
the Bayh-Dole and Stevenson-Wydler acts were
passed. Not the least of these changes is an in
creasing concern for global health, a concern
arising from a recognition that the health issues
of poor country populations and the U.S. popu
lation are connected, as are the health of poor
country populations and their economic and
social prospects. For example, the devastating
impact of HIV/AIDS and the limited use in im
poverished developing countries of technologi
cal advances for diagnosis and management of
this infection and its complications is very much
in the news today. As a consequence, many
countries are trying to figure out how to deliver
health technology to poor and technologically
marginalized populations. In the process, ques
tions are being raised about the balance of in
terests between the use of new technology to re
duce threats to health and the ownership rights
to that technology.
. Current debates

The obligations to a larger, more global public—and the rights of this public—are raising
critical questions: just who is the public and
what return on the investment is due the public?
Debate continues about how to ensure the avail
ability of effective treatments to all in need while
ensuring that research partnerships with industry
remain viable and productive. Public research
and research funding agencies such as NIH, the
academic community, and industry will be chal
lenged to consider how to interpret and apply IP
laws and regulations in the context of how a pat
ent or a license, granted or denied, will affect the
public good. Not only are economic, legal, and
policy issues involved, but there are also complex
ethical and social considerations created by deci
sions to apply IP laws.
The controversial nature of IP for biomedi
cal research is illustrated in public debate and in
proposals in recent sessions of the U.S.
Congress:28
• disputes over competing claims to IP devel
oped under government/industry ventures
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• delays in negotiating Cooperative Re
search and Development Agreements
[CRADAs] because of issues related to
dispensation of IP
• controversies over the rights of drug com
panies to set prices on drugs developed in
part with federal funding
• uncertainties due to the increasing mix of
funding sources among government, founda
tions and the private sector, and the portion
of IP that represents the public good return
• problems obtaining technologies for re
search developed in the private sector for
use in federal laboratories (A more general
problem of access to research tools has not
been considered by Congress.)
This list of issues is not exhaustive and raises
more questions than answers. Moreover, each
could be—and indeed most have been—the sub
ject of a rousing debate and the occasion for a
flurry of letters, testimony, articles, op-ed pieces,
and books. One place to start searching for ways
to increase the return to the public—both global
and U.S.—of the public investment in research
is to review the arrangements currently or poten
tially in use to deliver these benefits.

4. THE PuBlIC SECTOR AND GlOBAl
HEAlTH RESEARCH
There are several ways that government research
funders can increase the resources and tools de
voted to the public health needs of the developing
world. At the upstream end they can direct funds
toward research on specific diseases; they can also
partner with private and nonprofit entities wish
ing to do the same. At the downstream end they
can directly provide products to users in poor
countries, reduce barriers to the transfer of tech
nology, or partner with industry and academia
to expedite the development of products from
research. Some of these steps could be adopted
by academic recipients of public funds, especially
those that actively develop IP ownership derived
from public research funds.
The following specific actions could be taken
by public funders and their academic and private
10 | HANDBOOK OF BEST PRACTICES

sector partners to increase global public goods for
health. Many of these actions could also be adapt
ed, by implementing IP rules and procedures, for
use in developing countries.
.1 Action within the research enterprise

Strengthen capacity for research in developing
world. Increasing funding for research in devel
oping countries is, if sustained, one of the most
direct ways to create a global benefit and ulti
mately increase access to the results of scientific
research for the world’s poor. Such funding can
also lead to collaborations between developed
and developing country scientists, creating more
sustainable research environments and the oppor
tunity for human capacity building and research
infrastructure development.
Government research awards can contain
provisions requiring researchers to train develop
ing country scientists in these highly successful
laboratories. In the health sciences, for example, a
portion of the royalties from the NIH intramural
program is returned to the lab that discovers and
invents new technology—this also applies to uni
versity labs that produce patentable inventions.
These funds could be devoted to training new sci
entists. In addition, the same opportunities could
be provided in developing countries.
Academic/industry partnerships. Both
within and apart from the university research en
vironment, the relative importance of private sec
tor funding has increased. Private companies are
now estimated to spend three times as much on
biomedical research as the NIH, most of it within
their own research laboratories.29 However, industry-funded university research is also growing.
It is unclear how involved industry is in academ
ic biomedical research at present, although one
source indicates that a small portion of private
R&D (about 12%) is conducted within U.S.
academic institutions.30 Whatever the magnitude
of industry’s involvement, it is large enough to
possibly blur the distinction between the objec
tives of universities and private industry, and it
has caused some to question university motives
for carrying out research.31
The nature of science and its conduct has
also changed since Bayh-Dole was instituted.
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Few academic or public research organizations
have the particular combination of scientific
know-how, application tools, and commercial
ization potential that it takes to turn ideas into
real deliverable products. Public/private part
nerships are increasingly looked to as the mode
of operation for future biomedical research
that rapidly develops products. Nowadays, the
complementary human capital and financial re
sources of the public sector, academia, and in
dustry are all needed to bring scientific inquiry
to fruition. The power of the Gates Foundation
to influence this process is a major new force
shaping this landscape.
In recent years, new approaches have been
devised to sweeten the pot and bring new players
into the development of health technologies for
the poor. These include public/private partner
ships such as MIHR (Centre for the Management
of Intellectual Property in Health R & D,) estab
lished in 2002 precisely to address public sector
needs in IP management. It provides a forum for
multiple public and private entities to improve the
management of health IP for the benefit of devel
oping countries through information exchange,
training, defining best practices in licensing, and
help in developing norms for IP management.32
MIHR is working with developing countries to
help them bridge the gaps between what the pub
lic and private sectors can provide in addressing
global health needs.33
Many universities prominent in health re
search are also seeking to balance their financial
objectives, their charge to advance scientific dis
covery, and their dissemination of the benefits
of those discoveries to the public. Universities in
both developed and developing countries could
explore how to create research partnerships with
one another and with the private sector that
achieve a public benefit goal, while still meeting
the profit motive of private companies.
.2 Technology transfer options

The evolution of technology transfer practices
since Bayh-Dole has placed public sector insti
tutions and research universities in a difficult
position. The delicate balancing of their scien
tific interests, their responsibilities to the public,

and their need to maintain a competitive posi
tion vis-a-vis the private sector to retain expertise
has been jarred repeatedly in the past few years.
Developing country institutions are particularly
challenged by the lure of greater research oppor
tunities and higher salaries and benefits for their
top and young scientists in the U.S.
The following list suggests how public invest
ment can use technology transfer more effectively
to create global public-health goods. The list also
makes the important point that all possibilities
should be open to discussion among committed
and interested parties—including policy-mak
ers and research leaders in the developing world.
Many of the suggestions are derived from NIH
experiences, but they could be applied far more
widely. Most importantly, the engagement and
involvement of all stakeholders is essential, with
out this it will be impossible to change current
operating principles. Change will not be accom
plished by fiat.
1. A straightforward way to deliver social
dividends from research is to write provi
sions into licensing agreements. On an ad
hoc basis, NIH has incorporated voluntary
provisions for public benefits into license
agreements with private industry. As a re
sult, many licenses granted by NIH include
a public benefit of some sort.34 The types
of public benefits called for in these purely
voluntary arrangements include education
al Web sites, product donations, and drug
delivery to needy communities. The initia
tive has been palatable because no specific
level of benefit or outcomes is requested in
the license provisions. It appears, however,
that the public benefit delivered through
this approach has been, at best, modest.
Public-benefit provisions in licens
ing agreements could state a specific aim
to benefit poor countries. Both publicly
funded research agencies and university
technology transfer offices could increase
the use of such provisions. If employed
in developing country licensing agree
ments, the provisions could ensure the
delivery of drugs or technologies to the
poor by whatever direct mechanism the
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commercial partner prefers (for example,
drug donations or reduced prices), or
even indirectly through a nonprofit or
ganization. For instance, a reasonable
proportion (however difficult it is to de
termine the meaning of reasonable) of the
royalties to a university from the license
would be placed within a foundation es
tablished to support global public-health
goods. It is necessary to recognize that the
funds available for diversion are meager,
if they exist at all, at most universities.
2. The private sector lacks interest in many
available technologies because of its per
ceived lack of profitability. Therefore, ways
to increase profitability need to be explored.
One method open to the public sector and
academic institutions is to bundle technol
ogies developed in their laboratories. This
would require companies to license anoth
er, less profitable technology for develop
ment in order to obtain a license for more
lucrative technologies. This is consistent
with the paramount aim of the Bayh-Dole
Act to get technologies used.
So far in the United States, there have
been few takers for this type of arrange
ment, and its impact will likely be small.
The argument is that bundling may help li
cense less-attractive technologies, although
it will not make them more profitable for
companies to develop. However, in a de
veloping country setting, the economics of
bundling may be different. For instance,
if the public institution can help identify
a large buyer to take the initial output, a
profitability threshold might be reached
if the price from the bulk purchaser met
minimum average cost of production at
the appropriate scale. A private company
wishing to expand its capacity in a devel
oping country could anticipate potential
profits.35 Merck reached such a level when
it chose to produce recombinant hepatitis
B antigens in China for that market. It
even built a state-of-the-art plant to pro
duce vaccine. This led to widespread use
of the vaccine in China and a foothold for
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the company in the country—a win-win
situation.
The economics of bringing products to
market in developing countries differs from
those in developed countries.36 Human
clinical trials are the most costly phase of
product development; this phase is also
when most experimental technologies fail.
Developing countries have the opportunity
to streamline procedures for carrying out
clinical trials, including establishing more
rational and less time-consuming institu
tional review board (IRB) processes. Other
components of the R&D process that
generally cost less in developing countries
are legal, marketing, and regulatory fees.
Also, the medical research companies in
developing countries may be more willing
to take risks than are those companies in
the United States. Moreover, both compa
nies and their government regulators may
be more strongly motivated by the clear,
urgent need for improved diagnostics and
therapeutics.
Developing country markets can also be
segmented: the technology could be pro
vided at low or no cost to the poorest coun
tries through a subsidy mechanism (market
pull), at a sustained rather than reduced
price in middle-income developing coun
tries, and at a higher price as the market
develops. Such an arrangement would be
consistent with economic theory, in which
price discrimination can increase market ef
ficiency and equity.37 It actually resembles
the pricing methods that pharmaceuti
cal companies currently use in developed
country markets and could make some
technologies suddenly more financially at
tractive. For this approach to work, mea
sures must be taken to ensure that there is
no parallel importation or smuggling from
the low price to the higher price nations.
This is a difficult goal, but one that might
be expedited through TRIPS to allow trade
in generics among developing countries.
A variant of this approach would be
for technology transfer offices (TTOs) to
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work more with nonprofit organizations
to deliver technology, instead of seeking
commercial avenues. NIH currently uses
CRADAs to work with the World Health
Organization (WHO) and nongovern
mental organizations (NGOs) (for ex
ample, PATH) to move malaria drugs and
other less-profitable technologies into use.
The overriding concern for a CRADA is
whether the organization can carry out the
necessary R&D to develop a product. The
current fully capitalized cost (including
post-approval R&D costs) to the private
sector to develop one drug is estimated
to be nearly US$900 million. And with
more than eight years required for the
clinical and approval phases of develop
ment alone, nonprofit organizations just
do not have the capacity to sustain such an
investment.38 However, as already noted,
it is extremely difficult to make such esti
mates because the necessary information is
not in the public domain; it is likely that
goals can be achieved at much lower cost
in developing countries , and this can be
put to the test.
3. In an effort to increase the licensing of
vaccine technology in selected developing
countries, the NIH is now requiring com
panies seeking to license NIH technology
to produce a plan to market the technology
in developing countries within two years of
regulatory agency approval. They can either
opt to deliver the product themselves or ini
tiate a joint venture with another company.
The goal is to use the potential profits from
sales in developed countries to encourage
companies to manufacture for the devel
oping world at or near cost, although the
expense of adding manufacturing capacity
or the opportunity cost of shifting exist
ing production to this product should be
factored in. Another way to achieve access
and affordability for the poor is by manu
facturing in developing countries at lower
cost than in the United States.39 This sort
of a tie-in is difficult to accomplish from
the United States, but a developing country

government could arrange it much more
easily.
4. Delivering technologies for developing
country use through multiple-use licensing
is too rarely used. This approach identifies
and licenses basic technology for specific
fields of use (for example, a cancer vaccine)
and requires the same (or another) company
to do parallel development of the same tech
nology for another field of use (for instance,
an HIV vaccine). In the existing regulatory
framework, an expansion of this approach
would require renegotiating existing li
censing agreements and would certainly
be strongly resisted by licensees. However,
in an open playing field such as exists in
some developing countries, it could become
common.
5. A radical approach open to the U.S. gov
ernment but not to universities is to exert
march-in rights on already-licensed NIHderived technology to meet special health
or safety needs that are not being satisfied.
This option, referred to as compulsory li
censing, should be retained by develop
ing country governments in case of public
health emergency—and it should be used
when necessary, and never frivolously.
6. Finally, all activities—from early-stage de
velopment to manufacture and distribu
tion—could theoretically be performed by
a government agency, university, or con
tractor. For instance, government research
institutions could move their own involve
ment further down the development pipe
line to include whatever steps would be
needed to get the product ready for uptake
by a private or nonprofit entity. Although
this is clearly not a priority for a research
agency such as NIH, there are already some
programs to develop medications at NIH
instead of relying on the private sector. It
is worth emphasizing that, within the con
text of the Bayh-Dole Act in the United
States, by far the greatest impact from IP
innovations will come from decisions made
by university presidents and their technol
ogy transfer officials. They control how IP
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derived from publicly supported research
is used.
If universities decide to adopt any of these
options, the decision, in our view, should
come from a consultative process among
all interested parties, including public re
search agencies, developing country repre
sentatives, potential funding partners, and
industry. Universities and their faculties
would have to embrace the moral and so
cial imperative of enhanced delivery mech
anisms and become full partners in the
means selected to achieve them. Because
most of the relevant technology is devel
oped by a small subset of research-intensive
universities, it would not be necessary to
bring all universities on board; instead, a
focus on the leaders would establish stan
dards that others could follow. The process
would be strengthened if developing coun
tries joined and were led, for example, by
a multinational organization such as the
Inter-Academy Medical Panel.

5. CONCluSION
.1

Considerations for senior policy-makers

Economic development, drugs for the poor, break
through technologies for the world’s most com
mon diseases, and scientific advances for treating
tropical diseases are legitimate social goals for all
nations. But these goals vie for limited financial
and expert resources and are not always compat
ible with each other. Policy-makers must ensure
that the public’s investment in research is reward
ed. A system should spur economic development
and creative innovation, as was the intent of the
Bayh-Dole Act. Just as importantly, the IP system
should clearly articulate and codify an overarch
ing social goal.
It is understood that subsidies to research
universities in the form of indirect costs in
grants funded by the government may not cover
the actual cost of supporting research infrastruc
ture, and that industry risks capital in R&D for
products that fail somewhere along the path,
and that this has implications in terms of fi
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duciary responsibility to stockholders due a
return on investment for success in product
development. None-the-less, policy-makers
should insist that, as a condition of receiving the
protections of patents and licensing, companies
and universities must pay some “dividend” back
to the public. This dividend could be indirect
and used to support further research to address
needs the market alone does not satisfy. Further,
policy-makers should retain the government’s
right to exercise a technology license on behalf
of the public, as well as full march-in rights.
The government should be prepared to exercise
these rights in the event of a real public-health
emergency or in the event that the private sec
tor licensee fails to develop or bring to market
a product that has potential public benefit. The
government must accept its responsibility to en
sure that the public’s investment pays returns to
the public. As it turns out, the option for gov
ernment action itself will likely provide compa
nies with a strong incentive to make products
available in the market. Government should also
embrace principles of segmented markets and
tiered pricing for vulnerable populations in the
U.S. and abroad—the poor, the elderly and the
vulnerable in particular. In this way, the govern
ment accepts its responsibility to ensure that the
public investment pays returns.
.2 For presidents of universities

In their approach to IP laws, the academic com
munity is faced with complex ethical and social
issues. If partnerships are to promote research
that leads to global benefits, there should be
agreements that explicitly commit all of the part
ners to this goal at the outset. Creative financ
ing and IP sharing arrangements will have to be
developed. And scientists will need to prioritize
the delivery of global benefits. Similarly, univer
sity officials will have to fully embrace the larger
role of universities in society and in the global
community. Leadership must come from the
very top of the institution, for example valuing
applied research and including the creation of
global public goods among the criteria for aca
demic advancement.
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Many universities prominent in health re
search are seeking to balance their financial ob
jectives, their commitment to scientific discovery,
and the dissemination of benefits to the public.
PIIPA (Public Interest Intellectual Property
Advisors) is one example of how U.S. universi
ties can use their stock-in-trade to serve the global
public need by offering expertise and training.40
PIIPA is a newly formed consortium of universi
ties and companies that provides pro bono legal
and professional assistance about IP issues to en
tities in developing countries, including govern
ments and universities.
There are many ways that universities can
help meet global public health needs. They can
include including public benefit clauses in their
licenses to the private sector, investing part of
their royalty stream in a foundation, ensuring
that returns to the university itself are used
in part to support capacity building and ap
plied research of global relevance, establishing
an “ethical” investment fund,41 licensing tech
nologies to nonprofits or others who would
develop and manufacture for poor countries,
or bundling technologies to encourage the de
velopment of medicines aimed at diseases of
the poor. Research universities or public fund
ing agencies could unilaterally adopt any or all
of these options, but a multilateral approach
would have far greater public awareness and
public health impacts. Ideally, this approach
would be an international, multi-institutional
effort.
. For the technology transfer officer

The job of the TTO is to create the incentives
needed to move discovery into the product devel
opment arena, motivating academic researchers
not by the sole promise of high profits—which
rarely appear—but by applying royalty toward
the support of research in the inventor’s laborato
ry, and by balancing some financial reward to the
inventor with the satisfaction of seeing his or her
work used for public benefit. Although not the
responsibility of the technology transfer officer,
the latter can become so. This will require creat
ing opportunities for various forms of licensing
(including exclusive licensing where appropriate,

but a nonexclusive license should be insisted upon
if that is likely to move a promising technology
to market sooner), maintaining a very low paper
work and expense burden for private (including
nonprofit) companies wishing to license govern
ment-funded technology and insisting on explicit
public-benefit clauses. Technology transfer offi
cers should report such efforts and their potential
impact to the President him/herself.
. For a university scientist

Individual researchers in the United States have
established product development companies in
large numbers, and developing country research
scientists and their institutions will feel pressure
to do the same. When considering a research col
laboration with a scientist from the United States,
developing country scientists should be certain
that they receive equitable treatment in whatever
IP ownership arrangements are made. While IP
protection is often necessary to convince indus
try to move discovery into product development,
something neither academia nor government, for
that matter, do with distinction, not every dis
covery should or need be protected. Scientists
should be capable of participating in these dis
cussions. Developing country scientists should
also resist the excessive protections that are some
times placed on research output in the United
States—protections that delay and sometimes
prevent discoveries from being published and
shared in the scientific community. It is very im
portant for developing country researchers to get
the professional exposure and opportunities that
scientific publication can offer. Narrow-minded
efforts to establish property rights can inhibit
those benefits.
. A global vision

Creating and delivering global public health
goods is much more difficult than creating and
delivering national public health goods. Yet we are
committed, in the words of Tennyson, “to strive,
to seek, to find, and not to yield.” To change the
current reality will require a coalition of univer
sity officials, government, industry, foundations,
and NGOs to identify priorities and opportuni
ties and then collectively carry them out.
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Although IP has clearly spurred the devel
opment of technologies that promote the public
health of wealthier nations, the impact of IP in
promoting global public health goods is mixed
at best. Although the fundamental premise of IP
protection—that it acts as a spur to innovation
and a reward for risk-taking—applies equally to
all industries, some characteristics of the health
care industry set it apart from other fields where
IP is important. Quite simply, in health care, the
outcomes of technology development and its
availability are matters of life and death.
In 2002, The Economist observed “Rich coun
tries should accept that considerations of how IP
rights affect poor countries are not just a concern
of overseas aid agencies but play a part in broader
trade and economic relations too.”42 This chapter
builds upon the truth of that insight. Indeed, if
Bayh-Dole were being debated today, then surely
the economic development objectives at the core
of the legislation would take on a much broader
meaning. n
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gRegoRy d. gRaff, Research Economist, PIPRA, U.S.A., and Visiting Research Fellow, Department of Agricultural

and Resource Economics, University of California, Berkeley, U.S.A.

ABSTRACT

Seeking to drive economic growth within the knowl
edge economy, governments have increasingly sought to
commercialize the results of publicly funded research.
The ability to use intellectual property (IP) as a tool to
encourage and facilitate commercialization hinges on
three fundamental policy concerns: protection, owner
ship, and management capacity. This chapter surveys
the policies and practices across an array of emerging
and developing economies, including Argentina, Brazil,
Chile, China, Ethiopia, India, Indonesia, Jordan, Kenya,
Malaysia, Mexico, the Philippines, Poland, Russia, South
Africa, Tanzania, Uganda, and Vietnam. In regard to the
availability of intellectual property protections, the sur
vey finds that countries can logically be sorted into three
tiers. The first tier contains the most innovative countries,
those with an active intellectual property system used vig
orously by domestic patentees. The second tier consists
of countries actively seeking to become more innovative,
with intellectual property systems that are only beginning
to be used by domestic patentees. The third-tier countries
are those with limited or nascent intellectual property
systems and virtually no domestic patentees. Almost all
first tier innovative countries, about half of second-tier
countries, and no third-tier countries have formally ad
dressed the question of intellectual property ownership
through national policy. Among those that have, how
ever, the survey finds a wide range of policy approaches
used to address the question of intellectual property own
ership, including patent law, labor law, government pro
curement or contract law, and laws governing national
R&D or innovation systems, as well as rulings by min
istries of science and technology or ministries of higher
education. With regard to institutional intellectual prop
erty management capacity, the survey finds a very broad

range of sophistication and expertise, both across and
within countries of all three tiers. Higher capacities for
institutional intellectual property management appear to
be more closely associated with levels of R&D expendi
ture than with the existence or absence of national poli
cies that allow or encourage institutional ownership. The
implication is that intellectual property management at
the institutional level grows in tandem with strong R&D
and the capacity for the local economy to commercialize
the technology.

1. InTRoduCTIon
As governments in countries with emerging and
developing economies confront the issues of
globalization and technological advance, many
have focused on how domestic universities and
research institutes can promote economic growth
by supporting and seeding innovation in the pri
vate sector. Such institutions have traditionally
served two core missions: to educate the elites of
the workforce and to conduct applied or adap
tive research to address domestic economic and
social needs. Institutions in developing coun
tries are also often concerned with carving out a
place for the country within the global scientific
community.
Increasingly, government officials in devel
oping countries are under pressure to democra
tize higher education and fund a broader range
of research and development priorities. At the
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same time, commercializing innovation is being
emphasized as a core mission of publicly funded
research. To advance this mission, the tools of pat
enting, technology transfer, and venture creation
are increasingly deployed. Indeed, in countries
like China and India, student numbers are swell
ing, rates of publication in prestigious interna
tional journals are climbing, academic patents are
growing, and the number of start-up companies
is increasing. Like other areas of development
policy, academic innovation may be an area in
which developing countries can leapfrog directly
to the standards and practices of the knowledge
economy.
National systems of innovation are not made
overnight; they evolve over generations. Those
economies that are today actively seeking to ex
pand the private economic impact of their pub
licly funded R&D are building upon the legacies
of past investment in their institutions and in
the human capital that is the very source of in
novation. Today’s challenge is to adapt the policy
environment to improve the social rate of return
on those investments. This can be achieved by in
creasing the flow of technologies into the private
sector. It is therefore important to understand
how technology transfer from universities and
public research institutions is affected by national
policies. The three fundamental policy questions
that any country must answer are:
1. To what extent are intellectual property
(IP) protections available?
2. To whom can/should the ownership of
those property rights be assigned? (To
the government or third-party sponsor of
the research? To the institution where the
work was conducted, or to the individual
inventor?)
3. What capacity, in the form of dedicated in
frastructure, programs, or other resources,
will be provided to identify, protect, and
commercialize new technologies and to
support industrial development and tech
nology-based entrepreneurship activities?
IP is just one part of an economy’s system of
innovation. The research base, the legal IP regime,
and the institutional infrastructure all co-evolve
10 | HANDBOOK OF BEST PRACTICES

in a synergistic process with each part supporting,
and supported by, the others, just as the differ
ent parts of an ecosystem co-evolve. This chapter
provides brief sketches of the national policies
governing university and public sector technology
transfer by means of intellectual property, looking
at how the three basic policy questions have been
addressed around the world. From these observa
tions, we can distill general trends in legislative,
regulatory, and institutional reforms from around
the world.

2. pRIMARy AREAS of poLICy AffECTInG
TECHnoLoGy TRAnSfER
2.1 Availability of IP protection

The first policy question is whether privateproperty rights can be claimed over the intangi
ble results of research. This issue is governed by a
country’s intellectual or industrial property laws.
Some degree of global standardization has been
achieved through multilateral agreements. The
Paris Convention of 1883 ensures that foreign
inventors from signatory countries are treated as
nationals. The Patent Cooperation Treaty (PCT)
of 1970 provides a common patent application
clearinghouse for inventors wishing to file for
patents in multiple countries. The Agreement on
Trade-Related Aspects of Intellectual Property
(TRIPS) of the WTO, adopted in 1994 and
entered into force in 1995, stipulates minimum
IP standards for members of the WTO. In ad
dition, provisions or conditions for IP protec
tion are often the subject of bilateral trade agree
ments. Influential centers of trade such as the
United States and the European Union exert a
harmonizing influence on the national policies
of trade partners with whom they have con
cluded bilateral trade agreements. These trade
leaders often set standards for IP protection that
are even higher than the conditions set forth in
TRIPS. In the specific area of newly bred plant
varieties, the Union for the Protection of New
Plant Varieties (UPOV) Convention, adopted
in 1961 and revised in 1972, 1978, and 1991,
has established international standards for plant
variety protection (PVP). Each revision of the
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treaty outlined increasing levels of protection
that countries can decide to adopt.
Even if domestic IP rights are not available
for a newly invented technology, the inventor
does have the option of filing in other countries
where IP rights may be granted. It is common
for inventors around the world to minimally file
in the major triad of the United States, Europe,
and Japan.
2.2 Ownership of intellectual property

The second policy question concerns the locus
of ownership of intellectual property that results
from work done at publicly funded organizations.
Legislative reforms have been introduced in many
countries seeking to systematize and promote
the commercialization of technologies. Many
of these efforts have taken inspiration from the
experience of the United States under the BayhDole Act of 1980, which harmonized the variety
of U.S. government agency IP ownership poli
cies. The Bayh-Dole Act specifically focused on
the rules concerning the disposition of IP rights
over inventions that result from federally funded
research. It effectively limited the government’s
role in ownership, vesting ownership rights to the
organization where the invention is made, along
with responsibilities and conditions for how the
intellectual property is to be managed. It is pos
sible, however, for other areas of law, including
patent law and labor law, to shape how universi
ties manage intellectual property.1
2.2.1

IP, industrial property, or
patent laws and regulations

IP or patent law often provides conditions for the
disposition of patent rights between the individ
ual inventor, the institution that employs him or
her, and a designated assignee of the rights, which
can be either the employing institution or a third
party.
2.2.2 Labor or employment
laws and regulations

Employment laws and regulations can stipulate
the privileges, rights, and responsibilities of em
ployees, including the disposition of rights to in
ventions made during the course of employment.

These commonly specify that inventions made in
the natural course of employment are to become
the property of the employer, although conditions
may be put in place, such as requiring additional
compensation for the employee-inventor. In some
countries, particularly in continental Europe and
Scandinavia, an exemption to labor law has been
historically granted to university faculty, dubbed
the “professor’s exemption.” This exemption gives
faculty the right to take ownership over any intel
lectual property resulting from the research they
conduct at the university.
2.2. Laws of funded or contracted research

Government funds or contracts, including those
granted for the conduct of research, often carry re
quirements for the recipients of those funds or for
the parties to that contract. In some (increasingly
rare) cases, a government may explicitly require
that the results of research funded by the govern
ment be made freely available to the public, thus
prohibiting any private IP claims. In other cases,
a government may itself take ownership of IP
rights over the results of research. Alternatively, a
government may choose to devolve the rights of
ownership, either to the institution that hosted
the research or to the individual inventor. The pri
mary justification of the latter two policies is that
putting the IP rights into the hands of the host
institution or the inventor properly aligns private
economic incentives to encourage inventions and
entrepreneurial activity. The premise is that eco
nomic activity governed by the market will better
serve the economy and consumers—while at the
same time generating rewards and incentives for
institutions and researchers based on the actual
market impact of their contribution.
2.2. Laws and regulations of
the national R&D system

Governments in many countries are taking specif
ic steps to develop national innovation or R&D
systems supported by an integrated set of policies
covering the creation of new research institutions,
increased research funding, management of hu
man resources, and the provision of grants and
subsidies. These policies might include tax incen
tives for industry R&D and institutions along
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with funds to support venture investment and
entrepreneurship. As part of the integrated policy,
there may be rules for the provenance of intellectual
property created within the national system.
2.2. Ownership questions in the absence of
domestic policies

In cases when IP rights are not available in an
inventor’s home country, the question of owner
ship may still arise, in particular the ownership
of available foreign IP rights, whether it be by
the individual inventor, their government, their
employing institution, or a third-party assignee.
Importantly, in the absence of laws specifi
cally enabling or restricting ownership of intel
lectual property, universities and public research
institutions are free to establish their own policies
and practices. This is the situation in many coun
tries, including developed countries such as the
U.K. Such openness can allow a research insti
tution greater IP management flexibility. On the
other hand, the lack of a specific national policy
on IP ownership often indicates a lack of coordi
nation or transparency.
2. IP management capacities

The third fundamental policy question concerns
the provision for IP management and technol
ogy commercialization. Merely providing for the
existence of private-property rights over intellec
tual assets is not enough. Public institutions need
more than rights to own intellectual assets; they
need to develop the infrastructure and expertise
required to manage these intellectual assets and
engage in productive commercial relationships
with private companies and investors. Even in
high-income countries such as the United States,
institutional developments took a decade or more
to spread through universities. While universities
were left to create infrastructure and expertise on
their own in the United States, many other coun
tries have pursued policies that range from pro
viding subsidies to universities to set up technol
ogy transfer offices (TTOs)—Denmark is a good
example—to establishing national networks or
central offices to coordinate and assist universi
ties in developing their technology transfer opera
tions (such as Chile).2
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While national laws and regulations provide
a legal framework within which universities and
public research institutes operate, these are ulti
mately implemented by the staff dedicated to the
management of technology commercialization.
Institutional policies can be slow to take shape,
and dedicating resources, establishing offices,
and deploying staff takes time and commitment.
However, while universities develop or adapt for
mal policies, rules, and regulations, the informal
norms and practices within the academic culture
are equally crucial. Once policies and capacity are
established at the institutional level, an effective
IP management program can take up to ten years
to develop and mature into a self-sustaining en
terprise that is supported by the academic com
munity. These capacity developments are often
most visible in the creation of offices or units for
IP management, technology transfer, or commer
cialization, and in the volume of patents, licensing
deals, or spinouts coming from the public sector.

. CuRREnT poLICIES In
EMERGInG EConoMIES
.1 Argentina

IP protection. Argentina’s current patent law, the
Law on Patents and Utility Models No. 24.481
was adopted in 1995, amended by Law No.
24.572 in 1995, and harmonized in 1996 by
Executive Decree No. 260.96. Argentina joined
the WTO and became signatory to TRIPS in
1995, which entered into force in Argentina on
1 January 2000.3, 4 Under Article 100 of the new
Law on Patents, pharmaceutical products became
patentable as of 2000 (with patent applications
accepted as of 1995). Article 6 of the new Law
on Patents, however, clearly stipulates that plants,
animals, and indeed “all classes of living materials
and substances existing in nature” cannot be pat
ented. Article 7 reinforces this, excluding from
patentability “the totality of biological and genetic
material existing in nature…”5 Patents are admin
istered by the Instituto Nacional de la Propiedad
Industrial (INPI).6
Plant varieties are protected in Argentina
under the 1973 Law No. 20.247 on Seed and
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Phytogenetical Creation (the Plant Varieties
Law). Argentina joined UPOV in 1994, as en
acted by Law No. 24.376 on the Protection New
Varieties of Plants.7, 8
In 2004, the National Agency of Scientific
and Technologic Promotion announced an ini
tiative to help researchers, both in industry and
government laboratories, to pay for foreign pat
ent filings, in an effort to boost the rate of do
mestic patenting (in many jurisdictions, domes
tic filing is a prerequisite for foreign filing). In
2000, 145 patents issued by Argentina went to
residents of Argentina, while 1,442 went to for
eign residents.9
Ownership. The 1990 Law on the Promotion
of Technological Innovation No. 23.877 and the
1995 Law on Higher Education No. 24.521 pro
vided certain conditions for institutional owner
ship and transfer of intellectual property result
ing from the work of researchers.10 The 1990 law
allows national research institutions to establish
or outsource TTOs, but leaves the question of
internal distribution of income up to institu
tional policy. It allows for researchers to receive
income beyond their government salaries from
technology commercialization activities. The law
also provides for government funding of TTOs
for collaborations with (preferably small) busi
nesses and establishes a fund for this purpose. In
the 1995 law, Article 59 establishes the financial
autonomy of national universities and their right
to seek additional sources of revenue from the
provision of services, products, contributions,
fees charged, and any other resources, including
technology transfer and commercialization. The
law also allows national universities to form or
own corporations.11
However, the 1995 Law on Patents and
Utility Models (24.481, modified by 24.572) es
tablished that the ownership of inventions made
by employees in the course of their jobs goes to
the employer, in most cases. But the law also re
quires the distribution of a share of the income to
the inventor, and for researchers at national uni
versities, it, in effect, gives joint ownership to the
university and the centralized agency CONICET
(Consejo Nacional de Investigaciones Cientificas
y Tecnicas), which manages employment and pays

salaries for most university-based scientists in the
country. TTOs of individual institutions may es
tablish individual agreements with CONICET
for the assignment and management of particular
inventions. CONICET does not, however, have a
general policy on handling joint inventions.12
Institutional capacities. As a result of owner
ship laws, there is both some IP management and
coordination capacity at the government level.
TTOs exist at some universities, and IP manage
ment is also contracted out to third-party man
agement companies or centers. Among the most
developed programs are:13
• University of Quilmes
• University of Cordoba
• University of Litoral
• Inis Biotech (the TTO for Instituto Leloir)
• Some capacity for IP management is central
ized at CONICET, within its Directive for
Science and Technology Links (Dirección
de Vinculación Científico Tecnológica).
This lists on its Web site more than 60 pat
ents registered in Argentina, 12 registered
in other Latin American countries, and
four registered in the European Union, the
United States, and Canada14
• The Constituyentes Technology Pole (Polo
Tecnológico Constituyentes) was created
in 1997 to facilitate technology transfer
for several research institutions, includ
ing the National University of General
San Martín (UNSAM), the Atomic
Energy Commission, (Cómision Nacional
de Energia Atómica - CNEA), and the
National Institute of Industrial Technology
(Instituto Nacional de Tecnología Industrial
- INTI)
The Secretary of University Policies, which is
part of the Ministry of Education, has established
a Technology Network (Red de Vinculacion
Tecnologica) that holds meetings and provides
general information. Its main mission is to main
tain professional networks.
.2 Brazil

IP protection. Brazil has a long history of IP rights,
having first introduced a system of protection in
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1809. Brazil was also an original signatory to
the Paris Convention in 1884. Beginning in the
1950s, Brazil pursued an aggressive science and
technology policy designed in part to engen
der economic development under an importsubstitution development policy. The previous
Industrial Property Code (Law No. 5.772), dat
ing from 1971, supported this policy by exclud
ing patent protection for certain areas of tech
nology, such as pharmaceuticals and chemicals.
Following political and economic reforms, IP
laws changed significantly in the 1990s. Brazil
became a founding member of WTO and thus
a signatory to the TRIPS Agreement in January
1995. The Law on Industrial Property No.
9.279 of 1996 entered into force in May 1997
to implement TRIPS. It has since been amended
several times. Patents are administered in Brazil
by the National Institute of Industrial Property
(Instituto Nacional da Propriedade Industrial
- INPI).15 Article 10 of the Law on Industrial
Property excludes from patentability materials
existing in nature: “all or part of natural living
beings and biological materials found in nature,
even if isolated therefrom, including the genome
or germplasm of any natural living being, and
natural biological processes.”16, 17
Plant varieties are protected under Law No.
9.456, adopted in April 1997, and implement
ed by Decree No. 2.366, in November 1997.
They are also protected by the Ordinances of the
Ministry of Agriculture No. 503, in December
1997, and No. 8, in June 1999. Brazil has been a
member of UPOV since May 1999.18
In 2002, Brazil issued 666 patents to resi
dents of Brazil and 1,366 to foreign residents.19
Ownership. For purposes of invention
ownership, researchers at universities and pub
lic research institutes are not considered, under
Brazilian law, to be different from other kinds of
employees. The Law on Industrial Property gives
inventors the right to apply for a patent, but gives
employers the right to ownership of an inven
tion by an employee that is “hired to invent,”
according to the terms of their employment
contract. The law thus differentiates between in
ventions made in the course of employed work,
inventions made separately from employed work
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(free inventions), and inventions that combine
both (mixed inventions). Universities thus need
to establish the type of inventions on a case-by
case basis and can take title to those made in the
course of employed work. According to Article
93 of the Law on Industrial Property and spelled
out in Presidential Decree No. 2.553, of April
1998, inventors who are employees in public in
stitutions are to receive remuneration from the
income created by the patent, as an incentive or
bonus for inventing. The exact share to be dis
tributed is left to institutional policy, but is not
to exceed one-third of the value of the invention.
Terms of IP ownership and revenue sharing are
further spelled out in implementing orders of the
Ministry of Science and Technology, No. 88, of
1998, and the Ministry of Education and Sport
(No. 322 of April 1998).20
Institutional capacities. As early as 1982, un
der the former military regime, a central office for
technological innovation was established at the
National Council for Scientific and Technological
Development to promote innovation at uni
versities and encourage technology transfer to
Brazilian industry. Thereafter, 12 Technological
Innovation Centers were established at Brazilian
universities to protect intellectual property and
facilitate the university–industry interface. Today,
more than 30 universities and research institutes
operate TTOs.21 Among the largest and most ex
perienced are:
• the Agency for Innovation at Unicamp
(Inova Unicamp)22 at the State University
of Campinas (Unicamp)23
• the USP Agency for Innovation (Agência
USP de Inovação)24 at the University of Sao
Paolo
• the Brazilian Agricultural Research
Corporation (Empresa Brasileira de
Pesquisa Agropecuária - EMBRAPA),25
which adopted an institutional IP policy in
1996 and opened its IP Secretariat in 1998
to handle intellectual property and tech
nology transfer26
• the Technology Development Support
Center (Centro de Apoio ao Desenvolvim
ento Tecnológico - CDT), created in 1989
at the University of Brasília, and among the
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earliest university centers for technology
transfer 27, 28
• the Secretariat for Technology Development
(Secretaria de Desenvolvimento Tecnológico
- Sedetec) at the Federal University of Rio
Grande do Sul, formed by merging the op
erations of a TTO and an incubator net
work in 200029
Patenting by Brazilian public sector institu
tions has grown dramatically. In 2003, the top
seven universities plus EMBRAPA received 153
patents in just one year.30 In contrast, over the 15
years between 1980 and 1995, all Brazilian uni
versities and EMBRAPA received just 264 pat
ents combined.31
. Chile

IP protection. IP protection over technological
inventions in Chile is based upon the Industrial
Property Law (No. 19.039) of 1991. A 2005
modification (No. 19.996) brings Chilean law
into line with the minimum requirements in
TRIPS and the IP requirements in the bilateral
free-trade agreements concluded with the United
States and the European Union. Chile has been a
member of the WTO and a signatory to TRIPS
since 1995. However, Chile is not a member of
the PCT. In Chile, patents are administered by
the Department of Industrial Property. 32, 33, 34
Plant varieties are protected in Chile under the
Rights of Breeders of New Varieties of Plants (No
19.342) of April 1997. Chile joined UPOV in
1996.
In 2000, Chile granted 32 patents to resi
dents of Chile and 569 to foreign residents.
Ownership. The Industrial Property Law
(No. 19.039) regulates the ownership of intel
lectual property resulting from work conducted
under contract or employment. A section spe
cifically on universities stipulates that IP rights
derived from the work of university employees
belong to the university or its designee, since
that inventive or creative work is understood to
be part of the job obligation. However, certain
limitations on the assignment of IP ownership
are set by workers’ rights provisions in Chilean
labor law, namely that universities cannot ask

employees to completely waive the portion of IP
rights due to them as inventors. Major Chilean
research funding sources (such as FONDEF and
CONICYT) now require IP protection of results
by those organizations receiving funding, includ
ing universities.35
Institutional capacities. Among leading
Chilean organizations with an organizational ca
pacity for IP management are:
• University of Concepción, with its Center
for Industrial Property (Unidad de
Propriedad Industrial)36
• In 2003, the University of Chile formed
the Central Commission for Industrial
Property (Comisión Central de Propiedad
Industrial)37
• Fundación Chile, which coordinates inno
vation and entrepreneurship projects based
upon Chilean R&D, provides expertise and
resources for IP management38
• NEOS, a consulting company located in
Santiago, provides professional IP services
for universities in Chile39
. China

IP protection. IP law is widely viewed in China
as a western import, with a first patent law adopt
ed relatively recently in 1984 and a copyright law
adopted in 1990. While protection and enforce
ment under these has been of ongoing concern
for outsiders, the internal political climate has
been shaped by the desire to join WTO and the
growing prowess of Chinese companies in science
and technology. It is largely these internal forces
that led to the strengthening of the patent law in
1992 and in 2001.
New plant varieties are protected under
the Regulation on the Protection of New Plant
Varieties, implemented in 1997. China joined
UPOV in 1999.40
In 2004, China granted 18,241 patents to
residents of China and 31,119 patents to foreign
residents.41
Ownership. As early as 1985, just five years
after Bayh-Dole passed in the United States, pro
visional regulations issued by the State Council
on Technology Transfer gave Chinese universi
ties the right to manage and use the inventions
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of university researchers, even though owner
ship formally remained with the State.42 The
government, however, has only recently encour
aged universities to assert such rights. China
adopted its Act for Promotion of Technology
Transfer in 1996, later reinforced by the Decision
on Reinforcing Technological Innovation and
Realizing Industrialization of the State Council
in 1999 and by the Opinion on Exerting the
Role of Universities in Science and Technological
Innovation issued jointly by the Ministry of
Education and the Ministry of Science and
Technology in 2002.43 The latter is often called
the “Chinese Bayh-Dole Act.” In 2003, the
Ministry of Education again clarified the rights
of IP ownership by institutions undertaking re
search sponsored by the government in its Key
Points on Promoting Science and Technology of
Universities.44
Institutional capacities. Internal organiza
tional capacity for IP management is most readily
found at leading universities, such as:
• Tsinghua University, with probably the
most well-developed university TTO in
China45
• Beijing University
The number of patent applications from
across the full range of Chinese universities is
significant. It quadrupled in the four years from
1999 (with 988 applications) to 2002 (with 4,282
applications).46 For comparison, U.S. universities
reported total patent applications increasing less
than two fold between 1999 (with 8,457 appli
cations) and 2002 (with 12,222 applications).47
However, some caution should be taken in inter
preting these figures, since the practice of patent
ing by Chinese academics appears to have been
adopted as something of a proxy for published
research. In fact, inventorship on patents is wide
ly admitted as a criterion for academic promo
tion. Significantly, far fewer Chinese university
patents are being licensed or commercialized.
Still, Tsinghua University reports having spun off
more than 38 companies, generating annual sales
of US$1.8 billion and actively incubating more
than 200 companies at the Tsinghua Science Park
during 2003 alone.48
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. Ethiopia

IP protection. Ethiopia is an example of a coun
try still largely outside of the global IP system.
Ethiopia has a basic patent code, created in 1995
by Proclamation No. 123 Concerning Inventions,
Minor Inventions, and Industrial Designs, and
instituted in 1997 by Regulation No. 12. The
stated purpose is to encourage local innovation
(mostly minor adaptations of existing technolo
gies) and transfer in foreign technologies. The
proclamation precludes the patenting of plants,
animals, and essentially biological processes.49
The country is an observer but not a signatory
to WTO, and is thus not bound to compliance
with TRIPS. Ethiopia protects copyright under
its civil code.50
PVP was introduced in February 2006 by
Proclamation No. 481, Plant Breeder’s Rights.51
In 2000, the Ethiopian Intellectual Property
Office received just seven patent applications
and granted just one, to a foreign resident. In
the same year it granted 19 industrial designs,
12 to residents of Ethiopia and seven to foreign
residents.52
Ownership. There is no national framework
and an apparent lack of clarity or transparency
about the terms and conditions under which
public research institution or individual inventors
might be owners of any IP rights.
Institutional capacities. The largest research
organizations in the life sciences are Addis Ababa
University, Alemaya University, the Ethiopian
Health and Nutrition Research Center, the
Ethiopian Agricultural Research Organization,
the National Veterinary Institute, and the
International Livestock Research Institute (ILRI),
all producing locally or regionally marketable re
search results. Only the Ethiopian Agricultural
Research Organization has an IP unit in forma
tion. The rest have no IP management units, and
their scientists and staff have a very low level of
awareness and knowledge about IP rights. The
Ethiopian Intellectual Property Office has re
ceived only a handful of patent applications from
university researchers in Ethiopia, (primarily in
agriculture, pharmaceuticals, and mechanics)
and only one from the Ethiopian Agricultural
Research Organization.53
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. India

IP protection. India’s history with IP law is deeper
than that of many developing countries. The first
patent law was adopted in 1856, and by 1911
Indian patent law conformed to the standards
of developed countries. Copyright, trade secrecy,
and design laws have been in place equally as long.
However, patent law was relaxed in 1970 under
the import-substitution industrial policy, which
encouraged economic development through the
reverse engineering of western technologies. Since
adopting market-oriented reforms and seeking
WTO membership in the 1990s, reform in IP
law has been rapid. India joined the WTO and
became signatory to TRIPS in 1995. Patent law
was strengthened in 1999 and again in 2002 to
become compliant with TRIPS.54 Legislation that
passed in 2005 reinstated the patenting of phar
maceutical compounds, reversing legislation from
1970 that limited patenting to the processes for
the manufacture of pharmaceuticals.55 Today, an
elite cadre of Indian pharmaceutical companies
has emerged with the capacity to engage in glob
ally competitive R&D, significantly influencing
India’s internal IP policy debate.
Plant varieties are covered by the Protection
of Plant Varieties and Farmers’ Rights Act of
2001.56 India has not joined UPOV.
In 2004, India granted 851 patents to resi
dents of India and 1,466 to foreign residents.57
Ownership. In 2000, the Ministry of Science
and Technology issued a ruling that gave title to
intellectual property to those institutions that
receive funding from the Ministry. While this is
not a legislated policy, it signaled a milestone in
an ongoing trend of shifting technology transfer
activities away from the government to research
institutions. This trend has been underway since
at least 1995.58
Institutional capacities. The bulk of intel
lectual property and technology transfer expertise
in the public sector remains located in govern
ment agencies, particularly in the Council for
Scientific and Industrial Research (CSIR), the
Department of Science and Technology (DST),
and the Department of Biotechnology (DBT).
The Ministry of Science and Technology, the
Indian Council of Medical Research (ICMR),

and the National Research and Development
Council (NRDC) are also involved in technology
transfer activities.59
Most academic intuitions still lack IP man
agement capacity, with the exception of the lead
ing Indian Institutes of Technology (IITs) and a
few other universities. TTOs or centers are now
found at:
• IIT New Delhi
• IIT Bombay
• IIT Kharagpur
• IIT Kanpur
• IIT Guwahati
• IIT Roorkee
• IIT Chennai
• Delhi University
• Govind Ballabh Pant University of
Agriculture & Technology, Pant Nagar
• Bidhan Chandra Krishi Vishwavidyalaya
• Jadavpur University60
Only a small portion of the 277 Indian
universities listed by the Association of Indian
Universities have functioning TTOs.61 In April
2005, a professional association for technol
ogy transfer was launched—the Society for
Technology Management (STEM).62 In April
2006, the Minister of Science and Technology
announced plans to set up an Indian Institute for
Intellectual Property Management.63
. Indonesia

IP protection. Intellectual property is a relatively
new concept in Indonesia. Indonesia signed the
Paris Convention in 1950. It joined WIPO in
1979. Industrial Designs were introduced by Law
No. 5, Concerning Industry, in 1984. Patents
were introduced by Law No. 6, Patent Law, in
1989 and amended by Law No. 13 in 1997.
Indonesia has been a member of WTO and a sig
natory to TRIPS since 1995.64, 65
In Indonesia, a plant variety can be protected
by a patent if it fulfils the basic requirements for
patentability. In addition, in 2001 the Indonesian
parliament passed a Plant Variety Protection Act,
based on the UPOV 1991 standards, to estab
lish a PVP system.66 Indonesia has, however, not
joined UPOV.
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In 1996, Indonesia granted 16 patents to
residents of Indonesia and 615 to foreign resi
dents.67 In 2003, however, Indonesia granted
2,902 patents, including both residents and
nonresidents.68
Ownership. The 2002 Law No. 18, titled
National Systems for Research, Development,
and Application of Technology, stipulates that
institutions and universities in Indonesia should
establish units for IP management and that they
may use the income derived from the exploitation
of intellectual property.69
Institutional capacities. There are now, at
least nominally, over 90 IP management units at
institutes and universities throughout Indonesia.
Leading centers of public sector IP management
include:
• more than 30 research institutes of the
Agency for Agricultural Research and
Development (AARD) have their technol
ogy transfer needs handled by Kekayaan
Intellectual dan Alich Teknologi (KIAT),
established in 1999
• Indonesian Institute of Science (LIPI)
• University of Indonesia
• Bandung Institute of Technology
• Bogor Agricultural University (IPB)70
. Jordan

IP protection. Jordan joined the WTO in 1999,
as the 136th member of the WTO. It became a
member and signatory to TRIPS in April 2000.
The Patents of Invention Law No. 32 was adopted
in 1999. In 2001, Jordan signed the U.S.-Jordan
Free Trade Agreement, which led to further
IP reforms. Patents are issued by the Industrial
Property Protection Directorate (IPPD) of the
Ministry of Industry and Trade.71, 72, 73
Plant varieties are protected under the Plant
Varieties Law No. 24 of 2000. Jordan acceded to
UPOV in October 2004.
In 2004, Jordan granted four patents to
residents of Jordan and 56 patents to foreign
residents.
Ownership. Jordanian law is flexible in its
approach to commercializing technology devel
oped in public sector institutions. Currently, a
high-level comprehensive review is underway
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of all relevant legislation and supporting regu
lations to outline areas that could be improved
by an explicit act promoting commercialization.
This legal and regulatory review will lead to spe
cific improvements in their technology transfer
infrastructure.74
Institutional capacities. Few universities or
research organizations have had time to adapt
to the new IP legislation, and thus far only the
Royal Scientific Society, the premier government
research institution, reports having established its
Technology Transfer Centre.75
. Kenya

IP protection. The application of IP regimes is
not deeply rooted in the history of Kenya or in
other countries of eastern Africa, and the coun
try has typically responded to colonial influ
ence or international developments. Kenya first
introduced its Patent Registration Ordinance
in 1914, which was modeled and dependent
upon the British system. However, the Industrial
Property Act of 1989 established the first inde
pendent patent system in Kenya. Kenya joined
the WTO and became signatory to TRIPS
in 1995. The 1989 Act was superseded by the
Industrial Property Act of 2001, which set up the
Kenya Industrial Property Institute (KIPI)76 as an
autonomous office to administer patents, utility
models, trademarks, and service marks. Section
26 of the Industrial Property Act includes stan
dard TRIPS exemptions from patentability:
methods for treatment of human or animal,
diagnostic methods, any drugs or compounds
necessary to combat threats to public health, and
plant varieties.77
PVP was established in 1972 by the Seeds
and Plant Varieties Act and implemented un
der the Seeds and Plant Varieties Regulations of
1994. Kenya acceded to UPOV in 1999 under
the terms of the 1978 Act. PVP is administered
by the Kenya Plant Health Inspectorate Service
(KEPHIS), under the Ministry of Agriculture
and Rural Development.78
In 2001, Kenya granted no patents to resi
dents of Kenya and 33 patents to foreign resi
dents. That year just two applications were re
ceived from residents of Kenya.79

CHAPTER .

Ownership. A national policy for IP owner
ship, beyond that stipulated in the employment
and inventorship clauses of the Industrial Property
Act, is largely irrelevant because public sector re
search institutions make up most of the R&D in
frastructure in Kenya. Many were founded with a
mandate for conducting innovation and product
development, since R&D is almost nonexistent
in the private sector. Thus, public institutions are
neither prohibited nor mandated to take owner
ship; they are left to themselves to adopt institu
tional policies and capacities to assert ownership,
as long as the institutions operate according to
the basic requirements of national IP law.
Institutional capacities. The development of
institutional IP management capacity has been
motivated partly by reports that the University of
Nairobi, the premier university in Kenya, has had
to forego IP rights for some innovations due to a
lack of clear policy and structures. These innova
tions included a fermented milk product, a beer
product, a disease-resistant pea variety, a pesticide
compound, a database of medicinal plants, and a
potential AIDS vaccine.80 The following research
institutions are currently engaged in developing
IP policies and creating IP offices:
• University of Nairobi has recently adopted
an IP policy that establishes an internal
TTO.81
• Moi University has established Moi
University Holdings Ltd., a fully owned
subsidiary with a TTO to manage the uni
versity’s intellectual property.82
• Jomo Kenyatta University of Agriculture
and Technology (JKUAT) has drafted an
IP policy and employs one IP manager.
• At Kenya Agricultural Research Institute
(KARI) a legal officer manages intellectual
property.
• The International Livestock Research
Institute (ILRI) adopted an IP policy in
1998 and has an IP office at its Nairobi
center.83, 84, 85
.10

Malaysia

IP protection. Malaysia instituted a range of IP
laws in the 1980s, including the Patents Act of
1983 (Act No. 291). The Patents Act has been

amended several times, both before and after
Malaysia joined the WTO and signed TRIPS in
1995. The Patents Act excludes from patentabil
ity the same life-science subject matter excluded
in TRIPS, including plant and animal varieties,
essentially biological processes, and methods of
medical diagnosis and treatment. Since the 1983
Act, Malaysia has allowed product patents on
pharmaceutical and agricultural chemical com
pounds. The Intellectual Property Corporation of
Malaysia Act of 2002 (Act No. 617) established
the Intellectual Property Corporation of Malaysia
as the new patent office. Malaysia joined the PCT
in August 2006.86
The Protection of New Plant Varieties Act
of 2004 (Act No. 634) is largely compliant with
UPOV, even though Malaysia has not yet joined
UPOV.87
In 2003, Malaysia granted 31 patents to resi
dents of Malaysia and 1,542 patents to foreign
residents.88
Ownership. Under the Patent Act of 1983,
employers, including publicly funded research in
stitutions, are the rightful owners of intellectual
property created by employees in the course of
employment. However, there have been recent
ministerial examinations of IP ownership issues
in cases where government funding is involved.
In 2003, the government announced the Second
National Science and Technology Policy, which
included the following clauses:
• “to promote adoption of sound research man
agement practices including intellectual prop
erty management and commercialisation of
research outputs in all PRls [public research
institutes] and universities.”
• “to enhance the management of intellectual
property rights including patent advisory and
other services.”
• “to review existing legislation or to develop
new legislation related to policy.”89
In 2004, Malaysia’s Ministry of Science,
Technology, and Innovation (MOSTI), at the
prompting of the prime minister, began a review of
incentive systems to attract and retain Malaysian
scientists, including the availability of R&D fa
cilities, financial assistance, and venture capital.90
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The Ministry also considered IP policy options
similar to those in the United States under the
Bayh-Dole Act.91 The government then indicated
that it would instead pursue a policy of three-way
IP rights sharing: the government, research insti
tute, and inventor would all jointly own research
results.92 In a March 2006 announcement, the
head of MOSTI announced, “research work un
dertaken with government grants should be jointly
owned by the Government, the respective university,
as well as the scientists involved.”93
Institutional capacities. Most universities
and institutes established their internal IP policies
under the Patent Act of 1983, asserting institu
tional ownership of inventions made by employ
ees and managing them accordingly. Currently,
17 out of the 45 or so universities in Malaysia
have established TTOs.94 IP management offices
found at leading universities and research insti
tutes include:
• University of Malaya’s Technology Transfer
and Commercialization Unit (UPTK)
was founded in 1998 as part of the uni
versity administration, but in 2001 it was
transferred to the university’s Institute of
Research Management and Consultancy
(IPPP), which handles the full range of re
search interactions with industry.
• At Universiti Sains Malaysia (USM), the
Research Creativity and Management
Office (RCMO) handles many issues re
lated to R&D relations with industry, in
cluding IP marketing.95 Some aspects of
patenting and commercialization are also
handled by the Corporate and Sustainable
Development Division (BPLK).96
• Univeristi Teknologi Malaysia (UTM) is the
premier engineering institute in Malaysia.
In 1993, the university created a Bureau of
Innovation and Consultancy to promote
technology commercialization within its
Research and Consultancy Unit, which has
managed research relations with industry
since 1981.97
• Universiti Malaysia Sarawak (UNIMAS)
has recently established the new Intellectual
Property and Commercialization Unit
(IPMCU) within the university’s Research
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and Innovation Management Centre
(RIMC), which was formed in 2005 out
of the previous Research Management
Unit established in 2003.98 Some IP com
mercialization services are also offered by
the Centre for Technology Transfer and
Consultancy (CTTC), formed in 1993 to
facilitate collaboration between university
experts and local industry.99
• The Malaysian Palm Oil Board (MPOB) has
been one of the most successful organizations
in the country in using intellectual property
to commercialize technology.100 MPOB of
fers an extensive list of technologies available
for transfer and commercialization, with
licensing managed by the Licensing and
Enforcement Division.101, 102, 103
• The Malaysian Agriculture Research and
Development Institute (MARDI) has a siz
able technology transfer and commercializa
tion unit and list of technologies available
for transfer and commercialization.104, 105
.11

Mexico

IP protection. Mexican patent law has been
in place since the early 1800s. Today, intellec
tual property protection is governed under the
Industrial Property Law, adopted in 1994 and
amended in 1997 and 1999.106 Mexico joined
the WTO and signed TRIPS in 1995. Mexico’s
Industrial Property Law excludes from patentability any essential biological process for the pro
duction, reproduction, and propagation of plants
and animals; biological and genetic materials as
found in nature; animal species; the human body
and its living components; and plant varieties.107
Patents are administered by the Mexican Institute
for Industrial Property (Instituto Mexicano de la
Propriedad Industrial).108
Mexico protects plant varieties through the
1997 Federal Law on Plant Varieties (Ley Federal
de Variedades Vegetales), under regulations imple
mented in 2000 by the Ministry of Agriculture.
Mexico joined UPOV in 1997, but joined under
the terms of the 1978 Act.109
In 2004, Mexico granted 162 patents to
residents of Mexico and 6,677 patents to foreign
residents.110
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Ownership. In Mexico, Article 163 of the
Federal Labor Law (Ley Federal del Trabajo),
adopted in 1970 and reformed in 1998, gov
erns the ownership of inventions made by
employees.111 The law indicates that results of
research are owned by the employer, who has
the right to exploit patents. The employee,
however, is to be given additional compensa
tion, and in some cases the right of ownership.
In all cases, the employee’s name is listed as in
ventor. The Industrial Property Law, Article 14,
reflects these protections of the employee. The
2002 Law of the National Council of Science
and Technology (Ley de Ciencia y Tecnología),
Articles 47–59, discusses invention ownership
in cases where the national science council
(CONACYT) finances research and develop
ment in universities or any other nongovern
mental organizations and in the 60 or so public
research institutes and agricultural R&D centers
in Mexico. In both cases, the ownership of the
results is determined according to the policies
of the organization where the research is car
ried out. Many organizations, like universities
and large companies, have policies that indicate
that the ownership of research results goes to
the institution, but in most cases the inventor
will get some share of the financial benefits.
Usually in the case of universities, the research
ers are named as the inventors on the patent but
sign full ownership rights over to the university.
Within universities, the distribution of benefits
follows the terms of an internal agreement or
institutional policies.112
Institutional capacities. Development of
institutional IP policies and discrete offices of
IP management is minimal, but includes the
following:
• At the National Autonomous University of
Mexico (UNAM), the General Counsel’s
Office oversees IP policy and management.
However, according to a critique in Nature
Biotechnology, “there is no support, even at
the university level, for patenting: the level of
technology transfer is low… UNAM has nei
ther sufficiently trained personnel, nor, appar
ently, the interest to fight for its share on the
patents.”113

• Instituto Tecnológico de Estudios
Superiores de Monterrey (ITESM) has en
gaged in several projects involving technol
ogy transfer in aerospace and expert systems
engineering
• CINVESTAV is engaged in a number of
biotechnology projects and has mediated
transfers of proprietary biotechnologies.
.12

Philippines

IP protection. IP protection has a somewhat
deeper history in the Philippines than in some of
its neighboring Asian countries. After achieving
independence from the United States in 1946 at
the end of World War II, the Philippines provid
ed for the protection of inventions, utility mod
els, and industrial designs under the Republic Act
(No. 165) of 1947. Borrowing heavily from U.S.
patent law, it provided 17 years of protection from
the date the patent is granted and recognized pri
ority based on “first to invent.” The Philippines
joined the WTO at its founding in 1995 and be
came a signatory to TRIPS. IP law was brought
into compliance with TRIPS provisions in 1998
with Republic Act (No. 8293), the Intellectual
Property Code of the Philippines. This changed
patent terms to 20 years from date of filing and
recognized priority based on first to file. The Act
also created the Intellectual Property Office of
the Philippines. In accordance with TRIPS pro
visions, the Act treats as non-patentable plants,
animals, and essentially biological processes for
the production of plants and animals.114
Republic Act (No. 9168) of 2002, titled Act
to Provide Protection to New Plant Varieties,
provides for sui generis protection of plant vari
eties and established the National Plant Variety
Protection Board. The Philippines is not a mem
ber of UPOV.115
In 2003, the Intellectual Property Office
of the Philippines granted 11 patents to resi
dents of the Philippines and 1,160 patents to
nonresidents.116
Ownership. The Philippines has no enabling
legislation to give ownership of inventions to uni
versities or research institutes, effectively leaving
them free to develop their own institutional IP
ownership policies.
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Institutional capacities. Policies and offices
for IP management are being developed both
centrally and at leading research institutions:
• The Department of Science and Technology
(DOST) has developed IP guidelines and
the Technology Application and Promotion
Institute (TAPI) to provide centralized
services in technology transfer for pubic
institutions.117
• A central University Intellectual Property
Office (UIPO) for the University of the
Philippines was established in 1997 to co
ordinate offices at its six semiautonomous
campuses.118, 119
• IP and technology transfer needs of faculty
at the University of the Philippines, Diliman
campus, is served by an intellectual property
section within the Research Dissemination
and Utilization Office (RDUO) of the
Office of the Vice Chancellor for Research
and Development.
• The University of the Philippines, Manila,
the main medical research university, has
an intellectual property rights office in the
Office of the Vice Chancellor for Research.
• The University of the Philippines, Los
Baños, has an intellectual property rights
office in the Office of the Vice Chancellor
for Research and Extension.
• The Philippine Rice Research Institute
(PhilRice) of the Department of Agriculture
created a TTO in 2004.
• The International Rice Research Institute
(IRRI) adopted an IP policy in 1994 that
specifies that IP protection will only be
used selectively to serve the needs of farm
ers in developing countries. IRRI coordi
nates intellectual property for some biotech
projects for other institutions with which it
partners.
Thus far, only a few dozen patents have issued
to public sector institutions in the Philippines.120
.1

Poland

IP protection. Poland’s IP system is relatively
mature, with the Polish Patent Office formed in
1918. However, the intervening years of socialist
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government had some effects, with Poland join
ing the PCT only in 1990. Poland became a sig
natory to TRIPS along with WTO membership
in 1995. The Industrial Property Law of 2000
(in force since August 2001) brought Polish pat
ents and trademark law into compliance with
TRIPS, and its amendment in 2002 brought
Polish law into harmony with E.U. directives on
biotechnology intellectual property, including
patentability of biological materials, methods,
and uses.121
The Law on Seed Industry of 1995 conforms
to UPOV, of which Poland has been a member
since 1989.122
In 2004, Poland granted 778 patents
to residents of Poland and 1,016 to foreign
residents.123
Ownership. The Industrial Property Law,
Article 11(3) stipulates that an employer or a
contractor is the rightful owner of an invention
produced under work for hire or contract, unless
otherwise agreed upon by the parties involved.
This gives universities flexibility to arrange for
ownership through terms of employment and
research agreements.124 In recent years the Polish
government has been shifting R&D spending
away from relatively inefficient industry research
institutes and state-owned companies and toward
universities.125 This shift in funding, however, has
not been accompanied by any new policy specifi
cally affirming or denying institutional ownership
of IP rights resulting from research conducted
with state funds.
Institutional capacities. In practice, univer
sities own the intellectual property resulting from
research they conduct.126 IP management offices
in Poland are still developing and are found most
ly at the leading universities, including:
• The Wroclaw Center for Technology
Transfer (WCTT) formed in 1995 at the
University of Wroclaw.127
• The Technology Transfer Center (Centrum
Transferu Technologii - CTT) formed
in 1997 at the Cracow University of
Technology.
• The Centre of Innovation, Technology
Transfer, and University Development
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(CITTRU), formed in 2003 at Jagiellonian
University.128
• The Technology Accelerator and the Inno
vation Center at the University of Lodz129
formed in 2003 through a mentoring col
laboration involving technology commer
cialization and entrepreneurship established
between the University of Texas at Austin
and the University of Lodz. This was an
offset commitment under an agreement be
tween Lockheed Martin and the Polish Gov
ernment for the purchase of F-16 fighters.
• Poland has four regional Innovation Relay
Centres (IRCs) hosted at university tech
nology centers, such as the IRC South
Poland, which is coordinated by the CTT
at Cracow University of Technology.130
The IRC Network was established by the
European Commission in 1995 and now
consists of 71 regional centers through
out Europe. It seeks to support innovation
and transnational technology cooperation
through coordinated activities and a com
mon technology database.
.1

Russia

IP protection. Russia has a history of intellectual
property that dates to the time of the czars. The
first patent law was adopted in 1812, and then re
formed in 1896.131 During the Soviet period, the
State effectively exercised monopoly power over
all technological innovations, including those
arising from universities and research institutes,
with a Committee on Inventions and Discoveries
issuing authorship certificates to inventors.132
In 1991, the U.S.S.R. Law on Inventions radi
cally departed from the Soviet system, creating
a form of patent protection that gave exclusive
rights of ownership to inventors. In 1992, follow
ing the establishment of the Russian Federation,
a range of IP legislation was adopted, including
the Patent Law of 1992. The Committee for
Patents and Trademarks was created, and in 1996
it was changed to the current Federal Service for
Intellectual Property, Patents, and Trademarks
or ROSPATENT.133 In 2003, the Patent Law
was amended to bring it into alignment with the
provisions of TRIPS.134 As of 2006, the Russian

Federation is still only an observer to the WTO
and is thus not bound to compliance with
TRIPS.
The Russian Federation provides for PVP
under the Law on Protection of Achievements in
Plant Breeding, adopted in 1992 when the range
of new IP legislation was introduced. In 1998,
Russia became a member of UPOV under the
terms of the 1991 Act.135
In 2005, Russia issued 19,447 patents to resi
dents of Russia and 3,943 to foreign residents.136
Ownership. Attempts were first made to
clarify the question of ownership by public re
search organizations in 1998 with the Decree of
the President No. 863 “On state policy for the in
troduction of the results of scientific and technolog
ical activity and objects of intellectual property into
economic turnover,” and implemented in 1999 by
Resolution No. 982 “On the use of the results of
scientific and technological activity.”137, 138 While
stating in principle that a research organization
might take IP rights over inventions made un
der work funded by the federal budget, in effect,
the policies gave the Russian government first
right to any intellectual property by giving the
government rights to any military, dual-use, or
other technologies deemed “of use to the State,”
and by requiring all inventions made under
federal funding to be recorded with the federal
government. These conditions meant that very
few publicly funded inventions were reported
and that few patents were sought through offi
cial channels.139 A fundamental shift in the gov
ernment’s position, which provided clarity over
the rights of the organization conducting the re
search, only came about in the 2003 revision of
the Patent Law. Article 9 states that the right to
patent an invention created under state funding
belongs to the contracted research organization,
unless the research agreement specifies that the
right belongs to the government.140
Institutional capacities. Despite the State
centralization and lack of formal IP rights un
der the Soviet system, some attention was paid
to developing mechanisms for the administrative
management of technology transfer at the institu
tional level. While technology transfers were free
of charge, they did occur between public research
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organizations and state companies in the Soviet
Union and in other Soviet bloc nations.
As a result, a significant number of univer
sities and research institutes today have well-de
veloped technology transfer policies and offices
in place. In addition, a number of private, thirdparty companies and centers have emerged to
coordinate technology transfer services for mul
tiple clients, including universities, institutes, and
companies, within particular regions or particular
fields of technology. Leading examples include:
• the intellectual property and technology
transfer department of the St. Petersburg
State University, founded in 1967 as the
Patent and Licensing Department (PLD)
of the university141
• the Puschino Center for Technology Transfer
of the Puschino Scientific Center142
• the Innovation and Technology Center of
the University of Nizhny Novgorod143
• the Patent Service Center of the Saratov
State University144
• the Obninsk Center for Science and
Technology, which manages technology
transfer and business development proj
ects for the Institute of Physics and Power
Engineering (IPPE), as well as for R&D
centers in the Russian Ministry of Atomic
Energy and the Russian Ministry of Science
and Technology. 145
• the Urals Regional Technology Transfer
Center 146
• the Southern Center for Technology
Transfer 147
In 2005, a professional association for tech
nology transfer was launched in Russia and oth
er former Soviet republics, called the Eurasian
Association of Technological Transfer Managers
(EATTM).148
.1

South Africa

IP protection. IP law in South Africa historically
derives from U.K. law. South Africa’s first Patents
Act (No. 37) of 1952 was modeled on the British
Patents Act of 1949.149 It was superseded by the
Patents Act No. 57 of 1978, which is in force
today, though amended at least eight times.150
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South Africa signed the TRIPS agreement in
1995. Patent Amendment Act No. 58 of 2002
was largely responsible for bringing the provi
sions of the Patents Act into line with TRIPS re
quirements. The Act excludes from patentability
“any variety of animal or plant or any essentially
biological process for the production of animals
or plants.”151 Patents in South Africa are adminis
tered by the Companies and Intellectual Property
Registration Office (CIPRO).152
Plant varieties are protected in South Africa
under the Plant Breeder’s Rights Act No. 15 of
1976. South Africa became a member of UPOV
in 1977 and still adheres to the 1978 Act.
In 1995, the last year in which data was re
ported to WIPO, 5,549 patent applications were
received from residents of South Africa, and
5,501 patent applications were received from for
eign residents.153
Ownership. The patent law of South Africa
contains IP ownership terms typical of many
countries, but it does not detail public sector
employers’ rights of ownership or provide terms
for publicly funded research.154 However, a na
tional policy for the ownership of patent rights
by public research organizations is currently in
development.155 In the absence of such policies,
the question of ownership has historically been
shaped by institutional IP policies. But these are
not uniform across or within institutions. While
most universities prefer to take ownership of in
tellectual property whenever possible, a relatively
high level of their research funding (about 58%)
comes from industry contracts, which typically
stipulate industry control of IP rights resulting
from the funded project.156 As a result, most uni
versities maintain flexible policies and relinquish
ownership of intellectual property as needed to
obtain industry research funding.157
The National R&D Strategy of 2002 con
tained language recommending improved protec
tion and commercialization of intellectual prop
erty from public research.158
In 2006, draft legislation embodying these
recommendations was proposed: the Framework
for Intellectual Property Rights from Publicly
Financed Research. The Framework is largely
modeled on the U.S. Bayh-Dole Act. It seeks to
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unify IP policies across different government
agencies that fund R&D and gives primary
rights and responsibilities over intellectual prop
erty to the funded research organization. The
draft legislation also retains certain privileges for
the government to use protected technologies
and gives preference for licensing to domestic
companies.159
Institutional capacities. In order to sup
port their important funding relationships with
industry, a cadre of elite research universities in
South Africa has developed significant IP policies
and internal capacities for IP management. These
include:160
• University of Stellenbosch has a technology
transfer officer in the Office of Research
and has established Unistel, a wholly
owned subsidiary, to commercialize re
search through start-up companies.
• University of Cape Town (UCT) has a welldeveloped IP policy and an office called
UCT Innovation with a staff that handles a
range of activities, including management
of research contracts, protection of intellec
tual property, and technology commercial
ization and entrepreneurship.
• University of Pretoria and the Council for
Scientific and Industrial Research (CSIR),
the national research agency, have col
laborated to form a private company, the
Southern Educational Regional Alliance
(SERA) Ltd., to handle licensing and com
mercialization for both institutions.
• The South African Medical Research
Council has a technology commercial
ization unit called the MRC Innovation
Centre.161
With the pending advent of the Framework,
the government has also proposed a centralized
office, the Innovation Fund Commercialization
Office (IFCO), to assist public institutions with
IP management and to help cover some of the
costs associated with IP protection.162
In 2002 a regional association for technol
ogy transfer professionals was launched, called
the Southern African Research and Innovation
Managers (SARIMA).163

.1 Tanzania

IP protection. Like other east African coun
tries, Tanzania inherited a colonial IP system
from the U.K., including the Patent Registration
Ordinance 217 of 1931. The patent ordinance
was superseded by the Patent Act No. 1, adopted
in 1987 and implemented in 1994. Tanzania
joined the WTO and became signatory to
TRIPS in 1995, but under the terms for devel
oping countries it had until 2006 to become
fully compliant with its provisions. In 1997,
under the Government Executive Agencies Act
No. 30, the Business Registrations and Licensing
Agency (BRELA) was established to administer
industrial property. Tanzania has been a mem
ber of the African Regional Industrial Property
Organization (ARIPO) since 1983.164, 165
Tanzania is not a member of UPOV, but in
compliance with its obligations under TRIPS,
it adopted the Plant Breeder’s Right Act No.
22 in 2002 to provide protection for new plant
varieties.166
In 1989, the last year for which data were
reported, Tanzania granted 23 patents, all to for
eign residents.167
Ownership. Similar to other African nations,
the Patent Act serves as the policy for IP owner
ship. Public sector research institutions make up
most of the R&D infrastructure in Tanzania; pri
vate sector R&D is almost nonexistent. The pub
lic institutions are neither specifically prohibited
nor mandated by law to take ownership, but are
left to adopt institutional policies and capacities
to assert any ownership under the terms of na
tional IP law.
Institutional capacities. Several of the lead
ing universities and research institutes have taken
the first steps to establish institutional IP policies
and are just beginning to set up IP management
offices:168
• Sokoine University of Agriculture, the first
institution in Tanzania to develop an insti
tutional IP policy, adopted in December
2003
• Dar es Salaam Institute of Technology
• Tanzania Industry Research and Develop
ment Organization
• Tropical Pesticides Research Institute
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.1 Uganda

IP protection. After independence in 1962,
Uganda maintained a patent system inherited
from the U.K. until the Patents Statue No. 10
was adopted in 1991. Subsequently, the Patents
Act, Chapter 216 was passed and regulations
were implemented in 1993. Section 3 created
the Office of the Registrar of Patents and a pat
ent registry office to administer the granting of
patents. Uganda was a founding member of the
WTO and became signatory to TRIPS in 1995.
The Patents Amendment Act No. 7 of 2002
brought Uganda into the PCT mechanism, but
Uganda is still developing legislation to bring
patent law into full compliance with TRIPS.
Uganda has been a member of the African
Regional Industrial Property Organization
(ARIPO) since 1978.169, 170
Although not a member of UPOV, Uganda
is a member of the Organization of African Unity
(OAU), which has advocated a separate set of
standards for PVP in African countries. Uganda
passed the Agricultural Seeds and Plants Act in
1994 to provide for the registration of new plant
varieties.
In 2001, Uganda granted no patents to resi
dents of Uganda and 34 patents to foreign resi
dents. That year only two patent applications
were received from residents of Uganda.171
Ownership. No specific requirements, con
straints, or distinctions are made in Ugandan law
regarding the ownership of intellectual property
by public sector research institutions or owner
ship of intellectual property from work funded by
the Ugandan government. As such, universities
and research institutes are left to adopt institu
tional policies and capacities to assert IP owner
ship under the terms of national IP law.
Institutional capacities. IP management
in Ugandan institutions is, at best, embryonic,
with the following developments reported for the
country’s leading research institutions:172
• The Uganda National Council for Science
and Technology (UNCST) has plans to de
velop an IP management policy and office
that could serve as a central advisor on IP
management issues for R&D institutions
that lack such capacity.
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• The Ugandan Industrial Research Institute,
which is very active in collaborating with
local industry, has a single liaison officer in
charge of IP issues.
• Makerere University, the oldest and largest
university in Uganda, has no IP manage
ment policy or office.
.1 Vietnam

IP protection. Chapter II of Part Six of the
Civil Code of 1995, on intellectual property
and technology transfer, covers industrial prop
erty and was the first legislation to introduce IP
protections and include basic TRIPS provisions.
Decree No. 63/CP of the Government, pro
mulgated in October 1996, contained detailed
regulations concerning Industrial Property.173
Enacted in November 2005 and entered into
force in July 2006, the new Intellectual Property
Law has introduced comprehensive TRIPScompliant IP standards, with the decrees and
circulars needed to implement this law likely
to be out by the end of 2006.174 Vietnam en
tered into a bilateral free trade agreement with
the United States in 2004, which obliges it to
protect U.S. intellectual property. Vietnam also
joined the WTO in December 2006, bringing
with it the formal commitment to comply with
TRIPS obligations.
Vietnam introduced PVP in 1995. However,
only the new Ordinance on Plant Varieties of
March 2004 made it a workable system. PVP
is also included in the new Intellectual Property
Law of 2006. Vietnam’s membership in UPOV is
slated for late 2006.175
In 2005, Vietnam issued 17 patents to resi
dents of Vietnam and 756 to foreign residents.176
So far, only about 14 instances of PVP have been
granted in Vietnam, almost all going to foreign
entities. There are currently 18 new applications
for PVP, with some coming from domestic com
panies and universities.177
Ownership. In general, property rights are
still weak in Vietnam. There are few mecha
nisms in Vietnam to clarify and ensure the
rights of ownership over technology created at
universities and research institutes.178 The situ
ation is further complicated because, despite
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increasing autonomy, universities are still in
many respects regarded as part of the State ap
paratus.179 Industry is also still in the process of
being privatized, and in most cases the State still
holds a large minority stake in, if not outright
control of, private companies.
Institutional capacities. Currently, univer
sity researchers and administrators in Vietnam
do not have much understanding of intellectual
property. Their organizations largely lack IP man
agement capacity, although some are beginning
to seek patents and plant variety protections.
Leading research institutions in the life sciences
are beginning to orient toward intellectual prop
erty as a tool for technology transfer. These insti
tutions include:
• The Institute for Biotechnology of
the Vietnam Academy of Science and
Technology, which does not yet have a
formally adopted IP policy, has registered
about 20 patents. Inventions and royalty
distributions are decided on a case-by-case
basis.
• Hanoi Agricultural University’s Science
Management Office has handled IP is
sues for its researchers. Estimates are that
university faculty members have registered
three or four patents and six to seven trade
marks, largely on new crop varieties.180
• The Institute of Agricultural Genetics of
the Ministry of Agriculture and Rural
Development states that technology trans
fer is an important goal of new research
projects, particularly technology transfer to
farmers, but it has not registered intellec
tual property over any inventions.
• The University of Technology of Hanoi: In
the last five years, 20 of the leading techni
cal and agricultural universities in Vietnam
have signed 13,000 contracts worth VND
1,188 billion (approximately US$74 mil
lion). From 2000 to 2004, 22 Technology
and Equipment Fairs, called Techmarts,
were held in Vietnam, through which uni
versities and research institutes sold more
than 2,000 technology contracts worth
up to VND 4,000 billion (approximately
US$250 million).181

. TREndS And ConCLuSIonS
The 18 countries examined above provide a rep
resentative cross-sampling of emerging and devel
oping economies. They represent an enormously
broad cultural, social, and economic landscape.
Still, trends are discernable in the three areas
reviewed: the availability of IP protections, the
ownership of intellectual property over publicly
funded research, and the institutional exercise of
IP rights.
.1 Trends in IP protection

Trends in the availability of IP rights follow sev
eral fundamental determinants. The first is the
domestic science and technology capacity in the
public and private sector and the level of eco
nomic development, both of which serve to drive
the formation of IP policies and the use of the
IP system by residents. A second and somewhat
correlated determinant is the history of IP laws
within the country; this factor is more difficult to
measure than the first. Some countries have had
systems in place for over a century, particularly
in Europe (Russia and Poland) and those that
were major European, and particularly British,
colonies (India and South Africa). This leaves a
legacy of IP practices, even if IP rights have not
been extensively used or enforced. Third, nation
al agreements, in particular TRIPS and UPOV,
have driven IP legislation in virtually every coun
try reviewed.
Roughly three tiers emerge when gauging
the robustness of domestic IP systems (Table 1).
The first tier consists of a handful of countries
that have functioning IP policies and institu
tions, along with substantial numbers of domes
tic patent applications. These countries include
the most-advanced innovators among emerging
and developing economies, such as Brazil, China,
India, and Russia.
These countries all generate something in the
range of 3,000 to 30,000 science and engineer
ing articles per year. Their national patent offices
grant 1,000 to 30,000 patents per year. Crucially,
residents account for at least 50% of patent re
cipients, signifying a significant level of domes
tic innovation that is generated by national IP
systems.
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The second tier contains the bulk of middleincome countries that have recently developed
or improved their IP policies but that still grant
most of their patents to foreigners. These include
countries like Argentina, Indonesia, Malaysia, and
Mexico. These countries have some research capac
ity, evidenced by the generation of 300 to 3,000
science and engineering articles per year. Their na
tional patent offices are functioning, granting sev
eral hundred to several thousand patents per year.
Crucially, however, domestic inventors are receiv
ing less than 10% as many patents as foreigner ap
plicants. Thus, the patent system is primarily being
used to protect imported technologies. Still, com
panies and governments are typically seeking ways
to better exploit the IP system’s R&D efforts.
The third tier consists of the lowest-income
countries, in which there is neither a strong IP
system in place nor a great number of domes
tic patents applicants. These include countries
like Ethiopia, Kenya, Tanzania, and Uganda. In
this survey, all of the representatives of the third
group are in Sub-Saharan Africa. These countries
have little research or technological capacity, gen
erating less than 300, and on average less than
100, science and engineering articles per year.
Their national patent offices are not very active,
granting less than 50 patents per year. Most sig
nificantly, no patents are granted to domestic in
ventors, only to foreigners.
.2 Trends in IP ownership policies

On the question of ownership over inventions
developed from government-funded research,
policies appear to be converging on the practice
of giving the rights and responsibilities of own
ership to research institutions, with some flex
ibility for exceptions depending on the national
context. This convergence typically stems from
strengthening IP protections and/or increasing
government spending on R&D, but it also grows
out of an awareness of global policy trends and a
desire on the part of governments to enhance the
impact that their spending on R&D will have on
economic development.
The mechanisms through which policies on
ownership of intellectual property arise are more
diverse (Table 2). These include:

•
•
•
•

ownership clauses in patent law
ownership clauses in labor law
national R&D system laws
ministerial rulings

In several countries (Jordan, Malaysia, South
Africa) new policies are currently under review or
exist in draft form. In a number of other coun
tries, no explicit policy addresses IP ownership
by universities or research institutes under public
funding. In these cases, ownership questions are
typically covered by the general ownership clauses
of patent law, without specific reference to uni
versities or research institutes, publicly funded
R&D, or technology transfer.
. Trends in institutional IP management

The more than 80 specific institutions named in
this survey have all to some degree developed an
IP policy and management infrastructure. They
cover many of the leading research universities
and institutes in the countries surveyed. Many
more IP management programs, in hundreds of
other emerging and developing countries, could
not be mentioned here. Still, the range of strength
and sophistication in this representative sample is
vast. Some operations efficiently review hundreds
of technology disclosures and file dozens of pat
ent applications a year; in others, IP policy is in
draft form and no action has been taken to imple
ment an IP management system.
If anything, strong, sophisticated institu
tional IP management is most strongly correlated
with the underlying determinants of scientific
and technological capacity, including, most im
portantly, the amount spent annually on R&D at
universities and in the public sector. Institutional
IP management is more weakly correlated with
the adoption of national-level policies explic
itly encouraging IP ownership by public sector
research institutions. In a number of cases, the
practice of IP management has preceded policy
changes governing IP ownership.
. Conclusions

While the call for policy reforms modeled on
the U.S. Bayh-Dole Act has been made around
the world, the particular policy reforms and
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proposals exhibited in developing and emerging
economies have varied. In some, the Bayh-Dole
model is clearly discernible, but in many others
the approaches to reform are more specifically
adapted to local legal, political, and economic sit
uations. Some national policies, such as those of
China or those emerging in South Africa, clearly
attempt to institute stronger IP protections in the
economy and to emulate Bayh-Dole in the public
sector. But many others merely make perfunctory
efforts at conforming to TRIPS and only borrow
the basic idea of encouraging institutional owner
ship of IP. Some national policies set institutional
ownership and management of IP as the default
option among several possible modes of technol
ogy commercialization. Others provide it as one
alternative among multiple options, without a
clearly defined preference. This survey noted one
general trend: that strong IP protections and the
institutional capacity to manage them grow in
tandem, driven primarily by the amount of R&D
being conducted and, secondarily, by the ability
of the local economy to absorb new technologies
into existing industry or an entrepreneurial sec
tor. These insights may offer lessons for policy
makers and practitioners seeking to use IP as part
of an integrated strategy to drive economic devel
opment through the public financing and com
mercialization of innovation. n
auThoR’s noTe: By their nature, the policies and in

stitutions reviewed in this chapter are constantly evolv
ing and changing. The author invites any corrections,
updates, and additional information, including policy
studies or institutional case studies. New information
will be used to update future reviews on this topic and
may be added to the online version of the IP Handbook at
www.IPHandbook.org.
gRegoRy d. gRaff, Research Economist, PIPRA, Plant

Sciences, Mail Stop 5, University of California, Davis, CA
95616, U.S.A. gdgraff@ucdavis.edu; and Visiting Research
Fellow, Agricultural and Resource Economics, 340 Giannini
Hall, University of California, Berkeley, CA, 94720, U.S.A.
ggraff@are.berkeley.edu.
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CHAPTER 3.4

Technology Transfer Snapshots
from Middle-Income Countries:
Creating Socio-Economic Benefits through Innovation
susan K. finsTon, Principal and Founder, Finston Consulting, LLC, U.S.A.

ABSTRACT

This chapter examines the outcomes of technology trans
fer policies adopted in the past 20 years by five middle-in
come countries: Brazil, India, Ireland, Israel, and Jordan.
The outcomes in those countries suggest that nations
whose governments enable the assimilation of new tech
nologies grow faster, create more jobs, and reduce poverty
levels. The outcomes suggest also that a mixture of gov
ernment and market strengths are needed to efficiently
use technology transfer. Without this balance, technology
transfer will have limited effects.

1. InTRoduCTIon
The founders of the United States understood the
importance of innovation and took pains to pro
mote and protect it in the U.S. Constitution:
The Congress shall have power to lay and collect
taxes, duties, imposts and excises, to pay the debts and
provide for the common defense and general welfare
of the United States; but all duties, imposts and ex
cises shall be uniform throughout the United States;
… to promote the progress of science and useful arts,
by securing for limited times to authors and inven
tors the exclusive right to their respective writings and
discoveries. (U.S. Const. article I, § 8, cl. 8)
The same principles embodied in this
Constitution are used around the world today
to encourage research and development. For ex
ample, inventors and developers can apply for

patent rights that give them exclusive use of their
own innovations for a limited period of time.
Patent rights are essentially “negative” rights: that
is, they allow one party to exclude others from
gaining benefit from an inventor’s work, but, of
course, they cannot ensure that the invention will
be profitable. In return for the patent right, the
inventor discloses information in the patent that
would enable a person who is “skilled in the art”
(that is, knowledgeable in the field of the inven
tion) to understand and replicate the invention
for him- or herself. Patents thus seek to serve both
the inventor’s and the community’s interests.
We can see this dual effect in the case of a
well-known American. George Washington was
a mill owner and operator eager to improve his
mill’s productivity. He was interested in new ag
ricultural technologies, particularly in the Evans
Mill System, patented by the prolific inventor
Oliver Evans (U.S. Patent No. 3), and now rec
ognized as the first mass production process. As
president, Washington reviewed and signed all
of the patents issued in 1790; and as the owner
of the Mount Vernon Gristmill, Washington was
one of the first to license the new technology.
This automated mill produced high-quality flour
using two men instead of six; the mill operated
continuously and turned out greater quantities of
flour than the traditional process in a fraction of
the time. In addition to Washington, within two
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years, over a hundred other U.S. mills were us
ing the new Evans technology. Evans’ invention
changed U.S. mills forever and boosted U.S. ag
ricultural exports to Europe. It benefited not just
Evans but the entire country, including George
Washington.1
Another example, predating Bayh-Dole,
involving the contrasting paths of penicillin
and streptomycin underscores the importance
of incentives to ensure commercialization of
science. Penicillin was first discovered in 1928,
and is often cited as a laudable case where the
innovator, Dr. Louis Pasteur, did not seek a pat
ent or licensing for the drug. As a result, how
ever, there was no commercial development of
penicillin, for more than a decade, until World
War II necessitated scale-up and mass manu
facture of the drug.2 In contrast, streptomycin,
developed by Dr. Salman Waksman at Rutgers
University in the 1930s, was on a faster track,
enabled by an early exclusive licensing agree
ment with Merck.3
Then as now, a climate that encourages the
adoption of new technologies will also encourage
increased rates of job creation, lower poverty lev
els, and create greater opportunities for economic
growth. We live in an unprecedented era, how
ever, when the investment assets of companies are
increasingly intangible, and particularly suited
to forms of IP protection.4 Microsoft® founder
Bill Gates concludes that the nature of the global
economy increases the need for incentives to in
novation given “the economic competition between
nations going forward, particularly with regard to
the rapid innovation and development in emerging
countries … We need incentive systems that drive
that innovation in an appropriate manner, because
we can no longer compete exclusively on the basis of
cost of labor.”5 This chapter looks at how technol
ogy transfer policies have affected countries from
three different regions (the Middle East, Asia, and
Europe) in the past 20 years.

2. WHAT IS TECHnoLoGy TRAnSfER?
Technology transfer is the process of developing
practical applications from the results of scientific
research. Defined more broadly, technology
1 | HANDBOOK OF BEST PRACTICES

transfer is anything that increases the capacity
of people to benefit economically and/or socially
from innovation.
Technology transfer is a complicated process,
and the journey from exploratory research to suc
cessful product can be a long one. R&D falls into
three categories or phases:
• The primary objective of basic research is
the advancement of knowledge for its own
sake. This type of research is exploratory or
investigative and is often driven by the re
searcher’s curiosity, interest, and hunches.
• The primary objective of applied research is
to answer specific questions that have prac
tical ramifications. These questions may or
may not arise out of basic research. Applied
research can be exploratory, but is usually
more focused.
• In commercial development, ideas arising
from basic and/or applied research are used
to create a product intended for commer
cial sale.
An example of an R&D process that in
cludes all three phases is the discovery and de
velopment of pharmacogenetic drugs: decoding
the human genome (basic research) led to the
identification and isolation of particular en
zymes (applied research), which in turn led to
the development and testing of drugs (commer
cial development). This example suggests that
governments have a significant role to play in
identifying which areas of innovative research
can and should be promoted (the initial re
search on the human genome was a public ef
fort). Governments also have a role in moving
inventions from the theoretical level to the ap
plied level (government-funded research drives
a good deal of this movement) and in provid
ing incentives to encourage the development of
new products and processes arising out of ap
plied research (for example, forms of intellectu
al property). But as research moves further from
basic research toward product development, the
government’s role in directing this process di
minishes. For the most part, the market distrib
utes investment resources much more efficiently
than the government.
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. WHAT fACToRS pRoMoTE

TECHnoLoGy TRAnSfER?
The core elements of a robust technology transfer
system are:
1. a durable government commitment to science
education, research, and related infrastruc
ture. Governments create an enabling envi
ronment for science and technology by in
vesting in education and training (both at
home and abroad, at secondary and univer
sity levels), funding basic and early applied
research, and improving technology-related
physical infrastructure.
2. broad rule-of-law protections, including
strong IP protections. Rule-of-law protec
tions give individuals the ability to enter
into enforceable agreements or contracts
with others; they promise predictable and
timely judicial remedies in case these agree
ments or contracts are breached.
3. reliance on market forces as the engine for
technology transfer. Market-oriented policies
encourage risk taking and increased private
sector investment.
These three pillars of technology transfer are
like the three legs of a stool: all are necessary, and
none of them is sufficient by itself. However, it
can be difficult to provide all three simultaneously.
In the mid-20th century, the U.S. government
thought it strongly supported science, rule-of-law
protections, and market incentives, but it did not
grant private rights to publicly funded inventions.
The effect of this was to greatly weaken market
incentives for investing in new technologies. Such
rights only became part of the U.S. technology
transfer regime with the passage of the Bayh-Dole
Act of 1980.6 Once government-funded scientists
were allowed to engage with those who had the
skills needed to bring products to market, an ex
plosion of innovation ensued, bringing remark
able new products in health, agriculture, and other
fields.

. TECHnoLoGy TRAnSfER pRofILES
The power of technology transfer is available to
people everywhere, and it is a power that can

facilitate not just a nation’s research abilities but
its overall economy. Drawing on his experience in
Bangladesh, David Sack, observed that:
[W]ell-qualified local scientists generally prefer
to remain in their home country if they can find
meaningful employment in institutions where they
can be productive. Well-functioning institutions con
tribute to “brain-gain,” thus increasing the scientific
and economic resources of a country as a whole.7
No matter what stage of development a coun
try is in, its government can train scientists and
encourage them to remain at home by promoting
a sensible, well-functioning technology transfer
system. The remainder of this chapter provides
brief profiles of five middle-income countries
whose governments, over the past two decades,
have supported science and education, created
effective IP protections within a broader frame
work of strong rule-of-law protections, and used
the market to efficiently distribute investments
in commercialization. These countries have de
veloped successful innovation-intensive sectors
like biotechnology and information technology
that have, in turn, produced widespread social
and economic benefits. The experiences of these
countries can provide all of us with valuable les
sons and insight into how to harness effectively—
and fairly—the power of technology transfer.
.1 Brazil

The strength and durability of the Brazilian gov
ernment’s commitment to science education and
infrastructure are impressive. The State of São
Paulo Research Foundation (Fundação de Amparo
à Pesquisa do Estado de São Paulo, also known as
FAPESP) has supported basic scientific research
and graduate education at several universities in
São Paulo for the last half-century. The federal
Ministry of Health has funded two major pub
lic research institutes: the Instituto Butantan and
the Oswaldo Cruz Foundation. In recent years,
the Instituto Bhutantan has been recognized for
its role in the development of a hepatitis B vac
cine.8 The Oswaldo Cruz Foundation has a long
and distinguished history, including historic
health and sanitation campaigns against bubon
ic plague, yellow fever, and small pox,9 and the
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foundation most recently announced advances in
development of an algae-based microbiocide for
use against HIV/AIDS.10
However, Brazil lacks market-based incentives
to drive private capital into commercial develop
ment. As Michael Ryan observes, “The Brazilian
public sector has made substantial investment into
university and public laboratory research, thereby
establishing the potential for biomedical technology
innovations, but the lack of private sector R&D ca
pabilities and lack of public-private linkages has tra
ditionally prevented technology from being commer
cialized into the marketplace.”11 Partly due to these
weaknesses in its technology innovation system,
the country’s economic growth in the 1970s and
1980s faltered.12 Currently, two-thirds of R&D
spending in Brazil is funded directly by the gov
ernment (for comparison, only one-third of R&D
spending in the United States is funded directly by
the government), and only 18% of scientists and
technicians work in the private sector.13 The dyna
mism and flexibility of market forces were stymied
by the government’s decisive intervention in the
innovation process, and the resulting inefficiencies
contributed to slow economic growth.
Currently, a number of reforms are under
way in Brazil to encourage private sector invest
ment in R&D activities. As a result, there are
more international patent applications being
filed by Brazilian companies through the World
Intellectual Property Organization (WIPO)
Patent Cooperation Treaty,14 and new products
are beginning to enter the market.15 This trend
should strengthen the economy and provide
Brazil’s people with more and better products in
every economic sector.
According to Ryan, Brazil was not alone in
giving a dominant role to government in the pur
suit of scientific and technological development.
He cites a number of large developing countries
that had also followed a policy of state-led eco
nomic development. Many of these have since re
vamped policies to promote greater private sector
investment in the commercialization of new tech
nologies. These include China, Mexico, Egypt,
India, and Turkey. The lesson here is not that gov
ernment should not provide funding to develop
new technologies but that such funding should
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be focused on basic research (which functions as
a kind of “seeding” for innovations). Applied re
search and research focused on commercializing
an innovation should rely more on investments
from the private sector to ensure maximum ef
ficiency and economic growth.
.2 Israel

Israel is another state with a commitment to long
term investment in science and infrastructure.
Recent investment data show that at least 50%
of science funding in Israel comes from the State
of Israel and international public sector sources.16
Each of Israel’s ministries includes a chief scien
tist,17 and Israel’s primary and secondary schools
have a strong basic science curriculum.18
Israel is a world leader in areas related to
information and communications technology.
These technological areas do not require capital
investments to the same high degree as biotech
nology and are characterized by short lead-times
and low regulatory barriers to market entry. In
fields such as biotechnology, however, Israel is
not as innovative. As Avi Molcho observes, “Israel
is among the world leaders in many fields of tech
nology. It is a hub for innovative technologies in
communications, semiconductors, information tech
nology, and medical devices—innovation that has
been translated into commercial success. While the
same, if not greater, degree of innovation is found in
Israeli life sciences research, this has yet to be trans
formed into a more mature biotechnology start-up
industry.”19 In fact, Israel’s patent prowess appears
formidable: “Israel ranks first worldwide in the pro
portion of life-science patents to the total number
of patents written by Israeli inventors. The country
ranks fourth in total number of biopharma patents
granted, in terms of patents per capita, and 12th in
the absolute number of biopharma patents.”20 Alla
Katsnelson suggests that this is because patents
are underutilized: “Israeli life-sciences patents com
prise almost a third of the country’s total patents.
What seems to be lacking is the ability to turn all
this life-sciences-focused intellectual property into
biotech products.”21
The Milken report cites the lack of sufficient
market incentives for commercialization of sci
ence, 22 while others point to relatively weak levels
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of patent protection and data exclusivity.23 Some
identify the market dominance of the generic
pharmaceutical manufacturer Teva,24 as one rea
son why Israel has not strengthened market and/
or IP incentives for international biotechnology
companies to enter or remain in the market.
Interestingly, Israel has maintained weaker
levels of IP protection at the same time many
of its neighbors, including Bahrain, Jordan,
Morocco, Saudi Arabia and the United Arab
Emirates (UAE), have strengthened their IP sys
tems through WTO accession, bilateral free trade
agreements and/or unilateral reforms.25
Whatever the reason or combination of rea
sons, Israel continues to suffer from a dearth of
private clinical biotechnology research. David
Haselkorn succinctly notes, “Not one single [multi
national pharma] company has developed an R&D
center here.”26 The Milken Institute goes farther,
stating that the Israeli biotechnology sector is in
decline, “as measured by the amount of venture
capital funding.”27
. Jordan

Until the early 1990s, the Hashemite Kingdom
of Jordan was best characterized as an aid- and
remittance-based economy, with an estimated per
capita gross domestic product (GDP) of about
US$800. Over the past 15 years, however, the
Jordanian government has increased its commit
ment to science education and infrastructure, im
proved its IP laws and the enforcement of those
laws, and adopted a model of economic planning
that relies on the private sector for job and wealth
creation. The impact of these changes has been
profound: the country has become more integrat
ed into the world economy and enjoyed a more
than five-fold increase in per capita GDP since
the mid-1980s, reaching US$4,700 in 2006.28
The growth of Jordan’s export-led pharmaceu
tical industry is particularly remarkable. In 2001,
production in the pharmaceutical sector totaled
US$180 million; in 2002, it was US$210 mil
lion; and in 2003, it reached US$275 million.29
This was achieved both through higher levels of
domestic IP protections and through trade ben
efits provided by the World Trade Organization
(WTO) and the United States–Jordan Free

Trade Agreement.30 Jordanian pharmaceutical
companies are beginning to invest more in research
and product development. For example, local
Jordanian companies Triumpharma and Advanced
Pharmaceuticals are both investing in research to
produce and patent drug delivery mechanisms. In
addition, two new clinical research organizations
have been established in the last three years.31
Today, Jordan exports its pharmaceutical products
to over 60 markets worldwide.
In addition, Jordan has adopted marketfriendly policies that are attractive to interna
tional pharmaceutical companies. Major in
ternational pharmaceutical companies, such as
Organon, Novartis, and Aventis, have worked
with new Jordanian clinical research organiza
tions and Jordanian hospitals to conduct clini
cal trials. Since 2000, Jordanian companies have
established licensing relationships with phar
maceutical companies from Italy, Japan, Korea,
Italy, Switzerland, the United Kingdom, and the
United States. These foreign companies often rely
on their Jordanian partners to provide marketing
and distribution expertise in the Middle East. In
return, Jordanian companies benefit from foreign
investment by gaining a broader product base for
sale, both at home and into export markets, and
for the in flow of know-how and technology.32
The government of Jordan continues to in
vest in science and technology. Areas of invest
ment include: natural products development;
early diagnostics using monoclonal antibodies;
applied microbiology in food; production of
biogas, biofertilizers, pesticides, and yeast; and
the development of new biotech equipment.
Moreover, Jordan has recently established the
King Hussein Cancer Center and Biotechnology
Institute with support from the U.S. National
Institutes of Health through the Cancer
Biomedical Informatics Grid program.
. India

When it comes to adopting technology-friendly
policies, few countries have faced as many chal
lenges as India. R. A. Mashelkar, recently retired as
the Director General (1995-2006) of the Council
of Science and Industrial Research (CSIR), an
early and persistent advocate for India’s adoption
HANDBOOK OF BEST PRACTICES | 201

FINSTON

of technology transfer policies, calls India’s his
tory with such policies “a series of missed bus
ses,” in terms of lost opportunities for leveraging
India’s intellectual assets in the global knowledge
economy.33
Many have cited India’s confidence in bio
technology as rooted in its earlier success in the
information technology (IT) sector. It is less well
known, though, that patent protection also fu
eled India’s original IT success, in the form of
Dr. Sam Pitroda’s software patents.34 In 1980,
prominent nonresident Indian and software
guru Pitroda sold his first U.S. company and
brought the profits to India to support his dream
of installing telephones throughout rural India.35
Telecommunications has been widely recognized
in India as foundational to the entire industry sec
tor known as “Information and Communications
Technology (ICT),” as well as the related sub-sec
tors known as “Business Process Outsourcing
(BPO)” (which include back-office operations
for multinational corporations, and call centers,
among others) , and BioInformatics (the analytic
processing of data generated as part of clinical re
search in the life sciences and provided India’s
initiation into biotechnology).36 Pitroda’s soft
ware patents helped him to made his first fortune
and provided the resources he needed to bring te
lephony to rural India, laying the foundation for
India’s IT revolution.
Now the government of India is preparing to
introduce comprehensive technology transfer leg
islation in 2007. Under the bill, academic inven
tors and their institutions would share royalties,
and academic entrepreneurs will be encouraged to
file patents to gain both increased research fund
ing for their institutions and individual benefits
for themselves, in the form of royalties. 37 The law
would also include key mechanisms to bench
mark patentable research undertaken by Indian
academic and research institutions with support
from the government of India.38 In the past year,
product patent protection has been adopted and
implemented in several fields, including pharma
ceuticals. Patent processing reform has improved
efficiency and reduced patent review times, and,
increasingly, domestic companies are recommend
ing that India adopt protection for commercially
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valuable clinical research dossiers (a protection
known as data exclusivity).39
India is engaged in a cooperative internal di
alogue about how to implement these IP reforms.
The Indian government continues to promote
India as a global biotechnology R&D hub, and
the country has become a primary global loca
tion for preclinical and clinical R&D. Most
recently, the 2006 Ernst and Young European
Attractiveness Survey placed India among the
top five countries as a pharmaceutical and bio
pharmaceutical R&D destination. Commercial
biotechnology, which crossed the billion-dollar
mark in 2005, has now reached nearly US$1.5
billion, with 36% annual growth.
. Ireland

Over the past 20 years, Ireland has gone from
“net brain-drain” to “net brain-gain” by system
atically adopting pro-technology transfer policies
and becoming a major importer of foreign direct
investment in the area of life science. Ireland of
fers strong patents and data exclusivity for terms
of up to 11 years. There is substantial government
support for science education and technology-re
lated infrastructure, and the government’s cor
porate regulatory policies ensure greater market
orientation in terms of increased moderation in
labor policies,40 reduced corporate taxation,41 and
other reforms:
Foreign direct investment in Ireland has been
attracted by low rates of corporate tax. Today, Ireland
has one of the world’s lowest rates of corporation tax,
with the maximum rate for trading profits being
12 percent. Other factors that help attract biophar
maceutical companies to Ireland include the ready
availability of the required specialist skills. Output
from the third-level institutions is being continually
refined to meet the sector’s needs. Further, the consid
erable growth in the Irish economy over the past ten
years has seen very significant repatriation of skilled
people. In addition, Ireland is seen as a desirable ex
patriate location with a minimum of bureaucratic
obstacles and an excellent educational system that
facilitates family relocation. The free movement of
labor within the enlarged European Union has fa
cilitated the swift acquisition of a further pool of
skilled people.42
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As a result, Ireland has become more attractive
to foreign investors for biotechnology and other
high technology sectors43 and is also winning the
global competition to attract and retain well-edu
cated, creative workers.44 More than 170 compa
nies employ 35,000 people in Ireland’s chemi
cal, pharmaceutical, biopharmaceutical, medical
device, and diagnostics industries.45 Together,
these sectors generated more than US$52 billion
in exports in 2005. Ireland’s per capita income
has grown from about US$5,000 in 198646 to
US$43,600 in 2006,47 a level of per capita in
come that is comparable to that of the United
States and the United Arab Emirates.

. ConCLuSIon
Technology transfer can improve lives by intro
ducing innovations that directly contribute to
improved public health, nutrition, and communi
cations. Less obviously, but more importantly, the
policies that promote technology transfer—such as
an emphasis on personal rights and education—
also promote economic development. Ideally, any
positive changes in political and economic climate
will create a self-perpetuating cycle: an improved
economic environment and a general increase in
education levels will lead to improved public health,
which will in turn strengthen the economy.
The above overview strongly suggests that
such technology transfer works best when there
is strong, consistent government support of basic
research—including science education and technology-related infrastructure—and robust IP pro
tection. Government policies should also strive to
encourage market guidance and private sector in
vestment in applied research and commercializa
tion efforts. In this way, the strengths of the gov
ernment and of the market can be synergistically
applied to improve the lives of all of us. n
susan K. finsTon, Principal and Founder, Finston
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CHAPTER 3.5

Benchmarking of Technology Transfer Offices and
What It Means for Developing Countries
anThony d. heheR, Director, Associates for Economic Development, South Africa

ABSTRACT

At universities in both developed and developing coun
tries, increasing emphasis has been placed on promoting
technology transfer. Unfortunately, technology transfer is
sometimes undertaken for the wrong reasons, especially
in the mistaken belief that technology transfer will lead to
substantial additional income for the institution. While it
is important to protect intellectual property arising from
research and to actively promote the transfer of research
results, generating income should not be the primary ob
jective in the transfer of technology. This is particularly
important for health science, where there is a risk that
research results, if not properly protected, will be inac
cessible to private or public entities seeking to use the
research for public benefit.
International technology transfer benchmark data
can be used to understand the implications of promot
ing technology transfer and the likely outcomes of a tech
nology transfer initiative. The benchmarks indicate that
average income to an institution, after eight to ten years
of activity, is likely to be a modest 1%–2% of annual
research expenditure. The income is, moreover, highly
uncertain and variable. Institutional and public sector
managers must understand the nature of this income and
the dynamics of the technology transfer process in order
to manage this emerging discipline effectively, because
unrealistic expectations can lead to dysfunctional policy
decisions. The data and dynamic model presented in this
paper are intended to promote better decisions.

1. InTRoduCTIon
The successful technology transfer programs of
universities in Canada and the United States have
prompted other countries to emulate them, and

major technology transfer and commercializa
tion support programs have been launched in
Australia, Japan, the United Kingdom, and many
other countries. The high-profile successes of rela
tively few institutions have, however, generated
unrealistic expectations. Additionally, it is not
always clear that the success, measured in terms
of income earned from commercialization, is pro
portional to the magnitude of the investment in
research. Without a well-funded, high-quality re
search system, it is highly unlikely that a technol
ogy transfer program will contribute significantly
to economic or social development. Moreover,
it is doubtful whether other countries can easily
emulate the performance of the United States,
due to differing social and economic conditions.
The income-earning potential of technology
transfer activities can, in fact, be a hindrance to
effective programs. Technology transfer needs to
be undertaken for good reasons, apart from the
possibility of earning income. In health sciences
and agriculture, in particular, appropriate IP (in
tellectual property) protection may be essential
to effectively exploit research results and ensure
that the benefits are widely available to society.
Whether exploitation of research is for commer
cial or humanitarian uses, effective and appropri
ate transfer of knowledge is still required, in ad
dition to the normal academic requirements to
publish.
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However, even with comparable investments
in research, the performance of individual insti
tutions is highly variable and unpredictable. This
is true even for institutions that are comparable in
size and maturity. A large portfolio of patents and
licenses is required to give a reasonable probabil
ity of a net positive income. A large portfolio may
be possible at a national level but is problematic
in smaller countries, and even more so for smaller
institutions. Because the benefits of the innova
tion system are captured largely at the national
level, institutions need public sector support to
reduce the institutional risk necessary to develop
profitable investments.
Technology transfer is, of course, only one el
ement of the overall research and innovation value-chain. All elements must function effectively
for an institution to derive economic and social
benefits from its research. In addition to a strong
research system, a university must offer academics
adequate incentives to encourage their participa
tion, particularly with regard to the crucial initial
step of invention disclosure. Universities must
possess adequate institutional capacity to take an
idea, evaluate it, appropriately protect intellectual
property, and then seek a path to commercializa
tion through licensing or a spinout.
It is widely recognized that monetary re
turns are not, and should not be, the primary
motivation for engaging in technology transfer.
Increasingly, it is a public research organization’s
social responsibility to ensure that research re
sults are effectively transferred in a timely manner
into the public domain for the good of society.
The production of graduates and publication of
research results remain the most important ways
of affecting knowledge transfer; the more direct
transfer of knowledge through technology trans
fer is, however, an essential adjunct. Far from
undermining conventional approaches, effective
technology transfer can support and enhance tra
ditional knowledge transfer.
Technology transfer affects a society’s eco
nomic well being directly and indirectly. In this
chapter, both the conditions necessary for deriv
ing economic benefit and the factors that influ
ence the performance of a technology transfer
office (TTO) are outlined. The data and models
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highlight the need for skilled technology transfer
professionals. If a country is to profit from its in
vestment in research, then training and capacity
building at the institutional and national levels
are key requirements.

2. RESEARCH And InnovATIon
vALuE- CHAIn BEnCHMARk dATA
Universities and research institutions in North
America have been benchmarking the research
and innovation value-chain for a number of
years.1 This data covers each step in the value
chain, including expenditure on research; num
bers of invention disclosures, patents, licenses,
and spinout companies; income from licensing;
and expenditure on IP protection. A few other
countries are following a similar approach, facili
tating cross-country comparisons. (A selection of
the data is shown in Table 1.)
To assist with comparisons across countries,
benchmarks are generally converted to normal
ized values. The most commonly used approach
is to normalize in terms of total research expen
diture, converted to equivalent U.S. dollars. This
approach is called the adjusted total research
expenditure (ATRE). The most commonly used
reporting basis is per US$1billion ATRE or
US$100 million ATRE. Table 2 presents normal
ized values of the raw data in Table 1 based on
US$100 million ATRE. For simplicity, only se
lected variables are shown. This normalized data
can be considered typical data for a small- to midsized U.S. university or a large university in a de
veloping country.
The normalized data shows a remarkably con
sistent pattern across different countries (summa
rized in Table 3). While there are variations from
year to year and from country to country, they
are relatively small and statistically insignificant
compared to the variations between institutions
in one country.
The data presented in Tables 1, 2, and 3 is
for all research disciplines, as no desegregation
to field of research was undertaken by any of the
countries that conducted the survey. Although
such results would be interesting, there is a lack
of clear definition of the different fields, even
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within one country, let alone across countries,
making classification difficult. However, it is
well recorded that medical and health-related
research constitutes around 50% of all research
expenditure. An analysis of individual results of
commercialization efforts also shows that healthrelated products make up around 50% of tech
nology transfer outputs, so the available evidence
indicates it is likely that the data for all fields is
broadly representative for health sciences. Given
that a relatively small proportion of total research
is devoted to agricultural research, it is not possi
ble to make similar conclusions about technology
transfer in the agricultural sciences. Indications
are, however, that it is likely to follow a similar
pattern; there is little evidence that one field of
research has significantly different results from
another in terms of average performance, as indi
cated in Table 3.
A widely used proxy for the overall perfor
mance of the technology transfer system is the to
tal license income earned per year as a percentage
of the total research expenditure. This measure is
used in this chapter, and elsewhere, but it must be
remembered that the measure is a proxy for a com
plex system and does not, by itself, tell the whole
story. License income as a percentage of research
expenditure is often referred to, for simplicity, as
the “return” from an investment in technology
transfer. The concept represents one form of re
turn, with returns to the economy through direct
and indirect benefits being equally, if not more,
important. The benefits to society, particularly in
health and agriculture, are often far more impor
tant than any financial return the institution may
earn. The difficulty, however, is that the institution
bears the costs of undertaking technology transfer,
particularly, in terms of IP protection costs. The
benefits, in contrast, may be enjoyed by the wider
society, or even by another country.
Over the years that data has been collected,
the trend in total license income is instructive
(the graph is shown in Figure 1). In the United
States, the value has increased from 1.5% in
the first year of surveys by the Association of
University Technology Managers (AUTM) in
1991 to around 3.5% in recent years, ignoring
the anomalous peak during the dot-com boom in

2000. Excluding medical research institutes and
considering only universities, the figure is slightly
lower, at around 3%. The available figures for the
United Kingdom, Australia, and Canada are also
plotted in Figure 1. Again ignoring anomalous
figures in 2000/2001, averages are in the vicin
ity of 1% to 1.5%. Interestingly, no evidence yet
exists of other countries having the same rising
trend that was observed in the United States in
the early years. Whether a similar trend will oc
cur in the years ahead, or whether there is a sys
tematic difference between the United States and
other countries, is still unclear.
The average data set is misleading, however,
and the full data set, showing individual institu
tions, needs to be scrutinized. The AUTM data
is excellent in this respect, as is the Australian
survey. It is unfortunate that cultural norms in
Europe tend to hide individual performance, as
this impedes an understanding of the data.
The characteristic distribution of this data is
illustrated in Figure 2, which shows the returns of
all reporting U.S. universities in rank order. The
data is more easily understood when plotted on a
logarithmic scale, as shown in Figure 3. The dot
ted line in Figure 3 shows the approximate trend
line for U.S. data. Figure 4 shows the same data
for Canadian universities and Figure 5 shows
the date for Australian universities, both with
the U.S. trend line superimposed. The distribu
tion of returns is remarkably consistent in these
three reporting countries. The data for the United
Kingdom shows a similar trend, but cannot be
displayed in the same way because individual in
stitutional performance is not reported.
Table 4 summarizes the returns for the
United States, Canada, Australia, and the United
Kingdom in three bands. The first is for all report
ing universities, the second for the lower 95%,
excluding the upper 5%, while the last row shows
the performance of the lower 50%. Excluding
the upper 5% removes eight universities in the
United States, two in Canada, one in Australia,
and five in the United Kingdom.
The affect of the skewness of the returns is
evident: 95% of universities have returns of less
than half the averages, while 50% earn only very
small amounts from technology transfer. This
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has important implications whether TTOs earn
enough to cover operating costs or if they need
to be subsidized. (This is discussed in more detail
below.)
An important reason for undertaking bench
marking is the understanding and insight that
the process fosters. This is what Lundvall2 calls
a learning-by-comparing approach, and it is especially important when using benchmarks in
a different environment. Inherently, long-time
delays make innovation-system benchmark data
particularly difficult to collect and interpret. A
good understanding of the origins and structure
is necessary to avoid misuse of the data. The model that has been developed here assists with the
interpretation of the raw benchmark data and the
underlying processes it reflects.
Analysis of the data is complicated by the
existence of a few exceptional cases. In Australia,
for example, the omission of a single equity transaction in 2000 changed the income earned by
over 50%; while in 2001 and 2002, one univer
sity accounted for 66% of all income earned. In
Canada, omission of two universities had a simi
lar impact, while in Europe omitting two uni
versities reduced the income by 70%. The affect
of a few large transactions makes measuring and
interpreting the benchmark data more difficult,
particularly for projections and comparisons.
Some observations, with respect to the coun
try average data, are relevant:
• The invention disclosure rate of 40 to 50
disclosures per US$100 million ATRE
(or US$2 million to US$2.5 million of
research expenditure per invention disclo
sure) is remarkably consistent across coun
tries and over time. The most recent U.K.
data set is an exception and would seem
to indicate a difference in policy approach,
with the invention disclosure rate increas
ing by nearly 50% from 2001 to 2002.
Not all disclosures are equal, however, and
in some instances a higher disclosure rate
would appear to indicate a lower “quality”
of disclosure, as indicated by the fact that
a smaller percentage of the disclosures are
converted to license or spinout opportuni
ties, as shown in Table 2.
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• The rate at which disclosures are converted
into a patent or license varies from 30% to
50%. This is a relatively close correspon
dence with differences explainable by different national policies and support measures.
• The spinout-company rate shows a similar
range, explainable by the greater emphasis
on company formation in Europe and in
the United Kingdom, in contrast with the
emphasis in the United States on licensing.
The United Kingdom and Europe gener
ated four to six times more spinout companies in 2000/2001, but the number had
dropped in 2002, reflecting a much more
difficult venture-capital environment after
the dot-com bust.
• A recent report in the United Kingdom,
however, has asserted that the reported
rate of spinout-company formation is 50%
more than the real rate. If true, this would
make the United Kingdom data more comparable to other countries and illustrates
the importance of clear definitions when
collecting benchmark data.
• It is noteworthy that the total percentage of
invention disclosures that result in either a
license or a spinout is roughly similar in all
countries examined, at around 30% to 40%.
• The staffing of TTOs shows interesting
variations. The United States averages four
staff (per US$100 million ATRE), whereas
Australia and Canada have eight to ten staff
(per US$100 million ATRE). This reflects
economies of scale in the United States,
as the average number of staff per institu
tion is similar. Staffing levels in the United
Kingdom, however, are six times higher
than the United States per ATRE. This
reflects the emphasis on spinout-company
formation (known to be much more peo
ple-intensive than licensing) in the United
Kingdom and the strong national support
schemes that are in place.
• The cost of operating a TTO can be esti
mated from the reported staffing levels and
salary survey results, formal or informal. As
shown in Table 5, these budgets fall into
two categories and three groupings. For the
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United States, Canada, and Australia, the
budget for a small university is about 1% to
2% of total research expenditure and 0.2%
to 0.5% at the larger institutions. U.K.
universities typically have budgets approxi
mately double these figures.
• The average returns shown in Table 4, cou
pled with the typical budgets shown in Table
5, enable an estimate of the profitability of
the various classes of offices. These results
are shown in Table 6. In the United States
and Canada, the bottom 50% of all univer
sities operate at a loss, and only the 50% to
95% group are operating at a break-even or
slightly profitable level. Only the top 5%
are very profitable. It is this skewness that
contributes to the all-too-common expec
tations of unrealistic performance. In the
United Kingdom and Australia, only a few
universities are profitable, with over 95%
operating at a loss.
The similarity in performance among coun
tries with different innovation systems and
cultures indicates that the creative innovation
process is inherently similar regardless of the en
vironment. The single biggest factor that dwarfs
all others is the expenditure on research, and it
appears that no innovation system is significantly
different with respect to the effectiveness with
which ideas are generated and transformed.
This is not to imply that active innovation
support systems are not required. All the coun
tries examined and reported in the benchmarks
in Table 2 have strong systems of support and
are actively involved in training and developing
capacity to manage the research and innova
tion process. Without such capacity, it is highly
unlikely that the performance of any institution,
region, or country will come even close to match
ing the average benchmarks.3

. pHASInG of THE
InnovATIon-vALuE-CHAIn
The benchmark data is masked by the long de
lays inherent in the technology transfer process.
Each step in the value chain takes a few years;

typically six to ten years elapses from the mo
ment of invention disclosure to the time when
significant income can be generated from a li
cense. These delays are depicted in Figure 6, and
the impact of these delays is illustrated in Table
7 and Figure 7.
This phasing makes interpretation of the
benchmark data difficult, because data for a par
ticular year depends on activities that happened
many years earlier. The total license income in
any one year, for example, depends on the accu
mulated sum of invention disclosure and patent
ing activities from prior years and is independent
of the disclosure rate in that particular year. For
ease of analysis and reporting, ratios are used to
measure the relationship between variables that
may in fact be years apart. In a steady-state envi
ronment, these ratios are correct, but the dynamic
relationship must be understood.
The data presented in Table 2 is therefore
primarily useful as a steady-state approximation,
particularly when used to make projections for
a new institution or a country just establishing
an innovation system. Misunderstanding these
dynamics can contribute to false expectations of
returns that are more properly based on observa
tions of essentially steady-state data from mature
systems.
The dynamic model combines knowledge of
the phasing of the value chain and the time du
ration of the various steps with the steady-state
benchmark data in Table 2. The primary purpose
of the model is to provide estimates of the likely
rate of return and cash-flow forecasts (institution
al and national) of alternative innovation-system
scenarios. As the parameters of any particular in
novation system are not known in advance (and
are difficult to measure even in retrospect), the
main use of the model is as a “what-if tool” to ex
plore alternative approaches and understand the
impact of policy decisions.
Table 7 illustrates one possible model based
on a hypothetical institution expending US$100
million in research expenditure per year for 20
years. (The model is currency independent and
whether this is US$ or any other currency makes
no difference to the rate of return.) The model
has also been used for actual institutions, where
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past and future research expenditure is known or
can be forecast. Any available data on past inven
tion disclosures, patents, or licenses can be used
as initial conditions; the model can incorporate
as much past data as is available to generate
forecasts.
Figure 7 shows the results of using a range
of parameters to represent the three main TTO
operating models, called the income, service,
or economic models. The choice of office op
erating model depends on institutional and
national policy, and upon capabilities and re
sources. In practice, a mix of models is normal.
Each model can be defined by a set of innova
tion value-chain operating parameters. These
parameters enable the future performance of an
office (or country) to be calculated, including
investment outlay required, patent prosecution
costs, time to break even, and potential internal
rate of return (IRR). The IRR is the estimated
return to the institution from investing in es
tablishing a TTO, including staff costs and IP
protection expenses.
The importance of the model is not the ac
curacy of its predictions, which will, of course,
be no better than the underlying parameters and
assumptions underpinning their use. The prima
ry benefit is in understanding the dynamics and
relatively long timescales involved in technology
transfer. The model can thus help avoid unrealis
tic expectations and can also provide the basis for
a series of intermediate benchmarks that can help
ensure that the innovation system is moving in
the right direction. Invention disclosure, for ex
ample, is clearly an important early indicator to
measure both the health and the vibrancy of the
research system.

. EConoMIC-IMpACT ESTIMATIon
The ability to calculate, or even estimate, the eco
nomic impact of technology transfer activities has
been actively debated for a number of years. The
statement below from the AUTM licensing sur
vey for fiscal year 1999 has been disputed, and in
subsequent years AUTM has refrained from mak
ing claims in the survey, suggesting instead on the
need for ongoing research.
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“The economic impact of the licensing of
technologies developed at academic institutions
is remarkable. The responses from member in
stitutions estimate that the licensing of innova
tions made at academic institutions contributed
over [US]$40 billion in economic activity and
supported more than 270,000 jobs in Fiscal Year
1999. In addition, business activity associated
with sales of products is estimated to generate
[US]$5 billion in United States tax revenues at
the federal, state, and local levels.”4
Despite contention over specific claims of
economic impact, it is widely accepted that the
process is of economic benefit in all countries that
have active innovation systems and promote uni
versity technology transfer. The many countries
that are investing resources in technology trans
fer development confirm that there is widespread
confidence that the investment is worthwhile and
generates a positive return.
With considerable justification, developed
countries use the overriding argument that,
when a research program is already in place,
technology transfer can result in significant ad
ditional benefits for a small additional cost (as
shown in Table 4). But in developing countries
with smaller economies, less-developed innova
tion systems, and many competing demands for
resources, the situation is less clear. The bench
mark data shows that the volume of innovation
activities arising from research is directly pro
portional to the amount of research funding. If
additional investment in research is proposed on
the grounds that it supports economic growth,
some justification for this needs to be shown (for
example, that there will be a positive return from
that investment).
While there is some financial benefit to the in
stitution performing the research, the benefit is, at
best, around 1% to 2% of research expenditure, as
shown in Tables 2 and 3, and is generally between
0.5% and 1.5%. Income generation from tech
nology transfer is therefore clearly not an adequate
reason for an institution to invest in research. The
financial benefits of technology transfer activities
are captured primarily at the national economic
level through business creation, with national re
turns arising from direct and indirect economic
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effects. The data makes a compelling case for pub
lic funding, not only of research itself, but also of
technology transfer activities.
Even when the public sector invests funds
in research (whether for economic development
reasons or otherwise), a research institution must
invest in technology transfer activities over an ex
tended period (eight to ten years) before a posi
tive return can be expected. The highly uncertain
and variable nature of the returns compounds
these difficulties. Indeed, measuring the national
economic impact of technology transfer is diffi
cult and has been the subject of intense discus
sion and debate. A simplistic model has been
developed to illustrate the concepts and motivate
the development of more comprehensive models
(the approach used here follows that described by
Pressman5).
Universities report that the typical average
royalty rate, from which license revenues are de
rived, is within the range of 2% to 4%. Direct
business activity generated by technology trans
fer activities is therefore of the order of 25 to 50
times the revenue received by the licensing insti
tution. Using an appropriate multiplier (typically
1.5 to 2.0), the overall direct economic impact
can be estimated. This is not strictly an economic
model. It is an estimate of the multiplier effects
that are required to obtain a positive return. More
work is needed to determine the actual multiplier
effects that occur or are achievable. In addition to
these benefits, the pre-production benefits associ
ated with technology transfer activities have been
shown to be significant.6
This economic return is the direct return from
the activities measured and managed by the insti
tutions’ TTOs. There is strong evidence that the
entrepreneurial culture resulting from the focus on
technology transfer results in many other benefits
that are neither captured nor measured by the in
stitution, but which have an impact on the local
economy.7 These are the indirect multiplier effects.
Whether similar benefits will accrue in developing
countries is difficult to say and requires more re
search. Certainly, the factors noted by Tornatzky
generate cause for concern. He noted that states
with strong entrepreneurial support (such as
Massachusetts and California) tend to draw

entrepreneurial talent and opportunities from states
with less support, resulting in a loss of economic
benefits accruing to the states where the research
was undertaken. This migration constitutes a leak
age of benefits from states with less-well-developed
entrepreneurial environments to those with a more
nurturing environment. If leakages from poorer to
richer states in the United States (in terms of entre
preneurial support) have an impact in the United
States, the effect in developing countries is likely to
be even more pronounced.
Figure 8 illustrates these concepts in an ex
ample projecting the returns arising from the
technology to an investment in research illustrat
ed in Figure 7. These projections are, of course,
sensitive to the assumptions made. The model
shows, for example, that a positive national IRR
can only be achieved if the indirect multiplier ef
fects are at least three to four times more than the
direct effects. This reinforces the need for a more
in-depth understanding of innovation system
dynamics so that these effects can be understood
and measured.
What is clear from the model is that the direct
returns resulting from technology transfer are far
from adequate to justify additional expenditure on
research. In developing countries, the debate on
whether higher expenditure on research is justified
is intense and the model illustrates the need for
more in-depth analysis and better economic data.

. vARIABILITy of BEnCHMARkS
And RETuRnS
The benchmark data from individual institutions
(from all countries and over hundreds of institu
tions) shows a very high variability from year to year
and from institution to institution. This variabil
ity is observed on all measures in the value chain:
invention disclosures, patents, licenses, spinout
companies, and income. The variations are up to
two orders of magnitude, even for institutions that
in other respects are similar. Some of these trends
were illustrated in Figures 2, 3, 4, and 5. Analysis
of the data by income, size of the institution, ma
turity, or size of the TTO indicates that none of
these variables is strongly correlated with efficiency
or performance measures. The only significant
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correlation is that innovation output measures are
proportional to the volume of research, as mea
sured by expenditure on research. Even this figure
is proportional only in aggregate over a large port
folio, with strong institutional variations.
Figure 9, for example, shows the variation
in invention disclosure rate in terms of millions
of dollars of research expenditure per invention
disclosure, as a function of both the age of the
office and the magnitude of research expenditure.
Although in aggregate over time and across coun
tries the figure is relatively constant, at the insti
tutional level very strong variations occur, irre
spective of the size or maturity of the institution.
The European, United Kingdom, and Australian
surveys show a similar distribution, so this is not
unique to the United States.
Figure 10 shows the variation in license in
come (as a percentage of research expenditure) for
U.S. and Canadian institutions. The graphs con
firm the theoretical model presented above and
demonstrate the ten-year lag before significant
revenue is generated. But even after this portfo
lio-establishing period, returns to offices of simi
lar size and experience vary greatly.
This high variability in returns has been not
ed and studied.8,9,10 The variability in innovation
returns appears to be inherent to the nature of in
novation, but the variation in returns in early in
termediate benchmarks (for example, invention
disclosure rates) is not affected by the same fac
tors. While still variable, this variability is less in
herent and more manageable. Economic returns
are determined by an unpredictable set of market
factors, while the intermediate benchmarks are
more controllable by the institution and TTOs.
Institutional commitment, coupled with skilled,
experienced staff, can significantly contribute by
identifying opportunities and motivating inven
tion disclosure, and, of course, by managing all
the subsequent steps in the value chain.
The impact that skilled staff could have on
the overall innovation process and benchmark
figures is a topic for further research. If best prac
tices could be identified and disseminated, they
could potentially increase innovation returns sub
stantially. This is particularly relevant to smaller,
more-isolated offices, and offices in developing
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countries where peer learning is absent. Strong
professional networks are critical, and these need
to be promoted and developed.
Sherer and Harhoff11 performed an in-depth
study on innovation returns. Based on their analysis
of eight large patent portfolios in both the United
States and Germany, the researchers concluded:
“Our empirical research reveals, at a high level
of confidence, that the size distribution of private
value returns from individual technological innova
tions is quite skew—most likely adhering to a log
normal law. A small minority of innovations yield
the lion’s share of all innovations’ total economic val
ue. This implies difficulty in averting risk through
portfolio strategies and in assessing individual orga
nizations’ innovative track records. Assuming simi
lar degrees of skewness in the returns from projects
undertaken under government sponsorship, public
sector programs seeking to support major technologi
cal advances must strive to let many flowers bloom.
The skewness of innovative returns almost surely per
sists to add instability to the profit returns of whole
industries and may extend even up to the macroeco
nomic level. Although much remains to be learned,
some important lessons for technology policy have
begun to emerge.”
The AUTM data confirms that this skewness
is even more apparent in university portfolios,
with an average of only one in 200 licenses gener
ating more than US$1 million in revenue.12 This
concurs with Sherer’s data: of the eight portfolios
he analyzed, the three from universities all had
higher levels of skewness than the industry port
folios. This skewness is of particular relevance to
smaller institutions and countries.
This disparity in outcome, which can oc
cur even between institutions of similar size, ca
pability, and investment, can lead to problems.
Without an in-depth understanding, the bench
marks can result in dysfunctional policy decisions
at both national and institutional levels.

. IMpLICATIonS foR
dEvELopInG CounTRIES
Data on the actual performance of developing
countries is not available, or at least none has
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been discovered in the course of conducting this
research and making presentations in a number
of countries.13 A limited set of data, which has
been obtained by personal contact with a number
of institutions, is available for South Africa. This
data is shown in Table 8, together with projec
tions of the possible outcome if South Africa was
operating within the international ranges sum
marized in Table 3.
If South Africa was to attain an innovation
performance similar to comparable institutions
elsewhere, the entire South African higher-edu
cation research system could be expected to
generate 200 to 300 invention disclosures per
year. After seven to ten years, such a disclosure
rate should lead to a portfolio of around 500 ac
tive licenses, two of which would be likely to be
generating revenue of greater than US$1 million
per year, with total revenue of US$5 million to
US$10 million per year.
Furthermore, the distribution of returns
would almost certainly be skewed, even among
the five or six major research universities, let alone
the 15 smaller institutions. A few institutions are
likely to perform relatively well, while the major
ity are likely to operate at a net loss, even after
ten or 15 years. Furthermore, the skewness and
variability of returns means that it is not possible
to predict who is likely to succeed and who will
be considered to have “failed.” Given the finan
cial constraints that exist in higher education
institutions, continued institutional support for
technology transfer is likely to be a risk, unless
external support or stimulus is provided.
In the United States, the Bayh-Dole act of
1980 provided a major stimulus for technology
transfer, but the difficulty of using a similar mea
sure in South Africa is illustrated by the funding
differences. In the United States, the proportion
of research from federal funding is 61%, while
industry contributes only 9% of total research
funding.14 In South Africa, industry funding is
58% and government funding makes up 28% of
total research funding.15 This funding pattern has
implications for IP generation and ownership, as
well, and is an example of the differences that
need to be considered when making projections
based on international benchmarks.

One argument that carries some weight is
that the high levels of industry-sponsored re
search in South Africa and other countries with
a similar pattern of funding, represent consider
able informal technology transfer embedded in
research contracts. The true performance of these
institutions, therefore, may be much higher than
is indicated by the simple “AUTM-like” technol
ogy transfer indicators.
Whether the benchmarks from countries
with large, well-developed research and innova
tion systems will scale to smaller countries is at
present unknown. More detailed analysis and
measurement are required to determine appropri
ate benchmarks and to construct a more robust
and accurate economic impact model.

. ConCLuSIonS
The similar relative performance of higher-edu
cation technology transfer systems in developed
countries indicates that the creative innovation
process is inherently similar and that no one
country is significantly better in terms of the ef
ficiency with which ideas are generated and trans
ferred. The impact of a technology transfer pro
gram is determined primarily by the magnitude
of the expenditure on research and the length of
time the program has been in operation, provided
active innovation programs exist and well-trained
technology transfer professionals are in place.
These are essential requirements if institutions
and countries aspire to attain international norms
of performance.
To avoid unrealistic expectations of the ben
efits of technology transfer in smaller countries
and institutions, this data set must be under
stood. Effective models of the innovation system,
preferably based on local data, can help predict
budget requirements, the possible return on in
vestment, and the timescales to attain these goals.
Measurement of the local innovation system
should commence at the earliest possible stage,
because early indicators (such as the invention
disclosure rate) can provide insight into how the
remainder of the value chain is likely to develop.
The long time-period required for individual
institutions to derive benefits, and the fact that
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the benefits are largely to the national economy,
indicate that appropriate national support mea
sures are needed to encourage innovation devel
opment and to overcome institutional resistance
in resource-constrained environments. Using an
innovation-system model (where appropriate)
to evaluate and quantify alternatives, further re
search is needed to determine the most effective
support measures.
Institutions and innovation systems need to
take into account the skewness and inherent vari
ability of innovation returns. In the early stages,
more emphasis needs to be placed on intermedi
ate benchmark measures and less on such tradi
tional measures as license revenues and spinout
company formation. n
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Table 3: Research and Innovation Value Chain
Typical Ranges per $100m ATRE
Invention disclosures

40 – 50

Patents

20 – 30

Licenses

10 – 15

Spinout companies

1–5

Income

$1m – $3m
(1% – 3% of research expenditure)

Table 4: Average Returns in 2002
(license Income as % of Total Research Income)
Group

u.S.

All universities

Australia

u.K.

3%

1.60%

1.50%

1.10%

1.60%

0.80%

0.60%

0.55%

8

2

1

5

0.28%

0.23%

0.08%

0.02%

Lower 95%
No. of universities excluded
from average
Bottom 50%

Canada

Note:“Group” refers to university rankings by percentage of license income, as indicated in Figures 2–5.

Table 5: Typical Technology Transfer Office Budgets
(As % of Total Research Expenditure)
university size

Budget
(u.S./Australia model)

Small
Medium
Large

Budget
(u.K. model)

1%–2%

2%–3%

0.5%–1%

1%–2%

0.2%–0.5%

0.5%–1%

Table 6: likely Outcomes (Estimated Budget vs. likely Income)
Group

u.S. & Canada

u.K. & Australia

Bottom 50% (of all universities)

Loss

Large loss

50%–95%

Break even–profitable

Loss

Top 5% (of all universities)

Very profitable

Profitable

Note:“Group” refers to university rankings by percentage of license income, as indicated in Figures 2–5.
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Table 8: Projections of TTO Activity for South Africa
International
ranges
(from Table 3)

Current (2004)
(based
on five
universities)

Projections
if at
international
norms

US$194m

ZAR2b

Research expenditure (ATRE)

per US$100m

per US$100m

US$500m

Invention disclosures (total)

40–60

23

200–300

Patents filed

20–30

6

100–150

Licenses

10–15

4

60–100

Start-ups

1–5

3

5–20

Patent budget (as % income)

0.2%–0.5%

0.30%

License income

1%–2% of total

0.1% of total

US$5m–US$10m

Size of staff

4–20

9

20–100

Note: Projections are based on likely ranges from international benchmarks.

Figure 1: license Income
(1991–2004 for u.S., 2000-2003 for Other Countries)
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Figure 2: license Income for u.S. universities for Fy 2002
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Figure 3: license Income for u.S. universities for Fy 2002
(logorithmic plot)
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Figure 4: license Income for Canadian universities for Fy 2002
(logorithmic plot)
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Figure 5: license Income for Australian universities for Fy 2002
(logorithmic plot)
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Figure 6: Typical Phasing of the Value Chain
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Figure 7: Impact of Policy Choices on Performance
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Figure 8: Estimation of National Internal Rate of Return (IRR)
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Figure 9A: Disclosure Rate vs. Age of Office
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Figure 9B: Disclosure Rate vs. Research Expenditure
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Figure 10A: TTO Age as a Determinate of licensing Income (u.S.)
30
Average Income

license Income (uS$m)

25

Median Income

20
15
10
5
0
Before 1971

1971-1980

1981-1985
1986-1990
year TTO Established

1991-1995

1996-2000

Source: IIPI Report on South African University Technology Transfer: A Comparative Analysis, Jan 2004.

HANDBOOK OF BEST PRACTICES | 22

HEHER

Figure 10B:TTO Age as a Determinate of licensing Income (Canada)
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Public Sector IP Management in the Life Sciences:
Reconciling Practice and Policy—
Perspectives from WIPO
anTony TaubMan, Acting Director and Head, Global IP Issues Division, Life Sciences Program,

World Intellectual Property Organization, Switzerland

Roya ghafele, Economic Consultant, Global IP Issues Division, Life Sciences Program,

World Intellectual Property Organization, Switzerland

ABSTRACT

This chapter reviews the options for effective public sec
tor management of intellectual property (IP) in the life
sciences, focusing on the need for a judicious, pragmatic
choice of options along two axes: (1) deployment of
exclusive rights over technology and (2) use of market
mechanisms to bring a new technology to the public.
The essence of public sector IP management is finding
the right settings along these two axes that will deliver
tangible outcomes in line with defined public-interest
objectives. Experience shows that ex ante assumptions
about how to gain optimal leverage from exclusive rights,
and the appropriate degree of reliance on market mecha
nisms, are unlikely to serve a public sector IP manager
well. In clarifying objectives and the practical means of
achieving them, pragmatic coordination between the
practical and policy levels is essential. Public sector IP
managers are more likely to be assessed against public
interest expectations than their private sector colleagues.
In IP management in the life sciences, policy and prac
tice are ultimately two sides of the same coin; practi
tioners cannot hope, expect, or plan to operate outside
the broader policy perspective. Policy-makers therefore
need to consider the actual practice of IP management
when assessing a policy framework for innovation in
the life sciences. IP managers should be open to using
legal mechanisms flexibly for inclusion, or exclusion, as
required to achieve their goals. Finally, managers should
seek mechanisms to pragmatically structure and promote
partnerships with those who have the resources necessary
to bring life-sciences innovation to the public. Such part
nerships may be centered in the public, philanthropic, or
private sectors, but more likely fall into a hybrid mix of
these categories.

1. ovERvIEW And ConTExT
1.1

Toward policy-rich practice and
practice-informed policy

Researchers, technology managers, and intellec
tual property (IP) advisors who work in the life
sciences and who use the IP system are not oper
ating in a policy-neutral, strictly technical envi
ronment. An overarching public interest in lifesciences innovation means that the accumulated
impact of many seemingly independent, individ
ual choices will in fact have implications for how
the IP system is perceived by policy-makers and
will therefore help to determine policy directions.
The practical choices made when managing IP
rights therefore ultimately influence public policy
debate. Indeed, given public expectations for lifesciences innovation, choices over when and how
to exercise IP rights are inevitably assessed from a
policy point of view.
Practitioners need to be sensitive to the poli
cy environment and alert to the debates that swirl
around two related aspects of public concerns:
(1) the impact of life-sciences developments in
themselves and (2) the impact when intellectual
property is applied to life-sciences innovation.
While this may frustrate legally trained practitio
ners, how the IP system is used, and the perceived
equities of access to the benefits of a life-sciences

Taubman A and R Ghafele. 2007. Public Sector IP Management in the Life Sciences: Reconciling Practice and Policy—Perspectives from WIPO. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org.
© 2007. A Taubman and R Ghafele. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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technology, can affect public perceptions of the
legitimacy of that technology. Juma and Konde
write:
Resistance to new technologies is likely to be re
duced by changing perceptions of access to the new
technologies as well as to their markets. This has not
been the case with agricultural biotechnology, which
involves worldwide exports with the potential for
product displacement, while leaving wide margins
of uncertainty for technology followers.1
Moreover, the policy debate cannot oper
ate in isolation from the practical realm. Policy
makers need a robust, practical understanding of
the technologies concerned, of the nature of lifesciences innovation, of the overall trends in the
IP landscape, and of the real-world impact of the
actual exercise of IP rights. Only then can policy
makers effectively balance concerns about equity
of access with the proper exercise of exclusive
rights. Optimal policy choices require the widest
range of distilled, neutral empirical information
about the use of intellectual property in relation
to key life-sciences technologies. Indeed, the ex
perience of practitioners contributes valuable in
sights needed to guide and buttress policy debate
over the future of life-sciences innovation.
1.2 Resolving the paradox: public
interest through private rights

Reconciling the public policy role of the IP system
with the management and exercise of private IP
rights addresses the central paradox of IP policy:
what legal exclusions from the public domain are
required to promote the public interest? And how
can those exclusive rights, once granted, be best
deployed for IP law to function as a public policy
tool? Life sciences concern the basic human needs
of food, health, and a safe environment. How
then can IP rights be best managed to promote
public welfare by making available the fruits of
life-sciences innovation and spurring economic
development? These benefits arise not from the
mere presence of a formal system of assessing,
granting, and enforcing IP rights, but from the
judicious, skillful application of these legal mech
anisms in practice. Positive welfare gains from
IP mechanisms emerge from an accumulation
20 | HANDBOOK OF BEST PRACTICES

of individual choices, not just from the abstract
process of shaping a legislative framework This
is most directly illustrated by the experience of
managing rights held by public sector institutions,
which can be held more immediately responsible
than their private sector counterparts for securing
tangible benefit gains directly from public invest
ment in research and development. Thus, we see
the emergence of public sector IP management
as a distinct subset within the broader discipline
of IP management. For instance, pharmaceutical
public-private partnerships “must be as aggressive
in the way they use IP as any commercial unit, but
for a different purpose—namely to pursue their so
cial objective of getting quality, affordable products
to developing country patients.”2
The optimal implementation of IP rights re
quires a practical understanding of the full range
of options for exercising exclusive rights and a ca
pacity to assess and implement those options as
part of a broader strategy. IP rights are exclusive
in their formal legal character, but the modes of
exercising such rights are highly diverse and will
correspond to an institution’s broader objectives.
A predetermined license template, for example,
will not lead to best practice in IP management
in the life sciences, because its use may effectively
foreclose the full range of choices available and
preempt the objective assessment of the implica
tions of each option. A good manager will instead
judiciously use IP mechanisms to leverage the re
sources needed and obtain the freedom to oper
ate, while prudently assessing the likely impact of
various forms of IP rights exploitation.
Workable public sector–management models
do not normally entail an exclusive reliance on re
lease into the public domain nor on wholly exclu
sive licensing. While it is rare to see a life-sciences
product delivered without some engagement of
private sector actors responding to market signals,
it is usually misleading to set the full product de
velopment pipeline wholly in the public or private
sectors. Given especially the necessarily stringent
regulatory environment confronting the life sci
ences and the need to garner resources for the full
product development process, investments will
likely draw on both public and private resources.
Therefore, rather than employing simple public/
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private or open/exclusive labels, the full range of
options available to public sector IP managers can
be more usefully analyzed along two continuums:
(1) degree of exclusivity, ranging from defensive
publishing in the public domain through open
source or commons-based constructs, and nonex
clusive and exclusive licensing, to direct exploita
tion of exclusive rights; and (2) degree of market
engagement, from pure research, through mak
ing some use of private resources in the develop
ment pipeline, to various modes of outsourcing
product development and the dissemination of
a proven life-sciences technology, including spi
noffs and transfer of rights to private firms. Even
if a public sector IP manager’s core responsibility
is to deliver welfare gains to the public in the form

of accessible new life-sciences technologies, she or
he is likely to have to assess the full range of op
tions across these two spectra when formulating
a practical strategy. These options are presented
schematically in Figure 1 (which is also further
discussed in section 4.2 below).
1. The meaning of global
intellectual property

Participation in the international patent system
continues to grow and diversify in three overlap
ping ways, each with direct ramifications for the
field of public sector IP management:
1. Greater geographical and cultural diversity.
Membership in the Patent Cooperation
Treaty (PCT) has shifted from an early

Figure 1: Public Interest IP Management Goes Beyond licensing Arrangements
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preponderance of developed and transi
tional economies to a clear majority of de
veloping countries. In terms of the actual
use of the system, patent applicants from
the developed world continue to predomi
nate, but current trends reveal double-digit
growth, sustained over five years or more,
on the part of certain key developing coun
tries. This trend, if sustained in the medium
term, would significantly shift the center of
international patent activity. PCT interna
tional applications received from develop
ing countries in 2005 rose 24.8% com
pared to 2004, and constituted 6.9% of all
filings. China, Mexico, and the Republic of
Korea are among those countries register
ing double-digit percentage increases in use
of the PCT.3 (Figure 2)
2. Greater use of the system by public sec
tor and not-for-profit entities. In the
life-sciences domain, these are as di
verse as India’s Council of Scientific and
Industrial Research, Empresa Brasileria
de Pesquisa Agropecuaria (Embrapa), the
Korea Research Institute of Bioscience
and Biotechnology, the International
Aids Vaccine Initiative, the Medicines for
Malaria Venture, and CAMBIA.
3. Growth in use of the system in life-scienc
es technologies stronger than the general
trend. For instance, PCT publications in
the technical field represented by IPC Class
A61K (Preparations for Medical, Dental,
or Toilet Purposes) rose 5.1% in 2005.
In the next highest field (G06F—Electric
Digital Data Processing) the growth rate
was 4.6%.4
Public sector users of the patent system who
are working in the life sciences face practical
questions about how to manage a patent estate
to advance their institutional objectives. While
this has been the subject of a longstanding de
bate in the developed world, it is increasingly a
practical issue for developing countries as well.
The rate of public sector patenting in life-sciences
research in developing countries is growing expo
nentially. These countries are, of course, starting
22 | HANDBOOK OF BEST PRACTICES

from a small base, so the actual impact will be
felt over time as international activity translates
into distinct national rights. It is certain, how
ever, that government agencies and other public
sector institutions in developing countries will be
increasingly responsible for managing a growing
stock of life-sciences intellectual property result
ing from investment of public resources, or from
combined private and public sector inputs. These
governments will assume the task in light of their
overarching responsibility to promote the public
interest through the management of this intel
lectual property. Doing so entails working on
a broader canvas than the mainstream manage
ment of intellectual property the essential focus
of which is to promote commercial outcomes.
Such social or institutional responsibilities
require that public sector IP managers develop
and apply practical skills to manage intellectual
property effectively. They may need to look be
yond conventional, private sector methodologies
to find appropriate ways of managing intellec
tual property to ensure the desired public inter
est outcomes. These might include ensuring the
development and effective dissemination of new
technologies to the public (for example, new
pharmaceuticals), promoting economic and social
development, creating skilled jobs, or enhancing
urgent research funding.
Effectively managing public interest IP is a
task that requires judgment and acute sensitivity,
acutely so in life-sciences domains. It requires ad
vanced skills. There is a wide spectrum of possible
approaches, and there are many distinct objectives
that may be pursued. IP management to produce
public health outcomes is particularly demand
ing, yet vitally important for the public interest.
1. Choices for public sector IP management

While often debated in abstract terms, the impact
of IP laws and IP rights is ultimately determined
by a series of practical, yet critical, choices. For
the public sector, these choices are increasingly
guided by IP management policies. Tom Ogada
has categorized these choices in terms of:
• Who owns the intellectual property gen
erated by government-funded research
activities?
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• How will revenues/benefits from the com
mercialization of intellectual property be
shared between the researcher/inventors,
the department, the institution, and gov
ernment funding providers?
• Which, if any, government rights/stipula
tions are attached to the commercialization
of intellectual property generated under
government-funded research?
• In the case of privately funded research, who
will own any resulting intellectual property?
• Will spinout companies or licensing con
tracts be used to transfer technology to the
private sector for commercialization?
• Who will manage IP assets, including the
negotiation of licenses and royalty sharing?

• To what extent will the institution encour
age research commercialization through
entrepreneurial activity?
• How will the costs of IP protection and
maintenance be paid?
• How should any invention disclosure pro
cedure be managed?
• How will conflicts of interest between
teaching/research duties and commercially
driven projects be handled?
To assist public sector IP managers and
policy-makers in making these decisions, Ogada
has authored Guidelines on Developing Intellectual
Property Policy for Universities and R&D
Institutions in African Countries.5 Other relevant

Figure 2: PCT Applications of Select Research Centers
in India, the Republic of Korea and South Africa
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World Intellectual Property Organization
(WIPO) resources include:
• Successful Technology Licensing. This booklet,
written for use by business managers, technol
ogy managers, and scientists who deal with
licensing questions, aims to help its readers
negotiate win-win licensing agreements, in
which all parties receive and exchange ap
proximately equal benefits and value.
• Exchanging Value—Negotiating Technology
Licensing Agreements: A Training Manual.
This text focuses on the practical business
needs and concerns of nonspecialists who
have to deal with licensing in or licensing
out of technology. The manual includes an
outline for a program schedule and practical
guidelines for creating and managing teams/
groups for conducting mock negotiations.
(These are from a five-day practical workshop
on negotiating technology licenses, includ
ing a case study on tuberculosis vaccines.)
• Advanced Distance Learning Course on
Biotechnology and Intellectual Property. This
addresses aspects of patenting biotechno
logical inventions and the plant breeder’s
rights systems, as well as IP in research and
development, and the management and
practical use of IP rights.

custodian countries derive social and economic
benefits from these vital feedstocks for life-science
research. Accordingly, delivering on the promise
of life-sciences innovation requires outcomes tai
lored to the circumstances of individual countries.
This means democratizing innovation to address
neglected diseases that disproportionately afflict
the developing world, or to respond to the agro
nomic, environmental, and nutritional context of
developing country agriculture.
Many developing countries possess the hu
man capital necessary for life-sciences innovation,
and they seek the practical pathways to realize this
potential, not only from the point of view of eco
nomic development, but also from the broader
perspective of public welfare. For instance, local
health practitioners have extensive practical expe
rience in traditional knowledge systems, as heirs
of generations of “clinical trials.” In dealing with
endemic diseases, the knowledge reserves of the
health practitioners need to be drawn on more
systematically as part of a sustainable, bottomup approach to development. The recent launch
of the South African Indigenous Knowledge
Systems (Box 1) places traditional knowledge
policy squarely in the context of innovation pol
icy and the equitable sharing of benefits.

2. BIoMEdICAL InnovATIon
And dEvELopMEnT

Debate continues over the overall role and impact
of IP protection in relation to meeting the twin
goals of fostering innovation and promoting the
effective dissemination of the fruits of innova
tion.8 Adopting the approach of this Handbook,
this chapter does not enter into the debate be
yond pointing out that the policy context is a
highly dynamic one, greatly influenced by feed
back from the actual and perceived impact of the
accumulated choices of IP managers. It is clear
that the effectiveness of the patent system for at
taining these objectives depends on its practical
context, which can be addressed on three levels:
1. the regulatory and administrative level (dis
cussed in more detail below)
2. the level of skills and capacity (As a com
plex policy mechanism, the patent system
requires skilled operators.)

2.1 Capturing the benefits of
indigenous innovation

Concentrating on technology transfer as a key
innovation strategy, mainstream discourse on in
novation and development tends to cast develop
ing countries as recipients of technology produced
elsewhere. While access to foreign technology is
clearly integral to development, it is increasingly
important to focus directly on capturing the in
digenous innovation potential of developing coun
tries.6 Given that developing countries hold signif
icant traditional knowledge and genetic resources,
this arguably applies in the life sciences more than
in any other field. At least one of the lessons of
the biopiracy debate is the need to ensure that
2 | HANDBOOK OF BEST PRACTICES

2.2 Innovation and intellectual
property—the practical context

CHAPTER .

3. the level of individual users of the system:
applicants, opponents, licensees, advisors,
and advocates, with a special focus here on
public interest users
At the regulatory and administrative level,
the key elements of a practically effective system
include:
• patent quality, construed here as the great
est possible convergence between actual
patenting outcomes and the public inter
est as delineated in the principles of patent
law, especially the conventional criteria for
patentability
• the transparency, clarity, and predictability
that effective administration provides in
terms of the practical accessibility of timely
patent information, the clarity of scope and
title, and functional patent quality
• practical equity of access to the system, so
that the skew of accessibility that favors al
ready dominant private sector players can
be reduced
• persuasive deterrents and remedies against
the misuse of patent rights once granted
2. System functionality and the capacity
to make the system function

In sum, much of the public welfare impact of the
system and actual delivery of equity depend on
system functionality—not merely on the formal
legal settings that form the focus of international

debate. Effective functionality depends on de
ploying three special skill sets:
1. The legal and policy skills required to draft
and implement suitable legislation and
policy mechanisms within the framework
of international standards but also tailored
to national needs and priorities
2. The technological know-how and legal
skills required to draft patent documenta
tion and to objectively assess the validity
and legitimate scope of patents in patent
examination and judicial processes
3. Technological management skills, includ
ing valuation of disclosed innovations
in light of institutional goals (not just in
terms of commercial value), assessment of
potential technology development and dis
semination pathways, and the formulation
of patenting and licensing strategies
As a rough generalization, capacity-building
processes in developing countries have tended to
focus on each of these skill sets in turn, beginning
with a top-down legislative perspective. This has
been most conspicuous in the decade of the im
plementation of the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS).
This sequence of shifting priorities for capacity
building reflects a natural evolution from a legalis
tic view of implementation and a reactive, or defen
sive, posture followed by a greater concentration on
building administrative and institutional capacity,

Box 1: Traditional Knowledge and Innovation in South Africa
South Africa’s Indigenous Knowledge Systems (IKS) Policy aims at “positive synergy between South
African IKS and the South African National System of Innovation” through:
• the creation of a legal benefit-sharing framework
• the establishment of a formal recording system for IK
• legislation to ensure minimum standards in information and material transfer agreements
with respect to IK research
• the promotion of IK links with the science base by means of targeted funding instruments
• amendments to patent legislation to enforce IK prior art declaration
Source: WIPO.7
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to the current growing emphasis on strategies that
practically and proactively capture direct benefits
from indigenous research capacity and comparative
advantage in knowledge resources. This Handbook
is emblematic of the culmination of this last trend.
But capacity building must continue on these three
tracks in parallel, mutually informing and reinforc
ing one another, especially in the life sciences. In
particular, the practical view from the bottom up
should inform the view from the top down in a re
spectful dialogue between policy-conscious practi
tioner and practically informed policy-maker.
2. The policy impact of effective users

Clearly, it is the central role and responsibility of
administrators to promote the effective and efficient
functioning of the system as a system. But users are
not just customers of the system; they function as
active agents engaged in safeguarding patent quali
ty: “users” have responsibilities as patent applicants,
as patent opponents, as litigants, and as licensors
or licensees. Adversarial legal processes have shaped
much of the important detail of patent law. The
costs and limitations of the existing administrative
and legal systems have led to calls to more system
atically include a user perspective on patenting out
comes.9 The growth in life-sciences patent filings by
government agencies and public sector institutions
may lead to further blurring of the boundaries be
tween administration and knowledge management
within public sector agencies and to the implemen
tation of a broader, more holistic array of innova
tion policy settings. Ideally, the responsibility to ef
ficiently manage IP portfolios will be understood in
relation to the broader responsibility to contribute
to public policy outcomes. This extra layer of opera
tional and ethical complexity creates a distinct chal
lenge for the public sector IP manager. Managers of
private sector IP portfolios in the life sciences may
need to consider ethical and social constraints, such
as professional ethics and corporate social respon
sibility programs, but this chapter concentrates on
the public sector manager.
2. The public sector IP manager
as a system user

Since the informed, judicious management of lifesciences IP is the most realistic way of boosting
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actual availability of vital life-sciences technolo
gies, the public sector IP manager has fundamen
tally important responsibilities. IP management
is a practical craft, not a rigid legal discipline,
difficult to capture in terms of checklists and
licensing templates. This section reviews best
practice for public sector IP managers in life-sci
ences technologies. The discussion focuses on two
broad categories of responsibility: policy-orient
ed, or systemic, and outcome-oriented, or practi
cal. Experience has shown that early assumptions
about the right mix of exclusivity or openness of
access, and the right proportion of a reliance on
public resources and an engagement of private
interests, are unlikely to be effective or even de
fensibly fair. Public sector research programs that
routinely consign publicly funded research to the
public domain can attract just as much criticism
as those programs that seek excessive exclusivity
in the management of public-funded intellectual
property. Inattentively letting research outcomes
fall into the public domain can allow richer and
more nimble private interests to benefit dispro
portionately from access to this publicly funded
knowledge. Public sector IP management must
therefore be viewed with a strong pragmatic, em
pirical perspective. Accordingly, an outcome-ori
ented approach to public interest IP management
includes:
• promoting an in-house invention disclo
sure under effective confidentiality rules
• analysis of disclosures in the light of institu
tional objectives
• assessment of technologies against priori
ties, categorizing them for public domain
release or defensive publication, for open
licensing, for nonexclusive licensing, or for
a strategic in-house focus
• review of the obstacles to the effective use
and dissemination of the new technology,
including resource limitations, regulatory
obstacles, and constraints on freedom to
operate in target markets, noting that de
veloping countries generally have greater
freedom to operate due to the relatively low
levels of patenting
• formulation of strategies, and identifica
tion of potential partnerships, that aim to
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bring a life-sciences innovation to targeted
groups, which entails considering commer
cial, technological, and regulatory issues, as
well as an assessment of external require
ments that include background intellectual
property, project management capacity,
technological and manufacturing capacity,
regulatory process capacity, and investment
capital
• leveraging intellectual property holdings
to:
- promote the dissemination of techno
logical knowledge
- ensure the availability of improvements,
further applications, and derivatives of
licensed technology
- secure access to regulatory data and
background/platform technology
- reserve rights for third-party use in hu
manitarian applications
- reserve exclusively licensed rights in the
event that licensees fail to meet public
interest performance criteria (such as
low-cost or cross-subsidized distribution
to target markets)
- safeguard grant-back of background in
tellectual property, project intellectual
property, or regulatory dossiers in the
event that licensees fail to meet public
interest performance criteria
- bolster institutional research capacity,
through licensing fees, partnerships, ac
cess to research tools and other platform
technologies
In the hands of the public sector IP manager,
an IP portfolio is not necessarily viewed purely as
a commercial asset, although commercial valua
tion and product development and dissemination
will normally be essential. An IP portfolio also
functions as:
• a transactional asset, used to promote, expe
dite, and clarify the formation of technolo
gy partnerships, and to define and structure
specific contributions and expectations in
partnerships
• an institutional asset, used to leverage access to necessary resources to achieve

institutional goals, ranging from specific
R&D expertise to research financing
• a policy asset, used to influence choices of
technology partners, including private sec
tor partners in public–private partnerships,
and to promote humanitarian or cross-sub
sidized access to life-science technologies in
developing countries or in other beneficiary
groups
The public sector IP manager in the life sci
ences may also need to consider the public-policy
expectations placed upon her or him, explicitly,
implicitly, or even retrospectively. She or he
should, in particular, consider the following poli
cy-oriented or systemic responsibilities:
• influencing positive innovation patterns,
promoting the effective collaboration and
open dissemination of upstream research
findings, both for the inherent value of the
knowledge as a public good and as a means
of promoting the widest possible applica
tion of upstream biotechnologies, such as
research tools, diagnostic tools, and genetic
modification technologies
• promoting analysis, adaptation, and up
take of practical-innovation structures that
make effective use of diverse resources, such
as strategic partnerships with other public
institutions, public–private partnerships,
and open collaborative mechanisms
• good-faith participation in the patenting
process, focusing on strategic and systemic
outcomes, rather than on the tactical use of
the system, and actively promoting patent
quality
• fostering an interdisciplinary approach to
public policy formulation in the life sciences
and a comprehensive view of the innovation
process within the broader policy context
• promoting open licensing models for re
search or for humanitarian uses in pub
lic health and agricultural development
programs for the benefit of developing
countries
Exemplifying the crossover between policy
and practice is the humanitarian licensing of
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medical and agricultural research generated by
universities or other public research institutions.
“Humanitarian licensing” describes a range of
public policy licensing strategies. These might
include providing an open license to developing
country technology users to sell derivative prod
ucts back to commercial markets, as in the case of
agricultural biotechnology. Humanitarian licens
ing might also mean establishing reach-through
rights reserving access to derivative innovations
(for example, for use in licensing early-stage phar
maceutical research). These practices may be seen
as a movement to promote certain technology li
censing norms, even to create de facto exceptions
to patent rights in the life sciences. They might
also be imagined as a suite of practical options
for public sector technology managers to deploy
in pursuit of institutional objectives. But the
movement towards humanitarian licensing or re
serving rights for humanitarian use still begs im
portant questions at the core of public sector IP
management:
• How does the deployment of exclusive rights
over life-science technologies promote the
public welfare, and when is deployment of
exclusivity contrary to humanitarian goals
(the exclusivity axis)?
• To what extent, and how, should public
sector IP managers engage private interest
and private sector resources to draw tech
nologies through a demanding product
development process, and when will hu
manitarian interest be enough to impel a
product through the product pipeline (the
market axis)?
See Box 2 for a recent exchange that high
lights the broader range of options open to pub
lic interest IP managers who have objectives that
extend beyond the simple commercialization of
research.

. puBLIC poLICy Ip MAnAGEMEnT
In THE LIfE SCIEnCES
IP management is not an end in itself, but an es
sential part of a wider array of policy tools that
need coordinated implementation to achieve
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desired outcomes. The efficiency and effective
ness of IP management needs to be measured
against broader objectives, including its ability
to complement innovation policy and public in
vestment in R&D infrastructure. Optimal use of
intellectual property in the life sciences requires a
well-managed IP system, clear policies about the
ownership of intellectual property generated by
the public sector or from public sector inputs, ad
equate R&D resources and infrastructure, tech
nology transfer centers at universities and other
research institutes, and mechanisms to bring re
search outcomes to the market. We focus on three
elements in particular:
1. Setting the regulatory and policy
framework
2. Building functioning public institutions
3. Managing public–private partnerships
.1 The examples of Jordan and Indonesia
.1.1

Overview

This section reviews information gathered in field
interviews with practitioners in biomedical in
novation in two disparate developing countries:
Jordan and Indonesia. Despite fundamental dif
ferences in size, structure, resources, and geopo
litical context, Indonesia and Jordan have both
set up IP strategies to promote the social benefits
of domestic biomedical innovation. The countries
have sought the right institutional framework to
link IP policy and IP management for the ad
vance of public welfare. Indonesia is the fourth
most populous country in the world and, after
Brazil, is host to the greatest range of biodiversity
worldwide. Jordan, with four million inhabitants,
is a relatively small country with little biodiver
sity, few natural resources, and no oil reserves.
Both countries have strong potential for bio
medical innovation. Indonesia’s opportunities are
linked to the natural medicines market. Jordan’s
pharmaceutical industry is the country’s second
largest export earner, after textiles.
Jordan’s pharmaceutical industry is making
a structural shift from focusing solely on generic
manufacturing to promoting biomedical inno
vation. Six out of 12 Jordanian pharmaceutical
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Box 2: Alternatives to Commercialization in Public Sector IP Management:
Four Points of View
According to Tom Ogada, who is responsible for putting in place a formal policy for dealing with
IP issues at Moi University,“an institutional IP policy serves to promote the generation, protection,
and commercialization of IP rights. Universities and R&D institutions are key generators of IP assets,
but there are many stakeholders involved in the process—researchers, students, private sponsors,
technology transfer units, national patent offices, the public, and so on. An IP policy is needed
to harmonize the conflicting interests of the various stakeholders.” Thus, a university’s IP policy
should aim to “create an environment that encourages and expedites the dissemination of new
knowledge for the greatest public benefit, while protecting the traditional rights of scholars to
control the products of their scholarly work. It should ensure that the financial or other benefits of
commercialization are distributed in a fair and equitable manner that recognizes the contributions
of the inventors and the institution as well as other stakeholders. It should promote, preserve,
encourage, and aid scientific investigation and research. It should sensitize students to IP and tap the
creativity of the young. It should create incentives for researchers to conduct research and provide
rewards for intellectual capital. In developing country universities, it should also stimulate research
efforts to find solutions for pressing problems, such as medicines, clean water, and energy.”
Dana Bostrom, Industry Alliances Office, University of California, Berkeley, adds that “most
university technology transfer offices do not have a primary goal of revenue generation. Professor
Ogada captures the goals of technology transfer well, including: promoting the dissemination of
knowledge, and assuring stakeholders that risks, benefits and credit are distributed equitably. The
Association of University Technology Managers (AUTM) does not tend to use revenue generation
as an indicator of benefit. Rather, [AUTM] uses information about how the university distributes
revenue received under licenses to benefit the university community; how products which are
brought to market benefit everyone;and how innovative,university-led licensing programs can push
an industry or technology forward (among other measures). A blanket give-it-away approach, on
the other hand, usually benefits large companies, who are able to create and patent improvements
to the “free” intellectual property more rapidly than other organizations or individuals. For
developing economies, or early-stage technology of all kinds, “free” can come with a heavy cost.
Although free intellectual property can still achieve the best outcomes for everyone, this strategy is
best determined on a case-by-case basis. Without resources to sustain a free commons, often only
those with resources can benefit from what was released. More than 500 new products became
available last year as a result of licenses from U.S. and Canadian academic technology transfer
efforts. More intangibly, universities benefit from the interaction with companies, to see how
academic thinking and solutions can be applied to commercial problems. Ironically, universities
also benefit from our academic community’s greater awareness of intellectual property; we live in
a world where intellectual property plays a greater role, and companies, in their interactions with
universities, demand greater accountability. Ultimately, universities are increasingly being asked to
demonstrate to their community the benefit they provide in the knowledge economy.”
Gavin Moodie, Principal Policy Advisor at Griffith University, Australia, notes that “the
fundamental question for a public university’s IP policy should not be: ‘How can the commercial
potential of the property be maximized?’ but ‘How can the transfer of new ideas be maximized?’
Commercializing intellectual property is only one way—and often the worst way—to transfer new
ideas. Concentrating on commercializing intellectual property encourages universities to overvalue
their property, leading to protracted negotiations using lawyers and other intermediaries, which
frustrates rather than facilitates the free flow of ideas necessary for research and innovation to
flourish. Revenue from licensing intellectual property in fields other than biotechnology is a trivial
(Continued on Next Page)

HANDBOOK OF BEST PRACTICES | 2

TAuBMAN & GHAFElE

Box 2 (continued)

proportion of university revenue. And, of course, licensing revenue isn’t all surplus or “profit”—
with their business development managers, IP lawyers, and accountants, commercialization
units are very expensive. They also impose heavy indirect costs on researchers who must explain
their research and its implications to intermediaries. Joshua B. Powers reported in The Chronicle
of Higher Education (September 22, 2006) that more than half of U.S. universities consistently
lose money on technology transfer. And as the Australian policy and management consultant
John Howard observes, researchers and research organizations will, except in very rare
situations, earn more from being paid for their work input in contracts and consultancies than
from licenses and royalties flowing from intellectual property or from income earned in spinout
companies. I therefore suggest that—with the exception of biotechnology—public universities
simply give away most intellectual property as a contribution to the general good. This could
be subject to universities including in their IP licensing agreements a standard “blockbuster” or
“jackpot” clause that provides that should their intellectual property contribute to blockbuster
revenues of, say, $50 million over 10 years, there would be a sharing of revenue determined by a
nominated commercial arbitrator.”
Bernardo Marcos Diez,Secretariat for Technology Transfer (New Technologies Research Group),
Faculty of Law, Universidad Nacional de Mar del Plata, Argentina, advised that the Governing
Council of the University had “recently approved a regulation which defines the scope, players,
and procedures regarding the protection of any intellectual creation resulting from scientific or
cultural research carried out within the university and/or with third parties.We have adopted an
active IP awareness policy to reach those involved in this process, from the researchers, teaching
staff, and students, to members of the decision-making bodies. We are running conferences in
the different academic units in order to explain the objectives, implications, and advantages
of IP protection, as well as of technology transfer between the university and external social/
commercial milieu.We have also applied to join the WIPO University Initiative in order to appoint
a coordinator and benefit from relevant IP reference materials. So we are in the early phase of
what will be a lengthy process, but one which, it is already clear, will bring economic, scientific
and developmental benefits, not only to our university, but also to our broader society.”
Source: WIPO Magazine.10
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companies have now developed patent portfo
lios, several of which are potential blockbusters
(remarkably, until recently most of these com
panies made no use at all of the patent system).
Indonesia is taking several measures to bolster its
overall innovation strategy. It is, for instance, pro
moting awareness among public research institu
tions and the private sector of the opportunities
in the natural medicines market. This market of
fers annual growth rates as high as 20%.
These countries are steadily increasing their
IP holdings on indigenous research activities,
particularly in the critical areas of the life sci
ences: medical and agricultural research. As they
do, broad public interest issues arise. How can
or should private firms be encouraged to man
age their IP holdings to contribute optimally
to national social and economic development?
Additionally, how can public sector or publicfunded IP estates be best managed to safeguard
the public interest by capturing and equitably
distributing the benefits of innovation? Finally,
what broader institutional settings are needed to
bolster public welfare outcomes from research?
A public interest IP management perspective
can help technology transfer centers at public
research institutions find answers to these ques
tions. Additionally, effective IP management en
courages public–private partnerships that address
humanitarian goals, in particular, the creation of
affordable new medicines.
The experiences of both Indonesia and
Jordan illustrate the broader need for appro
priate domestic institutional settings in order
for the countries to be able to reap the benefits
of biomedical innovation. Their experiences
of Indonesia and Jordan also reveal the im
portance of the interplay between investment
in institutional infrastructure and the more
diverse and tailored approaches to managing
intellectual property within a public interest
paradigm. The discipline of IP management
has focused on the needs of firms. However,
the high level of public concern with capturing
public benefits from life-sciences research un
derscores that countries, and public sector in
stitutions, also need to make strategic decisions
about the deployment of intellectual property

on a broader base than the traditional focus of
private firms.
.1.2

Setting the regulatory framework

IP law and practice cannot be viewed in isolation
from the broader regulatory context. This is es
pecially true in the field of life sciences, which is
concerned with needs as basic as health, food, and
the environment. Public interest IP management
in biomedical innovation therefore needs to rec
oncile public health needs with commercial goals,
ideally helping to harness private sector resources
to achieve public welfare outcomes.
Indonesia and Jordan have effective IP leg
islation in place, and both have undertaken ex
tensive legislative programs to bring their laws
into compliance with the TRIPS Agreement.
Indonesia also adhered to the PCT in 1997, and
Jordan has entered a bilateral trade agreement
with the United States, which has implications
for Jordan’s IP laws. In both countries, IP policy
has been developed in an interdisciplinary way,
as part of a broader public policy mix, rather
than as a narrow, specialized discipline. Jordan’s
Ministry of Planning is responsible for coordi
nating public policies regarding innovation, and
for measuring Jordan’s global competitiveness
in achieving this goal. Jordan’s main innovation
policy, King Abdullah II’s Vision 2020, proposes
the strategic use of IP mechanisms to achieve
society’s goals. Likewise, Indonesia coordinates
intellectual property across policy portfolios, in
cooperation with the Ministry of Research and
the Directorate General of Intellectual Property,
which screens research grants given to public re
search institutions and conducts patent searches,
supplementing the conventional literature review.
Indonesia also provides funding to patent appli
cants to make patent protection more affordable
to local companies and public research institu
tions, which is one way to address the issue of
practical equity in access to the IP system.
Jordan is reviewing possible legislative ini
tiatives regarding the management of intellec
tual property generated in public institutions.
Indonesia has passed laws that give ownership
over intellectual property generated within
public research institutions to the institutions
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themselves. This regulatory measure has been ac
companied by the establishment of technology
transfer offices (TTOs). Ten TTOs were created
throughout the country with modest start-up
capital. The offices have confounded some expec
tations by establishing successful business opera
tions in recent years. The Technology Institute of
Bandung, for example, has struck international
licensing agreements and research collaborations
with local companies that are actively seeking to
meet local needs. One public-private partnership
resulted in the development of a new machine for
harvesting local agricultural crops.
.1.

Building accountable and
effective public institutions

The benefits of the regulatory framework will
depend on establishing public institutions that
are both accountable to the public and effective
in serving it. These obligations go beyond the
traditional institutional objectives of IP offices
concerning administration of the patent system.
Their responsibilities broaden into a wider policy
role in the knowledge economy. IP mechanisms
are actively harnessed to promote the overarch
ing public interest. In both Indonesia and Jordan,
the IP office reports to the ministries responsible
for commerce and industry. This helps align IP
policy with the countries’ overall economic and
trade policy objectives. As in all countries, there
are important choices to be made between the
value of administrative independence, self-suf
ficiency and direct accountability to political
masters, and the benefits of linkages to a major
policy ministry that can encourage high-level
political attention to IP policy-making. In both
Jordan and Indonesia, the IP offices focus on the
operational challenges of using limited resources
to serve diverse stakeholders. The two offices dif
fer in size: Indonesia currently deals with a higher
patent filing rate (4,303 applications in 2005); it
was reported that Jordan had 200. But Indonesia
confronts a problem experienced in many devel
oping countries–that of finding and retaining
suitably qualified technical staff to deal with the
increasingly complex field of life sciences, effec
tive examination capacity being one important
safeguard of patent quality.
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.2 Managing public–private partnerships

Life sciences R&D is often characterized by up
stream, or basic, research conducted by public
sector or academic researchers. Public sector in
stitutions then depend on the private sector to
take life-sciences innovations through the devel
opment pipeline to yield finished products. Thus,
life-sciences innovation pathways are increasingly
characterized by an array of public–private part
nerships. Those conducting early research and
those investing in the product development phase
will naturally have different approaches to the re
lationship. But because life-sciences research has
such a strong public interest element, close atten
tion has been paid to how to manage intellectual
property for specific public interest outcomes.
Public sector research institutions are learning
to pursue the option of leveraging their IP hold
ings to ensure adequate returns from public in
vestment in research, whether those returns are
conceived in terms of narrow financial benefits or
broader social ones. And public sector IP manag
ers are trying to ensure that promising innova
tions are not left on the shelf for want of practical
mechanisms to garner the necessary resources—
finance, expertise, regulatory approval capacity,
product development, and manufacturing know
how. TTOs, situated within universities, have
also discovered the dual goal of helping to meet
humanitarian needs and to mediating between
academics and the market, which ultimately may
determine a society’s capacity to nurture innova
tion based growth.
The interaction between the public and the
private sector in health innovation can result
in philanthropic achievements that also satisfy
business interests. Successful examples of this in
the field of public health include the Medicines
for Malaria Initiative, the Drugs for Neglected
Disease Initiative, PATH, One World Health,
and the Bill and Melinda Gates Foundation.
Publicly funded innovation provides an ad
ditional mission and incentive system for busi
nesses. A tension is usually perceived to arise
between research and development. Research
is often guided by the search for new insights;
market interests are generally of secondary rel
evance. In development, however, the market is
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the defining element, since the substantial costs
and risks associated with the development of new
products and services can often only be justified
by expected earnings.11 Currently, research tends
to be concentrated in the public sector, whereas
development is most often left to business. The
relationship between research and development
is usually mediated by the protection and subse
quent exchange of intellectual property between
the public and private sectors. This means that it
is crucial to establish equity and negotiating sym
metry between these sectors, bridging between
distinct sets of goals and cultural settings. By
using the IP system, public research institutions
avoid giving away valuable knowledge without
maintaining some leverage over how it is devel
oped and disseminated, and without securing
an adequate return, whether that return is in the
form of money or social return. In this way, intel
lectual property provides a mechanism to achieve
equity with the private sector.
Motivating researchers to patent innovation
judiciously is an essential part of participating
in the IP system, and institutions need to raise
awareness about the necessity and advantages of
an active but selective patenting strategy. Incentive
structures for academics often help to pave the
way from the research lab to the TTO. One way
to achieve this is to allow academics to generate
additional revenues from consulting agreements,
royalties, and licensing agreements. Clearly, this
should not provide businesses the opportunity
to dictate the research agenda of public research
institutions, nor should it compromise the funda
mental freedom of research. Institutional policies
need to protect these values. Nevertheless, relax
ing the institutional restrictions on the interaction
between the public sector and business in healthrelated innovation might allow public research
to generate new questions and find alternative
approaches to a subject. Engagement in product
development in health-related innovation has
proven to be a valuable experience that enhances
the quality of basic research. Faculty, for example,
might develop innovative insights while resolving
problems encountered in industrial consulting.
Mansfield found that coauthorship by indus
try and academics increased the overall research

productivity in health-related innovation, con
cluding that such activity can bring a new sense
of urgency and reality to the public sector.12 In
Sweden, for example, 10% of articles on healthrelated innovation are coauthored by scientists
working in the private sector.13 Government
funding for such exchanges can provide a useful
push to such initiatives. Austria illustrates how
such a program can operate. In Austria, academ
ics have the opportunity to spend a year or two
in a company and then return to their university.
They are guaranteed their post and granted fund
ing for the exchange.
To obtain the best outcomes for public
health, researchers and institutions must under
stand the value of intellectual property, commu
nicate the worth of their intellectual property to
potential trading partners, negotiate attractive
licensing agreements, and enter agreements that
will generate appropriate returns. IP manage
ment comprises several components, including
the prioritization and identification of research
targets, decisions as to whether and which form
of IP protection to seek, and methods to gain the
attention of prospective investors/buyers of the
product.
Technology transfer centers within public re
search institutions fill an important role in secur
ing IP rights. They help researchers understand the
need for intellectual property, give support in the
application for IP protection, and help to transfer
research results to the market. As in many other
developing countries, the staff at these centers
needs IP management training. In fact, a train
the-trainers program is often needed to enhance
IP management competencies. An exchange with
IP management centers in the developed world
may, in this context, be beneficial.
To accomplish all of this, researchers and pub
lic institutions need to identify potential licens
ees, facilitate research collaboration, pool patents,
and avoid unnecessary duplication. Other ways
of encouraging public–private partnerships in
clude commissioning research projects, operating
joint research studies, financing doctoral studies
with industrial laboratory funds (with due regard
to the needs of the doctoral student to publish
results), encouraging faculty consulting work,
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and creating spinout companies. Establishing
research clusters, in which public and private
sector researchers and institutions work on com
mon research projects, provides opportunities
to exchange both tacit knowledge (know-how)
and formal knowledge (such as publications and
patents). Through the provision of a clear, trans
parent regulatory framework and publication of
basic research, anticompetitive problems can be
avoided.
From a health-equity point of view, the ef
fectiveness of licensing agreements will depend
on the conditions negotiated in these agreements
and the overall innovation market. Licensing can
lessen competition and raise anticompetition is
sues, even when there is no cumulative aspect.
Exclusive licensing arrangements may hamper
public health if the cost reduction of one mar
ket participant forces competitors to exit the
market, or if the licensing agreement facilitates
collusion.14
Indonesia and Jordan both report positive
experiences with public–private partnerships in
biomedical innovation. Indonesia has developed
an excellent framework for public–private part
nerships. The Indonesian Science Foundation
(LIPI) may be taken as a best practice example
of public interest IP management. LIPI provides
IP courses for its researchers, has developed its
own in-house IP policy, and manages an active
technology transfer center that has already issued
several licenses. LIPI has also entered into allianc
es with research institutions abroad, such as the
Max Planck Institute, with whom jointly gener
ated intellectual property is jointly owned.
Technology transfer centers in Indonesia
are attached to research institutions, such as
public universities or research organizations.
These technology transfer centers use different
names, such as Gugus HaKI (IP Units), Sentra
HKI (IPR Centers), Klinik HKI (IPR Clinics),
IPR Management Office, or IPR, and Licensing
Office. With the exception of the Eijkman
Institute, all major public research institutions
dealing with biomedical innovation have their
own technology transfer center. The extent of the
activities carried out by these centers varies from
the most advanced, which provide assistance on
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IP licensing agreements, to those that assist pri
marily with applying for IP protection or helping
raise awareness about intellectual property among
researchers. The statutes of Indonesia’s technology
transfer offices suggest very clearly that intellectu
al property held by public institutions should be
licensed under a public interest paradigm.
In Jordan, there are several examples of fac
ulty–private sector biomedical R&D collabora
tive projects, but the emphasis so far has been
on research led by the private sector. Discussions
reportedly continue regarding a suitable frame
work for the ownership of innovation created in
the public domain. The Royal Scientific Society
of Jordan has an applied, rather than a research,
orientation.
Jordanian universities do not have TTOs to
administer patent applications or negotiate licens
ing agreements. However, companies increasingly
refer to universities as subcontractors for specific
biomedical tests. So far, the universities provide
skilled labor and conduct some basic research.
These activities appear to promise more institu
tionalized partnerships and the beginning of a rela
tionship between academia and the private sector.

. ConCLuSIonS: REConCILInG poLICy
And pRACTICE
.1 Exclusivity or inclusion: public
or private interest?

The long history of patent law and patent policy
has been a dynamic record of attempts to recon
cile two complementary goals:
1. The promotion of innovation by directing
resources toward beneficial research and
development
2. The practical and equitable availability of
the fruits of innovation
Public interest IP management in the life sci
ences is itself a search for practical means of achiev
ing these twin goals. It seeks first to garner neces
sary resources and then to focus them on finding
technological solutions to neglected needs in the
public health and agricultural domains. The tangi
ble and intangible resources required for IP devel
opment include know-how, research, and product
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development capacity, clinical or field trial exper
tise, regulatory infrastructure, background/plat
form technologies, and the investment of public
and private capital. IP management strategies will
be effective if they help to apply these resources
toward unmet needs. This requires finding these
resources via new private resources (such as incen
tives and market interventions) and via new public
resources (additional funding and infrastructure
development). IP managers must also work to
better apply existing resources by leveraging access
to technologies and by drawing on private sec
tor development skills and R&D infrastructure,
indigenous research and innovation capacity, and
traditional medical knowledge.
It is tempting to argue that the traditional
conception of two distinct public and private
spheres in the life sciences is breaking down. But
it is more accurate to characterize it as a form of
evolution, a broadening of the scope of inter
action, and the creation of a far-broader policy
canvas that can accommodate more geographical,
cultural, and economic diversity in the use of the
patent system. Figure 1 (see section 1.2 above),
as discussed earlier, illustrates the options for IP
management in pharmaceutical product develop
ment. The figure illustrates how workable mecha
nisms for bringing new biomedical innovations
to the public may require (1) a range of strategic
choices to engage or eschew market mechanisms
to various degrees in order to secure the necessary
resources and freedom to operate, rather than
electing a wholly “public” or “private” technol
ogy development and dissemination model, and
(2) deployment of exclusive rights afforded by IP
protection to greater or lesser degrees of exclu
sivity and openness, ranging from direct exclu
sive exploitation or exclusive licensing, through
a range of options of decreasing exclusivity, to
simple public-domain disclosure.
Though it may seem counterintuitive, some
public sector technology-development strategies
may require exceptional degrees of exclusivity. This
may be useful, for example, when seeking access to
a private sector compound library or when nego
tiating access to an existing regulatory dossier. In
contrast, as the SNP consortium (single-nucleo
tide polymorphism) and the human genome proj

ect have demonstrated, private sector players may
see commercial advantage in deploying nonexclu
sive IP management structures, particularly for
technologies that are considered precompetitive.
No single template is likely to be anything but an
indicative guide or catalog of options. Ultimately,
good practice is good policy: the same exclusive
right may be viewed very differently if it is held
by a private firm, by a public sector agency, or by
a private charity. Equally, the exclusive right will
be viewed very differently depending on how it is
deployed in practice.16
.2 Fostering interdisciplinary IP policies

Indonesia and Jordan provide complementary
and contrasting examples of the role of judicious
institutional settings in promoting investment in
life-sciences research, tailored to the social and
economic needs of developing countries. A coun
try’s capacity to set up an effective institutional
framework for public-interest-minded intellec
tual property is the decisive factor. Used in an ef
fective, informed and judicious manner, it creates
a positive link between the exercise of exclusive
commercial rights and a fairer distribution of
the benefits of technological advancement, with
strategies carefully tailored to a country’s level of
wealth or economic development. n
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ABSTRACT

This chapter provides an overview of the current and
potential impact of the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS) on
low- and middle-income countries. The chapter also
summarizes the findings of a meeting in New Delhi,
India and explores the legitimacy of concerns about
TRIPS. Access to health products relies on many fac
tors, including the successful innovation of new tech
nologies. Innovation, in turn, is a complex process, in
volving many factors (intellectual property [IP] is just
one) that influences product availability and price.
Pointing to the growth of global and national public–private product-development partnerships (PDPs),
the chapter highlights one way these countries are seiz
ing opportunities—and reveals how important effec
tive IP management has become for them. Focused on
high-priority diseases such as AIDS, malaria, and TB,
PDPs require the development and implementation
of sophisticated IP management policies and practices
in both developed and developing countries in which
PDPs operate. Finally, the chapter discusses the pos
sible role of compulsory licensing and parallel trade.
The value of these flexible options, provided by TRIPS,
is yet undocumented and successfully implementing
them represents a significant challenge. Crucially, coun
tries have considerable freedom to control the effects of
TRIPS on the availability of new health technologies.
The countries can do this most effectively by building
capacity for IP management and by formulating poli
cies and practices, for courts, patent offices, and other
institutions, that favor the poor.

1. BACkGRound
The Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS), under
WTO (World Trade Organization), mandates a
minimum set of IP (intellectual property) pro
tection for patented pharmaceutical products.
TRIPS raises questions about how new global
standards for patent protection will affect innova
tion, R&D investment, and product availability,
especially for developing economies with signifi
cant innovative capacities in health R&D (such
as Brazil, China, India, and South Africa). To ex
plore these issues, the Indian Council of Medical
Research (ICMR), in India, and the Centre for
Management of Intellectual Property in Health
Research and Development (MIHR), based in
the United Kingdom, convened an international
meeting in New Delhi in December 2005, titled
“Living with TRIPS: Innovation of New Health
Technologies for the Poor.” This chapter summa
rizes the findings of that meeting. A full report
has been published elsewhere.1
Attention has focused on India because of
its established strengths in generic-drug pro
duction, large prospective market for low-cost
medicines, and potential cost advantages as an
R&D base for multinational firms. These factors
make India a bellwether for gauging the impact
of TRIPS on health-product innovation and ac
cess. Vigorous debates in India and elsewhere
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preceded the implementation of TRIPS, and
it is timely to follow up on some of the ques
tions raised in that debate. Will TRIPS lead to
monopolies on new drugs where, previously,
imitation was possible? Will TRIPS encourage
foreign investment for the health industry or
create external constraints? Will TRIPS lessen
interest, by developing country firms, in diseases
of the poor where markets are uncertain, or will
it motivate the development of innovative drugs
against priority diseases in these countries? And
will international product-development part
nerships (PDPs) that are now generating a pipe
line of drugs for poverty-related diseases find it
easier to form partnerships with institutions and
emerging suppliers in developing countries?

2. puTTInG TRIpS In ConTExT
Conclusively documenting the benefits or costs
of TRIPS for developing countries may be impos
sible. Innovation is a dynamic process influenced
by many external variables. These include the lev
el of government support for science and technol
ogy, government programs to promote trade, the
capabilities of national drug-regulatory agencies,
and government efforts to enhance competencies
in these and other areas. Despite the difficulties
of measuring the effects of TRIPS, we can at least
point to historical precedent, which suggests that
strengthening intellectual property will increase
foreign direct investment and flows of technology
transfer, as long as essential preconditions exist
(namely, supportive R&D environments, effec
tive judicial systems to enforce patent law, and
viable domestic and export markets). And while
definitive measurements cannot be obtained at
this time, it is possible to determine the most im
portant trends to measure.
Perhaps the most controversial issue sur
rounding TRIPS is its impact on the price and
availability of new medicines. If patents are ob
tained and enforced in developing countries,
TRIPS could reduce the availability of copies of
patented medicines, thus adversely affecting a de
facto price control on medicines in these coun
tries. The manufacture of products that were
unprotected by patents led to competition that
248 | HANDBOOK OF BEST PRACTICES

played a key role in determining prices for HIV
antiretrovirals in Brazil, India, South Africa, and
other countries.
Accordingly, the price effects of implementing
TRIPS should be monitored closely, both in coun
tries with strong generic industries and in coun
tries relying on imports of generic substitutes. But
there are other underlying structural impediments
to access besides price. These include the equity
and efficiency of health-care financing and drug/
vaccine distribution systems, the availability of evi
dence-based analysis to improve current practice,
and local community involvement. An instructive
and often-cited example of delivery failure is the
uneven access to medicines on the World Health
Organization’s (WHO’s) list of essential drugs, of
which less than 5% are on-patent. To accurately
measure access requires carefully considering the
historical and social contexts of drug delivery.
Apart from the potential effects of patents on
post-TRIPS pricing and availability, the compar
ative therapeutic benefits of new chemical entities
over available generics will have health implica
tions. So, in assessing TRIPS over time, the rate
of pharmaceutical innovation will be a key vari
able in measuring the health impact of strength
ened patent regimes.
IP management skills will need to be devel
oped so that TRIPS can be adapted to a nation’s
advantage. Developing countries that choose to
invest in science and technology must, of neces
sity, address IP issues to participate in the interna
tional marketplace. IP competencies will enable
these countries to gain access to emerging tools,
technologies, and resources. Indeed, an acute need
exists to establish policies and procedures and to
train staff in effectively managing intellectual
property. Priorities include training in contract
negotiation, statutory protection, patent search
ing and filing, technology valuation and business
strategy development, as well as the development
and implementation of IP policies and strategies
at the institutional level, especially within public
research institutions and universities. To provide
the most useful and most accurate information,
evaluations of the costs and benefits of TRIPS
should consider investments in capacity building
as an important variable.
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3. EMERGInG STRATEGIES
To REACH THE pooR
Assessing the implications of TRIPS for the de
velopment of new products to treat diseases of
poverty is difficult. Technology transfer and inno
vation, in general, are strongly viewed as ways to
strengthen an economy; clearly, however, emerg
ing pharmaceutical industries can do more than
generate new knowledge, skilled labor, and mar
kets. These industries can address social objectives
by developing health-related products to meet lo
cal needs. But will the emerging pharmaceutical
industries in Brazil, China, India, and elsewhere
become sources of new medicines for diseases that
disproportionately affect low- and middle-in
come nations? Early evidence suggests the answer
is no. Pharmaceutical firms in India are focusing
globally, exploiting their strengths to develop or
improve therapeutic drugs for well-characterized
medical conditions that exist in robust global
markets. For example, based on projected sales
growth, Ranbaxy Laboratories aspires to increase
its percentage of revenue from sales to member
countries of the Organisation for Economic Co
operation and Development (OECD) from 20%
in 2000 to 70% in 2007 (presentation at inves
tors conference in Mumbai, September 2004).
The public sector predominantly remains
responsible for promoting the development of
new technologies to meet local needs. For ex
ample, the government of India is addressing this
task by promoting investment in drug develop
ment through several innovative schemes, such
as increased R&D tax benefits and subsidies to
support industry–university partnerships. The
New Millennium Indian Technology Leadership
Initiative, for example, supports local technology
partnerships between publicly supported R&D
institutes and industrial companies. Among
health-related activities, the program supports
the development of new targets, drug delivery
systems, bioenhancers, and therapeutics for la
tent mycobacterium tuberculosis to better man
age India’s high disease-burden of tuberculosis.
Researchers are also working to identify genebased drug targets for prevalent cancers in India.
The program may serve as a model for supporting
local public–private partnerships in other regions,

especially as firms seek academic ties to enhance
their R&D base in drug discovery. Importantly,
when the public sector invests in product devel
opment, it can control the intellectual property
to help benefit the poor (for example, by setting
conditions for how the covered technology is to
be distributed or marketed).
Equally important, the new global IP stan
dards have emerged just as public–private prod
uct-development partnerships (PDPs) are pio
neering creative forms of IP management. PDPs
use intellectual property as a negotiating tool for
developing high-quality, affordable therapeutics
and vaccines for diseases of the poor. For exam
ple, the Medicines for Malaria Venture (MMV)
has formed technology partnerships to develop
an artemisinin-derived lead compound for ma
laria. In explaining the success of the partnership,
MMV points to its pragmatic approach to col
laboration with the private sector, an approach
made possible by the effective identification and
management of intellectual property. Indeed,
each PDP must adapt its IP strategies to the con
tributions of its public sector and industrial part
ners. Nonetheless, PDPs share the common goal
of constructing deals that both provide incentives
to the private sector and meet the social objec
tives of the public sector. These deals are achieved
through negotiated agreements on territorial
markets, pricing structures for public and private
markets, or field of use, among other areas. The
synergistic relationships of PDPs are represented
in Figure 1.

4. TRIpS And puBLIC-HEALTH
SAfEGuARdS
TRIPS also raises issues related to compulsory li
censing and parallel trade.2 These public-health
safeguards are provided under the TRIPS agree
ment and were reinforced by the Doha Ministerial
Conference. In December 2005, the WTO
Council permanently adopted a key policy on
compulsory licenses that had existed as a waiver
since 2003. The waiver has significantly improved
the ability of developing countries without man
ufacturing capabilities to import patented drugs
from sources other than the originator company.
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The waiver will become a formal part of the agree
ment after WTO members ratify it.
Production under compulsory licenses, how
ever, presents some operational challenges. First,
companies need to secure adequate know-how
from the original manufacturer, or from else
where, to recreate products. Second, the prod
ucts must reach markets that are large enough to
enable compulsory licensees to recoup develop
ment and production costs. While compulsory
licenses are potentially beneficial tools, develop
ing countries can use other ways to help ensure
that intellectual property does not create barriers
to access. These include both conventional licens
ing arrangements and, notably, the enactment of
laws to permit and regulate the government’s use
of patented inventions. Other options include
the actions of patent courts to protect the public
interest, the thoughtful management of genetic
resources and traditional knowledge, and the ju
dicious framing of competition law and policy.
In sum, the international IP standards man
dated by TRIPS allow member nations consider
able discretion to enact laws and provisions that
both meet treaty obligations and support national
innovation policies and development priorities.

5. ConCLuSIonS
Issues discussed at the New Delhi conference
and the analysis of those issues, presented in
this chapter, have raised important consider
ations for countries adapting to the TRIPS
Agreement:
• Intellectual property is one of several inno
vation determinants in health R&D; when
assessing impact, intellectual property
must be considered in the context of other
competencies.
• Creatively managed, a global IP regime
can be used in the public interest to im
prove the access of poor populations
to new medicines and public health
interventions.
• Countries aspiring to use TRIPS to national
advantage must build institutional IP capa
bilities and policies in order to participate
in the global marketplace and benefit from
emerging technologies.
• TRIPS enables countries to establish na
tional patent policies and practices that both
meet treaty obligations and address nation
al economic needs and social values. n

Figure 1: Relationships within PDPs in Bringing
Products to Developing Countries
PDP Input
• Funds

PDP Gets
• Availability

• Background IP

• Affordability
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• Access

• Disease expertise

• IP in ‘feld’

• Link to public sector
institutions

• Markets in low–and
middle–income countries

Pharma Input
• IP
• R&D capability
• Marketing knowledge
• Manufacturing capability
• Regulatory capacity
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ABSTRACT

This chapter sets out the provisions of the Agreement
on Trade-Related Aspects of Intellectual Property Rights
(TRIPS) as related to intellectual property in health and
agriculture and the policy work done in the World Trade
Organization (WTO). The first part focuses on matters re
lated to public health, including the protection of patents
and undisclosed information. An overview is given of the
three key instruments addressing the flexibilities available
to Members of the WTO: the Doha Declaration on the
TRIPS Agreement and Public Health, the Decision on the
Implementation of Paragraph 6 of this Declaration, and
the Protocol amending the TRIPS Agreement. The second
part looks into TRIPS provisions relevant to agriculture
and sets out the issues reviewed in the Council for TRIPS
with respect to optional exclusions to patentability and the
protection to be given to plant varieties. The second part
also addresses work related to the relationship between
the TRIPS Agreement and the Convention on Biological
Diversity (CBD), including the suggested introduction of
a disclosure requirement into the patent system, as well as
the protection of traditional knowledge. In addition, two
issues relating to geographical indications are taken up,
namely, the ongoing negotiations on the establishment of
a multilateral register of geographical indications for wines
and spirits, and the extension of the higher level of pro
tection currently available for wines and spirits to other
products. To complete the picture, the third part discusses
WTO programs aimed at enhancing capacities in the de
veloping world with respect to the TRIPS Agreement.

1. INTRODuCTION
This chapter describes provisions of the Agreement
on Trade-Related Aspects of Intellectual Property

Rights (TRIPS) and the policy work done by the
World Trade Organization (WTO) with respect
to intellectual property (IP) in health and agri
culture, as of July 2006. The chapter discusses
WTO programs aimed at enhancing capacities in
the developing world with respect to the TRIPS
Agreement.
The WTO came into existence in January
1995. Its 149 current Members account for over
97% of world trade, and around 30 other coun
tries are negotiating membership. Decisions are
made through the consensus of the entire WTO
membership, and the TRIPS Agreement applies
to all Members.
The TRIPS Agreement establishes minimum
levels of protection that each government has to
provide to the IP of fellow WTO Members. By
establishing these minimum levels, the WTO
seeks to strike a balance between the long-term
benefits and possible short-term costs to society.
Society benefits in the long term when IP protec
tion encourages creation and invention, especially
when the period of protection expires and the
creations and inventions enter the public domain.
The Agreement contains provisions enabling
governments to reduce short-term costs (for ex
ample, through various exceptions to the rights
conferred). The WTO’s dispute settlement sys
tem is available to resolve disputes between WTO
Members about compliance with TRIPS rules.
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The Agreement covers five broad issues1:
• how basic principles of the trading sys
tem and other international IP agreements
should be applied
• how to give adequate protection to IP
rights
• how countries should provide for those
rights to be adequately enforced in their
own territories
• how to settle IP disputes between Members
of the WTO
• how to accommodate transitional ar
rangements during the new system’s
introduction

2. RElEVANT PROVISIONS OF
THE TRIPS AGREEMENT
The TRIPS Agreement requires Member coun
tries to make patents available for all inventions,
whether products or processes, in all fields of
technology without discrimination, subject to
the normal tests of novelty, inventiveness, and
industrial applicability. The Agreement also re
quires that patents be available and patent rights
enjoyable without discrimination as to the place
of invention or whether products are imported or
locally produced (Article 27.1). Although many
aspects of the TRIPS Agreement could poten
tially bear on health or agriculture, the sections
on patents, test data protection, and geographical
indications are perhaps the most relevant.
There are three permissible exclusions from
patent grant. One is for inventions contrary to
ordre public or morality; this explicitly includes
inventions that are dangerous to human, ani
mal, and plant life or health or that are seriously
prejudicial to the environment. The use of this
exclusion is subject to the conditions that the
commercial exploitation of the invention must
also be prevented and that this prevention must
be necessary for the protection of ordre public or
morality (Article 27.2).
The second exclusion is for inventions that
are diagnostic, therapeutic, and surgical meth
ods for the treatment of humans or animals
(Article 27.3(a)). The final exclusion is for in
ventions that are plants and animals (other than
254 | HAndBook of BEST pRACTICES

microorganisms) and essentially biological pro
cesses (other than nonbiological and microbio
logical processes) for the production of plants or
animals. However, any country excluding plant
varieties from patent protection must provide
an effective sui generis system of protection.
Moreover, the whole Provision is subject to re
view four years after the Agreement comes into
force (Article 27.3(b)).
A product patent must confer the following
exclusive rights on the right holder: making, us
ing, offering for sale, selling, and importing the
patented product. Process patent protection must
give exclusive rights not only over use of the pro
cess but also over products obtained directly by
the process. Patent owners shall also have the
right to assign, or transfer by succession, the pat
ent and to conclude licensing contracts (Article
28). Members may provide limited exceptions to
the exclusive rights conferred by a patent, pro
vided that such exceptions do not unreasonably
conflict with a normal exploitation of the patent
and do not unreasonably prejudice the legitimate
interests of the patent owner, taking into ac
count the legitimate interests of third parties, as
well (Article 30). Finally, the term of protection
available shall not end before the expiration of a
period of 20 years counted from the filing date
(Article 33).
Members shall require that an applicant for
a patent shall disclose the invention in a manner
sufficiently clear and complete for the invention
to be carried out by a person skilled in the art.
Members may require the applicant to indicate
the best mode for carrying out the invention
known to the inventor at the filing date or, where
priority is claimed, at the priority date of the ap
plication (Article 29.1). If the subject matter of a
patent is a process for obtaining a product, the ju
dicial authorities shall have the authority to order
the defendant to prove that the process to obtain
an identical product is different from the patent
ed process, where certain conditions indicating a
likelihood that the protected process was used are
met (Article 34).
Compulsory licensing and government use
without the authorization of the right holder
are allowed, but they are subject to conditions
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aimed at protecting the legitimate interests of
the right holder. Mainly contained in Article 31,
these conditions include the obligation not to,
as a general rule, grant such licenses unless an
unsuccessful attempt has been made to acquire a
voluntary license on reasonable terms and condi
tions within a reasonable period of time. The re
quirement to pay adequate remuneration in the
circumstances of each case, taking into account
the economic value of the license, must also be
observed, as must a requirement that decisions
be subject to judicial or other independent re
view by a distinct higher authority. Another im
portant condition is that such use must be made
predominantly to supply the domestic market.
Some of these conditions are relaxed when com
pulsory licenses are employed to remedy practices
that have been established as anticompetitive by
a legal process or in cases of emergency or public
noncommercial use.
The TRIPS Agreement also contains pro
visions to protect undisclosed information.
The Agreement requires that a person lawfully
in control of such information must have the
possibility of preventing it from being disclosed
to, acquired by, or used by others without his
or her consent in a manner contrary to hon
est commercial practices. “Manner contrary to
honest commercial practices” includes breach of
contract, breach of confidence and inducement
to breach, as well as the acquisition of undis
closed information by third parties who knew,
or were grossly negligent in failing to know, that
such practices were involved in the acquisition
(Article 39.2). In addition, undisclosed test data
and other data that governments require to be
submitted as a condition of approving the mar
keting of pharmaceutical or agricultural chemi
cal products that use new chemical entities must
be protected against unfair commercial use.
Members must also protect such data against
disclosure, except where necessary to protect the
public, or unless steps are taken to ensure that
the data are protected against unfair commercial
use (Article 39.3).
For the purposes of the TRIPS Agreement,
geographical indications identify a good as
originating in the territory of a Member, or

a region or locality in that territory, where a
given quality, reputation, or other characteris
tic of the good is essentially attributable to its
geographical origin. The TRIPS Agreement re
quires a standard level of protection to be avail
able for all geographical indications (Article
22). In essence, interested parties must have the
legal means to prevent geographical indications
from being used to mislead the public or in a
way that constitutes unfair competition. Article
23 provides a higher level of protection for geo
graphical indications for wines and spirits: sub
ject to a number of exceptions, they have to be
protected even if use would not cause the public
to be misled or constitute unfair competition.
Information supplied by Members shows that
countries employ a wide variety of legal means
to protect geographical indications: ranging
from specific geographical indications laws to
trademark law, consumer protection law, and
common law. The TRIPS Agreement and cur
rent work in the WTO’s TRIPS Council takes
account of that diversity.
In some cases, however, geographical indica
tions do not have to be protected or the protec
tion can be limited. Among the exceptions that
Article 24 allows are: continuous use of the geo
graphical indication for at least 10 years preced
ing 15 April 1994 or in good faith prior to that
date; pre-existing trademark rights; and when a
name has become a common (or “generic”) term
for describing that type of product.

3. ClARIFICATIONS AND FlExIBIlITy
REGARDING TRIPS AND PuBlIC HEAlTH
On the issue of TRIPS and public health (includ
ing access to patented medicines), the WTO has
adopted three instruments:
• The Doha Declaration on the TRIPS
Agreement and Public Health, November
2001
• The Decision on the Implementation of
Paragraph 6 of the Doha Declaration on
the TRIPS Agreement and Public Health,
Geneva, August 2003
• A Protocol amending the TRIPS Agreement,
December 2005.
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3.1 The Doha Declaration on the TRIPS
Agreement and public health

The Doha Declaration on the TRIPS Agreement
and Public Health2 responded to concerns about
the possible implications of the TRIPS Agreement
for public health, in particular, access to patent
ed medicines. As mentioned earlier, the TRIPS
Agreement allows countries to take various kinds
of measures to qualify or limit IP rights, includ
ing for public health purposes. However, some
doubts had arisen as to whether the flexibility in
the TRIPS Agreement was sufficient to ensure
that it supported public health. It was unclear
whether it promoted affordable access to existing
medicines, while supporting research, and devel
opment into new ones.
The Declaration responds to these concerns
in a number of ways. First, it emphasizes that the
TRIPS Agreement does not and should not pre
vent Members from taking measures to protect
public health. It reaffirms the right of Members to
use, to the full, the terms of the TRIPS Agreement
that provide flexibility for this purpose. Through
these important declarations, all WTO Members
have signaled that they will not seek to prevent
other members from using the provisions.
Second, the Declaration makes clear that
the TRIPS Agreement should be interpreted and
implemented in a way that supports the right of
Members of the WTO to protect public health
and, in particular, to promote access to medi
cines for all. Further, it highlights the importance
of the objectives and principles of the TRIPS
Agreement regarding the interpretation of its
provisions. These statements thus provide impor
tant guidance to both individual Members and,
in the event of disputes, WTO dispute settlement
bodies.
Third, the Declaration clarifies some of the
flexibilities contained in the TRIPS Agreement.
It makes clear that each Member is free to de
termine the grounds upon which compulsory li
censes are granted. This is a useful corrective to
views often expressed in some quarters that some
form of emergency is a precondition for compul
sory licensing. The TRIPS Agreement does refer
to national emergencies or other circumstances of
extreme urgency in connection with compulsory
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licensing, but this is only to indicate that, in these
circumstances, the usual condition that an effort
must first be made to seek a voluntary license
does not apply. The Declaration makes it clear
that each Member has the right to determine
what constitutes a national emergency or other
circumstances of extreme urgency. It also declares
that public health crises, including those relating
to HIV/AIDS, tuberculosis, malaria, and other
epidemics, can represent such circumstances.
With regard to the exhaustion of IP rights
and a Member’s right to permit parallel imports,
the TRIPS Agreement states that a Member’s
practices in this area cannot be challenged un
der the WTO dispute settlement system. The
Declaration makes clear that the effect on exhaus
tion of the provisions in the TRIPS Agreement
is to leave each Member free to establish its own
regime without challenge—subject to the general
TRIPS provisions that prohibit discrimination
on the basis of the nationality of persons.
For Members of the WTO that are least de
veloped countries, the Declaration agrees to pro
vide them with an extension of their transition
period until the beginning of 2016 for protect
ing and enforcing patents and rights in undis
closed information with respect to pharmaceuti
cal products. This was given legal effect through
a Decision of the TRIPS Council that extended
the transition period for least developed countries
until 1 January 20163 and another Decision of
the General Council that waived the exclusive
marketing rights provisions of Article 70.94 for
the same period. In 2005, the TRIPS Council
extended, to July 2013, the time given for these
countries to implement other provisions of the
TRIPS Agreement.5
While emphasizing the flexibility in the
TRIPS Agreement to take measures to promote
access to medicines, the Declaration also recogniz
es the importance of IP protection for developing
new medicines and reaffirms the commitments of
WTO Members in the TRIPS Agreement.
3.2 Paragraph 6 of the Doha Declaration

In paragraph 6, the Doha Declaration recognized
the problem of countries with insufficient or no
manufacturing capacities in the pharmaceutical
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sector in making effective use of compulsory licens
ing. Such countries could, under normal TRIPS
rules, import under a compulsory license as there is
no special problem with Members issuing compul
sory licenses for importation as well as for domestic
production. The problem, however, was whether
sources of supply from generic producers in other
countries to meet such demand would be avail
able, particularly given Article 31(f) of the TRIPS
Agreement, according to which production under
a compulsory license in those other countries must
be “predominantly for the supply of the domestic mar
ket of the Member.” The problems facing countries
with insufficient capacities in the pharmaceutical
sector in accessing sources of supply were expected
to increase as some countries with important ge
neric industries were coming under an obligation
to provide patent protection for pharmaceutical
products as from 2005.
In order to solve this problem, the WTO
General Council adopted on 30 August 2003 a
Decision6 that waives in certain circumstances
Article 31(f ) and (h) of the TRIPS Agreement.
This Decision was adopted in the light of a
Chairman’s statement7 that set out several key
shared understandings of Members on how the
Decision would be interpreted and implemented.
The Decision covers any patented pharmaceutical
products, or pharmaceutical products manufac
tured through a patented process, needed to ad
dress public health problems recognized in para
graph 1 of the Doha Declaration on the TRIPS
Agreement and Public Health, including active
ingredients necessary for the manufacture of phar
maceutical products and diagnostic kits needed
for their use. The Decision grants three waivers
from the obligations set out in subparagraphs (f )
and (h) of Article 31 of the TRIPS Agreement
with respect to pharmaceutical products, subject
to certain conditions. The three waivers are:
1. A waiver of the obligation of an exporting
Member under Article 31(f ) of the TRIPS
Agreement to the extent necessary for the pur
poses of production and export of the needed
pharmaceutical products to those countries
that do not have sufficient capacity to manu
facture them. This waiver is subject to cer
tain conditions to ensure transparency in the

operation of the system and that only coun
tries with insufficient domestic capacity im
port under it, and to provide for safeguards
against the diversion of products to markets
for which they are not intended.
2. A waiver of the obligation under Article 31(h)
of the TRIPS Agreement on the importing
country to provide adequate remuneration
to the right holder in situations where remu
neration in accordance with Article 31(h) is
being paid in the exporting Member for the
same products. The purpose of this waiver is
to avoid double remuneration of the patent
owner for the same product consignment.
3. A waiver of the obligation under Article
31(f ) of the TRIPS Agreement on any de
veloping or least developed country that is
party to a regional trade arrangement at least
half of the current membership of which is
made up of countries presently on the United
Nations list of least developed countries. The
purpose of this waiver is to enable such coun
tries to better harness economies of scale for
the purposes of enhancing purchasing power
for, and facilitating the local production of,
pharmaceutical products.
The above Chairman’s statement was designed
to meet the concerns of those who feared that the
Decision was too open ended and might be abused
to undermine the benefits of the patent system.
It recognizes that the paragraph 6 system set out
in the Decision should be used in good faith to
protect public health and not to pursue industrial
or commercial policy objectives. It addresses some
concerns relating to the risk of diversion, and it sets
out ways in which any differences arising from the
implementation of the system can be settled expe
ditiously and adequately. The Decision also records
that the 33 most-advanced countries have agreed to
opt out of the system as importers, including since
their accession to the European Communities,
the 10 acceding countries.8 In addition, 11 other
Members have agreed to use the system only as
importers in situations of national emergency or
other circumstances of extreme urgency.9
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The Decision went into effect on 30 August
2003, and since then a number of Members have
modified their laws/regulations to enable exports
under their legislation. As of July 2006, Canada,
Norway, India and the European Communities
have notified the WTO of these modifications.10
3.3 A Protocol amending the TRIPS Agreement

Paragraph 11 of the August 2003 Decision called
for the TRIPS Council to prepare an amendment,
based, where appropriate, on the Decision that
would replace its provisions. Agreement on such
an amendment was reached on 6 December 2005,
when the General Council adopted a Protocol
amending the TRIPS Agreement and submitted
it to WTO Members for acceptance. In substance,
the amendment closely tracks the August 2003
text. The Decision on the amendment was also
taken in the light of a rereading by the General
Council Chairman of the statement of August
2003. The Protocol will enter into force upon
acceptance by two thirds of the Members. The
waiver provisions of the August 2003 Decision
remain applicable until the date on which the
amendment takes effect for a Member.

4. WORK ON TRIPS PROVISIONS
RElATING TO AGRICulTuRE
4.1 Article 27.3(b)

As mentioned earlier, Article 27 of the TRIPS
Agreement defines which inventions govern
ments are obliged to make eligible for patent
ing and what they can exclude from patenting.
Inventions that can be patented include both
products and processes, and should generally
cover all fields of technology. Part (b) of para
graph 3 allows governments to exclude some
kinds of inventions from patenting (for exam
ple, plants, animals, and other “essentially biolog
ical ” processes—but microorganisms and nonbiological and microbiological processes have to
be eligible for patents). However, plant varieties
have to be eligible for protection either through
patent protection or a system created specifically
for the purpose (“sui generis”), or a combination
of the two.
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A review of Article 27.3(b) began in 1999
as required by the TRIPS Agreement. The top
ics raised in the TRIPS Council’s discussions
included:
• how to apply the existing TRIPS provi
sions on whether or not to patent plants
and animals, and whether they need to be
modified
• how to handle moral and ethical issues (for
example, to what extent invented life forms
should be eligible for protection)
• how to deal with the commercial use of tra
ditional knowledge and genetic material by
those other than the communities or coun
tries where these originate, especially when
these are the subject of patent applications
• how to ensure that the TRIPS Agreement
and the Convention on Biological Diversity
(CBD) support each other.
With respect to the protection of plant vari
eties, the meaning of effective protection for new
plant varieties has been a part of the discussion
under this review.11 The discussion has includ
ed consideration of the kind of flexibility that
should be available (for example, allowing tradi
tional farmers to continue to save and exchange
seeds that they have harvested). It is widely agreed
that, while the standards of protection under the
UPOV Convention would be considered ade
quate for TRIPS purposes (with some differences
of view about whether the 1978 or 1991 version
is the most appropriate point of reference), WTO
Members are not bound to apply UPOV stan
dards as long as they can ensure effective protec
tion of plant varieties.12 The privilege of farmers
to replant, on their own holdings, propagating
material of protected plant varieties that have
been harvested is not in dispute, but no conclu
sion has yet been reached about how much further
the flexibilities might go and be consistent with
TRIPS. There is no authoritative guidance in the
WTO on these matters. However, the responses
of some Members to a questionnaire about do
mestic implementation of Article 27.3(b) are
contained in a TRIPS Council document.13
Following the 2001 Doha Ministerial
Conference, the review of Article 27.3(b) has

CHAPTER .

been accompanied by parallel work on the rela
tionship between the TRIPS Agreement and the
CBD, as well as on protecting traditional knowl
edge and folklore.14
4.2 Biodiversity and Traditional Knowledge

Discussions on the relationship between the
TRIPS Agreement and the CBD first began
in the WTO in the Committee on Trade and
Environment in 1995. They were brought into
the TRIPS Council through the built-in review of
Article 27.3(b) in 1999. In the Doha Ministerial
Declaration under paragraph 19, the ministers in
structed the Council for TRIPS “to examine, inter
alia, the relationship between the TRIPS Agreement
and the Convention on Biological Diversity, the pro
tection of traditional knowledge and folklore.” The
Hong Kong Ministerial Declaration of December
200515 calls for the TRIPS Council to continue
this work and for the General Council to report
on it to the next ministerial meeting.
In paragraph 12, the Doha Ministerial
Declaration also addressed the question of out
standing implementation issues (that is, out
standing issues and concerns raised by develop
ing countries about some existing WTO rules,
including a number relating to biotechnology,
biodiversity, and traditional knowledge). With
regard to these issues, the work has focused on
the relation between the TRIPS Agreement and
the CBD. Some countries want a solution to the
their related concerns to be negotiated as part
of the ongoing Doha Round of trade negotia
tions. Other WTO Members contend that there
is no negotiating mandate on this matter and
that it would not be appropriate to create one.
Consultations on this issue have been held un
der the auspices of the Director General of the
WTO since the end of 2002. The Hong Kong
Ministerial Declaration of December 2005 pro
vided for the consultative process to be intensified
further and for the Director General to report to
each regular meeting of the Trade Negotiating
Committee (TNC) and the General Council.
This issue is one of the two outstanding imple
mentation issues explicitly referred to in the text
of the Hong Kong Declaration (alongside that of
the extension of the protection of geographical

indications). The General Council is to review
progress and take any appropriate action no later
than 31 July 2006.
In the TRIPS Council sessions and at other
discussions relating to the relationship between
the TRIPS Agreement and the CBD,16 Members’
positions fall into three broad categories. First, a
group of developing countries propose to amend
the TRIPS Agreement to make obligatory dis
closure in patent applications of (a) the origin
of biological resources and/or traditional knowl
edge used in the claimed invention, (b) evidence
of prior informed consent under the relevant
national laws/regulations/procedures, and (c)
evidence of fair and equitable benefits sharing
with those holding such resources or knowledge.
Second, the European developed countries are
willing to envisage some measure of disclosure of
source or origin within the patent system, but not
of access or benefit sharing. Those who agree with
the disclosure approach differ on several other
aspects, such as whether the requirement should
be mandatory or voluntary, and under what in
strument (the TRIPS Agreement or the Patent
Cooperation Treaty of the World Intellectual
Property Organization [WIPO]). There is also
disagreement about the legal effects of wrongful
disclosure or nondisclosure (invalidation of the
patent or outside the patent system under civil/
criminal law).
Third, other WTO Members are opposed to
a disclosure requirement but are willing to engage
substantively on the issue of how the shared ob
jectives in these areas, such as the avoidance of
erroneously granted patents and compliance with
national access and benefit–sharing regimes, can
most effectively be realized. They hold the posi
tion that a national-based approach using tailored
national solutions, including contracts, is suffi
cient to ensure that the objectives of the CBD
in relation to access and benefit sharing are met.
They believe that it would be neither helpful nor
desirable to involve the patent system.
The TRIPS Agreement has no specific provi
sions regarding traditional knowledge. Members
are obliged to protect traditional knowledge
when it falls under covered IP rights, and they
are free to introduce a sui generis law to protect
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it, as long as that does not conflict with TRIPS.
They can similarly implement Article 8(j) of the
CBD (to respect, preserve, maintain knowledge,
innovations and practices of indigenous and lo
cal communities and encourage the equitable
sharing of benefits). Quite detailed work is going
on in the WIPO Intergovernmental Committee
on Intellectual Property, Genetic Resources,
Traditional Knowledge, and Folklore. The ques
tion of the appropriate forum for fleshing out the
details of the subject comes up repeatedly in the
TRIPS Council discussions. Some want to wait
for WIPO to develop an appropriate framework
so that it can be determined to what extent such
protection can be included in TRIPS. Finally, as
indicated above, the focus in the TRIPS Council
is presently on the relationship between the
TRIPS Agreement and the CBD, which covers
some aspects of traditional knowledge.
4.3 Geographical indications

Two issues relating to geographical indications are
debated under the 2001 Doha Work Program:
the establishment of a multilateral register of geo
graphical indications for wines and spirits and the
extension of the higher Article 23 level of protec
tion beyond wines and spirits.
4.3.1 Multilateral register

The agreed aim of the multilateral system of no
tification and registration that is currently under
negotiation is to facilitate the protection of geo
graphical indications for wines and spirits. Work
was initiated as early as 1997 and is mandated
under TRIPS Article 23.4 and paragraph 18 (the
first sentence of the Doha Declaration). The ne
gotiations on this matter are being conducted in a
Special Session of the council for TRIPS.
Two main lines of argument have been
advanced in the negotiations. The “joint pro
posal” of Argentina, Australia, Canada, Chile,
Dominican Republic, Ecuador, El Salvador,
Guatemala, Honduras, Japan, Mexico, New
Zealand, Paraguay, Chinese Taipei,17 and the
United States18 suggests that the Council for
TRIPS should decide to set up a voluntary sys
tem under which notified geographical indica
tions would be registered in a database. Those
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governments choosing to participate in the sys
tem would have to consult the database when
deciding on the protection of geographical indi
cations and trademarks for wines and spirits in
their own countries. Non-participating Members
would be encouraged, but not obliged, to con
sult the database. At the other end of the spec
trum, the European Communities propose a
TRIPS amendment to establish a system under
which the registration of a geographical indica
tion should lead to rebuttable presumptions of
its protectability, except where a reservation has
been lodged within a specified period, for exam
ple, 18 months. Permitted grounds for a reser
vation would include when a term has become
generic or when it does not meet the definition
of a geographical indication. In the absence of
any reservation, a Member could not refuse pro
tection on these grounds after the term has been
registered. These proposals, together with a com
promise proposal from Hong Kong, China, have
been set forth side by side in a WTO Secretariat
document.19
Important differences remain, particularly
on two key issues: (1) the extent to which legal
effects at the national level should be consequent
on the registration of a geographical indication
for a wine or a spirit in the system and (2) the
question of participation, including whether any
legal effects under the system should apply to all
WTO Members or only to those opting to par
ticipate in the system. The Special Session has
also discussed a range of other points, including
questions of costs and administrative burdens
for WTO Members, particularly for developing
countries.20
4.3.2 Extension

Article 22 requires protecting geographical indi
cations for all goods. The issue here is whether
to expand the higher level of protection under
Article 23, currently required only for wines and
spirits, to other products, including agricultural
products and foodstuffs, handicrafts, and indus
trial products.
Paragraph 18 of the Doha Declaration notes
that the TRIPS Council will handle work on ex
tension under paragraph 12 of the Declaration,
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which deals with implementation issues. As in
dicated earlier, WTO Members interpret para
graph 12 differently. Many developing country
and European Members argue that the so-called
outstanding implementation issues are already
part of the “single undertaking” and therefore are
also part of the negotiating agenda of the Doha
Round. Others argue that these issues can only
become negotiating subjects if the TNC decides
to include them in the talks—and so far it has
not done so. Presently, the topic is the subject of
consultations under the auspices of the WTO
Director General. At the Hong Kong Ministerial
Conference, ministers requested the DirectorGeneral to intensify consultations on all out
standing implementation issues, including the
extension of the protection of geographical indi
cations, and 31 July 2006 was set as the deadline
for the General Council to review progress and
take any appropriate action.21
With regard to the substance of the TRIPS
Agreement, Members remain divided, but there
is a willingness to continue discussing the issue.
The proponents consider, among other things,
that progress on geographical indications would
make it easier for them to agree to a significant
deal in agriculture. The proponents see the higher
level of protection as a tool to enhance rural de
velopment, support quality production, and en
able them to improve the marketing of products
by differentiating them more effectively from
other competing products. Consequently, the lat
est proposal from the European Union calls for
the TRIPS Agreement to be amended so that all
products would be eligible for the higher level of
protection in Article 23.22 To meet the concerns
of other countries, the exceptions in Article 24
would also apply, adapted as necessary. Opponents
argue that the existing level of protection pursu
ant to Article 22 is adequate. They caution that
providing enhanced protection would be burden
some and disruptive to existing, legitimate mar
keting practices, that the interests of prior trade
mark right holders and other third parties may be
affected, and that considerable costs may result
from the need to re-label their products.
The issues raised and the views expressed in
this debate have been compiled in a document

prepared by the WTO Secretariat.23 The issues
include, among others, those relating to the pro
tectable subject matter (definition and eligibility),
potential implications for administrative costs
and burdens, and the impact of extension on (1)
producers in and outside the area designated by
geographical indications, (2) the relationship be
tween trademarks and geographical indications,
and (3) consumers.

5. TRANSFER OF TECHNOlOGy
Article 7 of the TRIPS Agreement reflects the ob
jective that the transfer of technology should be
promoted by the protection of IP. Some develop
ing countries have expressed the view that more
needs to be done to “operationalize” this notion.
The TRIPS Agreement calls for more proactive
measures to promote technology transfer and dis
semination in the case of the least developed coun
tries. Article 66.2 obligates developed countries to
provide incentives for the transfer of technology to
these countries. The effective monitoring of this
obligation through regular reporting and TRIPS
Council reviews was the subject of a political agree
ment at Doha that was turned into the TRIPS
Council Decision of February 2003.24 Reports un
der this new mechanism, submitted at the end of
2003, 2004, and 2005, are being studied by the
Members that are least-developed countries.
6. TECHNICAl COOPERATION AND
CAPACITy BuIlDING PROGRAMS
Article 67 of the TRIPS Agreement obligates de
veloped country WTO Members to provide, on
request and according to mutually agreed terms
and conditions, technical and financial coopera
tion in favour of developing and least-developed
country Members. This cooperation includes as
sistance in preparing laws and regulations for the
protection and enforcement of IP rights, as well
as the prevention of their abuse. The coopera
tion also includes support for the establishment
or reinforcement of domestic offices and agencies
relevant to these matters, including the training
of personnel. On the basis of annual reports from
developed-country Members, each autumn the
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TRIPS Council reviews the technical cooperation
that is being provided.25
Considerable assistance is also provided by
other intergovernmental organizations, notably
WIPO, UPOV, the World Bank, and the WHO.
Such organizations are annually invited to share
information on their activities with the TRIPS
Council.26 In addition, the WTO Secretariat’s
technical cooperation program includes activities
related to the TRIPS Agreement.27 These activi
ties seek to help Members understand their rights
and obligations—including the options and flex
ibilities—under the TRIPS Agreement and rel
evant decisions of WTO bodies. The cooperation
program encourages Members to participate fully
in the ongoing work of the WTO on TRIPS mat
ters and emphasizes the importance of ensuring
complementarity and cooperation with other in
tergovernmental organizations, in particular the
WIPO and the WHO.
These activities include regional workshops
on topical issues under discussion, examination,
or negotiation in the TRIPS context, in particular
TRIPS and public health, biotechnology, tradi
tional knowledge, biodiversity, and geographical
indications. These regional workshops, as well as
specialized workshops held in the regions and
Geneva, also aim to provide information that will
assist developing-country Members in implementing
and making effective use of the mechanism set
out in the Decision on Paragraph 6 of the Doha
Declaration on the TRIPS Agreement and Public
Health. Upon request by developing- country
Members, the WTO Secretariat regularly orga
nizes national seminars or workshops devoted to
IP matters. TRIPS issues also figure prominently
in broader WTO training courses, seminars, and
workshops held in Geneva and in developing
countries. An important new component of the
Secretariat’s capacity-building activities is the an
nual joint WIPO/WTO colloquiums for teachers
of intellectual property in Geneva, for partici
pants from developing countries. This program
seeks to enhance the capacity for teachers to train
IP personnel in their own countries, by providing
teachers with expertise on international aspects
and allowing them to provide informed policy
advice to their governments. n
262 | HAndBook of BEST pRACTICES

ACkNOWLEdgMENTS

We are grateful to Adrian Otten, Director of the WTO’s
Intellectual Property Division, who provided very helpful
comments.
The paper has been prepared strictly in a personal capacity.
The views expressed must not be attributed to the WTO,
its Secretariat, or any of its Member governments.
JAyASHREE WATAL, Counselor, Intellectual Property
Division, World Trade Organization, Switzerland, Centre
William Rappard, Rue de Lausanne 154, 1211 Geneva,
Switzerland. Jayashree.Watal@wto.org
ROgER kAMPF, Counselor, Intellectual Property Division,

World Trade Organization, Centre William Rappard,
Rue de Lausanne 154, 1211 Geneva, Switzerland. Roger.
Kampf@wto.org

1

For more details, see www.wto.org/english/tratop_e/
trips_e/trips_e.htm#WhatAre.

2

Document WT/MIN(01)/DEC/2.

3

Document IP/C/25, June 2002.

4

Document WT/L/478, July 2002.

5

Document IP/C/40.

6

Documen
Documents
ts WT
WT/L
/L//540 and C
Corr
orr.1.
.1.

7

Con
ontained
tained in par
paragr
agraph
aph 29 of documen
documentt WT
WT//GC/
M/82.

8

The Czech Republic, Cyprus, Estonia, Hungary, Latvia,
Lithuania, Malta, Poland, the Slovak Republic, and
Slovenia.

9

Hong Kong, China; Israel; Korea; Kuwait; Macao, China;
Mexico; Qatar; Singapore; Chinese Taipei; Turkey; and
the United Arab Emirates.

10 Notifications about the use of the system will be
accessible through a dedicated Web page on the WTO
Web site: www.wto.org/english/tratop_e/trips_e/
public_health_e.htm.
11 See document IP/C/W/369/Rev.1, paragraphs 51–60
available at www.wto.org/english/tratop_e/trips_e/
art27_3b_e.htm.
12 See document IP/C/W/369/Rev.1, paragraphs 61–66
available at www.wto.org/english/tratop_e/trips_e/
art27_3b_e.htm.
13 Document IP/C/W/273/Rev.1, available at www.wto.
org/english/tratop_e/trips_e/art27_3b_e.htm.
14 Secretariat summary notes of the work done on these
issues (IP/C/W/368/Rev.1, IP/C/W/369/Rev.1, IP/C/
W/370/Rev.1) are available at www.wto.org/english/
tratop_e/trips_e/art27_3b_e.htm.
15 Document WT/MIN(05)/DEC.
16 Summarized in Secretariat paper IP/C/W/368/Rev. 1.

CHAPTER .

17 In the WTO accession document, Chinese Taipei is
referred to as Separate Customs Territory of Taiwan,
Penghu, Kinmen and Matsu.
18 Document TN/IP/W/10 and Add.1.
19 Document TN/IP/W/12.
20 See Chairman’s report on the work done in 2005,
document TN/IP/14.
21 Paragraph 39 of document WT/MIN(05)/DEC.

23 Document WT/GC/W/546, document TN/C/W/25.
24 Documen
Documentt IP/C/28.
C/28.
25 The most recent reports can be found in document
IPC/W/445 and addenda.
26 The most recent information documents are in
document IPC/W/456 and addenda.
27 The most recent information can be found in document
IP/C/W/454.

22 Document TN/IP/W/11.

HAndBook of BEST pRACTICES | 263

CHAPTER 3.9

U.S. Laws Affecting the Transfer
of Intellectual Property
HOWARd BREMER, Counsel Emeritus, Wisconsin Alumni Research Foundation, WARF, U.S.A.

ABSTRACT

This chapter provides an overview of some of the legisla
tive bills that have profoundly affected the evolution of
technology transfer and intellectual property (IP) rights
in the United States. The chapter references provisions of
the specific bills as codified in U.S. law and explains their
goals and historical circumstances. While not an exhaus
tive presentation of all of the bills that have contributed
to laws governing IP, the codification references will pro
vide a useful starting point for those researching the ap
plicability of the laws to particular situations.

1. INTRODuCTION
In the United States, the fundamental basis for
the transfer of technology as property lies in the
U.S. Constitution. In an effort to protect the
rights of its more creative citizens, the framers of
the Constitution struck a compromise position:
creators of intellectual property (IP) would own
it and be able to exclude others from using it for
a limited period of time. After this time period
expired, the right to use the IP was extended
to all. By agreeing to accept the “disclosure in
ducement theory” of advancing science and the
arts, the framers also allowed a creator of IP to
deny others the use of that property for a lim
ited period of time in exchange for disclosing
the nature of the property to all. The conveyed
right is expressed in article I, section 8, clause 8
of the U.S. Constitution:

The Congress shall have Power—
to promote the progress
Of Science and useful arts, by securing
for limited Times
To Authors and Inventors the exclusive
Right to their Respective Writings
and Discoveries.

2. u.S. PATENT SySTEMS
The U.S. patent system finds its origin in the U.S.
Constitution (art. I, § 8, cl. 8). The system de
scribed therein is the primary vehicle for transfer
ring IP from the university and nonprofit sectors
to the private sector or, as is often the case, from
the government to the private sector. Within its
scope, the clause includes trademarks and copy
rights. Indeed, all of these elements—patents,
trademarks, and copyrights—are classified as in
tellectual property and in the United States have
the imprimatur of personal property rights. The
terms and provisions governing these forms of
IP are codified in various statutes: U.S. Code,
title 35 for patents (35 U.S.C.); U.S. Code, title
15 (15 U.S.C.), chapter 22 for trademarks; and
U.S. Code, title 17 (17 U.S.C.) for copyrights.
Detailed regulations governing the application of
these statutes are found in title 37 of the Code
of Federal Regulations (37 C.F.R.), chapters
I and II. These laws and regulations outline
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the obligations for obtaining and maintaining IP
protection and for asserting the property rights
that the laws convey.
2.1 Specific legislation

Two pieces of legislation, both of which were
passed in 1980, are of particular interest. The
first gave the government authority to engage in
the transfer of federally owned or federally origi
nated technology. The second gave the govern
ment statutory authority to patent and license
federally owned inventions and was instrumental
in enhancing the nonprofit sector’s technology
transfer function—especially for universities.
The first law was the Stevenson-Wydler Act.
Its reach expanded by amendments over a pe
riod of years, the law is codified in title 15 (15
U.S.C.), chapter 63 of the U.S. Code, under the
heading “Technology Innovation.” Its funda
mental purpose was to promote the utilization of
technology owned by the federal government and
generated with its help. The act accomplished its
purpose by aiding the transfer of that technology
to the private sector and to state and local gov
ernments. The act initially called for setting aside
0.5% of each federal laboratory’s budget to fund
technology transfer activities; a later amendment
required “sufficient funding to support technol
ogy transfer activities.”
The second law was the Patent and Trademark
Amendment Act of 1980—known as the BayhDole Act. The terms and provisions of this act,
as amended by the Trademarks Clarification Act
of 1984, are codified in title 35 of the U.S. Code
(35 U.S.C. § 200–212). The Bayh-Dole Act
changed the presumption of title in and to in
ventions made, in whole or in part, with federal
monies at nonprofit organizations—including
universities and small businesses—from the gov
ernment to those entities. For the first time, the
law established a uniform federal patent policy
and provided the first statutory authority for the
U.S. government to take title to and hold patents
through its agencies. The regulations pertaining
to the Bayh-Dole Act are found in the Code of
Federal Regulations, title 37 (37 C.F.R.), part
401; those regulations pertaining to the licensing
of government-owned inventions are set forth
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in part 404, and those pertaining to inventions
made by government employees are set forth in
part 501.
The Bayh-Dole Act also embraces any novel
variety of plant that is or may be protected under
the Plant Variety Protection Act, which is codi
fied in title 7 of the U.S. Code (7 U.S.C.), chap
ter 57, and includes sections 1545 and 2353 of
title 28 (28 U.S.C. §§ 1545 and 2353), amend
ments to title 27, sections 1551 and 1562 (27
U.S.C. §§ 1551 and 1562) (the Federal Seed
Act), and sections 1338 and 1498 of 28 U.S.C
(28 U.S.C. §§ 1338, 1498).
Because the Bayh-Dole Act depends upon
the U.S. patent system to transfer technology
from the nonprofit, university, and small business
sectors, it is axiomatic that changes in the patent
system and in the regulations governing that sys
tem can affect the ability to protect and transfer
technology.
2.2 Patents and antitrust laws

Many people classify patents as monopolies, a
view that brings into sharp focus the issue of an
titrust laws and patents, particularly the right of
the patent holder to exclude. The passage of an
titrust legislation in the United States was driven
by the growth and expansion of business and
the efforts of competitors to stabilize markets
through price and quota arrangements. These
activities made it clear that growing industrial
combinations and monopolies would have to be
controlled.
As a result, in 1890 the Sherman Act was
passed (codified at 15 U.S.C. §§ 1–7). The
Clayton Act (codified at 15 U.S.C. §§ 12–29
and 29 U.S.C. § 52) followed in 1916. As a
supplement to the Sherman and Clayton acts,
the Federal Trade Commission Act was passed in
1914, amended in 1980 and1994, and reautho
rized in 1996 (codified at 15 U.S.C. §§ 41–58).
The Sherman Act prohibits the restraint of
trade and monopolies. Antitrust law and patents
oppose each other because according to the act,
patents can contribute or be a part of an attempt
to restrain trade or to establish a monopoly of
“any part of the trade or commerce between the sev
eral States (of the United States) or with foreign
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nations.” Specifically, the substantive governing
provisions are:
• Section 1. Every contract, combination in
the form of trust or otherwise, or conspiracy,
in restraint of trade or commerce among the
several States, or with foreign nations, is de
clared to be illegal.…
• Section 2. Every person who shall monopo
lize, or combine or conspire with any other
person or persons, to monopolize any part
of the trade or commerce among the sever
al States, or with foreign nations, shall be
deemed guilty of a misdemeanor.
It should be noted that under section 1, re
straint of trade requires action by two or more
parties, but monopolization requires action by
just one party.
In contrast to the broad language of the
Sherman Act, the Clayton Act focuses on more
specific trade abuses: price discrimination, the
acquisition of one corporation by another, re
strictions forbidding a purchaser of goods to
deal in the goods of competition, and the use
of interlocking directorates among large cor
porations. The relevant, specific statutory lan
guage is:
• Section 3. …[I]t shall be unlawful for any per
son engaged in [interstate] commerce, in the
course of such commerce, to lease or make a sale
or contract for sale of goods, wares, merchan
dise, machinery, supplies or other commodities,
whether patented or unpatented, for use, con
sumption or resale within the United States or
any Territory thereof or the District of Columbia
of any insular possession or other place under the
jurisdiction of the United States, or fix a price
charged therefore, or discount from, or rebate
upon, such prices, on the condition, agreement
or understanding that the lessee or purchaser
thereof shall not use or deal in the goods, wares,
merchandise, machinery, supplies or other com
modities of a competitor or competitors of the
lessor or seller, where the effect of such lease, sale,
or contract for sale on such condition, agreement
or understanding may be to substantially lessen
competition or tend to create a monopoly in any
line of commerce.

• Section 7. …[N]o corporation engaged in [in
terstate] commerce shall acquire, directly or
indirectly, the whole or any part of the stock or
other share capital and no corporation subject to
the jurisdiction of the Federal Trade Commission
shall acquire the whole or any part of the assets of
another corporation engaged also in commerce,
where in any line of commerce in any section of
the country, the effect of such acquisition may be
substantially to lessen competition, or to tend to
create a monopoly.
The early historical perception that patents
and antitrust principles are antithetical has been
ameliorated over the years; today they are rec
ognized as complementary tools that enhance
competition. Nevertheless, the inherent right
to-exclude conveyed by a patent forecloses third
parties from practicing the invention patented,
and patents can be used for various kinds of
conveyances. (For example, patents can be the
basis for exclusive, partially exclusive, or non
exclusive licenses, bailments, or actual sales.)
Attention must be paid to the nature of those
conveyances and to the context within which
and purpose for which they are generated and
will be used. At present, patents, per se, are not
viewed as conveyers of market power. But when
coupled with other assets, or when patents are
acquired in order to build a monopolistic posi
tion (other than through internal research and
development efforts), patents do contribute to
market power. When combined with apparent
predatory practices that restrain trade, such a po
sition can invite antitrust scrutiny. For example,
a violation of the Clayton Act would occur if a
purchaser were forced to purchase certain mate
rials or supplies from a specified supplier to the
exclusion of a competitor—this is referred to as
a tying arrangement. In terms of antitrust issues,
this arrangement would be viewed as extending
the scope of a patent by restricting the use of the
patented invention to goods necessary for its op
eration but not part of the patented invention.
For example, the license (or franchise) under the
patent might require the purchase of nonpatent
ed items from the licensor as a condition for the
license itself. Without the element of coercion,
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however, the parties are free to enter into such
a supply agreement.
2. Export Administration Regulations and
International Traffic in Arms Regulations

The Department of Commerce administers the
Export Administration Regulations (EAR) to pro
tect trade, while the Department of State adminis
ters the International Traffic in Arms Regulations
(ITAR) to protect national security. The regulations
apply not only to the transfer of physical items to
persons and/or entities outside the United States,
but also to the transfer of technology—whether
or not it is associated with a physical item. The
regulations also cover disclosure to foreign per
sons while in the United States of technical data
or information on controlled items, as well as to
the training and offering of services involving con
trolled equipment to foreign persons.
The EAR can be found at title 15, sections
730–74 of the Code of Federal Regulations.
EAR regulations apply to and regulate the ex
port of goods and related technology on the
Commodity Control List (15 C.F.R. § 774,
supplement 1). The ITAR can be found at 22
C.F.R. 120–30. The regulations control the
export of articles, services, and related techni
cal data that are inherently military in nature.
Regulated items are specified in the Munitions
List at 22 C.F.R. 121.
Additionally, the regulations restrict the ex
port of goods and technology that could hamper
the economic vitality of the United States or that
might contribute to the military capability and
potential of its adversaries. Because of global ter
rorism, the latter has been particularly empha
sized in recent years.
IP, as represented by patents, know-how,
trade secrets, and copyright can also be affected
by EAR and ITAR. The Patent and Trademark
Office asserts some control over the export of
sensitive technology by issuing export licenses—
in most cases, automatically, during the early
consideration of a patent application, or upon
request from the applicant. In some cases, the
office will impose a secrecy order on a patent
application that contains sensitive materials.
In such cases, an applicant may prosecute the
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application so ordered in a special group in
the examining corps, but the patent will not
be issued until the restriction has been lifted.
Corresponding applications can be filed and
prosecuted in other approved countries to the
point of acceptance, but the patent itself will
not be issued. With the patented technology
embargoed, the technology itself would fall un
der the EAR or ITAR.
Inasmuch as they embrace transfers of con
trolled information (including technical data,
physical items—inclusive of scientific equip
ment—and verbal, written, electronic and/or
visual disclosures of controlled scientific and
technical information), the EAR and ITAR
can affect university research and development,
as well as university technology-transfer func
tions, via patent licensing and/or other means.
Because of the tradition of academic freedom
and the open nature of research and develop
ment in U.S. universities, the EAR and ITAR
can be more difficult to administer; nevertheless,
universities must comply with the regulations.
Although EAR and ITAR cover virtually all of
the same science and engineering fields that uni
versities research and develop, compliance tends
not to be viewed as essential. This is partly be
cause of the open environment of universities.
Control is more difficult, and neither the EAR
nor the ITAR require an export license to dis
close technical information to foreign nationals
in the United States inside classes, laboratories,
or conferences, or in publications, if the infor
mation is in the public domain. Information is
considered to be in the public domain if it is, at
least in part, published and generally accessible
to the public through unlimited and unrestricted
distribution. This public-domain exemption,
however, may not apply to all information that a
university generates. There are circumstances in
which a specific export license may be required
or, particularly where a secrecy order has been
imposed, export of the information and/or tech
nology is illegal.
Ancillary to the EAR and ITAR is the Treasury
Department Office of Foreign Assets Control
(OFAC). OFAC acts under presidential war
time and national emergency powers and has the

CHAPTER .

authority of specific legislation to prohibit transac
tions, including the provision of services, and freeze
foreign assets under U.S. jurisdiction of targeted
persons and entities. Individuals may not provide
technologies or services to countries on OFAC’s
list of embargoed entities or to specially desig
nated persons without first obtaining licenses from
OFAC and the state or commerce department.
2. The Cooperative Research and Technology
Enhancement Act of 2004

In 2004, the U.S. Congress passed the
Cooperative Research and Technology
Enhancement Act, (CREATE Act). The law is
codified at 35 U.S.C. § 103(c) and applies to
any patent (including reissued patents) granted
on or after December 10, 2004. The law was
designed to overrule a judicial decision that
held that confidential information derived
from another individual (termed secret prior art)
could render an invention obvious and thereby
preclude patentability of the invention. Since
such an exchange of information tends to occur
most frequently where researchers, engaged by
different entities, are collaborating on a given
research project, the decision was construed to
have a “chilling effect” on collaborative research
among different entities. The CREATE Act en
ables two or more entities to obtain and sepa
rately own patents containing claims that are
not patentably distinct from each other (where
one claim in one patent would be “obvious” in
view of a claim in the other patent). To involve
the provisions of the CREATE Act, the col
laborative research must have been conducted
under a Joint Research Agreement that was in
effect on or before the claimed invention was
made, the claimed invention must have been
made as a result of activities undertaken within
the scope of the agreement, and the application
for patent for the claimed invention, initially or
by amendment, must have disclosed the names
of the parties to the agreement.
2.5 Cooperative Research and
Development Agreements

Authority for Cooperative Research and
Development Agreements (CRADAs) is found at

35 U.S.C. § 3710(a). The purpose of CRADAs
is to promote technology innovation in govern
ment-operated federal laboratories and govern
ment-owned, contractor-operated laboratories
across all federal government agencies. The
specific authorization language at 35 U.S.C. §
3710(a) is reproduced below:
(a) General authority. Each Federal agen
cy may permit the director of any of its
Government-operated Federal laboratories,
and, to the extent provided in an agency-ap
proved joint work statement or, if permitted
by the agency, in an agency-approved an
nual strategic plan, the director of any of
its Government-owned, contractor-operated
laboratories—
(1) to enter into cooperative research and de
velopment agreements on behalf of such
agency (subject to subsection (c) of this
section) with other Federal agencies; units
of State or local government; industrial
organizations (including corporations,
partnerships, and limited partnerships,
and industrial development organiza
tions); public and private foundations;
nonprofit organizations (including uni
versities); or other persons (including li
censees of inventions owned by the Federal
agency); and
(2) to negotiate licensing agreements under
section 207 of title 35, United States
Code, or under other authorities (in the
case of a Government-owned, contractoroperator laboratory, subject to subsection
(c) of this section) for inventions made or
other intellectual property developed at the
laboratory and other inventions or other
intellectual property that may be volun
tarily assigned to the Government.
Under a CRADA, the involved labora
tory may grant, or agree to grant, in advance
to a collaborating party patent licenses, or
assignment, or options thereto, in any inven
tion made, in whole or in part, by a laboratory
employee under the agreement for reasonable
compensation (35 U.S.C. § 3710a(b) enumer
ated authority).
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2. Department of Energy/Nuclear Regulatory
Commission inventions and atomic weapons

The laws pertaining to this subject are codified at
title 42 U.S. Code, beginning with section 2014
and continuing with section 2181 (42 U.S.C.
§§ 2014–181). The law specifically prohibits
the granting of any patent for any invention or
discovery for the utilization of special nuclear
material or atomic energy in an atomic weapon;
the law revokes any patent granted for such an
invention or discovery. The prohibition extends
even further to state that no patent granted shall
confer any rights with respect to any invention
or discovery insofar as it is used in the utilization
of special nuclear material or atomic energy in
an atomic weapon.
2. National Aeronautics and
Space Administration

The property rights for inventions made under
the aegis of the National Aeronautics and Space
Administration (NASA) or in contracts issued
by NASA are codified at 42 U.S.C. § 2457.
Generally, inventions made in the performance
of any work under a contract with NASA shall
be the property of the United States. The provi
sions of 42 U.S.C. § 2457c extend beyond the
obligation arising under contract with NASA to
all patents that “have significant utility in the
conduct of aeronautical and space activities sub
ject to a patent applicant’s positive action to dis
pute ownership by the United States.” A right
of appeal presents an opportunity to obtain a
waiver of rights by NASA (42 U.S.C. § 2457f ).
Even if the agency waives its right of ownership
in a given patent, the government will, never
theless, retain or receive an irrevocable, nonex
clusive, nontransferable, royalty-free license to
practice the inventions of such patent on behalf
of the United States or any foreign government
pursuant to any treaty or agreement with the
United States.
2. IP and international trade

The applicable law under the general heading of
IP and international trade can be found at 19
U.S.C. § 1337 under “unfair practices in import
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trade.” Such issues fall under the aegis of the
International Trade Commission. The provi
sions under subsection (a), titled “Unlawful
activities; covered industries; definitions,” are
self-explanatory and are reproduced in Box 1.
Moreover, 19 U.S.C. § 2242 requires the
identification of countries that deny adequate
protection or market access for IP rights before
suitable action can be taken by the U.S. Trade
Representative to counter, correct, or suspend
the benefits afforded in trade and related activi
ties to such a country. (The authorization for ac
tions available to the Trade Representative can
be found at 19 U.S.C. § 1526(c).)
2. Small Business Innovation
Development Act of 1982

Codified at 15 U.S.C. § 631, et sequens, the
Small Business Innovation Development Act
(SBIR) was intended to strengthen the role of
small, innovative firms in federally funded re
search and development and to utilize federal
research and development as a base for tech
nological innovation. An important feature of
the SBIR is the directive for federal agencies
to set aside a portion of each agency’s funding
for small business R&D. The Bayh-Dole Act
allows small businesses to retain title to inven
tions made, in whole or in part, with federal
funds. SBIR enhances the position of small
business.
2.10 Small Business Technology Transfer Program

The Small Business Technology Transfer Program
(STTR) (15 U.S.C. § 638) supplements the
SBIR program. STTR requires a set-aside for
applicable agencies to support cooperative research-and -development projects involving
small businesses and a nonprofit research insti
tutions. STTR provides the latter with the op
portunity to call upon the funding federal agen
cy for technical assistance. IP rights between the
United States and the recipient small business
are required to be set forth in the funding agree
ment, along with any right to carry out followon research.
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Box 1: unlawful activities; covered industries; definitions
(1) Subject to paragraph (2), the following are unlawful, and when found by the Commission to
exist shall be dealt with, in addition to any other provision of law, as provided in this section:
(A) Unfair methods of competition and unfair acts in the importation of articles (other than
articles provided for in subparagraphs (B), (C), (D), and (E) into the United States, or in the
sale of such articles by the owner, importer, or consignee, the threat or effect of which
is—
(i) To destroy or substantially injure an industry in the United States;
(ii) To prevent the establishment of such an industry; or
(iii) To restrain or monopolize trade and commerce in the United States.
(B) The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner, importer, or consignee, of articles that—
(i) infringe a valid and enforceable United States patent or a valid and enforceable
United States copyright registered under title 17, United States Code; or
(ii) are made, produced, processed, or mined under, or by means of, a process covered by
the claims of a valid and enforceable United States patent.
(C) The importation into the United States, the sale for importation, or the sale within
the United States after importation by the owner, importer, or consignee, of articles
that infringe a valid and enforceable United States Trademark registered under the
Trademark Act of 1946.
(D) The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner,importer,or consignee,of a semiconductor
chip product in a manner that constitutes infringement of a mask work registered
under chapter 9 of title 17, United States Code.
(E) The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner, importer, or consigner, of an article that
constitutes infringement of the exclusive rights in a design protected under chapter 13
of title 17, United States Code.
(2) Subparagraphs (B),(C), and (D) of paragraph (1) apply only if an industry in the United States,
relating to the articles protected by the patent, copyright, Trademark, mask work, or design
concerned, exists or is in the process of being established.
(3) For purposes of paragraph (2), an industry in the United States shall be considered to exist if
there is in the United States, with respect to the articles protected by the patent, copyright,
Trademark, mask work, or design concerned—
(A) significant investment in plant and equipment;
(B) significant employment of labor or capital; or
(C) substantial investment in its exploitation, including engineering, research and
development, or licensing.
(4) For the purposes of this section, the phrase “owner, importer, or consignee” includes any agent
of the owner, importer, or consignee.
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3. CONCluSIONS
This overview of the laws and regulations gov
erning IP in the United States provides a general
orientation to the goals and historical concerns
of the legislation. As these goals and concerns
change, so will the laws addressing IP rights.
Moreover, issues surrounding IP rights are ad
dressed in many pieces of legislation, including
authorization bills for funding various federal
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agencies. The effects of the legislation may be
temporary or permanent, another reason for
understanding not just the statutes, but also the
motivation and reasoning behind them. n
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Compulsory Licensing:
How to Gain Access to Patented Technology
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ABSTRACT

Voluntary patent licenses are often difficult for institu
tions to obtain, particularly those in developing coun
tries. This chapter discusses why, how, and by whom
compulsory patent licenses may be obtained and used.
The main focus is on patented research tools rather than
patented end products.

1. InTRoduCTIon
Some scientific discoveries and inventions, partic
ularly in biotechnology, have no obvious practical
application; to use the metaphor of a river, we
might say that they are patented at a point up
stream from practical application. Broad patent
claims often hamper the development of down
stream applications.1 For instance, in the United
States, DNA sequences (genes) are legally consid
ered to be chemical compounds and can there
fore be patented. The gene’s functions, even those
that are not yet known, can therefore be exploited
only by authorization of the patent owner.
One example of the problems that can oc
cur when downstream researchers need to use up
stream discoveries is the case of antigen MSP-1,
an important candidate for the development of an
antimalaria vaccine. The Program for Appropriate
Technology in Health (PATH), which is work
ing to develop such a vaccine, found that the
antigen was protected by more than 20 partially
overlapping patents. Extensive negotiations and

a considerable amount of time and money were
required to obtain permission to use it. A repre
sentative of the program notes:
Why does the IP landscape for MSP-1 not
sort itself out through traditional channels such
as technology transfer and the courts? Developers
who want assurance of the rights to use MSP-1
would have to obtain licenses from no less than
eight organizations.Though theoretically pos
sible, a licensing transaction of this type would
take years, require significant staff time, and cost
hundreds of thousands of dollars in attorney fees.
While companies routinely make such efforts on
behalf of commercial products, the economics
of malaria vaccines make developers more reluc
tant to invest in such cumbersome technology
acquisition.2
Several studies in the United States3 and else
where4 have examined the potential impact of re
search tool patents. Although the U.S. National
Academies of Sciences found that private com
panies and research institutions in developed
countries are generally able to deal with the com
plexities of patent law, it warned that “the patent
landscape, which already is becoming complicated in
areas such as gene expression and protein-protein in
teractions, could become considerably more complex
and burdensome over time.”5 A Swiss survey on the
obstacles to research stemming from patent pro
tection found that a majority of companies and
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institutions favored the creation of either an ex
ception for the clinical use of the patented subject
matter or the granting of compulsory licenses.6
Small companies and research institutions
will likely be more adversely affected by upstream
patents than will large companies or institutions.
Entities in developing countries that lack the le
gal, financial, technological and negotiating ca
pacity to engage in complex negotiations, may be
significantly constrained. For instance, a survey
of 103 Indian pharmaceutical companies revealed
that the most common reason firms decided to
abandon R&D projects was because of restricted
access to patented upstream technologies.7
Some initiatives are being considered that
would allow low-income countries access to tech
nology under special conditions. The Science and
Intellectual Property in the Public Interest proj
ect (SIPPI) of the American Association for the
Advancement of Science (AAAS)8 has promoted
the idea that technology managers in developed
countries should include legally enforceable pro
visions in licensing agreements to preserve the
possibility of sharing protected technologies
with third parties for humanitarian reasons in
developing countries.9
Patented upstream technology can create bar
riers to agricultural research,10 unless the use of
the protected subject matter is permitted under
a research exception or otherwise consented by
the patent owner. Golden Rice, which has been
genetically modified to contain pro-Vitamin A
or beta-carotene, is a tool for combating vitamin
A deficiency in developing countries. Syngenta
Seeds AG negotiated access to all major technolo
gies necessary for Golden Rice production11 and
then granted the inventors of Golden Rice the
right to sublicense breeding institutions in devel
oping countries, free of charge, provided that the
rice would be used only for subsistence farming
and not for commercial purposes. Subsistence
farming has been defined as any farm not gener
ating income more than US$10,000 from the sale
of rice. Syngenta is not interested in commercial
izing Golden Rice in developed countries, where
vitamin A deficiency is almost unheard of.12
Other examples of remo
emovval of patent barriers
through “humanitarian IP management” include
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Cornell University’s transfer of papaya-rings
pot-virus-resistant papaya to Thailand; several
projects brokered by the International Service
for the Acquisition of Agri-biotech Applications
(ISAAA); and the agreement between Yale
University and Bristol-Myers Squibb regarding
the patent on stavudine (d4T), a widely used
HIV/AIDS antiretroviral drug. Humanitarian IP
management could be expanded to involve re
search and experimentation as well as the transfer
of patented technologies.

2. pATEnTS And doWnSTREAM
RESEARCH
A compulsory license is an authorization given by
a “national authority” to a natural or legal person
for the exploitation of the subject matter pro
tected by a patent; the consent of the patent title
holder is not necessary. Compulsory licenses may
be required to import or produce a given product,
or to use a patented technology for research. They
are especially important when there are no close
substitutes for a product or process and a research
exception is not available or is too narrow.13
Compulsory licenses are granted in order to
attain various public-policy objectives, such as: to
address emergencies and public-health needs, to
counteract anticompetitive business practices, or
to permit the exploitation of a patent in cases of
lack of working thereof.
The right to use compulsory licenses was
recognized in the World Trade Organization
(WTO) Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) in 1994.14
The Doha Declaration on the TRIPS Agreement
and Public Health (the Doha Declaration), ad
opted by the 4th WTO Ministerial Conference
in November 2001,15 confirmed, inter alia, that
each WTO member was free to determine the
grounds under which it would grant compulsory
licenses.16
In the United States, compulsory licenses
have been widely used for government use and in
settlements for antitrust cases.17 Countries such as
Zambia and Zimbabwe have recently issued com
pulsory licenses to facilitate access to cheap medi
cines; others, such as Malaysia and Indonesia, have
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issued government-use provisions for the same
purpose. A public non-commercial use provision
is somewhat different from a compulsory license
for commercial production. Public non-commer
cial use provisions, which exist in many countries,
authorize a government department to exploit,
by itself or through a contractor, a patented in
vention, without the consent of the patent right
holder, as long as such exploitation is to provide
a public service and for noncommercial purposes.
Other countries, such as Brazil and South Africa,
have threatened to grant compulsory licenses in
order to obtain cheaper medicines.18 A compul
sory license is likely to be less advantageous to the
patent owner than a voluntary license. It is there
fore to the advantage of patent owners to price
their products fairly and grant voluntary patent
licenses with reasonable terms and conditions.
Compulsory licenses may be needed when
patents restrict the freedom to operate (FTO) 19
in a given field of R&D. Such licenses are subject
to several conditions, notably that the licensee
must remunerate the patent holder. These condi
tions are examined in section 3 below.

. CoMpuLSoRy LICEnSES foR RESEARCH
.1 Who can apply?

National laws normally allow companies, non
governmental organizations, and research institu
tions to apply for compulsory licenses. In some
countries, licensees must first demonstrate that
they have the technical or economic capacity to
utilize the license properly.
.2 When can a compulsory
license be applied for?

Some types of compulsory licenses, such as those
granted to remedy abuses, for example, lack of
working, cannot be granted until four years after
the date of filing of the patent application or three
years from the date of the grant of the patent,
whichever date comes second.20 These terms do
not apply when the compulsory licenses are grant
ed on other grounds, such as when public health is
at stake, in emergency situations, or where neces
sary to remedy anti-competitive practices.

. Prior negotiation of a voluntary license

Except in the case of emergency, anti-competi
tive practices, and government use, the potential
compulsory licensee must first request a volun
tary license on reasonable commercial terms from
the patent owner.21 Such “reasonable commercial
terms” must be consistent with standard com
mercial practice and must ultimately be in accor
dance with the requirements set by national law
and by the competent authority. If such a volun
tary license is denied, the potential licensee may
apply for a compulsory license—though it may
be necessary to prove that the patent owner has
refused to grant a voluntary license within a rea
sonable time period.
Many patents for research tools are held by
universities—where the initial invention has of
ten been made—that sometimes decline to pro
vide voluntary licenses to certain applicants or
are unable to do so. The reasons for this may be
multifold. One reason may be that the university
has already granted an exclusive license; another
reason may be that the university is in licensing
negotiations with another party. Determining
reasonable commercial terms when the patent
owner is a university is also difficult. However,
there are many universities with extensive experi
ence in these matters, and their standard practices
may serve as models. This is certainly one reason
why universities should be encouraged to retain
humanitarian-use rights.22
. How should the application be made?

National laws govern both the substantive re
quirements and the relevant procedures for ob
taining a compulsory license.
..1 The appropriate authority

In most countries, compulsory licenses are grant
ed by the government’s executive branch. In oth
ers, such authority lies with the judiciary branch.
The services of legal professionals are not gener
ally required, but may be advisable.
..2 Grounds for the application

The appropriate authority should be provided
with a reasoned justification for the application.
The application should, to the greatest extent
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possible, specify the legal provisions and grounds
on which it is sought. Requests must abide by the
restrictions set by national law.23
The application should specify the scope and
duration of the requested compulsory license. An
application may request access to all of the sub
ject matter covered by a patent, or it may request
access to only certain elements of a patent, or cer
tain uses of a patented invention.
To avoid the trouble of having to file future
license extensions, it is advisable to request the
license for the full remaining term of the patent.
.. Identification of the applicant

The applicant, if not a natural person, will nor
mally have to submit copies of the relevant stat
utes or bylaws. In addition, any person represent
ing the applicant will have to demonstrate his or
her capacity to do so. Depending on national law,
the applicant may also have to provide evidence
of sufficient economic or technical capacity to
utilize the compulsory license (information about
personnel, funding, activities, partnerships, pub
lications, and so on).
.. Identification of patents

The identification of the patents involved can be
determined by indicating the product or tech
nologies at stake. The compulsory license ap
plication may refer to all patents relating to the
products or technologies the applicant seeks to
exploit. In other words, one application can re
quest the rights to many patents. In the United
States, there have been cases in which compulsory
licenses were even granted for both current and
future patents.24
.. Conditions of the
compulsory license

Remuneration. Governments have considerable
discretion to define the level and kind of remu
neration that the patent owner should receive.
The general rule is that remuneration should be
adequate, taking into account both the particu
lar circumstances of each case and the economic
value of the compulsory license.25 Following are
some of the methods that have been used to cal
culate remuneration:26
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• The 1998 Japan Patent Office (JPO)
Guidelines (for government-owned drug
patents) specify royalties that amount to
2%–4% of the generic product price; this
amount can be increased or decreased by as
much as 2%, for a range of 0%–6%.
• The 2001 United Nations Development
Programme (UNDP) Human Development
Report proposed a base royalty rate of 4%
of the generic drug price. This can be in
creased or decreased by 2%, for a range of
2%–6%, depending upon various factors
(how innovative the medicine is, or the role
of governments in paying for research and
development).
• In accordance with the WTO Decision of
30 August 2003, the 2005 Canadian gov
ernment established royalty guidelines for
compulsory licensing of patents to coun
tries that lack the capacity to manufacture
medicines. The royalty rate (between 0.02%
and 4% of the price of a generic drug) is
determined by a country’s rank in the UN
Human Development Index. For most de
veloping countries, the royalty rate is less
than 3%. For most countries in Africa, the
rate is less than 1%.
• The tiered-royalty method is unusual in
that the royalty rate is based upon the price
of a brand-name drug, not the generic
equivalent, in the high-income country in
which the patent is owned. The base royalty
(4% of the brand-name price) is adjusted
to account for relative income per capita or,
for countries with a particularly high bur
den of disease, relative income per diseased
person.
These guidelines are used to determine roy
alty rates for products, not research tools. For re
search tools, royalty payments may be lower since
no products are yet on the market.
With regard to agricultural technology, a
relevant precedent may be the determination
of 1,1% of the net sales of products within the
Multilateral System in the context of the stan
dard material transfer agreement adopted, in
June 2006, by the Governing Body of the FAO
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International Treaty on Plant Genetic Resources
for Food and Agriculture.27
Finally, the act granting a compulsory license
should specify time of payment, basis for the cal
culation of fees or royalties, currency of payment,
the bank account where the payment will be de
posited, and other relevant details.
Other conditions. In all cases, a compulsory
license will be nonexclusive:28 that is, the patent
owner or other voluntary or compulsory licensors
may simultaneously exploit the patented inven
tion or research tool. According to some national
laws, the license may be revoked if not utilized
within a certain term. Moreover, a compulsory
licensor can request that a license be terminated,
if and when the circumstances that first necessi
tated the license cease to exist and are unlikely to
recur.29

products that were developed under compulsory
licenses. This is one reason for further invest
ments in capacity building and the establishment
of strong institutional networks. n
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The Role of Clusters in Driving Innovation
PETER W. B. PHILLIPS, Professor, Department of Political Studies, University of Saskatchewan, Canada
CAMILLE d. RyAN, Postdoctoral Fellow, Faculty of Communication & Culture, University of Calgary, Canada

ABSTRACT

The promise of biotechnology relies on new science that
is increasingly complex and specialized and depends on
sophisticated, global intellectual property rights systems.
This complexity requires a more open system of knowl
edge sharing than previous research and development
programs. Studies suggest that successful innovation
requires developing clusters of institutions, businesses,
and personnel. “Location, location, location,” the battle
cry for property realtors everywhere, is increasingly be
coming the key phrase in studies of innovation dynam
ics and knowledge-based growth. Offering an overview
of recent research on clusters in Canada, this chapter
suggests that governments have an important role to
play in the process of cluster formation and that ensur
ing a mix of “local buzz” and “global reach” is part of the
recipe for success.

1. INTRODuCTION
Biotechnology has changed the discussion about
research and development in agriculture and
medicine. In the past, research tended to be dis
tributed widely to meet agronomic and human
health needs, but now we are seeing agglomera
tions forming around the research, development,
and commercialization of globally mandated
technologies and products. Governments view
this change as an opportunity to invest in and
create comparative advantages or as a threat to
their competitive status and ability to access new
technologies.

Theory and evidence suggest that competing,
innovative companies and their related industries
will tend to concentrate in a few locations. Most
innovation involves a lot of learning-by-doing,
which creates a barrier for imitators who want to
use the innovation: they can do so only after they
have gone through their own learning process.
Furthermore, the cumulative impact of learning
by-doing creates stronger competition in moreinnovative companies and sectors, thus erecting
barriers to less-innovative actors. While basic
science and inventions (usually codified through
scientific journals and patents) can often be trans
ferred at low or no marginal cost, know-how and
experience are very difficult to transfer across long
distances. Applied science (know-how) does spill
over to others in the sector, but estimates suggest
that the spillover benefits of tacit knowledge are
limited to between ten and 100 miles of the epi
center. This pattern is frequently seen in the inno
vation corridors of Silicon Valley, Boston’s Route
128, and Austin in the United States, Cambridge
in England, Bangalore in India, and Saskatoon in
Canada.
Grossman and Helpman1 argue that techno
logical spillovers limited to a specific location (due,
for example, to climate or industrial structure)
create an opportunity for endogenously gener
ated comparative advantage. According to the au
thors, countries that engage in technology-related
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competitive activity can produce comparative
advantage over time. If technological spillovers
are geographically concentrated, then the initial
and sequentially established conditions will af
fect subsequent economic growth. Grossman
and Helpman further argue that, as a result, the
high-technology share of GDP and exports will be
greater in first movers than elsewhere. In the ex
treme, a country that inherits even a small techno
logical lead could come to dominate world mar
kets for high-technology products. A productivity
differential then becomes self-sustaining.
Gilpin2 argues that the new theories of eco
nomic growth create a new role for the state.
Governments can generate growth, and numer
ous countries and regions have sought to do just
that. By some counts, all large industrial econo
mies, almost all major cities around the world
and many smaller countries, cities, and regions
have decided to invest in and nurture some form
of a biotechnology cluster. There are literally hun
dreds of putative biotechnology clusters around
the world right now.

2. BIOTECHNOlOGy, HEAlTH,
AND AGRICulTuRE
Some 40% of the world’s market economy is based
upon biological products and processes—mainly
food, protein and fiber production, and human
health.3 The security and the supply of food and
fiber are threatened by increasing consumer de
mand, shrinking cultivable land, limited water,
and diminishing returns on existing technologies.
Further, while great strides have been made in ex
tending and improving the quality of life, disease
remains a constant daily threat in many countries.
Food-supply insecurities and unchecked disease
go hand in hand in many low-income developing
economies, yielding a dismal, Malthusian outlook
for a large portion of the world’s population.
Biotechnology has potential to transform
food production and health. A number of key
scientific discoveries since 1970 in the fields of
genomics and proteomics (for example, gene se
lection, gene splicing, and metabolic profiling)
have opened up vast novel avenues of research,
on new plants, animals, and microbes, that could
22 | HANDBOOK OF BEST PRACTICES

have applications in medicine, agriculture, extrac
tion, processing, and the environment. Despite
some major obstacles, many scientists and policy
advisors see great potential in modern, molecu
lar-based biotechnology, especially through the
new capacities to genetically modify plants and
to detect and treat disease. In 2001, Daar and
colleagues4 undertook a Delphi survey of more
than 30 scientists and bioethicists from around
the world to identify the top ten technologies
that could address a wide range of problems in
the developing world. The list included eight
biomedical applications: molecular technologies
for affordable, simple diagnosis of infectious dis
eases; recombinant technologies to develop vac
cines against infectious diseases; technologies for
more-efficient drug and vaccine delivery systems;
sequencing pathogen genomes to understand
their biology and to identify new antimicrobi
als; female-controlled protection against sexually
transmitted diseases, both with and without con
traceptive effect; bioinformatics to identify drug
targets and to examine pathogen-host interac
tions; recombinant technology to make therapeu
tic products such as insulin and interferon more
affordable; and combinatorial chemistry for drug
discovery. It also included one agricultural use:
genetically modified crops with higher yields and
increased nutrients that resist biotic and abiotic
stresses, and an environmental application: tech
nologies for sanitation, clean water, and bioreme
diation. If realized, these technologies would go a
long way towards addressing the biggest food and
health challenges of many developing countries.

3. lIFE-SCIENCE INNOVATION SySTEMS
One opportunity or constraint, depending on how
one looks at it, in achieving a better future is the
relationship of innovation systems to life science
research, development, and commercialization.
In the classical model of innovation, relatively
small groups of researchers (either in public labo
ratories or in private research groups) engaged in
a mostly self-contained, linear process of research
and development, a process that ultimately led to
commercialization through direct or contracted
production and marketing. This type of structure
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was exemplified by the research departments at
Consolidated Edison, 3M, and Xerox, where ful
ly dedicated research staff were given the freedom
to investigate and invent new products for com
mercialization by the host company.
Much of the early life-science research also
conformed to this model, except that it was often
carried out in public laboratories (for example,
the discovery of insulin by Banting and Best at
the University of Toronto in 1922, the discovery
of the structure of DNA for which Watson and
Crick at Cambridge University received a Nobel
Prize, and the creation of low-erucic acid, low
glucosinolate rapeseed in Canada). While these
individual efforts drew upon knowledge gener
ated by others, most of them operated in relative
isolation, with little formal or informal exchange
of information during the discovery phase. This
“standing on the shoulders of giants” model has
generally been the basis for research efforts since
the scientific and industrial revolutions of the
seventeenth century. While the model may have
been appropriate in earlier times, since many in
novations were simply the product of inventors’
ingenuity, in more recent years, many institu
tions, companies, and industries have used a dif
ferent strategy to develop and exploit life science
inventions.
Indeed, the global life-science research ef
fort has been significantly transformed. Two
specific trends have led to this change. First, this
new science has become increasing complex and
specialized, which makes it increasingly difficult
for isolated or independent scientists to realize
breakthroughs or to pursue comprehensive re
search programs. Instead, teams or networks of
researchers pursue investigations. Second, intel
lectual property (IP) rights have been extended
into new subject areas and new jurisdictions. The
United States started the process by extending
patents through the Chakrabarty case in 1980 to
living, single-celled organisms; patents were then
extended through a series of subsequent decisions
to whole plants, animals, and many human organs
(but not the whole human being). Patent grant
ing on living matter was internationalized over
the past 20 years as other countries (for example,
Australia, Canada, the European Union [E.U.],

and Japan) either amended their own patent
laws or issued judicial decisions extending rights.
This IP rights system has been extended globally
through the adoption of the Agreement on TradeRelated Aspects of Intellectual Property (TRIPS)
of the World Trade Organization (WTO), which,
in 2006, began to require that all member states
(virtually all countries) offer patents, plant breed
ers rights, or some other sui generis system of pro
tection for IP embodied in living matter. Private
(and public) inventors have adapted rapidly to
this new regime, patenting almost all of their
inventions (including the tools of discovery and
the resulting products). By 2005 there were an
estimated 58,000 patents relating to biotechnol
ogy tools and products in the United States, and
a confusing array of rights claimed or allocated in
other countries around the world. The increased
role of profit seeking and the extensive use of for
mal IP rights mechanisms such as patents have
created barriers to the free exchange of knowl
edge, which is now heavily scrutinized.
The specialization of science and the fragmen
tation of IP rights have forced scientists to col
laborate and network more extensively to achieve
research results (the Human Genome Project rep
resents one type of widespread research network).
Networks of institutions and researchers have
evolved to handle the transfer, acquisition, and
use of various forms of knowledge. Increasingly,
research programs are not simply standing on
others’ shoulders but instead are working side-by
side through formal or informal collaborations
or research networks. Sometimes these structures
have grown organically; sometimes they have
been actively supported and encouraged by gov
ernment. Typically, they operate above the level
of the company or the organization but below
the global level; they are inherently regional and
supraorganizational.

4. NETWORKED KNOWlEDGE
Networked knowledge exhibits three important
attributes. First, it comes from a nonlinear re
search system, perhaps best illustrated by a chainlink model of innovation.5 In essence, a chain-link
system embeds the traditional linear development
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process in a series of feedback loops. At the core,
new technology or product development still
goes through a relatively linear process, begin
ning with identification of the potential market,
and involving successive efforts to design, adapt
and adopt a new technology or product to the
market need. But, unlike the linear model, where
many of these steps were taken inside a closed
R&D system (either inside a single company or
involving only a few, formally aligned partners),
the chain-link now involves extensive search and
discovery functions, with innovators often going
out beyond their own system to seek out exist
ing knowledge or to undertake or commission
research to solve specific problems in the innova
tion process. At the root, such a system depends
on the efficacy and efficiency of the relationships
that link the often disparate actors together.
Second, multiple types of knowledge are in
volved in such a system. Malecki6 identifies four
distinct types of knowledge: “know-why,” “know
what,” “know-how,” and “know-who.” Each type
of knowledge has specific features.7 Know-why re
fers to scientific knowledge of the principles and
laws of nature. It is almost always derived from
research efforts undertaken in publicly funded
universities and nonprofit research institutes and
is subsequently codified, published, and made
accessible in academic or professional journals.
Know-what refers to knowledge of techniques;
usually it can be codified and transferred through
the commercial marketplace. Know-how refers to
the combination of skills, analytical capacity, and
intellectual, educational, and physical dexterity of
individuals and systems to effectively combine the
know-why and know-what to innovate. This ca
pacity is often learned through education and tech
nical training and perfected by doing. This makes
it more difficult to codify and also more difficult
to transfer to others. Finally, know-who, which
“involves information about who knows what and
who knows how to do what,”8 is becoming increas
ingly important in biotechnology-based industry.
The breadth of knowledge that is required to in
novate has expanded to such extent that collabo
ration has become indispensable. In today’s con
text, know-who also requires knowledge of—and
access to—private-sector knowledge generators
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who, at times, may hold back the flow of crucial
enabling information, expertise, and knowledge.
Know-who knowledge is seldom codified; instead,
it often accumulates within an organization or, at
times, in communities where a cluster of public
and private entities are all engaged in the same
type of research and development. These clusters
often exchange technologies, biological materials
and resources, and pursue common staff training
or cross-training opportunities.
Third, each of the above-mentioned types of
knowledge is likely to be subject to some form
of exchange costs. Different types of knowledge
are likely to be delivered by different actors.9
Depending on the nature of the knowledge
(whether it is easily codified as well as the cost
of exchanging it), the exchange may be an armslength market transaction (for example, contracts
or spot markets) or may involve nonmarket or
ganization (for example, intracompany transfer,
development and use in the public sector or via
collective institutions).
The public sector is optimally structured
to create know-why scientific knowledge for
the public good. Private companies and mar
kets are generally well suited to managing
codified knowledge, often in the form of pat
ents. Collective organizations are often best for
delivering knowledge, such as know-how and
know-who.10 Different domains, moreover, fa
vor different formal or informal IP mechanisms,
according to organizational objectives and abili
ties. Academics developing pure science empha
size publication and the use of copyright, while
actors developing technology look to patents
and trade secrets to protect interests. Collective
institutions use less formal, open, pooled or net
worked knowledge, controlling access through a
shared language, a common culture, and exten
sive collective experience.11
In sum, to understand networks and net
worked knowledge, we must consider the nature
of the knowledge being developed and used, the
transactional forms mediating the exchanges,
and the institutional structure of the relation
ships that manage the development and use of IP.
Increasingly, networks or communities of innova
tors are locating in aggregated clusters.
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5. CluSTER THEORy
“Location, location, location,” the battle cry for
property realtors everywhere, is increasingly be
coming the key phrase in studies of innovation
dynamics and knowledge-based growth. Theories
about how innovation occurs, and more specifi
cally about how and why companies and other
actors co-locate in clusters, are incomplete but
continue to evolve. As our understanding of in
novation grows, so does our ability to direct its
revolutionary power.
Widely used both in the academic literature
and among economic development practitioners,
the term cluster is helpful. The Oxford English
Dictionary defines the generic term to mean
a “group of similar things, especially such as grow
together.” Although companies and various notfor-profit entities in the same sector or product
market have been observed since the beginning
of recorded economic history to locate themselves
in specific geographic regions (rather than spread
ing out evenly across the geography or economy),
the search for ways to encourage clustering has
only recently begun. Economists first began to
develop models to explain such agglomerations
in the 1700s. By the mid-1800s, economists were
beginning to develop new theories and undertake
intensive analyses of the phenomena. While that
work continued on and off into the 1900s, the
rise to dominance of the neoclassical economic
paradigm after 1950 pushed these studies (and
related policy prescriptions) to the margins.
That all changed in the 1990s. Beginning in
the early part of the decade, economists began
to refocus their attention on the microeconomic
foundations of growth. After a decade of stagfla
tion, new “conservative” governments shifted to
a low-inflation macroeconomic stance and be
gan to look for new microeconomic options to
accelerate productivity and economic growth.
Michael Porter’s well-timed release in 1990 of the
Comparative Advantage of Nations12 reintroduced
the concept of clusters, this time in a paradigm
that posited that local competition is the primary
dynamic behind cluster development and sustain
ability. This concept dovetailed with the shift in
strategies by governments. Since then, the general
concept of “similar things… growing together” has

been applied widely to economic and industrial
policy around the world.
Cluster theory is now a fabric of many
threads drawn from economic geography, re
gional economic innovation systems, national
innovation systems, and knowledge transfer and
social networks. While there is no consensus on
a complete theoretical explanation for clusters, a
few threads are becoming common to most ex
planations of the phenomena. These return to the
basic observations by Marshall,13 who identified
three clear and straightforward sources of exter
nal economies (Krugman14 calls them “centripetal
forces”) that explained the location of some indus
try: knowledge spillovers, related and supporting
industry, and specialized labor markets.
Much of the literature on clusters focuses on
the potential for external economies to develop
from information spillovers. Beyond the basic
economies of scale in knowledge-based industry,
external factors can significantly influence the in
dustry due to “mysteries being in the air.”15 The
literature on “national systems of innovation” (ini
tiated by Lundvall16) posits that such systems in
volve “that set of distinct institutions which jointly
and individually contribute to the development and
diffusion of new technology and which provide the
framework within which governments form and im
plement policies to influence the innovation process.
As such it is a system of interconnected institutions
to create, store, and transfer the knowledge, skills,
and artefacts which define new technologies.”17 In
other words, innovation now involves and gener
ates significant externalities—innovators increas
ingly rely on an array of formal and informal col
laborators, and the efficacy of those relationships
will determine their ability to successfully launch
a new innovation. Mowery and Oxley18 point out
that these systems must include more than the
research actors. They also require public programs
intended to support technology adoption and
diffusion, as well as an array of laws and regula
tions that define IP rights and manage discovery,
production, and marketing.
Studies have focused mostly on the role of
universities in innovation systems. The traditional
role of a university is to generate and diffuse basic
or explorative knowledge and to develop a skilled
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academic and technical labor force. However,
these traditional roles (in terms of knowledgegeneration activity and culture) are evolving. As
Cooke19 argues, a strong local science base needs
to be complemented by a thick entrepreneurial
culture in both the regional business and academic
communities. Brown and Duguid20 suggest call
ing these connections “communities of practice.”
Not surprisingly, measuring such connections is
complex and difficult because such knowledge is
often tacit and nebulous.
A similarly large amount of research has con
centrated on evaluating extensive local and regional
networks of related and supporting industry (of
ten called “backward linkages”) and their access to
large, sophisticated markets (“forward linkages”).
Porter21 analyzed 2,500 potential clusters around
the world based on the strength and value of their
arrays of forward and backward linkages. The
Innovation Systems Research Network, a consor
tium of scholars examining 27 clusters in Canada,
similarly evaluated the importance of industrial
and supply-chain relationships on competitive
ness and innovation. While these studies have
shown that linkages are important, the evidence is
still out on whether the linkages are a causal factor
or are a result of effective innovation.
Finally, a number of researchers have at
tempted to evaluate the role of labor market
dynamics for growth. These studies argue that
when local labor markets expand and special
ize, this creates incentives both for companies
to co-locate and for specially skilled employees
to migrate to those locations. This reduces the
searching and negotiating costs for operating in
the region. In addition, these labor force dynam
ics sustain and support the flow of knowledge
among actors. Zucker, Darby, and Brewer,22 for
example, looked at the role of research stars such
as high-impact academic researchers that were
concentrated geographically, concluding that
agglomerations of stars are positively correlated
with greater local innovation. Stars appear to
provide valuable signaling functions for capital
markets to facilitate commercialization of new
technologies and products.
Metcalfe23 notes that Malerba’s 1991 study
of Italy identified two discrete, independent
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systems of innovation. One, typified by the
computer software industry, is based on flexible
networks of small- and medium-size companies,
often co-located in distinct industrial districts
(such as Silicon Valley). These companies were
both very volatile and growing rapidly. The oth
er type of system, which perhaps better reflects
current biotechnology systems, is based on
universities, public research laboratories, and
large firms performing and commercializing
R&D—called “the triple helix” by Etzkowitz
and Leydesdorff.24 It has been further argued
that, regardless of the prevailing model, no
institution can be self-contained in its techno
logical activities.25 All companies, large or small,
have to rely on knowledge from other sources.
Systems that support a company’s ability to ac
cess, absorb, and use external knowledge can be
critical to the growth of companies, sectors, and
regions. This is especially so in the early stages
of a technology’s development or when a tech
nology has a rapidly changing knowledge base,
as is the case with biotechnology.
Critics argue that the term cluster is vague
and has become mere rhetoric. Markusen26 ar
gues that the cluster literature involves “fuzzy
concepts” based on “scanty evidence” that produc
es “wimpy policy.” According to the OECD, the
definition of a cluster “provides little guidance
for narrowing the scope of inquiry in a meaning
ful way.”27 Similarly, according to Martin and
Sunley,28 “[Clusters have been] accepted largely
on faith as a valid and meaningful way of think
ing about the national economy, as a template or
procedure with which to decompose the economy
into distinct industrial-geographic groups for the
purposes of understanding and promoting com
petitiveness and innovation.” Finally, some critics
argue that clusters can be interpreted to imply
rising self-sufficiency, which may work against
the economic benefits of specialization and
open trade based on comparative advantage.

6. CluSTER PRACTICE
No matter how vague the term, this has not pre
vented its rapid adoption. Economic development
agencies in developed and developing countries
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have applied Porter’s generalized approach to
clusters, customizing it to their particular geopo
litical region. More than 1,100 clusters have been
examined in recent years,29 but few of these have
examined the research components of health or
agriculture, and only three major studies have fo
cused on clusters in the life-science area.
Ryan and Phillips,30 for example, identified
and categorized 14 life-science clusters in seven
countries in 2001, concluding that life-science
based innovation clusters vary in scope and scale
across the regions of Australia, Europe, and
North America (see Table 1). Some clusters are
discrete communities in which development and
preservation are driven by clearly defined pub
lic policy. The communities often have names

signifying their status as an innovation cluster
(for example, BioBelt, BioValley, and Innovation
Place). Ryan and Phillips discovered that most
clusters were based on a core of biomedical re
search. In those that claimed to have an agri
food focus, the effort was often only a small,
relatively insignificant adjunct to the core. There
are very few established clusters dedicated to ag
ricultural or agricultural biotechnology other
than Canada’s Innovation Place in Saskatoon,
Saskatchewan; the Agri-Food Quality Cluster in
Guelph, Ontario; and perhaps Adelaide Centre
in Australia. In each case, a large percentage of
the primary and supporting (private and public)
actors are directly involved in food quality and
agricultural biotechnology.

Table 1: Selected life Science Clusters
Country

Canada

United
States

Number
of actors

Private
sector
presence

Innovation Place, Saskatoon,
Saskatchewan

115

73%

29%

Agri-Food Quality Cluster (AFQC),
Guelph, Ontario

41

76%

49%

Connecticut Bioscience Cluster

110+

98%

1%

The Research Triangle Park (RTP),
Raleigh-Durham and Chapel Hill, North
Carolina

145

92%

3%

1,183

90%+

24%

Biotech Beach, San Diego, California

700

90%+

3%

Innovation Triangle, Edinburgh, Dundee
and Glasgow, Scotland

428

95%

2%

BioValley, France, Germany, and
Switzerland

459

90%

6%

Qbio, Brisbane, Queensland

43

42%

5%

BioHub, Sydney, New South Wales

28

75%

18%

Bio21, Melbourne, Victoria

24

0%

4%

Adelaide, South Australia

25+

44%

Perth, Western Australia

27

65%
80–
90%

Region

BioBelt, St. Louis, Missouri and Illinois

Europe

Australia

Ag/agbiotech
component

20%

Source: Adapted from Ryan and Phillips. 31
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Cluster models appear to be very different.32
The United States focuses on commercial out
comes and investment attraction, placing key
multinational companies (some might call them
national champions) at the center of their re
gional clusters. In Europe, the public sector (uni
versities and large research institutes) is the main
driver. Canada’s key clusters tend to be commu
nity led, while Australia appears to use a blend of
cluster approaches. Phillips and colleagues33 ex
amined the seven Canadian biotechnology-based
clusters studied through the Innovation Systems
Research Network.34 These seven communities
represent a wide range of size, scope, foci and
histories (table 2).35
Consisting of both large pharmaceutical and
small biotechnology companies, the Montreal
cluster is the largest biotechnology cluster in
Canada. It benefits significantly from provincialgovernment programs and national research labs.
Recent surveys identified 351 actors: 130 in hu
man health, 26 in human nutrition, 12 in agri
cultural biotechnology; and seven environmental
companies; 171 service and supporting enter
prises; one government lab; and four related uni
versities. As of 2002, 29 companies in Montreal
had patented 234 locally invented technologies,
but 89% of the patents were owned by the eight
largest companies. Growth in the region since
1999—when only 14 companies had 66 patents
in total—has been explosive.
The Toronto cluster is a two-part cluster: one
part is dedicated to core biotechnology activities
and the other to biomedical devices. Anchored
by the Medical and Related Sciences (MaRS)
Discovery District, the University of Toronto (U of
T), and the Health Network have also been identi
fied as primary knowledge generators. A concen
tration of companies is situated downtown while
some skilled workers are concentrated in peripheral
regions. It appears that once firms or organizations
move from exploration to exploitation activities,
they move to the neighboring cities of Etobicoke
or Mississauga to take advantage of lower costs.
This contributes to weak network coherence, al
though Mississauga appears to be more cohesive.
While the U of T has a significant number of stars,
it has historically been considered unsuccessful in
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facilitating spinouts. This has been variously cited
as the reason for limited local expertise in biotech
nology financing.
It is not yet clear whether London, Ontario
has a distinct biotechnology cluster or whether
the activity there is merely an extension of the
Toronto cluster. With an established biomedi
cal-devices competency that started in the 1970s,
London would appear to be an early-stage, emerg
ing biotechnology cluster focused on biopharma
ceutical applications. Linkages among local actors
appear to be weak, with most acknowledging that
they are more connected to actors in the Toronto
core than they are to one another.
The Vancouver cluster, which focuses largely
on biomedical biotechnology, is essentially a re
search community with the University of British
Columbia (UBC) at the core. UBC and, to a
much lesser extent, Simon Fraser University, are
home to almost 80 research stars who produce
a wide array of IP. While there have been some
spinouts from UBC, more than two-thirds of
which have survived at least five years, the prime
focus of the cluster is on developing IP rather
than products. Government and industrial sup
port has not fundamentally altered the cluster.
Early research suggests that lifestyle may be one
of the critical factors that sustains the university
and attracts both companies and individuals to
the region.
The Saskatoon cluster is almost purely an
agricultural-biotechnology cluster, focused pre
dominantly on oilseed crops. While the univer
sity is home to the largest number of researchers
in the community, many of the stars and much
of the IP that is developed and used have come
from federal labs. NRC’s Plant Biotechnology
Institute (NRC/PBI), the focus of considerable
research collaboration, appears to share leadership
with the local industry association, AgWest Bio.
While the cluster is research focused, it has suc
ceeded in commercialising world-first genetically
modified plants, vaccines, and inoculants. Recent
public investment in the university—including
the Canadian Light Source Inc. (CLSI) synchro
tron project and various genomics projects—has
the potential to change the direction of the cluster
over the coming years.
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Table 2: Comparison of Canadian Biotechnology-Based Clusters
Stars

Preliminary
observations

Cluster

Focus

Core actor(s)

Montreal

Pharmaceutical
and biotechnology

A handful of generic
and multinationalenterprise patent
drug companies

70

• provincial government
leads in terms of
progressive policies
• 15 spinouts University
of Montreal

Toronto

Biotechnology
and biomedical

Medical and Related
Sciences (MaRS)
Centre; University
of Toronto; and the
Health Network

47

• concentrated in
Toronto at exploration
stage; moved to
peripheral regions
(Etobicoke) at
exploitation stage
• limited network
coherence

London

Biotechnology /
biomedical devices
(established in
1970s)

University of
Western Ontario;
Robart’s Research
Institute; and Lawson
Health Research
Institute

5

• early-stage
biotechnology cluster
• cluster or merely TO
‘cohort’?
• transportation
considered a weakness

Vancouver

Biotechnology

University of British
Columbia

80

• producer of IP, not
products

Saskatoon

Agricultural
biotechnology

National Research
Council-Plant
Biotechnology
Institute; AgWest Bio

45

• research based
• new investments in
genomics, Canadian
Light Source Inc.,
and University of
Saskatoon may
change direction

Ottawa

Biomedical and
biotechnology

Gamma Dynacare
(Ottawa Life Sciences
Technology Park)

6

Halifax

Pharmaceuticals,
health,
nutraceuticals,
information
technology, and
biomedical

none

min.

• more than 40 research
institutes
• 18,000 people
employed in life
sciences
• 15–20 spinouts
• a variety of
companies, with little
product focus
• not clearly a cluster
• weak networks
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The evidence available to date suggests that,
based on the traditional definition of the con
cept, neither Ottawa nor Halifax are clusters.
While Ottawa appears to have a large number of
research institutes, its identifiable biotechnology
cluster is quite small. As of 2002, there were only
47 actors: 30 small biotech companies, six gov
ernment labs, one connected university, and ten
service/support organizations. Only two of the
Ottawa-based companies had generated patents
by 2002, and the University of Ottawa had only
a few stars and limited success with patents (11 as
of 2002). Meanwhile, Halifax hosts a variety of
companies with little or no market focus. Actors
are not focused on any specific technology or
product application. Instead, some actors are in
the heath sector (devices, pharmaceuticals, infor
mation technology, and neutraceuticals), while
others work on horticulture, environmental ap
plications, and food quality. There is currently no
obvious anchor organization, and actors in the
region are loosely connected. In contrast to most
other clusters, this one has seen little investment
in infrastructure in the past few decades. Local
surveys suggest that there has been little or no
success in facilitating technology transfer, which
has led to limited engagement between business
and academic scientists.
This review of Canada’s clusters offers a num
ber of insights into cluster practice. Although bio
technology-based industries have common, “deep
er science” aspects, they appear to differ widely in
terms of organization. The significant differences
in size (Montreal versus Saskatoon), market focus
(core biotech in Vancouver versus medical devices
in Toronto), and cohesion (strong in Saskatoon
and Montreal but weak in other centers) suggest
that the way in which the cluster is organized—its
position in a product or technology life cycle and
how its actors interact—can vary widely.
Phillips36 examined the dynamics of the
Saskatoon-based ag-biotechnology cluster by fo
cusing on knowledge flows. Wolfe and Gertler37
suggest that a more-sophisticated approach to
clusters is to consider them as regional systems
of innovation that embody local interdependen
cies (what Wolfe and Gertler call “local buzz”)
and engagement with the broader international
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economy (“global reach”). A local buzz and glob
al reach, or entrepôt, approach would highlight
the balance needed between local, regional, na
tional, and global capacities. Phillips38 analyzed
the stocks, flows, and accomplishments of the
Saskatoon innovation system through the mech
anism of an entrepôt model. It looked at the
community’s capacity to create knowledge, use
knowledge, and commercialize new products.
Saskatoon’s claim to fame is arguably the devel
opment of canola (based on its record as the lead
innovator and early adopter of all new traits over
the past 40 years). Analysis showed, however,
that a significant share of the applied research
to develop the processes used in the creation of
those varieties has been done in other countries.
Moreover, much of the application-based re
search (for example, uses for new oils) is happen
ing elsewhere. This suggests that Saskatoon has
actually operated in a niche of this global, knowl
edge-based industry—as an entrepôt undertak
ing and assembling the know-why, know-how,
and know-who of varietal breeding and primary
production—but that the bulk of the activities
up- and downstream of that stage in the produc
tion system are now, and may continue to be,
carried on elsewhere. Figure 1 illustrates the re
lationships between the global industry and the
Saskatoon entrepôt.39

7. CluSTERS AND IP MANAGEMENT
Research is increasingly generating networked
knowledge. This new asset potentially has new
economic and commercial value, but it faces a
new set of complex relationships and transaction
costs. Recent research into cluster structures in
the Saskatoon-based agricultural-biotechnology
cluster suggests that one driver for agglomera
tion may be the development of a cost-effec
tive, efficacious system of IP management. This
community has been host to a number of highly
competitive multinational companies, has pat
ented many critical life-science inventions, and
has delivered a number of world-first technolo
gies to the marketplace. Its experiences offer
some insights into another possible objective of
clusters.
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In a perfect world with full information
and no transaction costs, complete contracts to
finance and undertake common research would
be optimal. However, we know that transac
tion costs (especially with highly fragmented IP
rights) are nontrivial, and that the probability of
having a commercial success in any given project
is relatively low (usually, less than 10% of proj
ects return the costs of investment). Hence, as
transaction costs rise, full contracts become less

likely. Furthermore, it tends to be difficult to
measure the often-tacit inputs to research pro
grams. Attributing respective contributions to
success in the discovery process is also tricky. In
addition, any resulting outputs often have very
specific uses, which makes them hostage to their
potential users. These factors can lead to a classic
case of “hold up,” whereby investors may not be
willing to invest because their bargaining power
after any research breakthrough would be very

Figure 1: The Saskatoon Biotechnology Entrepôt
and Its Global Connections
Saskatoon RSI
Germplasm

Global
know-how

100%

Global
know-why

50%
70%

Global
know-what
88%

Why

How

Global
know-who

Who

50%

Assembly of new
plant varieties

50%

Exported
varieties

80%

Exports of
raw and
semi-processed
product

What

100%
Commercial
services

33%

Commercialization of
new plant varieties
66%

Global new
plant varieties

33%

Production of
new varieties

Source: Phillips 2002 36
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low.40 While long-term contracts would be one
way to resolve this conundrum, few contracts
will be negotiated for one-time projects. An al
ternate solution is to use social capital (for ex
ample, norms and relationships) in a community
or cluster. In essence, by using the cluster as the
basis for a research relationship, the difficulties of
negotiating one-time deals can be overcome: the
research community operates as if it is engaged in
repeated exchanges. Participants in a cluster thus
often will not negotiate each deal as if it were
a one-time event. Rather, they would be willing
to leave some terms and conditions unspeci
fied, on the (usually justified) assumption that
the strength of overall community relationships
would reduce the probability that any company
or actor would act with guile.
The Saskatoon-based agri-food research clus
ter gives a sense of how clusters or regional systems
of innovation can lower transactional costs.41 This
community is credited with a series of world-mar
ket firsts (for example, agrobacterium technologies)
and product firsts (for example, herbicide-tolerant
canola and flax). It took the lead in the develop
ment of the concept for a National Agricultural
Genome Centre (which, although unsuccessful
in reaching that particular goal, ended up pro
viding a model for Genome Canada) and leads
four major genomics agri-food projects. Most of
these initiatives were developed without formal
ex ante contracts; instead, leaders in the commu
nity developed the projects under the assumption
that any gains and losses would be apportioned
equitably, or at least that any short-term losses
would be compensated by future joint projects.
This apparent altruism is nothing more than an
extension of the community’s business model, as
Phillips and Khachatourians42 and Phillips43 show
in their examinations of how Saskatoon became a
national center for the generation, transmission,
and consolidation of noncodified knowledge in
the agricultural biotechnology industry. At the
core of this community are Agriculture and Agri
food Canada and the National Research Council.
Both have extensive arrangements with each
other, public universities, and private companies,
which allow them to learn from their collabora
tions, thereby adding further to the local stock
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of know-how knowledge and providing a vis
ible, efficient point of entry for nonresidents to
access know-how and know-who capacity. The
public institutes also provide a home base for
research stars, which, according to Zucker and
colleagues,44 reduces the search costs for other
researchers and subsequent commercialization.
The largest single geographic concentration of
stars and near-stars in the canola research world
is located in Saskatoon, where 11 out of 69,
or 16%, of the top scientists live and work.45
Phillips and Khachatourians46 report that mul
tinational enterprises (MNEs) and smaller com
panies in Saskatoon were primarily attracted by
the presence of key personnel in collaborating
and competing organizations. Although the
public and private institutions have changed in
recent years, the social capital built up appears
to continue to sustain collaborative activities.

8. lESSONS FOR DEVElOPMENT
AND IP MANAGEMENT
Knowledge-based development is inherently dif
ferent from traditional industrial development.
While a traditional industrial strategy that pro
moted infant industry via protection made some
sense in the industrial world, it is not clear wheth
er it has any value in a knowledge-based world.
This emerging global pipelines/local buzz
cluster model of innovation poses some serious
challenges for development policy. Much of the
current biotechnology-development effort has
a strong mercantilist orientation that focuses
on self-sufficiency. Governments at all levels in
many countries are actively using their tax and
fiscal policy to encourage more local R&D and
to attract global companies to relocate their
R&D programs so that higher-value exports can
be generated and imports replaced. This often
involves preferential support for national cham
pions or exclusive deals to encourage MNEs to
relocate their activities. Usually governments do
this without considering the corresponding rela
tionships and interactions that knowledge-based
companies require to succeed. If innovation can
be thought of as limited to within a company or
within a regional or national community, then
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such a narrow approach might have some chance
of succeeding. But the increasing complexity and
fragmentation of knowledge and IP rights in
the biotechnology sector suggests there likely is
no single center that can effectively develop new
biotechnologies or applications. Networking and
partnerships are going to be the order of the day.
And, if innovation is truly global, as appears to be
the case in many of the life sciences, then narrow,
mechanistic, self-sufficiency strategies may either
simply fail or prove counterproductive.
One key to success in these circumstances
will be to invest in the institutions and mecha
nisms that encourage the development of and
access to the four knowledge factors (know why,
know what, know how and know who), which
provide the foundation of a research economy.
A number of strategic options might be appro
priate. First, effective mechanisms to protect and
legally transfer IP across international boundar
ies are the price of admission to collaborations.
Second, clusters that are open to new knowledge,
IP, and highly qualified personnel and compa
nies will likely be more successful in creating and
commercializing new biotechnologies or related
products. Third, simply declaring that a region
is a cluster is not enough. There must be some
regional investment in infrastructure, as well as
openness and/or support for the emergence of
one or more anchor institutions. While private
companies may have the greatest drive for com
mercial development, governments often have
only limited direct influence on their location
and operation. Governments can strengthen
their hand by considering how their universities
or public research labs can be used to anchor the
community. Ultimately, the goal should be to
create some platform to generate mysteries in the
air. Whatever forms this platform takes, it will
need to generate both local buzz and tap into
global pipelines.
In short, innovation clusters are very attrac
tive economic development and IP management
tools, but they must be nurtured with an appreci
ation for their partial and incomplete nature. Part
of a global innovation system, they cannot thrive
if cut off from the lifeblood of that system—ideas,
skilled labor, and collaborative platforms. n
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What Does It Take to Build a Local Biotechnology
Cluster in a Small Country? The Case of Turku, Finland
kIMMO VILJAMAA, Research Affiliate, University of Tampere, and Consultant, Advansis Ltd., Finland

ABSTRACT

There seem to be new biotechnology initiatives spring
ing up in almost every country and every region, no mat
ter how big or small. This is the case for both developed
countries and many developing countries. At the same
time, many studies seem to suggest that the industrial dy
namics of the biotechnology sector strongly favor only a
few globally important locations. These are characterized
by well-established relations between small R&D compa
nies and the presence of venture capitalists, big multina
tional corporations, and service providers. The tendency
of biotechnology clusters to form in certain locations
raises some questions. Can all these new initiatives be
successful? Can biotechnology research clusters develop
and prosper on a smaller scale? The aim of this chapter
is to discuss ideas for building successful biotechnology
clusters in less-developed places. Using the example of
Turku, Finland, the chapter analyzes how public policy
and local activity can “fill the gaps” in the innovation
system, thereby facilitating the emergence of a biotech
nology industry. Although this case study is from a de
veloped country, many developing countries face similar
challenges to those Turku has faced.

1. INTRODuCTION
The economic literature of the past decade has of
ten argued that innovation is the most important
source of competitiveness, especially for hightech industries working within global markets. At
the same time, it is widely known that particular
industries tend to cluster in certain areas and that
the clustering of knowledge is an important rea
son for this phenomenon.

Biotechnology, one of the most prominent
new industrial sectors, is typically a very spatially
clustered industry. Biotechnology companies are
often located close to major universities, hospi
tals, and research centers, and are sometimes as
sociated with supportive bigger companies inter
acting with small- to medium-sized enterprises.
Moreover, the biotechnology sector usually makes
extensive use of external services in R&D—test
ing, financing, and marketing—which also tend
to be located close by.
Biotechnology activities also tend to con
centrate strongly in specific areas of the globe.
A few local concentrations (such as Cambridge,
Massachusetts, and San Francisco/San Jose,
California, both in the U.S.A.) are globally domi
nant.1 In the past, biotechnology has been very
much dominated by the United States and, to a
lesser extent, by the United Kingdom.2 But the
past decade has seen a huge increase in biotechnology-related development in many other places.
Countries, regions, and cities all over the world
have realized that biotechnology is the next big
thing following the success of information and
communication technologies (ICT).
Previous studies have shown that the indus
trial dynamics of the biotechnology sector, espe
cially in biopharmaceuticals, strongly favor only a
few globally important clusters characterized by
well-established relations between small R&D
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companies, venture capitalists, big multination
al corporations, and service providers. It would
seem to be at least difficult, and perhaps entirely
impossible, to develop an industry when some or
most of these factors are missing. Nevertheless,
the biotechnology industry is growing in many
places that may at first seem unfavorable: in de
veloped countries like Finland, but also in many
developing countries such as India, China, Brazil,
and South Africa.3
This chapter analyzes how public policy and
local activity can “fill the gaps” in the innovation
system so that it is possible for a biotechnology
industry to emerge and grow in seemingly unfa
vorable places. The basic questions I will answer
are: What policies and institutions best support
the knowledge generation and dissemination
processes of high-tech industries in smaller, more
peripheral, or less developed regions? In other
words, what are alternative ways of developing
a favorable environment for the emergence and
development of a local biotechnology concentra
tion? What sorts of relationships between local
actors encourage the development process?
My argument is that it is possible, at least
to some extent, to compensate for vital resourc
es that may be missing in small economies and
clusters. However, there seem to be several basic
conditions for success. First, there has to be a sub
stantial local knowledge base (often a university).
Second, the national or regional innovation sys
tem must compensate for any missing resources
(public venture capital, R&D funding, services,
and so on). Third, a network of capable local ac
tors (public or private) must develop and strategi
cally direct a local innovation system.
To support the argument that it is possible to
compensate for missing vital resources, the chap
ter analyzes the recent development of the bio
technology industry in Turku, Finland. The de
velopment of the biotechnology sector in Finland
during the past fifteen years has been largely due
to active national innovation policies. In terms of
numbers of biotech firms, Finland ranks tenth in
Europe.4 The biotechnology industry in Turku has
grown thanks to local activity, and Turku itself is
home to the second-largest concentration of bio
technology-related activities in Finland.
2 | HANDBOOK OF BEST PRACTICES

The recent rise of biotechnology in Turku is
largely due to the fact that it has drawn on de
cades-old capabilities across a variety of sectors in
food processing, pharmaceuticals, and materials
sciences. Furthermore, local development activi
ties and a national science and technology inno
vation program have encouraged development.
It remains to be seen whether or not biotech
nology will continue to prosper inTurku. However,
this study finds that active policy measures can al
low smaller, more peripheral places to attract the
interest of biotechnology entrepreneurs.

2. THE BIOTECHNOlOGy INDuSTRy
In this chapter, “biotechnology” refers to a broad
range of life sciences (biosciences) and their uti
lization in medicine, primary production,5 in
dustry, and services. Biotechnology is a set of
powerful tools that employs living organisms
(or parts of organisms) to make or modify prod
ucts, improve plants or animals, or develop mi
croorganisms for specific uses. The Organisation
for Economic Co-operation and Development
(OECD) defines biotechnology as “the applica
tion of science and technology to living organisms as
well as parts, products, and models thereof, to alter
living or nonliving materials for the production of
knowledge, goods and services.”
The development of biotechnology can be
divided into three phases. Early first-phase bio
technology includes traditional animal and plant
breeding techniques, as well as the use of yeast in
making bread, beer, wine, and cheese. The second
phase started in the 1940s when biotechnology
was introduced into modern industry. Modern,
or third-phase, biotechnology includes the indus
trial use of recombinant DNA, cell fusion, novel
bioprocessing techniques, and bioremediation.
This phase started in the 1970s, when new tools
for modifying the genetic structure of living or
ganisms were introduced.6
Interestingly, new advances in the biosciences
have blurred the boundaries between historically
separate disciplines. Biology has begun to overlap
with other fields, such as medicine, chemistry,
informatics, and physics, thereby increasing the
need for interdisciplinary research and bringing
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different industries closer to each other. Many
new technologies developed for molecular biology
research, such as high-throughput DNA sequenc
ing, protein structure determination, and gene ex
pression analysis on “DNA chips,” are also used in
ecology, agriculture, forestry, and the biotechnol
ogy and pharmaceutical industries.7
The nature of an industry greatly influ
ences how it develops in any given location.
Biotechnology is very demanding in terms of
R&D. Bioscientific research is also time-consum
ing and requires methods and instrumentation
that are rapidly evolving and expensive.8 Because
the cost of R&D is so high, funding becomes es
pecially crucial for both universities and industry.
Furthermore, many biotechnology innovations
are based on basic research, which means that the
time from innovation to market is very long.
Cooke9 has observed that the focus of knowl
edge creation has changed. In the past, the world
of pharmaceutical R&D was dominated by large
multinational companies (MNCs). However,
there is growing evidence that university or public
laboratory research with associated spinouts and
dedicated biotechnology firms (DBFs) are now
responsible for most knowledge generation and
exploitation, while global MNCs are specializing
in distribution and marketing. The combination
of two factors—spatially highly concentrated
R&D and global marketing and distribution
strategies—means that the innovation system in
biotechnology has become both highly regional
ized and highly globalized. The tendency of bio
technology activities to congregate means that
local clusters of biotechnology activities are an
important unit of analysis.

3. ON INDuSTRy CluSTERING
AND KNOWlEDGE
This chapter focuses on local concentrations of
biotechnology-related activities. The first stud
ies on the economics of territorial agglomeration
were in the nineteenth and early twentieth centu
ries: the works of Marshall.10,11,12 Traditional anal
ysis of spatial clustering tries to analyze the advan
tages that firms get by locating near to each other
(localization economies). According to Malmberg

and Maskell13 there are at least three factors that
traditionally encourage spatial clustering:
1. Reduced costs of producing and maintain
ing a dedicated infrastructure and other
collective resources
2. Well-functioning markets for specialized
skills
3. Reduced interaction costs for co-located
trading partners
In the last few decades, researchers have tried
to explain the relationship between the spa
tial clustering of firms and the innovation
process. Several different approaches have
been developed, including innovative mi
lieu, new industrial spaces, spatial clusters
of innovation, regional innovation systems,
and learning regions.14 The topic has be
come more relevant in recent years because
technological change and globalization have
led to intrinsic economic changes.
Globalized markets, increased competition,
and the development of information and
communications technologies have forced
companies to find new ways of increas
ing their competitiveness. Furthermore,
new scientific developments are occurring
all the time. This combination of external
pressures and opportunities makes for a
very turbulent corporate environment.15
Companies respond to these pressures in
two ways: by specializing and by innovat
ing. They outsource in areas where they
are weak and try to maximize the profits
of their core competencies through innova
tion. Both of these strategies tend to create
local as well as global connections. Many
services and external functions have to op
erate locally. This is typically because of the
economics of scale that local clustering of
associated actors brings; economies of time
and smaller transaction costs are generated
by trust and easy face-to-face interaction.
Firms can increase their competitiveness
by sharing an infrastructure and by shar
ing supplier and service networks. In or
der to facilitate knowledge generation and
transfer, companies locate themselves near
knowledge sources and each other so they
HANDBOOK OF BEST PRACTICES | 2
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can make better use of local knowledge
spillovers16 and informal types of social in
teraction that form the basis for innovation
and learning.
The fact that knowledge, learning, and in
novation are important if an industry is to
retain its competitiveness suggests a fourth
advantage to spatial clustering:
4. Facilitation of knowledge spillovers, learn
ing, and adaptation
Local industrial structure with many firms
competing in the same industry or collabo
rating across related industries tends to be
dynamic, flexible, and innovative; the ex
istence of a local culture facilitates knowl
edge transfer. The co-location of firms cuts
the expenses of identifying, accessing, and
transferring knowledge.17 There are several
reasons why innovation capability is related
to spatial clustering:
• new knowledge. Usually difficult to
codify and therefore difficult to trans
fer. New knowledge is best transferred
through repeated and frequent face-to
face contacts. Innovation is therefore fa
cilitated by geographical proximity.
• knowledge exchange. Can happen
through knowledge spillovers. On the
other hand, most actors are unwilling to
share crucial information when there is a
danger that it could end up in the hands
of competitors. Knowledge exchange
may happen as a result of long-term co
operation with universities and research
institutions.
• the availability of a high-level work
force. A very important requirement for
innovation. The mobility of labor, espe
cially in Europe, is lower than the mobil
ity of other resources, and so labor tends
to concentrate in certain regions.
All these knowledge-related factors are im
portant because biotechnology typically has a
much greater need for basic research and a highly
educated workforce than does any other industry.
It also tends to collaborate more with universities
than do most other industries.18
2 | HANDBOOK OF BEST PRACTICES

This chapter also investigates the process of
cluster formation and the conditions that enable
a local biotechnology cluster to emerge and grow.
Much of the conventional wisdom regarding suc
cessful industry clusters is based on studies of fully
functioning innovation systems such as Silicon
Valley.19 However, the conditions under which
mature clusters operate are not, in many cases,
present at the creation of new clusters. The history
of each cluster is unique, suggesting that cluster de
velopment is either path-dependent or heavily in
fluenced by chance historical events.20 The current
economic strengths of a particular region are often
based on developments and activities that took
place over the course of several decades. Examples
of this phenomenon are the Research Triangle
Park in North Carolina, U.S.A.,21 Silicon Valley,
U.S.A.,22 and Oulu and Tampere, in Finland.23
New clusters often develop thanks to pre-ex
isting local expertise in related fields. Many places
with ICT centers were founded in areas that al
ready had expertise in electronics (for example,
in Silicon Valley and Oulu). Therefore, it is im
portant to understand both regional assets and
the cluster formation process in order to develop
policies that will support emerging clusters.
Feldman and Francis24 have concluded that
cluster formation appears to be characterized by
three general stages.25,26 In the initial stage, there
are typically few, if any, spinout companies, but
there are some needed assets such as large com
panies and universities. An exogenous shock that
lowers the opportunity cost for entrepreneurship
(such as a merger and acquisition or a change in
the funding environment) tends to encourage ac
tive entrepreneurship and the subsequent appear
ance of new spinout companies.
The second stage is typically characterized by in
creased interaction between entrepreneurs and their
environment.27 In this stage, the cluster self-orga
nizes in order to better serve its own needs. Various
institutions may be created to support the cluster,
and these institutions may, in turn, stimulate further
innovation and promote localized learning.28
In the final stage, the success of the first
spinouts and the synergy between them gener
ate new possibilities for other firms in the same
field. At the same time, an enhanced innovation

CHAPTER .12

environment develops around the cluster (con
sisting of universities, technology centers, local
policy-makers, service providers, and so on). At
this final stage of cluster formation, a critical mass
of resources provides locational advantages.

4. INNOVATION AND INDuSTRy
STRuCTuRE IN BIOTECHNOlOGy
The geographical concentration of biotechnology
is also the concentration of knowledge. Universities
and R&D institutions are local concentrations of
knowledge and expertise, and they can poten
tially provide a workforce for local firms. Many
knowledge spillovers are local, either because they
are based on tacit knowledge or because people
are usually well informed about developments in
side their own local knowledge base. For example,
Jaffe and colleagues29 show that most knowledge
was used within a 50-mile radius of the university
from which it originated. Also, the successful de
velopment of biotechnology, especially in the early
phases, seems to require a considerable amount of
tacit knowledge, which itself often relies on shortdistance or face-to-face interaction.30
The local existence of high-level knowledge
and research seems to have more of an effect on
the development of biotechnology clusters than
do local knowledge spillovers. According to
Cooke and colleagues,31 the biosciences do not
typically make wide use of informal local tacit
knowledge and face-to-face exchanges, informal
networks, or other indirect region-specific assets
that are often referred to as untraded interdepen
dencies.32 Because biotechnology techniques are
so specific and specialized, there is typically not
much knowledge transfer through social ties or
networking between firms. In the early phases of
the creation of biotechnology clusters, localiza
tion effects seem to be due to the so-called star
scientists who are invaluable to R&D and tend to
locate near their home universities.33
Another factor in the creation of biotechnol
ogy research clusters is the increasingly multidis
ciplinary nature of biotechnology R&D. In many
cases, development work requires a heterogeneous
set of cognitive skills and, therefore, a need for
transdisciplinary network relationships that are

most easily found within a larger concentration
of related activities.34
What Cooke and colleagues call “exploi
tation knowledge”—that is, the knowledge of
how to use basic research for practical applica
tions—is found in clusters for several reasons. As
small DBFs rely on research scientists to translate
noncodified knowledge so that it can be further
developed into commercial products or services,
people with experience in both research and in
dustry tend to be magnets for new companies.
In many cases, special services also play an
important role. Business services and specialized
expert services tend to locate close to key custom
ers and thereby make these locations more attrac
tive to new companies. I suggest that even if R&D
companies trade very little knowledge with each
other, they interact quite a bit with companies in
fields like business expertise and services.
Biotechnology companies tend to be located
close to major universities, hospitals, research cen
ters, and sometimes supportive larger companies
that interact with small- to medium-sized enter
prises. At least initially, most new ideas and spinouts seem to originate from universities. However,
Feldman argues that even though universities
seem to be necessary for the development of bio
tech research clusters, the mere existence of a large
knowledge base is not always enough.35 Orsenigo
argues that the existence of a strong scientific base
does not guarantee that new companies will start
up or that an industry will emerge.36 There is also
no firm correlation between the number of spinouts and either university financing or the num
ber of patents applied for.37
As a biotechnology research cluster develops
from the “science stage” to commercial application,
the cluster may become dependent on a few bigger
anchor firms. Larger companies can act as pools
of skilled labor and demand special inputs such
as specific products and services that may benefit
smaller spinouts.38 Large established companies
can also act as sources for new entrepreneurial ac
tivity in the form of spinouts or outsourcing.
The mechanisms of co-location and spatial
clustering seem to be especially strong in the
biotechnology industry. However, the pres
ence of favorable conditions (for example, a
HANDBOOK OF BEST PRACTICES | 2
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strong science base and a working labor mar
ket) is insufficient to explain why an industry
develops in a particular region. Favorable condi
tions in a particular locale may encourage the
establishment of an industry, but its growth is
determined by other factors: its structure, tech
nological change, economic factors, and changes
in the institutional base and local development
policies.
.1 Typical characteristics of successful
biotechnology clusters

Many studies and strategy papers have analyzed
the factors that are needed for the biotechnology
sector to prosper, and most of them have come
to similar conclusions. They emphasize the role
of a strong science base, a skilled workforce, sup
portive infrastructure, and the availability of ser
vices and financing. A British study39 identified
the following factors for successful biotechnology
clusters:
• a strong science base
• an entrepreneurial culture
• a growing company base
• the ability to attract key staff
• the availability of financing
• appropriate premises and R&D infra
structure
• the close proximity of business support
services and large companies in related
industries
• a skilled workforce
• effective networks (for example, associa
tions and cluster councils)
• supportive (national, regional and local)
government policies
Although many industries benefit from the
factors listed above, they apply especially well
to biotechnology. Biotechnology is a sciencedriven business,40 which means that clustering
often occurs in close proximity to key knowl
edge centers, usually universities or public re
search institutes conducting top-level research.
Because this knowledge is very often tacit and
tied to individual researchers or research groups,
effective utilization requires close interaction
between actors and multilevel partnerships.
00 | HANDBOOK OF BEST PRACTICES

According to Cooke,41 because research
tends to concentrate near the key magnets (that
is, universities or public research institutes), it
favors the development of a localized “biosci
ences knowledge value chain.” (Agglomerations
that are more than mere clusters of commercial
firms with some links to local knowledge centers
are called “megacenters,” which seem to be few
and far between.) At the same time, the global
“biotech boom” means that many countries and
regions are investing in biotechnology. This leaves
us with some questions: How successful can these
initiatives be? Is it possible for smaller and more
peripheral biotechnology clusters to survive?
The development of a smaller biotechnology
research cluster in Turku, Finland, offers some an
swers to these questions. The primary data consist
of detailed, interviews and analyses of industry sta
tistics; the policy documents of national, regional,
and city governments; and previous studies of the
development of industrial activities in Turku, es
pecially those conducted between the mid-1980s
and 2004. Over a six-month period in 2002, 36
detailed semistructured interviews were conducted
with academics (scientists), policy-makers at vari
ous levels, CEOs or R&D heads of companies,
city officials, and actors in intermediary organi
zations, such as economic development agencies
and hybrid organizations for sectoral growth.

5. THE CASE OF TuRKu: DEVElOPMENT OF
A SMAll BIOTECHNOlOGy CluSTER
Turku is home to the second largest concentra
tion (after Helsinki) of biotechnology activities in
Finland.42 Other regions with dedicated centers for
biotechnology development are Oulu, Tampere,
and Kuopio. There are also many Finnish universi
ties engaged in biotechnology-related research and
education. The period 1996–2000 saw the sharpest
rise to date in the number of new biotech firms in
Finland. Turku underwent a similar growth spurt,
with most new biotechnology companies emerg
ing during the 1990s.43 Biotechnology companies
that were started in the period 1998–2000 can be
broadly categorized as biomedicine (37%), diag
nostics (31%), biomaterials (13%), and “other”
(19%).44,45 However, during the past few years,
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industry growth has almost stopped, and the num
ber of companies has remained relatively constant.
The Turku region is especially strong in bio
pharmaceuticals, but its firms are also involved in
diagnostics, biomaterials, and functional foods.
In March 2006, there were approximately 80
biotechnology-related companies in Turku, em
ploying approximately 3,000 people. Two large
pharmaceutical companies, Schering and Orion,
conduct R&D in Turku, as do a number of smaller
drug discovery companies, such as Tie Therapies,
Hormos Medical (a subsidiary of QuatRx), and
Juvantia Pharma Ltd. These firms, along with the
universities and service companies, form a rela
tively tight drug-development network.
Although the growth of biotechnology in
Turku has been very rapid, the roots of the in
dustry are much older. The first drug companies
(Leiras [a Nycomed Co.] and Farmos Ltd.) were
established in the 1940s, as was Wallac Inc. (now
part of the PerkinElmer group). These mid-sized
companies cooperated with the universities when
such cooperation was not common practice in
Finland. A good example of this is the diagnostic
company Wallac, which already cooperated with
universities in the 1960s. Interactions with uni
versity researchers were institutionalized in many
ways, and this culture seems to have diffused to
other companies.46 At the time Wallac also need
ed a steady supply of professional employees, and
the university cooperation provided a good op
portunity for them to develop this resource.
Older, larger companies have provided lo
cal expertise in business and development activi
ties, as well as labor pools for new spinouts. In
fact, many key people in the universities and the
smaller companies have worked for these larger
companies at some point. Many ideas have also
been exported by individual workers leaving their
jobs and establishing new start-ups or by dedi
cated spinout strategies of larger companies.
Several studies have noted that in biotech,
the performance, strength, and width of the sci
entific base are perhaps the most important fac
tors affecting industry development.47 Indeed,
Turku’s scientific knowledge base did not emerge
overnight: it has been developing since the
1960s or 1970s. Moreover, the level of scientific

research in biotechnology-related fields has been
on par with top research around the world. The
establishment of spinouts owes much to strong
academic links with the United States. When
the molecular biology revolution occurred in the
1970s, many Ph.D.s and M.D.s from Turku did
their postdoctoral research work in some of the
best American laboratories. During their time
abroad, they witnessed the birth of commercial
ized biotechnology firsthand and saw the many
ways that academics can become involved in the
business of medical biotechnology. A few leading
researchers subsequently returned to Turku and
became intimately involved in the establishment
of both the Center for Biotechnology and several
promising start-ups.
.1

Strong national support for biotechnology
research and business

The Finnish model for supporting biotechnol
ogy has been described as a “science-led strat
egy from above.”48 In Finland, the national in
novation system has played a significant role in
developing the biotechnology sector. Various
government agencies support science-based and
resource-intensive businesses. The Academy
of Finland funds basic research: TEKES (the
Finnish Funding Agency for Technology and
Innovation) funds applied research, develop
ment, and knowledge transfer; VTT Technical
Research Center conducts applied and contract
research; and Sitra (the Finnish National Fund
for Research and Development) used to provide
venture capital funding for small high technology
firms particularly in the 1990s.49 Furthermore,
public programs, such as the regional Centers
of Expertise, coordinate and focus resources in
key industries in many cities. Many of the in
stitutions and organizations affiliated with the
national biotechnology innovation system are
located in the Helsinki region.
In the late 1980s, the Ministry of Education
started the first biotechnology research program.
Since then, public funding in the form of vari
ous research and technology programs (especial
ly those provided to universities by The Center
of Excellence) and public venture capital have
all increased tremendously. Roughly 40% of the
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national R&D budget is spent on the bioscienc
es. TEKES has invested some US$90 million, or
27% of the total amount spent on biotechnology
in Finland. The Ministry of Education has also
created new centers of excellence in universities.
These efforts have paid off: in 2000, nine of the
26 most highly ranked university departments in
Finland were in the field of biotechnology.
In Turku, the impact of the national science
and technology policy has been remarkable. Partly
because local actors have been active in national
development programs, the newly dedicated uni
versity research units have received a lot of public
funding. Public venture capital has also played a
big part in the growth of new firms. However,
in Turku, national institutions have been used
as resources for local activity rather than initiat
ing new activities themselves. Turku was not very
visible in the biotechnology industry (compared
with, for example, Helsinki) until the late 1980s.
In 1987, the Ministry of Education launched a
new biotechnology research program that was
Helsinki centered, despite the fact that Turku had
a biotechnology sector that was not much smaller
than Helsinki’s. The Turku research community
protested this “injustice,” and local informal
initiatives, designed to increase the visibility of
Turku’s biotechnology activities, were instrumen
tal in developing a local biotechnology cluster.50
.2 Local networks and local initiatives
facilitate cluster building

The development of Finnish biotechnology has
been aided not only by national policies but also
by the local efforts of actors in business, academia,
university administration, and city governments.
Individuals have promoted change, whether or
not they had strategic support from their own in
stitutions; this is important to note because the
role of individuals as instigators of change has of
ten been overlooked.51
The first changes in Turku’s innovation net
work occurred in the mid 1980s. Particularly
important was the first dedicated project for im
proving biotechnology research, the South-West
Finland Biotechnology Project (SWB), started
in the mid 1980s. At approximately the same
time (1986), the Foundation of New Technology
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(FNT) was established. This was a very informal
organization, composed of approximately 30
people, most of them drawn from industry and ac
ademia. The FNT was originally formed to estab
lish Turku’s first technology center, DataCity.52
The Turku Technology Center Ltd. region
al development company is owned by the city
of Turku (90%). It consists of two subsidiaries
(100% ownership): Turku Bio Valley Ltd. and
ICT Turku Ltd. The second stage of the tech
nology center, BioCity, was built in 1989, after
DataCity achieved some success. People with dif
ferent needs joined for a common cause: the real
estate business saw a new business opportunity;
biotechnology firms saw an opportunity to gain
more contacts and influence by cooperating with
universities; and universities saw an opportunity
to obtain better resources for research and edu
cation. Because city governments played a cen
tral role in planning five of the seven technology
parks existing in Finland in 1989,53 it is interest
ing that the city of Turku did not participate in
the planning of BioCity.
BioCity has been very important to Turku’s
biotechnology cluster. It was not merely a physi
cal structure but an ambitious new concept. Its
founders wanted to create synergy between in
dustry and academia by gathering a critical mass
of researchers in various fields.54 This critical
mass was achieved by establishing new facilities
and labs that were jointly administrated by the
University of Turku and Åbo Akademi. The uni
versities entered the project not so much because
they shared the founders’ vision but because they
were suffering from a lack of resources. Today, the
BioCity Turku research community consists of
more than 50 research groups and more than 500
people working in different fields.
A recession in Finland in the early 1990s
made local actors and the Turku city government
look for new industries to develop. Compared
with other mid-sized cities in Finland, like Oulu,
Tampere, and Jyväskylä, Turku became active in
the local economic development quite late. This
was partly because of the local industrial struc
ture—the impacts of economic restructuring
in the 1970s and 1980s were not as severe as in
many other cities. The Finnish recession and the
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collapse of the Russian markets, which were im
portant for many local industries, also made local
authorities pay more attention to economic de
velopment. Since then, the city of Turku has been
very active in promoting new industries, particu
larly biotechnology, and investing in infrastruc
ture. The government has encouraged life-sci
ences research and commercialization in Turku,
partly because the city did not have pre-existing
information-technology-related skills and indus
try like many other midsize cities in Finland.
Local authorities have supported the nation
al Center of Expertise program, which organizes
cooperation within the biotechnology sector in
Turku. In general, local actors have taken advan
tage of opportunities provided by national and
regional policies regarding science and technol
ogy. The use of biotechnology as a leading theme
in city marketing should not be underestimated.
. Turku as a biotechnology cluster

Turku has created a successful biotechnology
cluster, but substantial efforts have been needed
to guarantee its success. Below is an analysis of
the aforementioned factors for successful biotech
nology clusters, as they apply to Turku:
• a strong science base. In recent interna
tional evaluations, Turku’s science base was
highly rated.
• an entrepreneurial culture. Although many
new companies have been created, there is
no strong entrepreneurial culture.
• a growing company base. The company
base has grown rapidly in many fields in
the latter part of the 1990s, but there have
not been many new DBFs in the past few
years.
• the ability to attract key staff. So far, em
ployees have come from within Finland.
Many companies have noted that Turku is
too small to be attractive.
• the presence of investors. Missing are
MNCs and international venture capi
tal (VC), though domestic VC (especially
public) has made up for a lack of interna
tional VC. Recently, VC money has been
less available and there have been substan
tial problems in attracting financing.

• infrastructure. Generally, the infrastructure
for both research and business is very good.
The public sector (especially the City of
Turku) has recently supported the building
of new infrastructure. This has been crucial,
since university funding has been tight.
• business support services and large com
panies in related industries. Larger compa
nies do not use local services very much.
Many specialized services are in Helsinki
and abroad. There are some good local ser
vices but the number is still quite small.
• a skilled workforce. The local universities
have so far provided an adequate source
of new employees. The region’s traditional
strengths in pharmaceuticals and diag
nostics provide some experienced people,
though not enough. The city is too small
to provide an adequate labor pool. There is
also a lack of local business expertise.
• effective networks. Local networks work
effectively. Many of the networks arose vol
untarily from local needs and have there
fore been very active as opposed to policyled network initiatives, which often turn
out to be rather artificial. Networks linking
Turku with the rest of the globe are quite
extensive and important for research and
commercialization.
• a supportive policy environment. National
policy has been very important in providing
financing for both research and commercial
development. Local policy is increasingly
supportive of infrastructure. University
policies have neither helped nor hindered.
Turku has been able to overcome the weak
nesses mentioned above for two reasons: strong
national support and the ability of local actors
to exploit both internal and external resources.
The factors contributing to Turku’s success can be
summarized as follows:
(A) A strong science base with local and
international networks
• Expertise from older, medium-sized
companies provided the cluster with the
experience and skills that new univer
sity-based start-ups often lack.
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• Early on, companies established long
term relationships with university re
searchers, thereby developing a culture
of collaboration.
• Pre-existing scientific networks and
cutting-edge research in medicine, bi
ology, and chemistry compensated for
the lack of local expertise and local in
stitutions, such as business support ser
vices, banks, consultancies, and venture
capital funds. Strong research ties to the
United States, for example, have been
very important.
• The difficulty of recruiting foreign em
ployees has been at least partially com
pensated for by the expertise of Finnish
researchers who have spent time abroad.
(B) National policies
• Extensive research funding and educa
tion supports the science base.
• The TEKES technology programs sup
port R&D.
• Public VC partly compensates for a lack
of foreign VC.
• Local centers of expertise facilitate
networking.
(C) Local initiative
• Local initiative has led to improved in
frastructure, as well as improved organi
zation in universities and R&D firms.
• The success of Turku has been crucial in
influencing national policy-makers to
invest in biotechnology.
• BioTurku has brought various actors to
gether, thereby improving the integrity
of the local biotechnology cluster.
Despite its relative success in compensating
for the missing success factors, Turku still faces
problems. First, its small size makes it difficult
to maintain local services. Lack of foreign VC is
also a potential problem, because public support
for biotechnology is limited. Technology trans
fer mechanisms are still underdeveloped, even
though there are close connections between uni
versity researchers and companies. In addition,
universities do not have a clear strategy for capi
talizing on biotechnology research. The biggest
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problem, however, is that Turku lacks many parts
of the value chain. There are few services, venture
capitalists, and big MNCs with expertise in com
mercialization and marketing. This is a problem
because external links are usually more difficult
and costly to maintain than internal ones, espe
cially for small companies.

6. DISCuSSION AND CONCluSIONS
A small, peripheral biotechnology cluster can
prosper under the right conditions. First, a strong
local science base must already exist. Second,
there must be a way to compensate for any miss
ing links in the value chain. Turku has been fairly
well able to provide adequate conditions for its
biotechnology industry. Although its biotechnol
ogy cluster is young, quite small, and in many
ways peripheral, its development has been suc
cessful because of the region’s strong science base
and well-established strengths in medicine and
diagnostics. Both national innovation policies
and strong local initiatives have been important
in overcoming obstacles.
Several lessons can be learned from the
Finnish experience. First, a good educational sys
tem is important. There are many ways to com
pensate for missing links in the value chain, but it
is extremely difficult to build new entrepreneurial
activity in biotechnology without a good local
knowledge base.
Second, human capital formation (in the form
of educated people and research groups) should
be drawn mostly from the local pool, though it
is often necessary to bring in experienced people
to work in R&D. It is difficult for developing
countries to compete with major research centers
in Europe and the United States. However, bio
technology requires the best available scientific
knowledge and expertise. If it is difficult to attract
people from abroad, locals should go abroad to
study, conduct research, and build international
networks. It is easier to attract expatriates than it is
to attract foreigners.
Third, the development of clusters is path-de
pendent and based on previous historical events
and existing capabilities. It is extremely difficult
to build new clusters from scratch. It is therefore
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advisable to match research activities and start-up
formations to the existing strengths of the region.
In many countries, this may mean concentrating
on specific fields, such as agriculture or health
care, in which local expertise is strong. A strong
health care system is important for the develop
ment of biotechnology because it is a consumer
of local products, a source of new ideas, and an
environment for testing and clinical trials. It is
also important to make good use of the R&D
capacity and expertise of existing companies and
universities. Many successful clusters in emerging
technologies have been created around older but
related industries. For example, the biotechnolo
gy industry was created around pre-existing food
and medical industries in Turku, and the semi
conductor industry was created around a pre-ex
isting electronics industry in Silicon Valley.
Fourth, local and national policy support
of emergent industries is important, especially if
there are problems with the innovation support
system. This support can take many forms: sub
stituting public services for missing private ser
vices, supporting research, building up a work
ing education and research system, creating a
favorable legal and economic environment for
new start-up companies, and working to prevent
“brain drain.”
Fifth, the role of individuals, especially in the
early stages of cluster formation, should not be
underestimated. The Finnish experience demon
strates that local networks of key individuals in
crease the capabilities of the cluster as a whole and
help different actors achieve consensus. Support
for key individuals in enterprises, universities,
and research institutes is therefore important, and
networking should be promoted.
There is indeed hope that smaller and more
peripheral biotechnology clusters can prosper.
However, it is also clear that strong, well-de
signed policy support is needed to overcome the
various setbacks that these small clusters tend to
face. Of course, there still remains the question
of how this should be accomplished. So far, the
“Finnish way” has worked quite well, but it is
always difficult to determine how well policies
and practices will work in the future or how well
they will work in other institutional environ

ments. There also remain the perennial questions
of how much a government should invest, and
how much it would be ready to invest, in a new
industry sector such as biotechnology. Success in
such endeavors is not guaranteed. n
ACkNOWLEdgEMENTS

The chapter is based on a study by Smita Srinivas and
Kimmo Viljamaa55 for the Local Innovation Systems
Project (LIS), led by the M.I.T. Industrial Performance
Center and funded by the Finnish Agency for Technology
and Innovation (TEKES). The study is also part of the
project The Invisible Dynamics of the Urban Development
Processes: Emerging Patterns of Networks, Knowledge,
Images and Power [ID-UD], funded by the Academy of
Finland (No. 78071).
kIMMO VILJAMAA, Research Affiliate, Research Unit for
Urban and Regional Development Studies, University of
Tampere, 33014 Tampere, Finland, kimmo.viljamaa@uta.
fi and Consultant, Advansis Ltd., Itälahdenkatu 22 A b,
00210 Helsinki, Finland. kimmo.viljamaa@advansis.fi

1

Cooke P. 2002. Towards Regional Science Policy? The
Rationale from Biosciences. Prepared for Conference
on Rethinking Science Policy: Analytical Frameworks
for Evidence-Based Policy, SPRU, University of Sussex,
21–23 March 2002.

2

Breschi S, F Lissoni and L Orsenigo. 2001. Success and
Failure in the Development of Biotechnology Clusters:
The Case of Lombardy. In Comparing the development
of Biotechnology Clusters (ed. G Fuchs). Harwood
Academic Publishers (forthcoming).

3

Thorsteinsdóttir H, U Quach, DK Martin, AS Daar and
PA Singer. 2004. Promting Biotechnology in Developing
Countries. Nature Biotechnology. vol. 22, Supplement.

4

Critical I. 2006. Comparative study for EuropaBio.
Critical I Ltd. www.finbio.net/download/criticali-2006.
pdf.

5

Primary production refers to agriculture, forestry and
fishing.

6

Tulkki P, A Järvenisvu and A Lyytinen. 2001. The
Emergence of Finnish Life Sciences Industries, Sitra
Report Series. Helsinki.

7

Biotechnology in Finland. 2002. Impact Of Public
Research Funding And Strategies for the Future
Evaluation Report. Publications of the Academy of
Finland. November 2002.

8

See supra note 7, p. 15.

9

See supra note 1.

10 Malmberg A and P Maskell. 2001. The Elusive Concept
of Localization Economies: Towards a Knowledgebased Theory of Spatial Clustering. ISRN working

HANDBOOK OF BEST PRACTICES | 0

VIlJAMAA

papers 2.10.2002. May 2001. www.utoronto.ca/isrn/
working_papers.htm.
11 Moulaert F and F Sekia. 2003. Territorial Innovation
Models: A Critical Survey. Regional Studies vol. 37 (3):
289–302.
12 Simmie J. 2001. Innovation and Agglomeration Theory.
In Innovative Cities (ed. J Simmie). Spon Press. Taylor &
Francis.
13 See supra note 10.
14 See supra note 11.
15 Schienstock G and T hämäläinen. 2001. Transformation
of the Finnish Innovation System: A Network Approach.
Sitra Report Series 7. Helsinki.
16 The concept of knowledge spillover is based on the
notion that knowledge cannot be totally appropriated
and, therefore, knowledge may spill over across
organizations. This is especially true when different
organizations work closely in the same fields or have
shared networks. Labour mobility, close observation,
and information leakages typically provide knowledge
spillovers.
17 See supra note 11.
18 Cohen W, R Nelson and J Walsh. 2002. Links and
Impacts: The Influence of Public Research on Industrial
R&D. Management Science, 48 (1):1–23.
19 Feldman M and Francis J. 2004. Homegrown Solutions:
Fostering Cluster Formation. Economic Development
Quarterly, May 2004 18 (2):127–137.
20 Kenney M and U Von Burg. 1999. Technology,
Entrepreneurship and Path Dependence: Industrial
Clustering in Silicon Valley and Route 128. Industrial
and Corporate Change 8:67–103.
21 Link AN. 2002. From Seed to Harvest: The History of the
Growth of Research Triangle Park. Chapel Hill: University
of North Carolina Press.
22 Sturgeon TJ. 2000. How Silicon Valley Came to Be.
In Understanding Silicon Valley: The Anatomy of an
Entrepreneurial Region, p.15-47. Stanford University
Press: Stanford, California.
23 Sotarauta M and K Viljamaa. 2003. Mitkä tekijät tekevät
kasvukeskuksesta kasvukeskuksen? In Tulkintoja
kaupunkiseutujen kehityksestä ja kehittämisestä. Kooste
usean tutkimuksen tuloksista. (Interpretations about
development of city-regions: Compilation of several
studies; eds. M Sotarauta and K Viljamaa). pp. 33–64.
The Finnish Association of Graduate Engineers. TEK ry.
Cityoffset Oy, Tampere.
24 See supra note 19.
25 Bresnahan T, A Gambardella and A Saxenian. 2001.
“Old Economy” Inputs for “New Economy” Outcomes:
Cluster Formation in the New Silicon Valleys. Industrial
and Corporate Change 10:835–860.
26 DTI. 2003. A Practical Guide to Cluster Development: A
Report to the Department of Trade and Industry and
the English RDAs by Ecotec Research & Consulting.
Department of Trade and Industry: London.

0 | HANDBOOK OF BEST PRACTICES

www.dti.gov.uk/files/file14008.pdf.
27 See supra note 19.
28 Maskell P and A Malmberg. 1999. The Competitiveness
of Firms and Regions, ‘Ubiquitication’ and the
Importance of Localized Learning. European Urban and
Regional Studies 6:9–25.
29 Jaffe A, M Trajtenberg and R Henderson. 1993.
Geographic Localization of Knowledge Spillovers as
Evidenced by Patent Citations. Quarterly Journal of
Economics, 108:577–598.
30 Zucker L, M darby and M Brewer. 1998. Intellectual
Human Capital and the Birth of U.S. Biotechnology
Enterprises. American Economic Review 88(1):290–306.
31 Cooke P, D Kaufmann and C Levin. 2003.The Biosciences
Knowledge Value Chain and Comparative Incubation
Models. Paper prepared for Regional Studies
Association Conference on Reinventing Regions in
the Global Economy 12-15 April 2003. Scuola Superiore
Sant’ Anna, Pisa, Italy.
32 Storper M. 1995.The Resurgence of Regional Economies,
Ten Years Later: The Region as a Nexus of Untraded
Interdependencies. European Urban and Regional
Studies 2:161–221.
33 See supra note 28.
34 Orsenigo L, F Pammolli and M Riccaboni. 2001.
Technological Change and Network Dynamics: Lessons
from the Pharmaceutical Industry. Research Policy
30:485–508.
35 Feldman M. 2002. The Locational Dynamics of the U.S.
Biotech Industry: Knowledge Externalities and the
Anchor Hypothesis. Plenary Paper for DRUID’s New
Economy Conference, June 2002. 4.4.2003. www.druid.
dk/conferences/summer2002/Papers/Feldman.pdf.
36 Orsenigo L. 2001. The (Failed) Development of a
Biotechnology Cluster. The Case of Lombardy. Small
Business Economics 17: 81-82.
37 See supra note 35.
38 See supra note 19.
39 Biotechnology Clusters. Report of a team led by Lord
Sainsbury, Minister for Science. Department of Trade
and Industry. August 1999. Internet Article 3.2.2003.
www.dti.gov.uk/biotechclusters/bioclust.pdf.
40 Cooke P. 2003. The Evolution of Biotechnology in Three
Continents: Schumpeterian or Penrosian? European
Planning Studies 11 (7):757–763.
41 See supra note 1.
42 Part of this section is based on: Srinivas S and K
Viljamaa. 2003. BioTurku: “Newly” innovative? The Rise
of Bio-Pharmaceuticals and the Biotech Concentration
in Southwest Finland. M.I.T. IPC Local Innovation
Systems Working Paper 03-001.
43 Orava M, M Brännback, M Renko, S Suoniemi, S
Söderlund and P Wiklund. 2001. Turun bioalan
riskianalyysi [Risk analysis of the Bioindustry in Turku].
Innomarket, Turku School of Economics and Business
Administration. FINBIO.

CHAPTER .12

44 Finnish Bioindustries 28 November 2003. www.finbio.
net.

53–70.

45 Turku Biotechnology Strategy. 2004. Bio Turku.
Unpublished policy document.

51 Walcock SM. 2002. Analysing an Innovative
Environmnet: San Diego as a Bioscience Beachead.
Economic Development Quarterly 16 (2): 99–114.

46 See supra note 42.

52 See supra note 50.

47 See supra note 2.

53 Höyssä M. 2001. Teknologiakeskusta tekemässä.
Biocity-hankkeen vaiheet ideasta osaamiskeskuksen
osaksi. [Making a technology park] Unpublished study.

48 See supra note 1.
49 See www.research.fi for a more thorough description
of the Finnish national innovation system.
50 BRuun H, M Höyssä and J Hukkinen. 2001. Networks
of Ephemeral Empowerment: The Birth of a
Biotechnology Centre in Turku, Finland, Technology,
Society, Environment February 2001. Helsinki University
of Technology Laboratory of Environmental Protection,

54 See supra note 50.
55 See supra note 44.

HANDBOOK OF BEST PRACTICES | 0

CHAPTER 3.13

The Activities and Roles of M.I.T. in Forming Clusters
and Strengthening Entrepreneurship
LITA NELSEN, Director, M.I.T. Technology Licensing Office, U.S.A.

ABSTRACT

Thischapterdescribesthestructure,policies,andoperations
of the Technology Licensing Office at the Massachusetts
Institute of Technology (M.I.T.). The chapter emphasizes
the licensing office’s role in generating spinout companies
and considers the importance of the biotechnology cluster
within the state of Massachusetts and it’s surrounding re
gions. Also discussed is M.I.T.’s approach to ensuring that
licensing procedures maximize access to medicines and
vaccines arising from M.I.T.’s research.

1. INTRODuCTION
The Massachusetts Institute of Technology
(M.I.T.) is probably not a direct model for uni
versities and research institutes just beginning
their technology-transfer activities, whether in
the United States or in developing countries.
Instead, the institute is an example of what can be
achieved by a mature organization that has built
its patent portfolio and technology-transfer skills
over the course of half a century. We, at M.I.T.,
live in an entrepreneurially advanced city, where
technology-based companies originating from
university research inventions have become an
important part of the Massachusetts area’s econo
my. M.I.T. and the other major research institu
tions in the area, such as the Whitehead Institute
for Biomedical Research, Harvard University,
Massachusetts General Hospital, Brigham and
Women’s Hospital, and Boston University, have

helped to build this entrepreneurial cluster and
have benefited from it.
Nevertheless, other organizations can
learn from our experiences, and M.I.T.’s
Technology Licensing Office1 is both honored
and pleased to help in the transfer of technologytransfer practices.
1.1

History and mission

M.I.T.’s Technology Licensing Office is one of
the most active university patent and licensing
offices in the country. M.I.T. has had more than
1,500 issued U.S. patents in its portfolio, many
with foreign counterparts.
M.I.T.’s technology licensing endeavors
follow the mandate of the U.S. Congress who,
in 1980, gave to universities title to inventions
developed with federal funds through the BayhDole Act. Technology licensing from univer
sities was greatly accelerated by Bayh-Dole,
which allowed universities to own the patents
arising from federally funded research, to grant
exclusive licenses, and to charge royalties that
could be shared with inventors. Since nearly
90% of the basic research funds in U.S. univer
sities comes from U.S. federal funds, the new
law drastically changed the face of university
technology transfer.
The theory behind the law’s application
to university research was based on Congress’
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understanding of the embryonic nature of uni
versity discoveries and inventions. Since universi
ties do not develop products, early investment by
industry is needed to turn university findings
into commercial realities. Typically, such invest
ment involves high risk, since neither the prac
ticality of the inventions nor their market utility
has been proven. Patents, and particularly exclu
sive licenses, can be used as incentives for first
mover companies to make the investment: if the
product were to succeed, the patent would pro
tect the initial investor from competition for a
period of time, rewarding the initial risk taking.
Finally, the law provided an economic in
centive for both universities and their research
ers to patent their inventions and to participate
in the technology-transfer process. Although
the royalties gained from technology transfer
are only a very small contribution to univer
sity budgets (averaging about 3% of university
research budgets for U.S. universities), there is
enough economic return to support the pro
cess—and considerable incentive for individual
researchers. More importantly for the biotech
nology industry, the technology-transfer process
is an organized, effective method of transferring
university findings via protected IP for the pur
pose of forming a protected technology dowry
for new companies. Investors in most technolo
gy companies—and certainly in such high-risk/
high-investment fields as biotechnology—must
have proof of the exclusive rights to patents and
other forms of IP by the company before they
will invest.
Consequently, we use licenses to our IP
to stimulate the development of our inven
tions into products that serve the public good.
Through our patenting, licensing, and copy
right protections, we encourage companies to
take the necessary risks to develop our inven
tions into products and/or services that benefit
humanity. Royalties derived from licenses sup
port further research and are shared with inven
tors. These, in turn, provide incentives for fur
ther innovation.
Each year, more than US$1.2 billion in
sponsored research is conducted on the campus
of M.I.T., at the Lincoln Laboratory, and at the
10 | HANDBOOK OF BEST PRACTICES

Whitehead Institute for Biomedical Research.
This research leads to more than 500 new inven
tions per year. These inventions and software are
marketed through M.I.T.’s Technology Licensing
Office. The core of this office is a group of techni
cally trained and business-oriented people. They
work with industry, venture capital sources, and
entrepreneurs to find the best ways to commer
cialize new technologies.
The Technology Licensing Office at M.I.T.
began its operations many decades ago as the
Patent, Copyright, and Licensing Office. It was
reorganized in 1986 and became the Technology
Licensing Office. It is administered by the Vice
President for Research/Associate Provost and is
now part of the academic arm of the university.
Its mission statement declares that:
The mission of the M.I.T. Technology Licensing
Office is to benefit the public by moving results of
M.I.T. research into societal use via technology li
censing, through a process which is consistent with
academic principles, demonstrates a concern for the
welfare of students and faculty, and conforms to the
highest ethical standards.
This process will benefit the public by cre
ating new products and promoting economic
development.
It will help M.I.T.:
• show tangible benefits of taxpayers support
for fundamental research
• attract faculty and students
• generate industrial support of research
• generate discretionary income
• generate new job opportunities for
graduates
We will continue to be a world-class
model of excellence in university technology
licensing.
1.2 Staffing

The Technology Licensing Office is staffed by:
• Director Lita Nelsen, chemical engineer
ing background (BS, MS, MBA) with 20
years experience in industry in the fields
of medical devices, membrane separations,
and biotechnology
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• Associate Director Jack Turner, electri
cal engineering background (BS) with 18
years of experience in industry
• seven technology licensing officers, all
with degrees in engineering or science,
each with one to two decades of industrial
experience; each is responsible for one of
the seven technology areas: biotechnol
ogy, chemistry, medical devices, semicon
ductors, communications, software, and
nanotechnology
• four technology licensing associates, all
with BS degrees in science and little or no
other experience; associates assist the tech
nology licensing officers
• legal personnel: one corporate attorney, one
junior lawyer, and one legal assistant; these
staff members provide advice on licensing
and particularly on corporate structure,
manage outside attorneys for litigation,
and manage M.I.T.’s trademark and enduse software licensing; patent prosecution
is handled by outside attorneys and patent
agents
• financial and computer systems personnel:
one financial manager, two accountants,
one programmer, and one desktop support
administrator
• office management and clerical support:
office manager, compliance manager (gov
ernment reporting), three secretaries, a re
ceptionist, a files manager, and a file clerk
1. Numbers of patents and licenses

M.I.T. currently holds about 1,500 active U.S.
patents and many corresponding foreign patents.
About 150 U.S. patents are issued to M.I.T. each
year. We have about 600 active licenses and issue
around 100 new licenses every year.
The gross annual revenue of the office is about
US$40 million. Net revenue is about US$10 mil
lion (after patent expenses, personnel expenses, and
distribution of a portion of royalties to inventors).
The majority of our licenses are to existing
companies—both small and large. But about
25% of the licenses are to new spinout compa
nies, which are specifically formed to develop a
licensed technology.

2. THE ROlE OF THE TECHNOlOGy
lICENSING OFFICE IN THE BuSINESS
COMMuNITy
2.1 The “virtual incubator” for spinouts

Twenty to 30 new companies are spun out from
M.I.T. each year. All of them are based on M.I.T.
inventions and are built upon licenses to our pat
ents and software. The companies based on our
biomedical inventions form an important part of
the biotechnology cluster in the Massachusetts
area (see section 3 below).
Our formal role in starting up new compa
nies is confined to filing patents and negotiat
ing license agreements with the companies, and
although we will often take equity shares in the
company as partial payment of royalties, we do
not take board seats on the company or any man
agement role. The purpose of these restrictions is
to keep the company clearly separate from the
university. We believe this separation is necessary
for the university to concentrate on its mission of
basic discovery research, dissemination of knowl
edge, and education. Through these policies, the
management of technology transfer essentially
becomes a by-product of the academic process
and will not distort the long-range mission of the
institution.
We can only achieve this mission through
clear and transparent conflict-of-interest policies
and procedures (see Box 1). The conflict-of-in
terest rules may seem unusually strict, but this
careful approach is necessary because of the very
large number of companies spun out (more than
250 since 1987). Management that allows excep
tions to the rules would not be possible given
this large number. Our task is not to use these
rules as deterrents but to efficiently and cre
atively craft arrangements within the rules. Put
differently, our operating motto is “A firm wall
between university and industry—but a wall with
many doors.”
We do not formally incubate these spinouts;
we do not invest M.I.T. money in any of these
companies; we do not allow the companies to use
M.I.T. laboratory facilities; and we do not write
their business plans nor do we participate in their
management.
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Box 1: M.I.T.’s Conflict-of-Interest Rules for Spinout Companies
(last Revised February 2005)

1. Faculty member may consult but not be a line officer in any company. Consulting activities
should not use university resources and should not use students.
2. Faculty member must distinguish direction of research at university from responsibilities at
company in which he/she owns equity.
. The university will not accept sponsored-research grants from the company if the faculty
member owns equity.
. No confidentiality of research results (anytime). All research must be publishable.
. Only patents, copyrights and tangible property can be licensed for compensation (no knowhow or trade secret licensing can be done since this would preclude open publication).
. Faculty members may not conduct the license negotiations (nor attend the negotiations).
. Consulting is third-party, between the faculty member and the company. No tie-in with the
license.
. Only very minimum commitment of future inventions (those dominated by previously
licensed patents). No pipelining of improvements.
. Faculty member/founder who holds equity signs Conflict Avoidance Statement promising:
• Not to accept research support from company
• Not to suppress dissemination of research findings
• Not to use students on company-related work at M.I.T.
10. Arm’s length relationship between the university and the company
• No M.I.T. monetary investment in the company
• No board seat
• Equity managed by Treasurer of M.I.T.—not the Technology
Licensing Office
11. Technology Licensing Office enforces diligence terms, payment of patent costs, other license
obligations just like any other company. No special status for M.I.T. spinouts.
12. Yearly departmental overview of faculty outside professional activities.

Common sense: Emphasis on the spirit (not just the letter) of the rules, administered by people
with judgment and authority.
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Our informal role, however, is much broader.
We call it a “virtual incubation” function, which
encourages and accelerates the formation and
growth of our spinout companies. The initial
license agreement itself includes contract terms
that help. Our financial terms are quite generous
for the first few years of operation, reflecting our
understanding that new companies are often cash
poor. Similarly, our royalties on products are low,
because we know that the company will have to
make substantial investments and develop and
contribute substantial IP of its own before the
product can be successfully commercialized.
An important part of the license agreement—
both for us and for the company—is that which
defines the milestones, or diligence terms. These re
quire companies to raise minimum amounts of
capital and achieve progress in product develop
ment. Milestones related to raising capital assure
us that the outside market finds the company
worthy of investment and that sufficient capital
will be raised to fund product development.
Our virtual incubation incorporates many
other functions. We meet with inventors, help
ing them to define the direction of the company
and their own career aspirations. We introduce
them to consultants, potential executives, and
other advisors who can help them formulate their
business strategy and write business plans. And,
because of our long relationships with sources of
investment capital, we can introduce inventors to
venture capitalists and angel investors who may
be willing to invest in the new companies.
2.2 The role of students in
entrepreneurship at M.I.T.

The admission criteria for prospective M.I.T.
students, particularly those for undergraduates,
contribute to the entrepreneurial spirit at the in
stitute and the ultimate impact of our graduates
on the economy. In evaluating candidates for ad
mission as undergraduates, we look not only for
academic achievement (such as high grades and
strong standardized test scores), but also for a cer
tain quality of potential leadership—an intensity
and focus that fosters achievement and also influ
ences others. Young people who are strong po
tential leaders often possess a self-confidence that

allows them to think unconventionally and take
risks—including the risk of joining (or forming)
an entrepreneurial company.
Our education of these students (and of their
“big brothers and big sisters” in graduate school)
stresses the fundamentals of science, rather than
short-term applications. The students are in
volved in leading-edge research projects early in
the course of their studies. We seek to produce
graduates who will have leadership capabilities
based on a solid grounding in science and a fa
miliarity with the state of the art.
Role models in business are an important
influence on these students during their years at
M.I.T.. Many of the professors and many alumni
who visit campus—and not a few of the students’
friends—have started companies based on M.I.T.
technology. These entrepreneurs expose students
to entrepreneurial thinking. The presence of
strong role models is important for developing an
entrepreneurial culture; the plethora of such role
models at M.I.T. and in the Boston/Cambridge
area leads others to think that “I can do it too”—
and offers resources for advice and strategy.
Finally, our culture at M.I.T. stresses that
risk taking is necessary for achievement. And,
importantly, that “failure is a learning opportu
nity—not a black mark.” We assume that our
students are good enough to take risks and suc
ceed. They have sufficient talent, energy, and selfconfidence to recover rapidly from failure and to
learn from failure to become more effective in
their next endeavor. A willingness to take risks
and the ability to learn from failure are critical
for entrepreneurship.
2. Interaction with the business community

A key part of the technology-transfer function at
the university is to develop and maintain a wide
range of contacts with the surrounding business
community and to leverage these resources to
help build our spinout companies. Our model
for spinning out companies depends on a ma
ture, entrepreneurial community surrounding
the university.
The geographic area of M.I.T. is the
Cambridge/Boston area, which in many ways
provides an infrastructure of support for spinout
HANDBOOK OF BEST PRACTICES | 1

NElSEN

companies. High technology companies have been
regularly spawned here for more than 40 years.
As a result, there are many executives, lawyers,
accountants, consultants, real estate managers,
and other professionals who are experienced at
working with new companies. And the commu
nity is well connected. Networking organizations,
such as the M.I.T. Enterprise Forum and the
Massachusetts Biotechnology Council (MBC),
keep people in contact with one another.
Finally, the community has developed
“knowledgeable money”: investors who contrib
ute to spinout companies not only funds, but wis
dom, guidance, and connections to management
talent, business development opportunities, and
follow-on money. A new breed of high-technol
ogy angel investors—former entrepreneurs who
founded and cashed out from successful compa
nies—is now bringing wisdom, connections, and
experience, along with money.
There are also venture capital funds that
specialize in technology-based spinouts. Many
even subspecialize in biotechnology and have
partners and associates with MD and PhD de
grees in biology who are experienced in the bio
technology industry.

3. THE BIOTECHNOlOGy CluSTER:
ExPERIENCES FROM MASSACHuSETTS
It is helpful for those who are involved in technol
ogy transfer to be in proximity to others with sim
ilar issues and challenges. The Boston/Cambridge
area is one of the three main biotechnology clus
ters in the United States. (Biotechnology clusters
are geographical regions where a disproportion
ately large number of biotechnology companies
are located.)2 The other two biotechnology clus
ters are:
• the San Francisco Bay Area of northern
California
• the San Diego/La Jolla area of southern
California
Many factors have led to the formation and
growth of the Massachusetts cluster, with research
institutions playing a critical role. This cluster of
more than 280 companies accounts for almost
1 | HANDBOOK OF BEST PRACTICES

20% of the total number of U.S. biotechnology
companies. Almost all of these companies started
as small, entrepreneurial companies within the
last two decades, the majority having been formed
within the last 12 to 15 years. According to data
from the Massachusetts Biotechnology Council,
these companies now employ more than 30,000
people. In addition, there are more than 220
medical device companies in the area that employ
an additional 25,000 people.
.1 Key elements for a biotechnology cluster

It all starts with early fundamental support of
basic research by the U.S. government. Leading
research institutions make the discoveries, devel
op the IP, and train the scientists that form the
biotechnology companies. Where the research
institutions cluster, the new companies eventu
ally form. The process continues with alliances
developing between biotechnology companies
and large pharmaceutical companies, which will
often provide necessary testing, manufacturing,
and distribution of the drugs discovered by the
biotechnology companies.
For a robust cluster to form, the area needs
investment capital (and experienced investors),
executive talent, trained scientists, and a host of
supporting professionals—lawyers, accountants,
real estate professionals, and others—who un
derstand biotechnology entrepreneurship and
can help fledgling companies establish themselves.
Good airports are critical, and local communities
that are attractive to highly talented personnel and
their families create a competitive advantage.
The Boston/Cambridge area of Massachusetts
has an unusually large concentration of worldclass research institutions (universities and re
search hospitals) funded in large part by the U.S.
government—particularly the National Institutes
of Health (NIH)—to perform basic discovery
research in biology and biomedicine. Together,
Massachusetts research institutions received more
than $2.1 billion in NIH research grants in fis
cal year 2003, approximately 10% of the national
total.
From this research comes much of the
“feedstock” for new biotechnology companies:
new discoveries, IP, knowledgeable scientific
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advisors for new companies, and, importantly,
well-trained scientists to staff the new companies.
.2 The self-feeding cluster

Even with a base of world-class university research
and its resulting technology and IP, getting a clus
ter started is difficult—there is no simple formula
for doing so. But once started, a cluster begins to
feed itself in a virtual cycle. The biotechnology
cluster feeds itself through:
• role models. These are people who have
founded companies and can offer examples
of success and advice to new entrepreneurs.
• management/founders. Often new com
pany management is recruited from other
companies in the area. People who were
employees of early companies in the cluster
acquire the skills and interests to become
founders of new companies. New compa
nies also can recruit other skilled personnel
from the older cluster companies.
• retention of new graduates. A cluster of
biotechnology companies in an area en
courages new graduates from nearby uni
versities to seek employment in the area,
consolidating skills.
• infrastructure support. The area’s patent
attorneys, lawyers, accountants, recruit
ers, real estate managers, consultants, and
equipment suppliers develop special skills
in biotechnology as they respond to the
needs of the cluster.
• technology transfer. As the universities
and other research institutions become
more experienced in dealing with bio
technology companies and biotechnology
startups, they become more effective in
starting new companies that strengthen
the clusters. Successful technology licens
ing and spinouts lead to revenue, which
funds the filing of more patents and more
opportunities.
• angel investors. Local angel investors bol
ster the process, since they can offer their
skills and experience in addition to their
money. As clusters mature, founders of the
early companies frequently become inves
tors in new companies.

At some point venture capital moves in.
At the start of the Massachusetts biotechnol
ogy cluster, there was little indigenous ven
ture capital. Most venture capital money came
from investment funds located in New York,
California, and other states. With the growth
of high-tech clusters in Massachusetts (both
biotechnology and telecom), many of these
funds opened new offices in Massachusetts, and
many new venture funds were formed locally.
Currently, the majority of new company financ
ings in Massachusetts are led by venture funds
with offices in Massachusetts.

4. CONCluSIONS
.1 The importance of clusters

Many elements contribute to the success of a
biotechnology cluster. Its origin and continued
health depend on a continuing source of state-of
the-art science, usually provided by universities
and research hospitals funded for basic research.
The source of this funding probably needs to be
from government: no private institutions can af
ford to fund sufficient speculative basic research
to sustain the flow of discoveries necessary to sup
port a cluster’s growth.
Effective technology transfer is also neces
sary. The legal infrastructure for transferring in
ventions from universities must be in place (and
relatively nonbureaucratic), and sufficient funds
must be available for universities to file patents
and protect their IP.
The formation of new companies also re
quires a business infrastructure in the communi
ty. A simple legal system for company formation,
consulting, accounting, and legal professionals to
advise the company—as well as adequate physi
cal space—are all necessary. Good transportation
into the area is important, since investors and
business partners need to visit the company. And
investment capital is, of course, critical.
Most of all, the formation of companies and
the subsequent development of clusters requires
talented people: world-class researchers to lead
the discovery, trained and talented technologytransfer professionals, entrepreneurial company
HANDBOOK OF BEST PRACTICES | 1
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founders, scientists and managers to staff the
companies, and knowledgeable investors who
can both fund and guide the company. All will
need the support of a variety of professionals in
the community. It takes a whole community to
build a biotechnology cluster—but once built,
the cluster can achieve a self-sustaining life that
strengthens itself and the community.
4.2 The importance of policies for ensuring the
availability of products for the poor

M.I.T. usually files patents only in North America,
Europe, and Japan (though occasionally we file in
China, Singapore, Republic of China, and Korea
for the electronics field). Thus, the biomedicinerelated patents we file are not often likely to affect
the development and distribution of medicines
and vaccines in developing countries.
We are, however, mindful of the issues sur
rounding the development and distribution of
new health-related products for developing coun
tries, and we consider both our patenting proce
dures and our licensing terms when working with
relevant technologies. For example, it may some
times be advisable for patents to be filed in some
developing countries so that local companies in
those countries can protect their investments in
further developing our technology. In other cases,
we may choose not to file patents in those coun
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tries and may prohibit our licensees from doing
so—or we may refrain from granting exclusive
licenses in developing countries unless we feel
exclusivity will enhance development and access.
Other agreements could require preferential pric
ing for the public sector of developing countries.
There are no rigid written policies guid
ing the way we handle technologies; instead, we
leave our options open, creatively crafting agree
ments to maximize access. However, the number
of technologies arising from our research that are
relevant to neglected diseases is relatively small,
since we do not have a medical school nor a
school of public health. Our experience with such
technologies is relatively scant, as is our experi
ence in crafting such agreements. We discuss our
approach to those technologies in greater detail in
another chapter. ■
LITA NELSEN, Director, M.I.T. Technology Licensing Office,
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Building Research Clusters: Exploring Public Policy
Options for Supporting Regional Innovation
peTeR w. b. phillips, Professor, Department of Political Studies, University of Saskatchewan, Canada
caMille d. Ryan, Postdoctoral Fellow, Faculty of Communication & Culture, University of Calgary, Canada

ABSTRACT

Governments at all levels are showing great interest—and
some are spending lots of money—in developing research
clusters that they hope will benefit their local and nation
al economies. Clusters are complex, however, and this
chapter aims to help policy-makers maximize their ben
efits. The chapter offers a taxonomy of countries and their
potential for cluster development and explains a five-stage
process for realistic cluster building. Stage one assesses ca
pacities, resources, and opportunities. Stage two involves
choosing an anchor strategy. In stage three, organizational
and institutional leaders are identified to take the lead in
developing the cluster. In stage four, proactive tactics are
chosen. Stage five identifies the cluster’s lifecycle and the
strategies needed to sustain it. Cluster building is knowl
edge-based development, which is inherently different
from traditional industrial development. For one thing,
cluster building requires global links. Companies and
skilled employees are less interested in fiscal incentives,
public infrastructure, or other government support than
in the innovation community and its networks.

1. InTRoduCTIon
Theory suggests that competing companies and
their related industries often concentrate in a
few locations and generate higher value, more
jobs, and more innovation than companies that
do not locate near clusters with companies in
related businesses. Ultimately, those that do are
benefiting from some traded or untraded interde
pendencies: economies of scale in related or sup
porting industries, economies of scope in labor

and capital markets, or knowledge spillovers from
competitors and collaborators.1
Some analysts estimate that the benefits of
scale, scope, and—perhaps most importantly—
tacit knowledge spillovers are usually limited to
between 10 and 100 miles of the epicenter of a
community. Given that the cities, regions, and
countries that host these clusters would likely
benefit, all levels of government are greatly inter
ested in doing whatever is appropriate to spur lo
cal development of these clusters.
While analysts do not agree about much,
they generally accept that clusters are complex.
Subject to industrial evolution, changes in global
markets, the knowledge bases that drive them,
and the geopolitical forces that influence their
development and success, clusters are diverse and
their characterizations are open to interpretation.
Additionally, clusters go through cycles. There
are periods when they require high reinvestments
(public, private, or both) of money, time, and re
sources. At other times they provide high payouts.
No one cookie-cutter approach or measure can be
employed to develop and manage a cluster.
Assuming that the cluster is a dynamic phe
nomenon and subject to a lifecycle, a number of
important factors come into play when assessing
and supporting innovative capacity. This chapter
first examines a taxonomy of countries and their
potential for cluster development. It then looks

Phillips PWB and CD Ryan. 2007. Building Research Clusters: Exploring Public Policy Options for Supporting Regional Innovation. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. PWB Phillips and CD Ryan. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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at a five-stage process for cluster building. Stage
one involves using an array of common analytical
tools to assess a candidate for a cluster: these tools
include an overview of discrete measures along
with some more general analytical tools, such
as social network analysis and emerging markets
analysis. Stage two involves choosing one of the
strategic options. Stage three identifies and mo
bilizes actors or organizations within the region
(public, private, and others) to take a lead in the
cluster. Stage four involves choosing from a set
of proactive tactics for encouraging companies
to cluster. Stage five identifies the lifecycle of the
chosen cluster and the strategies needed to sustain
the initiative.

2. THE ConTExT
According to Mashelkar,2 building indigenous
technological capacity, in any context, requires a
number of conditions: a conducive policy environ
ment, entrepreneurship, promotion of a culture
of innovation, access to technology (where neces
sary, through international technology transfer),
an educated and skilled workforce, and a “learn
ing by doing” mentality. Although Mashelkar
explores indigenous technological capacity ex
clusively from a developing country perspective,

his approach can be applied to examine, not only
the disparities between developed and developing
countries, but also disparities within and between
developed countries as well.
Morel and colleagues3 present a taxonomy to
assess economic strength and innovation capacity
in health and health-related organizations. Six di
mensions (manufacturing capacity, domestic mar
ket, export market, R&D, IP system, and drug
regulatory system) are explored across three stages
of development that, in combination, are used to
measure the capacity for developing countries to
progress in terms of innovation. We have adapted
this taxonomy to assess the capacities of different
groups of nations for supporting cluster develop
ment and growth (see Table 1).
Most countries can be relatively cleanly as
signed to one of Mashelkar’s four quadrants.
Quadrant I countries consist of leading indus
trial nations, such as the United States, Canada,
Australia, Japan, and E.U. countries. Quadrant II
countries, which have relatively low per capita in
comes but high innovative capacity, include Korea,
China, Brazil, India, and some eastern European
countries. Quadrant III includes resource-rich
and resource-dependent countries such as those
in the Middle East. Finally, Quadrant IV consists
of developing nations, such as those in southeast

Table 1: Taxonomy for Determining Nation/State Cluster Capacity
Quadrant I
countries

Quadrant II
countries

Quadrant III
countries

Quadrant IV
countries

Economic strength

high

low

high

low

Innovative capacity

high

high

low

low

Comprehensive cluster policies

advanced

emerging

n/a

n/a

Incidence of formalized clusters

high

moderate

low/none

low/none

Degree of specialization

high

moderate
to high

moderate to
low

low

Source: Adapted from Mashelkar4 and Morel5 and colleagues.
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Asia countries, Sub-Saharan Africa, and south
and central America.
Quadrant I countries rank highly in terms
of economic strength and science and technol
ogy capacity: by most measures they have the
lion’s share of the clusters and are the most ag
gressive supporters of cluster development. A
closer look at the United States shows that there
are more than 160 clusters identified across 25
states, with cluster activity ranging from nar
rowly defined categories such as oil and gas (for
example, Louisiana) or gun manufacturing (for
example, South Dakota) to more broadly based
categories such as biotechnology6 or life sciences.7
Moreover, nine state legislatures in the United
States have either written into law, or at the very
least recommended, that the State apply a clus
ter approach to economic development,8 while
seven other states9 have nonlegislated, clusterbased economic development strategies in place.
In contrast, while Canada has no formalized na
tional cluster policy,10 most of the provinces have
examined and attempted to support clusters in
their jurisdictions; there would appear to be at
least 25 clusters or emerging clusters in nine sec
tors across Canada.11 In Australia, a national clus
ter policy has been proposed that advocates for
strategic, proactive polices rather than the current
laissez-faire approach, but the program has yet to
be formally implemented.12
On the opposite end of the continuum,
Quadrant IV nations rank low in terms of eco
nomic strength and innovative capacity. This is
due to a range of limitations, including weak in
frastructure and incomplete IP regimes. However,
some cluster activity is emerging. Several small
artisan or trade-type clusters (for example, the
garment industry in Kenya) have emerged in
Sub-Saharan African regions,13 but these clusters
are characterized as low in terms of specialization
and are often composed of networks of “petty
commodity producers.”14 Another approach has
been to create export-processing zones. Mauritius
was the first African country to establish an export-processing zone (EPZ) in the early 1970s.15
Meanwhile, in Asia, despite the financial crisis of
the 1990s, countries such as Indonesia, Malaysia,
and Thailand have encouraged significant

economic development by emphasizing indus
trial exports.
The middle quadrants (II and III) include
countries that have low to medium capacities
in terms of economic strength and innovation.
Clusters, if present, often exhibit low techno
logical or industrial application. The exception
is Korea. Although categorized as a Quadrant
II country, it has developed significant cluster
capacity in such specialized areas as movies and
animation, information technology, and digital
media.16 Similarly, China and India are growing
in terms of economic strength and innovative
capacity. In India, the United Nations Industrial
Development Organization (UNIDO) and the
national government support over 350 smallscale industry (SSI), rural and artisan-based clus
ters. India has also had some acknowledged suc
cess in creating world-class clusters in Bangalore
in biomedical research and software engineer
ing.17 Some Middle Eastern countries, although
ranked high in terms of economic strength, are
often solely dependent upon the extraction and
processing of natural resources such as oil and
petrochemicals; scientific and technological ca
pacity is limited in these countries.18
In short, while clusters are both stronger
and more prevalent in Quadrant I countries, all
countries have the potential to benefit from clus
ters. Every region needs to evaluate its capacities
and opportunities, make strategic choices about
which areas to nurture, choose specific tactics,
and identify and support indigenous leadership.
Such choices, moreover, will need to be tailored
to the capacities and opportunities of the indi
vidual countries and regions.
2.1 Step 1: Evaluation

The first and most important step in developing
clusters is to assess capacities, resources, and op
portunities. Given the importance of planning,
the tools are surprisingly weak. No one triedand-true acid test for cluster capacity or potential
exists. A number of methods have been used—
ranging from ad hoc to formalized consulting and
opinion formation, to valuing or analyzing cluster
capacity through descriptive or institutional anal
ysis, to empirical, statistical analyses of detailed
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industrial data—but to truly understand or evalu
ate the potential efficacy of a cluster likely requires a
blend of quantitative and qualitative approaches.
Given that clusters are to some extent self-de
fining, one approach often used is to convene an
industrial, expert, or community forum to iden
tify common interests and opportunities. While
useful for identifying actors, or at least companies
that would willingly participate, these processes
are simply a starting point. In the first instance,
they will likely determine whether the necessary
number of interested/engaged actors can foster
effort to develop a cluster. The processes can also
be valuable for identifying the scale and scope of
current traded or untraded interdependencies, as
well as for planning future development that may
either require or generate greater connections in
a community. They often run the risk, however,
of becoming either subject to groupthink (where
everyone goes along with the most important or
loudest participant) or unfocused debates about
what is, is not, could be, or should be happen
ing locally. Every process needs to move beyond
rhetoric. Depending on local capacities, two main
approaches have been tried.
One common analytical approach is to look
at the institutional composition and leadership of
the industry, supply chain, technology, or market.
Generally speaking, clusters always represent a
high concentration of people and activity within
a particular region. Thus, a quantitative analysis
of clusters would use measures that reflect those
concentrations relative to benchmarks or other
regions. A foundational theory that underlies any
number of quantitative approaches is central place
theory, a geographical theory that seeks to explain
the size and spacing of human populations. The
theory relies on the notion that centralization is a
natural principle of human order and that nested
hierarchies of people and institutions will fol
low this principle.19 In the context of that the
ory, many communities will seek to identify the
community’s array of industry (for example, lead
ing companies and suppliers), supply chain (the
linked suppliers ranging from input industries
through production to transportation, wholesale,
and retail trade), and functional actors (finance,
marketing, research, and labor services).
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Both of the above approaches can be used by
all countries in all quadrants. As data becomes
available (often only as a country becomes more
developed), a number of other approaches can
be used, including location quotient measures,
shift/share analyses, and emerging-industry clus
ter analyses.
The location quotient (LQ) measures com
petitiveness by comparing a region’s relative share
of a particular activity to the share of that activity
in some reference economy. This identifies spe
cializations in a given regional economy. A com
monly utilized economic-analysis method, it was
developed in part to offer a slightly more com
plex model to input/output analysis.20 A location
quotient of less than one indicates that there is
lower share of activity or nominal competitive
ness within that region—in other words, the area
has less than its share of activity or is less com
petitive than the larger region or country. A loca
tion quotient equal to one indicates the area has a
share of activity in accordance with its share of the
base. Finally, a location quotient greater than one
indicates that the area is more competitive rela
tive to other regions or the nation-state as whole.
The location quotient can be applied similarly to
regional wage levels relative to national or state
levels. Additionally, the measure may be used to
highlight policy impacts (for example, federal
funding initiatives or support of science and tech
nology) within a cluster or region. If a location
quotient for support activities is significantly less
than one, but the LQ for the cluster is greater
than one, then there may be a case for reallocat
ing effort more in line with natural competitive
ness. The Boston Consulting Group adapted this
methodology and examined year-to-year changes
in location quotients to test the specialization of
regions in particular industrial sectors. It arranged
the results into four categories of clusters: stars
(specialized with increasing specialization), ma
ture (specialized with decreasing specialization),
emerging (unspecialized with increasing special
ization) and transforming (unspecialized with
decreasing specialization). This methodology was
then used to analyze Indiana’s cluster data: of the
15 Indiana-based clusters identified, most were
categorized as stars or “transforming.”21
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Shift/share analysis is another technique used
to determine how much of an area’s employment
change is due to the nature of the national econ
omy, the industrial mix, and local competitive
ness. This approach makes it possible to separate
growth into three components: national growth,
industrial structure, and regional competition.22
The shift/share analysis tool is composed of three
components or equations. First, the national
growth component measures the effect of nation
al growth on a given local economy. Second, the
industrial mix component identifies the relative
growth or decline of local industries as compared
to overall economic performance. Third, the dif
ferential shift component measures the change
in the local economy that is attributed to local
economic advantages, such as natural resources,
or disadvantages, such as low wages. Shift/share
analysis was used to analyze the composition of
the growth of the southern United States in the
1980s.23 More recently, shift/share analysis has
been used to assess the competitiveness level of
Singapore’s exports.24
Emerging cluster analysis is a broader tool.
It begins by using employment levels to identify
a dominant industry or a fast-growing, emerg
ing industry. The measure compares employment
and wage changes in an area’s cluster over a de
fined period of time with the larger region, state,
province, or even the nation. Overall, if the net
change in employment and/or wages is greater
than or equal to 100%, the cluster is considered
to be emerging. However, if the change is be
tween zero and 99%, the cluster is considered to
be relatively stable. A cluster is considered mature
when the percent change is less than zero.25
Social networks analysis (SNA) is yet another
diagnostic tool for cluster analysis. It is primarily
used to collect and analyze data about relation
ship patterns among individuals, though it does
not simply examine the economic consequences
of those relationships. According to Wellman, it
is a powerful method for “explaining variances in
resources, social behavior and socio-economic out
comes.”26 SNA is guided by a focus on the dialec
tical relationships between agents, nodes, and ac
tors. It makes the invisible work visible.27 When
applied to knowledge management, it can identify

patterns of interaction and knowledge-exchange
flows within a network. It shows how knowledgeintensive work is done and can illustrate complex
communication channels within a network. As a
tool for analysis, SNA views “actors and actions …
as interdependent” units and acknowledges that
the “relational ties” between actors are “channels
for transfer or flow of resources.” It can also pro
vide “opportunities for or constraints on individual
action,” which is antithetical to more traditional
economic approaches.28 SNA helps to identify
boundary spanners, gatekeepers, and knowledge
bottlenecks, as well as under- and overutilized
individuals or organizations. So many things are
coordinated in networks (for example, work
place environments, clubs, and memberships)
that SNA appears to have almost universal ap
plication. Indeed, multiple levels of analysis can
be employed: the dyad, the node itself, or even
the entire network. The entire incidence matrix
(agent by agent or agent by event) can become
the target of analysis, or it can merely become one
variable in an adjacency matrix to explore correla
tions between variables.
A number of measures inherent in SNA help
to illustrate realities that cannot otherwise be ob
served in the social setting. Density measures how
many potential linkages within a social setting
(that is, pairings of different actors) are actually
operational. Theory suggests that some nontrivial
amount of density is required, but that too dense a
community can stifle innovation and change. The
concept of centrality refers to the importance of
particular actors and the hierarchical nature of an
entire network. In general, centrality measures are
used to “… describe and measure properties of ‘actor
location’ in a social network.”29 Centrality (applied
to the node level) is a family of three measures,
each answering a different theoretical question.
High degree centrality refers to a high number of
ties and the level of power or informal leadership
capacity of an actor, agent or node. High closeness
centrality builds upon high-degree centrality but
also looks to the nature of the distance between
nodes. Betweenness centrality identifies the critical
route for flows in the network and the dominant
node or agent that has more close relationships to
other dyads. In terms of centrality, it is not just
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how many connections an agent or node has, but
how central its connected actors or agents are.30
The power of a node or actor can be measured
as a function of its position within a given net
work.31 The eigenvector measure is useful for this
analysis. An actor or agent who is high on eigen
vector centrality is connected to many actors who
are themselves connected to many actors, thus
multiplying their risk and/or opportunity: this is
their power indicator.32 While the data require
ments for SNA can be large, there are a number
of generally available proxies. Co-publications
(bibliometrics) and co-patents (technometrics)
are often used as proxies for social interactions
among agents.33

These discrete measures and analytical ap
proaches have been employed to varying degrees
in a number of regions or countries around the
world. Table 2 provides a provisional assessment
of analytical approaches and measures used to ana
lyze regional competencies across a select number
of regions worldwide. Upon closer examination,
it appears that when multiple clusters are ana
lyzed within a region, more analytical approaches
are required or undertaken. Also, specialized or
knowledge-based clusters often demand a more
complex blend of analytical methods. For ex
ample, Minnesota’s (low technology) industrial
clusters were analyzed using location quotients
and input/output analysis alone, while Iowa’s

I/O or descriptive
analysis

Indiana (1) (multiple)

med
to high

√

√

Iowa (2) (multiple)

high

√

√

Pennsylvania (3) (multiple)

low to
high

√

√

√

Minnesota (4) (multiple)

low

√

√

Canadian communities (50+ cmas) (5)

low to
high

√

Calgary wireless cluster (6)

high

√

√

Mississauga’s ICT cluster (7)

high

√

√

Quebec photonics cluster (8)

high

√

√

Saskatoon’s canola research cluster (9)

high

√

√

Singapore’s export industry (10)

low to
high

Cluster(s) or region(s) of interest

SNA

location
quotient

Emerging
industry analysis

Shift/Share
analysis

knowledge
intensiveness

Table 2: Cluster Analysis Methods across Select Countries and Regions

√
√

√

√
Sources: See endnotes for full list of sources.34
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more-advanced technological clusters were ana
lyzed using a combination of approaches. SNA
appears to be less commonly used as a cluster
analysis approach, at least partly because the pro
cess can be resource and time intensive and fre
quently requires gathering primary data, which is
often not pragmatic from a practitioner’s point of
view. Past practice suggests that input/output and
institutional or descriptive-based analyses are the
most commonly used approaches for exploring
clusters. Additionally, the location quotient ap
pears to be the quantitative tool most commonly
used in this selection of regions or clusters.
No matter what approach or tool is used
to analyze a given cluster, the efficacy of such
measures depends upon the quality of the data.
Knowledge-based industries in particular, such
as biotechnology, often are not adequately re
flected in data collected through North American
Industry Classification System (NAICS) codes.
Furthermore, there is no consensus on where to
draw lines or pull together multiple codes to best
represent a cluster. Cluster boundaries, particu
larly in advanced technology sectors, cannot be
defined by conventional product-based industrial
or sectoral boundaries. This limitation is particu
larly important with respect to biotechnology.
2.2 Step 2: Choosing a cluster strategy

Table 3 outlines a chronological typology of clus
ter definitions, beginning with Porter’s industrial
approach. Different cluster approaches will have
a different set of requirements, a different mix of
leaders and tactics, and will fit better with some
categories of countries than others. Economic de
velopment agencies in developed and developing
countries have usually applied Porter’s generalized
approach to clusters, customizing it to the par
ticular geopolitical region (see chapter 3.12 for
examples). Indeed, despite the lack of consensus
about what a cluster does and how it operates,
Porter’s version of a cluster has been rapidly ad
opted by practitioners from all over the world.
Porter’s industrial managerial characteriza
tion focuses heavily on the local and regional
relationships between competing and collaborat
ing companies, often without any specific indus
trial, product, or technological core. These types

of clusters appear to emerge and succeed where
there are a number of highly competitive compa
nies or competing supply chains that rely on the
economies of scope and scale delivered by related
and supporting industries. Porter emphasizes that
the most successful clusters of this type have ei
ther a direct local or a strong link to demanding,
leading-edge consumers. Few centers in the world
(especially in Quadrants II–IV but even in some
of the more-advanced Quadrant I countries, such
as Australia, Canada, and New Zealand) can meet
this criterion. In this sense, these types of clusters
have a greater chance of success in Quadrant I na
tions, such as the United States, European Union,
and Japan, all of which have large, wealthy, and
demanding (that is, trend-setting) indigenous lo
cal markets.
The product/market, flagship company, and
value chain models are all variations on cluster
ing focused around a technology, product supply
chain, or product market. As companies in these
types of clusters seek greater efficiencies, they be
gin to formally and informally acknowledge their
local and regional interdependencies with other
competing and completive companies. Over
time, various types of nontrade interdependencies
arise, which strengthen the collective. This model
has perhaps more applicability to a wider range
of countries because all economies, regardless of
their local capacity, are fundamentally linked to
a technology, product, or market through some
form of supply chain or industrial structure. The
difference in the three approaches is who takes the
lead. In the product/market cluster there often is
no single formal leader; instead, varying combi
nations of companies and civic leaders will work
to build the needed infrastructure, scale, and
scope to realize the cluster’s potential. A number
of clusters actually have sole leadership vested in a
flagship company or national champion. The val
ue chain model usually vests leadership in some
“integrator.” This can vary widely depending on
the nature of the supply chain: it can be the larg
est enterprise in the chain; a logistics, wholesale,
or retail actor; the owner of some key technology,
infrastructure, or product in the chain; or it can
be a leader of some industrial, technical, research,
educational, or financial organization. This type
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Table 3: Chronological Typology of Cluster Definitions and Examples
Cluster type

Definition/description

Example(s)

Industrial/managerial
characterization

a geographic concentration of competing
and cooperating companies, suppliers, service
providers, and associated institutions

Italian textile
districts, Third
Italy36

based on industrial interdependence (supply
and demand linkages)
Product/market focus

characterized as networks of production of
strongly interdependent companies,knowledge
producing agents, and customers linked to each
other in a value-adding production chain

Italian footwear
cluster
Australian wine
cluster

Flagship/company

Multinational-enterprise-ledclusters/anchor;
act as flagships

Monsanto-led
St. Louis, Missouri,
BioBelt Cluster

Value chain (horizontal
and/or vertical)

includes final market producers, and first-,
second-, and third-tier suppliers that directly
and indirectly engage in trade (A value chain
cluster is an industry cluster identified as an
extended input/output or buyer/supplier
chain. The cluster comprises multiple sectors or
industries.)

Silicon Valley
Boston Life
Sciences Cluster

system of market and nonmarket links between
geographically concentrated companies and
institutions (The links enable cooperation
among suppliers and competitors on business
processes, purchases, investments, strategies,
and technical research.)
Networks

most salient in a domain between the
flexibility of markets and the visible hand of
organizational or political authority

Biovalley (borders
France,Switzerland,
and Germany)

Innovative entrepôt

geographic specialization in a few linked
stages in the innovation supply chain (for
example, research, development, gestation, and
adaptation)

Saskatoon canola
research cluster
(Canada)

Source: Adapted from Phillips37

2 | HANDBOOK OF BEST PRACTICES

CHAPTER .1

of model would appear to be scalable to all of the
categories.
Finally, some clusters are defined by their role
in developing useful knowledge. The networked
model is increasingly common in large centers in
Europe and the United States. Examples include
world-scale universities (for example, Stanford/
UC Berkeley in San Francisco), critical research
infrastructure (CERN in Switzerland), and of
ten the head offices and research centers for large
multinationals. Malerba38 identified two discrete,
independent systems of innovation that would fit
the networked model. Typified by the computer
software industry, one system is based on flexible
networks of small- and medium-sized companies,
often co-located in distinct industrial districts (for
example, Silicon Valley), and coordinated by a
range of commercial venture-capital corporations
and angel investors. Companies in these commu
nities tend to be significantly volatile and rapidly
growing. The other type of system, which perhaps
better reflects the biotechnology world, is based
on the universities, public research laboratories,
and large companies that perform and commer
cialize R&D. While clearly attractive, this model
has limited scope to expand beyond the largest
agglomerations. These are currently in the United
States, the European Union, and Japan (and per
haps in the larger research centers at Melbourne,
Australia, and Toronto, Canada). In time, howev
er, it could be attractive, especially to Quadrant II
countries with large populations (such as China,
India, and Brazil), which are increasingly focused
on adopting, adapting, and increasingly develop
ing new technology.
An alternate “innovative entrepôt” model be
ing adopted by some smaller, research-intensive
communities concentrates on a narrower range of
inventive areas and seeks to fashion some com
parative advantages by being an expert in some
thing in a particular location. While this model39
requires most of the elements of the larger net
worked clusters, it relies on small, nimble, highly
specialized networks to create a comparative
advantage for the region. This has particular ap
peal to many communities because it does not
require the scale of the networked model, and it
can be adapted and adopted realistically in most

countries. Scale is less important than focus and
strong networking. The challenge of this model,
however, is that it requires the capacity for a high
degree of trade in people, knowledge, technolo
gies, and products, making it less attractive to
Quadrant III and IV countries where there re
main significant economic, legal, social, cultural,
and physical barriers to the flows necessary for
such a model to work.
2. Step 3: Finding institutional and
organizational leaders

Actors provide varying levels of leadership based
on the dominant activity of different stages of the
industrial life cycle. Key actors in most clusters are
often the university, public sector research labo
ratories and institutions, and the private sector.
The first two categories of clusters—Porter’s in
dustrial managerial model and the product, mar
ket, value chain approach—tend to be led by pri
vate companies, while more innovative networks
or entrepôts will have varying arrays of leaders,
depending on the rate of innovation. Zilberman
and colleagues40 undertook a conceptual analysis
of agricultural biotechnology, proposing a fivestage linear development process (including dis
covery, development, gestation, production, and
marketing), with different actors (universities,
public labs, and corporations), taking the lead at
different stages. In early stages, public labs and
universities tend to lead, with corporations doing
little beyond marketing any resulting products.
The model suggests that as the technology ma
tures, corporations contribute more and increas
ingly take the lead.
Almost all scholars and practitioners agree
that competitive, profit-seeking companies are at
the core of any cluster. While some clusters seem
to be able to operate without a clear dominant
player, many scholars have noted that some of
the strongest clusters are formed around mul
tinational enterprises (MNEs).41 Rugman and
D’Cruz42 argue that MNEs frequently act as flag
ships to lead, direct, coordinate, and manage stra
tegic, value-added activities of collaborative com
panies in combined business and social networks.
According to their research, 14 of the world’s 20
largest international MNEs (defined by revenues
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and global presence) were largely home-based
organizations with strong regional strategies and
networks. Gassman and Gaso43 argue that regard
less of whether the MNE is home-based or not,
it can act as a broker of knowledge in a cluster.
Some MNEs contribute information in disem
bodied forms: they set up “listening posts” in
many regions around the world and distribute in
formation. Other MNEs transfer knowledge em
bodied in new technologies, new processes, and
new products. Regardless of the method, compa
nies are a necessary condition for a cluster.
The regional university can also directly or
indirectly drive the evolution and success of a
technology cluster. According to Niosi and Bas,44
innovation in emerging technologies and indus
trial clusters can be spurred indirectly through
decentralized, horizontal policies that include
the creation of both government laboratories
and research universities. A source for skilled la
bor, the university acts as a magnet (directly and
indirectly) for “stars” and business. Moreover,
its publications can be a conduit for local and
nonlocal knowledge exchanges. The traditional
role of a university is to generate and diffuse basic
or explorative (know-why) knowledge and gener
ate a skilled academic and technical labor force.
However, these traditional roles are evolving. As
Cooke45 argues, a strong local science base needs
to be complemented by a rich entrepreneurial cul
ture not only within the regional business com
munity but also within the academic community.
He further suggests that “… the science base is a
magnet, even if only indirectly ... for biotechnology
business.” This is supported in previous research,
which found that the existence of a diversified,
mainly academic, knowledge base is a prerequi
site for successful, localized innovative activity
in knowledge-based sectors like biotechnology.46
Niosi suggests also that universities are a founda
tional element of the “virtuous cycle” embedded
within the cluster phenomenon—star scientists
become entrepreneurs and spinout commercial
ventures.47
Regional leadership is not limited to just or
ganizations and companies. Key individuals can
be ambassadors or civic entrepreneurs for regions
and/or act as catalysts for change. For example,
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Robert Mondavi altered the face of the wine in
dustry when he founded the wine cluster in the
Napa Valley in California. Wine producers were
already in the region, but most guarded their op
erations with secrecy. Mondavi opened the doors
of his winery to tourists, customers, and competi
tors alike, effectively transforming the regional
wine industry into an open platform of pooled
knowledge and diverse products that eventually
spelled success for the region.48
Finally, collaborative leadership has been an
other powerful tool in some regions. For exam
ple, the BioValley network (located in the Rhine
valley where France, Germany, and Switzerland
meet) was initiated in 1996 following the merg
er of Ciba-Geigy AG and Sandoz AG, both of
Basel, Switzerland, to form Novartis AG. The re
gion had lost jobs from the merger, so advocates,
both key individuals and existing organizations,
led revitalization efforts. The original BioValley
concept, developed by Georg Endress and Hans
Briner, was to re-create the region as a “Silicon
Valley” dedicated to biotechnology and chemical
technologies.
Cooperation or collaboration among public/
private actors and individuals is important for the
innovation process. Cross-fertilization through
partnerships, either in projects or in efforts to
build innovative regions, alerts the public sector
to market demands and provides companies with
access to basic research.
2. Step 4: Choosing tactics

While many purposive, directed strategies can
help, perhaps a cluster’s most important require
ment is that the economic and business climate
support market efforts. Because clusters involve
both traded and untraded interdependences
that can thrive only with strong underpinnings
for market and social activity, centrally planned
markets are unlikely to develop a true cluster.
Minimally, a country needs to have the legal and
social structures that create certainty for what
would otherwise be risky transactions: the rule
of law; effective and efficient mechanisms to
protect and adjudicate property; the lowest pos
sible barriers for entering or exiting any of the
key input and output markets; the ability to trade
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domestically and internationally; and effective
tax, regulatory, and trade rules. Moreover, clusters
tend to thrive best when at least a base investment
has been made in education, training, and general
community infrastructure. Clusters do not go in
search of the lowest cost site; rather, they locate
where things can get done. Unfortunately, such
basic conditions are absent in many regions of the
world, but especially in Quadrant IV countries.
Any proactive measures to create a cluster with
out most if not all of these basic preconditions
would likely be useless. In some instances, one
or more of these foundational conditions may be
missing (or weak) and a cluster might emerge,
but generally proactive efforts will only succeed if
markets can function.
Beyond ensuring an appropriate climate, an
almost limitless array of proactive investments
can nurture one or more cluster types. Some are
more appropriate for some types of cluster than
others. (Of course, there is no guarantee that the
efforts will create the benefits envisaged.) A favor
ite tactic is to start with a cluster’s core actors. All
successful clusters appear to have a hub or anchor.
Depending on whether the cluster is industrial/
managerial or product, technology, or supply
chain-focused, this could be a set of competing
companies, a leading company, a university, a
public laboratory, or an industry association. If
an anchor does not already exist, most regional
planners and politicians will instinctively think of
an investment-attraction program; virtually every
jurisdiction in the world has someone marketing
their location as a place to do business. But while
expectations are often high, prospects are poor.
Few companies are truly mobile. Most that are
mobile would need inducements: large subsidies
that could have a higher impact in other areas and
that, in the end, would add little to job creation
and wealth generation in the long term. In the
absence of an obvious anchor, it usually makes
more sense to build on potential local candidates
than to try to lure others with subsidies. In lieu of
a dominant companies, regions have sometimes
been able to nurture Porterian or supply-chain
type models, as long as they have been able to tap
into distribution systems that provide access to
global markets.

A second common model is to build poten
tially attractive infrastructure on the assumption
that “if we build it they will come.” Unfortunately
for many of these ventures, infrastructure is only
a minor attraction: “You will build it and they will
not come.” Increasingly, infrastructure needs to
be tailored to the specific needs of a user, so if it
is built on speculation, it often can be far more
costly than if it is built to suit. Having said that,
industrial actors often cite infrastructure, in the
form of labs, incubators, and sophisticated ma
chinery that benefits a wide range of users, as a
key reason for their presence in a community. The
physical plans for any infrastructure may be less
important in the long run than the business mod
el. An operator of infrastructure—be it a research
park, special laboratory, or experimental facil
ity—will need to tailor the terms of access and
use to ensure that highly volatile and competitive
research and development programs are able to
access the facilities at the right time and under
the right terms (for example, clearly defined IP
rules). In research today, timing and terms are of
ten more important than cost. Nevertheless, there
is no single infrastructure set that is necessary or
sufficient to make any cluster work.
Some think money is the key to the problem:
If only more programs were created and more
money made available, a cluster would emerge.
It is true that money drives activity, but not all
activity is desired. While in theory money is fun
gible—it shouldn’t matter where it comes from—
in practice money comes with strings attached.
Who provides it and under what conditions can
influence what others are able to accomplish with
it. MNEs and other for-profit companies provide
the lion’s share of capital in almost all markets,
so engaging profitable operating enterprises is
almost a prerequisite for creating a sustainable
cluster. During growth phases, however, public
and private venture capital can be a critical con
tributor to the success of new technologies, prod
ucts, and ventures. In the early stages of research,
public funding tends to dominate, with private
capital taking over as technologies, products, and
processes mature and get closer to the market. In
fact, public funds at later stages can be both good
and bad. Government decision-making processes
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(designed to ensure accountability and transpar
ency) are generally inimical to effective and ef
ficient financing: many companies ultimately
supported by government grants or subsidies find
the benefits are dissipated by slow decisions and
inflexible terms. Furthermore, governments often
have difficultly exerting the same influence as pri
vate investors. For example, it is hard for most
governments to change management in a venture
they have invested in or to divest or write down
their equity. Public funds tend to be most effec
tive when they are partnered and leveraged with
private funds or private management skills (for
example, microcredit systems and public/private
venture pools with private management).
Locations lacking an anchor, an irresistible
piece of infrastructure, and unlimited financial
resources often look to their public research insti
tutes or universities, especially in the early stages
of developing a new technology area. Particularly
with knowledge-intensive industries such as bio
technology, universities’ public investment in
R&D facilities is arguably a crucial precondition
for a knowledge-based innovation system. Their
capacity to create social capital, nurture and sup
port stars, and provide a basis for collaboration
and innovation—while harder but not impos
sible to measure—is ultimately the real value of
such investments. As previously mentioned, the
regional university can drive (directly and indi
rectly) the evolution and success of a technology
cluster. Niosi and Bas49 assert that universities do
four main things: they generate know-why knowl
edge; they provide skilled, educated labor; they
draw (directly and indirectly) stars and business;
and they facilitate local and nonlocal knowledge
exchanges (for example, publications and joint
research). Many argue that a university’s most im
portant output is the base that it provides for the
“absorptive capacity” of an economy. While the
university is vital, it will only be able to perform
this function in conjunction with a number of
other essential elements. First, there must be an ef
fective mechanism to both practically and legally
transfer knowledge. At a minimum, this requires
a domestic research community with interna
tional collaborations, companies with proprietary
technologies, and an appropriate national system
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to legally protect IP. Second, there must be open
and accessible labor markets for skilled and edu
cated workers. Third, an institutional platform,
such as a major national laboratory, a university,
or a big research institute/program, is needed for
community-based interaction and synergies to
develop. These provide the foundation for ab
sorbing global knowledge. Other elements, such
as preferential financing and specialty commer
cial services, may be important but appear to be
second-order requirements.
Ultimately, many theorists and practitioners
are looking to “people policies” to nurture clus
ters. People are at the heart of generating new
ideas and technologies, people lead and work in
companies and institutions, and people are the
core of networks. Some clusters seek to build
up their local talent by creating new educational
and skills training programs focused on the mar
ket needs of their local companies and clusters.
Others work on building bridges to attach gradu
ating students to the local labor market. These
programs range in focus from technical train
ing, entrepreneurial training, and mentoring to
specialized advanced research techniques. Some
clusters seek to attract highly skilled, educated,
motivated, and experienced stars from elsewhere
to populate their community and provide new
ideas and leadership. Florida and Gates50 have
suggested that the most vital and vibrant commu
nities in the United States and Canada are those
that value and support tolerance and talent. They
suggest that creative, entrepreneurial people will
tend to vote with their feet and move to com
munities with the most accommodating lifestyle.
Other researchers suggest that good climate, cul
ture, civic amenities, tax levels, and other qual
ity-of-life measures are vital to creating a cluster.
There is, however, some contradictory evidence:
attraction to clusters may be less about quality
of life and more about the depth of local labor
markets (for example, the potential of there be
ing more than one employer for one’s specialized
skills in the area) and the nature of the job (for
example, one that is on the cutting edge of a tech
nology or market).51
A closely related people-policy strategy is
to target local stars in a community. Zucker
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and colleagues52 have noted that in the U.S.
biotechnology field, academic and professional
research stars (that is, those with a significant
number of patents or publications) appeared to
be instrumental in attracting major peer-reviewed
grants, were key players in translating knowledge
between academic and applied research, and were
major contributors to the spinout of many new
biotechnology companies. These stars assisted
other researchers and industry. When the stars
became affiliated with new spinouts, this signaled
the presence of an opportunity to the market
place. Some regions have attempted to collect
more clusters of stars by collecting research exper
tise in national centers of excellence in public labs
or universities. These regions and stars have also
provided added incentives for the scholars and
scientists to engage in more external activities,
on public and private boards and commissions,
or through consulting work. Similarly, many
communities promote or nurture civic entrepre
neurs. Often in university, industry, or industry
associations, these individuals undertake efforts
to defend, explain, or inform the entire cluster
to its members and others outside. These civic
entrepreneurs are highly valued—they will often
personify and coalesce a cluster’s spirit and aspira
tions. The regional entrepreneurial culture is also
considered important, but it is not clear whether
it is an independent variable or is simply deter
mined by local economic development.
2. Step 5: Sustaining a cluster
through its life cycle

Clusters appear to have life cycles. Sometimes
strong centripetal forces pull activity to the
community (for example, through knowledge
spillovers and economies of scale and scope); at
other times, centrifugal forces will dominate (for
example, diseconomies and congestion costs).53
Lundvall54 offered a neo-Schumpeterian model
of industrial development that explains localiza
tion patterns based on the degree of technological
development: innovative clusters have the high
est incentive to agglomerate, but markets become
concentrated and profits stagnate as benefits de
cline, costs rise, and products are standardized.
Sustaining a cluster, therefore, is not ensured.

Successful clusters continue to focus on innova
tion (rather than on production efficiencies),
which requires sustained investment in R&D.
The cycle of investment and return in clusters
has been explored also by Davis and Schaefer,55
who outline a five-stage evolutionary process. In
the first stage, assets are accumulated, with in
vestments often coming from the public sector
(for example, the recent worldwide infusion in
genomics research). In the following stage, as
sets are converted into business resources through
entrepreneurial effort. Next, the cluster is estab
lished and companies grow by exploiting new re
sources and capabilities in external markets. Then
as production and markets mature, collective
efficiencies are realized. Finally, various market
and non-market selection processes lead to lo
cal specialization. Crone offers a more formally
delineated and stylized five-stage cluster-devel
opment model: precluster, protocluster, emerg
ing cluster, established cluster, and restructuring
or renewal states.56 According to Crone, these
stages are not intended to constitute a determin
istic life cycle model but to serve as an analytical
tool. Rosenfeld57 alludes to yet another life cycle
model in his exploration of clusters and cluster
policy in less favored regions of the European
Union. According to Rosenfeld, clusters progress
from an embryonic stage through growth and
maturity until they finally decay. The embryonic
stage is stimulated through innovations, inven
tions, or inward investment. During the growth
stage, markets develop sufficiently to spinout and
attract imitators and competitors; entrepreneur
ship is also cultivated. In the maturity stage, the
activities of the cluster have become more rou
tine. More imitators enter the market, and lower
costs become the key competitive advantage. The
decay stage is when products or processes become
expendable and are easily substituted in the mar
ketplace by more cost-effective alternatives.
Just as in the industrial life cycle, clusters dif
ferentiate according to scale, scope, character, and
activities. Regardless of how a cluster is character
ized, it is still likely to be subject to the evolu
tionary dynamics of markets. At any given point
in the developmental cycle—cluster or indus
trial—activities must shift. Different actors take
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on differentiated roles. At some points, activities
may be concentrated or centralized within one
institution. At other times, activities may be car
ried out collectively by a number of actors work
ing in collaboration. Such responses to global
market signals and industry developments must
be orchestrated to avoid the declining stage of in
dustrial development or the decay of a cluster.

. ConCLuSIonS
Cluster strategies would appear to be high-risk,
high-return economic policies. While not all
types of clusters are appropriate for all coun
tries, most countries could attempt at least one
or more options. If thoughtfully and prudently
undertaken, the investments in analysis, strat
egizing, building local leadership, and pursuing
various tactics would generate positive social re
turns even if a sustainable cluster did not devel
op. Indeed, most of the options appropriate for
clusters are also just good economic policy. One
point that anyone interested in economic devel
opment should keep in mind is that most sectors
are becoming more knowledge intensive. Even in
low specialized areas, such as garment industries
in developing nations, technologies are being
adopted to increase productivity and flexibility.
In short, while clusters are attractive economic
development tools, they must be nurtured with
an appreciation for their partial and incomplete
nature. Fundamentally, they are part of a global
innovation system, and cannot thrive if cut off
from the lifeblood of the system—ideas, skilled
labor, capital, and competing and collaborating
companies and organizations.
Knowledge-based development is inherently
different from traditional industrial development.
While infant industry protection made some sense
in the industrial context, it is not clear whether it
has any value in a knowledge-based world. The
imperatives of innovation pose some serious chal
lenges for development policy. Many current
development efforts have a strong mercantilist
orientation, with a focus on self-sufficiency. In
an effort to generate higher-value exports or to
replace imports, governments at all levels in many
countries are using their tax and fiscal policy to
0 | HANDBOOK OF BEST PRACTICES

encourage greater local R&D or to attract global
companies to relocate their R&D programs into
their jurisdiction. This often involves preferential
support for national champions or exclusive deals
to encourage MNEs to relocate their activities.
Usually governments do this without consider
ing the corresponding relationships and interac
tions that knowledge-based companies require
to succeed. If innovation can happen within a
company, companies, or a regional or national
community, then such a narrow approach might
have some chance of success. But if innovation
is truly global, as appears to be the case in many
of the life sciences, then narrow, mechanistic selfsufficiency strategies may either simply fail or be
counterproductive. This is why both companies
and skilled employees are more interested in the
innovation community than in fiscal incentives,
public infrastructure, or other government sup
port. By extension, a mercantilist policy that dis
courages global links could not only fail to attract
global companies but could also drive out local
companies or researchers as they seek access to the
global community. n
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ABSTRACT

This chapter presents the main forms of statutory intel
lectual property (IP) protection with emphasis on utility
patents, trademarks, geographical indications, copyright,
and trade secrets. Basic questions with regard to who can
get protection, the subject matter of each form of protec
tion, statutory requirements, and certain exceptions. The
chapter concludes with short sections on institutional as
pects including employee agreements, how to mark the
protected intellectual property, how to integrate the vari
ous rights, and how to identify infringement. The authors
conclude that the form of protection chosen for a given
invention should be guided by the mission of the institu
tion (whether public or private), the purpose of the work
it conducts, and the nature of the invention, or other IP,
that will be subject to IP rights protections.

1. InTRoduCTIon: WHAT IS
InTELLECTuAL pRopERTy?
Intellectual property (IP), sometimes called in
tangible property is any product of the human
mind or intellect. Intellectual property can there
fore be almost anything: a technical invention
or an improvement of an earlier invention; it
can be a unique name or logo, design, method,
software, database, domain name, a chapter in a
book (like this chapter), or an entire book (like
this Handbook). The broad area of intellectual
property is subdivided into different types, each
clearly defined and protected through statutes
or laws, which then can be protected by differ
ent means. In the United States, for example,

IP rights protection is even enshrined in the
Constitution of the United States of America:
The Congress shall have power … to pro
mote the progress of science and useful arts, by
securing for limited times to authors and inven
tors the exclusive right to their respective writings
and discoveries … .1
By this clause the Constitution grants the
rights to patent and copyright protection. Even
though trademarks are not expressly protected
by the Constitution, trademarks have a long his
tory of use and protection in the United States
and globally. Likewise, trade secret protection has
long been accepted as a means for protecting IP
rights. Other forms of IP protection include plant
breeders’ rights.
What makes these forms of IP protection
particularly useful is that they have been able to
adapt to the changing times. Even if the present
technologies are different from the technology
that was protected in Thomas Jefferson’s day, the
means to protect are similar. But the essential
nature of patents was “invented” well before the
Constitution was written. They emerged in me
dieval Europe where first rights were granted to
individuals for what they owned, using a remu
neration or an award as a means to encourage in
dividuals to generate “property desired by them
selves.” A more formal system of patents was born
in the Venetian Republic where the first patent

Dodds J and A Krattiger. 2007. The Statutory Toolbox: An Introduction. In Intellectual Property Management in Health and
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. J Dodds and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet
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was granted in 1443 to a manufacturer of con
veyors for loading and unloading ships.2 Two cen
turies later, in 1623, the British Crown passed a
patent law, then called the Statute of Monopolies.
This law defined basic concepts that continue to
influence to this day the interpretation of patents
around the world.
In the United States, the first patent law was
adopted in 1790, shortly after the Constitution
was ratified. The first U.S. patent was signed
by President George Washington on July 31,
1790 and was issued to Samuel Hopkins (of
Pennsylvania) for his improvement of the pot
ash manufacturing process. The invention saved
what was then the country’s leading export
industry.
In the following chapters we will look briefly
at issues related to the protection of intellectual
property; Table 1 provides an overview of the
main tools of IP protection. We especially focus
on the law in the U.S., though in general terms,
similarity exists throughout many parts of the
world. Where international agreements regulate
IP protection, that is noted. In national laws
there are differences: some countries give broad
er protection to intellectual property, others,
narrower, but basically the forms of protection
are similar, especially in member countries of the
World Trade Organization (WTO), which ad
here to the Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS).

2. pATEnTS
2.1 What is a patent?
A patent, which usually refers to a utility patent,
can be granted to anyone who invents a new and
useful process, machine, article, manufacture,
composition of matter, or any new and useful
improvement thereof. A utility patent is usually
granted for a period ending 20 years after the fil
ing date. A patent gives the inventor a right to
exclude others from making, using, offering for
sale, or selling the invention in the country where
the patent is issued or importing the invention
to the country where the patent is issued. In ex
change for being granted a patent, the inventor
 | HANDBOOK OF BEST PRACTICES

agrees to disclose in the patent application, the
invention in detail as well as the best mode of
practicing the invention. The disclosure is pub
lished normally 18 months after the filing but, at
the latest, when the patent issues. Disclosing the
invention to the public will help others to invent
further, thus pushing technology forward for the
benefit of the society.
In the United States, there are three different
kinds of patents: utility patents, design patents,
and plant patents. Plant patents are essentially
specific to the United States. In addition to these
types of patents, several counties provide addi
tionally utility model protection. Utility models
are also called petty patents. Basically they allow
the right holder to prevent others from com
mercially using the protected invention during a
limited time period. Therefore, a utility model is
basically similar to a patent. The main difference
is that the requirement of nonobviousness, or in
novative step, is not as stringent for utility mod
els as it is for patents. Moreover, the duration of
the protection given by utility models is shorter
than that given by patents. The duration depends
on the country; usually the protection is between
seven and ten years. In Estonia and Finland, for
example, an invention can be protected by utility
model for ten years, at most.
In the United States, a utility patent can be
filed as a provisional or a nonprovisional applica
tion. A provisional patent application is a lowercost first patent application, which does not have
to contain any claims. A provisional patent ap
plication has a pendency of 12 months from the
date of its filing. A provisional patent application
cannot mature to an issued patent but it gives the
inventor an early filing date, and the term patent
pending is applicable. In order to benefit from the
early filing date of the provisional application, a
nonprovisional patent application has to be filed
before the end of the 12 months pendency of the
provisional application. It is possible to extend
the period of patent life up to 21 years by first
filing a provisional application and then later a
nonprovisional one.4
A design patent can be granted to anyone who
invents a new, original and ornamental design
for an article of manufacture. A design patent is

Any useful, novel, and
nonobvious invention;
design patents can be
filed on new, original, or
ornamental design
Words, phrases, and logos
that can distinguish the
goods and services from
those of others
Literary works, software,
dramatic works, music,
pictures, sound recordings,
architectural works, movies
Any technical or business
information that is secret
and that gives the holder
an advantage over a
competitor who does not
have the information

Patents

Trademarks

Copyright

Trade Secrets

Keep secret; no registration
available

Apply for federal
registration

Use or have a bona fide
intent to use and apply for
a federal registration

Submit a patent application

How to protect

Unlimited duration as long
as the subject matter is
secret

Life of the author plus 70
years

Unlimited duration as long
as the mark is in use; the
mark has to be renewed
every tenth year

20 years from filing of the
priority application; for
design patent, 14 years
from the date of issuance.

Term of protection

Note: An overview and introduction of protections available for plants are treated elsewhere in this Handbook. 1

What can be protected

Means of protection

Table 1: What is the intellectual property of your business?

Right to prevent unlawful
use

Right to prevent
unauthorized copying or
public performance

Right to exclude others from
using the mark and other
marks so similar they cause
confusion

Right to exclude others
from making, using,
manufacturing, selling, and
offering to sell

The rights of the owner
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granted for a period of 14 years from the date of
issuance.
Certain countries provide protection called
registered or industrial designs, which is similar to
the U.S. design patent. In some countries, indus
trial design provides protection of up to 25 years.
Since April 2003, one can also get a Community
Design in the European Union, which protects
the design in all the member countries of the
European Union for up to 25 years.
Plant patents are a form specific to the United
States. A plant patent can be granted to anyone
who invents or discovers and asexually reproduces
any distinct and new plant variety. Tuber-propa
gated plants are excluded from plant-patent pro
tection. For sexually reproduced (by seeds) or tu
ber-propagated plants, one can get protection via
the Plant Variety Protection Office administered
by the U.S. Department of Agriculture. Several
countries provide protection to sexually repro
duced plant breeds through plant breeders’ rights.5
It is important to note the distinction between
plant patents and utility patents on plants.6
2.2 Who can get a patent?

According to the law in perhaps any country
with patent law, only the inventor can apply for
a U.S. patent. However, if the inventor is dead,
a legal representative can make the application.
Similarly, if an inventor assigned the right to his
or her employer or any third party, that entity
may file for the patent. In any case, it is impor
tant that the true inventors are named in the pat
ent application. If there is more than one inven
tor, the inventors apply for the patent jointly. A
person who contributed to the invention only
financially cannot be a joint inventor. None of
the inventors needs to be a U.S. citizen or live
in the United States in order to be entitled to a
U.S. patent.
2. U.S. and “international” (PCT) patent
applications

A patent is territorial. This means that there is no
such a thing as a world patent. A U.S. patent is
valid only in the United States and the owner of a
U.S. patent therefore can, based on the U.S. pat
ent, only claim rights in the United States.
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The Patent Cooperation Treaty (PCT) is an
international treaty harmonizing patent applica
tion procedures in its member countries. Through
a PCT patent application, the inventor can get a
filing date with one application in all the member
countries. Thirty months after the filing, the ap
plicant has to decide in which member countries
he or she actually wants and needs a national pat
ent. The benefit of PCT application is that there
is no need to file separately in all the countries;
the procedure can be done by one application.
Moreover, the PCT system gives the inventor ap
proximately 30 months to shop around before
deciding in which countries a national patent
would be relevant.
All the PCT applications will be published 18
months from the filing if not abandoned before
that. Usually, a U.S. patent application is published
18 months after the filing, if nonpublication is not
specifically requested. The applicant is entitled to
request nonpublication if the application is not
and will not be a subject of filing in any country
publishing the patent application 18 months after
filing. Nor may the invention be subject to a PCT
application. When the patent has issued it will be
published. Due to the publishing policy of PCT,
some inventors prefer to file a U.S. patent and re
quest no publishing, thereby keeping the inven
tion secret until the patent issues.7
2. First to file versus first to invent

The United States is the only country in the
world not applying the first-to-file concept.
In the United States a patent is granted to the
party that first invented. Because of this concept
the U.S. patent system is known for its interfer
ence practices. Interference is a proceeding con
ducted before the Board of Patent Appeals and
Interferences to determine priority on inven
tion between a pending application and another
pending application or unexpired patent. The key
elements of determining priority are the date of
conception, the date of reduction to practice, and
diligence or lack of it.
2. Subject matter of patents

In the United States, statutory subject matter of
a patent is defined as “any new and useful process,
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machine, manufacture, or composition of matter or
any new and useful improvement thereto.”8
The Supreme Court acknowledged through
legislative history that Congress intended that
statutory subject matter includes “anything under
the sun that is made by man.”9
The Supreme Court has specifically identi
fied three categories that are not patentable. Laws
of nature, natural phenomena, and abstract ideas
do not fall into any statutory class and they are,
therefore, unpatentable. Furthermore, items from
these categories are not patentable according to
the national legislations of many other countries.
Some national laws give further provisions for
nonpatentable subject matter. For example, India
does not allow patents on agricultural methods.
The European Union and many other countries
do not allow patents on methods to treat a hu
man condition or surgical methods.
Mathematical algorithms as such are abstract
ideas when they stand alone and are not reduced
to a practical application. However, when an ab
stract idea is reduced to a practical application, the
practical application of the abstract idea can be a
useful, concrete, and tangible result and therefore
patentable.10 In the United States, such applica
tions of mathematical algorithms are increasingly
patented as business-method patents. Businessmethod patents are, however, not allowable in
several countries; for example, the European
Patent Office does not currently examine applica
tions disclosing a business methods.
2. Statutory requirements for patentability
2..1 Novelty

Because patents are granted to promote the prog
ress of the useful arts, a product or process is not
patentable unless it is new. A product or process
is not new if all the claimed elements are pres
ent expressly or inherently in a single piece of rel
evant prior art. If a single piece of relevant prior
art contains all the claimed elements, it is said to
anticipate the product or process. An invention is
not new and therefore not patentable, if “it was
known or used by others in this country or patented
or described in a printed publication in this or a for
eign country …”11 Known has been interpreted to

mean that the knowledge is accessible to the pub
lic. An oral presentation may be enough to make
the knowledge accessible to the public. Used in
this clause means publicly accessible use. A ma
chine that is operated in an open field is publicly
accessible use even if no one sees the machine,12
but a machine in a windowless building where
no one can enter without swearing to secrecy has
been ruled not to be public use.13 Printed publica
tion has been very broadly interpreted to mean
all material accessible to the public in tangible
form.14 Oral communication is excluded, but if
copies of a paper were distributed at a conference,
they would be publications. However, if those re
ceiving the copies were asked to keep the content
of the communication secret, the paper would
not be a publication.
An invention is not patentable “if the inven
tion was patented or described in a printed publica
tion in this or a foreign country or in public use
or on sale in this country, more than one year prior
to the date of the application for the patent in the
United States.”15 This section creates the one-year
grace period, during which the inventor may de
velop the invention further, market it, and pre
pare a patent application.
It is noteworthy that the U.S. patent sys
tem is different from systems of the most other
countries because of this grace period. In most
other countries the inventor would lose the rights
to patent if the invention were published before
filing the patent. In European countries, for ex
ample, a public disclosure is an absolute bar to
patentability. Japan gives a six-month grace pe
riod for filing a patent if the public disclosure was
a presentation at a scientific meeting.
2..2 Utility

The purpose of granting patents is to promote the
progress of the useful arts. Therefore, in order to
be patentable an invention has to be useful. For
a product or process to be useful it must, at least,
work, although it does not have to work perfectly
or even better than any competing products or
processes. However, products or processes that
are working but can be used, for example, only
for immoral or illegal purposes are not consid
ered useful. Also, products and processes that
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are regarded as useless are not considered useful.
A process for producing a steroid that had no
known use, for instance, was found to be not use
ful and therefore not patentable.16
2..

Nonobviousness

A new and useful product or process is not patent
able unless it was nonobvious when it was made.
The nonobviousness requirement is included in
Section 103 of the Patent Act. Different from the
novelty determination, the nonobviousness de
termination does not include a strict identity re
quirement. Therefore, prior art that does not dis
close all the elements of the claim at issue might
be relevant when determining obviousness. When
making a decision of obviousness, the examiner
has to determine the level of ordinary skill in the
art at the time the invention was made.
2. Experimental-use exemption

U.S. patent law does not have a written researchexemption clause, but current practices are based
on case law, that is, on court decisions. The basic
rule says the patentee shall not be allowed to pre
vent experimentation using a patented product or
process for bona fide research activities designed
to further scientific knowledge.
However, the experimental-use exception
is very narrow, such that any research aimed at
commercialization (with even the slightest com
mercial implication) will not fall under the ex
emption and will hence be subject to infringe
ment liability.

. TRAdEMARkS And RELATEd RIGHTS
A trademark is a word, phrase, symbol, design or a
combination of those items, that distinguishes the
source of one’s goods or services from the goods
or services of others. A trademark can be valid
only when it is used in, or in connection with,
goods or services in the course of commerce.
There are various types of marks that can be
registered with the Patent andTrademark Office. In
addition to trademarks17 and service marks (marks
that indicate a specific service, such as a rental
or leasing service), the Trademark Act provides
for registration of collective marks, membership
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marks, and certification marks. Collective marks
are trademarks or service marks that are used by
a member of cooperation, an association, or oth
er collective group or organization. One type of
collective mark is a membership mark. These are
not trademarks in the ordinary sense. Membership
marks do not indicate the origin of the good or
service. The purpose of a membership mark is,
rather, to indicate that the user of the mark is a
member of a particular organization.
There are generally three types of certification
marks. First, there are marks that certify that the
good or product is from a certain geographic re
gion; for example Cognac for the distilled brandy
from a certain region in France. Second, there are
marks that certify that the goods or services meet
certain standards, for example, quality standards or
safety standards. Third, there are marks that certify
that a member of a union or other organization per
formed the work or labor on the goods or services
and that the performer meets certain standards.
In addition, one can register a trade dress of a
good or service. Trade dress can, for example, be
product design, packaging, or color. Trade dress
of a service can be, for example, the overall look
of restaurant.
The most effective way to get trademark regis
tration is to choose a mark that is fanciful or arbi
trary. An example of a fanciful mark is EXXON—a
made-up word—something that does not mean
anything in itself. An example of an arbitrary
mark is Apple used by Apple Computer—an exist
ing English word that itself has no connection to
computers.
A mark that resembles another mark already
in use in the United States cannot be registered
because of the likelihood of customer confusion.
Therefore, before filing a trademark registration
it is important to perform a trademark search to
discover whether the mark or a similar one is al
ready in use.
An important element of trademark law is
the naked licensing doctrine. Quality assurance
and protection of the public is a central purpose
of the trademark law. Therefore, an indispensable
condition of a valid trademark license is that the
licensor controls the nature and quality of the
good or service sold by the licensee under the
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mark. Naked licensing results when the licensor
does not adequately supervise the quality of the
licensee’s products or services. Naked licensing
can be regarded as abandonment of a mark and
therefore leads to cancellation of registration.

. GEoGRApHICAL IndICATIonS
A geographical indication is a sign used on goods
that have a specific geographic origin and possess
qualities or a reputation that are derived from
that place of origin. Geographical indications are
defined in the TRIPS agreement as a type of in
tellectual property. WTO members provide legal
means for interested parties to prevent the use of
a geographical indication that indicates or sug
gests that a good originates in a geographical area
other than the true place or origin in a manner
that is misleading to the public or constitutes an
act of unfair competition.
Most commonly, a geographical indica
tion consists of the name of the place of origin
of the goods. Agricultural products typically have
qualities that derive from their place of produc
tion and are influenced by specific local factors,
such as climate and soil. Examples of geographi
cal indications are Idaho (potatoes) and Roquefort
(cheese).
Whether a sign functions as a geographical
indication is a matter of national law and con
sumer perception. The TRIPS Agreement does
not require that a WTO member extend protec
tion to a geographical indication if that geograph
ical indication is the generic name for the goods
in that member country. Therefore, the word
champagne is not registrable as a geographical in
dication in the United States, because champagne
is a generic term, in the United States, meaning a
light-colored wine with bubbles.
The United States offers robust protection
for geographical indications, generally through
registration as a certification mark.
. CopyRIGHT
A copyright is a type of intellectual property pro
tection for authors of original works. Generally
the categories of works that are protected are:

• literary works
• musical works, including words accompa
nying music
• dramatic works
• pantomimes and choreographic works
• pictorial graphic and sculptural works
• motion pictures and other audiovisual
works
• sound recordings
• architectural works
A copyright protects an original work and al
lows the author an exclusive right to:
• reproduce the work exclusively
• prepare derivative works
• distribute copies or phonorecords by sale,
transfer of ownership, lease, rent or lend
• perform the work publicly
• display
An original work of authorship is immedi
ately protected by copyright after it is fixed in a
tangible medium. The duration of a copyright
protection on or after 1978 is that of the author’s
lifetime plus 70 years. If there are two or more
authors, the term is 70 years after the death of
the last surviving author. If the creation is a work
for hire, and the works are created anonymously,
the duration is 95 years from publication or 120
years from creation, whichever is shorter.
Only the author, or those deriving rights
from the author, can claim the copyright. A copy
right requires no registration or publication to be
protected, but a copyrightable work is protected
automatically when the creation is fixed in a tan
gible form.
Importantly, federal copyright registration is
a legal formality intended to make a public re
cord of the basic facts of a particular copyright.
Copyright registration may be filed at any time
during the life of a work. Even if registration is
not a requirement for protection, registration
brings several advantages. For example, before
an infringement suit may be filed in the court,
registration is required for a work of U.S. ori
gin. Moreover, if registration is filed within five
years of publication of the work, the registration
will establish prima facie evidence, in court, of
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validity and of the facts stated in the copyright
certificate. Registration makes available to the
copyright owner statutory damages and attorney
fees, in case of an infringement suit, if the regis
tration was made three months after publication
of the work or prior to an infringement of the
work. Registration also enables the U.S. Customs
Service to protect the copyright owner against
importation of infringing copies.
To be copyrightable, a work has to be original
and in a fixed medium. This means that a work
has to be the independent creation of an author
and that it has required a modest quantum of cre
ativity. Being in a “fixed medium” means that the
creation is in a tangible form: a short story is writ
ten down, a song is recorded, and so on. A pure
idea or concept cannot be copyrighted without
description or illustration.
An important question is whether software
and databases can be protected. The last decades
have seen a revolution in knowledge manage
ment, library services, and information-resource
database configurations. The use of integrated
computer networks and the ability to produce
and distribute information have had far-reach
ing implications for IP (intellectual property)
protection. In order to demonstrate IP laws and
their application, another chapter discusses these
aspects together with respect to geographic infor
mation systems and remote sensing.18
As mentioned earlier, the author of a work
owns the copyright. In a case of work for hire the
employer is regarded as the author and, therefore,
the employee does not own the copyright. A work
for hire is defined in copyright law as a work pre
pared by an employee, within the scope of his or
her employment, or a work specially ordered or
commissioned for use as a contribution to a col
lective work, a part of a motion picture or other
audiovisual work, a translation, a supplementary
work, a compilation, an instructional text, a test,
answer material for a test, or an atlas, if the par
ties expressly agree in a written instrument signed
by them that the work shall be considered a work
made for hire.
Copyright protection subsists from the time
the work is created in fixed form. The owner
of a copyright can assign all his or her rights
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unconditionally to another. Alternatively, the
owner can license the rights exclusively or nonexclusively. If, at the time of creation, the authors
intend to combine their contributions into insep
arable or interdependent parts, the work is con
sidered joint work and the authors are considered
joint copyright owners. Each copyright owner has
an equal right to exploit her or his rights. In such
a case, a company can license or get an assign
ment for the copyright of the whole work from
only one of the authors. If at the time of creation
the authors did not intend their works to be part
of an inseparable whole, the fact that their works
are later put together implicates the work as a col
lective work. In such a case, each author owns a
copyright in only the material she or he added to
the final product. In this case, the company needs
to have an agreement with each of the authors to
convey the copyrights.
It should be noted that in countries of the
European Union, greater protection of data
bases is provided than in the United States. The
European Union Database Directive adopted by
the European Parliament in 1996 sets out two
rights for the makers of databases:
• the right to prevent unauthorized acts of
extraction from a database
• the right to prevent unauthorized acts of
reutilization of the contents of a database
The first right is similar to that provided un
der the U.S. Copyright Act. With this right the
directive provides protection to a database but not
to the underlying data, and the right is limited
to databases containing a sufficient degree of cre
ativity in the selection or arrangement of the data.
The second right, however, provides for a sui ge
neris right that prohibits the extraction or reuti
lization of any database in which there has been a
substantial investment in obtaining, verification,
or presentation of the data contents. Under this
second right, there is no requirement for creativi
ty or originality. The protection is available for 15
years from creation of the database. If substantial
changes are made to the content of the database,
the modified database will be protected a new
term of 15 years. Protection under the directive
is available only to nationals of member countries
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of European Union. Other countries will obtain
such protection only if they offer comparable
protection to databases of a European national
and if a bilateral agreement is reached.
In the U.S. Copyright Act, there is a fair
use exception that states that use of an author’s
original creation is authorized for the purposes
of criticism, comment, news reporting, teaching,
scholarship, or research. Fair use takes into con
sideration the purpose and character of the use,
the nature of the copyrighted work, the amount
and substantiality of the portion used in relation
to copyrighted work as a whole, and the effect of
the use on the potential market. There are four
aspects to the fair-use exception:
1. Classroom use. Certain educational estab
lishments are allowed to publicly display
and perform others’ works in the course
of face-to-face teaching activities. But this
exemption applies only to the use of legally
acquired works.
2. Copying in a library. In academic and
research institutions, copying limited por
tions of certain copyrighted works19 is not
an infringement, provided that libraries (or
their users) make single copies of the works,
provided that all of the following apply:
− only individual articles (for example, of a
book) or small portions of a larger work
be copied
− the copies become the property of the
person making the copies
− the copies are used for private study,
scholarship, or research
− the copying is not done for commercial
advantage
− the library displays prominently a notice
warning of copyright restrictions in ac
cord with requirements published by the
U.S. Copyright Office20
Finally, it should be noted that no “interna
tional copyright“ exists. But since most countries
offer protection to foreign works under simplified
international copyright treaties and conventions,
a rule of thumb is that if a work could be pro
tected as a U.S. domestic work, it is protected as
a foreign work. There are cases, however, where

foreign copyright law is less restrictive than the
U.S. code, so the work may still be protected even
though in the United States the work would be in
the public domain.

6. TRAdE SECRETS
.1 What can be a trade secret?

Trade secrets are an important and widely used
business asset in the United States. Both small
and large businesses rely on trade secret protec
tion, often without even realizing it. It has been
estimated that 90 percent of inventions are pro
tected by trade secrets.
There are various kinds of trade secrets. The
most popular example of a trade secret is the for
mula for Coca Cola, which has been kept suc
cessfully in secrecy now for more than 100 years.
In addition to chemical formulas or processing
methods, trade secrets can involve software, ac
counting records, customer lists, plant designs,
and so on. Although trade secrets may overlap
with patentable subject matter, they go well be
yond that.
A generally accepted definition of a trade
secret appears in the 1939 Restatement of Torts.
The subject matter of a trade secret must be se
cret. Matters of public knowledge or of general
knowledge in an industry cannot be appropri
ated by anyone as a secret, nor can matters that
are completely disclosed by the goods one markets
be trade secrets. Therefore, a trade secret is known
only in the particular business in which it is used.
.2 How are trade secrets protected?

Intentional theft of trade secrets can constitute a
crime under both federal and state law. The most
significant federal law dealing with trade secret
theft is the Economic Espionage Act (EEA) of
1996.21 The EEA applies not only to thefts that
occur within the United States, but also to con
duct outside the United States, if the thief is a
U.S. citizen or corporation, or if any act in fur
therance of the offense occurred in the United
States. All of the 50 U.S. states have enacted trade
secret laws, most of which are some version of the
Uniform Trade Secret Act (UTSA).
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. To file a patent or to keep a trade secret?

Before filing a patent one should always consider
the possibility of keeping the invention in secre
cy, because there are situations when one of these
two protection methods is more useful than the
other.
There is no limitation in the time that a trade
secret can protect the invention. On the contrary,
a patent is normally enforceable for a period of
20 years after the filing. If the subject matter is
easy to keep in secret, if there will be no products
being marketed that could be used to reverse en
gineer the trade secret, then keeping trade secret
might be worth considering.
Sometimes it is very difficult to prove that
someone has infringed a patent. For example, in
fringement of a patent on a laboratory method
might be difficult to prove, and, therefore, keep
ing the method as a trade secret might be a better
means of protection.
In order to be patentable an invention has
to be useful, novel, and nonobvious. There are
no such requirements for trade secrets. The only
“usefulness” requirement for a trade secret ac
cording to the Restatement of Torts § 757, is that
“it confers the owner an opportunity to obtain an
advantage over competitors who do not know or use
it.” Therefore, an improvement or a variation of a
method, for example, can be a trade secret, but it
might not be patentable. The field of trade secrets
is much wider than that of patents.
. Misappropriation of trade secrets

Based on the definition given in the 1939
Restatement of Torts, one who discovers a trade
secret properly, for example, by analyzing a com
mercial product embodying the secret, reverse
engineering the secret, or by independent inven
tion, is free to disclose it or to use it in his or her
own business without liability to the owner. The
cases rising from trade secret misappropriation
are basically of three types:
1. Cases in which a trade secret is learned
by improper means, as through industrial
espionage
2. Cases in which an employee knowing a trade
secret is hired by a competitor to whom the
employee discloses the trade secret, or the
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employee knowing the trade secret begins
his or her own business basing it on the
trade secret
3. Cases in which a trade secret is disclosed
during licensing negotiations, and the li
censee later refuses to pay royalties but con
tinues to use the trade secret22

. oWnERSHIp of RIGHTS
Ownership of rights is an important question with
regard to licensing and transfer of the rights to
another party. It may be that there are some rights
belonging, for example, to an employee of an or
ganization, that might interfere with the interest
of the organization to license the rights further.
In order to prevent misunderstandings related to
such situations, it is worthwhile to think how the
technology was created: Did the organization hire
a consultant? What were the conditions of the
agreements? Who sponsored the research? Where
are the inventors now?
.1

Ownership of patent rights

Employed to invent. As a general rule, the inventor
owns the patent rights to the subject matter of his
or her invention, even if the inventor conceived it
or reduced it to practice during his or her employ
ment. The main exception to this rule is the em
ployed-to-invent-exception. An employer owns the
invention of the employee if the employee was em
ployed to invent something or to solve a problem.
Shop right. When an employee makes an
invention or discovery that is outside her or his
employment, but she or he uses the employer’s
resources, the invention may be owned and pat
ented by the employee, but the employer has a
shop right to the invention. A shop right is a roy
alty-free, nonexclusive, nontransferable, impliedin-law license granted to an employer to use the
employees patented invention.
A shop right exists for the life of a patent,
regardless of whether the employment contin
ues or not. The employer having a shop right
can make, use, and sell articles embodying the
patented invention. The employer may, however,
not sell articles outside his or her normal range
of business.
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Joint inventors. In the Code of Federal
Regulations, the term joint inventor is defined as
one who “must have made a contribution, individ
ually or jointly, to the subject matter of at least one
claim of the application.” To be legally named as an
inventor, a person must have contributed to the
discovery of the way of obtaining the wished-for
results. Creating the idea of the general wishedfor result desired is not, by itself, sufficient to
constitute joint invention.
It is important to remember that any patent
with a named inventor who cannot meet the legal
test for the minimal requirement of inventorship
will lead to that patent becoming invalidated.
Similarly, if all joint inventors are not named, the
patent is invalid.
In absence of an assignment of the patent,
the joint inventors are co-owners of the patent.
Each of the co-owners has all the rights of a pat
ent owner. This means that each of them may
make, use, or sell the patented invention without
the permission of or the need to account to the
other joint owners.
.2

Ownership of copyright

As a general rule, a person who creates a work is
the author and therefore owns the rights to the
work. However, a work made for hire is an excep
tion to this rule. If an employee within the scope
of his or her employment prepares a work, the
employer and not the employee is considered to
be the author.

8. pRoTECTInG THE oRGAnIzATIon’S Ip
.1 Notebook keeping

Under U.S. law, a patent is granted to the first to
conceive the idea for an invention, not to the per
son who first files a patent application. Because
of the first-to-invent concept, a notebook must
be able to serve as essential evidence of the date
of conception. In a case of interference, the note
book might also be essential for proving diligence
in developing the invention after the conception.
For these purposes proper notebook keeping is
important.23 All notebook entries should be made
with permanent ink. The pages of the notebook

should be numbered and filled consecutively, with
no intervening pages left blank. Someone able to
understand the work, but not participating in it,
should witness all of the entries.
.2 Employee agreements

Employees make the majority of inventions pat
ented in the United States. Therefore, it is im
portant for an organization to establish practices
related to inventions made by its employees.
Employee agreements often contain clauses that
require protection of trade secrets and confiden
tial information, require the employee to assign
inventions to the employer, require the employee
to cooperate in disclosing inventive activity, and
require the employee to cooperate in patent-pros
ecution activities. Employee agreements can also
include trailer clauses requiring the employee to
assign inventions made for a certain period after
leaving employment.
Some states have recently enacted state stat
utes attempting to prevent an employer from
abusing his or her unequal bargaining power. The
statutes are limiting the type of inventions that
an employer can contractually require an inven
tor to assign.
. Marking the protected intellectual
property

Patent marking. Patent law gives a patent owner
an option to mark the patented product. Marking
the product is not required, but owner failure to
mark a patented product may raise a risk that the
owner would not be able to collect damages from
infringers during the time the product was not
marked. An appropriate way to make the mark
ing is: U.S. Patent No 5,555,555 or U.S. Pat.
No. 5,555,555. After obtaining a filing date one
can also use the marking: Patent Pending or Pat.
Pending.
Trademark marking. The designation TM
indicates that a particular word, symbol, or logo
is considered by its user to function as a trade
mark. Similarly, the designation SM indicates a
service mark.
When a mark becomes registered with the
U.S. Patent Office, the designation should change
from TM or SM to the registered-mark symbol,
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. Instead of this symbol, the mark owner can
use the designation Registered in the U.S. Patent
and Trademark Office or Reg. U.S. Pat & TM off.
A marking Registered trademark is not appropriate
because it could be misleading by not indicating
where the mark is registered. It is important to
indicate that the mark is registered with the U.S.
Patent and Trademark Office, because the law
provides that the owner of the mark is precluded
from recovering profits and damages unless it can
be established that the defendant had actual no
tice of the registration.
Copyright marking. The copyright symbol,
, or the designations Copr. and Copyright are the
proper legal notices for copyright protection. The
copyright notice is usually included directly on
the product or product label and typically takes
this form:
 ABC Corporation 2007.
or
© MIHR and PIPRA. All Rights Reserved.
Failure to include the notice of copyright
once was, but is no longer, fatal to the owner’s
rights. Before the United States acceded to the
Berne Convention, the author lost his or her
rights if failing to include notice of copyright.
It is still good practice, however, to include the
traditional copyright notice where applicable.
Very often a copyrighted work carries the notice
All Rights Reserved, in addition to the copyright
symbol. This is because the All Rights Reserved
designation is required under the Buenos Aires
Copyright Convention, which is important in
several South American countries.

. InTEGRATIon of Ip RIGHTS
A question that often comes up is whether a
party can one have a patent and a trade secret
simultaneously? At first sight it might seem that
patents and trade secrets would exclude each
other: patent application will become public, at
the latest, when the patent is issued, and trade
secret has to be kept in secrecy. Furthermore,
the patent law requires the patent applicant to
disclose the best mode of the invention in the
patent application. It seems as if there would
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be no room for trade secret if one has filed a
patent.
This, however, is not the case. One can have
a patent and also keep trade secret. One very
common situation is that after filing a patent, the
invention has been developed further and after
filing, the development is kept secret. The pat
ent law requires the inventor to disclose the best
mode known when the patent is filed, but there
is no requirement to disclose any improvements
made later. In addition, sometimes trade secrets
can be “negative know-how.” For example, in
formation learned during research and develop
ment that shows some formula or process does
not work can be kept as a trade secret. It has
been estimated that 80 percent of all license and
technology transfer agreements cover proprietary
know-how or trade secrets.
Importantly, trademarks can prolong the pro
tection of a patented good. The life of a patent is
usually 20 years, while there is no limit to the life
of a trademark as long as it is used. Many compa
nies use trademarks to prolong the protection of a
patented good. During the lifetime of the patent,
the product is well protected, but if the company
has also trademarked the product, the public will
recognize the patented product also after expira
tion of the patent. When filing a trademark for a
patented product, the applicant should, however,
remember that one cannot get trademark protec
tion for any functional features.

10. Ip InfRInGEMEnT
Patent infringement can be either direct or indirect.
Direct infringement is either literal or it takes place
under the Doctrine of Equivalents. Direct infringe
ment occurs when a party makes, uses, offers to sell,
or sells any patented invention, within the United
States, or imports the patented invention in the
United States during the patent term without the
patentee’s authorization during the term of patent.
An infringement is literal when every limita
tion recited in any claim in the patent appear in
the alleged infringing product or process. If the
alleged infringing product or process is missing
on one of the claim limitations, there is no literal
infringement.
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In a case where the accused product or pro
cess is missing a component or step of the claims,
there can still be direct infringement, if the ac
cused product or process has a component or step
that is insubstantially different from the missing
one. Such a case is known as infringement under
the Doctrine of Equivalents. In such a case, the
alleged infringing device (or method) substantial
ly performs the same function, in the same way,
with the same result as the patented invention.
In addition to direct infringement, the pat
ent law describes indirect infringement. Indirect
infringement can be either induced infringement
(knowingly aiding another in an act of infringe
ment; aiding and abetting infringement) or a
contributory infringement (knowingly selling an
article that has no other use than as part of a pat
ented invention).24
A copyright is infringed if the defendant cop
ied from the plaintiff’s copyrighted work. A plain
tiff can prove copying through direct evidence of
copying, or through circumstantial evidence that
the defendant had access to the plaintiff’s work
and the work is substantially similar to the work
of the plaintiff.

11. So I HAvE InTELLECTuAL pRopERTy.
noW WHAT?
Evidently, intellectual property is really only use
ful if indeed the invention is used, applied, and
incorporated into a productive process. This can
be done either by those who own it or by au
thorized third parties, called licensees. Inventing
something new is important. Protecting such an
invention might also be important. But bringing
an invention from “bench to bedside” is undis
putedly the most important. For this, IP protec
tion might not always be the most efficient way as
other chapters in this Handbook suggest.25 Equally
important are the complex decisions regarding
when, to whom, and how to license intellectual
property in order to optimize both economic and
humanitarian value.26 Suffice it to say that the
form of protection chosen for a given invention
should be guided by the mission of the institution
and the purpose of the work conducted, as well as
by the specific subject of the invention. n
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35 U.S.C. 101.
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Diamond v. Chakrabarty. 447 U.S. 303 (1980).
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establish the concept of business-method patents. As
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patents.
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35 U.S.C. § 102(a).

12 Rosaire v. Baroid Sales. Div. 218 F 2d 72.
13
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Somersalo, SP Kowalski and A Krattiger.
19 Musical works, graphic, pictorial or sculptural works,
motion pictures, or other audiovisual works are not
included in this exception.
20 Note that libraries may make copies of entire works if
the work cannot be obtained after a reasonable search
and at a reasonable price. This exemption is also the
basis of the fair-use doctrine that libraries may copy
and place materials on course reserve.
21 18 U.S.C. §§ 1831–1839.
22 For further information on trade secrets, especially
the licensing of trade secrets, see, in this Handbook,
chapter 11.4 by KF Jorda.

HANDBOOK OF BEST PRACTICES | 

DODDS & KRATTIGER

23 See, also in this Handbook, chapter 8.2 by JA Thomson.
24 See, also in this Handbook, chapter 17.26 by M
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25 For example, see, in the Handbook, chapter 10.1 by S
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CHAPTER 4.2

How to Read a Biotech Patent
CAROL NOTTENBURg, Principal/Patent Lawyer, Cougar Patent Law, U.S.A.

ABSTRACT

This chapter provides an annotated description of a sam
ple U.S. patent. The U.S. patent is a convenient model
because its format is well laid out and is similar to the
required formats of patents granted in other major juris
dictions, including Europe.

INTRODuCTION
A patent is an exclusionary grant of intellec
tual property (IP) rights, typically awarded by
a government through a patent office, and ef
fective for a limited period of time. Article 28
of the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS), bind
ing for member countries of the World Trade
Organization (WTO), states that a patent owner
has the right “to prevent third parties … from the
acts of: making, using, offering for sale, selling or
importing” the protected product. If the protect
ed invention is a process, the owner can prevent
third parties not only from using the process, but
also from using, offering for sale, selling, or im
porting “at least the product obtained directly by
that process.” It is important to note that under
TRIPS the patent owner does not have the right
to practice her or his invention, only the right to
prevent others from practicing it.
The TRIPS Agreement requires the time
limit of the patent (patent term) to be at least
20 years. Most countries allow a 20-year term,

starting from the date on which the application
for the patent was first filed. Extensions of the
patent term may be available in cases of regula
tory or patent office delays that were imposed be
fore a product is commercialized. Significantly, a
patent grant is only legally binding in the country
in which it was awarded.

2. PATENT PuBlICATION
Box 1 (at the end of this chapter) contains the
front page of U.S. Patent No. 6,551,586,1 and
Box 2 contains extracts of U.S. Patent No.
5,723,765 (hereafter referred to as “the ’765
patent”).2 A cursory review of the ’765 patent
reveals that it has three main sections:
• a front page, which presents bibliographic
information (Box 2a, also at the end of this
chapter),
• text, which describes the invention (Box
2b), and
• claims, starting in column 35 (Box 2c),
which define the limit of the protected
invention.3
2.1 Cover Page

The cover page primarily contains bibliographic
information, historical facts about prior patent
applications, and identifying elements, none of
which has any legal import for interpreting the

Nottenburg C. 2007. How to Read a Biotech Patent. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
Available online at www.ipHandbook.org.
© 2007. C Nottenburg. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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patent. The bracketed number adjacent to each
data subsection is used by the patent office for
internal identification purposes.
At the top of the cover page is the vital iden
tification of Patent No. 6,551,586 (Box 1):
[12] nature of the publication. In this case,
United States Patent and, below, the first
inventor’s name, Davidson et al.4
[10] patent number. In the United States, the
patent number is sequentially assigned by
the patent office. Prior to early 2000, the
patent number was the only publication
number.5
[45] date the patent was issued. This date (in
this case, Apr. 22, 2003) is important for
two reasons: (1) if the patent was not pub
lished as a patent application, then this is
the date it became public knowledge and
thus prior art for non-U.S. jurisdictions;6
and (2) in the case of applications filed
in the United States prior to the General
Agreement on Tariffs and Trade (GATT)
treaty (8 June 1995), as in this example, it
is the date that initiates the patent term.7
The remainder of the front page presents the
main bibliographic data:
[54] title of the patent. Should be representative
of the content, is written by the inventors
or their attorney and has no impact on the
interpretation of the patent. In many cases,
the title is wishful thinking.
[75] inventor(s)’ name(s) and place(s) of resi
dence. For patent purposes, the order of
the names is not important; the applicant
determines the order, not the patent office.
In the United States, the inventors and their
assignees (see below) can independently
practice or license all of the patent rights
without the permission of the other inven
tors. It is important to note that Australia
and Europe, among other countries, have
the opposite rule: an inventor cannot prac
tice or license patent rights without the
permission of the other inventors.
[73] assignee(s) and his/her/their place(s) of
business.8 An assignee is an owner of the
patent because an inventor or inventors
2 | HANDBOOK OF BEST PRACTICES

[21]
[22]

[63]

[60]

[51]

have signed over the rights to the inven
tion. Typically, an inventor who is also an
employee in a company or university is ob
ligated to formally assign invention rights
to the employer. In the United States, such
assignment documents are recorded by the
patent office and are publicly accessible,
once the patent application is published.
The identity of the owner of a patent is
public knowledge, but the identity of those
who have licensed a patent is not necessar
ily available to the public.
application number. Assigned by the pat
ent office
filing date of the subject patent applica
tion. If there are no related U.S. applica
tion data (see below), this date is used to
determine the beginning of the 20-year
patent term.
related applications. It is from these re
lated applications that the patent claims
priority. The United States is unusual in
allowing applications to be refiled, either
with or without new disclosure. A refiled
application is called a continuation, or, if it
contains new disclosure, a continuation-in
part. U.S. Patent 6,551,586 was filed on
27 November 1998 (field 21); however, an
earlier application filed on Jan. 29, 1996
(serial number 08/593,006) contained at
least some of the disclosure of the subject
patent; in other words, this patent is a con
tinuation-in-part of the earlier application.9
As the patent term begins from the filing
date of the earlier application, this patent
expires on 29 January 2016.
provisional applications. The filing date
of a provisional application does not af
fect the patent term, but it is critical for
considering prior art that might affect
patentability.
International Patent Classification (IPC)
code. A combination of letters and num
bers.10 A patent application’s IPC code is
assigned by the national or regional patent
office that publishes it. The IPC is an indis
pensable tool for patent-issuing authorities,
potential inventors, attorneys, and others
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[52]
[58]
[56]

[74]
[57]

concerned with the application or develop
ment of technology.
U. S. Classification Code. Assigned by the
U.S. Patent Office.
field of search. Contains the U.S. classifica
tion codes that the examiner used to per
form searches for prior art.
references. Subdivided into U.S. patent
documents, foreign patent documents, and
other publications that the examiner con
sidered when evaluating the patentability
of the claimed invention.11
[no number] examiners. The names of the
primary examiner at the patent office and
the assistant examiner (if any).
attorney, agent, or firm. Representatives of
the inventor or assignee.
abstract. A short description of the inven
tion written by the applicant(s). The ab
stract enables the patent office and the
public to quickly determine the content of
the patent. Although the “abstract shall not
be used for interpreting the scope of the
claims,” courts have taken it under consid
eration on one or two occasions.12
[no number] number of claims and draw
ings. In this patent, there are eight claims
and 13 drawings.

2.2 Text of the patent

The text of the patent is also called the disclosure
(In the United States, it may also be called the
specification). According to the TRIPS Agreement,
the invention must be disclosed “in a manner suf
ficiently clear and complete for the invention to be
carried out by a person skilled in the art” (Article
29.1). Each country specifies its own require
ments; the U.S. Patent Office requires a written
description of the invention, a so-called enable
ment, and a so-called best mode.13
The layout of the patent varies somewhat
from country to country. The United States and
Europe have a similar required layout, except that
(b) and (c) below are unique to the United States:
a. title of the invention
b. cross-reference to related applications
c. statement regarding federally sponsored re
search, if applicable

d.
e.
f.
g.
h.

background of the invention
summary of the invention
description of the drawings
detailed description of the invention
listing of relevant nucleotide and peptide
sequences
i. claims defining the scope of the invention
2. Background of the invention

The background is typically drafted for the patent
examiner and a jury audience, in case the patent
is ever litigated. It compares selected art in the
field with the current invention and explains why
the current invention is necessary. As one can see
from downloading the full patent (and the extract
on Box 2b), a large part of the background of the
’765 patent explains the technologies of several
relevant references.
2. Summary of the invention

The summary of the invention is distinct from the
abstract and summarizes the scope of the inven
tion (the claims). It often discusses the advantages
of the invention or explains how it solves prob
lems existing in the art.
The summary of the ’765 patent discusses
the invention as embodied in the claims. It also
describes the specific advantages of the invention
(see, for example, col. 1, lines 61–64; col. 2, lines
1–6; and col. 2, lines 51–54; not shown here).
The inventors believe that the advantages of their
invention include: positive control of gene expres
sion by an external stimulus without the need for
continued application of the stimulus, the ability
to grow plants under various conditions with ex
pression of different phenotypes, and the ability
to develop seed where a trait is desirable only in
the first or in subsequent generations.
2. Detailed description of the invention

The detailed description of the invention is the
most substantial section of the patent. It is made
up of two sections: the first section (col. 2, line
58–col. 8, line 40) explains the invention and how
to practice it; the second section (col. 8, line 43
to col. 20, line 33) provides specific examples of
the invention. Many new readers mistakenly as
sume that examples are intended to delineate how
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the invention must be practiced or used, but this
is not the case. The examples are merely meant
“to illustrate, but in no way to limit, the claimed
invention.” While examples are not required by
the patentability statutes, in practice the enable
ment requirement is difficult, if not impossible,
to satisfy for biotechnology inventions without
examples.
Paragraphs 1 and 2 describe the broadest
concept of the invention, explaining how DNA
constructs are used to create transgenic plants
and then describing how the invention works to
control gene expression.
Paragraphs 3–11 (col. 4, lines–1-39) set forth
some definitions of key terms. Definitions are ex
tremely important in interpreting the scope of
the claims. For example, this patent defines the
term “plant-active promoter” as “any promoter that
is active in cells of a plant of interest.” The pro
moter can be derived not only from plants, but
also from viruses, bacteria, fungi, and so on. This
list only provides examples of sources from which
promoters can be derived and the inventors do
not intend it to be exhaustive.
The next three paragraphs (col. 4, line 10–
col. 5, line 47) describe preferred embodiments
of the invention. These are usually more limited
versions of the broadest concept. They provide a
“safety net” for the inventors in case the broader
concept is not patentable.
In paragraph 12 (col. 4, line 10), the pre
ferred embodiment is a “transiently-active pro
moter” (active only in late embryogenesis) and
a “gene linked to this promoter” that is a “lethal
gene.” The next two paragraphs describe an em
bodiment in which a pair of transgenic plants is
crossed to produce progeny that display an al
tered phenotype, and an embodiment in which
the recombinase is linked to an inducible pro
moter. In addition, the paragraph provides a few
examples of inducible promoters.
The next several paragraphs (col. 5, line
48–col. 7, line 48) define and give examples of
some of the important elements of the claim
(transiently active promoters, genes whose ex
pression results in a detectable phenotype, lethal
genes, blocking sequences, repressor and re
pressible promoters, and recombinase/excision
 | HANDBOOK OF BEST PRACTICES

sequences). These paragraphs support the scope
of the inventors’ claim. In col. 6, lines 47-60,
the inventors define “lethal gene,” then provide
a single example (saporin-6, which acts by cleav
ing the large ribosomal RNA molecule and thus
inhibiting protein synthesis). Overall, the disclo
sure in this patent is relatively thin.
The next four paragraphs (col. 7, line 49–col.
8, line 29) discuss the techniques that can be used
to transform the target plant (col. 7, lines 62-65).
This is a classic style of patent drafting and clearly
indicates that the actual method used for trans
formation is not critical. Other methods of in
troducing the DNA constructs are described in
paragraphs 21–23.
Finally, paragraph 24 (col. 8, lines 30–40)
discusses suitable plant species. The inventors do
not believe that the process they describe need be
limited to particular species.
The next section presents the examples.
Typically, the examples show how one or more
specific embodiments of the invention could be
put into practice. The examples may or may not
be based on successful experiments performed
by the inventors. If the experiments have been
performed, the examples are called “working” ex
amples; if not, the examples are called “prophetic”
examples and are always written in the present or
future tense. In the ’765 patent, examples 1–6
(Box 2c) describe the cloning of three DNA se
quences: (1) a lethal gene, saporin-6, under control
of a late embryogenesis promoter, and separated
by a blocking sequence, LOX; (2) a tet repressor
gene under the control of a CaMV 35S promoter;
and (3) a CRE (recombinase) gene under the con
trol of a tetracycline-derepressible 35S promoter.
Examples 7–10, which describe the introduction
of the constructs into plants and activation of the
system are written in a future tense because the
relevant experiments were not performed as of the
filing date of the application.
2. Sequence listing

The sequence listing includes all nucleic acid
molecules mentioned in the patent application
that are comprised of at least 10 nucleotides and
all peptide sequences comprised of at least four
amino acids.
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2. Claims

The claims must “particularly point out and dis
tinctly claim the subject matter which the appli
cant regards as his invention.”14 The claims define
the boundaries of the patent owner’s right against
possible infringement.
Each claim must be written as a single sen
tence. A claim is presented in two parts, the pre
amble and the body, with a transition word or
phrase between them.
• The preamble is an introductory statement
that names the subject of the claim. For ex
ample, the preamble of claim 1. is: “A method
for making a genetically modified plant.”
• The body of the claim describes the ele
ments or steps that compose the claimed
subject. In claim one, the body of the claim
consists of the steps of “stably transforming
…” and “regenerating …”
The transition words or phrases between
the preamble and the body of the claim indi
cate whether the claim encompasses at least the
listed elements or steps or whether the claim en
compasses only the listed elements or steps. The
transition word comprising means “including the
following elements but not excluding others.”15 In
claim one of the ’765 patent, comprising is used
in two places: (1) in the preamble (“A method...
comprising …”) and (2) in the body (“a … DNA
sequence comprising …”). If someone were to use
the patented method with small changes—addi
tional steps or a DNA sequence with additional
elements, for example—he or she would still be
infringing on the claim.
In contrast, the transition “consisting of ”
limits the claim scope to the recited elements or
steps. If the claim were “a DNA sequence con
sisting of ACGTGC,” a person would be able to
make the DNA sequence “ACGTGCTA” with
out infringing on the claim.
The meaning of the transition phrase con
sisting essentially of falls somewhere between the
other two. It indicates that the patent does not
regulate the use of variables that do not affect
the basic and novel characteristics of the meth
od or product. It is not often used in biotech
nology patents.

Furthermore, there are two kinds of claims:
independent and dependent. An independent
claim (for example, claims 1, 10, 19, 28, 37, 46,
and 55) includes all necessary limitations and
does not depend on nor include limitations from
any other claim. Curiously, although dependent
claim is defined in the patent rules of the United
States, independent claim is not. U.S. patent rules
state that a dependent claim must “refer[s] back
to and further limit[s] another claim or claims.”16
Moreover, a dependent claim “shall be construed
to include all the limitations of the claim incorpo
rated by reference.”17
Claim 4. of the ’765 patent is an instructive
dependent claim. Since claim 4. depends upon
claim 1., the transiently active promoter is lim
ited to the LEA promoter. All other elements of
claim 1. remain intact and are not limited any
further.
Dependent claims serve several very impor
tant purposes. In the first place, they help with
so-called claim differentiation: in patent law, no
two claims can have the same scope. Therefore,
the transiently active promoter in claim 1. must
encompass more than the LEA promoter men
tioned in claim 1.; otherwise, claims 1. and 4.
would have the same scope. Dependent claims
are also written to protect specific embodiments
of an invention. Should the main claim fail in a
court case, a dependent claim may still stand. In
addition, it is easier for a jury to have the alleged
infringing activity clearly spelled out.

3. CONCluSION
Patent documents contain substantial information
that has value to researchers, even if infringement
isn’t an issue. While many patent documents are
readily available on the Internet for free—gener
ally from patent offices—they may not always be
capable of being understood or appreciated. One
reason for inaccessibility is that patent applica
tions are written in a special style that does not
follow the conventions of scientific or technical
literature. To understand a patent document, a
roadmap helps until the route is familiar.
This chapter provides a roadmap for read
ing a patent document. The various sections of a
HANDBOOK OF BEST PRACTICES | 

NOTTENBuRG

document are explained in view of their purposes.
The purposes especially delineate the amount and
type of reliance that can be made of each of the
sections. Each section contains its own set of use
ful information. The importance of the claims is
paramount for knowing the boundaries of the
patent right, however, interpreting claims re
quires more of a roadmap than this chapter pro
vides. Even without a full appreciation of claim
boundaries, much information may still be ob
tained from patent documents. n
CAROL NOTTENBURg, Principal/Patent Lawyer, Cougar
Patent Law, 814 32nd Ave. South, Seattle, WA, 98144,
U.S.A. carol.nottenburg@cougarlaw.com

1

patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&S
ect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPT
O%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,551,586.
PN.&OS=PN/6,551,586&RS=PN/6,551,586.

2

patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&S
ect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPT
O%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,723,765.
PN.&OS=PN/5,723,765&RS=PN/5,723,765.

3

More typically, patents contain four sections with
drawings comprising the last section.

4

In the United States, a patent application must be
filed for in the name of the inventors. In most of the
rest of the world, patent applications can be filed for
in the name of the inventors or in the name of the
assignee(s).

5

Patent applications are generally published 18 months
after the earliest priority application date. Depending
on the country, the publication number may or may
not differ from the patent number. If the numbers
are the same, a suffix is usually used to denote the
status of the application. For example, in Europe, the
publication and patent numbers are the same, but the
suffix A is used to indicate an application and B is used
to indicate an issued patent.

6

In the United States, inventions that are disclosed but
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not claimed are prior art against other U.S. applications
and patents, as of their filing date. 35 U.S.C. § 102(e).
7

Before the GATT treaty implementation, the patent
term in the United States was 17 years from the date of
issuance. Under GATT, the patent term is 20 years from
the earliest claimed priority date.

8

An assignee in the United States is called an applicant
in the rest of the world.

9

Priority applications determine both patent term and
which prior art can be applied in a patent examination.
A particular claim has a priority date as of the earliest
application that contains the patentable subject
matter. Art available after the priority date cannot
be cited against the claim. In practice, U.S. examiners
rarely determine the priority date of a claim, whereas
European examiners frequently review priority
applications to determine priority dates of claims.

10 The IPC system is a hierarchical classification system
administered by the World Intellectual Property
Organization. For more information on international
classifications and IPC, see WIPO’s Web site at
www.wipo.org.
11 In the United States, each individual associated with
the filing and prosecution of a patent application (for
example, inventor, patent attorney, assignee) has a
duty to disclose all material information to the patent
office.
12 37 C.F.R. 1.72(b).
13 The written description shows that the inventor has
the invention in mind. The enablement describes the
invention clearly enough that one skilled in the art
can understand it, make it, and use it without undue
experimentation. In the best mode, an inventor
discloses the most effective method of practicing or
using the claimed invention. The patent office does
not ask applicants whether or not they have disclosed
the best mode, a question which usually only arises
during litigation.
14 35 U.S.C. § 112.
15 Equivalent words are having and including, but most
practitioners use comprising because it has become a
standard term of art.
16 37 C.F.R. 1.75(c).
17 See supra note 16.

CHAPTER .2

Box 1: Sample Front Page of Issued u.S. Patent
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Box 2a: Front Page of Patent No. 5,723,765
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Box 2b: Extract of Patent No. 5,723,765 Describing the Invention
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Box 2c: Extract of Patent No. 5,723,765 Containing the Claims
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CHAPTER 4.3

Trademark Primer
WILLIAM NEEdLE, President and Founder, Needle and Rosenberg PC, U.S.A.

ABSTRACT

Trademarks, in the broadest sense, encompass a range
of indicators for goods and/or services, including ser
vice marks, collective marks, certification marks, trade
names and trade dress. A trademark, which may be a
name, symbol, feature, or design, functions as an indi
cator of source and identifies and distinguishes a good
or service, enabling customers to ascertain the quality
of the good (or service) based on the trademark. Unlike
other forms of intellectual property rights (for example,
copyrights and patents), the rights extended by trade
marks are not generated from the creative activity of
an author or inventor, but rather via their use in com
merce, and it is the customer’s association of the trade
mark with a specific product (or service) that is the key
factor in establishing rights. The relative effectiveness
of a trademark depends on its degree of distinctiveness.
By way of classifying trademarks, a hierarchy based on
strength of protection, from fanciful to merely descrip
tive, has been established. Whereas fanciful trademarks
are inherently distinctive because they are terms invent
ed solely for a specific purpose (for example, Kotex),
descriptive marks (for example, Chap-Stick) must ac
quire secondary meaning to become protectable. In the
United States, trademarks are protected by both state
and federal laws. Although federal trademark registra
tion is not necessary to assert trademark rights, it af
fords many advantages and benefits to the owner, and
hence is by far the preferred means of protection. It is
important to remember, however, that trademarks must
always be maintained, protected, and correctly used.
Their strength, and therefore value, is directly linked to
public perception.

1. INTRODuCTION

This trademark primer is intended both to provide
a general understanding for technology transfer
practitioners and to introduce a protection tool
for those who might, in the future, need to license
trademarks for their own inventions or those of
others. As trademarks are a distinct, legal form of
intellectual property (IP), a working knowledge of
trademarks will be useful for individuals who are
active in the field of technology licensing.
While trademarks, patents, and copyrights
all are referred to as IP, they do, of course, serve
different functions: patents protect inventions,
trademarks protect unique product or service
identifiers, and copyrights protect original artistic
or literary works. While the meaning of inven
tion is generally known, the distinction between
a trademark and a copyright is often confused.
As an example, the contents (for example, for
mat, photos, text) of a periodical are protected
under copyright law, but the title of a publication
(such as Newsweek) is protected under trademark
law. More information about these topics can be
found on the World Wide Web.1
Unlike patents and copyrights, trademarks
(often called brands or marks) are regulated under
federal and state laws. A mark may be registrable

Needle W. 2007.Trademark Primer. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook
of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online
at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual (Third Edition, Part IV: Chapter 2.4).
© 2007. W Needle. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.

HANDBOOK OF BEST PRACTICES | 1

NEEDlE

in the United States under the federal trademark
legislation known as the Lanham Act (Title 15 of
the U.S. Code of Federal Regulations). Federal
registration provides protection throughout the
United States. A mark may also be registrable in
individual states; registration in a particular state
is enforceable only inside that state. Registration
is not required to establish rights in a mark; ac
tual use in commerce is all that is necessary. A
federal application can be filed in the U.S. Patent
and Trademark Office (PTO) based only upon a
good-faith intent that the mark will be used in
interstate commerce, but a registration will not
issue until actual use of the mark occurs in inter
state commerce. Unregistered marks are protectable under common law but only in the market
area in which they are actually used.
2. TERMINOlOGy
2.1 Trademark

A trademark, or brand name, is any word, name,
symbol, device, or any combination of these ele
ments that is adopted for use in commerce by a
manufacturer or businessperson to (1) identify the
company or person’s goods or products, (2) distin
guish those goods from goods manufactured or sold
by another person or company, and (3) indicate
the source of the goods carrying the trademark.
Examples of what may function as a trade
mark include the following:
• a word or group of words, such as a slogan
(Tide®, Cabbage Patch Kids®, Don’t Leave
Home Without It®)
• a logo, symbol, pictorial representation, or
design (Nike’s Swoosh symbol, McDonald’s

•

•
•

•
•
•

golden arches, the five interlocking
Olympic rings)
a combination of a word or words plus a
symbol, pictorial representation, or de
sign (the word Nestea plus its design, the
phrase Cabbage Patch Kids plus its design
[see Figure 1])
numerals, letters, or combinations thereof
(Levi® 501® Original Jeans, IBM®, V8®
[juice made by Campbell Soup Co.])
the shape of a container or other packag
ing (Coke’s bottle shape, the conical shape
of the top of a Cross pen, the shape of
Toblerone chocolate packaging)
color (The Home Depot’s orange, Owens
Corning pink insulation)
sound (MGM’s lion roar, NBC’s chimes)
scent (“the high impact, fresh flower fra
grance reminiscent of Plumeria blossoms”
owned by Celia Clarke, doing business as
Clarke’s OSEWEZ)

2.2 Service mark

A service mark is similar to a trademark; however,
the service mark is used in the sale or advertising
of services, rather than goods. A service mark is
used to identify the services of one person and
to distinguish them from the services of others,
(McDonald’s® and Office Depot®). Service marks
are afforded the same legal protection as trade
marks and are registrable in the same manner and
have the same effect.
2. Trade name

Normally, the name of a business entity is not
registrable unless it is also used as a trademark
or service mark, that is, in conjunction with the

Figure 1: Sample Trademark
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goods and/or services of the business entity. A trade
name is usually identified by its ending in the term
Company/Co., Corporation/Corp., Incorporated/
Inc., or Limited/Ltd. (for example, McDonald’s
Corp. [trade name] versus McDonald’s® restau
rants [service mark]). Trade name infringement is
actionable under federal and state laws.

site, it is being used to identify the source of spe
cific services and, therefore, is acting as a service
mark. Similarly, the domain name Amazon.com
also functions as a service mark because it, along
with the service mark Amazon®, is used in advertis
ing to designate the source of the services.2

2. Trade dress

Certification marks certify that products or servic
es manufactured or provided by others have cer
tain qualities. Vidalia® of Vidalia onions provide
an example. According to Georgia’s Department
of Agriculture, “The certification mark is intend
ed to be used by persons authorized by the certifier
and will certify that the goods in connection with
which it is used are yellow Granex type onions and
are grown by authorized growers within the Vidalia
onion production area in Georgia as defined in the
Georgia Vidalia Onion Act of 1986.”3

Trademark protection has been expanded by courts
beyond words, slogans, symbols, and other devices
to protect distinguishing, albeit unregistered, fea
tures of products.While trade dress originally referred
exclusively to a product’s packaging or dressing that
was not protectable by registration, the concept has
grown to include product designs, for example, the
decor of a chain of Mexican restaurants (“a festive
eating atmosphere having interior dining and patio
areas decorated with artifacts, bright colors, paint
ings, and murals”) and even sales techniques, such
as Original Appalachian Artworks’ simulation of
adoption procedures and provision of birth certifi
cates for the Cabbage Patch Kids® dolls.
To recover damages for trade dress infringe
ment, a plaintiff must prove by a preponderance
of evidence that (1) the trade dress has obtained
secondary meaning in the marketplace (that is,
that the primary significance of the trade dress, in
the minds of the public, is to identify the prod
uct’s source rather than the product itself ); (2) the
trade dress of the two competing products is con
fusingly similar; and (3) the appropriated features
of the trade dress are primarily nonfunctional.
2. Domain names

A domain name is a name that identifies one or
more Internet addresses and is part of the URL
for a Web site (examples are .com, .org, and .net).
Domain names do not act as marks in identifying
the source of goods or services, however, where
a domain name is used as something other than
merely an address, it becomes a trademark or a ser
vice mark. For example, in Amazon.com, the do
main name (.com) is functioning as a service mark
because .com is part of the identity of the service of
the Amazon.com Web site. For example, when the
term Google® is used on the home page of Google
or is used in advertising or promoting the Web

2. Certification marks

2. Collective marks

Collective marks are used by members of a group or
organization to identify the goods it produces or
services it provides. An example of a collective mark
is ILGU® (International Ladies Garment Union).
. SElECTION AND ADOPTION OF A MARK
.1 Types of marks

A hierarchy of marks exists within this protection
system, with the more distinctive marks being af
forded a wider scope of protection than the less
distinctive ones. The order of marks from most
distinctive to least distinctive is: fanciful mark,
arbitrary mark, suggestive mark, and descriptive
mark (see Figure 1). It is best to select a mark that
is fanciful, arbitrary, or suggestive. As one might
expect, the more distinctive the mark, the better
the chance of protecting and registering it.
A fanciful mark is one that is created solely for
the purpose of functioning as a mark and has no
other meaning. Examples are Xerox®, Pentium®,
Kodak®, Exxon®, Clorox®, Kotex®, and Polaroid®.
An arbitrary mark is one that comprises
a common word or symbol that is arbitrarily
applied to the goods or services in question
such that the word or symbol does not describe
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or suggest the product. Nor would the words
normally be associated with the product.
Examples are Command® (hair-care prod
ucts), Shell® (gasoline), Apple® (computers), Ice
Cream® (chewing gum), Guess?® (jeans), and
Die-Hard® (batteries).
A suggestive mark is one that suggests, but
does not describe qualities or functions of a par
ticular product or service. If the qualities are not
instantly apparent from the mark, but with an
exercise of imagination could convey the char
acteristics or qualities of the product or service,
the mark is “suggestive.” Examples are Crosstalk®
(software), Stronghold® (nails), 7-Eleven® (retail
store services), Coppertone® (tanning products),
Rapid Shave® (shaving cream), Gleem® (tooth
paste), Roach Motel® (roach bait), Woolite® (wool
cleaner), and Honey Maid® (graham crackers).
Arbitrary, fanciful, and suggestive marks are
inherently distinctive and are given a high de
gree of protection.
A merely descriptive mark generally affords
the narrowest scope of protection. The descrip
tive mark immediately identifies or brings to
mind the characteristics, qualities, ingredients,
functions, composition, purpose, attribute, use,
or other features of a product or service. A merely
descriptive mark is not protectable because the
word or words comprising the merely descriptive
mark should be available for all competitors to
use. It is sometimes difficult to distinguish a sug
gestive mark from a merely descriptive mark. A
merely descriptive term is protectable only when
it holds a secondary meaning or distinctiveness,
that is, the consumer accepts and recognizes it as

denoting only one source (product or service) and
the term is synonymous with that product or ser
vice (and, thus, functions as a mark), rather than
merely being a descriptor of the goods or services.
Courts will often look to the following when de
ciding whether a term is merely descriptive:
• the amount and manner of use of the term
in advertising
• the volume of sales of products/services
bearing the mark
• the length and manner of the term’s use
• the results of consumer surveys
Marks that have been found to be merely
descriptive include: Chap-Stick® (chapped lip
treatment), Shear Pleasure® (beauty salon), Hair
Color So Natural Only Her Hairdresser Knows
for Sure® (hair coloring), Beef and Brew® (res
taurants), Hour after Hour® (deodorant), and
Raisin-Bran® (cereal). To illustrate, the term bril
liant would be merely descriptive for diamonds,
suggestive for furniture polish, and arbitrary for
applesauce.
Finally, generic terms are the common name
of a class of things and are, by definition, inca
pable of indicating source and can never function
as a trademark or service mark (examples of ge
neric terms are blended whiskey, computer software,
mouse, disk, or keyboard).
In some cases, generic terms are those that,
at one time, functioned as trademarks but
that, as a result of widespread use, lost their
ability to function as a source identifier and
came to mean, to the general public, the prod
uct itself (specifically) rather than merely one

Figure 2: Types of Marks
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manufacturer’s brand or version of the product.
Such loss of distinctiveness in a trademark, socalled genericide, happens when a mark, via
misuse, becomes a generic term (for example,
Frigidaire® becomes equivalent with refrigera
tor) and thus, ceases to indicate the source and
falls into the public domain where it is thereaf
ter owned by no one.
Such former trademarks are numerous, in
cluding: aspirin, cellophane, cola, cornflakes, cube
steak, dry ice, escalator, high octane, kerosene, lano
lin, linoleum, mimeograph, Murphy bed, nylon,
raisin bran, refrigerator, shredded wheat, thermos,
trampoline, yo-yo, monopoly, and zipper. As an ex
ample, the term escalator was first used as a trade
mark (Escalator® [moving stairs]) but, over time,
the public stopped using the term as a trademark
(an adjective, or modifier, such as in Escalator®
stairs) and started to designate any moving stairs,
regardless of the manufacturer, as escalator and
thus, the trademark term became the name of
the product.
.2 Preadoption investigation

Once a mark is selected, but prior to its use, a
thorough search should be undertaken to de
termine whether the mark is available for both
use and federal registration. Sources of informa
tion on existing registered marks are discussed
below.
.2.1 Records of the U.S. Patent and
Trademark Office

A prospective trademark user is charged with con
structive notice of any identical or confusingly
similar mark that is federally registered. A search
of the PTO records can be conducted online on
the PTO database,4 by hand in the office records,
or by means of the Trademarkscan® database5 (File
226)6 of Dialog services. Also, File 116 (brand
names) of Trademarkscan can be searched.
Private search companies undertake record
searches for a fee. These companies include:
• Thompson & Thompson7
• Dialog8
• Questel/Orbit9
• Micropatent10
• Corsearch11

The companies will search the federal reg
ister and pending application records as well as
phone directories, yellow pages, industrial direc
tories, and state trademark registers in an effort
to determine if a particular mark or a similar
mark is already in use.
Also, if use of the mark is contemplated in
any foreign countries, the trademark and ser
vice mark records of those countries should
be searched. Searching of trademark records
of countries such as Canada (File 127), France
(File 657), Germany (File 672), and the United
Kingdom (File 126) can be performed on the
Trademarkscan database.
.2.2

State trademark records

The Trademarkscan database (for state records,
File 246) can be utilized to search the trademark
and service mark records of all states.
Related information can be accessed using
Internet searches. Network Solutions’ Web site12
provides a convenient search tool to determine if
a proposed mark is being used in a domain name
and who owns it (the “WOSIT” button). One
can also use a browser to search for directly con
flicting Web sites or for business names across the
country. The following sites are useful for such
searches:
• Big Book13
• Switchboard14
• GTE Superpages15
• World Pages16
• ZIP217
. Misconceptions

Below is a list of some common misconceptions
about trademark protections:
• The fact that an individual has incorporat
ed, qualified to do business under a name,
or registered the name in the assumed
name records of a particular state does not
automatically bestow to that individual
the right to use the name as a mark.
• A person does not have an absolute right
to use his or her own name as a trade
mark or service mark (for example, Old
McDonald would likely be barred from
using his surname as a trademark and
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service mark for his own national chain of
fast food hamburger franchises).
• Registration in one state (or jurisdiction)
of a mark for use as a trademark or service
mark does not necessarily allow use of the
mark elsewhere.
• Even though a mark appears in an aban
doned application or an expired registra
tion, the owner of that mark may still be
using it, and, thus, have protectable com
mon law rights against a subsequent user.
. REGISTRATION OF A MARK IN THE PTO
.1 Process

It is not necessary to obtain either a state or fed
eral registration to be able to protect a mark, as
rights in a mark are based upon use, not regis
tration, of the mark. Generally, the owner of
a mark is considered to be the first person or
company to use a mark, or to file an intent
to-use application in the PTO, for a particular
product or service or for related products and
services. However, registration of a mark in the
PTO is highly recommended, as registration
confers significant nationwide benefit upon the
owner, even if the actual use in commerce of the
mark is limited to a small geographic area—the
term commerce is broadly construed to mean
any commerce that may lawfully be regulated
by the U.S. Congress.
The Trademark Act (15 U.S.C. § 1127)
defines use in commerce as follows:
The term use in commerce means the bona
fide use of a mark in the ordinary course of trade,
and not made merely to reserve a right in a mark.
For purposes of this Act, a mark shall be deemed to
be in use in commerce:
(1) on goods when (A) it is placed in any
manner on the goods or their containers
or the displays associated therewith or on
the tags or labels affixed thereto, or if the
nature of the goods makes such place
ment impracticable, then on documents
associated with the goods or their sale, and
(B) the goods are sold or transported in
commerce, and
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(2) on services when it is used or displayed in
the sale or advertising of services and the
services are rendered in commerce, or the
services are rendered in more than one State
or in the United States and a foreign coun
try and the person rendering the services is
engaged in commerce in connection with
the services.
.2 Advantages of registration

Registration of a mark on the Principal
Register18 of the U.S. Patent Office allows
an owner to:
• prevent registration of the identical or
confusingly similar marks
• secure injunctive relief and damages
against infringers nationally in federal
court (whereas unregistered marks may
be protectable only in the specific market
where they are used)
• assert the registration in federal court as
prima facie evidence of the validity of
the registration, of the ownership of the
mark, and of the right to exclusively use
the mark in commerce
• have the mark treated as incontestable af
ter five years’ use
• eliminate the defense of innocent adop
tion by anyone using the mark after the
date of registration, thereby affording na
tionwide protection to registered marks,
regardless of the areas in which the mark
is actually used
• prevent the importation of goods bearing
infringing or counterfeit marks by record
ing the mark with U.S. Customs
. Actual use versus intent-to-use
applications

A dual-application system exists in the PTO that
permits the filing of trademark/service mark ap
plications based upon an intent to use the mark,
as well as applications based on actual use of the
mark in commerce. However, while an applica
tion may be filed based on a bona fide intent to
use the mark, the applicant will still have to make
actual use of the mark in commerce before the
mark can be registered.
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The intent-to-use procedure encourages the
early filing of an application because, while the
application is pending, the applicant will have the
benefit of constructive-use priority. Thus, subject
to the mark actually being registered, the appli
cant will have prior rights in the mark against
all others nationwide (except for those who used
the mark before the application was filed, or who
filed an earlier application, or who had priority
based on a foreign application).
. Term of a federal registration

Federal trademark/service mark registrations are
valid for a period of ten years and are renewable
for ten-year periods as long as the mark remains
in actual use.
Additionally, between the fifth and sixth year
from the date of a federal registration, the regis
trant must file a declaration or affidavit that the
mark is still in use as of that date (as of the sixth
year after registration). An affidavit of use must
also be filed in the year prior to the end of each
registration term. Failure to file such a statement
will cause the registration to be canceled by the
PTO.
. State registrations

A state registration does not confer the same
rights and benefits as a federally registered mark.
For example, a state registration is enforceable
only within that state while federal registration
provides nationwide protection and constructive
notice.19 Usually there is no need to seek a state
registration if the mark is registered in the PTO.
A state registration should be obtained only if the
mark is not registrable in the PTO.
. INFRINGEMENT OF A MARK

Protection of a mark, whether registered or
not, involves actions against other marks that
are likely to cause confusion. For a trademark
owner to prevail against an accused party, nei
ther the respective marks nor the respective
goods or services need to be identical. Instead,
likelihood of confusion (the test for trademark
infringement) is determined by considering the
following factors:

• the strength or weakness of the
plaintiff’s mark
• similarity of the marks in sound (for ex
ample, SO found confusingly similar to
Esso), appearance (Old Forester infringed by
Old Foster), or meaning (Tornado for wire
fencing held confusingly similar to Cyclone
[wire fencing])
• similarity of the product or services
• likelihood that the prior owner will bridge
the gap between the parties’ respective
products or services
• presence or absence of actual confusion (ac
tual confusion obviously being the best test
of whether there is a likelihood of confusion
occurring between two conflicting marks)
• defendant’s good faith in adopting the mark
• sophistication of the potential purchasers
(buyers of expensive goods may be more
discerning purchasers and less likely to be
confused between two similar marks for the
same goods)
• channels of trade (the goods/services are
sold, or are not sold, in the same mar
keting channels to the same general class
of customers)
• similarity of the advertising media
. THE “CARE AND FEEDING” OF MARKS

Trademarks and service marks are valuable assets,
so their proper use, maintenance, and protection
should be a paramount concern of the owner. It
is critical to avoid misuse of a trademark, which
can destroy the legal significance of the mark, for
example, misuse leading to genericide, with the
unfortunate outcome of a valuable trademark
becoming a generic term. There is also the neces
sity of maintaining trademarks so as to avoid any
possibility of creating unfavorable commercial
impressions; solid, strong, and maintained trade
marks are source indicators that attract business.
Proper usage for trademarks and service marks
will go a long way to protect marks and prevent
genericide:
• Always use the mark as a proper adjective that
modifies a noun, such as Cabbage Patch Kids®
dolls, Levis® jeans, Xerox® copy machines.
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• Never use a mark in the possessive form, in
the plural form, or as a verb.
• Avoid prefixes, suffixes, additions, or dele
tions of the mark.
• Distinguish the mark in use from sur
rounding text such as a distinctive typeface,
quotation marks, all capital letters or, at the
very least, capitalize the first letter of each
word of the mark.
• For marks registered in the PTO, use the
symbol of registration, namely, , or the
phrase Registered in the U.S. Patent and
Trademark Office or Reg. U.S. Pat. Tm. Off.
• For unregistered marks, use either the in
formal notice TM or SM (or the corre
sponding symbols) or an asterisk indicating
A trademark/service mark of XYZ Company.

®

The following ditty was a prize-winning sub
mission at the Coca-Cola Co., which should be kept
in mind to promote the proper usage of any mark:
Three laws bind the Kingdom of Coke.
This trio must never be broke:
The “C” should be tall,
Not possessive at all,
And the plural should never be spoke.
. lICENSES

Never allow a third party to use your mark with
out entering into a written license agreement,
which, at a minimum, enables you to monitor
and control the nature and quality of the goods
or services in connection with which the mark is
being used by the licensee. Otherwise, you may
end up with a naked license,20 which could nega
tively affect the distinctiveness of your mark, pos
sibly leading to the de facto abandonment of the
trademark. Also, provide in any license agreement
for the licensee to notify you of potentially in
fringing marks so that you may police your mark,
as unauthorized uses of your mark will similarly
negatively influence your scope of protection.
An assignment of a mark must be in writing
and, whether registered or not, must include “the
good will of the business associated with the mark”
or the assignment is invalid. The basis for this pro
vision is that a mark is merely the symbol of good
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will (that is, the owner’s reputation for quality in
connection with the goods or services sold un
der the mark). An assignment of a mark without
the accompanying good will is an assignment in
gross21 and is invalid. Also, an intent-to-use ap
plication cannot be assigned as there is nothing to
assign until the mark is in actual use.
. CONCluSIONS

When properly managed, maintained, protected,
and used, trademarks are a valuable form of IP
rights. In a comprehensive and coordinated IP
strategy, trademarks can augment other forms
of IP rights protection, for example, patents
and trade secrets, and therefore should not be
overlooked as additional options in a layered IP
portfolio. A single product, such as crop variety,
can have multiple forms of IP rights protection,
including patents, trade secrets, and trademarks.
It is therefore important to understand what a
trademark is, how to select a strong mark and es
tablish rights, the importance of registration, and
the necessity of policing the trademark, whether
to maintain the integrity of licensees or to identi
fy potential infringers. Finally, strong trademarks
are distinct and specific indicators of source.
Protecting this function, an owner never wants to
find his or her mark in a dictionary. That would
mean the mark had joined the ranks of the unfor
tunate victims of genericide, like the yo-yo. n
WILLIAM NEEdLE, President and Founder, Needle and

Rosenberg PC, Suite 1000, 999 Peachtree Street, Atlanta,
GA, 30309, U.S.A. bneedle@needlerosenberg.com

1

For copyright information, go to www.copyright.gov;
for patent information, go to www.uspto.gov/main/
patents.htm. The U.S. Patent and Trademark Office has
a very informative Web site at www.uspto.gov/web/
menu/tm.html.

2

See www.uspto.gov/web/offices/tac/notices/
guide299.htm.

3

Registration No. 1,709,019.

4

www.uspto.gov.

5

http://library.dialog.com/bluesheets/htmlaa/bl0246.
html.

6

See library.dialog.com/bluesheets/html/bl0226.html.
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7

www.t-tlaw.com.

8

www.dialog.com.

9

www.questel.orbit.com/patents/.

10 www.micropat.com/trademarkwebindex.html.
11 www.corsearch.com.
12 www.networksolutions.com.
13 www.bigbook.com.
14 www.switchboard.com.
15 www.superpages.com.
16 www.worldpages.com.
17 www.zip2/com.
18 A trademark or service mark may be registered with the
united states patent and trademark office on either the
principal or supplemental registers. Arbitrary, fanciful,
and suggestive marks are on the principal register,
while suggestive marks with secondary meaning are on
the supplemental register: “A certificate of registration
of a mark upon the principal register provided by this
act shall be prima facie evidence of the validity of the
registered mark and of the registration of the mark,
of the registrant’s ownership of the mark, and of the
registrant’s exclusive right to use the registered mark in
commerce on or in connection with the goods or services

specified in the certificate, subject to any conditions or
limitations stated in the certificate.” 15 u.s.c. § 1057 (b).
19 Constructive notice is a notice to the public of the
registrant’s claim of ownership of the mark.
20 Naked licensing means the licensing of trademarks
without that trademark owner’s retaining the right
to approve the said use of the mark in connection
with the licensee’s goods or services. As a result, the
trademark would be deemed abandoned (Barcamerica
International USA Trust v. Tyfield Imports, Inc., 289 F.3d
589-598 [9th Cir. 2002]).
21

Assignment in gross: A mark is a symbol of the mark
owner’s goodwill in the goods or services associated
with the mark. The rule both under the common law
and the Lanham act is that a mark cannot be assigned
apart from the goodwill in the mark. An assignment in
gross is an assignment of a mark without the associated
goodwill. This rule is intended to protect the public
from the deception that might arise if the assigned
mark becomes associated with goods or services
of a different nature or quality than was previously
the case. An assignment in gross is invalid, and the
assignee acquires no rights by such an assignment. See
www.inta.org/index.php?option=com_content&task=
view&id=174&itemid=132&getcontent=1.
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The Statutory Toolbox: Plants
JAy P. kESAN, Professor and Director, Program in Intellectual Property & Technology Law, University of Illinois, U.S.A.

ABSTRACT

Different forms of intellectual property protection are
available for agri-biotech inventions: utility patents, plant
variety protection, plant patents, trade secrets, geographic
indications, trademark, and copyright. Each form has its
own strengths and weaknesses. In general, stronger protec
tions require meeting more stringent requirements. The
three most important regimes for agri-biotech inventions
are utility patents, plant variety protection, and trade se
crets. A careful consideration of the relative demands and
benefits of each regime will allow custom-tailored ap
proaches to suit the needs of the inventor and the nature
of the invention.

1. INTRODuCTION
Several intellectual property (IP) regimes protect
agricultural biotechnology. They may be used
alone or in combination. In general, the easier it
is to obtain a particular form of IP protection,
the weaker the protection it affords. Conversely,
the more robust the protection, the more strin
gent are the requirements for obtaining it. This
chapter provides an overview of the various forms
of IP that are available for protecting agricultural
biotechnology innovation.
2. PATENT AND RElATED REGIMES
Patent and somewhat patent-like IP protection
regimes provide the most important protection
for agricultural biotechnology innovation. In

general, a patent grants an inventor of a novel,
nonobvious, and useful invention an exclusive
monopoly of fixed duration in exchange for
public disclosure of the invention. Patent and
related regimes offer the strongest IP protection.
It is not mutually exclusive, and concurrent
protection under multiple regimes is permitted.
This section describes the utility patent, plant
variety protection, and plant patent regimes,
exploring the advantages and disadvantages of
each regime.
2.1 Utility patents

The first regime, the utility patent, provides the
most extensive coverage for inventions. In the
context of agricultural biotechnology, the util
ity patent may be obtained to protect everything
from genetically modified seeds and geneti
cally modified plants, to transformation meth
ods. Under the U.S. statute governing utility
patents:
Whoever invents or discovers any new and
useful process, machine, manufacture, or composi
tion of matter, or any new and useful improvement
thereof, may obtain a patent thereof, subject to the
conditions and requirements of this title.1
Plants are eligible subject matter for utility
patent protection under the category of “compo
sitions of matter.”
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2.1.1 Scope of protection

In the United States, utility patents grant a broad
right to exclude others from making, using, offering
to sell, selling, or importing into the United States,
the patented invention.2 Unauthorized exploitation
of the patented invention by others within the pat
ent term constitutes patent infringement. The broad
scope of protection afforded by utility patents pro
vides great flexibility for tailoring protection to vari
ous plant innovations.
Utility patents may cover individual compo
nents of a plant, including the plant’s genome,
cells, cell culture, and tissues, as well as methods
for making the plant. For example, Monsanto, an
agrichemical corporation, holds U.S. patents on
Roundup Ready® soybeans, which are genetically
modified to withstand the company’s broad-spec
trum herbicide, Roundup®. The company creates
Roundup Ready® soybeans by inserting a gene
sequence that allows the plant to survive the her
bicide. Monsanto’s utility patents allow the com
pany to claim protection not only for methods
of producing the Roundup Ready® soybeans, but
also for the DNA molecule that encodes the her
bicide-resistant trait, for the herbicide-resistant
plant cell, for the seed of the herbicide-resistant
plant, and for the final Roundup Ready® soybean
plant itself.
A utility patent may also cover multiple va
rieties at once. And if the applicant meets the
disclosure requirements discussed below, the
patent can cover an entire species or genus.
Moreover, the scope of the protection is broader
than the specific plant variety developed. Under
the patent law’s doctrine of equivalents, trivial
variations to an invention that may not fall
within the literal terms of the claims of the pat
ent may nevertheless infringe as an equivalent of
the claimed invention.
2.1.2

Requirements for obtaining
a utility patent

To obtain the protection of a utility patent, an
applicant must meet the highest threshold for ac
quiring IP protection: an invention must be new,
useful, and nonobvious.3 First, it is considered new
if it is not already known to the public.4 An in
vention fails to meet the novelty requirement if it
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was in public use, was described in a printed pub
lication, or was covered in a preexisting patent. In
the United States, there is a one-year grace period
on the bar on public use and printed publication.
Second, an invention must be useful, that is, ca
pable of providing a specific benefit.5 Failure to
identify a specific use for a gene sequence renders
the gene sequence ineligible for patent protec
tion. Finally, an invention must be nonobvious,
that is, the invention is not obvious to a person of
ordinary skill in the art. The nonobvious require
ment takes into account the scope and content of
the prior art and the level of ordinary skill in the
pertinent art. Patent may be denied if the inven
tion is a combination of previously known com
ponents A, B, and C, and the idea to combine
the components A, B, and C were obvious to a
person of ordinary skill in the art.
At minimum, a patent application must
contain specifications and at least one claim. In
the specifications, an applicant must disclose in
writing what the applicant believes he or she has
invented. The specifications must describe the
invention in sufficient detail to enable others of
ordinary skill in the pertinent art to practice the
invention.6 For example, in an application claim
ing DNA as the invention, a description of the
DNA is adequate if it includes a definition of the
physical properties, formula, chemical name, or
structure of the claimed invention; a description
that merely states that DNA is involved in the
invention falls short of the requirement. In situ
ations where the starting materials required to
practice the invention are not readily available to
the public, the applicant may also be required
to place the materials in a depository in order
to fulfill the enablement requirement. The writ
ten description of the invention must also reveal
what the inventor believes is the best way to
practice the invention.
The claims in a patent define the boundaries
of a patentee’s right to exclude. The patent appli
cation must therefore describe what the inventor
claims as his invention, by including
…one or more claims particularly pointing out
and distinctly claiming the subject matter which the
applicant regards as his invention.7
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Ideally, claims should be both broad enough
to afford the patentee a wide scope of protection,
and narrow enough to avoid invalidation by the
prior art. In general, claim language that contains
fewer limitations provides broader patent pro
tection than claim language that includes many
limitations. Consider the following two simpli
fied claims for a bucket:
A claim that reads:
A bucket comprising a wooden circular bottom,
wooden side walls, and a stainless steel handle
provides narrower protection than a claim that
reads:
A bucket comprising a bottom, side walls, and
a handle
A competitor’s metal bucket with a square
bottom would fall outside the claim language of
the first example, but would infringe the second
example by falling within its claim language.
Additionally, claims may be classified as either
independent or dependent. Independent claims
generally are the broadest claims and do not re
fer to any other claim in the patent. Dependent
claims, on the other hand, incorporate other
claims by reference and add additional limita
tions. Consequently, dependent claims provide a
narrower scope of protection than independent
claims. Consider the following example:
I claim:
1. a bucket comprising a bottom and side
walls
2. the bucket of claim 1 further comprising a
handle
3. the bucket of claim 2 wherein the bottom
and side walls are wooden
4. the bucket of claim 2 wherein the bottom
is circular
In this example, claim 1 is the independent
claim. Claims 2 through 4 are the dependent
claims that rely on claims that have come before.
Ultimately, a patent covers only what the applicant
describes and claims in the patent application.
2.1.

Procedure for obtaining a patent

a) Patent protection in the United States. In the
United States, utility patents are administered by
the Patent and Trademark Office (PTO), an arm

of the U.S. Department of Commerce. The PTO
receives and examines applications and has power
to grant patents if it is convinced that the inven
tion is new, useful, nonobvious, and meets other
conditions and requirements as set forth in the
statute.8 The first step in acquiring a patent is to
file a patent application with the PTO. Thereafter,
a series of communications between the applicant
and the PTO follows. Six months to two years
after the filing date of the patent application, the
PTO will send communications to the applicant
known as an Office Action. This communication
notifies the applicant of whether the claims have
been allowed and provides reasons for rejections of
claims. The applicant then has a chance to respond
to the PTO within a time specified in the Office
Action, typically three months. The applicant may
amend the application to overcome the rejections.
Two to six months after the PTO receives the ap
plicant’s response to the Office Action, the PTO
may send another Office Action to the applicant
or it may send a Notice of Allowance. A Notice of
Allowance indicates that the PTO has allowed all
of the claims in the application. A patent will issue
after the applicant pays an issue fee.
Once granted, utility patent protection lasts
for a term of 20 years, measured from the date the
patentee filed the application. It is not subject to
exemptions from enforcement. During the term
of the issued patent, the patent holder must pay
periodic maintenance fees to the PTO.
b) International patent protection: The Patent
Cooperation Treaty (PCT).9 In the current glob
al economy, an inventor may wish to procure pat
ent protection for his or her invention in more
than one country. A patent confers rights, how
ever, only in the jurisdiction in which the pat
ent application was filed. Outside of the country
where the patent is issued, others are free to use
the invention without incurring patent infringe
ment liability. A patent that issues in the United
States, for example, confers no automatic patent
protection for the invention in France. To protect
an invention internationally, an inventor must se
cure a patent in each country in which he or she
desires protection.
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Many nations have adopted international
agreements that make the process of obtaining
multiple patents easier. One of these agreements is
the Patent Cooperation Treaty (PCT). The PCT,
administered by the World Intellectual Property
Organization (WIPO), is an international agree
ment that streamlines the process of securing
patents for an invention in multiple countries. A
patent applicant may seek simultaneous patent
protection in multiple countries by filing a single
application and designating the countries where
protection is desired. While PCT does not alter
the substantive requirements of patentability in
each country, it does eliminate the duplicative ef
fort wasted in filing separate patent applications
for the same invention.
An inventor who wishes to take advantage of
the PCT, first files an application in his or her
home patent office, designated the Receiving
Office. The home office conducts an initial prior
art search and gives the applicant the opportunity
to request an international preliminary exami
nation. The preliminary examination, while not
binding, indicates the patentability of the inven
tion, which may assist the applicant in deciding
whether to commit to an expensive filing abroad.
In the next step, called the “national stage,” an
applicant has 30 months to convert the PCT ap
plication into parallel patent applications in the
countries in which he or she desires patent pro
tection. From there, the patent application pro
cess proceeds according to the procedures estab
lished by each designated country.
2.1. Rights of the inventor

A patent grants its owner the right to exclude
others from making, using, offering for sale, and
selling the patented invention without the patent
owner’s permission. Patents are personal property
and therefore may be licensed or assigned to oth
ers, including companies. An assignment transfers
the rights of the patent from the current owner to a
new owner. In contrast, a license grants a revocable
permission to engage in conduct that would other
wise constitute patent infringement without trans
ferring ownership of the patent. Licenses may be
either exclusive (issued strictly to one licensee) or
nonexclusive (issued to several licensees at once).
 | HANDBOOK OF BEST PRACTICES

2.2 Plant variety protection

While utility patents provide the most robust pro
tection for plant innovation, only a few countries
afford utility patent protection for agricultural
biotechnology. A more common regime is plant
variety protection, also known as plant breeder’s
rights. In general, plant variety protection pro
vides a sui generis form of IP protection to breed
ers of new varieties of plants.
2.2.1

International protection: UPOV–
The International Convention for the
Protection of New Varieties of Plants

Many countries with a system for protect
ing new varieties of plants have based it on the
International Convention for the Protection of
New Varieties of Plants (UPOV Convention).10
Originally adopted in Paris in 1961 with the ob
jective of providing IP protection for new plant
varieties, the UPOV Convention has undergone
several revisions, first in 1972, again in 1978, and
most recently in 1991. The International Union
for the Protection of New Varieties of Plants
(UPOV), an intergovernmental organization
headquartered in Geneva, Switzerland, adminis
ters the UPOV Convention.
The UPOV Convention defines a minimum
scope of protection that enables plant breeders to
prohibit the unauthorized exploitation of their
protected variety. Under the UPOV Convention,
the authorization of the breeder of an eligible
plant variety is required to produce or reproduce,
condition for the purpose of propagation, offer
for sale, sell, export, import, and stock the propa
gating material of the protected variety. Where the
plant breeder has not had a reasonable opportuni
ty to exercise his or her rights as to the propagat
ing material, the same rights are extended to the
harvested material of the protected variety. The
rights also attach to varieties “essentially derived”
from the protected variety, varieties “not clearly
distinguishable from the protected variety,” and
varieties that “require the repeated use of the pro
tected variety.”11 The Convention explains that
“essentially derived varieties” are those that
…may be obtained, for example, by the selec
tion of a natural or induced mutant, or of a somaclonal variant, the selection of a variant individual
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from plants of the initial variety, backcrossing, or
transformation by genetic engineering.12
To obtain plant variety protection, UPOV
must examine an application to ensure that the
proposed variety meets the conditions for protec
tion. To qualify for UPOV protection, a plant
variety must be:
(i) distinct from existing, commonly known
varieties,
(ii) sufficiently uniform,
(iii) stable, and
(iv) new in the sense that they must not have
been commercialized prior to certain dates
established by reference to the date of the
application for protection13
Once granted, UPOV dictates that plant
breeder’s rights shall last for at least 20 years; for
trees and vines, the term should endure for no
less than 25 years from the date of the grant.
UPOV also defines acts that are exempt from
the plant breeder’s rights. The plant breeder’s per
mission is not required for acts done privately and
for noncommercial purposes, experimental use of
the protected variety, and acts done for the pur
pose of breeding other varieties. In addition to
the compulsory exceptions, an optional excep
tion allows farmers to save harvested seeds for
replanting.
Member nations of the UPOV Convention
agree to adopt all measures necessary to im
plement the plant breeder’s rights as outlined
in the Convention and to extend to foreign
nationals the same rights it provides to its own
citizens. Implementation of the Convention
entails the establishment of legal remedies and
enforcement mechanisms for breeder’s rights,
as well as the designation of an authority en
trusted with the power to grant such rights to
applicants. UPOV provides the basic frame
work for plant variety protection. However,
since countries are free to tailor their laws
to domestic circumstances when implement
ing the provisions of the UPOV Convention,
different countries have adopted slightly dif
ferent versions of the plant variety protection
regime.

2.2.2 Protection in the United States: The Plant
Variety Protection Act (PVPA)

The United States is a member of UPOV, having
implemented the UPOV Convention in 1981.
Plant variety protection certificates, issued by
the Plant Variety Protection (PVP) Office of
the U.S. Department of Agriculture (USDA),
supply patent-like protection for new varieties
of seed-bearing plants and may be obtained to
protect new plant varieties. Governed by the
Plant Variety Protection Act (PVPA), rights are
granted to
[T]he breeder of any sexually reproduced or
tuber propagated plant variety (other than fungi
or bacteria) who has so reproduced the variety,
[…] subject to the conditions and requirements of
this Act.14
The PVPA protects discrete varieties from
unauthorized exploitation by others. Following
the UPOV Convention, a PVP certificate grants
its holder the right to exclude others from sell
ing, offering for sale, reproducing, importing or
exporting the protected variety, and from using
the protected variety to produce (as distinguished
from to develop) a hybrid or different variety. As
per the UPOV Convention, protection under the
PVPA extends not only to the protected plant
variety, but also to “essentially derived varieties,”
narrowly defined in the PVPA to include two
generations of derivation. The PVPA defines the
term as a variety that:
• …is predominantly derived from another
variety (referred to in this paragraph as the
“initial variety”) or from a variety that is pre
dominantly derived from the initial variety,
while retaining the expression of the essential
characteristics that result from the genotype
or combination of genotypes of the initial
variety
• is clearly distinguishable from the initial
variety
• except for differences that result from the
act of derivation, conforms to the initial
variety in the expression of the essential
characteristics that result from the genotype
or combination of genotypes of the initial
variety. 15
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Inclusion of essentially derived varieties
within the limits of the breeder’s rights guards
against acts that border on blatant copying.
Essentially derived varieties delineate a zone of
protection around the protected variety that
captures plants produced by inducing minor
changes to a protected variety. As an example,
a hybrid variety of corn produced from a pro
tected variety may exhibit cosmetic differences
that make the hybrid distinct from its parent;
but as an essentially derived variety, the hybrid
nevertheless falls within the scope of PVP pro
tection for the parent.
As required by the UPOV Convention
guidelines, the PVPA includes several excep
tions that shield certain acts from infringe
ment liability. Private noncommercial use of a
protected variety does not constitute infringe
ment.16 Saving seed for replanting “a crop for use
on the farm” and sale of such seeds “for other
than reproductive purposes” also do not consti
tute infringement.17 Also, the PVPA explicitly
provides a research exemption. The statute states
that “use and reproduction of a protected variety
for plant breeding or other bona fide research shall
not constitute an infringement of the protection
provided under this Act.”18
Furthermore, though not an exemption from
infringement liability, the PVPA is subject to a
requirement that allows the secretary of USDA to
declare a compulsory license allowing use of the
protected variety for two years, in exchange for
a royalty, if such action is deemed necessary for
the public interest to maintain a sufficient food
supply. The many exceptions to the PVPA allow
others, under certain circumstances, to exploit a
protected plant variety without the owner’s au
thorization and therefore diminish the strength
of plant variety protection.
As a trade-off for the narrower scope of pro
tection, the PVPA demands a lower threshold for
obtaining protection. Unlike the utility patent,
the PVPA does not call for rigorous disclosure
of the claimed invention, nor does it impose a
nonobvious requirement. Instead, applicants for
a plant variety protection certificate must show
that the variety qualifies for protection, must
 | HANDBOOK OF BEST PRACTICES

provide a description of the variety, and must de
posit seed in a repository.
To qualify for protection under the PVPA, a
plant variety must be new, distinct, uniform, and
stable. The statute defines each of these terms.
First, a variety is “new” if “the variety has not been
sold or otherwise disposed of to other persons” for
more than one year before the date the applicant
filed the application for PVP.19
Second, a variety is “distinct” if
… the variety is clearly distinguishable from
any other variety the existence of which is publicly
known or a matter of common knowledge at the
time of the filing of the application. 20
Moreover,
… [t]he distinctness of one variety from an
other may be based on one or more identifiable
morphological, physiological, or other character
istics (including any characteristics evidenced by
processing or product characteristics, such as mill
ing and baking characteristics in the case of wheat)
with respect to which a difference in genealogy may
contribute evidence.21
Third, a variety is “uniform” when
… any variations are describable, predictable,
and commercially acceptable.22
Finally, a variety is “stable” if
… the variety, when reproduced, will remain
unchanged with regard to the essential and distinc
tive characteristics of the variety, with a reasonable
degree of reliability commensurate with that of vari
eties of the same category in which the same breeding
method is employed.23
Once a plant protection certificate issues,
the term of protection lasts for 20 years from
the date of issue of the certificate, or 25 years
in the case of a tree or vine.24 Unlike utility pat
ents and plant patents, which must issue under
an individual inventor’s name, a plant variety
protection certificate may issue in the name of
a corporation, which allows a corporation to file
under its own name. Additionally, as a require
ment for maintaining PVP, the certificate holder
must periodically replenish the repository of
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seeds of the protected plant variety. The PVPA
does not, however, require payment of mainte
nance fees for the certificate. When compared
to a utility patent, the scope of protection under
the PVP regime is limited. But one advantage
of the PVPA is the immediacy of protection: as
soon as a plant variety protection application
is filed and the fee is paid, provisional protec
tion attaches to the plant variety. By marking
the seed with protection notices “Unauthorized
Propagation Prohibited” or “Unauthorized Seed
Multiplication Prohibited,” the seed owner ac
quires protection prior to the issuance of the
plant variety protection certificate.25
2. Plant patents

Plant patent protection is the narrowest of the
three patent and patent-like IP regimes available
to agricultural innovation. The scope of protec
tion extends only to asexually reproduced plant
varieties. In general, the U.S. statute grants plant
patents to one who
… invents or discovers and asexually reproduces
any distinct and new variety of plant, including cul
tivated sports, mutants, hybrids, and newly found
seedlings, other than a tuber propagated plant or a
plant found in an uncultivated state…26
For example, a person who discovers and
asexually reproduces a new pineapple variety
may obtain plant patent protection. If he or
she later discovers a second variety of pineapple
that is separated from the first by a single trait,
the second variety may also obtain plant patent
protection.
The plant patent regime affords protection
against unauthorized asexual reproduction of
protected plant varieties. A plant patent grants
its holder “the right to exclude others from asexu
ally reproducing the plant, and from using, offering
for sale, or selling the plant so reproduced, or any of
its parts…”27 To qualify for plant patent protec
tion, a plant must be produced asexually, through
means such as grafting, cutting, budding, layer
ing, and inarching.
The cornerstone of plant patent protection
is asexual reproduction, but asexual reproduction
also severely limits the protection afforded and is

therefore its Achilles’ heel. The asexual reproduc
tion requirement effectively limits infringement
to the narrow circumstance where stock from the
patentee’s original parent plant is obtained and
asexually reproduced. Independent breeding of a
variety that closely resembles the subject of a plant
patent escapes infringement liability. So too does
seed propagation and sexual crosses of the plant,
since such acts fall outside the scope of plant pat
ent rights. Because its scope of protection is
exceptionally narrow, a plant patent ordinarily
should not be the sole source of protection for a
plant innovation.
The requirements for obtaining a plant pat
ent are, arguably, the least strict of the three pat
ent and patent-like regimes. In the United States,
the Patent and Trademark Office administers
both plant patent and utility patents. Like a util
ity patent application, a plant patent application
must meet the patent law’s nonobvious require
ment. Applications for plant patents must also
fulfill a disclosure and claiming requirement. The
plant patent disclosure requirement may be met
by a description that “is as complete as reasonably
possible”28 and a color drawing of the plant. Plant
patents need not disclose how to make or use the
claimed invention. The claiming requirement re
stricts the plant patent to a single claim to the
whole plant.
Plant patent protection shares some of the
requirements for PVPA protection, but there are
some differences. Like plant variety protection, a
variety must be new and distinct—new, mean
ing that the plant variety was not sold or used
more than one year prior to the application date,
and distinct meaning that the characteristics of
the variety are clearly distinguishable from those
of existing varieties. Unlike plant variety protec
tion, however, plant patents do not require that
the plant variety be uniform and stable. Whereas
PVPA protection is unavailable for plants that do
not breed true, such plants may receive protec
tion under a plant patent.
If the requirements are met, the PTO issues
a plant patent, which offers a term of protection
of 20 years from the date of patent application.
Like a utility patent, there are no exceptions to
enforcement. Also like a utility patent, the patent
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holder must pay periodic maintenance fees to the
PTO.

3. OTHER FORMS OF
IP PROTECTION IN PlANTS
.1 Trade secrets

Along with utility patents and plant variety protec
tion, trade secret protection represents another es
sential tool for protecting plant innovation. Most
significantly, trade secret protection is available for
inventions that do not otherwise qualify for pro
tection under a patent or patent-like regime.
In general, the purpose of trade secret protec
tion is to uphold commercial morality by prevent
ing the unauthorized use and disclosure of secret
information, while leaving other parties free to
independently develop the same matter. The sub
ject matter protected by a trade secret coincides
with the subject matter protected under patent
regimes. Typically, protection attaches to infor
mation that is used in business, gives a competi
tive advantage, and has been kept confidential.
Unlike patents, trade secret protection arises
instantly and requires no formal application or re
view process. Once trade secret protection is estab
lished, it grants recourse against one who wrong
fully acquires the secret information. To recover
for trade secret misappropriation, however, the
trade secret owner must show that the information
was protected by reasonable measures to ensure
the secrecy of the trade secret. The requirement
of maintaining the confidentiality of the informa
tion is critical: trade secret protection evaporates if
the underlying information is no longer a secret.
The cost of maintaining a trade secret is therefore
largely the cost of maintaining secrecy measures.
Keeping a trade secret may involve continuous and
costly expenditures on measures to prevent the un
authorized use or disclosure of the information.
Unlike other IP regimes, trade secrets provide
protection for an indefinite period rather than for
a fixed term of protection. So long as the underly
ing information continues to be a secret, the infor
mation remains protected as a trade secret. Some
trade secrets, most notably the secret formula for
the beverage Coca-Cola, have been maintained as
 | HANDBOOK OF BEST PRACTICES

trade secrets for a very long time indeed. However,
trade secret protection can end at any time, since
once the underlying information is no longer a se
cret, the trade secret protection disappears. Loss of
trade secret protection may result from disclosure,
successful reverse engineering, or independent
development by others. Unlike patent protec
tion, trade secret protection provides no recourse
against one who reverse engineers or independent
ly discovers the same matter. This uncertainty of
protection is the risk borne by one who chooses
trade secret protection.
In the context of plant innovation, trade
secret protection is a mixed bag. For seed com
panies, protecting plant varieties under trade
secrets alone may prove difficult. Maintaining
the secrecy of information is challenging be
cause crops are grown in open fields and seed
is sold on the open market with no assurances
of confidentiality. Hybrid seed varieties are the
easiest to maintain as a trade secrets. Since the
exact characteristics of the parental lines of a
hybrid cross are difficult for others to ascer
tain, the owner of the hybrid plant variety may
maintain the parental lines as a trade secret and
sell only the seed resulting from the cross of the
parental lines. Trade secret protection might
also be employed to protect know-how, or the
methods and techniques of the plant breeder.
Additionally, trade secret protection may be
used to protect an invention during the patent
examination period in order to protect an in
vention until a patent issues.
Most importantly, trade secret protection is
instrumental for protection of innovations that
do not otherwise qualify for protection under
patent and patent-like protection regimes. Trade
secret protection extends to the same subject mat
ter covered by patents and requires only secrecy.
Consequently, trade secret protection is vital for
protecting matter where patent and patent-like
protection is unavailable.
.2 Geographic indications, trademark,
and copyright protection

To a much lesser extent than patents (and to some
extent trade secrets), the protection provided
under geographic indications, trademark, and
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copyright may also be used to protect plant in
novations. The first of these three, the geographic
indications regime, is not traditionally protected
under U.S. law, but is recognized under a treaty of
the World Trade Organization. Geographic indi
cators communicate to consumers the association
between a product and the territory from which it
originates, which may indicate the product’s qual
ity, reputation, or other characteristic. The most
prominent example of geographic indicators is
the designation given to wines, for example cham
pagne and Bordeaux. Geographic indicators may
be used to differentiate among plants originating
from different territories.
The second regime, trademarks, focuses on
communicating to the consumer the association
between a product and the source of the product,
such as its manufacturer. This may reflect on the
product’s quality or authenticity. Trademarks may
differentiate one plant breeder’s product from an
other breeder’s products, stopping competitors
from using the good name a plant breeder has
built in its popular varieties. The leading inter
national treaties governing trademark protec
tion include the Paris Convention, the Madrid
Agreement, and the Madrid Protocol, all of which
are administered by WIPO.
The last of the regimes, copyright, protects
works “fixed in any tangible medium of expres
sion.”29 Copyright may be used to protect works
of authorship such as descriptions of processes,
training materials, and brochures, as well as ar
tistic renderings of plant varieties and other an
cillary materials. While copyright protects the
expression of an idea, the copyright does not
protect the underlying idea itself. Anyone is
free to use the ideas contained in a copyrighted
work. Therefore, while a copyright may protect
the written expression that describes a new plant
variety, the copyright does not offer protection
for the plant variety itself. Internationally, the
minimum substantive standards of protection for
copyrights are set forth in the Berne Convention,
a multinational agreement established in 1886,
and in the Agreement on Trade Related Aspects of
Intellectual Property Rights (TRIPS Agreement),
an agreement administered by the World Trade
Organization.

4. CONCluSION
In the context of agricultural biotechnology, sev
eral IP regimes are available to provide protection
for plant innovation. The three most important re
gimes are utility patents, plant variety protection,
and trade secrets. Through careful consideration of
the relative demands and benefits of each regime
in terms of the protection it offers for different
types of plant innovation, individual approaches
may be custom-tailored to suit the needs of the
inventor and the nature of the invention. n
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Protection des Obtentions Végétales.
11 “International Convention for the Protection of New
Varieties of Plants,” art. 14, 19 March 1991, available at
www.upov.int/en/publications/conventions/1991/w_
up911_.htm.
12 See note 11.
13 UPOV, “International Union for the Protection of
New Varieties of Plants: What It Is, What It Does,”
www.upov.int/en/about/pdf/pub437.pdf.
14 7 U.S.C. § 2402(a)
15 7 U.S.C. § 2401(a)(3)
16 7 U.S.C. § 2541(e)
17 7 U.S.C. § 2543
18 7 U.S.C. § 2544
19 7 U.S.C. § 2402(a)(1)
20 7 U.S.C. § 2402(a)(2)
21 7 U.S.C. § 2401(b)(5)
22 7 U.S.C. § 2402(a)(3)
23 7 U.S.C. § 2402(a)(4)
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24 7 U.S.C. § 2483(b)
25 7 U.S.C. § 2567
26 35 U.S.C. § 161
27 35 U.S.C. § 163
28 35 U.S.C. § 162
29 17 U.S.C. § 102(a)
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CHAPTER 4.5

Plant Breeders’ Rights: An Introduction
williaM h. lesseR, Susan Eckert Lynch Professor of Science and Business,
Chair of the Department of Applied Economics and Management, Cornell University, U.S.A

ABSTRACT

Based on the averages, there is a good chance that your
country has decided to fulfill its TRIPS (Trade-Related
Aspects of Intellectual Property Rights) Agreement com
mitments by selecting an “effective sui generis system” over
patents for plants, something more commonly known as
plant breeders’ rights. This chapter attempts to explain
what plant breeders’ rights are by describing the organi
zation and function of the plant breeders’ rights system.
Covering the objectives, scope, protection requirements,
and examination provisions, the chapter compares the
plant breeders’ rights system with the patent system and
attempts to clarify specific puzzling issues. These include
concerns that the latest UPOV Act does not address farm
er seed savings (the choice is left to individual countries,
with virtually all countries choosing to allow seed saving).
Plant breeders’ rights are less puzzling once the intent and
structure of the system are understood. The system is, in
fact, one with very specific, if narrow, objectives.

1. InTRoduCTIon
Guild members in mid-15th century Venice,
averse to direct competition from former ap
prentices, passed a law prohibiting the apprentice
from entering the trade until about 18 years had
lapsed. That edict, according to intellectual prop
erty (IP) historians, marked the origins of pat
ents. Indeed, the duration of a patent (20 years
from date of filing the application) is said to be
modeled after that apprenticeship period in longago Venice. Yet some easily copied creations were
not granted similar IP protection, in Venice or

anywhere else, until many centuries had passed.
Plants are one example of this. Food, fiber, and
ornamental crops (F1 hybrids excepted) carry in
themselves the ability to regenerate true to form,
whether sexually or asexually. Anyone hold
ing a seed or a cutting immediately possesses all
the skills of the master to recreate the variety of
plant from which the seed or cutting came. Yet
not until 1930 (the U.S. Plant Patent Act) did
legal restrictions apply to the use of plant ma
terials for regenerative purposes, and even then
protection only applied to asexually propagated
plants (excluding tubers). An additional 30 years
passed before a harmonized format for legisla
tion covering IP protection for all plant varieties
emerged. That is the International Convention
for the Protection of New Varieties of Plants, or
UPOV in its French acronym, an international
treaty first adopted in 1961 and revised several
times, the latest in 1991. The form of intellectual
property created by UPOV is known widely, if
informally, as plants breeders’ rights (PBR). This
chapter describes the acts and modes of opera
tion of PBR under UPOV-compatible national
legislation. While every effort is made here to
be complete and accurate, it would be impos
sible discuss all of the considerations needed to
appreciate every possible contingency. Persons
wanting to learn more should refer to the text
of UPOV and other official documents, such as

Lesser WH. 2007. Plant Breeders’ Rights: An Introduction. In Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org.
© 2007. WH Lesser. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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at the UPOV Web site.1 The Handbook chapter
PBR in the Developing World, discusses the ef
fects of PBR laws and the available alternatives at
the national level.

2. WHAT ARE pLAnT BREEdERS’ RIGHTS?
PBR is a patent-like system that allows the plant
variety owner to prohibit specific unauthorized
uses of the variety. PBR laws apply only to plants,
and hence are among the class of sui generis sys
tems, that is, special purpose systems. Laws ap
plying to computer chips (that is, mask works …
the set of templates used to manufacture chips)
form another sui generis system. In fact, sui gene
ris systems have been applied to everything from
aeronautics to Xerox® machines. These systems
differ significantly from patent laws. The differ
ences between the two systems—and the similari
ties—are explained below.
PBRs, like patents and other forms of IP law,
are forms of national legislation. That is, protec
tion applies only in countries where protection
has been sought and granted. Thus, the owner of
a sunflower variety protected in the United States
would have no legal control over how that vari
ety was used inside Canada. Critically, however,
the variety owner could prevent the importation
into the United States of the variety, including (in
most cases but depending on the specific coun
try’s sui generis laws with regard to plant varieties)
grain, plants, plant parts, and, in some countries,
even manufactured products produced using the
protected variety. In the case of a U.S. PVP-pro
tected sunflower variety, the variety owner could
not prevent it from being planted, grown, har
vested, or sold inside Canada, but U.S. PVP-pro
tected sunflower seed, sunflower meal, sunflower
oil, and similar products could be prevented from
entering the U.S. stream of commerce.
PBR under the TRIPS Agreement (Agreement
on Trade-Related Aspects of Intellectual Property
Rights) is a component of the World Trade
Organization (WTO). Signatories of WTO (cur
rently about 150) are committed to comply with
the TRIPS requirements of a harmonized mini
mum level of IP rights protection. Although the
TRIPS text is quite exhaustive in most regards,
2 | HANDBOOK OF BEST PRACTICES

only a single sentence refers to PBR. Article
27.3(b) reads, in part, that WTO members must
provide plant variety patents, “an effective sui ge
neris system,” or both. Most countries new to pro
tecting plants are opting for PBR over patents.
PBR is clearly a sui generis system, but what con
stitutes “effective” is less clear.

. WHAT RoLE doES upov pLAy?
If PBR is based on national law, what role does
UPOV, an international convention, play?
Essentially, UPOV establishes a framework law
that may be adopted by countries into their own
national laws. After having done so, a country
could submit its national law to the governing
body of UPOV for evaluation and, if the law was
found to have similar critical elements, the coun
try could become a UPOV-signatory nation. In
practice, there is usually an informal assessment
done by UPOV prior to final diplomatic submis
sion. UPOV does provide a mechanism for har
monizing national laws and providing standard
ized definitions/interpretations of terms. UPOV
also requires nondiscrimination against foreign
applicants of other Union members (National
Treatment, Article 4 of 1991 Act). However, that
Article has largely been supplanted by the geo
graphically broader national treatment require
ments of TRIPS (Article 3). UPOV member states
have training and other technical support avail
able to them, although an annual membership fee
based on national income is imposed. Countries
can and do have PBR systems without joining
UPOV, but little is known about their opera
tion and few countries have implemented them.
Since its inception, UPOV has adopted four acts
(1961, 1972, 1978, and 1991). Members may
at their discretion adopt a more recent Act, but
older acts are closed. Presently, the 1991 Act is
the only one now open to new members. There
are some important differences between the 1978
and 1991 acts, to which essentially all current
members belong. These differences are discussed
below. All terms and references here refer to these
acts. There are some national-level differences,
but for the most part identifying them involves a
greater level of detail than is possible here.

CHAPTER .

. HoW do pBRS WoRk?
PBR systems, like other IP systems, have three
major components:
1. Definition/identification of protectable sub
ject matter
2. Requirements that must be met to receive
protection
3. Rights of the variety owner
.1 Identifying what can be protected

As a sui generis system, protection is limited to
plant “varieties,” but this term lacks a standard
definition. The definition in the 1991 Act (Article
1(vi)) reads in part:
a plant grouping . . .
• defined by the expression of the character
istics …
• distinguished … by the expression of at
least one of the said characteristics and
• [having] suitability for being propagated
unchanged
Beyond its technical relevance, this defini
tion is significant since it departs from the lan
guage of earlier acts. The 1978 Act lacked any
such definition, while the 1961 Act (Article 2.2)
refers to a variety as “any cultivar, clone, line,
stock, or hybrid which is capable of cultivation….”
Certainly, one purpose for defining variety is to
distinguish what is protectable under UPOV
from those “plant genetic resources” that fall
under the Convention on Biological Diversity
(CBD). As a general matter, a plant variety under
UPOV would also be a plant genetic resource as
defined by the CBD. Furthermore, the interna
tional convention typically (but not universally)
allows the more recent convention to supercede
the prior one. The CBD was ratified in 1992 and
went into effect in 1993. However, the CBD
(Article 16.2) does provide for the “adequate and
effective protection of intellectual property rights,”
so PBRs would seem to operate independently of
national laws enacted under the CBD, although
exceptions could arise. There might be conflict,
for example, over traditional farmer-bred variet
ies, often referred to as landraces. Landraces are
certainly genetic resources and, arguably, plant
varieties. However, as a practical matter, hetero

geneous landraces rarely satisfy the uniformity
and stability requirements for PBR protection,
so a conflict in practice seldom arises. This does
not mean that a landrace is specifically excluded
from PBR protection, or that one could not be
protected. Rather, the UPOV protection re
quirements demand more specific attention to a
landrace (such as backcrossing), so the issue of
whether, or not, landraces qualify for PBR pro
tection actually seldom arises. As to UPOV, it
is quite evident that the system is intended for
planting materials, whether they are food crops
or horticultural varieties, that will be sold on a
commercial basis.
Another area of potential overlap is with
the offering of patents and PBR for a plant. The
TRIPS Agreement specifically allows patents for
plants, and, in the United States, both forms of
protection have been available for some time. The
matter has, however, not been so straightforward
in E.U. countries, due to the adoption of the
European Patent Convention (EPC). The EPC
(Article 53(b)) excludes protection for “plant or
animal varieties,” raising the question of just what
the appropriate definition of variety is. Rulings
on this question have seesawed back and forth
for decades, but the current (and likely sustain
able) rule is that a plant variety is in a fixed form
regarding all of its characteristics. An invention
that is applicable to a number of varieties is not
a plant variety and is thus patentable. This inter
pretation, while not binding in other countries, is
of relevance since Article 53(b) wording has been
adopted into the patent laws of a number of other
countries.
.1 Protection requirements

To be eligible for protection under UPOV-based
laws, a variety must be (Article 5, 1991 Act,
Article 6, 1978 Act):
• new
• distinct
• uniform
• stable
These requirements are often abbreviated
as DUS. Newness (or novelty) requires that the
applicant variety has not been “sold or otherwise
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disposed of to others” for more than one year in
the country of application or for four years (six
for trees or vines) elsewhere. This requirement
assures that the public is not giving away exclu
sivity rights to something already available, while
recognizing that some limited use or testing will
typically be required prior to application.
Uniformity and stability necessitate a certain
amount of backcrossing, so that the variety repro
duces true to form across individual plants (unifor
mity) and across generations (stability). Stability
and uniformity serve the important function of
making a variety identifiable after propagation.
The two also serve important commercial needs.
UPOV has sometimes been criticized for promot
ing genetic uniformity through the stability and
uniformity requirements. The text reads “suffi
ciently uniform in its relevant characteristics” (Article
8, 1991 Act) and “stable [in] its relevant character
istics” (Article 9, 1991 Act). That is, stability and
uniformity are required only to a degree, and only
in certain characteristics. The requirements are
variable and limited, beyond which a protectable
variety can be as heterogeneous as is feasible from
the prospective of UPOV. Commercial require
ments may necessitate broader uniformity, but this
is not relevant to UPOV. Rather, distinctness is the
driving characteristic: “A variety shall be deemed
to be distinct if it is clearly distinguishable from any
other variety whose existence is a matter of common
knowledge at the time of the filing of the application”
(Article 87, 1991 Act). The wording in the 1978
Act (Article 6.1(a)) is nearly identical, except for
the inclusion of “by one or more important charac
teristics.” That is, the variety must be distinguish
able by one or more characteristics, such as flavor,
color, or virus resistance. What characteristics are
considered to be distinguishing ones is a matter of
national interpretation.
. Rights of variety owner

Under the 1978 Act (Article 5.1), the permission
of the owner is required for:
• production, for purposes of commercial
marketing
• offering for sale or offering marketing rights
to reproductive or vegetative propagating
material
 | HANDBOOK OF BEST PRACTICES

To those activities, the 1991 Act (Article
14.1) added the following activities for which
permission of the owner must be given:
• production or reproduction
(multiplication)
• conditioning for the purposes of
propagation
• exporting
• importing
• stocking for any of [these] purposes
The specificity of these rights enhances the
ability of the rights owner to exclude access, the
only right granted by PBR and other IP rights
systems. For example, under the 1991 Act, it is
sufficient to show unauthorized reproduction,
while the 1978 Act required proof of intent to
“commercial[ly] market” the material. Similarly,
under the 1991 Act (Article 14.2) protection is
extended to “harvested materials, including entire
plants or parts of plants.” This means, for example,
that the blooms from an unauthorized propaga
tion of a rose variety overseas can be barred access.
Under the 1978 Act (Article 5.4), such an exten
sion of protection was optional. Finally, under
Article 14.3 in the 1991 Act, a signatory country
may choose (but is not required) to extend pro
tection to “products made directly from harvested
material of the protected variety.”
Two important exceptions to these rights
exist. First, protected varieties may be used for
breeding and experimental purposes (Article
15.1, 1991 Act and Article 5.3, 1978 Act). This
is a right mandated by UPOV, and typically re
ferred to as breeders’ rights. The freedom to use the
variety resulting from the breeder’s effort, how
ever, differs between the two acts. It is an impor
tant and arcane enough issue to warrant separate
treatment.
The second major exception to the rights
listed above is the right of a grower (farmer) to
retain the crop as a seed source for a subsequent
season. This right is absolute under the 1978
Act because, as there is no commercial market
ing involved, it is not prohibited. The 1991 Act
(Article 15.2) makes this right (typically known
as the “farmer’s privilege”) optional. This Article
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is sometimes misconstrued as the elimination of
the farmer’s privilege, when what it really does is
allow each nation to choose. At present, almost
all countries have chosen to retain the farmer’s
privilege. A notable distinction is the European
Union, which requires farmers to pay a royalty on
saved seed. “Small” farmers are exempted. Note
also that this right is completely different and
separate from Farmers Rights as defined by the
Food and Agriculture Organization of the United
Nations (FAO).
Under UPOV, the PBR protection period is a
minimum of 15 years, which extends to 18 years
for woody plants under the 1978 Act (Article 8).
The 1991 Act (Article 19.2) extends the periods
to 20 and 25 years respectively.
..1 Testing (examination) methods

According to the 1991 Act, “Any decision to grant
a breeder’s right shall require an examination for
compliance with the [protection] requirements”
(Article 12, 1991 Act). The wording of Article 7,
1978 Act, is similar. Signatory countries nonethe
less have substantial latitude in how to conduct
the examination. The distinctness requirement
does, however, require a comparison with “any
other variety whose existence is a matter of common
knowledge at the time.” Thus, at a minimum, a
national examination system must maintain (or
have access to) a large database of variety descrip
tions, both protected and not protected, includ
ing varieties used both inside and outside the
country. Beyond that, countries exercise consid
erable flexibility. The E.U. nations, for example,
carry out a two-year field trial where the applicant
variety is compared to an established reference va
riety. Distinctness is recognized only in specified
characteristics by crop, and sometimes a quanti
tative basis is defined by a “crop committee.” For
example, an onion variety may be distinct in re
sistance to sprouting if 3% fewer sproutings oc
cur than in the reference variety after X months
of storage. As a variation of this approach, some
countries (such as Canada) require the applicant
to conduct the growouts (field evaluation of the
variety) under the supervision of the plant variety
office. Most PBR offices are within a ministry of
agriculture. Using the opposite approach is the

United States, where growouts are rarely under
taken. Instead, the claim of the applicant is essen
tially taken at face value. Moreover, distinctness
may be claimed in any characteristic, including
in those of no practical value. Improper claims
of distinctness are resolved in court between the
parties. To date there have been few if any court
cases resulting from improper claims. From an
economic perspective, the U.S. approach is sim
pler and less costly, while allowing more rapid
access to new varieties. Because a variety is pro
tected, however, does not necessarily mean it has
agronomic merit. Cosmetic breeding (“cosmetic”
traits do not contribute to the productivity of the
crop, for example, flower color for pulses) raises
costs, although the proliferation of available vari
eties would reduce their market prices. Choosing
a single approach, or choosing to adopt a combi
nation system, is a significant national decision.
The U.S. approach does rely more on an efficient
and transparent court system, something not
available everywhere. To emphasize that point, a
study done of Argentina’s PBR act (one of the first
in a developing country) determined that such a
system of PBR would not be effective until the
rights could be adequately enforced.
..2

Initial and dependent varieties

The 1991 Act (Article 14.5) does add a signifi
cantly new component: that of essentially derived
varieties. This component provides an exception
to breeders’ rights: protected materials may still be
used in a breeding program, but if the resultant
variety is judged to be essentially derived, it can
not be commercialized without the permission of
the initial variety’s owner. Before considering the
technical aspects of this article, it is perhaps help
ful to consider several justifications. If the back
ground or development breeder spends 15 years
breeding disease resistance from a wild relative
into a commercial variety, then under the 1978
Act provisions, the resultant variety could be used
as a basis of subsequent breeding, and within a
few years competitive varieties would appear. The
development breeder would then have difficul
ty recovering the costs of the 15 years of work,
meaning that, as a practical matter, background
breeding would have to be left to the public
HANDBOOK OF BEST PRACTICES | 

lESSER

sector. The owner of a leading commercial variety
would be in a similar situation regarding the in
sertion of a genetically modified trait by another
party. Under the 1978 Act, if herbicide resistance
had been produced by cross-breeding patented
genes into that leading commercial variety, then
the resulting genetically modified herbicide-resis
tant variety could be commercialized, with noth
ing owing to the original variety owner. Yet that
original variety owner would be prevented from
using the patented genes in its breeding program,
thus producing a distinct asymmetry of rights.
Article 14.5 is intended to correct this imbalance
by establishing two levels of protection:
• Initial varieties are those on which essen
tially derived varieties depend. If the initial
variety is protected, these essentially derived
varieties can be bred from an initial variety
but not commercialized without permission
from the variety owner. Essentially derived
varieties are often referred to informally as
dependent varieties. If the background-bred
variety were an initial variety, any minor
derivative varieties would be dependent
and, in practice, could expect to pay roy
alties. UPOV (Article 14.5(b), 1991 Act)
uses terms such as “predominately derived.”
• Other varieties retain the expression of the
“essential characteristics.” Essentially derived
varieties may be produced in a number of
ways, including by selection, back-crossing,
or transformation by genetic engineering.
Several UPOV-associated committees have
used words such as “the preponderance of ge
netic material.” Just how initial and derived
varieties are distinguished can be quite crit
ical, but this may not be clearly determined
until there are actual decisions settling dis
putes revolving around this issue. We do
know that many national PBR offices are
treating the matter as an infringement, that
is, the self-identified initial-variety owner is
left to sue the purported dependent-variety
holder, and it is up to the courts to resolve
the counterclaims. This approach relieves a
national office from having to making diffi
cult distinctions, but could prolong the pro
cess of identifying operational definitions.
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. HoW do pBRS CoMpARE
WITH pATEnTS?
There are more similarities than differences be
tween patent and PBR systems. Both operate by
temporarily privatizing something that would
otherwise have been freely available in the public
domain. A fee can be assessed for access as well as
for any rewards derived through market sales. In
their particulars, however, critical differences exist
between PBRs and patents.
.1

Protection requirements

Protection requirements for patents include nov
elty, inventive step (nonobviousness under U.S.
law), and utility (or industrial application). The
concept of novelty in the two systems is simi
lar, although most patent systems operate with
absolute novelty, or no prior public disclosure.
Inventive step in the patent system is similar to
the distinctness requirement in the PBR system.
Patents have always operated with a dependencytype system similar to the initial variety concept
in the 1991 UPOV Act, except that in the patent
system there are no statutory (text-based) state
ments about the dependency relationship or how
dependency might be achieved. A dependent pat
ent could, for example, be an improvement on
an existing product or process or a new use for
an existing product. The new product/new use
could be protectable in its own right, so that nei
ther owner could use the other invention without
permission. These details are worked out between
interested parties.
The utility requirement, stated as simply as
possible, means that some use for the product
must be identified. When applied to patents for
genes and gene fragments, the utility requirement
has raised serious issues that generally do not exist
for PBR. Protected varieties, as noted, are intend
ed for sale and, under many examination systems,
must display some practical merit. Uniformity
and stability have no comparable requirements
under patent law.
.2 Protectable subject matter

With respect to protectable subject matter, the
patent and PBR systems are quite different from
each other. Under patent acts, everything is pat
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entable except for identified exceptions. One
common exception is for “plant and animal vari
eties.” PBRs cover all genera and species, with cer
tain minimums under the several acts, as follows:
• 1978 Act (Article 4): on adoption, three
rising to at least 24 genera or species within
eight years
• 1991 Act (Article 3): for new members on
adoption, at least 15 genera or species, rising
to all genera and species within ten years
. Other components

PBR systems are distinct from patents in allow
ing an option, under the 1991 Act, for farmers to
save seed for subsequent seasons. Under patents,
such actions would constitute infringement. The
breeder’s right is statutory with PBR and hence is
relatively clear in its scope. National patent sys
tems do allow some research on patented inven
tions, but the form and extent of research allowed
is based on case law and so this is more difficult to
assess. The difference in this matter between pat
ents and PBR is one of clarity alone; however, this
makes research use under PBR a more clear-cut
process than for patented inventions. Provisions
for farmer’s privilege (where allowed) and breed
ers’ rights are generally considered to give hold
ers of PBR certificates weaker protection than do
patents. This helps explain why, where the choice
is available, commercial breeders often prefer pat
ents, or patents plus PBR, over PBR alone.
Patents are, however, typically far more costly
to apply for and to maintain. The difference is
not in the application fees structure, which may
in fact be lower for patents, but rather, a patent
usually requires an attorney’s assistance to prepare
the application. PBR applications are typically
completed by the breeders. Adding the elaborate
translation requirements under some patent laws,
and the annual maintenance fees can also make
patenting a costly process, compared with PBR.

. ConCLuSIonS
Although some legal ambiguity does still ex
ist within PBR legislation, the objectives of the
system are specific, and the laws and provisions,
if clearly understood, are manageable. The PBR
system shares several features with more conven
tional patent systems, but the two systems differ
in several crucial respects. As a sui generis system,
PBR laws apply only to plants and plant materi
als. But they work, like patents, to prohibit unau
thorized use of these materials.
UPOV establishes a framework to guide
signatory nations in adopting PBR provisions
in their own national laws. The acts have been
amended several times; currently, most nations
are operating under either the 1978 or the 1991
versions.
To be eligible for protection, a plant variety
must demonstrate novelty, distinctiveness, uni
formity, and stability. If protected, a potential
user must seek permission from the owner before
producing, selling, importing, or exporting the
variety or, in some cases, products made from or
with that variety. A few important exceptions to
this apply; for example, a breeder’s exemption al
lows researchers to use the variety for experimen
tal purposes, and farmers are generally allowed to
retain the variety for seed. In an important new
component of the 1991 Act, if research produces
a variety judged to be essentially derived from a
protected variety, it cannot be commercialized
without the permission of the initial variety’s
owner. n
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ABSTRACT

In ever-increasing numbers, institutions are establishing
technology transfer offices (TTOs). These offices serve a
variety of functions, all of which must be integrated to
cost effectively transfer technologies and to benefit the in
stitutions. A critical function of the TTO is to proactive
ly manage intellectual property (IP) issues pertinent to
crops. Crops can be covered by more than one form of IP
rights protection, often simultaneously. These rights pro
tections include trademarks, trade secrets, plant and util
ity patents, and plant variety protection (PVP). Closely
related is the importance of careful and organized genebank management, a critical component of an overall IP
and tangible property management system. PVP provides
one type of protection that allows TTOs to responsively
serve clients and generate revenue. PVP is a form of IP
rights protection for crops with potentially global appli
cations, and either a PVP office, or a PVP subsection in
the TTO, would be wisely established by an institution.
In addition, this chapter provides important information
to assist in establishing a national PVP office and in the
selection and implementation of various types of IP rights
protection for crops and germplasm.

1. INTRODuCTION
Plants affect people’s everyday lives in terms of
quality and cost—the cost of food, feed, fiber,
fuel, and other necessities. Plants provide raw
materials for industry, such as vegetable oils, rub
ber, and drugs and other health care items. By
2020 the Earth’s population is likely to reach 9
billion. To meet the increasing demand, annual

global food production will have to increase to
more than 3,000 million metric tons from the
current 1,800 million metric tons. At the same
time, productive farmland is, and will continue
to be, diverted at an increasing rate to nonfarm
uses, and access to water will continue to be a ma
jor limiting factor for agricultural productivity.
To address the challenge of meeting the
needs of the world’s growing population, plant
breeders are developing improved plants that
can produce more, while using less land and less
water. As trained professionals whose endeavor is
developing plants that are genetically equipped to
produce higher yields of quality products, plant
breeders will contribute significantly to meeting
these challenges. While producing higher yields,
these improved plants will also be more resistant
to pests and diseases, so they can potentially re
duce the need for large (and expensive) applica
tions of fertilizers and crop protection chemicals.
Finally, these plants reduce the need for additional
irrigation from precious water resources, thereby
contributing to further conservation.
The breeding of new plant varieties is thus
an economically important activity that con
tributes in many different ways to the social
and economic well-being of societies. In many
cases, new plant varieties are absolutely essential
for human survival. However, there are many

Dodds J, A Krattiger and SP Kowalski. 2007. Plants, Germplasm, Genebanks, and Intellectual Property: Principles, Options, and Management. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
© 2007. J Dodds, A Krattiger and SP Kowalski. Sharing the Art of IP Management: Photocopying and distribution through
the Internet for noncommercial purposes is permitted and encouraged.

HANDBOOK OF BEST PRACTICES | 

DODDS, KRATTIGER & KOWAlSKI

challenges associated with crop breeding. For
example, experience has shown that a breeder
has difficulty recovering his financial investment
when he sells his initial supplies in the first years
of a new variety’s life. The breeder’s competitors
can secure supplies of propagating material and,
in a short time, be in a position to compete with
the breeder, thus profiting from the many years of
effort invested by the breeder. In this way, the re
wards of the plant breeder’s innovative efforts can
be rapidly lost to himself or herself. The initial
phase of protection is therefore critical, because
developing new varieties in most plant species
may take between ten and 20 years.
These new varieties are crucial to the needs
of modern society. They contribute to a varied
diet and provide for a wide choice of ornamental
and amenity plants. Generating sufficient variety,
however, requires substantial investment in crop
breeding programs. Accordingly, many countries,
while continuing to invest in public sector plant
breeding research, have established open freemarket systems in which exclusive rights of ex
ploitation (patent-like protections) are granted to
the breeders of new varieties of plants.
This chapter presents a general overview of
the types of IP protections that are available for
plants. It then focuses on plant variety protection
(PVP) as one key example of plant IP rights pro
tection, an option that can be broadly applied to
the needs of developing countries.

2. DEFINITIONS
Before discussing some specific issues in relation
to crops, germplasm, and genebanks, it is impor
tant to have a common understanding of what is
meant by certain words:
• breed. To develop new or improved strains
of organisms, chiefly through controlled
mating or pollination and the selection of
offspring for desirable traits.
• breeding line. Genetic group that has been
selected and bred for special combinations
of traits.
• enhancement. The process of improving
germplasm accessions by breeding, while re
taining the important genetic contributions
0 | HANDBOOK OF BEST PRACTICES
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of the accessions. This process may entail
simple selection.
gene. The fundamental physical and func
tional unit of heredity. A gene is an ordered
sequence of nucleotides in a particular po
sition, on a particular chromosome, encod
ing a specific functional product.
genebank. A genebank is a special facility
that stores living samples of the diversity of
crop varieties and their wild relatives. These
samples are usually in the form of seeds or
other plant parts. Some of the plants that
genebanks hold are extinct in the wild. The
value of the genetic resources conserved
in genebanks encompasses not only their
current use value and expected future use
value, but also the option value associated
with the flexibility to respond to some un
known future events.
genetic resource. Often used as a synonym
to germplasm, this is a seed, plant, or plant
part that is useful in crop breeding, research,
or conservation because of its genetic attri
butes. Genetic resources are maintained for
the purposes of studying, managing, or us
ing the genetic information they possess.
improved material. An elite breeding line.
landrace. A population of plants, typically
genetically heterogeneous, commonly de
veloped in traditional agriculture from
many years of farmer-directed selection and
specifically adapted to local conditions.
public domain. Public ownership status of
information not protected by patents or
copyrights.
wild species. A species that has not been sub
ject to breeding with intent to alter them
from their wild state.

3. IP ISSuES THAT AFFECT GENETIC
RESOuRCE MANAGEMENT
It is useful to recall that plant breeding is a knowl
edge-based activity. Consequently, it is a nonex
haustive activity. In other words, the results of ap
plying the knowledge are not decreased if shared
with others. What is lost in sharing, however, is
market value. In other words, a plant breeder who

CHAPTER .

has invested millions of dollars over many years
cannot extract value if others appropriate the new
variety and sell it at the mere cost of seed produc
tion. The free distribution of varieties provides
the breeder with no incentive to invest. IP sys
tems remedy this situation by providing a level of
protection to breeders.
IP rights is a broad term for the various rights
that the law provides for the protection of eco
nomic investment in creative effort. The principal
categories of IP protections relevant to agricultur
al research are patents, plant variety rights, trade
secrets, copyrights, and trademarks.
.1 Patents

Patents are a statutory form of protection that
allows an inventor rights of exclusivity on the
sale or use of his or her invention for a lim
ited period of time, in a particular territory,
in exchange for a full public disclosure of the
invention.
In the case of plants, there are two forms
of patenting. The first is called a plant patent.
It applies only to materials that are asexually
propagated, such as pineapples and bananas.
The second is called a “utility patent.” This does
not protect the plant per se, but rather the in
vention that is embodied in the plant (for ex
ample, a method for conferring insect resistance
through the incorporation of resistant genes into
the plant).
.2 Plant variety protection

Plant variety protection (PVP) is another form of
IP protection for plants. PVP gives the breeder
exclusive rights to a new and distinct plant variety
so that the breeder can exploit it.
The breeder is defined by the 1991 UPOV
(International Union for the Protection of New
Varieties of Plants) Convention as the person
who bred, or discovered, and developed a variety.
Therefore, protection is not limited to breeders
who produce a variety as a result of crossing par
ent plants and selecting from the progeny. The
term breeder also includes a person who discov
ers a mutation and converts that discovery into
a cultivated variety by a process of selective

propagation. Discovery itself, however, does not
constitute breeding.
The PVP Act (PVPA), enacted in December
of 1970 and amended in 1994, provides legal IP
rights protection to developers of new varieties
of plants that are sexually reproduced (by seed)
or are tuber propagated. Bacteria and fungi are
excluded. The PVPA is administered by the U.S.
Department of Agriculture.
A Certificate of Protection is awarded to an
owner of a variety after an examination shows that
the variety is new and distinct from other variet
ies and is genetically uniform and stable though
successive generations. The term of protection is
20 years, for most crops, and 25 years for trees,
shrubs, and vines. The owner of a U.S.-protected
variety has exclusive rights to multiply and mar
ket the seed of that variety.
The characteristics of the PVP systems are
summarized in Table 1 and are compared both
to plant patents and utility patents. A detailed
discussion of PVP and its global applicability is
published by Blakeney and colleagues.1
. Trade secrets

U.S. trade secret laws have been used to protect
in-house breeding materials, such as the inbred
lines of maize used as parents of hybrids. These
laws do not, however, protect against indepen
dent discovery or reverse engineering of products
by the purchasers.
It should be remembered, moreover, that ge
netic resources have a dual property nature: they
are physical material (tangible property) that may
be associated with human-made improvements
(IP). This dual nature is the reason for genetic re
sources to be, on the one hand, physical property
in the form of germplasm and, on the other hand,
IP in the form of modified genetic information
constituting inventions, trade secrets, and new
plant varieties.
. Copyrights

Copyrights are becoming more important for pro
tecting IP in the field of plant breeding because
the databases that hold information about plant
genes can often be copyrighted. Such copyrights
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Single varietal claim

Varietal claim, generic claims, claims
to plant genes, gene transfer vectors,
processes for producing plants, and
so on

Prevents others from making, using,
or selling claimed invention, or from
selling a component of the claimed
invention

Not determined

Claims

Duration of
protection

Double
protection

Protection allowed by both patents
and PVP

15 years for most crops
(20 years for grapevines
and trees)

Exemptions

Protection by both patent
and PVP not allowed

20 years for most crops (25 years for
grapevines and trees)

Exemptions for breeding
and for farmers to save
own seed mandatory

Rights

Priority

Breeders’ rights and farmers’ rights,
in principle compatible with TRIPS
but not yet tested

Exemptions for breeding except
where new variety is essentially
derived; optional farmers’
exemption and only for use on same
farm and subject to a license and/or
fee; private use and research

Prevents others from
producing for commercial
purpose, offering for sale,
marketing

20 years from date of filing

Prevents others from making
the patented product, using the
patented process, or using, offering
for sale, selling or importing for
those purposes the patented
product or the product obtained by
the patented process (extends to
harvested material)

Prevents others from producing or
reproducing, conditioning for the
purpose of propagation, offering
for sale, selling or other marketing,
importing, exporting, stocking for
any purposes detailed above

First to invent in the United States

20 years from effective filing date
(after 8 June 1995); 17 years from issue
date (prior to 8 June 1995)

As complete as possible
photographs or drawings

Protected while application is
pending, plus 20 years from
issuance date for most crops
(25 years for vines and trees)
First to file in the United
States or another UPOV
member country

Exemptions for developing
a new hybrid or variety and
for farmers’ saving and sale
of seed; compulsory license
provision

Prevents others from
importing or selling, sexually
or asexually reproducing,
distributing without proper
notice, producing a hybrid
or new variety, using the
claimed plant

Single varietal claim

Description of novel
characteristics and
genealogy, seed deposit

First-generation hybrids,
uncultivated plants
Distinctness, uniformity,
stability

Sexually reproduced plants

(since 1970; united States)

PVP Act3

Source: Modified from Krattiger and Potter. 4

First to invent in the United States

20 years from effective filing date
(after 8 June 1995); 17 years from
issue date (prior to 8 June 1995)

Does not protect sexual
reproduction of claimed plant;
does not protect plant products

Prevents others from asexually
reproducing, selling, or using
claimed plant

Novelty, distinctness, stability

Enabling disclosure, best mode
disclosure, deposit of novel material

Requires
Description of novel characteristics
and genealogy, enabling disclosure,
deposit of novel material

Uncultivated and tuberpropagated plants

Asexually reproduced plants,
including cultivated, mutant, and
hybrid

Plant Patent Act

(since 1930; united States)

Disclosure

Plant genotypes not normally found
in nature

(since 1985; united States)

utility Patents

Novelty, utility, nonobviousness,
enablement

Novelty, distinctness, uniformity,
stability

All plant species and enabling
technologies

TRIPS Compatible
Patent law2

Novelty, inventiveness, enablement

Novelty, distinctness,
uniformity, stability

Varieties of all genera and species

Varieties of selected
genera and species as
listed

Protects

Excludes

uPOV 91

uPOV 78

Action or
stipulation

Table 1: Comparison of Plant Variety Protection Systems
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do not, however, affect trade in products devel
oped using the protected information.
. Trademarks

Trademarks can be used to protect brand names,
such as Monsanto’s Roundup Ready®. But trade
marks protect only the names and other symbols
denoting products or technologies, not the tech
nologies themselves. Still, trademarks may give
customers a proof of quality, and so they may be
as important as variety protection.

4. “NON-IP” MATTERS AFFECTING
GENETIC RESOuRCES MANAGEMENT
As indicated above, there are tangible property
rights that have a bearing on the ownership of
genetic resources. The Convention on Biological
Diversity (see below) affirmed the sovereign rights
of nations over their genetic resources. Such own
ership is a tangible property right on the owner
ship of the actual material.
There exist, however, a number of other
non-IP matters that affect the day-to-day lives
of genetic resource specialists working in the
field. These most typically include indigenous
knowledge issues and access to and transfer of
materials.
.1 Indigenous knowledge

The formal IP system of patents, PVP, copy
rights, and so on is based on a set of statutory
(legislative) rules. The current system allows
so-called prior art to be used as a way of deter
mining whether novelty exists with regard to an
invention. The current formal system does not
adequately allow for indigenous knowledge to
form the basis of prior art or allow indigenous
people to be the inventors or breeders. This has
led to significant controversy in the international
community. Both WIPO (World Intellectual
Property Organization) and UPOV are actively
reviewing and debating this topic to try to devel
op a mechanism that would prescribe a role for
such knowledge within the formal system. One
noteworthy example within a national program
is the PVP Office of the Philippines’ mechanism

for allowing the registration of descriptors for
indigenous materials. These descriptors are re
viewed as part of the examination process for
awarding a PVP certificate.
.2 Material transfer agreements

When genetic resources are transferred, it is in
creasingly common for them to be accompanied
by an MTA. Such a document forms a contractual
relationship between the shipper and the recipi
ent. It is common for MTA agreements to attach
terms and conditions regarding both the approved
use of genetic resources and the rights to owner
ship of such materials or their derivatives.
MTA agreements can appear in a number of
forms. While the most common is a conventional
sheet of paper, it is also possible for the material
to come with language included on the bag. The
use of so-called bag-tag language is becoming in
creasingly common. At issue, however, is whether
the “shipper” who applies the MTA language ac
tually owns title to the materials and has the right
to allocate ownership rights.

5. INTERNATIONAl TREATIES
Generally, plant genetic resources are governed by
national, regional and international laws, which
regulate ownership, access, and benefit sharing.
Internationally, these concerns are regulated by
treaties such as the CBD, the International Union
for the Protection of New Varieties of Plants
(UPOV) Convention, the International Treaty
of Plant Genetic Resources, and the Agreement
on Trade-Related Aspects of Intellectual Property
Rights (TRIPS).
.1

The Convention on Biological Diversity (CBD)

The CBD is the central instrument related to
international biodiversity. It broadly delimits
the rights of states and other relevant actors over
biological resources and affirms the sovereign
rights of states to exploit their own resources
pursuant to their own environmental policies.
The sovereign rights of states over their own bio
logical resources are limited by the recognition
that these resources are a common concern of
humankind.
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The Convention also provides a broad frame
work for member states’ policies concerning
access, development and the transfer of technolo
gies. It also acknowledges the necessity for all par
ties to recognize and protect IP rights in this field.
The Convention further recognizes both the de
pendence of local communities on biological re
sources and the roles that these communities play
in the conservation and sustainable use of these re
sources. Finally, it points to the need for equitably
sharing the benefits that arise from the use of tra
ditional knowledge, innovations, and practices.
.2 UPOV

The UPOV Covention is the only international
treaty focusing on PVP. It recognizes not only the
rights of individual plant breeders who have de
veloped or discovered plant varieties that are new,
distinct, uniform, and stable, but also accords cer
tain rights to farmers. Under the 1978 version of
the Convention, farmers are permitted to reuse
propagating material from the previous year’s har
vest, and they can freely exchange the seeds of pro
tected varieties with other farmers. Plant breeders
are also allowed to use protected varieties to breed
and commercialize other new varieties.
The latest revision of the Convention, ad
opted in 1991, has further strengthened the
rights of commercial plant breeders. These revi
sions include the obligation for member states to
provide protection to all plant genera and species.
Furthermore, it extends breeders’ rights to all seed
production of a protected variety, even though
countries can decide on their own internal laws
regarding this issue. In some cases, the revision
grants to commercial breeders the rights to the
harvested material of the variety and extends pro
tection to varieties that are “essentially derived”
from a protected variety.
. The International Treaty on Plant Genetic
Resources for Food and Agriculture

The International Treaty on Plant Genetic
Resources for Food and Agriculture was adopted
by consensus of the member states of the United
Nations Food and Agriculture Organization
(FAO) in November 2001. The Treaty envisions
a multilateral system to facilitate access to key
 | HANDBOOK OF BEST PRACTICES

genetic resources, with minimal procedural and
administrative costs. Initially, the treaty applies
to 35 crops and some 80 forages that are un
der the control of member governments and
that are not subject to IP rights. Thus, the treaty
includes practically all the crops that humanity
depends on for its food supply. The treaty in
vites all holders of listed plant genetic resources
to join the multilateral system. The list itself can
be changed with the consensus of the parties to
the treaty.
The multilateral system is intended to be ef
ficient, effective, and transparent. It aims to ease
access, not only to plant genetic resources for
food and agriculture, but also to information
about those resources, so that any benefits that
may arise from their use can be shared fairly and
equitably.
In this context, it is worth dwelling briefly on
the difference between farmers’ rights and farmers’
exemption/privilege. Because the terms are often
used interchangeably, there has been significant
confusion regarding their use. Farmers’ rights
is a term developed by FAO under the Revised
Undertaking for Plant Genetic Resources.
Resolution 5/89 of the treaty states, “…rights
arising from the past, present and future contribu
tions of farmers in conserving, improving and mak
ing available plant genetic resources.” Resolution
3/91 states that these rights are to be “implement
ed through an international fund on plant genetic
resources that will support plant genetic conserva
tion and utilisation programmes, particularly, but
not exclusively, in the developing countries….”
The difference is further elaborated in the
FAO Treaty. However, no specific future action
is targeted here; instead, the treaty gives voice to
a general equity objective. These areas are still the
subject of much debate, and the mechanism with
which to ensure both participation and benefit
sharing has not yet been elucidated.
The concept of farmers’ exemption or farm
ers’ privilege in PVP legislation, on the other
hand, hinges on the notion that a farmer has a
right to “fair use” of his or her own produced
seed. Most national legislations embrace this no
tion of fair use, as do UPOV’s model laws, and
allow farmers to use seed produced on their own
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farms for further sowing. Only if the farmer sells
or trades the seeds is an infringement of the PVP
holder’s rights committed. Article 15 of UPOV
1991 states that:
a) [Compulsory exception] The breeder’s right
shall not extend to:
(i) Acts done privately and for non-com
mercial purposes;
(ii) Acts done for experimental purposes;
[…]
b) [Optional exception] Notwithstanding
Article 14, each Contracting Party may,
within reasonable limits and subject to the
safeguarding of the legitimate interests of the
breeder, restrict the breeder’s right in relation
to any variety in order to permit farmers to
use for propagating purposes, on their own
holdings, the product of the harvest that
they have obtained by planting, on their
own holdings, the protected variety or a va
riety covered by Article 14(5)(a)(i) or (ii).
. The TRIPS Agreement

TRIPS was the result of an initiative by developed
countries to introduce more stringent IP rights
trade rules. The agreement sought to extend the
security of IP rights internationally. Article 27.1
of the TRIPS Agreement implies that patents
may be available in biotechnology fields, a posi
tion that Article 27.3 consolidates with regard to
granting IP rights in biotechnology, particularly
as it relates to plants.

6. SPECIFIC ISSuES RElATED TO
GENEBANK MANAGEMENT
A genebank manager addresses both the many
technical aspects relevant to the use of genetic
resources and issues related to the ownership
of genetic resources. As outlined below, these
issues usually come in different phases of the
work.
In accordance with the CBD, incoming
material must be acquired with the consent of
the nation that “owns” these resources. This
is achieved through a germplasm acquisition
agreement (GAA) or an MTA that clearly indi

cates the rights that the owner is giving to the
genebank in terms of using and distributing
such materials.
In-house materials may include those acquired
prior to the CBD. These may be in the form of
genebanks, botanic gardens, and so on. While the
ownership of in-house materials is still conten
tious, the law is clear that such materials may be
used freely without prior permissions. It is very
important here to distinguish between “genetic
resources” collected in nature and “improved
materials.” IP rights will attach only to the latter.
Indeed, a sound knowledge of the biology of the
materials and the ownership and legal rights as
sociated with them is essential.
Outgoing materials are those materials the
genebank manager distributes to others, either
for research, direct use, or for use in improve
ment programs. This is often when problems
arise. Carefully using appropriate MTAs is the
most effective way to deal with these issues. The
MTA should reflect a range of matters: interna
tional law, policy of the organization, nature of
the material, nature of the recipient, nature of the
acquisition of the material, and conditions relat
ing to incoming MTA on the material (see ex
amples included in this Handbook).
Genebank management has recently become
a very sensitive issue. An organized, stepwise ap
proach is vital for effectively managing a genebank
and for avoiding difficulties. Potential ownership
issues about genetic resources must be clearly ana
lyzed, and documentation procedures for the ac
quisition and distribution of such materials must
be effective and thorough.
The legal issues surrounding genebanks have
changed dramatically over the last decade. Such
changes will continue, and genebank manag
ers must be alert to the effects of these changes.
When appropriate, managers should seek profes
sional advice about how these changes affect their
respective institutions. Genebank managers must
not, however, lose sight of their crucial social role:
they guard and preserve the basic building blocks
upon which human survival and food security de
pend. They work not only for this generation but
for generations to come.
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7. PVP: IP PROTECTION FOR CROP
VARIETIES
PVP addresses a specific need that applies broadly
across the globe, in both developed and develop
ing countries. So-called PVP regimes are imple
mented in order to:
• provide breeders (both public and private
sectors) with an opportunity to receive a
reasonable return on past investments
• provide an incentive for continued or in
creased investment in future breeding
research
• recognize the legal right of the innovator to
be recognized as such
• acknowledge his or her economic right to
remuneration for his or her efforts
In order to foster these laws and agreements
within the global economy, UPOV was formed
through a union of states. These states agreed to
grant exclusive exploitation rights to the breeders
of new plant varieties on an internationally har
monized basis. UPOV developed a set of model
laws that provided a general legislative framework
for PVP. Indeed, some provisions of TRIPS re
fer to the use of UPOV standards as an effective
mechanism for complying with WTO standards.
One very effective aspect of this arrangement is
the provision for mutuality, which allows cross
protection between jurisdictions for states that
are members of the UPOV system. Countries
often use the model law produced by UPOV as
a framework for developing their own legisla
tive standards. This is not to say that the system
is wrinkle free. For example, the differences be
tween protected varieties and other forms of plant
genetic material (including genetic resources and
landraces) has yet to be established.
The U.S. system is a useful model and be
cause of the UPOV system’s efforts toward har
monization, most of the provisions in the U.S.
PVP system are consistent with those in other ju
risdictions. It should be noted that many jurisdic
tions have patent laws allowing for the protection
of plants. This is complementary to the PVP leg
islation. It is possible, and increasingly common
in the United States, for protection to be taken on
the variety, and, in addition, for a patent on the
 | HANDBOOK OF BEST PRACTICES

inventive nature of the product and/or process to
be filed. Finally, the new variety name is usually
trademarked. (For more information about the
U.S. PVP system, see section 3.2.)
The model law of UPOV, and effectively of
all national legislatures, also allows a government
to issue a compulsory use license. In effect, if a
country has a compelling need to multiply a pro
tected variety, then the government can issue a li
cense for its use. The PVP holder would, however,
still have the legal right to be given a reasonable
royalty payment.
To qualify as a protected variety, the plant va
riety coming out of a breeding program must be
able to demonstrate:
• distinctness
• uniformity
• stability
The way in which these criteria are met is de
scribed in more detail in section 7.3 below.
.1

PVP application process

PVP application forms and the supporting docu
mentation, such as the UPOV crop guides, will
guide the applicant (and examiner) through the
steps of describing the history, breeding origin,
and variety, making seed deposits, paying fees,
and, if all is as required, obtaining a PVP certifi
cate. If application materials exist, the relevant
ministry of agriculture will have them; if applica
tion materials are not available, this chapter pro
vides information to help develop them.
Anyone who is the owner, breeder, de
veloper, or discoverer of a unique cultivar of a
sexually reproduced or tuber-propagated plant
may apply for PVP. This applies to any citizen
in any UPOV member country. The applicant
may be an individual, a public institution, or a
corporation.
The protection works by prohibiting a per
son from selling, marketing, offering, delivering,
consigning, exchanging, or exposing the variety
for sale without explicit consent of the owner. In
addition, a person is prohibited from soliciting
an offer to buy the variety, or transfer or possess
it in any manner. It is also illegal to import or ex
port the variety, sexually multiply it, propagate it
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by tuber, use the variety in producing (as distin
guished from developing) a hybrid, or condition
the variety for the purpose of propagation. It is
worth adding here that plant parts (flowers, pol
len, and so on) are also protected. This is critical
in reviewing infringement actions to determine
where the material has been used.
In general, there are two exemptions to the
protection provided: 1) a research exemption
and 2) a farmer’s exemption (also called farmer’s
privilege).5
A research exemption allows for breeding to
develop a new variety; a farmer’s exemption allows
for the saving of seed for the sole use of replanting
the farmer’s land. However, if the farmer sells or
trades the seeds, he infringes on the rights of the
PVP holder. The controversies surrounding this
provision turn largely on the definition of terms.
It should be noted that neither plant patents nor
utility patents provide these exemptions.

distinctness. In the United States, the PVP office
does not perform tests to confirm the distinct
ness of a variety. That responsibility rests with the
applicant.
For uniformity, a statement must report
the level of variability in any characteristic of
the variety. Variation, which is predictable, de
scribable, and commercially acceptable, may be
allowed.
For stability, a statement of genetic stability
is required, showing the number of cycles of seed
reproduction for which the variety has remained
unchanged in all distinguishing characteristics.
Special mention should be made of essential
ly derived materials. Good examples are so called
“sports.” If PVP protection has been obtained on
a potato variety that has a red skin after decades of
breeding, and then someone selects a field sport
with a white skin, the new white skin material
is determined to be essentially derived from the
original variety and will be protected under the
1991 UPOV act.

. Examination standards

. Enforcement

.2 Exemptions

The owner must prove the distinctness, uni
formity, and stability of the new variety. The bur
den is entirely on the applicant.
For distinctness, the applicant may:
• list the single variety he or she believes is
most similar to the new variety and de
scribe how the new variety differs from it
• list a group of varieties that are similar to
the new variety and describe how it differs
from varieties within that group
• describe how the variety differs from all
other known varieties in the crop kind
The PVP office maintains databases of both
public and private varieties of crops. The exam
iner uses these and other sources to determine
which, if any, varieties are indistinguishable from
the new one. If the examiner finds varieties that
appear to be indistinguishable from the applica
tion variety, the applicant will be notified that
supplemental data is necessary. To obtain addi
tional data, applicants may perform additional
field or greenhouse replications and may use
DNA profiling and other analyses to substantiate

The owner of a protected variety may bring civil
action against persons infringing on his or her
rights, and the owner may ask a court to issue an
injunction to prevent others from further viola
tions. The owner of the protected variety must
bring suit in such cases—the USDA will not take
that action. In the United States, IP protection
for plants is provided through plant patents, PVP,
and utility patents. Plant patents provide protec
tion for asexually reproduced (by vegetation) va
rieties excluding tubers. PVP provides protection
for sexually (by seed) reproduced varieties includ
ing tubers, F1 hybrids, and essentially derived va
rieties. Utility patents currently offer protection
for any plant type or plant parts. A plant variety
can also receive double protection under a utility
patent and PVP.
. Contents of a complete application and
exhibit forms

A PVP application consists of a completed and
signed form that includes Exhibits A, B, C, and E
(Exhibit D is optional):
A) Exhibit A (Breeding History)
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B) Exhibit B (Statement of Distinctness, pre
viously called “Novelty Statement”)
C) Exhibit C (Objective Description)
D)Exhibit D (Additional descriptive
Information)
E) Exhibit E (Statement of Ownership)
Also required is a sample of at least 2,500 un
treated viable seeds, capable of propagating the
application variety, and, for a tuber-propagated
variety, verification that a viable cell culture will
be deposited. A check for the filing fee is also
required.
..1 Exhibit A: Breeding History

The applicant is required to provide the
following:
• full disclosure of the genealogy back to
publicly known varieties, lines, or clones,
including the breeding method
• details of subsequent stages of selection and
multiplication used to develop the variety
• statement of uniformity reporting the level
of variability in any characteristics of the
variety (commercially acceptable variability
is allowed)
• statement of genetic stability showing the
number of cycles of seed reproduction for
which the variety has remained unchanged
in all distinguishing characteristics
• information about the type and frequency
of variants observed during reproduction
and multiplication
• information about the frequency of offtypes (in other words, impure lines) ob
served or known to occur
..2

Exhibit B: Statement of Distinctness

The applicant is required to give a summary of
the variety’s distinctness, stating clearly how the
application variety may be distinguished from all
other varieties in the same crop. If the variety is
most similar to one variety or group of varieties,
the applicant must (1) identify these varieties and
state all differences objectively, (2) attach statisti
cal data for characters expressed numerically and
demonstrate that these are clear differences and
(3) submit, if helpful, seed and plant specimens
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or photographs (prints) of seed and plant com
parisons that clearly indicate distinctness.
..

Exhibit C: Objective Description of Variety

The PVP office has prepared forms for the appli
cant to provide a botanical description of the va
riety for most crops. These forms list the botanical
characteristics for a kind of crop and the degree
of expression of each characteristic. These forms
also provide a list of recommended varieties that
the applicant should compare to the application
variety. The applicant needs to complete the form
for his or her variety as thoroughly as possible.
.. Exhibit D: Optional Supporting
Information

The applicant may provide additional informa
tion, specimens, and/or materials in support of
the claims of the application.
..

Exhibit E: Statement of Ownership

The applicant is required to furnish a statement
for the basis of the applicant’s ownership. The
PVP office has prepared a form to simplify this
requirement. The form also includes a statement
to verify that the applicant is eligible to file for
PVP in the United States.
. Steps needed to start and operate
a national PVP office

You may be reading this chapter because you are
in the process of setting up a PVP office. If that
is the case, then the topics below will help you ef
fectively and efficiently establish the office.
The basic operation of this office and its ac
tions can be translated into the following steps:
1. Setting up the office. The initial setting up
of the office will have a physical component
(obtaining the necessary space, equipment,
and other physical resources) and a legis
lative component (setting up the laws and
regulations, and examining guidelines).
2. Appointing the staff. A registrar for the
PVP office, a number of examiners, and
support staff, both clerical and technical,
will need to be appointed.
3. Training the staff. The PVP office staff
needs to be trained in both the technical
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4.

5.

6.

7.

8.

9.

10.

11.

12.

processes related to the examination and
the legal and clerical matters related to is
suing and registering the certificate.
Establishing the formal procedure. The of
fice must set up formal procedures, such as
law enactment, rule approval, and exami
nation standards.
Notifying the public that the office is func
tional. Once the PVP office is functional,
staff must inform the public that they may
avail themselves of the services the office
provides.
Distributing information and application
material. As part of the public awareness
campaign, staff should make information
and forms publicly available. In an increas
ing number of jurisdictions, application
forms are available online at the PVP office
Web site.
Informing and educating the public
about how to apply. Attorneys and agents
may need to be educated about the actual
mechanics of preparing and submitting
applications.
Receiving application. The filing date is a
critical component of the application pro
cess, and detailed rules should inform ap
plicants about the application filing date.
Reviewing the applications. This is the
heart of the process. Applications are re
viewed (1) for compliance with general ap
plications standards and (2) for technical
content.
Examinations standards and their applica
tion. The 1991 UPOV act, the rules, and
possibly the examiner’s manual provide an
objective set of standards that can be ap
plied to particular applications. The impor
tance of such objectivity for the credibility
of the system cannot be overstated.
Communicating with the client. Effective
communication with the applicant is abso
lutely essential. All correspondence must be
consistently dated, numbered, and sent by
registered or certified mail.
Communicating with policy-makers.
When establishing the office, it will be
crucial to keep in very close communi

13.

14.

15.

16.

cation with senior policy-makers. The
act and regulations will need legislative
action, and they must also be consistent
with other domestic laws. Regulations
will also often need to comply with WTO
requirements.
Storing deposits. Facilities must be
arranged for storing exhibits of the
materials.
Preparing certificates. A format and style
must be established for the production and
registration of PVP certificates.
Dealing with disputes. The legislation and
regulations will usually contain provisions
allowing for applicants who are refused a
PVP certificate to appeal the decision either
through the PVP office and/or through the
judicial system.
Sample deposits. An appropriate, adequate
system must be in place for applicants to
deposit seed or plant materials. This facility
may belong to the ministry of agriculture
in most countries or may be managed by
a related organization. The facility should
meet appropriate international seed stor
age guidelines and have adequate mecha
nisms for safekeeping/security of the seed
samples.

8. CONCluSIONS
It is clear that a PVP regime effectively harmo
nized across different countries would significant
ly lower the costs for users, and hence increase re
turns on plant-breeding investments. This would
undoubtedly lead to more varieties and more
choices for farmers. A costly regime, on the other
hand, discourages smaller national companies
from filing for PVP protection and increases the
cost of participating in foreign markets that, in
turn, favors large multinational companies with
the resources and infrastructure to operate across
multiple national regimes.
All of the IP protection mechanisms dis
cussed in this chapter depend upon enforcement
by national governments. If a law is only as good
as its enforcement, then a regulatory body such
as a PVP office is only as good as the people who
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implement the regulations. In order to reinforce
national policy initiatives in many countries, a
comprehensive, in-depth training program is
recommended to equip personnel with the infor
mation and experience required to establish the
long-term health of a PVP system. This training
could be combined with a coordinated effort to
regionalize the PVP system through jointly train
ing administrators from a number of countries,
which would increase cooperation and harmoni
zation within the region.
Of course, different people within the system
require different training. As a starting point, all
participants, whether officers, management, or
even individuals in breeding companies, need to
be brought to a certain minimum level of com
petence in the application of the regulations. A
general program, such as a Web-based training
course or other distance-learning approaches,
could help to achieve this goal. For management
staff, tailored workshops could be used to expose
staff members to areas of conflict and to increase
their knowledge of the importance of PVP in the
development of plant breeding businesses. These
courses and workshops could be augmented by
an internship program, in which selected indi
viduals would be given more intensive training
through collaboration with public and private
institutions from countries with well-established
PVP systems. These highly trained individuals
could form a core group that would then further
develop staff expertise. n
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CHAPTER 4.7

Plant Variety Protection, International
Agricultural Research, and Exchange of Germplasm:
Legal Aspects of Sui Generis and Patent Regimes
MICHAEL BLAkENEy, Director, Queen Mary Intellectual Property Research Institute, University of London, U.K.

ABSTRACT

This chapter outlines the range of plant variety protec
tion regimes that currently exist internationally, includ
ing the International Convention for the Protection of
New Varieties of Plants, the Convention on Biological
Diversity, the Agreement on Trade-Related Aspects of
Intellectual Property Rights, and the International Treaty
on Plant Genetic Resources for Food and Agriculture. The
chapter commences with a history of intellectual property
laws affecting plant breeding and the genetic modification
of plants. It explores the trend toward the harmonization
of international standards and concludes with an examina
tion of the impact of these developments upon germplasm
exchange, international agricultural research, and food
security.

1. INTEllECTuAl PROPERTy RIGHTS
AND AGRICulTuRE
The first international intellectual property (IP)
convention was the 1883 Paris Convention for
the Protection of Industrial Property. In this in
strument, agriculture was envisaged as an area of
enterprise in which property rights could be se
cured, thus Article 1(3) of the Paris Convention
declared that:
Industrial property shall be understood in the
broadest sense and shall apply not only to industry
and commerce proper, but likewise to agricultural
and extractive industries and to all manufactured or
natural products, for example, wines, grain, tobacco
leaf, fruit, cattle, minerals, mineral waters, beer,
flowers, and flour.

Given the state of technology in 1883, the
inclusion of these agricultural subjects within the
Paris Convention was for the purpose of protect
ing trademarks and indications of source.
The first inclusion of biological agricul
tural innovations in an IP statute was in the
U.S. Plant Patents Act of 1930, which created
a sui generis system confining protection to
asexually reproduced plants, so confined be
cause of the view that sexually reproduced va
rieties lacked stability.1 The Act also excluded
tuber-propagated plants principally because of
a concern that protecting such plants would
lead to monopolies in basic foodstuffs such as
potatoes.2 Applicants for plant patents were
required to asexually reproduce the plant for
which protection was sought, to demonstrate
the stability of the characteristics of the plant
being claimed. Section 161 required that new
varieties be “distinct.” The statute did not de
fine this requirement, although the Senate
Committee report accompanying the act stated
that “in order for a new variety to be distinct it
must have characteristics clearly distinguishable
from those of existing varieties” and that it was
not necessary for the new variety to constitute
“a new species.”3
Legislation similar to the Plant Patents Act
was adopted in Cuba in 1937, in South Africa in
1952, and in the Republic of Korea in 1973.

Blakeney M. 2007. Plant Variety Protection, International Agricultural Research, and Exchange of Germplasm: Legal Aspects of Sui Generis and Patent Regimes. In Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. M Blakeney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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2. INTERNATIONAl STANDARDS FOR
SuI GENERIS PVP
As with other categories of IP, a key role in the
inclusion of agricultural innovations within the
international regulatory regime was played by in
dustry associations. The Congrès Pomologique de
France, held in 1911, had called for special pro
tection for plant varieties. This agitation contin
ued in the 1920s and 1930s, culminating in the
founding, in Amsterdam in November 1938, of
the International Association of Plant Breeders for
the Protection of Plant Varieties (ASSINSEL). At
its Semmering Congress in June 1956 a resolution
of ASSINSEL called for an international confer
ence to promulgate an international system for
the protection of new plant varieties. In February
1957, the French government issued invitations
to 12 western European countries4 to attend a dip
lomatic conference in Paris in May of that year to
consider establishing such a system. Participation
was limited by the French to those states who were
known to have similar concerns to it on this sub
ject. The conclusions of the 1957 Paris conference
were set down in its Final Act, adopted in May
1957. This recognized the legitimacy of breeders’
rights and established as the preconditions for pro
tection that a variety had to be distinct from pre
existing varieties and sufficiently homogenous and
stable in its essential characteristics. The act de
fined the rights of the breeder and acknowledged
the principle of the independence of protection.
At the second session of the conference, held in
Paris in late 1961, the International Convention
for the Protection of New Varieties of Plants, or
Union pour la Protection des Obtentions Végétales
(UPOV), was adopted. Article 4(1) applied the
Convention to “all botanical genera and species,”
but it was envisaged that the Convention would
have a gradual introduction. A list of 13 genera
was annexed to the Convention: wheat, barley,
oats or rice, maize, potato, peas, beans, Lucerne,
red clover, ryegrass, lettuce, apples, and roses or
carnations. Article 4(3) required each member
state, upon entry into force of the Convention,
to apply it to at least five genera from this list and,
within eight years, to all the listed genera.
Article 27 of the 1961 Convention provid
ed for its periodic review, with the first revision
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scheduled for 1972. Within the first 19 years of
its life, the UPOV Convention had attracted the
accession of only 12 states. A reason identified for
the reluctance of states to adopt the Convention
was the stringency of its provisions, in particu
lar the obligation of states to select either patent
or UPOV-style protection for plant varieties,
but not both. Article 2 of the Convention was
amended to permit the accession of countries,
like the United States, which had laws allowing
for the double protection of varieties under both
patent and UPOV-style sui generis laws. The list
of genera, annexed to the 1961 Convention was
removed. This list had contained mainly species
from temperate climates. Under the new Article
4, member states agreed to apply the Convention
to at least five genera, rising to 24 genera within
eight years. Additionally, a grace period was in
troduced to permit the marketing of varieties for
up to 12 months prior to submitting an applica
tion for plant variety protection (PVP).
A further broadening of the UPOV
Convention occurred with the 1991 revision. The
1991 Act requires states to protect at least 15 plant
genera, upon becoming members, and to extend
protection to all plants within 10 years (Article
3(2)). In response to demands from breeders in
developed countries, the 1991 Act removed the
prohibition against dual protection. The 1991 Act
recognized breeders’ rights to use protected variet
ies to create new varieties. However, this excep
tion is itself restricted to such new varieties as were
not “essentially derived” from protected varieties
(Articles 14(5) and 15). The drafters added this
restriction to prevent second generation breeders
from making merely cosmetic changes to existing
varieties in order to claim protection for a new
variety. The concept of essential derivation has,
however, proved highly controversial in practice.
Breeders have been unable to agree on a defini
tion of the minimum genetic distance required
for second generation varieties to be treated as
not essentially derived from an earlier variety and
thus outside of the first breeder’s control.5
From the perspective of farmers, probably
the most contentious aspect of the 1991 Act was
the limitation of farmers’ rights to save seed for
propagating “on their own holdings” the product
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of the harvest that they obtained by planting a
protected variety on their own holdings, “within
reasonable limits and subject to the safeguarding
of the legitimate interests of the breeder” (Article
15(2)). Unlike the 1978 Act, the 1991 version of
the farmers’ privilege does not authorize farmers
to sell or exchange seeds with other farmers for
propagating purposes. This is criticized as incon
sistent with the practices of farmers in many de
veloping nations, where seeds are exchanged for
purposes of crop and variety rotation.6
A number of developing countries have re
sisted the adoption of the 1991 Act as the stan
dard for PVP laws. The foreign ministers of the
Organization for African Unity issued a statement
at a January 1999 meeting calling for a morato
rium on IP protection for plant varieties until
an Africa-wide system had been developed that
granted greater recognition to the cultivation
practices of indigenous communities.

3. THE uPOV SySTEM
In most countries the implementation of
the UPOV Convention requires domestic
legislation.
.1 Scope of plant breeders’ rights

Generally, the plant breeders’ rights (PBRs) con
ferred by domestic legislation modeled on UPOV
are defined as the exclusive right to do or to li
cense the following acts in relation to propagating
material of the plant variety:
• produce or reproduce the material
• condition the material for the purpose of
propagation
• offer the material for sale
• sell the material
• import the material
• export the material
• stock the material for all of the purposes
described above
.2 Exceptions

Excepted from these rights, under the UPOV
Convention, are acts performed privately and for
noncommercial purposes, for experimental pur
poses, or for the purpose of breeding other plant

varieties. As was mentioned above, seed saved by
a farmer from harvested material and treated for
the purpose of sowing a crop on that farmer’s own
land is considered not to be an infringement by
legislation based on UPOV 1991.
Legislation may also provide that PBRs are
not infringed when propagating material is used
as a food, food ingredient, or fuel, or for any other
purpose not leading to or involving the produc
tion or reproduction of propagating material.
Also, it may be provided that PBRs are ex
hausted following the sale of propagating mate
rial by a grantee unless there is a multiplication of
the material after the sale.
. Duration of plant breeders’ rights

The general duration of PBRs, provided by leg
islation implementing UPOV 1991, is to be 25
years in the case of trees and vines and 20 years
for any other plant type. This duration period
commences on the date of grant of PBRs in the
variety. Where a plant variety is declared to be es
sentially derived from an initial variety, the total
duration of protection for the dependent or es
sentially derived variety generally can last for no
longer than the duration of the protection of the
initial variety.
. Application for plant breeders’ right

Eligible applicants are usually plant breeders who
are citizens or residents of the country in which
they are applying for the permit, if the variety is
bred in the country. On the other hand, a coun
try might permit anyone, domestic or foreign, to
apply for a variety under the country’s laws.
Ineligible applications will generally involve
varieties previously sold in the country.
. Form of application

The form of application for PBRs will be pre
scribed by the national legislation. It will provide
that an application must contain:
1. the name and address of the applicant
2. the name and address of the agent, if any,
making the application on the applicant’s
behalf
3. a statement to that effect if the applicant is
the breeder of the variety
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4. if the applicant is not the breeder of the va
riety, details of the applicant’s right to make
the application
5. a brief description, with a photograph, if
appropriate, of a plant of the variety suf
ficient to establish a prima facie case that
the variety is distinct from other varieties of
common knowledge
6. the name, and any proposed synonym, for
the variety
7. particulars of the location at which and the
manner in which the variety was bred, in
cluding particulars of the names by which
the variety is known and sold in the coun
try and particulars of any PBRs granted in
the country or in another country that is a
signatory to the UPOV Convention
8. particulars of any application for, or grants
of, rights of any kind in the variety in any
other country
9. the name of an approved person who will
verify the particulars of the application and
who will supervise any test growing of the
variety required under Section 37 of the
Act and who will verify a detailed descrip
tion of the variety; and
10. such other particulars, if any, as are required
by the approved form.
. Application fee

An application fee will usually be prescribed un
der the legislation.
. Acceptance or rejection

The authority or official that is responsible for
the administration of the relevant law will be
required to decide, as soon as is practicable af
ter an application is filed, whether to accept or
reject the application. Where the authority or
official is satisfied that the application is prior in
time to any other application and that it com
plies with the requirements of the legislation
and establishes a prima facie case for treating
the plant variety as distinct from other varieties,
the application must be accepted. Upon accep
tance, the applicant must be notified that the
application has been accepted and public notice
of the acceptance must also be given. Similar
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notification obligations apply when an applica
tion is rejected.
. Variation of application

After an application for PBRs has been accepted,
but before concluding the examination of that
application, the authority or official may permit
an applicant to vary an application, subject to the
payment of a prescribed fee.
An application is usually permitted to be
withdrawn by an applicant at any time. If this
occurs after public notice of the application, the
authority or official must, as soon as is practical,
give public notice of the withdrawal.
. Detailed description of the plant variety

Whenever it is practical, but not later than 12
months after an application has been accepted, or
within such further period granted by the author
ity or official, the applicant is usually required to
give a detailed description of the plant variety to
which the application relates. Failure to supply
this description will result in the application be
ing deemed to have been withdrawn. The detailed
description must be in writing and in an approved
form, containing particulars of:
1. the characteristics that distinguish the plant
variety from other varieties, the existence
of which is deemed a matter of common
knowledge
2. any test growing carried out
3. any test growing outside the country that
tends to establish that the variety will, if
grown in the country, be distinct, uniform
and stable; and
4. other such particulars that may be
prescribed.
.10 Objection to an application for PBRs

The administering authority is usually obliged to
give public notice of the detailed description as
soon as is practicable after it has been received.
A person may object to an application for PBRs
if they can establish that their commercial in
terests would be affected by the grant of PBRs
to the applicant and that the authority cannot
be satisfied that the various substantive require
ments of the law have been met by an applicant.
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The objection must set out the particulars of the
manner in which the person believes his or her
commercial interests would be affected and the
reasons why the person considers that the author
ity cannot be satisfied that the various substantive
requirements of the law have been met.
.11 Inspection of application and objections

A person may, at any reasonable time, inspect an
application for PBRs over a plant variety, or an
objection lodged in respect to that application.
Upon payment of a prescribed fee, a copy of an
application or an objection to an application is to
be provided.
.12 Test growing of plant varieties

In the case of an application that has been ac
cepted, or an objection to such application, or
a request for revocation of PBRs, the authority
may require a test growing, or a further test grow
ing, of the variety. In such case, notice may be
required to be provided to all relevant persons.
The notice, in addition to telling the applicant,
objector, or grantee of the authority’s decision,
must specify the purpose of the test growing and
may require the person to supply the authority
with sufficient plants or propagating material and
with any necessary information to permit the au
thority to arrange a test growing, or to make ar
rangements for an approved person to supervise
the test growing and to be supplied with plants
or propagating materials. The expense of a test
growing must be borne by the applicant, objec
tor, or person requesting revocation of the PBR.
Provision may be made for a test growing outside
the country of a plant variety that was bred out
side the country.
.1 Provisional protection

Where an application for PBRs is accepted, the
applicant is taken to be the grantee of that right
from the date that the application is received
until the application is disposed of. During this
period of provisional protection, the applicant is
prevented from commencing any infringement
action with respect to the PBRs, until such time
as the application is finally resolved in the appli
cant’s favor.

.1 Declarations of essential derivation

Where a person is the grantee of PBRs over a par
ticular plant variety (the initial variety) and an
other person is the grantee of, or has applied for,
PBRs in another variety (the second variety) the
grantee of PBRs in the initial variety may seek
a declaration that the second variety is an essen
tially derived variety of the initial variety. A plant
variety is defined to be an essentially derived vari
ety of another plant variety if:
1. it is predominantly derived from the other
plant variety
2. it retains the essential characteristics that
result from the genotype or combination of
genotypes of that other variety; and
3. it does not exhibit any important (as dis
tinct from cosmetic) features that differen
tiate it from that other variety.
The application for essential derivation
must be in an approved form and contain such
information relevant to establishing a prima fa
cie case of essential derivation. If the authority
is satisfied, or not satisfied, as the case may be,
that a prima facie case has or has not been estab
lished, the applicant and the grantee of PBRs in
the second variety must be informed and pro
vided an opportunity to rebut the prima facie
case. The authority may order a test growing
in order to rebut a prima facie case of essential
derivation.
.1 Grant of PBRs

Where an application for PBRs in a plant variety
is accepted, the law will provide that following
examination of the application. The authority
must grant the right to the applicant where it is
satisfied that:
1. there is such a variety
2. the variety is registrable within the law
3. the applicant is entitled to make the
application
4. the grant of that right is not prohibited by
the law
5. the right has not been granted to another
person
6. the name of the variety complies with
Section 27
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7. propagating material of the variety has been
deposited for storage, at the expense of the
applicant, in a genetic resource center ap
proved by the authority
8. a satisfactory specimen plant must be sup
plied to a prescribed herbarium; and
9. all fees have been paid.
PBRs are granted by the issue of a certificate
in approved form.
.1 Effect of a grant of PBRs

If a person is granted PBRs over a plant variety,
the grantee will take precedence over any other
person who was entitled to make an application
for the right in the variety. Such person is not pre
vented, however, from applying for a revocation
of rights or to seek administrative review of the
authority’s actions in relation to the grant of PBR
or to request the authority to make a declaration
that the variety over which rights were granted
was essentially derived from another plant variety.
Where it has been determined that another per
son was entitled in law or equity to an assignment
of the right to make an application for the PBRs,
that person may be entitled to an assignment of
the PBRs.
Where the relevant Minister for Agriculture
considers it appropriate, PBRs may be granted
subject to conditions. The Minister would prob
ably take the advice of any Plant Breeders’ Rights
Advisory Committee established under the law.
.1 Revocation

There may be provision for the revocation of
PBRs, or a declaration that a plant variety is es
sentially derived from another plant variety, if the
authority becomes satisfied that facts had existed
that, if known before the grant of the right or the
making of the declaration, would have resulted in
the refusal to grant the right or make the declara
tion. Revocation may also result from a failure to
pay prescribed fees. Within a prescribed number
of days of the decision to revoke, the grantee or
transferee of PBRs may be provided with particu
lars of the grounds of proposed revocation.
Applications for revocation may be made by
a person whose interests are affected by the grant
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of PBRs over a plant variety or by a declaration
of essential derivation. In the event of revocation
or surrender of PBRs, particulars of revocation
or surrender will usually be entered in the PBRs
Register and published.
.1 Compulsory licensing

National laws usually require the grantee of PBRs in
a plant variety to take all reasonable steps to ensure
reasonable public access to that plant variety. This
requirement is considered to be satisfied if propa
gating material of reasonable quality is available
to the public at reasonable prices, or as gifts to the
public, in sufficient quantities to meet demand. For
the purpose of ensuring reasonable public access,
the law may permit the relevant authority to license
an appropriate person to sell propagating material
of plants of that variety, or to produce propagat
ing material of plants of that variety for sale, during
such period as the authority considers appropriate
and on such terms and conditions (including the
provision of reasonable remuneration to the grant
ee) as the authority considers would be granted by
the grantee in the normal course of business.
A person may make a written request to the
authority for the grant of a license where a per
son considers that a grantee is failing to ensure
reasonable public access to a plant variety and
that failure affects that person’s interests. The re
quest must set out particulars of the alleged fail
ure and of the effect upon the person’s interests.
The authority is then usually required to provide
the grantee an opportunity within a prescribed
period to satisfy the authority that the grantee is
providing reasonable public access to a plant vari
ety, or that he or she will comply within a reason
able period of time. Where the authority decides
to grant a license, a public notice will be issued
identifying the variety, detailing the particulars of
the license that is proposed to be granted and an
invitation to persons to apply for a license. The
authority is usually required to consider all appli
cations and publicly notify the proposed licensee,
as well as notifying each of the applicants.
.1 Infringement of PBRs

Generally speaking, PBRs in a plant variety are
infringed by an unauthorized person:
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1. performing acts that are included in the
PBRs
2. claiming the right to perform one of those
acts; and
3. using the name of a registered variety in
relation to another plant or another plant
variety.
An infringement will not occur where the act
complained of is exempted from the operation of
the law. A defendant in an action for infringe
ment of rights may counterclaim for revocation
of the rights on the grounds that the variety was
not a new plant variety or that facts existed that
would have resulted in the refusal of the grant of
those rights.
.20 Remedies

In an infringement action, a nominated court
may grant an injunction subject to any terms
that the court thinks fit and, at the option of the
plaintiff, either damages or an account of profits.
Where a person satisfies the court that at the time
of the infringement he or she was not aware of
that right, and had no reasonable grounds for sus
pecting the existence of the right, it may refuse to
award damages or order an account of profits.
.21 Administration

Most laws provide for the establishment of the
Office of the Registrar of Plant Breeders’ Rights,
which is responsible for the general administra
tion of the Act and for the maintenance of the
Register of Plant Varieties.
The office of the Registrar will usually issue
an official Plant Varieties Journal in which all
public notices are to be published.
.22 Genetic resource centers and herbaria

The law may provide for the nomination of ge
netic resource centers for the storage and mainte
nance of germplasm material.

4. PATENTS ON PlANTS, VARIETIES, SEEDS,
AND OTHER PROPAGATING MATERIAl
As mentioned above, PVP laws were developed
in response to industry calls for sui generis

protection of agricultural and horticultural in
novations. However, a seed-saving exception for
farmers was included as a public policy safeguard,
an early reflection of food security concerns. Such
a safeguard does not generally exist in patent stat
utes, and this absence was an inducement for seed
companies to shift their attention to the patent
system as a means of protecting their innovations.
This shift in attention also coincided with the de
velopment of modern biotechnologies.
Patent protection was not originally consid
ered to be a particularly effective system for the
protection of plant varieties. Prior to the develop
ment of modern biotechnology, the breeding of
a new variety could not be said to involve an in
ventive step, and such innovations as were made
could be considered to be obvious rather than
inventive. However, with the extension of patent
protection to recombinant DNA methods for
producing transgenic plants and their resulting
products, patents have been assuming increasing
significance in PVP. The broader ambit of patent
rights is one particular advantage of this form of
IP protection, covering, as it does, plants, seeds,
and enabling technologies. Plant variety rights
are highly specific to the variety, and their scope
is limited by reference to the physical (propagat
ing) material itself, combined with the descrip
tion of the variety given in the documentary
grant of the rights.
.1 European prohibitions on patentability

Article 53(b) of the European Patent Convention
(EPC) excludes plant varieties, as well as “es
sentially biological processes” from the scope of
patentable subject matter. This raises, in the first
instance, the definitional distinction between
plants and plant varieties. The UPOV Convention
defines plant variety in terms of a plant group
ing within a single biological taxon of the lowest
known rank. The grouping can be:
• defined by the expression of characteristics
(such as shape, height, color, and habit) re
sulting from a given genotype or combina
tion of genotypes
• distinguished from any other plant group
ing by the expression of at least one of these
characteristics
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• considered as a unit with regard to its suit
ability for being propagated unchanged
The first consideration of the distinction be
tween plant and plant variety by the Technical
Board of Appeal of the European Patent Office
(EPO) occurred in 1984 in the Ciba-Geigy de
termination.7 This case concerned a plant that
had been treated with a chemical compound to
confer on the plant a degree of protection from
the toxic side effects of certain herbicides. The
Examination Division had refused the patent
application on the basis of Article 53(c). This
was reversed by the Technical Board of Appeal,
which, applying the definition of plant variety
in the UPOV Convention, stated that “Article
53(c) prohibits only the patenting of plants or their
propagating material in the genetically fixed form
of the plant variety… Plant varieties in this sense
are all cultivated varieties, clones, lines, strains and
hybrids.”8 In this case the claims covered merely
the application of a chemical treatment and not
plant varieties as such.
This approach was applied by the Technical
Board of Appeal in the case Lubrizol (Hybrid
Plants)9 where the Board held that “the term plant
varieties means a multiplicity of plants which are
largely the same in their characteristics (that is, homo
geneity) and remain the same within specific toleranc
es after every propagation or every propagation cycle
(that is, ‘stability’).”10 The Board then ruled that as
the hybrids in issue were not stable, they did not
fall within the excluded category of plant varieties.
The European Directive on the Legal Protection
of Biotechnological Inventions (the Directive) per
mits the patentability of inventions concerning
plants, where “the technical feasibility is not confined
to a particular plant … variety.”11 Patent claims can
therefore be made with respect to plant groupings,
or as stated in Recital 31 to the Directive,
Whereas a plant grouping which is character
ized by a particular gene (and not its whole genome)
is not covered by the protection of new varieties and
is not excluded from patentability even if it com
prises new varieties of plants.
This qualification was addressed by the
Technical Board of Appeal in Novartis/Transgenic
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Plant.12 The application concerned a patent
containing claims to transgenic plants compris
ing in their genomes specific foreign genes, the
expression of which resulted in the production
of antipathologically active substances, and to
methods of preparing such plants. The EPO had
denied registration. The denial was supported by
the Technical Board of Appeal on the ground that
Article 53(b) denied the patentability of an in
vention that could embrace plant varieties.
In its decision in December 1999, the
Enlarged Board of Appeal indicated that it would
favor the application because, in substance, it
did not involve an application for a plant variety.
This determination contains some useful guid
ance on the legal definition of plant varieties. The
Enlarged Board of Appeal noted that the defini
tions of plant variety in the UPOV Convention
and the Council of the European Union (EU)
Regulation on Community Plant Variety Rights
refer to “the entire constitution of a plant or a set of
genetic information,” whereas a plant defined by
a single recombinant DNA sequence “is not an
individual plant grouping to which an entire con
stitution can be attributed.” The Enlarged Board
observed that the claimed transgenic plants in the
application were defined by certain characteristics
that allowed the plants to inhibit the growth of
plant pathogens. No claim was made for anything
resembling a plant variety. The board noted that
in the case of PBRs, an applicant had to develop
a plant group, fulfilling in particular the require
ments of homogeneity and stability, whereas in
the case of a typical genetic engineering inven
tion, a tool was provided whereby a desired char
acteristic could be bestowed on plants by insert
ing a gene into the genome of a specific plant.
The board observed that the development of spe
cific varieties was not necessarily the objective of
inventors involved in genetic engineering.
.2 Patentability outside of Europe

Outside of Europe the prohibition against the
patenting of plant varieties is absent. In the
United States, for example, the Federal Circuit
resolved any potential conflict between patent
protection and protection under the Plant Variety
Protection Act in its decision in Pioneer Hi-Bred
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International Inc. v. J.E.M. Ag Supply Inc.13 The
defendants objected that Pioneer had obtained
both patent protection and certificates of protec
tion under the Plant Variety Protection Act for
the same seed-produced varieties of corn. The de
fendants argued that the enactment of the Plant
Variety Protection Act had removed seed-pro
duced plants from the realm of patentable subject
matter in the Patents Act. The Federal Circuit
rejected this argument noting that the Supreme
Court held that “when two statutes are capable of
coexistence, it is the duty of the courts ... to regard
each as effective.”
The patenting of plant varieties in Canada
was upheld by the recent Canadian Federal
Court of Appeal case of Monsanto Canada v.
Schmeiser.14 This case concerned the cultivation
by a farmer of canola that contained chime
ric genes conferring tolerance to glyphosphate
herbicides. Monsanto had patented the canola
and had marketed these genes in its product
Roundup® Ready Canola. Schmeiser had cul
tivated canola derived from plants on his land
that he claimed had developed the tolerance
from wind-borne genetic pollination. The trial
court found that cultivation of a plant was not
an infringement of patented genes contained in
that plant; however, the majority of the Federal
Court of Appeal agreed with Monsanto that this
was infringing use.
Counsel for Schmeiser raised the moral ques
tion of whether it was right to manipulate genes
in order to obtain better weed control or higher
yields. The Federal Court of Appeal ruled that his
was a question for the parliament to consider and
that the court’s job was to “interpret the Patents
Act as it stands.”15 The majority explained that,
“Under the present Act, an invention in the domain
of agriculture is as deserving of protection as an in
vention in the domain of mechanical science. Where
Parliament has not seen fit to distinguish between
inventions concerning plants or other inventions,
neither should the courts.”16
As the minority judge pointed out that
the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) of the
World Trade Organization (WTO), in Article
27.2(b), permits the exclusion of plants from

patentability but that plant varieties might be
patented. The Novartis determination, among
others, argues that the addition or modification
of genetic material to confer disease resistance is
not the creation of a new plant variety. If the view
of the majority in Schmeiser that the patenting of
a cell confers exclusive patent rights over a plant
in which that cell is included, then the Article
27.2(b) exception becomes meaningless.
The Joint Communication of the African
Group to the TRIPS Council17 suggested that
Article 29 of the TRIPS Agreement seemed to
be the most suitable for an appropriate modifi
cation to deal with the issue of patenting plant
variety rights, by including the requirements for
equity, disclosure of the community of origin of
the genetic resources and traditional knowledge,
and demonstration of compliance with applicable
domestic procedures. Thus the Group suggested
that Article 29 be modified by adding the follow
ing as paragraph 3:
Members shall require an applicant for a pat
ent to disclose the country and area of origin of any
biological resources and traditional knowledge used
or involved in the invention, and to provide confir
mation of compliance with all access regulations in
the country of origin.
. IP and the research exemption

Plant breeders have tended to stress the necessity
of being able to freely access genetic material, in
cluding that which is IP protected. This is why
the UPOV Convention contains a broad breeders’
exemption. Patent law tends to have a much nar
rower research exemption, and it is often limited
to noncommercial scientific or experimental use.
The narrowness of the research exception in
patents law is illustrated by the recent U.S. deci
sion in Madey v. Duke University,18 which held that
a university that undertook commercial research
contracts could not avail itself of the defense. The
ambit of the experimental research exception in
patents law in the United Kingdom was examined
in Monsanto v. Stauffer.19 In that case, Stauffer had
developed a market variant, called Touchdown®,
of Monsanto’s successful patented weed-killer
Roundup® for which Stauffer had obtained provi
sional clearance from relevant authorities. In order
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to obtain final clearances, Stauffer had established
tests at its own research farm and also organized
a series of tests outside the farm, where interested
parties could observe the results. Monsanto moved
for an interlocutory injunction, on the grounds
of patent infringement, which was granted by the
patents court, negating the ground that tests done
outside the research farm to check the product
in different soil and climatic conditions amounts
to an experimental use. The Court of Appeal,
although it agreed that tests done outside could
not qualify for an experimental-use exception, ex
empted all trials carried out at Stauffer’s research
farm and at laboratories and greenhouses in the
United Kingdom. The Court limited the inter
pretation of the word experimental in accordance
with the size, scale, recipient, and methodology of
the experiment. This case has raised uncertainty
as to how far university researchers can apply the
experimental-use exception to agricultural field
trials.20
Another illustration of the relative narrow
ness of the experimental-use exception in patents
law, compared with PVP laws, is that while a
protected plant variety is covered by a single ti
tle, plant-related biotechnological inventions are
likely to be protected by a patent and, in some
cases, several patents. The patents may cover not
just plants, but also seeds, genes, and DNA se
quences. The effect of patents is to restrict access
to the patented “products.” It has been argued
that “locking up” genetic resources with patents
is a bad thing because innovation in plant breed
ing is cumulative and depends on being able to
use as wide a stock of material as is possible. The
International Treaty on Plant Genetic Resources
for Food and Agriculture (the Treaty) introduced
a number of provisions to deal with this concern.
The provisions are laid out below.
Apart from patents, the restrictions on access
to breeding material may have causes other than
IPRs. For one thing, some countries have cho
sen to provide exception for certain categories of
plant genetic resources they consider to be stra
tegically important from the Multilateral System
to be set up under the Treaty. Also, some devel
oping countries have been exercising their rights
under the Convention on Biological Diversity
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(CBD), administered under the United Nations
Environment Programme (UNEP), to regulate
access to their genetic resources, and in doing so
have restricted the free flow of those resources.
This practice may well be detrimental to those
countries and others, in terms of long-term food
security.21
But beyond the issues of how specific IP
rights privatize genetic material needed for
breeding is the association of IP rights with the
privatization of agricultural research, the shrink
age of nonproprietary public sector research,
and the increased concentration of ownership
of breeding material, research tools, and tech
nologies in the hands of a small number of giant
corporations.22 Not only does this privatization
trend toward greater restriction on access reduce
the free circulation of breeding material, but it
can also make public policy aimed at enhancing
food security harder to put into practice. This is
true because it is much more difficult for gov
ernments to influence companies than the public
institutions they partly or wholly fund.
. Ethical issues relating to the
patentability of life-forms

There is a substantial body of literature on the
ethical implications of permitting the propertiza
tion of the “building blocks of life” or at least to
“reduce the value of life and nature to the merely
economic.” The Joint Communication of the
African Group to the TRIPS Council on tak
ing forward the review of Article 27.3(b) of the
TRIPS Agreement,23 stated that patents on life
forms were unethical and “contrary to the moral
and cultural norms of many societies in Members
of the WTO.” The Joint Communication invoked
the exception in Article 27.2 for protecting ordre
public and morality as justification for outlawing
patents on life-forms.
An important question for which empirical
work is required concerns the impact of oligop
olization in the biotechnology market on the
capacity of international institutions to provide
public goods to developing countries in the ag
ricultural sector. The proprietization of enabling
technologies, as well as genetic resources, raises
concerns about the capacity of the public agri
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cultural research system to fulfill its public-good
mission in contributing to the elimination of food
insecurity. As Drahos observed, “in biotechnology
and agriculture, it is likely that much research will
end up as an international rather than public good
and that it will be distributed according to complex
licensing structures.”24
In addition to the possible adverse impacts
this market concentration might have upon the
vigor of competition, the market dominance of
these private corporations also has an important
influence upon the sort of biotechnological re
search that is undertaken. For example, to what
extent will the dominance of private corporations
in biomedical and agricultural research direct that
research toward northern concerns and away from
southern health problems25 and southern food
priorities?26 Will the owners of IP rights in key en
abling technologies make them available to public
research institutions on affordable terms?27
Article 27.2 of the TRIPS Agreement per
mits members to disallow the exploitation of in
ventions “which is necessary to protect ordre public
or morality, including to protect human or plant life
or health or to avoid serious prejudice to the environ
ment… .” Member states would have to show that
the commercial exploitation of the specific inven
tion would be contrary to ordre public or moral
ity. In light of the interpretation and application
of the equivalent provision within the European
Patent Convention, and recently reinforced in the
Directive, it is unlikely that this exception would
permit a general exclusion of living material from
patentability. It is also questionable whether pat
ent offices are the proper bodies to adjudicate
the application of moral and ethical issues to the
patent system.28 In any event, the patent offices
have abstained from exercising moral judgments
in this area. Thus, for example, in Greenpeace v.
Plant Genetic Systems NV,29 in an opposition to
an application for a patent directed to transgenic
plants engineered to be resistant to the herbicide
Basta®, Greenpeace argued that it was immoral,
and therefore in breach of Article 53(a) of the
European Patent Convention, to “own” plants
that were the common heritage of humankind.
The Appeal Board of the EPO sustained the
Examination Division’s view that it was not the

proper forum for discussing the advantages and
disadvantages of genetic engineering. Similarly, in
Novartis/Transgenic Plants30 the Extended Board
of Appeal of the EPO considered the debate over
genetic engineering to be too controversial for the
board to sustain Greenpeace’s opposition to the
patent. The Extended Board of Appeal noted that
the Directive was an indication that the European
Parliament considered there to be some benefit in
genetic engineering.

5. PVP, PlANT GENETIC RESOuRCES, AND
THE TRIPS AGREEMENT
Access to the plant genetic resources of a country
is governed by an evolving composite of national
legislation pursuant to CBD, TRIPS, UPOV, and
the Treaty.
The interrelationship between these instru
ments has been addressed by the Council on TRIPS
pursuant to its review of Article 27.3(b), which
commenced in 1999. At a March 2001 meeting of
the Council on TRIPS, the chairman set out a list
of key issues that had arisen in the review of Article
27.3(b) (IP/C/M/26). These included:
• technical issues relating to patent and PVP
under Article 27.3(b)
• technical issues relating to the sui generis
protection of plant varieties
• the relationship to the conservation and
sustainable use of genetic material
• the relationship with the concepts of tradi
tional knowledge and farmers’ rights
Article 27.3(b) of the TRIPS Agreement per
mits the exclusion from patentability of :
plants and animals, other than microorganisms,
and essentially biological processes for the production
of plants and animals, other than nonbiological and
microbiological processes. However, Members shall
provide for the protection of plant varieties either by
patents or by an effective sui generis system or by any
combination thereof.
However, Article 27.3(b) provides no guid
ance on what is meant by effective, the debate in
the TRIPS Council having focused upon which
sui generis systems satisfy the obligation. A sui
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generis option in the IP context is usually taken to
refer to a specially coined IP right, outside of the
traditional categories of IP protection. UPOV has
advanced its system as the principal workable ex
ample of a sui generis PVP system. It is interesting
to note that the drafters of the TRIPS Agreement,
who felt free to import into the agreement provi
sions from other named international instruments,
such as the Paris, Berne, and Rome conventions
and the Washington Treaty on Integrated Circuits,
desisted from specifically importing provisions
from the UPOV Convention in the area of plant
varieties.
The failure of the drafters of TRIPS to define
what was meant by sui generis leaves considerable
scope for nations in the range of legislation that
they may implement in compliance with this pro
vision. One option is to include the benefit-shar
ing and informed-consent provisions of the CBD
in a UPOV-style statute. A problem with doing so
is that although the CBD provisions would apply
in the countries that introduce them, they will not
apply in countries that do not introduce them. In
the countries that do introduce the provisions and
also adopt an approach based on UPOV 1991 or
patents, there is no guarantee of benefit sharing and
informed consent, or even of the right to save seed.
TheDohaMinisterialDeclarationofNovember
2001, in Clause 19, provided:
We instruct the Council for TRIPS, in pursuing
its work programme including under the review of
Article 27.3(b), the review of the implementation of
the TRIPS Agreement under Article 71.1 and the work
foreseen pursuant to paragraph 12 of this Declaration,
to examine, inter alia, the relationship between the
TRIPS Agreement and the Convention on Biological
Diversity, the protection of traditional knowledge and
folklore, and other relevant new developments raised
by Members pursuant to Article 71.1. In undertaking
this work, the TRIPS Council shall be guided by the
objectives and principles set out in Articles 7 and 8 of
the TRIPS Agreement and shall take fully into account
the development dimension.
.1

Technical issues relating to patent
and PVP under Article 27.3(b)

The following technical issues are suggested by
the terminology of Article 27.3(b):
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• What is a patentable invention for the pur
poses of Article 27.3(b)?
• What are microorganisms for the purposes
of Article 27.2?
• What are plant varieties for the purposes of
Article 27.3(b)?
• Should there be a research exception in re
lation to patents over plant material?
.1.1

What is a patentable invention?

.1.2

What are microorganisms for the
purposes of Article 27.3(b)?

IP law attempts to draw a distinction between
inventions and discoveries. The latter are not
protectable. This distinction may be made in the
relevant legislation. For example, European laws
based on the Directive, which specifically provides
in Article 3.2 that “Biological material which is iso
lated from its natural environment or produced by
means of a technical process may be the subject of an
invention even if it previously occurred in nature.”
Of course, it is equally open to a court or a
legislature to rule or provide that genetic material
is not patentable, even in its isolated or purified
form, on the grounds that it is a mere discovery.
Indeed, nothing in the TRIPS Agreement obliges
countries to deem the isolation of genetic mate
rials to be inventions. A number of developing
countries exclude the patentability of genetic
materials (Mexico), or of materials existing in na
ture (Argentina, Brazil, and the Andean Group
Decision 486).

Article 27.3(b) permits WTO Members to ex
clude from patent protection plants, animals, and
essentially biological processes for the production
of plants and animals. Members are specifically
not permitted to exclude from patent protection
microorganisms and nonbiological and micro
biological processes. The language used in Article
27.3(b) implies that a clear distinction can be
made between plants and animals on the one
hand and microorganisms on the other. However,
there is no commonly accepted definition of mi
croorganism, either in science or in patent office
practice. The lack of any definition permits great
variations between members in practicing this
exclusion.
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The practice of patent offices in developed
countries suggests that there is no perceived need
for a definition: the key issue for protection being
not its subject matter, but whether or not the in
vention meets the patent-granting criteria.
An invention involving biological material
will be regarded as lacking an inventive step if
it: (1) merely identifies the biological material;
and/or (2) merely identifies the natural function
of the biological material. An invention will dem
onstrate an inventive step if it takes the form of a
significant technical application of an identified
function of the biological material. This technical
application must go beyond a mere simple rep
lication of the natural function of the biological
material, and the technical application must rep
resent a significant technical advance on the prior
art. What about processes and uses?
An invention involving biological material
will be regarded as being capable of industrial ap
plication if it can be shown that the invention is
capable of being used in a manner that provides a
demonstrable public benefit. Public benefit means
that the invention must be capable of being used
in a manner conducive to public health and to
social, environmental, and economic welfare.
.1.

What is a plant variety for the
purposes of Article 27.3(b)?

As noted above, a crucial issue in the establishment
of a sui generis regime would be the definition of
the protected subject matter. Article 27.3(b) of
the TRIPS Agreement requires the protection of
“plant varieties,” but does not provide (as in the
case of inventions) a definition thereof. Therefore,
national laws have ample room to determine what
is to be deemed a plant variety for the purposes of
protection. Which are the possible definitions?
The law may require certain characteristics for a
protected variety that may not be essential for a
scientific definition.
.2 Technical issues relating to the sui generis
protection of plant varieties.

Article 27.3(b) provides no guidance on what
is meant by effective, the debate in the TRIPS
Council having focused upon which sui generis
systems satisfy the obligation.

Sui generis systems are generally defined as
those that fall outside of the traditional categories
of IP protection and are created to deal with a
unique category of creativity. The UPOV system
has been urged by the industrialized group of
countries as the principal workable example of a
sui generis PVP system. In excess of 50 states have
acceded to the UPOV Convention.
Developing countries in the TRIPS Council
have argued that the TRIPS Agreement is in ten
sion with the CBD, particularly with the provi
sions in the latter convention concerned with
informed consent to biological materials and eq
uitable benefit sharing following access.
A communication to the WTO from Kenya,
on behalf of the African Group, to assist the prep
arations for the 1999 Ministerial Conference,
suggested that:
“After the sentence on plant variety protection
in Article 27.3(b), a footnote should be inserted stat
ing that any sui generis law for plant variety protec
tion can provide for:
(i) the protection of the innovations of indig
enous and local farming communities in
developing countries, consistent with the
Convention on Biological Diversity and
the International Undertaking on Plant
Genetic Resources;
(ii) the continuation of the traditional farming
practices including the right to use, exchange
and save seeds, and sell their harvest;
(iii) preventing anti-competitive rights or prac
tices which will threaten food sovereignty of
people in developing countries, as is permit
ted by Article 31 of the TRIPS Agreement.
This African proposal is reflected, in part, in
clause 19 of the Doha Ministerial Declaration of
November 2001 mentioned above.
In order to help countries devise an ap
propriate sui generis system, the International
Plant Genetic Resources Institute (IPGRI, now
Bioversity International) came up with a list of
key questions that decision makers should take
into account.31 These are as follows:
• What kind of domestic seed industry exists?
• What kind of public breeding sector
exists?
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• What kind of seed supply system is in
place?
• To what extent is farm-saved seed used in
the country?
• What is the current capacity of breeders?
• What do local breeders want to do in the
next 5–10 years?
• Are external inputs to agriculture low or
high?
• What are the country’s production needs
and objectives?
• What is the country’s biotechnology
capacity?
• What are the goals and realistic expecta
tions of the biotechnology sector?
• What kinds of strategic alliances will the
country want to enter into in the next 5–10
years and how involved will other countries
be?
The fact that the answers to these questions
will vary widely from one country to another sug
gests that, as with patents, one size is unlikely to
fit all.

6. THE INTERNATIONAl TREATy
ON PlANT GENETIC RESOuRCES
FOR FOOD AND AGRICulTuRE
Plant genetic resources for food and agriculture
(PGRFA) were freely exchanged by the inter
national agricultural research institutes of the
Consultative Group on International Agricultural
Research (CGIAR), as well as by their national
counterparts, on the basis that they were “the com
mon heritage of humankind.” This principle was
embodied in the International Undertaking on
Plant Genetic Resources for Food and Agriculture
(the Undertaking) adopted by the Food and
Agriculture (FAO) Conference in 1983. The
Undertaking was adopted as a nonbinding con
ference resolution. In subsequent years the prin
ciple of free exchange was gradually narrowed
by the impact of IP rights upon agriculture. In
November 1989, the 25th Session of the FAO
Conference adopted two resolutions providing an
“agreed interpretation” that plant breeders’ rights
were not incompatible with the Undertaking. The
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acknowledgment of plant variety rights obviously
benefited industrialized countries that were active
in seed production. In exchange for this conces
sion, developing countries won endorsement of
the concept of farmers’ rights. A further resolu
tion in 1991 recognized the sovereign rights of na
tions over their own genetic resources. Agenda 21,
promulgated at the Rio Earth Summit in 1992
called for the strengthening of the FAO Global
System on Plant Genetic Resources. Resolution 3
of the Final Act to the CBD noted that the ac
cess to ex situ germplasm collections, such as
those maintained by the CGIAR, and the realiza
tion of farmers’ rights were the province of the
Undertaking. The 1993 FAO Conference called
on member states to harmonize the Undertaking
with the CBD. Negotiations for revision of the
Undertaking to take account of both the CBD and
the TRIPS Agreement commenced in November
1994 and were consummated with the adoption
of the Undertaking as the Treaty.
.1 The main objectives and innovations
of the Treaty

The objectives of the Treaty are stated in Article 1
to be “the conservation and sustainable use of plant
genetic resources for food and agriculture and the
fair and equitable sharing of the benefits arising out
of their use, in harmony with the Convention on
Biological Diversity, for sustainable agriculture and
food security.”
Article 4 of the Treaty requires signatories
“where appropriate” to “promote an integrated ap
proach to the exploration, conservation and sustain
able use of plant genetic resources for food and ag
riculture.” Article 10.2 contains the agreement of
the Contracting Parties to “establish a multilateral
system, which is efficient, effective and transparent,
both to facilitate access to [PGRFA] and to share, in
a fair and equitable way, the benefits arising from
the utilisation of these resources, on a complemen
tary and mutually reinforcing basis.” Facilitated ac
cess to PGRFA is to be provided in accordance
with the conditions prescribed in Article 12.3.
Paragraph (d) of this provision provides that the
recipients “shall not claim any intellectual property
or other rights that limit the facilitated access” to
PGRFA, or their “genetic parts or components,” in
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the form received from the Multilateral System.
This, of course, does not prevent IP rights being
claimed in relation to germplasm that is modified
by the recipient.
Article 13.1 recognizes that benefits accruing
from facilitated access to PGRFA shall be shared
fairly and equitably under this Article. Article 13.2
envisages that this sharing of benefits includes
the exchange of technical information, access to
technology, capacity building, and the sharing of
monetary benefits from commercialization.
Article 28 provides that the Treaty would en
ter into force 90 days after accession by 40 coun
tries. Until that date, the Undertaking would
remain operative. Having acquired the necessary
accessions in March 2004, the Treaty entered into
force in June 2004.
The establishment of the Multilateral System
was the principal innovation introduced by the
Treaty. This asserts the primacy of national sov
ereignty over biological resources, but, in fact,
imposes limitations on countries on their ability
to restrict access to other states. Facilitated access
has to be provided to the crops, listed in Annex I,
that account for a significant part of human nu
trition. Member states are obliged to make avail
able all passport data and, subject to applicable
law, any other associated nonconfidential descrip
tive information. In relation to material that is
under development by farmers or breeders at the
time when access is requested, the Treaty gives the
country of origin the right to delay access dur
ing the period of development. Two compromises
were necessary to secure this right of access: first
is the limitation imposed by Article 12 upon re
cipients seeking IP rights in material obtained
under the Treaty; second is the right of donors
to receive some form of benefit sharing. Benefitsharing mechanisms under the Treaty include the
exchange of information, access to and transfer of
technology, capacity building, and the sharing of
benefits arising from commercialization.
The CGIAR Centres signed agreements with
the FAO in 1994, placing the acquisitions to
their germplasm collections after that date under
the trusteeship of the FAO. Under the Treaty,
new agreements were invited to determine that
the access provisions of the Treaty would govern

the Centres’ germplasm collections that fell with
in Annex I list that were collected after the entry
into force of the Treaty.
.2 Farmers’ rights and food security

Article 9 of the Treaty implements the proposal
that was developed under the Undertaking for
the recognition of farmers’ rights. The policy
behind this recognition is stated in Article 9.1,
namely that:
The Contracting Parties recognize the enormous
contribution that the local and indigenous com
munities and farmers of all regions of the world,
particularly those in the centres of origin and crop
diversity, have made and will continue to make for
the conservation and development of plant genetic
resources which constitute the basis of food and agri
culture production throughout the world.
The principal contribution of traditional farm
ers to agrobiodiversity has been their conserva
tion of landraces, which are crop varieties that are
primitive cultivars, developed by local farmers to
deal with the local climate and diseases and to ca
ter to local tastes and food-preparation practices.32
This development may involve the interbreeding
of locally occurring undomesticated plants with
cultivated plants, as well as the exchange of differ
ent genotypes among farmers and farms.33
. Traditional knowledge and food security

A significant contribution has been made by the
knowledge of indigenous peoples and traditional
farmers in the development of new crop types
and biodiversity conservation. These groups have
been an important agency in the conservation of
plant genetic resources and the transmission of
these resources to seed companies, plant breeders,
and research institutions. The contributors have
not typically been paid for the value they have
delivered, whereas breeders and seed companies
have resorted to IP rights to recover their devel
opment expenditures.
The economic value of biological diversity
conserved by traditional farmers for agriculture
is difficult to quantify. It has recently been sug
gested that “the value of farmers’ varieties is not
directly dependent on their current use in convenHANDBOOK OF BEST PRACTICES | 1
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tional breeding, since the gene flow from landraces
to privately marketed cultivars of major crops is very
modest”34 because “conventional breeding increas
ingly focuses on crosses among elite materials from
the breeders own collections and advanced lines de
veloped in public institutions.” On the other hand,
those collections and advanced breeding lines are
often originally derived from germplasm contrib
uted by traditional groups.
An increasingly significant economic value of
biodiversity is the extent to which it provides a
reservoir of species available for domestication, as
well as genetic resources available for the enhance
ment of already domesticated species. The mod
ern biotechnological revolution has enabled the
engineering of desirable genetic traits from useful
local species. It is estimated that about 6.5% of
all genetic research undertaken in agriculture is
focused upon germplasm derived from wild spe
cies and landraces.35
Traditional knowledge is particularly im
portant in the development of farming systems
adapted to local conditions and farming prac
tices. This may enable the utilization of marginal
lands, contributing to food security by enabling
access to food in remote areas, as well as contrib
uting to the management of the environment by
preventing erosion, maintaining soil fertility, and
maintaining agricultural biodiversity.
Farmers in subsistence systems have tended to
utilize a diverse selection of crop species in order
to assure their annual harvests and thus to guaran
tee a minimal level of production and to prevent
food shortage. Seed production in many instances
has been on the collection of and domestication
of locally known wild varieties. Modern agricul
tural practices depend on crop species that pro
mote productivity and resistance to disease that
can only be maintained with the continuous input
of new germplasm. The diversity of landraces and
the associated information on their specific quali
ties contribute invaluable information to formal
breeding processes. It has been noted that the loss
of biological diversity is paralleled by the loss of
traditional knowledge. Where a plant variety be
comes extinct, then the entire body of knowledge
about its properties is condemned to irrelevancy.
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An assumption of Article 9.1 is that the landraces used by traditional farmers are a dynamic
genetic reservoir for the development of new vari
eties and for the transmission of desirable genetic
traits. The traditional knowledge of local and in
digenous communities is similarly perceived. As a
means of remunerating these groups for their past
contributions to the development of plant genet
ic resources for food and agriculture production,
there can be little argument, except about the
quantum and distribution of this remuneration.
Inevitably, any calculation of the equitable
share that traditional farmers and indigenous
communities might enjoy under a farmers’ rights
or traditional knowledge regime will be arbitrary.
However, the IP system is no stranger to arbitrary
calculations, thus the 20-year length of a patent
term is intended to provide an opportunity for
the compensation of all inventors, whatever the
area of technology. Similarly the 25-year exclu
sivity, which the UPOV Convention provides for
new varieties of trees and vines, takes no account
of variations in R&D costs between the different
varieties.
The principal ways in which plant genetic re
sources are translated into food and agriculture
production is through plant breeding and plant
patenting. Standing at the heart of a farmers’
rights regime is the concept of equitable benefitsharing with farmers for their contribution to
innovations in plant breeding and plant patent
ing. It is estimated that about 6.5% of all genetic
research undertaken in agriculture is focused
upon germplasm derived from wild species and
landraces.36
Article 9.2 of the Treaty envisages that “the
responsibility for realizing Farmers’ Rights, as they
relate to Plant Genetic Resources for Food and
Agriculture, rests with national governments” and
that national legislation should include measures
relating to:
• protection of traditional knowledge rele
vant to plant genetic resources for food and
agriculture
• the right to equitably participate in sharing
benefits arising from the utilization of plant
genetic resources for food and agriculture
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• the right to participate in making deci
sions, at the national level, on matters re
lated to the conservation and sustainable
use of plant genetic resources for food and
agriculture
Article 9.2 obliges the Contracting Parties to
the Treaty “to take measures,” subject to their na
tional legislation to protect and promote farmers’
rights. The content of these rights is defined in the
balance of that provision and embraces the pro
tection of traditional knowledge, equitable benefit
sharing, and the right to participate in decision
making. The Treaty leaves open the legal context
within which farmers’ rights are to be enacted.
Finally, Article 9.3 provides that the Article
shall not be interpreted “to limit any rights that
farmers have to save, use, exchange, and sell farmsaved seed/propagating material.”
National legislation on farmers’ rights tends
to combine one of the versions of UPOV with
some of the access principles of the CBD. The
African Model Legislation for the Protection of
the Rights of Local Communities, Farmers and
Breeders, and for the Regulation of Access to
Biological Resources, which was adopted by the
Organization of African Unity (OAU), Heads of
States Summit at Ouagadougou in June 1998,
adopts a sui generis regime based on UPOV 1991.
However, most national statutes prefer access leg
islation combined with UPOV 1978 (for example,
the Andean Community’s Common System on
Access to Genetic Resources, 1996; Costa Rica’s
Biodiversity Law of 1998; India’s Community
Intellectual Property Rights Act of 1999; Kenya’s
Seeds and Plant Varieties Act of 1975).

7. ASSESSMENT OF THE RElATIONSHIP
BETWEEN IP AND FOOD SECuRITy
The role of IP in eliminating food insecurity
has to be placed in its proper policy perspective.
Development experience over the last 50 years
attributes rural poverty and food insecurity in
developing countries to development strategies
that overlooked the importance of the develop
ment of the agricultural sector, particularly the
production of staple foods.37 Thus the enhance

ment of food security in developing countries re
quires a package of policies that address the sup
ply, distribution and consumption aspects of the
food chain. The FAO has noted that the policy
options that are available to poor countries are
constrained by a number of factors including: (1)
limited resources for public spending programs;
(2) the dilemma between remunerative prices for
producers and prices that a large number of poor
households can afford, thus making the option
of border protection less attractive despite high
bound tariffs; (c) major constraints on foreign
exchange availability leading to pressure to boost
production of export crops.38
Where IP could make its greatest contribu
tion is in the incentivization of beneficial agri
cultural innovations. Historically, the strongest
incentives have been those arising from the mar
keting of hybrid seeds that provide higher yields,
with the commercial benefit to the seed marketer
that the seeds of the offspring cannot be used by
the farmer because these seeds do not breed true
to-type. As is discussed above, the evidence for
incentives to breeding research for crop plants
is limited—in developing countries even more
so—whether PVP and patenting will be useful in
encouraging a national seed industry. Barton sug
gests that a developing country “is probably bestoff adopting minimum compliance with TRIPS,
which requires at least some form of sui generis pro
tection for plants—although there is the possibility
that a number of nations with similar agricultural
conditions could combine their markets in some way
that encouraged private investment. Moreover, use
of UPOV-style laws might help in commercializing
varieties developed by the public sector.”39
The question of whether a developing coun
try will adopt a sui generis PVP system or a pat
ent-based system, to comply with Article 27.3(b)
of the TRIPS Agreement will depend upon the
technological sophistication of agricultural re
search in that country. n
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ABSTRACT

The last decades have seen a revolution in knowledge
management, library services, and information resource
database configurations. The use of integrated computer
networks and the ability to produce and distribute infor
mation have had far-reaching implications for IP (intel
lectual property) protection. In order to demonstrate IP
laws and their application, this chapter will use, as its
primary example, Geographic Information Systems and
Remote Sensing (GIS/RS), a technology that presents in
teresting and complex IP issues.

1. InTRoduCTIon
The management of databases and library vol
umes is becoming increasingly complex. In many
organizations, library staff are responsible for the
storage and retrieval of information, as well as the
development of new books or articles. Library
staff face ever-increasing challenges regarding the
intellectual protection (IP) rights that apply to
these various materials.
IP is a term that refers to creations of the
mind: inventions; literary and artistic works;
and symbols, names, images, and designs used in
commerce. U.S. law allows for various sorts of IP
protection.
Much of this chapter focuses on a technol
ogy that creates a unique IP management chal
lenge: Geographic Information Systems (GIS)

and Remote Sensing (RS). GIS/RS is a particu
larly interesting example of intellectual property
because it combines and interfaces a series of dif
ferent component parts: hardware, software, and
other protectable components (including maps,
survey data, aerial photographs, information from
land records, and so on). Each of these compo
nents may carry its own IP protections and restric
tions through various licenses. As a result, the final
product will also have various IP protections and
restrictions attached to it. In other words, GIS/
RS systems are affected by IP issues in relation to
databases and software, as well as in relation to
the technologies that create entirely novel sets of
data. These are not always straightforward: for one
thing, many different intellectual property and li
censing terms appear to have overlapping mean
ings. Box 1 at the end of this chapter provides a
list of the most common technical and legal terms
encountered in the context of data, databases,
GIS, and software.
In almost all countries, various forms of IP
protection are available for the protection of data
and data-related products. These are copyrights,
trademarks and trade secrets. Thus:
• Symbols, names, and images used in com
merce can be protected by trademarks.
• Creative works can be protected by
copyrights.

Dodds J, S Somersalo, SP Kowalski and A Krattiger. 2007. IP and Information Management: Libraries, Databases, Geographic Information Systems, and Software. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available
online at www.ipHandbook.org.
© 2007. J Dodds, et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.

HANDBOOK OF BEST PRACTICES | 1

DODDS, SOMERSAlO, KOWAlSKI & KRATTIGER

• Information can be protected by keeping it
a trade secret.
GIS/RS is protected by copyrights and trade
marks and, to some extent, trade secrets.

2. CopyRIGHT And THE puBLIC doMAIn
A copyright protects an original work and allows
the author the exclusive right to:
• reproduce the work exclusively
• prepare derivative works
• distribute copies by sale, transfer of owner
ship, lease, renting, or lending
• perform the work publicly
• display the work
Generally, the types of works that are pro
tected by copyright are: literary works; musical
works (including accompanying words); dramat
ic works; pantomimes and choreographic works;
pictorial, graphic, and sculptural works; motion
pictures and other audiovisual works; sound re
cordings; and architectural works.
2.1 Public domain

Works in public domain are not protected by
copyright and are publicly available. They may
be used by anyone, anywhere, any time, without
permission or license. A work may enter into the
public domain if its term of copyright protection
has expired. In the United States, works of the
U.S. government are all in public domain (Title
17 U.S.C. § 105); they cannot be protected by
copyrights. However, U.S. government employees
may produce copyrighted work not created during
the course of their official duties. If U.S. govern
ment works are disseminated in foreign countries,
such works may be copyrighted to the extent al
lowed by the domestic laws of those countries.
It is very important to note that authors are
not required to give notice that their work is
copyrighted. Therefore, it is the responsibility of
the potential user to determine whether or not a
work is in public domain. This may become an
issue for example in a case where a private work
has been included in a government publication
by permission of its author. Under U.S. law, such
20 | HANDBOOK OF BEST PRACTICES

private work is not in the public domain, and
therefore one using the government publication
may still need permission, or license, to use such
private portions of the publication.
2.2 Fair use exemption

Section 107 of the U.S. Copyright Act states that
an author’s original creation is subject to “fair
use”: that is, the work can be used in special cases
without permission for purposes of criticism,
comment, news reporting, teaching, scholarship,
or research. This exemption is one of the most
important copyright limitations. De facto fair use
should never be assumed. Fair use is determined
on a case-by-case basis, taking into consideration
the purpose and character of the use, the nature
of the copyrighted work, the amount and sub
stantiality of the portion of the work used in re
lation to the work as a whole, and the potential
effect of the use on marketing and distribution of
the work.
2. Copyright registration

Copyright is automatically granted at the creation
of a work. Registration of the copyright with the
U.S. Copyright Office is not necessary, but a copy
right cannot be enforced, or damages collected for
improper use, unless it is registered. Currently, the
cost for registering a copyright is $30.
2. Copyright duration

In the United States, a work that is created and
fixed in tangible form for the first time on or after
1 January 1978, is automatically protected from
the moment of its creation for the lifetime of the
author, plus an additional 70 years after the au
thor’s death. In case of a joint work, the term lasts
for 70 years after the last surviving author’s death.
For works made for hire, and for anonymous
works, the duration of copyright is 95 years from
publication or 120 years from creation, whichever
is shorter. A work that was copyright registered or
published with a copyright notice before 1 January
1978 can be protected at most for 95 years from
the date of securing.
It is important to note that duration of copy
right varies somewhat from country to coun
try. In European Union member countries the
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copyright, generally speaking, protects the work
for the lifetime of the author plus 70 years. In
Japan the protection is generally lifetime plus 50
years. In Mexico the protection is lifetime plus
100 years.
2. First sale doctrine

The first sale doctrine, codified at 17 U.S.C. 109,
limits the rights of copyright holders to control
the distribution and display of copies of their
works. The owner of a particular copy is entitled
to “sell or otherwise dispose of the possession of
that copy” and to “display the copy publicly ... to
viewers present at the place where the copy is lo
cated.” Therefore, the first sale doctrine gives the
copyright owner the right to control only the first
sale of the work. The owner of a lawfully made
copy may in turn dispose of it by any means. The
first sale doctrine is the legal basis for public li
braries, which lend copies that they have previ
ously purchased. The first sale doctrine does not,
however, allow anyone except the copyright own
er to make more copies. The Digital Millennium
Copyright Act of 1998 authorizes the creation of
digital copies for archival and preservation pur
poses nonprofit libraries and archives. The right
to distribute such copies requires authorization
from the copyright owner.
2. Copyright ownership

Generally speaking, the author of a work owns its
copyright. In case of work for hire, the employer
is considered to be the author and the owner of
the copyright.
In the case of GIS/RS, if all work (including
aerial photography and geographical data entry)
is completed by the employees of a company
under the terms of their employment, then the
work-for-hire requirements would be fulfilled
and the company would own any relevant copy
rights. It is important that companies have writ
ten agreements (with appropriate work-for-hire
language) with any independent contractors that
they hire.
If, at the time of creation, the authors in
tend to combine their contributions into an
inseparable or interdependent whole, the re
sulting work is considered a joint work and the

authors are considered joint copyright owners.
Each copyright owner has an equal right to ex
ploit her or his copyrights. A company can li
cense or obtain an assignment for the copyright
of the joint work from only one of the authors.
If, on the other hand, at the time of creation the
authors did not intend their works to be parts
of an inseparable whole, the resulting work is
considered a collective work and the authors are
considered collective copyright owners. A col
lective copyright owner only owns copyrights
for the material that she or he added to the final
product.
2. Work for hire

A work for hire is defined in copyright law as
that which is prepared by an employee within the
scope of his or her employment, or a work spe
cially ordered or commissioned for use as a con
tribution to a collective work, a part of a motion
picture or other audiovisual work, a translation, a
supplementary work, a compilation, an instruc
tional text, a test or the answer key to a test, or an
atlas. The parties must expressly agree by signing
a written instrument that the work shall be con
sidered a work made for hire.
In academic environments, the terms of em
ployment typically require inventors to assign ex
ante their patentable inventions (but not neces
sarily their copyrightable works) to the univer
sity. If a company hires consultants who are also
academics, it is important that their consultancy
contracts explicitly state that the contracting in
stitution owns all work done by the consultant.
The following is an example of such a clause:
Property and Property Rights. Consultant
agrees that any computer programs, software,
documentation, copyrightable work, discover
ies, inventions, or improvements developed by
Consultant solely, or with others, resulting from
the performance of Services pursuant to this
Agreement, are the property of Contractor, and
Consultant agrees to assign all rights therein to
Contractor. Consultant agrees that the Services
constitute a Work for Hire as such term is used
and defined in the Copyright Act. This provision
shall survive expiration and termination of this
Agreement.
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2. Assigning and licensing copyright

The owner of copyright may transfer the copyright
wholly or partially to another party. A transfer is
usually done by an assignment or by licensing.
With an assignment the copyright owner sells his
or her rights to the assignee, while with a license
the copyright owner retains the ownership but
grants the licensee a right to use the copyright
ed material according to the limitations in the
agreement.
It is important to realize here that copyright
includes numerous rights (for example, a right to
reproduce the work, a right to prepare derivative
works, and a right to distribute copies). Therefore,
the copyright owner can transfer the copyright via
an assignment or a license partially or wholly. The
copyright owner may, as well, transfer the copy
right on an exclusive or a nonexclusive basis. The
transfer of exclusive rights is not valid unless that
transfer is in writing and signed by the owner of
the rights. Transfer of a right on a nonexclusive
basis does not require a written agreement.
As an example, the author and copyright
owner of a database, could transfer to a compa
ny a right to copy and distribute the database.
However, the author could also transfer a right
for another company to make a derivative work
using the database. Either of these rights granted
could be exclusive or nonexclusive ones. Probably
both of them would be made via a license.
Works by the U. S. government, including
maps, are not eligible for U. S. copyright protec
tion. A map, in pictorial form, would not lose
its copyright protection if its information were to
be digitized and stored in an electronic database.
However, a geographical information system
whose data have never existed in a coherent pic
torial form would be considered a compilation.
2. Databases

A compilation is only copyrightable if its facts
have been selected, coordinated, or arranged in
such a way that the resulting work, as a whole,
constitutes an original work of authorship (joint
work, see Section 2.6). Copyright is meant to
reward originality, not effort. Therefore, not all
databases are protectable under copyright law.
An example of a compilation that did not have
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the requisite originality for being protectable un
der the Copyright Act was a telephone catalog, for
which the telephone company has simply selected
names and arranged them in alphabetical order.
Such a database is not original or creative and
would not warrant protection.1 It is, however,
important to note that there is no requirement of
novelty; therefore, the data or information that is
used for the compilation may well be known. The
way to select, organize, and arrange the informa
tion has, however, to amount to some minimal
originality or creativity.
Copyright Act Section 102(b) reads, in part:
“in no case does copyright protection for an original
work of authorship extend to any idea, procedure,
process, system, method of operation, concept, prin
ciple, or discovery, regardless of the form in which it is
described, explained, illustrated, or embodied in such
work.” This clause has been interpreted to mean
that the individual data in a database are not pro
tected under the Copyright Act. Therefore, even
if a database may be copyrighted, a user may use
data extracted from it. However, the original data/
images that were used to develop the new work
must not be passed to any third party or used in
a way inconsistent with the terms and conditions
under which they were given. In order to prevent
such use, the copyright owner usually includes
preventing clauses into the licensing agreements.
2.10 Maps

Even if a map’s geographical features are not protectable by copyright law, the map may still be original
enough to warrant copyright protection, depend
ing on what information it includes, from which
sources the information was collected, and how the
information is represented in pictorial form.
2.11 Photographic Images

GIS/RS may use aerial photographs instead of
maps. A photograph may be protectable under
the Copyright Act if it exhibits a certain amount
of uniqueness. The U.S. Court of Appeals, 11th
Circuit, has stated that copyright law protects
“the selection of lighting, shading, timing, angle
and film” of a photograph.2 Copyright protection
does not, however, extend to physical facts the
photograph expresses.
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. TRAdE SECRETS
Under U.S. law, spatial databases are granted
fewer IP protections than even the most mun
dane cloak-and-dagger international spy novel.
Therefore, keeping the database a trade secret
may be the best way to protect it. A generally
accepted definition of trade secret appears in the
1939 Restatement of Torts. The subject matter of
a trade secret must be secret, and only known to
those involved in the particular business in which
it is used. Matters of public knowledge or of gen
eral knowledge in an industry cannot be appro
priated by anyone as his or her secret. Matters
that are completely disclosed by marketed goods
cannot be trade secrets, either.
. Ip pRoTECTIon foR SofTWARE
.1

Protection

A software program is potentially covered by two
types of statutory IP protection:3
• The software code is protected by copyright
• The algorithm of the software, if original, is
protectable in the United States (but not in
most other countries) by patent
Because software algorithms cannot be copy
righted, it is possible for a third party to repro
duce the flow and function of the software pro
gram and (provided he or she did not derive the
new code from the original code) legally use and
sell the resulting software.
Patents may offer better protection from
competition, but they have several drawbacks:
• Patents are expensive to file and prosecute
(and software patents are often even more
expensive than the average utility patent).
Depending on the number of countries
where patent protection is sought, the cost
of a patent may amount anywhere from
$10,000 and beyond.
• The algorithm must be demonstrably
original.
• The patent laws of most countries do not
cover software.
• By the time the patent is issued, the pro
gram may well have become obsolete.

.2 Licensing

Both copyrights and patents can be licensed for
commercialization. Some software licenses in the
United States are combined copyright-and-patent
licenses. Generally, copyright-alone licenses for
software are of limited value unless the program
in question is very large and was developed over
many years and is therefore difficult for a user to
replicate.
A number of different types of licenses are
applicable to software:
• end-use licenses. The licensee may use the
software but not distribute it. These licenses
are almost always nonexclusive. The licen
sor may or may not provide a source code.
• nonexclusive distribution licenses. The li
censee may distribute the software, either as
code or in hardware form (such as a semi
conductor). The licensor usually provides a
source code.
• exclusive distribution licenses. The licensee
will distribute the software to end-users and
will also improve and support the software.
The licensor always provides a source code.
• open-source licensing. The software is
provided free to users, usually over the
Internet. There are many different forms
of open-source licenses, each with different
restrictions on use.4 Two of the most com
mon are described below:
• minimally restrictive. The licensee may
use, improve, sell, and even establish pro
prietary rights to any improvements he or
she makes to the software, provided that he
or she acknowledges the licensor’s owner
ship of the copyright.
• quite restrictive. The licensee may use and
improve the software, but any improve
ments or modifications to the software
must be made available to other licensees
under the same conditions. Any licenses
the licensee grants to his or her improve
ments must carry the same obligations and
restrictions for the licensees; that is, the
rights granted originally to the licensee who
made improvements to the originally copy
righted product has to flow through to the
improved versions.
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. Collaboratively developed software

Software created for later distribution or com
mercialization is a special case. Software programs
often have a number of authors and frequently
incorporate software that was written by third
parties and obtained either formally (through
license agreements or open-source licensing) or
informally (such as through colleagues).
Technology transfer offices should make sure
ahead of time that they are legally able to license
software programs, especially if they hope to
grant exclusive licenses. In order to determine the
legality of licensing, the following questions must
be considered:
• Does the potential licensor own the copy
right for the primary software program?
Are all authors obliged to assign their copy
rights to the potential licensor? To ensure
this, the potential licensor should:
- have in place clear policies that delineate
under which circumstances students and
employees must assign their copyrights
to the licensor
- have written agreements with any other
authors (such as consultants or students)
that software produced under the con
sulting arrangement will be assigned to
the potential licensor
• Is there any code in the program that was
written by a third party? If so, the licensor
should:
- find out from whom or what the code
was obtained and whether copyright per
mission has been granted by this party;
learn what restrictions, if any, have been
imposed on making and/or distributing
derivatives of the software that incorpo
rate the original code
- if the code was obtained from an open
source, determine what type of opensource license was involved and what
restrictions have been imposed on the
distribution of the code
Technology transfer offices should take steps
to educate creators of commercializable software
about ownership issues. A lack of knowledge about
IP rights may lead to an unmarketable product.
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The Uniform Computer Information
Transaction Act (UCITA) standardizes the rules
for licensing digital information, including soft
ware. UCITA is, however, very controversial
and at this point only two states (Virginia and
Maryland) have implemented it.
. Shrink-wrap and click-wrap licenses

Shrink-wrap and click-wrap licenses are com
mon in software licensing. Shrink-wrap licenses
are enclosed in the plastic shrink-wrap packaging
of software products; they inform the buyer that
if he or she does not agree with the terms of the
agreement, he or she should return the software
and its packaging to the retailer. Click-wrap li
censes appear on the screen before the software
installation begins, and typically read: “Before
downloading this software, you must read and agree
to the following license terms and click the ‘I Agree’
button to accept.” In the United States, these types
of licenses are enforceable.

. InTERnATIonAL ASpECTS
Sometimes, data is obtained from multiple juris
dictions, each with its own laws. IP protection
for databases is stronger in Europe than it is in
the United States. The European Union Database
Directive, adopted by the European Parliament
in 1996, grants two rights to the makers of
databases:
1. The right to prevent unauthorized use of
the database
2. The right to prevent unauthorized acts of
extraction and reutilization of the contents
of a database
The first right, which is similar to that pro
vided under the U.S. Copyright Act, protects da
tabases that are sufficiently original in their selec
tion or arrangement of data. This right does not,
however, protect the data itself.
The second right is a sui generis right that
prohibits the extraction or reutilization of any
database that has required a substantial effort
to obtain, verify, or present. Under this second
right, there is no requirement for creativity or
originality.
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A database is protected for 15 years from the
date of its creation. If substantial changes are made
to the content of the database, the modified data
base will be protected for an additional 15 years.
Protection under the directive is available only to
nationals of member countries of the European
Union. Other countries will obtain such protec
tion only if they offer comparable protection to
databases of European national and if a bilateral
agreement is reached.

. ConCLuSIonS And TWo
HypoTHETICAL SITuATIonS
Library and database management professionals
are faced with a wide range of IP issues regarding
who owns what and how and by whom various
media can be used. There is no need to obtain
permission to use a work if it is in public domain
or if a license or agreement allows the intended
use. Nor is it necessary to obtain permission to
use facts from a copyrighted source, because the
Copyright Act does not protect facts. However,
charts, graphs, or figures that use these facts may
be copyrighted. It is extremely important to know
who the owner of a copyrighted work is: the po
tential user needs to know whether it is a work
for hire or a collective work. Also, it is important
to carefully inspect the terms of any licensing
agreement in order to determine what rights the
licensee will have. In order to place these criti
cal conclusions into perspective, Box 2 presents

hypothetical examples of the various IP issues
that emerge from library and database issues, and
Box 3 offers examples from software development
and use. n
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Box 1: Common Technical and legal Terms Related to IP and Information
author. either the person who creates a copyrightable work or the employer of the person who
creates a copyrightable work as a work for hire (see Section 2.7) (The word author in copyright
law includes not only writers of novels, plays, and treatises, but also those who create computer
programs, arrange data in telephone books, choreograph dances, take photographs, sculpt stone,
paint murals, write songs, record sounds, and translate books from one language to another.)
book. a printed literary composition
collective work. a work, such as an issue of a periodical, anthology, or encyclopedia, in which a
number of contributions, each a separate and independent work in itself, are assembled into a
collective whole
compilation. as defined by Section 103 of the Copyright Act, “a work formed by the collection and
assembling of preexisting material or of data that are selected, coordinated, or arranged in such a
way that the resulting work as a whole constitutes an original work of authorship”
copyright assignment. the giving away or selling, by the copyright owner, all rights to the
copyright
copyright license. a license by which an owner retains ownership to a copyright but allows
another person to use or sell the copyrighted material under defined conditions (for example, for
a certain purpose, for a certain period of time, or inside a limited geographical area)
copyright. an intangible, incorporeal right granted by statute to the author (or originator, in the
case of certain literary or artistic productions), whereby he or she is invested for a specified period
of time with the sole and exclusive privilege of multiplying, publishing, and selling copies of the
work
creative works. works in which the content does not change, whether the work is in printed,
recorded, or electronic form (Materials such as books, sound recordings, downloadable songs,
downloadable ring tones, videocassettes, DVDs, audio CDs and films, are usually single creative
works. Creative works that are serialized, that is, the mark identifies the entire work but the work is
issued in sections or chapters, are also considered single creative works. A theatrical performance
is also considered a single creative work, because the content of the play, musical, opera, or similar
production does not significantly change from one performance to another.5)
data. organized information often collected for a specific purpose and generally used as the basis
for adjudication in case of litigation
database or data bank. a computer-readable compilation of data and/or information, arranged
for ease of search and retrieval
design. the visual ornamental characteristics embodied in an article of manufacture
electronic copy. a computer-readable copy of data or information
facts. a statement or assertion of verified information about something that is the case or has
happened (From a more legal perspective, a fact is an actual thing or happening [which must be
proved at trial by presentation of evidence and which is evaluated by the finder of fact].)
Geographical Information System (GIS). a computer system capable of assembling, storing,
manipulating, and displaying geographically referenced information
image. a reproduction of the form of a person or object, especially a sculptured likeness (An image
can be an original visual image or a copy of the original image; for example, it can be a digital
image of a painting or a digital image made from a slide of the painting printed in a book.)
joint work. collaboration between two or more authors in which their contributions are joined
into a single cohesive work.
continued on next page
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Box 1 (continued)

patent license. an agreement between licensor and licensee allowing the licensee to practice the
invention with agreed provisions while the licensor retains the ownership of the patent
photograph. an image, especially a positive print, recorded by a camera and reproduced on a
photosensitive surface
public domain. the realm in which there are no laws that restrict a work from use by the public
at large
text. the body of a printed work, as distinct from headings and illustrative matter (on a page) or
from front and back matter (in a book)
trade secret. any valuable business information that is not generally known and is subject to
reasonable efforts to preserve confidentiality
transfer of copyright. the transfer of any or all of the copyright owner’s exclusive rights or any
subdivision of those rights (Transfers of copyrights are normally made by contract; usually by a
license or an assignment.)
work. something that has been produced or accomplished through the effort, activity, or agency
of a person
work for hire/work made for hire. a work prepared by an employee within the scope of his or her
employment or a commissioned work that all parties agree in writing to treat as work for hire
(The real person, partnership, or corporation for which the work is prepared is considered to be
both the author and the owner of copyright from the moment the work is created.)
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Box 2: Hypothetical Example: library and Database Issues
Let us imagine that a librarian is in the process of assembling a work that recounts and reflects
upon a research institution’s 50-year history. In order to complete this project, the librarian will
use various materials that may or may not carry IP restrictions:
(A) photographic images stored in the institution’s archives for 20–50 years
Although the organization has had physical custody of these images for as long as 50 years,
they are still protected by copyright.
(B) photographic images taken by staff members and donated to the library
If the photos were taken in the course of the employee’s duties, they are the property of the
institution. If taken outside of work, they may have been given to the institution with attached
terms and conditions.
(C) photographic images of the institution taken by a commercial photographer
The commercial photographer may have issued a use license to the institution, thereby
preventing further use of the images.
(D) articles written by staff members, some of whom are now retired
If the articles were written during the course of an employee’s duties, they are owned by
the institution. If they were written after the employee’s retirement, the following questions
should be asked: Did the employment or separation contracts assign copyright to one party
or another? Is the information contained in the article based on knowledge that the author
acquired while an employee?
(E) a foreword written by a retired director general, who has been awarded a Nobel Prize
The author owns copyright over the document and should sign a waiver or copyright
assignment document so that the material can be legally used.
(F) reproduction of key research articles published by scientists in peer-reviewed journals
It is very likely that the peer-reviewed journals requested and were granted the copyright over
the authors’ material; the institution will therefore need permission from the owners of the
journals to reproduce these articles. Such requests are almost always granted so long as there
are no clear competition issues identified.
(G) a text written by professional media consultants on the history of the institution
The consultants should sign contracts indicating that all intellectual property developed
during the term of the consultancy is property of the institution.
(H) data (generated by the institution’s employees in cooperation with colleagues around the
world) showing that the institution is still producing Nobel-Prize-quality data
Care must be taken that the disclosure of data does not infringe on the IP rights of the
scientists or their institutions. The terms of the agreement with the external scientists (there
had better be one!) may also limit the institution’s data ownership and distribution rights.
(I) a special 50-year anniversary logo
The logo may be trademarked.
In many cases, the most important IP protection is common sense. If the probability of a dispute
over IP infringement is extremely low, the institution might choose to judiciously cut corners.
The institution can, of course, seek protection for the final document, regardless of whether it is in
print or electronic form. However, the IP protection of the final document must not infringe upon
the IP ownership of its collective authors.
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Box 3: Hypothetical Example: Software Issues
Now, let us consider another example:a GIS/RS project to create maps that will assist in cultivating
new plant varieties, conducted by an employee of a research university. In order to develop the
project, the principal researcher has to deal with various types of materials, each with its own IP
restrictions.
(A) a soil map of country X (obtained from government X)
The U.S. government does not, of course, have copyright on the maps it produces; this may
or may not be the case for the IP laws of country X. It will be necessary to draw up a material
transfer agreement (MTA) that delineates the specialist’s rights of use. The agreement might
include a reach-through clause that gives the government of country X rights over new
materials created through the project.
(B) a meteorological dataset (purchased from the Meteorological Office of country X)
The principal researcher should check to make sure that there is no specific language in the
license that would prohibit commercial use of the dataset (a research-only license) or restrict
its distribution.
(C) photographic images of the area of interest (from a commercial source)
As mentioned above, purchased materials almost always come with restrictions; see the
previous paragraph.
(D) information on the agricultural performance of a certain plant variety (obtained from an
international development organization)
Just because information comes from an international development organization does not
mean that it is not protected.The organization may require potential users of this information
to sign a material transfer agreement.
(E) a topographical map of country X (obtained informally from a collaborating scientist)
Informally shared information usually leads to IP conflicts. The employer of the collaborating
scientist may have ownership rights to the map. If the employer is a U.S. university, it will
probably protect its intellectual property and sell information only when it sees fit to do so.
There is also a chance that the government of country X has rights to the map.
(F) a software program bought by the principal researcher, using university grant money
The software may have been licensed with an “educational use only” license
(G) data collected in the field by the principal researcher
Since the principal researcher is a university employee, the university may claim ownership
over any data he or she collects.
(H) a data manipulation algorithm developed by the principal researcher during the course of his
or her employment
As mentioned above, the university may claim ownership over the algorithm, since it was
developed during the course of his or her duties as an employee of the university.
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Data Protection and Data Exclusivity in
Pharmaceuticals and Agrochemicals
CHARLES CLIFT, London, U.K.

ABSTRACT

The chapter discusses the meanings of data protection
and data exclusivity in the context of the provisions of
the Trade-Related Aspects of Intellectual Property Rights
agreement. In addition, it outlines the relationship be
tween data exclusivity and patent protection and briefly
reviews the possible costs and benefits of introducing data
exclusivity laws. Finally, the chapter explains that coun
tries need to consider the costs and benefits when nego
tiating bilateral trade agreements that might require the
introduction of these laws.

1. INTRODuCTION
The development of a new drug or agrochemi
cal, such as a pesticide, usually requires extensive
testing, inside the laboratory or in the field, on
animals, humans, plants, or the environment, de
pending on the nature of the drug or chemical.
The way in which these tests are undertaken are,
at least in the later stages, governed by rules set by
the regulatory authorities. These rules are designed
to ensure the safety, quality, and efficacy of prod
ucts being developed for use by humans or in the
environment (in the case of agrochemicals). In the
United States, for instance, this regulatory author
ity is the Food and Drug Administration (FDA) for
medicines and vaccines and is the Environmental
Protection Agency (EPA) for agrochemicals.
Meeting the requirements, which is nec
essary for permission to place products on the
market, involves a considerable cost. Studies on

pharmaceutical industry data, albeit disputed by
some, have suggested that the average total de
velopment cost of a new drug is on the order of
US$800 million, of which about 60% would be
incurred in the conduct of trials (a substantial
portion of these trials would be required for reg
ulatory approval).1 In agrochemicals, it has been
estimated that the average development cost is
more than US$180 million.2
Because of the size of the required investment
in clinical test data, the pharmaceutical and ag
rochemical industries argue that the use of such
data by third parties (other than the regulatory
authority) must be prevented. If the regulator,
relying on test data provided by the originator
company at great expense, allows an equivalent
product to enter the market, originator compa
nies would have no incentive to incur the heavy
costs necessary to bring new products to market
in the first place. In practical terms, a rule that
prevents use of the data by a third party (or the
regulator relying on that data to approve a third
party’s generic product) also has the effect of pro
viding exclusivity to the originator product. This
is principally because the cost of replicating the
investment in trials to satisfy regulatory require
ments would be sufficiently prohibitive to deter
a potential competitor. In the case of medicines,
even if the cost were not prohibitive, there are
also ethical concerns about repeating trials (that
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MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. C Clift. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial
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include an untreated control group) with a drug
known to be efficacious.
This chapter seeks to explain the quite com
plicated issues related to data protection and data
exclusivity and how they are treated in different
jurisdictions. Particular consideration is given to
the position of developing countries who are con
templating, or being obliged to contemplate, data
protection or exclusivity regimes.

2. WHAT IS THE DIFFERENCE BETWEEN
DATA PROTECTION AND DATA
ExCluSIVITy?
The modern debate about data protection and data
exclusivity largely derives from differing interpre
tations of what the agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS)
says on the subject.
The relevant article (Article 39(3)) says:
Members, when requiring, as a condition of
approving the marketing of pharmaceutical or of
agricultural chemical products which utilize new
chemical entities, the submission of undisclosed test
or other data, the origination of which involves a
considerable effort, shall protect such data against
unfair commercial use. In addition, Members shall
protect such data against disclosure, except where
necessary to protect the public, or unless steps are
taken to ensure that the data are protected against
unfair commercial use.
There are unreconciled views on what this para
graph, the subject of protracted discussion when
the agreement was negotiated, means in practice.
It is important to note that Article 39, as a
whole, constitutes the section of the agreement
“protection of undisclosed information” that re
lates broadly to what are generally known as trade
secrets. Article 39(2) is a general clause about
World Trade Organization (WTO) members’
obligations with respect to trade secrets. Article
39(3) covers such obligations in the particular
case where such trade secret data are submitted
to governments or government agencies as a pre
condition for obtaining marketing approval.
Article 39(3) essentially imposes three obli
gations on governments:
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1. To protect data on new chemical entities,
the collection of which involved consider
able effort, against unfair commercial use
2. To protect such data against disclosure, ex
cept where necessary to protect the public
3. To protect such data against disclosure, un
less steps are taken to ensure that the data is
protected against unfair commercial use
The first obligation is simply about protect
ing data submitted to regulatory agencies against
unfair commercial use. No time limit is specified.
Examples of unfair commercial use could include,
for example, the government itself using the data
for a commercial purpose or various kinds of dis
honest commercial behavior. The World Intel
lectual Property Organization (WIPO)3 provides
a set of model provisions on protection against
unfair competition.
The second and third obligations concern
protecting data against disclosure to third par
ties, in the case of one or another exception.
Although there is some lack of clarity, arising
from the generality of the wording, about when
disclosure would be justified by the exceptions
(particularly in the third case), the essential
point is that the obligation creates a presump
tion that the regulatory authority would not dis
close data, without due reason, to a third party.
Again, no time limit is specified. The purpose of
avoiding disclosure is to avoid unfair commer
cial use. The third obligation implies, therefore,
that disclosure is acceptable provided it can be
ensured that disclosure will not lead to unfair
commercial use.
Most observers regard what is referred to in
TRIPS Article 39 as “data protection,” dealing as
it does with the protection of undisclosed infor
mation or trade secrets. Article 39(3) does not
create new property rights, nor a right to prevent
reliance on the test data submitted by an origina
tor for the marketing approval of an equivalent
product by a third party, except where unfair
commercial practices are involved. The article is
an articulation of widely accepted legal precepts
regarding trade secrets and unfair competition,
not an invitation to create a new intellectual
property right for test data.
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However, industry groups and some devel
oped countries, for example, the United States
and the European Union, have argued that Ar
ticle 39(3) requires countries to create a regime
of “data exclusivity,” a form of time-limited in
tellectual property right. In the United States
and countries in the European Union a data
exclusivity regime for both medicines and ag
rochemicals was adopted prior to the TRIPS
agreement (for example, in 1984 in the United
States and in 1987 in the European Union, for
medicines). For a period of five years from mar
keting approval of an originator product, no
other company may seek regulatory approval in
the United States of an equivalent product based
on data submitted by the originator company
without the latter’s approval. During the period
of exclusivity, regulators cannot use (rely on) the
originator’s data to approve a generic product,
even if the product is demonstrated to be exactly
equivalent in chemical composition and in its
behavior within the body.
The European Union now provides more ex
tensive exclusivity, up to 10 years, for medicines.
Unlike TRIPS provisions for data protection,
data exclusivity regimes often extend beyond new
chemical entities. For instance, in the United
States only chemical entities never previously ap
proved are entitled to exclusivity for a five-year
period, but new uses or indications of an already
approved entity are also entitled to exclusivity for
three years. In the European Union, exclusivity
is provided to new medicinal products, not just
new chemical entities. Details of the European
Union and United States regimes are described
in Sanjuan.4
In the United States, agrochemicals have
been entitled to a ten-year exclusivity period;
the period is five years for medicines. This dif
ference exists because the act that introduced
data exclusivity for medicines in 1984 (known as
Hatch-Waxman) also introduced a provision al
lowing for patent extensions of up to five years to
compensate for the loss of patent life in meeting
regulatory requirements (principally the time lost
compiling the test data required by the FDA).
Thus the term of data exclusivity for medicines
was reduced as a trade-off.

In addition, the United States provisions for
agrochemicals allow for a further five years of ex
clusivity during which the originator data may be
relied on to approve a generic product, provided
compensation for the use of the data is paid to
the originator.
In summary, a data exclusivity regime re
lates to how long the regulatory agency may be
prevented from relying on originator’s data to
approve the products of potential generic com
petitors. Data exclusivity does not relate to the
question of disclosure to third parties and trade
secrets dealt with in TRIPS Article 39(3) (and
39(2)) in which no time limits are specified.

3. DATA ExCluSIVITy AND PATENTS
If the patent period has expired, or there is no
patent on a product, data exclusivity will act in
dependently to delay the entry of any generic
companies wishing to enter the market until the
period of data exclusivity is over. It should be not
ed that in most cases the period of data exclusiv
ity may have no material effect if it is within the
patent period, because exclusivity is protected by
the patent.
However, the data exclusivity right is a
much stronger right than a patent because, un
like patent law, there are no exceptions or flex
ibilities that allow governments to tailor the law
to national circumstances. For example, there is
no ability for governments to provide the equiv
alent of a compulsory license, or data exclusivity
may act as a barrier to compulsory licensing of a
patent on the same product by preventing mar
keting authorization for a compulsory licensee.
Data exclusivity is attractive to originator com
panies because unlike a patent, data exclusivity
is automatic (rather like copyright). No fees are
incurred for application or maintenance of the
right, and there is more limited scope than ex
ists in patent law for legal challenges, which are
expensive to mount and to defend. For these
reasons pharmaceutical companies are strong
proponents of data exclusivity regimes. What
ever the benefits, which depend on exclusivity
extending beyond the patent term, the costs to
these companies are very low.
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4. COSTS AND BENEFITS
The claimed benefits of data exclusivity relate, to
a great extent, to the additional incentives offered
to companies in the long and expensive process
of pharmaceutical R&D. Data exclusivity gives
companies an incentive to extend the original use
of the product (for example, to a wider popula
tion, by age or geography, or in new indications
for therapeutic use) where, for one reason or an
other, no patent protection is available. Data ex
clusivity provides an additional opportunity for
originator companies to recoup their investments
where marketing approval is given late in the pat
ent life, so that the protection afforded extends
beyond patent expiry. Experts argue that data
exclusivity offers benefits to domestic innovators
in developing countries, and, in particular, that it
provides incentives for research to identify new
uses for existing unpatented products and for
originator companies to introduce products into
developing countries, since, in effect, exclusivity
would protect the companies from generic com
petition.
On the other hand, in developing countries
where there is little or no innovative research ca
pacity, the benefits of data exclusivity are likely to
be limited. In those circumstances, data exclusivity
would not promote R&D and the benefits to the
companies themselves, and a potential addition
to the R&D incentive, would be small because of
the limited market potential in most developing
countries. However, data exclusivity would allow
additional periods of exclusivity for originator
products, and it therefore would correspondingly
delay the onset of generic competition. Specifical
ly, exclusivity would preclude possible reductions
in the cost of medicines in the developing country,
keeping healthcare costs higher.
Data exclusivity is likely to have the largest
effect in countries where, for historical or other
reasons, there are many products with no current
patent protection that may gain rights to exclu
sivity. For example, in many developing coun
tries there are numerous medicines that are not
patented (even if they are patented in developed
countries). This is often the case in developing
countries where TRIPS-based laws have only re
cently been introduced (for example, India only
 | HANDBOOK OF BEST PRACTICES

introduced TRIPS-compliant laws in 2005 on
the expiry of its transitional period allowed under
TRIPS). In addition, even where there are pat
ent laws, companies may not have considered
the market sufficiently valuable to justify the ex
pense and administrative cost of securing patents.
In that case, the introduction of data exclusivity
laws may bring into exclusivity drugs that would
otherwise be open to generic competition. The
perceived absence of strong patent protection
in India, even after the law was revised in 2005,
and the presence of a large number of products
without patent protection due to the absence of
product patent protection before 2005, is a major
reason why the international pharmaceutical in
dustry lobbied very hard for a strong data exclu
sivity regime in India. By contrast, Indian com
panies focusing principally on generics argued for
a weaker data protection regime.5

5. BIlATERAl TRADE AGREEMENTS
Earlier drafts of the TRIPS agreement, which was
in negotiation for nearly a decade before coming
into force in 1995, contained, in addition to lan
guage closely following the final form of Article
39(3), text reflecting the U.S. five-year data ex
clusivity regime, which had been enacted in 1984
in the Hatch-Waxman Act. The North American
Free Trade Agreement (NAFTA6), which was
agreed in 1992, contained a close equivalent of
Article 39(3) followed by a paragraph prevent
ing the regulator from relying on the originator’s
data for a reasonable period, normally meaning
not less than five years.
From the point of view of supporters of
data exclusivity, the TRIPS agreement was,
therefore, in this particular respect, something
of a backward step. Although supporters of
data exclusivity argued that exclusivity, taking
account of the negotiating history, was what
TRIPS Article 39(3) really meant, most observ
ers have noted that the fact that a specific clause
on data exclusivity along the lines of NAFTA
was omitted from the final agreement indicated
the opposite. If TRIPS had meant to sanction
“data exclusivity,” it would have done so explic
itly, as does NAFTA.

CHAPTER .

The United States in particular has sought, in
post-TRIPS negotiations, to insert the language
of NAFTA on data exclusivity, or even stronger
provisions, in negotiating bilateral free-trade
agreements with developing countries. Coun
tries that have reached such agreements include
Bahrain, Jordan, Morocco, Chile, the Dominican
Republic, and the countries of Central America.
Negotiations are ongoing with Thailand, Ecua
dor, Peru, and Columbia.
Most United States bilateral treaties involve
agreement to the five-year rule as it is followed in
the United States. In other cases, such as the Cen
tral American Free Trade Agreement (CAFTA),
approved in 2005, the five-year rule applies also to
a product approved in another party to the agreement—that is, marketing approval in Country A
deters generic entry in country B for a period of
five years. If the originator seeks marketing ap
proval in Country B within five years, there will
be an additional five years of data protection in
Country B from the time of obtaining marketing
approval, providing a maximum exclusivity of up
to 10 years. CAFTA also obliges parties to pro
vide extensions to the patent term on the grounds
of unreasonable delays in granting a patent (for
example, five years from filing) or unreasonable
delays in procuring marketing approval.

context of pharmaceuticals and agrochemicals.
The protection of commercially valuable data
held by governments is a duty of government,
formalized in the TRIPS agreement, essentially
to protect such data against unfair commercial
use. Data exclusivity, by contrast, is a timebound form of intellectual property protection
that seeks to allow companies to recoup the cost
of investment in producing data required by the
regulatory authority. The effect of data exclusiv
ity is to prevent the entry of generic competitors,
independent of the patent status of the product
in question. The costs and benefits of data ex
clusivity depend on the particular economic cir
cumstances of countries. In developing countries
with little innovative capacity, the benefits may
be less obvious than the costs in terms of reduced
competition in the market for medicines or ag
rochemicals. These costs and benefits need to be
considered in the context of bilateral trade agree
ments, particularly with the United States, where
data exclusivity is likely to be part of the package
of intellectual property measures governments
are asked to accept. n

Developing countries need to consider the
extent to which the demands for data exclusivity
in bilateral trade agreements reflect the lobby
ing of the pharmaceutical industry in developed
countries, particularly the United States, where
there are close and legally institutionalized links
between the industry and negotiators, in partic
ular through the Industry Trade Advisory Com
mittee on Intellectual Property Rights (ITAC
15). This Committee evaluates successive free
trade agreements as to whether or not they meet
the objectives of U.S. intellectual property-based
industries. The committee’s objectives do not in
clude consideration of what measures might be
in the best interests of developing countries.
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of data protection and data exclusivity in the
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CHAPTER 4.10

Regulatory Data Protection in
Pharmaceuticals and Other Sectors
TRevoR cooK, Partner, Bird & Bird, U.K.

ABSTRACT

Generating data to secure regulatory approval in sectors,
such as pharmaceuticals and agricultural chemicals in
which product safety and efficacy is paramount, has be
come ever more extensive and expensive. There is thus
a need to provide an incentive to undertake such datageneration efforts by protecting the investment in them
against free riding. Article 39.3 of the Agreement on TradeRelated Aspects of Intellectual Property Rights (TRIPS)
recognizes as an intellectual property right the need for
such protection in those sectors. This chapter discusses
how certain jurisdictions, and in particular the European
Community, have implemented the TRIPS requirement
involving regulatory data protection regimes. Such protec
tion is not provided by the patent system, which instead
protects invention.

1. InTRoduCTIon
When a company or institution spends the time
and money to demonstrate that a product is
safe and efficacious, the investment pays off, in
part, by protecting the data generated through
this effort. This protection has become crucial in
highly regulated sectors, such as pharmaceuticals
and agricultural chemicals, where product safety
and efficacy are paramount. The importance of
protecting such data is reflected in their recogni
tion by the Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS), Article
39.3, as intellectual property (IP) rights. The need
for such protection has arisen because the testing
required to secure regulatory approvals has be
come more extensive and expensive. Thus, greater

incentives for undertaking such work are needed,
especially since no other forms of protection may
be available for a product that regulatory agencies
have authorized for the market.
The protection of data generated for regula
tory purposes prevents direct or indirect use of the
data filed in support of a marketing authorization
by subsequent applicants seeking marketing au
thorization for the same product. The protection
applies unless the subsequent applicant has ob
tained the consent of the party that first filed the
data and obtained the original marketing authori
zation. It is often uneconomic for subsequent ap
plicants to generate their own data independently,
so this exclusivity effectively confers a de facto
right in favor of the first applicant. However, the
protection is for a limited time, so that subsequent
applicants can use it after an appropriate period.
This avoids the need for repetitive testing, which
whether on animals or people, is undesirable both
from economic and ethical points of view.

2. REGuLAToRy dATA pRoTECTIon
vERSuS oTHER foRMS
2.1 How regulatory data protection differs

from confidential information protection

Although the protection of regulatory data has its
origins in laws regulating confidential information

Cook T. 2007. Regulatory Data Protection in Pharmaceuticals and Other Sectors. In Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. T Cook. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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(including trade secrets), and indeed is addressed
in the same article of TRIPS that mandates the
protection of confidential information, it is a
separate right that requires separate analysis.1 The
two types of IP right are different, and a balance
between private and public interests struck in one
should not affect how that balance is struck in the
other. For example, while there would seem to
be no compelling reason why the protection af
forded to confidential information should ever be
limited in duration, the term of regulatory data
protection ought to be limited.
Some experts might argue that there is no
need for a separate legal regime to protect regula
tory data because the data can be protected un
der the law governing confidential information.
Indeed, viewed from an English common law
perspective, regulatory data is typically confiden
tial in nature and is communicated to regulatory
authorities with an obligation of confidence.
However, trade secrets law has proved inadequate
for protecting data filed with regulatory authori
ties. First, the issue has not been about the disclo
sure of data but about its use (although freedom
of information considerations today make a lim
ited measure of disclosures inevitable, which can
undermine its confidential nature.) Second, it is
unclear whether regulatory authorities in fact do
“use” the data in a way that is subject to the law of
confidential information, especially when officials
merely rely on the existence of such data and do
not actively refer to it. Third, even assuming that
such reliance does constitute use, is there some
“public policy” or “implied permission” defense
that permits this use?
On this third point the various Cimetidine
cases,2 each of which was decided effectively on
public policy or implied-permission grounds,
demonstrated the difficulties faced by those who
file confidential regulatory data in the common
law countries of England, Australia, and New
Zealand. When regulators assessed in these cas
es an application for approval of an equivalent
medicinal product by a generic competitor, the
original data filings could not be protected via
traditional concepts of confidential information.
The law of confidential information could not
prevent the regulatory authority from referring
 | HANDBOOK OF BEST PRACTICES

to the originator’s file or from relying on the
mere fact of the earlier authorization.3 Thus the
decision of the House of Lords in the English
Cimetidine case confirmed that the information
was confidential and that a breach of confidenti
ality would have occurred if the information had
been disclosed to third parties or the informa
tion used for purposes unrelated to the function
of the regulatory authorities. But that was not
the case. Instead, the regulatory authorities had
been using the data to carry out the regulatory
function. The legal decision went on to confirm
that regulatory authorities have a right and duty
to make use of such information. The court ob
served that “the licensing authority should not be
deterred from exercising its rights and powers so as
to ensure public safety....”
2.2 Regulatory data protection versus patents

Some experts argue that the protection of innova
tion in regulated areas, such as pharmaceuticals
and agrochemicals, ought to be left to the patent
system, and that no other system of protection
is needed. This objection, however, fails to rec
ognize that proving safety and efficacy for regu
latory authorities is a very different matter from
demonstrating that an invention is patentable.
From a regulatory perspective, much of the re
quired expenditure of time and money is directed
to R&D that rarely yields patentable inventions.
Indeed in some cases, patent protection for a
product approved by regulatory authorities may
be very weak or impossible to obtain, especial
ly when the patent protection is not for a new
chemical entity or other new active substance but
is instead for a new physical form, new formu
lation, new synthetic process, or new use of an
old substance. Such “second generation” patents
are at greater risk of successful attacks on their
validity, because patent validity depends less on
the work done to bring inventions to market, or
to prove that inventions are safe and efficacious,
than on the discovery of the invention in the first
place. Such patent validity considerations are
wholly unrelated to regulatory data protection,
which may therefore provide the sole protection
for a medicinal product. The ability of patents
to give only limited protection—and thus to
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provide a limited incentive for completing the
important work required to secure a marketing
authorization—was recognized in the English
patent case Merck & Co. Inc.’s Patents.4 Having
found invalid certain patents for the medical uses
of alendronate, a compound used to treat medi
cal disorders of excess bone destruction, the trial
judge observed:
Accordingly I hold both patents invalid. I do
so with some regret. Merck [has] only had a few
years’ exclusive exploitation of alendronate. [The
company] must surely have had to make a very con
siderable investment and incurred considerable risk
in bringing [the product] to market. And mankind
is better off as a result. But the patent system does
not confer monopolies on those who develop obvi
ous or old products, even if they have never been
exploited. A workable system for that might be a
good idea, particularly in the field of medicine and
analogous fields.
The framework for such a workable system
has existed for some time in the law of regulatory
data protection, which in the United Kingdom
provided longer effective protection than did
the patents at issue in this case.5 However, the
regulatory data protection system for medicinal
products, at least in Europe and as mandated by
Article 39.3 of TRIPS, provides for only limited
compensation for the shortcomings of the patent
system. This is because regulatory data protection
is available only for data filed in support of a new
active chemical and not (with one exception only
recently introduced) for data filed in support of a
new indication, new formulation, or new dosing
schedule of an already-authorized active chemi
cal. The exception, discussed further below, ex
tends the total period of data protection for all
uses of a medicinal product by one year, if one or
more new therapeutic indications are authorized
that are held to bring significant clinical benefits
in comparison with existing therapies. To fail
to protect data filed in support of a new indica
tion, new formulation, or new dosing schedule
of an already authorized active chemical has two
baleful consequences. It not only discourages
development work on existing medicinal prod
ucts, but also encourages work on new medicinal

products that may be no better in practice than
those they replace. This robs from investments in
public health since the “innovations” add no ben
efit to the public but still require resources to be
spent for new research and market authorization.
Clearly, the pursuit of better IP protection in this
case is a perverse incentive. A revised approach
is needed, one that recognizes the differences
between regulatory data protection and patents.
In short, the former differs from patents in three
ways: (1) its apparently shorter duration; (2) the
lack of any need to comply with conventional
concepts associated with patentability, such as
novelty and obviousness; and (3) it protects only
the regulated product. Table 1 lays out these dif
ferences in more detail.
Notwithstanding the fundamental con
ceptual differences between the two systems of
protection, some links between the systems have
been created. The regime in the United States
for granting authorizations for medicinal prod
ucts (and as required to a degree, by many bilat
eral trade agreements between the United States
and third countries) provides that, when a pat
ent protects a product, in most cases the term
of regulatory data protection is extended for 30
months or longer. In Europe, however, if there is
no sample submission to the regulatory authori
ties (which itself would constitute an infringing
act under applicable patents in Europe), the mere
application for a marketing authorization does
not constitute an act of patent infringement. In
fact, a marketing authorization may be granted
to any party that complies with the applicable
technical requirements without, thereby, infring
ing any patent6.
2. Regulatory data protection versus
other forms of marketing exclusivity

Rights protecting regulatory data need to be dis
tinguished from and contrasted with other types
of marketing exclusivity conferred for other rea
sons. Because both provide a form of market
exclusivity, the distinctions are not always very
clear.
Internationally, one example of market ex
clusivity that contrasts with regulatory data pro
tection is the exclusive marketing rights conferred
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under Article 70.9 of TRIPS for pharmaceuti
cals and agricultural chemical products in those
countries that did not provide full product patent
protection for such chemicals when TRIPS came
into force.
Another type of marketing exclusivity is
available in both Europe and the United States
for orphan medicinal products. Because of their
small potential market, these products require
incentives for development over and above the
norm. In a sense, the exclusivity for orphan
medicinal products could be said to protect in
directly the data submitted by the entity that
secures the first such orphan-drug authoriza
tion, but it goes much further. During the term

of orphan-drug marketing exclusivity, a second
applicant will not be able to obtain market au
thorization even if it submits its own data. Thus
orphan-product status does not simply protect
regulatory data but confers true marketing
exclusivity.
As is to be expected for a right that has only
recently been developed and is only now starting
to be analyzed in detail, there was considerable
international variation in the protection afforded
to regulatory data. This was the case when the text
of TRIPS was finalized in 1994 and it remains the
case today in 2007. In consequence, Article 39.3
leaves much latitude in relation to its national
implementation (see Box 1).

Table 1: Patents and Regulatory Data Protection Contrasted
Patent

Data Protection

Protects

claimed compound and analogues,
and/or uses, and/or formulations,
and/or synthetic processes

compound (and sometimes
formulation) which has an
authorization to market

Prevents

• manufacture, sale, use, or import grant to a subsequent
of a claimed product or the direct applicant of an authorization
product of a claimed process
to market based on
originator’s data
• use of a claimed process
• indirect infringement

Relevant excepted use - private and noncommercial use
- use for purposes of securing
regulatory authorization

any use which does not
require an authorization to
market

- experimental use relating to the
subject matter of the invention
(outside the United States)
Period of protection

20 years from application

variable, but typically
5–10 years from the first
authorization to market

Requires

patentability: novelty, inventive step,
sufficiency, etc.

demonstration of safety and
efficacy
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Box 1: Article 39.3 of TRIPS
Propositions as to the scope of Article 39.3 TRIPS
The importance of regulatory data protection and its international recognition as a sui generis
type of intellectual property right are embodied in Article 39.3 of TRIPS.This embodiment, together
with Article 39.1 and Article 39.2, (which are expressed in somewhat different terms and mandate
the protection of confidential information) provides:
1. In the course of ensuring effective protection against unfair competition as provided in
Article 10 bis of the Paris Convention (1967), Members shall protect undisclosed information in
accordance with paragraph 2 and data submitted to governments or government agencies in
accordance with paragraph 3.
2. Natural and legal persons shall have the possibility of preventing information lawfully within
their control from being disclosed to, acquired by, or used by others without their consent in a
manner contrary to honest commercial practices so long as such information:
a) is secret in the sense that it is not, as a body or in the precise configuration and assembly
of its components, generally known among or readily accessible to persons within the
circles that normally dealt with the kind of information in question;
b) has commercial value because it is secret; and
c) has been subject to reasonable steps under the circumstances, by the person lawfully in
control of the information, to keep it secret.
Note: For the purpose of this provision, “a manner contrary to honest commercial practices” shall
mean at a minimum practices such as breach of contract, breach of confidence, and inducement
to breach, and includes the acquisition of undisclosed information by third parties who know, or
were grossly negligent in failing to know, that such practices were involved in the acquisition.
3. Members, when requiring, as a condition of approving the marketing of
pharmaceutical or of agricultural chemical products which utilise new chemical
entities, the submission of undisclosed test or other data, the origination of which
involves a considerable effort, shall protect such data against unfair commercial
use. In addition, Members shall protect such data against disclosure, except where
necessary to protect the public, or steps are taken to ensure that the data are
protected against unfair commercial use.
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To date, there have been no cases brought
under the WTO (World Trade Organization)
dispute-resolution mechanism in relation to
Article 39.3 to provide guidance. Nonetheless,
the following propositions about the minimum
thresholds of protection that it mandates can be
advanced:
• Article 39.3 addresses two issues: use of the
data in its first sentence and disclosure in the
second. However the data to be protected
are in each case the same.
• In each case the data protected are required
“as a condition of approving the marketing
of pharmaceutical or of agricultural chemi
cal products,” suggesting that this does not
require that data submitted for these products for other purposes, or submitted as a
condition of approving the marketing of
other types of product, be protected. (The
European Community, for example, also
provides for regulatory data protection in
other fields, such as animal feedingstuffs
and biocidal products but TRIPS does not
recognize it).
• In each case, the data protected are required
“as a condition of approving the marketing of
… products which utilise new chemical enti
ties.” The expression new chemical entity is
not defined. Thus this provision does not
necessarily impose a patent standard of nov
elty, and indeed it should not be expected
that it do so, given the different nature of
the right. In any event, if one were to ap
ply a patent standard of novelty, would this
be absolute (worldwide) or relative (local)?
TRIPS is silent on this issue with regard
to patents, and although over time there
has been a trend to absolute novelty, it has
by no means been universally adopted. It
should be noted that the term new chemical
entity is widely used in a regulatory context.
Accordingly, a new chemical entity could
be regarded as an active substance approved
for the first time within a particular regu
latory framework, since the same chemical
may have activity within the context of dif
ferent regulatory frameworks. Moreover,
2 | HANDBOOK OF BEST PRACTICES

because in some regulatory systems the term
new chemical entity is in practice limited to
“small molecules” (as opposed to the “large
molecules” that designate biotechnology
products, such as therapeutic proteins, and
are usually termed new active substances in
such systems), the term ought to be regard
ed as comprising new active substances.
However, this does not mandate the protection of new data, no matter how much
effort their origination has involved, for an
old, or already authorized, chemical entity
or active substance, although such protec
tion ought to be regarded as desirable on
public policy grounds.
• In each case, the origination of the data
protected must “involve a considerable ef
fort.” This no doubt would cover safety and
efficacy data, such as that generated in the
course of clinical trials for pharmaceuticals
or field trials for agricultural chemicals, but
it leaves open the question of what other
data should also be protected on these
grounds.
• In relation to prohibited use, the use must
be “unfair commercial use.” This expression
is not defined, but clearly excludes non
commercial use, such as for public health
and safety. As to commercial use, such as
that made when a subsequent applicant relies on the existence of such data (whether
or not actually referred to), or to be more
accurate, when the regulatory authority assesses the second applicant’s application in
light of the data provided by the original
applicant, the issue is whether or not such
use is unfair. It is in this context that such
matters arise as the appropriate term of
protection and whether or not the protec
tion should be an exclusive right or merely
a remuneration right (and thus available for
compulsory licensing).
• In relation to disclosure, such data must
be protected except in two cases: where it
is either “necessary to protect the public” or
where “steps are taken to ensure that the data
are protected against unfair commercial use.”
Thus, in these two alternative cases there is
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no absolute prohibition on the disclosure
of such data. The first permitted exception,
namely that of “[necessity] to protect the
public” appears narrow in scope and should
not properly be equated with transparency,
which is the principle behind disclosures
under freedom of information consider
ations. Thus in relation to disclosures for
purposes of transparency, TRIPS would
appear to require that “steps [be] taken to
ensure that the data are protected against
unfair commercial use.” This would appear
to require the regulatory authority not to
treat information disclosed for such pur
poses as detracting from the undisclosed
nature of the underlying data. Indeed, in
the European medicinal products regime,
the Notice to Applicants expressly provides
that the information set out in a European
Public Assessment Report (EPAR) cannot
be used to apply for a marketing authori
zation for a medicinal product on a bib
liographic or published data basis (see also
Box 2 at the end of this chapter).

The Background to and Negotiating
History of Article 39.3 TRIPS
Before TRIPS came into force on 1 January
1995, regulatory data was already protected
throughout the European Community and in
the United States by statutory provisions for
both pharmaceuticals and agricultural chemicals.
Since 1987, the member states of the European
Community have provided protection for data
filed in support of marketing authorizations for
medicinal products, and since 1991 for data filed
in support of marketing authorizations for plant
protection products. Similarly since 1982, the
United States has had its own regulatory data
protection provisions for pesticides, and since
1984, such provisions for medicines. Moreover,
as discussed earlier, in both jurisdictions the case
law had made plain the limitations of the law of
confidential information as a means for protect
ing regulatory data.
Moreover, TRIPS was not the first multi
national agreement to mandate that its Member

States provide regulatory data protection. This
honor fell to the North American Free Trade
Agreement (NAFTA)7, paragraphs 5 through 7 of
Article 1711 of which provide:
5. If a Party requires, as a condition for ap
proving the marketing of pharmaceutical
or agricultural chemical products that uti
lize new chemical entities, the submission
of undisclosed test or other data necessary
to determine whether the use of such prod
ucts is safe and effective, the Party shall pro
tect against disclosure of the data of persons
making such submissions, where the origi
nation of such data involves considerable
effort, except where the disclosure is neces
sary to protect the public or unless steps are
taken to ensure that the data is protected
against unfair commercial use.
6. Each Party shall provide that for data sub
ject to paragraph 5 that are submitted to
the Party after the date of entry into force
of this Agreement, no person other than the
person that submitted them may, without
the latter’s permission, rely on such data in
support of an application for product ap
proval during a reasonable period of time
after their submission. For this purpose, a
reasonable period shall normally mean not
less than five years from the date on which
the Party granted approval to the person
that produced the data for approval to mar
ket its product, taking account of the na
ture of the data and the person’s efforts and
expenditures in producing them. Subject to
this provision, there shall be no limitation
on any Party to implement abbreviated ap
proval procedures for such products on the
basis of bioequivalence and bioavailability
studies.
7. Where a Party relies on a marketing approv
al granted by another Party, the reasonable
period of exclusive use of the data submit
ted in connection with obtaining the ap
proval relied on shall begin with the date of
the first marketing approval relied on.
The “not less than five years” term of pro
tection that the North American Free Trade
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Agreement (NAFTA) accepts in Article 1711(6)
as “reasonable” reflected, no doubt, the U.S.
position regarding pharmaceuticals,8 but such
a term is now widely regarded on the researchbased side of the pharmaceuticals industry as
inadequate. However, the NAFTA formulation
has a significant place in the history of regulatory
data protection because it is the first to reflect the
principles of regulatory data protection in treaty
language and because its language parallels that
found in TRIPS.

. THE E.u. And u.S. IMpLEMEnTATIonS
of ARTICLE 39.3 TRIpS
.1 Background

Although the obligations mandated under Article
39.3 are generally expressed, it is instructive to
consider how they have been implemented by the
world’s two major trading blocks—the European
Union and the United States—especially since it
has become increasingly common for each to try
to impose its own IP norms on trading partners
through regional or bilateral trade agreements.
.2 Pharmaceuticals

A variety of national regulatory data protection
regimes for pharmaceuticals have emerged. The
regimes differ both in terms of the length of pro
tection and the categories of data protected. For
example, European Community Member States
previously provided (depending on the coun
try or the regulatory route followed) six or ten
years protection for data filed in support of an
authorization for a new pharmaceutical chemical
entity, but none for data relating to a new indi
cation for an already-authorized pharmaceutical.
For new chemical entities authorized as phar
maceuticals in the European Community after
October 2005, second applicants may apply for
a marketing authorization eight years after the
first authorization is granted, but such authoriza
tion cannot be granted less than ten years after
the date of such first authorization.9 In each case
the protection runs from the first authorization
in the Community. Under the new system, the
ten-year period is extended by a further year if
 | HANDBOOK OF BEST PRACTICES

authorization for a significant new indication for
the pharmaceutical is secured before the eightyear period expires.
In the United States, a second applicant can
not (assuming no patents cover the product) ap
ply for such an authorization until five years af
ter the first marketing authorization.10 Assuming
a typical review period of 18 months, the result
is a total effective protection period of six and a
half years. However, the more usual situation is
that the relevant regulatory authority (the U.S.
Food and Drug Administration (FDA)) has been
advised that one or more patents apply to the
pharmaceutical in question, in which case the
link between the regulatory regime and the pat
ents regime comes into play (see section 2.2).11
This link exists in the United States but not in the
European Union.
In the United States, a company wishing to
market a generic version of a pharmaceutical by
relying on the first applicant’s regulatory data
must certify one of the following to the FDA: (1)
no patent applies, (2) the relevant patent has ex
pired, (3) approval is sought only after the patent
expires; or (4) there is a patent but it is asserted to
be invalid or not to be infringed. Once a generic
manufacturer provides a certification that it con
siders the patent to be invalid or not infringed (a
“Paragraph IV Certification”), the manufacturer
must notify the patentee, which then has an im
mediate right to sue for patent infringement. A
patent infringement action filed within 45 days of
notice delays approval of the first generic authori
zation for 30 months.12 The practical result of the
linkage is thus to extend the effective regulatorydata protection period by at least 30 months to
seven and a half years, even when the Paragraph
IV certification proves to be correct and the listed
patent turns out to be either invalid or not in
fringed. Thus at first sight the duration of protec
tion in the United States for data filed in support
of an authorization for a pharmaceutical as a new
chemical entity may seem less than that afforded
by the European Community. In practice howev
er, the difference is much less, especially because
of this patent linkage.
Moreover, in the United States, data based
on new clinical investigations (other than
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bioavailability studies), relating to an already-au
thorized product, that are essential to a further
authorization (such as that required for a new in
dication) are protected for three years. Although
the protection for new data in support of a new
indication for an old product is apparently more
generous in the United States than in the European
Community, which provides for an extension of
only one year, it is important to appreciate that in
the European Community the protection is ex
tended for all indications and not just, as in the
United States, for the new indication.
. Agricultural Chemical Products

In general, the agricultural-data protection
systems for authorizations in the European
Community and the United States provides for
a longer period of protection than for pharma
ceuticals. They also give a considerably higher
level of protection for new data used in relation
to old active compounds than that mandated in
the pharmaceutical systems.
The system in the European Community,
subject to special provisions for products already
on the market when the system came into force,
provides for ten years of Community-level pro
tection for a new active compound.13 The system
also provides ten years of protection at a national
level (running from the first such authorization
in the Community) for data filed in support of
a formulated plant protection product contain
ing an already authorized active compound.
However, these periods of protection are subject
to provisions intended to promote data regarding
vertebrates to be shared, so that duplicate testing
on animals can be avoided. Failing agreement on
this issue, Member States are empowered to com
pel sharing of such data, which typically involves
arbitration over compensation. As a result of
these compulsory licensing provisions, test data
derived from vertebrate animals does not benefit
from exclusivity. The conferred data protection
can to this extent thus be seen as a remuneration
right rather than an exclusive right.
For pesticides, in the U.S. regulatory data for
old and new products is protected for a ten-year
period.14 For a further five-year period, others can
use the data only when the would-be users have

offered to compensate the first filer of the data (in
the absence of agreement as to the level of com
pensation, there are provisions for arbitration),
but after this 15-year period there is no restric
tion on use. Thus the protection for the last five
years of the 15-year period of protection is not
exclusivity but remuneration.
. Regulatory data protection in bilateral
and regional trade agreements

NAFTA is an example of a regional free trade
agreement, but since the negotiation of TRIPS,
both the United States and the European
Community have entered into a number of bilat
eral trade agreements with third countries. There
have also been some regional trade agreements.
Such agreements typically contain chapters ad
dressing IP, including regulatory data protection.
The approach of the European Community Trade
Agreements, such as that with the Ukraine, is sim
ply to require the trading partner to harmonize
its laws with European Community standards. In
contrast, the U.S. free trade agreements (FTAs)
contain specific provisions to tighten up matters
left vague by the TRIPS Agreement. Several FTAs
are in force, including one with Australia. The
texts of several others have been finalized, and ne
gotiations are under way on a number of others.15
The texts spell out the approach to be adopted
in implementing the TRIPS standards. The obli
gations, expressed as mutual obligations, usually
require the other party to adopt at least some el
ements of the U.S. implementation. This is the
approach in the provisions concerning regulatory
data protection.
In most cases, the FTAs that the United
States has negotiated specify minimum five-year
periods of regulatory data protection for phar
maceuticals and ten-year periods for agricultural
chemicals. Some countries permit the granting
of marketing approval based upon the existence
of an approval for the same pharmaceuticals in
another country. In some of these cases, the FTAs
require the second country to protect the regula
tory data filed in the first country for the same
length of time as the first country does, or for
an independent period.16 Protection is sometimes
required for test data submitted in support not
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only of authorizations for pharmaceutical prod
ucts incorporating new chemical entities, but for
any pharmaceutical product.17 In comparison,
Europe offers such protection for new data filed
in relation to an old active compound in a phar
maceutical product only when such data is filed in
support of one or more new indications that bring
a significant clinical benefit. However, regulatory
data protection in the European Community for
data filed in support of an authorization of a new
pharmaceutical chemical entity is longer than the
minimum five years required under the FTAs.
Several of the FTAs also require the parties to
adopt the U.S. system for pharmaceutical prod
ucts: the patent holder is notified of any attempt
by a second applicant generic company to apply
for a marketing authorization before patent ex
piry.18 Indeed, in many cases, the regulatory au
thority is prohibited from granting a marketing
authorization before patent expiry.19 The impact
of the FTA provisions requiring a link between
marketing approval and patent protection, which
is not mandated by TRIPS, depends very much
upon the precise mechanism involved. Some
mandate mere notification. Others mandate that
no authorization be granted while patents con
tinue in force, the effect of which is to increase
considerably the effective period of protection.
Moreover, unless they have an incentive to chal
lenge patents in the form of their own brief pe
riod of generic exclusivity as provided by the U.S
system, they may be unlikely even to try, because
all they will achieve is to clear the path for other
generic competitors.

. ConCLuSIonS
Regulatory data protection provides an impor
tant incentive for developing safe and efficacious
pharmaceuticals and agricultural chemicals. It is
an incentive that patents alone cannot provide.
The obligations in TRIPS Article 39.3 concern
ing the protection of regulatory data are broadly
expressed and permit numerous flexibilities of
implementation. However, the United States
and the European Union, as the two major trad
ing entities, have each developed specific imple
mentations of these obligations, each with its
 | HANDBOOK OF BEST PRACTICES

own carefully crafted checks and balances. Each
adopts a different approach to protecting regula
tory data for pharmaceuticals and for agricultural
chemicals. Each is also in the process of extending
its specific approach to implementing these obli
gations to some of its trading partners. They are
doing this through trade agreements that specify
the minimum standard of IP protection that the
parties must afford. It is important, therefore, to
be aware of the differences between the U.S. and
European Community systems for protecting
regulatory data for pharmaceuticals and agricul
tural chemicals, the different checks and balances
within such systems, and the reasons for and con
sequences of such differences. Such differences
make it dangerous to cherry-pick only certain
aspects of such systems, or indeed to try to merge
and harmonize their respective features into one
system, for doing so is likely to result in an up
ward harmonization that will produce a system of
regulatory data protection that is more stringent
than that provided by either system on its own. n
TRevoR cooK, Partner, Bird & Bird, 15 Fetter Lane,
London, EC4A 1JP, U.K. trevor.cook@twobirds.com

1

Article 39.2 TRIPS mandates the protection for confi
fi-dential information. There are, however, considerable
disparities in the manner in which countries comply
or enforce this protection (even within the European
Community), in the remedies conferred (for example,
are they are enforced in the criminal or civil courts?),
and in the legal bases for such laws (are they contractual or, as tends to be the case in common law jurisdictions, equitable? Or are they seen as a species of
unfair competition, as tends to be the case in civil law
countries?)

2

Sm
mith Kline & French Laboratories Ltd. v Attorney
General FSR 418 (1989), In re Smith Kline & French
Laboratories Ltd. 1 AC 64 (1990) (England), Smith Kline
& French Laboratories (Australia) Ltd. v Secretary to
the Department of Community Services and Health,
and Alphapharm Ltd. v Secretary to the Department
of Community Services and Health FSR 617 (1990),
relating respectively to New Zealand, England, and
Australia.

3

Likewise in the United States, Ruckelshaus v Monsanto
Co. (467 U.S. 986, 1019–20 (1984)) shows the reluctance
of the courts to impose an unqualified restriction on
regulatory authorities’ use of the data filed with them.
Ruckelhaus was analyzed extensively in the Australian
Cimetidine case Alphapharm Ltd. v Secretary to the
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Department of Community Services and Health [1990]
FSR 617.
4

Merck & Co. Inc’s FSR, p. 498 (2003).

5

However, one of the patents in issue in this case was for
a new dosing schedule (seven days as opposed to one,
with a concomitant difference in dose), and neither
the old regulatory data protection law in Europe, nor
the current one that replaces it, protects new data in
support of a new dosing schedule for an old active
compound, as was confirmed under the old law in the
unsuccessful challenge to the grant of a marketing
authorization to a second applicant in The Queen on
the application of Merck Sharp and Dohme Limited v
The Licensing Authority (acting by the Medicines and
Healthcare products Regulatory Agency, and Approved
Prescription Services (U.K.) Ltd., Generics (U.K.) Ltd. and
Arrow Generics Ltd. EWHC 710 (Admin, 2005) (Moses J,
28 June 2005).

6

The earlier regulatory data protection regime in Europe
as introduced by the amendments made in 1987 by
Directive 87/21/EEC to Directive 65/65/EEC allowed
Member States the option not to confer regulatory
data protection for medicinal product “after patent
expiry” and thus undermine the effect of regulatory
data protection in such countries. However, although
some countries, such as Denmark, initially availed
themselves of this option, they rapidly abandoned
it. The current regulatory data protection regime
in Europe, which applies to active compounds the
application for the first marketing authorization of
which was made since November 2005, provides no
such option.

7

NAFTA was signed on 12 August 1992 and entered into
force (subject to transitional provisions) on 1 January
1994.

8

Although, as observed in Section 3.2 where the
pharmaceutical is the subject of a patent, this can in
practice prove to be rather longer.

9

For specifics of the current European Community
system for the regulatory data protection of medicinal
products see Box 2 of this chapter.

10 See the Federal Food Drug and Cosmetic Act (21 U.S.C.
355), “New Drugs,” and in particular the amendments
here introduced by the Drug Price Competition and
Patent Term Restoration Act 1984 (Hatch-Waxman
Act).
11 Such declarations are listed in the so-called Orange
Book, the electronic version of which is available at
www.fda.gov/cder/ob/.
12 There is an exception to this in the unlikely event that
a final judgment disposes of the patent in less than 30
months. The U.S. system also provides an incentive to
be the first applicant to file a Paragraph IV Certification:
no other such applicant can go to market until 180
days after the first applicant to file such a certification
goes itself to market or disposes of the patent in a final
judgment.
13 See Articles 13 and 14 of Directive 91/414/EC of 15

July 1991 concerning the placing of plant protection
products on the market.
14 See the Federal Insecticide, Fungicide, and Rodenticide
Act (7 U.S.C. 136a),“Registration of pesticides.”
15 Details of those U.S. FTAs signed to date and the
progress of the others can be found at www.ustr.gov/
Trade_Agreements/Bilateral/Section_Index.html.
16 For example United States-Australia FTA Article 17.10,
CAFTA Article 15.10, United States-Jordan FTA Article
4(22), United States-Bahrain FTA Article 14.9.
17 For example United States-Jordan FTA, Article 22
Footnote 10, United States-Singapore FTA, Article 16.8.
18 For example United States-Chile FTA Article 17.10,
United States-Singapore FTA Article 16.8(4), CAFTA
Article 15.10(3).
19 For example United States-Singapore FTA, United
States-Chile FTA, CAFTA, United States-Australia FTA,
United States-Morocco FTA.
20 Namely, “any substance or combination of substances
presented as having properties for treating or
preventing disease in human beings” or “any substance
or combination of substances which may be used in
or administered to human beings either with a view
to restoring, correcting or modifying physiological
functions by exerting a pharmacological, immunologic
or metabolic action, or to making a medical diagnosis.”
21 Separate is here meant in the sense that an
authorization secured under one system cannot form
the basis for securing another authorization in the
other system. One exception to this is provided by
Article 3(3) of the Regulation, which allows Member
States to apply the Article 10 abridged authorization
procedure to grant a national authorization for a
generic medicinal product of a reference medicinal
product first authorized by the Community.
22 The centralized system has long been obligatory for
medicinal products produced by most biotechnological
processes, and has with effect from 20 November
2005 been obligatory also for medicinal products for
human use containing a new active substance for the
treatment of AIDS, cancer, neurodegenerative disorder,
and diabetes, and for medicinal products that are
designated as orphan medicinal products. It is optional
for other new active substances and for medicinal
products shown by the applicant to constitute “a
significant therapeutic scientific or technical innovation
or that the granting of authorisation in accordance
with [the] Regulation is in the interests of patients or
animal health at Community level.”This latter provision
provides a theoretical possibility of securing an entirely
new period of data protection via the centralized route
in relation to an active compound that has already
been authorized via the national route.
23 See Article 14(11) and 89 of the Regulation, paralleling
part of Article 10 of the Directive, as amended, and
Article 2 of the amending Directive.
24 See Article 6 of the Regulation, incorporating by
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reference, inter alia, Articles 10, 10a and 10b of the
Directive, as amended.
25 Moreover by New Article 10(5) “… where an application
is made for a new indication for a well-established
substance, a non-cumulative period of one year of data
exclusivity shall be granted,provided that significant preclinical or clinical studies were carried out in relation to
the new indication.” The precise application and scope
of this provision (which was added at the final stage
of the legislative process and for which there are no
travaux preparatoires) is yet to be established.The EMEA
takes the view that the expression well-established
substance means that the product no longer benefits
from data exclusivity, and that the new period of data
protection can be granted independently at any time
after the initial protection period has expired, but can
only be granted once.
26 Case C-368/96, R v Licensing Authority, ex parte Generics
(UK) Ltd. 2 CMLR 181 (1999).
27 The proviso under the old regulatory regime stated,
“However, where the medicinal product is intended
for a different therapeutic use from that of the other
medicinal products marketed or is to be administered
by different routes or in different doses, the results of
appropriate toxicological and pharmacological tests
and/or of appropriate clinical trials must be provided.”
28 In Case C-106/01, v R v Licensing Authority, ex parte
Novartis the abridged authorization that the ECJ held
to be lawful concerned a formulation of an active that
was suprabioavailable to the formulation that had
been authorized for longer than the data protection
period but was bioequivalent to a formulation for the
same active that had been authorized for less than
that period. In Case C-36/03, v R v Licensing Authority,
ex parte Approved Prescription Services the abridged
authorization that the ECJ held to be lawful concerned
a pharmaceutical form of an active compound that was
different to the pharmaceutical form that had been
authorized for longer than the data protection period
but was the same as that for the same active that had
been authorized for less than that period. In Case C74/03, SmithKline Beecham plc v Laegemiddelstyrelsen,
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the abridged authorization that the ECJ held to be
lawful concerned a different salt of the active moiety
to that in the originally authorized product.
29 Whether or not such a mechanism was in effect
implicit in the old regulatory regime was the subject
of a challenge to a Commission Decision under the
old regulatory regime concerning a human growth
hormone product in Cases T-15/04 & T-105/04 Sandoz
GmbH v Commission of the European Communities.
However as the product in question (Omnitrop
(somatropin)) has now received an authorization under
the new regime, this litigation may well not continue.
30 See www.emea.eu.int/pdfs/human/ewp/309702en.
pdf
and
www.emea.eu.int/pdfs/human/bwp/
320700en.pdf for already-adopted general guidelines
and the listing at www.emea.eu.int/htms/human/
biosimilar/biosimilardraft.htm for various draft
guidelines including specific draft guidelines as
to recombinant EPO, G-CSF, human insulin, and
somatropin.
31 C-440/93, R v Licensing Authority of the Department
of Health (Norgine intervening) ex parte Scotia
Pharmaceuticals Ltd. 3 CMLR 657 (1995).
32 “The Parties acknowledge that, at the time of entry
into force of this Agreement, neither Party permits third
persons, not having the consent of the person that
previously submitted information concerning the safety
and efficacy of a product in order to obtain marketing
approval in another territory, to market a same or
similar product in the territory of the Party on the basis
of such information or evidence of prior marketing
approval in another territory.” [Footnotes 17 and 18 in
original Annex].
33 “As an alternative to this paragraph, where a Party, on
the date of entry into force of this Agreement, has in
place a system for protecting information submitted
in connection with the approval of a pharmaceutical
product that utilizes a previously approved chemical
component from unfair commercial use, the Party may
retain that system, notwithstanding the obligations of
this paragraph.” [Footnotes 17–19 in original Annex].
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Box 2: Regulatory Data Protection for Medicinal Products
in the European Community (extracts)
Introduction
This section sets out in detail the provisions relating to regulatory data protection for medicinal
products for human use in the European Community.20 Parallel provisions,which differ with regard
to certain specifics involving regulatory data protection, apply to veterinary medical products.
The legal basis for such provisions changed as from:
• 30 October 2005, the date by which Member States were mandated to bring the
provisions of Directive 2004/27/EC amending Directive 2001/83/EC on the Community
code relating to medicinal products for human use (for medicinal products in the national
systems) into effect
• 20 November 2005, the date on which the relevant provisions of Regulation 726/2004
laying down Community procedures for the authorization and supervision of medicinal
products for human and veterinary use (for medicinal products in the centralized
Community system), and replacing those under Regulation 2309/93, comes into effect.
The relevant extracts from the Directive as amended are set out at the end of this Box. However,
it should be noted that certain aspects of the former provisions (notably the period of protection
and the nonavailability of extended protection for new uses) continue to apply to medicinal
products for which an application for authorization was submitted before such dates, and
since much of the litigation concerning the scope and effect of the old provisions informs the
interpretation of the new ones, it is appropriate also to bear in mind the old provisions when
discussing the new ones. Moreover, it is convenient to analyze these issues by reference to the
Directive, dealing with medicinal products in the national, decentralized, and mutual recognition
systems, rather than by reference to the Regulation, which deals with the generally separate,
from a regulatory perspective,21 centralized system,22 because the substantive law in each case
is the same as a result of the Regulation either repeating,23 or in some cases incorporating by
reference the relevant provisions of the Directive.24
This Box does not address the separate system of protection that may also be available in some
cases under Regulation (EC) No 141/2000 (the Orphan Medicinal Products Regulation).
General Principles
The regulatory data protection provisions for medicinal products operate by providing an exception,
after a specific period, to the requirement for someone seeking a marketing authorization for a
medicinal product to provide the results of toxicological and pharmacological tests or the results
of clinical trials for such medicinal product if such a medicinal product has already been the
subject of an authorization. Thus these provisions enable the authorization of a generic version
of an already authorized product after such period and without such data. Such an authorization
may conveniently be termed an abridged authorization.
Term of Protection
Where a medicinal product has been the subject of an authorization submitted before November
2005, then the periods of protection under the old regime (old Article 10(1)(a)(iii)) apply, by which
a product must have been authorized within the Community, in accordance with Community
provisions in force, for not less than a six or ten-year period, and be marketed in the Member
State for which the application is made. The ten-year period applies to medicinal products
authorized under the centralized procedure of the Regulation and its predecessor, throughout
the Community, and also in respect of authorizations secured nationally in those Member States
that elected to apply it, namely Belgium, France, Germany, Italy, Netherlands, Sweden and the
United Kingdom The six-year period applies to authorizations secured nationally in other Member
States. This is the regime that will continue in effect for abridged authorizations for some time
to come.
(Continued on Next Page)
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Box 2 (continued)

Where a medicinal product is the subject of an authorization submitted after October 2005, then
the periods of protection under the new regime apply. By new Article 10(1), an application for
an abridged authorization cannot be filed until a period of eight years after the first marketing
authorization in the Community has been granted, but a product so authorized cannot be placed
on the market less than ten years from the first marketing authorization in the Community.
This ten-year period is extended to 11 years when, during the first eight years, the marketing
authorization holder obtains an authorization for one or more new therapeutic indications that,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical
benefit in comparison with existing therapies. The first requests for abridged authorizations
under the new regime cannot be filed before November 2013.
Variations and line Extensions of an Already Authorized Medicinal Product:
New Indications, New Strengths, Pharmaceutical Forms, Administration Routes,
Presentations, and so on
As noted earlier, the new ten-year period of protection available to medicinal products the subject
of an authorization submitted after October 2005 will be extended to 11 years where, during the
first eight years, the marketing authorization holder obtains an authorization for one or more new
therapeutic indications which, during the scientific evaluation prior to their authorization, are held
to bring a significant clinical benefit in comparison with existing therapies.25 No such provision
existed under the old regulatory regime, it having been established in the Generics case26 that new
indications for an already authorized active did not secure a new period of protection running from
the date of authorization of such new indication,and that accordingly an abridged authorization for
a particular medicinal product could be granted with respect to all indications already authorized
for that particular medicinal product as at the date of such abridged authorization. This case also
established that new dosage forms, doses, and dosage schedules likewise did not secure a new
period of protection running from the date of authorization of such new dosage forms, doses
and dosage schedules, and that accordingly an abridged authorization for a particular medicinal
product could be granted in respect of all dosage forms, doses and dosage schedules already
authorized for that particular medicinal product as at the date of such abridged authorization.
The decision in the Generics case was based on the determination under the old regulatory
regime that the product the subject of the abridged authorization was properly to be regarded
as “essentially similar,” as the term was used in Article 10(1)(a)(iii), to the originally authorized
product, if it satisfied “the criteria of having the same qualitative and quantitative composition
in terms of active principles, of having the same pharmaceutical form and of being bioequivalent,
unless it is apparent in the light of scientific knowledge that it differs significantly from the original
product as regards safety and efficacy.” Subsequent cases under the old regulatory regime
established that even where there might not be such essential similarity, the proviso to Article
10(1)(a)27 allowed for bridging data to be filed, or for bridging data filed by the originator to be
relied on, provided that the originally authorized product and the product that is the subject of
the abridged authorization had the same active principle.28
These principles have been retained under the new regulatory regime by virtue of new Article
6 and Article 10(1). Article 6 clarifies the issues of interpretation addressed in the Novartis
and Approved Prescription Services cases by introducing the concept of the global marketing
authorization which covers “any additional strengths, pharmaceutical forms, administration
routes, presentations, as well as any variations and extensions.” Article 10(1) requires the applicant
for an abridged authorization to demonstrate that the medicinal product that is the subject of
the application “is a generic of a reference medicinal product which is or has been authorized under
Article 6 for not less than eight years in a Member State or in the Community.” The definition of
generic medicinal product under Article 10(2)(b) preserves the concept of essential similarity as
refined by ECJ case law in Generics and subsequent cases.
(Continued on Next Page)
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Box 2 (continued)

New Combinations
New Article 10b replaces old Article 10(1)(b) and concerns medicinal products containing active
substances used in the composition of authorized medicinal products but not hitherto used in
combination for therapeutic purposes. In such a case, the results of new preclinical tests or new
clinical trials relating to that combination shall be provided, but it is not necessary to provide
scientific references relating to each individual active substance. The matter has not been the
subject of litigation, but it has generally been accepted that, by virtue of this provision, a new
combination has its own period of data protection calculated from the date of the first marketing
authorization for that particular combination in the Community, as if that new combination were
a new active substance.
Biological Medicinal Products
New Article 10(4) provides a framework that did not exist under the old regulatory regime.29
It would enable guidelines to be established by which biological medicinal products could be
authorized without full results of toxicological and pharmacological tests, or the results of clinical
trials, on the basis of an earlier authorization for a “biosimilar” product. The EMEA is at present
developing such guidelines, but so far the only specific guidelines that have so far been published
concern certain specified recombinant proteins.30
Bibliographic Applications
New Article 10a replaces old Article 10(1)(a)(ii) and, as before, allows for an authorization to be
sought without full results of toxicological and pharmacological tests or the results of clinical
trials but which does not refer to an authorized reference product where “the active substances
of the medicinal product have been in well-established medicinal use within the Community for a
period of at least ten years, with recognised efficacy and an acceptable level of safety”. It is under
this provision that authorization can, for example, be sought for medicinal products containing
active substances such as aspirin for the relief of pain. The narrow scope of the provision was
emphasized under an earlier version of the provision under the old regulatory regime in the
Scotia case.31
Relevant Provisions of Directive 2001/83/EC on the Community Code in Regard
to Medicinal Products for Human use as Amended by Directive 2004/27/EC
Article 6
1. No medicinal product may be placed on the market of a Member State unless a marketing
authorisation has been issued by the competent authorities of that Member State in accordance
with this Directive or an authorisation has been granted in accordance with Regulation (EEC)
No. 2309/93.
When a medicinal product has been granted an initial marketing authorisation in accordance
with the first subparagraph, any additional strengths, pharmaceutical forms, administration
routes, presentations, as well as any variations and extensions shall also be granted an
authorisation in accordance with the first subparagraph or be included in the initial marketing
authorisation. All these marketing authorisations shall be considered as belonging to the
same global marketing authorisation, in particular for the purpose of the application of Article
10(1).
Article 10
1. By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the
protection of industrial and commercial property, the applicant shall not be required to provide
the results of pre-clinical tests and of clinical trials if he [or she] can demonstrate that the
(Continued on Next Page)
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Box 2 (continued)

medicinal product is a generic of a reference medicinal product which is or has been authorised
under Article 6 for not less than eight years in a Member State or in the Community.
A generic medicinal product authorised pursuant to this provision shall not be placed on the
market until ten years have elapsed from the initial authorisation of the reference product.
The first subparagraph shall also apply if the reference medicinal product was not authorised
in the Member State in which the application for the generic medicinal product is submitted.
In this case, the applicant shall indicate in the application form the name of the Member
State in which the reference medicinal product is or has been authorised. At the request of
the competent authority of the Member State in which the application is submitted, the
competent authority of the other Member State shall transmit within a period of one month,
a confirmation that the reference medicinal product is or has been authorised together with
the full composition of the reference product and if necessary other relevant documentation.
The ten-year period referred to in the second subparagraph shall be extended to a maximum
of eleven years if, during the first eight years of those ten years, the marketing authorisation
holder obtains an authorisation for one or more new therapeutic indications which, during
the scientific evaluation prior to their authorisation, are held to bring a significant clinical
benefit in comparison with existing therapies.
2. For the purposes of this Article:
(a) “reference medicinal product” shall mean a medicinal product authorised under Article 6,
in accordance with the provisions of Article 8;
(b)“generic medicinal product”shall mean a medicinal product which has the same qualitative
and quantitative composition in active substances and the same pharmaceutical form as
the reference medicinal product, and whose bioequivalence with the reference medicinal
product has been demonstrated by appropriate bioavailability studies. The different salts,
esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance
shall be considered to be the same active substance unless they differ significantly in
properties with regard to safety and/or efficacy. In such cases, additional information
providing proof of the safety and/or efficacy of the various salts, esters, or derivatives
of an authorised active substance must be supplied by the applicant. The various
immediate-release oral pharmaceutical forms shall be considered to be one and the same
pharmaceutical form. Bioavailability studies need not be required of the applicant if he can
demonstrate that the generic medicinal product meets the relevant criteria as defined in
the appropriate detailed guidelines.
3. In cases where the medicinal product does not fall within the definition of a generic medicinal
product as provided in paragraph 2(b) or where the bioequivalence cannot be demonstrated
through bioavailability studies or in case of changes in the active substance(s), therapeutic
indications, strength, pharmaceutical form or route of administration, vis-à-vis the reference
medicinal product, the results of the appropriate pre-clinical tests or clinical trials shall be
provided.
4. Where a biological medicinal product which is similar to a reference biological product
does not meet the conditions in the definition of generic medicinal products, owing to, in
particular, differences relating to raw materials or differences in manufacturing processes of
the biological medicinal product and the reference biological medicinal product, the results of
appropriate pre-clinical tests or clinical trials relating to these conditions must be provided.
(Continued on Next Page)
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Box 2 (continued)

The type and quantity of supplementary data to be provided must comply with the relevant
criteria stated in the Annex and the related detailed guidelines. The results of other tests and
trials from the reference medicinal product’s dossier shall not be provided.
5. In addition to the provisions laid down in paragraph 1, where an application is made for
a new indication for a well-established substance, a non-cumulative period of one year of
data exclusivity shall be granted, provided that significant pre-clinical or clinical studies were
carried out in relation to the new indication.
6. Conducting the necessary studies and trials with a view to the application of paragraphs 1,
2, 3 and 4 and the consequential practical requirements shall not be regarded as contrary to
patent rights or to supplementary protection certificates for medicinal products.
Article 10a
By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the
protection of industrial and commercial property, the applicant shall not be required to provide
the results of pre-clinical tests or clinical trials if he can demonstrate that the active substances
of the medicinal product have been in well-established medicinal use within the Community
for at least ten years, with recognised efficacy and an acceptable level of safety in terms of the
conditions set out in the Annex. In that event, the test and trial results shall be replaced by
appropriate scientific literature.
Article 10b
In the case of medicinal products containing active substances used in the composition of
authorised medicinal products but not hitherto used in combination for therapeutic purposes,
the results of new pre-clinical tests or new clinical trials relating to that combination shall be
provided in accordance with Article 8(3)(i), but it shall not be necessary to provide scientific
references relating to each individual active substance.
Article 10c
Following the granting of a marketing authorisation, the authorisation holder may allow use
to be made of the pharmaceutical, preclinical and clinical documentation contained in the file
on the medicinal product, with a view to examining subsequent applications relating to other
medicinal products possessing the same qualitative and quantitative composition in terms of
active substances and the same pharmaceutical form.
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Box 3: Regulatory Data Protection Provisions of the united States-Australia
FTA Articles 17.10: Measures Related to Certain Regulated Products
1. (a) If a Party requires,as a condition of approving the marketing of a new pharmaceutical product,
the submission of undisclosed test or other data concerning safety or efficacy of the product,
the Party shall not permit third persons, without the consent of the person who provided the
information, to market the same or a similar product on the basis of that information, or the
marketing approval granted to the person who submitted such information, for at least five
years from the date of marketing approval by the Party.
(b) If a Party requires, as a condition of approving the marketing of a new agricultural chemical
product, including certain new uses of the same product, the submission of undisclosed
test or other data concerning safety or efficacy of that product, the Party shall not permit
third persons, without the consent of the person who provided the information, to market
the same or a similar product on the basis of that information, or the marketing approval
granted to the person who submitted such information, for ten years from the date of the
marketing approval of the new agricultural chemical product by the Party.
(c) If a Party permits, as a condition of approving the marketing of a new pharmaceutical or
agricultural chemical product, third persons to submit evidence concerning the safety or
efficacy of a product that was previously approved in another territory, such as evidence of
prior marketing approval, the Party shall not permit third persons, without the consent of
the person who previously submitted information concerning safety or efficacy, to market
the same or a similar product on the basis of evidence of prior marketing approval in another
territory, or information concerning safety or efficacy that was previously submitted to obtain
marketing approval in another territory, for at least five years, and ten years for agricultural
chemical products, from the date of marketing approval by the Party, or the other territory,
whichever is later.32
(d) For the purposes of this Article, a new product is one that does not contain a chemical entity
that has been previously approved for marketing in the Party.
(e) If any undisclosed information concerning the safety or efficacy of a product submitted to
a government entity, or entity acting on behalf of a government, for purposes of obtaining
marketing approval is disclosed by a government entity, or entity acting on behalf of a
government, each Party is required to protect such information from unfair commercial use
in the manner set forth in this Article.
2.

With respect to pharmaceutical products, if a Party requires the submission of: (a) new
clinical information (other than information related to bioequivalency) or (b) evidence of
prior approval of the product in another territory that requires such new information, which
is essential to the approval of a pharmaceutical product, the Party shall not permit third
persons not having the consent of the person providing the information to market the same
or a similar pharmaceutical product on the basis of the marketing approval granted to a
person submitting the information for a period of at least three years from the date of the
marketing approval by the Party or the other territory, whichever is later.33

3.

When a product is subject to a system of marketing approval in accordance with paragraph 1
or 2, as applicable, and is also subject to a patent in the territory of that Party, the Party shall
not alter the term of protection that it provides pursuant to paragraph 1 or 2 in the event that
the patent protection terminates on a date earlier than the end of the term of protection
specified in paragraph 1 or 2, as applicable.

(Continued on Next Page)
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Box 3 (continued)

4.

Where a Party permits,as a condition of approving the marketing of a pharmaceutical product,
persons, other than the person originally submitting the safety or efficacy information, to rely
on evidence or information concerning the safety or efficacy of a product that was previously
approved, such as evidence of prior marketing approval by the Party or in another territory:
(a) that Party shall provide measures in its marketing approval process to prevent those other
persons from:
(i) marketing a product, where that product is claimed in a patent; or
(ii) marketing a product for an approved use, where that approved use is claimed in a
patent, during the term of that patent, unless by consent or acquiescence of the
patent owner; and
(b) if the Party permits a third person to request marketing approval to enter the market
with:
(i) a product during the term of a patent identified as claiming the product; or
(ii) a product for an approved use, during the term of a patent identified as claiming
that approved use, the Party shall provide for the patent owner to be notified of such
request and the identity of any such other person.
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IP Strategy
RobeRT piTKeThly, University Lecturer, Said Business School; Fellow and Tutor in Management, St. Peter’s College;

and Senior Research Associate, Oxford Intellectual Property Research Centre, University of Oxford, U.K.

ABSTRACT

This chapter gives an overview of the aims of an IP (in
tellectual property) strategy and discusses management
issues involved in implementing such a strategy. Other
chapters in this Handbook provide more-detailed infor
mation about managing intellectual property; the purpose
of this chapter is to provide an integrated framework for
giving IP rights the balanced consideration they deserve.

1. InTRoduCTIon
IP (intellectual property) strategy can mean many
things. In order to understand the relevance and
implications of the term, we first need to look at
what is meant by the terms intellectual property and
strategy, how they work in combination, and the
implications of an IP strategy for organizations. For
some people, it means the tactics used to manage
an IP rights program, with detailed attention to li
censing, filing, and litigation strategies. For others,
the term refers to a general business strategy that
uses IP rights to manage technology. Still others
might assume that an IP strategy is only a concern
for large for-profit corporations and irrelevant to
smaller or not-for-profit organizations. However,
an IP strategy, and the informed use of IP rights, is
important to organizations of all sizes.
2. InTELLECTuAL pRopERTy
IP rights are commonly regarded as simply a means
of protecting innovation, with the assumption that

this protection benefits the innovator.1 However,
such a view emphasizes too strongly the private
benefits that can accrue to IP rights holders while
neglecting the important public benefits provided
by an IP system. Viewed broadly, an IP rights
system has several components that contribute to
the system’s overall effectiveness. These roles need
to be kept in balance, so that private interests do
not dominate the public interest. Nor should
public interests, considered in the short term,
dominate the long-term private interests that
drive the system.
IP rights are beneficial in a number of ways.
By providing incentives or rewards for innova
tion, by packaging or defining intellectual assets,
and by diffusing technical information and con
trolling intellectual assets, they are a powerful en
gine for innovation. In contrast to these utilitar
ian functions, IP rights also can be seen to protect
a natural, even moral, right of inventors to their
creations, a view that has its origins in Lockean
conceptions of property.2
Whatever theoretical justifications are used to
support them, the difficulty with IP systems is in
striking the optimal balance between private rights
and public benefits. From a public-policy perspec
tive, this goal is elusive, and even after several hun
dred years of debate by economists, political lead
ers, and inventors, a precise way of balancing these
competing concerns has yet to be found.

Pitkethly R. 2007. IP Strategy. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of
Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
© 2007. R Pitkethly. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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IP systems play a significant but uncertain
role in policy measures used to encourage in
vestment in innovation. Fritz Machlup is often
cited, for example, to support the view that the
uncertainty inherent in the patent system makes
that system difficult both to implement and to
abolish.3 But Edith Penrose made this same
point seven years earlier in her study of the in
ternational patent system: “If national patent
laws did not exist, it would be difficult to make a
conclusive case for introducing them; but the fact
that they do exist shifts the burden of proof and
it is equally difficult to make a really conclusive
case for abolishing them.”4 Penrose was referring
to the 19th century debate about patents, and
Machlup and Penrose’s earlier discussion of the
19th century patent system controversy dealt, in
large part, with the debate over its abolition.5
However, they observed in the same article that
“little, if anything, has been said for or against the
patent system in the 20th century that was not said
equally well in the 19th.” That statement is also
likely to be true for the 21st century.
Indeed, despite the longstanding theoretical
uncertainty about IP rights systems, they have
proved remarkably resilient in the countries that
have implemented them. It is arguable that IP
rights systems are, so far as we can tell, better
than any of the alternatives that have been pro
posed over the years. Of course, this raises the
possibility of interpreting IP strategy as that at
the national not corporate level. In fact, there are
many interesting examples that could be studied
in support of this claim.6 The U.S. Constitution,
for example, provided for IP rights from its in
ception.7 And Japan’s rapid modernization from
a feudal society in the 1850s to an industrialized
nation by the early 1900s included the relatively
rapid adoption of an IP rights system.8 Even in
the United Kingdom, the gradually evolving
patent system had a role to play in the first in
dustrial revolution.9 Patent systems are known
to support the interests of industrialized nations,
and in most cases such systems also played a role
in encouraging early industrialization efforts.
This suggests that some form of IP strategy, at a
national level, is relevant to all nations regardless
of their level of industrialization.
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2.1 Organizational roles of IP rights

Although the different justifications for IP systems
and the different national strategies for implement
ing them are worthwhile topics, this chapter has a
more pragmatic goal, to help provide an under
standing of the practical implications of the vari
ous IP systems. Accordingly, it considers the four
practical roles of an IP system. These are (1) acting
as an incentive system for innovation, (2) packag
ing intellectual assets, (3) diffusing technical infor
mation, and (4) controlling intellectual assets.
An IP system’s role of providing incentives or
rewards for innovation is achieved through pro
tecting that innovation by restricting use by oth
ers. The restriction, by protecting the inventor,
enables them to command monopoly prices and
benefit from the innovation to a greater extent
than would be possible without such protection.
This has implications for strategy in that potential
restrictions on use confer control, and that con
trol can be exercised not just to limit but also to
expand the market for an innovation.
With technology-based innovation, IP sys
tems also help package and define intellectual as
sets. Intellectual assets, by definition, start as tacit
ideas, literally embodied in the inventor. IP rights,
and particularly patent specifications, facilitate
these tacit inventions by providing a more eas
ily transmissible and protectable embodiment for
these intellectual assets. This ability to enable pre
viously tacit or secret information to be identified
and made the subject of transactions and com
munications is a critical function of Intellectual
property, and this dimension of IP rights has
strategic implications. For example, this function
facilitates licensing. Kenneth Arrow’s informa
tion paradox, where transactions in confidential
information are made more difficult where trust
is absent, can be eased by the use of IP rights and
the laws of contract.10
An IP system—especially a patent system—
plays a key role in diffusing technological
information. The threat of free riders and
competition may tempt an innovator to keep an
invention secret. Historically, there have been
cases, notably the Chamberlen family’s secret use
of obstetric forceps in their medical practice for
more than 130 years, where society has been denied
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life-saving technologies because an invention was
kept secret.11 Modern analytical methods and job
mobility make such tactics less likely today, but
an IP system still has an important role in both
facilitating the publication of inventions and
making information easier to find. The challenge
is, of course, that an IP system must be arranged
so that the rights granted to innovators do not
end up costing the rest of society more by unduly
hindering access to other innovations.
Finally, intellectual property rights may be
thought of as a means of, not just protecting, but,
controlling, the underlying intellectual assets. This
is particularly critical when IP rights are consid
ered from the point of view of organizations or
individuals with a concern for the public interest.
The fact that IP rights give the power to prevent
use means that they also give the right to license
use, which enables IP rights holders to exert sig
nificant control over their innovations. The ex
tent of that control will depend on a number of
other factors (see section 4 below). If an organiza
tion ignores or fails to obtain IP rights, it risks
abdicating control over an invention. In the case
of a fundamental invention, this may have major
strategic implications.
This point is illustrated by the different ways
in which penicillin and the subsequent cepha
losporin antibiotics were protected by patents.
When penicillin was discovered in 1929, chemical
product patents were not available in the United
Kingdom. At the time, some felt that the discovery
and work associated with penicillin’s production
should not be subject to patent protection. As a
result, neither penicillin itself nor the initial pro
duction methods were patented by the discoverer,
Alexander Fleming, in London and the developers
in Howard Florey’s team in Oxford. In contrast,
the crucial factor in the widespread use of penicil
lin in the latter part of the 1940s turned out to be
the development of bulk fermentation methods
of production, and these were patented by their
inventors in the United States.12 As a result, the
potential for control over the commercialization
of penicillin largely belonged to the U.S. compa
nies involved. Several years later, scientists from
Florey’s research group in Oxford discovered and
developed the cephalosporin group of antibiotics.

Patents were obtained by the National Research
and Development Organization (NRDC), which
was then responsible for commercializing univer
sity-based inventions.13 Using the royalties derived
from licensing these patents, the two main inven
tors, Guy Newton and Edward Abraham, set up
two charitable trusts, the E. P. Abraham Research
Fund and the Guy Newton Trust, which still to
day support medical, biological, and chemical re
search in Oxford.
The point behind these two stories is that, in
the first case, control and financial benefit were
effectively ceded to subsequent developers of crit
ical enabling technology. In the second case, pat
ents were used to not only retain that control but
also to put financial proceeds under the inventors’
control—in this case, for charitable purposes. A
similarly significant financial decision was made
by the NRDC many years later when it did not
patent the initial discovery of monoclonal anti
bodies by Georges Köhler and César Milstein.
In retrospect, this arguably forfeited several mil
lion British pounds of potential royalty income.
However, it is worth noting César Milstein’s com
ment about his approach to patenting and licens
ing his laboratory’s work:
Within our laboratory we established a set of
principles. The public interest should come first, the
scientific interest of the inventors, second, and mak
ing money should be considered only in the light of
the first two priorities.14
But did the first two principles receive the
priority they could have had if there had been
more interest in the commercial aspects of the
laboratory’s work? Indeed, such principles do
not preclude the use of IP rights. They simply
suggest how the rights might be used. More im
portantly, the public may benefit when those
who are obliged to be concerned with the public
interest exercise control over their innovations.
Intellectual property represents one of the few
means of control available to scientific and re
search establishments, even for those organiza
tions not directly involved in commercializing
their research.
More generally, it is much more useful
to consider IP rights as a means of control,
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rather than as a barrier to be placed in the path
of the competition.

. STRATEGIC MAnAGEMEnT THEoRy
Having considered the roles that intellectual prop
erty can play, the nature and scope of IP strategy
should be considered. There are many definitions
of strategy from a business perspective. A com
mon, widely applicable definition is provided by
business historian Alfred Chandler:
Strategy can be defined as the determination of
the long-run goals and objectives of an enterprise and
the adoption of courses of action and the allocation of
resources necessary for carrying out these goals.15
The word objectives is used in the plural, and
it is important to realize that organizations may
have multiple objectives. Businesses tend to be
thought of as unidirectional, as devoted solely to
the pursuit of profit, or maximizing shareholder
value. In reality, most organizations have mul
tiple objectives and pursue more than just profit.
In the case of not-for-profit organizations, this
is usually explicit. Objectives such as widening
access to medicines, eradicating disease, and im
proving social conditions may constitute primary
objectives for organizations, and these objectives
may make profit seeking impossible. However,
whatever the organization and whatever the ob
jectives it sets for itself, the resources it has under
its control must still be managed to best effect.
For a company to say it will forego profit by not
bothering to exploit a resource may sound accept
able, if financially inefficient. For an organization
to say it will forego the chance to save lives by not
bothering to exploit a resource can hardly be seen
in the same light. Indeed, if not-for-profit organi
zations opt out of the global IP system, they may
not be the biggest losers. This point once again
highlights the importance of intellectual property
and of understanding its challenge, which lies in
the need to balance the management, control,
and use of resources with the achievement of the
organization’s objectives. Intellectual property
is a resource. As such, it should not be thrown
away—even with the best of intentions. As with
many aspects of intellectual property, it is no
2 | HANDBOOK OF BEST PRACTICES

surprise that the choices may not always be clear
and are almost always controversial; the challeng
es should be expected to be unexpected.
A conventional view of business strategy
might divide the subject into a consideration of
the external environment, in which the business
competes, and the internal resources it uses to
compete. In the early 1980s, studies of strategy
tended to concentrate more on external environ
ment, including work originating in industrial
organization economics. This work, emphasizing
barriers to entry, by authors such as Bain16 and
Mason,17 eventually led to Porter’s work on in
dustry structure analysis.18 Porter considered IP
rights primarily as examples of barriers of entry,
though they also form “isolating mechanisms”
necessary to preserve competitive advantage.19
However, concentration on such external issues
as the choice of where to invest and compete
made the strategic analysis of the day less di
rectly relevant to IP issues. In the latter half of
the 1980s and 1990s, the development of the
resource-based view of companies, with their
internal focus on managing the resources of an
organization, gradually drew the field of strategy
closer to that of IP management.20
The resources of the organization essentially
comprise the organization’s staff, its financial re
sources, any tangible assets, and the intangible or
intellectual assets that the organization controls.
The aim of strategy is to manage the resources
available in order to achieve the objectives set.
Since in most cases resources are tradeable as
sets, any organization in possession of valuable
resources is obliged to put those resources to the
best use possible, even if they lack direct relevance
to the organization’s immediate objectives.
A publicly acknowledged failure to make
the best use of a company’s assets may result in a
bid for control of the company by those who feel
they can extract more value from resources than
managers have. Even with not-for-profit organi
zations, not making the best use of the resources
available is a serious failure.
IP rights are one of an organization’s intangi
ble resources, and thus they need to be exploited
to the fullest extent consistent with the organiza
tion’s objectives. How this should be done may
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not always be clear, but what is certain is that no
resource should just be given, or thrown, away.
One final aspect of general strategic-man
agement theory that is relevant to the study of
intellectual property is the concept of managing
added value. In any business where resources are
employed and processed through a value chain of
parties—each adding some small amount of value
before the product reaches the end customer—the
relationship between the organization and those
with whom it buys and sells is crucial. Just as im
portant is how the value created by the entire chain
of parties is distributed among the parties in, or
closely associated with, the chain. If the innova
tor tries to capture the entire added value in the
business, perhaps by using particularly effective
IP rights, the innovator may find it impossible to
get any distributors to sell the product. The inno
vator might then be forced to rely on direct sales,
resulting in a loss of competitiveness. Equally, if
each business or licensor involved in a production
chain insists on a substantial proportion of the
final retail price, the royalty stacking produced
may make the goods concerned uncompetitive.
While the concept of the value chain is inherent
in a number of strategic models, whether at the
industry level21 or business-unit level, the “value
net” advocated by Brandenburger and Nalebuff
deals nicely with the issue of how value added is
distributed over a network of parties involved di
rectly, or indirectly, with a business.22
In considering how to exploit and appropri
ate the benefits of a given piece of intellectual
property, consideration must always be given to
how the dynamics of an industry, the access to
complementary assets, and the strength of IP
rights will affect the ability of any one party to
appropriate the benefits of the innovation.

. Ip STRATEGy
Having identified IP rights and how they fit into
the larger scheme of strategic management, the
immediate question is what exactly an IP strategy
requires beyond the general exhortation to make
the best use possible of the resource.
A simple taxonomy of IP strategy to di
vide the field is needed, just as the larger field

of strategic management is divided into internal
and external resources. On the one hand, there
are activities external to the organization that in
volve interaction with other parties. On the other
hand, there are internal activities concerned with
management within the organization. The word
strategy tends to invoke images of competitive ac
tion, but the internal perspective on IP strategy
must not be neglected in favor of the external,
since both are directly concerned with the value
and allocation of resources.
A further distinction to be drawn is that be
tween IP strategy and IP management. This might
be likened to the difference between strategy and
tactics; the difference is between the general prin
ciples and aims that govern the courses of action
(strategy) and the actual implementation of those
courses of action (management).
.1 External IP strategy

The key components of an external IP strategy
are the issues of exploitation and what might be
termed litigation, licensing, and learning. In a
sense, litigation and licensing are opposites, since
one denies and the other allows what would oth
erwise be an infringement of IP rights. The fact
that both are choices within an IP rights holder’s
range of strategies illustrates the power of con
trol provided by an IP strategy. The possessor of
an IP right has the power to stop, allow, or even
encourage the use of that right, depending on the
strength of the IP rights concerned.
Regarding litigation, perhaps the main
distinction to be drawn is between litigation
tactics, for example, deciding in which country
to litigate against multiple infringers or deciding
which arguments to use. In contrast, litigation
strategy involves, for example, deciding whether
to resist or grant licenses to infringers, so that
litigation can be settled before it reaches court.
Especially where IP rights held overseas are
infringed, IP rights holders may be persuaded
to solve infringement by granting licenses to
convert local infringers into licensees. This may
not, however, always be the best course of action;
certainly the best licensees may not always be
found among former infringers. The infringers
may have deliberately infringed with the aim of
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acquiring licenses on advantageous terms. Indeed,
a focus on litigation strategy may encourage the
IP rights holder to make poor decisions about
whom to grant a license. Moreover, while a
patentee’s options may be more limited when
operating overseas, a litigation strategy should
not be decided by the infringers but by the IP
rights holder. Wherever possible, any decision
about licensing should be driven by licensing
considerations rather than by a desire to avoid
litigation. For institutions and organizations
whose main aim is to maximize the use of their
innovations, litigation should be secondary—far
behind exploitation and licensing.
When seeking to exploit intellectual proper
ty, an organization has at least three main options.
First, it can sell the technology outright and exit
from the field (except perhaps for providing tech
nical advice during a transitional period). Or it
might choose to exploit the technology in-house,
using its resources to develop and market prod
ucts and services. Finally, an organization could
choose to license-out the technology.
In all cases, the implications of each ap
proach must be considered. The organization
aims to make the greatest use of resources under
its control. In the case of intellectual assets, such
as a patented technology, a key question must be
what resources are required to successfully exploit
the technology. Teece has suggested that firms
need more than IP rights: success in a competi
tive market requires strong IP rights plus access
to “complementary assets.”23 For most technolo
gies, getting from laboratory to market or to the
patient, recipient, or other beneficiary of the
technology requires much more than just invent
ing and announcing the technology. Process de
velopment, testing, trials, approval, production
engineering, production facilities, distribution
chains, and marketing skills are just some of the
resources required to exploit a technology. Not
all organizations have the needed resources. Even
those that do have the resources may only possess
them in limited markets, putting international
exploitation beyond their reach. So, if we assume
that a new technology is well protected using IP
rights, then the question remains as to whether
the organization has the complementary assets
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needed to exploit the technology. Leaving aside
the question of whether the innovator keeps most
of the benefits from the innovation, the key issue
is whether the innovation can be exploited to the
fullest extent by the organization at which it was
invented.
Indeed, if a new invention gives substantial
advantages over existing technologies, it can be
assumed that the invention will be a technologi
cal success. What cannot be known is whether
the organization inventing it will be more suc
cessful than its competitors in making the inven
tion widely available. Organizations with limited
resources, the case for all but the very largest
multinational firms, are very unlikely to be able
to exploit new products or services quickly. This
means that the organization’s assets will have to
be used or traded in order to acquire the needed
resources. Especially for smaller organizations
with limited staff, finances, and physical assets,
the only resource likely to be sufficiently scaleable
to expand to meet the resources needed for over
seas exploitation will be the intellectual property
associated with the invention.
The returns from out-licensing technology are
inevitably less than the potential proceeds from
exploiting those assets in-house. But licensing can
make access to markets and technical fields pos
sible. Thus, the cost of such licensing may be well
worthwhile, since the amount of value added will
likely be substantial, relative to costs. Even for a
not-for-profit organization, some form of con
tract that effectively trades returns for opportuni
ties to exploit is all but unavoidable.
There are, however, two potential concerns
with licensing agreements. Licensing is just one
option on a continuum of possible interactions
between organizations, ranging from sale, pur
chase-through-licensing, and joint ventures and
alliances to full acquisition and merger of the or
ganizations. These options should be considered
as alternatives to licensing if in-house exploita
tion or outright sale of the technology is impos
sible. For an organization with limited resources,
licensing may be the easiest option, but it may
not necessarily be the most efficient for maximiz
ing control and returns available to the innovat
ing organization.
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Outright sale involves loss of control and,
more importantly, may fix the returns available.
As an alternative to an outright sale, some form of
exclusive license may be preferable, since contracts
can be written to include options enabling the
innovator to benefit from unexpected increases
in revenue and new opportunities to exploit the
invention. This approach essentially applies the
concept of real options to help the organization
limit its downside risk, while still allowing the
organization to take advantage of any unexpected
upside advantage. Another way of achieving this
real option effect is to license technology to a
spinout company formed by the organization to
develop the technology independently. Forming
a spinout, however, requires raising additional
financing from other sources, with the original
organization recouping its investment from
the eventual capital appreciation of its shares
in the company. But the demands on those
involved in the spinout are arguably greater
than those involved with exploitation either
through licensing or sale. That is true because
the interests of investors, industry, and those in
the organization must all be reconciled. Such a
spinout strategy may, however, provide higher
returns to the organization and, because outside
investment could be generated, the strategy may
enable exploitation on a scale that would have
been impossible either by licensing or by selling
the technology to existing companies. Spinouts
can be used by any organization, including
public sector organizations such as universities.
Indeed, there are many examples of their use by
technology transfer offices (TTOs).24
The objective of all licensing or sale of intel
lectual assets is for the organization to extract the
maximum benefit from the innovation so that
it can achieve its objectives. This means seeking
the maximum benefit not just for immediate
opportunities but also for future opportunities,
such as overseas expansion. IP strategy cannot
be short sighted, in terms of either markets or
time. Just as a patent attorney drafting claims
will frame them as broadly as the prior art al
lows, enabling the full scope of patent protection
to be obtained and not unnecessarily restricted
as new uses of the invention develop, means a

TTO should construct contracts and licensing
arrangements to take advantage of all possibili
ties. In fact, such practices should be a normal
part of the responsible strategic management of
an organization’s intellectual assets.
One final aspect of licensing, equally impor
tant to not-for-profit organizations, is the issue
of learning, or technology diffusion. In a com
petitive market, out-licensing by a technological
leader will give access, not only to the technology
licensed, but to learning opportunities.25 Where
the aim is to diffuse technology as widely as possi
ble, such dual access may be a positive advantage.
On the other hand, where the aim is to maintain a
competitive advantage over those who might learn
by licensing-in, it may prove a considerable disad
vantage that is not outweighed by the income that
licensing brings. Licensors of intellectual assets
may need to balance the effects of learning with
the potential revenue from licensing.
Finally, one sometimes neglected aspect of
licensing concerns network externalities where
the worth of a technology to users increases the
more users it attracts. In such cases, even in a
competitive situation, it may be preferable for an
organization to license-out or otherwise make the
technology available even at low or below cost,
since this will generate a large user base and en
courage further adoption of the technology. (An
organization should, of course, be aware of any
competition law restrictions that might be rele
vant.) In such cases, the reluctance to license-out
the technology may actually lead to a competi
tive disadvantage, even though it is thought that
the innovation is being protected and exploited.
Once again, the lesson here is that the control
that IP rights give is more important than the
mere ability to prevent exploitation by others; too
restrictive an attitude toward IP rights can act to
an organization’s disadvantage.
.2 Internal IP strategy

IP strategy involves not just external issues but
a variety of internal issues related to resources
within an organization. A few of these issues that
are particularly relevant to IP strategy are: valua
tion, information, coordination, and education,
including the management of researchers in their
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roles as creators and preservers of intellectual
property within an organization.
.2.1 Valuation

The valuation of intellectual property reflects the
nature of the IP system in general. Despite the
best efforts of economists, it is often arguable
how valuable the IP system is for any general class
of innovations. Likewise, despite the best efforts
of managers and accountants, it is often unclear
exactly how valuable a particular intellectual
property right is, despite the fact that deciding
to obtain or preserve the right implies a specific
value.26 If organizations are to go to the expense
of obtaining and protecting intellectual property,
especially intellectual property that requires a
complex application procedure such as overseas
patent applications, then the considerable costs
have to be justified.
It is easy enough to justify long-established
legal fees to preserve an established income
stream, for example, from licensing a successful
piece of intellectual property. However, far more
often IP managers will be required to make deci
sions about incurring costs for intellectual prop
erty of unknown value. Such decision making in
the early stages of the life of a patent, for example,
is inevitably problematic because the decisions
require speculation about the invention’s future
prospects. After all, such predictions about the
future can certainly be wrong.
In response, two potential approaches can
be taken. The first is simply to adopt a portfolio
management view of innovation and to assume
that, although much expenditure on R&D and
IP protection may be wasted, there will be enough
successes to more than pay for the failures. While
this approach is adopted often by larger compa
nies that can afford such an approach, such an
approach is not easy to sustain when financial
pressures mount and organizations are looking
for short-term costs to cut. The consequence of
such financial pressures are that companies oper
ating near the margins of profitability may find
that their IP rights coverage is patchy, reflecting
fluctuations in their financial position. In unfor
tunate cases, financial hardship coincides with
the creation of a valuable innovation, which then
 | HANDBOOK OF BEST PRACTICES

is left unprotected and less exploitable than it
might have been.
The second approach is to adopt a case-by
case analysis of each development, taking into ac
count all the information that is available about
the innovation’s future prospects. The key feature
of such an analysis is the fact that the absence of
current revenue early in the life of an invention
should not count against it as much as its absence
later in the invention’s life. Of course, it is easy
to value a stable income stream once an inven
tion has become successful. The essence of valu
ing early-stage innovation is to be aware that such
IP rights represent real options on the future extra
income that might be derived from the IP rights
that protect the invention.27 But calculating pat
ent values, taking such real options into account,
is not straightforward. In practice, patent attor
neys and IP managers make implicit valuations
of this sort whenever they justify preserving an
IP right that is currently unproductive, as long
as they foresee some chance of it producing an
income stream in the future.
In terms of evaluating alternative courses of
action, some form of valuation is essential for
assessing the potential outcomes against the po
tential costs. Strategy is thus intimately linked to
valuation. However, beyond such assessments,
there is the more general issue of the values driv
ing the objectives of the organization. Issues may
exist where the values of the organization drive
decisions that are not solely based on a financial
analysis. That said, even where such plural stra
tegic objectives and nonfinancial values are in
volved, financial analysis might still be a perfectly
valid basis for making many IP-related decisions.
Valuation is a critical, unavoidable element of
IP management and strategy. This, however, does
not make valuation any easier to carry out reliably
when making important strategic decisions.
.2.2 Information

One of the roles of IP rights is to diffuse informa
tion. The patent system, for example, promotes
the public benefit by forcing inventors to dis
close their inventions to the world in return for
the grant of patent rights. Of course, publishing
such information has its drawbacks. Publishing
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provides a source of information of great use to
the organization and also of use to competitors.
Besides publications, researchers should
conduct patent searches along with literature
searches. Though academic publications might
be issued before related patent applications, of
ten the patent application is the only, or the first,
publication available related to a competing tech
nology. In addition to establishing what already
exists in the prior art, patent searching can give a
very good view of the technological trajectory of
organizations and thus has strategic importance
for dealing with competitors or when negotiat
ing licenses or other deals. Patent and other IPrelated information thus play, not just a technical,
but a strategic role.
Strategy is almost always formulated with re
liance on imperfect information. Consequently,
any access to information that can inform deci
sions is a valuable resource.
.2. Coordination

Those involved in managing intellectual prop
erty need coordination, and such coordination
is essential to the strategic process of “allocating
resources” identified in Chandler’s definition of
strategy. The problem often encountered in the
strategic management of intellectual property is
that the range of people, skills, and qualifications
required is such that no one person or group of
people can easily carry out, in an integrated way,
all the tasks required. The range of skills needed
will include those of legal specialists, such as pat
ent attorneys skilled in drafting and prosecuting
patent and trademark applications; lawyers spe
cializing in intellectual property who can assist
with litigation or licensing contracts; and R&D
managers who can provide suitable incentives
and motivation to keep personnel involved in ob
taining and protecting IP rights. Other person
nel such as licensing managers, who may not be
legally or technically qualified but have substan
tial commercial experience, also have a significant
part to play in managing intellectual property.
Finally, senior managers are needed to guide
and oversee the overall strategic management
of the organization’s intellectual property. The
person ultimately responsible for intellectual

property in a company might come from a legal,
business, or technical background. However,
since it would be unusual for any one of such
managers to have all the requisite skills to manage
intellectual property, an essential feature of good
IP rights management is good communication
and coordination among those who, as a group,
possess the requisite skills. Communication and
coordination are key concepts to keep in mind
when assembling staff to provide the skills for
the organization. These concepts are especially
important when making decisions about where
to locate staff or find outsource specialists.
For example, locating patent attorneys near
to the R&D scientists the attorneys are meant to
interact with will facilitate the process of patent
ing and technology transfer. Conversely, isolat
ing a specialist IP department from the strategic
management of the organization will not help in
tegrate the management of intellectual property
into the strategic thinking of the organization as
a whole. Compromises may have to be reached to
reconcile conflicting demands of the R&D lab,
IP legal department, and the organization’s head
quarters. The aim, however, should be to enable
R&D, IP law, general law, and general strategy to
work together efficiently.
.2. Education

Finally, there must be a minimum level of IP
awareness training for all staff, especially the ma
jority who are not IP specialists. Such training is
necessary to avoid employees compromising valu
able intellectual property because they do not
know, for example, that publication before filing a
patent application invalidates the application. IP
training can also serve to improve communication
between researchers and IP specialists. Training
sessions can provide a forum for publicizing the
organization’s policy on incentives offered to em
ployees to support the process of obtaining and
preserving IP rights. Preliminary research results
in the United Kingdom and of the common expe
rience of those working as in-house patent attor
neys show that, while most managers have heard
of patents, they have only a limited knowledge
of more-detailed information, such as what type
of disclosure will prejudice a patent application.
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The aim of an organization’s IP awareness activ
ity should therefore be to dispel such ignorance
without trying to turn all employees into patent
attorneys, thus ensuring that employees are rea
sonably equipped to preserve the organization’s IP
interests.

. InSTITuTIonAL dIffEREnCES
In Ip STRATEGy
Governments, public sector organizations, spinout companies, small and medium enterprises
(SMEs), and large companies all need to pay at
tention to IP issues. However, the issues that each
will be concerned with will differ from institution
to institution, as will the various IP strategies and
practices the institutions adopt.
.1

Governmental IP strategy

In addition to having institutions to administer
IP laws, most industrialized nations will need
an IP policy, for dealing with trade-related IP
aspects, as part of their general trade and indus
try policies. However, any national government
intellectual property or patent office has both an
administrative role and an internal policy-mak
ing and promotional role. The first IP systems
in the U.K. resulted not from external trade
pressure, but from the original goal of encour
aging innovation. Today, battles commonly are
fought to choose between trade pressures that
protect external intellectual property and the
perceived local, short-term advantages of mini
mizing such protection and free riding on such
external intellectual property. This conflict can
lead to insufficient attention being paid to one
of the original roles of IP systems: promoting
innovation and diffusion of inventions. In the
face of such distractions local innovators will fail
to take advantage of the information that IP sys
tems can diffuse (for example, through patent
information systems) and will also likely fail to
be influenced by, or even aware of, innovationpromoting incentives. Thus, one of the most im
portant things a government can do is to provide
an effective, enforceable system for protecting
and promoting local innovation that not only
provides the infrastructure to administer the
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system and spread knowledge, but also actively
promotes the use and benefits of the IP system
to potential users.
Such promotion can be carried nationally by
the central government, as illustrated by the pro
motional activities of the Danish patent office28
and the traveling seminars of the U.K. patent of
fice.29 Promotional activities can also be under
taken at the local government level, as has been
shown by the Tokyo metropolitan government’s
IP center, which not only promotes IP aware
ness but can even help pay for some IP work and
applications.30 Obviously, exactly how awareness
is promoted and which aspects of intellectual
property are emphasized will vary from country
to country. In any case, an IP system that po
tential users are unaware of is guaranteed to be
ineffective, since it will serve only the interests
of the few who are aware of the benefits.
.2 Public sector IP strategy

IP strategy might appear to be of interest only
to for-profit commercial organizations. Granted,
the innovation-promoting role of IP rights may
be less relevant for a public sector organization in
volved in R&D as a matter of government policy,
than for a private company seeking a commercial
return. However, the controlling and intellec
tual-resource-management aspects of IP strategy
are nonetheless highly relevant to any institu
tion—particularly public institutions that have
a duty to manage their resources as best they can
to achieve their public objectives. Government
services, such as health services, government re
search departments, university research laborato
ries, and other public sector institutions involved
in creating intellectual property will certainly
need to formulate an IP strategy. They will need
to ensure that staff are aware of the organization’s
valuable IP assets and that these assets need man
aging and preserving as much as any other as
sets of the organization. An IP strategy can also
help to ensure that any liabilities that might be
incurred by the use—especially the inadvertent
use—of intellectual property owned by other
parties are minimized.
Given, for example, the IP management
functions within a university or government
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research laboratory, an IP strategy is likely to
emphasize protecting and exploiting intellectual
property through licensing or spinout compa
nies.31 Noncontractual and nonlitigious aspects
of work, such as drafting patent applications,
may be outsourced to patent attorneys in private
practice. So one key role of a public organiza
tion involved in R&D—especially collaborative
R&D—will be to manage the IP elements that
govern research contracts.
In the case of public or charitably funded re
search organizations, the absence of an IP strategy
is likely to result in the organization effectively
giving away its IP assets to others. Ignoring the
need to manage IP resources is as serious a failing
as neglecting to manage an organization’s physical
or human resources.
. Spinout and SME company IP strategy

Small companies, especially those in the very early
start-up phase of their existence, may not have the
resources to employ any specialist staff (such as
qualified patent attorneys). However, one might
argue that companies at that stage of their exis
tence have the largest portion of their overall val
ue embedded in intellectual property. As such, an
IP strategy is one of the most essential elements of
a company’s overall strategy, and because of lim
ited resources and information, the IP strategy
will be difficult to formulate. Thus, because small
companies lack resources and the complementary
assets mentioned above, these companies, includ
ing IP spinouts, run the risk of failing to appro
priate returns from their innovations.
To counter this potential loss of advantage,
smaller companies need to spend what may seem
like a disproportionate amount of their resources
on protecting and exploiting their intellectual
property. If necessary, these organizations should
rely on external sources of advice and help to ac
complish such protection and exploitation. A risk,
which may be unavoidable at times, is that cash
constraints may limit the ability of a company to
protect and exploit its intellectual property. Thus,
the company may be unable to reap as much of the
benefit from its innovations as it otherwise might.
By investing in the initial innovations to ex
tract more value from them, a small company can

use protected intellectual property to generate the
financial and other resources needed to grow the
business. A spin-out company may likely find it
difficult to extract the maximum value from its
innovations, especially if its IP rights are weak.
However, as the company gradually increases the
resources available to it, its ability to exploit subse
quent innovations should improve. An IP strategy
is not something that a small company cannot af
ford to have, but rather something it cannot afford
to be without.
. Large-company IP strategy

Large companies might be considered to have the
simplest task when it comes to IP strategy, since
they are likely to have enough resources to deal
with IP issues promptly and, very often, in-house.
But large companies face IP strategy problems
that smaller companies or public institutions are
unlikely to encounter.
First, a large company is likely to have been
built on the strength of its past technological
successes. Most forms of intellectual property
(apart from trademarks) have a limited lifetime,
so past success is no guarantee of future suc
cess. Indeed, the ability of a company to reap
large financial rewards from out-licensing previ
ously neglected IP assets may just be a prelude
to the company’s demise, unless some of those
proceeds from past success are invested in the
future. Repeating success is never easy, especial
ly in areas where technological uncertainty can
undermine technical and commercial ability. In
the absence of continued investment, decline is
inevitable, since IP rights erode and technology
gradually becomes obsolete. No company, how
ever large, can afford to rest on its technological
laurels.
Second, communication and integration may
present a challenge. One benefit of being a small
company is that all the key personnel involved in
IP issues probably work in the same building and
interact with each other every day. For a large com
pany, especially one with a separate in-house IP
department, IP specialists must be continuously
encouraged to communicate with those inventing
and exploiting innovations within the company.
Moreover, the IP department must communicate
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well with senior management and convince it of
the importance of IP management.
A third challenge is that IP departments
within a larger company may be tempted to fo
cus on internal department interests, rather than
on the interests of the company as a whole. This
might result in too many patent applications be
ing filed or excessive licensing of technology that
should instead be kept in-house.
None of these challenges should force larger
companies to outsource such IP management
functions; they are just good reasons to make sure
that IP is properly managed. In terms of commu
nication alone, the benefits of keeping IP man
agement functions in-house can be considerable
if IP departments are managed well.

. IMpRovInG Ip STRATEGy
IP strategies inevitably differ with size and type
of organization. As we have seen, the key ele
ments of an IP strategy involve both external
and internal factors. External factors include
issues of licensing and litigation; internal fac
tors include issues of valuation, information,
coordination, and education. All these aspects
of IP strategy should concern all types of insti
tutions to some extent, though emphasis will
vary. Public institutions may tend to concen
trate more on licensing, information, and edu
cation. Spinouts and small companies will be
more concerned with external issues of licens
ing and litigation, and, consequently, valua
tion. Large companies will be concerned equal
ly with all issues, and the companies may be
more aware of IP issues due to their in-house
IP departments.
Each kind of institution can take basic ac
tions to improve its own IP strategy. For govern
ments, these might include:
• promoting awareness of intellectual prop
erty, from both a creator’s (potential in
novators) and a user’s (potential infring
ers) perspective
• promoting use of information contained
in patent and other IP databases to both
source technology and inform further
innovation
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• providing both central and local sources of
advice and assistance with innovation ex
ploitation, especially in overseas markets
• providing basic education in innovation
exploitation to IP lawyers (Although they
may be the first point of contact for IP ad
vice for many, they are generally only legal
ly and not commercially trained. Having
someone to whom companies could refer
to for specific advice would help.)
• organizing a network of innovationsupport centers to provide communal
TTO/IP advice (Infrastructure to ex
ploit innovations exists internationally;
the problem in many countries is getting
from the inventor to the overseas licens
ee. Such centers might not be able to do
all the work of normal TTOs, but would
be able to coordinate IP exploitation
and protection.)
• involving external trade organizations,
which can help market technology overseas
for those companies/organizations without
the resources to do so
• taking steps to enable organizations to
use, protect, and exploit nontechnologi
cal intellectual property—in particular
copyright and trademarks, including col
lective and certification trademarks and
designations of origin—even where tech
nological innovation is less common or
absent
For public sector institutions and research
laboratories, basic actions to improve IP strategy
might include:
• promoting an awareness of intellectual
property from the innovator’s perspective,
including its value to the institution
• promoting use of the information con
tained in patent and other IP databases to
inform further innovation
• providing sources of advice and
assistance with intellectual property and
innovation exploitation, especially in
overseas markets
• giving a manager within the organization
specific responsibility for IP management
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• combining the role of IP manager with
that of TTO manager in order to control
the exploitation of technology produced
by the organization and to provide advice
on research contracts with external orga
nizations (This approach will work in an
R&D-related organization)
• taking action to facilitate good communi
cation between IP generators and IP man
agers, as well as between IP managers and
those controlling the organization overall
Spinouts and other small and medium enter
prises could undertake these actions:
• promoting awareness of the basics of IP law
and IP exploitation among staff so that ev
eryone knows what crucial errors to avoid
• encouraging organizations to spend
money in order to preserve and exploit
commercially valuable intellectual prop
erty, where doing so is obviously eco
nomically justifiable
• encouraging companies to use IP informa
tion sources, such as patent and trademark
databases, to supplement literature searches
and to inform companies of competitors’
activities both at home and abroad
• enabling companies to manage and provide
incentives for those inventors who are the
source of a company’s intellectual property
and who may well be the source of future
intellectual property
• being prepared to form alliances and li
censing deals to supplement the com
pany’s resources and to exploit markets
earlier than would otherwise be the case,
especially in the early stages of a compa
ny’s life, during which period resources
are scarce (Such licensing should not be
so late that competitors have sunk invest
ments into developing their own compet
ing technology, nor so early that the value
of the company’s technology would not be
fully appreciated or valued.)
• being prepared for the exploitation of a
succession of innovations (The company’s
ability to fully exploit its inventions should
gradually increase over time as proceeds

from the exploitation of initial inventions
are reinvested.)
With public sector institutions and research
laboratory scientists activities to improve IP
strategy could include:
• ensuring that laboratory notebooks are
properly kept and that any publication is
preceded by an assessment of patentability
and commercial potential
• ensuring that all research staff are aware
of the basics of IP law, especially that
publishing technology before an application
is filed may preclude patent protection
• ensuring that all research staff are familiar
with IP-related staff in the organization
or, if necessary, external TTO or patent
attorneys who can provide expert advice
at short notice
• ensure that all scientists entering collabora
tive agreements with other institutions have
such agreements vetted by IP experts before
they are signed
Finally, larger companies will need to bear in
mind the following points:
• Even though a large company may have
access to all the resources required for suc
cessful IP exploitation, these may be ren
dered useless by inadequate communica
tion among the various people involved.
Action should be taken to facilitate good
communication between IP generators and
IP managers, as well as between IP manag
ers and those controlling the organization
overall.
• Intellectual property should be considered
both a source of technology to exploit and
a means of exploiting technology: a “Not
Invented Here” attitude to externally
sourced technology can be shortsighted.

. ConCLuSIon
IP strategy encompasses a far greater range of is
sues than can be dealt with here. Strategic issues
connected with intellectual property—in par
ticular, the interaction between the strength of
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IP rights and access to complementary assets, as
well as the specialist nature of the skills required
to manage it—are particular to IP management.
However, IP strategy can fit within a number of
conventional strategic-management theoretical
frameworks, particularly the resource-based view
of the company, with its consideration of intan
gible assets as a resource of the organization, and
also game theoretical considerations of value-add
ed distribution. As with any other resource, intel
lectual assets should be used to best advantage to
pursue the organization’s objectives.
IP systems are always controversial, because
they appear to be cases of means justifying ends:
they use something generally considered undesir
able (monopoly, even if temporary) to achieve
something desirable (technical or commercial
progress). Nonetheless, IP-rights systems are
now institutionally embedded in many societies
to such an extent that abolishing them or even
weakening them would be extremely difficult
without coordinated international cooperation.
Such cooperation is highly unlikely to occur.
Thus, whatever views are held of the system, or
ganizations have no option, for now, but to work
as best they can within it.
The following is an essential tenet for any or
ganization, including not-for-profit organizations:
that if innovators do not use the IP rights at their
disposal to try to influence or control the exploita
tion of their own inventions, then others will do it
for them. If this happens, the organization’s inven
tions may be exploited in ways that do not conform
or contribute to the organization’s objectives. n
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IP Management Policy: A Donor’s Perspective
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ABSTRACT

This chapter describes how the Wellcome Trust, a ma
jor charitable funder of biomedical research, manages
intellectual property arising from Wellcome-sponsored
research. The trust recognizes that the development of
new health technologies requires the enlightened man
agement of intellectual property through partnerships
involving funders, scientists, institutions, and companies.
This chapter explains how the charitable mission of the
trust influences its decision-making process. The chapter
includes case studies to illustrate the concerns of the trust
and to identify key procedures.

1. THE WELLCoME TRuST
The Wellcome Trust is an independent, U.K.
based biomedical research charity. In the year
2006–2007, the trust will invest nearly US$1 bil
lion in biomedical research, both in the United
Kingdom and internationally. The Wellcome
Trust was established in 1936 after the death
of Sir Henry Wellcome. In his will, Sir Henry
vested the entire share capital of a drug com
pany he founded, The Wellcome Foundation,
into the Wellcome Trust. The Wellcome drug
company was absorbed, by a series of mergers,
into GlaxoSmithKline, and, in the process, the
trust diversified its investment portfolio. The
trust no longer has a significant shareholding in
GlaxoSmithKline but operates entirely indepen
dently of the drug company.

The mission of the trust is to foster and pro
mote research to improve human and animal
health (see Box 1 for a statement of the organi
zation’s mission and general policy). Funding by
the trust supports a wide range of work in the
biomedical arena, including basic science, tech
nology transfer, medical humanities, and public
engagement with science. In order to support
scientific research of the highest caliber, grant
schemes include not only career-based schemes
for scientists, from Ph.D. studentships to fellow
ships, but project and program grants, equipment
grants, and infrastructure initiatives.
The majority of trust funding goes to research
ers in U.K. academic institutions, but the trust has
also always supported research for tropical diseas
es, particularly in developing countries. Support
schemes are available for U.K. researchers who
wish to carry out tropical medicine research in the
developing world, as well as for researchers, based
in developing world institutions, who are conduct
ing research in public health or infectious diseases.

2. Ip MAnAGEMEnT
When considering IP (intellectual property)
management, the trust’s key aims are (1) to
ensure that intellectual property arising from
the research that it funds is prudently used to

Ballantyne Z and D Nelki. 2007. IP Management Policy: A Donor’s Perspective. In Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. Z Ballantyne and D Nelki. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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Box 1: Wellcome Trust Policy on Intellectual Property and Patenting
Note that the policy is currently under revision and is expected to be approved in spring 2007.1

Preamble
The mission of the Wellcome Trust is to foster and promote research with the aim of improving
human and animal health. This is the driving force behind all of the Trust’s activities, and the
basis for its policy on the protection and use of intellectual property rights. The aim of this
policy is to provide a clear statement for Trust-funded scientists on the Trust’s position on the
protection and provide a clear statement for Trust-funded scientists on the Trust’s position
on the protection and use of intellectual property through patents; and to inform other Trust
activities, particularly those relating to genomics.
In developing this policy, the Trust has considered a wide range of issues, in particular the role of
intellectual property rights in creating the best conditions for research and in translating that
research into tangible healthcare benefits. The Trust supports the appropriate protection and
use of intellectual property where this will maximise healthcare benefits and enable biomedical
research to flourish.
In order for research advances to qualify for intellectual property protection, the legal criteria
for patent protection must be fulfilled. This means that, to be patentable, the results of research
must describe an invention that is:
• novel, i.e., not described elsewhere before
• non-obvious, i.e., involving a step sufficiently inventive that most people working in that field
could not have predicted it
• capable of industrial application, i.e., described in such a way that it can be made or used.

Patents, including those covering genes and their products, are no exception, and the Trust is
supportive of these if there is sufficient information to indicate that the DNA sequences in
question can be used to develop healthcare benefits. The Trust does not support the patenting of
raw DNA sequences in the absence of such information. This is in line with EU law, which states
that a gene sequence, whether partial or complete, is only patentable when it has been isolated
and its function described.
The Trust is particularly concerned about patents and patent applications which are unreasonably
broad and opportunistic, e.g., when there is limited functional data available to support those
patent claims. The Trust may challenge such speculative patents if it believes that they are being
applied for or used in ways that could be detrimental to research or limiting to the development of
healthcare benefits.
As a charity the Trust is under an obligation to ensure that useful results from the research that
it funds are applied for the public good. Technology Transfer at the Wellcome Trust aims to bring
together researchers, universities, industry and investors to help ensure that promising lines
of research yield practical healthcare benefits. Given the importance of these issues and the
potential health gains which should flow from genomics research, the Trust will continue to keep
this policy under review.
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achieve health care benefits and (2) to maintain
and promote a supportive environment for
future biomedical research. The trust has
historically taken an open and innovative
approach to IP management, some examples of
this are discussed below.
Other donors, of course, will have different
perspectives, mechanisms, and processes for
achieving their respective missions. The trust’s
approach to managing intellectual property
has developed in a way that the trust considers
appropriate for achieving its own objectives. This
chapter is not intended to set out any form of best
practice. The authors’ aim is simply to present
experiences, from their work in technology
transfer at the trust, that might be instructive
to other practitioners.

. MAnAGInG InTELLECTuAL pRopERTy
fRoM TRuST GRAnTS
The trust awards the majority of its grants based
on its standard grant conditions.2 The trust does
not normally seek to own intellectual property
arising from the research it funds, but the trust
does require a sponsored academic and research
host-institution to establish agreements with
personnel involved in the research that vest in
the institution any intellectual property gener
ated. Under the trust grant conditions, the in
stitution must also have established systems for
identifying and managing intellectual property
generated under a trust grant (for example, a sys
tem for invention disclosures and evaluation by
the institution’s technology transfer office or the
equivalent function).
If trust-funded intellectual property is gen
erated, the grant conditions require the hostinstitution to consider whether protecting the
intellectual property is an appropriate way for
that research to benefit the public.3 The usual
rationale for doing so is that attracting further
research and development funding—which
may likely be from a third-party commercial
organization such as a venture capital company
or a pharmaceutical or biotechnology compa
ny—requires protecting the intellectual prop
erty, often through a patent filing. Such patent

filings offer a potential limited monopoly to any
party who might wish to develop the intellec
tual property.
In some cases, of course, IP protection may
not be the best way to obtain a public benefit.
Instead, allowing immediate and unprotect
ed access to the research results may directly
improve public health or enable other research
ers to build upon the results with the aim, for
example, of aiding related health research
through the creation of large data sets (see also
section 7.1.3 below). Alternatively, the research
results may be of insufficient value on their own,
making patenting worthless.
.1 Exploiting Intellectual Property

Since part of the mission of the trust is to improve
human and animal health, translating research
successes into health care applications is essential.
In the vast majority of cases, further development
and investment in the results of trust-funded re
search are necessary for it to have a health impact.
Under the trust’s grant conditions, the host-insti
tution has the responsibility to decide whether the
exploitation of trust-funded intellectual property
is an appropriate way to achieve public benefit. If
the institution decides that exploiting the intellec
tual property is appropriate, then before it grants
any rights to the intellectual property, it must first
seek the agreement of the trust on this matter.
The trust’s consent would normally be contingent
upon the institution accepting the trust’s standard
revenue and equity-sharing terms.
Under the trust grant conditions, if the trust
reasonably considers that the institution is not
adequately protecting, managing, or exploiting
trust-funded intellectual property, the trust has
the right to take over such activities instead. In
addition, to ensure that potential grant recipients
can adhere to the trust’s policies, the applicant(s)
and institution are required to disclose at the
grant application stage whether the research will
use any technology or materials that are subject
to agreements with third parties (such as com
panies or other research institutions) that might
affect the research institution’s ability to develop
the potential trust-funded intellectual property as
envisaged.
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.2 The consent process

During the consent process, the institution pro
vides as much detail as possible about the pro
posed method of exploitation (such as draft li
cense terms, material transfer agreements, and
collaboration agreements). In the case of a pro
posed transfer of intellectual property into a spinout company, the institution should provide the
draft shareholders’ agreement and the company’s
articles of association. The trust will assess on a
case-by-case basis whether the terms set out an
appropriate means by which the intellectual prop
erty can achieve a public benefit. If the proposed
development route and associated agreement
terms are determined to be consistent with the
trust’s public benefit objectives, the trust will nor
mally enter into a benefit-sharing arrangement
with the institution and with any other involved
parties. This can include a percentage share of
milestone and/or royalty payments. In the case of
spinout companies, it will usually involve a share
of the equity of that company.
Because of its charitable status, the trust is
required to assess any benefit-sharing terms and
their public benefit impact. It is a fundamental
principle of English charity law that any “private
benefit” coming to an individual or company
from a charity must be necessarily incidental to
the public benefit resulting from the implementa
tion of the charity’s objectives. Accordingly, where
the trust’s charitable funding gives rise to valu
able intellectual property and that value is to be
shared with other parties, such as the researcher,
the host-institution, and a licensee, it is impor
tant that those parties receive only a portion of
the total value of that intellectual property. The
amount should be appropriately related to the
amount that the party has contributed to the cre
ation and further development of the intellectual
property. The trust must also receive an appropri
ate share of the value of the intellectual property
that its funding helped create.
Because most of the host-institutions that
receive funding from the Wellcome Trust are
themselves U.K. charities (for example, univer
sities) and are governed by equivalent charity
law, the research institutions themselves will
consider the public and private benefit balance
 | HANDBOOK OF BEST PRACTICES

when establishing any IP exploitation agree
ment. The consent process, therefore, is usually
straightforward, since the proposed exploitation
terms will likely be consistent with the trust’s
objectives.

. ExAMpLES of TRuST Ip MAnAGEMEnT
.1 Material transfer agreements

When a trust researcher requires biological ma
terials from a third party, the consent of the
trust is required if the relevant material trans
fer agreement (MTA) grants any rights over
trust-funded intellectual property. The trust
has often encountered what it considers to be
reach-through clauses in such agreements that
give the provider of the material a paymentfree license, for commercial purposes, to any
invention made through the recipient’s use of
the materials. The trust considers this unac
ceptable in a situation in which the provider of
the materials makes no inventive contribution
to new intellectual property created by the re
cipient other than providing materials. In such
situations, although a case-by-case approach
is taken, the trust will often recommend that
either (1) the license for such intellectual prop
erty, to the provider, be limited to a nonexclu
sive, noncommercial research license, or, (2) if
the provider has significantly contributed to the
new intellectual property and is considered to
be a suitable partner for developing it further,
the provider should be granted a time-limited
option to negotiate a commercial, royalty-bear
ing license (with the ability for the institution
to license the invention to other partners, if
license terms cannot be agreed to within the
time period). However, where the recipient
files patents on inventions that are directly and
principally related to the materials, it is usu
ally appropriate for the provider to be granted a
nonexclusive license to use the patents solely in
connection with the materials, so the provider
can continue to use its own materials. Offering
the provider a time-limited option to negotiate
an exclusive license of such patents can be ap
propriate in many cases.
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.2 Pipeline agreements

Pipeline agreements usually give a company an
exclusive license to all future intellectual proper
ty arising from, for example, an institution’s de
partments. This type of arrangement is problem
atic for the trust because should any trust funds
be going into such a department, the automatic
license prevents the trust from assessing, on a
case-by-case basis, whether the proposed exploi
tation plan of the new intellectual property is a
suitable way of achieving a health-care benefit.
The breadth of the pipeline arrangement often
makes it unlikely that an automatic license to a
company would be the most appropriate route
of exploitation, particularly if the company’s
resources are limited and the license field is
much wider than that of the company’s focus.
In such cases, the trust will normally agree with
the relevant institution that, prior to granting
any license of trust-funded intellectual property
to the company under the pipeline agreement,
the institution will request the trust’s approval
of an exploitation plan and the license terms.
However, such an arrangement may be consid
ered acceptable if the pipeline arrangement is
appropriately narrow, the anticipated intellec
tual property can be well defined, the company
in question is suitably qualified and resourced
to exploit the relevant intellectual property, and
revenue sharing terms with the host-institution
can be agreed on in advance.
. Licensing arrangements

The trust commonly consents to the grant of
exclusive license, or even the assignment of a
patent, to a university spinout company. The
trust recognizes that exclusive licensing or as
signment will often encourage further invest
ment in and development of trust-funded in
tellectual property because it gives the investor
or developer a competitive advantage. Where
appropriate, the trust also uses co-exclusive li
censing (the grant of licenses to a small num
ber of partners—typically less than five) to bal
ance incentives for commercial investment in
product development, manufacturing, and dis
tribution with wider public access to the new
product.

Sometimes, the patent in question is rela
tively broad. It may address a number of diseas
es, or it could be widely used by third parties to
develop health-care applications without an un
necessarily negative impact on their respective
markets or applications. In such cases, the trust
may conclude that there is a risk that a single li
censee (especially in the case of a resource-limit
ed, early-stage spinout) would be unable to fully
exploit the patent across all applicable fields. In
addition, if licensing is not carefully handled in
such cases, there is a further danger that the re
search fields would be unnecessarily inhibited.
Thus, the trust would normally propose a pro
gram of nonexclusive licensing, or careful, selec
tive field-of-use licensing as a more appropriate
means of achieving a public benefit.

. puBLICATIonS
The trust grant conditions require that the results
of research funded by the trust be published in
an appropriate form, although it is accepted that
publication may be reasonably delayed to allow
IP protection. The trust sees publication as a key
process in maintaining an active, healthy research
base and allows scientists to keep up-to-date with
the latest discoveries, makes it possible for their
research findings to be challenged and tested by
their peers, and lets other scientists build upon and
benefit from the new knowledge. Indeed, in the
right circumstances, publication alone can there
fore be a means of achieving a public benefit.
In 2003–2004, the trust commissioned two
reports on the scientific research publishing mar
ket.4 They concluded that although many scien
tific articles were available electronically, pub
lishers’ access policies posed potential barriers to
dissemination, and journal subscriptions were a
heavy cost burden on institutional libraries and
researchers. After these reports were issued, the
trust added a new condition to its grants that
requires all trust-funded researchers to deposit a
copy of their scientific publications relating to
trust-funded research into PubMed Central (a
free-access, digital repository of full-text, peer-re
viewed biomedical journals that was developed by
and is maintained by the U.S. National Library of
HANDBOOK OF BEST PRACTICES | 

BAllANTYNE & NElKI

Medicine). The trust is also part of a consortium
composed of medical-research charities and government-funding bodies that is funding and de
veloping a U.K. counterpart of PubMed Central.
This initiative aims to ensure that research is dis
seminated as widely as possible and that both ac
cess to articles and long-term preservation of the
archive is ensured.

. Ip And TECHnoLoGy
TRAnSfER AWARdS
Technology Transfer at the trust makes trans
lation awards to facilitate the development of
early-stage health-care inventions to the point
at which they can be further developed, usually
by a commercial company. Funding through
these awards aims to fill what the trust consid
ers to be the funding gap between basic research
outcomes in academic research and the point at
which the research is sufficiently developed to
attract investment by venture capital firms or
potential commercial licensees. Trust translation
awards may be made to companies, usually earlystage spinouts, or to academic host-institutions.
Funding for spinout companies is normally in
the form of a program-related investment. With
this type of funding—permissible for chari
ties—a “charitable investment” is made into a
specific research project with the primary aim of
achieving the mission of that charity. Such fund
ing provisions enable the trust to offer charitable
funds to commercial vehicles where there is an
ongoing research and development project for
particular health care applications. While receiv
ing a potential return on such a program-related
investment is not the primary objective of mak
ing such an award, it is nonetheless important
(for balancing public and private benefits arising
from charitable assets) for the trust to receive
an appropriate share of any benefits that might
result from the program-related investment.
Accordingly, Technology Transfer normally
structures its translation awards into companies
as convertible loans rather than as grants.5
Because of the critical nature of this stage
of the development of a technology, appropri
ate IP generation, identification, filing, ongoing
0 | HANDBOOK OF BEST PRACTICES

monitoring, and prosecution are vital. As part of
the application process for a translation award,
Technology Transfer requires information about
whether patents have already been filed, on the
technology in question, or will be filed in the
course of the funding. The application also typi
cally requires disclosure of information about
freedom-to-operate issues related to the relevant
technology.
For translation awards in areas of particular
high-strategic interest or relevance to the trust,
Technology Transfer may make strategic trans
lation awards available. Through such awards,
Technology Transfer will often actively partici
pate in project management, including the man
agement of intellectual property that might arise.
This involvement may even include assistance
with finding commercial partners or further
funding. Funding agreements tend to be much
more customized for strategic translation awards,
but a number of commonly used provisions have
been developed to address IP issues that may
arise. Two broad categories are addressed in these
provisions: 1) keeping the research field open
and 2) ensuring the appropriate management
and exploitation of intellectual property for a
health-care benefit:
1) Keeping the research field open:
(a) a prohibition on enforcing trust-funded
intellectual property against universities/
research institutions carrying out non
commercial research
(b) the grant or reservation of a license
for research purposes (which may be
sub-licensable) to the trust or relevant
institution(s)
2) Ensuring appropriate management and
exploitation of intellectual property for a
health-care benefit:
(a)formation of an IP management group,
comprising the researchers, independent
experts, and representatives from the
trust, to provide opinion and guidance
on IP strategy
(b) terms to ensure that the results of re
search that have a potential developing
country application are developed for
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such purpose and made available in the
developing world
.1 Case studies
.1.1

Typhoid vaccine

With Trust funding, the company Emergent
(Europe) Limited is testing its one-dose oral ty
phoid vaccine in healthy Vietnamese adults and
children in preparation for proof-of-concept and
phase III studies in the southeast Asia region.
Emergent owns the underpinning intellectual
property in the vaccine. Typhoid has both a de
veloped-world travellers’ market and a less-prof
itable developing-world endemic market, so the
Trust wanted to ensure that the developing world
market would benefit from the development of
the vaccine. Terms were therefore negotiated,
giving timescales within which the vaccine has
to be launched in developing world markets. If
launch does not take place within the relevant
timescale, and there are no concrete plans to do
so within a reasonable time, the Trust can acquire
the rights to manufacture and sell the vaccine in
those countries.
.1.2 Drugs for malaria

The Trust, the Medicines for Malaria Venture,
and the Singapore Economic Development Board
agreed to fund the Novartis Institute for Tropical
Diseases (NITD) to carry out a program of drug
discovery in the field of malaria, the main aims
being to find a one-dose cure for Plasmodium fal
ciparum and a curative modality for Plasmodium
vivax. Novartis agreed to make contributions in
kind to the cost of the program.
NITD owns, (or in the case of intellectual
property generated by collaborators, has rights to
acquire rights to), all intellectual property gener
ated during the funded program, but the Trust and
MMV have a noncommercial research license to
enable basic research on any findings of the pro
gram. If NITD decides not to file or prosecute
such IP, the Trust and MMV may, so that valu
able IP protection is not lost. In addition, NITD
has agreed to covenants not to sue for infringe
ment of the program patents any not-for-profit
institutions that may carry out noncommercial

research. NITD cannot develop and commercial
ize products comprising Trust-funded IP without
the consent of the Trust and MMV. Consent, not
to be unreasonably withheld, is subject to a ben
efit-sharing arrangement. In the event that NITD
puts development on hold for certain periods, or
fails to make any sales into developing countries
within a certain period following launch, the Trust
and MMV have the option to take over the neces
sary IP rights, to ensure that developing countries
benefit from the outcomes of the research.

. Ip MAnAGEMEnT foR
SpECIAL InITIATIvES
The trust has been involved in a number of large
initiatives to create data resources (principally
DNA sequence information) for the scientific
community. In each case, IP management has been
considered from the outset as a key aspect of the re
source. In the case of DNA sequencing, the trust’s
position is that basic DNA sequence information
should be placed in the public domain as soon as it
is practical to do so without limitations on use.
.1

Case Studies

.1.1

The human genome project

.1.2

The SNP Consortium

The Wellcome Trust Sanger Institute, which is
largely funded by the Trust, took a major role in the
Human Genome Project for its part in sequencing
almost one-third of the human genome. The par
ticipants in the Human Genome Project decided
that all the information produced by public hu
man-sequencing centers should be made immedi
ately and freely available to the biomedical-research
community, via the Internet, without seeking any
IP rights and without restrictions on how the in
formation could be used. These principles were
enshrined in an agreement on human sequencing
brokered at a strategy meeting sponsored by the
Trust in Bermuda in February 1996 and extended
to data on other organisms at a later meeting.
In partnership with several large pharmaceutical
and technology companies, the Trust is a major
funder of the SNP Consortium, which aims to
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produce a high-quality map of human genetic
markers, known as single nucleotide polymor
phisms (SNPs). An SNP is a site in DNA where
there is a change in a single “letter” of the DNA
code. Sometimes this change in a single letter can
cause a visible effect or cause a disease, but even
if there is no obvious effect, knowing the location
of the change can still be useful. The SNP map
may be used to identify specific genes involved
in disease processes, to develop novel diagnos
tic tests, and to predict individuals’ responses to
medical therapy.
As SNPs by themselves are only a small fac
tor in the development of new drugs, the map
was considered to be a precompetitive resource
that would be of huge benefit to the biomedical
research community. The consortium therefore
agreed to put the SNP map into the public do
main. Consortium members have access to the
data on the same terms as other users: there is no
preferential access. To keep the SNP map freely
available to the public, the consortium filed pat
ent applications on SNPs as evidence of dates of
discovery (so that these would act as prior art to
any subsequently filed patent). The patent appli
cations would be abandoned prior to grant.
.1.

The international HapMap project

The Trust, through the Sanger Institute, is a major
participant in the HapMap consortium, which is
made up of members from the United Kingdom,
Japan, United States, Canada, Nigeria, and
China. The HapMap consortium aims to build a
map of haplotypes, or “blocks” of SNPs that are
inherited together in humans, to aid in pinpoint
ing genetic variations associated with disease.
These data represent a valuable precompetitive
resource for the biomedical research community,
and it was decided to make SNPs and haplotypes
available to the public as they were identified.
There was a concern that in the early stages of
the project, when data were not sufficiently dense
to derive haplotypes, third parties could combine
HapMap data with their own data and file patents
on haplotypes. These filings could prevent the
HapMap Project from continuing. Accordingly,
data were initially released under a “click-wrap”
nonexclusive license,6 which required researchers
2 | HANDBOOK OF BEST PRACTICES

accessing the database to agree (by clicking a box
on the HapMap Web page) to the following stan
dard terms of access:
1. not to restrict access to or the use of
HapMap data by others
2. not to file composition-of-matter patents
on SNPs, genotypes, or haplotypes based
on HapMap data
3. not to file patents containing claims to par
ticular uses of any SNP, genotype, or hap
lotype data based on HapMap data unless
such claims do not restrict, or are licensed
on such terms that do not restrict, the abil
ity of others to use at no cost the HapMap
data for other purposes
4. to share data with other licensees only un
der the same license
The main disadvantage of this approach was
that HapMap data could not be shared with oth
er large-scale genomic databases. In December
2004, following release of over 1 million SNPs
by the HapMap project, a further release into the
public domain of 1.6 million SNPs by Perlegen
Sciences Inc. and the development of new hap
lotype analysis tools, the consortium decided that
sufficient data were in the public domain to consti
tute prior art and that derivation of haplotypes and
haplotype tag SNPs from HapMap data would be
considered to be obvious and not patentable. The
click-wrap license was therefore abandoned.

. ConCLuSIonS
The trust’s primary aim when considering IP
management is whether it is an appropriate
mechanism for achieving part of the trust’s mis
sion, namely improving human and animal
health. Practically, this translates into a focus
on promoting a healthy research community
and exploitation of research for health care out
comes. By encouraging exchange of research re
sults, making large-scale databases freely available
for researchers, and discouraging restrictions on
the research use of inventions, the trust aims to
keep the research-base broad and to benefit from
the exchange of ideas. The role for commercial
(or noncommercial) exploitation is recognized
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and encouraged, provided that there is a clear
health care benefit as the ultimate outcome. The
trust sees intellectual property as a useful tool for
achieving these aims and encourages the intel
ligent management of intellectual property by
its grantees to ensure that trust-funded research
achieves its full potential.
The trust also recognizes that, on the whole,
given the inherently varied nature of research
and the diversity of health care applications that
may arise, potential intellectual property emerg
ing from trust funding should be considered on
a case-by-case basis to determine how to best
disseminate, protect, and develop the results.
For this reason, the trust has a devoted group,
Technology Transfer, to manage these processes
and considerations. The trust is also in the ad
vantageous position of being a significant funder
in the area of biomedical research. This position
offers the opportunity to contribute its perspec
tive as a charitable funder to both governmental
policies and institutional mechanisms for manag
ing intellectual property. The trust’s collaborators,
partners, and IP developers recognize the trust’s
charitable motives and are usually accommodat
ing to the trust’s IP policies and related goals with
respect to health impacts. This accommodation is
critical because the trust recognizes that the devel
opment of new health technologies requires the
enlightened management of intellectual property

through partnerships of funders, scientists, insti
tutions, and companies. n
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Making the Most of Intellectual Property:
Developing an Institutional IP Policy
sTanley p. KowalsKi, The Franklin Pierce Law Center, U.S.A

ABSTRACT

An institutional IP (intellectual property) policy forms the
very foundation of IP management and, as such, serves as
the starting point for a system of institutional best prac
tices. The IP policy should be entirely consistent with the
mission of the institution. Whether the role of the insti
tution, as defined by its mission, is primarily disseminator
of knowledge through teaching and publication, genera
tor of research, technology transfer engine, or promoter
of economic development through education and service
and/or through technology transfer, the institutional IP
policy should be drafted and enforced in a manner consis
tent with the mission. Doing so will bring efficiency and
clarity to IP management, since all the components of the
policy, including IP ownership, patenting, confidentiality,
and disclosure can be written into the policy. Moreover,
the intellectual property will serve the mission in a way
that strengthens the institution’s credibility, reputation,
and public image.

1. InTRoduCTIon
Establishing an IP (intellectual property) policy
is necessary for several important reasons. IP
rights, including patents, copyrights, trademarks,
and industrial property rights attach to research,
administrative, and scholarly (including courseware) work products. Therefore, any public sector
institution entering into research contracts with
private sector entities will encounter IP issues.
These matters will also need to be addressed in
cases involving government-funding agreements,
which often carry provisions for the disposition
of intellectual property.

Of course, most universities already have IP
policies in place in a number of areas. Faculty and
students have an interest in publishing scholarly
works, and publishing carries with it copyright
ownership issues. Most often publishers require
assignment of copyright, but what about the in
terests of the author or the institution? Lectures
and course curriculam are also copyrightable.
Who owns these? The faculty or the university?
These same concerns govern other ostensibly
more-complicated IP areas. For example, univer
sities have an interest in owning or controlling
the work product of nonacademic employees. Is
there an operable work for hire doctrine that gov
erns the country where the university is located?
If not, agreements transferring ownership to the
university must be in force.
These kinds of issues will grow increasingly
relevant for public sector research institutions as
they become more involved with national and
global IP systems. Indeed, for a university wishing
to adopt a technology transfer program structured
around licensing, a conceptually solid, pragmatic
IP policy will be an essential building block for
the program. It is the foundation upon which all
other IP activities and initiatives are built. For de
veloping countries, putting an IP policy in place
is an especially important step for protecting their
interests. When a university in a developing coun
try commercializes an invention, an IP policy can

Kowalski SP. 2007. Making the Most of Intellectual Property: Developing an Institutional IP Policy. In Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et
al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. SP Kowalski. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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be used to establish an equitable basis for resolv
ing issues related to ownership, disclosure, and
the distribution of income. In fact, the World
Intellectual Property Organization (WIPO) has
documented that universities and R&D insti
tutions in developed countries, and also some
countries in Asia and Latin America can generate
significant income from sources such as:
• royalties and fees from licensed patents
from staff innovations and inventions
• consultancy
• research contracts
• sponsored research
• university-owned companies and joint
ventures1
Remember that it is too late to begin formu
lating IP policy when negotiations about IP have
already begun. As Lita Nelsen, Director of the
Massachusetts Institute of Technology (M.I.T.)
Licensing Office, observes, “Although policies will
change over time as the program evolves, the ma
jor issues must be decided in advance. Otherwise,
a new program is likely to stall or fail altogether
in an entangled committee indecision and policy
ambiguity.”2

2. MATCHInG THE MISSIon To Ip poLICy
Certain steps should be considered when estab
lishing an institutional IP policy. Initially, admin
istrators of the institution will need to assess its
mission. This will involve examining not only the
university’s mission statement but also prioritiz
ing the institution’s roles with respect to the mis
sion. These may include:
• disseminator of knowledge through teach
ing and publication
• generator of research
• technology transfer engine
• promoter of economic development
through education and service and/or
through technology transfer
Such considerations will help establish an in
stitutional IP policy that supports mission priori
ties. For example, if the top priority is education
and dissemination of knowledge, then IP policy
 | HANDBOOK OF BEST PRACTICES

should favor faculty ownership or release of in
tellectual property into the public domain, with
less emphasis on IP protection. If R&D activities
are the institution’s top priority, then the insti
tution should have greater control of intellectual
property (for example, more-flexible licensing ar
rangements with industry, to encourage industry
funding, or more emphasis on industry needs).
If the institutional mission emphasizes technol
ogy transfer and commercialization, then even
greater institutional control of intellectual prop
erty may be most appropriate. This would involve
IP strategies geared towards commercialization
through inducing investment (exclusive licensing
preferred), more-flexible royalty sharing with in
ventors to induce disclosures, and choosing the
best commercial partners for any given technol
ogy. Finally, if the institutional mission priority
is economic development, then a more-balanced
IP ownership policy that promotes technology
transfer, driven by economic development op
portunities, may be preferred. Such an approach
might focus on licensing regional companies and
encouraging local spinouts by providing incuba
tor facilities. Since economic policies will drive
development and implementation of the IP pol
icy that most supports economic growth, there
should also be built-in flexibility to accommodate
changes in economic climate.
An exemplary case of an organization’s mis
sion matching its IP policy can be found at the
Drugs for Neglected Diseases Initiative (DNDi).
Its mission statement proclaims that “[t]he mis
sion of DNDi is to develop safe, effective and af
fordable new treatments for patients suffering from
neglected diseases, and to ensure equitable access to
these.”3 This mission provides the framework for
the institution’s IP policy (see Box 1).
Note that DNDi explains how it “will pursue
creative and innovative strategies to make the fruits
of research projects readily available” in terms of its
approach to managing intellectual property. This
type of language provides for a flexible intellec
tual property management style that is consistent
with its core mission. Strong IP policies, such as
DNDi’s, incorporate such language to allow the
institution to operate without being constrained
by its own IP policies.
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. foRMS of InTELLECTuAL pRopERTy/Ip
RIGHTS CovEREd
Designers of an institution’s IP policy will need
to define IP categories and the IP rights covered.
Covered categories might include patents, copy
rights, trademarks, industrial rights and designs,
plants, computer software, video, multimedia, or
courseware.
It will be important for policy designers to
understand the criteria the university will use to
decide when to seek IP (generally patent) protec
tion, and what happens if patent protection is not
sought. To handle the latter, a procedure for waiv
ing title back to inventors/authors in such an event
needs to be developed. Furthermore, attention

will need to be given to deciding which rights
should be granted back to the university (grant
backs), such as use for education and research.

. oWnERSHIp of
InTELLECTuAL pRopERTy
Of course, issues relating to ownership are central.
Such issues include the role of federal/local/state
laws that directly relate to IP ownership, as well as
the legal rights of employers/employees, contract
obligations, and so forth. The prevailing customs
of the country where intellectual property is de
veloped also need to taken into account. There
are a number of possibilities for ownership:

Box 1: Drugs for Neglected Diseases Initiative (DNDi)
Intellectual Property Policy
III. Intellectual property and dndi’s Work: Basic principles
In implementing the IP strategy, DNDi will adhere to the following basic principles:
DNDi will ensure that the results of the work carried out under its auspices are disseminated
as widely as possible and its products made readily available and affordable in developing
countries. Where the acquisition of IP is not necessary to promote its mission and goals, DNDi
will make all possible efforts to ensure that the results of its work are placed and remain
in the public domain. However, it is possible that promoting DNDi’s mission and goals will
sometimes require outputs to be protected by IP (see Sections IV and V). Given the costs
involved, patenting is likely to be the exception rather than the rule. Other nonpatent types
of IP such as confidential information (“trade secrets”) and copyrights will also need to be
considered.
To make the results of its work useful and encourage the research community to engage in
additional or follow-on research in the field of neglected diseases, DNDi will seek—whenever
possible and without undermining its rationale for acquiring IP—to disseminate its research
through publications, presentations, the Internet (emulating the Human Genome Project),
and other appropriate channels.
DNDi does not seek to finance its research and operations through IP rent revenues. Although
they will constitute an exception rather than the rule, patents might be sought to strengthen
DNDi’s ability to ensure control of the development process and to negotiate with partners.
When IP is generated through DNDi-sponsored research projects, it should be used to achieve
DNDi’s mission. To this end, DNDi will pursue creative and innovative strategies to make the
fruits of research projects readily available to patients affected by neglected diseases. This
will require avoiding prohibitively costly approaches, restrictive IP strategies, or other issues
that may inhibit or delay the rapid adoption of the invention to the benefit of developing
countries.
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•
•
•
•
•

inventor/author owns
university owns
company providing research funds owns
government providing research funds owns
public domain, that is, no one owns

In designing an effective institutional IP pol
icy, the inventor’s/author’s rights for IP assigned
to the university should be clearly defined and
could include a formula for sharing cash royal
ties earned, sharing of equity interests taken by
university in a spinout, or retention by inven
tors/authors of personal rights to use intellec
tual property they develop (generally these are
copyrights). Normally, a university would own
“any intellectual property that is made, designed,
discovered or created by a member of staff, stu
dents, guest researchers, etc., in the course of their
employment and responsibilities or which makes
significant use of the institution’s resources (in
cluding institution-administered funds or R&D
institution-funded time, facilities, or equipment)
in connection with its development.”4 The policy
of M.I.T., for example, states that the university
owns all intellectual property that arises under re
search grant funding or from significant use of
M.I.T. facilities.5 In order to avoid potential dis
putes, the policy should clearly state what consti
tutes “institutional resources.” In the case of spon
sored research, whether private or government,
the usual approach to resolving ownership issues
is to make them dependent on the terms of the
grant, agreement, or prevailing law. Usually, the
agreement would give the university ownership.
It would also be a good idea to specifically address
the ownership of intellectual property that stu
dents and visiting researchers generate. At M.I.T.
faculty researchers and visiting scientists (includ
ing scientists who are assigned to M.I.T. for a
limited period of time) must sign an Inventions
and Proprietary Information Agreement prior to
beginning work. It is highly recommended that
universities have such IP forms.6
An institutional IP policy should also con
sider whether the institution will reserve a shop
right in intellectual property created by faculty,
students, and staff but not owned by the institu
tion. (Under the shop right rule, an employer is
 | HANDBOOK OF BEST PRACTICES

granted an irrevocable, nonexclusive license to in
ventions that originate with employees not hired
to invent when such employees invent during
working hours with the employer’s materials and
facilities.7) Such intellectual property could in
clude publications, software, theses, works of art,
or student works. To address this issue, it will be
important to ask for what purposes such a shop
right is reserved. For example, would it be for in
ternal use only, or, possibly, for Internet delivery
for distance learning programs?
An institutional IP policy should also cover
stranded IP by establishing a default for intellec
tual property not covered by the policy.8 In other
words, what intellectual property is owned by the
inventor, author, or institution? Despite efforts to
be clear about these matters, disputes are prob
ably inevitable. A carefully crafted institutional IP
policy will therefore consider establishing an IP
disputes-resolution committee. It is better to set
this up in advance of potential disputes so that it
can be used to deal with problems as they arise.
Indeed, an IP policy should seek to harmo
nize the conflicting interests of all the stakehold
ers. WIPO suggests that “in order to harmonize
the various conflicting interests of stakeholders
and achieve broad-based objectives, an intellec
tual property policy for universities and R&D
institutions should address some of the following
issues:
• coverage of intellectual property policy
• ownership of intellectual property
• disclosure of intellectual property
• marketing, commercialization and licens
ing of patents
• distribution of income
• rights and obligations of an inventor and
the institution
• other pertinent issues9
Again, despite such efforts and the best in
tentions of all involved, conflicts of interest will
likely arise. For example, the goals of sponsored
research may conflict with the aim of the univer
sity to disseminate research results quickly and
widely. Or there may be other legitimate but op
posing goals between the institution and private
interests that put researchers in conflict with their
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employer. Universities and R&D institutions
must therefore develop policies and procedures
for the disclosure and management of conflicts
of interests.10
It is also difficult to ensure compliance with
policies related to the disclosure of inventions. A
comprehensive review procedure is often used in
the private sector, but the resources and time re
quired for such procedures make them impracti
cal for the university. The best way to ensure com
pliance, therefore, is to educate researchers about
the potential value—to the university and them
selves—of their discoveries. Enlightened self-in
terest has always been an effective motivator.

. AdMInISTERInG THE Ip poLICy
Identification of who shall administer and enforce
institutional IP policy is another key ingredient
of the policy. Possible administrators include:
• vice president for research
• technology transfer office
• IP office
• provost
A patent committee that will address patent
policy issues, and make decisions on patent fil
ings, may also be established.

. BuILdInG, IMpRovInG, And
SELLInG THE Ip poLICy
For more mature institutions, officials, at some
point, will need to assess whether to design and
implement a new policy or revise an old one. An
initial step in this assessment might be to take a
snapshot of “what is” so that the effectiveness of
existing policies, contractual commitments, and
legal constraints can be determined.
When pursuing these efforts, it would be
wise to gain the support of the highest levels of
administration and to determine a path of least
resistance for the process, perhaps via the fac
ulty senate or the administrative committee. In
addition, it will be critical to persuade faculty of
the need to change the IP policy or to implement
a new one. Gaining such backing will lend impor
tance, urgency, and credibility to the endeavor.

Policy developers may want to make available for
comparison other universities’ policies in order to
show that any suggested changes are not out of the
mainstream. Providing such material, and oppor
tunities for informed discussion and debate as to
the pros and cons of suggested changes to the IP
policy, will ease anxieties and highlight the ben
efits the changes will provide. Indeed, throughout
the entire process, it will be important to focus on
the positive aspects that any changes to the policy
may bring.
The IP policy will have to be “sold,” both in
side and outside the institution. Educating stake
holder communities as to what the policy is and
why it is will promote acceptance. However, to be
successful, the proper pitch must be made. This
will most likely involve:
• making the policy comprehensible to the
reader
• providing incentives for participants
• establishing IP management as a service to
the community
• applying the policy with consistency
• showcasing the benefits
One of the primary benefits of the policy will
be shared licensing revenue, and a firm, cut-and
-dried policy will be music to everyone’s ears. It
should be straightforward with very few excep
tions. M.I.T., for example, gives the inventor(s)
one-third of net royalties (after taking 15% for
administration and any unrecovered patenting
costs for the case). The remaining funds are shared
between academic departments and the university
general fund under a formula involving patenting
costs for unlicensed cases.11 WIPO’s recommen
dations are equally clear:
100% of the revenue goes to the institution un
til all out-of-pocket expenses associated with protec
tion and exploitation of the patent or copyright have
been reimbursed. Such expenses include fees associat
ed with patent filing and copyright registration and
any other continuing costs associated with licens
ing and other commercialization of the intellectual
property. Thereafter, the net income is shared be
tween the inventor and the institution; the general
trend is that the inventor’s percentage share decreases
whereas that of the institution increases as total net
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revenue increases. For example, one U.S. university
gives the inventor 50% for the first $100,000 of net
revenue, 40% for the next $300,000, 30% for the
next $600,000 and 25% for net income in excess of
100,000.

. M.I.T.’S Ip poLICy
M.I.T. provides a vigorous example of institution
al IP policy. The main missions of the institution
are the dissemination of knowledge, education
and research, but the institution also is commit
ted to public service, which involves technology
transfer, as is shown in this excerpt from M.I.T.’s
IP policy (see Box 2).
M.I.T.’s IP policy on ownership of intellec
tual property is carefully laid out. For example,
ownership of patents is either (1) assigned to
M.I.T. if the invention occurs from sponsored
research or is made with significant use of M.I.T.
funds or facilities or (2) owned by the inventor(s)
if the inventions are made on the inventor’s own
time, without use of facilities, and are outside of
the M.I.T. programs the inventor is assigned to
work on. If appropriate, and with no outside ob
ligations, M.I.T. will waive ownership to inven
tors (see Box 2).
This statement from M.I.T.’s IP policy
clearly articulates the various foreseeable situa
tions wherein IP ownership issues might arise.
Significantly, these details are all placed within
the purview of the overarching institutional mis
sion of M.I.T. The policy goes on to explain, for
example, that, with regard to copyrights to schol
arly publications, textbooks, and course materi
als, these copyrights are owned by the authors.
However, M.I.T. owns “work for hire” made by
staff. In other words, M.I.T. owns, by assign
ment or as work for hire, copyrightable works
developed by faculty and staff under sponsored
research or with significant funds or facilities of
M.I.T.
For ownership of mask works and tangible
research property, the policy is the same as for
patents. The ownership of data is not specifically
covered, but it is treated as M.I.T. owned un
der the same situations as for patents and
copyrights.
0 | HANDBOOK OF BEST PRACTICES

Technology transfer, which is a by-product
of M.I.T.’s primary missions of education and
research, is conducted to fulfill institutional
goals:
• to foster continuing public support for
basic research by showing public benefit
(namely, new products)
• to stimulate more industrial support for
research
• to foster community support by creating
jobs and new companies
• to help students learn entrepreneurial
attitudes
• to enable faculty to see the practical results
of research

. SpECIAL pLAnT ISSuES
The International Maize and Wheat Improvement
Center’s (CIMMYT) policy on intellectual prop
erty12 is exemplary. The policy shows how a pub
lic sector research institution involved in crop im
provement seeks to achieve a balance between the
institutions express mission of serving the greater
global public interest and acknowledging issues
relating to IP rights protection. The CIMMYT
IP policy articulates these concerns, providing a
coherent, comprehensive, and comprehensible
statement that is the foundation of an institu
tional IP policy that is consistent with and true to
the institutional mission:
As a publicly-funded international research
institute, CIMMYT regards its research products as
international public goods. Yet, in the current politi
cal and legal environment, producing and keeping
the products of its research in the public domain,
free for use and development both by scientists and
farmers, have become increasingly problematic. It is
in this context that CIMMYT has examined, and
will continue to examine, its policies and practices
in regard to intellectual property rights. CIMMYT’s
commitment to the resource-poor remains as strong
and passionate as ever. As a direct consequence of
this commitment, CIMMYT has a responsibility to
be alert to changes in the political, legal and market
environments. When necessary, CIMMYT must also
be ready to adopt new tools and strategies in order to
keep faith with its mission.13
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Box 2: M.I.T.’s Policy on Intellectual Property
13.1 Intellectual property
M.I.T. Policies and Procedures
The aim of the Institute’s policy on patents, copyrights, and other Intellectual Property is
to make available Institute technology to industry and others for the public benefit, while
providing recognition to individual inventors and encouraging the prompt and open
dissemination of research results.

13.1.1 ownership of Intellectual property
With the exception of student theses as described below in Section 13.1.3 (Ownership of
Copyrights in Theses), rights in patentable inventions, mask works, tangible research property,
trademarks, and copyrightable works, including software (“Intellectual Property”), made or
created by M.I.T. faculty, students, staff, and others participating in M.I.T. programs, including
visitors, are as follows:
a) Inventor(s)/author(s) will own Intellectual Property that is:
i) not developed in the course of or pursuant to a sponsored research or other agreement
(the faculty advisor, administrative officer, or the Office of Sponsored Programs contracts
administrator can advise on the terms of the agreements that apply to specific research);
and
ii) not created as a “work-for-hire” by operation of copyright law (a “work-for-hire” is defined,
in part, as a work prepared by an employee within the scope of his or her employment)
and not created pursuant to a written agreement with M.I.T. providing for a transfer of
copyright or ownership of Intellectual Property to M.I.T.; and
iii) not developed with the significant use of funds or facilities administered by M.I.T.
(“significant use” is discussed in Section 2.1.2 of the Guide).

b) Ownership of all other Intellectual Property will be as follows:
i) ownership of Intellectual Property developed in the course of or pursuant to a sponsored
research or other agreement will be determined according to the terms of such
agreement;
ii) ownership of copyrightable works created as “works-for-hire” or pursuant to a written
agreement with M.I.T. providing for the transfer of any Intellectual Property or ownership
to M.I.T. will vest with M.I.T.;
iii) ownership of Intellectual Property developed by faculty, students, staff, and others
participating in M.I.T. programs, including visitors, with the significant use of funds or
facilities administered by M.I.T. will vest with M.I.T.
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Importantly, with regard to access to germplasm resources, CIMMYT encourages the avail
ability of such resources in a manner consistent
with its greater mission of serving the poor of de
veloping countries.
This commitment is reiterated several times
in CIMMYT’s IP policy, which is clearly articu
lated within the overall context of the guiding
principles that establish the foundation of the
CIMMYT global mission (see Box 3).
This theme is repeated again in the CIMMYT
IP policy, making CIMMYT’s mission the pre
dominant determinative factor throughout the
entire document (see Box 4).
In addition to the provisions found in the
CIMMYT IP policy, other provisions that would
be applicable to plants and IP issues are related to:
• genetically modified plants
• essentially derived varieties
• hybrid crops (issues relating to inbred pa
rental lines)
• designated and nondesignated germplasm
as per the treaty, under the FAO
• status of land races
• freedom to operate
• access issues relating to the Convention on
Biological Diversity
These issues relate directly to how crops are
actually improved, that is, by:
• conventional crossing of preexisting varieties
• introgression of genes from wild germplasm
resources
• genetic engineering via plant transformation

. ConCLuSIonS
The establishment—or revision—of institutional
IP policies is a great tool for advancing internal
institutional discussions on the role and function
of intellectual property. Once finalized, an effec
tive IP policy should fulfill three fundamental
criteria:
1. It should be based on and reinforce the core
mission of the institution the policy serves.
The mission drives IP management, not
vice versa.
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2. It should indicate areas of flexibility that al
low an institution to pursue creative deals
and arrangements.
3. It should be a succinct statement, as op
posed to a detailed list of procedures. The
latter can be accessed elsewhere, while the
IP policy should be the basis of regularly
updated IP strategies and serve as a guiding
principle for the management of intellec
tual property.
Following the above criteria will allow you to
successfully navigate the sometimes choppy seas
of the IP system, and the end results of such a
voyage will certainly be worthwhile. n
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Box 3: CIMMyT Intellectual Property Policy
Iv.

oBJECTIvES And opERATInG poLICIES

1.

CIMMYT will manage intellectual property issues with:
• integrity;
• equity;
• responsibility; and
• accountability.

2.

In the pursuit and management of intellectual property rights, CIMMYT will be
guided by:
• its mission; and
• its special responsibilities to the resource poor arising from its role as a provider of
germplasm, technologies, and information.
However, the CIMMYT IP policy does not leave the articulation of its mission and its
views on IP issues so general. The policy also specifically states how it views IP issues
within the context of the CIMMYT mission. Hence, the IP policy is built upon, and indeed
interwoven with, the mission:

IV, 4. On occasion, CIMMYT may enter into contracts that provide for the acquisition and
management of confidential materials. CIMMYT may also seek to protect the products
of its research by obtaining intellectual property protection through patents, plant
breeders’ rights, copyrights, trademarks, statutory invention registrations or their
equivalent, and/or trade secrets to serve the resource poor in the following kinds of
situations:
1.

to support public and private partnerships which pursue mission-based research or
which develop and apply research results;

2.

to assure ready access by others to research products developed or funded by CIMMYT;

3.

to avoid possible restrictions arising from “blocking” patents and to ensure CIMMYT’s
ability to pursue its research without undue hindrance;

4.

to facilitate the transfer of technology, research products and other benefits to the
resource poor including, where appropriate, through commercialization or utilization
of research products; and/or

5.

to facilitate the negotiation and conclusion of agreements for access to proprietary
technologies of use to CIMMYT’s research and in furtherance of its mission.

Box 4: CIMMyT Intellectual Property Policy
IV, 8. In seeking intellectual property rights, CIMMYT will be guided by its commitment to
serve the resource poor, rather than by opportunities to obtain recurring revenues.
To the extent that financial returns are generated via intellectual property, they will
be used by CIMMYT to support its efforts to implement the FAO Global Plan for the
Conservation and Sustainable Utilization of Plant Genetic Resources for Food and
Agriculture, adopted by 150 countries in 1996.
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CHAPTER 5.4

Ownership of University Inventions:
Practical Considerations
b. Jean weideMieR, Principal, Cambridge Licensing Law, LLC, U.S.A.

ABSTRACT

Several factors help to establish who owns a university
invention and what rights the university may, or may not,
have. These factors include whether (1) there are express
or implied agreements to assign ownership, (2) the in
ventor is employed by the university, (3) the invention
was made within the scope of employment, and (4) where
and when the invention was made. Under U.S. law, in
dividuals own their inventions, except where there is an
express agreement providing for assignment of owner
ship of inventions to an employer or where an implied
agreement to assign is found because the employee was
hired or assigned to invent or solve a specific problem or
served the employer in a fiduciary capacity. Therefore, in
addition to implementing clearly delineated policies, it is
critically important for a university to absolutely require
all employees and visitors to sign invention assignment
agreements (IAAs) on their date of arrival. It is unwise to
rely on policy statements to determine whether or not a
university employee owns his or her invention: univer
sities should always obtain signed (express) agreements,
and both the employee and the technology transfer office
should retain copies. Research contracts with the govern
ment and other sponsors should have a checklist item on
the existence of IAAs for the principal investigator and
other researchers (whether or not a university should
have undergraduates routinely sign IAAs is up to each
university). Upon termination of employment, personnel
should be asked to sign an exit form indicating that they
have disclosed all inventions falling within the terms of
the IAA to the university licensing office.

1. InTRoduCTIon
Who owns an idea? A prototype? A patent? To a
free-thinking university researcher, assigning in
ventions to an employer could seem illogical. So
what can a university administrator do to mini
mize friction, between an employer and an em
ployee, related to patent ownership? When is the
law black and white? When gray?
The starting point of the law is that individu
als own their inventions, except: (1) where there
is an express agreement providing for assignment
of inventions to an employer; and (2) where an
implied agreement to assign is found because the
employee:
(a) was hired or assigned to invent
(b) was hired or assigned to solve a specific
problem
(c) served the employer in a fiduciary (president
of a commercial company, for example)
Where no written agreement exists and no
implied contract to assign is found, the inventor
will own the invention, subject to the employ
er’s “shop right” to use the invention if the in
vention was made with the employer’s resources
or facilities. The often-discussed, but frequently
misunderstood shop right refers to an employee’s
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obligation to accord an employer a royalty-free,
nonexclusive license to practice the employee’s
invention, if the employee, even if not specifically
hired to invent, uses the employer’s facilities to
make the invention. In other words, a shop right
is an implied-in-law license of a patent from an
employee to an employer. What differentiates the
shop-right license from the agreements discussed
above is that there is no assignment of patent
rights from employee to employer; the employee
retains full title to the patent.

2. AppLyInG THE RuLES
But, how are these rules applied? Is a professor
hired to invent? The following scenarios provide
a framework for analyzing the practical applica
tion of the above rules in the daily business of a
university licensing office.
2.1 Example 1: The unreasonable inventor

The day Professor Z started work at the university,
she signed a clear, unambiguous invention assign
ment agreement (IAA; see Box 1 for a sample),
along with his W-2 form. She signed a three-year
federal contract to perform “research in the area of
solar light bulbs.” She invented a solar light bulb
while working in her university laboratory be
tween 9 a.m. and 5 p.m. on a Wednesday. She has
refused to assign the invention to the university,
because as she says, “After all, it was my idea.”
There is no question under the law that
Professor Z must assign her invention to the uni
versity. In order to compel the assignment of an
employee invention, pursuant to a written IAA,
an employer must show: (1) that the invention
was conceived during the term of employment;
(2) that the assignment was governed by a valid,
binding, and enforceable contract; and (3) that
all conditions in the assignment contract were
met by the employer (Mosser Industries, Inc. v.
Hagar).1 In this example, all of these elements
could be demonstrated.
To diffuse the situation, the university could
suggest that Professor Z contact the university’s
attorney or his own attorney. By seeking profes
sional advice, Professor Z should become con
vinced that this issue would not be worth fighting.
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In addition, the university may want to remind
Professor Z of any university policy that rewards
inventors with royalty revenue from the licensing
of university inventions.
2.2 Example 2: The unreasonable
inventor you missed

Professor Z invented her solar light bulb under
the same circumstances as in Example 1 above;
however, the personnel clerk was out sick with
the flu on Professor Z’s first day of work, and the
clerk’s substitute thought Professor Z only had
to sign the W-2 form. Thus, Professor Z never
signed an IAA.
Because Professor Z received federal funding,
37 C.F.R. § 401(14) applies regarding election
of title by the contractor (the university) within
two years of disclosure of the invention. At 37
C.F.R § 401.14 (f ), the regulations also require
the contractor to have written agreements with its
employees (other than clerical and nontechnical
employees) requiring (1) the disclosure of all sub
ject inventions promptly and (2) the execution
of all papers necessary to file patent applications.
Unfortunately, the university is in breach of its
federal contract covering Professor Z’s invention.
Professor Z has hired an attorney, whose wages
are being subsidized by Professor Z’s potential li
censee, who has locked Z into a sweetheart deal.
The university scrambles to locate a copy of its
latest patent policy, which was revised and mailed
to all faculty members last year, and that states:
It is the policy of the university that individuals,
through their employment by university, or by par
ticipating in a sponsored research project, or using
university-administered funds or facilities, thereby
accept the principles of ownership of technology as
stated in this policy. In furthering such undertak
ing, all participants will sign invention assignment
agreements …
The patent policy also stipulates that inven
tors/authors will own inventions/materials if they
are (1) not developed in the course of or pursu
ant to a sponsored research or other agreement;
(2) not created as a work-for-hire by operation of
copyright law and not created pursuant to a writ
ten agreement with the university providing for a
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transfer of copyright or ownership to university;
and (3) not developed with the significant use of
funds or facilities administered by university.
The university’s lawyer produces the oftencited case of United States v. Dubilier Condenser
Corp.,2 which states:
One employed to make an invention, who
succeeds, during his[or her] term of service, in ac
complishing that task is bound to assign to his [or
her] employer any patent obtained. The reason is
that he [or she] has only produced that which he [or
she] was employed to invent. On the other hand, if
the employment is general, albeit it covers a field
of labor and effort in the performance of which
the employee conceived the invention for which he
[or she] obtained a patent, the contract is not so
broadly construed as to require an assignment of the
patent.
Another early case brought to the university’s
attention is Solomons v. United States,3 which states:
If one is employed to devise or perfect an instru
ment, or a means for accomplishing a prescribed re
sult, he [or she] cannot, after successfully accomplish
ing the work for which he [or she] was employed,
plead title thereto as against his [or her] employer.
That which he [or she] has been employed and paid
to accomplish becomes, when accomplished, the
property of his [or her] employer.
In this example, the key question in deter
mining the ownership of the invention is wheth
er Professor Z was hired to invent a solar light
bulb, or whether her employment was “general.”
Actually, in this case, on the fateful day she was
hired ten years ago, no one had even remotely
considered the idea of a solar light bulb. Professor
Z was employed to teach several classes and to
conduct research generally on solar power. Her
first seven years of research were devoted to solarpowered cars.
The hired-to-invent rule clearly envisions
that specific job assignments can change during
the course of employment and the question of
fact turns on the circumstances and current job
assignment at the time of invention. Therefore,
the change in focus of Professor Z’s research from
solar cars to solar light bulbs over the ten-year

period is relevant. “An employee, who undertakes
upon the direction of his employer to solve a specific
problem within the scope of his general employment,
is as truly employed and paid for the particular
project as if it had been described at the outset in
the contract of employment” (Houghton v. United
States).4
In Standard Parts Co. v. Peck,5 Peck was em
ployed to solve a particular problem, and a writ
ten contract required him, “to devote his time to
the development of a process and machinery for
the production of the front spring now used on the
product of the Ford Motor company,” in return for
US$300 per month, plus several bonuses. The
contract was silent on the matter of invention
ownership, which became the subject of the law
suit. The Court found the answer “inevitable and
resistless”: the “process and machinery” contracted
to be developed for the company belonged to the
company, not to Peck, who was otherwise paid
for his services.
Whether the work statement in Professor
Z’s federal contract is specific enough to cover
the development of a solar light bulb would be a
question of fact under a Standard Parts rationale.
In Patent Law Fundamentals (Section 11.04,
Rights of Employer and Employee Inter Se), the
analysis goes one step farther; it is stated that
“apparently” an employer would own inventions
if an employee were “employed to plan and con
duct fundamental and practical investigations and
such lead directly to an invention,” so long as the
employee’s area of activity was defined with “suf
ficient specificity.”
In Speck v. North Carolina Dairy Foundation,
Inc. et al.,6 the inventors were professors and re
searchers who developed a secret process; they
had not signed IAAs. They were paid by the uni
versity and acknowledged that the process was
developed at the university using university re
sources. The Supreme Court of North Carolina
found that, although there were no signed IAAs,
professors and researchers were hired to invent
and their invention belonged to the university:
“[T]hey developed the secret process ... while em
ployed as teachers and researchers to engage inter
alia in just such research and development for the
University.”7
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An even more recent university case is
University Patents, Inc. v. Kligman et al.8 Dr.
Kligman invented a Vitamin A preparation to
slow the effects of skin aging. As with Professor Z,
Dr. Kligman did not sign an IAA, nor did he sign
an invention disclosure statement. Some univer
sity resources were used, though Dr. Kligman was
not as closely connected to the university as the
inventors in the Speck case. Animal studies were
conducted at the university by Dr. Kligman’s wife,
Lorraine, pursuant to a Johnson & Johnson con
tract, and a clinical study was performed at the
university’s Aging Skin Clinic.
University Patents, Inc., with whom the
University of Pennsylvania had contracted to
exploit its patents, relied primarily on the uni
versity’s patent policy set forth in the employee
handbook to prove an implied contract to assign.
Under the University of Pennsylvania’s policy,
all inventions resulting from work performed
on university time or at university expense were
owned by the university.
Pennsylvania law is unclear on the question
of whether an employee handbook can create an
employment contract. The Court applied tradi
tional patent assignment principles to the more
controversial handbook concepts and found
that the University of Pennsylvania’s handbook
“clearly was not communicated as a definite offer
of employment.”9 The opening comments in the
handbook provided in part that, “we hope that
this Handbook will serve as a useful traveler’s
guide [emphasis added],” rather than as a contrac
tual legal document.
In April, 1991, the U.S. District Court for
the Eastern District of Pennsylvania concluded
that a “jury reasonably could find that an im
plied contract to assign the patent in question was
formed between Dr. Kligman and the University
[of Pennsylvania].”10 The university conveyed and
enforced its patent policy in a rather lax manner
over the years, but the court found “[T]here is
evidence, however scant, from which one could find
that Dr. Kligman was aware of the Patent Policy
since August, 1967, and manifested an intent to be
bound by it.”11 The court cautioned that employ
ers are advised not to rely on handbooks to gov
ern the assignment of patent rights; rather, they
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should address such issues explicitly in an express
IAA. However, the issue of whether professors
and university researchers, as a class, are hired to
invent when pursuing their field of research was
not addressed.
Although involving a different central issue,
a third case, Regents of University of Colorado v. K.
D. I. Precision Products, Inc.,12 stated that “[T]he
subject of the University’s employment was research
directed towards the obtaining of patents.” This
supports the concept that university professors
and researchers are employees hired to invent.
But with regard to Professor Z in our earlier
example, the law is not settled as to whether uni
versity professors and researchers are hired to in
vent. What is the likely outcome for Professor Z?
In the university’s favor are the following points:
• The failure to have Professor Z sign the IAA
was a one-time error, not the result of a
pattern of negligence.
• All professors were recently mailed a copy
of the patent policy.
• Professor Z’s invention fell squarely within
her federal contract’s statement of work.
In Professor Z’s favor are these points:
• She did not sign an IAA.
• It was her first invention, and she had never
gone through the procedure before. (see
Mainland Industries, Inc. v. Timberland Ma
chine and Engineering Corp.13)
As a practical matter, a university should
tighten its process for requiring all regular em
ployees and visitors to sign IAAs on their date of
arrival. Before action is taken on new invention
disclosures by the university licensing office, staff
should double check the existence of such agree
ments for particular inventors. Research con
tracts, with the government and other sponsors,
should have a checklist item referencing the exis
tence of IAAs for the principal investigator and
other researchers.
2. Example 3: Saturday afternoon
conception at home

Professor Z invents the solar light bulb in her
driveway on Saturday afternoon after she incurred
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a minor hit on the head falling off her son’s skate
board. She refuses to assign the invention to the
university because, “I invented it on my own
time.”
In this case, Professor Z properly signed the
IAA on her first day of work. Ownership, in this
case, would depend on the exact wording of the
IAA. As a matter of policy, each university must
decide what is fair and what is beyond the scope
of the IAA. A university would be most pru
dent to require inventors to assign this concep
tion-at-home type of invention to the university.
Otherwise, university sponsors would be short
changed by the fact that the invention was con
ceived in the driveway, even though the inventor
most certainly relied for years on governmentfunded background research at the university and
the invention most certainly would have been in
spired, at least in part, by that research.
In Mainland Industries, the inventor was
a salaried employee who did not work specific
hours and did not sign an IAA. He was uncer
tain whether the patentable idea was conceived
at home or at the office. The court stated at 665,
“the place where an invention is developed is not de
terminative of whether the employer or the employee
is entitled to a patent.”
As a practical matter, most likely Professor Z
will return to work at the university on Monday
morning, will revamp her work schedule and list
of priorities toward the goal of making Saturday’s
idea into a working prototype, and will assign
three graduate students to start implementing the
idea. Professor Z is now clearly using universityadministered funds and facilities to develop the
invention, and the university would own the pat
ent rights, under the hypothetical IAA in Box 1.
2. Example 4: The eclectic inventor

Professor Z, instead of inventing a solar light bulb,
as a diversion from her solar projects instead de
velops a remarkable new fertilizer for tulip bulbs,
after borrowing a colleague’s lab in the botany de
partment and two research assistants on Tuesday
afternoons. A frantic search of the records is fu
tile; Professor Z never signed the IAA.
The Dubilier case referenced in Example
2 above presented a similar set of facts. Francis

Dunmore and Percival Lowell were employed by
the government in the radio section of the Bureau
of Standards and performed research and testing
in that laboratory. In the fall of 1921, Dunmore
and Lowell were considering the problem of ap
plying alternating current to broadcast receiving
sets. This project was unrelated to the work of the
radio section and not assigned to them by any
superior. The employees took on the research in
dependently and voluntarily.
Dunmore and Lowell discovered a remotecontrol system for airplane bombs and torpedoes
and were permitted to pursue their work in the
laboratory and to perfect the prototypes after
disclosing their discovery to their section chief.
Dunmore and Lowell did not sign IAAs, and no
one advised them that they would be expected to
assign their rights to the United States. Dunmore
and Lowell instead assigned the invention to the
Dubilier Condenser Corporation.
The Supreme Court held that the work was
not part of the work specifically assigned to them,
and therefore, the employees had title. The gov
ernment was granted the royalty-free right to
practice the inventions, which is known as a shop
right: when “a servant [employee] during his [or
her] hours of employment, working with his [her]
master’s materials and appliances, conceives and
perfects an invention for which he [or she] obtains a
patent, he [or she] must accord his master a nonex
clusive right to practice the invention.”14
In addition to the shop-right issue, Dubilier
settled the question of whether the character of
service calls for different rules regarding the rela
tive rights of the government, as the employer,
and its employees. The answer was no, the same
principles of employer–employee apply.
These court decisions are all good news for
Professor Z. She would probably own her tulip
bulb invention; the university would have a roy
alty-free, nonassignable right to practice it.
The controversy could have been avoided, had
the personnel clerk been able to handle Professor
Z’s paperwork. If Professor Z had duly executed
the hypothetical IAA, the university would have
owned the tulip bulb invention, because the sig
nificant use of university-administered funds and
facilities was covered in the standard agreement.
HANDBOOK OF BEST PRACTICES | 

WEIDEMIER

2.

Example 5: The precocious undergrad

Professor Z is filled with joy. After years of lectur
ing to a sea of bored, young faces, Jane, then a
sophomore, appears in the professor’s advanced
solar class. While chatting after class about
Professor Z’s long struggle to harness the sun’s
power in a 60-watt light bulb, Jane asks the key
question, “Why not do it this way...?” Jane per
forms a simple experiment demonstrating that her
idea will work. Professor Z puts the lab at Jane’s
disposal, and Jane spends every free moment for
the next year in the lab developing a prototype.
Undergraduates at the university are not
routinely requested to sign intellectual property
agreements unless they are employed as research
assistants. Jane is not in need of employment
while at school and never signed the agreement.
Students were not issued copies of the patent pol
icy, and frankly, Jane had not even considered the
patent-ownership issue.
When Professor Z filed an invention disclo
sure with the university licensing office citing the
federal research support and naming herself and
Jane as co-inventors, problems arose. Jane refused
to assign her invention to the university and de
nied that Professor Z was a co-inventor. Professor
Z ultimately conceded this issue after the univer
sity’s patent counsel defined inventorship for her,
and all agreed that Jane was sole inventor.
In this case, as in University Patents, there is
no signed IAA, and the university is relying solely
on its patent policy. Under the hypothetical pol
icy described in Example 2, the university would
own Jane’s invention because of her use of signifi
cant funds and facilities, regardless of the lack of
a signed IAA.
In a court battle, had Jane the financial re
sources to fight it, the university would have had
an uphill battle to prevail. Jane probably could
not have been assumed to have had reasonable
knowledge of the terms of the patent policy and
its applicability to her, and so the university might
be left with just a shop right.
If Jane had signed the IAA, the result would
be different; most likely the university would own
the invention because of her significant use of
funds and facilities. Whether or not a university
should routinely have undergraduates sign IAAs
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should be a matter of thoughtful policy making
for each university.
2. Example 6: The better-late-than-never
agreement

Professor Z did not sign the IAA on her first day
of work. She invented the solar light bulb five
years later, and coincidentally two weeks after the
discovery received an IAA form, as part of a uni
versity licensing office clean-up project, and she
signed it.
The courts are divided on whether continua
tion of employment is adequate consideration for
such an agreement when it is signed after the em
ployer–employee relationship has been formed
(see Mirafi, Inc. v. Murphy15). Any agreement
after the employer–employee relationship has
been formed must have new consideration to be
enforceable; Harsco Corp. v. Zlotnicki16 held that
an agreement to cover the assignment of inven
tion to the employer, although not executed by
the employee until after he made the invention,
as agreement used past and present tenses and re
ferred to entire term of employment.
Regarding General Signal Corp. v. Primary
Flow Signal, Inc. et al.,17 Dezsoe Halmi was em
ployed by General Signal (GSC) and rose from
the position of draftsperson to products develop
ment manager. Mr. Halmi was employed for 15
years before he was asked to sign an “Employee
Confidential Information and Invention
Agreement,” which he then signed. The agree
ment required that he assign, to GSC, his inven
tions made while working at GSC and for a sixmonth period following employment.
On April 5, 1983, five days after the sixmonth period ended, Mr. Halmi recorded the
conception of a universal flowmeter that was
patented and then manufactured and sold by
Primary Flow Signal, Inc., a company that Mr.
Halmi established after leaving GSC.
The court found that his continuing employ
ment was adequate consideration for the inven
tion agreement. The court also found that:
The perfection of a flowmeter proved to be a
painstakingly intricate process involving extensive
testing. It is therefore difficult to believe that after
a long and distinguished career with Plaintiff, Mr.
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Halmi in his musing five days after the trailer clause
expired for the first time came up with the idea for
the NTV. Although the word ‘Eureka!’ has allegedly
been uttered by more than one inventor over the
years, the concept at issue does not lend itself to such
sudden discovery.
The court concluded that the idea must have
occurred to Mr. Halmi while employed at GSC,
and, therefore, Mr. Halmi was in violation of the
invention agreement.
The university can take some steps to protect
itself from situations where the IAA is not signed
on the first day of employment, or for inventions
not reported by employees who leave the univer
sity. As mentioned in Example 2, various catch
mechanisms can be put in place to ensure that
IAAs are on file. If it is discovered that an em
ployee has not signed an agreement, a carefully
worded agreement, signed later, provides some
assistance in many jurisdictions. The agreement
should state that the consideration is the continu
ation of employment and the continued use of
university funds and facilities, and that the en
tire term of employment is covered. Some addi
tional consideration could be given, for example,
the payment of the sum of US$10. Any royaltysharing right under the university’s patent policy
should also be cited.
On termination of employment, person
nel should be asked to sign an exit form that in
cludes a statement such as this: “I have disclosed
all my inventions falling within the terms of the
Invention Assignment Agreement to the univer
sity licensing office.”
2. Example 7: The visiting scientist

Professor Z corresponds regularly with her col
lege classmate Martin Xcaliber, who is a tenured
professor at another university halfway across the
country. One hot summer day, Professor Z is feel
ing stultified in her work and invites Professor
Xcaliber to spend some time collaborating in her
solar lab. He is compensated through funds from
Professor Z’s federal contract. The collaboration
succeeds, and Professor Xcaliber breaks through
the impasse Professor Z had been struggling with
for almost a year. He reduces his idea to practice

that summer, and the invention is clearly novel and
patentable. But he did not sign the visiting scien
tist IAA from Professor Z’s university. His univer
sity is claiming ownership and produces a valid,
unambiguous IAA, which covers all inventions
made during his period of employment, regardless
of where conceived or reduced to practice.
Again, the university is in a bit of trouble
under its federal contract because this researcher
did not sign an IAA. Once again, the university
is left relying on a patent policy that states that
the university owns inventions made by visiting
scientists making significant use of funds or facili
ties. Professor Xcaliber may never have seen the
patent policy document.
The university could argue that Professor
Xcaliber should have known that Professor Z’s
university would have some sort of patent policy
and that he should have made reasonable inquiry.
No case law was discovered relevant to this situa
tion, but most likely Professor Xcaliber’s univer
sity would own the invention, with Professor Z’s
university getting a shop right. This might be a
good case to negotiate for joint ownership by the
universities. Another possibility for compromise
is to recognize the contribution of both universi
ties through a patent cost and license royalty-shar
ing arrangement. Aside from the equities on both
sides, as a practical matter Professor Xcaliber’s
university may find itself on the other side of a
similar situation in the future and may want to
generate goodwill.
2. Example 8: The inventor who does not
play well with others

Professor Z was not asked to sign the IAA on
her first day of work but, instead, five years lat
er during the licensing office’s clean-up project.
She replied, “My ideas and thoughts are not for
sale.” Fearing that Professor Z may be upset, the
department head and administration instruct the
license office not to insist on the signing.
Without upper-level pressure on the matter
of Professor Z’s job security, the licensing office
can only argue that:
• The patent policy applies in any event, and
Professor Z should sign the IAA merely to
affirm.
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• Licensing of inventions would be blocked by
the potential of future ownership disputes
between Professor Z and the university.
• The university would take legal steps to
pursue its ownership rights to inventions
made by Professor Z falling within the pat
ent policy.

. ConCLuSIonS
Under the hypothetical patent policy stated
under Example 2, an employee of a university
is required to assign to the university all inven
tions made with university-administered funds
and facilities if the employee signed a clear and
unambiguous IAA. Even if no written contract
exists, the university may own the invention. It
is a question to be decided in view of the circum
stances, and the contract may be implied from
the relation of the parties.
The principles underlying this policy have
evolved from the line of court cases that, in the
absence of a written agreement, hold that an in
vention belongs to an employee-inventor unless
the employee was hired to invent or assigned to
solve a particular problem (Standard Parts Co. v.
Peck18). In all of the cases, an implied contract
to assign was found, because the employee had
only accomplished what he was hired to do. The
employer also owns the invention if the inventor
owes a fiduciary duty to the company (see Great
Lakes Press Corp. v. Froom,19 where the relation
ship of president to company found to be one of
special trust).
Where no written contract and no implied
contract to assign is found, the inventor owns the
invention, subject to the employer’s shop right to
use the invention if it was made with the employ
er’s resources or facilities.
One expert in IP law concluded that, “[T]he
common expectations concerning university em
ployment are not the same as the expectations con
cerning employees within private industry.”20 It is
this author’s opinion that the Speck court’s “classi
fication of university faculty as persons hired to invent
is contrary to the premises upon which higher educa
tion is based.”21 The author suggests that professors
are principally encouraged to acquire knowledge
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only through research. This conclusion is unsup
ported by the case law, which does not distinguish
between university and commercial employees; in
fact, the cases of Speck v. K. D. I. Precision Products
Inc. found specifically that university professors
and researchers are, by definition, hired to invent.
The Supreme Court stated that government em
ployees are governed by the same rules as private
industry employees in Dubilier. The logical exten
sion of Dubilier is to treat university employees,
the bulk of whom perform research under govern
ment funding, equivalent to government research
ers, and therefore, to be the treated the same as
commercial employees.
In Houghton, the employee-inventor argued
that the hired-to-invent rule should not be ap
plied to cases in which an employer, such as the
government, does not seek a monopoly (the es
sence of a patent). The Court responded vehe
mently that:
It is unthinkable that, where a valuable instru
ment in the war against disease is developed by a
public agency through the use of public funds, the
public servants employed in its production should be
allowed to monopolize it for private gain and levy a
tribute upon the public which has paid for its pro
duction, upon merely granting a nonexclusive license
for its use to the governmental department in which
they are employed.
Ultimately, without a written agreement, the
facts of each case determine ownership; a particu
lar professor may or may not be found to have
been hired to invent or to resolve a particular
problem. As with any class of employees, proba
bly no blanket statement can be made as to when
university professors and researchers are consid
ered to have been hired to invent.
For managing intellectual property, inven
tion, and ownership issues, the best approach is
always to require employees and visitors in a posi
tion to invent to sign IAAs as often as employees
sign W-2 forms. n
b. Jean weideMieR, Principal, Cambridge Licensing
Law, LLC, 124 Mt. Auburn Street, Suite 200,

North Cambridge, MA, 02138, U.S.A. Weidemier@
cambridgelicensing.com
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Box 1: Invention Assignment Agreement
Name (please print or type):

In consideration of the sum of One Dollar ($1.00) and:
• my past, present, and/or future employment at UNIVERSITY; and/or
• my past, present, and/or future participation in research at UNIVERSITY; and/or
• opportunities that have been made or will be made available to me to make significant use of
UNIVERSITY-administered funds or facilities; and/or
• opportunities to share in royalties and other inventors’/authors’ rights outlined in the “Guide
to the Ownership, Distribution and Commercial Development of UNIVERSITY Technology,”

A. agree to disclose promptly to UNIVERSITY and hereby assign all rights to all inventions,
copyrightable materials, computer software, semiconductor mask works, tangible research
property and trademarks (“Intellectual Property”) conceived, invented, authored, or reduced
to practice by me, either solely or jointly with others, that:
(i)

are developed in the course of, or pursuant to, a sponsored research or other agreement in
which I am a participant, as defined in Paragraph X of the UNIVERSITY Technology Policy
Guide; or

(ii) result from the significant use of UNIVERSITY-administered funds or facilities as “significant
use,” as defined in Paragraph X of the UNIVERSITY Technology Policy Guide; or
(iii) result from a work for hire funded by UNIVERSITY, as defined in Paragraph X of the
UNIVERSITY Technology Policy Guide; and
B. agree to execute all necessary papers and otherwise provide proper assistance,at UNIVERSITY’s
expense, during and subsequent to the period of my UNIVERSITY affiliation, to enable
UNIVERSITY to obtain, maintain, or enforce, for itself or its nominees, patents, copyrights, or
other legal protection for such Intellectual Property; and
C. agree to make and maintain for UNIVERSITY adequate and current written records of all such
UNIVERSITY Intellectual Property; and
D. agree to deliver promptly to UNIVERSITY, when I terminate employment with UNIVERSITY
for any reason, and at any other time as UNIVERSITY may request, copies of all written
records referred to in Paragraph C, above, as well as all related memoranda, notes, records,
schedules, plans, or other documents, made by, compiled by, delivered to, or manufactured,
used, developed, or investigated by UNIVERSITY, which will at all times be the property of
UNIVERSITY; and
E. will not to disclose to UNIVERSITY or use in my work at UNIVERSITY (unless otherwise agreed
in writing with UNIVERSITY):
(i)

any proprietary information of any of my prior employers, or of any third party, such
information to include, without limitation, any trade secrets or confidential information
with respect to the business, work, or investigations of such prior employer or other third
party; or
continued on next page
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Box 1 (continued)

(ii) any ideas, writings, or intellectual property of my own that are not included in Paragraph
A, above, within the scope of this Agreement (please note that inventions previously
conceived, even though a patent application has been filed or a patent issued, are subject
to this Agreement if they are actually first reduced to practice under the circumstances
included in Paragraph A above).
After the date hereof, this Agreement supersedes all previous agreements relating in whole or in
part to the same or similar matters that I may have entered into with UNIVERSITY
This Agreement may not be modified or terminated, in whole or in part, except in writing signed
by an authorized representative of UNIVERSITY Discharge of my undertakings in this Agreement
will be an obligation of my executors, administrators, heirs, or other legal representatives or
assignees.
I represent that, except as identified on the reverse side hereof, I have no agreements with, or
obligations to, others in conflict with the foregoing.

Witness

Signature (to include first name in full)

Date

Note: This Agreement is completed and signed in triplicate and distributed in the following
manner: original copy to the employee’s personnel file, second copy to the employee; third copy
to the Technology Licensing Office.
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CHAPTER 5.5

The Role of the Inventor in the
Technology Transfer Process
ANNE C. dI SANTE, Director, Technology Transfer Office, Wayne State University, U.S.A.

ABSTRACT

Without inventors, there would be no technology to
transfer. But without technology transfer professionals,
there would be limited transfer of technology. Good rela
tions between inventors and technology transfer profes
sionals are therefore essential for the commercialization
enterprise to succeed. Relationships should be established
long before the transfer services of the technology trans
fer office (TTO) are required. A healthy relationship will
allow technology managers to negotiate both faculty and
business concerns about licensing agreements. Making
sure that the inventor is sympathetic to the aims of the
TTO will also make it much easier for everyone to under
stand how a technology may meet market needs, recognize
potential licenses, and determine whether a licensee is ful
filling its obligations. For all of these reasons and more, a
TTO should always go the extra mile to educate, develop,
and maintain good working relationships with inventors.

1. INTRODuCTION
The skills of the technology transfer professional
are specific and unique to the profession and are
crucial for the management and licensing of in
tellectual property (IP). The successful transfer of
a technology, however, cannot be accomplished
without the inventor. The challenge for the tech
nology transfer professional is to obtain full sup
port for his or her efforts from the inventor, an
individual over whom the technology transfer

manager has no real control. In addition to gain
ing inventor support, the technology transfer
professional must expertly handle inventor rela
tions, both with the technology transfer office
(TTO) and within the university. The technol
ogy transfer professional must also make sure
that the inventor has realistic expectations about
marketability. This chapter will describe both the
various roles the inventor plays in the technol
ogy transfer process and the technology transfer
professional’s many responsibilities with respect
to the inventor.

2. INVENTOR AS CREATOR
OF TECHNOlOGy
The essential role played by the inventor is to create
and develop the technology that will be transferred.
No one else will understand the technology as well
as the inventor, so the inventor’s full cooperation
in disclosure and participation in the technology
transfer process is necessary. To develop the best
working relationship possible with the inventor,
the reputation of the TTO and of the technology
transfer manager are important. Public relations
within the institution are critical for sustaining
these relationships and forging new ones.

Di Sante AC. 2007. The Role of the Inventor in the Technology Transfer Process. In Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual (Second Edition, Part V: Chapter 2).
© 2007. AC Di Sante. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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The technology professional should strive to
ensure that the inventor hears of the TTO before
coming up with a great invention. For many rea
sons,1 the technology transfer professional needs
to learn earlier, rather than later, about the inven
tion. Academic faculty are now significantly more
aware of the technology transfer process than they
were a decade ago, but a manager should not as
sume that this is enough to motivate faculty to file
invention disclosures. The inventor must be fully
aware of the importance of making timely disclo
sure of an invention to the technology transfer of
fice. However, educating faculty on the hazards of
premature disclosure (including in publications)
may mean more calls to the office about technol
ogy not prime for licensing. It is easier to respond
not yet than to explain that the big one got away.
The technology transfer professional is chal
lenged to develop systems that promote early
information delivery, while remaining conscious
of the specific academic environment of the uni
versity and the pressures on faculty. The proce
dures developed for information delivery must be
relatively easy to access and use, since it is criti
cal that the TTO receive not just timely but full
disclosure of the invention. The technology man
ager may also be faced with a faculty member’s
concern about confidentiality. For example, the
inventor may be willing to disclose to academic
peers, even at another institutions, but may view
the staff in the TTO as outsiders or as admin
istrative bureaucracy. The technology transfer
manager will need to ease these concerns to so
licit complete participation of the inventor in the
technology transfer process.

3. ROlE IN THE PROTECTION PROCESS
Once the decision to file a patent application has
been made, the most frequent question a technol
ogy transfer professional will hear is: “How much of
my time will this take?” While one may be tempted
to minimize the efforts needed, it is important
to provide realistic estimates in order to prevent
unrealistic expectations. Depending on the tech
nology and the detail in the invention disclosure
document, inventor input at the drafting and fil
ing stages varies from minimal to substantial.
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The inventor and patent counsel should inter
act early in order to form the critical relationship
necessary for a solid patent application. The in
ventor must be assured of confidentiality and con
vinced of the value of providing a full disclosure
of the technology to patent counsel. In addition
to assisting in the drafting process, the inventor
is needed for inventorship determinations. For
example, many faculty equate inventorship with
authorship, so they will list collaborating inven
tors using the same criteria for naming authors on
scientific manuscripts. Fortunately, patent counsel
can assume the role of adjudicator for inventorship matters, although the TTO may be required
to enlist the assistance of department chairs and
other university administrators for difficult cases.2
The inventor must be a willing partner dur
ing the actual prosecution of the patent applica
tion, as well. While the concept of nonobvious
ness can be difficult to grasp,3 a skilled patent
attorney will work closely with the inventor to
develop the responses necessary to overcome this
type of rejection. The inventor should be encour
aged to read the materials and provide answers
to the attorney’s questions; after all, the inventor
knows the field better than anyone else. Most fac
ulty respond well to patent counsel’s translation
of the rejection from “patentese” to plain English.
Direct questions are easier for the inventor to ad
dress than a general “please read and give me your
thoughts on this” request. While it will cost more
in attorney time to have patent counsel read, ana
lyze, and develop questions to address an office
action, the investment will prove worthwhile if
needed responses are shared from the start.
Filing a patent application and having a
patent issue are not the only goals of the TTO.
Nearly 100% of the time, the technology transfer
professional will also need the inventor to actu
ally transfer the technology to the licensee later in
the process. In addition, once the patent is issued
and the technology licensed, the inventor may
take on the unofficial role of “infringement po
lice officer” by recognizing when a product is sold
that may infringe the patent. An inventor should
be encouraged to report suspected infringement
to the TTO, which can then assign responsibility
for pursuing infringers.
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Developers of software and multimedia
should be well educated about the use of copy
right notices; it should be second nature for the
appropriate notice to be placed in a new program.
Of course, this depends on the specific copyright
policy in effect at the institution.
Biological materials with commercial poten
tial are another form of IP not always associated
with patent protection. The inventor must un
derstand the difference between transfer to non
profit research institutions and transfer to forprofit institutions that may use the technology
as a product development tool. It is important
for the inventor to understand that the value of
the material will be maintained if the release of
the material is controlled. This control does not
prevent the inventor from fulfilling the obliga
tion to provide samples of the materials to those
who wish to repeat experiments, as required by
many scientific journals, or from meeting fed
eral guidelines on the dissemination of research
tools. In the management of biological materi
als, it is essential for the technology transfer pro
fessional and the inventor to design and agree
upon a distribution plan that maximizes com
mercial potential without negatively affecting
scientific research.4

4. ROlE IN THE TECHNOlOGy
TRANSFER PROCESS
The technology transfer process involves many
steps, some occurring concurrently. An inventor
participates at various levels in each step, although
the degree to which the inventor is involved will
depend on many factors, including university
corporate culture and the players involved.
.1 Marketing

The technology transfer professional cannot ex
pect to understand every industrial sector, mar
ket, or niche into which technologies may fit.
Most often, it is the inventor who will know
both the academic and industrial players in
the field. Additionally, the inventor may have a
clearer understanding of unmet market need and
whether the technology addresses this need. This
information may allow the technology transfer

professional to perform a general SWOT analy
sis (strengths, weaknesses, opportunities, threats)
with relatively minor market research. An inven
tor can also prove to be a good source of other
marketing information, such as market size, mar
ket location, and competitive technology, both
in academia and industry. While any numbers
should be verified with an outside source, an in
ventor can be a one-stop source of market in
formation with which to get marketing efforts
started.
.2 Identification of potential licensees

A manager can expect an inventor to be contact
ed by potential licensees because of the inventor’s
publications, meeting presentations, and indus
trial contacts. Many inventors call friends in the
industry to discuss their research. It is important
to encourage the inventor to direct commercial
inquiries to the TTO. The referral of these calls
to the technology manager will help accomplish
many objectives. First, it allows the technology
transfer professional to manage the commercial
ization of the technology by keeping tabs on
commercial interest, allowing consideration of all
potential licensees when making final decisions.
Second, it establishes early in the process who will
be the key licensee contact in making the licensing
decision. Third, it keeps the inventor from selling
the well twice. Fourth, by moving the inventor
to a secondary role in negotiations, the inventor
becomes insulated from licensing decisions, thus
allowing the inventor and the industrial scientist
to develop and maintain a relationship based on
the interests of science—not business. Indeed,
the industrial scientist hopefully will become the
internal champion within the licensee for the in
novation, with the first step in this process involv
ing the inventor.
. Information to the potential licensee

Who provides what information to a potential li
censee is partly intuitive. For example, the technol
ogy transfer professional generally addresses issues
regarding the patent application, IP policies, and
licensing, while technical questions, prototypes,
demonstrations, and materials for evaluation will
most likely come from the inventor. With regard
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to the latter, the inventor knows the technology
best—what it can and cannot do—and thus is in
the best position to share such information. The
technology transfer manager may wish to en
courage the inventor to brainstorm with his/her
industrial counterpart on issues that may come
up during scale-up. An inventor may become
nervous about providing a full disclosure of the
technology to industry. The technology transfer
professional should work with the inventor to en
sure that the time is right in the review process
to provide full disclosure, and that the disclosure
can be documented in some manner.
. Licensing negotiations

An inventor’s level of participation in licensing
negotiations truly depends on the individual.
The decision about how far to involve an in
ventor rests on the shoulders of the technology
transfer professional. The manager must weigh
the inventor’s personality, interpersonal skills,
and knowledge of business negotiations, as well
as the inventor’s understanding of office policy,
knowledge of the licensee, and ability to func
tion as part of a negotiation team. The technol
ogy transfer professional should be on guard for
signs that the inventor is starting to sway to the
side of the licensee during negotiations, which
sometimes occurs. Often, the manager can re
solve this by investing in discussions with the
inventor to identify the underlying reason(s) for
the inventor’s sympathy towards the licensee’s
point of view. It is important for the inventor
to agree to the deal breakers and to be prepared
to walk away from the deal. If the inventor is
apprehensive of business negotiations, he/she
should remain on the sidelines. If this should be
necessary, the technology transfer professional
still should keep the inventor updated on the
status of license negotiations in order to man
age expectations and to preserve a good relation
ship with the inventor. The inventor, in turn,
should be encouraged to keep the technology
transfer manager updated on what he/she may
have heard from contacts within the company.
The technology transfer professional should be
notified of any technical updates that occur, es
pecially during the negotiation period, since it
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may be important to promptly disclose this in
formation to the company. It may be advanta
geous to routinely schedule discussions with the
inventor during negotiations. Such discussions
can serve the dual purpose of a negotiation up
date and a technical update. Prior to signing the
agreement, the inventor should identify exactly
what materials, know-how, and so on, must be
transferred to the licensee. The inventor should
also discuss with the licensee how this transfer
is best accomplished. The licensee may wish to
have access to the inventor once the agreement is
in place, for example, by hiring the inventor as a
consultant. The technology transfer professional
must stay informed of these activities and verify
that any obligations of the university under the
agreement are fulfilled, and that any new rela
tionships between the licensee and the inventor
work within the framework of the license and
institutional policies.
. Licensee diligence and license compliance

Following execution of the license, the inventor is
a major source of information. It is extremely im
portant for the TTO to develop systems to follow
license compliance and diligence.5 In a perfect
world, the technology transfer professional would
maintain close ties with his or her counterpart
at the licensee. Frequently, however, the inven
tor will have more information than anyone else
about technology development by the licensee. In
most cases, contact with the scientific counterpart
at the licensee is key for good information flow.
Indeed, the relationship between the inventor and
the scientific counterpart may provide the insight
that will help the technology manager determine
whether the licensee is diligently pursuing the
technology’s development. The technology trans
fer professional should encourage the inventor to
inform the TTO of concerns about the voracity
of the licensee’s efforts (or lack thereof ). Specific
information about the likelihood of meeting tech
nical milestones is also helpful. Encourage the li
censee to involve the inventor (as an observer) in
product development discussions. That way, the
inventor will stay informed and may be able to
help with any technical glitches that might arise
when the licensee scales up the technology.
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. When things go well

When there is an unqualified success in a tech
nology transfer effort, the inventor, licensee, uni
versity (including the TTO), and the public all
benefit. The inventor might also experience fame
and fortune, depending on the discovery. Positive
feedback has the potential to reach other faculty
and may encourage those who have not yet tested
the waters of the TTO to disclose an invention.
Conversely, success can also bring unwanted at
tention, often related to the anticipated revenue
stream. Disputes may arise about royalty distribu
tions among the inventor, his or her department
head, or dean. The university’s royalty distribution
policy may be challenged. If significant revenue is
expected, funds traditionally earmarked for one
purpose might be considered for reallocation. A
wise technology transfer professional will remain
in touch with the inventor to ward off these oc
currences and/or to be available for assistance, if
needed. When challenges are raised, the TTO
may be called upon for suggestions and may be
engaged in the discussions, even if its preference
would have been to remain neutral.
. When things go badly

The earliest signs that a license agreement is not
proceeding as planned are usually given (inten
tionally or not) to the inventor. The technology
transfer professional, therefore, should counsel the
inventor to recognize trouble spots. It is a good
idea to provide pointers to the inventor about
what to look for and when to contact the office
to relate issues of concern. Better yet, the tech
nology transfer professional should routinely stay
in touch with the inventor in order to stay aware
of the licensee’s R&D efforts. If a license is ter
minated (for whatever reason), the inventor can
help ensure that the institution retrieves from the
licensee what is due. Should the technology man
ager find himself or herself in the unenviable po
sition of terminating a license, the inventor may
be instrumental in establishing breach of diligence
obligations. Managers should be cautious, how
ever, of the overzealous phone call from the in
ventor calling for the termination of a license. For
example, an inventor who has difficulty moving
past the point of research to product development

may perceive progression from research to develop
ment as a sign of an incompetent licensee.
If litigation is a possibility, the technology
transfer professional may wish to enlist the help
of the university’s Office of the General Counsel
to make sure that the inventor understands the
process. Specifically, the inventor needs to know
what is expected of him or her as inventor, and
what is involved in such a proceeding. Litigation
is complex and requires coordination and coop
eration. Indeed, should the TTO need to litigate
on a matter related to a license, the technology
transfer professional and the inventor will both
benefit from having previously established a longlasting, supportive relationship.

5. INVENTOR AS ENTREPRENEuR
With the increased emphasis on the role of tech
nology transfer in economic development activity,
managers can expect a change in the relationship
when the inventor moves into the role of entre
preneur. Many factors will influence the evolving
relationship, including whether it is the inventor
or the TTO pushing the entrepreneurial activity.
Regardless, it is important for the inventor to rec
ognize that the technology transfer professional’s
fiduciary duty is to the university. In past cases of
third-party licensing, the inventor’s interests and
the university’s were closely aligned. But now the
situation is different. Be diligent in notifying the
entrepreneur about the university’s expectations
for him or her to provide appropriate business
and legal support. To prevent problems down the
road from which it may be difficult to recover, the
inventor-entrepreneur must understand the uni
versity’s conflict-of-interest and conflict-of- com
mitment policies. The technology transfer profes
sional should encourage the inventor to provide a
frequent flow of information to his or her depart
ment chair and dean. Concurrently, the technol
ogy transfer professional should also provide the
appropriate information to the administration,
department chair, and dean. The inventor-entre
preneur must recognize that license negotiations
with the company must be arm’s-length negotia
tions and that they often require high-level ap
proval, which may delay the execution of the
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agreement for weeks. The inventor-entrepre
neur has the potential to become a spokesperson
for the university’s technology transfer efforts.
Conversely, the inventor-entrepreneur could be
come the strongest critic of such activity, depend
ing on how these relationships are managed and
balanced.

6. MANAGEMENT ISSuES
.1 Other technology transfer roles
for the inventor

The inventor participates in many other technol
ogy transfer activities throughout his or her aca
demic career that occur without the involvement
of the technology transfer professional. These ac
tivities, such as consulting, educating/graduating
students, publishing manuscripts, giving confer
ence presentations, distributing posters, partici
pating in a consortium, and becoming involved in
sponsored research agreements, may be described
as know-how transfer without a license.
While the technology transfer professional
may not be involved in any of these activities at
the start, some (if not all, at some time) will af
fect the technology manager’s efforts. In these in
stances, it is best to take the education approach.
When possible, educate faculty about the effects
of publication or of signing away rights in con
sulting agreements, and so on. Raising awareness
about those effects means more inquiries to the
TTO, but early input may prevent impossible
situations later.
.2 Management of relationships

It is imperative for the technology transfer profes
sional to keep in mind the numerous groups the
inventor needs to deal with in academia: patent
attorneys, TTO staff, grants and contracts of
ficers, department chairs, deans, sponsors, aca
demic collaborators, licensees, and students, to
name only a few. Remember, both the inventor
and the technology transfer professional function
within the organization’s corporate culture. In ad
dition, the university’s corporate culture may be
an island in the local culture, subject to frequent
analysis and possibly criticism.
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It is important for the technology transfer
professional to stay high on the inventor’s prior
ity list of individuals with whom to nurture a re
lationship. Faculty, however, are not universally
evaluated by the number of disclosures submitted
or patents awarded; publications and grants re
main the priority. Remember this, and be assured
that if the technology transfer professional un
conditionally accepts the academic environment,
an open, trusting relationship with the inventor
will develop over time.
The TTO may be enlisted to function as a gobetween, negotiator, or advocate for the inventor
with any of the above groups. This is a challenging
responsibility, since the TTO needs to maintain
its own relationship with each of these groups as
well. All potential outcomes and ramifications for
both the inventor and the TTO (when assuming
this role) need to be considered.
. Management of expectations

A significant part of managing the relationship
between the TTO and the inventor is making
sure the inventor maintains realistic expectations.
A former colleague coined this hypothetical disclosure-form question: “Please indicate the value
of this technology: Is it worth millions, billions, or
priceless?” And while this was suggested tongue
in cheek, the sentiment does ring true. There is
frequently a big disconnect between the inven
tor and the TTO when it comes to an invention’s
marketability. The challenge faced by the tech
nology transfer professional is how to tactfully
keep inventor’s expectations in line with realistic
expectations. Soliciting an opinion from anoth
er party may help. For example, the technology
transfer manager may wish to enlist a trusted
faculty member who has experience with trans
fer technology. A patent attorney or an outside
consultant can help deliver the news. Evaluations
from industrial representatives may be the only
validation an inventor will accept. A manager may
wish to identify to whom the inventor best relates
and enlist them to help. It is in the best interests
of everyone to be realistic from the start. If the
inventor’s value perception is skewed, his or her
chair may also have skewed expectations, and the
inventor’s dean may be overanticipating, as well.
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In these situations, the technology transfer office
spends a great deal of time (and political capital)
explaining away unrealistic expectations and re
defining what is reasonable to expect. Recovery
from disappointed expectations may take years,
and the gap between expectations and what was
actually achieved could possibly end in an office
reorganization.

7. CONCluSIONS
While the technology transfer professional is con
stantly challenged to manage diverse technology,
he or she is further challenged to effectively in
teract with a diverse group of inventors. While
these complex relationships and interpersonal
dynamics may be overwhelming at times—both
for the inventor and the technology transfer
manager—working together can be extremely re
warding. These interactions add an unanticipated
dimension to the job of the technology transfer
professional that is often enjoyable. n
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CHAPTER 5.6

Conducting IP Audits
Michael blaKeney, Director, Queen Mary Intellectual Property Research Institute, University of London, U.K.

ABSTRACT

This chapter explains how important it is for a research
institute to audit both the intellectual property (IP) that
it generates and the third party IP that its researchers uti
lize. Such an audit will have the practical consequence
of enabling the research institute (when appropriate) to
secure ownership, maintain, and manage the IP for which
it is responsible.

1. InTRoduCTIon
For a number of years, intellectual property (IP)
rights were considered private rights and not of
concern to the public research community. A
number of developments have changed this per
ception. First, genetic materials have been priva
tized, limiting the genetic materials available
for public research. Second, IP rights have been
asserted over enabling biotechnologies, which
has the potential to thwart the ability of public
research institutions to pursue modern biotech
nological research. Third, funding for public re
search institutes has been reduced, making them
aware of their need to take an active role in IP
management. Indeed, because of the above de
velopments, public research institutes are now us
ing their IP assets to bargain for access to private
proprietary rights.
The first step in IP management is to con
duct an IP audit. This will identify the IP that
the institution’s researchers generate, allowing

it to be used as an asset and aiding in the
identification of the IP of third parties. The lat
ter is particularly important for the institution’s
ability to avoid liability for the misuse of thirdparty IP.

2. METHodoLoGy
The usual objectives of an IP audit are to identify
relevant IP, establish the ownership of that IP, put
in place procedures to manage the IP, and assist
in the formulation and execution of the research
institute’s IP policy.
Of course, before any of these processes can
begin, the scope of the audit must be determined.
In some cases, an audit might be done to satisfy
donor institutions or for external accreditation.
On the other hand, it might be prefatory to the
research institution’s collaboration with the pri
vate sector. In each case, those commissioning the
audit must determine the objectives. A decision
will have to be made about who gets the results
of the audit. It may be confined to the board, to
donors, to management, or be made available to
the public.
The audit may be conducted through:
• online surveys of senior administrative and
research staff
• follow-up interviews, by phone or in per
son, with those staff

Blakeney M. 2007. Conducting IP Audits. In Intellectual Property Management in Health and Agricultural Innovation: A
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• analysis of contracts, material transfer
agreements (MTAs) and other documents
held at the central administration
• analysis of relevant documents identified
through interviews
Before the audit, it is often useful to sensitize
staff about the relevance of IP to the research insti
tution’s operations. This can be achieved through
workshops or distributing explanatory material,
both of which can be done online. Surveys to
identify agreements and activities with potential
IP implications can also be administered online.
Follow-up interviews will explore this informa
tion and identify documents that need analysis..
Of course, all of the institution’s contracts should
be scrutinized for their IP implications.
Keeping the results of the audit confidential
will be essential for securing the full cooperation
of the institute. After all, the audit might disclose
matters that the institute may find damaging to
its reputation. More positively, areas of education
and training for staff may be identified and the
results of the audit translated into best manage
ment practices.

. oWnERSHIp And ConTRoL of Ip
.1 Introduction

A key goal for any IP audit is helping to establish
the research institute’s ownership and control of
the audited IP. This requires examining all docu
ments relevant to: (1) the legal status of the insti
tute; (2) the obligations of personnel under their
service agreements and employment contracts, to
gether with their obligations under the institute’s
IP policy; (3) agreements with research collabora
tors; (4) agreements with funding bodies and do
nors; and (5) documents relevant to the research
institute’s status within any research network.
The ability of a research institute to assert
ownership and control over any IP depends upon
its legal capacity. In the case of an incorporated in
stitute, this will be set out in its constitution and
bylaws (memorandum and articles of association).
The laws governing the place of incorporation will
usually govern these documents. But if the research
1 | HANDBOOK OF BEST PRACTICES

institute has international status, its powers may
be derived from a headquarters agreement between
the host state, donor bodies, and the institute.
Once it has the legal power to exercise do
minion over property, including IP, the institute
will also have the power to contract with its em
ployees. Typically, IP clauses will be inserted in
contracts of employment or in an institute IP
policy or code referred to in the employment con
tract. The simplest of these clauses will oblige an
employee to comply with the institute’s IP policy,
which will typically be available in printed form
or on the institute’s Web site.
For example, Washington State University’s
IP policy states:
All employees accept the terms of these policies
as conditions of employment or gratis association.
Employees shall agree to execute an assignment of
their future patentable works and discoveries to the
University. These policies may be modified by the
administration with approval from the Board of
Regents after consulting with faculty and staff of
the University.1
As indicated below, this policy obliges em
ployees to notify their employers of any innova
tions that might generate IP rights. For example,
Texas A & M’s IP policy applies to:
(i) all persons employed by the System; and
(ii) any persons using the System facilities un
der the supervision of System personnel, in
cluding but not limited to visiting faculty
and adjunct faculty, unless special terms for
management of the work of such individuals
are negotiated by the System or the appli
cable System component. System employees
should not enter into intellectual property
agreements related to outside employment,
such as consulting or summer employment
agreements, without affirmative notice to
the prospective employer that the intellec
tual property rights of the System cannot be
subordinated to a third party consulting or
employment agreement.2
It will be up to the institution to decide what
to do with such IP. In some cases, IP rights might
be waived. More usually, there is a procedure to
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share the benefits of any exploitation of IP. The IP
policy of Texas State University is typical:
In those instances where the System licenses
rights in intellectual property to third parties, the
costs of licensing, including the costs to operate and
support a technology transfer office and departmen
tal or institutional intellectual property advisory
committees, and the costs of obtaining a patent or
other protection for the property on behalf of the
Board shall first be recaptured from any royalties or
other license payments received by the System, and
the remainder of such income (including, but not
limited to, license fees, prepaid royalties, minimum
royalties, running royalties, milestone payments, and
sublicense payments) shall be divided as follows:
• 50% to creator
• 50% to System
With the prior approval of the Board … com
ponent institution may include provisions in its
Handbook of Operating Procedures to adjust the al
location of royalties set forth herein, but in no event
shall the creator receive more than 50% or less than
25% of such proceeds.
A similar situation will apply in research in
stitutes operated by government departments. In
each case the government department will have to
decide whether any IP generated by its employees
will be made available to the employee, whether
it will be secured by the relevant department for
exploitation or, alternatively, made available to
the wider research community.
.2 Headquarters agreements

For international research institutes, the agree
ment between donors and host governments will
usually delineate the institute’s legal personality.
It will usually be designated as “an autonomous,
philanthropic, tax-free, nonprofit, nonstock, benevo
lent corporation.”4 There will usually be a term for
which the institute is to exist, such as 50 years
from the date of incorporation, with a possibility
for renewal. It will usually be indicated who owns
the assets of the institute at the end of the term.
Should an institute establish a collection of bio
logical resources from other countries, biopiracy
objections may arise if their ownership is lost at
the end of the term.

The headquarters agreement will usually in
dicate the power of the institute to “receive and
acquire by donation, grant, exchange, devise, be
quest, purchase, or lease, either absolutely or in trust,
contributions of such properties, real and personal as
may be necessary to carry out the objects and pur
poses” of the institute. This provision will have no
operative effect, as the power will be conferred by
incorporation.5
. Incorporation

Typically, a research institute will be incorporated
under the law of the host country. This law will
contain provisions about the types of corpora
tions and their powers. Companies are usually
divided into nonprofit and profit-making enter
prises, and the ownership and assets structure
of each may differ. Invariably, the voting rights
of the company will be allocated by reference to
shares. Management will consist of a board under
a panel of directors and a chief executive officer.
The powers of the company are usually set out in
a constitution or a memorandum of association
and detailed in its bylaws or articles of associa
tion. These documents should be scrutinized to
see what powers the institute has to own and to
deal with IP. The documents will also explain the
powers of the corporation’s officers to enter into
transactions on behalf of the corporation. The
procedures for terminating the existence of the
institute and the disposal of its assets on termina
tion should also be described.
The constitutive documents of a corporation
are commonly silent about the fate of intangible
property, such as IP, that is generated by the cor
poration during its life. This is because IP has only
relatively recently become a corporate concern.
However, where the tangible property is specifi
cally disposed of, it is likely that the intangibles
will follow the same route.
. Charter of the institute

Public research institutes commonly indicate their
public service function in a governing charter. The
board, under the corporation’s bylaws, will usu
ally promulgate such a charter. As such, the char
ter will be subordinate to the general operation of
the articles of incorporation and confer no powers
HANDBOOK OF BEST PRACTICES | 1

BlAKENEY

that are greater than those defined by the articles
of incorporation.
. Personnel documents

Typically, the personnel at a public research in
stitute include national staff, internationally re
cruited staff, visiting scientists, consultants, af
filiate scientists, project scientists, collaborative
research fellows, and doctoral and postdoctoral
students. Asserting ownership and control over
the IP that personnel may generate will depend
upon the terms of their engagement. For conve
nience, we can categorize these persons as staff
and nonstaff.
..1

Staff

The ownership and control of IP generated or
held by staff will be handled by a combination
of personnel contracts and the institute’s person
nel policies and procedures. These will usually be
gathered in a personnel manual. Given the grow
ing concern about IP staff, some institutes have
been requested to sign an IP rights statement or
a nondisclosure agreement. At the International
Rice Research Institute (IRRI), for example, the
statement is an IPR Agreement in which staff agree
that “all inventions, improvements, data, processes,
technologies, discoveries and other intellectual prop
erties” generated by them, while employed by
IRRI, “that relate to the research and development
programs of IRRI or result from tasks” assigned to
them “are the sole property of IRRI.”6
Publication is a significant issue if a partner
desires nondisclosure and the ethos of the insti
tute is to publish its research. Premature publi
cation in articles, research papers, and at confer
ences and meetings may destroy the novelty of a
patentable invention. This is in tension with the
desire of researchers to place their scholarship into
the public arena. The IP audit can be an oppor
tunity to introduce staff to the impact of IP upon
their research. When proprietary technologies are
licensed from the private sector, the license agree
ment may sometimes restrict publication until
the commercial opportunities generated by the
research have been evaluated. Nonresearch staff
and board members should also be bound by a
confidentiality obligation.
1 | HANDBOOK OF BEST PRACTICES

This list of IP categories embraced by the agree
ment is presumably intended to be informative and
exhaustive for the staff members who sign it:
• The IRRI IPR agreement obliges staff to dis
close the listed categories of IP “promptly
to IRRI.” A procedure for such disclosure
should be established, identifying the per
son or office to whom/which disclosure
should be made.
• The IRRI IPR agreement requires that
employees assign relevant IP to IRRI and
“do all things necessary, including executing
documents” to assist IRRI in obtaining legal
protection for its IP. This is a fairly effec
tive means for IRRI to secure title to the IP
generated by its staff.
• The IPR agreement also obliges staff to use
confidential information only in the perfor
mance of duties for IRRI and not to disclose
information to unauthorized persons both
during employment with IRRI and for a
five-year period after the termination of their
employment. This provision appears to ef
fectively impose confidentiality obligations.
Staff includes those employed outside the in
stitution, such as those working in the field or
attached to other institutions. They are bound
by their employment contracts and potentially
by the IP policies of the external institutions for
which they work. The legislation of the countries
where they work may also apply. For example, a
number of countries have enacted legislation to
regulate access to biological materials that might
become the subject of patent applications. A re
search institute would be in breach of that law if
it filed IP applications related to biological mate
rial that was obtained without consent.
Usefully supplementing the IPR agreement
could be a reference to any institute policy on IP
rights and a definition of those rights. Box 1 sets
out a comprehensive definition of IP.
..2 Non-staff

Research institutes frequently host various cat
egories of nonstaff, such as visiting scientists, con
sultants, project scientists, collaborative research
fellows, and students. Maintaining ownership
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and control of the institute’s IP can be a particular
problem where non-staff are concerned. Without
an agreement with them, the institute will be un
able to assert control over IP that these visitors
might generate or use. Indeed, problems have aris
en from the uncertain status of visiting researchers,
who in some instances have acquired patent rights
over the subject of their research while a visitor.
Accommodating researchers funded by outside
donors has also been an issue. Uncertainty about
the ownership of the research of such donors can
be clarified in the institute’s IP policy. Accordingly,
a number of countries commonly require nonstaff
to execute an IP and confidentiality agreement.
. Policy on IP

Currently, public research institutes commonly
formulate policies to deal with IP ownership
and control. The policy is usually agreed to and

approved at the board level. As a general prin
ciple, the institutes emphasize the free availabil
ity of the information, inventions, and biological
material that they develop. Institutes are obliged,
however, to seek IP protection to ensure the avail
ability of advanced biological technologies or bio
logical materials for developing countries. Some
institutes declare that they may seek to protect
technologies or materials that they develop for
their client communities. Protection may also be
pursued to prevent third parties from obtaining
IP rights over their innovations. For example, by
filing a provisional patent application, knowledge
about an institute’s innovations will be placed in
the public domain. This is intended to destroy the
novelty—and hence the patentability—of inno
vations that are required for the benefit of devel
oping countries. This will prevent such inventions
from being appropriated by the private sector.

Box 1: Intellectual Property
Intellectual property means information, ideas, inventions, innovations, art work, designs, literary
texts and any other matter or thing whatsoever as may be capable of legal protection or the
subject of legal rights and includes the following protections:
• patents
• confidentiality (for information which is of a kind and which has been communicated in such
a way as to give rise to a duty of confidentiality)
• copyright vesting in literary works (including computer programs), dramatic works, musical
works, artistic works, films, sound recordings, multimedia works, broadcasts, published
editions, and certain types of performances
• registered trademarks
• unregistered trademarks used or intended for use in business
• registered designs and designs capable of being registered
• rights of breeders for new plant varieties
• rights associated with designs
• rights related to databases
• other rights resulting from intellectual activity in the industrial, commercial, scientific, literary,
and artistic fields
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A number of public research institutes include
their IP policy within a policy on partnership with
the private sector. These research institutes will of
ten concede that to ensure that developing coun
tries have access to biotechnology-derived products
and advanced biotechnologies, it may be necessary
to enter into special agreements that stipulate some
limitations on distributing derived and associated
materials. Within the context of this policy, the in
stitute may assemble a list of IP that it is willing to
share with the private sector in exchange for access
to its IP, under mutually acceptable terms.

. IdEnTIfICATIon of Ip GEnERATEd
By A RESEARCH InSTITuTE
.1 Background

An IP audit obviously has to identify all the IP
generated by the research institute, whether ex
isting in a registered or unregistered form. This
requires analyzing questionnaires completed by
management and research staff, as well as the
examination of contracts, MTAs, licenses, col
laboration agreements, memorandums of under
standing, collaborative work plans, employment
contracts and other legal arrangements. This will
allow the auditor to: (1) clarify the terms under
which IP is being accessed; (2) determine whether
the terms of access impose restrictions on the in
stitute’s ability to distribute products and services
produced with the help of this IP; (3) identify
ownership of relevant IP; (4) identify the source
of IP in order to identify areas in which IP access
and ownership issues may have to be reexamined
to ensure compliance with the institute’s current
IP policy; (5) assess the importance of the IP to
the institute’s activities; and (6) identify all new IP
being developed at the institute (specifically, the
IP opportunities perceived by the institute, for its
own and third-party IP).
Typically, an audit will identify the following
main types of IP:
• patents and know-how associated with the
biological assets of the institute
• patents and industrial design rights
• IP associated with agricultural equipment
developed by the institute
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• copyright, database rights, and know-how
associated with publications, computer
programs, and databases generated by the
institute
• copyright databases and know-how devel
oped from the functional genomics research
undertaken at the institute
• trademarks
• industrial designs
.2 Patentable biological assets

The principal biological assets located at a scien
tific research institute will include:
• germplasm collection
• DNA collection
• biological tools for gene discovery
• enabling technologies (for example, marker
genes and probes)
• advanced mapping populations
• near isogenic lines
• introgression lines: mutants (characterized/
uncharacterized); BAC library
• introgression lines
• gene pyramids
• advanced lines from conventional breed
ing: conventional lines; new plant types
• inbred lines for hybrids: a, b, and restorer
lines
• varieties/cultivars
• hybrids
• transgenic lines
These biological assets represent a consider
able investment by the institute, its partners, and
collaborators. Insofar as they contain potentially
patentable or licensable information, they also
represent various levels of added value, utility,
and inventiveness.
. Patents, utility models, and
industrial design rights

A medical or agricultural research institute is like
ly to develop equipment and tools that need IP
protection.
. Technological know-how

Not all IP is protected through a system of regis
tration. An important unregistered category of IP
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in medical research is confidential information. It
is often an adjunct to registered IP rights. For ex
ample, patent protection is conferred in exchange
for the disclosure of enough information in a pat
ent application to permit the invention, which
is the subject of the application, to be used. To
protect its competitive advantage, the applicant
inevitably will withhold information about how
to effectively commercialize an invention. This
information, or know-how, may include plant
design and setup, training, marketing plans, cus
tomer lists, and accounting and survey methods.
Similarly, a protected trademark is of limited com
mercial utility without an associated scheme for
advertising, licensing, franchising, and marketing
the goods or services under that mark. Ensuring
the quality control of the licensed goods will usu
ally entail the application of trade secrets.
At the center of the attempt to protect con
fidential information are efforts to restrain the
disclosure of trade secrets by former employees or
researchers. A particular difficulty in these cases is
distinguishing between information that can be
regarded as the skilled employee’s or researcher’s
own expertise and other information gained dur
ing employment, such as secret industrial formu
lae or processes, which may properly be regarded
as the employer’s. Generally speaking, if the in
formation in question can fairly be regarded as a
separate part of the employee or researcher’s stock
of knowledge that a person of ordinary honesty
and intelligence would recognize, the informa
tion would be considered to be the property of
the employee. In applying this objective test, the
courts have tended to look, among other things,
at the nature of the employment, the nature of
the information, and whether the information
was capable of being isolated from other un
protected information. Chemical formulas and
recipes and engineering drawings and designs
are usually considered to be discrete categories of
undisclosed information that fall within the cat
egory of protectable confidential information.
National laws protecting confidential infor
mation differ. Article 39 of the Agreement on
Trade-Related Aspects of Intellectual Property
Rights (TRIPS) administered by the World Trade
Organization (WTO) deals with the preservation

of confidential test data submitted to government
approval agencies. Given the long approval pro
cess, particularly for pharmaceutical products, the
opportunities for wrongful appropriation of such
data by competitors was self-evident. Accordingly,
Article 39 (3) provides that:
Members, when requiring, as a condition of
approving the marketing of pharmaceutical or of
agricultural chemical products which utilize new
chemical entities, the submission of undisclosed test
or other data, the origination of which involves a
considerable effort, shall protect such data against
unfair commercial use. In addition, Members shall
protect such data against disclosure, except where
necessary to protect the public, or unless steps are
taken to ensure that the data are protected against
unfair commercial use.
. Biological assets protectable
as plant varieties

New plant varieties developed by agricultural re
search institutes may be protectable under plant
breeders’ rights legislation. Such varieties can
also be patented in the United States but not in
Europe.
. Rights associated with publications,
computer programs, and databases

Copyright arises in relation to publications, CDROMs, databases, online displays, and software.
Governing the protection of works created within a
country, copyright laws are territorial. But through
international agreements a particular country’s
laws can be respected outside its territory. Most
countries are signatories to the TRIPS Agreement,
which affirms the Berne Copyright Convention
and adds some additional protection.
Most copyright laws provide protec
tion for printed works, such as books, confer
ence proceedings, research reports, and jour
nals. Copyright protection is also available for
research notes, provided that these are in writ
ten form. Copyright protection is also available
for films, photographs, sound recordings, and
CDs. Under the Berne Convention and TRIPS
Agreement, computer programs are treated as
if they were literary works. Finally, copyright
protection is available for online materials and
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screen displays. The period of copyright protec
tion is conventionally 50 years from the date of
a work’s publication.

procedures have to be put in place to obtain copy
right authorization and copyright indemnities.

..1 Publications

The various research projects undertaken or un
derwritten by an institute generate considerable
bodies of data. Under current copyright law, raw
data or information is not protectable. But legis
lation is being considered in a number of coun
tries that would allow databases and possibly raw
data itself to become the subject of sui generis, or
special, IP protection. However, while raw data
contained in databases may not be copyright
protected, the way in which information is ex
pressed can offer some protection. For example,
a passage of text, a diagram, or chart contained
in a database may be protected by copyright.
It is also possible that in certain circumstances,
where sufficient originality or creativity in the
arrangement of data is present, the database as
a whole may be protected by copyright on the
basis that it is a compilation. Because individual
components of the database may be protected
by copyright, there must be mechanisms and
procedures to ensure that the database does not
contain material that infringes the copyrights of
others. IP rights are of particular concern when
the creation of a database is collaborative. In this
case, when copyright exists in individual entries
it may be unclear whether the copyright belongs
to one collaborator or to all the collaborators
jointly. Moreover, when material is contributed
from diverse sources, each collaborator may be
come liable as an infringer—even if only one of
the collaborator infringes the copyright of a third
party.
To deal with some of these copyright issues,
the Document by Bioversity International recom
mends that the copyright notification page con
tain a general notification hyperlinked to a page
of specific copyright notifications. These would
identify which part, or center, of the institute owns
copyright in the relevant material. The document
suggests the following general notification:
This site is protected by international copyrights
in the design of the site including the layout, ty
pography, and graphics reproduced herein, and in
the expression of the information contained herein,

Copyright will exist in the textual material, pho
tographs, graphic designs, diagrams, charts, and
the compilation or arrangement of a publication.
A research institute will publish scientific books
(including monographs, conference proceedings,
manuals, and field guides); discussion papers;
proceedings of conferences, meetings and work
shops; technical bulletins; and scientific posters.
..2 CD-ROMs

A number of different copyright interests may
arise for material on a CD-ROM. Copyright
may arise with respect to text, artistic works (such
as photographs, drawings, diagrams), musical
works, sound recordings, and films, as well as
in relation to the compilation of material con
tained in the CD. An institute may produce CD
ROMS as part of its training materials. For ex
ample, the asynchronous Internet-based courses
in Experimental Design and Data Analysis and
in Agricultural English, created and administered
by IRRI, are available on CD-ROM. When ma
terials have not been generated at the institute,
the audit should ascertain whether permission
or clearance has been obtained from the author
or original source prior to publication. The au
dit should also determine whether the author or
original source is acknowledged. When material
appearing on CD-ROM is generated at the in
stitute, the CD-ROM should carry a copyright
notification with respect to the compilation and
the individual elements of the CD.
.. Video materials

Video materials produced for the purpose of train
ing are copyright protectable. Thus video materi
als produced at the institute should acknowledge
it as the source and carry a copyright notice. If
desired, this could be accompanied by a notice
authorizing reproduction or copying of the ma
terial provided the institute is acknowledged as
the source. If videos are produced involving ma
terial generated from outside the institute, then
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.. Copyright databases and know-how
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whether as a compilation, literary or artistic work
or otherwise.
The form of the specific copyright notifica
tions recommended in the Bioversity International
document is:
Copyright [full name of copyright owner] [year
of creation of work] in [describe] as [compilation/
published edition/literary work/artistic work] or
otherwise.
.. Online materials

The copyright principles that apply to printed
works and CD-ROMs apply equally to online
materials. Thus an institute would have to secure
permission and indemnities to use copyrighted
material that it displays on its Web site.
IP approval for hypertext links to other World
Wide Web sites has recently raised some copy
right concerns. If the institute’s home page links
to a large number of Internet resources, it should
be ensured that the proprietors of those online
resources have no objections to those linkages.
Copyright issues are also raised by mirroring
and framing. Mirroring occurs when a site is du
plicated on another server. Framing occurs when
one Web site imports material from another site
and makes it part of its own site. When such fram
ing or mirroring occurs, it is essential that copy
right clearances and indemnities are obtained.
.. Computer programs

Copyright subsists in both source and object
codes of computer programs. Where commercial
ly available programs are used or are incorporated
in larger programs developed by the institute, li
censes are available from the suppliers of those
programs. It should be noted that a license to use
commercially available software will not necessar
ily authorize the development or improvement of
that software. The development or improvement
of commercially available software for the pur
poses of, for example, facilitating or improving
the accessibility of information stored on a data
base will infringe the copyright unless a license to
develop the program has been obtained. Where
programs are written in-house by institute em
ployees, copyright problems do not arise.

In order to provide evidence that computer
programs have been generated in-house, it is rec
ommended that when institute personnel gener
ate such material they complete a declaration of
originality. Such a declaration could be made in
electronic form in order to facilitate and central
ize collection and storage.
. Trademarks

Research institutes commonly seek trademark
protection for their names and key research
products. The acronym and name of a research
institute, for example, could be registered in
Class 16 of the Nice Trademark Classification
in relation to “research and educational mate
rials.” Registrations can be obtained in each
country in which research is undertaken. When
an institute makes products such as seeds, these
could be registered in Class 30, in relation to
“[plant] variety/breeding lines.” Trademarks
can also be sought for equipment and tools, for
example in Class 7, which covers agricultural
equipment.
. Confidential information

Research data compiled in institute projects by
institute researchers may be protectable as con
fidential information. To be protected, the in
stitute has to impose confidentiality through
confidentiality agreements with employees and
researchers. These will inform them that the in
stitute attaches the quality of confidence to its
research data and to its research methods. For the
most part, a public research institute will waive
its rights to the confidential information that it
generates in its research findings. However, for
agreements according to which the institute
undertakes to share unpublished research find
ings and data with its collaborators, some en
forcement of confidentiality agreements will be
necessary to ensure that the research findings
are shared and not dissipated. As awareness of
IP protocols becomes more widespread, research
collaborators will begin to insist upon an enforce
able confidentiality regime. It will be increasingly
important, therefore, to put in place mechanisms
and procedures that ensure that confidential ma
terial is not publicly disclosed.
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. Biodiversity rights

The Convention on Biological Diversity (CBD)
seeks to establish an international program for the
conservation and utilization of the world’s biolog
ical resources, as well as for the “fair and equitable
sharing of the benefits arising from the utilization
of genetic resources.” A similar policy animates the
International Treaty on Plant Genetic Resources
for Food and Agriculture. For example, the CBD
contains provisions dealing with access to genetic
resources. Article 15 requires contracting parties
to “endeavour to create conditions to facilitate ac
cess to genetic resources for environmentally sound
purposes” by other contracting parties accord
ing to mutually agreed terms and conditions on
the basis of “prior informed consent.” A detailed
code of access to biotechnology is prescribed in
Article 16. Access and transfer are to be “provided
on terms which recognize and are consistent with
the adequate and effective protection of intellectual
property rights.” The Article provides that devel
oping countries that provide genetic resources
shall be granted “access to and transfer of technol
ogy which makes use of those resources.” In addition,
Article 19.2 provides for the grant of access on a
fair and equitable basis and on mutually agreed
terms to contracting parties, “particularly devel
oping countries, to the results and benefits arising
from biotechnologies based upon genetic resources
provided by those contracting parties.” Additionally,
Article 8(j) of the CBD envisages that where the
knowledge, innovations, and practices of indig
enous and local communities are utilized, the
benefits arising from their utilization should be
shared equitably.
A number of developing countries have in
troduced legislation that seeks to enact the ben
efit sharing provisions of the CBD. Thus, when a
patentable invention results from institute germplasm that is contributed by indigenous persons
or local communities, or that is collected as a re
sult of the utilization of the knowledge of those
persons or communities, a compensation liability
may arise. Indigenous groups and local commu
nities have begun to insist upon the collection of
samples under the terms of bioprospecting agree
ments, which invariably define the distribution of
benefits from any royalties that may result from
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patents. In a number of developing countries, the
use of bioprospecting agreements is becoming
mandatory.

. THIRd-pARTy Ip
.1

Patents and know-how associated
with biological technologies

Most research institutes will have third-party pro
prietary technology licenses. The basis of the pro
prietary claims made by most of the licensors will
be the confidentiality of the biological materials
or know-how that is licensed to the research insti
tute. Additionally, patented research technologies
may be licensed.
The salient features of these licenses are:
• permissible use of the licensed material
confined to scientific research
• confidentiality of licensed material to be
preserved
• all information concerning improvements
in the material or inventions associated with
the material to be reported to the licensor
• research progress to be reported
periodically
• use of material only by identified institute
scientists
• advance copies of manuscripts of publica
tions to be provided to licensor
The various obligations these agreements
with third parties impose emphasize the impor
tance of an IP management facility at a research
institute.
.2 Genetic material

Medical and agricultural research increasingly
utilizes genetic material provided to an institute
under an MTA or confidentiality agreement. The
terms of that MTA may restrict how that mate
rial can be used. For example, it may be on the
condition that IP rights are not sought in rela
tion to that material, or that it is not used for
commercial purposes. Sometimes the MTA will
require that material derived from the supplied
material should also be supplied under those con
ditions. In each of these cases, the responsibility
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to observe those conditions will be imposed on
the institute; it will be the purpose of the audit
to identify these obligations and document how
they are being managed.
On occasion, genetic material is made avail
able informally by a scientist from a third party,
acting without the authority of that third party.
In this case, the unauthorized use could involve
the research institute in liability. Consequently,
the audit should identify the terms of all acces
sions of third-party genetic material.
. IP rights associated with equipment
utilized by a research institute

A number of items of research equipment ob
tained from commercial suppliers may generate
IP obligations. For example the Bio-Rad Biolistic
PDS-1000/He apparatus is often supplied to re
searchers at IRRI subject to an agreement that it
be used “for research purposes only.” The Hybaid
PCR Express Thermal Cycler is also subject to a
license “to practise the PCR process for internal re
search and development.”

. Ip MAnAGEMEnT STRuCTuRES
An IP audit should analyze the management of
IP at a research institute from the perspective of
the adequacy of the management structures and
procedures. It should also consider IP manage
ment in terms of the staff’s awareness of IP obli
gations. Finally, the institutional mechanisms for
dealing with institute and third-party IP should
be examined.
.1 IP management culture

A critical feature of effective IP management is
the existence of a research culture in which IP
awareness is communicated to researchers. In
order to ascertain the extent of IP knowledge
and of IP management practices within an in
stitute, questionnaires could be administered to
administrative and research staff. To supplement
the general IP consciousness-raising activities
mentioned above, it would be very useful for staff
to be provided with an IP handbook, containing
a general primer on IP, as well as all relevant IP
documents and procedures. This IP handbook

could also be made available online and accessed
from the institute’s Web site.
.2 Office of IP coordination

As IP becomes increasingly significant for sci
entific research, establishing an IP coordination
office or officer for an institute becomes more
important. This office, which may be within the
research institute or located within the offices of
a third-party subcontractor, would be responsible
for coordinating both IP administration and pro
cedures within the institute. The IP office would
also be responsible for external IP liaison. The
coordination of IP procedures would include
securing the IP compliance of staff and visitors;
ensuring the inclusion of IP provisions in relevant
third-party agreements; ensuring the utilization
of appropriate MTAs by the institute, both as a
recipient and distributor of germplasm and bio
logical tools; maintenance of a central repository
of IP documents; maintenance of the institute’s
IP database; and raising awareness of about IP is
sues. Externally, an IP coordinator could provide
an IP dimension to negotiations with research
collaborators and act as a liaison with IP officials
of other institutes.
The IP coordination office would ensure that:
• staff and visitors sign and adhere to IP and
confidentiality agreements
• copyright permissions and indemnities are
secured for various publications
• Copies of MTAs and other IP agreements
are filed centrally and provided to appropri
ate staff members
• Proper research records are made, main
tained, and filed
• the MTA granting procedure is coordinated
• the IP provisions of other agreements are
supervised
• the institute’s legal advisers are updated on
IP matters
. Research records

Establishing provenance for research is central to
any policy of securing and exploiting the IP rights
that might be generated from an institution’s
research. The practice of maintaining laboratory
notebooks with consecutively numbered pages
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that are signed at the end of each day by the su
pervising scientist is normal in private enterprise,
but may be alien to the research culture at a pub
lic research institute. However, without this sort
of management practice, it would be difficult to
contest a first to invent dispute under patent law.
Similarly, it would be difficult to identify the
technological know-how brought by a scientist
to the institute and to distinguish it from that
which has been developed at the institute. This
is important in delineating the respective confi
dential information of a staff member and the
institute.
. Material transfer agreements (MTAs)

Guidelines and procedures for the approval of
material transfer agreements could efficiently di
rect the management of IP in a scientific research
institute. For germplasm designated under the
International Treaty on Plant Genetic Resources
for Food and Agriculture, an established procedure
already exists. Some of the Consultative Group
on International Agricultural Research (CGIAR)
genebanks distinguish between designated germplasm and germplasm that they themselves have
developed, which is accordingly regarded as nondesignated. Separate MTAs are being developed
by research centers to deal with the distribution
of this material.
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. ConCLuSIonS
Modern scientific research often requires expen
ditures to enable the generation of protectable IP.
The institute will have to decide whether this IP
will be placed into the public domain or regis
tered, either to pursue commercial exploitation
or to prevent its privatization by unauthorized
third parties. Before any of these actions can be
taken, however, the research institute must iden
tify the IP that its researchers generate or utilize.
An effective IP audit is therefore an important
tool for supporting the research objectives of the
institute. n
Michael blaKeney, Director, Queen Mary Intellectual

Property Research Institute, Center for Commercial Law
Studies, University of London, 13-14 Charterhouse Square,
London, EC1M 6AX, U.K. m.blakeney@qmul.ac.uk
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CHAPTER 5.7

Conflict of Interest and Conflict of Commitment
Management in Technology Transfer
alan b. benneTT, Associate Vice Chancellor, Office of Research, University of California, Davis;

and Executive Director, PIPRA, U.S.A.

ABSTRACT

The potential for personal interests to influence institu
tional decisions in universities and public sector research
institutions continues to grow. This is because of the in
creasing activity in intellectual property (IP) management
and technology transfer undertaken by these institutions.
The activities have the potential to generate both personal
and institutional financial gain, making conflict of inter
est and conflict of commitment issues unavoidable. This
chapter explains the nature of these conflicts and discusses
the policies, regarding conflict of interest, of several uni
versities, offering them as potential models for crafting
these indispensable policies.

1. INTRODuCTION
Universities and public research institutions have
been characterized historically by their selfless ef
forts to expand knowledge for the public good
rather than for private gain. This has contributed
to a high level of public trust in the integrity of
these institutions, and they are seen as providers
of unbiased information. This institutional integ
rity rests on the personal integrity of the people
employed by or associated with that institution,
which collectively represent the greatest asset of
the institution. Indeed, any erosion of institu
tional integrity or of the public’s trust can have
devastating consequences in terms of public sup
port for the institution.
One significant danger with regard to com
promising the integrity of a university or public

research institution is the potential for personal
interests (often financial) to adversely affect an
employee’s professional judgment when exercis
ing a university duty or responsibility, for exam
ple, the direction and conduct of research. The
potential for a divergence between an individual’s
institutional obligations and his or her private or
personal interests can become a conflict of inter
est: and a perceived conflict of interest can be as
damaging as a real one.
The potential for personal interests to influ
ence institutional decisions is greater today be
cause every institution is doing more in the area
of IP management and technology transfer, and
because these activities have the potential to gen
erate both personal and institutional financial
gains, conflict of interest issues are a constant
concern. Indeed, in today’s modern research uni
versities, the missions of which explicitly include
the transfer of research to commercial partners,
conflicts of interest are practically unavoidable.
These conflicts need to be managed in ways that
allow institutions to meet their technology trans
fer mission without compromising their integrity
and the public’s trust.
Another closely related pitfall is the pressure
that technology transfer and commercialization
activities place on employees’ primary allegiance
to their institution. In an era when researchers are
encouraged to actively participate in technology

Bennett AB. 2007. Conflict of Interest and Conflict of Commitment Management in Technology Transfer. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen,
et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. AB Bennett. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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transfer—and even in the development of new
companies—it is necessary to ensure that the em
ployee’s primary professional loyalty is to the insti
tution rather than to a private, extramural activity.
When outside activities cross boundaries in ways
that compromise, or appear to compromise, the
employee’s primary allegiance to the institution,
a conflict of commitment exists. Because both
conflicts of interest and conflicts of commitment
are potential pitfalls in the technology transfer
process, both are addressed in this chapter. Some
universities address both conflicts in a single com
bined policy (for example, Stanford University),
while most treat conflicts of interest and conflicts
of commitment in separate policies.

2. ConfLICT of InTEREST RELATEd To
Ip MAnAGEMEnT
Fundamentally, a conflict of interest is any situation
in which there is a conflict between an individual’s
private interests and his or her professional obli
gations such that an independent observer might
reasonably question whether the individual’s pro
fessional actions or decisions are affected by his
or her private interest.1 It is important to note, a
conflict of interest exists whether or not decisions
are made that are influenced by personal interests.
The conflict only indicates the potential for mak
ing biased decisions—not any likelihood of doing
so or any a priori misconduct. One should also
note that the precise definitions of conflict of in
terest are guided by national and local laws, re
search sponsor policies, and institutional policies;
thus the definitions may vary widely depending
on the geographic and institutional context.
The potential for financial conflicts of inter
est for individual researchers increases dramati
cally when an institution begins to actively sup
port and promote the transfer of research results
for commercial applications.2 In many cases, the
commercial development of early-stage research
results can be carried out best by a start-up
company. Typically, the university researcher is
either a founder of or a consultant to the com
pany and has substantial financial interests in the
company. This gives rise to a personal conflict
of interest, and any future decisions on research
2 | HANDBOOK OF BEST PRACTICES

directions, assignment of research topics to stu
dents, the supervision of clinical trials, or any
influence over institutional IP licensing deci
sions by the researcher/entrepreneur should be
viewed through the lens of the institution’s con
flict of interest policies. Again, it is important to
note that the existence of the personal financial
interests should not, in themselves, but in gen
eral the conflict should be openly disclosed and
any future activities and decisions by the con
flicted individual reviewed and managed by the
institution.
The potential for a researcher to have a sig
nificant financial interest in an outside potential
licensee can be quite high, particularly if the
licensee is a start-up company founded by the
researcher/inventor. When the researcher partici
pates in the licensing negotiations or even in dis
cussions with the institutional licensing officer,
the researcher is in a conflict of interest position:
the researcher has the potential to influence an
institutional licensing decision in which he or
she has a direct financial interest. In California,
such a position constitutes a criminal conflict of
interest under the Political Reform Act of 1974.
As a consequence of the Act, the University of
California developed detailed guidelines and
guidance on the disclosure and management of
conflicts of interest in licensing. These guidelines
permit participation in licensing negotiations by
an inventor, even when he or she has a disqualify
ing personal financial interest. As the guidelines
observe, such participation “is appropriate and
represents a useful contribution, because the transfer
of University technology to industry is in the pub
lic interest and is consistent with the University’s
mission.”3 Such participation, however, requires
an appropriate intervening substantive review,
called a Licensing Decision Review, which deter
mines whether licensing decisions are inappro
priately influenced (see Box 1). Although these
guidelines for managing conflicts of interest in
licensing are very specific to the laws of the State
of California, they raise and consider a number
of important issues that are both generic and spe
cific to technology transfer.
An additional level of conflict of interest has
also emerged as a result of universities taking an
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Box 1: university of California Guidelines for a licensing Decision Review
What is licensing Decision Review?
Licensing Decision Review means there is a review by a noninterested person or persons before
a proposed licensing decision goes to the final decision maker for approval. The review must be
based on an independent consideration and assessment of the facts of the case. The Licensing
Decision Review body, composed of qualified staff with appropriate expertise, knowledge, and
professional judgment, must independently check the original data and analysis upon which the
selection of licensees proposed by the licensing professional and other licensing decisions were
made and make its independent recommendations concerning the decisions.
Who conducts the licensing Decision Review?

Each University of California campus and laboratory was directed in a June 18, 2001, letter to
chancellors and laboratory directors from Provost King and Senior Vice President Mullinix to
establish a plan for conducting intervening substantive review of licensing decisions (in this case,
called Licensing Decision Reviews), whether those licensing decisions are made in the systemwide
Office of Technology Transfer (OTT) or at a campus or Laboratory Authorized Licensing Office. Each
local Licensing Decision Review plan, including the processes, mechanisms, and bodies (individuals
or committees) established to carry out Licensing Decision Reviews may accommodate local needs
and circumstances, but must be responsive to the direction provided in that letter and, consistent
with these Guidelines, must be filed with the OTT.
Source: University of California. 4

active role in IP licensing, particularly to start-up
companies. Typically, the university will accept eq
uity in a company in lieu of upfront license issue
fees, which gives the university itself a financial in
terest in the company. This leads to an institution
al conflict of interest. Such institutional conflicts
of interest have been particularly problematic in
research involving human subjects, so institution
al policies are being developed to ensure that the
financial interests of the researcher and the institu
tion do not create a conflict of interest in enrolling
and ensuring the safety of human research sub
jects. Stanford University’s Institutional Conflict
of Interest Policy provides a concise approach to
ensuring that all human-subject institutional re
views include a review of whether the university
has any financial interests in drugs or devices un
der study or financial interests in the company
that is sponsoring the research (See Box 2).5

. ConfLICT of CoMMITMEnT RELATEd
To Ip MAnAGEMEnT
Faculty and researchers working in educational
and research institutions are expected to give

primary allegiance and professional commitment
to the institutions that employ them and devote
primary energy to teaching and research. Even
so, most institutions value their staff’s contribu
tions to professional and public service, including
pro bono work and paid consulting. In addition,
public institutions increasingly value the role of
employees in technology transfer and its contri
bution to economic development. Effective tech
nology transfer inevitably requires faculty and
researchers to actively participate in the commer
cialization process, which often includes taking
an active role in starting up new companies that
are capable of developing and exploiting univer
sity inventions. These multiple institutional goals
create the potential for a conflict of commitment
between the institution’s primary educational and
research mission and the institution’s interest in
effectively supporting economic development
and technology transfer through the external ac
tivities of its faculty and researchers.
Conflicts of commitment typically require
determining the appropriate balance of time al
location between institutional and external ac
tivities—the critical test is that external activities
HANDBOOK OF BEST PRACTICES | 2
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Box 2: Highlights of Stanford university’s Institutional
Conflict-of-Interest Policy
The goal of this policy is to preclude situations in which human-subjects research is carried out
at Stanford or by Stanford researchers involving organizations in which the University holds
ownership equity or rights to equity that is not publicly traded. The fundamental assumption
underlying the policy is that such situations present a significant risk to the perceived objectivity
of the research. The policy requires that the Office of the Dean of Research be informed of all such
situations and provides that, after a review of the facts and circumstances, the Associate Dean of
Research may either arrange the divestment of the University’s holdings through the Office of
Technology Licensing or, if that cannot be done, refuse to allow the research to proceed.
DISCuSSION AND DETAIl
1. Review by the office of Technology Licensing (oTL) of all human-subjects research protocols
proposed by university principal Investigators:
At the request of the Office of the Dean of Research, the Stanford Research Compliance
Office has established a procedure that requires all new human subjects research protocols
submitted for regular or expedited review to the IRBs to indicate (1) the nature and source(s) of
all drugs, devices, or biologics (e.g., vaccine products, gene therapeutics) which will be used in
the proposed research and (2) the source(s) of all funding to be used in supporting the research.
Per this procedure, the information provided is then reviewed by the Director of OTL to identify
situations in which the proposed research involves (1) the use of drugs, devices, or biologics
that make use of Stanford-owned intellectual property or (2) funding from nonpublicly traded
organizations in which Stanford owns equity or the right to acquire equity through a licensing
agreement.
2. Review by the office of the dean of Research of all protocols that might be
subject to this policy:
Per the procedure described above, the Director of OTL flags for further review by the Office
of the Dean of Research all proposed new human subjects research proposals involving the
use of drugs, devices, or biologics that make use of Stanford-owned intellectual property or
are funded in whole or in part by nonpublicly traded organizations in which Stanford holds
equity or the right to acquire equity through a licensing agreement. Based on the facts and
circumstances identified in this review, the Associate Dean of Research will (1) require OTL to
divest that equity on behalf of the University or (2) prohibit or require modifications to the
proposed human-subjects research which would remove any possibility for the University as an
institution, or any University department, to benefit as a result of the conduct or outcomes of
the proposed research. In the event the University’s financial interest is in the form of royalties
payable as a result of exclusive technology licensing rights, OTL will inform the Associate Dean
of Research, who will determine on a case-by-case basis the significance and management, if
appropriate, of the potential institutional conflict of interest.
3. Monitoring compliance:
The University’s Internal Audit Department will periodically review a sample of human subjects
research protocols to ensure that all situations in which a potential exists for institutional
conflict of interest have been properly identified and all risks to human subjects have been
properly mitigated.
4. Responsibilities of the dean of Research:
The Vice Provost and Dean of Research is the University officer responsible for interpreting and
overseeing implementation of and compliance with this Policy. Questions may be addressed
to the Assistant Dean of Research.
Source: Stanford University.6

0 | HANDBOOK OF BEST PRACTICES

CHAPTER .

should not detract from their primary institu
tional responsibilities. Institutions vary widely
regarding permissible external activities, which
may reflect differing institutional priorities as
well as whether the institution is public or pri
vate. Stanford University, for example, integrates
both conflict of interest and conflict of commit
ment into a single policy that specifies the appro
priate balance of time commitment to external
activities to be approximately one day per week
(see Box 3).

. STRuCTuRE of A ConfLICT of
InTEREST/CoMMITMEnT poLICy
The development of institutional conflict of in
terest and conflict of commitment policies is a
critical step in developing technology transfer
capabilities and programs. Developing the policy
will require identifying and articulating institu
tional priorities and determining the appropri
ate balance between institutional interests and
the interests—both internal and external—of its
researchers. In addition, the effort will require
an in-depth analysis of the requirements placed
on the institution by national or local laws and
by the policies of agencies that sponsor research
in the institution. The elements of a conflict of
interest/commitment policy are outlined below;
actual policies take many forms.
.1 The purpose of the policy and applicability

The preamble of the policy should reiterate the
primary mission of the institution and indicate
in general terms how the institution views the
balance between internal and external activities
and the potential for developing conflicts. For
example, the Washington University in St. Louis
Conflict of Interest Policy is presented, in part, in
Box 4.
The preamble should identify to whom the
policy applies. In some cases, the policy may be
broadly applicable to all institutional staff, while
in other cases different policies may be required
for teaching faculty, for clinical faculty, and for
nonfaculty staff. Whatever the case, the applica
bility of the policy needs to be clearly stated early
in the policy document.

.2 Definitions

Definitions of key terms are typically provided to
ensure the policy’s clarity. For example, the defi
nition of “significant financial interests” should
be explicit with regard to applicable instruments
of monetary value such as stocks and stock op
tions. It should also explicitly state the extent to
which such interests extend to the researcher’s
spouse, children, or domestic partner. Examples
of terms that have been useful to define at our the
University of California include:
• business entity
• clinical research
• compensation
• conflict of interest
• gift
• intellectual property
• investigator
• management plan
• research
• select officials
• significant financial or other interest
. Policy

The policy statement should clearly describe ac
ceptable and prohibited activities, requirements
for reporting and disclosure, and processes for
evaluating and managing specific situations that
are not directly addressed by the policy.
. Process, roles, and responsibilities

The policy should clearly describe the institu
tional processes for disclosing external activities,
if there is a requirement to do so, as well as de
scribing the processes for seeking a review and
evaluation of conflict of interest disclosures. Most
institutions have one authorized official with this
responsibility and a committee that participates
in evaluations. The policy should describe the
processes for appointing the relevant commit
tees and identify the institutional officials with
responsibility for conflict of interest evaluations
and management.
. References and links to source documents

Finally, a conflict of interest/commitment policy
does not exist in isolation but typically relies on
the synthesis of a number of source documents,
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Box 3: Summary of Stanford university’s Faculty Policy on
Conflict of Commitment and Interest
1. Faculty must maintain a significant physical presence on campus (main or overseas) throughout
each quarter they are on active duty.
2. Faculty must not allow other professional activities to detract from their primary allegiance
to Stanford. For example, a faculty member on full-time active duty must not have significant
outside managerial responsibilities nor act as a principal investigator on sponsored projects
that could be conducted at Stanford University but instead are submitted and managed
through another institution.
3. Faculty must foster an atmosphere of academic freedom by promoting the open and timely
exchange of results of scholarly activities, ensuring that their advising of students and
postdoctoral scholars is independent of personal commercial interests, and informing students
and colleagues about outside obligations that might influence the free exchange of scholarly
information between them and the faculty member.
4. Faculty may not use University resources, including facilities, personnel, equipment, or
confidential information, except in a purely incidental way, as part of their outside consulting
activities or for any other purposes that are unrelated to the education, research, scholarship,
and public service missions of the University.
5. Faculty must disclose on a timely basis the creation or discovery of all potentially patentable
inventions created or discovered in the course of their University activities or with more than
incidental use of University resources. Ownership of such inventions must be assigned to the
University regardless of source of funding. The inventor will share in royalties earned.
6. Faculty must disclose to the University whether they (or members of the immediate family, as
defined below) have consulting or employment relationships with, and/or significant financial
interests (also defined below) in, an outside entity before the University will approve the
following proposed arrangements involving them between such entities and Stanford: a) gifts;
b) sponsored projects; c) technology licensing arrangements; and d) certain procurements. In
such cases, approval by the school dean will be required prior to entering into each proposed
arrangement.
7. In situations in which the objectivity of a faculty member could reasonably be questioned, the
dean of a school may establish an independent oversight committee to take steps including
(but not limited to) the following: to review the appropriateness of the proposed research to be
conducted at Stanford, to oversee the conduct of the research, and to ensure open and timely
dissemination of the research results. Such oversight committees will be required for all clinical
trials raising questions of conflict of interest.
8. On an annual basis all faculty members must certify to their school deans their compliance
with Stanford’s policies related to conflict of interest and commitment. They must also disclose
information about their (and their immediate family members’, as described below) financial
relationships with outside organizations that are sponsors of their teaching or research
programs or are otherwise involved in current, proposed, or pending financial relationships with
the University that involve the faculty member. In addition, faculty must disclose to their school
dean on an ad hoc basis current, proposed or pending situations that may raise questions of
conflict of commitment or interest, as soon as such situations become known to the faculty
member.
9. School deans shall establish procedures to ensure timely review of their faculty’s annual and ad
hoc disclosures of potential or apparent conflicts, and to ensure (in consultation with the Dean
of Research office) the appropriate management of such conflicts. Such procedures may involve
representatives from the school’s faculty as part of a reviewing body. School deans will file their
own annual disclosures and certifications of compliance with the Dean of Research.
10. The Dean of Research shall approve each school dean’s plans for implementing this policy,
interpret policy provisions in consultation with school deans, respond to faculty wishing to
appeal school deans’decisions, and report to the Committee on Research annually on the status
of this policy and its implementation.
11. Should a faculty member wish to appeal a decision made by the Dean of Research, he or she may
present the appeal to the Provost, who will consider the case in consultation with the Advisory
Board.
Source: Stanford University.7
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Box 4: Excerpt of Washington university’s Conflict of Interest Policy
The faculty and administrators at Washington University recognize a shared responsibility to
ensure that they conduct themselves in an unbiased manner and serve the goals of the University.
It is thus the responsibility of the University and its employees to guard against conflicts of
interest that might compromise the integrity and objectivity of the University community.
It is understood that the faculty, as developers of knowledge, have a unique opportunity and
responsibility to disseminate that knowledge to the public. By adopting this Conflict of Interest
Policy, the University reaffirms the value of collaboration with industry as a means of fostering
public access to the practical benefits of University research. By adopting this Conflict of Interest
Policy, the University also (i) demonstrates its commitment to the ethical principles that guide
University research and (ii) establishes a mechanism to safeguard University and faculty integrity
and objectivity so that University/industry interactions can optimally benefit society.
Source: Washington University. 8

policies, and laws. These sources should be listed
and hyperlinked from the policy.

. ConCLuSIonS
In addition to the legal reasons to develop and
enforce rigorous conflict of interest and conflict
of commitment policies, the fundamental
reputation of the institution rests on setting
and maintaining high ethical standards. As
Johns Hopkins University’s policy states:
“public confidence in the University’s integrity
undoubtedly ranks among its greatest assets.”9
Although technology transfer activities are only
one of many areas in which the potential for
conflict of interest exists, the interface between
the mission of the university and the demands
of industry and of private sector collaboration
is a rich breeding ground for such potential
conflicts. As an institution becomes engaged
with the private sector and with technology
transfer, the adoption of a thoughtful conflict
of interest and conflict of commitment policy is
essential. Not only is the policy itself an essential
administrative tool, but the analytical process of
developing the policy will reveal the institution’s
priorities. The process will also clarify what the
university considers the appropriate balance of
allowed and prohibited activities for achieving
the university’s mission(s). In the United
States, there has been a convergence of norms
in conflict of interest/commitment policies

that is driven by our legal framework and by
the policies of national research sponsors. It
is likely, however, that other countries facing
very different demands for research-based
economic development may find that the U.S.
approach does not conform to their regional and
institutional needs. n
alan b. benneTT, Associate Vice Chancellor, Executive
Director, PIPRA, Office of Research, University of
California, Davis, 1850 Research Park Drive, Davis, CA,
95616, U.S.A. abbennett@ucdavis.edu
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6

Establishing and Operating
Technology Transfer Offices

CHAPTER 6.1

Ten Things Heads of Institutions Should Know about
Setting Up a Technology Transfer Office
liTa nelsEN, Director, M.I.T. Technology Licensing Office, U.S.A.

ABSTRACT

Technology transfer is a rewarding process for the uni
versity, researchers, students, the business community,
the public, and the professionals who make it all happen.
Technology transfer brings new products, services, and
jobs. But it is a complex process, one that requires sus
tained dedication at every level. This chapter offers advice
about some of the most important policy and strategy
issues: five are economic issues and five relate to imple
mentation. The chapter concludes with a discussion of
technology transfer pitfalls caused by unrealistic expecta
tions. The chapter emphasizes the role of senior manage
ment in changing the IP (intellectual property) culture,
the need for transparent conflict-of-interest policies, and
the importance of sufficient autonomy and infrastructure
support for technology transfer officers.

1. InTRoduCTIon
The widely touted success of technology trans
fer from U.S. universities has attracted interest
from universities and research institutes around
the world. Such diverse countries as Germany,
the Republic of China, South Africa, the United
Kingdom, and many others have changed their
laws and policies, modeling them after U.S. prac
tices, to allow universities and faculty members to
manage and transfer intellectual property (IP). In
the United States, smaller universities and research
institutes are looking to imitate the successes of
their larger counterparts. Such changes are moti
vated primarily by two economic interests:

1. enhancing economic development by trans
ferring new technologies to local industries
2. obtaining financial support from industry
to support university programs
The advice offered in this chapter aims to pro
vide to heads of a research institutes and universi
ties perspective on what challenges to expect when
setting up a technology transfer office. These “Ten
Things” are based on almost 20 years of experi
ence in the Technology Licensing Office of the
Massachusetts Institute of Technology. The ideas
expressed in this chapter reflect also my long-time
experiences with the Association of University
Technology Managers (AUTM), including a
stint as president, during which I watched many
North American technology transfer programs
grow. The ideas expressed here have been influ
enced by my experiences visiting with universi
ties in almost 20 different countries and learning
about their technology transfer activities.

2. THE LIST of TEn
Many items in the list of ten may surprise you
(Box 1). The economic five may sound dis
couraging even, but that is not the intention.
It is to encourage a realistic time frame and
the sustained investments in time and money
are needed to reap the substantial societal and

Nelsen L 2007.Ten Things Heads of Universities Should Know about Setting Up a Technology Transfer Office. In Intellectual
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. L Nelsen. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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Box 1: Ten Things to Know about Setting up a Technology transfer Office
The economic five
1. Technology transfer will not make your university rich. A successful program will make a
small profit but will not support the university. It will, however, provide many other benefits
to the institution and the community.
2. Building a robust technology transfer program takes sustained financial investment.
Investments are required to develop a patent portfolio, attract expert talent, and train office
professionals.
3. It will likely take eight to ten years before your program stops losing money—and it may
never make your institution any substantial amount. It takes time to build an IP portfolio,
establish contacts, and develop skills in technology transfer. Following the set up, the TTO
may begin to make money.
4. It may take two decades or more before a university technology transfer program (including
entrepreneurial spinouts) substantially affects the local economy. Impact in regional
economic development takes 20 to 30 years. Expecting substantial returns in a few years
leads to underinvestment and disappointment.
5. The ultimate impact may be very large—both economically and culturally—for the university,
its graduates, and the community.
The implementation five
6. Sustained effort requires visible support—fiscal and otherwise—from senior administration.
Senior management must not only lead the way, but also sustain the effort to change the
culture of research and investment.
7. only senior administration can set the mission, policies, and priorities for the program. Clear
mandates will help technology transfer professionals choose among competing priorities
and the ever-present trade-offs between business and academic values. These policies will
ultimately help to define the university. They need to be clearly stated, and supported from
the top, so that technology transfer professionals can make the best decisions and withstand
pressure from competing interests.
8. Clear policies on Ip ownership, the roles of researchers in interactions with industry, and
other ground rules should be set up before the program begins. Working out such policies
in the middle of making deals leads to confusion and bureaucratic lethargy, slows down the
learning process, and hurts a university’s reputation for being able to consummate deals.
9. Conflicts of interest, both real and perceived, are inevitable. Clear policies and a wellunderstood review and appeal process need to be put in place early. Much can be learned
from the experience of others in the technology transfer field. Again, support from senior
administration is critical.
10.Technology transfer is a talent-based business. It is difficult to find people who can speak the
two languages of academia and industry and who also have the creativity to craft agreements
that meet the needs of both sides. One should not underestimate the combination and level
of skills required.These skills and experiences are very different from those needed to conduct
research.
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economic benefits of a successful technology
transfer program. A few TTOs have performed
atypically and these provide exceptions to the
principles described, especially with respect to
the economic five. But these exceptions depend
mostly on luck and planning—they cannot be
counted on. The issues are discussed in more de
tail following the list.
The sections that follow discuss more
fully the promise of technology transfer, the
economic issues and expectations involved
with technology transfer, and implementation
matters.
2.1 The promise of technology transfer

There is little doubt about the ultimate potential
of university technology transfer programs when
it comes to accelerating the adoption of new tech
nologies, enhancing entrepreneurship, creating
new medicines and other products, creating jobs,
and adding prosperity through economic devel
opment. The clustering of high technology and
biotechnology companies around major univer
sities has been well described, and AUTM and
others have documented the creation of hundreds
of thousands of jobs directly related to university
licenses and startups.
Within universities, robust technology
transfer programs also have many important
benefits that are quite separate from royalty
income (royalty income as used here includes
royalties from licenses to university intellec
tual property and monetary return from equity
holdings in spinout companies formed around
university intellectual property). Among others,
these include:
• productive interaction with the industrial
community: ideas shuttling back and forth
between the academy and the private sector,
which often increases the quality of research
• increased industrial support of university
research
• more willingness from central and local
governments to support university research
for economic development
• student exposure to the world of industry
and to the commercial opportunities of re
search (including training in entrepreneur

ship), thus influencing their future career
aspirations and ultimately impacting the
country’s economy
• financial support from grateful alumni
and other entrepreneurs who have grown
wealthy from companies started from uni
versity research
Such programs can have a major impact on
the economy of the surrounding regions—and
not only directly from entrepreneurial spinout
companies from the university. The entrepre
neurial ferment and capability resulting from
university spinouts leads in turn to the formation
of many other new companies. Larger companies
also often move to the region to take advantage of
relationships with entrepreneurial companies and
the skilled employee base.
2.2 Expectations in setting up a program

Despite the promises of successful technology
transfer programs, when communities and their
universities try to start new technology transfer
programs or to accelerate existing ones, the road
is rocky. Unrealistic expectations are a major
cause of failure and frustration. Universities of
ten expect their programs not only to bring in in
dustrial sponsorship for research but to provide
royalty income and entrepreneurial spinouts that
will support the entire university.
Unfortunately, government expectations are
often equally unrealistic. Some governments, for
example, have expected royalty income from tech
nology transfer to replace government support of
their universities. Too often, local and national
governments believe that just a few years of fi
nancial support for technology transfer—coupled
with pressures on universities to produce measur
able impacts—will almost instantly create thriv
ing clusters of biotechnology,1 software, or tele
com companies akin to those in Boston, Silicon
Valley, or San Diego.
A more realistic picture, however, is pro
vided by almost a quarter century of technology
transfer experience in the United States under
the Bayh-Dole Act of 1979, which allowed uni
versities to own patents from federally funded
research.
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2.2.1

Licensing income

Income from royalties and equity in spinouts is
measured most easily. Data from the AUTM sur
vey of U.S. universities (not including hospitals
and research institutions for fiscal year 2002 shows
that total gross royalties (including income from
equity) for 158 universities was US$959 million.
This from a research expenditure base of over US
$32 billion during that year!
Thus, even before subtracting expenses for
patenting and staff costs, technology licensing
and spinout equity income averages less than
3% of the amount universities spend on research.
And the income distribution is skewed: ten uni
versities in the United States (6.3% of the total)
account for almost 60% of the total royalty in
come for all U.S. universities.
The income distribution is skewed because a
good fraction of the total U.S. university income
from technology licensing is from a few block
busters: single inventions that yield very high
royalties (millions or tens of millions of dollars
per year, often for over ten years, until the patent
expires). These blockbusters are few and far between—there are no more than two or three ones
each year in the United States.
It is therefore unwise to look to technology
licensing and income from spinouts (royalties or
equity) to support the university.
2.2.2. Program profitability

Building a program to break-even profitability
takes time and money. Again, the North American
experience is instructive. Studies have shown that
it can take a technology transfer program eight to
ten years or more to reach profitability, although
most programs become profitable if the effort to
build them is sustained.2
If measured only by royalty income, uni
versities with smaller research bases have a
more difficult time breaking-even. Less research
means fewer inventions, lowering the statistical
probability of a blockbuster invention. Fewer
opportunities for licensing also mean that the
technology transfer staff gains less experience
and learns the craft more slowly. Small tech
nology transfer programs, therefore, may have
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to be sustained financially for a long period
of time, with the revenue shortfall justified by
their nonroyalty contributions to the university
and community.
Finally, it should be noted that new technol
ogy transfer programs are too often starved—
both for money to file patents and for staff. A
university frequently expects its program to
somehow bootstrap itself into profitability and
expansion. An “anorexic” program, however,
climbs the learning curve—and reaches profit
ability—much more slowly and has a much low
er impact on the university and the community
along the way.
Thus, the university must have a wellthought-out, long-term financial plan for build
ing its technology transfer office. The plan should
be based on expected benefits—both financial
and especially, nonfinancial—and on what the
university can afford during the decade or so it
takes to build a mature program.
2.2. Regional economic development

Governments most frequently support technol
ogy transfer in universities directly because they
hope that entrepreneurial spinout companies
will revivify the regional economy surround
ing the university. This is not an unfounded
hope—a number of regions have demonstrated
the success of such programs over time. But it
takes time: more than ten years for more than a
few spinouts to be formed, and as long as 20 to
30 years before a substantial cluster of techno
logically-based companies forms—and this only
when such development has been purposefully
planned and robustly supported financially. (The
Research Triangle region in North Carolina,
U.S.A., is one such success—after about a quar
ter century!)
Thus, government programs that support
technology transfer for four to five years and
then expect the programs to be self-support
ing and surrounded by a flourishing cluster
of companies are unrealistic. It will not hap
pen that fast. Building a regional economy
based on entrepreneurialism is a slow, gradual
process.
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. IMPlEMENTATION
.1 The role of the upper administration:
culture change

Founding a successful technology transfer pro
gram means changing a culture. Researchers must
become aware of how useful and rewarding it is to
identify potentially commercializable inventions
from their research. They also need to see the
benefits of cooperating with industry to transfer
such technology. For most researchers this will be
a new way of thinking, and some will feel that it
threatens the very purpose of the university.
This change in culture must start from above.
The upper administration needs to clearly delineate
the purpose and potential benefits of a technology
transfer program—not only to the individual and
the university but to the community at large. The
administration of the university can thus allay mis
trust by making it clear that technology transfer
will not be allowed to distort traditional academic
principles: investigator-initiated fundamental
research, uncensored publication, and open ex
change of information within the university.
.2 Defining the mission

The upper administration and the faculty must
define the mission and priorities of the technology
transfer office: Is it primarily to produce licensing
income? Or industrial support of research? Is the
mission primarily to get technology developed for
the public? Or is it primarily to generate startups
and regional economic development?
There are inevitably trade-offs among these
potential primary missions. Unless priorities are
explicitly set, the practices of the technology
transfer office may well diverge in time from the
best interests of the university. Surprisingly, even
in the United States, with a quarter century of
experience in university technology transfer, dis
cussions about mission and priorities rarely are
held between university management and the
technology transfer office.
. Setting the ground rules:
policies and practices

The technology transfer office—and the research
ers, companies, and investors that it deals with

on a daily basis—must all know the ground rules
before work can begin. The growth and learning
process of the office will by stymied if each new
invention or license-in-negotiation must be run
through a committee. Accordingly, policy guide
lines concerning such issues as IP ownership; the
rights, duties, and obligations of the faculty in
regard to technology transfer; sharing of revenue
and equity with inventors; use of university fa
cilities by companies; and related issues should be
clearly defined as early as possible.
New offices will find that there are many
guides available from experienced universities to
help them write their ground rules—but only the
administration and faculty of the university can
decide which rules make the most sense for their
particular institution.
. Conflicts of interest

Technology transfer inevitably brings conflicts of
interest.3 The challenge is to manage them.
For the university itself, conflicts may exist
between the goals of maximizing royalty income
and promoting publication, between commit
ments to fostering spinout companies (for ex
ample, by allowing the use of university facilities,
staff, or even students) and preserving university
resources or between strong IP ownership poli
cies or indirect cost rates and attempts to bring
in more research support from industry. One big
conflict of interest arises when university admin
istrations are called upon to make exceptions to
long-standing policies in order to bring in a big
program; the exception itself may be only mar
ginally harmful to the university, but the will
ingness to make an exception for enough money
or for a very senior person can be a dangerous
precedent.
For faculty members, conflicts of interest may
involve time commitments (often called conflict
of commitment). For example, conflicts may arise
between time spent in university teaching and re
search and time spent with the spinout company.
Faculty may also be tempted to withhold research
data from university research efforts because of
potential usefulness to the company for the data
to remain secret—or because of harm to the com
pany publishing might cause. Using students on
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company projects presents another potential con
flict of interest, as does company use of university
equipment. A conflict of interest also arises when
a researcher has to decide whether his or her new
patent belongs to the university, to him- or her
self, or to the spinout company.
Even a national government can find itself
with a conflict of interest: Does it want to sup
port basic research in its university, keeping its
scientific community at a world-class level in the
pursuit of new frontier technology for the com
ing decades, or should it shift its support to prac
tical research that is more likely to quickly usher
in new transfer technologies, new spinout com
panies, and regional economic development?
For universities and their faculty members,
written policies that are well thought out and
consistently applied can avoid many conflicts of
interest. There are, inevitably, gray areas or ap
peals for exceptions that will intensify with time
as the technology transfer program matures. The
university needs to define a clear chain of com
mand for ruling on most of these issues. Only
rare exceptions should find their way to oversight
committees; otherwise the process bogs down in
the interminable wait for committees to be as
sembled and convened. Twenty years of experi
ence suggests that exceptions to policy should be
granted very, very rarely. It is difficult in a uni
versity to make an exception for one researcher
without soon being called upon to make a simi
lar exception for the next one—and policies soon
erode and become meaningless.

• at least a minimal understanding of venture
capital, spinout formation, and smallcom
pany operation
• more than a passing familiarity with patent
law
• an understanding and sympathy with how
academia operates, academic principles,
and the career development paths and aspi
rations of students and professors
• outstanding written and verbal communi
cations skills in both formal and informal
situations
• good negotiation skills—or the innate tal
ent, intelligence, emotional control, and
“people skills” needed to learn them
• ability to deal with multiple constituencies
with conflicting objectives, most of whom
one has no authority over
• ability to deal with highly ambiguous, con
fusing situations
• both the drive and creativity to solve com
plex multidimensional problems and arrive
at win-win solutions
• drive to get the job done, or follow
through
• very high personal integrity and the wis
dom to avoid situations that get close to
the line on ethics—no matter how profit
able the situation may be to the univer
sity, a faculty member, or the licensor. A
university’s reputation is priceless. It must
not be endangered by unethical behavior—
or naiveté.

. Talent

And finally:
• the willingness to work at a university sal
ary because of the inherent satisfactions of
the technology transfer job: great technol
ogy, complex and always-interesting issues,
the satisfaction of seeing new companies
form and new technologies reach the mar
ket, and, above all, the opportunity to con
tribute to the university, its students, and
the community

Technology transfer officers need an unusual
combination of qualifications:
• an understanding of state-of-the-art re
search (though not necessarily as a practi
tioner), often over a fairly broad range of
technologies in a multidisciplinary uni
versity. (This usually requires a solid back
ground in science or engineering.)
• an understanding of the language of indus
try (Officers must be familiar with markets,
how technology is developed into products,
accounting and finance principles, and decision-making processes.)
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People who embody all of these qualifica
tions are indeed difficult to find, but one should
not underestimate the need for a very high level
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of talent. My experience in hiring and supervising
technology transfer professionals have taught me
that it is a talent-based business—some can do it
and some cannot. Those who can will perform
many times better than those who cannot. They
will also build much better relationships with re
searchers and the business community over time,
thereby enhancing the office’s effectiveness.
In choosing staff, some formal qualifica
tions in technology and business are a sine qua
non. These qualifications, unlike personal char
acteristics, can be easily be checked on a résumé.
Whether the technical background is at a bach
elor’s or Ph.D. level is relatively unimportant,
provided that the person is very bright and can
understand how research is done and how uni
versities operate. Unfortunately, until the candi
date has taken the job, it is difficult to determine
whether an individual has the creativity, interper
sonal skills, ability to deal with ambiguity, and
drive to completion that the job requires.
Staff should be given sufficient clerical and
infrastructure support and sufficient autonomy
so that they can do their jobs well. Clearly written
policies help define the limits of that autonomy.
Good training coupled with oversight supervi
sion—but not micromanagement—allows the
talented professional to learn and grow on the job

while bringing his or her talents to bear on the
tasks at hand. Plus, he or she can make decisions
and get deals done quickly, without waiting for
multiple levels of approval at each point along the
way.
They must also be given adequate clerical
support. Clerical support seems trivial: it is not.
Regrettably, technology transfer is not only a tal
ent-based business but also a paperwork-intensive
business. If good computer systems and clerical
help are not available, your very talented technol
ogy transfer professionals will spend far too much
of their time on clerical work—which is both
wasteful and demoralizing. n
liTa nelsen, Director, M.I.T. Technology Licensing Office,
Massachusetts Institute of Technology, Five Cambridge
Center, Kendall Square, Room NE25-230, Cambridge,
MA, 02142-1493, U.S.A. lita@mit.edu
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Establishing a Technology Transfer Office
TERRy A. yOUNg, Director of Research Development, University of South Dakota, U.S.A.

ABSTRACT

Technology transfer does not just happen. Transferring
knowledge and innovation from a public research organiza
tion to the private sector for commercial application and
public benefit requires a formal mechanism—a technology
transfer office (TTO)—to protect and license intellectual
property. Establishing a new TTO is no trivial matter, and
the decision to create one should be made within the con
text of a long-term plan that takes into consideration the
following questions: (1) Does “research commercializa
tion” align with the institution’s mission? (2) Do the qual
ity and quantity of research within the institution warrant
the establishment of a TTO? (3) Is the institution willing
to make a long-term commitment to required institutional
changes and to adequately invest in resources and people? If
the answer to all of these questions is yes, then it is time to
develop a clear TTO business plan. In this effort, a strong
dose of patience will help. An often-quoted rule of thumb
in professional circles suggests that even under the very best
circumstances, TTOs do not become successful for seven
to ten years after they are established. This chapter provides
practical advice for creating a proactive TTO and also of
fers historical examples from around the globe of TTO
launches.

1. THREE FuNDAMENTAl QuESTIONS
Before initiating a planning process for a new
TTO, a research organization must first address
three fundamental questions.
1.1

Does “research commercialization”
align with the mission?

If the institution’s primary mission is education,
or if its mission does not support research as a

primary institutional focus, establishing a TTO
may not be warranted. Without a strong research
focus, the organization would do well to find
alternatives for meeting the occasional need for
technology transfer services.
With more than twenty years of experi
ence, the international Association of University
Technology Managers (AUTM)1 has identified
four key reasons for public research organizations
to advance academic technology transfer:
• facilitate the commercialization of research
results for the public good
• reward, retain, and recruit high-quality
researchers
• build closer ties to industry
• generate income for further research and
education, and, thus, promote economic
growth
If these reasons make sense for your institu
tion, then it may be time to set up a TTO.
1.2 Do the quality and quantity of research
warrant the establishment of a TTO?

All technology transfer opportunities flow from
research. The 2003 AUTM Annual Licensing
Survey™ indicates that, on average, one formal
disclosure of invention was made for every US$2
million in research activity at research universities
in the United States. One U.S. patent application

Young TA. 2007. Establishing a Technology Transfer Office. In Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org.
© 2007. TA Young. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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was filed for every US$5 million in research expen
ditures, and one technology transfer or licensing
agreement was executed for every US$8.5 million
in research expenditures.2 These statistics indicate
that public research organizations review many
more innovations (disclosures of invention) than
are acted upon. Clearly, substantial research is re
quired to generate technology transfer opportuni
ties. Using the above averages, a TTO in a public
research organization with a research budget of
US$100 million might expect to record 50 disclo
sures of invention, 20 patent applications, and 11–
12 license agreements per year. An institution must
therefore determine whether its research volume is
sufficient to warrant investing in a new TTO.
The quality of research accomplished within
an institution is another critical variable. This may
be affected by an institution’s ability to recruit and
retain world-class researchers who are at the cutting
edge of science and engineering advancements.
Furthermore, pursuing basic research may generate
fewer opportunities than would applied research. If
the estimated quantity and quality of research are
below the AUTM averages cited above, the institu
tion should use alternative means to address its oc
casional need for technology transfer services.
1. Is the institution willing to make
a long-term commitment to the TTO?

Time may be the greatest predictor of success
for a TTO. In other words, the longer a TTO
operates, the better will be its cumulative results
and performance measures. This makes sense in
tuitively: as innovations, patent applications, and
license agreements are added cumulatively each
year to the institution’s portfolio, there is a greater
chance that a fraction of these will eventually gen
erate returns. Technology transfer practitioners
suggest that it typically takes five or more years
for technology that is licensed to an industry
partner to result in a marketable product. Thus,
according to these practitioners, TTOs require
seven to ten years to be successful, regardless of
how one chooses to measure success. Institutions
should expect similar experiences and be prepared
to subsidize the office for many years to come. A
commitment to support a TTO is more than a
two- or three-year financial obligation.
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1. If the institution does not meet
the four criteria, then what?

If the research organization does not, in its initial
planning processes, answer yes to the fundamen
tal questions, the following alternative models,
which have proven successful globally, can be
used:
• An external organization, which can be not
for profit or for profit, contracts with the
institution to manage the occasional disclo
sure of invention on an ad hoc basis. There
are many examples of these organizations
utilized in smaller research organizations
globally.
• An individual or small internal office
could review, filter, and rank disclosed
innovations and an external for-profit
company could implement commercial
ization of the most promising opportuni
ties. Consider the model offered by Baylor
College of Medicine Office of Technology
Administration and BCMT Technologies
in Houston, Texas, both in the United
States.3
• One TTO could serve a consortium of
several public research organizations in a
region. The Chinese Northern Technology
Exchange Market offers a good example of
this approach.4
• One office, funded by the national govern
ment or a philanthropic institution, could
serve as a TTO for several public research
institutes. Examples include the U.S.
National Institutes of Health Office of
Technology Transfer5 and the Innovation
Fund Commercialisation Office in South
Africa.6

2. All GO? DEVElOP A
TTO BuSINESS PlAN
When the four fundamental questions have been
satisfactorily explored and a TTO has been decid
ed upon, both short- and long-range plans should
be developed, much as a for-profit organization
would develop its business plan. At the very least,
an executive-summary plan addressing the essen
tial elements should be crafted.

CHAPTER .2

2.1. Developing a mission statement

First, the TTO should establish a transparent
mission statement developed in concert with its
constituents (including but not limited to its
administration, inventors, and external clients,
including potential industry partners). TTO mis
sions may focus upon three primary objectives or
combinations thereof: (1) service, (2) economic
development, or (3) income.7
2.1.1

Service mission

2.1.2

Economic development mission

2.1.

Income mission

The TTO can be considered a service unit to the
researcher, similar to an institution’s human re
sources office or a contracts and grants office. In
this model, the institution may not share with the
office a percentage of the income from successful
commercialization. Instead, it fully subsidizes the
office—just like any other internal department.
Researcher satisfaction typically is high because
all innovations receive TTO attention and work.
Institutions inspired by the goal of economic de
velopment see their primary mission in terms of
creating jobs and economic growth in the local
community—and perhaps the region, state, or
nation—through spinout companies and through
licensing to local companies. A cluster of compa
nies (centers of excellence) may be created around
a core area of technology. Significantly, a recent
Milken Institute study on the high-tech economy
concludes that “research centers and institutions are
indisputably the most important factor in incubat
ing high-tech industries.” The same study found
that 29 of the top 30 high-tech clusters in the
United States were home to a comprehensive re
search university.8
As expected, earning income from the transfer of
innovations to commercial concerns is nearly al
ways the primary focus of the operation with in
come as its main objective. Such institutions are
very selective, identifying innovations with the
highest potential and quickly abandoning others.
Not surprisingly, this can lead to overall research
er dissatisfaction; this is not usually the case with
institutions that have a strong researcher-service

orientation. Institutions with higher income lev
els from licensing are typically teaching/research
hospitals at which the possibility of an outstand
ing commercial success is more realistic.
Of course, TTOs do not focus on a single
mission but combine their vision in ways that best
satisfy their own constituents. The mission state
ment serves as a guide for implementing these
goals and sets forth the activities expected from
the new TTO. A short and simple mission state
ment might be: The TTO serves to assist research
ers in the transfer of the institution’s research results
to industry for commercial application, economic
development, and public benefit. TTOs must be
careful to avoid “mission creep.” This can occur
when TTOs are charged with managing activi
ties not directly related to commercializing in
novations (research administration, institutional
export regulation requirements, conflict of inter
est compliance, and other tasks not within its
stated mission).
Finally, while TTOs are business offices
within academic institutions, the mission state
ments of these offices increasingly announce a
societal role. As the managers of institutional
innovations for commercial use, do TTOs also
have a social responsibility to improve the well
being of humanity? The answer is a resound
ing YES! Social responsibility and a contribu
tion to societal wellbeing must fit within the
TTO’s mission. These can easily be incorpo
rated into the service mission of the office and
the institution. Indeed, public research agencies
should be in full support of the United Nations’
Millennium Development Goals.9 Furthermore,
given that the current debate opposes corporate
profit flowing to a range of important social
goals—sustainable development, the health of
the environment, the indigenous farmer, and
free or low-cost treatment of AIDS, malaria,
and other diseases in developing countries of the
world—public research institutions must make
sure to align themselves with societal welfare.
The TTO mission statement is a powerful place
to announce these aims.
There are many ways to balance these goals
with commercialization. One relatively simple
way would be to carefully craft license agreements
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to ensure that social benefits for developing coun
tries are incorporated into the grant section. For
example, a grant for an improved agricultural va
riety could require the corporate licensee to sell
seed for commercial production with royalty or
added-value premium pricing but to indigenous
farmers in developing countries at cost (or at least
without requiring them to pay royalty to the uni
versity or the added-value premium charged by
the company to commercial producers).
2.2 Policies and procedures

The system for managing innovations should
be easily understood, and transparent policies
should guide the implementation of the institu
tion’s mission statement. Defining the ownership
of intellectual property (IP) resulting from insti
tutional research must be at the very heart of the
institution’s policy. A disposition of ownership
can take many forms, but the disposition must
be defined clearly without question or ambigu
ity. In some countries, ownership is defined by
national law. In other countries, each institution
holds the prerogative to determine the ownership
of research results: the government, the inventor,
the institution, or two or more of these parties.
In the United States, for example, each research
institution is free to determine how ownership
is allocated, with the exception (under the U.S.
Patent and Trademark Law) that if the innovation
is developed with government sponsorship, own
ership lies with the institution. Regardless of the
approach the institution chooses or is compelled
to adopt, technology transfer is impossible with
out a clearly defined, written policy concerning
ownership (including written assignment of title,
when required).
Even after more than 20 years of proactive
technology transfer practice in North America
and throughout the globe, debate continues
about the best model of IP ownership for aca
demic institutions and other public research
organizations. The inventor-owned model and
the institution-owned model both have posi
tive and negative attributes, as seen in the ex
amples of success in both the United States
(institution-owned, except for the University
of Wisconsin) and Canada (inventor-owned in
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many institutions). Several countries in various
parts of the world have moved recently to the
institution-owned model (Japan, Germany, and
the United Kingdom, for example). It seems
clear that either approach can work well.
However, a disturbing trend has been seen
in the recent laws of various countries just enter
ing the technology transfer arena. In some cases,
the new national laws require that the ownership
of IP arising from sponsored research be shared
between the research sponsor and the institu
tion. Ownership is shared equally to begin with,
but later becomes negotiable (such a provision
is stated in Brazil’s new technology transfer law
of 2005). Such an arrangement is not viable, as
these countries will find as they seek to imple
ment a national technology transfer regime. In
seeking to be politically correct and not offend
the country’s corporate sector, the governments
have created a situation in which neither par
ty wins: the transfer of research results will be
blocked by the inability of either party to main
tain exclusivity. This will create an impenetrable
barrier that will prevent any corporate partner
from investing the energy and money necessary
to take an embryonic technology to market. The
result will be impasse; the transfer of technology
will by stymied.
Obviously, policies should address a multi
tude of other issues that are critical to the suc
cess of technology transfer programs, such as roy
alty-income distribution, the disclosure process,
assignment of responsibility for seeking patent
protection, researcher and institutional conflict
of interest, dispute resolution, management of li
censees’ contractual performance, management of
equity interests in spinout companies, and many
more requirements. As examples, the policies for
most research-intensive universities in the United
States and in many other countries are found on
the AUTM Web site.10
2. Financing the TTO

As previously established, an institution’s new
TTO will require subsidies for years under the
very best of circumstances. However, as different
countries have discovered, there are many differ
ent funding models.
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2..1

Australia’s models

In Australia, public research organizations, within
a relatively unregulated environment, are respon
sible for financing their own technology transfer
operations. Two primary models have emerged:
(1) the formation of an external company, and
(2) the establishment of an internal institutional
department or office. Using the company model,
the corporation generates cash flow through a va
riety of related business activities such as consult
ing, conference management, and professional
development courses. The proceeds enable the
company to support the organization’s technol
ogy transfer function. In some cases, a university
has provided seed funding to initiate the compa
ny’s operations.
In the internal-office model, the organization
provides funding directly to the TTO, which is
then considered one of the organization’s cen
tral administrative functions. The amount and
adequacy of TTO funding depends upon how
important innovation management is to the
central administration and upon the TTO’s abil
ity to demonstrate the benefits it brings to the
institution.11
2..2 India’s model

No formal legislation for organizing and financ
ing TTOs exists in India. However, during the
last ten years, most technical universities and
research institutes independently established or
ganizations to interface with industry. Such orga
nizations perform many of the technology trans
fer activities typically assigned to TTOs in other
countries. Some of these autonomous entities
were initiated with seed funding provided from
state governments or the central government. For
example, the Indian Institute of Technology in
Delhi established the Foundation for Innovation
and Technology Transfer (FITT) with a corpus
grant equivalent to US$400,000 from the Indian
Ministry of Human Resource Development. In
other cases, TTOs were formed by funds appro
priated by a governing board of the autonomous
university or research institute.
In all cases, such support is provided only for
a limited time. These organizations are expected to
attain self-sufficiency, working as “profit centers”

with a well-managed business plan. As in Australia,
income may be derived from service charges levied
for business-development activities that may have
little to do with managing the innovations from
the research institute (for example, industrial con
sultancies and other business services provided to
small and medium enterprises). In addition, each
center typically receives a percentage of the roy
alty income for the technology transfer transac
tions it manages for the public research organiza
tion.12 In April 2005, the Society for Technology
Management (STEM) was formally launched as
India’s professional technology transfer society, in
cluding institutional and individual members.13
2.. Japan’s model

In 1998, the Japanese government enacted legis
lation to create government-approved university
TTOs. Once a TTO was approved, the govern
ment would provide two-thirds of its operating
cost, up to the equivalent of US$300,000 per year
for five years; the universities or other universityrelated organizations were expected to match gov
ernment support by contributing one-third of the
funding. At the end of the five-year period, the
TTOs were expected to be able to sustain them
selves without the income streams resulting from
commercialization. However, when the Japanese
government realized that such expectations could
not be achieved, it extended its direct subsidy of
a portion of the cost of TTO operations, includ
ing the direct allocation of funds to secure pat
ent applications for selected top-tier or so called
Super TTOs. Furthermore, in 2004, Japanese law
gave all national universities independent legal
status, allowing them to participate in these TTO
initiatives.
Finally, a number of Japanese TTOs quickly
discerned that the funding from the government
was insufficient to support their operations. They
therefore created associated for-profit companies
that facilitated the creation of spinout companies.
Faculty members were asked to invest in these
companies, which commercialized university
R&D. Now, several faculty-owned companies
associated with university TTOs exist to assist
the commercialization of R&D through spinout
companies. This provides incentives for faculty
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members to disclose their inventions, because
they have a personal stake in the commercializa
tion company. The government and universities
realize, however, that this expanding strategy will
require new support systems, such as incubators
and risk capital, in order for these Japanese insti
tutions to become entrepreneurial universities.14
2.. People’s Republic of China

In 1998, inside China, only Tsinghua University
and Peking University in Beijing operated TTOs.
Today, most public research organizations in
China have a TTO. These were originally sup
ported by the Chinese government, but as China
moves from a state-planned economy to one that
is more market based, this TTO funding model
is changing. Most of the TTOs today operate as
associated private companies, solely owned by the
corresponding university and initially supported
with university funds. As private companies,
these TTOs are very active in business-develop
ment services, such as setting up incubators, as
sisting small- and medium-sized enterprises to
prepare business plans, helping develop spinout
company requirements, investing in new spinout
companies with university-based venture funds,
and so on. Most often, the TTOs negotiate for
significant equity shares in new university spinout companies and may wholly own some spinout companies. Eventually, the TTOs—often
called technomarts—are expected to become
self-sufficient from their equity holdings and the
income received from licensing and other related
business-development activities.15
2.. South Africa

South Africa has made government support for
research and innovation a key part of the national
economic-development strategy. In August 2002,
South Africa’s government approved a new na
tional R&D strategy, and discussions continue
for implementing the new strategy, including na
tional funding for technology transfer. Funding
for commercialization activities and patents is
critical, but a major capacity-building and devel
opment effort is under way. This effort will build
upon capabilities that exist in a few universities
and public research councils.
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South Africa is seeking to build strong links
between its emerging technology transfer system
and its research system. This means building
a new culture of innovation inside the research
community and ensuring that all benefits of re
search (including noncommercial and social
benefits) are understood and exploited. To sup
port this integrated approach, the Southern
African Research and Innovation Management
Association (SARIMA) was formed in 2002 to
assume the lead role in national efforts to build
capability in research and innovation. SARIMA
is supported by the government, participating
academic institutions, and U.S. and European
philanthropic donors.16
As part of its national strategy, the South
African government established its Innovation
Fund to promote technology innovation, which
has increased networking and cross-sectoral col
laboration. The fund has invested South African
Rand ZAR650 million in more than 100 proj
ects. Many of these have produced patents and
in some cases spinout companies. Most recently,
the government established the Innovation Fund
Commercialisation Office (IFCO), a centralized
office to provide one-stop support for protecting
and commercializing intellectual property rights
for all of the nation’s public research organiza
tions. IFCO complements existing technology
transfer offices in South African public research
organizations.17
2.. United Kingdom

Shortly after the 1998 report White Paper on
the United Kingdom’s Competitiveness, issued
by the government of the United Kingdom,
many policy initiatives and government funding
streams were established to stimulate cooperation
between the researchers at universities and the
country’s industrial entrepreneurs. This coopera
tion significantly changed the way universities in
the United Kingdom organize their technology
transfer activities. Several prominent universi
ties created separate companies to commercialize
IP, especially innovations that were thought to
have potential to serve as foundations for spinout
companies (university companies or UNICOs18).
Nonetheless, the majority of universities also have
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internal TTOs that collaborate closely with the
sponsored-research office and with the UNICOs
to develop industry relationships. The growth
and development of TTOs have been stimulated
more recently by direct government funding to
universities for this third stream activity via the
Higher Education Innovation Fund in England
and Wales (HEIF)19 and the Scottish Executive
Expertise, Knowledge, and Innovation Transfer
Programme (SEEKIT).20
Initially, HEIF financial support was awarded
to institutions through competitive solicitation.
Today, the government distributes HEIF funds
directly to universities through a formula funding
process that is based upon numerous criteria, in
cluding but not limited to institutional research
capacity (quantity and quality) and TTO perfor
mance measures.21
2.. Russian Federation

A major initiative began in 2002 to establish
TTOs in leading universities in the Russian
Federation. This was led by the U.S. Civilian
Research and Development Foundation (CRDF)
of Arlington, Virginia, in cooperation with the
Russian Ministry of Education. The 19 universi
ties participating in the so-called Basic Research in
Higher Education (BRHE) program were identi
fied for R&D development and technology trans
fer focus. Funding was provided primarily by the
John D. and Catherine T. MacArthur Foundation
through CRDF and the Russian Federation
Ministry of Education. In 2003, CRDF and
the Ministry held a joint competition in which
BRHE universities submitted proposals to estab
lish TTOs with dedicated funding. Four univer
sities were selected by CRDF to receive funding
for TTO establishment, which provides a good
example of financing TTOs through a thirdparty philanthropic source. The awards ranged
from US$75,000 to US$150,000 and were paid
out over three years. Most recently, the U.S.
Department of Commerce and the Russian
Ministry of Education and Science executed a
bilateral agreement that included establishing
the U.S.-Russian Innovation Council on High
Technologies. The first meeting of the council was
convened in Moscow in June 2005. One of the

four focused working groups established by the
council will address the role of universities and re
search organizations in the process of innovations
and commercialization. This will include con
sidering how to establish and finance TTO op
erations in the Russian Federation. Finally, most
research in the Russian Federation is conducted
by the research centers of the Russian Academy
of Science. Many of these centers have extensive
technology transfer operations funded internally
and directly by government allocations made to
research centers at the academy.22
2.. The United States

No government funding for TTOs is provided to
universities inside the United States, and there are
no national universities. However, the Bayh-Dole
Act of 1980, enacted as PL 96-817 and codified in
the U.S. Code of Federal Regulations23 provides
a legal basis for TTO funding. The act states that
income recorded from commercializing government-funded-research results can be utilized for
only three purposes: (1) to fund the administra
tion of the technology transfer function (TTO),
(2) to provide a share of income to the inventor as
an incentive to participate in technology transfer,
and (3) to support education and further R&D
at the institution.
The act does not specify the percentages of
income to be allocated for these three purposes.
Universities are free to determine how to allocate
commercialization income as they see fit. Most
institutions have set aside a portion of the income
stream to fund the TTO: allocations for TTO op
erations usually range from 10% to 25%. Typically,
after allocating a portion of commercialization
income to support the TTO, the university di
rectly subsidizes the TTO from internal sources
during the first years of its operation. Then, as
income is realized from license agreements, the
subsidy required from the university for the TTO
operations is reduced over time. Eventually, the
institution expects that the income stream gen
erated by the TTO will eventually eliminate the
need for direct university subsidy. As mentioned
above, several years are required for a TTO to be
come entirely self-supporting from the allocated
income. In a few rare cases, a TTO has become
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self-sufficient early in its growth from a successful
project that immediately generated a large stream
of royalty income. Finally, it should be men
tioned that other public research organizations
in the United States (such as federal laboratories)
are funded directly through a set-aside of the an
nual appropriation provided to departments of
the executive branch of government, such as the
U.S. departments of defense, energy, and com
merce (see Federal Laboratory Consortium for
Technology Transfer24).
2..10 Assessing the options

The previous examples demonstrate how TTO
funding models vary around the globe. Each
model has developed to fit the cultural, political,
and economic conditions of the corresponding
country. Two themes are found in most interna
tional models:
1. The TTO typically is allocated a percentage
of the income stream from the commercial
ization of innovations.
2. The TTO is expected to eventually become
self-supporting from this allocation of in
come and perhaps other related incomegenerating services.
Despite a new axiom (discussed in sec
tion 2.5), many countries or regions may have
no choice but to establish a regional or interinstitutional model, for the reasons presented,
with regard to the costs of establishing a TTO
and the quantity and quality of an institution’s
research results. The greater the distance from
the regional office to the institutions the office
serves, however, the greater are the challenges
for identifying research results with commercial
potential, protecting such results, and finding
corporate partners for commercialization. Here
are a few recommendations that, when followed,
can diminish the negative impact of physical
distance:
• Within each institution served by a regional
office, an individual must be identified to act
as the institution’s liaison with the regional
TTO. (This individual would have other re
sponsibilities as well.) Having a specific point
of contact is necessary for coordinating even
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the simplest administrative tasks. Ideally,
this individual should not be a rector, vice
president, provost, or dean, but rather a sec
ond-tier administrator who reports to such
institutional authorities.
• The best communication infrastructure
possible must be in place between the re
gional TTO and the institutions it serves,
including, but not limited to, video-confer
encing capabilities when possible.
• Key staff of the regional TTO must make
regular, frequent visits to each of the insti
tutions it serves in order to have adequate
face-to-face contact.
• Transparency in the operations of the re
gional TTO is essential. Transparency re
quires: (1) sharing costs between served
institutions on a negotiated and equitable
basis (if the regional office is not fully gov
ernment supported), and (2) equal treat
ment and consideration toward all in
stitutions served by the TTO (that is, no
favoritism shown to any one institution).
For 13 years I directed a TTO that served
ten academic institutions within the Texas
A&M University system. At one time during
those years, the TTO sought to serve smaller
Texas universities outside the A&M system.
The greatest challenge I found in seeking to
manage such a broad program was that despite
all efforts on the part of the TTO against it,
favoritism was perceived by the institutions
served. Such perceptions are likely unavoidable
and simply must be managed. Once one of the
served institutions records a significant success,
the other institutions want to know and under
stand why they have not achieved, or are not
achieving, similar success. Individuals who per
ceive that their institutions have been slighted
will frequently blame the “failure” on the TTO
and its staff. Over the years, I spent many hours
addressing this issue in high-level meetings with
institutional officers and system-level officials,
even though the TTO office and staff sought
to be impartial. Thus, a regional TTO must be
prepared to address this critical issue, or the col
lective approach is likely to fail.
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2. Staffing the TTO

Staffing a new TTO is a major challenge. Engaging
the right individual or individuals to operate the
office often is the factor that determines failure or
success. In the United States, the number of TTOs
began to increase in the 1980s, and selected to di
rect the new TTOs were individuals from various
backgrounds including high-level administrators,
staff from other departments (contracts and grants
staff, for example), clerical staff, scientists, attor
neys, businesspeople, and so on. Significant de
bate went on in the 1980s and 1990s as to which
combination of skills was most desirable for direc
tors and licensing associates to possess: scientific
skills, legal skills, or business skills? At the same
time, many offices evolved from simple one- or
two-person operations to complex operations
with many different positions to address specific
job tasks, such as general administrative manage
ment, clerical support, accounting support, para
legal services, and project management (evalua
tion, marketing, licensing, and so forth).
For the university contemplating a new of
fice, two would be the fewest number of positions
to start with:
• a director/licensing associate. In an ideal
world, a person charged with setting-up a
new office should have significant business
experience (marketing, management, and
business development), combined with a
science or engineering education. Generally,
neither scientists nor attorneys have the
business acumen necessary to establish, or
ganize, and manage a TTO. The director/
licensing associate should have excellent
communication skills to effectively market
innovations and to work successfully with
both internal constituents (researchers and
administration) and external constituents
(potential corporate licensees).
Unless the new TTO recruits an expe
rienced technology transfer professional,
the new director/licensing associate should
be trained before operations begin. There
are many opportunities for workshops
and other training events internation
ally, through such organizations as AUTM
and the Licensing Executives Society

International.25 Additionally, internships
are available in numerous countries, for
instance, in the United States, the Special
American Business Internship Program
(SABIT) is offered by the Department of
Commerce.26 AUTM offers scholarships
for training, such as the Howard Bremer
Scholarship and the Developing Economies
Scholarships (five awards). Each of these
scholarships is offered annually through a
competitive solicitation process.
• clerical support. TTO operations require
significant clerical and administrative sup
port. TTO activities generate tremendous
volumes of paper in the form of patent ap
plication drafts, license agreements, project
summaries, and marketing materials, as
well as daily correspondence with attor
neys, potential licensees, and researchers.
Project files and docketing systems must be
prepared to manage the progress of ongo
ing work on each innovation, which not
only requires clerical support but also ap
propriate computer and electronic database
resources. The telephone rings constantly
with calls from inventors and potential
corporate partners. Additionally, Web
sites must be created and maintained, and
incoming e-mails can be overwhelming.
Excellent clerical/administrative assistance
for the director is essential when establish
ing a new TTO.
When helping countries and institutions
to establish TTOs, I have frequently heard this
question: “Should we hire an in-house attorney
to file patent applications for the institution?”
Generally, in-house counsel retained for the
drafting and filing of patent applications is not
recommended for the following reasons:
• By and large, the breadth of an institution’s
research is too wide to be within the techni
cal expertise and knowledge of any one pat
ent attorney. Furthermore, the cost of hiring
several attorneys with the relevant technical
skills to address this breadth is not cost ef
fective. Exceptions to these conclusions
may be Centers of the Consultative Group
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•

•

•

•

on International Agricultural Research
(CGIAR) or similarly focused research in
stitutions with narrower institutional re
search results.
The claims of a patent application form
the basis for products and companies.
Especially in human-health research, tens
and even hundreds of millions of dollars
are spent to bring an embryonic technol
ogy to market. Such investments depend
upon and are protected by the strength and
enforceability of the patent rights to the
subject technology. An institution would
be extremely shortsighted to cut its pat
ent application costs by using an in-house
attorney made to be responsible for too
many fields of technology. Given the high
stakes, it is far better to secure the best pos
sible patent counsel available to draft the
strongest claims possible for the subject
invention.
Corporate licensees prefer to use the best
counsel available to back their investments,
and they may not have full confidence in
the capabilities of an in-house attorney.
In today’s litigious world, use of outside
counsel creates a third-party buffer, an
entity that must take responsibility for
conducting thorough prior art claims,
meeting filing deadlines, drafting the best
claims possible, and managing the patent
prosecution process from start to finish in
the most professional manner. If problems
arise along the way, as they often do, the
institution is best served by having the
attorney’s firm, and not the institution, be
responsible for all of the constituents: the
inventor, the institution, and the licensee.
It is not advisable, when things go wrong,
for the university to be in the position of
defending the patent prosecution with inhouse counsel.
Finally, many institutions have legal coun
sel in an office of the general counsel (or simi
lar name) that can offer assistance to the
TTO, from time to time, for contractual
questions, contract enforcement, and other
legal issues.
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Many TTOs in the United States—includ
ing the TTO of the Texas A&M University system—have hired an in-house paralegal specialist,
rather than in-house counsel, to manage the in
terface between the institution and its patent at
torneys engaged under contract. The paralegal is
responsible for ensuring that all documents are
properly executed and filed with the attorney
firm, for maintaining “suspense files” or tickler
files to provide a backup system to ensure that
no filing deadlines are missed at domestic and in
ternational patent offices, for filing copyright ap
plications for software and other works on behalf
of the institution and its faculty, and for main
taining a relational database of all official project
documentation.
2. Organizing the TTO

During the initial growth of the technology trans
fer industry in the United States in the 1980s and
1990s, TTOs were located in a variety of admin
istrative units within public research organiza
tions, including (1) offices of general counsel, (2)
business administration offices, (3) offices of the
vice president for research, and (4) contracts and
grants offices. Over time, however, TTOs typical
ly were placed within the research administrative
unit of the institution, which usually reports to
the vice president for research. In many cases, an
individual serves as the organization’s officer for
research and technology transfer, combining the
functions within one administrative unit.
Additionally, as TTO offices grew in the
United States and other industrialized countries,
the offices diversified to create individual operat
ing divisions to manage focused tasks:
• general administrative office management
• clerical support
• project management services through a li
censing associate (responsible for evaluat
ing inventions, marketing, coordinating
industry relations, and negotiating license
agreements)
• accounting services (responsible for man
aging general fiscal operations, as well as
accounts receivable from licensees, and accounts payable to consultants, patent attor
ney firms, and other service agents)
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• paralegal services (responsible for manag
ing the volumes of correspondence and
carrying out discussions with patent attor
ney firms, executing and notarizing legal
documents, and docketing critical dates to
ensure filing deadlines are met)
• marketing/public relations (responsible for
managing Web sites and producing bro
chures, press releases, and other marketing
materials, as well as organizing frequent
promotional events for researchers and
industry)
More entrepreneurial offices may even create
divisions to establish new spinout ventures, in
cubators, university venture funds, and the like.
Obviously, new TTOs may utilize existing units
outside the office to manage some of these ac
tivities—such as working with a university com
munications office to produce marketing materi
als—until such time as the growth of the office
warrants a dedicated person inside the TTO.
As has been suggested, TTOs have taken vari
ous organizational forms, in addition to the tradi
tional stand-alone unit or department within the
public research organization. These include (1)
an external company owned by or closely affili
ated with the institution to manage its technol
ogy transfer activities, (2) a service or consulting
contract with a third-party company to manage
occasional innovations disclosed by researchers,
(3) one office serving multiple institutions in a
region under collaboration agreements, and (4) a
government agency serving as a TTO for univer
sities and other research organizations in a region,
state, or nation.
How to choose? This chapter suggests a new
“TTO axiom” to help guide planners toward the
most effective organizational form: The closer the
TTO is physically to the scientists and researchers it
serves, the more effective it will be. The reverse is
also true: TTO effectiveness diminishes the further
it moves physically from its customer base. This latter
holds true even in our age of e-mail, instant text
messaging, and other video, voice, and digital com
munication techniques. None of these techniques
can replace frequent face-to-face communication
needed between the TTO staff and its inventors,

or the ability to call, on short notice, meetings be
tween project stakeholders—inventors, TTO staff,
academic administrators, potential licensees, and so
forth. At times potential corporate partners arrive
at the TTO with little or no advance notice, and
getting the inventor to join the group for a meet
ing, lunch, or dinner obviously is not possible if
the individual is in a faraway city. Moreover, simple
administrative and logistical requirements in man
aging innovation suggest that physical proximity
is important. Consider the example of an inventor
receiving a call from the attorney-of-record on a
patent application saying that the inventor’s signa
ture is needed on an affidavit before the end of the
day. Such a situation could only be addressed if the
TTO were on-site.

3. OPERATIONS
The degree to which TTOs participate broadly
in research, technology transfer, and industry
relations varies widely from institution to insti
tution and from country to country. The degree
of participation depends upon many factors, the
most important being the entrepreneurial culture
of the institution and of the region or nation.
Institutional culture is determined most often by
the attitude and degree of support from the presi
dent or chancellor of the institution. Some entre
preneurial chief executive officers have expanded
their initial TTO operations to include activities
in support of their industry partners. This can
create closer connections to the corporate sec
tor, such as the development of spinout-company
business plans by a university’s college of business
administration; the creation of university-based
technology business incubators, and/or research
and science parks; organizational venture funds,
and so on. Constituents of a new TTO, however,
expect the following minimal activities:
• Assist faculty and researchers in identifying
research results that have commercial value
and document the discoveries through a
disclosure process. The disclosure-of-inven
tion form should be simple and make it easy
for the inventor to document the discov
ery; more detailed information can be ob
tained through interviews and subsequent
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interactions with the inventor. The com
plexity of the disclosure form should never
be a deterrent to faculty participation in the
technology transfer process.
• Evaluate commercial potential of disclosed
innovations. A TTO exists to find commercial applications for technology and
partners to realize the commercial poten
tial, not to judge the value of the science.
Such evaluations may be the most difficult
of all tasks for a TTO. There are many ap
proaches to invention evaluation.27 The
evaluation process lays the foundation for
future decisions about IP protection and
marketing.
• Determine whether or not to protect IP
rights in the innovation; secure funding
for filing patent, trademark, or copyright
applications; and manage the protection
process. The challenge of securing fund
ing for protection of intellectual property
internationally—especially when seeking
protection in highly industrialized coun
tries where the primary markets for the ex
pected products lie—is often overwhelm
ing and perhaps even impossible in many
developing economies because of the tre
mendous expense. Yet, there may be very
small or nonexistent commercial markets
for the innovation in the country of origin,
which can present a serious dilemma. The
only solution in many cases is to first secure
protection in the country of origin, thereby
“buying time” under the requirements of
the Patent Cooperation Treaty (PCT)28 to
find a corporate partner to pay the patent
costs internationally as a business expense
in the license agreement.
• Conduct market research to identify po
tential industry partners, and then market
the innovations. Research has shown that
in the United States, the primary source
for identification of licensees is the inven
tor. In industrialized countries, inventors
typically are familiar with the market
place29 in their area of scientific expertise;
they may even know their counterparts in
industry (potential licensees) on a personal
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basis through their professional network
ing activities.
• Once one or more industry partners are
identified for an innovation, negotiate
legal contracts (license agreements) with
these industry partners to transfer IP
rights in the innovation in exchange for
royalties or other consideration. The goal
is to negotiate a fair arrangement that facili
tates and assists the commercial partner in
successfully developing and marketing the
product, rather than simply seeking to ne
gotiate the absolute highest fees and royal
ties in the agreement. Developing industry
partnerships can lead to many unexpected
benefits, such as sponsored research, stu
dent employment opportunities, consult
ing opportunities, and even philanthropic
donations to the institution.
• Maintain and manage administrative func
tions in support of the primary functions
of IP protection and technology transfer.
These functions can include accounting,
royalty distributions, licensee performance
management, and patent application
management.
• If the TTO decides not to pursue IP pro
tection and commercialization of an in
novation, implement a process to ensure
that others have an opportunity to pursue
protection and commercialization, if they
chose to do so. The “others” will most often
be inventors.

4. ExEMPlARy TTOS AND CONCluSION
In 2000, Dr. Louis Tornatsky conducted a study
for the National Governors Association in the
United States to identify the common practices
of the most exemplary TTOs in the country. The
study highlighted seven characteristics that were
common to most exemplary offices:
1. A clearly stated TTO mission
2. Transparent TTO policies and procedures
3. Entrepreneurial staffing and an entrepre
neurial environment
4. Customer-friendly relations with both inter
nal and external constituents by TTO staff
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5. A highly supportive university administra
tion and community (local, regional, and
national)
6. Strong TTO links to potential industry
partners
7. TTO access to risk, or venture, capital30
TTOs exist in all shapes and sizes around the
world, ranging from a part-time individual at a
small research organization, to offices with several
hundred professionals (such as the University of
California system), to a contracted third-party or
ganization that manages an occasional innovation
with commercial potential. Furthermore, sources
of TTO funding, the organizational structure of
the office, the scope of activities, and many other
operational factors vary from office to office and
from country to country.
The most compelling forces that determine a
TTO’s characteristics and performance have been
a primary focus of this chapter: the volume of re
search activity within the institution and the qual
ity of the research results. Research is the source
from which all innovations and opportunities for
TTO management originate. Public research or
ganizations contemplating the creation of a TTO
should always first consider whether the research
quantity and quality of their institutions justify
the endeavor. n
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How to Set Up a Technology Transfer Office:
Experiences from Europe
ALISON F. CAMPBELL, Managing Director, KCL Enterprises Ltd., U.K.

ABSTRACT

Technology transfer has an important role to play in the
today’s world, where access to know-how and knowledge
are valuable economic commodities. A technology trans
fer office (TTO) can be set up in many different ways.
The TTO should be tightly aligned with its supporting
institution’s missions and goals. Available external re
sources will affect the TTO’s strategy and its operational
structures, so it is important to consider the TTO’s exter
nal environment. Income generation is typically one of
the main objectives for the TTO, but technology transfer
is valuable also because of its capacity to facilitate innova
tion and broker the exchange of knowledge for society’s
benefit. This chapter discusses the key elements involved
in building a TTO—from structure and staffing to ex
ternal engagement—and how to lay the foundations for
success. A number of European models and trends are
described to provide greater context.

1. INTRODuCTION
There is no “right” way to set up a technology transfer
office (TTO), but success does require considering
some key issues. This chapter discusses how to estab
lish and run a TTO, and, drawing on experiences
from a number of such offices, the chapter provides
case studies to illuminate these issues. Emerging
trends in funding TTOs are also discussed.
2. FOuNDATIONS
Any technology transfer office should be aligned
with and supported by the institution it serves.

The TTO’s mission should be consistent with the
institutional mission, and the TTO’s approach
and activities should support and add value to the
institution. The TTO and the institution should
agree upon what adds value, because financial re
turns alone are an insufficient measure of value
for universities viewing their commercial activities
strategically and contextually. Long-term returns,
such as sustained partnerships, cultural change,
job creation, and societal well-being should be
part of the value provided by TTOs. These long
term returns supplement shorter-term, more tan
gible returns such as income, access to resources
and expertise, and program delivery. This point
has been emphasized by the U.S. technology
transfer association, the Association of University
Technology Managers (AUTM) and the U.K.
association for technology transfer (UNICO1),
which have disseminated data and case studies of
how technology and knowledge transfer can ben
efit society.2
Deciding whether the TTO should un
dertake pure commercialization or broader
knowledge transfer is important for developing
an operational strategy. In a knowledge-based
economy, access to know-how and use of knowl
edge (outside of the environment in which the
knowledge was gained) is a valuable commod
ity.3 The U.K. Research Councils define such
knowledge transfer as:
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[T]he two-way flow of people and ideas be
tween the research environment and wider economy,
[which] thereby contribute[s] to national prosperity,
the quality of life of U.K. citizens, and cultural en
richment of our society. Knowledge Transfer encom
passes the systems and processes by which knowledge,
expertise and skilled people transfer between the
research environment (universities, centers and in
stitutes) and its user communities in industry, com
merce, public and service sectors.4
While the public good is always a part of a
TTO’s agenda, some have made income genera
tion the prime objective. Others base their agenda
on public benefit or economic development. De
ciding upon the TTO’s objectives will determine
how the office should be configured, resourced,
and operated. (Examples are presented at the end
of this chapter.)
The senior management of the host insti
tution must actively support establishing these
foundations. To do so, managers will need to
understand the relevance of technology transfer
to the institution. Understanding the TTO life
cycle is essential for helping the TTO office to
encourage academics to participate in technology
transfer and will help maintain support when re
turns seem slow or when a partnering decision
appears unappealing on the surface. Such an un
derstanding involves vision from both partners
in the transfer and an ongoing dialogue between
principals. In particular, it should be clear to all
parties that, while technology transfer may be an
extra income stream, it should not be relied upon
to generate significant revenue for institutional
planning. At Isis Innovation (Oxford University),
perhaps one of the best-known European exam
ples of technology transfer success, the gross in
come from technology transfer is about 0.005%
of annual turnover. This is based upon annual
turnover for the University of UK£530 million,
gross income from technology transfer activity of
UK£2.7 million, and net income from technol
ogy transfer (after the costs of undertaking the
business), UK£260,000 (2005–2006 figures).
National and regional policies and objectives
also should serve as a framework for shaping the
office and directing priorities. When TTOs benefit
0 | HANDBOOK OF BEST PRACTICES

from funding for local development, for example,
they have been able to secure partnerships and
fund specific activities of interest to the local re
gion. In the Aachen region of Germany, for ex
ample, regional imperatives have engineered local
economic development to ensure that an exhaust
ed traditional coal mining region transitions into
a high-technology center for innovation. Special
initiatives and funding have encouraged the de
velopment of new businesses within the region.
The scientific institute in Julich (Fachhochschule
Aachen5) has been central to this redevelopment,
having been built up to offer a variety of support
ing technology-transfer services, including con
sultancy, provision of facilities, and the brokering
of business advice.
An early step in setting up the TTO—and
an essential ongoing activity—is identifying and
fostering relationships with stakeholders. This
group will include academics, representatives of
the business and user community, and regional
and governmental offices. The most important
group at the outset is the internal community.
Successful and meaningful technology transfer is
demand driven, so it is important to understand
the external partner’s needs. If the internal aca
demic community does not support the technol
ogy transfer process, there will be scope for failure
at various stages of the process. Although time
consuming for the technology transfer manager,
he or she should be seen in the academic depart
ments being served. This visibility will accelerate
culture change and help integrate the TTO into
the fabric of the university. The institutional mes
sage must be one of support and encouragement
for engaging in technology transfer. TTO staff
must work with academics at all levels to educate
them in entrepreneurial behaviors at the macro
and micro scales. This work could include train
ing in how to engage with business and respond
to its needs, how to act as consultants, and how
to identify partnership or licensing opportunities.
All academics will need to be aware of the intel
lectual property (IP) rights process, including
disclosure, confidentiality, types of protection,
and so forth. Such awareness training may be de
livered by the TTO itself or in partnership with
external providers. For example, IP specialists,
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lawyers, and research sponsors are often willing
to provide limited training. In the United King
dom, government funding of universities consor
tia has established a number of enterprise centers
for such training.
Incentive schemes for academic staff need to
be carefully considered; policies should be imple
mented early. Experience has shown that acknowl
edging an employee’s participation in technology
transfer and sharing some of the financial reward
are clear incentives to encouraging engagement in
technology transfer. Siegel and colleagues6 high
light the importance of faculty reward systems—
along with removing cultural barriers and staffing
the TTO, the reward system is one of the three
key factors for success in technology transfer.

3. STRuCTuRING THE TECHNOlOGy
TRANSFER OFFICE
.1 Personnel

The core element for successful technology trans
fer is people. Technology transfer is a “contact
sport,” so managers must have the ability to en
gage with people at all levels and across national
boundaries. Managers need to understand the
potential of their offerings and be highly flexible.
Technology transfer managers need to be capable
of engaging equally well with academics and busi
ness; they must be both inward and outward fac
ing. Business skills are important but hiring an
MBA graduate is not essential. The office should
be led, however, by an individual who under
stands the details of running a business. Staff with
work experience in the relevant business/user sec
tor who can appreciate its requirements and tailor
opportunities accordingly are also very useful. To
build up an understanding of the potential for
new opportunities, the technology transfer man
ager needs to win the confidence of academics,
which is why it is helpful for the TTO to be em
bedded in the institution and for the office to be
perceived as part of the institution. Staff should
be able to spend time with academics to better
understand what they can offer to the business
and user community—as well as how these op
portunities can best be developed for mutual gain

by the institution and the community. Similarly,
staff must actively engage with businesses to bet
ter understand market needs and gain agility in
matching proposals with the institution.
An effective TTO is a team with complemen
tary abilities. There is no one rule for the type of
background that TTO staff need; much can be
learned on the job and through specific training.
However, if the office will be brokering opportu
nities in particular technical areas, then it is wise
to recruit technical specialists. They will need to
be able to use technical language with academ
ics and customers, understand an opportunity
and its applications, research areas of interest to a
partner, and translate their ideas into an offering
that business professionals will understand. Not
all TTOs need to be large. A core viable unit at
the outset may have three staff members, two of
whom have business and technical skills and have
or can develop expertise in IP rights and commer
cialization. The third staff member would provide
administrative support. Often it is hard to resist
the seduction of employing specialist staff in pref
erence to administrative staff. However, an office
that does not have access to appropriate adminis
trative support will always be inefficient.
Specialist advice can be outsourced (for ex
ample patent and legal counsel). A growing
number of legal firms have experience with the
academic technology transfer sector, and they can
provide a service that responds to the needs of
this sector—both in terms of the type and level
of advice and in the cost of counsel. When op
tions have not been identified, a discussion with
in technology transfer networks will often reveal
a number of suitable choices. While most offices
use external legal advisors, a growing number of
TTOs now employ in-house advisors, which may
be desirable but naturally depends on whether
the volume and complexity of work make such
an appointment financially sensible.
Free business advice—which can be useful—
is abundantly available to TTOs. Peer advice, in
cluding participation in technology transfer net
works, can be invaluable. Other sources include
funders of research (for example, Wellcome Trust,
the Centre for the Management of Intellectual
Property in Health Research and Development
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(MIHR), and the Bill and Melinda Gates Foun
dation) and government and regional bodies.
Business itself is an eager ally of the academic in
stitution and the TTO. Often, experienced peo
ple will give their time to advise on specific issues
or to become part of an advisory group. Many are
delighted to be asked, and few refuse to help.
.2 Building skill sets

As technology transfer has become a recognized
profession within many countries, an inventory
of best practices has accrued. There are many
opportunities to build core skills in the team
through networking, training, and literature.
Some ways to improve the skills of the office will
be free, through personal networks and mentors,
for example. Secondments, where a member of
one organization spends time in another, and in
ternships with business and other TTOs are an
attractive way to bolster skills, gain understand
ing, and share best practices. Such arrangements
always work two ways, and both parties in the
arrangement will normally be keen to participate.
For the most part, however, specific training is
needed for a team to acquire core skills and—as
business needs and the landscape evolve—attain
new ones. In Europe, the most prominent net
uropean
opean
working forum is the Association of Eur
Science and Technology Transfer Professionals
(ASTP)7, a professional membership organiza
tion for technology transfer managers that hosts
conferences across Europe. For technology trans
fer training, Praxis (a not-for-profit organization)
offers a full range of courses that are delivered by
practitioners.8 Emphasizing experiential learning
and networking, Praxis offers training both for
new entrants and for more experienced profes
sionals. Its courses are open to international dele
gates. In the United Kingdom, UNICO has pub
lished a series titled UNICO Practical Guides in
a handy, readable format that provides in-depth
advice on the range of technology transfer activi
ties, from student IP rights to legal agreements
and company formation.9 There are also numer
ous guides available both for purchase and free of
charge. The MIHR Handbook of Best Practices for
Management of Intellectual Property in Health10 is
a good example of the latter.
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. Managing information

When setting up an office, adequate attention
must be paid to information management. It is
crucial to establish business processes at the out
set. Technology transfer is naturally a long-term
prospect, and key information on IP rights and
legal agreements must be captured, organized,
and maintained for a long time. The life of a
patent, for example, may last for up to 20 years.
Naturally, so will the license obligations. More
over, most litigation requiring access to initial
documents comes after a successful product is
on the market, often several years after patent
filing and licensing. Without adequate access
to records, patent positions may not be sustain
able and income may be lost. To develop busi
ness, project and contact information must be
captured and shared across the organization, so
a CRM (customer relationship management)
style of database is desirable. It can be purchased
off the shelf or developed internally. Each ap
proach has its own strengths and weaknesses. A
number of producers and many TTOs who have
tried different systems are happy to share their
expertise.
. Budget

An office without an appropriate budget will
struggle. As described above, technology transfer
requires a complex combination of activities and
skills. All technology transfer outcomes involve a
transaction based on hard or soft IP rights (that
is, patent or know-how). Invariably, the transac
tion will be by way of a legal agreement, which
requires legal drafting (or use of template agree
ments) and negotiation skills. The transaction will
have a financial component that must be clearly
understood, and it will be based upon IP rights
and/or access to resources that will need to be
valued and protected. This means that someone
must understand what elements can and need to
be protected. The drafting and filing of a patent
application are best done in conjunction with a
patent agent, and there is a requirement for on
going patent prosecution. All of these activities
require funding; however, some costs may be
recovered through a business deal or by passing
them onto a partner.
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. Business model

Offices tend to be departments within institu
tions or subsidiary companies. As a department,
the TTO is embedded in the institution and has
its interests clearly aligned with institutional ob
jectives. TTO staff will be on par with academic
colleagues. Running technology transfer through
a subsidiary company, however, may encour
age a positive perception of technology transfer
and demonstrate the seriousness with which it
is viewed by the institution. A subsidiary com
pany gives more operational flexibility and the
ability to structure staff remuneration packages.
Debates over TTO staff pay and incentives are
frequent, and it is increasingly common to award
performance-related pay and bonuses for meet
ing targets. This works well when the targets can
be easily defined and measured and when reward
is against outcomes rather than activities. How
ever, this reward system skews behavior in favor
of reaching those targets, so care needs to be
taken to ensure that reward systems are properly
cast to promote core business objectives. This is
another reason why the TTO should have clear
objectives that can be easily communicated to its
staff—regardless of whether they are employed
by the company or by the university. As a final
twist on the internal/external TTO, staff do not
necessarily need to be employed by the company;
they may be employed by the university (and sub
jected to the university pay and pension scheme
structure) and then seconded to the company.
Chain of command and accountability must
be clear. A departmental TTO should report to a
senior university staff member. A company will be
responsible to a board, which may be chaired by a
university senior staff member. In either case, the
TTO will be accountable to the university gov
erning body and will be expected to produce at
least annual reports of activity. For both types of
organizational structure, it will be helpful to have
a group of advisors inside and outside of the in
stitution. The advisors can bring new experience
to the organization and act as internal and exter
nal champions. Advice on the most tax-efficient
structures for establishing and running the TTO,
for example, may help to determine whether it
should be treated as a department or as a separate

business. Governance should be considered where
a company is formed and may be accomplished
by forming a board with nonexecutive directors
and/or an advisory board.
A final option is to outsource technology
transfer to an independent third party. Outsourc
ing minimizes investments and the risks for the
institution but also reduces the returns to the
institution since the partner will take the lion’s
share of them. Such models are usually predicat
ed upon income, and so the partner will likely
pursue activities directed towards high-value, income-generating opportunities rather than tech
nology transfer for the broader public good.

4. TRENDS IN TECHNOlOGy
TRANSFER OFFICES
The landscape of technology transfer activity is
changing. As Campbell11 discusses, the United
Kingdom is particularly progressive. Universities
are creating innovative partnerships and devel
oping expertise in technology transfer to secure
financial investment and build future returns.
Research funders are looking for initiatives to fill
gaps in the technology transfer process.
Sheffield University is an interesting model.
It lacked the funding needed to fulfill its tech
nology transfer ambitions, so the director of the
TTO set about developing a relationship with ex
ternal experts, an initiative that led to establishing
a separate company: BioFusion PLC (Sheffield,
U.K.).12 With a ten-year exclusive agreement with
Sheffield University to commercialize all Univer
sity-owned medical IP rights, BioFusion is run
independently of the University and its TTO. In
2005, BioFusion listed on the Alternative Invest
ment Market (AIM) of the London Stock Ex
change, raising UK£8.23 million. The University
is one of the shareholders. This funding allows the
company to manage and fund both existing and
new portfolio companies within the life sciences
area. BioFusion has made clear its intention to de
velop similar relationships within the sector. With
the increasing interest in technology transfer as an
area for external investment, academic technol
ogy transfer companies have been able to secure
funding when there is a clear income-generation
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model. The most prominent example is Imperial
Innovations of Imperial College, London. With
a solid track record in commercialization and a
robust pipeline of spinout companies, Innova
tions (and in turn Imperial College) has benefited
from private institutional investment and intends
to become a publicly listed company. Of course,
this model of external funding does not work for
all TTOs because it applies only to those organi
zations with potentially high investment returns.
This will not be the case for most technology or
knowledge transfer activities because most offices
are brokering partnership deals to bring cash to
a university for specific research rather than to
generate unencumbered income. At Imperial,
knowledge transfer and research partnership de
velopment has remained within the institution;
Innovations concentrates on the cash-generating
activities of licensing and spinouts.

5. ExAMPlES OF TECHNOlOGy TRANSFER
OFFICE MODElS
At King’s College London (KCL), technology and
knowledge transfer is managed within one orga
nization, KCL Enterprises Ltd., a wholly owned
subsidiary of the university. KCL Enterprises is
responsible for new opportunities and research
support, which bring all the external business fac
ing and research funding activities together. This
combining of functions weaves the activities of
the organization together and creates an extend
ed, integrated team. Established 12 years ago, the
initial team was a small technology transfer unit
of staff specializing in the protection and com
mercialization of college IP rights. Over time, the
research grants and contracts office of the univer
sity was incorporated into the organization. The
company has since grown to 50 people and now
encompasses business development, consultancy,
work placement, marketing, technology transfer,
spinout company incubation, and research sup
port. The mission of the organization is to lever
age the intellectual capital of the university to
generate income and benefit society. The business
development team underpins the activities of the
company; specialist functions take on the leads
appropriate to them. Eight business development
 | HANDBOOK OF BEST PRACTICES

managers specialize in different sectors and are
co-located in both Enterprises and their relevant
academic departments. Their objectives include
developing collaborative research with business
and promoting enterprise within King’s and ex
ternally. The technology transfer team focuses on
the identification, management, and exploitation
of IP. They are skilled in patent prosecution, due
diligence, and drafting and negotiating license
agreements, and are supported by a team dedi
cated to mentoring and incubating new company
spinouts from the university. The expansion of the
team has been possible through funding from the
university and from government, both of which
recognize the increasing importance of the knowl
edge economy and applied research. Particularly
active in promoting knowledge transfer, the U.K.
government has established a specific stream of
funding, the Higher Education Innovation Fund,
which is available to universities within England.
This has allowed many universities to develop
knowledge transfer capabilities and capacity. It
also allows them to take some risks in finding
mechanisms to encourage and capture new op
portunities at the institutional level.
The government has been keen to encourage
development of knowledge transfer through the
public sector research establishments within the
United Kingdom. An early leader in this sector is
Medical Research Council Technology (MRCT),
a wholly owned subsidiary of the Medical Re
search Council (MRC). This technology transfer
company grew from a team of four MRC staff in
1990 to a company that currently employs more
than 60 people and that this year saw a windfall
of over UK£140 million in income from royalty
sales. MRCT in many ways is a unique example
of technology transfer, but in other ways it points
the way for others to follow. MRCT became a
separate entity by merging with another appliedresearch activity of the MRC, thus gaining staff
and expanding its technology transfer offerings
to include applied-development laboratories. Its
expansion was enabled through a record of good
work and the vision and support of its parent insti
tution. While the amount of income it generates
is unusual, the sources of the income are typical:
a suite of related technologies and their various,
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carefully crafted exploitation. (This case still sup
ports the general notion—discussed by Scherer
and Harhoff13—that big wins in commercializa
tion come from only a few deals.) Continuing its
expansion into applied research, MRCT has de
veloped new activities to add value and speed the
uptake of academic IP. One approach has been
to create a drug discovery team that identifies
academic IP and develops licensing leads in in
dustry. U.K. funders and international initiatives
have also tried to expedite the process. For ex
ample, Cancer Research Technology (CRT) has a
drug development laboratory, and the Wellcome
Trust offers Translational Awards for developing
early-stage opportunities into more commercially
attractive offerings. International approaches
include Medicines for Malaria Ventures, which
brings public, private, and philanthropic sec
tor partners together to fund and manage the
discovery, development, and registration of new
medicines to treat and prevent malaria in diseaseendemic countries.
A push for technology transfer in the past
ten years has created more than 20 technolo
gy transfer offices across Switzerland. To build
critical mass, the two universities of Bern and
Zürich jointly own a subsidiary nonprofit tech
nology transfer company that they established
in1999: Unitechtra. With a staff of seven and
serving two other research institutes, Unitechtra
has a clear mission to contribute to the economy,
facilitate research uptake for the public good,
develop mutual beneficial close ties with indus
try, motivate and retain academic staff, and,
ultimately to increase income to the institutes.
These objectives are pursued through activities
that include the commercialization of research
results, the negotiation of research agreements,
support for the creation of new spinout compa
nies, and training and education for scientists
in the field of technology transfer. As a natural
next step in the evolution of Swiss technology
transfer, in 2003 the Swiss Technology Transfer
Association (swiTT14) was formed. A network
organization, it aims to bring together TTOs
and specialists in the field to improve the provi
sion of services and to share information and
resources. The Swiss Network for Innovation

(SNI) and the Swiss federal government provide
funding to swiTT.

6. CONCluSION
TTOs can be set up in a variety of ways, but in
all cases it is helpful to draw on external skill re
sources where possible. Possessing clarity of pur
pose and building the right foundations is es
sential for planning the operations of the TTO.
Making money will always be a consideration
when setting objectives, but technology transfer
adds value in other important ways: as a resource
to facilitate innovation for the public good and
as a way to broker the exchange of knowledge
between the business and public sectors for soci
ety’s benefit. Transferring knowledge across such
disciplines as the humanities, law, and social sci
ences is as important as transferring knowledge
and technology across the applied sciences, and
TTOs should be set up to have the flexibility
to accomplish this broader knowledge-transfer
objective. n
ALISON F. CAMPBELL, Managing Director, KCL Enterprises
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CHAPTER 6.4

How to Set Up a Technology Transfer
System in a Developing Country
caRlos feRnandeZ, Director, Strategic Studies, Foundation for Agriculture Innovation (FIA), Chile

ABSTRACT

This chapter reports the results of a recent study of the
current state of technology transfer in Chile, including
recommendations for the development of a new technol
ogy transfer system. Currently in Chile, few commercially
viable technologies are transferred from research institu
tions to the private sector. This means that many univer
sities should review their role and implement innovative
ways of contributing to society.

1. InTRoduCTIon
In emerging economies, existing R&D capabilities
tend to be highly concentrated within universi
ties and public research institutes. In Chile, about
85% of scientists are formally linked to universi
ties, and the Chilean government contributes an
estimated 80% of funds spent on R&D.
In early 2004, the Ministry of the Economy
entrusted Fundación Chile, a private, indepen
dent, nonprofit research organization located in
Santiago, with studying the technology transfer
units at Chile’s universities.1 The ministry’s aim
was to find ways to improve the mechanisms for
transferring the results of R&D performed at
Chile’s universities and research institutes to the
private sector. In order to carry out this study,
Fundación Chile assembled a team of six local
specialists and three foreign experts.2

First, Fundación Chile set out to assess the
current state of university technology transfer
in Chile. Interviews and surveys were conduct
ed at seven universities that together currently
conduct 51% of all university research proj
ects in Chile. Surveys were also conducted at
four technology transfer offices (TTOs) located
within business incubators associated with these
universities.
Second, a workshop was held involving
specialists from the Ministry of the Economy,
CORFO (Corporación de Fomento de la
Producción),3 CONICYT (Comisión Nacional de
Investigación Científica y Tecnológica),4 and the
team of experts assembled by Fundación Chile.
The first day, the workshop focused on the cur
rent condition of technology transfer at universi
ties and research institutes in Chile (see Section 2
in this chapter). The second day, the participants
discussed their experiences of technology transfer
in other countries. The participants then created
guidelines for technology transfer from Chile’s
universities and research institutes to its commer
cial sector.
The assessment of Chile’s current conditions
and the guidelines created by the workshop par
ticipants were used to develop a proposal for the
creation of a new national technology transfer
system (described in Section 3).

Fernandez C. 2007. How to Set Up a Technology Transfer System in a Developing Country. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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2. THE CuRREnT STATuS of
TECHnoLoGy TRAnSfER In CHILE
2.1 The role of universities within
the national R&D context

Traditionally, universities have fulfilled two pri
mary societal functions: educating students and
conducting research. In recent years, however,
universities have had to fulfill an additional func
tion: promoting the commercialization of the
results of their research. This expansion has re
quired changes, not only in policy and allocation
of resources, but also in academic culture itself.
In an ideal environment, many mecha
nisms link the academic and business worlds.
Researchers exchange information through semi
nars and publications, and there are informal and
formal ties between researchers in various types
of institutions. Additionally, academics work as
consultants and as company board members and
are involved in professional training, contract re
search, and the spinout and incubation of new
businesses. And, of course, universities educate
the researchers of the future.
In Chile, however, the lack of systematic
policies for technology transfer has hindered pro
ductive interaction between the academic and
business worlds. This, in turn, has led to other
challenges:
• There are few incentives for academic re
searchers to participate in technology trans
fer and commercialization.
• Academic culture does not see technology
transfer and commercialization as “legiti
mate” activities.
• The academic and business worlds have
different ideas about technology transfer:
different short- and long-term visions, dif
ferent expectations about how resources
should be used, and different priorities
when it comes to meeting shared targets.
For the past 20 years, Chile’s growth has been
sustained by industries exploiting the country’s
rich natural resources. Technology transfer during
this period mostly occurred by importing capital
and by receiving foreign investment, virtually ex
cluding the local innovation system of Chile. As
 | HANDBOOK OF BEST PRACTICES

a result, both the formation of innovative compa
nies and the development of an entrepreneurial
culture in Chile were inhibited.
In Chile, around US$480 million is spent
annually in R&D; only about one-fifth of this
money comes from private sources. Universities
carry out some 58% of ongoing R&D projects
in Chile; 4,800 specialists—or three out of ev
ery five scientists and engineers in Chile—work
on such projects. Only 6% of those working in
R&D do so in a private company.
Furthermore, no more than 13% of the na
tional budget for R&D goes toward commercial
development activities. The rest goes to basic and
applied research projects. In contrast, about 60%
of the R&D expenditure in developed countries
supports development activities, and only 40%
goes to basic and applied research.
In a recent study, Benavente5 suggests that
joint activities between universities and the pri
vate sector should receive more financing from
government and that TTOs should to be estab
lished in order to promote the commercial ap
plication of university research results.
2.2 A survey of technology transfer
units at universities in Chile

The results of the surveys conducted by Fundación
Chile of seven universities and four technology
transfer offices are summarized in the following
nine items:
1. IP-protection activities in universities. The
concept of intellectual property embodies
the right of ownership protected by law to
intangible (that is, intellectual) works or
information, or representations of informa
tion such as literary works, trademarks, lo
gos, data, and know-how. In Chile, intellec
tual property can be protected by patents,
copyrights, trademarks, industrial designs,
or rights for plant varieties. Like any other
goods or assets, intellectual property can be
bought, sold, or licensed.
The surveyed universities were asked
what specific IP protection activities (such
as signing confidentiality agreements or ap
plying for IP protections) they engaged in
each year. Most of these activities involved
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agricultural, health, and energy technolo
gies. The total number of such activities
for all eleven institutions was fewer than
100. Signing confidentiality agreements
accounted for almost half of the activities;
filing applications for patents accounted for
another quarter. The remaining quarter pri
marily involved copyright and plant-variety
registrations. Only about four confidential
ity agreements were signed per institution
per year.
2. Communications between universities and
the private sector. At 73% of the institu
tions surveyed reported that their technol
ogy transfer offices (TTOs) and/or investi
gators contacted private companies. Other
methods of contacting companies included
publications and the Internet (55%), fairs
and exhibitions (36%), and technology
brokers (27%).
3. Procedures for evaluating potential tech
nologies. Formal evaluations (those that
do not rely solely on the opinions of the
research team) are the best way for uni
versities to determine which technologies
should be transferred to private companies.
However, only one of the seven universities
surveyed claimed to have a formal proce
dure for evaluating technologies. Three of
the four TTOs associated with the incuba
tors did have such a procedure.
4. Policies regarding ownership of research
results. It is important to clearly define who
owns the rights to research results. Only
three of the seven universities surveyed had
a formal institutional policy regarding the
ownership of research results. None of the
TTOs associated with the incubators had
such a policy.
5. Policies regarding conflicts of interest.
TTOs need to have the resources to man
age potential conflicts of interest. Only two
of the eleven offices surveyed had a specific
policy regarding conflicts of interest.
6. Distribution of income generated by tech
nology transfers. On average, the universi
ties distributed revenues from technology
transfers as follows:

- 38% to the researchers
- 15% to the research units (departments)
- 18% to the central administration
- 8% to the technology transfer office
- 21% to other actors
The offices associated with incubators dis
tributed revenues as follows:
- 37% to the research units and to the
researchers
- 12% to the central administration
- 10% to its own transfer office
- 41% to other actors
7. Networks for collaboration. The surveys
reveal that institutions do not collaborate
with each other to any appreciable extent.
For example, of the universities surveyed
only half of them belong to networks with
other universities, and only two of them
are part of networks with business organi
zations. Of the offices associated with incu
bators, only one participates in a network
of research centers.
8. The influence of technology transfer on
university researchers’ careers. Four of the
seven universities stated that technology
transfer has no influence on their research
ers’ academic careers. Two of the seven
noted that successful technology transfer
may raise researchers’ salaries, and one of
the seven reported that it influences pro
motion decisions. The technology trans
fer experience of potential candidates for
academic jobs has no influence on hiring
at any of the seven universities surveyed.
Therefore, it is not surprising that 78% of
the university investigators participating in
Fondef projects consider this fund only as
a source of financing for their own projects
and Institutions.6
9. Spinouts and startups. Over the last 19
years, the 11 surveyed technology transfer
units have created a total of 28 compa
nies using the results of their institutions’
R&D. Of these new companies, two-thirds
are spinouts and the rest are start-ups.
Over 13 years, from 1991 to 2003,
Fondef. has financed a total of 159 R&D
projects:
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-

Agriculture
37 projects
Fisheries and Aquaculture 35 projects
Forestry
34 projects
Mining
17 projects
Education
13 projects
Other
23 projects
A total of US$126 million was invested
in these projects, of which only 28% was
contributed, in money or in kind, by com
panies or other institutions interested in
using the technologies produced by these
projects.
These 159 projects led to the creation
of 33 companies, 13 business units, and
12 new lines of business in existing com
panies. Two-thirds of these institutions are
still operating today. By the end of 2002,
these projects had generated an accumu
lated sales total of US$8.9 million.
These results show that technologies de
veloped by Chilean universities lead to very
few start-ups or spinouts.

2. The current state of university
technology transfer in Chile

The existence of TTOs in Chilean universities is a
recent phenomenon. The capabilities of these offic
es are still limited. Generally, they have small staffs.
Many have yet to establish essential policies regard
ing the formal disclosure and evaluation of technol
ogies, the ownership of intellectual property, and
conflicts of interest. Most have little experience in
such areas as technology management, IP protec
tion, and commercial agreement negotiation.
Academics are not encouraged to engage in or
initiate technology transfer to the productive sec
tor. Moreover, very few university projects result in
commercially viable innovations, so few technolo
gies leave the universities, and few spinouts or start
ups are created. Therefore, many universities see
little reason to set up technology transfer offices.

. A pRopoSAL foR A nATIonAL
SySTEM of TToS
The participants in the cross-disciplinary work
shop proposed the creation of an institutional
consortium, the members of which would share a
0 | HANDBOOK OF BEST PRACTICES

central TTO. Each institution in the consortium
would also have a local TTO to assist in relation
ships between researchers and private companies,
as well as with technology marketing. The consor
tium would represent the interests of the member
institutions and operate with the double aim of
improving Chile’s technological capabilities and
developing a national entrepreneurial culture.
The consortium would be a private, nonprof
it organization, governed by a board of directors
made up of representatives from the member in
stitutions. These offices would be established us
ing public funds; once they are operational, they
would support themselves with fees they earn for
the services they provide.
.1 A business model for the TTO system

The central TTO would need to have the capacity
to manage 20 to 30 technology transfer projects
annually. The TTO system would be involved in
these projects from gestation to final commer
cialization. The system would also be required
to participate in the analysis of about a dozen
completed Fondef and FDI projects, in order to
identify opportunities for the commercialization
of the technologies they have developed.
The central TTO system would require an an
nual budget of approximately US$650,000. The
member institutions would make annual con
tributions based on the volume of research that
each has conducted. The TTO would also charge
member institutions an ex ante fee for each proj
ect based on its size and complexity. Furthermore,
the TTO system would receive fees from compa
nies that it assists, as well as from other users of
its professional services. The institutions belong
ing to the consortium also would be expected to
pay annual dues for the right to participate in
the consortium. During the system’s first three to
five years of operation, any additional financing
needed would come from public sources; how
ever, this public subsidy would be granted only if
the TTO system continued to receive positive an
nual performance evaluations. The consortium’s
board of directors would be responsible for secur
ing outside financing for the TTO system.
The TTO system’s financial manage
ment would be based on annual accounting (an
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examination of the system’s total income and ex
penses) and separate accounting (an examination of
the income and expenses relating to each individ
ual project). The following formula for the distri
bution of royalties is recommended: the university
distributes one third of net income to the inventor
and another third to the inventor’s department or
research unit; this formula is aligned with inter
national practices. The remaining third typically
goes to the university’s general fund, but may go to
other specified funds, including the TTO system’s
own fund. Royalties would be distributed after the
end of each fiscal year. General expenses such as
salaries, rent, office equipment, and general travel
would be paid for by the TTO system’s fund. Any
project-specific expenses (such as the legal fees in
volved in a patent prosecution) would be paid for
by royalties that accrue from the licensing of the
corresponding technology. The board of directors
would review this distribution of funds annually
and modify it as necessary.
.2 Central and Local TTOs
.2.1

Contracts between central and local TTOs

The central TTO would supervise and work to
gether with each of the local TTOs to protect
and market the technologies resulting from R&D
conducted at member universities and insti
tutes. The contracts between the central and lo
cal TTOs would need to include the following
information:
• Policies outlining:
- the legal supervision of the consortium
by consortium members
- the ownership of intellectual property
- the distribution of income from the de
velopment of intellectual property
- conflict of interest resolution and what
obligations each party has to the others
• terms and conditions for the formal eval
uation of inventions with commercial
potential
• plans for marketing and licensing the
inventions, both domestically and
internationally
• plans for a follow-up system to track the
success of inventions

• plans to disseminate and communicate the
results of the TTO system
• plans to establish national and internation
al strategic alliances in technology develop
ment and commercialization
.2.2 Function of the central and local TTOs

The main functions of the central TTO would be
to:
• evaluate the results of R&D projects ex
pected to have commercial potential
• apply for patents and other forms of IP
protection
• market technologies
• provide expertise and technical assistance
to the local TTOs
• establish national and international strate
gic alliances in areas important for success
ful technology transfer
The main functions of the local TTOs would
be to:
• facilitate interactions between their in
stitutions and industry (duties would in
clude developing research contracts, iden
tifying collaborative research projects, and
consulting)
• educate academic investigators about op
portunities and techniques for marketing
research results
• stay abreast of new technologies developed
at their institutions and identify marketing
opportunities for these technologies
• serve as a contact point between the central
TTO and the institution
• help researchers gain funding for R&D
projects
As the local TTO gains experience and be
comes more effective, it may take on other func
tions, such as offering its services to other institu
tions (for example, local business incubators) that
are not part of the national consortium.
. Human resources and infrastructure

A fully functioning TTO system would have the
following personnel needs, some of which could
be fulfilled by outsourcing, either for the long
HANDBOOK OF BEST PRACTICES | 1
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term (as would be appropriate for the office’s legal
experts) or on a short-term basis (as would be ap
propriate for consultants hired to conduct market
studies, for example).
..1

Central TTO personnel

The central TTO would need to employ skilled
individuals to fill key roles:
Director. The director would need proven
leadership skills; excellent ability to create net
works and establish alliances; business vision; ex
perience in technology management; knowledge
about national and local laws and regulations;
and an understanding of the national university
system, the national innovation system, and the
status of local industry. In addition, the director
would need a minimum of ten years’ experience
in a relevant field, and good written and spoken
English.
Program managers. International experts
recommend that the central TTO initially be
staffed by program managers. This encourages
specialization and focused searching. It also takes
advantage of the synergies that can be generated
via networks. Program managers would need to
have within their ranks:
• a Ph.D. in biological sciences and/or bio
technology with both laboratory experience
and experience in product development, a
minimum of ten years of professional ex
perience, and good written and spoken
English
• a Ph.D. in the engineering sciences with
broad knowledge of the product develop
ment process, at least ten years of profes
sional experience, and good written and
spoken English
Project analysts. The central TTO would
need at least two economists and/or engineers.
They would need to have completed at least some
graduate studies, with a minimum of five years
of experience in the profession, and good written
and spoken English.
..2 Local TTO personnel

The local TTOs would need a staff composed of:
• a director or manager
2 | HANDBOOK OF BEST PRACTICES

• two or three professionals with graduate
degrees, preferably Ph.D.s, with at least
five years of professional experience in ei
ther biological sciences/biotechnology or
engineering
• project analysts
The volume and type of R&D being carried
out at each university or institute would determine
the size of the office and the discipline(s) in which
its staff members would need to specialize.
.. Office support staff and infrastructure

The central and local TTOs would need an ad
ministrative and support staff. At minimum, each
office would need a computer for each profes
sional, a printer, local and international commu
nications networks, filing space for documents,
and the space and equipment to make formal
presentations.
. Policies

The TTO consortium would design collectively
the key policies regarding the technology transfer
process, and these policies would form an integral
part of the consortium’s charter or proposal. They
should clearly establish the terms of IP owner
ship, the distribution of income, and the resolv
ing of conflicts of interest:
Ownership of IP rights. The universities or
institutes participating in the technology transfer
consortium would need to have uniform guide
lines for assigning IP ownership. Uniform practic
es help to reduce transaction costs, increase trans
parency, and facilitate utilization of intellectual
property protected by third parties. Government
agencies could encourage members to agree on
common guidelines through “codes of practice”
or by making adherence to certain guidelines a re
quirement for receiving funds from the state.
Distribution of income. Fair distribution of
income generated from technology commercial
ization is common practice around the world,
and it is a powerful incentive for the various play
ers in the technology transfer process. There are
many options for how to distribute such income,
and the options taken would have to depend on
institutional and national context.
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Resolving conflicts of interest. The consor
tium members would need to include clear policies
and procedures for resolving potential conflicts of
interest in the initial proposal for the creation of
the technology transfer system.
. Early phase

Planners/developers of the TTO consortium
would need to consider a few issues early on in
the creation of the national system:
• Skills at different levels would need to be
developed.
• The concept of the national TTO system
would need public support so that the cen
tral TTO could assume a leading role by
establishing its own trademark.
• Initially, the TTOs could help address their
institutions’ weakness through training
and educational efforts that would provide
them with the necessary skills.

. ConCLuSIon
A foundation of innovative technology compa
nies and the development of an entrepreneurial
culture will drive the development of new indus
try and enhance the global competitiveness of
Chile’s economy. The author believes these goals
can be best achieved through a TTO system such
as the one proposed in this chapter. Such a system
could provide a full range of technology transfer
functions for the main universities and research
institutes in Chile in the most economically ef
ficient manner. n
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CHAPTER 6.5

Practical Considerations for the Establishment
of a Technology Transfer Office
John dodds, Founder, Dodds & Associates, U.S.A.
susanne soMeRsalo, IP Specialist and Patent Agent, Dodds & Associates, U.S.A.

ABSTRACT

The establishment of a technology transfer office (TTO) is
a complex undertaking, so it is important to decide—be
fore the office is established—about its operational scope,
how the office will be funded, how it will be managed,
and for what kind of issues the office should develop a
policy. This chapter provides basic information that is
indispensable for running effective TTOs. The chapter
explains what physical and human infrastructures are
needed, outlines the responsibilities and powers of TTOs,
emphasizes the importance of technology evaluation, and
stresses the centrality of good communication and nego
tiation skills.

1. InTRoduCTIon
The last decade has seen tremendous growth in
the use of IP (intellectual property) protection
in business ventures, particularly those concern
ing biotechnology. As a result, more and more
institutions are establishing technology transfer
offices (TTOs) to assist in the legal transfer of
technology. These offices serve a variety of func
tions, such as evaluating research results in regard
to potential commercialization, advising on IP
protection, filing and prosecuting patent applica
tions, assisting in funding issues, conducting fea
sibility studies, and so on.
Starting a TTO is a complex and costly en
deavor. The project must receive the support of
administrators and scientists, and it must get off
to a dynamic, effective start and focus on those
who will use it. First impressions count.

It is important to define the TTO’s scope of
operations—as well as how it will be funded and
managed—from the outset. Because several years
can pass before any revenues or royalties would be
collected from IP transfers, the office has to op
erate with the highest possible efficiency. Success
or failure will depend mostly on the human re
sources and physical infrastructure available to
the office.

2. pHySICAL InfRASTRuCTuRE
The location of the TTO is critical. An office that
is located close to the scientists’ workplace is most
efficient and the proximity will help to establish
cooperation and trust between the scientist/re
searchers and the TTO staff. Most TTOs start
in either a research office or an administration
building.
Elements of physical infrastructure that
might be required include but are not limited to:
• office space (presumably either leased or
rented). In cases of universities, locating
the office on campus may make it easier
for scientists to contact the TTO; on the
other hand, an off-campus location might
better serve potential licensees. Such fac
tors as the need for confidentiality, meet
ing rooms, and so on, should be take into
consideration.

Dodds J and S Somersalo. 2007. Practical Considerations for the Establishment of a Technology Transfer Office. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. J Dodds and S Somersalo. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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• office furniture, including desks, chairs, fil
ing cabinets, conference tables, decoration,
carpets, and so on. If budgets are very tight,
acquiring salvaged or second-hand furni
ture can save money.
• computer systems, including PCs, printers,
cameras, speakers, and so on. A high-speed
modem or DSL line is critical.
• phone equipment able to handle confer
ence calls, call transfers, and voice mail.
• a photocopier. If budgets are tight, se
lecting a small copier or a second-hand
machine can save money. Remember that
photocopiers are notorious for frequent
and inconvenient breakdowns.
• general office supplies, including pencils,
pens, paper and staples. Keep a good officesupplies catalog handy. Every office needs
a good coffee and tea service; guests appre
ciate this simple, yet thoughtful, form of
hospitality.
• a library of limited scope. It is useful to
have a few key handbooks, such as Black’s
Law Dictionary1 and McCarthy’s Desk
Encyclopedia of IP.2 CD-based IP manuals
can be handy references as well as being
easy to use and to store; a computer could
be dedicated for utilizing this resource.
• online legal databases, both paid-service
(such as LexisNexis®3 and WestLaw®4) and
others that are free of charge.5
• various software packages. A standard of
fice package should be adequate, at least at
first. It must contain anti-virus, firewall pro
tection, and disk-maintenance software.

. HuMAn InfRASTRuCTuRE
And TALEnTS
Human infrastructure is even more important
than physical infrastructure. A TTO needs to have
employees with expertise in intellectual property,
business, law, contracting, and negotiation. People
will be needed to fill the following positions to op
erate a typical TTO:
• office director (usually a scientist with ex
tensive business experience rather than a
lawyer)
 | HANDBOOK OF BEST PRACTICES

• administrative assistant
• licensing specialist
• attorney (either in-house or contracted
from outside)
• students (often local law students)
A TTO’s daily operations touch on a num
ber of different fields. An office should therefore
have access to external specialists for advice: an
advisory panel, hired consultants, or colleagues.
The types of specialists that are needed usually in
clude, but are not limited to:
• patent attorneys or patent agents (depend
ing on the field of invention)
• general legal counsel
• licensing specialists
• marketing specialists
• database specialists
• drawing and design specialists
One of the most important skills relates to
communication and negotiation. An office direc
tor should possess these communication and ne
gotiation skills:
• good interpersonal skills (especially impor
tant when interacting with inventors)
• good interaction skills for dealing with en
trepreneurs in the private sector, the public
sector, and small and large businesses
• good spoken and written language skills
• formal experience in negotiation

. THE SCopE of THE offICE
With the goal of providing comprehensive IP ser
vices as effectively as possible, the responsibilities
and powers of the TTO should be established at
the outset.
.1 Patenting and other protections

Patenting work may involve searching, freedom to
operate, filing, maintenance, and so on. If patent
ing is a key duty of your office, it may be worth
while to consider hiring a patent agent. Either
way, it is essential to have a clear understanding
of the various protection options including:
• utility or design patents
• filing a national patent application

CHAPTER .

• filing in foreign countries
• filing provisional patent applications to
get initial protection and later filing nonprovisional, national or even international
applications under the Patent Cooperation
Treaty (PCT).

TTOs should consider assembling an ethics and
conflicts panel to regularly review office actions.
A policy development document should
guide the institution in developing its own IP
policies.

Offices may need to consider the options
case by case with each invention or the office
may have a default process for most invention
disclosures. Some offices, for example, file a rela
tively cheap provisional patent application in
the United States, in each case, and then market
the technology for the year that the provisional
patent is valid, before spending more money on
patent prosecution. If it seems that there are in
terested licensees, you may then file national or
international applications. This is, of course, only
one strategy among many.
The TTO should also consider the role of
trademarks and service marks in its operation.
Product branding is a very important element
of global marketing, but trademark protection is
often underused. It may be wise even to protect
the mark of the TTO itself. Copyrights are a very
simple and cheap form of protection for books,
papers, and databases; the latter is becoming
common in genomics as a cost-effective form of
IP coverage. Trade secrets are the cheapest form of
coverage: they are free! Of course, relying on only
trade secret protections, a TTO runs the risk that
someone will reverse-engineer and IP-protect the
invention so the TTO cannot use it!

Licensing is the heart, the essence, indeed the
very bread and butter of a TTO. Remember that
the flow of information and materials is two-way:
some staff will access the IP of others through li
cense agreements, and the TTO will be licensing
its technologies through license agreements.

.2 Policy development

It is important to have an internal office policy
that addresses the following questions:
• How will licensing revenues be shared?
• Can the office accept equity in a company
as part of licensing-related transactions?
• Should the office represent competing
technologies?
A TTO must develop a system for identifying
and dealing with possible conflicts of interest and
questions of ethics. For example, it will need to
anticipate such questions as should a staff mem
ber be allowed to license an invention to a com
pany for whom he or she works as a consultant?

. Licensing

. Invention marketing

Great technologies do not sell themselves. TTOs
need good marketers and should pay them on a
contingency basis. Do not underestimate the role
of the inventors in identifying potential licensees.
. Negotiations support

Negotiation is an art form that takes skill, prac
tice, patience, and sharp wits. TTO personnel
should consider taking courses to improve their
negotiating skills. Alternatively, the TTO can
hire negotiating experts. Whatever is done, TTOs
should watch out for legal loopholes.
. Technology evaluation and assessment

One of the challenges facing any TTO, especially
at the beginning, is deciding which inventions to
protect, and to what extent. No office has the re
sources to patent all inventions, especially if they
are not likely to generate revenue for some time.
As a rule of thumb, ten invention disclosures may
lead to one patent, and one license might come
from ten patents. In other words, only 10% of
patents provide royalties. It is critical, therefore,
that the TTO invest in only those inventions
that are both truly innovative and appear to have
commercial value. Remember that some great
scientific advances cannot be marketed. At the
same time, some simple inventions have huge
commercial value.
TTOs usually have an internal committee
that reviews invention disclosures for commer
cial viability and gives feedback to inventors. If
the TTO manager needs to tell a scientist that
HANDBOOK OF BEST PRACTICES | 
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his or her invention will not be patented, good
communication skills are critical. Obviously, the
manager does not want to discourage an inventor
from coming forward again in the future with an
other idea that may be commercially viable.
As a result, TTO staff should be prepared
to spend time, effort, and money when deciding
what to protect. The decisions should be influ
enced by a product’s market potential—not by
the excellence of the science behind it nor the de
sires of the inventor. Remember, the goal is not
simply to patent inventions but to strategically
patent inventions with commercial potential.
The TTO director must make sure he or
she is fully aware of the TTOs legal rights before
starting the negotiating process. It would be un
fortunate to invest in a technology and later find
out it cannot be licensed.
. Monitoring royalty incomes and potential
licensing infringements

Once a technology has been licensed, the TTO
has to make sure that the licensee pays the royalties
it has agreed to. The licensing agreement should
give the licensor (the TTO) the right to audit the
licensee, and this right should be exercised.6
The office must also monitor potential licens
ing infringements. This is not an easy task: the office
may have to monitor companies that are using com
peting technologies, as well as minor distributors
who might sell patented products out of ignorance.
. A note on confidentiality

The nature of the IP business means that all em
ployees of a TTO must observe strict confidenti
ality and always adhere to office policy on such
matters as conflict of interest. These consider
ations should be taken into account during the
hiring process, and the office’s operations should
always be fully documented.

. ExpEnSES
The costs of evaluating, protecting, and maintain
ing IP coverage are substantial and might include
the following:
• patent and trademark search fees
• patent and trademark filing fees
 | HANDBOOK OF BEST PRACTICES

•
•
•
•
•
•

PVP fees
maintenance fees
copyright filing fees
issue fees
attorneys’ fees
drafting fees

In the United States, the cost of a trade
mark (including attorneys’ fees) is approximately
US$1,200–2,000. A provisional patent applica
tion costs US$2,500–8,000, and a nonprovi
sional application costs US$6,000–30,000. The
cost of filing and maintaining a patent globally
is approximately US$500,000. The TTO direc
tor must keep in mind that the filing of an inter
national patent will make it necessary to use the
services of a translator and that translation fees
add up fast.

. kEEpInG up To dATE
It is important for the TTO to keep a close eye
on developments in technology and markets. In
order to stay informed, TTO employees should
be active members of professional associations,
such as the Association of University Technology
Managers (AUTM) and the Biotechnology
Industry Organization (BIO).
Another aspect of keeping up to date relates
to obligations with contracts and agreements.
Producing and reviewing contracts and agreements
is a large part of the work of the TTO manager.
Therefore, it is important to establish a portfolio
of standard contract and agreement templates that
can be customized as needed.
It is often tempting to cut costs by using
standardized forms and agreements. However, it
is important to note that such standardized docu
ments are rarely drafted in favor of the person ini
tiating the deal. If standard forms and agreements
are used, a lawyer should review the final versions
and point out any specific clauses that need to be
further negotiated.
. offICE oRGAnIzATIon
A number of organizational matters need to be
addressed in the early stages of the establishment
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of the TTO. These include creating a staffing plan
and an employment handbook, incorporating (if
necessary), and establishing procedures for han
dling federal and state filing requirements, taxes,
and payroll.
• staffing plan. A coordinated and coherent
staffing plan should provide details of lines
of authority, job descriptions, and work
plans for each day. Early planning will pre
vent future headaches.
• employment handbook. The staff employ
ment handbook must state the company’s
policies regarding confidentiality, eth
ics, and conflicts of interest, among other
topics.
• procedures for federal and state filing re
quirements. The local representative of the
Secretary of State may be able to provide as
sistance with filing such documents as work
permits, pension plans, occupancy permits,
fire inspection permits, and so on.
• plan for incorporation. The office may wish
to (or need to) become an independent le
gal entity. In the United States, such inde
pendent offices (often called research cor
porations) have charitable, or “501(c)(3),”
tax status.
• tax strategy. It is money well spent for a
TTO to hire a good accountant and a good
audit firm.
• payroll plan. The TTO director must re
main aware of federal and state tax policies.
It is wise to hire a good accountant and a
good audit firm to oversee such matters.

12. ConCLuSIonS
A TTO serves many masters and has a range of
different functions. An effective and efficient of
fice needs employees with good business, legal,
technical, and contracting skills. And it is impor
tant to establish the office’s scope and to develop a
comprehensive office policy as soon as possible.
This chapter provides only a basic template
for a TTO. Naturally, each office will have unique
needs that will need to be addressed—creativity
and a good team spirit will make it much easier
to do so. n
John dodds, Founder, Dodds & Associates, 1707 N Street

NW, Washington, D.C., 20036, U.S.A. j.dodds@dodds
associates.com
susanne soMeRsalo, IP Specialist and Patent Agent,
Dodds & Associates, 1707 N Street NW, Washington, D.C.,
20036, U.S.A. s.somersalo@doddsassociates.com

1

Gardner BA, ed. 1999. Black’s Law Dictionary. West
Group, St. Paul, MN.

2

McCarthy JT, RE Schechter and DJ Franklyn. 2004.
McCarthy’s Desk Encyclopedia of Intellectual Property,
3rd edition.The Bureau of National Affairs:Washington,
DC.

3

www.lexis.com.

4

www.westlaw.com.

5

See also, in this Handbook, chapter 14.3 by H Thangaraj,
RH Potter and A Kra
Krattiger
ttiger..

6

See also in this Handbook, chapter 15.1 by HH Feindt.
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Administration of a Large Technology Transfer Office
sally hines, Administrative Services Manager, Office of Technology Licensing, Stanford University, U.S.A.

ABSTRACT

This chapter describes the organizational management of
a technology transfer and licensing office based on the
experience of Stanford University’s Office of Technology
Licensing (OTL). It consists of a director, seven licensing
associates, eight licensing liaisons, one copyright licensing
specialist, and an administration staff. The administrative
staff comprises an assistant to the director, an administra
tive services manager, a manager of information systems,
receptionist(s), a manager of compliance and assistant,
and an accountant and assistant. The industrial contracts
office is part of OTL and consists of a manager and three
associates.

1. BACkGRound
The mission of the Stanford University Office of
Technology Licensing (OTL) is to promote the
transfer of Stanford University’s technology for
society’s use and benefit, while generating unre
stricted income to support research and educa
tion. Thus, the primary focus of OTL has not
been to maximize income generation, but to fa
cilitate putting into use for society’s benefit the
innovations developed at Stanford University.
In the early years, staffing levels were kept
very low to control total expenses. There were
only two people on staff for the first five years
of operation. A third person was added in FY
1974–75 and total staffing was three people for

the next six years. Today, the OTL has the follow
ing employee composition:1
• director (1)
• assistant to the director (1)
• licensing associate I (0)
• licensing associate II (1)
• licensing associate III (6)
• marketing, software and copyright specialist (1)
• licensing liaison I (0)
• licensing liaison II (8)
• administrative services manager (1)
• administrative support personnel (7)
The benefits to Stanford resulting from the
formation and operation of the OTL have been
many. Although it took many years for substan
tial net revenues to be obtained, at the end of FY
2005–06, the OTL had received total revenues
of US$1 billion and had total operating expenses
of US$45 million. In its 36 years of operation,
the OTL has contributed US$591 million to
Stanford and its inventors

2. pERSonnEL ISSuES
Reporting to the director are the licensing associ
ates, administrative services manager, marketing,

Hines S. 2007. Administration of a Large Technology Transfer Office. In Intellectual Property Management in Health and
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual (Second Edition, Part II: Chapter 3).
© 2007. S Hines. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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software and copyright specialist, manager of
compliance, accountant, manager of the industrial
contracts office, and the director’s assistant. Each
of the licensing liaisons supports one licensing as
sociate; the liaisons report directly to the associ
ates. The manager of information systems reports
to a senior licensing associate. The receptionists
report to the administrative services manager.
Professional staff are divided into licensing
liaison and licensing associate positions (Table
1), whereas Figure 1 shows the organigramm.
Complete job descriptions are provided in Box 1,
at the end of this chapter.
2.1 Licensing associates

Each licensing associate has a specific area of ex
pertise (see OTL Web site2). Many of the Stanford

licensing associates have been recommended to
OTL by other universities or individuals in the
field. There are no lawyers in the licensing associ
ate category.
• The technology licensing associate I handles
routine cases (with supervision) and par
ticipates in the negotiation and preparation
of more complex cases. Some experience in
at least one of the following is necessary: li
censing, negotiation/contracts, marketing,
or patents.
• The technology licensing associate II handles
a variety of complex cases and requires a
high degree of technical and business ex
pertise, a familiarity with the legal issues in
volved, and at least four years of applicable
experience.

Table 1: Main Professional licensing Positions
Position

Job Description (corresponding appendix)

Licensing liaison I

Direction from supervisor, assist with marketing, routine
amendments, patent prosecution, database management;
position is 75% clerical

Licensing liaison II

With some supervision, market new inventions, including
carrying out market research and preparing abstracts; docket
administration; coordinate and monitor patent activities;
inventor meeting scheduling; handle administrative/clerical
responsibilities in support of licensing associate

Licensing associate I

Evaluate and handle licensing with respect to standard and
nonstandard cases with some guidance

Licensing associate II

Evaluate and handle licensing with respect to nonstandard
cases with independence; take appropriate, independent
action in a majority of situations

Licensing associate III

Evaluate and handle independently the licensing of complex
cases; appropriately handle a variety of IP

Note: Standard cases involve nonexclusive licenses and template-type agreements. Nonstandard cases
require creativity in resolving issues. Complex cases require unusual creativity in resolving new issues.
See also Box 1 at the end of this chapter for job descriptions.
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• The technology licensing associate III is re
served for individuals handling major cases
where licensing potential is estimated to
be in the millions of dollars. Because of
the magnitude of the cases, the work has
a significant impact on the university and
involves much coordination and complex
decision making. Eleven or more years of
applicable experience and/or two years of
experience at the OTL are required. After
an individual has been with the office for
five years (and has reached the associate III
level), he/she has the privilege of using the
title senior associate.
2. 2 Licensing liaisons

Stanford OTL has two levels of licensing liai
sons. The licensing liaison I level requires more
direction from the licensing associate than the
licensing liaison II level. There are many ways
to find good people. Probably the best ways are
referrals, ads on various Web sites, and through
licensing organizations such as the Association
of University Technology Managers and the
Licensing Executives Society.

. ConCLuSIonS And
THE nEEd foR SopS
Running and administering a technology trans
fer and licensing office is a challenging task from
many perspectives, ranging from policy to strat
egy. As Nelsen3 describes them, one of the key
aspects are rigorous, consistent, and authoritative
administrative approaches and procedures. This
chapter described the approach of one entity,
Stanford University’s OTL.

It is important to keep yearly statistics about
the office and collect them in a database for
analyzing the progress of the office and for use by
other entities. Such data for Stanford University’s
OTL are published annually and are available on
the OTL Web site.4
Finally, in order to ensure smooth operations,
each member of the staff of the office is trained
in and has access to the Standard Operating
Procedures (SOP’s) through the OTL Intranet.
These SOP’s consist of step-by-step instructions
about procedures for handling various docu
ments. Two sample SOPs are included in Box 2.
It is important to note, however, that the SOPs
are evolving, and each tech transfer office should
develop its own operating procedures, adjusted to
institutional policies and the prevailing adminis
trative procedures. n
sally hines, Administrative Services Manager, Stanford
University, Office of Technology Licensing, 1705 El Camino
Real, Palo Alto, CA, 94306 U.S.A. sally.hines@stanford.edu

1

The information provided here is current as of the publication date. As with any technology transfer office,
structure, job descriptions and responsibilities, and the
number of persons employed change over time.

2

otl.stanford.edu.

3

See, also in this Handbook, chapter 6.1 by L Nelsen,
which provides relevant information for heads of
research institutes and research hospitals, whether
private or government supported.

4

otl.stanford.edu/about/resources.html.

5

Note that SOPs are rarely shared with third parties
because they are highly specific for the particular
institution and environment in which an office
operates.
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Figure 1: Oranigramm of Stanford university’s Office of Technology licensing
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Box 1: OTl licensing Job Descriptions
Technology licensing associate I
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains
proprietary protection, markets, and negotiates the terms and conditions of the licensing
agreement with industry.
The Licensing Associate I typically performs the following functions:
• Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate
information; and make decisions and provide necessary notifications)
• Licensing (Develop licensing strategy; identify potential licensees; negotiate terms; prepare
draft agreements; and close the deal)
• Patent-related activities (selection of attorney; make decisions regarding when and where to file
patent applications; and manage inventory of unlicensed cases from a financial perspective)
• License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence
terms; prepare and execute amendments; process terminations; and hold meetings with
licensees to monitor progress in Licensed Product(s) development)
• Professional Development (participate in professional associations; attend association
conferences; and take training classes)
The Licensing Associate I level handles (with supervision) standard and nonstandard cases,
where agreements tend to be modifications of established patterns. The Licensing Associate also
participates in the negotiation and preparation of more complex cases.
Some experience is necessary in at least one of the following: licensing, negotiation/contracts,
marketing, and patents. Approximately four years of work experience is preferable. A minimum of a
BS/BA degree in a science or engineering field—or equivalent applicable experience—is required.

Technology licensing associate II
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains
proprietary protection, markets and negotiates the terms and conditions of the licensing
agreement with industry.
The Licensing Associate II typically performs the following functions:
• Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate
information; and make decisions and provide necessary notifications).
• Licensing (develop licensing strategy, identify potential licensees, negotiate terms, prepare
draft agreements, and close the deal.
(Continued on Next Page)
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Box 1 (continued)

• Patent related activities (selection of attorney; make decisions regarding when and where to file
patent applications; and manage inventory of unlicensed cases from a financial perspective)
• License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence
terms; prepare and execute amendments; process terminations; and hold meetings with
licensees to monitor progress in Licensed Product(s) development)
• Professional Development (participate in professional associations; attend association
conferences; and take training classes)
The Licensing Associate II independently handles a variety of nonstandard cases and would be
considered an experienced professional. These positions require a high degree of technical and
business expertise, a familiarity with the legal issues involved, and approximately four years of
applicable experience (for example,scientific,research,marketing,business development,patents,
and licensing). A minimum of a BS/BA degree in a science or engineering field is required.
The Licensing Associate II is a position in which qualified professionals may enhance their career
experience and move up the OTL career development ladder to a Licensing Associate III. The
Licensing Associate II must be able to participate as a member of the OTL team, while continually
assuming increased responsibility and independence.

Technology licensing associate III
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains
proprietary protection, markets and, negotiates the terms and conditions of the licensing
agreement with industry.
The Licensing Associate III typically performs the following functions:
• Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate
information; and make decisions and provide necessary notifications)
• Licensing (Develop licensing strategy; identify potential licensees; negotiate terms; prepare
draft agreements; and close the deal)
• Patent-related activities (selection of attorney;make decisions regarding when and where to file
patent applications; and manage inventory of unlicensed cases from a financial perspective)
• License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence
terms; prepare and execute amendments; process terminations; and hold meetings with
licensees to monitor progress in Licensed Product(s) development)
• Professional Development (participate in professional associations; attend association
conferences; and take training classes)
The Licensing Associate III level would be reserved for individuals handling major cases (for
example, Cohen/Boyer or FM Sound) where licensing potential is estimated to be in the millions
(Continued on Next Page)
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Box 1 (continued)

of dollars. Because of the magnitude of these cases, the work has significant impact on the
University and involves much coordination and complex decision making (for example, participating
in decisions on whether to pursue major litigation).
In order to qualify for the level of Licensing Associate III, an individual is required to have 11 or
more years of applicable experience and/or two years of experience at the Office of Technology
Licensing.
A Complex Case has one or more of the following attributes:
• Requires exceptional good judgment and special attention because of the following: exceptional
number of patent applications/patents involved; the level of royalty revenue (potential or actual);
and/or the number of licensees involved
• Involved in litigation in which Stanford is either responsible or intimately involved and where
Stanford’s involvement presents a significant liability or revenue opportunity for Stanford
• New and complex intellectual property issues are involved in the licensing such that creative
solutions must be developed
• The case has either the potential to generate $3–5 million or costs $1 million (in litigation costs or
claims against Stanford) or has a major impact to OTL’s licensing program

Examples of complex cases include:
• Sondius Program:the technology consists of a portfolio of patents,trademarks,copyrighted works;
licensees include a start-up, major corporation, and other companies, and the licensed fields
of use are varied; the revenue potential is considered significant; Stanford invested significant
resources into the development of the technology; the potential of litigation is relatively high.
• ARIM Portfolio: involves 20 patents and copyrighted technologies licensed exclusively and
nonexclusively to many companies; licensing strategy is to make the technology broadly available
while encouraging investment in the technology.
• Phycobiliprotein: Complicated license strategy (exclusive license to two companies, converting
one of these two licenses to a nonexclusive); sued one licensee; generating over $3 million/year
in royalties with the extensive management and monitoring of the licensees because the chain
of distribution is often unclear; auditing; each license is separately and individually negotiated.
The Licensing Associate must have demonstrated exceptional good judgment, breadth of knowledge
of patents, copyrights, and trademarks, and the ability to independently resolve complex issues and
deal with unusually difficult situations. The Associate must use exceptional creativity in structuring
win-win licenses in difficult and complex cases. Typically, complex cases present issues that have not
been dealt with in the past and, therefore, require particularly creative solutions.

(Continued on Next Page)
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licensing liaison I
With close supervision from Licensing Associate:
• Assist in the marketing of inventions to industry, including identifying potential licensees,
initiating contact, preparing and distributing promotional materials
• Research library and computer database resources to identify potential licensees in the
invention field of use
• Help monitor performance of licensees to ensure diligence provisions are met
• Prepare routine amendments to agreements, give notice and process termination of
agreements when required
• Assist in the coordination and monitoring of patent filing and prosecution
• Prepare financial and status reports and complete other tasks in the analysis and marketing of
inventions as assigned and designated by Licensing Associate
• Keep highly organized and indexed files (both paper and computer database) to track
evaluation, patenting, marketing, and maintenance functions for inventions
• Extensive database management including entry of information on new inventions, keeping
people, company records, and patent information up to date, and entry of license agreement
data
• Prepare and sign own correspondence whenever possible, and prepare correspondence for
associate’s signature
General:
Assist with general office-support tasks as needed for the efficient operation of the office. It
would be expected that 75% time would be devoted to clerical duties.
Qualifications:
College level training highly desirable, preferably in science or engineering. Demonstrated strong
oral and written communication skills. Ability to take initiative, to prioritize workload, and to
work independently. Exceptional organizational and analytical skills. Attention to detail. Interest/
experience desirable in technical marketing. Ability to use PCs, familiarity with databases
(preferably 4th Dimension) and software programs Microsoft Word and Microsoft Excel.

licensing liaison II
With some supervision from Associate, Licensing Liaison is responsible for marketing and
invention management assistance. The Licensing Liaison will work with the Licensing Associate
(with some supervision and good judgment on the part of the Licensing Liaison):
• Marketing, including identifying potential licensees through market research, initiating
contact, preparing and distributing promotional materials
(Continued on Next Page)
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• Market research using library and computer database resources
• Preparation of invention abstracts for database
• License Agreement monitoring ensuring compliance with diligence provisions and financial
terms of the agreement
• Patent-related activities including coordinating and monitoring patent filings and prosecution.
Coordination of inventor signatures on documents and licensee input
• Responsible for all sponsor compliance ensuring that all regulations and obligations are
fulfilled
• Prepare financial and status reports and complete other tasks in the analysis and marketing
of inventions as assigned and designated by Licensing Associate
• Preparation and execution of royalty sharing and nondisclosure agreements
• Processing of dropped cases and follow through
• Secondary administrative support and database entry for Associate
• Keep highly organized and indexed files (both paper and computer database) to track
evaluation, patenting, marketing, and maintenance functions for inventions.
• Schedule inventor meetings
• Assist with general support tasks, including reception, as needed for the efficient operation of
the office.This position will have administrative/clerical responsibilities in support of licensing
associate
Qualifications:
No licensing experience is required, but at least three years of experience as a paralegal or
other relevant experience is preferred. BS/BA strongly preferred. Experience with intellectual
property preferred. Ability to take initiative, to prioritize workload, follow-up consistently, and
work independently. Good communication skills (oral and written) important. Exceptional
organizational skills and attention to detail required. Experience with databases, word processing,
and spreadsheet software required.
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Box 2: Standard Operating procedures5
list of SOPs
Invention disclosures
Conceptual Disclosures
Preliminary Disclosure Information Entered into Database
Disclosure Notification of Government and Other Sponsors
Associate Docket Review
Royalty-Sharing Agreements (RSA)
Prepare Royalty-Sharing Agreement
Copy Distribution
Enter RSA Data into Database
Compliance—Government and other Sponsors
Government Sponsors
Disclosure Notification of Government Sponsors
Transmit Compliance Information to the Government
Copy Distribution
Corporate and Other Sponsors
Disclosure Notification of Corporate and Other Sponsors
Transmit Compliance Information to Corporate and Other Sponsors
Copy Distribution
processing patents
Patent Application
Patent Prosecution
Newly Issued Patents
Patent Maintenance
Patent Abandonment/Expiration
Marketing
Decision to Market
Develop Non-Confidential Abstract
Develop List of Companies
Marketing Letter—Have Inventors Review/Comment
Confidential disclosure Agreements (CdA)
Send Two Original CDAs to Potential Licensee(s) for Signature
File Stanford’s Original Agreement
License Agreements
Negotiate the Terms of the Agreement with Potential Licensee(s)
Agreement Signature Procedure
Enter License and License Terms into Database
Copy Distribution
License Agreement Process
Amendments
Terminated-Agreements Process
Equity
Receiving Stock Certificates from Company
(Continued on Next Page)
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Box 2 (continued)

Tabled dockets
Assess whether Invention Belongs in “The Pound”
Steps for Sending Invention to “The Pound”
Consider Re-Marketing While in “The Pound”
To Remove from “The Pound”
Terminated Agreements
Letter to Terminate Received/Issued
Update “Terminated” Safe Documents
Termination-Letter Distribution
dropped dockets
Decision to Drop a Docket
off-Site Storage
Files to Be Archived for First Time
Files to Be Re-filed at Off-Site Storage
Miscellaneous Documents to Be Archived
General Administrative filing
Outgoing Correspondence
General Filing

Sample SOPs for license Agreements4
1

negotiate the terms of the agreement with potential licensee .................................Associate
A Royalty-Sharing Agreement should be completed when a patent is filed or when a license
negotiation is initiated.
(See also Exhibit L, titled 1st Licensee Meeting Checklist and Exhibit M, titled Parameters of
an Exclusive License Agreement [not included in the Handbook].)
1.1

Term Sheet............................................................................................................. Associate/Team
Associate and Team determine the desired:
• financial terms
• BATNA (Best Alternative to No Agreement)
• walk-away conditions for the agreement
• type of license (non-exclusive, field exclusive,
or exclusive)
Associate either generates a term sheet (See Terms Sheet example [not included in
the Handbook]) or requests a proposal from a licensee. For all field and fully exclusive
licenses, Associate receives a development plan from licensee.
Associate and company representative agree on financial terms.

(Continued on Next Page)
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Box 2 (continued)

1.2

License Agreement ......................................................................................................... Associate
Once term sheet is agreed upon, enter financial terms, and docket-specific
information, into standard License Agreement (see standard document license
agreements on OTL Intranet; not included here). Utilize clauses library and input
from Team as needed. Keep Director informed, particularly if the license contains
nonstandard provisions.

1.3

Conflict of Interest Review ........................................................................................... Associate
Prepare Conflict of Interest Memo if inventor has a financial stake in the company or
other relationships with the company, including:
• has equity
• is or will be a consultant
• is or will be on the Scientific Advisory Board
• is or will have sponsored research or collaboration with company
a. Ask inventor to send their COI memo to Deans describing relationship with
company and how any potential conflict of interest would be managed. Suggest
inventor check out the COI Web site of their respective institution (for Stanford
University, see www.stanford.edu/dept/DoR/ad_hoc.html). ................... Associate
b. Obtain approval required by School Dean and Dean of Research before signing
the Agreement. ............................................................................................ Associate Tracks

2.

Agreement Signature procedure
Signature order not critical; if OTL signs first, include a deadline for the agreement to be
returned.

3.

2.1

Director reviews and approves final draft of agreement. .................................... Director

2.2

Prepare two original agreements for execution. ...................................................... Liaison

2.3

Licensee signs (preferably first). .................................................................................. Licensee

2.4

Director signs for OTL. ...................................................................................................... Director

2.5

Return one original to Licensee. .................................................................Associate/Liaison

Enter license and license terms into the database ...................................... Liaison/Associate
Be sure to add all necessary information, including:
- To License record
• All standard fields
• Equity (if applicable)
• Office of Scientific Research funds (if applicable)
• Corporate contact
• Entity size
• License-specific notes
(Continued on Next Page)
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Box 2 (continued)

- To License Terms:
• All royalty terms
• Progress report terms and
• Diligence terms or reminders to self
4.

Copy distribution ......................................................................................................Receptionist
• Original to SAFE file
• Routing copy, which is routed to:
1. OTL Accounting; then
2. OTL staff; then
3. Receptionist for scanning
• Personal copy to Associate (Associate should notify receptionist
if he/she already has a personal copy).

5.

processing and filing Stanford’s original agreement
5.1

After license terms entered: ........................................................................................ Associate
• If license issue fee was received, forward check to OTL Accounting
for processing.
• If license issue fee was not yet received, have OTL Accounting send invoice
to Licensee.

5.2

Notify inventors of license agreement, verify their address and update 4D.
................................................................................................................................. Associate/Liaison

5.3

If inventor requests a copy of the license agreement and there are no confidentiality
provisions in the agreement that prevent this: ..................................... Associate/Liaison
• The inventor must sign and return an Inventor Confidential Disclosure
Agreement.
• File original inventor CDA in SAFE and stamp “CONFIDENTIAL” on the copy of
the agreement before sending it to the inventor.

5.4

6.

When licensed, notify patent attorney to: .................................................................. Liaison
• Pay large entity fees.
• cc licensee on correspondence with the patent office
(for exclusive licensees only).

Amendments
Amend for “minor” changes; rewrite agreement if major changes.
6.1

Prepare up to two amendments per agreement, rewrite agreement thereafter.
................................................................................................................................Associate/Liaison

6.2

Associate and team determine desired terms and conditions. .......Associate/Liaison

(Continued on Next Page)
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7.

6.3

Follow same signature procedures for original agreements
(see Section 2, above) .....................................................................................Associate/Liaison

6.4

Update 4D license and license terms, if necessary. ..............................Associate/Liaison

6.5

Original Amendment filed in SAFE; Associate keeps a personal copy.
................................................................................................................................Associate/Liaison

Terminated-agreements process ........................................................................................... Associate
(See SOP section “Terminated Agreements” for further instructions [not included in the
Handbook].)

Sample SOPs for Invention Disclosures
1.

OTL/Associate receives new paper disclosure..................................................... Associate/Liaison
(for online disclosures, go to 3)
Give disclosure to Director.
(See http://otl.stanford.edu/inventors/resources/disclosure.pdf)

2.

Preliminary disclosure information entered in database ..................................................Director
2.1

Assign docket number, associate initials and title...................................................Director

2.2

Give copy of disclosure to Front Desk. ........................................ Assistant to the Director

2.3

Create correspondence folder and give folder to Associate. ......................... Front Desk
Give copy of disclosure to Compliance Manager.
(See SOP section “General Administrative Filing” [not included in the Handbook].)

2.4

Review, sign and witness disclosure, then give it to Liaison for
processing...........................................................................................................................Associate

2.5

Enter all remaining information from invention disclosure form into
database, including each inventor’s:
• Name
• Addresses
• E-mail address
• Phone number
• Fax number
• Department (please verify using Stanford Directory) .....................................Liaison
Also check each Database box that corresponds to a special affiliation or situation
(e.g., HHMI or SRC).
(Continued on Next Page)
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Box 2 (continued)

2.6

If invention is sponsored, and sponsor is already listed in the database:
enter sponsor name and contract number in the sponsor portion of the
docket screen. .........................................................................................................................Liaison
If no sponsor or “None” listed: double check with the inventor.
If an inventor is an HHMI employee: HHMI should be included as a sponsor.
If an inventor is a VA employee: VA should be included as a sponsor.
(See SOP section “Compliance: Government & Other Sponsors” [not included in the
Handbook].)

2.7

3.

4.

If sponsor not already in database, obtain copy of any nonfederal sponsored
agreement from Industrial Contracts Office, Office of Sponsored Research, or inventor
and put agreement in file. Then enter sponsor information/terms into database.
Verify sponsor requirements and communicate them to Compliance Manager as
needed. (See SOP section “Compliance: Government & Other Sponsors” [not included
in the Handbook].) ................................................................................................................Liaison

oTL receives new online disclosure, and database notifies director ............................Director
3.1

Director assigns docket to Associate and generates database e-mail to
Associate/Liaison team. ...................................................................................................Director

3.2

Print out attachment(s) included with Director’s e-mail, if any, for
correspondence file...............................................................................................................Liaison

3.3

Review disclosure (found in the Database Disclosures view):
• Add/update inventor and sponsor information in Database, as needed
• If no sponsor or “None” listed: double check with inventor
• If inventor is a Howard Hughes Medical Institute employee: HHMI should
be listed as a sponsor
• If inventor is a Veteran’s Administration employee: VA should be listed
as a sponsor
• Approve docket and generate database e-mail to director
• Print out disclosure

3.4

Director creates docket and sends 4D e-mail to Associate/Liaison team. ......Director

3.5

Once docket number has been assigned by Director, write docket number in upper
right-hand corner of printed disclosure and give original disclosure (with printouts of
attachment(s), if any) to Front Desk to create correspondence folder................Liaison

3.6

Database notifies Compliance Manager of new disclosure..............................Database

oTL notifies government and other sponsors of Stanford’s action on the disclosure
(See SOP section “Compliance: Government & Other Sponsors” [not included in the
Handbook].) ............................................................................................................ Compliance Manager
(Continued on Next Page)
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5.

Associate docket review
5.1

Read disclosure and arrange to meet with Inventor(s) within 1 month........Associate
Have the disclosure signed by inventor(s), witness, and Associate.
If there was a material transfer agreement (MTA): copy the MTA from
Industrial Contracts Office files and review for any IP requirements.
Confirm whether inventor(s) plan to publish or present, including online.
Enter status note (in Database Notes view) that describes inventor
meeting and docket evaluation.
(See also Exhibit B: 1st Inventor Meeting Checklist; [not included in the Handbook].)

5.2

Evaluate disclosure for patentability and commercial potential. Evaluation
may include input from:
• Biological or Physical Sciences Team
• Patent attorneys
• Industry contacts
• Technical Experts (for example other faculty, Niodesign Network)
• Full marketing ............................................................................................. Associate/Team

5.3

If not provided with disclosure,obtain marketing abstract information from inventor
or create marketing abstract........................................................................ Associate/Liaison
(See Exhibit D: Marketing Abstract [not included in the Handbook].)

5.4

Enter following information into database (these should be updated if there was an
online disclosure):
• Abstract
• Applications
• Advantages
• Publications
• Stage of Development
• Continuing Research
• Links to lab Web site
• Status
• Action
• Categories
• Bio/PhySci
• EPIC if applicable
• Patent Bar date......................................................................................... Associate/Liaison

5.5

Make preliminary domestic/foreign filing decision—defer if more research required
................................................................................................................................... Associate/Team

5.6

Send out standard royalty sharing agreement (RSA) memo if:
• Invention is being marketed
• Patent application is filed
• RSA not needed if invention is being dropped prior to marketing..............Liaison

(See SOP Section “Royalty Sharing Agreements” [not included in the Handbook].)
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Training Staff in IP Management
sibongile pefile, Group Manager, R&D Outcomes, Council for Scientific and Industrial Research (CSIR), South Africa
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University,

Chair, bioDevelopments-International Institute, and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

This chapter provides an overview of training opportuni
ties that developing country institutions can explore to
start to address problems related to a smooth implemen
tation and execution of all intellectual property-related
aspects (policy, management, procedures, and so forth).
The chapter offers to institutions guidelines for evaluat
ing training needs and reviews different kinds of training
programs, identifying the pros and cons of each. IP man
agement training is a long-term investment, but a cost-ef
fective one, leading to better utilization of third-party IP
resources, more effective internal IP management policies
and procedures, and higher efficiency in regard to outlicensing and partnership development. The chapter em
phasizes the importance of strategic and practical training
programs related to participants’ responsibilities within
an organization. Finally, multidimensional case studies
are provided to illustrate the myriad issues that may arise
with respect to the management of intellectual property.

1. InTRoduCTIon
Whether technology comprises new products and
services, or improvements of existing ones, and
whether it is simple or sophisticated, technology
is an important contributor to socio-economic
development. The processes by which knowledge
and technology are transferred ensure that tech
nologies can be applied in virtually all industry
sectors. But technology and knowledge transfer
capabilities in developing countries are not meet
ing local needs for socio-economic development
and for driving progress in such critical industry
sectors as health and agriculture. Despite an ac

tive research environment, developing countries
have been less effective in exploiting research out
puts, especially intellectual property. Institutions
in developing countries face numerous problems
in managing their own intellectual property.1
These include a limited understanding of the IP
system and how it can be applied in the public
sector research environment, a low appreciation
of the benefits that can be derived from manag
ing institutional intellectual property, and inad
equate human and financial resource capacity to
invest in institutional IP management policies
and resources.
In IP management, the importance of practi
cal training events cannot be overemphasized. For
this reason, we have included, at the end of this
chapter, a few brief case studies that can be used
for training purposes (Box 1 at the end of this
chapter). These case studies will allow the par
ticipants to play roles (that is, role-play situations
that arise in the day-to-day management of intel
lectual property) and, most importantly, will al
low participants to see how their specific roles in
real life affect (directly or indirectly) deal-making
activities. Even for those who are not involved in
deal-making, this practical approach is especially
useful as it enables participants to view their re
spective tasks in broader contexts and thus better
understand their roles and responsibilities, as well
as their importance in the process.

Pefile S and A Krattiger. 2007. Training Staff in IP Management. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. S Pefile and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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2. A STRATEGy foR Ip MAnAGEMEnT
CApACITy BuILdInG
2.1 Analyze institutional goals

Deciding upon a program to build IP manage
ment capacity begins with a thorough analysis
of institutional goals, recent policy changes, and
required adjustments in the institutional strategy,
with respect to IP management. Institutional ca
pacity in IP management means a range of things:
including clear and transparent policies (conflict
of interest, licensing, patent, and so forth); es
tablished procedures (for example, for incoming
and outgoing materials, laboratory notebooks);
and people at nearly every level of the organiza
tion being well informed on how the procedures
work, and why. It is essential to identify weak
nesses and strengths of the IP management sys
tem within an institution in order to take better
advantage of existing organizational structures.
This means identifying where the weakest links
are. A training program then will assist staff in
better understanding and helping the institution
to achieve its goals.
2.2 Identify training needs

The next step is to identify the competencies re
quired to accomplish the overall goals. This re
quires an analysis of the required proficiencies,
existing deficiencies, and the causes of the defi
ciencies. In general, the training requirements
of staff members are summarized in Table 1. In
order to ascertain specific needs, the following
question should be answered:
• What knowledge and skills are required
for optimal operation of the IP office and
therefore required among IP management
staff?
• What IP-related knowledge and skills are
required for the research staff?
• What are the communication gaps with re
spect to intellectual property both within
the institution and with third parties?
• What are the particular elements of the IP
policy that seem least well understood and
implemented?
• What resources are required to bring knowl
edge and skills to the required levels?
 | HANDBOOK OF BEST PRACTICES

Information on training needs can be gath
ered in various ways:
• interviews. one-on-one or group format;
face-to-face or by phone; formal interviews
and off-the-record discussions
• focus groups. conversations among teams
of workers from across the organization
• questionnaires and surveys. anonymous
or not
• document analysis. a study of policies,
strategies, and management procedures (for
example, employment agreements, grant
documents, and other contracts)
• observation.
2. Develop strategies to achieve
training goals

Ranking the training goals and determining
how to meet the highest-priority training needs
is difficult. A well-developed plan should have
specific and realistic objectives, include measur
able and achievable outcomes, schedule clear
time frames for all activities, and should un
dergo regular monitoring and evaluation.2 Of
course, different people have different under
standings, vested interests, and preferences, so
a lot of soft negotiation will be required. It may
be helpful to work with a third-party training
provider who, if they understand the organiza
tion, can take a more objective view and assist in
better designing the training program to meet
institutional goals.

. Ip TRAInInG pRoGRAMS
Initially, individuals interested in IP training were
limited to a small collection of course offerings
available through staff members of organizations
that, due to their practical experience in the field,
were able to share their know-how. But intellec
tual property as a field of study is growing in im
portance as institutions value it more and more.
In addition to the essential practical training of
fered by institutions such as the Centre for the
Management of Intellectual Property in Health
Research and Development (MIHR), formal
training in IP management is also available from

CHAPTER .

Table 1: Generalized Training Needs of Different Staff Groups
Group
Researchers

Training requirement (minimum)
• maintaining good laboratory records

• a basic understanding of the types of IP agreements,
especially in the context of exchanging research material and
information
• the importance of confidentiality, especially with respect to
publishing and delivering academic presentations
• when to disclose intellectual property to the relevant office
• institutional IP policy guidelines and procedures

Research managers
and institution
directors

• the importance of IP management and management functions
• IP protection processes and procedures; the investments
required to manage intellectual property effectively (include
key decisions required at different stages of intellectual
property and research development)
• implementing IP policies, processes, and procedures

• an appreciation of the role of technology in addressing socioeconomic needs
IP managers

• overview of IP management from the generation of intellectual
property to its exploitation and application
• awareness building

• understanding of science (some domain understanding of
certain fields of science an added benefit)
Operations

finance

• understanding of IP policy guidelines, namely, systems and
processes to handle IP payments and receipts, for example,
royalties; the administration of benefits to researchers and the
institution

human resources

• IP policy guidelines and interface with other institutional
policies such as, conditions of service, recruitment, conflicts of
interest and commitment, contracting with clients, and so on

legal services

• IP policy guidelines

• IP contracts and agreements

• What is intellectual property; and the different forms of IP
protection
• IP negotiation

grant and contract research

• IP contracts and agreements, especially clauses regarding IP
ownership
• IP policy guidelines
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MIHR.3 The online version of this Handbook will
list many other such programs and places.
IP training opportunities can be divided into
two distinct disciplines: law and IP management,
which includes deal making as the central focus.
.1 IP law

Although most training programs begin by cover
ing IP law, it is more appropriate to present this
topic at the end of the course. A brief overview at
the beginning might be appropriate, but placing
emphasis on it at the beginning diverts attention
from the more important issues, namely what an
institution is doing with its intellectual property
and with the intellectual property of third par
ties. Therefore, a training program really ought to
begin with the central issue, which is deal making
for most institutions.
IP law is concerned with statutory regimes
for the legal protection of IP rights. IP law studies
normally include:
• patent law. the study of patents for inven
tions, including international and regional
treaties that form part of an international
legal framework in patent law
• copyright law. the study of principles and
standards of protection under national and
international copyright and related rights
treaties
• trademark law. the study of legal provisions
relating to trademarks in national, interna
tional, and regional IP treaties
• industrial design law. the study of laws
pertaining to the registration and protec
tion of original and innovative designs. (In
some countries, design patents go under
different names, such as “utility model” in
France and the law for “minor inventions”
in Australia.)
Other training opportunities exist in areas
such as:
• legal aspects of traditional knowledge and
biodiversity
• legal aspects of electronic commerce
Many law faculties offer training for becom
ing a patent lawyer. Typically, patent lawyers are
00 | HANDBOOK OF BEST PRACTICES

responsible primarily for preparing and pros
ecuting patent applications, conducting patent
searches, patent infringement and litigation, and
preparing and filing applications for patent and
other IP protection. During the course of per
forming these duties, patent lawyers are required
to communicate with counsel and guide clients
on legal issues in this field.
.2 IP management

On the other hand, IP management courses train
individuals to become IP practitioners. An IP
practitioner may not necessarily have formal edu
cation or training related to intellectual property
but would have work experience and some infor
mal training in the field. IP management is the
convergence of basic IP law, business and research
management, and institutional policy adminis
tration. IP practitioners need to know the IP field
well enough to make appropriate strategic and
management decisions about the protection and
exploitation of institutional intellectual property.
Furthermore, IP practitioners are expected to:
develop institutional IP policy, advise on when,
where, what, why, and how to protect intellec
tual property; identify useful intellectual property
from their institutions; establish institutional sys
tems and processes to manage intellectual prop
erty; assess the value of intellectual property; re
port on IP activities; and build awareness of the
importance of intellectual property within the
research community. Essentially, the IP practi
tioner serves as a bridge between science and the
outside world. Such an individual should know,
therefore, how to articulate issues effectively to
different stakeholders and when to seek profes
sional counsel for highly technical matters.
. IP law vs. IP management training

Important issues to consider when deciding on
which type of IP training program would be ap
propriate for staff members include:
• training costs. It is important that the
institution receive value for its training
investment.
• duration of training. Legal training in IP
law takes several years; short courses in IP
management take weeks or months.
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• institutional needs. While it is not unheard
of for IP lawyers to be involved in IP man
agement activities, normally, these lawyers
are focused on legal issues. Institutions
can outsource legal functions to local law
firms. Depending on the type and volume
of work, institutions need to determine
whether their IP managers require a legal
qualification in addition to the scientific
and research management background that
most IP practitioners possess.
• access to and availability of training op
portunities. Unless an institution organizes
an internal IP training program, the institu
tion often relies on the training schedules of
other programs. Some training opportuni
ties may take place at awkward times in the
organization’s business cycle. Furthermore,
it can be exceedingly costly for developing
country institutions to fund individuals to
attend a one- or two-day training course
overseas as is often the case with such IP
training programs.
• size of institution and volume of IP activ
ity. Large institutions with a significant,
growing IP portfolio may need an IP law
yer in addition to an IP manager. For most
institutions, however, an IP practitioner
may be adequate.
. Training locations

A growing number of IP training programs are
available on the market. The list of programs
below is by no means exhaustive; an Internet
search of the topic will certainly yield many more
results.
..1 IP law

Degree programs or courses in IP law are offered
by numerous universities in both developing
and developed countries. The World Intellectual
Property Organization (WIPO), along with the
University of South Africa (UNISA) offer a dis
tance-learning course in IP law.
..2 IP management

Highly regarded IP management courses are of
fered by:

• MIHR4
• AUTM (The Association of University
Technology Transfer Managers)5
• NTTC (National Technology Transfer
Center)6
• WIPO Worldwide Academy7
• NIH (United States National Institutes of
Health) Office of Technology Transfer8
• PIIPA (Public Interest Intellectual Property
Advisors, Inc.)9
. Designing training programs

A training strategy should begin with a clear mis
sion and provide measurable training objectives
through which progress can be monitored. The
training program should facilitate the achieve
ment of the institution’s goals for promoting
and commercializing products that emerge from
research.
Training-program development can be bro
ken down into ten essential steps as illustrated in
Figure 1. Note that training is a continuous and
iterative process.
. Elements of a good training program

Given the many different types of training pro
grams available, how does one distinguish good
training opportunities from those with little
value? Key considerations to bear in mind when
planning an IP training program include:
• relevance to practical issues. For example,
whereas for lawyers, the course may well
center around the law, in most cases em
phasis on legal aspects, especially patent
law, for IP management practitioners is too
strong. Rather, equal emphasis should be
placed on deal making, which should run
like a thread through training programs for
technology transfer managers.
• reputation of trainers and programs. Over
the years, certain programs have built a
good track record and are often recom
mended by former course participants. It
is useful to seek the views of past trainees
and trainers about courses attended and the
value derived from those course.
• qualifications and experience of trainers.
Some training programs provide a biograHANDBOOK OF BEST PRACTICES | 01
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Arrange logistics

Prepare training
modules and materials

Develop training plan

Identify faculty

Deliver the training

Identify
training needs

Develop strategies to
achieve training goals

Analyze
institutional goals

Evaluate the training

Plan next steps

Point of Entry

Figure 1: Steps in the Training Development Cycle
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•

•

•

•

phy of trainers and presenters. The biog
raphies provide useful information about
the trainer’s knowledge and expertise in
the field, as well as experience in providing
training to a given audience.
training topics and relevance. It is pos
sible to rapidly appraise the usefulness of
the training opportunity by carefully ex
amining the training subject matter. To
maximize the benefit of the training op
portunity, course content should be cur
rent, provide new knowledge, and show
relevance to the training needs of the se
lected audience.
method of instruction. To ensure effective
learning, training should incorporate dif
ferent methods of instruction. Lecturing is
the most common form of instruction (al
though this may not be the most effective).
Demonstrations, group discussions, roleplaying, and simulations are other methods
of instruction that can be used to maximize
the training opportunity and maintain the
audience’s interest. Programs that use dif
ferent instruction methods and a mix of
student-teacher interactions tend to be the
most effective and offer the greatest benefit
to the trainee.
training environment. The location and
environment of the training site is of major
importance to the trainee and the trainer.
The training environment should not in
terfere negatively with the learning pro
cess. Venues and facilities need to be eas
ily accessible and conducive to learning.
Without a suitable setting, the training will
be compromised.
training schedule and session plans. A welldesigned session plan will focus on topics
that the audience needs to know. Session
objectives should be clearly stated, the tar
get audience identified, and the schedule
should communicate the method and con
tent of presentations and the time available
for questions and discussion. A detailed
analysis of the training schedule ahead of
time will reveal whether or not the program
is well planned and inform choices about

which training programs to invest time and
money in.
• training material. The merit of a course
can be evaluated based on the quality and
relevance of training material offered prior,
during, and after the event. Pre-training
material is important for introducing the
topic and preparing the trainee. Post-train
ing material should reinforce the training
and provide trainees with reference mate
rial that will be useful for applying the new
knowledge.
• post-training support. Support after the
training event is important. In most cases,
the real training takes place in the work en
vironment, which is where the learning can
be applied and utilized. Trainees may not
always be certain of themselves; when it is
possible for trainees to ask questions and
reaffirm learning, the chances of applying
the new learning successfully are greater.
Different forms of training programs exist,
and some programs will be more valuable than
others; if possible, trainees should experience
a range of opportunities. Post-training reports
should not only detail the outcomes of a given
training program but also explain how the train
ing experience will change work practice. The
measures that management can use to monitor
development should be clear. The institution
paying for the training should be able to measure
the outcomes of the training experience. Long
term outcomes should address the competency
gaps identified in the needs analysis and should
be evaluated using measurable indicators. Long
term outcome measures would include:
• increased research outputs
• more efficient resources utilized for IP man
agement activities
• improved financial performance of the
organization
• portfolio performance
Short-term outcome measures include:10
• improvements in skills performance
• improvements in the efficiency of conduct
ing procedures and tasks
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• showing an understanding and appreciation

of performing tasks in a prescribed way

Table 2 introduces the different types of train
ing and examines the pros and cons of each form.
Box 2 presents an outline of a workshop plan.

. ConCLuSIonS
The chapter provided an overview of training op
portunities that can enable developing-country
institutions—or indeed institutions anywhere in
the world—to strengthen staff competencies and
thus build internal IP management capacity. The
chapter offers to institutions guidelines for evalu
ating training needs and reviews different kinds
of training programs, identifying the pros and
cons of each.
The adage “reading is learning, seeing is be
lieving, and doing is knowing” is particularly ap
propriate in the context of training and capacity
building. Accompanying this chapter are several
case studies for short courses, each presenting a
different challenging IP management scenario.
Case studies give trainees opportunities to envi
sion how a technology transfer project might be
carried out.
Finally, a detailed workshop plan that pro
vides comprehensive steps is important. Such
an IP management training course so that it can
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then be successfully implemented, while engag
ing, educating, and motivating participants. n
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Table 2: Pros and Cons of Different Types of Training Programs
Type of
training
Short
courses

Pros
• trainee not absent from work for extended
periods

• no formally recognized
qualification

• can be inexpensive

• course coverage possibly
unfocused

• training opportunity focused and aimed at
professional development
• teaching specifically targeted to adult
learners

• possible to be selective and choose only the
most relevant training courses

Full-time
courses

Cons

• often leads to a formal qualification

• course content detailed and the learning
intense

• direct access to training material, lecturers,
and other resources
• better opportunity for trainee to build
lasting networks

• course content shallow

• value of learning
experience dependent on
the extent to which the
trainee can apply the new
knowledge
• trainee absent for a
longer period

• training might be costly
• not all of the course
content relevant to the
institution’s current
needs

• greater chances that trainee will complete
course within the stipulated period
Part-time
courses

• trainee not away for extended periods

• learning in segmented modules enabling
trainee to apply new knowledge in a more
structured manner

• overall training period
possibly longer than fulltime course
• overall cost of releasing
trainee from work not
necessarily cheaper

• possibility that trainee
may take longer to
complete course due to
flexibilities built into the
course
Distance
learning

• flexible learning schedule

• trainee can be situated anywhere

• training material is normally in a form
that makes it readily available for future
reference

• trainee may not necessarily need time off
work

• need for good timemanagement skills and
the discipline to study

• trainers and training
resources less accessible
• coursework coincident
with full-time
employment

(Continued on Next Page)
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Table 2 (continued)

Type of
training
Internship

Pros
• can be customized for the individual
• practical experience

• greater exposure for trainees through
secondments to different organizations

• training in depth and teacher/trainee
exchange better, resulting in a potentially
better cost benefit to the institution
supporting the training

Cons
• may necessitate extended
absence
• can be costly

• no formal qualification
obtained

• overall training experience typically varied
with broader exposure

Internal
training

• training customized and contextualized
• greater control over course content
• training intense and in depth

• can be structured to cater to the different
needs of different groupings within the
research community
• greater number of individuals can be
exposed to a single training episode

• assists with creating an internal culture of
learning and understanding intellectual
property
• helps to develop institutional IP networks
and systems
• post-training assistance is normally
available
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• the institution must pay
unless training is funded
• for the duration of the
course, productivity may
be lower

• institutions need to be
involved in the planning
and implementation of
the event; in some cases,
institution may need
to assign staff member
to assist with training
arrangements
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Box 1 : Case Studies for use in Training

EyEBoRn™ oRBITAL IMpLAnT
Your local research and technology institute (RTI), in collaboration with a clinical research
organization (CRO), a group of surgeons and the local university, have developed an
orbital implant to replace eyes lost due to disease or injury. The Eyeborn™ implant is to be
launched as a commercial product at the next International Ophthalmology Conference.
The central aim of the project, supported by an angel investor, is to develop an improved
and more cost-effective orbital implant. The hydroxyapatite material from which the
implant is made, allows tissue and blood vessels to grow into the porous ceramic. Since the
eye muscles are attached to the orbital implant, mobility of the implant is synchronized
with that of the normal eye. Once a polymer prosthesis, or cap, with artwork of an iris
and a pupil is placed over the implant, it is often difficult to discern a difference in the
eyes in appearance and movement. This means patients who receive an implant appear to
have normal ocular function. Presently, your product offers a more affordable, high-quality
alternative to existing implants. It will benefit a larger percentage of the poor population,
and, because of the lower cost, will be more accessible to government hospitals and clinics.
Presently at government hospitals, patients that have lost an eye are given either a silicon
eyeball or nothing at all.

Background
• A local patent has been granted for the eye orbital.

• There is a patent application for the orbital eye inserter.
• RTI owns the intellectual property.

• You have approached a local company to do the manufacturing.

• You would like to sell the product nationally and internationally.

• You would like to ensure that the product is available at an affordable price at all local public
health facilities.

• You have a three-year window of opportunity to get your product on the market and to secure
a sustainable market position.
Tasks
• Determine whether or not you will file international patents, stating where, how and why.
• Determine how benefits will be shared with the consortium of researchers.
• Identify any other forms of IP you may consider protecting.

• Summarize what commercialization vehicle you will use and why.

• Identify your key partners to help you get the product on the market.
• List agreements you require with your partners.

• Describe your business model for supplying private and public sector health facilities.

(Continued on Next Page)
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Box 1 (continued)

THE SMART-LoCk SAfETy SyRInGE
The Smart-Lock Safety Syringe provides improved protection against needle stick injury
and contamination. The device has an added benefit of being easier to use and providing
more accurate measuring.

Background
• The Smart-lock Safety Syringe technology is a new disclosure by your institution’s
researchers.
• A prototype has been developed.

• The market for syringes in your country is highly competitive and saturated. While there are
no Smart-Lock Safety Syringes on the market, there are many different other types of syringes
available.

• You have been promised significant distribution opportunities for your product in francophone
Africa, provided you establish a factory in one of the countries. Most countries in this region
have weak IP protection systems.
• To manufacture the Smart-Lock Safety Syringe is a highly technical process; the know-how or
the process resides with the small group of researchers at your institution.

Tasks
• Develop an IP protection strategy for the Smart-Lock Safety Syringe detailing:

- whether or not you wish to protect your intellectual property (if not, go to the next task);
if so:

- where to protect the intellectual property (taking into consideration national, regional,
and international patent systems)

- when to start applying for IP protection

• Given your answers to the questions above, develop a business plan that details how you
intend to exploit your intellectual property . In the summary of the plan, address the following
issues:
- partnerships and partnership agreement conditions
- other agreements required

- technology and knowledge transfer arrangements
- your business model

(Continued on Next Page)
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Box 1 (continued)

AvEnGInG MonTEzuMA’S REvEnGE!
The purpose of this case study is to consider basic strategies related to the building of
public–private partnerships, the pooling of resources, building on comparative advantages,
and achieving the dual goals of social needs and commercial objectives. Specifically,
trainees will be addressing the issues of licensing across public and private sectors that are
attempting to meet needs in developed and developing countries.
In this case study, trainees are encouraged to develop creative ways in which public and
private sectors can combine their resources, segment markets, and address the specific
needs of different constituencies (developed and developing countries).

Background
Viajes BioTech Inc.11 is a small biopharmaceutical company in North America, founded by Jose
(Pepe) Herrera, a Mexican immigrant to the U.S. Prior to establishing the company, Pepe worked
for his mother’s travel agency while he was studying for his doctorate degree at the Autonomous
University of Cancun, Mexico, and visited all corners of the world. During these times, he often
had intestinal discomfort and returned with diarrheal diseases. His doctoral thesis focused on
such diseases, and he collected many Escherichia coli specimens from around the world. After
making good money during the dot-com boom, he set up Viajes BioTech Inc. in San Diego, United
States, to build on his Ph.D. research with the primary purpose of alleviating the suffering of the
many millions of travelers to the developing world.
The Research To-Date

E. coli heat-labile enterotoxin (LT) is composed of catalytic A and noncatalytic homo-pentameric
B subunits and causes diarrheal disease in humans and animals. In order to produce a nontoxic
LT for vaccine and adjuvant development, two novel derivatives of LT were constructed by a sitedirected mutagenesis of A subunit; Ser63 to Tyr63 in LTS63Y and Glu110, Glu112 were deleted in
LT delta 110/112. Mice immunized with the purified mutant LTs (mLTs) either intragastrically or
intranasally elicited high titers of LT-specific serum and mucosal antibodies.These results indicate
that substitution of Ser63 to Tyr63 or deletion of Glu110 and Glu112 eliminate the toxicity of LT
and both mutants are immunogenic to LT itself. Therefore, both mLTs may be used to develop
novel antidiarrheal vaccines against enterotoxigenic E. coli.
Note that the particular strain used in this research originated from a sample collected from
a campesino at a clinic in Pepe’s grandparents’ hometown, Chulula, outside San Cristobal de
las Casas in the State of Chiapas. Whenever he visited his family at Christmas and Easter, Pepe
would spend a few days helping in a clinic in that village. Campesinos are generally poor farm
laborers.

Business Model of Viajes BioTech Inc.

The company focuses on the development and commercialization of a vaccine for diarrheal
diseases that occur predominantly in developing countries but that have a significant market in
developed countries among travelers for both business and leisure.
Viajes Biotech Inc. counts some 50 highly trained staff and has laboratories able to produce
nonGMP pilot lots of the vaccine but has no clinics or production facilities.

(Continued on Next Page)
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The company owns the key intellectual property for the vaccine in the form of a single
dominating patent (but a series of continuations in part are still at the patent office in the United
States). Pepe still has another two months to file for (PCT Patent Cooperation Treaty) applications
in foreign jurisdictions, having marked all possible boxes in the application. Money, however, is
relatively tight, and it is not clear whether the expense is warranted.
Because the infections are extremely rare in most developed countries, it is difficult to test
the vaccine in those countries. Thus Viajes BioTech Inc. is seeking a partner in the developing
world to assist in the clinical trials. Pepe, having lived the first 25 years of his life in Mexico, also
wants to find a way to extend the benefits of the vaccine to people in the developing world.

During his recent vacation trip over Christmas to the South African vineyards, Pepe visited
a former fellow student of his, Koreen Ramessar, who works on muscular dystrophy at the
Department of Human Genetics at the University of Cape Town medical school. Koreen heard
of the advances her classmate had made with his vaccine and introduced him to the director of
IIMR, the International Institute of Medical Research in Colombo, Sri Lanka. The current director,
D.C. Mokhobo, is originally from Cape Town and was visiting her family over the festive season.

Pepe and Dr. Mokhobo of IIMR had dinner just before New Year’s Eve and agreed, in principle,
on a joint effort to develop the vaccine further whereby Viajes BioTech would focus on introducing
the vaccine into developed countries, and IIMR, through appropriate partnerships, would focus
on developing countries.
The International Institute of Medical Research, IIMR

IIMR is an autonomous international nonprofit organization headquartered in Colombo, Sri
Lanka. It maintains a network of laboratories and research centers hosted by a series of leading
research institutions across the developing world.The institute also carries out research, teaching
and training in its facilities. The entity does not have its own clinics but arranges for clinical
studies through collaborating centers in developing countries.

Tasks
General

To develop a framework agreement between a public (IIMR) and a private entity (Viajes BioTech
Inc),sketching the outline of a business plan,with particular focus on the IP strategy,incorporating
all the available tools, as appropriate.
The Teams

Pepe and Dr. Mokhobo each requested the relevant people in their institutions to work out the
details on how the scheme could be made to work to benefit both parties. Two teams were
created:
• One team represents the business development and marketing side of Viajes BioTech Inc.

• Another team represents the R&D program of IIMR and also includes the deputy director for
International Cooperation.
The Specifics

First, meet in your own team for 60 minutes to determine the issues that need to be addressed.
Specifically, think of the needs of your entity to ensure that the primary policy of the entity is
(Continued on Next Page)
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Box 1 (continued)

respected in the deal. Also think of the needs of the other party. For example, Viajes BioTech must
find a way of making a return on its investment. IIMD, on the other hand, does not sell things
and will need to think of marketing alliances and licensing, as well as obtaining the funding to
conduct the work.
Second, the teams meet together and compare ideas, issues, and approaches. Note that this
is not primarily a negotiating exercise. Begin by developing the overall business plan for how the
vaccine would be tested and commercialized, both in the developing and developed worlds. Then
develop a coherent IP strategy that reinforces the business plan.

Remember that your bosses have made the policy decision, in principle, to get this venture
going. Your task is to flesh out the framework for how it could work in practice. Hence the other
party is not a hostile team but, essentially, in the same boat as you are. Also, you are not required
to develop a detailed investment plan with cash flow and royalty rates; rather, the principles of
the deal are to be developed.

The Assumptions

• The time required to develop the vaccine for clinical trials is 9 months.
• Clinical trials will take two years to complete if all goes well.

• The cost for clinical trials across five countries is estimated to be US$20 million.

• The cost of production for 1 million units is US$10 million. That cost could be reduced to US$5
million if produced in a high quality laboratory in India. Note that these costs do not include
marketing and distribution costs, commissions, advertising, and so forth.

• The total market in the United States, Europe, and Japan for business and leisure travelers is
estimated by Viajes BioTech Inc. to be approx. five million units per year in the first five years,
increasing to 15 million units per year thereafter. Viajes BioTech Inc. estimates that travelers
are willing to pay up to US$25 per shot/unit.
• The total market in the major cities in Asia, Africa, and Latin America is estimated to be at
least 100 million units per year.

• Viajes BioTech Inc. already invested US$7.5 million in the vaccine. The next round of financing
will be launched in three months and the company needs to show a sound business plan and
potential for significant profits, if it is to convince its current and prospective new investors of
putting up an additional US$30 million or so over the next three years.
The Report to Your Bosses

Specific issues you should address in your report (in the form of a slide presentation lasting no
more than 10 minutes), should include:
• Who supplies the vaccine for clinical trials?

• In which countries outside the U.S.A. should Viajes BioTech Inc. file for patent protection?
Remember that each such filing will cost some US$25,000 including translation and filing
fees.
• What other form of IP protection should be sought? When, where, and why?
• Who is liable for untoward events with the vaccine in clinical trials?

• Who should own potential new intellectual property generated from the clinical trials
conducted by IIMR?
• Means by which the vaccine could be (1) produced, (2) marketed, and (3) sold in the developing
world.

• How will you deal with third-party technologies that may have to be licensed-in for the
production of the vaccine?
(Continued on Next Page)
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• Are there any issues of compensating Mexico for use of the E. coli strain that led to the vaccine?
If so, what might they be and how could they be resolved?

• Prior review of the labeling of the vaccine for sale in any market. Include an explanation of why
there should be review.
Additional Considerations

• Should your group require specific technical,strategic,and legal advice,it can be made available
for a limited time. However, the external advisors will only respond to well-formulated and
relatively specific questions.

• Invent whatever additional information you feel you may need, but be sure to specify such
assumptions (amount of capital needed, types of IP protection sought and obtained, terms
of the commercial licenses required, the way that regulatory issues are addressed, and so on).
Make reasonable assumptions, given the milieu of your activities.
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Box 2: Sample Workshop Plan
objectives

• To provide quality training for sustainable knowledge and skills transfer in intellectual
property management.
• To develop appropriate skills for identifying, protecting, developing, valuing, and
commercializing research resources.

• To develop knowledge and skills in strategic IP management, focusing on the fundamentals
of IP rights: licensing issues and negotiating joint venture agreements that seek to enhance
the availability of research results for health products.
Workshop emphasis

The workshop will focus on providing participants basic/intermediate/ advanced [indicate which]
level training in IP management.
Background

Many developing country institutions lack the human capital and capacity required to design
and implement IP management systems that serve the IP management needs of academic
institutions. Without meeting the need to provide training to personnel in IP management, the
execution of IP management practices is less likely to succeed. The proposed capacity-building
initiative will focus on developing learning experiences that have immediate relevance to the
participant’s occupation and experience, thus providing the basis for activities that lead to
institutional IP management development.
partners

Acknowledge the organizations collaborating on or sponsoring the training.
Workshop format

• Tutorial work and presentations
• Case studies and role-play

• Materials for reading and future reference
Training topics

• The fundamentals of intellectual property management. This component will provide the
basic principles of intellectual property protection processes and an overview of IP regimes.

• IP strategies and methodologies. The purpose is to teach participants the approaches to
negotiation, establishing agreements, licensing, technology transfer processes, and business
development.
• Technology transfer management. An overview of technology management functions and
strategies is provided.

• Commercialization. Provide instruction on how to develop a commercialization plan, include
discussion of the key components of such a plan and guidance on aspects such as negotiation,
deal structuring, and venture fund sourcing.

(Continued on Next Page)
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Teaching and learning methods

The teaching techniques selected are designed to enable trainees to gain knowledge through
traditional tutoring methods and from each other’s experiences.
• lectures. knowledge transfer using conventional teaching techniques (direct instruction)

• presentations. “guest speakers” including IP professionals representing private and public
sector industries

• case studies. interactive practical exercises that encourage participants to apply the knowledge
they have acquired to solve complex intellectual property issues
• role play. exercises that expose trainees to strategies and approaches in operation in various
IP management disciplines
Workshop content and curriculum

The teaching content of the workshop will be developed in consultation with key partners. The
suggested agenda for a four-day workshop is presented below.
day 1. Refresher on IP processes and regimes: An overview of IP processes
day 2. IP management practices

• current practices and issues in IP management
• licensing fundamentals

day 3. IP management strategies: Managing an IP portfolio

day 4. Technology transfer strategies and commercialization
• fundamentals of technology transfer

• fundamentals of commercializing intellectual property
Training materials

• slide presentations
• case studies

• role-play supplies
• reading material

• CD of reference material and Web-based links
Accreditation

Participants will receive acknowledgement for full attendance of the training program.
Tutors

Tutors will include:

• three to four keynote speakers
• lecturers and presenters

• facilitators of interactive activities

(Continued on Next Page)
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Box 2 (continued)

Who should attend

This training program is directed at professionals in health R&D interested in acquiring skills in IP
management. The target audience includes:
• technology transfer office staff

• research managers and scientists
• senior management
venue

Accommodation will be provided at preferential rates. Refreshments and meals will also be
provided.
Costs

Participants will be required to pay their own travel costs. Participants will be required to make a
single payment [or other payment plan] when registering for the workshop.
Entry limitations

Entrance will be granted to the first 20 applicants who complete registration.
Subsequent training and support

Post-workshop activities will include issues identified during the training-needs analysis and also
take into account responses received following a workshop survey among participants.
Workshop evaluation

The assessment measures will be determined first by the specific objective of the workshop, and
second, by the expectations of participants. Evaluation measures will include:
• relevance of the workshop to participants
• choice of tutors

• professional diversity of trainees
• duration of workshop

• balance between theory and application
• training techniques

• discussion and exchange
• documentation

Suggestions for further improvement will be sought from trainers, trainees, and observers.
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Building Networks:
The National and International Experiences of AUTM
kAREN HERSEy, Visiting Professor of Law, Franklin Pierce Law Center, U.S.A.

ABSTRACT

Developing and implementing best practices in intellec
tual property (IP) management requires several critical
inputs, and building networks is among the most im
portant. The experience of the Association of University
Technology Managers (AUTM) serves as an excellent
example of how to build and maintain such networks.
The important lessons learned as AUTM grew and ex
panded its networks are broadly applicable to building
dynamic, productive, and sustainable networks anywhere
in the world. Furthermore, since AUTM is an association
of individual, rather than institutional or organizational
members, it functions all the more as a catalyst for net
working. Networking provides two important benefits.
First, it facilitates relationships between individuals with
varied experience, expertise, and skill sets, encouraging
individuals to contribute to each other’s professional
expertise. Second, the network itself contributes to the
overall quality of group performance. Working through
networks, practitioners exchange ideas and experiences to
form best practices that become performance standards
for individuals and their institutions. Networks thereby
contribute to building IP management capacity at both
the individual and institutional levels, and this capacity
building then feeds back to further support and expand
the network. This chapter considers the networking prac
tices established by AUTM. It charts the organization’s
growth over a period of 30 years from a small group of
U.S. and Canadian patent managers to an association of
more than 3,400 members from countries on every con
tinent.1 As the story of AUTM demonstrates, networks
can begin locally and gradually expand to operate on a
national, regional, and even international scale. However,
as AUTM has shown, the organization itself must begin
with—and steadfastly maintain—a clear and focused
central mission.

1. INTRODuCTION
Networking among peers in any profession gener
ally provides two important benefits. It encourag
es relationships between individual practitioners,
some of whom may be highly skilled while others
are less so. Regardless of the proficiency levels of
individuals, each one contributes to the experi
ence of every other. Whether individuals func
tion as mentors or apprentices, the one-on-one
interactions raise the level of each person’s exper
tise and professionalism. Moreover, networking
contributes to the overall quality of group perfor
mance. By working through networks, practitio
ners exchange ideas and experiences, developing
best practices that become standards for perfor
mance. The Association of University Technology
Managers (AUTM) provides a shining example of
how this process can benefit an organization. The
history of the AUTM provides a solid case study
of the usefulness and power of networking.
2. FORMING A NETWORK
TO SOlVE PROBlEMS
AUTM began its journey as a direct result of
networking. Coming together as a small group
to solve a set of common problems in the mid
1970s, a handful of individuals formed a net
work that would eventually grow into AUTM.
Midway through 2006, the total membership
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stood at 3,494. The organization plays a global
role in developing academic technology transfer
as a unique profession.
AUTM, or more accurately its antecedent,
the Society of University Patent Administrators
(SUPA), did not start out to establish a new pro
fession. Rather, it started as a loose organization
of individuals, notably not institutions, who saw
a need to work together to solve problems. The
problems of the day were specific to the then-cur
rent university patenting situation in the United
States. A jumbled array of inconsistent patent
policies among U.S. government agencies fund
ing research at U.S. universities made for a dif
ficult landscape for early practitioners of univer
sity technology transfer. At the same time, a few
experienced individuals recognized that other
issues involving patenting and licensing periodi
cally emerged in their daily activities as university
licensing professionals. Patenting and licensing
concerns were not commonly understood by the
colleagues of these individuals. Although there
were relatively few U.S. universities engaged in
technology transfer in the mid-1970s, there was
enough activity to suggest a need for an associa
tion of individuals who could help each other. In
the beginning, AUTM (SUPA, at the time) was
chartered to create networks of individuals who
would find solutions to problems arising from the
complex legislative landscape in the United States
and who could provide useful interpersonal link
ages to help understand and deal with the com
plexities of patent licensing.

3. EARly DAyS: DEVElOPING THE MISSION
Early efforts to draw new members into the fledg
ling organization could succeed only if organizing
filled a need. Articulating a mission was then, as
now, indispensable to creating sustainable net
works. While the word networking was not com
monly used in those days, the enumerated pur
poses for establishing the organization included,
among others, “generating self-help programs to
enable universities to establish an in-house patent
technology and licensing capability” and “effect
ing interchange of views amongst university patent
administrators.” These goals certainly match the
618 | HANDBOOK OF BEST PRACTICES

modern concept of networking. These early efforts
to articulate a useful mission were successful: at
its first annual meeting in 1976, some 51 indi
viduals paid a $30 fee to join SUPA.
No two networks are alike, nor is the pro
cess by which they are formed. Each network is a
unique creation formed by different people for dif
ferent purposes. Each grows according to the ac
tivities its members choose to focus on. Often, the
role a network takes on is influenced by external
factors that simply happen. Such was the case with
SUPA. Its unexpected ability to wield influence
through its networking capacity became apparent
early on, as its members were rallied to gather sup
port for the most significant piece of legislation to
affect university technology transfer in the United
States: the Bayh-Dole Act.2 By using the organi
zation as a pulpit from which information about
the Bayh-Dole bill could be broadcast, SUPA was
able to give members the information they needed
to urge their own congressional representatives to
support the bill. The organization gained public
recognition from this early experience of energiz
ing its member network. It continues to play a
role in virtually all U.S. federal policy efforts that
involve technology transfer at universities.

4. ExPANDING GEOGRAPHIC BOuNDARIES
Today, AUTM’s membership is an ethnically
and culturally diverse group with individuals
from around the globe. This diversity is due,
in part, to another external factor that played
an unanticipated role in expanding the AUTM
network. While there was no overt intention to
reach beyond U.S. boundaries during SUPA’s
formation in 1974 and 1975, the organization
embraced Canadian institutions nearly from the
start. It happened quite naturally that Canadian
members were included because of their person
al connections and relationships to SUPA’s orga
nizers and also, perhaps, because a mailing list
was used that reached across the United States/
Canadian border. The outreach encouraged a
contingent of six Canadians to attend SUPA’s
first annual meeting in 1976. By 1978, SUPA
had its first Canadian trustee, and a concerted
effort was made to extend information about
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SUPA to licensing practitioners in Canadian
universities. Another reason for AUTM’s inter
national membership had to do, no doubt, with
the omission of any geographical or national
limitations in early membership requirements.
Membership was open to “any individual who has
some responsibility for the administration of inven
tions and/or intellectual property at an institution of
higher learning….” Although not part of the early
planning, the fact of early Canadian involvement
paved the way for AUTM to grow as an inclu
sive, rather than exclusive, global network. By not
limiting its membership, SUPA was providing av
enues along which global networking could begin
to develop.

5. DEVElOPING A NETWORKING
STRuCTuRE
Early decisions to structure AUTM as an asso
ciation of individual, rather than institutional or
organizational members, laid the foundation for
the organization as a catalyst for networking. The
first step in developing its networking capacity
was to use regionalization as the best mode for
organizing subgroups, rather than using public/
private, big/small or other classification schemes.
Organizing by U.S. geographical regions (East,
Central, West), and then forming a Canadian
region, promoted networking in several im
portant ways. It helped individuals in the same
geographical region to become acquainted with
one another and provided opportunities for dis
cussing issues that were common to their region.
Closer regional associations also promoted faster
and more-satisfactory resolutions of ownership
and licensing issues where faculty and students
in neighboring institutions actively partnered in
research. Organizing in regional cohorts also laid
the groundwork for local summer meetings that
AUTM introduced in 1992. The purpose of the
new format of regional summer meetings was ex
pressly to provide small, informal meeting venues
that were more conducive to forming personal re
lationships than were general meetings attended
by the membership at large.
In 1978, the organization took a second step
to expand opportunities for member networking

by adopting a category of affiliate membership.
Individuals can be admitted as affiliate members
if they are, “engaged either directly or indirectly in
activities relating to the administration of intellec
tual property… and [their] organization interacts
with institutions of higher education or teaching
hospitals.”3 An important reason for introducing
the affiliate-member category was to provide an
opportunity for regular members to make con
tacts with prospective licensees, as well as with
service providers such as patent counsel. Through
these opportunities, members could begin to de
velop personal networks among companies con
sidered to be customers. AUTM recognized that
networking could be used as a marketing tool to
build relationships with potential customers. The
decision to do so had a tremendous impact on the
growth of the organization.
Through trial and error, AUTM adopted
an internal structure to support its networking
goals. Initially, the management structure did
not include any position dedicated to enriching
networking activities. But as the organization’s
membership grew and its educational activities
expanded, it became clear that AUTM had to
pay closer attention to specific member needs.
Over a period of two years, between 1993 and
1995, AUTM reorganized and made networking
a fundamental focus of its organization. This was
accomplished by adding two new positions to the
board of trustees: a vice president for member
ship and a vice president for communications.
Further strengthening its commitment to the
networking needs of its members, the organiza
tion added a vice president for affiliate members
to the AUTM board in 1997, and in 2000, the
organization created a vice president for interna
tional relations position. AUTM has made other
recent changes at the trustee level to support and
bring greater emphasis to its network. A vice
president for public policy supports the efforts of
AUTM’s members to speak in a collective voice
on relevant policy matters. In addition, because
the organizing of the annual meeting and the
data gathering function, overseen by the Metrics
and Survey Committee, have emerged as the pri
mary interests of the organization’s membership,
these two functions (formerly under a single vice
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president) are now represented on the AUTM
board by two separate vice presidents.

6. MEMBER NETWORKING
While supporting networking through the orga
nizational structure is an indispensable activity,
more than structure is needed to instill network
ing as a seamless part of a member’s experience.
Over the past 30 years, AUTM has pursued dif
ferent avenues to reach this goal:
• The AUTM Web site went online in 1995.
It provides members with online access to
shared information. Networking is spe
cifically addressed through a MEMBER
CONNECT capability that allows mem
bers to find and communicate directly with
one another through email.4
• The AUTM Newsletter provides informa
tion and articles of current interest. The
newsletter is now delivered six times a year
electronically, and members receive weekly
updates by email.
• Educational courses are held throughout
the year to provide professional education
to both new and more experienced mem
bers. These courses directly contribute to
the overall quality and influence of the
AUTM member network.
• Special interest groups (SIGs) encourage
members with particular interests to meet
together to discuss issues and solve prob
lems. Each SIG meets in conjunction with
AUTM’s annual meeting.
• Summer meetings are held in each AUTM
region, with networking opportunities
forming a major element of program plan
ning. Special workshops promoting net
working have been included in both sum
mer and annual meeting programs.
• Activities at AUTM’s annual meeting that
support its networking goals include:
- logistical and space planning to facili
tate networking breaks, which serve to
support prearranged and impromptu
meetings
- social events specifically arranged to
promote relationship building, such as
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-

-

sporting events, receptions, group din
ners, and a special reception for new
members to facilitate their first AUTM
networking opportunity
specific time set aside for each AUTM
region to meet
one afternoon dedicated to SIG meetings
the Networking Fair, first held in con
junction with the 2000 annual meeting,
providing a forum for members to meet
with affiliate members looking for new
licensing opportunities (The fair enables
members to build their own marketing
networks and has become a major an
nual meeting event.)
the Innovation Showcase, introduced at
the 2006 annual meeting, gives AUTM
members an opportunity to formally
present new and promising technolo
gies to AUTM’s network of affiliate
members (The 2006 showcase pro
duced several relationships with poten
tial licensees. As another successful ex
ample of promoting networking among
AUTM’s members and their customers,
the showcase will be repeated at the
2007 annual meeting and after, as in
terest warrants.)

Forming an integral part of the AUTM struc
ture, most of these efforts continue today.
Metrics are one way to measure the impor
tance of organizational activities to members and
to gauge the success of the organizational efforts
to support those activities. An AUTM survey
conducted in 2005 was especially instructive,
as it measured the importance of networking to
AUTM members. The survey results indicated
that networking with colleagues was cited as a
primary reason for joining AUTM by 22% of
respondents; and 51% of respondents cited net
working with colleagues as the reason for remain
ing an AUTM member. Networking was by far
the most important reason for retained member
ships. Thirty-eight percent of respondents se
lected networking as the second most important
reason for joining AUTM. It is clear from the
survey that working to build successful member
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networks should remain a primary focus for the
association.

7. BuIlDING AuTM’S
INTERNATIONAl NETWORKS
7.1

Options

AUTM has long debated how to extend its
member network beyond the United States and
Canada to include relationships with technol
ogy transfer professionals in other countries.
The importance of learning from counterparts
in Europe, Asia, South America, and elsewhere
was always regarded as an important goal.
Memberships were routinely accepted from
individuals from any country who fit the reg
ular-member or affiliate-member definitions.
However, member surveys and questionnaires
through the 1980s up until the mid-1990s
showed that most Canadian and U.S. members
were not engaged in enough global activities to
warrant placing the question of how to “interna
tionalize” on the AUTM agenda.
As globalization increased during the 1990s,
the situation changed. More institutions were
doing business abroad, and there were more and
more requests for memberships from foreign
countries (although foreign members still account
for only a small fraction of all AUTM member
ships). It is probably fair to say that a major factor
in AUTM’s thrust onto the global stage was the
publication of two important works by the orga
nization in 1994: the AUTM Technology Transfer
Practice Manual and the first annual AUTM
Licensing SurveyTM. These enhanced the organi
zation’s reputation for leadership in technology
transfer, both at home and abroad. Requests for
translation rights to the practice manual made
it clear that AUTM had provided a practical
resource for technology transfer professionals
regardless of nationality, and the AUTM licens
ing survey provided a model that other countries
and geopolitical units could look to in measuring
their own technology transfer activities.
Despite growing international interest,
AUTM responded slowly. This hesitation was
due not to any lack of interest in networking

with international colleagues, but rather to cau
tiousness about selecting the structure for the
interaction. Any networking organization that
begins regionally but wishes to expand must
consider how the expansion fits in with the its
mission. The organization must decide whether
it can expand without compromising that mis
sion and whether, in the case of AUTM, it
should attempt, as a wider organization, to ex
tend beyond its borders, or leave it to disparate
national regions to do so individually. AUTM
wrestled with these questions throughout the
1990s. It considered proposals for international
growth that ranged from marketing materials
worldwide, under the AUTM brand, to fran
chising. The organization weighed the options
of establishing an “international region,” that
would mirror the United States and Canadian
regions, with establishing a looser type of struc
ture where networking, sharing of educational
materials, and joint meetings would form the
basis for AUTM’s international relationships.
The path toward finding an appropriate inter
national role for AUTM formally began with its
agreement in 1997 to partner with Science Alliance
in sponsoring a conference in Amsterdam aimed at
European participation. The success of this con
ference resulted in similar conferences sponsored
jointly by AUTM and Science Alliance in 1998 and
1999. Partly as a result of networking at these con
ferences, Europe formed its own organization, the
Association of European Science and Technology
Transfer Professionals (ASTP) while UNICO,
among others, was formed in Britain. In a sense,
then, AUTM’s approach to internationalizing was
determined not by AUTM, but by the individuals
who would people the new international organi
zations. Those individuals answered the question
for themselves. They would have most to gain, in
terms of networking and education, by forming
their own independent organizations to focus on
regional issues. And as these organizations now be
gin to grow their own networking capacities, they
may find AUTM’s experience useful.
This is not the end of the story, however.
Although AUTM had decided neither to fran
chise itself nor to form an international region,
international interest in AUTM’s educational and
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networking activities was growing. Without com
promising its initial mission of education, net
working, and influencing academic technology
transfer directions in the United States, AUTM
added a vice president for international relations
to its board of trustees in 2000. In the same year,
AUTM hosted its first independent international
conference in Edinburgh, Scotland, attracting
182 participants from 18 countries.
7.2 Networking for a global impact

AUTM’s current challenge is to meet the net
working and educational needs of colleagues in
developing countries. A first major step in this
effort has been to offer very low-cost electronic
memberships (US$10 per year) to colleagues in
developing countries. Electronic memberships
give these members electronic access to AUTM’s
publications and news updates and provide
these members with opportunities to partici
pate directly in AUTM activities—all without
paying the higher costs associated with regular
memberships. In an effort to build a global net
work of partnerships, AUTM is seeking to form
sustainable relationships with organizations
such as MIHR (Centre for the Management of
Intellectual Property in Health Research and
Development) and WIPO (World Intellectual
Property Organization).
7.3 Networking as part of strategic planning

While network building has been central to
AUTM’s organizational efforts from its inception,
in many respects networking among members has
naturally happened without robust or direct plan
ning. Nonetheless, as a result of recent changes
in AUTM’s strategic planning, networking will
command a center stage with two strategic goals:
(1) to specifically identify and gather a number of
essential skills and best practices that have been
learned through AUTM’s networking activities,
and (2) to add a new networking component
that will establish networks with other organiza
tions that have related interests. The latter goal
is explained as an effort “[to] develop a network
ing map of key organizations, both for-profit and
not-for-profit, and individuals with whom AUTM
wishes to collaborate.”5
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8. CONCluSIONS
Network building by any professional organiza
tion or association comes from a unique combi
nation of individual member preferences, goals
adopted by the organization, and factors that hap
pen randomly. Thus, the experience of AUTM is
unique simply because there is only one AUTM.
It is not unique, however, in terms of adopting
networking practices and activities that are driven
by the fundamental interests of its members and
that seek to encourage both learning and mentorship based on shared experiences. This goal repre
sents a universal maxim of network building that
can be applied across the world, in both devel
oped and developing countries. Strong member
networks build quality and integrity by adopting
best practices that have been tested and found to
be successful. Building networks both among its
members and with aligned organizations provides
the credibility an organization needs if it aspires
to a leadership position in its sphere of operation.
The AUTM experience may be helpful for others
seeking to reach those goals.
Networks, as groups of like-minded, mis
sion-driven professionals, can be formed at dif
ferent geographical levels in order to serve vari
ous functions. This multilevel approach allows
organizations to address different aspects of their
respective missions:
• Local networking creates opportunities to
work with colleagues who are in the imme
diate vicinity. They might be working on
similar problems, and so such networks can
build synergistic collaborations.
• National networking can be a useful
mechanism for working with colleagues
to encourage national legislation that
addresses IP and technology transfer.
National networking can also be useful
for designing and implementing systems
for appropriate IP management, training,
and education.
• Regional networking provides opportuni
ties to work with neighboring countries
in coordinated research and development
endeavors and related IP management and
technology transfer initiatives and includes
building AUTM-like organizations.
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• International networking will become in
creasingly important as globalization ad
vances. Building networks with colleagues
from around the world will provide op
portunities for many forms of technology
transfer and for building IP management
capacity. n
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How to Select and Work with Patent Counsel
MICHAEL L. gOLdMAN, Partner, Nixon Peabody LLP, U.S.A.

ABSTRACT

Public sector technology transfer offices (TTOs) are in
the business of “moving” technology from research and
development to eventual commercialization in order to
advance their missions of serving the greater public good.
Intellectual property (IP) management is integral to this
process, and integral to IP management is patenting.
Maximal captured value for public sector technologies
will be greatly affected by the quality and scope of the pat
ent coverage and this, in turn, is greatly influenced by the
quality of work done by patent counsel. It is therefore es
sential for a TTO to select a patent attorney whose work
will enhance the institution’s prospects for obtaining op
timal licensing arrangements. From selection to hiring to
ongoing interactions, it is important for the TTO and
the patent counsel to develop and maintain a good work
ing relationship. Central to this relationship is ensuring
that patent counsel can prepare and prosecute patent ap
plications in a manner that achieves positive results cost
effectively. This is a complex process, and there are many
responsibilities that both counsel and the TTO must
assume. In addition, patent attorneys can provide gen
eral counseling: resolving inventorship issues, providing
licensing and agreement support, and settling disputes.
The TTO will be the patent attorney’s actual client and
function as the interface between counsel and the institu
tion. By selecting qualified patent counsel and then devel
oping a good relationship, a TTO can ease its workload
and facilitate its mission. Therefore, retaining a skilled
patent attorney and one that is well suited to the particu
lar needs of the TTO is an essential element for operating
a viable technology transfer program. The search for such
an attorney must be approached thoughtfully.

1. INTRODuCTION
Technology transfer offices (TTOs) at a univer
sity or other academic institution have only one
product to sell—technology. The value attributed
to such technology is influenced heavily by the
quality and scope of the patent coverage. If a pat
ent is drafted poorly or does not provide adequate
coverage for the technology and reasonable exten
sions thereof, licensing opportunities may either
be lost or greatly devalued. Unlike manufactured
goods, patents are not made by machines—they
are prepared by people, in other words patent at
torneys or patent agents. As a result, patents will
vary in style and quality as a function of who pre
pares them. Due to the possibility of such vari
ability, it is important to select carefully a pat
ent attorney whose patent work will enhance the
institution’s prospects for obtaining profitable li
censing arrangements. Guidelines on making this
selection are suggested in this chapter.
Once suitable patent counsel is selected, it is
important to develop a good working relationship
between the patent counsel, the technology trans
fer manager, and any other individuals involved
in these processes. One aspect of this developing
relationship involves ensuring that patent counsel
can prepare and prosecute patent applications in
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a manner that achieves good results in a cost-ef
fective fashion. Beyond that, however, it is im
portant to recognize that patent attorneys can
provide general counseling, resolve inventorship
issues, provide licensing and agreement support,
and resolve disputes. Suggestions on how TTOs
can work effectively with patent counsel in all
these areas are also provided.
By selecting qualified patent counsel and de
veloping a smooth working relationship with him
or her, TTOs can develop a resource that will ease
their workload and facilitate their ability to handle
difficult situations. Inevitably, when patents are
well prepared and prosecuted, they become more
valuable, and licensing income may be enhanced.
Making an appropriate selection of patent counsel
and developing a good working relationship with
him or her is one of the essential elements to oper
ating a viable technology transfer operation.

2. SElECTING PATENT COuNSEl
2.1 The patent attorney

Patent attorneys must be registered with the
U.S. Patent and Trademark Office (PTO) in or
der to practice before that governmental agency.
Obtaining such registration is not like register
ing to vote. Patent attorneys must pass a written
examination given by the PTO. In addition, pat
ent attorneys must have a degree in science or en
gineering or a sizable amount of course work in
those areas.
The PTO registers both patent attorneys
and patent agents. Those with law degrees and
admission to a state bar are registered as patent
attorneys, while individuals who are not lawyers
are registered as patent agents. In a law firm (as
opposed to in a university setting) the practice of
a patent agent is usually limited to preparing and
prosecuting patent applications before the PTO.
Patent attorneys also handle these responsibilities
and, additionally, may litigate patent disputes,
prepare and negotiate license agreements, and
provide legal advice. Because patent agents usu
ally handle only a limited scope of work within
a law firm, a TTO is best served by selecting a
patent attorney as its primary contact.
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Names of patent attorneys can be obtained
from a variety of sources. Like most profession
als, patent attorneys are best located by seeking
references and by “word-of-mouth.” Listings in
a telephone book and the PTO’s register of pat
ent attorneys are potential sources; however, they
provide no basis for distinguishing between the
listed individuals. The local bar association or
intellectual property (IP) law association may
be somewhat better resources, because these or
ganizations would have some knowledge about
individuals’ reputations in the community and,
presumably, would recommend someone with a
solid reputation.
As members of the Association of the
University of Technology Managers (AUTM),
technology transfer managers are an excellent
source of counsel who have experience with aca
demic institutions and have provided quality as
sistance to peers in other TTOs. A few calls to
the TTOs of other institutions should result in
names of recommended individuals.
Local companies are another source of pat
ent counsel recommendations. Companies with
their own in-house patent attorneys are likely to
use attorneys in private practice for some proj
ects, so in-house patent attorneys are likely to be
a very good resource. In companies with no inhouse patent attorney capability, the individual in
charge of research, development, or engineering
or the company’s general counsel are likely to be
working with outside patent counsel and should
be able to provide recommendations.
2.2 Evaluating the Patent Attorneys

Once the names of some patent attorneys have
been obtained, the technology transfer man
ager is ready to begin the evaluation of those
recommended. The following items are offered
as criteria to be considered when determining
which attorney will best meet the needs of the
institution:
• size of the attorney’s firm
• scope of the attorney’s legal experience
• the attorney’s experience with academic
institutions
• the attorney’s technological background
• the firm’s location
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2.2.1

Size of the firm

One consideration is the size of the firm with
which the attorney is affiliated. Large firms will
have a critical mass of patent attorneys and the
resources to handle whatever problems the insti
tution might encounter. These resources include
large libraries, access to databases, staff to main
tain and utilize the resources, and so on. The staff
of patent attorneys at a large law firm is likely to
include individuals with biotechnology, chemi
cal, mechanical engineering, software, and elec
trical engineering backgrounds, so that the firm
can handle work in virtually any technology. In
addition, these attorneys will collectively have
experience in patent prosecution, litigation, IP
counseling, interferences, and licensing. As a re
sult, a large law firm is generally able to handle
most any legal problem that confronts a technol
ogy transfer manager. On the other hand, small
er firms might have the advantage of lower cost
while having individuals with the skills needed
to service the institution. Although firm size is
a consideration, its significance should not be
overstated. The technology transfer manager will
be working with individual attorneys, and, there
fore, the attorney’s capabilities should receive the
bulk of the manager’s attention during this eval
uation process.
2.2.2 Scope of legal experience

A manager should know the patent counsel’s
scope of legal experience. Because a significant
portion of the work required by TTOs involves
preparation and prosecution of patent applica
tions, the attorney selected should have a solid
patent prosecution background. Careful scruti
ny of an individual’s capabilities in prosecuting
patent applications is appropriate. Ask how long
the attorney has been doing such work, how
many applications he or she has prepared and
prosecuted, and so on. Make sure the attorney
does a significant amount of original patent-ap
plication drafting as opposed to prosecuting cas
es that originated overseas. Ask to review patents
that the attorney prepared and the files of issued
patents he or she prosecuted (these are publicly
available after the patent issues or the patent ap
plication publishes). The technology transfer

manager should also examine whether the
attorney being considered has experience in
other areas, such as litigation, interferences, li
censing, and counseling. There will inevitably be
times when a TTO will need such skills.
2.2. Experience with academic institutions

It is also beneficial for the patent attorney se
lected to have experience representing academic
institutions. Attorneys with such a background
are comfortable working with TTOs as clients
and in dealing with faculty. Unfortunately, such
experience includes the ability to prepare patent
applications under the seemingly constant pres
sure of filing a case prior to publication. Another
facet of expertise in handling patent matters for
academic institutions is the ability to work with
faculty who have little knowledge about IP and
have a variety of undertakings competing for
their time and attention. Lastly, the attorney
needs to be acquainted with procedures com
monly used by TTOs to delay or minimize costs.
For example, patent counsel should be familiar
with the Patent Cooperation Treaty procedure
for foreign filing in order to delay payment of
national filing fees in the selected foreign coun
tries. Further, patent counsel without experi
ence working with universities may not know
that a reference to government rights should be
inserted in the specification. Rapport and mu
tual respect between patent counsel and faculty
inventors are also crucial to cost-effective, strong
patent protection.
2.2. Technological background

Another selection criterion is the extent that pat
ent counsel’s technological background matches
the needs of an academic institution. Larger in
stitutions may have work in myriad technologies
from electrical engineering to biotechnology. As
a result, such institutions must retain different
attorneys with these backgrounds (or a firm with
such attorneys). On the other hand, a smaller
institution, such as a medical center, may only
need an attorney with a biotechnology or medical
background. In selecting patent counsel, TTOs
should evaluate their needs technologically and
find someone with a matching background.
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2.2. The firm’s location

How close are patent counsel’s offices to the in
stitution? Generally, it is preferable to use a local
attorney if he or she is otherwise satisfactory. If
there is no local attorney with the necessary legal
and technical expertise, however, proximity must
give way to quality. If a manager needs to go out
side the local vicinity to find a patent attorney
with suitable credentials, the manager should try
to structure the relationship so that the attorney
has maximal opportunities to visit the institu
tion. For example, if possible, the technology
transfer manager should give the attorney more
than one project to work on at a time so that he
or she can come to campus, talk to the inventors,
and handle the matters in a cost-effective fash
ion. Personal meetings between TTO personnel
and patent counsel are important for fostering a
good working relationship, and making it easier
for the technology transfer manager and office
staff to receive advice. When personal meetings
are not possible or cost effective, a patent attor
ney outside the local area should be able to work
effectively with the technology manager and the
institution’s faculty by telephone, fax, e-mail, and
overnight courier.
2. Selecting one firm vs. many

Another criterion to consider in retaining pat
ent counsel is how many individuals or firms
the technology transfer manager should select.
This depends on the volume of work generated
at the institution. The technology transfer man
ager must, of course, select enough individuals
or firms to handle the institution’s work volume.
On the other hand, it is preferable to use as few
firms as possible to ease administrative require
ments on the TTO. It is also easier to establish
a good working relationship and to ensure that
the institution’s procedures are followed when
only a few firms are used. Nevertheless, it may
not be a good idea to use only one firm, be
cause that firm may not be able to handle cer
tain projects for any of a variety of reasons. For
example, the legal profession has rigorous con
flict of interest standards that prevent attorneys
from representing one client in an action against
another client. In patent matters, conflict of
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interest issues are complicated by the need to
avoid representing clients with technologically
similar inventions. It is difficult to anticipate
conflict of interest issues; they may never arise
or may arise years after patent counsel is first
retained. Another potential problem is that the
counsel or the firm selected may not, at some
distant time in the future, have the capacity
to handle a particular project. This may occur
because the attorney or the firm are otherwise
engaged or lack the required technical expertise.
Rather than dealing with a conflict of interest
or a lack of capacity situation on a crisis basis, it
may be better to select and work with a back-up
firm that can handle such projects.
2. Conditions of representation

Once the technology transfer manager has se
lected patent counsel, the conditions of rep
resentation should be established. In many
jurisdictions, lawyers are required to establish
such a relationship in writing through a retainer
letter.
One purpose of the retainer letter is to es
tablish contact people on both sides to handle
administrative matters, particularly billing is
sues. The TTO should select the person from its
staff who is most likely to interact with patent
counsel as counsel’s contact person. The retained
attorney or law firm will designate the attorney
who will prepare and send out bills. It may also
be appropriate to use one attorney as the point
of contact between the institution and the law
firm. That person can act as ombudsman with
in the law firm to ensure that the institution’s
special needs or requirements are met. It is still
a good idea, however, to know which attorney
will be taking primary responsibility for particu
lar projects and to ensure that the individual is
qualified.
The retainer letter should also establish
billing procedures. Because most law firms
work on an hourly rate basis, the retainer let
ter should specify billing rates for the attorneys
likely to be handling the institution’s work.
There is an occasional desire to utilize alterna
tive billing procedures, such as fixed fees or fee
and equity combinations. Further, some TTOs
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choose to pay their counsel a monthly retainer
fee to cover routine counseling and advice. This
makes TTO personnel and faculty less reluctant
to contact counsel with small but important
questions. The terms of any special fee arrange
ment should be stated in the retainer letter. The
retainer letter will also specify billing cycles.
Generally, bills are rendered by most law firms
every month.
Another feature of the retainer letter will
be a specification of the bill content. An accept
able bill will include, on a daily basis, an indica
tion of which attorney worked on a particular
project, the amount of time spent daily on that
project, and what that work involved. This will
make clear the services for which the TTO is
being charged. Block bills containing a narrative
of all work done on a particular project without
specifying which attorney did that work, how
much time the attorney spent on a particular
task, and when that task was done should not
be accepted.
TTOs should also prepare their own retain
er letter for newly selected patent counsel. In
the institution’s retainer letter, the TTO should
state what it expects from counsel. One impor
tant point that this letter should stress is that
the TTO—not the faculty—is counsel’s client.
This is a seemingly simple concept, because the
TTO is receiving and paying the attorney’s bills.
Nevertheless, things can become confusing in
academic settings where patent counsel is work
ing heavily with faculty members who generally
operate as “free agents” with respect to the in
stitution. It is easy for such faculty members to
regard patent counsel as their attorney and to
begin asking the attorney to handle their other
projects without approval from the TTO. In
such situations, patent counsel should refer such
requests back to the TTO. The TTO’s retainer
letter should emphasize this point and inform
counsel that charges for unauthorized work will
not be paid. To diminish further the possibil
ity of such a problem, the TTO should empha
size to faculty that patent counsel represents the
TTO—not the individual faculty member—
and that any patent work the faculty member

wants carried out should be channeled through
the TTO.

3. WORKING WITH OuTSIDE
PATENT COuNSEl
.1 Allocation of work

Having selected patent counsel, the TTO should
begin to establish a working relationship with
that attorney. Determining how work is to be al
located between patent counsel and the TTO is
an important starting point in establishing such a
relationship. Generally, the less work that is sent
to the attorney, the lower the TTO’s legal fees.
On the other hand, the more work the TTO re
tains for itself, the less time its staff will have for
other matters. It is, therefore, important for the
TTO to assess how its resources are to be utilized
and then to distribute its workload accordingly.
.2 Evaluating the invention disclosure

Quite often, a TTO will receive an invention dis
closure from a faculty member while the underly
ing research is ongoing. An evaluation must then
be made to determine whether the matter is ripe
for filing a patent application.11 The TTO should
consider:
• the invention’s commercial value
• whether there will soon be a public disclo
sure regarding the invention
• whether that publication will enable those
skilled in the art to practice the invention
• whether meaningful protection can be
obtained at this stage of the invention’s
development
Generally, the TTO should make an initial
effort to decide whether (and when) a patent ap
plication should be applied for on a particular
technology. However, where resolution of this is
sue becomes legally and technically complex, pat
ent counsel should be consulted.
Another important consideration with re
spect to a newly submitted invention is whether
that invention warrants an investment in patent
protection. This decision should be made by the
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TTO that has experience in marketing and valu
ing technology.
. Pre-filing patentability evaluation

Once the TTO makes a preliminary decision to
proceed with obtaining patent protection, it is
advisable to make a pre-filing patentability evalu
ation. An initial evaluation of this type can be
conducted by the TTO if it has access to comput
er-search databases or is willing to work directly
with an outside search firm. Generally, computer
searching is appropriate for biotechnology and
chemical inventions. On the other hand, devices
are best searched by manually reviewing the U.S.
Patent and Trademark Office’s collection of pat
ents in the relevant area. The TTO, of course,
must have the staff to conduct and/or evaluate
such searches.
One possibility to increase staff assistance in
a TTO is to use engineering, science, or law stu
dents on a part-time basis for such work. When
utilizing such part-timers, however, it is recom
mended that their role be restricted to gathering
information for evaluation by patent counsel or
a staff person who has experience in evaluating
patentability. Staff persons making initial pat
entability evaluations need to acquire a working
knowledge of patentability standards and what
is considered prior art (in other words, subject
matter capable of preventing issuance of a pat
ent). An ideal way to gain such an understand
ing is to attend AUTM programs on the subject.
Other organizations also have basic courses about
patents and patentability. Ultimately, however,
knowledge is best obtained over time by working
with (and learning from) patent counsel.
A TTO that does not have the staff to make
an initial patentability evaluation should send
disclosures out to patent counsel who can then
arrange for a patentability search and make an
evaluation. This, of course, is the most expensive
route, because patent counsel is taking respon
sibility for obtaining a patent search, evaluating
that search, and providing a recommendation.
Many TTOs, however, utilize this approach be
cause their staffing resources are committed to
marketing and technology transfer.
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. Preparation and prosecution of
a patent application

Once a patentability search has been obtained and
a decision is made to proceed with preparation
and prosecution of a patent application, patent
counsel will bear the bulk of work responsibility.
Nevertheless, the TTO should act to facilitate the
process (to minimize costs and to ensure that there
is valuable IP to license). This can be achieved in a
number of ways.
..1 Inventor participation

The TTO should make introductions between
patent counsel and the inventor(s), personally or
by mail. The TTO should insist that the number
of meetings between counsel and the inventor(s)
be held to a minimum. In most cases, one meet
ing to discuss the invention and one meeting to
discuss a draft application is sufficient. Brief tele
phone conferences can be used to fill in gaps left
by such meetings.
It is important to impress upon the inventor(s)
the need to cooperate with counsel’s requests for
information. The inventor should furnish any
draft journal article to facilitate preparation of
written examples for the patent application. If
the article does not provide sufficient information
for examples, the inventor will be requested to
provide additional experimental write-ups. This
often requires a fair bit of work, but the inven
tors are much better able to do this than patent
counsel. Moreover, having the inventors under
take this task (as opposed to patent counsel) will
reduce cost.
For biotechnology and chemical inventions,
patent applications will frequently be faced with
a rejection (35 U.S.C. §112, 1st paragraph: fail
ure to disclose and explain the invention in de
tail) because the application’s disclosure does
not support the broad scope of protection being
sought. To overcome this problem, the scope of
protection may have to be narrowed to an often
unacceptable extent. Applications based on little
more than draft publications are particularly sus
ceptible to such problems, because publications
generally report only the work actually carried
out by the researcher; it does not usually discuss
alternatives or way in which the invention can
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be expanded. To obtain a broad scope of protec
tion, the inventor(s) will be requested to assist
patent counsel by providing information about
how the invention can be utilized. The TTO
should impress upon the inventor(s) the impor
tance of their cooperation in this regard so that
commercially valuable patent rights are obtained
in a timely manner.
..2 Duty of disclosure

It is important for the TTO to understand the
duty of disclosure to the PTO. Under this duty,
patent applicants must disclose all information
that a reasonable examiner would consider im
portant in deciding whether a patent should is
sue. Inventors must not submit inaccurate data
and must disclose all patents, publications, and
other disclosures (such as prior art) which would
be relevant to patentability. This includes the in
ventor’s own efforts to disseminate information
as well as those of others. Published abstracts and
information disseminated at poster sessions must
also be disclosed. This duty is not extinguished
upon filing of the application. If the inventor dis
covers prior art after his application for patent has
been filed, he has a continuing duty to submit
such information to the PTO.
The TTO will need to advise patent counsel
which aspects of an invention it considers to be
valuable. The attorney can then frame the pat
ent claims in a way that will provide the desired
protection and enhance licensing opportunities.
It would be prudent for the TTO to monitor
what is being claimed initially and throughout
prosecution to ensure claim scope expectations
are met.
.. Office Actions

After the application has been filed, the PTO will
eventually issue an “Office Action” that must be
responded to by patent counsel. Generally, coun
sel will need input from the inventors when pre
paring this response. The technology transfer
manager can assist in this process by stressing
to the inventors that a prompt response to the
attorney’s request for information or additional
experimental data is imperative. If a response to
the PTO Office Action is filed without all the

information requested by counsel, it is likely that
the PTO will mail another Office Action; thus
requiring the TTO to incur the expense of fil
ing another response, which includes the infor
mation that should have been put into the prior
response.
In responding to Office Actions, extensions
of time can be obtained by payment of additional
fees. To minimize costs, there should be limited
use of such extensions.
.. Foreign filing

After an application is on file in the United
States, counsel will eventually inquire whether
the case needs to be filed overseas. Decisions on
foreign filing require consideration of whether:
• the return on foreign filing justifies the
expense
• such filing is going to be considered valu
able by domestic licensees
• the invention has sufficient value to attract
a licensee in a particular foreign country
There are, of course, other factors that must
be considered in deciding whether to foreign
file, but they are beyond the scope of this chap
ter. A technology transfer manager should pro
vide the attorney with plenty of advance notice
about foreign-filing plans. This will enable the
necessary papers to be prepared without a lastminute rush.
.. Further research and new data

After an application is filed, inventors often
breathe a sigh of relief and assume that they are
done with patent applications. They then con
tinue their research without informing the TTO
or patent counsel of any developments. This is
unfortunate, because such later work can be the
basis for further (and, indeed, often more valu
able) patent protection. The technology transfer
manager should impress upon the inventors the
need to keep either patent counsel or the TTO
apprised of future developments.
. Maintenance fees and annuities

Once patent protection is obtained in the United
States or overseas, it is necessary to decide who
HANDBOOK OF BEST PRACTICES | 1
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will be responsible for paying maintenance fees
and annuities. The TTO can undertake this
task itself or work directly with an annuity ser
vice. On the other hand, it can rely upon pat
ent counsel and counsel’s docketing system to
handle this task.

4. WORKING WITH PATENT COuNSEl ON
OTHER MATTERS
Working with patent counsel should not be thought
of only in terms of preparing and prosecuting pat
ent applications. There are a number of other areas
where counsel can provide valuable assistance.
.1 Dispute resolution

Quite frequently, inventorship disputes arise in
academic settings. These issues are best resolved
before any patent application is filed.
Inventorship disputes may arise between
faculty members and their graduate students.
Sometimes, graduate students are merely “a pair
of hands” who simply follow instructions from
the faculty member. In other situations, the stu
dent conceived or helped conceive the invention.
To make a proper inventorship determination, it
is necessary to interview the parties and to review
their documents to ascertain each inventors’ con
tribution. Patent counsel should have a level of
expertise in resolving inventorship disputes that
will make all parties involved feel that their views
have been properly considered.
Faculty often collaborate with scientists at
other institutions or companies. Such collabora
tion is rarely undertaken with an eye toward pat
ents. However, once a decision is made to go for
ward with a patent application, disputes can arise
regarding who will be named as inventors. Again,
patent counsel can be useful in investigating the
situation and providing an opinion on how to
resolve the matter. This is particularly important
when dealing with a collaborating institution or
company, because, in order to maintain what has
been up to that point a good working relationship
with the collaborating institution, the technology
transfer manager may choose to use patent counsel
as an advocate to resolve conflicts. Moreover, early
involvement of patent counsel in any such dispute
2 | HANDBOOK OF BEST PRACTICES

will enable the attorney to position the dispute to
the advantage of the client—the TTO.
.2 Preparation and negotiation of
agreements

Patent counsel can also provide TTOs with sup
port in the preparation and negotiation of licenses
and other agreements. Some TTOs have a great
deal of experience in these efforts and do not need
to use patent counsel for such services. On the
other hand, other TTOs lack this experience and
should strongly consider involving patent counsel
in these activities. For instance, counsel can pre
pare agreements, review draft agreements from
potential licensees or the TTO, provide selected
clauses for inclusion in any agreement, and ne
gotiate with potential licensees. Involving patent
counsel in such negotiations is particularly criti
cal where discussions are centered around sub
stantive patent issues, such as the scope of patent
protection available, and whether the potential
licensee has rights in the subject technology due
to a dispute over inventorship or over who was
first to invent. Patent counsel should be involved
in such negotiations to help persuade potential li
censees that the client has a meritorious position.
At the very least, patent counsel should be kept
apprised of the substance of any license negotia
tions so that any changes needed to enhance the
quality of the application can be promptly made.
. Interference proceedings

Issues of priority of invention (who was first to in
vent) are resolved in the PTO through proceed
ings known as interferences. Often, these issues
become apparent during license negotiations as
discussed above. Alternatively, the inventors may
become aware of similar work by others when
they attend conferences. No matter how this in
formation becomes known, it is important that
patent counsel be kept apprised. This enables the
attorney to undertake a strategy that will put the
TTO in the most advantageous position possi
ble in any interference proceeding. The attorney
should be involved in such situations at a very
early stage and should meet with the inventors to
discuss strategy. In the event that an interference
is declared, such a proceeding is like a mini-patent
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litigation. This is a complex proceeding, and pat
ent counsel will need to be involved. Indeed, the
attorney should be the institution’s representative
in any such proceeding.
. Getting questions answered

Lastly (and most importantly), patent counsel
can serve a TTO by being available to answer
simple questions on IP matters. Most patent
counsel are willing, without charge, to help a
technology transfer manager in patent awareness
efforts by giving seminars to groups of institution
faculty or participating in special events such as
invention fairs relating to the technology transfer
program. By providing such advice to that office
and faculty, patent counsel can help ensure that
protection for valuable technology is not lost but,
instead, enhanced.

5. CONCluSIONS
The mission of public sector research institutions
is research and development of technological ad
vances that will eventually provide benefits to the
public, especially in terms of health and nutrition.
IP management (of which patenting is integral) ad
vances this mission by facilitating the development
and commercialization of public sector innova
tions. Therefore, for public sector TTOs, the prod
ucts that they will want to disseminate will be their

technology and the patents covering this technolo
gy. To ensure that the greatest value is realized from
the fruits of the institutions’ research scientists, it is
essential that good patents are drafted, prosecuted
and maintained. Therefore, it is of the utmost im
portance to select the institution’s patent counsel
carefully. This will involve evaluating several key
factors, such as size of the attorney’s firm, scope of
the attorney’s legal experience and capabilities, the
attorney’s experience with academic institutions
and technological background, and the firm’s geo
graphic location. Once counsel is selected, a good
working relationship with him or her should be ac
tively pursued. This will require defining the condi
tions of representation, the allocation of work, and
the dynamics and management of patent counsel’s
relationship with its client (the TTO) and also with
the institution’s administration, staff and scientists.
By carefully taking all of these steps, the TTO can
ensure that quality patents are obtained and man
aged in a cost effective and timely manner. n
MICHAEL L. gOLdMAN, Partner, Nixon Peabody LLP,
Corner of Clinton Ave. and Broad Street, P. O. Box
31051, Clinton Square, Rochester, NY, 14603, U.S.A.
mgoldman@nixonpeabody.com
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See also in this Handbook, chapter 9.1 by L Nelsen and
chapter 9.3 by R Razgaitis
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How to Hire an IP Attorney and Not Go Bankrupt
JOHN dOddS, Founder, Dodds & Associates, U.S.A.

ABSTRACT

As a result of the growth in intellectual property (IP) pro
tection, more and more institutions are establishing tech
nology transfer offices (TTOs) to spearhead or support
the effective transfer of technology. These offices serve a
variety of functions, all of which must be integrated in
order to transfer the technology cost effectively and to
benefit the institution. One responsibility of a TTO is to
provide services: from strategy development to contracts
and agreements; from patenting to trademark protec
tion; and from conflict-of-interest analysis to negotiation
support. In all of these areas, legal inputs are important,
and few offices will have the necessary range of in-house
expertise. Gaining access to and developing relationships
with attorneys are important elements in any strategy to
set up effective TTOs. This chapter provides important
information for deciding how to select and work with an
attorney (or attorneys) who will provide IP backstopping
to the TTO.

1. INTRODuCTION
The process of hiring an attorney to represent
your IP interests can be complex and costly. It
is therefore important that your office finds dy
namic, effective, and user-oriented representation
from the beginning—first impressions really do
count. The support of administrators and scien
tists to the technology transfer office is critical,
especially in the first few months and years of its
operation. Hiring the right lawyer can really help
you achieve your IP goals.
The technology transfer office (TTO) serves
many masters and has a range of functions; this

makes it very important at the outset to clearly
define the scope of the office and the ways in
which work will be analyzed and implemented.

2. THE ATTORNEy-ClIENT RElATIONSHIP
The legal relationship between a lawyer and a cli
ent is protected under a special set of legal rules
that encompass the concepts of “client confiden
tiality” and “legal privilege.” This umbrella of
confidentiality and legal protection from disclo
sure is an important part of the relationship, that
allows attorneys and clients to deal with sensitive
issues without compromising a client’s privacy.
This confidentiality can be particularly important
when a staff member of a client company wishes
to discuss a matter that involves disclosing poten
tial wrongdoing but does not want to risk having
the disclosure made public. It is important early
on in the relationship for the client to understand
the nature of this special relationship and use it
effectively for the benefit of the TTO.
3. THE SCOPE OF THE TTO AND ITS
lEGAl-REPRESENTATION NEEDS
Establishing the scope of the work for the TTO
is an important initial step. The TTO should
be able to provide a comprehensive IP service
without being overwhelmed with work and

Dodds J. 2007. How to Hire an IP Attorney and Not Go Bankrupt. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. J Dodds. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.

HANDBOOK OF BEST PRACTICES | 

DODDS

obligations. The types of issues that need to be
debated and resolved will affect the type of legal
representation required and should include the
ten items discussed below (see also Box 1).
.1 Strategy development

A critical initial role of the lawyer should be to
work closely with the TTO to develop an IP
strategy that delivers benefits most effectively to
the institution or company (more about this will
be explained below). Early decisions on the goals
and strategies of the institution or company will
save funds later (for example, money can be saved
by not filing applications deemed frivolous to the
goals of the TTO). Helping the client to decide
goals and strategies may be one of the most criti
cal jobs for the lawyer, whose assistance in devis
ing the new strategy is crucial to the long-term
success of the IP office. Ensuring that expenses
are incurred only in those areas that fit the strat
egy is also crucial.
.2 Patenting

The area of patenting includes patent searches,
work related to freedom-to-operate, prior art
searches, patent filing, patent maintenance, and
so forth.
In your discussions you need to think about
whether the type of patenting done by the TTO
will involve utility or design patents, or utility
patents on plant. When should provisional appli
cations rather than nonprovisional applications
be used? If in doubt, use a provisional applica
tion to buy yourself a year to seek partners and
develop interest in the concept. (You also need to
be aware of the Patent Cooperation Treaty pro
visions and when to apply them in order to file
for multicountry coverage.) It is vital to involve a
patent attorney in these steps of the process and
to be guided by him or her as to the nature of the
subject matter. Try to develop a portfolio of ex
perts that can be called upon to advise you when
patents are being sought in their particular areas
of expertise.
. Trademarks and copyright work

The trademark area is often significantly under
used. Product branding is an important marketing
 | HANDBOOK OF BEST PRACTICES

element in a global environment. Think of the
brand value of names such as Coca-Cola® and
Kodak®. Again, use the guidance of the lawyer
when choosing for inventions, their names, lo
gos, slogans, and so forth, so as to minimize costs
later when dealing with potential infringement
actions.
Copyright is a simple and cheap form of pro
tection; it is useful for books, papers and databas
es. In the genomics area, more attention is being
given to using database protection as a cost-effec
tive form of IP coverage. The use of this type of IP
in the overall strategy development of an office is
critical. As an example, companies such as Celera
Genomics and Human Genome Systems have
used highly effective copyright and contract law
provisions to protect and exploit their databases
on sequence data.
. Trade secrets

Protecting innovative ideas from becoming pub
lic knowledge is the cheapest form of coverage—
it is free! And not very popular with IP lawyers!
The downside of this IP approach is that you must
keep your secret a secret. If you do not, you risk
having someone reverse engineer your invention
and patenting it. Then you could be precluded
from using your own invention! Protecting a se
cret in a commercial environment is really not
as simple as one might imagine, and substantial
effort is required to maintain secrecy, or to li
cense it.1
. Plant variety protection

An important area of IP specifically applied to
sexually propagated plant species is plant variety
protection. Separate chapters in this Handbook
deal with the topic in detail.2
. Contract and agreement development

Develop a good portfolio of standard agreements
and templates that can then be customized as need
ed and as appropriate. But take care to fully cus
tomize the required content. Use a lawyer to review
them and ensure that your interests are covered. It
is tempting to think that once you have used one
agreement you can just use the same for others with
out consultation—this is a mistake!
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. Policy development

You will need to create an internal office policy
document, which may well assist the institu
tion in developing its IP policy and guidelines.
Obtain a lawyer to review and comment on prog
ress during the initial strategy development stage.
Remember, it is hard to go against something
that is included in the policy document. Again,
this is a crucial area since the policy of the TTO
can be used as a tool in both negotiations and
litigation.

. Conflict analysis

Consider using a lawyer and an ethics-and-conflicts
panel to regularly review the TTO’s actions regard
ing potential conflicts. Conflicts are a surprisingly
common problem, especially where staffs develop
consulting contracts, serve on boards, and so forth.
Having a review panel is also valuable when faculty
or staff develop competing technologies. Effective
rules must be established so that support of one pat
ent does not affect a competing patent, a situation
that would breach a fiduciary relationship.

Box 1: Scope of TTO Activities—The Easily Forgotten Items
Legal
documentation:

One of the key outputs from your lawyer should be legal documentation.
Do not measure the volume of paper as an indication of output. Instead,
focus on a limited amount of high-value text such as opinion letters, contracts crafted, and so forth.

keeping
up to date:

It is very important for the TTO to maintain an active surveillance of keeping abreast of changes. The lawyer can be used to “police” agreements and
technologies. This can be an important way to identify infringers and potential licensees.

Legal Matters
Linked to office
organization:

A wide range of legal matters needs to be addressed early on in the establishment of the TTO. These include, but are not limited to, the following:
■

■

■

■

■

Staffing contract: This should lay out a staff line-of-authority plan and
work definitions. The employment contract needs to be reviewed by a
lawyer.
Staff employment handbook: This must include matters related to confidentiality, ethics, and conflict of interest. The lawyer should review and
give input on this.
Governmental and state filing requirements: Your local equivalent of the
Secretary of State can help on this. Requirements include work permits,
pension plan provisions, occupancy permits, fire inspection permits, and
other documents.
possible incorporation of the entity: The TTO may wish or may need to
form a separate legal entity. In the U.S., many of these offices are known
as research corporations and have charitable, so-called 501(c)(3) status.
This is the domain of the lawyer. Seek his or her counsel before you
proceed.
Tax matters: Be aware of all U.S. federal and state tax matters if you are
in the U.S. (Other countries have local, regional, and/or national laws)
Hire a good accountant and audit company. They are as important as
your lawyer.
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. Licensing

The bread and butter of a TTO is licensing. The
flow of information, ideas and materials is twoway. Some staff members will be accessing the
IP of others through license agreements, and the
TTO will be licensing technologies through li
cense agreements. Be careful, you will be bound
to abide by any agreements that you sign! Make
sure a lawyer reviews all major-deal documents.
You may also wish to seek advice from a lawyer on
creative arrangements for licensing your technol
ogy. Such arrangements may involve using your
IP as an investment by contributing to a joint
venture. Consider hiring a lawyer or technology
transfer company to do this on a contingency or
partial-contingency basis.
.10 Negotiations support

Successful negotiating is an art that takes skill,
practice, and sharp wits. Lawyers are trained in
the skills and use them each day. Moreover, the
representational responsibility of a lawyer can
make him or her an excellent advocate for the
TTO. Under certain circumstances, you may
wish to use a lawyer as your negotiator.
.11 Strategy development and technology
assessment

The area of strategy development and technology
assessment is one of great importance. It is per
haps the area to which money spent on lawyer
fees can be applied most effectively. If your TTO
strategy is ill conceived, all efforts in the other as
pects of your office are redundant.
One of the key challenges facing any TTO,
especially in the early stages, is trying to decide
which inventions to protect and to what extent
the protections should apply (that is, in which
countries or fields of use). Costs and fees are such
that no individual entity has the resources to pat
ent all inventions. Typically, ten invention disclo
sures will lead to one patent, one license will come
from ten patents, and royalties will come from
10% of the patents. That is why the lawyers’ input
here is so vital. Use patent attorneys to help you
evaluate the potential market for an invention.
It is critical to spend your money wisely and
try to evaluate only those inventions that are truly
 | HANDBOOK OF BEST PRACTICES

innovative and that appear to have commercial
value. Remember that some great science has no
market, and some simple inventions have huge
commercial value.
Most often, TTOs set up an internal com
mittee, or panel, to review invention disclosures
and give feedback to inventors. Use the lawyer as
a part of this evaluation process.

4. THINKING OuTSIDE THE BOx
The lawyer can be used highly effectively to think
of innovative ways of capturing value from an IP
portfolio. Patenting may not be a viable option in
some areas, and the use of creative instruments of
copyright, trademark, and contract law may be vi
able, and even preferable, alternatives to consider.
.1 Outsourcing services

An effective technology transfer office should
consider building access to a set of contracting
agents, who can provide external skills that can
be counted on for needed advice or service. This
might be achieved through the maintenance of
an advisory panel, through a series of consulting
contracts, or through a well-functioning personal
(business) network. The lawyer can play a criti
cal role in setting up such outsourcing arrange
ments. Before outsourcing services, consider the
following:
• Hiring patent attorneys: Choose an attor
ney with a range of qualifications and spe
cializations tailored to the nature of the in
vention portfolio. A chemical engineering
background might be helpful for advising
on a natural products patent, for example,
whereas a background in biological engi
neering might prove better for handling a
patent on a biolistic gun.
• Retaining general legal counsel: Find
someone who knows the big picture but
who understands the science of the inven
tion and the client as well. Be guided by
the attorney as to the big-picture issues.
.2 Costs and fees

The cost of evaluating, protecting, and maintaining
IP coverage is not insubstantial. A wide range of
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fees is payable in relation to IP protection. The types
of fees a TTO may face include the following:
• patent and trademark search fees
• patent and trademark filing fees
• plant variety protection fees
• maintenance fees
• copyright filing fees
• issue fees
• attorney fees
• drafting fees
These fees can be substantial. In the United
States you would pay US$1,200–$2,000 for a
trademark, US$2,500–$8,000 for a provisional
patent application, and US$6,000–$30,000 for
a nonprovisional application. A patent filed and
maintained worldwide over its entire life will cost
about US$500,000 in fees. When retaining a law
yer to negotiate for you, don’t neglect to negotiate
your legal fees!
. Use of form agreements and contracts

Lawyers often do not like the use of standard forms.
The forms are designed to be party neutral. The ob
ligation of a lawyer is to act on the client’s behalf,
which is why lawyers react adversely to such forms.
At times, it is tempting to use standard forms
and agreements to keep costs low. The situation can
be resolved by using standard forms and agreements
where appropriate, and then having a lawyer review

the final version to comment on any specific clauses
that need to be negotiated and agreed upon.

5. CONCluSIONS–AND A NOTE
ABOuT CONFIDENTIAlITy
The importance of confidentiality and trust can
not be underestimated. The inventions of the
clients, the nature of the business, and so forth,
requires that all TTO employees observe the
strictest rules in relation to confidentiality and
conflict-of-interest matters. The hiring of person
nel should take this into account. Moreover, full
and adequate documentation about confidential
ity and conflict-of-interest issues, in relation to
the TTO’s operations, should be used to further
strengthen compliance with the rules. The lawyer
has a special relationship to the TTO and can be
used as a valuable resource to deal with difficult
and delicate matters. Attorney privilege is a legal
strength to be used to your advantage. ■
JOHN dOddS, Founder, Dodds & Associates, 1707 N
Street NW, Washington, D.C., 20036, U.S.A. j.dodds@
doddsassociates.com
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See also in this Handbook, chapter 4.7 by M Blakeney
and chapter 10.11 by W Pardee.
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Technology Transfer Data Management
ROBERT g. SLOMAN, CEO, Inteum Company LLC, U.S.A.

ABSTRACT

A technology transfer office must be able to manage enor
mous amounts of dynamic data. This chapter examines
how electronic file systems can meet this need, focusing
on the importance of shared communication links and
the benefits of using advanced spreadsheet applications
developed by the private sector. It considers the relative
merits of spreadsheets, flat file databases, and relational
databases, and highlights the numerous benefits of a net
work solution. The chapter explains how to ensure data
integrity and manage “analysis paralysis” in such systems,
and it offers a self-questionnaire to guide decisions about
adopting a software management solution.

1. INTRODuCTION
Managing a technology transfer office (TTO) re
quires strong administrative, technical, and com
munication skills. To make informed decisions, a
tremendous diversity of information needs to be
captured and analyzed. A TTO’s ability to handle
this information is complicated by how rapidly
new information becomes available. Moreover,
the average academic TTO usually has limited
funds and staff with which to create such a so
phisticated data management system.
Meeting these challenges and making time
ly, informed decisions can be very rewarding.
However, as workflow increases, the ability to

maintain a high standard of decision making can
be compromised. If the TTO is a closed system, and
no additional professional or support resources can
be acquired to deal with the additional workflow,
other solutions must be found. These solutions will
very likely involve fundamentally changing how
the office uses its available tools.
Fortunately, being one or more generations
behind in implementing data management and
decision support software systems does not trans
late into years of catch-up for the TTO. TTOs
can reap the rewards of corporate investment in
these areas. For more than a decade, companies
have collectively spent many millions of dollars ex
perimenting with executive decision-support soft
ware and management information systems that
were designed to get information to organizations
quickly and thus increase efficiency and facilitate
rapid response. These objectives apply equally well
to TTOs.
Airline-booking applications are good exam
ples of large, end-user friendly, real-time informa
tion systems. Much has been learned about soft
ware design since the first implementation of such
systems, resulting in more accessible applications
that conform to the workflow logic of the end user.
While early linear programming efforts proved

Sloman RG. 2007. Technology Transfer Data Management. In Intellectual Property Management in Health and Agricultural
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California, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
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HANDBOOK OF BEST PRACTICES | 641

SLOMAN

inaccessible to end users, modern software applica
tion design is event driven and object oriented.
As computer prices have plummeted, the pow
er and sophistication of hardware computing have
increased dramatically. Decommissioning exotic
mainframe computers because of their exceptional
maintenance and professional support costs, com
panies are now implementing enterprise computing
models on local area networks (LAN) of worksta
tions, sharing resources from a file server.1 The com
puting advances pioneered in the corporate realm—
specifically, improved efficiency, reliability and work
throughput—are now available to TTO managers.

2. PHySICAl OR ElECTRONIC FIlES?
2.1 Considerations

A resource for shared information should be ac
cessible to those who need the information in or
der to make decisions. Often, technology transfer
and intellectual property (IP) management deci
sions depend on a mix of variables, including in
formation about the inventors, their ongoing re
search programs, the companies interested in the
technology, the relevant patent applications and
their status, and the amount of money invested in
each technology transfer case. In this complex en
vironment, electronic data management systems
provide the most rapidly adaptable support tool.
Physical files suffer from some fundamental
limitations. In a TTO, records (or documents) are
generally filed by case or technology according to
the manager’s guidelines. The technology transfer
manager will probably find physical files limited
and difficult to maintain because there will be only
a single physical copy—unless staff members make
multiple copies of files and place them in related
areas. The person doing the filing makes a judg
ment about where best to file each document. This
is why a manager may routinely find information
in the “wrong place”—or not find it at all. A man
ager may apply certain rules for filing documents,
but the rules are generally complex and loose, and
therefore are frequently bent or misapplied. Often,
a technology transfer manager must review an en
tire file to find the information in question. Another
problem with physical files is the time it takes for
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information to be processed and correctly filed. If
files are not up-to-date, a technology transfer man
ager may be forced to wade through stacks of pa
perwork to find a needed piece of information.
With an electronic system, however, a job
packet can be quickly delegated to an officemate.
All case-related data and activities can be transferred
easily, with instructions, to another manager or to
support staff. This is the electronic equivalent of
handing a physical file to a person with the neces
sary instructions and briefing information. With a
physical file, the recipient may miss relevant action
items. However, with an electronic file, the previous
manager can easily transfer a variety of action items
associated with that case to the new manager.
Of course, one of the most compelling reasons
to use a state-of-the-art data management system is
the unprecedented ability to interrogate enterprisewide data creatively. A manager can now rapidly for
mulate questions that in a physical file environment
would be unthinkable due to the time required to
assemble and analyze the information sets.
2.2 Connectivity

The key to achieving connectivity through net
worked computing environments is to create
shared communications links, including e-mail
facilities and a shared information pool. No alter
native method achieves the degree of connectiv
ity offered by a networked environment. Indeed,
networked computing environments can develop
connectivity between the files themselves in a way
that is not possible with physical files. For ex
ample, a technology transfer manager can check
to see if contact has been made with a particular
company or individual, regardless of what case
that contact is associated with. The labor required
to accomplish this task with physical files would
be prohibitive.

3. FINDING THE BEST TOOl FOR THE JOB
3.1 Computer applications
3.1.1 Spreadsheets

Financial modeling tools, called spreadsheets,
were the first applications developed for the PC.
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Since the release of Visicalc™,the first widely used
spreadsheet, many generations of powerful ana
lytical tools have been developed. (A secondary
market has developed for templates. These add
utility by providing spreadsheet layouts and builtin algorithms, enabling plug-and-play simplicity.
Unfortunately, few of these templates are useful
for the technology transfer professional.)
When a technology transfer manager is seek
ing to generate graphs from data for reports, the
spreadsheet has no equal. Users can create relation
ships between different spreadsheets, allowing data
to be shared and linked from one sheet to another.
However, users who have tried to create complex
links between several layers of spreadsheets know
that this can be a complex task, tantamount to
programming. Unfortunately, because of the soft
nature of the links, they can become corrupted.
One corrupt spreadsheet cell, or one with a pilot
error,2 can be copied into other spreadsheets with
catastrophic results. Such errors, moreover, are dif
ficult to trace.
Of course, spreadsheets are useful for budget
ing and license revenue forecasting. They are well
understood and provide dramatic visual outputs,
such as graphs. The modern spreadsheet is capable
of conducting “what if?” scenarios that can be par
ticularly useful when attempting to forecast patent
maintenance fees, for example. Some of these pack
ages also contain rudimentary database-like func
tions that create screens for data entry. However,
the sheer size and complexity of spreadsheets make
them difficult to program. In addition, they do not
compare favorably in this area to purpose-built da
tabase products.
Some very sophisticated, complex systems us
ing Microsoft’s Excel® and other software products
have been developed by TTOs. Sharing these sys
tems is encouraged, since the time required for de
signing linked spreadsheets suitable for managing
the forecasting and budget processes is daunting.
3.1.2 Flat file databases

Flat file databases create an environment where
the user can create records with data about a
particular class of event or package of informa
tion. For example, records on a technology and
the data elements directly related to it may be

contained in a single record. Patents, however,
would be in a separate database file. In a flat file
database, therefore, a user would need to consult
first one database and then the others in order to
connect the data in meaningful ways. Because a
programmer or user can change the data structure
of a particular table, these databases are quite flex
ible. Moreover, they can also be changed with
out upsetting relations with other databases. In
short, flat file databases have the benefits of de
sign simplicity, ready recognition by end-users,
and flexibility.
Though navigation is straightforward in a flat
file database, the burden is on the user to look
in the right place. There are other disadvantages.
Generally, the end user must purchase a flat file da
tabase engine and then design his or her own sys
tem. Experienced users of flat file databases work
out routines and patterns of interrogation at which
they become adept; new users, however, may have
a problem navigating around these systems with
sure-footedness.
In addition, reporting from a flat file database
is difficult because the links required to bring infor
mation together can be as complex as those used to
link cells in spreadsheets. If a technology transfer
manager is contemplating a flat file database struc
ture, she or he should consider preferred report de
sign and useful templates, which will reduce some
of the complexity.
3.1.3 Relational databases

Relational databases contain a group of tables
with various aspects of the information base cod
ed together or hard-linked to other tables. A datainput screen may draw on a number of tables to
show information in a pseudorelational mode. In
a truly relational database design, however, there
must be one or more linking fields between tables.
Technology transfer managers require access
to data on finances, faculty, patent prosecution,
and marketing contacts, among other things. Each
functional data element might be contained in a
separate data management resource, but this would
be inefficient. In programming parlance, access to
backroom (detail) data is important, but technol
ogy transfer managers increasingly value data that
can be easily navigated without any knowledge of
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the underlying data structure. A relational database
system can accommodate this need.
Relational database systems permit the ma
nipulation of larger sets, such as the technology
portfolios for each manager and each department,
among myriad other selectable criteria. Transferring
sets of physical files would require a review of the
file and, probably, a briefing from a previous man
ager. With a relational database, one can transfer
the entire project from one manager to another,
enabling a more efficient transfer of action items
and information than is possible with physical files.
This maximizes the use of professional management
talent, for example, if one manager needed to focus
attention on other urgent projects, such as infringe
ment support, cases could easily be temporarily re
deployed with a relational database tool.
The inherently rigid structure and connectivity
of data in a relational database gives unprecedented
power to look at the data and business models in
different and creative ways. Exception reports, run
with some frequency, can rapidly show where data
gaps exist, which can drive administrative proj
ects. Managers can forecast expenses and revenues
to isolate a variety of parameters and determine if
divisions are real. The ability to conduct nearly in
stantaneous audits can help managers plan office
activities, and this connectivity also enables a su
pervising manager to evaluate the performance of
technology transfer managers using data manage
ment systems.
Some argue that a disadvantage of a relational
database is that it uses a rigorous data structure that
does not allow variability. However, a rigid data
structure is essential if a technology transfer man
ager wants to get reliable results from an electronic
interrogation. To accommodate the real need for
free-form annotations, it is possible to provide
note or memo fields in which special details can
be recorded. Indeed, a technology transfer manager
should look for a balance between rules and flex
ibility when selecting or designing a relational data
management system.
In some relational database models, connec
tivity is enhanced by regularly downloading recent
data that can be read and interpreted by all office
members. This works best when the office eschews
a hierarchical structure. If the office director,
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managers, and support staff are electronically briefed
about cases and contacts, then meetings can proceed
more efficiently, and briefing sessions can be short
ened or eliminated. When meetings do occur, it is
more likely that decisions can be made with confi
dence; those who are not directly involved in the
case may still have sufficient information to contrib
ute useful ideas. Also, when support staff is kept cur
rent they can plan their workflow more efficiently.
In relational database design, there are rules
that describe how data should be “normalized.”3
Rigid rules dictate elegance and resource efficiency.
For transaction-based databases, the design can be
optimized to increase the speed of recording a sales
transaction or stock movement. Alternatively, the
design can be optimized for ready access to a large
pool of related data. This latter version most con
forms to the needs of a technology transfer man
agement information system. The reason is simple:
technology transfer decisions are based on complex,
variable information. A technology transfer manag
er requires access to a range of information, includ
ing IP status, commercial contacts, expenses, and
other information. The transaction- and relateddata design paradigms, however, need not be mu
tually exclusive. In other words, even if the demand
for data interconnectedness dominates, the goal of
high-speed response need not be abandoned.
When thinking about the complexity of tech
nology transfer data management requirements,
the relational database is the engine of choice be
cause it requires less data entry and can be easier
to maintain and audit. With expert programming
code, a relational database can quickly present the
information a technology transfer manager needs.
Because the complexity of the data sets requires
these powerful and capable computing tools, the
commercial databases used by the technology
transfer community are all relational or pseudorelational database engines.
One perceived disadvantage of licensing an
independent vendor’s technology transfer manage
ment system is that the vendor controls the struc
tural design. That is, during the next generation
of offerings, additions will invariably arise, and
the end user is not able to modify the data struc
tures as needed. Viewed from the perspectives of
the vendor and licensee, there are excellent reasons
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for this limitation. The cost of developing the code
generated for such applications frequently involves
many thousands of dollars, as well as years of care
ful thought and programming. The investment in
programming code of this type can cost in excess
of US$200,000!
3.2 Network solutions

All of the above database tools can be shared over
a local area network (LAN). However, only rela
tional databases can function reliably in multiuser
mode, with a number of users accessing the same
data pool simultaneously, without fear of data
corruption. For example, on a LAN, if a technol
ogy transfer manager were to open a spreadsheet
file that someone else had on his or her screen, the
manager would either receive an error message
indicating that the file was in use or be advised
that it was available in read-only mode. In the
later scenario, any changes made would be lost.
More accurately, they would be saved but then
overwritten by the person who had the file open
first and saved it. Flat file databases may be prob
lematic in the same way.
Relational databases have built-in record lock
ing and transaction-tracking features that control
the access to shared files and the procedures used to
update data. Many TTOs associate networks with
the Internet. This chapter, however, is addressing
LANs, a computing environment where one com
puter acts as the file server for client workstations.
LAN technology has advanced dramatically in the
last several years, with a number of well-supported
systems available. Even for small TTOs, the advan
tages of using a LAN in combination with a rela
tional database are remarkable.
3.3 Data portability

Most software applications are able to export
and import data. The advantages of data por
tability are evident. If a technology transfer
manager can enter data in one application and
transport it in an organized fashion to a differ
ent application, data doesn’t have to be entered
twice. Rekeying data not only wastes time but
also increases the likelihood of data integrity
problems if data is recorded differently in
two places (for example, if the date of receipt

of funds from a licensee or the response due
date for a patent application office action is
wrongly entered).
It is important to use the most appropri
ate tool for a given job. Relational databases
are the best all-around data management tool.
Spreadsheets are a good tool for financial analy
sis and graphics. A technology transfer manager
may choose to use a relational database engine to
store data and then export data to a spreadsheet
for manipulation and graphing.
Relational database engines are at the core of
all commercially available accounting packages. An
increasing number of commercially available ac
counting packages are designing their database file
structure to be compatible with DBase®. DBase data
file structures, in turn, are an example of so-called
XBase data structures. When the data structures
between two applications are equivalent or com
patible, fewer steps are required to translate data
between them. So, if an accounting package with
DBase-compatible data structure is used, it would
be advantageous to choose a management informa
tion system with a compatible data file structure.
DBase data file structure is currently supported
and promoted by two of the leading proprietary
relational-database engine suppliers. Accordingly, a
technology transfer manager should be aware that
not all relational database engines are compatible
with DBase.
3.4 Data distribution

Data distribution means providing rapid access
to current information to precisely those people
who require it to make informed decisions. The
ease with which data can be queried will deter
mine how often the database is used by the tech
nology transfer staff. With the power of relational
database engines and the connectivity of a LAN,
designs that can be easily interrogated by end us
ers are now possible.
The technology transfer manager should view
the investment in the acquisition of a system and
the time spent in data entry as an asset in produc
tion. This system data should be fully utilized by
the technology transfer manager to coordinate
office activities and generate reports sequentially or
on an ad hoc basis.
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3.5 Paradigms for data management

The main design paradigms for technology transfer
management information systems are driven either
by (1) committee and administration or (2) end-user
functionality. System designs that are driven by the
former usually prioritize the design of report out
puts. Administration, for example, may announce,
“We want a monthly report showing which patent
applications are due for a maintenance fee, sorted
by the technology licensing manager.” As a result, a
table structure may be defined and a report written
to support this management objective. But while
defining objectives is important, this approach may
create conflicts in terms of data structure. To create
a design of this type requires the consideration of
all the ways the data may be interrogated, while at
the same time avoiding massive data duplication,
rekeying, or excessive look-up requirements that
slow a system down.
If the system is designed around the very spe
cific interrogatory output paradigm, the administra
tive objectives will be supported, but the ease of use
for end users will be diminished. When a manage
ment information system provides little end-user
functionality, it will not be kept as current as one
that does. With daily functionality, end users more
easily navigate around other parts of the system.
Even though most users will spend 80% or more
of their time in a single module, they will be famil
iar enough with navigation techniques to find their
way to other relevant sections when the need arises.
A technology transfer manager may want to
opt for a system designed first for the end user, but
with powerful and flexible administrative report
functions. The design goal should be to create a
system that acts as a partner in real time, so that
data is entered as the workday unfolds. If users en
ter the data as they move along during their day,
data entry is more current and accurate. In addi
tion, the time burden decreases and the sense of
accomplishment is enhanced.

4. DATA INTEGRITy
4.1 Assigning data-entry tasks

For day-to-day contact functions, users should
have the flexibility to use the system in a way that
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supports their work habits. Relying on technol
ogy transfer managers to complete data entry on
their patents and licenses may not be the most
effective use of their time. Rather, this task could
more efficiently be delegated to the individual
responsible for administering the contracts or to
an experienced administrative staff person. It is
desirable that a single individual be delegated the
responsibility of entering specific sections of the
data (for example, the data on patent prosecution
and revenues and expenses for each technology
or case). This approach reduces the likelihood of
errors and data duplication. In general, a manage
ment information system should allow an admin
istrative support staff member to easily complete
such data entry.
4.2 Auditing

It is preferable to conduct audits of the informa
tion in all environments. Reports can accomplish
this function and can be set up to run at certain
intervals or to run on an as-needed basis. In ad
dition, for truly mission-critical information, re
ports should be created and submitted to outside
professional service providers for periodic review.
An example might be generating reports from the
database with current information about a par
ticular patent prosecution and presenting that
report, or portfolio of reports, to the patent at
torney. Staff could then request that the attorney
update the report.
One direct and immediate benefit of this ap
proach is improved data integrity. Another benefit
is that service providers may come to understand
how much information about a university’s tech
nology transfer assets, patent applications in this
case, is valued.
If a technology transfer manager is interested in
implementing such a review, doing so on a rotating
basis, rather than as a direct audit of all records, may
be sufficient and would reduce incremental costs.

5. ANAlySIS PARAlySIS
The term analysis paralysis is being used here to
describe a period of time when an office shuts
down operations, virtually stopping all services, to
allow the staff time to update, analyze, modify, and
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discuss the technology data. This process can be an
excellent educational experience for an entire of
fice staff. Generally, teams should be planned in
advance and assigned a batch of technology or case
files to find answers to predefined questions. This
process can help define the office’s future mode
of operations and may uncover areas in need of
attention. If the entire staff is engaged in the pro
cess, a sense of team building may be achieved.
Through this process, a technology transfer
manager may be able to anticipate questions from
the university’s administration. Moreover, if all
technology staff are involved in the production and
interpretation of the data, experts among the staff
may emerge in different fields. And finally, periodic
analysis of data results allows for a faster response

when a quick, unexpected analysis is needed. This
“time out” might seem an impossible goal, but the
rewards can far outweigh the cost.

6. EVAluATING SOFTWARE SOluTIONS
If a technology transfer manager is going to adopt a
software management set of solutions, this author
suggests taking the process to its most advanced
state possible. In determining suitability, a number
of questions should be asked (see Box 1).
The decision to design a system or acquire
a commercially available software package to
manage technology transfer data should be based
on the TTO’s needs. Like all computer solutions,
the system will be only as good as the people

Box 1: Key Questions for Decision Makers in Evaluating Software Solutions
1. How suitable to the task is the software solution?
The solution recommended in this chapter is not cheap, especially when a technology transfer
manager considers the cost of a LAN, a commercially available package, and training.
2. Is adopting the software solution worth the investment of both money and staff time?
Only the technology transfer manager can answer that question, taking into consideration
all variables of the university and the TTO. A technology manager may want to consider the
following advantages of incorporating a software solution:
a) Managers with ready access to current data can work faster and with greater accuracy and
can make decisions with increased confidence.
b) Staff will be more likely to bring important issues to the attention of the supervising
technology transfer manager, and necessary interventions will more likely occur.
c) As a training tool for new technology licensing managers, the software tools described in
this chapter can create an environment where staff can work more efficiently, with fewer work
projects falling behind schedule.
d) Software solutions can increase responsiveness to clients and the ability to analyze workflow
and make appropriate resource allocations.
3. Why is time being spent in entering the data (as opposed to completing the
day-to-day functions)?
One possible response to this question is that data entry creates a work environment where
relevant data can be readily accessed when needed by users, managers, and support staff so
informed decisions can be made in a timely fashion.
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using it. Therefore, a final consideration when
purchasing or developing any system is the likeli
hood that staff will actually use the software. It
is not necessarily true that staff who collectively
design a system will be more likely to use it. This
may sound counterintuitive, but it is based on
our real-world experience.

7. CONCluSIONS
A key element in developing a data management
system is setting clear goals of effective data man
agement. The technology transfer manager should
have information to support the essential tasks of
the office staff in both tactical and strategic modes.
Tactical support means ensuring ready and cur
rent access to information about all aspects of a
particular case. The strategic mode demands the
presentation of information that can illuminate
trends and assist in office organization, workflow
distribution, and planning. Other examples of
such data use include revenue forecasting and
cash-flow planning. While cash flow may not be
a prominent issue yet in all academic TTOs, the
cost of doing business in the field of technology
transfer is increasing rapidly, and cash-flow plan
ing may soon become imperative.
Data management tools should act in con
cert with the goals of managers and adapt to the
way managers work, instead of requiring users to
adopt a certain pattern of processing information.
Regimentation of data is important, but this need
not create a barrier to end users.
It also is important to think ahead and design
an application for the future. As programming
tools and desktop computers have become more
powerful, workgroup software with event-driven,
rather than programming-driven, applications have
emerged in full graphical user interface presenta
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tion formats. The industrial relational-database lit
erature reveals that the focus of applications devel
opment is moving away from the exotic hardware
of the mainframe and minicomputer and toward
the client-server model of distributed computing
environments such as LANs.
The TTO management experience is relatively
fresh, and the cost of failing to professionally man
age data is not yet widely recognized. Examples of
such costs include large, unpaid obligations that
persist because of inefficient methods for collecting
revenues, or poor management of a technologies
portfolio. Both of these situations could result in
real costs to the TTO, although it may take several
years for this to become evident.
With a properly designed and implemented
software solution, a manager can decide with
greater confidence that the data needed to sup
port a decision are at hand. Allowing managers
and staff to be more responsive to clients, data
management systems solutions can also dramati
cally enhance the general professionalism of an
office. n
ROBERT g. SLOMAN, CEO, Inteum Company LLC, 8826
NE 124th Street, Kirkland, WA, 90834, U.S.A. robs@in
teum.com

1

A file server is a high-powered personal computer
linked by communication cables to computer workstations. The file server provides storage of shared data
files and software applications, as well as printer sharing capabilities.

2

A spreadsheet “pilot error” is a data entry error made
in an algorithm or data cell that causes erroneous
results.

3

“Normalized” data has been organized into relationships in a way that seeks to minimize duplication of
data and maintain data integrity.
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WIIPS™: Whitehead Institute Intellectual
Property System (A Relational Database for
IP Management and Technology Transfer)
aMina haMZaoui, Associate Director, Intellectual Property, The Whitehead Institute for Biomedical Research, U.S.A.

We are pleased to announce that the Whitehead
Institute for Biomedical Research in Cambridge,
Massachusetts, U.S.A., has kindly allowed
MIHR and PIPRA to distribute the Institute’s
proprietary WIIPS™ Database. This database
offers tangible benefits to improve the function
and efficiency of any technology transfer office
(TTO). In accordance with the non-profit mis
sions of MIHR, PIPRA, and the Whitehead
Institute, the sharing of WIIPS™ will be free of
charge and is primarily aimed at assisting devel
oping country TTOs.
WIIPS™ is a relational database designed to
automate essential intellectual property man
agement and technology transfer functions. It
simplifies recordkeeping and generates useful
reports for technology disclosures, patent ap
plications, joint invention agreements, licenses,
and material transfer agreements. In addition,
the system stores essential information on every
inventor, owner, and licensee who has interacted
with a given TTO. Thus, the system effectively
automates all recordkeeping, and offers imme
diate and accurate information on the status of
every case, including documentation, patenting
and licensing information. Not only will it al
low TTOs to better manage volumes of IP data,
it will also increase productivity and accuracy,
since WIIPS™ allows for easy communication

among staff members. The system is easy to
learn and use and comes with detailed system
documentation. In addition, WIIPS™ provides
complete financial control, with financial audit
trails and automation to meet the compliance
requirements that are often required of TTOs.
WIIPS™ can be used to manage all the financial
aspects of the TTO, allowing better control of
patent-filing costs. The system permits effective
monitoring of expenses and legal bills, thus
helping to ensure timely expense reimburse
ment and accounts receivable management,
and it facilitates faster royalty calculation and
distribution.
In order to better adapt WIIPS™to the
needs of TTOs, users will be authorized to copy
and modify the software, and/or to re-write the
accompanying user guide, as long as any modi
fied products mention that the product is based
on WIIPS™ and has been modified by the user.
Users may also make and use as many copies of
WIIPS™ as are required.
The relational database and the user guide
can be downloaded for free, subject to the terms
of a license, from the online version of the
Handbook at www.ipHandbook.org as of August
2007. The database requires that users are run
ning Microsoft® Access® on a Windows XP or
higher system.

Hamzaoui A. 2007. WIIPS: Whitehead Institute Intellectual Property System: A Relational Database of IP Management
and Technology Transfer. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
© 2007. A Hamzaoui. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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As a non-profit, research and educational or
ganization with focus on research in the biomed
ical field, the Whitehead Institute is pleased to
further MIHR and PIPRA’s missions of dissemi
nating information and tools of best practices
in technology transfer and intellectual property
management, and we are keen to contribute to
these commendable efforts. n
aMina haMZaoui, Associate Director, Intellectual
Property, Whitehead Institute for Biomedical Research,
Five Cambridge Center, Cambridge, MA, 02142, U.S.A.
hamzaoui@wi.mit.edu
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Organizing and Managing Agreements and Contracts
ROBERT POTTER, Senior Associate, Agriculture & Biotechnology Strategies, Inc, Canada
HILd RygNESTAd, Managing Director, Rygnestad Canada, Canada

ABSTRACT

Agreements and contracts are not just pieces of paper to
be signed before money changes hands; they are vitally
important documents. If an organization hopes to prop
erly fulfill the terms of its contracts, to say nothing of
negotiating future contracts, it must have a system for or
ganizing and managing its contracts. Such a system must
make data accessible as well as keep it secure. Resources
and tools should be incorporated wherever possible to de
sign and implement a system within the available budget.
After it is implemented, the effectiveness of the contract
management system should be continuously monitored
and evaluated.

1. InTRoduCTIon
Social and cultural differences can cause people,
even good friends, to misunderstand each other.
Written agreements and contracts are therefore
critical in that they formalize the details of a deal
and ensure that all parties concerned understand
their rights and obligations. For these reasons, a
contract is not just a piece of paper that must be
signed before money changes hands, but a vital
document throughout the life span of the rela
tionship between the parties to a deal.
It is important for a company or institution
to be able to organize and manage contracts to
know what its existing contractual obligations are.
After all, there is no use negotiating a wonderful
deal for a piece of technology if your organiza
tion does not have the rights to the technology

(or has already licensed rights to certain parts of
the technology). Even worse, you will not be able
to sign a deal at all if you cannot find out whether
you have the rights to use a technology. Both of
these situations require that your organization can
quickly determine where you stand with existing
contractual obligations related to the technology
that is being developed.
This chapter will consider the life span of
a contract from the point of view of what is re
quired to manage the rights and obligations un
der that contract. Life span is defined as the entire
process (or the stages) from the initial idea of a
deal to the expiration of the contract or of its ob
ligations (Figure 1).

2. REquIREMEnTS of A ConTRACTMAnAGEMEnT SySTEM
Agreements and contracts have a life span and
the needs for contract management will change
over time: during negotiations, for active con
tracts, and after a contract has expired or been
terminated.
2.1 Requirements during negotiations

Contracts begin as a potential relationship be
tween two or more parties. Ideally, the parties
negotiate an agreement that ends in a signed con
tract, but the agreement may be put on hold, or

Potter R and H Rygnestad. 2007. Organizing and Managing Agreements and Contracts. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. R Potter and H Rygnestad. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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even dropped completely, if the parties cannot
agree or if the agreement process is somehow de
railed. The level to which pre-signing activity needs
to be captured in a contract-management system
depends on the parties involved and the way the
deal was initiated and brought to a close. The fol
lowing questions need to be considered: Would it
be valuable (for the parties involved or for future
negotiators) to have the history of the negotiation
on record? Did communications during the nego
tiations have any bearing on the final deal? Will
the negotiations (especially if they do not lead to
an agreement) affect potential future deals?1 The
staff that were a part of the negotiations will likely
be able to answer these questions. Generally speak
ing, in a small organization, it may not be criti
cal to formally record such information. However,
in larger organizations a high staff turnover and a
larger number of contracts often translates into a
shorter “institutional memory” and a greater need
for formally recording the information.
2.2 Requirements for active contracts

It is important to store a signed contract securely;
however, it is also critical that the staff respon
sible for implementing the terms of the contract
have access to the documents, so that they can
ensure that all rights are enforced and obligations
honored. For example, licenses fees must be paid
and reporting dates must be met. In addition,
a contract may oblige one of the parties to dis
perse funds, to follow up diligently on product
development, to grant rights to derived materi
als to third parties, or to obtain such rights from

third parties. The methods of storing and access
ing contracts will largely depend on the size and
resources of the organization, and is discussed in
detail in a later section.
2.3 Requirements after contract expiration

When a contract expires or is terminated before
its due date, the parties involved often still have
various legally binding obligations toward each
other. For example, all parties are typically bound
by confidentiality clauses that last longer than the
contract period. There may be other obligations,
as well, such as the obligation for one party to
give up the rights to original or derived materials.
The extent to which each party fulfills its obli
gations may directly affect the success of future
deals, so both administrative and management
staff must be familiar with the obligations of all
parties. To facilitate this information sharing, the
requirements of a contract-management system
are as much about enabling access as they are
about secure storage.

3. dESIGnInG A ConTRACTMAnAGEMEnT SySTEM
A contract-management system can be based on
many components such as institutional memory,
hard-copy filing, electronic filing, or a computer
ized database. However, a system composed of a
combination of these components is more robust.
Moreover, since it is not entirely dependent on
any one technology, the reassignment of staff, a
flood in the archive room, a fire in the computer

Figure 1: The “life Span” of a Typical Deal
Negotiation

Proposed
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room, or a failure of the database tool will not
cause a catastrophic loss of information.
Determining the right blend of components
requires input from all levels of the organization.
The staff knows how the current system works, or
why it does not work, and can offer suggestions
for improving the management system. All users
of the management system should be involved
during system design to ensure successful imple
mentation: when users are involved in the design
and take ownership of the system, it becomes a
useful tool rather than a resource-costly burden.
Designing a contract-management system is
more than picking a software tool and its starts by
finding the balance between accessibility and data
security that meets your organization’s require
ments. The desired design is subsequently guided
by available resources such as existing tools, per
sonnel, and information technology infrastruc
ture. In the end the desired design is adapted to
meet the available budget.
3.1 Requirements: Accessibility
versus data security

When designing a contract-management system
it is important to find the balance between mak
ing the system accessible and maintaining data
security.
3.1.1

Accessibility

One of the main purposes of implementing a
contract-management system is to minimize
reliance on one or a few persons to manage the
organization’s contracts and associated obliga
tions. This requires a certain level of accessibility
to contract documents as well as any other related
information.
Hard-copy filing systems. Maintaining and
using hard-copy systems do not require users to
have specialized technology skills, but hard-copy
systems may be difficult to organize and update.
If several people are involved in the management
of contracts and storage of documents, there
may be no central point allowing timely access
to required information including original docu
ments. No matter what other storage techniques
are used, hard-copy originals must always be
stored in a secure manner and kept on hand.

Electronic filing systems. With electronic filing
systems documents can be made easily accessible,
especially if they are stored on network-accessible
media. Documents are transferred to electronic
media such as scanned computer files and can be
copied and updated much more easily than for
hard-copy files. An electronic filing system can be
stored centrally and accessed directly from a stor
age location or viewed remotely over a computer
network.
Database. An electronic filing system makes
it easier to retrieve documents when these need to
be reviewed. However, it still remains time-con
suming to search for specific information and to
get an overview of all contracts and agreements.
Computer-based databases, including simple
ones kept as spreadsheets and text documents,
are useful because they are more easily searchable
than hard-copy files. Databases should record the
following information for each contract and re
lated documents:
• Name and address of contract parties
• Dates of execution and expiration
• Length of the confidentiality term
• Deadlines by which products or informa
tion must be delivered
• Deadlines by which funds must be
transferred
• Keywords or a brief summary describing
the scope of the contract
• Electronic links to the document(s)
Searchable databases have several fundamen
tal advantages. They can:
• Reduce the time and resources needed to
find physical or electronic documents
• Incorporate searches of electronic docu
ment texts provided these have been made
searchable through a process of Optical
Character Recognition (OCR)
• Produce automatic reminders of expiring
contracts and upcoming deadlines
• Help identify potential conflicts of interest
before new contracts are signed
When properly designed, searchable data
bases can help staff find the proverbial needle in
a haystack. Not only can databases retrieve any
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and all documents that contain a particular term,
but they can be designed to automate searches of
such information as outstanding payments, over
due reports, or upcoming deadlines.
System access. All employees will need a dif
ferent level of access to the system, depending on
their job duties. An employee who scans docu
ments and inputs data will probably require a
lower level of access than one who needs to ac
cess specific records or information. For example,
a system can be designed so that it only displays
the details of selected contracts to authorized us
ers. Staff can generate statistics on overall perfor
mance (such as the number of contracts finalized,
payments made, or reports overdue) without be
ing granted access to sensitive material. In a Webenabled application external parties can even have
direct access to information related to their own
obligations, thereby reducing the number of re
quests handled by the contracts-management
office.
A contract-management system that com
bines electronic filing of documents with a searchable database can also be designed such that it is
accessible by users at a central point or from a
workstation on an internal network (Intranet) in
one location or over a Virtual Private Network
(VPN) linking different geographical locations.
Access over a network is a benefit as long as the
connections are secure and reliable with minimal
downtime. This is particularly important if the
whole system is stored off-site with no central ac
cess point on-site if the network is down.
3.1.2 Data security

Regardless of the measures put in place, a con
tract-management system will be labored with
security problems related to both loss of data and
access by unauthorized users.
Data loss. Regardless of how you store your
data, it can be lost due to fire, flood, theft, or
a number of other catastrophes, so it is impor
tant to take steps to guard against data loss.
Preventative measures include safes, fire alarms,
sprinkler systems, burglar systems, and fire- and
waterproof filing cabinets. The chances of data
loss are minimized further if hard-copy and
electronic systems are maintained in separate
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locations. It is also a good idea to keep a backup
electronic copy in an off-site location. Off-site
storage and backup services can be purchased
and/or managed commercially or by other de
partments in your organization. These service
providers should guarantee that they have appro
priate measures in place to prevent unauthorized
access and accidental data loss.
Unauthorized access. Lockable storage fa
cilities, filing cabinets, and safes generally pre
vent unauthorized access to hard-copy mate
rial. Electronic material and databases may be
at greater risk of unauthorized access than hardcopy materials, especially if they are stored off
site. Network traffic should be encrypted and
usernames and passwords should be used to make
sure only authorized persons can input, view, or
alter data.
Information technology support. In-house
computer support is essential because of increased
reliance on information technology. If an orga
nization lacks the resources to employ full-time
computer support personnel, it must train some
staff members to deal with common computer
problems. More complex technical problems will
need to be addressed by a reliable and responsive
external party.
3.2 Available resources

The next step after having determined your orga
nization’s requirements for accessibility and data
security is to determine how available resources
will affect the system design and implementation.
When taking available resources into account the
original plan often needs revising to include is
sues such as: newly discovered needs, change in
staff expertise, new technologies, and declining
available funds.
3.2.1 Identify existing tools and procedures

The first step is to identify all–if any–tools that
already exist and are used currently for contract
management within the organization. Such tools
could be filing systems, procedures, spreadsheets,
or more-advanced databases and reminder sys
tems. These tools can be used as models for de
signing components of the new system. As noted
before, current contract managers can shed useful
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light on tools and procedures that work, but also
those that do not work, as this information is of
ten more useful.
3.2.2 Select new tool

Low-technology solutions. A contract-manage
ment system is more than a software tool such
as a database, and, with some limitations on
accessibility and security, low-technology solu
tions can still be viable solutions if resources
are particularly limiting. Some organizations
use hard-copy filing systems with continuously
updated hard-copy summary sheets for each
contract. The summary sheet is good for quickreference but may lack accessibility. As noted
before, a backup system is important to avoid
data loss.
Simple databases. Other organizations de
sign and maintain computer-based databases
in their simplest forms, for example in spread
sheets or text documents. This improves acces
sibility, enables a quicker overview, and can be
supplemented with some form of reminder sys
tem for upcoming deadlines and obligations.
Database software packages. Some organiza
tions decide to use internal or external expertise to
design a more complex database tool in software
packages such as Microsoft® Access or FileMaker®
Pro. These software packages provide a userfriendly front-end for designing and maintaining
databases. More advanced approaches could in
volve other software such as Oracle®, MySQL™,
Microsoft® SQL Server, and DB2®. Using these
packages allows for tools to be designed more to
order and is a good option if an organization has
some level of internal expertise with the software
of choice.
Off-the-shelf tools. There are software packages
designed for contract management that are more
or less ready for use off-the-shelf. It is important
to make sure that the software has the necessary
features. Although off-the-shelf tools can usually
be customized to some extent, it may make more
sense for an organization to redesign its proce
dures than to try to make an off-the-shelf tool
perform tasks that the system was not designed
to handle.

Custom built tools. Another option is to have
tools custom built. A provider tailors an applica
tion to the client’s needs. The more complex the
tool, the more time and resources will be required
for its design and implementation—and the
higher the cost. The implementation of custom
ized software should be expected to cost roughly
twice as much as the software tool itself. It is im
portant to remember that more advanced (and
more expensive) tools are not always the best or
most cost-effective solution.
Numerous companies provide software
systems for managing intellectual property assets—including filing patents (mostly U. S.
patents) and licensing inventions. A number
of these systems are customizable, including
software packages that either the clients or the
company must modify to fit their own needs.
All of the systems are quite expensive to pur
chase. They are likely to be most useful to larger
research institutions and research-based compa
nies. You can find a list of providers and links
to their Web sites in the endnotes following this
chapter.2
Finally, there are many other options for
less- specialized, less-expensive document man
agement system. A simple search will turn up
20 or 30 companies that provide such software.
It is quite possible that future versions of com
mon operating systems or office productivity
suites will include such applications. However, as
discussed in this chapter, contract management
is much more than just storage and retrieval of
documents.
3.2.3 Personnel considerations

When transferring information from the old sys
tem to the new, considerable time will be needed
to locate existing documents, convert them to
electronic files, and enter the corresponding data
into a database. At the same time, new contracts
must be entered into the system. After the initial
transfer is completed, keeping the filing system
and database up to date must be considered as a
time-consuming task. If a system design change
becomes necessary, time will also have to be allot
ted for accomplishing this task.
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The amount of staff training that is required
by a change in management system will depend
on the complexity of the system and on existing
staff skills. Staff may be trained in such skills as
filing, data entry, reporting, and day-to-day prob
lem solving. Providers of commercially purchased
management systems usually offer employee
training sessions for an additional fee.
3.2.4 Select information
technology infrastructure

The choice of Information Technology (IT) infra
structure is largely guided by the balance between
accessibility and security discussed above. A con
tract-management system might include some or
all of the following items:
• Physical storage facilities. Fire- and floodproof filing cabinets that can store hardcopy originals, or system-backup media,
that do not require frequent access
• Computer/server. A computer or server
with the necessary software that stores all
electronic documents and the database
tools —in other words, the central collec
tion point. The organization should obtain
professional IT advice and continued IT
support to ensure data security.
• Backup system. A system in the form of
another computer or storage medium that
automatically backs up the information
in the contract-management system on
an hourly, daily, or weekly basis, depend
ing on how frequently data is updated. If
automatic backups are impossible, manual
backups should be performed, for example,
on backup drives or other storage media,
and the copies stored safely away from the
central collection point.
• Scanning capability. Scanning hardware
and software, with or without optical
character recognition capabilities that can
convert documents into searchable elec
tronic media.
• Network. Computers connected to the
central collection point also with profes
sional IT support that can ensure stable ac
cessibility as well as data security over the
network.
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• IT and system support. Support both for
maintaining network infrastructure and
for running the system. If the system is
designed in-house, details of operations
should be extensively documented in order
to make future maintenance and develop
ment easier. If the system is purchased off
the shelf or designed by an external devel
oper, the service provider should provide
on-site or telephone support
3.2.5 Budget considerations

Finally, the desired system requirements, such
as accessibility, data security, existing tools,
personnel resources, choice of system tool, and
information technology infrastructure must be
compared to the available budget. Trade-offs
will be necessary and each organization must de
termine which needs are absolute requirements
and which are only desirable. While it is often
tempting to cut back on such expenditures as
training and support for users, it is important to
note that the system investment will be a waste
of money and resources if it is not used to its
capacity.
Some organizations have the resources to
think big and to implement systems with more
capability than is needed at the outset, thereby
delaying the cost of frequent upgrades. Where
possible, an organization should plan for success
and institute a system that seems too big now, as
it will likely appear too small in a few years time.
An organization with tighter budget restrictions
should aim for a system that will serve its cur
rent needs and implement a smaller or cheaper
system, but try to ensure that there is room to
expand it later.
3.3 Monitoring benefits of the new system

Because it is costly to implement a new contractmanagement system, and because the cost must
be justified to senior management, it is impor
tant to be able to measure the benefits of the new
system. Many, if not all, of the benefits can be
tracked and monitored automatically by the most
advanced systems. Table 1 outlines the baseline
data that should be established and against which
benefits can be measured.
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Table 1, below, provides only examples; each
organization will want to monitor itself according
to its own criteria. Monitoring the benefits of a
new system not only helps to justify its expense
but also helps to identify aspects of the system
that need revising.

4. ConCLuSIonS
Managing contracts and agreements is not glam
orous, but it is vital—especially if the organi
zation is involved in complicated technology
transfer deals with many rights and obligations.
Ideally, a contract-management system should be

Table 1: Examples of Criteria that Can Be used to Measure
Benefits of a New Contract-Management System
Baseline Data

Measurable Benefits

Time and resources spent searching and
managing contracts

Additional staff time available for
performing other tasks due to more-efficient
contract management

The value of successful proposals, less the
value of unsuccessful proposals

Increase in the value and number of
successful proposals, due to less time spent
researching potential conflicts with existing
contracts

The value of invitations to submit proposals

Improved reputation with collaborators,
funding bodies, boards, and contractors

Grounds for successful and unsuccessful
proposals
Resources spent or committed
without contract

Minimized exposure due to nonexistent or
expired contracts

Number of deliverables that are not
submitted according to contract

Fewer deliverables not submitted according
to contract

Number of delayed reports.

Time and resources saved because reports
(whether scheduled or ad hoc) are processed
timely and with minimal effort

Resources committed to preparing reports
Penalties for delayed payments

Money saved because payments are
processed on schedule.

Number of times that confidentiality terms
are broken

Confidentiality terms are adhered to
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established before any contracts are negotiated.
The sooner a functional system is implemented,
the easier it will be to keep it updated.
Identifying the system requirements starts
with balancing accessibility against data secu
rity throughout the life span of a contract. This
is followed by considerations for the available
resources, including personnel and budget. The
contract-management system should be planned
and implemented with the full involvement of all
levels of the organization to make sure that it be
comes a useful tool and not another administra
tive burden.
Smooth contract management is almost in
visible, but the marks of poor management are all
too evident: lost deals, a poor corporate reputa
tion, and, in the worst case, lawsuits. Investing
resources in management is like any preventive
measure: you will really never know how much
time and money it has saved you. n
ROBERT POTTER,

Senior Associate, Agriculture &
Biotechnology Strategies, Inc., 106 St John Street, PO Box
475, Merrickville, Ontario, K0G 1N0, Canada. rpotter@
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1

If negotiations are aborted, there may still be certain
obligations that affect future deals. These include
confidentiality agreements. Being aware of other
types of information about the party with which
negotiations were aborted, for example reasons for
failure or specific problems encountered, may also be
useful when future deals are being contemplated.

2

Knowligent has developed IP-Portfolio (an IP
management system) and many lab-management
software modules. www.knowligent.com/.
Computer Packages provides customized solutions for
managing IP portfolios and collecting royalties. www.
computerpackages.com/.
Inteum LLC is the maker of Inteum C/S® (the successor
to a widely used system called DEALS), a program
that manages the entire technology life cycle from
negotiations to final obligations. www.inteum.com/.
InfoEd supplies module-based software for managing
sponsored research programs, including technology
transfer modules. www.infoed.org/.
O P Solutions Inc. provides software to the IP legal
industry, including software for patent and trademark
filing and prosecution management.www.opsolutions.
com/.
Master Data Center provides IP management
software, including installation of software systems
and maintenance services. www.masdata.com/.
Knowledge Sharing Systems LLC makes TechTracs, a
complete management system covering sponsored
research, patent filing, and compliance with licenses
and agreements. www.knowledgesharing.com/.
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Monitoring, Evaluating, and Assessing Impact
sibongile pefile, Group Manager, R&D Outcomes, Council for Scientific and Industrial Research (CSIR), South Africa

ABSTRACT

Much has been written about the socio-economic ben
efits and competitive advantage achieved by developed
countries as a result of investing in scientific research and
technological innovation. For developing and emerging
economies, sustainable development is dependent on
establishing and supporting R&D institutions that not
only perform good science, but also effectively share their
knowledge and technology outputs. Both the extent to
which a return on an investment is realized from R&D
activities and the magnitude of the resulting impact on
intended beneficiaries are important to funders, policy
makers, taxpayers, government officials, development
agencies, and the research institutions themselves. This
chapter provides guidance on building organizational
capacity to plan, monitor, evaluate, and assess the im
pact of R&D investments. It should be noted that the
chapter does not address measuring the performance of a
Technology Transfer Office to manage intellectual prop
erty, but rather focuses on determining the socio-eco
nomic impact of transferred knowledge and technology.

1. InTRoduCTIon
Much has been written about the socio-economic
benefits and competitive advantage that devel
oped countries achieved by investing in scien
tific research and technological innovation.1 For
developing and emerging economies, it is recog
nized that sustainable development depends on
establishing and supporting R&D institutions
that both perform good science and share their
knowledge and technology outputs.2 A return

on R&D investment, and the magnitude of that
return, is important to policy-makers, tax pay
ers, government officials, development agencies
and, of course, those funding the research and
the research institutions themselves. This chapter
provides guidance on building organizational ca
pacity to plan, monitor, evaluate, and assess the
impact of R&D investment on society and in
the market. It should be noted that the chapter
does not evaluate the performance of Technology
Transfer Offices in managing intellectual prop
erty, but rather focuses on determining the socio
economic impact of transferred knowledge and
technology.
R&D institutions in developing countries
operate with limited financial resources for
R&D and even less funding for technology and
knowledge transfer. The socio-economic chal
lenges experienced by developing countries put
more pressure on R&D institutions, requiring
them to effectively and efficiently address local
social and economic development needs through
the transfer and adoption of innovative science.
To this end, a key responsibility of research in
stitutions in developing countries is to make re
search outputs available for use by society and
local industry. It is therefore critical that research
institutions not only generate relevant research,
but also transfer and diffuse research results in
a way that maximizes impact. A well-developed

Pefile S. 2007. Monitoring, Evaluating, and Assessing Impact. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org.
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and comprehensive monitoring, evaluation, and
impact assessment framework is necessary to
measure efforts by institutions to meet R&D
objectives. Such a framework can assist research
institutions in:
• improving the efficiency of research re
source allocation
• improving the standard and effectiveness of
project decision-making
• directing future research plans more
effectively
• obtaining evidence of resource mobilization
• prioritizing research based on the level
of economic returns and positive social
impact
Technological innovation transforms an idea
generated during research into a new or improved
product that can be introduced into a market, a
new or improved operational process used in in
dustry and commerce, or a new approach to a so
cial service.3 Monitoring, evaluation, and impact
assessment should be conducted throughout the
R&D continuum described below:
• research and technology generation. Basic
research, applied research, and experimen
tal development are included.
• technology development. During this
stage, knowledge from research is com
bined with practical experience to direct
the production of a new product.
• technology adaptation. This entails pilot
ing technology and simulating real-life
conditions for the production of the tech
nology are typically involved.
• technology transfer. An important com
ponent of technology transfer is IP (intel
lectual property) management. Typically,
institutions manage IP protection, routes
to commercialization or transfer, and con
tractual arrangements that facilitate the
transfer of intellectual property from the
lab to the market.
• technology adoption and diffusion. This
stage of the process is key, for it signifies
the point that products, transferred to the
market, achieve depth and spread widely.
Technology adoption is measured at one
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point in time and is associated with the use
of transferred technology; technology dif
fusion is the spread of a technology across a
population over time.
A robust monitoring, evaluation, and impact
assessment framework should demonstrate trans
parency and confer accountability. It is therefore
important that systems enable institutions to
document, analyze, and report on research and
technology transfer performance effectively.

2. THE fRAMEWoRk
There are different methodologies and processes
for monitoring, evaluation, and impact assess
ment. An impact assessment study can be custom
ized and structured to suit the information and
reporting requirements of an institution and its
stakeholders. Figure 1 illustrates a comprehensive
monitoring, evaluation, and impact assessment
framework. (The components of the diagram are
described in greater detail in subsequent sections
of this chapter.)
2.1 Diagnosis

For many developing country institutions, the
public expects the research to provide solutions to
health, food security, sanitation, water, poverty,
and environmental challenges. As institutions in
vest their limited resources in these important ar
eas, their research efforts must be focused so that
the resulting impact on society and the economy
is optimal. Institutions, therefore, must be able
to articulate the problem that the science sets
out to address. The needs assessment conducted
at the start of a project defines the problem and
provides baseline data for the ex ante evaluation.
At the diagnosis stage of the process, questions
should include:
• Who is responsible for collecting perfor
mance information?
• What information is being collected?
• When and how often is the performance
measure reported?
• How is the information reported?
• To whom is the performance measure
reported?
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The needs assessment should also seek to
determine:
• What is the nature and scope of the prob
lem requiring action?
• What intervention may be made to amelio
rate the problem?
• Who is the appropriate target population
for the intervention?
The outcome of the diagnosis should be a
document that:
• defines baseline information
• sets project targets
• states assumptions
• specifies measurement indicators
• could be tied with ex post evaluation, that
is, evalulation after the project has ended
2.2 Planning

Once the problem has been identified, a plan
should be drawn up to explain how the research

will address the challenges. A logical framework
can be used to structure the various activities and
specify means and ends. Information in a logical
framework should include:
• why a project is being conducted
• what a project is expected to achieve
• how the project is going to achieve these
results
• what external factors are crucial for the suc
cess of the project
• how the success of the project can be assessed
• where the data required to assess the success
of the project can be found
• what the project will cost
This information is then used to complete
the matrix summarizing information, which is
required both to design and evaluate the activity.
Table 1 illustrates such a matrix.
A logical framework (logframe) is a useful tool
for the assessor and has the following advantages:

Figure 1: The Planning, Monitoring, and Evaluation Cycle
Impact assessment

Rediagnosis
and planning

Monitoring
Technology
transfer
Recommendation

Diagnosis (identify
and define
the problem)

Evaluation
(impact) ex ante

Planning

Evaluation ex post
Implementation

Monitoring and
ongoing evaluation

Logframe
(indicators)
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• It makes the project appraisal transparent
by explicitly stating the assumptions under
lying the analysis and by allowing a check
on the proposed hypotheses and expected
results in an ex post analysis.
• It deals explicitly with a multitude of so
cial goals and does not require reducing the
benefits into one figure.
• It is understandable to nonscientists. It
can therefore be used as a tool to clarify
the trade-off among objectives and, thus,
specify the decision-making process.
• It is flexible with regard to information and
skill requirements. It can incorporate social
cost, benefit analysis, use input, output tables,
and partial models. It can also be used with
rudimentary information skills, albeit at the
cost of more hypotheses and uncertainties.
2. Implementation

Implementation is the actual evaluation; it en
tails data collection, analysis, and reporting.
Evaluation is systematically assessing a situation

at a given point in time, whether that point is in
the past, the present, or the future. Put another
way, an evaluation is the periodic and systematic
assessment of the relevance, performance, effi
ciency, quality, and impact of a project, in rela
tion to set objectives and goals. Evaluation seeks
to investigate and determine whether:
• the intervention is reaching the intended
target audience
• the intervention is being implemented as
envisioned
• the intervention is effective
• the costs of the intervention, relative to ef
fectiveness and benefits, is lower than the
benefits
Different monitoring and evaluation systems
can be used. The method chosen mainly depends
on the following considerations:
• What should be measured? The evalua
tion should be based on the project design.
Stakeholders should agree about how the
crucial project issues should be measured.

Table 1: logical Framework Structure
Narrative
summary

Objectively verifiable
indicators (OVI)

Means of verification
(MOV)

Important
assumptions

Inputs

• Nature and level of
resources

• Sources of information

• Initial project
assumptions

• Magnitudes of outputs

• Sources of information

• Planned completion
data

• Methods used

• Assumptions affecting
the input-output
linkage

• End-of-project status

• Sources of information

• Necessary cost
• Planned starting date
Outputs

Purpose

• Methods used
Goal
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• Measures of goal
achievement

• Sources of information
• Methods used

• Assumptions affecting
the output-purpose
linkage
• Assumptions affecting
the purpose-goal
linkage
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• For whom should it be measured? The us
ers of the evaluation results should be iden
tified and the results should correspond to
their expectations.
• For what purpose should it be measured?
This determines the sensitivity of the mea
sures and the degree of accuracy needed.
• How should it be measured? Consensus
is needed between the evaluator and pro
gram/project managers on whether a pro
posed measure truly indicates a change in
the desired direction.
• How should the data be collected? The de
sign of the evaluation system should be de
termined and the desired level of accuracy
in the information agreed upon.
• When and in what form is the informa
tion needed? It should be available when
needed in a usable format.
• Who collects, analyzes, and presents the
information? This is necessary to adapt the
monitoring and evaluation system to the
management realities of a program/proj
ect. Managers should not underestimate
the time needed to analyze and present the
information.

use several different methods in combination, bal
ancing quantitative and qualitative information.
Ongoing monitoring and evaluation pro
cesses measure:
• technical aspects: physical input-output of
goods and services
• institutional aspects: organizational and
managerial aspects, including customs,
tenure, local organizations, and cultural
setting
• socio-cultural aspects: broader social impli
cations, resource and income distribution,
and employment opportunities
• commercial aspects: business and financial,
securing supplies, and market demand
• economic aspects: economic efficiency,
costs and benefits
• environmental aspects: biological and phys
ical effects
2. Rediagnosis and replanning

The specific questions that an effective evalu
ation should answer are:
• Is the program effective in achieving its in
tended goals?
• Can the results of the program be explained
by alternative explanations that do not in
clude the program?
• Does the program have effects that were
not intended?
• What are the costs of delivering services
and benefits to program participants?
• Is the program an efficient use of resources?

Should the results of a monitoring and evaluation
exercise indicate that a project is not going ac
cording to plan, then rediagnosis and replanning
is required. Rediagnosis and replanning require
the measurement process to be continually im
proved, and changes in the measurement process
should be aligned with changing needs and pri
orities.4 Program replanning and rediagnosis may
also require going back to prior steps in the plan
ning process to review whether:
• the problem is well defined and described
• the objectives are adequately implemented
• a revised-impact model has been
developed
• the target population has been redefined
• the delivery system has been redesigned
• there are revised plans for monitoring im
pact and efficiency

Deciding which evaluation process to use de
pends on numerous factors, such as set objectives,
available time, skills, and resources. To guide your
choice, Table 2 summarizes data collection de
signs and their different characteristics.
Typically, data collection methods include
checklists, scoring models, cost-benefit analyses,
surveys, and case studies. The best approach is to

Research programs are dynamic, and evalu
ations should take this into consideration.
Naturally, the longer the research project lasts,
the greater the likelihood that a given project
will require modification and adjustment. Table
3 summarizes the design, implementation, and
assessment requirements of research projects at
different stages of maturation.
HANDBOOK OF BEST PRACTICES | 
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low

medium

relatively
low, if
feasible
medium

relatively
high
(variable)
expensive

Case study: two
measurements
(before and after)

Time series design
(prior trend vs. actual)

Case study with one
measurement and a
control group (with
and without)

Quasi-experimental
design

Experimental design

Cost

Case study: one
measurement (actual
vs. planned)

Characteristics
evaluation design

relatively
high
(variable)

low

medium

low

very low

Reliability

relatively
high

low

medium

low

low

Technical
expertise

evaluation
research

impact
evaluation

formative
evaluation

impact
evaluation

process
evaluation

reporting

Types of
evaluation
(primarily
adoptive to
the design)

very good

very good

low

very good

good

very low

Ability to
measure
what is
happening

Table 2: Data Collection Designs and Their Characteristics

very good

good (variable)

low

medium

low

nonexistent

Ability to
exclude rival
hypothesis
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2. Ex post evaluations

These take place at the end of a research project,
when the effects and results of the project can
be tracked and used in adoption studies. At this
stage, the evaluation:
• assesses the project’s performance, qual
ity, and relevance, immediately after its
completion
• works best when a pre-project baseline had
been defined, targets projected, and data
collected on important indicators
• is often done by professional and external
evaluators
• requires that classical criteria be broadened
to include user satisfaction
• should be an integral part of project
implementation
• demands advanced preparation
• uses a blend of interviews, field visits, ob
servations, and available reports
• provides lessons that can be systematically
incorporated into future activities, for

example ex ante evaluation, as well as proj
ect planning
• is usually only done for more important,
innovative, or controversial projects
Essentially, ex post evaluations determine im
pact and are used to demonstrate accountability.
The evaluations sum up the lessons learned from
the project. They provide a firm foundation for
future planning and for establishing the credibili
ty of public sector research. They can also be used
to justify an increased allocation of resources.
2. Recommendations

The recommendations that arise from evaluation
studies should assess the information collected.
Evaluations should also review:
• what turned out differently than expected
• which part of the strategy produced the de
sired results and which did not
• whether a cross-section of views were
sought and accommodated

Table 3: An Assessment Planning Guide

Conceptualizing

Innovative programs

Established programs

Fine-tuning

• problem description

• determining capacity
for evaluation

• identifying needed
program changes

• operationalizing
objectives

• developing evaluation
model
• developing intervention
• identifying potential
models
modification
• defining extent and
opportunities
distribution of target
population

• specifying delivery
system
Implementing

• formative research and
development

• designing program
modifications

• determining
accountability
requirements

• program monitoring
and accountability
studies

• R&D program
refinements

• impact studies

• impact studies

• impact studies

• efficiency analyses

• efficiency analyses

• efficiency analyses

• implementation
monitoring
Assessing

• redefining
objectives

• monitoring
program changes
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• with whom the findings need to be shared
• in what form the results should be
presented
There are various uses for evaluation find
ings. The outcomes of an evaluation can be cat
egorized into three basic types: direct, indirect,
and symbolic.5 Evaluation outcomes are direct
when information or findings are applied directly
to alter decisions and results in an operational
application. Indirect use refers to a more intel
lectual, gradual process, in which the decision
maker gleans a broader sense of the problems
addressed by a project or program. Indirect use
of study results produces a strategic or structural
application of outcomes. Symbolic use refers to
situations where the evaluation results are accept
ed on paper, but go no further. Unfortunately,
many evaluation studies end up as symbolic ini
tiatives. It is imperative that technology transfer
assessments do not end up simply as academic
exercises. When an assessment is not practically
applied or used, not only is the effort wasted, but
future programs may continue to repeat mistakes
and waste money.
2. Impact assessment

An impact-assessment study aims to determine
causality and to establish the extent of improve
ment for the intended beneficiaries. Impact
assessments are time sensitive and, there
fore, studies should be conducted periodically
throughout the duration of a project. An im
pact study should measure the rate of adoption
for technologies that have been made available
for social or industry use. Such studies should
assess the technology’s level of use by targeted
beneficiaries and estimate the benefits of R&D
investments. By following these guidelines, im
pact studies should be able to determine the
impact of technology generation and transfer.
Impact assessments should also seek to mea
sure both intended and unintended outcomes,
taking into account behavioral change among
potential users and beneficiaries. The resulting
effect on productivity and quality of life should
be measurable and, therefore, evaluated and
reported.
 | HANDBOOK OF BEST PRACTICES

When conducting an impact study, the im
pact is assessed by gathering information on the
number of users, degree of adoption, and the ef
fect of the technology on production costs and
outputs. Studies should be conducted at different
levels (for example, household; target population;
regional and national; and at primary, secondary,
or economy-wide sector levels.)
There are different types of impacts.
Production and economic impact measure the
extent to which the project addresses:
• risk reduction
• yield increases
• cost reduction
• reduction in necessary inputs
• employment creation
• implication for other sectors of the
economy
Socio-cultural impact measures the extent to
which the project contributes to:
• food security
• poverty reduction
• status of women
• increases in knowledge and skill level
• number and types of jobs
• distribution of benefits across gender and
geographical locations
• changes in resource allocation
• changes in cash requirement
• changes in labor distribution
• nutritional implications
Environmental impact measures the project’s
effects on:
• soil erosion and degradation
• silting
• compact soil
• soil contamination
• water contamination
• changes in hydrological regimes
• effects on biodiversity
• air pollution
• greenhouse gases
Institutional impact measure effects on:
• changes in organizational structure
• change in the number of scientists
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• change in the composition of the research
team
• multidisciplinary approaches and
improvements
• changes in funding allocated to the
program
• changes in public and private sector
participation
• new techniques or methods
2. Tools

Different tools are used to measure performance
over time. These include (1) secondary analysis
of data, (2) the screening of projects and research
orientations by peers and experts in the field, (3)
qualitative descriptions of case studies and anec
dotal accounts, and (4) matrix approaches, which
provide rich information and help to rationalize
and simplify choices.
Examples of the matrix approach include:
• systemic methods. can be used to imple
ment an evaluation (This method is not re
ally suitable for evaluating and can be very
difficult to implement.)
• financial methods. namely, cost-benefit
measures that take into account marketable
outputs and commercial resources (It is of
ten difficult to collect the information, and
some factors cannot be financially assessed.)
• technological forecasting methods. en
tail the use of scenario methods and allow
for the causality chain to be reversed (This
method also allows for forecasting and takes
into account social transformations.)
• quantitative indicators. for example, sci
ence and technology indicators and mea
surement, pure descriptiveness, and se
lection integration (Indicators provide
fundamental scientific output measures.)
To help select the most appropriate study
method, Table 4 maps the desired impact of a study
against the assessment method and technique.
2. Indicators

Developing indicators is a critical step in the eval
uation process. Ultimately, indicators drive im
pact assessment and influence how the assessment

is conducted. In summary, there are three evalua
tion methods used to assess impact. These can be
(1) qualitative, such as peer review, (2) semiquan
titative, such as tracking scientific evidence, or (3)
quantitative, such as econometric measures. The
evaluation method selected should depend on the
evaluation objectives of the study and the needs
of each stakeholder (Table 5). The strengths and
drawbacks of each tool are presented in more de
tail in Table 6 (at the end of this chapter).

. CHALLEnGES And kEy
SuCCESS fACToRS
Monitoring, evaluation, and impact assessment is
a complex field. The conditions, methodologies,
and projects described here present various chal
lenges that need to be factored into the evalua
tion and impact study. These challenges include
the relatively unpredictable nature of research
and technology transfer events. Certain research
outcomes are discrete and are thus difficult to
measure, track, and document. Moreover, there is
no single, accurate method to objectively evaluate
R&D performance. There are also institutional
challenges. Effective communication between
stakeholders can be a problem, partly because of
the difficulty of maintaining data quality. And
because assessments tend to focus on measuring
more immediate, short-term benefits, there is
the risk of overlooking some of the longer-term
benefits of R&D. This issue is also related to de
termining the frequency of assessment studies.
For example, the European Union has adopted
a system that calls for three impact assessment
studies: an ex ante study at the start of the proj
ect, a project-end assessment, and an ex post study
three years after the completion of the project.6
The frequency of the study may affect its tem
poral focus. Of course, without establishing the
commitment and resources to collect, process,
store, and make accessible key performance data,
trans
nothing can be accomplished. Technology transinfrastructuree
fer managers need to develop the infrastructur
necessary to have valid and reliable performance
information and use this data for decision-mak
ing. They should take the time to develop a
shared understanding with funders about the role
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Table 4: Impact Assessment Methods and Techniques
Impact Type

Method

Technique

Intermediate impact

Survey, monitoring

Simple comparison/trend
analysis

Direct product of research

Effectiveness analysis using
logical framework

Simple comparison: target vs.
actual

Economic impact
(micro, macro, spillovers)

Econometric approach,
surplus approach

Production function, total
factor productivity, index
number methods, and
derivatives

Socio-cultural impact

Socioeconomic survey/
adoption survey

Comparison over time

Environmental impact

Environmental impact
assessment

Various

• Institutional changes
• Changes in the enabling
environment

• Qualitative
• Quantitative

Table 5: A Summary of the Evaluation Needs of Different Stakeholders7
Evaluation activity

Research
managers/
program
leaders

Researchers

Policy-makers

Donors

X

X

X

X

In-depth review of component

X

X

X

Ex ante evaluation of program/
project

X

X

X

Ongoing evaluation/ monitoring
of research activities

X

X

X

Ex post evaluation of a research
program/project

X

X

X

X

X

X

Review of entire system

Impact assessment
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of public R&D within the national innovation
system. Such efforts may make it possible to alle
viate shortages of essential financial, human, and
knowledge resources.
It is essential to identify the key factors that,
if in place, will improve the effectiveness of an
assessment framework. Managers must strive to
have in place as many of the following key success
factors as possible:
• leadership commitment
• a desire for accountability
• a conceptual framework
• strategic alignment
• knowledgeable and trained staff members
• effective internal and external
communication
• a positive and not punitive culture
• rewards linked to performance
• effective data processing systems
• a commitment to and plan for using
performance information
• adequate resources and the authority to
deploy them effectively.

. ConCLuSIon
An effective evaluation system should strengthen
an institution’s ability to maintain leadership
across the frontiers of scientific knowledge. The
system should enhance connections between fun
damental research and national goals, such as im
proved health, environmental protection, pros
perity, national security, and quality of life. Such
an evaluation system also will stimulate partner
ships that promote investments in fundamental
science and engineering, as well as the overall
more effective use of physical, human, and finan
cial resources for social and economic benefit.
As a way of benchmarking progress, it is
helpful to examine how other organizations mea
sure impact. Impact measures are a sure way of
knowing that science is delivering on its objec
tives and that R&D projects are having their in
tended effect. Without a measurement process,
institutions cannot justify their efforts in R&D,

IP management, commercialization, and tech
nology transfer in relation to their economic and
social goals.
Finally, it is essential to take the time to di
gest, reflect upon, and learn from an impact-as
sessment process. Lessons can be learned from
both successes and mistakes, and these lessons
should not only be used to take corrective action
but also to improve future performance. n
sibongile pefile, Group Manager, R&D Outcomes, Council

for Scientific and Industrial Research (CSIR), PO BOX 395,
Pretoria 0001, South Africa. spefile@csir.co.za
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Interest depends on the activity and the role of the
stakeholder concerned.

HANDBOOK OF BEST PRACTICES | 

past and ongoing

past, can be
applied R&D
used for ongoing
and future
R&D in certain
circumstances

future, past (to a
certain extent)

User surveys
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Benefit-cost
methods

Costeffectiveness
analysis

applied R&D

applied R&D

all

past, ongoing,
and future

Modified peer
review

R&D type

R&D time frame

Methods
• qualitative information only

• can provide valuable information on
potential impacts

• medium cost

• does not require benefit information

• simplest

• provides a structure and a framework for
assessing R&D projects that forces the
right questions to be asked

• can provide reasonable defensible
estimates of potential benefits

(Continued on Next Page)

• if one of the alternatives costs less, but produces a
low quality product or has a different impact, then
the assessment becomes more complicated

• there is nothing to prove that any of the alternatives can yield benefits over and above costs

• data collection requirements are demanding

• relative cost is high

• because of cost and time requirements, can only be
used for a limited number of projects

• results are critically dependent on assumptions
that can be highly uncertain

• can be very time consuming and labor intensive

• often requires considerable time to identify users,
develop survey methodology, and analyze results

• possible to develop quantitative indices
• medium cost

• structuring the survey and analyzing the results
can be tricky

• overcomes the problem of a small number
of respondents

• low to medium cost

• probably the best method for basic/
strategic R&D

• relies on the opinions of a small number of people

Weaknesses

• relatively easy to organize

Strengths

Table 6: Comparison of Assessment Tools
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R&D time frame

past

past, ongoing,
and future

future

past, ongoing,
and future

Methods

Case studies

Partial
indicators

Integrated
partial
indicators

Mathematical
programming

applied R&D

applied R&D

all

applied R&D

R&D type

• high relative cost
• not particularly useful for evaluating too diverse a
set of R&D projects

• can handle simultaneous change in many
variables

(Continued on Next Page)

• if either the criteria or constraints are not well
defined, there is a risk of arriving at a nonsensical
“optimal” solution

• demanding in terms of data requirements

• enables one to select optimal portfolio

• there is a potential for bias in assigning weights to
different criteria

• relies heavily on the judgment of a few individuals

• provides only a very partial picture of impacts

• the individual indicators can generally only be
added up on a subjective basis, making overall
impact assessment more difficult

• the results cannot be extrapolated to other R&D
projects that are not in the group

• generally there is no way to add up the results of
a group of case studies to obtain a measure of the
total impact of the group

Weaknesses

• more powerful and sophisticated

• low relative cost

• forces decision makers to explicitly consider
the key determinants of impacts

• an easy but structured way to identify
research priorities

• low relative cost

• probably the best method for ongoing
monitoring

• the information required to specify the
indicators relatively easy to collect

• medium cost

• probably the best method for basic/
strategic R&D

• can provide good illustrations of the
relationship between R&D and its impacts

Strengths

Table 6 (continued)
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R&D time frame

past and future

past

Methods

Simulation
method

Production
function
approach
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applied R&D

applied R&D

R&D type

• demanding in terms of data
• selection of suitable functional form can be
difficult

• estimates marginal rates of return
• statistically isolates the effects of R&D
from other complementary inputs and
services

• relative cost is high

• serious econometric problems may be involved

• uncertainty in projecting past rates of returns to
future

• medium to high relative cost

• requires an extensive amount of time to construct
and validate data

• to be useful, it must accurately reflect the
relationship between technological advancement
and economic development

Weaknesses

• offers a more rigorous analysis of the
impact

• can handle simultaneous change in many
variables

• can estimate the effect of research on
prices, income, employment, or other
parameters

• can be used to estimate optimal level
of research at national, commodity, or
program level

• flexible

Strengths

Table 6 (continued)
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Contracts and Agreements
to Support Partnerships

CHAPTER 7.1

Agreements: A Review of Essential Tools
of IP Management
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative,

International Vaccine Institute, Republic of Korea

anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University; Chair,

bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

Public-sector research institutions can use a variety of
agreements to protect and manage intellectual property.
These agreements are powerful tools to foster competition
in the private sector and reduce prices for consumers in
developing countries. This chapter provides an overview
of the following types of major agreements—confidential
ity, material transfer, development (in which the licensee
is responsible for further development), co-development
(in which two parties collaborate on continued develop
ment), and distribution—explains the functions of those
agreements, and suggests strategies for their effective use.
The chapter also discusses the meaning and usefulness of
the standard elements and formulas found in such agree
ments. It explains the meaning and significance of the
terms and language used and discusses such key issues as
product liability, fees and royalties, and arbitration. The
chapter emphasizes the importance of establishing and
maintaining trust when negotiating and implementing
agreements.

1. InTRoduCTIon
One important goal of public sector licensing
should be to promote competition between pri
vate companies. Monopolies and high prices are
not caused by patents themselves but by how pat
ents are managed, so the goals of the public sec
tor can be served by using licensing strategies that
foster competition and reduce prices.
Many kinds of agreements are used to pro
tect and manage intellectual property (IP). These
include agreements for confidentiality, material
transfer, development (in which the licensee is

responsible for further development), co-develop
ment (in which two parties collaborate on contin
ued development), and distribution.
Most agreements are between two parties,
but some may involve three or more parties. The
public sector agency or the negotiating party may
provide the first draft of an agreement for nego
tiation. Whoever writes the first draft often has
the advantage, so public sector agencies should,
whenever possible, take the initiative to prepare
the agreement. Regardless of who provides the first
draft, the proposal should adhere to the principle
of good negotiations: offer an agreement that you
would be willing to sign, if you were the other
party. A good agreement benefits both parties. For
an agreement to work, the two parties must trust
each other and maintain this trust throughout the
implementation of the agreement. With a high
level of trust, moreover, a request to renegotiate
by either party may be better received should cir
cumstances change. Finally, since enforcing inter
national agreements through legal remedies may
be difficult, such agreements should be considered
solemn commitments that must be observed.

2. THE uSE And LIMITATIonS of
TEMpLATE AGREEMEnTS
The chapter provides a number of template or
sample agreements for each major type of contact.

Mahoney RT and A Krattiger. Agreements: A Review of Essential Tools of IP Management. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. RT Mahoney and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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The online version of this Handbook also provides
many agreements from different institutions from
countries around the world. Each of these agree
ments can be downloaded in Microsoft Word or
Adobe PDF formats.
Evidently, no template agreement can be nor
should be considered as the “correct” or “best”
agreement. Any agreement must embody, specifi
cally, the deal that has been struck between the par
ties, and a good deal for all parties will depend on
the purpose of the deal and the context in which
the deal takes place. The template agreements are
merely intended as illustrations and possibly be
come a starting point for discussions and negotia
tions. In the discussion of the agreements in the
Section 3, special reference is made to humanitar
ian-use clauses where appropriate and relevant.
It should be noted that template agreements
are useful when used judiciously and as a start
ing point in the total process that ends in a fi
nal agreement between or among the parties. A
template agreement may be more or less com
plete, but clauses will always have to be changed,
deleted, or added. It is useful, however, for any
organization to develop its own template agree
ments that include the major elements that are
regularly used. The final draft agreement should
be reviewed by the institution’s counsel before
signature (and in some cases even before sending
it to the other party for review).
TheonlineversionofthisHandbook1 willinclude
a section with several hundred actual downloadable
agreements from many different institutions.

. MAJoR TypES of AGREEMEnTS
Two parties establishing a long-term working
relationship could sign a series of agreements,
or they could sign one or two agreements that
combine several agreements within them. The
following list appears roughly in the order that
agreements would be signed when two parties are
engaged in the development and distribution of a
new or improved product.
.1 Confidentiality agreements

Confidential information will probably be part
of discussions to establish business relationships
 | HANDBOOK OF BEST PRACTICES

involving proprietary health products. Such con
fidential information could concern laboratory
data and other research data, sources of materi
als, methods of production, the nature of licensing
agreements, detailed design of specialized equip
ment, staff-training requirements, countries in
which the developer would like to sell the product,
and so on. It is wise to conclude a confidentiality
agreement before entering into serious discussions
about a relationship with another party. Aside
from the obvious aim of protecting confidential
information, such an agreement ensures that both
parties are treating the discussions seriously. An
agreement to convey and protect confidential in
formation is a measure of the willingness of both
parties to proceed. This is especially important for
the party receiving confidential information. They
should be able to ask any reasonable question and
expect a fairly detailed response. Without a confi
dentiality agreement, the other party can refuse to
provide information that they consider sensitive.
It is more difficult to negotiate a confidentiality
agreement after negotiations have begun, espe
cially if trust has been damaged.2
.2 Materials transfer agreement

Before agreeing to sign a license for further prod
uct development, a potential licensee may wish to
evaluate the new material(s) or products to see if
it works well in his or her hands. Although licen
sors should be willing to provide samples, they
have an interest in assuring that the prospective
licensee does not misuse the samples. Misuse
might involve passing on a portion of the sample
to a third party or using the sample to generate
additional material for future use without con
cluding a license. It is generally recommended
that public-sector research organizations use ei
ther a Simple Letter Agreement3 or the Uniform
Biological Materials Transfer Agreement and the
Implementing Letter format developed by the
National Institutes of Health.4 In cases where
large numbers of materials need to be transferred
on a regular basis, such as by plant breeders, a
simple material transfer agreement, such as that
developed by with the International Network
for Genetic Evaluation of Rice (INGER),5 vari
ous national agricultural research and extension
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systems in Asia and the International Rice
Research Institute (IRRI) might be most appro
priate (Box 1: see also Appendix of this Handbook
at the end of Volume 2, page 1853).
3.3 Invitations to collaborate

To achieve its product-development goals, a re
search institute will often need to collaborate with
another organization. This need may arise at any
point, from laboratory studies through licensure
and distribution. For example, when a public-sec
tor research program requires prototype products
for clinical trials, it will probably need to find a
partner because most public-sector research centers
lack high-quality production facilities. Likewise,
for many neglected diseases in developing coun
tries, highly specific, highly sensitive, affordable
diagnostics are unavailable, and so collaboration
might be needed when diagnostics are required
for surveillance or clinical trials. Collaborators are
such an important part of successful development
that public-sector research institutions should
have a thorough process for identifying them.
Collaborators may be sought through Invitations
to Collaboration, which should be widely distrib
uted in international journals or other media, in
cluding the Internet and an organization’s Internet
home page. Summaries of the goals of the collabo
ration might also be included in the invitation.
Responses to an invitation should be reviewed ac
cording to well-defined criteria, and all applicants
should receive a report on the outcome of the pro
cess. An open and transparent process (with ap
propriate protection of confidential information)
will establish a reputation for fairness. Sometimes,
sole sourcing for one of the collaborating entities
may be appropriate because of the undisputed ca
pability of one organization to undertake the work
rapidly, effectively, and inexpensively. Cases of sole
sourcing, however, should be clearly documented,
and management should be able to explain clearly
why the sole-source route was chosen (see Box 2).
Once a collaborator has been identified, it will be
timely to negotiate a co-development agreement.6
3.4 Co-development agreements

If research and development have reached a stage
at which further extending the work requires

additional capabilities that a public-sector research
institution either lacks or does not wish to allocate,
then the institution will want to enter into a codevelopment agreement with a partner identified
through the Invitation to Collaboration process.
Co-development agreements vary widely with
regard to the extent to which the original owner or
product developer retains control over the prod
uct. A lone inventor with no development capa
bility may have very little control over what hap
pens to the product once a co-developer is brought
into the picture. On the other hand, a large firm
that has completed virtually all of a product’s de
velopment, and only needs, for example, to clini
cally test the product at a new dosage, may retain
almost complete control (in such cases, the firm
may simply execute a subcontract with the clini
cal-testing organization). A co-development agree
ment will define the nature of the final product or
other output sought, the role of each party in the
development process, the resources (financial, per
sonnel, and institutional) each party will invest,
the process by which the project will be managed,
the interim goals (milestones) and timetable, and
provisions for sharing in the success or failure of
the effort. Of particular importance is the projectmanagement system. It is common to establish a
project-management committee comprising staff
from each party. The number of members from
each party, the authority of the committee, the
frequency of meetings, and the requirements for
written reports will be specified in the agreement
(see the Appendix of this Handbook for a sample
co-development agreement).7
3.5 Technology licensing agreement

These are the most common types of agreements
negotiated by universities. It allows one party to
use, make, or sell products involving the intellec
tual property of the other party. The agreement
has terms defining the length of time the license is
valid; the markets (territory) in which the licensee
can make, use, or sell the product; whether or not
sublicenses are permitted; the nature and amount
of up-front fees and royalties; and whether or not
the licensor has rights to any improvements de
veloped by the licensee. Many other terms can ap
pear in a licensing agreement. See Appendix for a
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sample technology-license agreement, and Sections
11 and 12 in this Handbook contain many chap
ters dealing with specific elements of licenses.
. Distributorship agreement

Distributorship agreements permit the licensee to
receive a product from a licensor or to purchase
a product from a third party for distribution in
a defined market under a number of conditions
involving price, quantities, quality, labeling, roy
alties, and so on. The agreement often allows the
distributor to arrange for clinical trials, submit
required documentation to the national licens
ing authority, and prepare and carry-out product
promotion. A public-sector research institute, for
example, may arrange for a diagnostic to be man
ufactured by a commercial company that may not
be interested in marketing the diagnostic in any
or all territories.
Because they place a valued product in the
hands of a second party, distributorship agree
ments are treated very carefully, especially the
negotiation and implementation phases of such
agreements. In cases of drugs, vaccines, and diag
nostics, a license grants the licensee the right to
obtain a regulatory permit to sell the product in a
given market. If the license should be terminated
because the licensee does not perform or loses in
terest in the product, the licensor and a new li
censee may find it difficult to get a new permit
from the regulatory authority. They may have to
repeat many expensive activities with the attendant
delays. One way to address this potential problem,
if local law permits, is to require the regulatory
license to be transferable to a third party selected
by the licensor. A distributorship agreement can
also be the first step in building a long-term re
lationship that can lead to technology-licensing
agreements and additional co-development agree
ments. The Appendix of this Handbook contains a
sample distributorship agreement.

. STAndARd ELEMEnTS of AGREEMEnTS
.1 Recitals, preamble, and whereas clauses

Laying out the broad motivations and goals of
the parties, this opening section is important,
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particularly in agreements between public and
private sector agencies. It documents that the
parties believe their motivations and goals are
complementary, and because the objective of an
agreement is to have a win-win outcome, this sec
tion should set the right tone and clearly state the
parties’ reasons for entering into the agreement.
If a dispute ever arises between the parties, the
information in this introductory section could be
invaluable should the dispute end up in arbitra
tion or litigation.
.2 The parties

The parties are those persons, companies, or in
stitutions that willingly enter into an agreement.
Most often, there are two parties, but the number
may be more than two. The agreement may be
between two institutions or two individuals, or
an institution and an individual. It is important
to note that if one of the parties is an institu
tion, then the entire institution is bound by the
agreement.
Note that the incorporated names of the in
stitutions involved, as well as their headquarters,
are included in the parties’ names and addresses
list. Some organizations have regional offices or
subsidiaries with authority to enter into agree
ments. The addresses here may be different from
the addresses to which notifications or data must
be sent.
. Definitions

Any agreement is built around the meaning of the
written words. Many words or phrases are legal
“terms of art” that do not require definitions if
the usage is standard within the corresponding
field. Including a definition section enables a
lawyer, in drawing up an agreement, to use the
language of the agreement precisely, clearly, and
consistently without deviation in either the forms
of terms or their meanings. For example, as a legal
term of art, the term infant refers to any child up
to the age of adulthood—not just a baby—and a
“foreign corporation” is one incorporated in any
jurisdiction, not necessarily another country. If
there is any doubt whether a term will be under
stood, it is advisable to define it, in order to avoid
any confusion later.
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. Confidentiality

Confidential information disclosed in tangible
form is managed very carefully. The informa
tion is placed in a secure, locked filing cabinet
or in a password-protected computer and marked
“CONFIDENTIAL.” Only those staff covered by
the confidentiality agreement have access to the
material. Either they should complete a checkout form when they remove the material, or, with
digital materials, a record should be made of the
materials being accessed. Orally transmitted in
formation should be put in writing soon after
it is provided and the written form checked in
and out as appropriate. Scientists commonly dis
cuss research findings freely and seek to publish
them early. However, if the generation of intel
lectual property is an important goal, scientists
will have to consider how they can disseminate
their findings while helping to produce the in
tellectual property. One way to overcome this
difficulty is for IP management offices to swiftly
evaluate whether to patent a new discovery. Some
technology transfer offices can complete such an
assessment in 30 days, which does not unrea
sonably delay the presentation or publication of
the work. It should always be remembered that
confidential information has commercial value
and its improper release can cause substantial
damage. The original owner of the confidential
information could seek financial damages for the
unauthorized release of confidential information.
Divulging confidential information might also be
grounds for terminating the agreement.
. Territory and exclusivity

In a licensing agreement, the territory is the geo
graphic region in which the licensee is permit
ted to make, use, or sell the product. Applying
mainly to distribution agreements, a territory can
be a part of a country, a whole country, several
countries, or the whole world. Exclusivity deter
mines whether the licensee will have to share the
territory with one or more other licensees of the
same products. Licensors grant nonexclusive li
censes to stimulate competition among licensees
and to provide alternate distributors in case one
licensee fails. For health products, a licensor rare
ly grants anything but an exclusive license when

the license is for the limited territory of a single
country. One reason for this is the cost and time
required to obtain the approval of the national li
censing authority. Few licensees would be willing
to take on this burden if others could freely take
advantage of their costs for obtaining regulatory
approval.
In general, licensees want the most territory
and the highest level of exclusivity. This gives
them the greatest opportunity to exploit mar
kets, seek profits, and keep competitors away.
Moreover, it generally lowers the licensee’s risk.
With an unproven licensee, it is prudent to limit
both territory and exclusivity to the minimum
necessary for the project to succeed (at least ini
tially). It is a licensor’s nightmare to spend several
years working with a licensee only to have that
licensee fail to develop the product’s market. A
compromise middle ground is for the licensor to
grant increasing levels of territory and exclusivity
as the licensee achieves various performance mile
stones. For example, the licensee could receive a
license to a new territory after successfully com
pleting a marketing plan for that territory and
investing some base levels of funds to implement
the plan. Or a licensee could be required to pay
a separate license fee for each additional territory
granted. The amount should be large enough to
ensure that the licensee will want to protect the
amount paid by actually developing the market
in the new territory. A good rule of thumb is that
a license should be granted only when it is prob
able that the licensee will be able to develop that
market. A key consideration for the licensor is to
calculate the minimum market size necessary to
reach its financial goals with the product. One is
sue with exclusive licenses is that they de facto
form monopolies, which can make it difficult for
the public sector to obtain the product at an af
fordable price.
. Product liability

Product liability is increasingly important. Once
an issue primarily of concern in the United
States, product liability is becoming a problem
in Europe as well as the rest of the world. It af
fects many aspects of the health product business,
from the conduct of clinical trials to product
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prices, which are increased to cover the cost of
liability self-insurance.
All health-product manufacturers and dis
tributors should be concerned about the safety of
their products. There is a chance that a product
will harm an individual. Preventive products (for
example, vaccines) are the cause of greater con
cern than therapeutics, since the former are given
to healthy individuals. When a health product
harms an individual, it is reasonable for that per
son to be compensated for the injury. The form
of compensation, however, will vary depending
on the country. Unfortunately, in developed
countries, “product liability” has, to some extent,
become a kind of lottery: individuals seek huge
awards based more on the ability of the company
to pay than on the actual losses. Sometimes the
awards are so large that the very survival of the
company is threatened. This situation has made
companies quite defensive regarding liability, af
fecting their willingness to enter new markets and
to develop new health products.
When negotiating a license, the key ques
tion with respect to liability is: who should accept
product liability and for what? For some matters
the answer is clear. A manufacturer, for example,
should be responsible for adhering to good man
ufacturing practices and should be responsible
for any injury caused by errors in the production
process. A public sector licensor will usually ex
pect the licensee to assume most of the liability
because the licensee sells the product. A licensor
may, as a condition for granting the license, make
acceptance of liability by the potential licensee,
which places a special burden on the licensee to
assess carefully the product’s potential liability
implications. It is extremely rare for a licensor to
be brought into a liability suit. If accused, it is
even rarer for a licensor to be found liable.
Even if a licensee holds the licensor harm
less, doing so would not prevent the licensor from
being named in a suit. The costs of defending a
suit, especially in the United States and Europe,
can be very large—sometimes almost as dam
aging as a liability judgment itself. The licensor
should therefore request, and have this specified
in the agreement, that the licensee meet all costs
incurred, within reasonable limits, by the licensor
0 | HANDBOOK OF BEST PRACTICES

in defending a liability case. Insurance is available
to cover just the legal costs of defense. The licen
sor should ask for proof that the licensee has ob
tained liability insurance and that the insurance
is kept in force. Liability is an extraordinarily im
portant issue, and public sector research groups
are well advised to obtain high-quality profes
sional advice.
. Up-front fees and royalties

A license transfers value. The up-front fees and
royalties, therefore, are the agreed price repre
senting that value. Since licenses are not trad
ed in open markets, where the price can be set
through supply and demand, each negotiation is
unique and reflects the evaluations of each party.
A licensor will have several considerations. First,
the licensor will want, at a minimum, to recover
the expense, or some reasonable portion of the
costs, already invested in the product. Second,
the licensor will want to generate a steady flow
of income.
Up-front fees have to balance two issues.
First, they should be high enough, if possible, to
meet the licensor’s need for short-term income
and to assure that the licensee is seriously seek
ing to develop the product. Second, they should
not be so high that they limit the ability of the
licensee to invest in the product and make it a
success. Other factors to consider are the ex
pected life of the product and the lifetime of the
IP rights being granted. The shorter the life of a
product (because other, better products are ex
pected to emerge quickly), the less the licensor
can ask for up-front fees and, to a lesser extent,
royalties. If the license is based on a patent, at
the end of the patent’s life the level of royalties
may decrease or the license may even expire. The
term of the license is more complicated when the
license is for know-how. A reasonable but com
plicated approach for such licenses is to have the
royalty diminish with time and eventually reach
zero when both parties agree that the know-how
is no longer valuable. Such an event might oc
cur when the licensor stops using the know-how.
But if the know-how is essential for successfully
manufacturing and selling the product through
out its lifetime, there is no reason for the royalty
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to change. Also, a licensor may make continual
changes in the know-how and pass those on to
the licensee. In this situation, royalties may be
collected for a very long time.8
Having said all this, it is important to remem
ber that the goal of the licensing strategies dis
cussed here is to maximize benefits for the public
sector. Possible up-front fees and royalties should
be seen simply as two ways to extract value for the
public sector—and perhaps not the most desirable
ways.
. Arbitration

Successful agreements are based on trusting re
lationships, and both parties in an agreement
should work to maintain trust in implementing
the agreement. Some agreements, usually those
negotiated between two parties in the same coun
try, can allow for disputes to be settled in court.
The more common practice, however, is to use
arbitration. The issues for consideration here are
the number of arbitrators, how they are chosen,
their operating rules, the location where the ar
bitration shall take place, which party shall bear
the costs of the arbitration process (or what share
each party will bear), and whether the arbitration
should or should not be administered by an arbi
tration institution.
In one formulation, three arbitrators are
used. Each party chooses one, and the two ar
bitrators, so chosen, choose the third. The third
arbitrator serves as the chairperson of the panel.
The arbitrators may operate according to various
rules. An international set of rules is a common
reference, and many arbitration institutions have
their own arbitration rules. In addition, most
countries have laws that govern arbitral proceed
ings conducted within their territory. These laws
should be carefully considered when choosing the
arbitral locale. Location is also important because
of costs. If arbitration occurs at the offices of one
party, the other party will have to incur costs to
be present for the proceedings. Cost allocation
can be specified in the agreement, or the arbitra
tors can allocate the costs. Arbitration can be very
costly, which further emphasizes the need to en
sure that the initial negotiations are as thorough
and specific as possible.9

. Term and termination

Term and termination clauses specify the term
over which an agreement is to last. The beginning
date can be either a specified calendar date or,
more usually, the date on which the last signature
is applied. A specified date might apply when cer
tain calendar-specific tax matters are important
or when it is essential to ensure that one party
does not delay initiation of the agreement.
Termination is a much more complex issue.
A standard termination provision should include
cases in which one party breaches a part of the
agreement. The party that feels there has been a
breach by the other party will be required to send
a notice of breach. Usually, a period of time is
provided during which the supposedly breach
ing party can correct the breach or prove that a
breach has not occurred. Also, since circumstanc
es can change, it may be desirable to allow one or
both parties to terminate the agreement follow
ing the expiration of a defined notice period (for
example, 60 days). It may be desirable to define
the circumstances under which such termination
is allowed.
.10 Jurisdiction, warranties, notices

The agreement will specify that, in the case of a
dispute, laws will apply in a particular country,
state, or province. The jurisdiction will usually be
that of the licensor, although there may be rea
sons to have a neutral third location.
Each party to the agreement should warrant
that it has the authority to do what is contained
in the agreement. For example, if the agreement
is a patent license, the licensor will warrant that
it owns the patent and that it is not aware of any
infringement of the patent. Conversely, this war
rant may include that the licensee cannot hold
the licensor liable for any unknowing infringe
ment that may be discovered. Warrants are of
ten symmetrical (that is, each party warrants the
same things).
An agreement will specify the name, address,
and other contact information of the individuals
or positions within each party to which official
communications should be directed. The notice
clause may also specify whether fax and electronic
documents are acceptable.
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.11 Other potentially important clauses

In certain types of agreements or jurisdic
tions, the following clauses may be of particular
importance:
.11.1 Illegal/unenforceable provisions

In some jurisdictions, it might be advisable to in
clude certain limitations:
Should any court of competent jurisdiction later
consider any provisions of this Agreement to be in
valid, illegal, or unenforceable, such provisions shall
be considered severed from this Agreement. All other
provisions, rights, and obligations shall continue
without regard to the severed provision, provided
that the remaining provisions of this Agreement are
in accordance with the intentions of the Parties.
.11.2 Statement of completeness

Many organizations have more than one agree
ment with a specific third party in place. If that
is the case, then the formerly existing agree
ments should be cited whenever possible and re
viewed for consistency with any new agreement.
Alternatively, the agreement may be limited to the
purpose that has previously been defined. Typical
language could read:
The above constitutes the full and complete
Agreement on this Purpose by and between the
Parties.
.11. Subject law

In the subject-law section, the Parties clarify where
they wish to have an agreement interpreted and
adjudicated. Such a determination is not always
necessary but can make future interpretation less
difficult, particularly if the Parties are located in
different countries. Typical language is:
This Agreement shall be interpreted, construed
and adjudicated under the laws of _____ province
[or state, canton, etc.] _____ within the nation of
_____.
.12 Signatories

Representatives with authority to bind their re
spective institutions are the persons who should
sign agreements. It is advisable to include the
person’s title to make clear that the person is
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representing the Party and not signing the agree
ment as an independent entity.
In some cases, more than one representative
from each party should sign an agreement. For ex
ample, when materials are transferred to a labora
tory of a specific scientist, it is important to ensure
that the scientist is fully aware of the obligations so
the scientist may be included as a signatory.
Further, in a university setting, different de
partments or even legal entities may have certain
responsibilities over in-licensing and out-licens
ing. For example, an office of sponsored pro
grams may be responsible for incoming materi
als, whereas a foundation that commercializes
university inventions may also have a stake in the
agreement. In such cases, there may be signatories
representing at least three entities, one of which
may include the chief scientist.

. ConCLuSIonS
No agreement will ever be perfect. Evidently,
there are good and not-so-good agreements (and
even poorly written ones or highly ineffectual
agreements). The better ones may take longer to
negotiate, but the good news is that each time
an agreement has been successfully developed by
two parties, the process gets easier. Taking time to
think through and discuss the terms of an agree
ment helps foster communication between the
partners. Such an activity, especially if carried out
early on, sets the project on a path for success. In
any case, the critical aspect of any agreement is
what the parties do after the agreement has been
signed; an agreement should always be seen as
just the beginning of a long and mutually benefi
cial relationship. n
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric
Dengue Vaccine Initiative, International Vaccine Institute,
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818,
Republic of Korea. rmahoney@pdvi.org
anaTole KRaTTigeR, Research Professor, the Biodesign
Institute at Arizona State University; Chair, bioDevel
opments-International Institute; and Adjunct Professor,
Cornell University, PO Box 26, Interlaken, NY, 14847,
U.S.A. afk3@cornell.edu
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www.ipHandbook.org. Included there are many actual
agreements including confidentiality, material transfer
(for germplasm, biological resources, materials for
testing, research tools, and experimental animals),
IP licenses for copyright, software, trademarks, trade
secrets, and various forms of exclusive, coexclusive and
nonexclusive licenses, as well as the Model Provisions
for an Equitable Access and Neglected Disease
License developed by the working group, based at
Yale University, convened by Universities Allied for
Essential Medicines. Other chapters in this Handbook
also contain sample agreements including nonasserts,
invention disclosure, licensing checklist, and more.
Please refer to the index for a list of agreements.

4

See http://ott.od.nih.gov/policy/rt_guide_final.html
and http://ott.od.nih.gov/NewPages/UBMTA.pdf.

5

The swift program at Cornell University and IRRI
collaborated at the time for the INGER TrainingWorkshop on IPR, 17-18 July, 2001, Maruay Garden Hotel,
Bangkok, Thailand.

6

See, also in this Handbook, chapter 17.10 by KR
Schubert.

7

Ibid. and chapter 7.4 by MB Steinbock.

8

See, also in this Handbook, chapter 5.4 by BJ
Weidemier.

9

See also, in this Handbook, chapter 15.3 by E-J Min.

2

See, also in this Handbook, chapter 7.2 by SP Kowalski
and A Krattiger.

3

See, also in this Handbook, Box 3 in chapter 5.7 by AB
Bennett.

10 Mahoney RT (ed.). 2004. Handbook of Best Practices
for Management of Intellectual Property in Health
Research and Development. MIHR: Oxford, U.K.
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Box 1: Material Transfer Agreement for the Genetic Evaluation
of Rice to and from INGER Collaborators
The International Rice Research Institute, MCPO Box 3127, Makati City 1271, Philippines (“IRRI”),
provides the “Material”
under the following terms and conditions:
1. The Material provided is not intended for the exclusive use of any single organization.
2. IRRI requires written notification if the recipient distributes the Material to a third party.
3. Recipients may not seek any form of intellectual property rights protection on the Material
without prior written consultation with IRRI. IRRI reserves the right to refuse to grant such
permission.
4. Use of the Material will be publicly recognized when and where appropriate, and recipient will
provide IRRI with reports on its use of the Material on a reasonably frequent basis.
5. IRRI does not warrant or guarantee the title, quality or correctness of the Material being
supplied and will not be held liable for the Material or its use.
6. IRRI provides the Material on acceptance of the terms and conditions of this MTA. Recipient’s
retention of the Material shall be deemed to constitute acceptance.
Name of Recipient
Title
Institution
Address
E-mail
Date
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Box 2: Invitation to Collaboration
Development of a Health Product A
objective
The Public Sector Research Centre (PSRC) is seeking collaborative relationships with one or
more organizations capable of completing the following tasks for prototype health products:
industrial development, manufacturing, clinical testing, and licensure by national regulatory
authorities.
Health Product A can be produced in a number of different ways. The PSRC believes that one or
more of these production methods could be viable for commercial scale-up.
The public Sector Research Centre
[insert a description of the PSRC including governance, funding, research programs, goals,
history, capabilities, etc.]

participating Scientists
The following scientists have played a leading role in the development of methods for
synthesizing Health Product A as described in the attached documents. [attach copies of
relevant publications]

and their collaborators.
Mode of operation
The PSRC has the ability to mobilize assistance for the health-product development process by a
variety of means including financial, technical, and in-kind support.
Companies should contact the PSRC to initiate an agreement on a development project.
The following issues are open for discussion with respect to a collaboration
agreement:
• Product development including consultation on details of manufacture, adjuvanting,
packaging, heat stability, etc.
• Cost sharing of the manufacture of sufficient health product for Phase I through Phase III
trials.
• Assessment and planning for the introduction of the health product into private-sector
markets.
• Assessment and planning for the introduction of the health product into public-sector
markets.

(Continued on Next Page)
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Box 2 (continued)

• Development of regulatory standards through interactions with national regulatory
authorities and the World Health Organization.
• Conduct of Phase I through Phase III trials in developed and developing countries in a variety
of populations.
• Obtaining regulatory approval in developed and developing countries.
Intellectual property Rights
Details on patent applications will be discussed with interested parties following execution of
a suitable confidentiality agreement. The PSRC possesses extensive know-how, which will be
essential for the cost-effective implementation of a health-product development program.
desired product
The envisaged health product is expected to consist of _______________________. Further
information on specific methods for health product manufacture is provided in the attached
documents.
In the developing world, the principal use of the product is expected to be _________________
______. In the developed world, the health product may find use in _______________________.
See the following dossier for further discussion of potential market.
Submission of Expression of Interest
At this time, a letter containing the following information is requested:
• the nature of your interest in this project
• if you wish, a summary of the capabilities and experience of the organization
• names of other collaborators or partners
• an indication of the types of assistance/collaboration desired from the Institute
Interested parties are requested to write to the PSRC ____________________________________
__________. Submissions are requested prior to _______________________.
For further information, contact either [name 1] _______________________or [name 2] _______
________________ of the PSRC at telephone _______________________ or fax _______________
________ or write to them at [e-mail address] _______________________or the above address.

Review and Contracting procedure
Interested parties will be contacted to arrange for meetings and development of collaborative
agreements.
Background on Health product A and Collaborating Scientists
Health Product A is involved in acute, chronic, and _______________________. Health Product A
is widespread in both developing and developed countries and infects _____________________.
Infection persists throughout life. Health Product A transmission is primarily by _____________
__________.
(Continued on Next Page)
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Box 2 (continued)

Health-Product-A–associated diseases are significant causes of morbidity and mortality.
For example, in developing countries ______________________________________________.
In developed countries, it leads to significant morbidity_______________________.
Short biographies of collaborating scientists [include as an attachment]
Market Potential for Health Product A
Scientific and other References
Source: Mahoney10
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Confidentiality Agreements: A Basis for Partnerships
sTanley p. KowalsKi, Franklin Pierce Law Center, U.S.A.
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University; Chair,

bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

Confidentiality agreements (also called nondisclosure
agreements, confidential disclosure agreements, and se
crecy agreements) are contracts that govern the disclosure
of confidential information by one party (the disclosing
party) to another party (the receiving party). Confidential
information is exchanged for a promise of secrecy. The
disclosure may be unilateral, bilateral or multilateral.
Confidential information disclosed in a confidentiality
agreement might pertain to scientific research results and
data, chemical compositions and formulas, software de
velopment information, recipes, laboratory methodology,
and manufacturing techniques trade secrets (in the form
of valuable know-how and/or show-how). The confiden
tial information has value precisely due to the fact that is
known to only a few, that is, open disclosure will be inju
rious to this value. Confidentiality agreements often pre
cede licensing negotiations or the acquisition of IP (intel
lectual property) rights and serve to strike an appropriate
balance between the needs of the disclosing and receiv
ing parties. A confidentiality agreement can either stand
alone or be included as part of a broader agreement. An
appropriately drafted confidentiality agreement should
contain a list of standard provisions and exceptions. In
special cases, where the disclosing party wishes to care
fully protect the confidential information, the agreement
might also include extra strong clauses and articulated
security provisions.

1. InTRoduCTIon: BuILdInG TRuST
Before entering into a relationship, a level of
trust between the parties must be established.
This trust is the basis for a confidentiality agree
ment, which is often the first step in developing

a mutually advantageous relationship. For exam
ple, a confidentiality agreement often precedes
licensing negotiations or the acquisition of intel
lectual property (IP) rights.
Depending on the perspective, whether a per
son or party is disclosing or receiving confidential
information, the disclosing party will want the re
ceiving party to maximize protection whereas the
receiving party will want to minimize constraints.
However, the disclosing party often wants to dis
close information, for example, as a first step in
licensing negotiations or other business develop
ment activities, or as required by a know-how li
censing agreement. But even the receiving party
may see problems in terms of future constraints
imposed by the agreement and its ability to use
the received information. In the end, a confiden
tiality agreement is intended to strike an appro
priate balance between the needs of a disclosing
party and the needs of a receiving party.
Confidential information is often passed
from one party to another when materials are
transferred, during collaborations, and in some
types of licensing agreements. A confidential
ity agreement is the simplest form of almost any
agreement, and confidentiality clauses generally
form an integral part of most other agreements.
But confidentiality agreements are also entered
into separately for the sole purpose of disclosing
confidential information, although perhaps they

Kowalski SP and A Krattiger. Confidentiality Agreements: A Basis for Partnerships. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. SP Kowalski and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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are used less often for that purpose. It is important
to note that obtaining third-party confidential in
formation may not always be a good option. The
knowledge could block important future research
or otherwise adversely affect the business of a re
ceiving party.

2. ConfIdEnTIALITy AGREEMEnTS
dEfInEd
Confidentiality agreements (also called nondis
closure agreements, confidential disclosure agree
ments, and secrecy agreements) are contracts that
govern the disclosure of confidential information
by one party (the disclosing party) to another
party (the receiving party). The disclosure may be
unilateral, with one party disclosing confidential
information to only one other party; bilateral,
with two parties mutually disclosing information;
or multilateral, with three or more parties disclos
ing information among themselves.
With regard to a confidentiality agreement,
confidential information is exchanged for a prom
ise of secrecy. Confidential information is infor
mation that is of value precisely because it is not
generally known to competitors or to the public.
Such information might pertain to scientific re
search results and data, chemical compositions
and formulas, software-development information,
recipes, laboratory methodology, manufacturingtechniques trade secrets (in the form of valuable
know-how and/or show-how), and so on. What
matters, within the context of the confidential
ity agreement, is that the information is of value
due to its state of being relatively unknown, and,
therefore, open disclosure would be injurious to
this value.
. kEy pRovISIonS
As stated above, confidentiality agreements come
in many different forms and lengths and should
be adapted to the particular circumstances and
legal environment.But they all have the same es
sential components and purpose: to ensure that
a privileged communication to a third party is
treated as confidential. But, along with the stan
dard terms of any agreement, such as boilerplate
0 | HANDBOOK OF BEST PRACTICES

contract terms, confidentiality agreements in
clude a number of terms that are important. Box
1 provides a fairly typical confidentiality agree
ment used by a university.
The following agreement is a sample of a
one-way, or unilateral, confidentiality agreement.
Two-way agreements, through which two parties
mutually disclose confidential information follow
the same approach in principle, except that both
parties usually have the same obligations to each
other. Specific samples of unilateral and bilat
eral agreements from different organizations are
available for download on the Handbook’s Web
version.
.1 Disclosing party

It should be noted that the disclosing party does
not necessarily need to be the party who actually
owns the confidential information. The disclos
ing party may instead be a party that lawfully pos
sesses the information and is legally permitted to
disclose it.
.2 Receiving party

Receiving parties, particularly in large organi
zations, are parties to a confidentiality agree
ment. The receiving party may thus be a series
of individuals, depending on the complexity
of the disclosure. In such cases, confidentiality
agreements, and disclosures, are made at differ
ent stages whereby, initially, one individual or
a small department receives the confidential in
formation. For example, if the receiving party
is not confident that the information is really
worth binding the entire large institution to an
agreement, an individual may be nominated to
receive the confidential information as a first
step before subsequent agreements are executed.
Unless otherwise articulated in the confidential
ity agreement, every person within the organi
zation that is named as a party may share the
confidential information with every other per
son within the same organization. However, as
per specific disclosure provisions in the agree
ment, disclosure may be limited to persons who
“need to know,” or to certain departments, or to
only scientists within a specific research group,
for example.
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Box 1: unilateral Confidentiality Agreement
This Agreement, effective on _________ (“Effective Date”),

is by and between _________________________(“Disclosing Party”),
with offices at ________________________, and

________________________ (“Receiving Party”),
with offices at ________________________.

The Disclosing Party intends to disclose certain Confidential Information to the Receiving Party
for the following purpose (the “Purpose”):
Now, therefore, in consideration of the Disclosing Party making such confidential information
available to the Receiving Party, the Receiving Party hereby agrees as follows:
1. As used in this Agreement,the term “Confidential Information”means any technical or business
information furnished by the Disclosing Party to the Receiving Party in furtherance of the
Purpose in connection with the Purpose, regardless of whether such information is specifically
designated as confidential and regardless of whether such information is in written, oral,
electronic, or other form. Such Confidential Information shall include, without limitation, trade
secrets, know-how, inventions, technical data or specifications, compilations of information,
records, testing methods, business or financial information, research and development
activities, product and marketing plans, and customer and supplier information.
2. Confidential Information shall not include disclosed information to the extent that the
Receiving Party can demonstrate that such disclosed information:
(a) was in the public domain prior to the time of its disclosure under this Agreement;
(b) entered the public domain after the time of its disclosure under this Agreement through
means other than an unauthorized disclosure resulting from an act or omission by the
Receiving Party;
(c) was independently developed or discovered by the Receiving Party without use of the
Confidential Information;
(d) is or was disclosed to the Receiving Party at any time, whether prior to or after the time
of its disclosure under this Agreement, by a third party having no fiduciary relationship
with the Disclosing Party and having no obligation of confidentiality with respect to such
Confidential Information; or
(e) is required to be disclosed to comply with applicable laws or regulations, or with a court
or administrative order, provided that the Disclosing Party receives prior written notice of
such disclosure.
3. The Receiving Party agrees that it shall:
(a) maintain all Confidential Information in strict confidence, except that the Receiving
Party may disclose or permit the disclosure of any Confidential Information to its
directors, officers, employees, consultants, and advisors who are obligated to maintain
the confidential nature of such Confidential Information and who need to know such
Confidential Information for the purposes of this Agreement;
(b) use all Confidential Information solely for the purposes of this Agreement; and
(c) upon the conclusion of the Purpose, or earlier at the request of the Disclosing Party, return
to the Disclosing Party all originals, copies, and summaries of documents, materials, and
other tangible manifestations of Confidential Information in the possession or control of
the Receiving Party.
(Continued on Next Page)
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Box 1 (continued)

4. The term of this Agreement is for the duration of one (1) year from the Effective Date
(“Termination”).
5. The obligations set forth in this Agreement shall remain in effect for a period of five (5) years
after Termination, except that the obligation of the Receiving Party to return Confidential
Information to the Disclosing Party shall survive until fulfilled.
6. The Receiving Party acknowledges that the Disclosing Party claims ownership of the
Confidential Information disclosed by the Disclosing Party and all intellectual property rights
in, or arising from, such Confidential Information. No option, license, or conveyance of such
rights to the Receiving Party is granted or implied under this Agreement.
In Witness whereof, the Parties hereto have caused this Agreement to be executed.
DISCLOSING PARTY

RECEIVING PARTY

Signature: _________________________

Signature: _________________________

Title: _____________________________

Title: _____________________________

Name: ____________________________
Date: _____________________________

Name: ____________________________

Date: _____________________________

. Purpose of the confidentiality agreement

. Limitations on disclosure

Such language provides an additional caveat
as to how the confidential information may be
used within the context of the confidentiality
agreement. That is, in addition to who may be a
receiving party and what the confidential infor
mation entails, purpose further specifies, or re
stricts, how the information may be used.

. Important exceptions

As with any agreement the definition and de
scription of the purpose are important for any
confidentiality agreement, with the aim of avoid
ing confusion and later disagreement. The text
could read:
… to evaluate XXX technology of the Disclosing
Party, or
… to evaluate entering into a sponsored research
agreement, or
… to evaluate the information to assess entering
into a license agreement

2 | HANDBOOK OF BEST PRACTICES

Information received under a confidentiality
agreement cannot be disclosed to a third party
that is not a party to the agreement, even if such
disclosure takes place under a separate agreement.
There are also examples when a receiving party
believes that the disclosing party has a separate
confidentiality agreement with a third party. This
might tempt the receiving party to disclose the
confidential information to this third party, per
haps mistakenly believing that the third party
might already have had access to the particular
confidential information from the disclosing par
ty. Such disclosures to third parties are not per
mitted (unless specifically allowed).
Confidentiality agreements usually contain ex
ceptions to the receiving party’s obligation to
maintain the confidence of the confidential
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information. These clauses are not generally
points of negotiation. Different agreements may
include different exceptions, though the follow
ing five are fairly typical:
1. The information that was in the public do
main prior to the time of its disclosure.
2. The information was already known by the
receiving party.
3. The information entered the public do
main after the time of its disclosure under
the agreement through means other than
an unauthorized disclosure resulting from
an act or omission by the receiving party.
4. The information was independently de
veloped or discovered by the receiving
party without use of the confidential
information.
5. The information is or was disclosed to the
receiving party at any time by a third party
having no fiduciary relationship with the
disclosing party and having no obligation
of confidentiality with respect to such con
fidential information.
6. The information is required to be disclosed
to comply with applicable laws or regula
tions, or with a court or administrative or
der, for example, a subpoena for produc
tion of the information pursuant to a grand
jury proceeding.
The fourth point is particularly important for
academic research establishments. The following
example serves to illustrate the point: Yuri works
at a university in the biochemistry department.
He has no connection with, nor knowledge of,
a particular set of confidential information. Yuri
independently develops an innovation that relies
on the same general knowledge as that of another
researcher, Irina, at the same university but in
the department of physical chemistry. With that
general knowledge, Yuri developed his invention
that concurrently leads to valuable data. Nearly
identical data had been obtained by Irina under
a confidentiality agreement from the BioChem
company. That confidential data has been previ
ously obtained by Irina.
Evidently, both professors, Yuri and Irina are
employed at the same university but in different

departments. Yet Irina’s confidentiality agree
ment is between BioChem and the university as
a whole since the Office of Sponsored Programs
signed it on behalf of the university. Since Irina
never shared the data with Yuri, Yuri may be un
der no obligation of confidentiality in regard to
the specific data he developed himself.
Referring now to the fourth point in the list
above, if a provision is included in the confiden
tiality agreement such that information indepen
dently developed or discovered by the receiving
party (someone at the university) without the use
of the confidential information will be an excep
tion to confidentiality, then Yuri is under no ob
ligation to keep the information secret. If this ex
ception were not included in Irina’s confidentiality
agreement with the BioChem company, then Yuri
would not be able to publish information about his
innovation without placing Irina at risk of breach
of the confidentiality agreement with BioChem.
Once Yuri made his data public, Irina likewise is
no longer under an obligation to keep her data se
cret (providing it is identical) since the data is now
public. This is perhaps the single most important
exception to keep in mind when drafting confi
dentiality agreements for research institutions.

. oTHER poSSIBLE CLAuSES
Nongrant of rights. In some confidentiality agree
ments, the disclosing party will state that there is
no confusion about the intent in disclosing confi
dential information. This is to prevent the receiv
ing party from later claiming that, by disclosing
the confidential information, the disclosing party
implied the granting of, to the receiving party, addi
tional rights or licenses. This limitation could read:
Nothing contained in this Agreement shall
be construed as an obligation to enter into any
further agreement concerning the Project or
Confidential Information, or as a grant of license
to the Confidential Information, other than for the
Project.
Limitations to disclose. Certain limitations may
apply to the amount of information to be dis
closed. Language such as the following can be
included in specifying such a limitation:
HANDBOOK OF BEST PRACTICES | 
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The amount of Confidential Information to be
disclosed is completely within the discretion of the
discloser.
Limitations on the use of the information.
Certain agreements contain a specific clause that
states certain limitations on the receiving party’s
use of the confidential information, for example:
The receiving Party may not use the Confidential
Information for commercial or noncommercial re
search (or for the production of prototypes; or for
obtaining regulatory approvals) without the prior
written approval of the disclosing Party.
Representation. In some cases, a receiving party
may demand representation. Language such as the
following can be included to address this issue:
Discloser of Confidential Information represents
that the disclosure of information is not in viola
tion of any commitment or obligation to any former
employer, present employer, or any other party and
that discloser has the right to make such a disclosure
and to make the promises and agreements expressed
herein.
Such representations are sometimes used
when individuals disclose information.
Requirements for documentation. There are no
standards as to whether disclosed confidential in
formation should be documented. Especially in
an academic setting, where disclosing and receiv
ing parties are scientists and converse by phone
and e-mail, such a requirement would, in many
cases, be ignored or forgotten. However, if in
cluded, the following clause may be used:
To the extent practical, Confidential Information
shall be disclosed in documentary or tangible form
marked “Proprietary” or “Confidential.” In the case
of disclosures in nondocumentary form made orally
or by visual inspection, the discloser shall have the
right or, if requested by the recipient, the obligation
to confirm in writing the fact and general nature of
each disclosure within a reasonable time after it is
made.
Extra strong clauses.1 Occasionally the
disclosing party may want the confidential
ity agreement to provide as much protection as
 | HANDBOOK OF BEST PRACTICES

possible. This will be the case when information
to be disclosed is of great value and importance
to the disclosing party. Under such circumstanc
es, the disclosing party can include extra strong
clauses in the agreement. These provisions will
not alter basic obligations articulated in the agree
ment, but rather clarify and emphasize the grav
ity of said obligations. Examples of extra strong
clauses could include:
• The receiving party is forbidden to use the
disclosed confidential information to make
inventions or other valuable developments.
• If the receiving party uses the disclosed con
fidential information to make inventions or
other valuable development, then all rights
to such shall be assigned to the disclosing
party.
• The receiving party will not attempt
to replicate the disclosed confidential
information.
• The receiving party will not engage in de
tailed research for the purpose of investigat
ing the details and aspects of the disclosed
confidential information.
• The receiving party will not use the dis
closed confidential information in a
manner that either confers commercial
benefit on the receiving party or places
the disclosing party at a commercial
disadvantage.
Security.2 Security is, naturally, a critical consider
ation in any confidentiality agreement. Common
provisions in agreements state that the receiving
party must treat the disclosed confidential infor
mation with the same degree of security as it does
its own confidential information, or there can be
a clause that specifies reasonable and proper mea
sures to safeguard and ensure security. However,
if the disclosing party wants to make certain
that a specific level of security is established and
maintained, then the following types of provi
sions might be included in the confidentiality
agreement:
• Disclosed confidential information must be
stored in designated, locked storage spaces.
• Only designated individuals can have access
to the disclosed confidential information.
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• Copying the disclosed confidential infor
mation is strictly prohibited.
• Disclosed confidential information cannot
be taken from the premises.
• Any viewing of the disclosed confidential
information must be duly recorded in a
log.
• All disclosed confidential information docu
ments have unique identifier numbers and all
are marked, in red, “CONFIDENTIAL.”

. ConCLuSIonS
There are two simple rules to keep in mind when
dealing with confidentiality agreements (and, in
fact, with any agreement): First, if there is no trust
between the parties, then perhaps it is best not
to proceed with the agreement, no matter how
simple the agreement may be. On the other hand,
a confidentiality agreement may be a rational first
step in developing the trust needed to build a re
lationship that may lead to further collaboration
and new opportunities. Second, by entering into

a confidentiality agreement with another party to
receive their confidential information, it is im
portant to ensure that everyone in the organiza
tion who has access to the confidential informa
tion is well informed of the obligation to keep it
confidential. n
sTanley p. KowalsKi, Franklin Pierce Law Center, 2 White

Street, Concord, New Hampshire, 03301, U.S.A. spk3@
cornell.edu and skowalski@piercelaw.edu

anaTole KRaTTigeR, Research Professor, the Biodesign
Institute at Arizona State University; Chair, bioDevel
opments-International Institute; and Adjunct Professor,
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This section is based on UNICO. 2006. UNICO Guides:
Confidentiality Agreements. UNICO; Cambridge, U.K.
www.unico.org.uk. The UNICO Guide provides additional and valuable discussions on confidentiality agreements, including a range of template agreements.
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Specific Issues with Material Transfer Agreements
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ABSTRACT

In the health and agricultural sciences, biological mate
rials were once freely and widely exchanged. But more
and more, these materials have gained commercial value.
Public sector institutions, as well as private companies,
have recognized, therefore, that proprietary protection of
these materials may be necessary. Material transfer agree
ments (MTAs) are legal instruments that define terms
for the transfer of tangible biological materials between
or among two or more parties. MTAs are bailments that
transfer possession but not title: the party who transfers
the materials retains full ownership; the party who receives
the materials holds them in trust. Transfer is governed by
contract, ideally specifying the term of the transfer, how
the materials may and may not be used, and other related
issues, such as confidentiality. In addition, an MTA may
contain licensing provisions for the transfer of embedded
intellectual property (IP) rights (patent rights). Hence,
an MTA can be a hybrid instrument, covering the trans
fer of both tangible property (via bailment and contract)
and intangible property (via licensing of patent rights).
Biological materials transferred using MTAs include re
agents, cell lines, antibodies, research tools, insertional
mutant populations, genome sequence databases, novel
vectors, and plant genetic resources. Due to divergent
institutional priorities, material transfers between the pri
vate and public sectors are generally more complex than
those between public sector institutions.

1. INTRODuCTION
There is a long history of sharing biological
materials, such as plant germplasm or genetic
stocks, and for the most part this has been done free
ly and often without any form of a legal agreement.

This has not typically been the case in health re
search, where reagents, cell lines or antibodies that
have potential therapeutic implications have been
transferred under specific agreements that define
the terms of the transfer. In both agricultural and
health research, the increasingly sophisticated re
search approaches that rely heavily on access to
biological or bioinformatic resources created by
other researchers have dramatically increased the
need for researchers to share research tools. This
trend has been advanced further by the investment
of federal agencies (notably the National Science
Foundation [NSF] and the National Institutes
of Health [NIH]) and private companies in the
development of genomic resources that are in
tended primarily as vehicles for further discovery
of gene function and/or gene regulation. These
types of biological and bioinformatic resources
(such as insertional mutant populations, genome
sequence databases, and novel vectors) are the
most problematic with regard to sharing, because
they are the research tools that can lead to po
tentially valuable discoveries, invariably leading
to the question of who will own or control those
downstream discoveries.
The NIH considers the sharing of research
tools so important to future research progress that
the agency issued strong guidelines on the ap
propriate terms for transfer of research materials
that contribute to, or result from, NIH-funded

Bennett AB, WD Streitz and RA Gacel. 2007. In Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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research.1 Similarly, the NSF has issued guide
lines for data and materials release and requires
investigators to describe the timing, constraints,
and means of release of materials developed, par
ticularly for programs (such as the Plant Genome
Research Program) that focus on the generation
of research resources and tools.2
Plant genetic resources represent another area
of increasing concern regarding how freely these
resources can be exchanged. Even those plant ge
netic resource centers that are most committed to
the free exchange of germplasm now utilize spe
cific agreements to govern the transfer of seeds,
if only to specify that the recipient cannot seek
intellectual property (IP) rights on the materials
(the African Rice Center, WARDA; Box 1 [see
end of chapter])3 or to ensure that the recipient
understands that there is no warranty on the
transferred material (Tomato Genetics Resource
Center; Box 2 [see end of chapter]).
Scientists have traditionally shared research
materials freely, and, indeed, an important criteri
on for scientific publication has been the ability of
other researchers to experimentally reproduce and
thereby test published results. The ability to repli
cate results will often rely on access to the under
lying biological materials or information, but that
access is not assured today. So what has changed?
Probably the most significant change has been the
narrowing of the gap between fundamental re
search and commercial developments, particularly
in health research, but also in agriculture.4 Materi
als that at one time would have been useful almost
exclusively for fundamental research purposes are
increasingly seen as having direct commercial val
ue, and this trend has generated a new breed of
researchers and companies that focus on leveraging
novel research tools to discover new commercially
valuable traits, genes, or compounds. Particularly,
in the case of companies, they may be reluctant
to share their “crown jewels” without making sure
that their business interests are protected. As a re
sult of the Bayh-Dole Act, many universities ac
tively use the patent system as a means to transfer
research results to industry. In addition, universi
ties increasingly conduct research that is sponsored
by industry. As a consequence, they may have con
cerns similar to those of private companies. So a
 | HANDBOOK OF BEST PRACTICES

company that traditionally had little concern over
a university’s use of its property may now be ap
propriately concerned that its proprietary materials
may lead to valuable inventions or even to fueling
a competitor’s business interests. Universities and
nonprofit research institutions have also become
much more aware and protective of research mate
rials. The result has been a slow but steady evapora
tion of unrestricted transfers of research materials
between scientists, in general, and particularly be
tween industry scientists and those in universities.
With growing regularity, the sharing of re
search materials takes place under material trans
fer agreements (MTAs). MTAs are legal agree
ments (bailments) that govern the transfer of a
tangible property between parties. For example,
the University of California, Davis, executed over
470 MTAs in 2005, and this number had been
increasing every year since 2001. At the same
time, the complexity of MTAs is increasing dra
matically, with restrictions and obligations poten
tially reaching far beyond the material itself, to
data or inventions made using the material and/
or to derivative materials. As a consequence, each
MTA has begun to take on the complexity of a li
cense agreement, and a high level of skill and time
are required to ensure that the MTA can be ex
ecuted without compromising key principles and
will not conflict with other agreements. Hence,
an MTA can be a hybrid instrument: covering the
transfer of both tangible property (via bailment
and contract) and intangible IP (via licensing of
patent rights). To complicate things even further,
provisions of an MTA may stipulate how any fu
ture IP rights, arising from the use of the materi
als transferred, will be allocated.
Because MTAs are contractual agreements
between two or more parties, the agreements
typically do not have the geographic or tempo
ral limitations of patented technologies (patents
are territorial, issued by countries, with limited
terms, typically 20 years from filing) and, con
sequently, can be much farther reaching than
the scope of patent rights. It is interesting to
note that an evaluation of the property rights
associated with “GoldenRice” indicated that
44 patented products or processes and at least
15 materials, many of which were governed by

CHAPTER .

MTAs, were potentially used in its development.5
In navigating the intellectual and technical prop
erty landscape surrounding “GoldenRice,” Po
trykus reported that the restrictions imposed by
one MTA had been particularly problematic.6
Just as universities are experiencing an in
crease in the use of MTAs for receiving and dis
seminating materials, so are companies. One large
pharmaceutical company indicated that it had
six administrators dealing with more than 1,000
MTAs in the year 2000 and that many of these
agreements required lengthy negotiations. Some
companies have questioned whether it is worth
their while to exchange research tools with uni
versity scientists at all.7 In our own experience,
agreements for transfer of research materials from
industry to the university often have a low priority
for attention within company legal departments,
particularly because such transfers are often only
incidental to, or may actually compromise, their
main commercial interests. We estimated that
10%–25% of MTAs received from industry for
incoming materials to the University of California
were never executed because the terms compro
mised fundamental academic principles or created
legal obligations that the university cannot fulfill.
An example of a deal-breaking term in an MTA is
one that specifies that the provider maintain own
ership of data resulting from use of the materials.
This term could prevent publication or prevent
the continuation of the very research that the ma
terial was intended to advance. Thus, universities
in general are in a situation in which the exchange
of research materials is of increasing and indeed
critical importance, but both universities and pri
vate companies are having difficulty finding easy
ways to share these resources. As Eisenberg sum
marized “Although there are many points on which
they disagree, most people from each of these quarters
seem to agree that the problem is growing rather than
diminishing.” 8

2. WHAT IS A MATERIAl
TRANSFER AGREEMENT?
Fundamentally, an MTA is a bailment, that is,
a transfer of tangible property without transfer
of title. Under such an agreement, the provider

maintains ownership of the property transferred.
Transferred property is held by the receiving party
according to terms stipulated in a legally bind
ing contract. The contract, therefore, governs the
transfer of tangible biological materials between
two or more parties. In addition to the tangible
property rights being owned by the provider, the
material(s) may be the subject of a patent or pat
ent application. In this case, the MTA may need to
account for the transfer of IP rights as well as the
transfer of tangible material. Transfer of IP rights
would be in the form of a license, for example, to
make, use, sell, and so forth, that is, a license is
permission to do what would otherwise violate the
provider’s IP rights. This chapter deals with mate
rials that are intended to be used for research pur
poses, usually in the absence of planned research
collaboration between the provider and recipient.
Such a collaboration could be accommodated by
a separate collaboration agreement that would ac
company the MTA. The MTA defines the rights
of the provider and recipient with respect to the
materials and derivatives of the materials.
At most institutions, researchers themselves
are not authorized to sign either outgoing or in
coming MTAs for their institutions. The MTAs
must be reviewed and approved by an autho
rized institutional official. Agreements that are
not signed by an institutional official may not
be valid or enforceable. These functions usually
reside in the Office of Research Administration
(Sponsored Programs) or the office that manages
IP and technology transfer for the institution. Be
cause the researcher utilizing the material(s) is ul
timately responsible for fulfilling the obligations
of the MTA, most MTAs require the signature of
the recipient of the material acknowledging their
recognition of their responsibilities and duties un
der the agreement.

3. STRuCTuRE OF A MATERIAl
TRANSFER AGREEMENT
An MTA can range in size from a few hundred
words on one page to several thousand words on
more than a dozen pages. The NIH’s “Simple Let
ter Agreement for the Transfer of Materials” (Box
3 [see end of chapter]) is an excellent example of
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a short, easy-to-understand, one-page MTA. The
Simple Letter Agreement requires no negotiation
and is used by academic institutions throughout
the United States to transfer materials, and, in the
case of research consortia composed of multiple
academic or nonprofit institutions, this type of
agreement can be modified to provide an umbrella
for easy transfer of materials between consortium
members. On the other end of the spectrum, a
complex and lengthy MTA from a company will
ing to provide innovative and highly proprietary
materials can take years to negotiate.
The standard MTA used by the Davis campus
of the University of California (Box 4 [see end of
chapter]) represents an MTA that a university would
use to provide materials to another university. An
MTA, regardless of its length and complexity, may
incorporate many if not all of the following:
• a preamble
• definitions
• a description of use of the materials
• confidential information
• IP rights
• warranties
• liability and/or indemnification
• publication
• governing law
• termination
• signatures
• exhibits or appendices
.1 The preamble

The preamble of an MTA is like an abstract of
a manuscript or a prologue to a novel. The pre
amble lays the groundwork for the MTA and
sets the stage for the legally binding terms and
conditions that follow. The preamble identifies
parties to the agreement and specifies the MTA’s
effective date. It may also include the addresses
of the parties. It may even contain recitals or
whereas clauses describing the material, the goal
of the research, and the intent of the parties.
.2 Definitions

An MTA may have a separate section to define spe
cific terms such as materials, use of the materials,
modifications, or inventions. On the other hand,
an MTA may define these terms as they first ap
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pear within the agreement. In a third approach,
an MTA may define the terms that will be used
throughout the agreement in a separate section
for definitions and define the terms that are used
only in one or two sections as they first appear
within the agreement.
The definition of materials should be limited
to that of the actual materials being transferred,
including progeny and unmodified derivatives,
and should not include substances or inventions
created by the recipient of the materials. Progeny,
as defined in the Uniform Biological Material
Transfer Agreement (UBMTA), are unmodified
descendents of the original material. Progeny can
include a virus from a virus, a cell from a cell,
or an organism from an organism. Unmodified
derivatives, according to the UBMTA, are sub
stances created by the recipient that constitute an
unmodified functional subunit or an expression
product of the original material that was provid
ed. Unmodified derivatives can include purified
or fractionated subsets of the original material;
progeny or products thereof; subclones of un
modified cell lines; transcription and translation
products, such as RNA and protein derived from
provided DNA; reverse transcription and reverse
translation products, such as DNA synthesized
on a template using provided RNA; monoclonal
antibodies secreted by a hybridoma cell line; and
chemically synthesized copies. Since a provider
usually asserts ownership of materials, the defini
tion of materials should not overreach to modi
fications, derivatives, crossbred progeny (in ani
mals), mutants, or other substances that are not
being provided by the provider.
. Use of the materials

An MTA specifies how the recipient can and can
not use the material. Usually, the MTA contains a
blank space for the researcher to include a descrip
tion of the research use with the material. Some
times an MTA has a separate appendix with a very
detailed description of the intended research use.
An MTA will usually prohibit the recipient from
using the materials in a manner other than that
intended by the original research. An MTA will
also typically prohibit provider’s material from
being tested in humans and used in plants and

CHAPTER .

animals consumed as food. Other prohibitions
may include using the material in research that
has IP obligations to third parties, or with other
materials from third parties, or transferring the
material to third parties or even to other research
ers within the recipient’s institution. Finally, most
MTAs have prohibitions for the material to be
used for commercial purposes.
. Confidential information

Often, providers of materials include, on the
MTA form, proprietary or confidential informa
tion. Therefore an MTA may contain a provision
to protect the provider’s confidential informa
tion. Confidential information can be defined
as “information, data, or material, in written or
other tangible form related to the material, that
is identified as confidential at the time of disclo
sure.” However, confidential information should
not include information that is:
• generally known to the public at the time
of disclosure to the recipient
• already in the recipient’s possession at the
time of disclosure by the provider
• disclosed to the recipient on a noncon
fidential basis by a third party having the
right to make such disclosure
• independently developed by the recipient
without the use of the confidential infor
mation disclosed by the provider as evi
denced by written records
• required to be disclosed by law or govern
mental rule or regulation
The MTA should include language to make
clear to the provider that the above information is
not considered confidential.
An MTA may also specify that the recipient
of the confidential information treat it as confi
dential and maintain it in confidence for a certain
period of time. A long period of nondisclosure,
for example, over five years, may be very difficult
for a university to manage. Generally, an MTA
may require that all confidential information
be marked “Confidential” and be reduced to
writing. Reducing confidential information to
writing places an additional administrative bur
den on both parties, but it does make it easier for

the recipient to know precisely what information
must be kept confidential.
The MTA may stipulate that the recipient
can disclose the provider’s confidential infor
mation only to the recipient’s own personnel
who have a need to know and who use the
confidential information. The MTA may also
require that the recipient take the same steps
and use the same methods to prevent the un
authorized use or disclosure of the provider’s
confidential information as the recipient would
take to protect its own confidential informa
tion. Requirements such as these are generally
appropriate when confidential information is
being exchanged.
. Intellectual property

Nearly every MTA will address IP matters such
as the disclosing of inventions, the prosecuting
of patents and plant variety protection certifi
cates, and the granting of options and licenses.
IP rights language is perhaps the most challeng
ing language to negotiate. An MTA may con
tain overarching IP language that can reach to a
researcher’s and/or institution’s past inventions
and future inventions, which may have little or
nothing to do with the materials provided, and
could impact the researchers ability to continue
doing related research.
The MTA may specify that the recipient
disclose, assign, and/or license any inventions to
the provider, free of any royalties and fees. While
most institutions will agree to certain licensing
rights, they are generally unable to assign an in
vention because doing so may violate:
1. the Bayh-Dole Act if the invention resulted
from research funded by the U.S. federal
government
2. the Tax Reform Act of 1986 by possibly
jeopardizing the U.S. federal tax-free status
of bonds that were issued to build or im
prove research facilities
3. the Principles and Guidelines for Recipients
of NIH Research Grants and Contracts on
Obtaining and Disseminating Biomedical
Research Resources, by restricting the ac
cessibility of research materials
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4. an institution’s own principles, policies,
and practices if the invention was not de
veloped for the public benefit
5. other laws, regulations, rules and policies
It is generally reasonable to grant a limited
subset of IP rights to the provider of the materi
als. For example, to the extent that the recipient
is legally able to do so, the recipient could grant
a nonexclusive royalty-free research license to any
inventions that necessarily use or necessarily in
corporate the material and are conceived and first
actually reduced to practice in the performance of
the research. The recipient, in many cases, may be
able to grant a first right or an option to negotiate
a non-exclusive or exclusive commercial license to
such inventions. In some cases, when a provider
provides innovative and valuable compounds, a
recipient may have to grant a nonexclusive, roy
alty-free research license to such inventions if the
provider is concerned about being blocked from
practicing new uses for its materials especially
when the provider is performing or sponsoring
similar research.
. Warranties

An MTA nearly always stipulates that the mate
rial does not come with any warranties. A typical
warranty clause, usually written in capital letters,
may read:
PROVIDER MAKES NO REPRESENTA
TIONS AND EXTENDS NO WARRANTIES
OF ANY KIND, EITHER EXPRESSED OR
IMPLIED. THERE ARE NO EXPRESS OR
IMPLIED WARRANTIES OF MERCHANT
ABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, OR THAT THE USE OF THE
MATERIAL WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR
OTHER PROPRIETARY RIGHTS.
The language is nearly always written in up
percase letters to make the clause stand out.
. Liability and indemnification

An MTA usually stipulates that the recipient of
the materials assumes all liability for damages
that may arise from the recipient’s use, storage
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or disposal of the material, and modifications. In
addition, many providers will stipulate that the
recipient indemnify, hold harmless, and defend
the provider against any claims, costs, or other
liabilities that may arise as a result of recipient’s
use, storage, or disposal of the material. A num
ber of state institutions, for example in Alabama,
Georgia, Kentucky, New York and other states,
are prohibited from indemnifying other parties
and must limit their indemnification to the ex
tent permitted by state law. In addition to recipi
ent liability, some MTAs will make the providers
liable for losses, claims, or demands made by the
recipient, or made against the recipient by any
other party, that are due to the provider’s negli
gence or misconduct.
. Publications

An MTA should enable the recipient of the ma
terials to publish or present the results of the
recipient’s research using the materials without
the approval of the provider. An MTA can re
quire that the recipient send the provider a copy
of any proposed manuscript, abstract, poster
session, or presentation prior to such publica
tion or presentation so that the provider can
review it, provide any comments, or request
the removal of the provider’s confidential in
formation. A review period of 30 to 45 days is
sufficient for most providers and is acceptable
to most academic recipients. The MTA may
require that the publication or presentation
be delayed for an additional period of time to
allow for the filing of patent applications. An
additional period of 30 to 45 days is sufficient
for most providers. An MTA can also require
the recipient to acknowledge the provider for
providing the materials in any publications or
presentations.
. Governing law

An MTA may specify that it is governed by
the laws of a particular jurisdiction, state, or
country. This may present a problem in cases in
which the provider and the recipient are located
in separate jurisdictions, states, or countries.
Most providers and recipients will agree to be
silent on governing law.
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.10 Termination

An MTA should specify an expiration date for the
agreement. Otherwise, the recipient’s obligations will
continue forever. The parties should be able to ter
minate the MTA earlier by providing advance, writ
ten notice. When the MTA expires or terminates,
the recipient is generally required to stop using the
material and may be required to return or destroy
any remaining material. A termination clause may
also delineate certain obligations that survive termi
nation. These surviving obligations may be related to
areas dealing with confidentiality, IP, warranties, lia
bility, and indemnification. The MTA can always be
extended by the mutual agreement of both parties.
.11 Signatures

The signature section is usually the last part of an
MTA. A typical MTA may have the signatures of
the following individuals:
• the authorized official of the organization
or company receiving the materials
• the researcher receiving the material
• the authorized official of the organization
or company providing the materials
• the researcher providing the material
Some MTAs may require only the signature(s)
of the authorized official and/or the researcher of
the recipient of the materials. Researchers may sign
as acknowledging, reading, and/or understanding
the MTA but should not sign as legal parties to the
MTA. Doing so could place them at risk of being
personally liable and being sued in a court of law.
.12 Exhibits or appendices

An MTA may include an exhibit or appendix that
is attached to the end of the agreement. In many
cases, the attachment is a detailed description of
the research, a protocol, or a long list of materials.
Sometimes confidential information is put in the
exhibits or appendices so that it can be redacted
more easily than if it were put into the agreement.

4. MATERIAl TRANSFER BETWEEN
uNIVERSITIES
Sharing of materials between university scientists
is generally less problematic than transfers between

industry and academia, primarily because the
cultures and motivations of each institution in
volved in the exchange are similar. In the United
States, most universities readily transfer materials
for academic research purposes under terms that
typically have no restrictions other than a require
ment not to transfer the materials to third parties
without approval or notification. These transfers
are often accomplished using the NIH-facilitated
UBMTA9, the NIH’s Simple Letter Agreement,
or an equivalently benign agreement. The UBM
TA incorporates a very narrow definition of the
material to be transferred and the agreement does
not give a provider rights beyond the “original
material, progeny and unmodified derivatives.” This
narrow definition and the lack of “reach through”
to new materials and to new research results is the
hallmark of agreements between universities that
greatly facilitates these transfers.
When a problem does occur in a transfer be
tween academic institutions, it is usually because
the material has been exclusively licensed and the
terms of that agreement impose some constraints
on the institution providing the material. Howev
er, this problem is usually avoidable, particularly if
such exclusive licenses specifically reserve the right
to use the materials for internal research purposes
and to transfer the materials for research at other
academic institutions. For example, the University
of California routinely incorporates the following
clause into its exclusive license agreements:
Nothing in this Agreement will be deemed to
limit the right of The Regents (i.e. University) …
to make and use the Invention … and associated
technology and allow other educational and non
profit institutions to do so for educational and
research purposes.

5. MATERIAl TRANSFER FROM PRIVATE
COMPANIES TO uNIVERSITIES
Material transfers between private and public sec
tor institutions are typically much more complex
than transfers between two universities and are
much more prone to failure, particularly when
the transfer is from a company to a university re
searcher.10 What are some of the features of these
MTAs that create difficulties, particularly for
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universities? Contrary to popular belief, the pri
mary issues for most universities do not concern
the ability to profit from licensing future inven
tions, but center on:
• a few fundamental academic principles
• the need to avoid incurring unfunded fi
nancial obligations
• the need to avoid creating conflicting legal
obligations with third parties
These issues primarily reflect most universi
ties’ concern with protecting the fundamental
mission of the institution and their low tolerance
for financial or legal risk.
.1

Dissemination of research results

The single most obvious and fundamental prin
ciple for the university and university researchers
is to preserve the unrestricted ability to publish
their research results. The freedom to publish can
be restricted by MTAs when the provider requires
editorial rights in a publication or the right to ap
prove and, by inference, to disapprove a publica
tion. Publication restrictions can show up in MTAs
in indirect ways as well. For example, the material
itself may be specified as confidential, making a
meaningful publication impossible. Of particular
concern are the serious consequences that a pub
lication restriction can have on students, whose
future depends so heavily on publication. Clearly,
this is one principle a university cannot compro
mise and the principle is so widely recognized that
one would think it would not even be on the table
for discussion. However, it occasionally is.
Typically, the material provider’s underlying
concern is not to restrict academic publication
but to protect its confidential information relat
ed to the material and to preserve patentability
of inventions. Both are legitimate concerns and
can usually be met by agreeing to remove a com
pany’s confidential information from publica
tions and to delay publication for a limited time
(usually 60 to 90 days) to permit the evaluation
of potentially patentable inventions and to file
patent applications, when appropriate. Univer
sities readily agree to these types of provisions,
but further restrictions on publication rights are
typically nonnegotiable.
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.2 Rights in research results

Universities also need to preserve the ability of
their researchers to use their own research results
in future research. This may seem obvious, but
if a provider of material insists that it own the
results of research conducted with its material
(sometimes including data, inventions, and re
ports), researchers and universities can lose all
access to these products of their own research,
making it difficult, if not impossible, to perform
any follow-on research. An example of how this
appears in an MTA would be a case in which
a provider asserts ownership of new substances
created by the university researcher while using
its proprietary material, sometimes reaching to
substances or compositions that don’t contain
the original material in any form (often referred
to as reach through rights). This type of provi
sion could have an impact on publication as
well, since many journals require that materi
als discussed in a paper be made available for
replication of the research. Yet in this case such
availability would be controlled by the material
provider, not the researcher. In many cases, a
for-profit provider may have a legitimate reason
to insist on retaining ownership of any modifi
cations of its original material. For example, if
a vector that took years to create could now be
easily modified to incorporate new functions,
the provider would be understandably reluctant
to relinquish rights to improvements that can
now be relatively easily incorporated. In these
cases, it may not be appropriate or possible to
share this material. However, in many cases this
kind of provision is the result of a provider us
ing too broad an approach to ensure no pos
sible loss of its own rights. Negotiations can
often identify a balanced solution in which
the provider is assured that it maintains own
ership of its proprietary material, and while a
recipient may own the narrow improvement it
created, the provider would still own the origi
nal material if it continued to be included as a
component.
. Conflicting legal obligations

Perhaps the most difficult issue presented by
MTAs is the potential for entering into agree
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ments that create conflicting legal obligations.
This situation routinely arises because, while the
material is coming from one source, the funding
for the research is usually provided by a differ
ent source, typically public agencies but also, po
tentially, other private companies. To the extent
that the MTA and relevant funding sources carry
IP obligations, it is easy to see how conflicts can
arise. While such obligations are typical of pri
vate research support, public funding also carries
legal IP obligations to the government. The most
prominent of these obligations includes require
ments in the United States under the Bayh-Dole
Act, such as, a prohibition on assigning title to
inventions to third parties, the provision of a
nonexclusive license to the government to prac
tice or have practiced the invention on behalf of
the government, and the right of the government
to march in. Clearly, the university cannot enter
into an MTA that creates a new obligation that
is in conflict with such obligations of law or its
contractual obligations to others. For example,
if access to a particular research tool or material
requires that the provider be offered an exclusive
license to inventions, then this restricts the proj
ect from receiving any other material or research
funding that carries a similar obligation—exclu
sive access to inventions from the same project
can be given only once! The university and its re
searchers need to be very careful in determining
how important are specific inputs to the project,
and they may need to decide which IP rights can
be apportioned to research sponsors and/or ma
terial providers and prioritize those rights. It is
clear from the complexity of inputs to research
projects and the increasing complexities of own
ership of research tools and materials, that access
to the full set of tools for certain projects may
simply be impossible. This situation is analogous
to that which has been described as the “tragedy
of the anticommons” where the fragmentation of
IP ownership becomes so complex that no single
entity can acquire all the rights it needs to devel
op products.11 In a similar sense, the fragmented
ownership of research materials or information
can impact the practical ability to conduct fun
damental research or at least to do so using the
most efficient research tools.

. Public benefit of university research

Universities, particularly public universities and
those whose research is supported largely by pub
lic funds, have an obligation to see that their inno
vations are made available to the public in a dili
gent and timely manner. In the United States, this
obligation is based on the Bayh-Dole Act, which
has a stated objective “to promote … public avail
ability of inventions,” as well as on the philosophi
cal missions of most universities. One means of
accomplishing availability is through the licensing
of inventions to private companies that can invest
the often substantial additional R&D effort re
quired to produce real products. The public ben
efit obligation can be compromised by MTAs that
require the granting of a nonexclusive, royalty-free
license to inventions back to the provider. If the
company were not interested in commercializing
the invention, the existence of its nonexclusive,
royalty-free license could prevent other companies
from entering into a license, because they would
lack the exclusivity needed to allow them to invest
in the development of the technology, effectively
“shelving” the technology. A solution that is often
acceptable is involves linking such a license very
narrowly to inventions that are dependent on the
company’s material. These inventions represent
the company’s legitimate business interest and
are inventions that, typically, only the company
providing the material would be in position to
commercialize. While broader language seeking a
license to inventions less closely linked to the ma
terial will not necessarily prevent a university from
signing an MTA, such language should certainly
provoke a careful evaluation of the situation.
. Fair consideration

Most universities seek a financial return in ex
change for the commercial use of their research
results. Public institutions, in particular, are
concerned that the public funds that are used
to support the institution should not be used to
indirectly support private companies. These con
siderations color the expectations of universities,
particularly if the provider of a material seeks free
license to resulting inventions. Here, the interests
of the university’s administration and researchers
may diverge, with researchers needing, primarily,
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to gain access to the material to advance their
research and with the administration seeking to
preserve the fundamental principles of the uni
versity and avoid costly legal battles. Where inter
ests are divergent, the situation can become very
complex. In our experience, a common underly
ing interest of all parties is to enable and acceler
ate research progress, and in most cases solutions
can be developed that satisfy the essential needs
of all parties. Unfortunately, developing these so
lutions can take a long time and, as mentioned
earlier, for many private companies, negotiating
MTAs for university researchers is a low priority
in relation to the many IP-related transactions
that may be more critical to the company’s pri
mary business interests.

6. CONCluSIONS
Overall, the transfer of materials between re
searchers has been getting more difficult, and it
appears that the days of open exchange of mate
rials, particularly from researchers in industry to
academic researchers in the life sciences, are over.
While some domains of free exchange continue
to thrive, and some funding agencies and foun
dations are actively promoting open exchange of
materials, these are becoming exceptions rather
than the rule. Both universities and private com
panies have legitimate interests, which they are
trying to support when engaging in material
transfers. When these interests collide, it can be
difficult to find common ground. However, the
mutual interest of both research-based private
companies and of universities is to support re
search advances; and when both parties keep this
overarching objective in mind, material transfers
usually are possible. ■
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Box 1: Material Transfer Agreement (MTA) for plant genetic resources held
in trust by the Africa Rice Center (WARDA) 1
The plant genetic resources (hereinafter referred to as the “material”) contained herein are being
furnished by Africa Rice Center (WARDA) under the following conditions:
•

Africa Rice Center (WARDA) is making the material described in the attached list available as
part of its policy of maximizing the utilization of material for research, breeding and training.
The material was either developed by Africa Rice Center (WARDA); or was acquired prior to the
entry into force of the Convention on Biological Diversity;or if it was acquired after the entering
into force of the Convention on Biological Diversity, it was obtained with the understanding
that it could be made available for any agricultural research, breeding and training purposes
under the terms and conditions set out in the agreement on 26 October 1994 between the
Africa Rice Center (WARDA) and the Food and Agriculture Organization of the United Nations
(FAO).

•

The material is held in trust under the terms of this agreement, and the recipient has no rights
to obtain Intellectual Property Rights (IPRs) on the material or related information.

•

The recipient may utilize and conserve the material for research, breeding and training and
may distribute it to other parties provided such other parties accept the terms and conditions
of this agreement.

•

The recipient, therefore, hereby agrees not to claim ownership over the material, nor to seek
IPRs over that material, or its genetic parts or components, in the form received. The recipient
also agrees not to seek IPRs over related information received.

•

The recipient further agrees to ensure that any subsequent person or institution to whom
he/she may make samples of the material available, is bound by the same provisions and
undertakes to pass on the same obligations to future recipients of the material.

•

Africa Rice Center (WARDA) makes no warranties as to the safety or title of the material, nor as
to the accuracy or correctness of any passport or other data provided with the material.Neither
does it make any warranties as to the quality, viability, or purity (genetic or mechanical) of the
material being furnished. The phytosanitary condition of the material is warranted only as
described in the attached phytosanitary certificate. The recipient assumes full responsibility
for complying with the recipient nation’s quarantine and biosafety regulations and rules as to
import or release of genetic material.

•

Upon request, Africa Rice Center (WARDA) will furnish information that may be available in
addition to whatever is furnished with the material. Recipients are requested to furnish Africa
Rice Center (WARDA) with related data and information collected during evaluation and
utilization.
(Continued on Next Page)

1. This MTA covers materials which are being transferred before the entry into force of the International Treaty on
Plant Genetic Resources for Food and Agriculture. The Treaty envisages that Africa Rice Center (WARDA) will enter
into an agreement with the Governing Body of the Treaty, once the Treaty enters into force. Africa Rice Center
(WARDA) has indicated its intention to conclude such an agreement with the Governing Body. This agreement, in
line with the Treaty, will provide for new MTAs and benefit-sharing arrangements for materials transferred after
the entry into force of the agreement. The attention of the recipient is drawn to the fact that the details of the
MTA, including the identity of the recipient, will be made available to the public.
2. This does not prevent the recipients from releasing the material for purposes of making it directly available to
farmers or consumers for cultivation, provided that the other conditions set out in this MTA are complied with.
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Box 1 (continued)

• The recipient of material provided under this MTA is encouraged to share the benefits accruing
from its use, including commercial use, through the mechanisms of exchange of information,
access to and transfer of technology, capacity building and sharing of benefits arising from
commercialization. Africa Rice Center (WARDA) is prepared to facilitate the sharing of such
benefits by directing them to the conservation and sustainable use of the plant genetic resources
in question, particularly in national and regional programs in developing countries and countries
with economies in transition, especially in centers of diversity and the least developed countries.
The material is supplied expressly conditional on acceptance of the terms of this Agreement.
The recipient’s acceptance of the material constitutes acceptance of the terms of this Agreement.
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Box 2: Material Transfer Agreement (MTA) for requesting plant
materials from the C.M. Rick Tomato Genetics Resource Center (TGRC)
THIS AGREEMENT is made by and between The Regents of the University of California (“THE REGENTS”)
on behalf of the C. M. Rick Tomato Genetics Resource Center (“TGRC”), and _______________________
_____________________(“RECIPIENT”). THE REGENTS asks that the RECIPIENT agree to the following
before the RECIPIENT receives the plant materials requested from the TGRC.
1. The TGRC will make substitutions, as necessary, for items that are currently unavailable for
distribution. For large requests, the TGRC may delete some items, as needed, to reduce its workload
and accommodate other requests. The TGRC will provide a packing list detailing which accessions
(“MATERIAL”) have been shipped.
2. The MATERIAL is provided free of charge and, except as stated herein, without restrictions by the
TGRC to support research, breeding, and/or educational projects involving tomato. The RECIPIENT
may distribute the MATERIAL to third parties under an MTA that includes the language of terms 3,
4, 5, and 6.
3. THE REGENTS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESSED OR IMPLIED, REGARDING THE FITNESS OR MERCHANTABILITY FOR A PARTICULAR
PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
4. The MATERIAL has not been thoroughly evaluated by the TGRC.THE REGENTS MAKES NO WARRANTIES
OF ANY KIND, EXPRESSED OR IMPLIED, REGARDING THE ACCURACY OF THE INFORMATION
PROVIDED BY THE TGRC; THE QUALITY, HEALTH, OR PHYTOSANITARY CONDITION OF THE MATERIAL;
OR THE GENETIC IDENTITY OF THE MATERIAL, INCLUDING ITS ORIGIN, PURITY, TRUENESS TO TYPE,
GENETIC BACKGROUND, AND THE PRESENCE OR ABSENCE OF ANY TRANSGENES. The RECIPIENT
is responsible for verifying that genetic identity is correct in its own plantings, and the RECIPIENT
will notify the TGRC of any potential problems it observes with the MATERIAL, such as aberrant
segregation, incorrect phenotypes, unexpected traits, or other problems.
5. Unless prohibited by law, the RECIPIENT assumes all liability for damages it incurs and for claims
by third parties which may arise from the RECIPIENT’s use, storage or disposal of the MATERIAL.
RECIPIENT shall hold harmless, defend, and indemnify THE REGENTS against any claims, costs
or other liabilities which may arise as a result of the RECIPIENT’S use, storage or disposal of the
MATERIAL.
6. The RECIPIENT shall acknowledge the TGRC as the supplier of the MATERIAL in any publications
which result from the RECIPIENT’s use of the MATERIAL, and shall provide the TGRC with copies of
the relevant publications.
7. Before the TGRC can send the MATERIAL, the RECIPIENT or other authorized official of the RECIPIENT’s
organization, must sign and deliver this MTA by mail, facsimile, e-mail or in person to the TGRC at
the following address:
c. M. Rick Tomato genetics Resource center
Department of Plant Sciences (Mail Stop 3)
University of California, Davis
One Shields Avenue
Davis, CA 95616, U.S.A.

Tel.: +1-530-754-6059
Fax: +1-530-752-9659
tgrc@ucdavis.edu
http://tgrc.ucdavis.edu

ceRTificaTion by RecipienT oR oTheR auThoRiZed official:
I have read and understand the conditions outlined in this Agreement and I agree to fully abide by
them in the receipt and use of the MATERIAL.
Signature, Name and Title: ____________________________________________________________

Institution:_______________________________________________________Date:______________
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Box 3: Simple letter Agreement for the Transfer of Materials
In response to RECIPIENT’s request for the MATERIAL ______________________________________
_____ the PROVIDER asks that the RECIPIENT and the RECIPIENT SCIENTIST agree to the following
before the RECIPIENT receives the MATERIAL:
1. The above MATERIAL is the property of the PROVIDER and is made available as a service to the
research community.
2. THIS MATERIAL IS NOT FOR USE IN HUMAN SUBJECTS.
3. The MATERIAL will be used for teaching or not-for-profit research purposes only.
4. The MATERIAL will not be further distributed to others without the PROVIDER’s written consent.
The RECIPIENT shall refer any request for the MATERIAL to the PROVIDER. To the extent supplies
are available, the PROVIDER or the PROVIDER SCIENTIST agree to make the MATERIAL available,
under a separate Simple Letter Agreement to other scientists for teaching or not-for-profit
research purposes only.
5. The RECIPIENT agrees to acknowledge the source of the MATERIAL in any publications reporting
use of it.
6. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in
nature and may have hazardous properties. THE PROVIDER MAKES NO REPRESENTATIONS AND
EXTENDS NO WARRANTIES OF ANY KIND,EITHER EXPRESSED OR IMPLIED.THERE ARE NO EXPRESS
OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR
THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK,
OR OTHER PROPRIETARY RIGHTS. Unless prohibited by law, RECIPIENT assumes all liability
for claims for damages against it by third parties which may arise from the RECIPIENT’S use,
storage or disposal of the MATERIAL except that, to the extent permitted by law, the PROVIDER
shall be liable to the RECIPIENT when the damage is caused by the gross negligence or willful
misconduct of the PROVIDER.
7. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and
regulations.
8. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the
PROVIDER for its preparation and distribution costs. If a fee is requested, the amount will be
indicated here: ______________
The PROVIDER, RECIPIENT and RECIPIENT SCIENTIST must sign both copies of this letter and return
one signed copy to the PROVIDER. The PROVIDER will then send the MATERIAL.
PROVIDER INFORMATION and AUTHORIZED SIGNATURE

Provider Scientist:______________________________________________________________

Provider Organization: __________________________________________________________
Address:______________________________________________________________________

Name of Authorized Official: _____________________________________________________
Title of Authorized Official:______________________________________________________
Certification of Authorized Official: This Simple Letter Agreement has
been modified. If modified, the modifications are attached.

/ has not

[check one]

(Continued on Next Page)
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Box 3 (continued)

______________________________ _______________________ _________________ _____
Signature of Authorized Official

RECIPIENT INFORMATION and AUTHORIZED SIGNATURE

Date

Recipient Scientist: ____________________________________________________________
Recipient Organization: ________________________________________________________

Address: _____________________________________________________________________

Name of Authorized Official: ____________________________________________________

Title of Authorized Official:______________________________________________________
Signature of Authorized Official:_________________________________________________

Date: ________________________________________________________________________

Certification of Recipient Scientist: I have read and understood the conditions outlined in

this Agreement and I agree to abide by them in the receipt and use of the MATERIAL.

_____________________________________________________________________________
Recipient Scientist

Date
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Box 4: Material Transfer Agreement with the university of California, Davis
This Agreement is made this _____ of ________________, by and between THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA, as represented by its Davis campus, (“UC DAVIS”), having an address
at the Office of Research, Technology and Industry Alliances, Technology Transfer Services;
University of California, Davis; 1850 Research Park Drive, Suite 100; Davis, CA 95616-6134, and ___
________________ (“RECIPIENT”), having its principal place of business at ____________________
(collectively “the PARTIES”).
RECIPIENT has requested from UC DAVIS the MATERIAL defined in Section 1.B. below for the
RESEARCH USE defined in Section 1.F. below by the RECIPIENT INVESTIGATOR(S) defined in Section
1.G. below. In consideration of the supply of MATERIAL from UC DAVIS to RECIPIENT, the PARTIES
agree as follows:
1. definitions
A. “ORIGINAL TRANSFERRED MATERIAL”: The physical material actually delivered to the
RECIPIENT by UC DAVIS, as identified in Exhibit A attached hereto.
B. “MATERIAL”: ORIGINAL TRANSFERRED MATERIAL, PROGENY, and UNMODIFIED
DERIVATIVES.
C. “PROGENY”: Unmodified descendant from the MATERIAL. Examples include but are not
limited to: virus from virus; cell from cell; and organism from organism.
D. “UNMODIFIED DERIVATIVES”: Substances created by the RECIPIENT that constitute an
unmodified functional sub-unit or an expression product of the ORIGINAL TRANSFERRED
MATERIAL. Examples include but are not limited to: purified or fractionated sub-sets
of the ORIGINAL TRANSFERRED MATERIAL; PROGENY or products thereof; subclones
of unmodified cell lines; transcription and translation products (e.g., RNA and protein
derived from provided DNA); reverse transcription and reverse translation products (e.g.,
DNA synthesized on a template using provided RNA); monoclonal antibodies secreted
by a hybridoma cell line; and chemically-synthesized copy or copies.
E. “MODIFICATIONS”: Substances created by the RECIPIENT that either contain or
incorporate the MATERIAL or were created through the use of the MATERIAL.
F. “RESEARCH USE”: The scientific RESEARCH USE specified in Exhibit A.
G. “RECIPIENT INVESTIGATOR(S)”: The RECIPIENT’s scientific investigator(s) specified in
Exhibit A.
H. “CONFIDENTIAL INFORMATION”: Information, data or material in written or other
tangible form related to the MATERIAL that is identified as confidential at the time of
disclosure. CONFIDENTIAL INFORMATION does NOT include information that is:
(i)

generally known to the public at the time of disclosure to the RECIPIENT;

(ii) already in RECIPIENT’s possession at the time of disclosure by UC DAVIS;
(iii) disclosed to RECIPIENT on a non-confidential basis by a third party having the right
to make such disclosure;
(iv) independently developed by RECIPIENT without the use of the CONFIDENTIAL
INFORMATION disclosed by UC DAVIS as evidenced by written records; or
(v) required to be disclosed by law or governmental rule or regulation.

(Continued on Next Page)
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Box 4 (continued)

2. Terms and conditions
A. Use
i. The RECIPIENT shall use the MATERIAL solely for the RESEARCH USE. Any other use of the
MATERIAL by the RECIPIENT is expressly prohibited without the prior written consent
of UC DAVIS. In addition, the RECIPIENT agrees to use the MATERIAL in compliance with
all applicable statutes and regulations, including, but not limited to, those related to
research involving the use of animals or recombinant DNA. The MATERIAL may not be
used on any human subjects or for commercial purposes or any other use other than the
RESEARCH USE.
ii. RECIPIENT will not analyze the MATERIAL for chemical composition or physical structure
or have or allow any component of the MATERIAL to be analyzed or make any use of any
such analysis. The RECIPIENT will not alter the chemical structure of the MATERIAL in
any way.
B. Tangible Property Ownership: UC DAVIS retains ownership of the MATERIAL, including any
MATERIAL contained or incorporated in MODIFICATIONS.
C. Confidentiality: Any CONFIDENTIAL INFORMATION disclosed by UC DAVIS to RECIPIENT
shall be treated as confidential and maintained in confidence by RECIPIENT for five (5)
years after disclosure. RECIPIENT shall not disclose any CONFIDENTIAL INFORMATION of
UC DAVIS, except to its own personnel who have a need to know. Without limiting the
foregoing, RECIPIENT agrees to take the same steps and use the same methods to prevent
the unauthorized use or disclosure of CONFIDENTIAL INFORMATION of UC DAVIS as it takes
to protect its own CONFIDENTIAL INFORMATION or proprietary information.
D. Distribution: RECIPIENT agrees NOT to transfer the MATERIAL or MODIFICATIONS to anyone
other than to one who works under the direct supervision of the RECIPIENT INVESTIGATOR
within the RESEARCH USE without the prior written consent of UC DAVIS.
E. Disclosure, Inventorship, and Intellectual Property Rights
i. Disclosure: The RECIPIENT shall promptly notify UC DAVIS of any potentially patentable
discoveries or inventions made through the use of the MATERIAL, whether or not made
within the specified limits of the approved RESEARCH USE.The RECIPIENT shall promptly
supply UC DAVIS with a copy of the invention disclosure.
ii. Inventorship: Inventorship shall be determined according to United States patent law.
iii. Intellectual Property Rights: Collaborative efforts of UC DAVIS and the RECIPIENT may
create inventorship rights under United States patent law as well as under the law
of any applicable jurisdiction in which a party or the PARTIES may elect to file patent
application(s). Each party shall own its undivided interest in joint inventions. The
PARTIES shall cooperate in discussing and securing intellectual property rights to protect
potentially patentable inventions.
iv. No Implied Rights: The RECIPIENT acknowledges that the MATERIAL is or may be the
subject of a patent application. Except as provided in this Agreement, no express or
implied license or other rights are provided to the RECIPIENT under any patents, patent
applications, trade secrets or other proprietary rights of UC DAVIS, including any altered
forms of the MATERIAL made by UC DAVIS. In particular, no express or implied licenses or
other rights are provided to use the MATERIAL, MODIFICATIONS or any related patents of
UC DAVIS for commercial use or any other use other than the RESEARCH USE.

(Continued on Next Page)
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Box 4 (continued)

F. Warranty and Licenses:
i. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental
in nature and may have hazardous properties.UC DAVIS MAKES NO REPRESENTATIONS
AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED.THERE
ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
ii. If the RECIPIENT desires to use the MATERIAL or MODIFICATIONS for profit-making
or commercial purposes, the RECIPIENT agrees, in advance of such use, to negotiate
in good faith and conclude a license agreement containing terms typically required
in license agreements executed by UC DAVIS. It is understood by the RECIPIENT that
UC DAVIS will have no obligation to grant such a license to RECIPIENT, that future
licensing rights, if any, may be subject to preexisting contractual obligations of UC
DAVIS, and that UC DAVIS may grant exclusive or non-exclusive commercial licenses
to others.
G. Liability: The RECIPIENT assumes all liability for damages that may arise from its use,
storage or disposal of the MATERIAL and MODIFICATIONS. UC DAVIS will not be liable to
the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the
RECIPIENT by any other party, due to or arising from the use, storage or disposal of the
MATERIAL and MODIFICATIONS by the RECIPIENT. The RECIPIENT agrees to indemnify, hold
harmless and defend UC DAVIS against any claims, costs or other liabilities which may
arise as a result of RECIPIENT’S use, storage or disposal of the MATERIAL.
H. Publication of Research Results: The RECIPIENT may publish or present results of research
relating to the MATERIAL, provided the RECIPIENT provides UC DAVIS with a copy of any
proposed manuscript, abstract, poster session or presentation at least thirty (30) days prior
to such publication or presentation. UC DAVIS shall review such publication or presentation
for CONFIDENTIAL INFORMATION or patentable material and may request a delay of the
proposed publication or presentation for up to an additional thirty (30) days to allow for
the removal of CONFIDENTIAL INFORMATION or the filing of patent application(s). Unless
UC DAVIS directs otherwise, any publication or presentation reporting the research carried
out with the MATERIAL shall contain proper referencing in academic journal format,
acknowledging UC DAVIS as the source of the MATERIAL.
I. Termination:
i. Date: This Agreement will terminate on the earliest of the following dates:
(a) on completion of RECIPIENT’S current RESEARCH USE with the MATERIAL;
(b) on thirty (30) days’ written notice by one party to the other; or
(c) (

) years from the date of execution of this Agreement by UC DAVIS.

ii. Surviving Obligations: Obligations with respect to Tangible Property Ownership (2.B.),
Confidentiality (2.C.), Distribution (2.D.), Disclosure, Inventorship, and Intellectual
Property Rights (2.E.),Warranty and Licenses (2.F.), Liability (2.G.), Publication of Research
Results (2.H.), and this Section (2.I.ii) shall survive termination.
iii. Return of MATERIAL: As directed by UC DAVIS, RECIPIENT shall stop using the MATERIAL
and shall return or destroy any remaining MATERIAL on the termination of this
Agreement.

(Continued on Next Page)
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Box 4 (continued)

J. Applicable Law:The validity and interpretation of this Agreement and legal relations of the
PARTIES in the performance of this Agreement shall be governed by the laws of the State
of California without regard to conflicts of law provisions.
K. Notice: Any notice required under this Agreement will be considered properly given and
effective on the date of the postmark if mailed by prepaid postage first-class certified mail;
on the date of delivery if delivered in person; or on the date of receipt if mailed by any global
express carrier service that requires the recipient to sign the documents demonstrating
the delivery of such notice. Notice shall be given to the designated authorized official at
the address provided below:
FOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
Authorized Official:
Executive Director,
Technology and Industry Alliances
Address:
Technology Transfer Services,
Office of Research,
Technology and Industry Alliances,
University of California, Davis
1850 Research Park Drive, Suite 100
City, State, Zip:
Davis, CA 95616-6134
Country:
USA
Telephone:
530.757.3432
Fax:

530.758.3276

FOR RECIPIENT:
Authorized Official:
Recipient Institution:
Address:
City/State/ZIP:
Country:
Telephone:
Fax:
3. complete agreement
This Agreement constitutes all the agreements between the PARTIES, both written and oral
with respect to the subject matter hereof. All prior agreements respecting the subject matter
hereof, either written or oral, expressed or implied, between the PARTIES are hereby canceled.

(Continued on Next Page)
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Box 4 (continued)

THE REGENTS OFTHE UNIVERSITY OF CALIFORNIA

RECIPIENT

Name:

Name:

Associate Director, Technology Transfer Services

Title:

Date:

Date:

UC DAVIS INVESTIGATOR and RECIPIENT INVESTIGATOR acknowledge reading and understanding
this Agreement and shall abide by the terms and conditions thereof.
UC DAVIS INVESTIGATOR

RECIPIENT INVESTIGATOR

Name:

Name:

Title:

Title:

Date:

Date:

exhibit a
1. ORIGINAL TRANSFERRED MATERIAL:
2. RESEARCH USE:
3. RECIPIENT INVESTIGATOR (name):
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How to Draft a Collaborative Research Agreement
MaRTha baiR sTeinbocK, Deputy Assistant Administrator, Office of Technology Transfer,

U.S. Department of Agriculture, Agricultural Research Service, U.S.A.

ABSTRACT

A collaborative research agreement has five major parts:
(1) statement of objectives, (2) statement of work, (3) gen
eral provisions, (4) budget, and (5) list of materials. This
chapter provides a step-by-step discussion of the issues
that need to be addressed in each part of the agreement,
emphasizing the importance of crafting an agreement
that is mutually beneficial and, above all, clearly written.
Whereas all parts of any agreement are important, for col
laborative research agreements, extra care should be taken
in describing the objectives and work of the collabora
tion, the research plan, and the mechanisms for agreeing
on changes in the research plan. Partnerships grow and
change; this invariably leads to the need for amendments.
Arguably, many of the best collaborative research agree
ments need numerous amendments in order to reflect the
evolving needs of the parties involved.

1. InTRoduCTIon
The objective of writing a collaborative research
agreement is to clarify for both parties what they
are trying to accomplish together and to clearly
set forth the rules that will govern the collabora
tive effort. A good partnership must be mutually
beneficial, and an effective collaborative research
agreement will help both parties understand and
accept mutual benefit as a goal. Of course, sim
ply writing that an agreement is mutually benefi
cial does not make it so. An effective agreement
must be based on an actual win-win relationship,
one that is truly mutually beneficial. So to start

with, the concept of the collaborative research
project must involve a research project through
which both parties benefit from the work that
will be done.
A poorly written agreement can tear apart an
otherwise harmonious relationship. On the other
hand, a well-written agreement, in which all par
ties understand their responsibilities, will build
and strengthen a productive scientific relation
ship. An effective agreement will be clear both to
the researchers doing the research work and to the
managers of both parties. And a well-written col
laborative research agreement can lay the ground
work for moving the results of research toward
commercialization.
For the sake of simplicity and to facilitate dis
cussion of the issues involved, the chapter focuses
on one scenario: developing a research agreement
between a National Agricultural Research System
(NARS) government laboratory and a private
company. Many of the points made are equally
valid for collaborative research agreements be
tween other types of entities.

2. pARTS of An AGREEMEnT
Most collaborative research agreements have five
general parts. The agreements can be somewhat
flexible in the terminology they use. The names

Steinbock MB. 2007. How to Draft a Collaborative Research Agreement. In Intellectual Property Management in Health and
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
This chapter was authored as part of the official duties of an employee of the U.S. Government. Copyright protection for
this work is not available in the United States (Title 17 U.S.C § 105). The views expressed are those of the author and do
not necessarily represent those of the U.S. Department of Agriculture.
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assigned to the subparts are not terribly impor
tant. What is important is that the agreement
covers each the following points:
1. statement of objectives
2. statement of work
3. general provisions
4. budget
5. list of materials

that is sent to the project, as well as the quantity
of each item and the dates those materials were
transferred from one party to the other. By updat
ing the list of materials each time new materials
are sent from one of the collaborating researchers
to the other, all parties are assured of having a
current and complete list.

The first part of the collaborative research
agreement is commonly called the statement of
objectives. This explains the overall setting of the
agreement. It describes what the parties want to
accomplish together and why the collaboration is
important.
The second part of a well-drafted collabora
tive research agreement is called the statement of
work. This may sometimes be called the research
plan. It describes the research that the parties pro
pose to conduct and includes which approaches
will be undertaken and which methodologies
will be used. Most importantly, this part of the
agreement specifies who is responsible for what
and specifies the due dates for completing each
part of the research project.
The third part of an effectively written col
laborative research agreement is called the general
provisions. These are sometimes known as the
legal provisions. They cover a series of impor
tant details, the mechanisms of collaboration,
and the rules by which the collaboration will be
conducted.
The fourth part of a agreement is the bud
get. This part sets forth the resources that each
party needs and contributes to the collaborative
research project.
For collaborative research agreements in which
biological or other materials (germplasm, plant
parts, biotech components, and so forth) are passed
from one party to the other for use in the project,
the agreement typically includes an additional sec
tion called the list of materials. This section is of
ten attached as an appendix to the agreement. In
some cases there may be more than one appendix,
since the materials being used and transferred may
change over the course of the project.
In its simplest form, the list of materials
should provide a unique name for each item

The statement of objectives should be concise
and clear. Use terms that nonscientists will read
ily understand and avoid the excessive use of sci
entific jargon. The statement of objectives should
explain the real-world issues that the collabora
tive research agreement will address. It should
articulate both the what and the why of the col
laboration. When someone outside of the science
community reads the agreement, they should be
able to tell why the parties believe it is important
to undertake the collaboration. In addition, the
statement of objectives should clearly specify the
scientific goals of the collaboration. Care should
be taken to differentiate long-term goals, which
may happen years after the agreement is complet
ed, and short-term goals, which will be accom
plished by the end of the agreement.
Consider the following examples from two
statements of objectives from actual agreements:
• Good: to develop, test, and evaluate trans
genic tomatoes expressing the “N” gene,
which encodes for resistance to tobacco
mosaic virus.
• Not as good: to determine basic breeding bi
ology, including ploidy levels of a resistance
biotype of Lolium.
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2.1 Statement of objectives

The first one is quite well written. It clearly
and specifically explains the objective. From this
clear statement, most readers will get a feel for
what the agreement hopes to accomplish.
The less well-written statement vaguely states
the goal. Phrases like basic breeding biology do
not really mean much unless they are further
defined, and terms like ploidy level may not be
well understood by the nonscientific community.
Remember, the goal of the statement of objectives
is to set the stage for the agreement by clearly stat
ing what the parties hope to accomplish.

CHAPTER .

2.2 Statement of work

The next part of a well-written collaborative re
search agreement is what is often referred to as
the statement of work. This is by far the most
important part of the agreement. Sometimes, the
statement of work is attached to the agreement
as an appendix. This is not to diminish its im
portance in any way. It is merely a convenience
to have this research plan slightly separated from
the general body of the agreement. The advantage
of having it self-contained is that it will be easier
for the scientists to relate to it, and in the event
of modifications to the work plan, it can be more
easily amended.
The statement of work contains the scien
tific objectives, methodologies, and approaches.
It should be broken down into subsections, with
each section explaining what “partner A” will
do and what “partner B” will do, with the time
frames and benchmarks specifically laid out.
In drafting this section of a collaborative re
search agreement, the parties must work together
closely. The other parts of a collaborative research
agreement can be initially drafted by a technol
ogy transfer officer and/or intellectual property
management officer and then can be exchanged
between the partners for review, comment, and
negotiation. But the collaborating researchers
themselves should prepare a first draft of the
statement of work, which can then be edited by
the technology transfer officer. This is because the
collaborating scientists are the ones who really
understand the complexity of what is to be un
dertaken, and it is the scientists who must fully
embrace the plan that is developed.
Within the statement of work, there should
be a section stating the project’s scientific objec
tives. With complicated or longer projects, there
may be many objectives and subobjectives. In
such cases, the use of a numbering or outlining
system makes the objectives clear and readable.
Each objective in the statement of work
should be followed by a description of the meth
odologies and approaches to be used to address
the scientific questions involved. Further, each
objective must include very clearly what each
partner (the institute scientists and the com
pany scientists) will be doing, separately and

collaboratively. This statement of responsibilities
is perhaps the most critical element of a research
agreement because without a clear understand
ing of responsibilities, the partners may have
unrealistic expectations and become frustrated.
If it is unclear who will be doing each piece of
experimentation, both parties may be sitting
back, waiting in vain for the other to produce
something. It cannot be stressed enough that it is
very important to break down each of the scientific
objectives of the statement of work into tasks and
clearly state who is responsible for each.
Another point to consider is to quantify the
work that is to be done. It may not be necessary
to use exact numbers (for example, the types and
replications of an experiment or the number of
test tubes you will be using), but do insert gen
eral guidance about the size and scope of the col
laborative research. For example, if you are go
ing to do a feeding study and will be using 30
mice per replication, state that in the agreement.
That way both parties will be clear as to the or
der of magnitude of the data types that are to be
generated and the level of resources needed for
their part of the work. Researchers often believe
they understand what the other has in mind, but
without written descriptions, such assumptions
often lead to misunderstandings. For example, if
an institute researcher says he or she will “field
test” a new variety, he or she may have in mind
a half-hectare plot necessary to generate enough
plants for a publication, while the company sci
entist has in mind 100 hectares. So, be as clear
as you can about the sizes or numbers of replica
tions and other quantifiable aspects in the state
ment of work.
Another aspect that is very important is to
build-in time frames and benchmarks. Generally,
you want to have built into the statement of work
at least an indication of when each party should
have completed their responsibilities under each
objective or subobjective. Often researchers will
object that time-frame specifics make them feel
pressured, but such a plan will help the collaborat
ing scientists make progress in an orderly fashion.
It also helps prevent one party from having to wait
for the other and causing lost time. Time frames
are important to make the experimentation run
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smoothly and they help the partners garner the
resources that will be needed to move the project
along.
Benchmarks are important to help measure
work progress. They specify that at a certain point
both parties expect certain pieces of data to have
been generated, certain parts of the experiments
to have been completed, or certain questions to
have been answered. You will want to write these
goals as benchmarks. In a larger agreement, with
multiple objectives and multiple people involved,
sometimes there may be activities that will flow
sequentially (one has to be completed before
another can begin). Other research may be oc
curring simultaneously in parallel experiments.
In these complicated situations, project-manage
ment software can be helpful when preparing the
statement of work.
A collaborative research agreement can grow
to be a lengthy document. However, you should
not think that it is like a grant application that
can be 20, 30, 40 or more pages. A collaborative
research agreement is not designed to convince
an outside party that the work is worthwhile, nor
does it aim to show that either of the collaborat
ing scientists are high-quality researchers. Rather,
it should clearly spell out the respective research
that the partners will be doing. So, a statement of
work should only be as long as it needs to be to
ensure that both parties know what is expected of
them. A typical agreement will be 10–15 pages,
and the statement of work is often no more than
two or three pages.

. GEnERAL pRovISIonS
The next part of a collaborative research agree
ment is the general provisions. This is the body of
the agreement that covers the how of working to
gether and provides mechanistic guidance to the
scientists at the institute and at the company, as
well as to managers. Normally, an institute or an
entity has a standardized set of general provisions
that has been reviewed by their legal counsel and
that can serve as a starting point for negotiating
agreements. Each person studying this chapter
should consider developing such template agree
ments. In the process of such development of
20 | HANDBOOK OF BEST PRACTICES

template agreements, a person can often begin to
fully understand which points are negotiable and
which legal provisions are required by organiza
tion policy or law. At the same time, collaborative
research agreements should be as user-friendly as
possible and avoid unnecessary stipulations.
There are a wide range of typical general
provisions. These include a public disclosure/
publication policy, which addresses how the par
ties will communicate with each other and the
outside world; reports; confidentiality issues; the
important issues of intellectual property manage
ment and technology transfer from the institute
to the company; regulatory approvals; indemnity
and liability statements; dispute resolution plans;
and provisions for termination. This part of the
agreement should also spell out an amendment
procedure and name the persons responsible for
the agreement, both managerially and scientifi
cally, at the institute and the company.
.1 Publications

Public disclosure is a crucial part of any research
agreement. Science is driven by the need to pub
lish, and scientific careers depend on such publi
cations. Public disclosure, including publication
in patent literature, keeps innovation going. The
phrase public disclosure is a broad term that in
cludes many types of disclosure of research re
sults. Public disclosure can include any form of
public dissemination of research results: articles,
abstracts, poster sessions, both informal and for
mal seminars, talks, information posted on the
Internet, and grant applications. Most organiza
tions that enter into collaborative research agree
ments will want to put some limitations on the
right to public disclosure. Such a delay in public
disclosure may be necessary to ensure that patent
applications can be filed for discoveries made un
der the agreement.
A publication clause should protect the inter
ests of both parties. Generally, there is a statement
that both parties reserve a right to review and
comment on all public disclosure by the other
party. Typically, a specific time frame (usually 60
or 90 days) is set up for such a review. Often there
is also a provision written into the collaborative
research agreement stating that one party requires
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the other party to delay public disclosure of proj
ect-derived information for a specific length of
time to allow for patent preparation or exclusive
use by the other party. The bottom line is that
a well-written agreement should clearly state all
such limitations of public disclosures.
.2 Confidentiality

Another aspect of the general provisions involves
confidential information, sometimes called confi
dential business information, or CBI. It is impor
tant for the collaborative research agreement to
differentiate between two types: (1) confidential
information that a party brings into the project
and that predates the agreement, and (2) confi
dential information that is generated under the
agreement and that the parties generated while
working together and conducting project experi
ments. A collaborative research agreement should
specify how both types of information are to be
handled by the parties.
For information that is created by one of
the parties prior to or outside the scope of the
agreement, you may find it helpful to use the
terms commonly found in a confidentiality or
nondisclosure agreement. Like any confidenti
ality agreement, these clauses should specify a
time limit during which the information is to be
kept confidential. Typically, such time limits are
between two and five years after the end of the
collaboration or from the point the information
is generated. If the parties have an earlier signed
nondisclosure or confidentiality agreement, that
document may simply be referenced in the col
laborative research agreement or the collaborative
research agreement can state that it replaces the
confidentiality agreement.
The confidential treatment of information
generated under the project will be closely tied
to the treatment of intellectual property (IP) and
tangible property.
. Intellectual property

Perhaps the most important section of the gener
al provisions deals with the intellectual property
and tangible property (TP) provisions. This sec
tion is important because what motivates most
collaborative research is the potential for gaining

access to such IP/TP as may be created under
the collaborative research agreement. For an in
stitute, working with a company is an effective
way to transfer technology. Many believe that it
is the most effective and efficient way for research
results to move from the laboratory, through a
development process by the company partner,
and finally into the marketplace. Without such
provisions, the benefits of collaboration may be
lost.
The first step in drafting this section is to
clearly define IP and TP rights.
IP rights are rights under various types of
statutory protection. These IP rights include the
intangible property rights obtained from:
• issued patents and patent applications
• plant variety protection (or a breeder’s
rights) applications and granted certificates
• copyrights (including software)
• trade secrets
• trademarks and service marks
TP rights are the second broad class of prop
erty rights. These include ownership rights in
various classes of biological materials, germplasm,
databases, business plans, research plans and pro
tocols, laboratory notebooks, and the like. They
involve the ownership of things that one can
touch, see, taste, smell, and hear.
The second step in dealing with IP/TP issues
is to establish who owns what. The collaborative
research agreement should clearly state that all
IP/TP contributed to the collaborative research,
but predating the project, should be owned by
the party who contributed its use to the project.
This is why there should be a clear inventory of
all IP/TP that either party contributes to the
project.
For example, if the company has a genetic
construct or a genomics database that the collab
orators will use, then whether or not these con
tributions are covered by a filed or issued patent
or some other sort of statutory protection, these
contributions need to be clearly identified in the
agreement. Similarly, if the institute brings germplasm lines, a site-specific promoter, or a transfor
mation vector into the project, these too should
be identified and documented in the agreement.
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In this way, collaboration can be promoted be
cause each party recognizes and acknowledges
the other party’s ownership of the contributed
materials.
After establishing an inventory (in the list of
materials) of the IP/TP that is brought into the
project, the next step is to clearly establish how
the ownership of new property discovered under
the project (new IP/TP) will be determined. In a
typical collaborative research project there is the
potential for three classes of new IP/TP:
1. New IP/TP that is solely discovered by the
institute researcher
2. New IP/TP that is solely discovered by the
company researcher
3. New IP/TP that is jointly discovered by
the institute researcher and the company
researcher
In collaborative research, many of the discov
eries fall into class three. A well-written collab
orative research agreement will address how and
by whom the ownership determinations are to be
made in cases in which the IP/TP is discovered by
one party or the other.
Globally, patent laws differ. Under the
patent laws of nearly all countries outside the
United States, inventorship is determined by
whomever files the patent first (and has been in
volved in the discovery process). In the United
States, inventorship is determined by first-to
invent and ownership follows inventorship,
that is, ownership goes to whoever files first.
This is the so-called first-to-file approach. It is
therefore necessary for a collaborative research
agreement to address the matter of ownership
determination, or refer to the national laws of
the partners.
Normally, inventorship is determined when
the patent attorney talks with the researchers. If
a patent is being sought in the United States,
great care must be taken to include on the pat
ent application only the actual inventors (those
researchers who make the creative, intellectual
contributions to the discovery). If someone who
is not an inventor is named as an inventor on the
patent application, this will prevent the issuing
of a legitimate U.S. patent.
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In a first-to-file country, the rules for the de
termination of actual inventorship are different.
As in a first-to-invent country, ownership follows
inventorship. So, whoever files first will be listed
as the inventor and as the owner. Clearly, it is im
portant to understand the rules of the country in
which the patent filing is taking place. Yet it must
be remembered that if the new IP/TP is to be
protected in the United States (and other first-to
invent countries), regardless of where the research
takes place, the rules of first-to-invent apply to all
patent filings.
In general, if only employees of the institute
are listed as inventors, then the institute owns the
invention. If only employees of the company are
listed as inventors, then the company owns the
invention. However, if at least one employee of
the institute and one employee of the company
are listed as inventors, then the invention is joint
ly owned by both the institute and the company.
Regardless of whether the patent filing is in a
first-to-invent country or a first-to-file country,
it is important to address the matter of patent
ownership in a well-written collaborative research
agreement. However, equally important than pat
ent ownership are the rights that are granted un
der the patent.
A key part of the IP provision is what the
agreement is actually promising in terms of
the granting of licensing rights, or the “grant.”
Normally, the parties enter into a collaborative
research agreement in order to obtain access to
the discoveries that flow from the collaborative
project.
The scope of the grant must be considered
very carefully. For example, if the scientists are
conducting mer research and are seeking a tech
nology for disease resistance, it is possible that
the technology may apply to other plants as well.
Thus, the collaborative research agreement should
be clear that the grant is for a license for mer only
(or for some other agreed-upon subset of plants).
This will be a key point in the negotiation of the
agreement. Normally, one party will want a very
broad grant of rights and the other party will keep
trying to narrow the grant.
The next thing to consider is whether the
grants will be for an option to a license or an actual
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license. There are pros and cons to both approach
es. Granting an option, with a preset fee struc
ture, is sometimes all that will be requested, be
cause such an option allows both parties adequate
time to thoroughly evaluate the invention before
signing an actual license. On the other hand, one
party may strongly prefer a direct grant of a li
cense, with the business licensing terms clearly
spelled out, because this reduces the amount of
uncertainty.
Granting an option normally makes a great
deal of sense because it is very difficult to pre
dict what IP/TP will be generated. Further, it is
difficult to predict the value of such new IP/TP.
Therefore, agreements that give a direct grant of
a license and fully spell out the license terms can
lead to a gross miscalculation of the new IP/TPs
worth, either undervaluing it or overvaluing it. If
the IP/TP is overvalued, this would likely act as a
disincentive for future development of such IP/
TP. If the new IP/TP is significantly undervalued,
this may act as a block on the future relationship
of the parties because one party has been treated
unfairly.
With either approach, the collaborative re
search agreement should include time frames
during which the party who receives the option
to a license must decide whether it wishes to ex
ecute its option and take a license. The option
grant should not be open ended. This will allow
another licensee to be sought if the collaborating
party does not wish to develop and market the
new IP/TP.
Likewise, it is important to specify the li
cense grant’s level of exclusivity. Is the license (or
the option to a license) for an exclusive license or
a nonexclusive license? Is the license exclusive by
country or region? Is the license limited by crop?
By product? By time? Or, is the license more gen
eral? Most companies (and many other collabora
tors as well) will want some sort of exclusivity in
their license (or option to a license). It may be
adequate for such a collaborating partner to have
an exclusive right for some specified time period,
or for a certain well-defined field of use, or for a
certain licensed territory, or for a combination of
these. Most organizations are reluctant to put their
resources into an agreement if the organization is

not assured of an exclusive license because their
competitors may also seek a license.
The negotiation of the grant of intellectual
property is a key part of the collaborative research
agreement. Take time to think it through clearly
and come up with a solution that meets the needs
of both parties.
. Amendments

The last part of the general provision section is
the amendment process. Strong partnerships
grow and change; therefore, agreements need
to be amended. In fact, many of the best col
laborative research agreements need constant
amendments. It is not unusual for a collaborative
research agreement to be amended as often as ev
ery six months or every year. This is because the
researchers often identify dynamic, new opportu
nities that the partners want to explore together.
Thus, a well-written agreement can be amended
so that the statement of objectives, the statement
of work, and the budget reflect the new needs.
All amendments should in writing and signed
by the proper authorities as an appendix to the
agreement. Guard against informal amendments
that may sneak in as the project gains momen
tum and the researchers become excited. If they
are not written down, such amendments can lead
to disputes and litigation. So make it clear to ev
eryone that all significant changes in the research
must be written and appended to the agreement.
. Termination

All agreements should have a specific date upon
which the cooporation ends. Termination clauses
may be added that stipulate when and under what
conditions each party may elect to terminate the
agreement before the end date. The end date may
be extended through the amendment process, if
both parties agree. This is common in successful
collaborations.

. BudGET
The fourth section of a well-written collaborative
research agreement is the budget. There is a ten
dency to view this as the most important section
because it documents the funding that the parties
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contribute. This, however, is an improper em
phasis. While it is true that public sector agricul
tural research is grossly underfunded, and there
fore funds obtained from collaborating partners
have an extremely important place in the overall
research budget, collaborative research should
never be viewed principally as a way to raise rev
enues. Collaboration is much more than that.
Concentrating only on research funding over
looks both the use of the agreement as a means of
technology transfer and as a way to build an intel
lectual synergism that can result when researchers
collaborate.
Developing the budget must begin with a
clear statement of work. This will help determine
for the collaborators the amount and the timing
of the resources required for the collaborative
project. This is the starting point. There must be
enough funding to undertake the project without
detracting from other projects that are already
underway.
Staff time should be considered, as well as
tangible resources (such as space and equipment
that will be required to support the project). For
example, if one partner will need to recruit gradu
ate students, technicians, or other personnel, then
salary and benefit costs for the new staff must be
included. Also, do not overlook in-kind contri
butions that a collaborating partner may be able
to provide. A company, for example, may have
very specialized equipment, expertise, formula
tion technology, or access to facilities that would
be extremely costly for an institute to procure on
its own. The value of such in-kind contributions
should be noted in the budget.
The budget for a collaborative research agree
ment should be absolutely clear as a research bud
get and be totally separate from any sort of licens
ing revenue that might be projected. The budget
should also specify when the payments will be
made and clearly indicate when the contributed
in-kind resources will be provided.

each party provides to the project. This is critical
because all such materials were developed outside
of the project and are owned by one partner or
the other. They are not new TP that will be di
vided according to the granting clauses. Rather,
materials that are included in the list of materi
als are fully owned by one of the collaborators.
Sometimes items listed in the list of materials
have IP rights associated with them; sometimes
they do not.
In truly collaborative research, the list of ma
terials may have to be amended on a regular basis.
This will require the agreement to be amended
easily (as noted above). A well-written collabora
tive research agreement, the list of materials will
dynamically respond to the emerging needs of the
researchers.

. LIST of MATERIALS
The final section of a collaborative research agree
ment is the list of materials. As with the budget,
this section provides a clear listing of the TP that
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. ConCLuSIon
Collaborative research agreements can be ex
tremely beneficial to both partners. No single
entity ever has adequate money, resources, and
intellectual capacity to do all the research it might
want to do. Forming partnerships can be an effec
tive and economical way of accessing resources.
Collaborative research agreements, moreover, are
often the first step in establishing longer-term
partnerships. They can be effective technology
transfer tools, as well. The benefits are much more
than monetary. Taking the time to think through
and discuss the terms of the collaborative research
agreement helps foster communication between
partners and sets the project on a path for suc
cess. Indeed, good partnerships spur creativity
and help innovation to serve the public welfare.
Lastly, it should be said that writing and
negotiating a collaborative research agreement
might seem like a very difficult process. In fact, a
first attempt to write such an agreement usually
is difficult. The good news is that each time one
does it, the process gets easier. n

Research Operations and Management, Office of Technology
Transfer, USDA-ARS, Room 4-1158, 5601 Sunnyside
Avenue, Beltsville, MD, 20705, U.S.A. martha.steinbock@
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Drafting Effective Collaborative Research
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ABSTRACT

Best practices in IP (intellectual property) management
are built on a foundation of licensing and contracting
expertise. A contract defines a bargain that parties enter
into, and, as such, defines the relationship and the expec
tations of the parties. It is therefore critical to carefully
draft contracts that clearly, and objectively, indicate the
intentions of the parties. Avoid stilted, legalistic jargon
when drafting contracts; instead, strive for direct, simple,
and accurate language. In written agreements, be sure to
include the terms and provisions covering the grant itself,
such as payments, dispute resolution, intellectual prop
erty emerging from the R&D, IP ownership and confi
dentiality, and other related legal terms and definitions.
However, remember that generic templates do not exist.
The relationship and goals of the parties will define how
the agreement is structured. The actual document will
also vary, depending on whether the parties are public or
private sector entities, on whether the license is a collab
orative-research agreement or a sponsorship agreement,
and on the business and legal culture.

1. InTRoduCTIon
Human relationships are the engine of innova
tion; they drive the creative use and management
of intellectual property (IP). Patents, trademarks,
and copyrights provide mechanisms through
which actors in the private and public sectors can
build relationships, coordinate activities, assign
responsibility, and allocate the benefits arising
from innovation and its distribution. The con
tract links these actors and the various IP regimes.

Contracts, which define in legal terms the form
relationships take, mediate the interaction among
those with knowledge, skills, and/or resources in
order to create something new, improve what al
ready exists, or distribute what has already been
created. In this chapter, we first discuss some of
the basic tenets of good contract drafting, that is,
emphasizing clarity and simplicity and avoiding
the slavish use of standard-form contracts, which
may contain provisions unsuitable to specific
contracting cultures and contexts. Later in the
chapter, we discuss sound drafting practices for
research contracts and for more complex collab
orative research and sponsorship contracts.
Because contracts are about relationships—
with all the ambiguities, pitfalls, and excitement
of human relationships—contracts are difficult
to capture on a dry document composed by law
yers. A written contract can never fully describe
a relationship nor the full set of contractual ar
rangements that embody the relationship. The
extent to which judges and arbitrators interpret
ing a dispute rely on the written document it
self—in contrast to the external evidence about
the relationship between the parties—varies from
jurisdiction to jurisdiction. For example, in com
mon law jurisdictions, contractual interpretation
tends to be more contextual, with greater allow
ance made for external evidence about the broad
er relationship. The civil law, however, tends to
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focus more on actual contractual wording and
the dictates of the civil code. However, irrespec
tive of jurisdiction, the written contract is the
strongest objective manifestation of the inten
tions of parties as they enter into a relationship.
Parties can most easily avoid disputes if the
contract describes, as fully and simply as possible,
the bargain made by the parties. This notion has
important consequences for contract document
drafting. Long-winded sentences, boilerplate
provisions and impossible-to-understand defini
tions only complicate lives and understanding in
a futile attempt to remove doubt concerning, and
ambiguity of, complex and evolving relationships.
Such lengthy documents are not only unreadable
by the actual signatories to the contract but do
little to provide guidance to the business people
and judges who may eventually have to settle dis
putes based on those documents.
Instead of thinking about contractual docu
ments as an attempt to pin down every last aspect
of a relationship between parties in complex legal
jargon, this chapter suggests a different approach,
one drawn from the experience of large corporate
law firms: explain the provisions of the bargain
as simply as possible, in a logical sequence, us
ing plain language. By explaining the bargain in
a clear and accessible manner, not only are the
chances better that the parties will comply with
the essence of the contractual relationship, but
also business people and judges will resolve dis
putes in conformity with the fundamental inten
tions of the parties.
Undoubtedly there is temptation to use stan
dard form contracts and boilerplate provisions to
lower transaction costs and legal fees, but in the
end, the use of poorly written or inappropriate
contractual provisions may lead to greater costs,
rather than save money. That is not to say that
every contract need be drafted from scratch; the
use of contractual precedents is a judicious use
of legal resources. Select precedents that are well
written and constructed. Parties to the contract
should question the relevance of each provi
sion to the bargain within the appropriate cul
tural context. When using clauses from standard
form contracts, the key question to ask is: do you
understand the language and does it accurately
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describe the arrangements between the parties,
given the cultural and legal context?
1.1

Explaining the bargain:
The art of contract drafting

If one were to read court decisions about con
tracts, one would soon see that judges struggle
not as much to determine what the documents
say, as to determine the nature of the relation
ships underlying the contracts. When judges
find this difficult because the contract docu
ment is confused and convoluted, they are more
likely to misinterpret the original agreement
between the parties. Such misinterpretations
lead to decisions that run against the allocation
of responsibilities and benefits that the parties
originally intended, increasing uncertainty and
undermining the business rationale for the con
tract. What judges seek to find in contractual
documents are objective indications of what
the parties intended to do: Who was to take on
what risks? Who was to benefit from the results
of the contract? How were the parties to deal
with disputes and controversies? Judges want
to understand what the parties bargained for so
that they can figure out who should do what,
when, and where.
A good contractual document is one that sets
out the bargain as clearly and simply as possible;
a bad document is one that muddles it with too
many words, arcane language, and legal mumbo
jumbo. The job of a lawyer is to identify the es
sence of the relationship so that the parties and
judges understand exactly what the business deal
is about. This involves setting out the contract in
a structured way that focuses on the essential ele
ments of the bargain.
The simplest contract is one in which one
party promises to deliver something to another
in return for something (monetary or otherwise).
If a dispute arises, the parties agree to follow a set
procedure (such as arbitration or mediation) or to
sue in court (litigation).1 This progression should
be defined in the contract (for example, mediation
procedures, followed by binding arbitration).
Further, the agreement should clearly explain
how one party is to deliver something to the other,
the heart of what Article 1 should cover. Article
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2 should deal with payment: to whom should
the payment be made? in what currency? in
which form (electronic, bank draft, for example)
and when? One could also add a few sentences
dealing with late payments: will there be inter
est charged and, if so, how much? how would a
currency crisis (for example, currency cannot be
exported out of the country) be dealt with? The
third article deals with resolving problems: steps
to be taken if the receiving person is unsatisfied
with what was delivered, either in terms of qual
ity or quantity; how the parties would resolve the
conflict; what the first person should do if he or
she is not paid. The parties can agree to litiga
tion or arbitration but may first prefer to set up
a mechanism through which they can elevate the
problem to senior management who, presumably,
want to avoid the costs and embarrassment of go
ing to court or arbitration.
The key to drafting these articles is to keep
the essence of the bargain clear and as uncompli
cated as possible. Sentences should be short, free
of vague adjectives, and be written in the active
voice. The vocabulary should be accessible both
to business people (with technical knowledge but
limited legal knowledge) and judges (with lim
ited technical knowledge but with extensive legal
knowledge). Use correct grammar and a simple
vocabulary. If the document would get low grades
from a secondary school teacher, do not use it. In
fact, sometimes legal disputes turn on grammar.
One recent commercial dispute in Canada, worth
$2 million (Canadian), was resolved on the basis
of a rogue comma.2
After the parties explain the main provisions
of the bargain, the parties will need to define
words and phrases used in the contract. The par
ties should include clauses that take into account
the local law that applies to the contract. These
clauses can have important implications for the
bargain, and so writing them requires expert le
gal knowledge. Such clauses can deal with what
would happen if there were natural disasters or
labor strikes, or how much leeway is given with
regard to time lines, or how to calculate exchange
rates. This information must be relevant to the lo
cal area, however, because the detailed legal rules
of one place, say California, U.S.A., may be quite

different from the detailed legal rules in another
place, say Uttar Pradesh, India.
Written contractual documents depend
to a large extent on local customs. That is, the
contract can be meaningful only within the set
of business practices and norms that exist in the
place where the contract is to be performed. As
practices and norms vary tremendously, so do the
contractual documents that serve to reflect con
tractual relationships. So, for example, contrac
tual documents in the United States tend to be
very detailed and long, while a contractual docu
ment on a similar topic will be shorter and much
less detailed in Germany. Exporting one style of
contractual document from one place to another
can be risky, since the business people and courts
will have difficulty interpreting a document writ
ten for a different place with different customs.
This is another good reason to avoid a slavish de
votion to standard-form contracts and why this
chapter does not include a sample contract with
boilerplate provisions, but instead sets out only
the main elements of a contract.
Of course, when the parties are from two dif
ferent places, say Uttar Pradesh and California,
the parties must adopt a more generic style of
contractual language that reflects, to the extent
possible, the practices in both jurisdictions. This
is not principally for legal reasons; the contractual
document will be interpreted in accordance with
the laws and customs of only one of the jurisdic
tions. Rather, the effort to reflect both cultures is
important to maintaining business relationships,
since people from both places must feel comfort
able with the contractual document.
Finally, it is helpful to recognize that, while
legal systems abound, there are two principal
ones that govern most commercial contracts:
the common law and the civil law. While some
countries use hybrid legal systems (for example,
Oman, Puerto Rico, and Indonesia), most con
tracts dealing with collaborations and research
will be subject to one or the other of these two
systems. Usually, common law countries are for
mer colonies of the United Kingdom and follow
the English legal system, while civil law countries
are generally the former colonies of continental
European powers.
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Common law and civil law systems are usual
ly similar in result, but there are differences in law
and in practice that could ambush the unwary.
For example, for a common law contract to be en
forceable there must be an exchange of something
of value, called consideration. Consideration can
be in the form of money, return promises, action,
or forbearance. On the other hand, civil law does
not require consideration. Therefore, a failure
to provide consideration (for example, a license
with no payment and no obligation of confiden
tiality) may not be enforceable in the common
law. Another difference between the two legal
systems is that the civil law imposes background
obligations of good faith as well as more limits on
what can be the subject of a contract than does
the common law. However, these differences are
relatively rare. They are unlikely, in most cases, to
affect collaborative or research agreements great
ly. The bigger difference is one of style: common
law contractual documents tend to be longer and
more detailed, while civil law contractual docu
ments tend to be short and refer to the civil code
for more detail.
1.2 Contracting to innovate

Contractual documents that deal with innovation
should follow the general rule of contracts: explain
the bargain in simple, straightforward sentences.
Clarity and simplicity are, once again, the keys to
a successful contractual document. If the contract
is well drafted, neither the institutions involved
nor judges will misunderstand the responsibilities
of the parties involved. Following the rule does
not, of course, avoid all conflict, but minimizes it
and provides business people and courts a frame
work within which to resolve disputes.
1.2.1

The license

Traditionally, a license is a grant of permission for
a party to enter onto the physical property of an
other, that is, an agreement not to hold the party
liable for illegal trespass. With respect to intel
lectual property (IP), a license is a promise not
to sue a party for actions that would otherwise
constitute infringement. In other words, a license
is permission to make use of another’s IP under
carefully laid out conditions and terms.
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There are a variety of contracts, and associated
documents, that relate to intellectual property. A
basic license is the simplest of these contracts. The
first article of a basic license should describe the
rights being licensed (patent rights, copyright,
trade secret rights, data-use rights, and so on) and
the scope of the license (limitations on geography,
users, and time). Article 1 should provide suffi
cient detail so that the business people and judges
understand as clearly as possible both the nature
and the limitations on what is being licensed.
Article 1 should also discuss any ancillary license
(for example, a license back or cross-license).
The second article should deal with payment.
Is there, for example, an up-front fee? Are there
royalty payments and, if so, how long will roy
alty payments have to be made? How and when
should payments be made? The third article will
set out the dispute-resolution mechanism: arbi
tration, courts, and/or some form of mediation.
One should supplement these articles with an
explanation of what brought the parties together
and what their goals are. The contract also should
either acknowledge or reject relevant local laws
regarding liability for problems that may arise
(those within the parties’ control, such as failure
to pay, and outside their control, such as flood
or fire). The contract should clearly state which
country’s (or state’s) law applies and so on. The
parties should take care in setting out definitions
and should include these at the end (or in the
introduction, if one prefers). The other issues can
be dealt with in a concluding article that would
include mundane, but essential topics, such as
how the parties are to notify one another.
Other forms of contractual documents deal
ing with intellectual property expand the license
agreement and may, in addition to the basic li
cense, include articles dealing with matters such
as information exchange, staff, and IP rights (as
in a consortium research agreement).
1. Types of contracts

Just as there are no real limits to the bargains we
can make, there is no limit to the type of con
tracts we can create. As circumstances change,
new technologies are introduced, and business
people and lawyers try to identify new niches, we
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encounter new ways of contracting. The imagina
tion is the only thing that limits what a contract
can be about. Therefore, instead of trying to cover
all possible forms of contracting with respect to
innovation—an impossible task—we will concen
trate on a discussion of the main types and leave it
to the reader to imagine different scenarios. Since
the key is, as always, to be clear and transparent,
one can adapt the basic forms of contractual ar
rangement covered here to other circumstances.
The remainder of the chapter concentrates
on two types of contracts: research contracts and
collaborative research or sponsorship agreements.
The collaborative research and sponsorship agree
ments are the more complicated and incorporate
most of the basic terms of the research contract.
Heeding the warning against using standardform agreements, the discussions below will con
centrate on some of the principal issues that arise
in the various types of contract. However, one
must adapt the contractual arrangements to the
fundamental underlying relationship and not get
overly caught up in presenting minutiae.

2. RESEARCH ConTRACTS
A research contract is one in which a researcher
seeks to obtain the rights to use some knowledge
(be it patented or protected as a trade secret) to
advance his or her research project. That is, the
rights obtained are an important ingredient in the
carrying out of a research project, whether at a
public, not-for-profit, or for-profit institution.
A basic outline of a research contract would
include the following:
• Article 1: the license
• Article 2: payment terms and process
• Article 3: problem escalation and dispute
resolution
• Article 4: intellectual property emerging
from research (where applicable)
• Article 5: confidentiality and publication
rights
• Article 6: legal terms, such as what to do
in case of an “act of God” or other inter
vention, timing issues, and notification
procedures
• Article 7: definitions

The simplest form of research contract would
begin, in Article 1, with a holder of intellectual
property granting a license (that is, promising not
to sue for infringement) to a researcher in order to
allow the latter to make use of a certain technolo
gy for a defined research use. Generally, however,
research contracts are more complex, and the li
cense forms only one part of the broader research
contract. The contract may include a promise to
provide a sample of the material.
Material transfer agreements are discussed
more fully elsewhere,3 but it is worth noting that
these agreements are not only particularly sig
nificant for research, but are also often the most
problematic of contracts to negotiate. There are
real worries about the sharing of research materi
als and results in a research environment that is
increasingly industry funded, competitive, and fo
cused on commercializing research results. These
agreements also give rise to significant practical
difficulties, such as the time and labor needed to
prepare and transfer research materials, and the
need to internationally ship biological material.4
The research contract may call for a payment
(often nominal, to cover expenses) in cash as well
as in-kind (for example, a promise not to do or
disclose certain things). The contract may also
discuss how to resolve disputes over exactly what
was licensed (for example, slight variations on the
initial technology), payment amounts (how to
handle the production of material that was never
used), and so on.
That is the basic bargain. With a clearly
written contract, one has already avoided most
possible conflicts. There remain, however, a few
contentious issues that we cover here in more
detail. These include publication rights, confi
dential information, tricky licensing concerns,
payment, and rights to the results of the research
performed.
2.1 Publication rights

It is seldom the case that a technology is solely
protected by patents that are available for review
by the public, and it is bad business practice to
use only patents if other forms of business protec
tion are also available. Therefore, when a party
licenses the use of a certain technology, that party
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often must provide associated confidential infor
mation. To protect the party against the disclo
sure of this information, he or she often asks for
a right to approve any publications. In addition,
if the research may result in new information that
may affect the technology owner’s interests (the
research shows that the technology does not work
or works better than expected), the technology
owner may wish to have time to prepare for this
eventuality prior to any public disclosure. This
also would lead the owner to seek the right to ap
prove publications.
Given the interests of technology owners
to guard against uncontrolled disclosures, these
owners may insist that a clause be added to the re
search contract providing that the researcher may
only publish articles after first getting permission
from the technology owner or after first giving
the technology owner enough time to prepare
itself for the publication. Delays of three to six
months for the technology owner to review pub
lications to ensure that no confidential informa
tion is disclosed are reasonable, provided that the
article’s author is permitted to submit the article
to the journal for a confidential review during
this time. As normal peer-review processes usu
ally take at least this much time, it provides little
inconvenience to the author.
If the technology owner also has the right to
new inventions coming out of the research (usu
ally this only happens in a sponsored-research
setting, which will be discussed later), then the
owner may also reasonably request a publication
delay in order to assess the publication for any
disclosure that could threaten the patentability of
the new invention.
2.2 Confidential information

Patents often represent only a part of a technol
ogy, for example, an early prototypical embodi
ment of an invention. The remainder, such as
secrets and know-how, are protected under most
legal regimes as trade secrets or as confidential
information. In addition, the research conducted
under a contract may result in the creation of
new confidential information. The person who
possesses confidential information can only pre
vent others from disclosing it, for example, to a
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competitor, if a confidential relationship exists
between the person and the party to whom the
information was initially disclosed. One of the
best ways of ensuring this protection from disclo
sure is through a contract.
The obligation to maintain confidentiality
will often be reciprocal. The technology owner
may seek to include a confidential information
clause in the research contract to prevent the re
searcher from disclosing confidential information
initially disclosed by the owner. The researcher
may wish to insert this type of clause into the
contract to protect the results of his or her re
search effort.
It is important to pay attention to how broad
ly one defines the term confidential information. A
narrow definition can be clear, but may leave out
important information. A broad definition may,
on the other hand, prevent the parties from get
ting on with their work. Therefore, both parties
to the research contract should review the defini
tion carefully and make sure it is clear to them.
There are several mechanisms that can increase
clarity. First, one can limit confidential informa
tion to material that is clearly identified (because
it is marked confidential) or limit confidential
information to clear and discrete categories of
information (for example, business plans or cus
tomer lists). Caution should be used in accepting
an open definition (for example, “Confidential
Information includes but is not limited to … .”),
especially where there is no requirement that the
confidential information be specifically marked
as such. In addition, some courts may strike
down an overly broad confidentiality provision.
This is because they sometimes see these provi
sions as contrary to public policy, since they limit
competition.
Overall, the scope of what is held to be confi
dential should not be so broad as to prevent pub
lication of research results and the use of research
by others. Moreover, since what should be kept
confidential will depend on how the information
is to be used, no single definition will apply well
in all cases.
The contractual provisions dealing with con
fidential information should make clear to whom
the information may be disclosed (for example,
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other researchers, including graduate students in
the same and other institutions, and so on). Care
should be taken to ensure that the obligations
would not prevent doctoral students or post-doc
toral fellows from publishing theses and making
presentations.
The confidentiality provisions should also
include a sunset clause that would end the ob
ligation of confidentiality under a variety of cir
cumstances, including situations where the infor
mation is made available to the public through
no fault of the receiving party and cases where a
court requires that the information be disclosed.
Finally, the contract should set out how
much care must be taken by the person receiving
the information to keep it confidential. For ex
ample, must the receiving party lock away the in
formation in a safe, or can he or she leave it filed
in office filing cabinets? This is important, since
it establishes the level of precaution the receiving
party must undertake to protect the information,
and how the party ought to address inadvertent
disclosures. The agreement should also specify
what information the recipient of information is
entitled to keep after the expiration of the con
tract and what must be returned or destroyed.

2. The license
The researcher’s freedom to carry on research us
ing a patented, or otherwise protected, invention
is determined by the scope of the license. A li
cense may be narrow and provide only for a de
fined field of use, such as use in conjunction with
certain vectors, or the license may be broad and
cover all research. The broader the scope, the more
freedom the researcher has to conduct research.
The researcher needs to recognize the coun
terintuitive fact that receiving a license to an in
vention does not guarantee that he or she is en
titled to use the invention. The researcher may
need, for example, regulatory approval, or may
need to license other inventions from the same
or different providers. It is therefore critically im
portant for the researcher to determine, normally
with the assistance of the licensor, how he or she
will be able to legally use the invention.
A license can be a nonexclusive license, a
sole license, or an exclusive license. A technology

owner who grants a nonexclusive license is per
mitted to grant the same or a similar license to
anyone else (however, the owner may not grant
someone else a sole or exclusive license). Unlike
a nonexclusive license, an exclusive license incor
porates two promises. The first is the license itself,
that is, a promise not to sue the researcher for pat
ent infringement. The second is a promise by the
technology owner to neither use the invention
himself or herself nor grant a license to anyone
else. Coexclusive licenses, prevent the owner from
granting a license outside of an identified group.
A sole license is similar to an exclusive license ex
cept that the technology owner retains the right
to use the invention herself or himself. Normally,
the greater the degree of exclusivity requested, the
greater the royalty paid by the researcher, since
fewer sources of revenue are available to the tech
nology owner. In an academic setting, researchers
usually require only nonexclusive licenses. In the
private sector, especially where a technology is key
to developing a particular application, a research
organization may need an exclusive or co-exclu
sive license that justifies the investments needed
to bring the technology to the market. This is of
ten the case if the research organization faces a
significant risk or the market for the technology
is expected to be small.
Some inventions in the biotechnology field,
such as genetic inventions and platform technol
ogy, tend to represent upstream inventions: these
are inventions that are needed in a large variety
of settings and applications. Granting exclusive
or sole licenses over all applications (generally re
ferred to as fields of use, in-license agreements)
for these types of inventions is not recommended.
Indeed, the Organisation for Economic Co-op
eration and Development (OECD) has recently
issued best practice guidelines for licensing ge
netic inventions that emphasize the general
preference for nonexclusive licensing for genetic
technologies.5 However, we can infer that non
exclusive licensing is more broadly preferred,
especially for platform technologies. One study
indicated that exclusive licensees often fail to ac
tually invest the necessary funds to move a tech
nology forward.6 This may happen if the licensee
lacks funds or loses interest in developing the
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technology. Thus, strong exclusive relationships
are generally not the best way to advance research
or commercialization.
If an exclusive license is necessary, particu
larly with respect to very early-stage research, it
is best to narrowly define fields of exclusive use
for the invention so that the technology owner
has the flexibility to permit researchers in other
fields with different applications the freedom to
conduct research. Where an exclusive license is
required, the parties should draft the license to
include provisions that enable the technology
owner to take back the rights granted in certain
circumstances. These circumstances might in
clude the failure of the research organization to
develop the invention in the manner described in
the license agreement, failure to fully exploit all
aspects of development for the invention, or fail
ure to sublicense as appropriate. These take-back
provisions should address, for example, the loss of
the license, the conversion of the exclusive license
into a nonexclusive license, or the reduction in
scope of the exclusive license.
To preserve the freedom of researchers, in
general, to engage in research for humanitar
ian purposes, licenses should, whenever possible,
explicitly recognize the rights of third parties to
conduct humanitarian research. This can be ac
complished by having one of the parties retain
the right to provide licenses to others who plan
to carry on such work. The parties may even go
so far as to impose an obligation to do so in spe
cifically defined circumstances. When seeking to
include this type of provision, a lawyer should be
consulted in the relevant country to make sure
that the obligation is enforceable, especially in
case of bankruptcy.
One important, but occasionally overlooked,
element of a license is a description of the orga
nizations and people that are entitled to benefit
from the license. Without such a list, the default
is that the license will apply only to the licensee.
Where the research is being used by researchers
at several institutions, or several locations, or
by research teams from multiple corporate en
tities within the same family of companies, the
license must be drafted so as to permit all of the
researchers to use the technology. To accomplish
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this, the license should specifically permit the re
search organization signing the license with the
right to allow others to use the invention through
a sublicense. On the other hand, the technology
owner will often want to ensure that this group
does not become too large. Thus, it is in both par
ties’ interests to specifically define the group to
which access to the inventions will be provided.
In addition, the license should identify all coun
tries where the researcher requires access to the
invention.
2. Payment

In general, those who receive a license for an in
vention pay a combination of up-front fees and
ongoing royalties for the right to use the inven
tion. Where the technology is a research tool and
the market for the technology consists primarily
of those conducting research, a market price will
be charged. In the case of research agreements,
however, it is standard practice to either not
demand these fees or to set them at a rate that
compensates the technology provider for out-of
pocket expenses. There are other cases where a fee
will normally not be requested, such as where the
license is provided as part of a cross-license ar
rangement or where the parties wish to contract
for the provision of know-how related to research
that falls within existing research exemptions.
Where payment is required, the amount of the
fees depends on many factors, including the scope
and nature of the license, the type of invention,
and whether the researcher is sponsored by the
private or the public sector. In general, care must
be taken in establishing up-front fees, especially
where these fees may present a barrier to access.
2. Rights to intellectual property
created through research

Research conducted using licensed innovation
may itself result in patentable inventions. Some
of these inventions may relate to the licensed-in
technology. For example, they may constitute a
modified or improved form of the original tech
nology, or they may be substantially different. If
the research agreement is silent on the ownership
of these new inventions, then the researcher or
the researcher’s employer, or a combination of
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the two, would be entitled to hold a patent over
it, depending on the IP policy of the particular
research institution. This means that the original
technology owner would, in the absence of any
agreement to the contrary, normally have no IP
right to this new invention and, therefore, no
right to use the new invention, let alone control
access to it. This situation can be changed through
an appropriate assignment, through grant-back
clauses, or through license provisions in the re
search contract.
2..1

Ownership

In the research setting, ownership of intellectual
property developed using licensed-in technology
should generally remain with the researcher or
the researcher’s employer. This is especially true
where the research takes place at a university or
public research center and where public funds are
used to conduct research. Thus, reach-through
license agreements, in which the original technol
ogy owner claims rights to research resulting from
the use of licensed inventions, should generally be
avoided.
The situation is different for sponsored re
search where the researcher is essentially hired to
conduct research for the original technology own
er. In this case, it is appropriate for the researcher
to assign IP rights to the technology owner, since
the default rule would leave the intellectual prop
erty in the researcher’s hands. Where there is an as
signment, the researcher should ensure that other
researchers, graduate students, and postdoctoral
fellows working on the project understand this
and agree to transfer intellectual property to the
original technology owner.
The contract should also set out whether the
researcher or the original technology owner has
the responsibility to file and maintain patents for
the new inventions. Normally, this would fall on
the party who ends up with the patent or who
holds an exclusive license to the invention.
2..2 License back

The research contract would not normally include
a license back from the researcher to the original
technology owner for inventions made during the
course of the research. This is because the risk and

responsibility for new inventions rests with the
researcher, not the original owner. The situation is
slightly different with respect to improvements to
licensed-in inventions. In this situation, the origi
nal technology owner may wish to have access to
those improvements both for his or her own sake
but also for the sake of his or her other licensees.
It may be appropriate for the researcher to license
back improvements on a nonexclusive basis to the
original technology owner, to the extent that this
is necessary for the owner and his or her other
licensees to continue using the (improved) inven
tion. A reasonable royalty may be required. The
scope of the license back should not be so large as
to prevent the researcher from licensing the im
provement to other parties.
2. Alternative structures for
research relationships

Researchers will often require access to many
inventions to accomplish their work. Indeed,
a researcher may be required to purchase many
licenses to carry out a particular research proj
ect. The need for multiple licenses, referred to as
patent stacking, can lead to problems, because
the costs, in terms of both time and money, as
sociated with obtaining those licenses to a large
number of patents simply is prohibitive. In order
to avoid potential problems, license agreements
need to ensure that the total royalty burden faced
by the researcher is reasonable. This can be ac
complished by setting a maximum total royalty
burden that the researcher must pay to all licen
sors. To the extent that the total royalty burden
exceeds that amount, the researcher would pay
the technology owner a pro rata amount of the
total royalty burden. The owner may wish, how
ever, to set minimum royalty rates.
Alternatively, licensors and licensees may
wish to contemplate creating patent pools, pat
ent clearinghouses, or other open-source means
to ensure that researchers at both public and pri
vate institutions have access to basic technology.
License agreements would then be standardized
and ensure access to a variety of inventions at a
reasonable cost.
A patent pool is an arrangement in which
“two or more patent owners agree to license certain
HANDBOOK OF BEST PRACTICES | 

GOlD & BuBElA

of their patents to one another and/or third parties.”7
Patent pools bring together patent holders in a
specific area of innovation, such as a viral genome,
to facilitate the efficient use and development of
a technology. The patents are pooled because the
arrangement allows inventors in the pool to use
all their patented inventions under favorable li
censing terms. The group then shares any benefits
that may materialize from this arrangement. The
motion picture industry, aeronautics firms, and
those developing new DVD technology have all
successfully used patent pools to advance their re
spective technologies.8
There are many challenges to setting up a pat
ent pool. For example, patent pools may trigger
anti-competition laws.9 Second, researchers may
choose not to join in the patent pool because,
even though these pools reduce research transac
tion costs and spread risk, they also decrease the
potential for large profits. Thus, parties need to
strike the right balance between research goals
and profit motives.10
Open source patent systems share the goal
of promoting the free dissemination of research
between inventors and the public, in contrast to
the creation of marketplace monopolies. Open
source systems can be directed at end products
or research tools used to develop products. There
are several functioning examples of open source
patent systems. One such initiative is the Public
Patent Foundation (PPF). It facilitates the cre
ation of free zones in which patents are pooled
and made freely available to other participants.11
The PPF accomplishes this by granting nonex
clusive and royalty-free licenses to participants.
Another example is the Biological Innovation
of Open Society (BIOS). It involves technolo
gies that have already been granted patent rights.
Focusing on research tools rather than on final
products, BIOS (like PPF) has established licens
ing terms to achieve their specific goals.12 One
final example of an open source patent system is
the Tropical Disease Initiative (TDI). With this
system, inventions are not necessarily subject to
patent rights. TDI’s aim is to maintain an ac
cessible Web database to facilitate research and
development and to make research information
readily accessible to researchers.13
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. CoLLABoRATIvE RESEARCH And
SponSoRSHIp AGREEMEnTS
While the research contract normally provides a
one-way flow of technology from the technology
holder to a researcher, more complex arrange
ments exist. This section considers two of them:
the collaborative research agreement and the
sponsorship agreement.
A collaborative research agreement involves
multiple partners, often a mixture of private and
public sector actors, working together on a par
ticular research project. The partners each con
tribute an amount of money, skilled talent, and
technology to a central pot that they then har
ness to conduct research. Usually, the private sec
tor actor either obtains the intellectual property
to the resulting research or, more often, a prior
ity right to license that intellectual property. By
adding additional players and providing a morecomplex ownership scheme for the resulting tech
nology, collaborative research agreements form a
more-complex transaction than the one-way flow
of technology in the research contract.
A basic collaborative research agreement
would include the following
• Article 1: joint obligations to participate in
the collaborative research effort
• Article 2: a high-level description of what
each party brings to the research project
(money, technology, material, skills) with
cross-references to articles 3, 4 and 5. The
details of each party’s contribution may be
attached as an appendix to the agreement.
• Article 3: payment terms and process
stipulations
• Article 4: licenses from the various parties
to use pre-existing technology (including a
mechanism to add additional technology)
• Article 5: a list of materials needed to be
transferred to conduct the research
• Article 6: provision for who holds intellec
tual property emerging from the research
• Article 7: licenses to technology emerging
from the research (including who has the
right to license-out the technology)
• Article 8: allocation of financial returns
from the use or license of emerging tech
nology and payment terms
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• Article 9: addition and removal of collab
orative team members
• Article 10: management structure that will
be used to supervise the research and re
search results
• Article 11: problem escalation and dispute
resolution
• Article 12: confidentiality and publication
rights
• Article 13: legal terms, such as what to do in
case of an “act of God” or other intervention,
timing issues, and notification procedures
• Article 14: definitions
A sponsorship agreement is a research contract
instigated by an actor, usually in the private sec
tor, for the benefit of that actor. In some ways, it
is research for hire. However, when the research
er or research organization being hired is in the
public sector, the agreement normally also creates
knowledge for that organization or the research
community in general. As in the collaborative re
search agreement, the sponsor will normally, in
addition to providing a license to original tech
nology, pay for the research and retain certain IP
rights in the outcome of that research.
The basic structure of a sponsorship agree
ment includes the following:
• Article 1: a description of the research to be
conducted by the researcher
• Article 2: payment terms and process
stipulations
• Article 3: the license to any technology nec
essary to conduct the research
• Article 4: any materials needed to be trans
ferred to conduct the research
• Article 5: ownership of intellectual prop
erty emerging from the research
• Article 6: any license to use technology re
sulting from the technology
• Article 7: problem escalation and dispute
resolution
• Article 8: confidentiality and publication
rights
• Article 9: legal terms, such as what to do in
case of an “act of God” or other interven
tion; payment schedules and other timing
issues; and notification procedures

• Article 10: definitions
Both collaborative research and sponsor
ship relationships are complex and so the nature
of these relationships will be context dependent.
This means that one should avoid the automatic
use of standard-form agreements and ensure that
the contract is context specific. The more com
plex the contract, the greater the need for clarity
and structure.
.1 Confidential information

The discussion that follows presumes the reader
understands the content of the previous discus
sion with respect to research contracts, and thus
only highlights areas of particular importance
and adds provisions not required for the ordinary
research contract. The reader is thus advised to
read carefully the previous section on research
contracts before continuing further.
A research sponsorship or collaborative
research relationship is designed to build new
knowledge and new inventions. While some of
these inventions may be patented, others may
be held as trade secrets. In the latter case, the
agreement should normally establish how to en
sure trade secret protection. In virtually all col
laborative research or sponsorship agreements,
all parties will be obliged to maintain confi
dentiality, in order to protect both what was
brought into the research project and what is to
be produced through the research partnership.
Unlike standard research contracts, it is highly
likely that, with both collaborative research
and sponsorship agreements, information will
likely flow back and forth between a number of
parties, perhaps in different jurisdictions. The
agreement must therefore clearly provide for
information sharing and for a mechanism to
keep track of who has accessed what informa
tion and when. Such provisions will not only
help maintain control over the information,
but make it easier to identify which party is
responsible for any security lapses, should they
occur. It is also important, in cross-jurisdic
tional agreements, to ensure that confidential
information provisions are enforceable in all
relevant jurisdictions.
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The parties should carefully describe what
should be done at the end of the project with
confidential information that is brought into or
created through the project. Thus, the agreement
should specify whether, at the end of the research,
other participants in the research project are en
titled to use the confidential information brought
into the project by another party. Similarly, the
parties must determine who will be entitled to
use information created through the research pro
gram and for what purposes.
In order to ensure that confidential informa
tion can be licensed to others, it is also important
for the agreement to stipulate which of the parties
is entitled to make decisions about the licensing
of the information. In the absence of such a pro
vision, it will be difficult to transfer confidential
information developed through the research pro
gram to eventual licensees of the technology.
.2 License to contributed
patented technologies

Participants in a research project will likely bring
with them not only confidential information, but
patented technology for use in the course of the
research. Given the evolving nature of complex
research projects, the parties are unlikely, at the
beginning of the project, to know exactly which
technology they will each need to contribute. To
handle this problem, the agreement should list
the technology and associated patents that need
to be included in the project. The parties should
establish a mechanism through which additional
technology (and associated patents) can be added,
for example, a committee that formally approves
the addition of new items to the technology and
patent list. By establishing such a mechanism,
the contract provides transparency to the partici
pants and yet includes flexibility to adjust to new
developments.
.2.1

License scope and nature

Unlike a standard research contract, which li
censes technology to one party, in the collabora
tive research agreement and occasionally in the
sponsored research agreement, the license will
need to extend to all research participants at all
institutions. Therefore, the agreement needs to
 | HANDBOOK OF BEST PRACTICES

describe the set of persons who are entitled to use
the technology, as well as set out a mechanism to
add additional researchers and institutions who
may later join the project.
Normally, material or information contrib
uted through a sponsorship or collaborative re
search agreement will be licensed on a nonexclu
sive basis to those carrying out the research. It is
good practice to include these provisions even in
countries where a formal research exception exists,
given both ambiguities in the law and differences
between the legal rules in different countries. The
parties should ensure that the scope of the license
is sufficiently broad as to accommodate changes
in research direction.
Where there are multiple parties to an agree
ment, the contract should provide a mechanism
through which participants can withdraw. This is
particularly important for bankruptcy issues that
otherwise could plague ongoing research. Such a
mechanism can also address any changes in sta
tus of one of the participating institutions (for
example, a subsidiary company merging with its
parent company). These agreements should nor
mally state that the remaining parties are entitled
to continue using material or information and
should also stipulate the process for adding new
parties to the collaboration, subject to national
bankruptcy and competition laws as well as other
contractual obligations.
Once again, one must recognize that a license
by itself does not guarantee that the licensee or
other parties named in the agreement can actually
use the invention.
.2.2 Payment

As licenses granted to researchers actively con
tribute to the research effort, they are usually
provided either free of charge or at a reasonable
rate.
. Rights to intellectual property
created through research

One of the most important goals of the spon
sorship or collaborative research arrangement is
to develop a new technology that can be com
mercialized. Because of this, some of the key
IP provisions in these agreements relate to the
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intellectual property produced through the re
search, rather than to existing inventions.
..1

IP rights associated with
the sponsorship agreement

If a sponsor wishes to alter the default legal pro
vision that the researcher or employer retains IP
rights to research results, the agreement ought to
clearly specify the respective ownership stake of
each of the parties in inventions resulting from
the research. The sponsor and researching organi
zation ought also to specify which of them has the
power to make decisions about the licensing of
these inventions. This need not be the same as the
ownership entitlements, although it frequently is.
The parties should also specify which of them has
the responsibility to file and maintain patents,
with respect to the inventions. In normal cases,
the sponsor holds the IP rights and the obligation
to maintain patents.
..2 IP rights associated with the
collaborative research agreement

The ownership of intellectual property that re
sults from a research collaboration can be dif
ficult to determine. Often the institutions have
different sets of rules governing the ownership
of intellectual property. Some institutions may
leave intellectual property in the hands of their
researchers and students, while others will claim
ownership to the intellectual property. In reality
the issue of ownership is more complicated, since
ownership rules often depend on who funds the
research (that is, the government, a philanthropic
foundation, or the private sector). Furthermore,
on a practical level, it may be difficult to assess
which party has the greater claim to inventions
made during the course of the research.
In the above circumstances, the parties
would be well advised to specifically address the
question of which of them will obtain ownership
of patents and other IP rights. If the parties fail
to address this issue, they risk blocking further
development and use of research results arising
from the collaboration. Ownership may also be
particularly important with respect to avoiding
seizure by others, as in the case of bankruptcy.
The parties ought also to specify which of them

has the responsibility to file and maintain patents
over those inventions.
A related issue is which party or parties will
have the power to make decisions about the fu
ture use of intellectual property, including deci
sions concerning licensing out technology devel
oped during the course of the research program.
What is important here is not actual ownership,
but which party has control over the use and fur
ther licensing of those inventions.
In general, no matter which party or parties
own the technology and associated intellectual
property, all of the parties ought to have the right
to use the developed technology on a nonexclu
sive basis for internal use and the use of their sub
sidiaries. There may, however, be cases where such
an arrangement is not practical or effective (for
example, when the parties do not plan to work
on the technology after the research project and
prefer to license it exclusively to a third party).
The power of a party with the right to grant
licenses to others should not be unconstrained.
For example, the collaboration agreement should
normally provide that licenses over research tools
or platform technology developed through col
laboration should be nonexclusively licensed. If
that is impossible, and the collaboration agree
ment provides that resulting technology can be
licensed exclusively, there should be limits. An
exclusive license should preserve the right of all
collaborating researchers, and preferably all re
searchers anywhere, to continue conducting re
search on the technology and using it in a teach
ing environment. Second, any exclusive license
should ensure that further development and use
of the technology is not blocked. This can be ac
complished through the use of provisions that
enable the collaboration to nullify licenses in
certain well-defined circumstances (for example,
the failure of the future license holder to develop
the technology in the manner described in the
license agreement, to fully exploit all aspects of
development for the technology, or to sublicense
as appropriate). The nullification provision can
take the form of a loss of the license, the conver
sion of the exclusive license into a nonexclusive
license, and the reduction in scope of the exclu
sive license.
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Just as the issues of technology ownership
should be separated from control of the technol
ogy, so should the issue of ownership be separated
from that of revenue allocation. What is critical
is that the agreement clearly states how licens
ing and other revenue is to be divided among the
collaborators.

. ConCLuSIon
The best contractual document is one that, once
signed, is never looked at again. This can be the
case when the parties have so well described their
relationship that it is obvious who is to do what
and who bears the risks. In the unfortunate and
rare situation where a dispute arises, a clearly
drafted contract is essential for assisting both the
business people administering the contract and
the judges that may be called upon to interpret it
to find an appropriate and fair solution.
The basic elements of a bargain between par
ties, whether with regard to a simple research
contract or to more complex sponsored research
or collaborative research agreements, determine
the structure, language, and length of a contrac
tual document. The goal of the contract drafter is
to capture the main components, laying them out
in order of importance to the overall relationship
between the parties. While legal detail cannot be
ignored, it should take second place to clear draft
ing practices. n
e. RichaRd gold, Director, Centre for Intellectual Property
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1W9, Canada. Richard.gold2@mcgill.ca
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The Use of Nonassertion Covenants:
A Tool to Facilitate Humanitarian Licensing,
Manage Liability, and Foster Global Access
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;
Chair, bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A.

ABSTRACT

Nonassertion covenants (nonasserts for short) grant per
mission to third parties to practice a patent they would
otherwise infringe. Legally, nonasserts are patent-in
fringement settlement agreements that are designed and
drafted with the purpose of preemptively resolving future
infringement disputes. Nonasserts can take three forms:
(1) an agreement between two parties, (2) an agreement
among several parties, or (3) a public statement. A nonassert can specify the release of only certain patent rights
or fields of use, or it can be broad and specify release
for entire patent families, including future inventions in
a certain area. Public statements effectively place rights
to patents, or elements thereof, into the public domain.
Nonasserts nevertheless need to specify, precisely, which
rights are granted in order to avoid ambiguity that could
lead to equitable estoppel.
Nonasserts can have wide-ranging implications in
terms of enhancing public sector R&D. One application
could be with patent rights covering research tools that
are critical for accelerating the development of essential
biotechnological applications. Specifically targeted nonasserts can also be effective instruments for industry to
permit the use of patented inventions anywhere in the
world, provided such use is for the express purposes of
addressing specific humanitarian needs in developing
countries. This could have broad-ranging and signifi
cant positive impact, as this approach reduces trans
action costs, encourages innovation to help the poor,
and accomplishes this without any loss of commercial
opportunities.

1. InTRoduCTIon
The concept of a nonassert agreement, or nonasser
tion covenant (NAC),1 has become well known
in 2006 in the context of open-source software.
During that year, several major software com
panies such as Sun Microsystems and Microsoft
Corp. announced that they would not seek to
enforce any of their enforceable patents with re
spect to defined portions of products related to
certain Web-based applications. Similarly, IBM
proclaimed that it would not assert its rights with
respect to 500 of the company’s patents on opensource software implementations. Similarly, the
Massachusetts Institute of Technology (M.I.T.)
and other public entities also use nonasserts in
the biotechnological areas.
The use of nonasserts spans a broad range
of applications. This chapter presents the main
types of nonasserts, provides sample language
from actual nonassert agreements, and discusses
the broader implications of the use of nonasserts
to respond to the overwhelming need for new ap
proaches in humanitarian licensing as public in
stitutions strive to bring about global access.
2. foRMS of nonASSERTS
A nonassert is an implied license. Put differently,
a nonassert is an agreement that certifies that the
party or parties to the implied agreement will not

Krattiger A. 2007. The Use of Nonassertion Covenants: A Tool to Facilitate Humanitarian Licensing, Manage Liability, and
Foster Global Access. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org.
© 2007. A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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assert or defend certain rights that they possess.
Such rights are typically related to patents. A
nonassert can take one of three forms:
• an agreement between two parties
(bilateral)
• an agreement among several parties
(multilateral)
• a public statement (proclamation)
When drafting a nonassert, the owner of the
intellectual property rights who pledges that it
will not enforce its rights should use precise lan
guage to specify which rights exactly will not be
enforced and whether or not any field-of-use re
strictions will apply. If the terms are left vague
or ambiguous, the ambiguity could leave open
the possibility of equitable estoppel at some time
in the future.2 This means that a person or party

could overcome an infringement action and be
come an unintended beneficiary of the nonas
sert, continuing to use the intellectual property
with impunity (perhaps on the grounds that the
nonassert was misleading and that the unintended
beneficiary would be materially prejudiced if the
patentee could assert his or her rights).
Box 1 provides a sample of a public nonassert
statement from the software industry and Box 2
gives a public nonassert statement from biomedi
cal area.

. THE BEnEfITS of nonASSERTS
Nonasserts are an important instrument of indus
try for promoting open standards or for the es
tablishment of industry standards. In the form of
public statements, nonasserts provide a number

Box 1 : Nonassertion covenant from the software industry:
Microsoft Open-specification Promise
Published: September 12, 2006 | Updated: February 15, 2007
Microsoft irrevocably promises not to assert any Microsoft Necessary Claims against you
for making, using, selling, offering for sale, importing or distributing any implementation to
the extent it conforms to a Covered Specification (“Covered Implementation”), subject to the
following. This is a personal promise directly from Microsoft to you, and you acknowledge
as a condition of benefiting from it that no Microsoft rights are received from suppliers,
distributors, or otherwise in connection with this promise. If you file, maintain or voluntarily
participate in a patent infringement lawsuit against a Microsoft implementation of such
Covered Specification, then this personal promise does not apply with respect to any Covered
Implementation of the same Covered Specification made or used by you. To clarify,“Microsoft
Necessary Claims” are those claims of Microsoft-owned or Microsoft-controlled patents that
are necessary to implement only the required portions of the Covered Specification that are
described in detail and not merely referenced in such Specification. “Covered Specifications”
are listed below.
This promise is not an assurance either (i) that any of Microsoft’s issued patent claims covers
a Covered Implementation or are enforceable or (ii) that a Covered Implementation would
not infringe patents or other intellectual property rights of any third party. No other rights
except those expressly stated in this promise shall be deemed granted, waived or received by
implication, exhaustion, estoppel, or otherwise.
“Covered Specifications” […] applies to the identified version of the following specifications.
New versions of previously covered specifications will be separately considered for addition
to the list.
[List of Specific Web services]
Source: Microsoft Corporation.3
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Box 2: Nonassertion Covenant from the Biomedical Area
for Tuschl I siRNA Patent Applications
In order to facilitate widespread distribution of an important class of research reagents,
the Massachusetts Institute of Technology, the Max Planck Gesellschaft zur Förderung der
Wissenschaften e.V., The Whitehead Institute for Biomedical Research, and The University of
Massachusetts (“the Patent Owners”) now announce that they will not assert the patents
listed below against companies that sell or use DNA vectors which induce production of siRNA
endogenously, provided that such vectors are only used for research purposes, and provided
that the RNA that mediates RNA interference is not isolated from the transformed cells. The
Patent Owners intend to enforce the patents listed below against any use not specifically
listed above.
The patents included in this announcement are listed below. Further continuations, divisionals,
issued patents, and reissuances are included as well.
“RNA Sequence-Specific Mediators of RNA Interference”
by David P. Bartel, Phillip A. Sharp, Thomas Tuschl and Phillip D. Zamore
• Australia Serial No. 2001249622, Filed March 30, 2001
• Brazil Serial No. P10107536-5, Filed March 30, 2001
• Canada Serial No. 2404890, Filed March 30, 2001

• European Patent Convention Serial No. 01922870.9, Filed March 30, 2001
• Israel Serial No. 151928, Filed March 30, 2001

• Japan Serial No. 2001-573036, Filed March 30, 2001

• Korea Serial No. 200270123832, Filed March 30, 2001

• New Zealand Serial No. 522045, Filed March 30, 2001

• Patent Convention Treaty Serial No. US01/10188, Filed March 30, 2001
“RNA Sequence Specific Mediators of RNA Interference”

• United States of America Serial No. 09/821,832, Filed March 30, 2001
• United States of America Serial No. 10/255,568, Filed September 26, 2002
Source: M.I.T. 4
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of advantages over traditional open-standards
committees or institutions:
1. Through nonasserts, the standards devel
opment is streamlined and the standards
implementation proceeds faster since free
licenses promote adoption. Importantly,
nonasserts can be issued unilaterally with
out the need for any complex negotiations
with third parties (such as open-standards
committees).
2. Commitments not to enforce certain pat
ent rights can be highly specific or broad,
or both. Under the somewhat stringent
U.S. antitrust laws, broad industry col
laborations may not be permitted in an
environment where multiple competitors
meet in the same place.
3. Also related to antitrust concerns is the lim
itation on specific price or terms whereby
price fixing and market manipulation al
legations may arise. Standard-setting ini
tiatives among competitors always entail
the potential for incurring significant legal
risk.
4. Nonasserts in the form of public statements
carry no enforcement cost. In essence, they
are self-executing. Once proclaimed, no legal
staff time is required to negotiate licenses.
Everyone gets the same deal and the deal is
free.
The result of the acceptance and use of nonasserts in the software industry is that a growing
“patent commons” has emerged supporting opensource software.
In agricultural biotechnology (agri-biotech)
applications and health-related research, nonas
serts are also emerging as an elegant solution to
certain well-defined problems. These solutions
include:
• A tool for the management of liability.
License agreements carry certain liabilities
even if the agreements contain all the nec
essary safeguards and warranties. This is
especially the case with agri-biotech appli
cations where little certainty exists, because
discussions on global liability and redress
regimes are ongoing.5
2 | HANDBOOK OF BEST PRACTICES

• Access to research tools. Nonasserts can
provide access to patented research tools,
for example (as illustrated in box 2 below),
by removing intellectual property barriers
that would otherwise inhibit the research
tool’s use by those who most need but can
least afford it. Specifically, nonasserts can
provide access to critical research tools for
use in designated institutions that con
duct R&D specifically to address needs
in developing countries. But the use of
nonasserts goes further: even drugs or
vaccines could be manufactured in coun
tries where such drugs or vaccines (or pro
cesses) have been granted for the express
purpose of producing them for develop
ing countries.
• Reduction of high-transaction costs as
sociated with negotiating bilateral or
multilateral licensing agreements. The
negotiation of any license agreement is a
time-consuming endeavor. In cases where
the license is for humanitarian purposes in
particular, the licensor generally gains no
material benefits and often places the nego
tiation of such agreements at the bottom of
the priority list. Nonasserts, even bilateral
ones, are relatively easy to negotiate as they
primarily require agreement on two fairly
simple aspects:
− listing of the patents (or other forms of
intellectual property protection)
− specific permitted use, or limitations to
the permitted use, or both
To be clear, nonasserts are not a form of a
patent pool. This distinction is important with
regard to liability management associated with
the commercialization of products, particularly
in the drug, vaccine, and food biotechnology
areas. A patent pool is an explicit granting of
right to other parties. A nonassert, on the other
hand, is a pledge not to sue someone who would
otherwise infringe on a right. As such, a nonas
sert can also be viewed as a preemptive infringe
ment-settlement agreement, granting permission
to practice the patent in spite of the actual legal
infringement thereof.

CHAPTER .

Box 3 provides a sample nonassert that is
based on an actual agreement signed by two U.S.
institutions, a company and a university. In the
case of humanitarian licensing, certain restric
tions may be included such as the limiting of use
to not-for-profit humanitarian purposes for the
exclusive benefit of people in developing coun
tries or even to for-profit entities solely for hu
manitarian purposes in developing countries.

. ConCLuSIonS
From a legal perspective, nonasserts are preemptive
patent-infringement settlement agreements that
are designed and drafted with the purpose of re
solving future infringement disputes. Nonasserts,
therefore, in essence, release certain patent rights
into specified sectors. These sectors are often the
public domain when it comes to software and of
ten bilateral agreements in applications related to
health and food biotechnology. But there are no
reasons really why nonasserts could not become a
more widespread tool in fostering important ad
vances and innovation to address needs in devel
oping countries.
Bilateral nonasserts should find much more
common use as the problems with equitable es
toppel are almost moot. Due to privity (in oth
er words, the degree of relationship between or
among the parties), the closer the relationship,
the less likely will be the potential for misunder
standings that could trigger equitable estoppel.
Hence, an agreement between two parties, or an
agreement among several parties, is a sufficiently
close relationship to permit communications to
resolve any misunderstandings or ambiguities,
much as with a license agreement.
But a patentee’s public declaration of nonenforcement of a patent via a nonassert can have
wide-ranging implications in terms of enhanc
ing public sector R&D. This would be the case
especially with patent rights covering research
tools, and particularly in the United States due
to limitations on research exemptions, which are
critical for accelerating the development of es
sential biotechnological applications in both the

health and agri-business areas. Carefully drafted,
targeted nonasserts permitting the use of these
tools—anywhere in the world—for developing
country–public-sector R&D institutions (and/or
for commercial purposes for the exclusive use to
address humanitarian needs could therefore have
broad-ranging and significant positive impact.
This approach reduces transaction costs, encour
ages innovation to help the poor, and accom
plishes this without much cost, time, or loss of
commercial opportunities. n
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They are also called nonassert agreements (when between two parties) or Covenant Not to Sue.
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“Equitable estoppel [is] an equitable defense to a claim
of patent infringement available when a defendant
has prejudicially relied on the patentee’s misleading
conduct concerning his intentions to enforce a patent.
The Federal Circuit [has] adopted a three-part test
for equitable estoppel, under which the defendant
[being sued in an action for patent infringement]
must show: (1) The patentee, through misleading
conduct, led the alleged infringer to reasonably infer
that the patentee did not intend to enforce its patent
against the alleged infringer. (2) The alleged infringer
relied on that conduct, and (3) Due to its reliance, the
alleged infringer would be materially prejudiced if the
patentee is allowed to proceed with its claim. When an
alleged infringer establishes the defense of equitable
estoppel, the patentee’s claim is entirely barred [that
is, an alleged infringer may continue to practice the
patented technology].” McCarthy JT, RE Schechter
and DJ Franklyn, 2004. McCarthy’s Desk Encyclopedia
of Intellectual Property: Third Edition; The Bureau of
National Affairs, Inc.: Washington, DC.
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www.microsoft.com/interop/osp/default.mspx;
see
also www.oasis-open.org/committees/security/ipr.php
for other samples.
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http://www.web.mit.edu/tlo/www/industry/non
assert_statements.html.
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See also in this Handbook, chapter 17.18 by RY Boadi.
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Box 3: Nonassertion Covenant in the Form of a Bilateral Agreement
Date:
To:
From:
Subject:

21 March 2007
Institute
Company
Nonassertion Letter under U.S. Patent No. X,XXX,XXX

Thank you for your interest in using Patented Technology owned by Company in your endeavors
aimed at improving the health and well-being of people in developing countries of the world.
Company is willing not to assert its rights under Company Patented Technology you requested,
as further described below.
As background, Company’s understanding is that your work aims at the development of _______
_____ for use in __________. Company is willing to not assert Company U.S. Patent No. X,XXX,XXX
nor any of the patents’ foreign counterparts, divisionals or continuations in part, or any other
rights that Company may have now, or hereafter, related to the technology contained in the
patents specified against Institute, or their trustees, directors, officers, employees, affiliates, their
agents, licensees, or successors in interest.
This Nonassertion Letter is limited to the aforementioned Patent and provided that such patented
technology is used solely for the production of ___________.
In consideration for Company’s Nonassertion Letter as described herein, Institute, their affiliates,
agents, licensees and successors of interest, agree to not assert any patent or patent application
against Company, it affiliates, agents, licensees, or successors that would prevent Company, its
affiliates, licensees, agents, licensees, or successors or customers of each, from practicing, for any
purpose(s), under the claims in the Company patents specified above. Upon change of control of
Institute or assignment by Institute to any party or entity, Institute shall concomitantly impose
the obligation to implement this Nonassertion Letter to Company with respect to such acquirer
or affiliate.
COMPANY MAKES NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER,
INCLUDING (1) THE CONDITION OF THE INTELLECTUAL PROPERTY THAT IS THE SUBJECT
OF THE NONASSERT, (2) THE MERCHANTABILITY AND FITNESS OF ANY MATERIAL, RESULT,
OR PRODUCT FOR A PARTICULAR PURPOSE, (3) NONINFRINGEMENT OR MISUSE OF ANY
INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY, OR (4) SAFETY OF EMPLOYEES,
WORKERS OR PURCHASERS OF PRODUCTS MADE USING THE COMPANY PATENTS.
Accordingly, Institute and their affiliates, agents, licensees, successors, and customers shall
have sole discretion, responsibility and full liability for their activities, provided for under this
Nonassertion Letter, including the research, design, manufacture, and potential sale of products
pursuant to this Letter. Institute shall hold Company, and its affiliates, officers, employees, and
consultants harmless from and against any and all claims, suits, obligations, causes of action,
liability, costs and damages, injuries to persons (including those that may result in death) or
property (including, without limitation, loss of use), product liability claims, claims for damage
to the environment or from the use, handling, or storage of materials and any other claim,
whatever the cause may be, based upon, arising out of, or related to the acts or omissions of an
Institute and/or its affiliates and/or any of their employees, officers, employees, and consultants
or other persons acting on behalf of the Institute or under Institute’s control, in connection with
the Institute’s execution, delivery, performance of, or failure to perform, or practice of its rights
granted under this Nonassertion Letter.
Please indicate your acceptance of the terms in this Nonassertion Letter by signing two copies
and returning one fully executed copy of the original to me at your earliest convenience.
Best regards and all the best in this endeavor,
Company Officer
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Inventors and Inventions

CHAPTER 8.1

Introduction to IP Issues In the University Setting:
A Primer for Scientists
MARTHA MUTSCHLER, Professor, Department of Plant Breeding and Genetics, Cornell University, U.S.A.
gREgORy d. gRAFF, Research Economist, PIPRA, and Visiting Research Fellow, Department of Agricultural and Resource

Economics. University of California, Berkeley, U.S.A.

ABSTRACT

Intellectual property (IP) is inherent to many of the
research, teaching, and extension functions of the uni
versity, and IP issues can occur in all phases of the cor
responding programs. A research program may utilize IP
generated and protected by others in its planning and
execution phases. As a research program advances, de
cisions made regarding disclosure of results may affect
whether or not discoveries made by the program can
eventually be protected.
A successful research program will generate discov
eries—and therefore IP—and decisions must be made
regarding whether to protect, and how to deploy, those
discoveries. The decisions must consider the manage
ment of IP as well as the goals and priorities of the re
search program and the university. It is also important to
consider IP in the teaching and extension functions of
the university, including the creation or use of written
materials, software, networked resources, or designs.
IP and IP issues are not the sole or even the primary
focus of a university. However, failure to properly consid
er IP issues can lead to frustrating and costly problems.
Fortunately, realistic and efficient management of IP in
research, teaching, and extension requires only a mini
mal working understanding of the issues and an ability
to access on-campus assistance in dealing with them.
This chapter presents basic information that any sci
entist should know about IP, discusses the importance
of IP management in a scientist’s work, and reviews ad
ditional sources of information regarding IP. We hope,
this chapter will assist the reader in avoiding simple yet
costly errors in IP management.

1. WHy you SHouLd LEARn ABouT Ip
And TECHnoLoGy TRAnSfER
1.1

Faculty and staff

A working understanding of intellectual property
(IP) is needed to realistically evaluate and man
age IP issues and make informed decisions, from
starting and running programs to deciding how
best to handle the resulting inventions. Lack of
basic information regarding IP and technology
transfer issues can result in problems that are
costly in terms of time, opportunity and money.
You must take an active role in decisions regard
ing IP management within your program. This
will have an impact on the directions you provide
to undergraduate and graduate students, post
doctoral fellows, and/or technicians working in
your program.
Ignoring IP management issues will not make
them go away. Failure to manage IP and make in
formed decisions are de facto decisions that may
result in outcomes that are undesirable and irre
versible. Errors made by students and staff in your
program can materially affect IP issues. Regardless
of whether you knew of the errors when they oc
curred, you may still be ultimately responsible.
Acquisition of the basic information re
garding the management of IP by faculty and
staff need not be difficult or time consuming.
You are not expected to become an expert in IP

Mutschler M and GD Graff. 2007. Introduction to IP Issues In the University Setting: A Primer for Scientists. In Intellectual
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. M Mutschler and GD Graff. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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management and technology transfer, just to be
sufficiently aware of the issues so that you can
use the resources available to avoid problems and
maximize your opportunities. This chapter pro
vides many links in the text to important online
resources. Pertinent additional resources are listed
in the endnote.1
1.2 Graduate students, postdoctoral
fellows, and technicians

Obtaining a basic understanding of IP is an im
portant part of your training, whether your fu
ture career lies in government, academia or in
dustry. Basic IP training is important to how you
will proceed in your research. Do not assume that
your advisor or supervisor—or the technology
transfer office (TTO)—can reverse the effects of
IP errors you make. Your status as a student or
postdoctoral fellow, and thus your status of be
ing “in training,” does not alter the regulations
regarding the use of IP protected by others or the
requirements that must be met for any inventions
you generate to be properly handled. In fact, ba
sic IP training is important in the direction of
staff you may be responsible for supervising in
the course of your activities.
1. Difficulties caused by
a lack of IP knowledge

Depending on the nature of the error, misjudg
ments in handling IP issues can result in dif
ficulties protecting your discovery or licensing
your invention. Even if these difficulties are sur
mountable, they can be extremely frustrating,
time consuming, and costly. Errors may even
result in the complete loss of opportunity to
protect your discovery, or in a severe narrowing
of the scope of protection obtained. Reduction
or loss of opportunity to market your discov
ery/invention can result. In fact, you may even
suffer a reduction or loss of opportunity to use
your own discovery or incur liability due to an
inadvertent infringement of IP protected by
others. However, with proper IP protection and
management, you can decide how to handle the
intellectual property you create as you see fit
and make sure that you receive the rewards that
mean the most to you.
 | HANDBOOK OF BEST PRACTICES

1. Applying basic information

As university faculty, staff, and students, you are
not expected to become experts in the manage
ment of IP. However, acquisition of some basic in
formation about management will allow you to:
• make informed decisions day to day, to
avoid errors that are time consuming and
costly
• know when to contact IP/TT personnel
• interact efficiently and successfully with the
university’s technology transfer staff
• achieve your goals
Furthermore, remember that there is most
definitely a lack of sufficiently trained personnel in
the field of university IP management and technol
ogy transfer, and thus considerable employment
opportunities exist if this area appeals to you.
Further information. To find out more about
employment opportunities, see the Association of
University Technology Managers (AUTM) Web
site: www.autm.net/directory/job_list.cfm.

2. unIvERSITy InTELLECTuAL pRopERTy
And TECHnoLoGy TRAnSfER poLICIES
A university will have a policy covering intellec
tual property that will be available to all university
personnel. All personnel are required to operate ac
cording to this policy. The university home page is
a central site for searching for university policy on
many topics. Your university may also have a pol
icy office, a technology transfer office or research
foundation, and a office of university counsel.
2.1 Bayh-Dole and university policy

The policy of any U.S. university must conform
to the obligations imposed by the Bayh-Dole
Act (Public Law 96-517). The Bayh-Dole Act is
intended to promote investment by the private
sector in commercialization of federally funded
research discoveries for the public good. It in
cludes preferences for small businesses and for
manufacturing in the United States. Under BayhDole, a university is required to file patents on
those inventions they elect to own and to encour
age collaboration with industry to promote the
utilization of inventions.
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Rights retained by the government under
Bayh-Dole include a nonexclusive license to
practice the patent and march-in rights. Marchin rights allow the government to “march in” and
take over an invention if commercialization of
an important invention is not being executed
with due diligence by a university or licensee.
The government has not, to date, invoked
march-in rights, but it is possible that someday
march-in rights could be applied. One situation
that could warrant such action might be one in
which a drug or vaccine is needed to control a
pandemic.
Further information. To find out more about
the background of Bayh-Dole as well as its implica
tions for university IP policies in the U.S., see the
Web site of the Council on Government Relations
(COGR), “The Bayh-Dole Act: A Guide to the
Law and Implementing Regulations,” October
1999. To find our more about similar legislation
in developing countries see chapter 6.1.14 by
Gregory D. Graff titled “Echoes of Bayh-Dole:
A Survey of IP and Technology Transfer Policies
in Emerging and Developing Countries” in this
Handbook.
2.2 Ownership of intellectual property

A central part of IP policy at any organization
concerns the ownership of intellectual property.
The approach differs somewhat between corpo
rate and university contexts.
2.2.1

Typical corporate policy

In industry, employment contracts regarding
the issue of IP ownership are binding. A com
pany usually holds total ownership of ideas and
inventions, while an employee’s salary is consid
ered the compensation to an employee/inventor
for his or her “inventing services” rendered to the
firm. Noncompete clauses are often included in
employment agreements and apply when an em
ployee leaves the company.
2.2.2 Typical university policy

In the university, employment contracts or IP
agreements are likewise binding with regard to
the issue of IP ownership. University policy cov
ers all personnel, including faculty, postdoctoral

fellows, technical staff, graduate students, and
visiting scholars. The employee contracts usu
ally assign property rights in all IP to the uni
versity, but the inventor(s) typically are given
a significant share in any revenues that are
earned, typically in the range of 25% to 50%
of royalties. One major exception to the policy
of assigning IP rights to the university involves
copyrighted materials (with some exclusions).
In addition, the IP agreement covers inventions
and creations in the individual’s area of employ
ment. Thus, if a molecular biologist invents a
better lawn mower at home in his or her free
time without use of university resources, that
invention would not be included under the em
ployment agreement.

. THE unIvERSITy TECHnoLoGy
TRAnSfER offICE
.1 A university’s IP, licensing, or technology
transfer office executes its IP policy

The university’s IP or technology transfer office
is your most important source of information
and assistance. The structure and functions of
such an office may differ somewhat from insti
tution to institution. Most often the technol
ogy transfer office will be in or affiliated with
the office of research, although in some cases it
may be an independent foundation owned by
or affiliated with the university. Most university
IP or technology transfer offices will evaluate in
ventions and pursue appropriate protection for
them. Some offices will also market or license
the inventions.
The technology transfer office will indicate
what materials you must provide so that the trans
fer manager can service your needs. Reasonable
expectations regarding this process will make it as
efficient as possible and prevent misunderstand
ings. The technology transfer personnel will not
be experts in your area of endeavor. You must
provide them with detailed information regarding
the creation and characteristics of your invention.
Expect that creating this documentation—and
working with the IP/tech transfer personnel to
create the documents supporting a utility patent
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or other forms of IP protection—may require as
much time and effort as creating a collaborative
grant proposal or a major publication.
Further information. For general informa
tion about university technology transfer offices
see the following:
• G Graff, A Heiman and D Zilberman.
2002. University Research and Offices
of Technology Transfer, California
Management Review, vol. 45, no. 1. are.
berkeley.edu/~ggraff/Graff-Heiman
Zilberman-CMR-2002.pdf
• EM Rogers, J Yin and J Hoffmann. 2000.
Assessing the Effectiveness of Technology
Transfer Offices at U.S. Research
Universities, Journal of the AUTM. www.
autm.net/pubs/journal/00/assessing.html
.2 The mission of the IP or
technology transfer office

The mission of a technology transfer office as the
responsible agent, fiduciary, or trustee for the
university’s intellectual property is to:
• foster creativity and inventiveness at the
university
• support the university’s educational and re
search missions
• enhance and protect the IP interests of the
university and its employees
• manage IP for the benefit of the university’s
research and educational enterprise and its
inventors
The roles of the office—in providing for the
protection and commercial development of in
ventions—are typically to:
• determine what type of protection, if any, is
possible and desirable for an invention
• evaluate commercial potential of an
invention
• obtain the appropriate intellectual property
protection
• locate suitable commercial development
partners or research and developmen col
laborators and market the intellectual prop
erty to them
• negotiate and manage licenses over the in
tellectual property
0 | HANDBOOK OF BEST PRACTICES

. Ip And TECHnoLoGy TRAnSfER
ISSuES THAT MAy AffECT unIvERSITy
SCIEnTISTS on A dAILy BASIS
Important issues and agreements that may af
fect university faculty or staff members include
the documentation of work with appropriate re
cordkeeping methods, the use of materials and
methods originating elsewhere, dealing with col
laborators outside the university, executing legally
binding agreements, and publicly disclosing re
search results.
.1 Documenting work: Notebooks, films,
electronic information, and beyond

Work must be efficiently and fully documented.
Documentation can of course be important for
the preparation of publications, reports, and
grant proposals, and it can be essential for the
preparation of documentation supporting an ap
plication for IP protection and for supporting IP
rights in the rare event that they are challenged.
The types and quality of documentation are im
portant, but there are ways this can be done ef
ficiently, so that proper documentation is not an
undue burden.
Further information. For good examples
of guidelines for keeping notebooks, see the
following:
• Cornell Center for Technology, Enterprise,
and Commercialization, “Lab Notebook
Guidelines.” www.cctec.cornell.edu/cctec/
researchers/protocols/guidelines/index.cfm
• Northwestern University, Technology
Transfer Program, “Maintaining Laboratory
Notebooks.” www.northwestern.edu/ttp/
investigators/lab_notebooks.html
• Florida State University, Office of IP
Development and Commercialization,
“Notebook Guidelines.” www.techtransfer.
fsu.edu/notebookguidelines.html
.2 Using materials or methods
originating elsewhere

The issue of using materials or methods originat
ing elsewhere arises in a number of ways or under
various circumstances including the use of copy
righted material and the use of protected mate
rials or processes. Using protected materials and
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processes in research could end up affecting your
freedom to operate (FTO).
.2.1 Using copyrighted material

There are standard rules governing the use of
copyrighted materials in publications, teaching,
and research. University libraries can provide in
formation regarding the use of copyrighted ma
terials for such purposes as class readings and re
serve lists. A university’s information technology
(IT) or computing policy may cover, specifically,
the use of copyrighted material on course Web
pages. Often the university counsel rather than
the technology transfer office handles copyright
issues on campus, including the acquisition of
copyrights on materials owned by the university.
.2.2 Using protected materials or processes

Protected materials and processes vary widely,
depending upon the field of endeavor. They can
include such things as:
• vectors used in genetically engineering
organisms
• enzymes, reagents, and other supplies used
in a laboratory
• computer programs
The use of protected materials or processes
leads to the question: Do you have full freedom
to operate in your research program, or do unrec
ognized, unresolved FTO issues exist?

4.2.3 Freedom to operate
Freedom to operate indicates that you are “free” to
use all of the materials, methods, and other re
sources needed for your programs and projects
and that this use does not infringe on the prop
erty rights of others. Just as your invention may
be protected because you are using some form
of intellectual property, the inventions of oth
ers may also be protected. Use of such protected
inventions of others, without permission, might
constitute infringement of their rights. The legal
and appropriate use of protected inventions may
require a formal agreement or license with the
inventors.
Published does not mean unprotected! A
publication by the scientist about a discovery or

invention merely indicates that if there is protec
tion, the application for that protection predates
the publication. You must be aware of IP protec
tion of any materials or processes you use in your
programs and projects.
A research exemption might apply to your use
of the materials or methods in your work at the
university, but this cannot be assumed in all cases.
In U.S. patent law there is no formal research ex
emption for university research. However, there
are strong social norms in place such that pat
ent owners have virtually never exercised their
property rights against university researchers for
conducting academic research. There are several
practical limitations that prevent patent lawsuits
from being filed against university researchers:
• In most cases it is a benefit to patent hold
ers to have academics testing, validating,
and refining the technologies they already
own.
• It may be difficult to define what damages
are suffered by the owner of a patent if the
technology is used in an academic research
project.
• Because establishing a clear precedent
against research use of patented technolo
gies by universities could open the door
for widespread litigation against universi
ties—thereby slowing down the pace of
academic research and draining public re
sources—patent owners generally view the
pursuit of such cases as detrimental to their
own long-term interests, or, if more short
sighted, simply conclude that it is highly
unlikely that any judge or court would
want to establish such a precedent by rul
ing in their favor.
Thus, there is something of a de facto research
exemption for university research.
FTO problems resulting from the use of oth
ers’ proprietary materials and methods are more
likely to show up further downstream, such as
when you attempt to patent and commercialize
the results you obtained. Your technology and any
patents you might receive are likely to be domi
nated by their patents. If your invention embod
ies their technology (for example, if you create a
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plasmid that contains their promoter), then they
may be able to stop you from commercializing
your invention altogether.
To prevent or at least to be cognizant of such
risks, consider freedom to operate issues when
you start using any new method or material, not
after your project is completed. After all, a patent
holder is not obligated to give you a license. If in
doubt whether freedom to operate issues apply to
your work, contact your technology transfer of
fice representative.
Examples of FTO issues are, in fact, com
mon in the university setting. Be aware of ma
terials or methods that can be used for research
purposes only. Examples of this can be found in
the fine print in molecular biology supply cata
logs. Likewise, be aware of limitations in an
agreement allowing use of protected materials or
processes. The agreement may limit you to use
for research purposes only, or it may restrict you
to a certain range of use for commercial prod
ucts, affecting your ability to protect and com
mercialize any inventions that may result from
your work.
It is advisable to search the patent literature
just as you would search for recent publications
in your line of research. While this might seem
tedious or redundant, in fact there can be impor
tant fringe benefits. Someone may have already
made the discovery or invention you are pursu
ing. If a patent already exists, you can study it
to determine whether your project can proceed
as planned, should be modified, or if you should
seek a license to the patented invention. In addi
tion, patents can be an excellent source of infor
mation. Since an application must fully disclose
the invention, including the best method for its
practice, a patent document may provide more
detail on how to reproduce a result than a peerreviewed research publication.
Further information. Your technology
transfer office representative or university coun
sel should be approached regarding concerns or
questions on freedom to operate, as ultimately it
is a legal question. Other chapters of relevance in
the Handbook are:
• Intellectual Property Freedom to Operate:
The Law Firm’s Approach and Role, by
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GM Fenton, C Chi-Ham and S Boettiger.
www.ipHandbook.org
• Freedom to Operate: The Preparations, by
SP Kowalski. www.ipHandbook.org
• Freedom to Operate Strategies: Why the
Public Sector Needs to Learn How to
Manage Risk, by A Krattiger. www.ipH
andbook.org
. Dealing with outside collaborators

It can be critical to discuss and document col
laborative agreements in the development of a
project. Consider which part of the work will be
performed by each cooperator, how responsibility
and credit will be shared, and who will be authors
on publications. It is best if such questions are
considered at the onset of a project and are re
assessed as the program continues. Problems are
most likely to occur if this is put off until a dis
covery is made.
..1 Material transfer agreements

A material transfer agreement (MTA) is a legal
agreement used when giving material to others
that limits the rights they have to use the mate
rial and lists their obligations with regard to use
of the material. In short, it details the conditions
of the agreement between the owner of protected
IP and the party wishing to use it. An MTA is
executed if you want to use material or methods
protected by others or if others want to use mate
rials or methods protected by you. An MTA must
be crafted carefully since it will be legally bind
ing. And it must be created and signed before the
transfer of the material in question occurs, not
after the fact.
Consult with your technology transfer repre
sentative regarding any MTA needed for obtain
ing other’s materials or for the release of your ma
terials. However, different offices of the university
may manage MTAs for incoming materials (often
sponsored programs or the research office) and for
outgoing materials (often the technology transfer
office).
Further information. To learn more about
material transfer agreements see the following:
• Cornell Center for Technology, Enterprise,
and Commercialization, “Material Transfer
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Agreements.” www.cctec.cornell.edu/cctec/
researchers/protocols/mta.cfm
• Northwestern University, Technology
Transfer Program, “Material Transfer
Agreements (MTAs).” www.northwestern.
edu/ttp/investigators/material_transfer.
html
• Council on Government Relations
(COGR), “Material Transfer in Academia.”
www.cogr.edu/docs/MTA_Final.pdf
..2 Confidentiality and
confidentiality agreements

A confidentiality agreement is a legally binding
agreement regarding the disclosure and use of
confidential proprietary information. A confi
dentiality agreement should be in place before
either sharing proprietary information with an
other party or seeking proprietary information
from another party.
Consideration of confidentiality agreements
can be different in a university setting than in an
industry setting. A faculty or staff member may
be asked to sign a confidentiality agreement if
he or she is consulting for a company outside of
the university. In this situtation, the individual
signs, and is obligated by the agreement, not the
university. Faculty and staff are not empowered
to obligate the university under a confidentiality
agreement and attempting to do so may make
them personally liable. The offices that are autho
rized to sign these agreements and create a legal
obligation for the university are typically in the
technology transfer office (signatory authority for
licenses, agreements, contacts, and so forth deal
ing with inventions) or an office such as spon
sored programs or the office of research (signa
tory authority for outgoing grant proposals and
agreements accompanying incoming funds from
the funded grants).
For example, the representative of a company
interested in possibly licensing intellectual prop
erty handled by the technology transfer office
would sign a confidentiality agreement before ob
taining detailed information on the technology.
Drafting and obtaining signatures on the confi
dentiality agreement is handled by the technology
transfer office for the inventor. This helps assure

that the agreement is properly drafted, and that
the correct individuals sign the agreement.
. What constitutes public disclosure?

A public disclosure is made when an inventor
reveals previously undisclosed (that is, secret)
information to members outside the circle of
inventors and the personnel they directly super
vise. There is interplay between the need for se
crecy, in order to be able to protect an invention,
and the need to reveal information to operate
a program within a university where disclosure
and transparency are the norm. The presence
of various functions important to the univer
sity—educating students, publishing, efforts to
acquire grant funding, and others—which are
generally not part of a corporate environment,
might have ramifications regarding disclosure.
Among the many different vehicles for disclosure
are lectures, discussions, seminars, group meet
ings, annual reports, grant proposals, and radio
and TV interviews.
Unintended public disclosure can have major
ramifications for protection of intellectual prop
erty. The more valuable the invention, the harder
companies will search for any inadvertant disclo
sure that will invalidate IP protection.
Further information. A good discussion of
disclosure by publications and by posting online
can be found in these online publications:
• GP Malilay, AM Mueting and AS Viksnins.
1996. Prior Art: Silent Time Bombs that
Can Blow Away Your Licensing Deals.
Journal of the AUTM, pp 18–28. www.
autm.net/pubs/journal/96/3-96.html
• SJ Braman. 1996. Are Your Patent Rights
Disappearing over the Internet? Journal
of the AUTM, pp. 29–31. www.autm.
net/pubs/journal/96/4-96.html

. So you (THInk you) HAvE An
InvEnTIon! GREAT! WHAT nExT?
.1

Overview

There are a few things that are important to un
derstand about working with the technology
transfer office. Foremost, it is essential for the
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inventor to be actively involved in all of the phas
es of the protection and marketing of the inven
tion. There are two main reasons for this: first, the
inventor has unique, detailed knowledge that is
critical to the characterization and description of
the invention and the drafting of the patent and
its claims; and second, inventors often have useful
leads, such as company contacts, that will assist
in the marketing of the invention. Collecting the
information and documentation needed to draft
a disclosure and a patent application takes time
and effort on the part of the inventor, something
on the order of the time and effort required to
write a major publication or grant proposal. If
you expect to seek patent protection for your in
vention, you need to make the commitment and
create time for it. This will make the process run
far smoother.
It is helpful to remember that the breadth
of research covered at a university is often far
greater in scope than that at even the largest of
companies. At the same time, university technol
ogy transfer offices have less staffing than analo
gous offices in industry. As a result, a technology
transfer officer at a university may be dealing with
more inventors and a broader scope of inventions
than his or her counterparts in industry. Input
from the inventor will directly assist the technol
ogy transfer staff in bringing projects to successful
completion.
Cooperative, responsive inventors often have
the best experiences, since they enable the tech
nology transfer staff to provide prompt and com
plete service.
The steps in the technology transfer process
follow a typical pattern:
• disclosure: starting the process of protect
ing/marketing an invention
• evaluation: deciding whether the invention
should be protected and, if so, how
• protecting: proceeding with an application
(also called prosecution)
• marketing: finding a licensee
• licensing: making a deal
.2 Invention disclosure

The inventor’s role in disclosure is to provide in
formation, including:
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• a description of the invention
• details about the funding of the research
that led to the discovery
• an explanation of why the invention may
be important or valuable in industry
• reasons why companies might be interested
in the invention
• the identity of the inventor (or inventors)
• a description of how the invention was
made
Remember, a clear, detailed disclosure allows
the technology transfer staff to serve you better
and faster.
The technology transfer officer’s role in dis
closure is to help the inventor fully describe the
invention by considering the material provided
and asking questions to elicit further informa
tion or details. In the process of discussing the
disclosure and deciding upon a protection and
licensing strategy, the technology transfer officer
will conduct an intellectual property audit. This
will reveal whether there is any preexisting IP that
may affect the process.
Further information. Details regarding the
disclosure process, including forms, can often be
found on a university’s technology transfer office
Web site. Some examples include:
• Cornell University, Center for Technology,
Enterprise,
and
Commercialization,
“Invention Disclosure Process.” www.cctec.
cornell.edu/cctec/researchers/disclosures/
index.cfm
• University of California, Office of
Technology Transfer, “Disclosing an
Invention.” www.ucop.edu/ott/faculty/dis
close.html
. Evaluation

The purpose of evaluation by the TTO is to de
termine what the technology does and what its
commercial potential may be. For example:
• Is it a research tool, software, compound,
new method, diagnostic, or therapeutic?
• Does it fill an unmet need, or fill a need
better than current methods?
• What is the size of the potential market or
markets?
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• Would it have competition from other
technologies in those markets?
• What companies are in those markets?
• Who is investing in those markets? Why
would investors be interested in the
technology?
Answering these questions will enable the
TTO to estimate the commercial value of the
technology.
. Deciding whether and how to protect

After disclosure and evaluation of an invention,
decisions must be made as to whether to protect
the invention and, if so, how. These decisions are
made jointly by the inventor(s) and the technol
ogy transfer office, based upon all of the technical
and legal information available and based upon
economic considerations.
Some disciplines routinely employ a par
ticular form of protection for the technology
generated in that discipline. Examples include
copyrights on writings; patents on vaccines,
medicines, chemicals, engineered processes and
materials; design patents on figures, graphics, or
artwork; and plant patents or plant variety certifi
cates (PVCs) on new varieties of plants.
In some areas, protection has long been possi
ble but not routinely employed by universities. For
example, plant patents have been available since
1930; however, prior to 1982 the apple breeding
programs at the Geneva Agricultural Experiment
Station in New York developed and released apple
varieties without protecting them. These unpro
tected cultivars include a number of widely grown
varieties, such as Empire (1968), Jonagold (1972),
and Liberty (1978). However, cultivars released
after 1982 were protected using plant patents and
are generating returns to the inventors and their
research units. These protected cultivars include
Freedom (1983), Empress (1988), Royal Empire
(1990) and Fortune (1995).
In some areas, the possibility of protecting
IP is a more recent development. For example,
before changes were made in the interpretation
of U.S. patent law beginning in the 1980s, it was
not possible to protect inventions involving mod
ified life forms with utility patents.

It is important to realize that the laws, inter
pretations of laws, and strategies used in protect
ing intellectual property develop and change over
time. It is the responsibility of the technology
transfer office to keep abreast of these develop
ments and to advise and assist university inven
tors as needed.
. Marketing and licensing

An invention will not generate financial returns
for a program unless it is successfully marketed
and licensed. Depending on the nature of an in
vention, the personnel of the technology transfer
office may or may not have a comprehensive list
of potential licensees for the technology. The in
ventors may play a critical role in providing such
information.
Depending on the invention, and the com
panies interested in the invention, the license
granted may be exclusive (made to only one com
pany, with that company holding all rights to sublicense) or nonexclusive (made to more than one
company). In some cases, a license to a company
transfers rights to the invention for just a limited
subset of its potential uses, rather than for any
and all possible uses. The decision as to the na
ture of the license granted (that is, the uses it will
cover) is made by the technology transfer office in
consultation with the inventor, and is thoroughly
negotiated with the licensee.
There are other options as well. In some cas
es, the university, through the technology transfer
office, encourages use of the invention in the de
velopment of a new start-up venture.
Patents require periodic servicing, such as pe
riodic payment of fees to the U.S. Patent Office
(PTO), which is managed by the technology
transfer office. The technology transfer office also
manages the license: receiving and distributing
payments, billing the licensee, and monitoring
whether the terms of the license are being re
spected by the licensee.
If an invention is valuable, it is not unusual
to find companies infringing the property rights
over it by using the invention without a license.
If this is determined to be occurring, the tech
nology transfer office will take the lead in rectify
ing the matter, seeking assistance as needed from
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the inventor. This involves a series of steps, from
contacting the infringing company and request
ing that it either cease infringement or obtain a
proper license, to filing a law suit. The more valu
able the invention, the more likely it is that some
company will test the resolve of the university to
assert its IP rights. Such situations occur regu
larly, but they are manageable, given the proper
expertise on the part of the technology transfer
office and other legal counsel representing the
university.
Marketing and licensing is obviously a large
and complicated endeavor. The best information
regarding this process can be obtained from rep
resentatives in the technology transfer office.

. TypES of InTELLECTuAL
pRopERTy pRoTECTIon
.1 Overview

Types of IP protection tend to be specific to par
ticular kinds of creations or technologies, but
they are not always mutually exclusive. There are
instances when an invention may be protected by
more than one type of IP.
The types of protection vary in many features
including:
• requirements to acquire the protection
• cost
• type of technology covered
• type of protection afforded
• length of time provided
A full study on any one type of IP protection
would be a book in itself. What follows is a brief
introduction to each of the types of IP protec
tion that might be of possible use to a university
researcher.
.2 Patents: utility patents, design patents, and
plant patents

A utility patent is what most people think of when
they hear the word patent. A utility patent is a
grant of a property right by the U.S. government
to the inventor for a term of 20 years.
The applicant is required in the patent ap
plication to fully disclose the invention, and,
 | HANDBOOK OF BEST PRACTICES

in so doing, to fully describe the best means of
practicing the invention so that an expert in the
relevant field of technology (one skilled in the art,
in patent terminology) can actually make and use
the invention relying only upon the information
presented in the application.
Subjects of patents can be any of the
following:
• mechanical devices: a machine or device
• processes: methods of doing or creating
something, for example, a diagnostic or
therapeutic method
• articles of manufacture: the paper clip is the
classic example
• compositions of matter: a new formulation
of plastic, a new alloy, a new medicinal
compound
• improvements in any of the above
Certain characteristics are required for an in
vention to be patentable. The invention must, of
course, be of proper subject matter. It also must
be novel. The invention must be something that
would not be obvious to an expert in the field.
And the invention must have some useful appli
cation industrially or commercially (that is, the
invention is not trivial).
There are two types of patent applications: a
regular application and a provisional application.
(A provisional application merely starts the ball
rolling and gives the inventor one year to file a
regular application.)
Once granted, a U.S. patent gives the owner
of the patent the right to exclude others from
making, using, offering for sale, or selling the
invention in the United States or importing it
to the United States for the term of the patent.
It is important to remember that patents are
country specific. For instance, a patent granted
by Canada gives the owner of that Canadian pat
ent similar rights within Canada. It is up to the
inventor and their technology transfer office to
decide in which countries to apply for foreign
patents (which foreign filings to make). In those
countries where rights are not sought or granted
over a technology, it is, in effect, left to the public
domain (unless some other means of protection
is utilized.)
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The inventor or inventors must be listed on
the patent application. The question of inventor
ship—Who is the inventor?—is sometimes a point
of contention, so consider this carefully. The
rules used under U.S. patent law to determine
who is an inventor for purposes of patent protec
tion are very different from the means generally
used to determine who should be an author on
a publication. Inventorship depends specifically
on the claims of patent. A person who gives piv
otal advice, even just once, in the course of a re
search project could be an inventor. A technician
doing much of the work under supervision, but
not making decisions, would probably not be an
inventor. However, if the technician made unex
pected observations or suggestions critical to the
development of the invention, he or she might
well be an inventor. Advice from the university
IP/technology transfer office may be useful in
cases in which inventorship is unclear.
Further information. To learn more
about inventorship, see SH Lieberstein. 1998.
Relevant Concepts in Determining Difficult
Disputes Over Ownership. Journal of the AUTM.
www.autm.net/pubs/journal/98/lieberstein.html.
.2.1 Utility patents

A utility patent is costly in terms of time and ef
fort. The time and effort you spend on filing and
prosecuting a utility patent could be equivalent to
the time and effort you would spend on produc
ing a major publication or a large collaborative
grant proposal.
A utility patent is also costly in terms of mon
ey. The cost of a U.S. patent application typically
ranges from about US$15,000 to US$30,000, al
though it can cost more. Costs of foreign patent
applications depend on the country but typically
are within a similar range in Germany, England,
France, Australia, and Japan. After a patent is is
sued, there are patent maintenance costs to cover.
At times, there are additional costs for defending
the application or the patent. The more valuable a
property is, the more likely it is to be challenged,
either as an interference (issuance of a conflicting
patent claiming some of the same technology) or
as an infringement (actions of a company using
the technology without permission).

At most universities, patent costs are ini
tially borne by the office of technology transfer,
but they are the first thing to be reimbursed once
revenues begin to come in when an invention
is licensed. It is crucial to consider whether a
license on the invention is even likely to return
more than the costs of applying for, maintaining,
and defending the patent; otherwise, perhaps a
less costly form of protection should be used. A
good rule of thumb is that if the technology is not
worth defending, one should not be applying for
a patent. Consultation with a technology transfer
representative can help to determine if a utility
patent is the appropriate means of protecting the
invention.
Further information. For useful information,
in increasing order of detail and complexity, on
the requirements and protection afforded by util
ity patents, see the following:
• L von Bargen Mueller. 1995 (with revi
sions by JT Sorensen, 2002). An Inventor’s
Guide to Patents and Patenting, AUTM
Educational Series No. 1
• American Bar Association, “Inventor’s
Committee: Short Description of the
Patent Process.” www.abanet.org/intel
prop/comm106/106patent.html
• U.S. Patent and Trademark Office,
“Frequently Asked Questions about
Patents.” www.uspto.gov/web/offices/pac/
doc/general/faq.htm
• U.S. Patent and Trademark Office, “A Guide
to Filing a Utility Patent Application.”
www.uspto.gov/web/offices/pac/utility/
utility.htm
• American Bar Association, “Comprehensive
Information on Patents.” www.abanet.org/
intelprop/comm106/106general.html
.2.2 Design patents

A design is a visual ornamental feature, such as
a logo, embodied in, or applied to, some article
of manufacture (for example, a mug, sweatshirt,
or poster), the shape of a bottle or the shape of
headlights of a car. Design patents protect new,
original, and ornamental designs for an article
of manufacture. The design patent protects the
appearance of design on the item, and not the
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structural or utilitarian features of the item—that
is, the design of the logo, not the cloth of the
sweatshirt or the ceramic of the mug. The term of
protection in the United States is 14 years from
the date the grant is awarded.
A design patent application must include:
• a preamble stating the name of the appli
cant, the title of the design, and a brief de
scription of the nature and intended use of
the design
• drawings or photographs of the design
claimed (Since this is the critical part of the
design patent, the PTO site listed below
has considerable detail about this portion
of the application.)
• a written description of the elements
of the design, shown in the drawing or
photograph
• a written description of the features of the
design
• the single claim for the design
• an executed oath or declaration by the
applicant
Further information. To learn more about
design patents, see the Web site of the United
States Patent and Trademark Office, “Frequently
Asked Questions (FAQ) about Design Patents.”
www.uspto.gov/web/offices/pac/design/desfaq.
html.
.2. Plant patents

A plant patent protects a distinctive new variety
of an asexually reproduced plant. Asexual repro
duction is the creation of identical genetic copies
of a plant without using genetically reproducing
seeds. Asexual reproduction includes the use of:
• root cuttings
• apomictic seeds
• bulbs
• slips
• rhizomes
• runners
• corms
...and methods such as:
• grafting and budding
• division
• layering
 | HANDBOOK OF BEST PRACTICES

• tissue culture
• nuclear embryos
Most plants covered by plant patents are
horticultural crops, such as apples, raspberries,
and almonds, or ornamentals, such as rhododen
drons, roses, and tulips. For historical reasons,
tuber crops, such as potatoes and Jerusalem arti
chokes, were specifically excluded from consider
ation. For the purpose of plant patents, algae and
macro fungi are allowed; bacteria are not.
A plant patent application must meet the
same requirements of utility patents. The plant
to be protected must have been developed or dis
covered by the applicant. It must fulfill the re
quirements for novelty and nonobviousness. The
plant cannot have been sold or released in the
U.S. more than one year prior to the date of the
application.
A plant patent must include a complete de
scription of the botanical features of the plant
and the characteristics that distinguish that plant
from known, related plants. A drawing or photo
graph of the plant showing its most distinguish
ing characteristics and text describing what is be
ing shown in the drawing or photograph help to
document the plant’s novelty.
Once granted, the plant that is protected
includes mutants, hybrids, and genetically trans
formed plants. The grant lasts for 20 years from
the date the application is filed. During this pe
riod, the plant patent protects the inventor’s right
to exclude others from asexually reproducing,
selling, or using the plant so reproduced. As with
utility patents, when the plant patent expires, the
subject matter of the patent (that is, the plant va
riety) enters the public domain.
Further information. To learn more about
plant patents, see the Web site of the United
States Patent and Trademark Office, “General
Information about Plant Patents.” www.uspto.
gov/web/offices/pac/plant/.
. Plant variety protection

Plant variety protection (PVP) is a means for
protecting sexually reproduced plant varieties.
Plant variety protection is a form of IP admin
istered and granted by the U.S. Department
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of Agriculture (USDA), rather than the U.S.
Patent Office. This is basically the U.S. version
of plant breeders rights, as agreed upon interna
tionally under the convention known as UPOV
(International Union for the Protection of New
Varieties of Plants). A PVP grants 20 years of pro
tection (for new varieties of plants) from date of
issue (and 25 years for trees and vines). A PVP
cannot be granted for uncultivated plants or ma
terials found in nature.
PVP regulations require that the plant culti
var to be protected must be:
• novel or new: cannot have been sold in the
United States for more than one year
• distinct: is clearly different from other com
mon varieties of the crop
• uniform: has no more variability than other
varieties of the crop
• stable: remains unchanged when repro
duced, particularly with regard to the dis
tinctive characteristics of the variety
In the application for the PVP, the applicant
provides the genealogy of the variety and describes
the variety and its novelty. A public deposit of
seed of the variety is also required.
Protection provided by the PVP applies to
the single variety claimed. The PVP prevents oth
ers from selling, sexually or asexually reproduc
ing, or distributing without a license from the
holder of the PVP. Since the mid-1990s, a PVP
also prevents others from producing a hybrid va
riety using the claimed variety as a parent.
Exclusions to the protection include use of
the cultivar in breeding, by farmers saving seed
for their own use, and for the sale of limited
amounts of seed.
Further information. To learn more about
plant variety protection, see the Web site of the
USDA Plant Variety Protection Office. www.
ams.usda.gov/science/PVPO/pvpindex.htm.
. Copyright

Copyright provides legal protection of an original
work set down in a fixed form or medium of ex
pression. The term of protection for works owned
by corporate entities is the lesser of 95 years from
publication date or 120 years from the creation

of the copyrighted work. The term of protection
for works owned by individuals is the life of the
author plus 70 years.
Items that can be copyright protected
include:
• literary works
• musical works, including accompanying
words
• dramatic works, including any accompany
ing music
• pantomimes and choreographic works
• pictorial, graphic, and sculptural works
• motion pictures and other audiovisual
works
• sound recordings
• architectural works
Examples of things that cannot be copyright
protected include:
• ideas or concepts
• lists showing no originality
• titles, names, short phrases, and slogans
• type styles
• factual information
• public domain information
• works not fixed in tangible form
A copyright gives to the holder the right to
reproduce one or more copies of the protected
work. Notwithstanding copyright protection,
other parties, such as archivists, educators, and
members of the media may reproduce protected
works for certain types of use known as fair use.
The copyright also gives certain limited rights to
distribute or disseminate copies, prepare deriva
tive works (including translations), and perform
or display publicly (with exceptions for instruc
tional use, broadcasting, and religious services).
Excluded from the fair use are digital movies, dig
ital games, and similar products since the entry
into force of The Digital Millennium Copyright
Act in late 1998.
At most universities copyright issues are
handled by the university counsel, rather than
the technology transfer office, with possible ex
ceptions for some technologies, such as software,
involving both copyright and utility patents for
protection.
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Further information. To learn more about
obtaining copyrights or using copyrighted mate
rial, see the following Web sites:
• Cornell University, “The Copyright
Information Center.” www.copyright.cor
nell.edu
• Stanford University Libraries, “Copyright
and Fair Use.” fairuse.stanford.edu
• Indiana University and Purdue University
Indianapolis, “Copyright Management
Center.” www.copyright.iupui.edu
• Library of Congress, United States
Copyright Office. www.copyright.gov
. Trademark

A trademark is essentially a brand name, which is
used to identify or distinguish in the marketplace
one company’s goods from another’s. A trademark
includes any word, name, symbol, or device, or
any combination of these. Many of the products
we buy sport trademarks, from Sunkist oranges
and Coke, to Levi Strauss jeans, Dell computers,
and Intel microprocessors.
There are other types of “marks” as well. The
service mark is similar to the trademark, but the
service mark identifies a service or the source of a
service, rather than goods or the source of goods
(for example, a cleaning service, rather than mops
and brooms). A certification mark identifies a “re
gional or other geographic origin, material, mode
of manufacture, quality, accuracy, or other charac
teristics of goods and services.” A collective mark
is a type of trademark or service mark used by
the members of a collective group and indicates
membership in the organization.
Trademarks, and the other types of marks, are
handled by the U.S. Patent Office. Application
involves filing a form, along with a drawing of
the mark to be protected and specimens of the
mark. (The specimen will be a prototype of the
design, such as a label or tag, which incorporates
the mark.) Before one files an application, it is
advisable to run a search to check that the mark
is not already registered. With proper mainte
nance (use, renewal, and so on) a trademark can
be perpetual.
At most universities, the university counsel
handles trademark and service mark applications.
0 | HANDBOOK OF BEST PRACTICES

Properties that many universities protect by copy
right, design patent, and perhaps trademark, are
the university’s name, logo, and other symbols,
such as a mascot. Some universities—particular
ly those with well-known sports programs—earn
considerable funds through the licensing of their
protected names and logos for merchandise.
A department wanting to use the university
logo, for example, on a T-shirt being designed
for an upcoming symposium, must first obtain
permission from the office that is responsible for
trademarks and such.
Further information. To learn more about
trademarks, see the Web site of the U.S. Patent and
Trademark Office, “Basic Facts about Trademarks.”
www.uspto.gov/web/offices/tac/doc/basic/.
. Trade Secrets

A trade secret is secret or confidential informa
tion that gives the company that possesses the
information an advantage over companies that
do not possess it. Trade secrets can protect any
information that provides a competitive ad
vantage. Examples include a process, method,
composition, or recipe. The recipe for CocaCola syrup, and many other food and beverage
products are protected as trade secrets. A trade
secret has a far longer term of protection than a
patent. A trade secret is in force as long as the
secret information is kept secret and not made
publicly available.
A trade secret protects information, quite
simply, by keeping it secret. Trade secrecy laws
make it illegal for someone to obtain the secret
by misappropriation (for example, breaking into
the vault in which the secret is kept). Of course,
a product must be able to be used or marketed
without revealing the secret to be protected as a
trade secret (for example, the product must not
be able to be reverse engineered). If someone in
nocently, independently discovers the same in
formation, they can use it without infringement.
Indeed, the second discoverer could in fact apply
for a utility patent, in some instances.
By university policy, no secret research is
conducted at the university, but an invention that
results from research could, in some instances,
be protected by trade secret at least temporarily,
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pending an application for another form of
IP protection.
. Bailment Law

Some inventions can be marketed without the
formal protection of a patent or other form of IP
protection though the use of bailment law. Under
this approach, control over use and dissemination
of the invention is obtained by careful use of ma
terial transfer agreements and licenses. Where ap
plicable, this method reduces paperwork and the
costs of preparation and application for patents
or other forms of protection. The method would
require careful coordination with the technology
transfer representative.
Further information. To learn more about
bailment law, see PM Simpson, Jr. 1998. Use
of Bailment in Transferring Technology from a
University. Journal of the AUTM. www.autm.net/
pubs/journal/98/simpson.html.

. SuMMARy
Managing the IP issues that arise in the course
of university research and teaching functions
is important. Though sometimes the issues are
complex, the management of these issues can be
handled efficiently, reducing time commitment.
The goal of this chapter is to provide basic infor
mation to enable university scientists/inventors
to manage intellectual property and technol
ogy transfer issues. The university scientist need
not be an IP expert. The ability to protect some
forms of IP is fairly recent, having undergone or
even still undergoing rapid changes in interpre
tation and strategy. Being knowledgeable and
capable in these areas is the task of those uni
versity personnel in the technology transfer of
fice and the outside legal experts who work with
the university on IP and technology transfer.
Researchers/inventors should consider how they
want to handle IP issues during day-to-day work
and know whom they should contact when they
have new IP or technology transfer issues. They
should not hesitate to use these resources when
ever needed. n
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How to Start–and Keep–a Laboratory Notebook:
Policy and Practical Guidelines
JENNIFER A. THOMSON, Professor, Department of Molecular and Cell Biology, University of Cape Town, South Africa

ABSTRACT

A laboratory notebook is an important tool that goes well
beyond research management and can have important
implications for issues ranging from intellectual property
management to the prevention of fraud. This chapter dis
cusses the key elements of a laboratory notebook, types
of notebooks, what should be included in the notebook,
ownership issues, archiving, and security. The chapter
provides sample notebook pages that illustrate some of
the recommended practices.

1. WHAT IS A lABORATORy NOTEBOOK?
Although you may think you will remember what
you did and why you did a certain experiment in
a week’s time, YOU WILL NOT! And nor will
anyone else in your laboratory. Hence the need
for laboratory notebooks. In short, a laboratory
notebooks is:
• a daily record of every experiment you do,
think of doing, or plan to do
• a daily record of your thoughts about each
experiment and the results thereof
• the basis of every paper and thesis you
write
• the record used by patent offices and, in the
case of disputes, courts of law (in the event
you file patents on your findings)
• a record that would enable successive scien
tists, working on the same project, to pick up
where you left off or reproduce your results

2. TyPES OF lABORATORy NOTEBOOKS
The following items explain a few important
things to know about lab notebooks and how
they may be used:
• Hardbound books with numbered pages
show that no pages have been deleted or
added.
• In companies or institutions aimed
mainly at producing patentable prod
ucts, carbon copies of each page are of
ten required. In addition, each page may
have to be signed and dated both by the
scientist and by an independent witness
within two weeks of work being done.
This scientist should be someone who is
likely to be traceable in some years time,
if needed, to confirm reading and coun
ter signing. The witness should not be
likely to be named as a co-inventor in a
patent application. The counter-signato
ry should sign and date each page of the
notebook to confirm that she or he has
read and understood the entry and is sat
isfied that the entry has been accurately
and correctly written.
• It is advisable to keep different note
books for different projects or different
aspects of the same project. Notebooks
should be clearly identified on the out
side cover.

Thomson JA. 2007. How to Start—and Keep—a Laboratory Notebook: Policy and Practical Guidelines. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. JA Thomson. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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3. WHAT GOES INTO A
lABORATORy NOTEBOOK?
On the front cover of the notebook should be a
description of what is contained in it (for exam
ple, cloning of the X gene and characterization
of its product). The first and last dates of entry
should also be written on the front cover.
The following items explain a few important
things that need to be recorded inside the lab
notebook. Remember, everything must be writ
ten in ink or other permanent medium.
• a detailed account of every planned and ex
ecuted experiment with the amount of de
tail that would enable a scientist “skilled in
the art” to determine what had been done,
why it had been done, and what the results
were
• dates accompanying every entry, account,
or record
• protocols, reagents, lot numbers in each
entry, and where appropriate, sketches, de
scriptions, and so on
• explanations of the significance of each
experiment, as well as the observations, re
sults and conclusions of the experiment
• details of each experiment (Remember,
what may seem trivial or obvious at the
time your experiment was conducted, may
later be of critical importance.)
• personal comments (It is a living docu
ment, so stamp it with your own person
ality. Comments such as “SUCCESS AT
LAST!! THIRD TIME LUCKY :)” are
highly appropriate. However, do not make
sweeping statements, such as, “This proce
dure is worthless” or “We infringe X’s patent
with this procedure.” Statements like this
could affect the future patentability of your
research.
• photographs, computer generated data,
and so forth should all be stuck into your
notebook in such a way that they will not
come loose (see Figure 1). If the format of
these data is too large for your laboratory
notebook, sign and date such data and file
them in a loose-leaf ring file that can clearly
be identified. Record the location of these
documents in your notebook.
 | HANDBOOK OF BEST PRACTICES

• cross-references (If you have already de
scribed an experiment earlier, or if you have
used a standard protocol and have not devi
ated from the previous descriptions of the
experiment for your current one, you may
reference the earlier information instead of
writing it out again. For example, if you are
starting a new experiment on page 48 and
are using the same protocol as already de
scribed on page 22, write on page 48, “fol
lowing the protocol as described on page 22 of
this laboratory notebook.”)
• using preprinted forms can save time, if
your experiments involve common, stan
dard procedures (see Figure 2)
• information with regard to any data that
has been electronically captured (These data
should be accessible to any scientist “skilled
in the art.” Such electronic data should be
backed-up and archived weekly.)
Corrections must be made by drawing a sin
gle line through the entry (see Figure 3). If you
leave more than four lines at the bottom of a page,
cross through the area to indicate that those lines
were unused (see Figure 4). Never use Whiteout.
Remember, laboratory notebooks and their
contents are confidential and of great value.
Store them in safe places and report any loss or
theft to your supervisor immediately. When you
leave your laboratory for any length of time, in
form your supervisor of the whereabouts of your
laboratory notebooks. When you leave the insti
tution permanently, ensure that your notebooks
are handed over to your supervisor.

4. WHO OWNS THE NOTEBOOK?
The person or organization who is paying the bills
owns your laboratory notebook. In most cases
this will be the company, university, or research
institute who employs you or your supervisor.
In the case of universities, you will probably
find that employees enter into a contract that
stipulates that all inventions developed while
employed are the property of the university.
Universities, and some companies, have agree
ments that income generated from discoveries

Figure 1: Example of a Gel Photograph
Pasted into a laboratory Notebook

Figure 2: using a Preprinted Form
for Standard Reactions Saves Time
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Figure 3: If you Make Mistakes,
Correct Very Clearly

Figure 4: Draw a line to
Fill Empty Space
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made by employees and/or students, will be divid
ed between the institution and the discoverers.

5. HOW DO yOu KEEP COPIES OF
lABORATORy NOTEBOOKS?
Some laboratory notebooks come equipped with
carbon copies. These types are the best and safest.
If your notebook is not of this type, you should
make photocopies of the complete notebook. But
why do you need copies?
• Once you have completed a laboratory
notebook, your supervisor will probably
want to keep the original. You will there
fore need copies to help you in completing
your research. You will often need to check
back on what you did a few months ago.
• You might leave your institution before
you have time to write up your research for
publication or patenting. You will need a
copy of your notebook to enable you to do
this. Your supervisor will also need a copy
to ensure correctness of data and interpre
tation. (The latter is just one reason why
it is so important for you to comment on
your data in your lab notebook, making
suggestions, interpretations, and so forth.)
• Another scientist might have to take up
where you left off. Although your supervi
sor will have your lab notebook, your suc
cessor will also need to have a copy to help
her or him continue your work. It will be
essential that your results can be repeated.
6. HOW DO yOu ARCHIVE yOuR
lABORATORy NOTEBOOK?
Archiving means keeping your notebooks in a
system that allows easy access. Your supervisor or
institute will probably have an archival system in
operation for this purpose. Here are some recom
mendations for archiving:
• The best option is a lockable bookcase, or
cupboard, or a locking file cabinet.

• Label your notebook along the spine with
your name, the project, and the start and
end dates for the notebook.
• Make sure your supervisor knows where
your notebooks are stored!

7. HOW DO yOu PROTECT yOuR
lAB NOTEBOOK?
It is essential to protect the security of your re
cords. Here are some important practices to
follow:
• When you leave the lab each day always
leave your lab notebook where your su
pervisor can find it, preferably in the same
place. It is not necessary to lock it away
every night, although it is a good habit to
form.
• Lock your lab when you are the last person
to leave. If you are not sure whether anyone
else will return to the lab, play safe and lock
it. People will soon learn to keep their keys
with them!
• If your supervisor allows you to keep past
notebooks, make sure she or he knows
where they are.
8. CONCluSIONS
A laboratory notebook is an important tool that
goes well beyond research management, and
keeping good records has implications for issues
ranging from intellectual property management
to the prevention of fraud. Institutions should
have a comprehensive policy that should be rig
orously implemented (see Box 1 for guidelines for
a notebook policy). n
JENNIFER A. THOMSON, Professor, Department of Molecular
and Cell Biology, University of Cape Town, Private Bag,
Rondebosch 7701, South Africa. jennifer.thomson@uct.ac.za
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Box 1: laboratory Notebook Policy
The following policy is a document originally prepared by SWIFFT at Cornell University in
the context of its collaboration with the centers of the Consultative Group on International
Agricultural Research (CGIAR). The policy itself is based on actual policies that are in effect in
several leading research centers and companies, but has been adapted to reflect the specific
needs of public sector research institutions.
Background
Many public organizations are entering a new era and are considering protecting their own
inventions and engaging in research with other organizations, both public and private. These
new relationships, often based on collaborative research agreements, may require precise
documentation of certain activities and results. Laboratory and research practices will frequently
need to be carefully formalized and noted in ways that will allow future IP auditors to review
the authenticity of results and certify the dates of occurrences. Such practices are important for
potentially patenting possible discoveries made by these institutions or by their collaborators,
especially when seeking patent protection in the United States.
Recording procedures are generally spelled out with respect to standard laboratory notebook
practices. These procedures inform all staff about the process for daily establishing and
maintaining of laboratory records that could become primary evidence for the resolution of
disputes or litigation. In court, dates of invention, description of an invention, and research
techniques can be established through carefully kept laboratory notebooks.
In order to achieve the goal of maintaining court-ready documentation, a bound laboratory
notebook, in whatever format, must be:
• an honest representation of the research work done by the researcher
• regularly written (daily recording is normally recommended)
• routinely witnessed (at least weekly) by another scientist
• duplicated when completed, if the researcher would like a working copy
• archived in a secure place and/or by a secure method.
The policies and procedures outlined below can be modified to suit almost any organization’s
needs and existing IP policies and to harmonize the lab notebook policy with other institutional
tools. It is essential, however, that any laboratory notebook policy be consistent with other
laboratory procedures, that all research staff be well trained in the execution of the policy, and
that the adopted policies be systematically enforced.
laboratory Notebook Policy
The purpose of this policy is to ensure that the institution is sufficiently protecting its inventions,
research, and products, so that discussions or allegations during disputes or litigation are based
on documented fact. This includes such things as the date of an invention or a description of
the invention or research, the dates or research techniques that were used, and the like. In order
to do this, the laboratory notebook, in whatever format, must be an honest representation of
the research work done by the institution, and must be acceptable to a court, the U.S. Patent
and Trademark Office, and other offices whose charge is regulating statutory protection of IP.
Therefore, certain standards apply to each type of notebook.
Guidelines
1. General
All ideas and data must be entered into the laboratory notebook. Entries must be complete
enough that another scientist would have little or no trouble understanding and repeating the
experiments.
(Continued on Next Page)
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Box 1 (continued)

Each page must be signed, and dated each day, by the scientist running and recording the
experiment, and signed and dated by a witness, if not immediately, then at least within one week
of the scientist’s signature.
In deciding the exact procedures to follow, it is important to keep in mind that any type of
laboratory notebook must achieve two goals:
1. Reflect its own integrity
2. Corroborate information independent of the person doing the research
Thus, the condition of the laboratory notebook must reflect that it is a clear and accurate
representation of activities that have taken place in the lab and that none of the information
has been falsified: any changes made to the recorded information should be clear and obvious
and the new information should be able to be compared with the old; and the notebook should
be completely in tact, with no pages missing or illegible. A witness who has not been involved in
the experiment, by signing and dating the notebook, must attest (by virtue of signing) that the
information, experimentation, and/or ideas that occurred were recorded on the date indicated.
2. Types of laboratory notebooks
A. Hardbound notebook
• Laboratory notebooks are checked out from the designated librarian in the department or
office specified and returned to the designated technician immediately upon being filled,
to be microfilmed.
• When signing out a new laboratory
notebook, the researcher will notice
that the laboratory notebook is
numbered, is permanently bound,
has index pages (Figure 5) and that
all pages are prenumbered.

Figure 5: An Index at the Back Makes
your Notebook More useable

• The researcher should enter a new
experiment in the index each time a
new experiment is started.
• Use each page in order. Leave no
blank pages between experiments.
• Record enough information so that a
scientist “skilled in the art” could pick up your laboratory notebook and easily determine
what had been done, why it had been done, and what the results were. Entries should
include procedures, reagents, lot numbers, where appropriate, sketches, descriptions, and
so on. The purpose and significance of the experiment as well as observations, results, and
conclusions should be made clear. Remember, what may seem trivial or obvious at the time
experiments are conducted, may later be of critical importance.
• If procedures have already been described in an earlier experiment or have used a
standard protocol, and the researcher has not deviated from the previous descriptions of
the experiment for the current one, the researcher may reference the earlier information
instead of writing it out again. For example, if the researcher was starting a new experiment
on page 42, and was using the same protocol as already described on page 25, he or she
(Continued on Next Page)
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Box 1 (continued)

could write on page 42, “Following the protocol as described on page 25 of this laboratory
notebook.”
• All data should be entered, in ink, directly into the laboratory notebook.
• Corrections should be made by drawing a single line through the entry. Erasers or whiteout
should never be used. The researcher should initial each lineout, and if possible, add next
to each lineout a note of explanation, such as, “wrong data.” The researcher should never
tear pages out of the laboratory notebook. Pages may be copied for the researcher’s own
use, but never removed.
• At the end of each day the researcher should put a line or a cross through any unused
space on that day’s page(s) in the laboratory notebook. If a blank line is left between
paragraphs, there is no need to lineout the one line, but if a number of lines have been
left at the bottom of the page, they should be marked through. This could prove it was
impossible to enter additional information in the laboratory notebook, in those empty
spaces, at a later date.
• If additional information, such as a machine-generated table or graph, an original photo, or
autorad, is part of the experiment and is small enough to be attached in the notebook, the
information should be attached using a permanent adhesive or nonremovable tape. The
researcher should sign his or her name over the border of the attachment, crossing over
onto the laboratory notebook page. Signing in this way would clearly show, if at any time
in the future the attachment had been removed.
• If the additional data is too large for the laboratory notebook (for example, a computer
printout that is a few pages long), such additional data can be signed and dated;
countersigned and dated by the witness; and given an appropriate ID number. The
researcher should note on such additional data which laboratory notebook and which page
number the additional data is referenced. Then, in the laboratory notebook the researcher
should reference the additional data’s ID number and note the secure-storage location
where the additional data is being held. Preferably, a drawer with a set of files that are
always used to store oversized information should be used. A summary of the data can be
placed in the laboratory notebook. The same sort of procedure should be followed with any
samples that are to be kept.
• Each original page of the laboratory notebook must be signed and dated by the researcher
and by a witness. A witness should be someone who has read each entry, who is competent
to understand what he or she has read, but who is not a co-inventor. Each research group
should designate a person who is responsible for assigning permanent witnessing partners.
However, if the assigned witness is not available when needed, another person who fulfills
the appropriate criteria may be used.
• If any changes are made after pages are signed or witnessed, the changes must be initialed
and dated by both the researcher and a witness. Care should be taken to use the current
date when signing or witnessing a laboratory notebook.
• Ideas should be recorded in the laboratory notebook, as these may be important in
determining a date of invention.
• It is important to return completed laboratory notebooks to the designated person as soon
as possible to ensure a duplicate copy of the laboratory notebook is captured on microfilm
(Continued on Next Page)
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or other permanent media. This process will be expedited so that the notebook can be
returned quickly to the researcher. A laboratory notebook can be retrieved at any time
during the microfilming process, if needed. Upon completion of the microfilm process, the
laboratory notebook will be returned to the researcher,for use as reference in the laboratory,
or put into permanent storage at the researcher’s request. One microfilmed copy will be
kept in the library for access at any time. One other copy of the microfilm copy will be put
into secured storage in the designated location.
B. Hardbound notebooks containing electronically captured data
• At laboratories where a large amount of data are generated and stored in the computer, a
written laboratory notebook, with all of the guidelines referred to above, is still required. In
this setting, however, much of the data referred to in the laboratory notebooks may exist
in electronic files. The laboratory notebooks should contain a summary of the information
in those files and also give the name of the file (and format) in which the data are stored.
• The electronic data should be backed up and archived weekly. A new and separate file
should be provided as a place to store data. Details of these files and the back-up procedure
should be described to all researchers and managers in a memo. These backed-up files
should never be opened except for litigation or U.S. Patent Office matters.
C. Hardbound notebooks generated by computers
• The same guidelines apply to hardbound notebooks generated by computers as for
hand-written laboratory notebooks. The difference is that rather than purchasing a
laboratory notebook and writing in it, research activity is documented electronically. The
documentation is printed out on a regular basis and then bound to form a laboratory
notebook. The printed material should be clearly labeled with the information that will
appear on the front of the bound book and sent to the appropriate person or department
for binding. Once bound, the laboratory notebook will be assigned a number, recorded, and
returned to the researcher or archived, upon request.
• Each experiment is to be described and each page should be numbered and signed,
countersigned, and dated. Each week these experiments are to be saved in the special data
file as described in a memo. Also, as with hardbound notebooks, data such as small graphs,
photos of gels, and so on, which can be attached to the laboratory notebook page should
be attached using the same methods as described above.
• Even though it may be a convenient way of recording experiments,electronic documentation
is not the recommended way, for a variety of reasons. If a number of experiments from
different days are printed on one page, for example, and the page is only signed and dated
after the last entry, it may be difficult or impossible to pinpoint dates of specific activity,
especially an exact date of invention.
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CHAPTER 8.3

Documentation of Inventions
w. MaRK cRowell, Associate Vice Chancellor for Economic Development and Technology Transfer,

University of North Carolina at Chapel Hill, U.S.A.

ABSTRACT

Documentation of research is a critical aspect of best
practices in IP management. This is true because research
and development activities that give rise to inventions
must be thoroughly documented in order to successfully
manage patents, including determining patentability,
drafting and prosecuting patent applications, and later,
if the need arises, protecting patents against third party
challenges, for example, a patent interference proceed
ing. Maintaining, for each invention, a complete record
of who made the invention, when it was made, and how
it was made, must therefore become a formal component
of a university’s policy and training programs and must be
carried our according to specific protocols. An organized
and methodical approach to documentation will support
patent management, provide a readily accessible source
of critical information, ensure the capture of maximum
value of inventions, and protect patent portfolios against
challenges when, and if, the need arises.

1. InTRoduCTIon
Documentation of inventions is an extremely
important issue, and yet this relatively straight
forward activity is one of the most forgotten,
overlooked or, simply, carelessly neglected aspects
of invention management. A lack of attention to
this activity can result in the loss of patent rights
that the applicant would otherwise possess. The
technology transfer office has a responsibility to

facilitate understanding among researchers of the
importance of keeping good records. In addi
tion, the technology transfer office must establish
fail-safe systems for documenting and diligently
pursuing the invention disclosures that the office
receives.
Why is record keeping so important? In a
research environment, good research records are
essential for a number of reasons—including for
assisting the institution in meeting its progressreporting requirements to research sponsors, for
documenting expenditures, and for promoting
research integrity. However, for the technology
transfer manager, U.S. patent laws provide an
altogether different reason for promoting good
practices in invention documentation.
Among the first lessons that U.S. technol
ogy managers learn is that the patent laws dictate
that a patent is awarded to the first party to in
vent. In the United States, unlike virtually every
other country, priority of invention is established
by the first-to-invent rule. However, the major
ity of nations follow a priority rule by which the
party who is first to file is entitled to a patent.
What this means, then, is that a contest can en
sue between parties who dispute priority of an invention, that is, who was actually first to invent.

Crowell WM. 2007. Documentation of Inventions. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual (Second Edition, Part VI: Chapter 2).
© 2007. WM Crowell. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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Such a contest is adjudicated by the U.S. Patent
and Trademark Office (PTO), Board of Patent
Appeals and Interferences, in an administrative
proceeding called a patent interference. The patent
interference proceeding determines who was the
first to invent, has priority, and thus is entitled to
the patent.
So, when two competing patent applications
claim the same subject matter, the PTO declares
an interference, that is, the patent applications
“interfere” with each other. Each inventor then
seeks to prove priority of invention, and reliable
evidence is sought that can document which party
was, in fact, the first to invent. Under U.S. patent
law, the inventive process, by definition, begins
with conception of an invention and proceeds
to reduction to practice (either actual construc
tion of the invention or filing of a patent applica
tion with the PTO). To comply with patent law,
the first party to conceive a patentable invention
must carry out certain activities to proceed with
reasonable diligence toward the development and
patenting of an invention. In other words, it is
possible that the first to conceive an invention
can fail to prevail in an interference proceeding if
he or she did not diligently work toward reduc
tion to practice of the invention or did, in fact,
diligently work toward reduction to practice but
cannot produce any documentation as evidence to
prove having done so. Therefore, an inability to
prove who is the first to conceive, or a lack of
evidence to refute a charge that an inventor was
not diligent in pursuing an invention, can lead
to the loss of valuable patent rights to which the
inventor and institution may otherwise have been
entitled.
Therefore, within the notoriously complex
context of an interference proceeding, careful
documentation of inventions and the inventive
process, from conception to reduction to practice,
will be extremely important in order to prevail if
such legal challenges arise. In addition to inter
ference proceedings, patents are, not infrequently,
challenged on such grounds as incorrect naming
of inventors or newly raised references that chal
lengers argue should have been submitted to the
PTO as proof of prior art at the time of the patent
application. In such situations, research records
 | HANDBOOK OF BEST PRACTICES

can be invaluable for documenting who contrib
uted to the invention and the critical dates and
facts of conception and reduction to practice of
the invention; these dates would refute the claim
that raised references identified relevant prior art
if the records documented conception and reduc
tion to practice (invention) as having occurred
before the raised references. This example under
scores the importance of maintaining clear, me
ticulous chronological records. Nothing will sub
stitute for comprehensive records if, and when,
complex legal challenges to a patent or patent ap
plication arise. Always assume that there could be
trouble, and assemble records accordingly so as to
protect valuable investments in research, develop
ment, and commercialization.

2. THE pRACTICAL IMpoRTAnCE of
RECoRd kEEpInG
In reality, there are occasions on which an inven
tion disclosure form (IDF) itself, or possibly a
grant application, will be the first viable record
that a researcher has adequately, and diligently,
proceeded through the inventive process, from
conception of the invention through to reduction
to practice. In such cases, the technology trans
fer office must ensure that such records are safely
stored, properly witnessed, and readily available
when the need arises. A lot depends on such care
being taken, and an investment in managing
and maintaining records will pay off in the long
term.
U.S. patent practice places immense impor
tance on witnessed records when two or more
parties claim the same invention. For example, an
applicant involved in an interference proceeding
must be able to prove the date of conception (the
date when the inventor formulated in his mind a
definite and complete idea of the invention) and
the date of reduction to practice (the date when
the conceived invention was actually built, with
every element of the conceived invention) even if
it is not yet commercially perfected. It is critical to
make clear to staff that the IDF used by the tech
nology transfer office must avoid using language
that refers to date of first conception or date of first
reduction to practice. Should legal adjudications
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arise, such a statement could be construed to be
an admission that no earlier conception or reduc
tion to practice occurred (when in fact it has), sig
nificantly damaging the institution’s position in a
priority contest. Instead, the IDF should simply
ask that the location of records documenting con
ception and reduction to practice be identified.
In addition to documenting the dates of
conception and reduction to practice, the PTO
interference proceeding may turn on the dili
gence shown by the contending inventors. In
this situation, the inventors’ witnessed records
must demonstrate that the invention’s develop
ment, including the act of filing a U.S. patent
application, was pursued in a reasonably diligent
manner, pursuant to the statutory requirements
of U.S. patent law. In an interference proceed
ing, the party that can prove that it was the first
to conceive will likely be awarded the patent. If
one party proves it was the first to conceive of an
idea, but a second party conceived of the idea and
pursued reduction to practice in a more diligent
manner, the second party may prevail in the in
terference proceeding.
In the private sector, most industrial research
is carried out under guidelines that impose strict
ly enforced record-keeping practices as a matter
of routine practice. Often, these records are made
on a daily basis, dated, witnessed, and stored. If
researchers working under such conditions are the
inventors named on a patent application involved
in an interference proceeding, proving the date of
conception and reduction to practice should be
without ambiguities and informational gaps and,
hence, relatively simple and straightforward.
On the other hand, research record keeping
in universities can be lax to the point of slop
piness, and, in such cases, much more challeng
ing to organize and manage. Laboratory research
tends to be conducted at any and all hours of the
day, and researchers often find it difficult to find
the resources, witnesses, or other means by which
documentation can be facilitated. Furthermore,
the culture of some universities is such that prac
tices of this type historically have been viewed
as inappropriate or unnecessary. Researchers may
neither understand, appreciate, nor wish to be
inconvenienced by attending to detailed and

chronologically consistent documentation, and
thus simply perceive such a requirement as an
other annoying administrative burden. Indeed,
in some laboratories, directors of research might
push staff to maximize time at the bench and
minimize time at the desk; record keeping will
inevitably suffer as a result of such prioritization
of time. And in some cases, graduate students
who come and go, and who work on research
projects, believe, or perhaps are told, that labora
tory notebooks belong solely to the students. If
important facts about the conception or reduc
tion to practice of an invention are included in
such notebooks, the documentation may not be
available (that is, it has “walked away” with the
student) at some future date when a patent is be
ing challenged.
Despite any difficulty that universities may
face with strict record-keeping protocols, the im
portance of this activity cannot be overlooked.
Most research universities now have active pat
enting and licensing programs, and sound re
search documentation and record keeping is
an essential component of successful programs.
This cannot be ignored or left to chance; there
is just too much at stake, and the stakes only get
higher.

. GuIdELInES foR RECoRd kEEpInG
Good laboratory record-keeping practices should
not be driven merely by IP (intellectual property)
concerns. Good laboratory records have long been
viewed as “good science,” and good laboratory
records can be extremely helpful if a lab should
ever face charges (however specious) of scientific
misconduct. Essentially, the same record-keeping
practices that are considered good science and ap
propriate for responding to scientific misconduct
charges are also good practices for purposes of
managing, securing and protecting IP rights.1
The following guidelines for record keep
ing are contained in the North Carolina State
University manual of patent and copyright pro
cedures and are highly recommended:
1. A good practice is to use bound notebooks
for records. Entries should be made on
a daily basis. The use of a “diary format”
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2.

3.

4.
5.

6.

provides a day-to-day chronology. (This
can be extremely important in document
ing diligence or other important issues.)
Use the notebook to record a conception (a
complete description of a means to accom
plish a particular purpose or result, ideally
including all elements of a conceptualized
invention), laboratory data, drawings, or
other observations. Each entry should be
dated, headed with a title, and continued
on successive pages.
Entries in the notebook should be made in
ink. Under no circumstances should entries
be erased or “whited out”; a line should be
drawn through text or drawings that are
being deleted, and the corrected material
should be entered. Any blank spaces on
pages should be drawn through.
Any material that cannot be incorporated
into the notebook should be glued in and
referred to in a notebook entry.
All entries in the notebook should be signed,
dated, and witnessed (by at least two peo
ple) at the time they are made. Witnesses
should have read the entered material and
be capable of understanding it but be im
partial observers of the work and have no
direct stake in the outcome. The witnesses
could be, for example, colleagues from an
other laboratory in the same department.
An extremely important or unusual discov
ery or observation (a potentially patentable
invention) may warrant having more than
two witnesses. Multiple inventors may not
serve as witnesses for each other. If impor
tant records lack the requisite witness sig
natures, the records should be signed as
soon as possible after the records are cre
ated. Even a witness signature made days
or weeks after the record was created is evi
dence that the document existed prior to
the date on which signature was made.
Laboratory heads should set aside a time for
all in their laboratory staff to stop working
at the bench (or, in agricultural research,
the greenhouse or field) and record entries
into their notebooks. This time should be
carefully and consistently observed. Be sure
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to invite individuals who can witness the
entries immediately after they are made.
7. In the event that notes are kept on a com
puter, be sure to make the appropriate en
tries into the computer system at the end of
each day. Each daily entry should be print
ed out, signed, and witnessed, following the
same procedure as that recommended for
written notebook entries. The final printed,
signed, and witnessed document should be
glued into a notebook.
8. Identify a safe method for storing and mon
itoring the records. Research data related to
pending or issued patents should not be
destroyed. Therefore, a retrievable archive
system needs to be organized, implemented
and maintained. Such an investment will
pay for itself many times over in the event
of a patent dispute.

. ConCLuSIonS
In general, best practices in documenting labora
tory research serves two purposes: scientific and
legal (IP management and patenting). These pur
poses are not mutually exclusive, and indeed there
is considerable overlap, as the means to the two
objectives are entirely consistent. Best practices in
documentation will provide the researcher with
a clear record for assembling publications, grant
proposals and, in the event of fraud or miscon
duct allegations, a clear record for establishing the
facts. Similarly, a best practices approach to docu
menting research will greatly facilitate managing
issues related to IP management and patenting.
This could include, but is not limited to, patent
application drafting and prosecution, patent chal
lenges by third parties, and evidence production
for patent interference proceedings. Each of these
will require documentation of research and devel
opment activities. Documentation policy must,
therefore, be carefully and thoughtfully institu
tionalized, as part of every university’s required
protocols. Such procedures and requirements
should be an integral part of overall IP manage
ment and training that the technology transfer
office provides to the university administration,
staff, and scientists. A lot of value might be at
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stake. The investment in building capacity and
appropriate IP management systems will pay off
in the long term. n
w. MaRK cRowell, Associate Vice Chancellor for Economic

Development and Technology Transfer, University of
North Carolina at Chapel Hill, Box 4000, 312 South
Building, Chapel Hill, NC, 27599-4000, U.S.A.
Mark_Crowell@unc.edu
1

See, also in this Handbook, chapter 8.2 by JA Thompson.
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Invention Disclosures and the Role of Inventors
dAVId R. MCgEE, Executive Director, Technology & Industry Alliances, University of California, Davis, U.S.A.

ABSTRACT

This chapter is intended to assist intellectual property pro
fessionals, in working with inventors, to develop a highquality invention disclosure and, eventually, to prosecute
a patent application. Major topics include the importance
of data records, utility and reduction to practice of inven
tions, understanding prior art (including the inventors’
own art), and determination of inventorship.

1. INTRODuCTION
Invention disclosure is more than the simple
completion of an institutional or corporate
form to satisfy some policy requirement. It
includes a complete description of something
novel and nonobvious given in such a manner
that anyone of ordinary skill in the particular
art could reproduce the invention. The disclo
sure represents the first official recording of the
invention and, if done properly, can establish
an irrefutable date and scope of the invention.
Often the disclosure document has been used
to defeat challenges to dates of invention, in
ventorship, invention scope, and prior art.
Conversely, improperly written invention dis
closures many times have resulted in disastrous
losses of patent rights.
This chapter explains the nuts and bolts of
invention disclosures (as well as some of the nu
ances), beginning with the responsibility of sci
entists to disclose inventions even before they are

made and ending with the use of disclosures to
create defensible patents.

2. CONCEPTION OF AN INVENTION
The term invention is occasionally confused with
the term idea. According to the U.S. Code of
Federal Regulations, (37 C.F.R. §501.3(d)), an
invention is defined as “any art, machine, manu
facture, design or composition of matter, or any new
and useful improvement thereof, or any variety of
plant, which is or may be patentable under the pat
ent laws.” An idea, by definition, is limited to a
thought, existing only in the mind; an idea may
or may not be patentable as a concept. Only in
ventions can be patented, not ideas.
In the legal sense, the conception of an in
vention occurs when someone has mentally de
veloped an idea that is novel, nonobvious, and
exists in enough enabling detail that someone
of ordinary skill in the relevant area of science
could practice the invention. Conception does
not necessarily require actual reduction to prac
tice of the invention, but it does require that the
invention be thought through completely. The
degree to which the conceptualization is incom
plete should not be such that it is renders the
invention inoperable.
Commonly, a complete conception occurs
over a lengthy period of time and may involve

McGee DR. 2007. Invention Disclosures and the Role of Inventors. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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other contributors. The date on which such con
ception is deemed to be complete, that is, it satis
fies all aspects required of an invention (novelty,
nonobviousness, and enablement), is considered
to be the date of invention. The date of inven
tion may be, but is not required to be, either the
actual date of reduction to practice of the inven
tion or the filing date of the patent application
(constructive reduction to practice).

3. INVENTORSHIP
Those individuals who contribute to an enabling
concept are known as the inventors. Inventorship
is, therefore, restricted to the intellectual concept.
It does not extend to those persons who may re
duce the invention to practice but did not con
tribute to the invention’s conception.
Inventorship relies on specific claims ul
timately approved by the patent office for the
granted or issued patent. Since patent prosecu
tion most commonly involves changes to the
claims filed with the application, the inventors
may change.
One of the most frequently misunderstood
and contentious issues between scientists and the
intellectual property (IP) professional is the con
fusion between inventorship and authorship. As
described above, inventorship is a legal determi
nation based on the contribution to the enabling
concept embodied in at least one allowed claim.
An individual who has spent extensive time and
effort in the laboratory reducing an invention to
practice is not an inventor in any sense unless he
or she has also contributed to at least one claim.
Teams of scientists conduct most research.
As such, research team members are constantly
discussing technical aspects of the research; over
a period of time, an idea may emerge that has
been jointly developed. From the idea, an inven
tion may be described. Frequently, conflicts arise
when an author is not included as an inventor on
a patent application and believes that the work
performed in actual reduction to practice should
mean that he or she be designated as an inventor.
Unintentionally including a noninventor or ex
cluding an inventor can usually be corrected in the
patent office. However, intentionally including a
0 | HANDBOOK OF BEST PRACTICES

person as an inventor who did not contribute to a
claim is patent fraud and would render the patent
invalid if discovered. Intentionally excluding an in
ventor could likewise render a patent invalid.
It is the responsibility of potential inven
tors to make a good faith effort to determine
who among themselves are actual inventors.
Ultimately, inventorship must be examined by
the patent attorney of record to ensure that the
inventors included on the patent filed are, in
fact, inventors.

4. PREPARING THE INVENTION
DISClOSuRE
.1 Education of inventors before they disclose

The IP professional should never assume that the
scientists in his or her organization are aware of
when, how, to whom, and why to properly make
an invention disclosure. As with many other busi
ness practices, acceptance of the patenting process
begins at the top of the organization. If top man
agement does not endorse patenting, then no one
else will either. An effective education program,
concerning the policies, practices, and practical
understanding of the patent process, is a must for
staff of the organization. The program must be
continuous, since new staff will not be aware of
the process, and existing staff will need to review
the process on a frequent basis. The best time to
educate new employees is during their orientation
programs. Instruction should be supplemented at
regular periods during the year to all potential in
ventors. Only the technology transfer office (TTO)
is really qualified to educate these scientists.
.2 Duty to disclose

It is essential that employees be aware of and fol
low the employer’s policy for duty to disclose an
invention. Many organizations have a policy that
requires all employees to disclose to the employer
all inventions made during the course of employ
ment. Depending on the specific policy, the duty
to disclose may extend beyond employment to
include inventions made outside of employment,
such as inventions made while consulting for an
other company or at home.
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. When the inventor calls

For the TTO to succeed, inventors must be con
fident that their inventions are going to receive
a thorough evaluation of their patentability and
commercialization potential. Nothing will alien
ate an entire cadre of inventors more quickly and
completely than if the TTO treats inventions
superficially or capriciously. The TTO must give
careful attention to every invention disclosure, re
gardless of its content.
..1 Understanding your institution’s IP
policies and your country’s IP laws

The IP official must be the expert on his or her
company and institutional IP policies and prac
tices. These policies and practices must be care
fully and patiently explained to each inventor.
Likewise, all laws pertinent to any aspect of IP
must be understood by the TTO and communi
cated whenever needed to the inventor.
..2 Understanding the inventor’s
timing of public disclosures

One of the most common complications accom
panying an invention disclosure is a publication or
a pending publication. If publication is imminent,
then a provisional patent application may be the
only recourse to avoiding loss of patent rights. In
the United States, a grant application is not consid
ered a publication until the Notice of Grant Award
is sent. Therefore, it is essential to completely un
derstand the nature and content of the intended
publication in order to determine whether or not
it will actually contain an enabling disclosure of
the invention. It also is necessary to know when
the invention will be disclosed. Abstracts for sci
entific meetings are now commonly e-mailed to
participants months before the meeting date.
Depending on the specific invention, an abstract
may easily be an enabling disclosure, so it is im
portant to question each inventor to determine if
and when a publication and/or abstract may oc
cur. Many times a disclosure (such as a speech)
does not provide enough detail to constitute an
enabling disclosure. The TTO should obtain cop
ies of all speeches, technical presentations, pend
ing grant applications, and so forth, and maintain
these with the patent file wrapper.

. Getting the big picture

When an invention is disclosed, the IP profes
sional should clearly understand not only the
technical details of the invention but also how
the new invention may relate to other inventions
as a portfolio. Additionally, the inventor may be
prolific and so it is important to know if there are
additional invention disclosures anticipated by
the inventor and, if so, whether those should be
combined with the invention disclosure at hand.
This knowledge could greatly influence whether
and/or when to file a patent application and
what the scope of the patent application may be
in light of other existing or expected invention
disclosure forms. The inventor must provide the
IP professional with his or her plans to continue
conducting research related to the invention. This
is especially important if the invention has not
been reduced to practice.
If the invention disclosed is incomplete be
cause the inventor has not completed an enabling
concept, or if reduction to practice is necessary
to determine enablement, then the inventor
must be clearly told what deficiency is present.
The invention disclosure form will be held by the
IP professional with no action taken until the in
ventor provides a complete disclosure. Periodic
follow-up with the inventor is advisable to en
sure that he or she remembers to provide the in
formation necessary to complete the invention
disclosure form.
. Inventorship versus ownership

The duty to disclose should be not be confused
with the assignment of an invention. Disclosure
of an invention means merely that the invention
has been described in complete (that is, enabling)
detail. Assignment means that ownership of, that
is, legal title to, the invention has been given by
the inventor to another party (for example, the
employer). Employers commonly combine the
duty to disclose and the assignment of inventions
on a single form to be signed by the new employ
ee upon reporting to work. But this is not always
done, so the actual language must be carefully re
viewed. The combination of the duty to disclose
and the assignment of invention into a single,
signed document is convenient in case there are
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ever any questions later during a patent prosecu
tion of the ownership of an invention.
For certain government organizations, the
duty to disclose may go beyond mere policy com
pliance and have additional legal consequences if
timely and complete disclosure is not made.
. When the invention disclosed is co-owned

Collaborative research projects between separate
entities are common. Usually these projects are
described in a contract, grant, or interinstitution
al agreement. These documents will usually con
tain one or more sections that address co-inven
torship and co-ownership of IP developed during
the term of the agreement. Nothing should be
assumed about the ownership of IP before thor
ough review of the agreement has been complet
ed. Once ownership has been determined, the
other party may need to be notified upon receipt
of an invention disclosure form and prior to filing
a patent application. Frequently, the other party
will have an opportunity to participate in some
manner during the IP process.
If an invention has been made by co-inven
tors and at least one of the co-inventors is from
a second entity, and if there is no contractual
agreement between the entities, then a decision
has to be made as to whether to inform the sec
ond entity of the invention disclosure form.
Prior to disclosure, it would be advisable for the
two institutions to sign a two-way confidentiality
agreement to avoid public disclosure and subse
quent loss of rights. Additionally, in first-to- file
countries, the first party should file a patent ap
plication prior to notifying the second party.
Subsequent agreements, such as an interinsti
tutional agreement, can be made to define each
party’s rights and determine how patent prosecu
tion costs will be shared.

5. WHEN TO DISClOSE AN INVENTION
It is good practice to disclose an invention as soon
as it is an invention. Filing an invention disclosure
declares the invention, the inventors, and the date
of invention. Even if a patent application is never
filed, a properly completed invention disclosure
may be able to provide some protection against
2 | HANDBOOK OF BEST PRACTICES

subsequent patent applications filed by other par
ties that could prohibit the first party from being
able to practice something it invented. This pre
caution may be especially helpful in the United
States, where first to invent takes precedence over
first to file. Most importantly, without a timely
disclosure, no decision can be made about wheth
er or not to file a patent application to preserve IP
rights. Occasionally, a delay in disclosure may be
appropriate, for example, if the inventor is con
tinuing to conduct experiments that may provide
better enablement or broader utility, which would
provide broader claims should a patent be sought.
However, the decision to delay filing an invention
disclosure should be made in consultation with
appropriate IP managers.
If an inventor is unable or resistant to com
pleting an invention disclosure form (See Box 1 at
end of chapter for a sample invention disclosure
form.), then an interview with an IP professional/
TTO officer of the same institution for the pur
pose of disclosure may be required. Completing
an invention disclosure without the inventor’s
input is not recommended, however, since the
inventor is, naturally, more familiar with the in
vention than anyone else. If a patent application
is prepared from an invention disclosure that has
been obtained from an interview, the patent ap
plication may take longer and cost more to pre
pare. Ultimately, each inventor must critically
review and affirm that the invention has been
correctly and completely described in the patent
application. In the United States, each inventor
must sign a declaration affirming that the inven
tion has been correctly and completely described,
in order to meet the filing requirements of the
U.S. Patent Office.
In some countries, patent offices do not re
quire filing an invention disclosure in order to
file a patent application. Under certain circum
stances, however, other government agencies may
require that invention disclosures be filed.
.1

Where to submit an invention disclosure

Invention disclosures may be submitted wherever
the employer’s policy dictates, for example, with
a company’s own IP department or outside patent
counsel or with an academic institution’s TTO.
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In the United States, patent law provides
for a disclosure document program that allows
an inventor to submit an invention disclosure to
the U.S. Patent and Trademark Office (PTO).
The program is described in detail in the Code
of Federal Regulations (37 C.F.R. §1.2.1(c)). It is
especially beneficial to individual inventors who
are not affiliated with an employer, because the
program provides evidence of disclosure that may
avoid the necessity of disclosing, to witnesses, in
formation the inventor wishes to keep confiden
tial. The U.S. PTO will keep the invention dis
closure for two years and then discard it unless it
is referred to in a pending patent application. The
disclosure document program is not a substitute
for filing a patent application and provides no fil
ing date for a patent application.
.2 Confidentiality of an invention disclosure

To avoid the potential undesired publication
of an invention prior to filing a patent applica
tion, all invention disclosures should be submit
ted confidentially. When disclosure is made by
an employee to a fellow employee, it should be
clearly understood that the disclosure is to be
kept confidential. As such, the disclosure would
not be considered a publication in most cases. In
very large institutions, the presumption of con
fidentiality may not exist. Consequently, if chal
lenged by an outside party, such disclosure may
be deemed by the patent to have not been a confi
dential disclosure but a publication. Even within
an organization, therefore, it is always important
to verify confidentiality prior to disclosure and to
execute a confidentiality agreement, if needed.
. Content of an invention disclosure form

There is no set format for an invention disclosure
form; however, there are certain types of required
information common to all invention disclosure
forms. Examples of the forms can be easily ob
tained from the Internet by selecting any search
engine and entering invention disclosure in the
search box. Numerous forms from institutions all
over the world are available.1 All the forms have
certain things in common: most request similar
kinds of information. Box 2 at end of chapter lists
items that appear commonly on the forms.

. uSE OF lABORATORy NOTEBOOKS AS

INVENTION DISClOSuRES
Laboratory notebooks are frequently relied upon
to ascertain the actual date of invention and to
identify the inventor. Unfortunately, most lab
notebooks are incomplete, illegible, and not wit
nessed, or witnessed erratically—if they are kept
at all. However, if kept appropriately, a labora
tory notebook can easily suffice as an invention
disclosure. The information must at least include
a detailed description of the invention and signed
and dated pages by the inventor and appropriate
witness(es). The actual discovery (that is, the in
vention) must be clearly explained.
IP professionals should educate scientists
about the need for complete disclosure if the note
book is to be useful at all. The scientists should
also be trained to avoid writing off-hand remarks
in the notebook (for example, “this was an obvi
ous experimental approach” or “I used an obvious
extension of Dr. X to conduct this research” or
“there is a paper that is prior art to my research”).
Such notebook disclosures would be discoverable
during litigation and could result in loss of patent
rights. As always, scientists should be counseled
to completely disclose the invention and to pro
vide only absolutely truthful disclosure.
7. ASSIGNMENT FORM
An assignment is the transference of legal title to
an invention. Assignment of all inventions may
be made in advance of any discovery by execut
ing a general assignment agreement. During pat
ent filing, assignment of an invention may be re
quired by the patent office. The employer should
obtain a second assignment of the specific inven
tion being filed as a patent application because
it provides the patent office with a simple, clear
assignment record. However, if an inventor can
not be reached or is unwilling to provide a signed
assignment, then the original general assignment
agreement can serve as evidence of assignment of
that invention.
Under U.S. patent law, all assignments for
patent applications and issued patents must be
recorded. This requirement may vary in other
countries.
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.1

What to do in the absence of a previous
assignment when there is a duty to disclose

Occasionally during the preparation of a pat
ent application, the IP professional discovers
that there is no record of assignment. A signed
acknowledgement of an employee’s duty to as
sign may also be lacking. These are serious is
sues, because ownership of a patent is joint and
severable; any owner can act independently of a
co-owner. In other words, co-owners can sepa
rately practice an invention or license it without
a co-owner’s permission. Therefore, obtaining
clear assignment of an invention is extremely
important.
.2 Obtaining signatures for duty to assign
and assignment documents

As soon as it is discovered that an inventor has
not fulfilled the duty to assign or has not executed
an assignment document, the TTO officer should
promptly review the organization’s policies to see
if they are clear. In addition, he or she should look
for other records that may include the employ
ee’s signed acknowledgment of compliance with
corporate or institutional policies. For example,
employee policy handbooks frequently contain
sections relating to IP. It is common practice for
human resources departments to obtain from
employees written acknowledgement that they
have read, understand, and will comply with all
policies. This written acknowledgement may be
useful if an inventor does not wish to provide a
written assignment for an invention.
Next, the IP professional should contact
the inventor, in person if possible, and explain
why an assignment is necessary. If a duty-to-dis
close agreement has not been signed, then the
IP professional should explain to the employer
why signing a duty-to-disclose agreement is
important. If the institution has a policy that
provides inventors with compensation, such as
royalties, then the IP professional should go over
those policies as well. He or she should have the
agreements ready to be signed in duplicate and
provide the inventor with a copy. (The original
should be kept on file.) Explain that additional
assignments for any future inventions will be
needed and why.
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It is advisable not to ask anyone to sign an
agreement upon which the signature date is dif
ferent than the actual date of signing—it may un
dercut the validity of the document. The agree
ment can, however, specify an effective date in the
text that predates the signature, providing that no
intervening and conflicting agreements have been
executed.

8. DIlIGENCE WHEN FIlING A PATENT
AFTER RECEIVING THE INVENTION
DISClOSuRE FORM
Because the U.S. PTO has a first-to-invent rule,
U.S. patent practice includes an obligation of
diligence to proceed with the filing of a patent
application once an invention is completed. A fil
ing delay can, under certain circumstances, result
in a loss of patent rights. This most commonly
occurs when a second, independent party invents
and files a patent application after the first party’s
date of invention, but before the first party’s filing
date. If a lack of diligence by the first party can
be shown, the second party may prevail and win
the patent filing. Obviously, diligence in filing is
rendered a moot issue in first-to-file countries.
9. uPDATING A SuBMITTED INVENTION
DISClOSuRE FORM AND COMBINING
DISClOSuRE FORMS
Frequently, when an invention disclosure form
is submitted, it represents ongoing research. As
such, it may not meet the standards of patentability or commercialization potential to warrant
a patent filing. Regardless, an IP professional
should receive the invention disclosure form and
assess whether or not to file a patent application.
Alternatively, he or she could hold the invention
disclosure form in anticipation of receiving new
data or matter from the inventor. The inventor
may then file a subsequent invention disclosure
form as an addendum to the first form. Invention
disclosure forms on related matter, if combined,
may greatly strengthen a patent application with
broader claims.
If the second invention disclosure form con
tains the best method of practicing the invention
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or new matter, then the date of invention may be
that of the second invention disclosure form and
not the first.

understood. During these discussions, the patent
attorney will develop the broadest claims pos
sible without becoming an inventor.

10. PATENT PREPARATION FROM THE
INVENTION DISClOSuRE FORM
A properly completed invention disclosure form
will greatly enhance the ability and speed with
which the patent attorney is able prepare the pat
ent draft. Expediting this process can dramatical
ly lower attorney fees. To aid in the process, the
attorney should receive a complete copy of the
invention disclosure form, copies of all referenc
es, clear instructions about the most important
aspects of the invention that need to be claimed
in the patent application, and an explanation
of why these aspects are important. The patent
attorney will be able to craft a patent applica
tion properly only if the client clearly describes
its strategic objectives within the context of the
invention.
Most inventors are unfamiliar with the pat
ent prosecution process, and so the IP profession
al should clearly describe the process to the inven
tor and explain how he or she will be expected to
assist in it. The inventor should be introduced to
the patent attorney, and the employer should take
care to ensure that a good, productive working
relationship is established between the inventor
and the patent attorney. The inventor is the ex
pert and will need to provide the patent attorney
with substantial assistance in drafting the inven
tion background, the technical description of the
invention, and access to any known references.
After filing, the inventor will likely assist the pat
ent attorney in providing technical rebuttal for
issues raised by the patent office. Depending on
the particular patent application, the inventor’s
involvement can occasionally require a substan
tial amount of time.
Patent counsel will prepare and file the pat
ent application based on the invention disclosure
form. It is the responsibility of the patent coun
sel to prepare a complete and enabling disclosure
of the invention. Most often the patent attorney
will discuss the invention at length with the in
ventor, in order to ensure that all its features are

11. MAINTAINING INVENTION
DISClOSuRE FORMS
Each TTO should establish a database of inven
tion disclosures and a secure-storage facility where
original copies of invention disclosure forms are
filed. A fireproof file cabinet is a good example
of such a facility. Invention disclosure forms
should be retained for the life of any related pat
ent. Duplicate copies should be stored off-site.
An outside patent firm will frequently provide
this service. The disclosure document program at
the U.S. PTO will maintain an invention disclo
sure form only for two years, unless the invention
disclosure form is referenced in a pending patent
application.
12. INVENTOR’S CERTIFICATE
An inventor’s certificate may be filed in lieu of
a patent application. The certificate will contain
a detailed description of the invention and most
of the components of a patent application. An
inventor’s certificate is, therefore, similar to an
invention disclosure form. However, unlike an
invention disclosure form, the inventor’s certifi
cate is part of a legal process (established in ac
cordance with each country’s respective patent
laws and procedures) to publicly recognize the
inventor(s) as an inventor for a defined invention
as of a specified date.
An inventor’s certificate is not a patent and
does not provide any of the IP protection rights
provided by patenting. Instead, many countries
commonly use certificates to provide a monetary
reward for an invention for which no patent is
intended.
13. MARKETING INTEllECTuAl PROPERTy
THROuGH AN INVENTION DISClOSuRE
It is common practice among academic institu
tions to market IP using the information con
tained in invention disclosure forms. Because
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the invention disclosure form contains enabling
detail of an invention, premature disclosure of
such information prior to filing a patent appli
cation could destroy patent rights. Care must be
taken to provide only general, nonconfidential
information that does not include any enabling
information. If a patent application has been filed
but not yet published, then the filing date or pat
ent application number should not be disclosed.
Unauthorized parties can use these numbers to
obtain confidential information about a pending
application. If the patent application has been
filed, then including information contained in
the pending application is acceptable. The dis
closed information in marketing abstracts made
available for previously unpublished patent appli
cations should be updated after the application is
published. It is inadvisable to include inventors’
names in marketing abstracts as points of contact;
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instead, the name of the licensing professional
should be used.
Many institutions provide nonconfidential
abstracts of IP on Web sites, which usually orga
nize the abstracts and contact information into
databases by technology area. These databases
can be efficiently marketed by technology area
through mass e-mailing or mailings to potential
licensees. n
dAVId R MCgEE, Executive Director, Technology and

Industry Alliances, University of California, Davis, Office of
Research, Technology Industry Alliances, 1850 Research Park
Drive, Davis, CA, 95616, U.S.A. drmcgee@ucdavis.edu

1

For example: http://research.ucdavis.edu/homecfm?id
=OVC,2,1025.
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Box 1: Sample invention disclosure form
[Insert Institution or Company Name Here]
CONFIDENTIAl
1. TITlE OF INVENTION:
2. OVERVIEW OR PuRPOSE OF INVENTION:

3. BRIEF DESCRIPTION OF INVENTION:
Provide a brief abstract of the invention including novel embodiments of the invention.

4. DETAIlED DESCRIPTION OF INVENTION:
Provide in plain language a numbered list of what attribute(s) you, the inventor, believe is/are
useful about the invention.
Provide a complete, enabling description of the invention. Include all descriptions, steps,
processes, and other data and information necessary, so that someone of ordinary skill in the
art could reproduce and practice this invention. If the invention is a composition of matter,
provide a complete formulary and any other information necessary to completely and accurately
describe the composition. If the invention requires software that has been developed as part
of the invention, provide a detailed program flow chart and copies of the software. Provide
detailed drawings and a description for any apparatus.
Attach additional sheets if necessary.

5. BACKGROuND (Optional):
If known, describe the state of the art as set forth in patents or journal references (identify
by patent number or journal citation, if possible) and indicate how the invention overcomes
any disadvantages to or problems in this art. Attach additional sheets if necessary. Also attach
complete copies of the references.
If any inventor knows of any art relevant to the invention, please provide such information
through description below with appropriate literature references. All cited references should
be attached to the invention disclosure form.

(Continued on Next Page)
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Box 1 (continued)

6. CONCEPTION:
Provide the date upon which a complete, enabling concept was known by the inventor(s).
Invention conceived on:
First written record:
7. FIRST DISClOSuRE TO OTHERS:
Provide the complete names and anyone to whom you have disclosed your invention in enabling
detail and the dates on which you made the disclosures.
Date:

Name:

Date:

Name:

Date:

Name:

Indicate how the disclosure was made (for example, orally or through a presentation, report, or
publication). Provide copies of any documents or other media you used to make the disclosure.

8. FIRST REDuCTION TO PRACTICE:
Provide the date of first preparation or isolation of compound molecule or microorganism; date
of first use of process, or date of construction of apparatus.
Date:
9. FIRST SAlE OR PuBlIC uSE OF INVENTION:
Describe and provide the date of any sale or public use made, or planned to be made, of your
invention in the United States or in any foreign countries. Provide details of any sale, use or
disclosure. The description should tell whether or not the use was for testing purposes, and
if there was an effort or intention to maintain secrecy around the invention after the use
commenced.

10.PROGRAM OR CONTRACT:
Was the invention made during the course of your work on a specific program, grant(s) or
contract?
Yes

No

If no, provide an explanation of how and where the invention was made.
If yes, provide below the name and applicable number of the funding agency.
Fund source

Grant or contract number

(Continued on Next Page)

 | HANDBOOK OF BEST PRACTICES

CHAPTER .

Box 1 (continued)

11. CONTACT INFORMATION
Provide the specified information about the inventor(s).
Signature of inventor:

Date:

Printed inventor name:
Affiliation:
Mailing address:
Citzenship:
E-mail:
Telephone:
Signature of inventor:

Date:

Printed inventor name:
Affiliation:
Mailing address:
Citzenship:
E-mail:
Telephone:
12. WITNESSES:
The invention was described to me by the above inventor(s), the description was examined and
clearly understood.
Signature of witness:

Date:

Printed name:
Affiliation:
Signature of witness:

Date:

Printed name:
Affiliation:
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Box 2: Information requested typically in
an invention disclosure form
Inventor
This should include the complete name of the inventor and his or her employer affiliation and
complete mailing address.
Invention
An invention should include a title of the invention, a short abstract, and a detailed description of
the invention. The advantages of the invention should be clearly described.The inventor(s) should
include as many features, embodiments, and uses of the invention as possible.
Date of invention
This is the date the invention was conceived in enabling detail. U.S. patent law (35 USC §104)
provides for the establishment of a filing date when an invention is made abroad, as long as
certain provisions are met: 1) the inventor must be domiciled in the United States or a North
American Free Trade Agreement [NAFTA] or World Trade Organization [WTO] country; 2) the
invention has been conceived in either the United States or a NAFTA or WTO country; and 3) the
inventor must be serving in a NAFTA or WTO country on behalf of one of those countries. Such a
provision may or may not be available in countries other than the United States. The provision
may have no significance at all for first-to-file countries.
Date of actual reduction to practice, if applicable (may be the date of invention)
Actual reduction to practice is not required but is helpful when preparing the patent
application.
Applicable research funding sources, if any
It is very important to know whether the invention has been funded by an entity, other than the
inventor’s employer, that may have ownership/licensing rights.
Date of public disclosure of the invention
This may be critically important if the date creates a statutory bar for patenting. If the date is in
the future, then it provides a timeframe within which a decision of whether or not to file a patent
application has to be made. Copies of any publications (for example, manuscripts, handouts,
posters, electronic presentations, and slides) should accompany the invention disclosure form.
In addition, any relevant supportive scientific references should be copied in full and attached to
the invention disclosure form.
References
The inventor should include complete references and photocopies of any other related science he
or she is aware of that could potentially be cited by the patent examiner as novelty-destroying or
as rendering the invention obvious. There is no duty for the inventor or the attorney of record to
conduct a literature search to determine whether there is any prior art to the present invention.
But if the inventor or the assigned institution is made aware of any such art, then it must be
disclosed to the patent office. There is no duty to provide the patent office with an opinion of the
relatedness of any reference cited to the patent office. The examiner is responsible for making
such a determination.
The inventors should be instructed not to provide written admission, directly or indirectly,
that any reference is prior art. In some countries such a statement is viewed as an irrevocable
admission that the reference is true prior art that renders the present invention as non-novel
and/or obvious.
(Continued on Next Page)

0 | HANDBOOK OF BEST PRACTICES

CHAPTER .

Box 2 (continued)

list of potential competitors/licensees
Since inventors are knowledgeable in the area of science related to the invention, they are usually
also knowledgeable about who is working in that area. This is valuable information, since it
provides direction in finding potential competitors, potential licensees, and potential areas of prior
art that can be reviewed before filing a patent application to help determine patentability and
claim drafting. Also, one can build a better patent portfolio by reviewing patents and file wrappers
filed by another institution or company.
Witnesses
Usually, at least two witnesses are required on an invention disclosure form. A witness should
be scientifically competent to understand the details of the invention and not directly affiliated
with the research being disclosed (for example, an inventor on the invention disclosure form or a
principle investigator of the research).
Signatures of all inventors
It is critical that at least one of the inventors has signed the invention disclosure form, otherwise,
the form cannot be considered to have been perfected. The TTO at the institution should try to
obtain original signatures from each of the inventors as soon as possible.
Receipt of electronically filed invention disclosure forms
Faxed signatures are generally accepted worldwide as sufficient evidence of an executed document.
Electronic signatures do not yet have such wide acceptance. Consequently, it is recommended that
invention disclosure forms not be sent electronically without the subsequent conveyance of an
original, signed copy.
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Evaluation and Valuation
of Technologies

CHAPTER 9.1

Evaluating Inventions from Research Institutions
LITA NELSEN, Director, M.I.T. Technology Licensing Office, U.S.A.

ABSTRACT

The patenting strategies of research institutions are based
on three key decisions. The first involves whether or not
to file a patent. This decision must be based on sound
information about the market, the uniqueness and use
fulness of the invention and/or technology, the likelihood
of being able to obtain patent protection, factors related
to the inventor, and the potentially paradoxical impact
of patenting on the institution’s social and humanitarian
responsibilities. The second decision involves whether to
market the invention to established companies or to de
velop a spinout business. The third involves how much to
charge for a license. Related to all of these decisions is the
key question of whether patenting is the most effective
route to global access. Negotiating licensing agreements
that are fair to the research institution, the private com
pany, and developing countries can be challenging be
cause research institutions may have difficulty determin
ing fair market values. In addition to outlining a process
for obtaining these values, this chapter offers some rough
numbers for guidance. In general, the author concludes
that it is far better to conclude a deal than to wait for
the best agreement while fighting interminably for perfect
financial terms.

1. INTRODuCTION
This chapter discusses how to evaluate new in
ventions arising from research at universities and
other research institutions. It considers early,
“university-stage inventions” arising out of ba
sic research, rather than development projects.
Most of these university-stage inventions will
require substantial investments in both money

and time to develop them into marketable prod
ucts. Such investments will usually be very risky;
neither the practicality of the technology nor its
ultimate market acceptance will be known with
any certainty.
It is assumed that the research institution’s
interest is primarily in the social functions of
technology transfer: bringing new medicines
and other useful products into public use, en
hancing the competitiveness of industry by
encouraging the use of new technology, and
enhancing economic development and job cre
ation. Revenue from royalties is assumed to be
a secondary consideration. (Even in the United
States, the Bayh-Dole Act, which gave U.S. re
search institutions the right to own and license
out inventions from government-funded re
search, was enacted in the cause of economic
development—not as a mechanism for fund
ing the institutions. Twenty-five years later, the
revenue produced, though useful to the institu
tions, makes up on average only a small per
centage of their research budgets.)

2. THE EVAluATION PROCESS
Technology transfer offices evaluate early-stage
inventions in order to make three decisions:
1. whether or not to file a patent on the
invention

Nelsen L. 2007. Evaluating Inventions from Research Institutions. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. L Nelsen. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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2. whether to market the invention to existing
companies or try to do a spinout
3. what to charge for the invention
Fortunately, these three decisions do not usu
ally have to be made at the same time. And, of
course, if the answer to the first question is no,
then the other two questions are moot.
2.1 Decision 1: Whether or not to file a patent

It is assumed that money for filing patents is avail
able but limited. The decision to file a patent
should take into account answers to the following
questions:
1. Is this invention likely to get awarded a pat
ent with broad enough claims to protect a
product or a product line—not just a mi
nor variation of an existing technology?
2. If patented, will this invention likely attract a
licensee or investment for commercialization
that will produce enough of a return to the
institution to justify the patenting expense?
3. Is patenting the right route to maximize so
cial access to the technology?
The answer to the first question on patentability is fairly easy to determine with relative
(though not absolute) certainty. If time allows, a
search of the literature that includes past and pub
lished pending patents will reveal prior art. When
possible, this search is best done by a professional
search librarian working side-by-side with one
of the inventors. If potentially important prior
art is found, a patent agent may be called in to
evaluate its significance and the likely claims to
be achieved by patent filing. The prior art search
may also turn up dominating patents that may
have to be taken into account.
The second question—will the technology
attract investment for commercialization if it is
patented—is far more difficult than the first to
answer with any certainty. Market research stud
ies take both time and labor. If the technology
transfer office receives many invention disclosures
(at the Massachusetts Institute of Technology
[M.I.T.] we receive about 450 disclosures per
year), there will not be enough resources to per
form a market research study on every one. In
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addition, there may not be enough time for such
a study before publication (particularly in aca
demic institutions with a policy against delaying
publication for patenting or other commercial
reasons). The requirement for confidentiality be
fore patenting also limits the depth of any market
research study.
Finally, it must be realized that the more in
novative the invention, the harder it is to get good
market feedback. Potential users of new technol
ogy cannot easily judge the value of something
they have never thought about before. Business
histories are replete with gross underestimations
of the potential of innovative products (for exam
ple, photocopy machines and home computers).
Innovative inventions from basic research in uni
versities should expect to suffer similar challenges.
So what is a technology licensing office to do?
Below are some questions to consider. They
will be answered, for the most part, through dis
cussions with the inventors, some library work
perhaps, some discussions with potential users
or investors maybe, and the experience and judg
ment of the technology transfer staff.
2.1.1

The market

2.1.2

The technology

It will be important to try to answer these ques
tions about what the market for the invention
might be:
• What need does this invention satisfy? Is
this a major, well-recognized need or a mi
nor one?
• How is this need being met now? Or is it
satisfied at all?
• What size is the market? Huge, large, small,
miniscule? (As will be discussed later un
der pricing, more precision here is not usu
ally needed by the patent holder, although
much more precision will be needed by the
licensee or investor.)
• Is the market already established, or will it
need developing?
• Is this a growing field or a dying one?
The institution will need answers to these ques
tions about the new and existing technology and
how to develop the invention:
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• How would this technology change how
the market presently addresses the need?
• Is the new technology not only different
from what is already available, but better?
If better, what are the major benefits it
offers?
• How certain is it that the technology will
work? Can this be demonstrated to a po
tential licensee or investor?
• How long and how much money will it
take to develop the invention into a com
mercial product?
2.1.

Likely degree of patent protection

Answering the following questions will help deci
sion makers determine whether obtaining a pat
ent is worth the expense:
• Did the prior art search (or what is known
about the state of the science) indicate that
broad claims are likely?
• Is the invention at such an early stage in
product development that the patent will
expire before products reach the market?
(Sadly, many have seen their patents expire
just as the market began rapid growth.)
• Is the field moving so quickly that patents
are irrelevant? By the time the patent is
sues, will the invention be obsolete? (This is
not uncommon for software patents in the
United States.)
• Can practice under the patent be detect
ed, thus allowing for patent enforcement
against infringers? (It may be impractical
to enforce the patent if the manufacturing
method is simple and requires no special
materials, and the invention is not evident
in the final product.)
2.1. The inventor

Inventor participation in the development of
university-stage technology is usually critical.
The inventor is most familiar with the technol
ogy and is most likely to have a vision for its use.
Some inventors (particularly students or research
associates) may wish to leave the research institu
tion and join (or help form) a company. Most
professors or senior researchers, however, will

probably choose to stay at the research institu
tion, although they may consult or work part
time for the company developing the invention.
On the other hand, if the inventor has no
interest in seeing the technology developed and
will not help to market the patent, these tasks can
be hopeless.
The following questions should be considered
to decide how effective the inventor might be in
finding a licensee or investor for the technology.
As we shall see, not all of the findings should be
documented!
• Is the invention in the inventor’s major field
of research? If not, is he or she at all familiar
with the market’s needs for the invention?
• Does the inventor have business connec
tions in the field of the invention?
• Is the inventor famous? (It’s a lot easier to
market a patent with a Nobel Laureate’s
name!)
• Will the inventor be cooperative in meet
ing with potential licensees or investors to
share his or her vision of the invention’s po
tential and the means of developing it?
• Does the inventor have realistic expecta
tions about the magnitude and uncertainty
of the development task and the potential
financial returns?
• Can relationships with investors or compa
nies proceed reasonably or is the inventor
too naïve or overly paranoid?
2.1.

Social responsibility

In terms of public policy, patents are two-edged
swords. They can protect investments very effec
tively. Moreover, the licensing of university pat
ents has been shown to stimulate much earlier
investment than the placement of inventions in
the public domain. They can also bring muchneeded revenue to research institutions (although
the revenue potential of university-stage inven
tions has been much exaggerated). On the other
hand, patents can limit investment in new tech
nologies when the patent holder (or exclusive
licensee) does not invest in all of the fields that
can use the patented technology. Patents can also
sometimes be used to maintain high prices on
necessary products by excluding competition.
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As a side note, patents are particularly para
doxical in the development and distribution of
drugs and vaccines for diseases in developing
countries.1 Indeed, if effective drugs and vac
cines for all diseases in developing countries ex
isted and could be manufactured at low cost, a
social philanthropist might wish that no patents
existed, since in theory the absence of patents
would allow competition, leading to lower prices
and wider availability. But in the absence of effec
tive drugs and vaccines, patents may be necessary
to ensure profits for pharmaceutical companies,
thus encouraging commercial investment in the
research, development, and clinical testing of
new drugs and vaccines. This paradox puts a spe
cial burden on technology transfer professionals.
When licensing health- and agriculture-related
patents from nonprofit research institutions,
technology transfer professionals must try to pat
ent strategically to protect profits in developed
countries and encourage commercial research and
development. At the same time, they must use
mechanisms to assure that the poor can access the
final products.
When deciding whether patenting a new in
vention is in the public interest, the following is
sues, among many others, should be considered:
• Is this technology self-evidently useful
without substantial further investment in
development? Will it be widely used even
if it is not patented but put in the public
domain?
• If the answer to the previous questions
is yes, can the patent-holding institution
nonetheless devise a nonexclusive licens
ing strategy that allows revenue to be gen
erated without impeding the use of the
technology?
• If the technology requires substantial highrisk investment, and therefore patent
ing and exclusive licensing is warranted,
should patents be foregone in developing
countries to encourage generic competi
tion? (This approach is reasonable, under
some circumstances, for health and agri
cultural patents.)
• Can the patent holder require sublicensing
of other mechanisms to promote low-cost
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manufacture and distribution in the public
sector of developing countries?
• If the drug or vaccine is expected to be used
only in developing countries, with little
or no market in developed countries, will
market aggregation through patenting and
limited licenses create a sufficiently profit
able market that will encourage develop
ment and clinical testing?
• Should the patent holder carve out free use
of a patented research tool for nonprofit re
search institutions?
2.1. Local considerations

The decision to patent depends, to some extent,
on the institution and its geographic location.
For example:
• In under-developed regions (of both de
veloped and developing countries), tech
nologies well-suited to local industry and
the technology skills of the region, espe
cially, may be promoted to create jobs and
strengthen the local economy.
• Public institutions, more than private in
stitutions, may emphasize technologies
that will enhance local economic develop
ment—particularly if technology transfer
is one of the metrics that legislators use
to decide how generously to fund a given
institution.
• Medical institutions may decide to patent a
product with a relatively small market, be
cause of the potential benefit to patients.
In all, this set of challenges is formidable.
For any given invention, most of the answers
will be guesses at best; still, these should be edu
cated guesses, and the judgment of the technol
ogy licensing office may be all that is available.
Both the technology licensing office and, even
more importantly, the senior administration of
the institution must realize that a decision to
file a patent is a decision to take a risk. Patents
are expensive, and patent budgets are limited.
Nonetheless, decision makers must realize that
although it is easier to say no than yes, the sin
of omission—not filing a patent on a technology
that later becomes important—may be worse
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than the sin of commission, the filing of a pat
ent that is never licensed. Decision makers should
consider that if the requirements for patenting are
too stringent, then only a few of the inventions
submitted to the technology licensing office will
be accepted for patenting. This will be discourag
ing to researchers and will result in fewer inven
tions reported in subsequent years.
2.2 Decision # 2: Whether to market the
invention to existing companies or license
to a spinout

Licensing to an existing company has many ad
vantages over licensing to a spinout (a new com
pany specifically formed to develop the licensed
technology). An existing company already has its
infrastructure in place, including management.
The company usually has sufficient funds to de
velop the invention, and its financial health often
can be readily assessed. The company also usually
has distribution channels, and its brand name and
market access will make final distribution of the
product easier and more effective. From the re
search institution’s point of view, the license agree
ment is much easier than spinout agreements, and
potential conflicts of interest are far less likely.
This is not to say that licensing to an existing
company has no difficulties and disadvantages.
For one, it is difficult to get the attention of an
existing company (particularly a large one) with
new but unproven inventions. Existing compa
nies have already set their research agenda and
priorities, and a new technology needing devel
opment could cause disruption. It is also difficult
to find within a large company a “champion” who
will enthusiastically support a new technology
that is not his or her own when it runs into the
inevitable problems in development.
The single biggest disadvantage of licens
ing to an existing company is the risk that the
company will lose interest in the technology, or,
perhaps worse in the case of an exclusive license,
that it will retain some interest in the invention
but that the project will be given less priority and
inadequate resources. When things do go wrong,
it is often difficult for large companies to identify
the right person to provide information or to ne
gotiate a change in the license agreement.

The advantages and disadvantages of licens
ing to a spinout are almost the reverse of those
for licensing to an existing company. At the be
ginning, at least, the spinout will be dedicated
to developing the invention as its first priority. It
will also usually be working very closely with one
or more of the inventors; moreover, the research
institution itself knows the people involved. The
financial arrangements of the license may include
both shares of stock and royalties, giving some
what more assurance that the institution will get
at least some return from its license. And, if the
company’s strategy does diverge from the origi
nal technology (or the technology doesn’t work),
although there will not be any royalties on the
patent, the equity shares may become liquid and
reward the research institution for its role in start
ing the company.
Spinout companies represent a substantial
risk of conflict of interest, which can be on the
part of the inventor/researcher or on the part of
the institution itself. Frequently, both the inven
tors and the institution will own stock in the
company. This can lead to an unhealthy interest
in the company’s fortunes—the parties involved
may encourage the institution to make conces
sions on future IP, to sequester data from publica
tion, or to misuse institutional resources or staff
time. The situation is exacerbated if the institu
tion also invests its own funds in the company.
Thus, research institutions need well-crafted and
well-enforced conflict of interest policies if they
plan to engage in spinning out companies around
their technologies.
Spinout companies are also fragile. They
must find management talent and raise invest
ment money. They are highly dependent on the
talent of the management team, and a bad hire
can set the company back for a year or more. A
spinout company often has difficulty in market
ing and developing distribution channels. In hard
economic times, further investment may be very
difficult to attract, and the research institution’s
equity shares may become valueless due to a
down round of investment or a low-price sale to
an acquiring company, made in desperation. And,
because of the complexity of equity investments,
the technology transfer agreement is likely to be
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considerably more difficult to negotiate than a
conventional license.
The advantages and disadvantages of conven
tional licenses and spinouts will be different for
different inventions. A spinout may be preferred
when the following criteria are met:
• The invention is a platform technology that
may lead to not just one but many products.
It is difficult to justify the risk of a spinout
when only a single product is envisioned.
Also, a spinout company is more likely to
try to exploit the full range of potential ap
plications of the technology, while an es
tablished company will more likely focus
on a single addition to its existing product
line.
• There is no existing industry making similar
products. It is difficult for a new company
to compete in an established market unless
the technology is overwhelmingly superior.
• The market is large enough to justify the risk.
This is particularly true for technology requir
ing substantial investment in development.
Since the failure rate of spinouts is often
high, investors expect a very large return on
their investments from the winners. A small
market, therefore, will not be sufficient.
• Strong intellectual property (IP) protection
exists in the country in which the spinout
exists and/or in the major markets to which
it intends to export. Patents are the prima
ry protection for small companies against
larger companies that enter a market after
a technology is proven successful. Without
them, the market strength of a large compa
ny that is the second to enter the market can
overpower the innovating small company.
• At least one credible inventor will join the
company as founder, consultant, and/or
employee (the most important criterion).
Without this human technology transfer,
it will be almost impossible to raise invest
ment money and much more difficult to
develop the technology.
In reality, the choice between a convention
al license and a spinout often is made for the
technology transfer office. If the inventor is not
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interested in contributing to the spinout, it is un
likely to be successful. On the other hand, if the
inventor wants to form a spinout and there are
no clear reasons why this is impractical, then it is
not advisable for the technology transfer office to
“take the baby from its parent” and give the job
to an existing company. Such an act would likely
cause political problems in the research institu
tion and could also discourage future inventors
from reporting their inventions.
2. Decision #3: What to charge
for the invention

Although research institutions may engage in
technology transfer primarily for social benefit,
most nonetheless expect to reap a reasonable fi
nancial return from those licenses. The company
expects to make a profit from the product with the
proviso that concessionary terms may be appro
priate for critical public goods where the markets
are small, or the ability to pay is very limited.
Under the usual (profit sector) conditions,
how does a technology transfer office decide
what is a reasonable return from licensing a
particular invention? Unfortunately, all too
many technology licensing offices spend far too
much time trying to evaluate the total value of
embryonic inventions in some supposedly sci
entific manner. Calculators are kept running
on Net Present Value calculations and other
more abstruse formulae, when the major inputs
to the formulae—cost of developing the tech
nology, cost of manufacture, the market adop
tion cycle, and the ultimate market size—are
all unknown and cannot even be reasonably
estimated. Thus, the calculations often fulfill
the “garbage in/garbage out” axiom, producing
largely meaningless results.
Fortunately, technology transfer offices are
almost never asked (or able) to sell a technology
outright for a single lump sum. (Few companies
or investors would be willing to pay any substan
tial sum up front for unproven technologies even
if the research institution was willing to make the
offer.) Thus, the full worth of an invention need
not be calculated at the time the technology is
transferred. License agreements and spinout agree
ments share the risk of this uncertainty between
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the research institution and the company through
a combination of payments, some at the begin
ning of the license and others later, depending on
future sales or the company’s future success.
In a conventional license to a company, the
financial components of the license may include
(among possible other terms, such as sublicens
ing fees):
• a license issue fee: a negotiated amount pay
able at the time the license is executed
• license maintenance fees: annual fees, usu
ally creditable against royalties in any year
where royalties are payable (Thus, the li
cense maintenance fees function as “mini
mum royalties” in years when the product
is sold.)
• patent cost reimbursement: almost always
required by universities
• milestone fees: usually applied only when
the technology is very risky and requires
significant investment (Meeting a mile
stone—such as approval for clinical testing
or regulatory approval for sale—validates
the technology, allowing the research in
stitution to expect more rewards after the
relatively low initial license fees.)
• running royalties: usually a percentage of
sales (Major value is expected here, but
it is contingent on the technology’s suc
cess and on the market’s acceptance of the
product.)
In a license to a spinout company2, the finan
cial components may include:
• a license issue fee
• license maintenance fees
• patent cost reimbursement
• milestone fees
• running royalties
• shares of stock (in other words, equity) in
the company
Shares of stock may or may not be the ma
jor source of return for the research institution.
Equity in the company is certainly the riskiest
component for the institution. In harsh economic
climates, the company may have a difficult time
reaching liquidity (that is, public stock trading

status or acquisition by a larger company). In ad
dition, if the company has to raise more money
later from investors and its progress-to-date has
not been good (or the economic climate for in
vestment is bad), the company may have to ac
cept funding in a “down round investment” that
makes the initial stock almost worthless.
If both running royalties and stock are taken,
then each is usually lower than if the deal were
“pure cash” or “pure equity.” In addition, license
fees are usually lower than from a large compa
ny, since a new company will typically be cash
poor and will need to use its cash to develop the
technology.
The main point for both conventional licens
es and spinouts is that if the technology is suc
cessful the major financial returns will be from li
cense fees and/or equity. With both conventional
licenses and spinouts, the returns are linear. That
is, once a running royalty rate is set (for example,
4% of net sales), then the formula will make “ap
propriate returns” regardless of whether the sales
of the final product are US$100,000 per year or
US$100 million per year:
• If the sales are only US$100,000 per year,
then the company pays the research institu
tion only US$4,000 per year; a small but
fair number, since the sales have not been
high.
• If the sales are US$100 million per year,
then the research institution receives US$4
million per year, reflecting the large success
of the product.
Similarly, if the research institution takes
100,000 shares of founders stock from a total of
one million shares of founders stock issued, rep
resenting 10% of the company, in exchange for
the technology (the total number of shares, one
million in this case, is totally arbitrary: the per
centage of the total is what counts), then:
• If the share price at liquidity is US$50 per
share (reflecting a successful company), then
the university will receive US$5 million.
• If the share price is low, reflecting a “despera
tion acquisition” price of only US$0.50 per
share, then the research institution will get
only US$5,000. (This is not unheard of.)
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It is worth reiterating that the research insti
tution does not need to know the total value of
the technology at the time of licensing/spinning
out, because the linearity of running royalties
and/or equity determines the amount the insti
tution will receive. The acquiring company (or
spinout), however, must have a much better es
timate of the final value of the technology and of
the cost of developing it, since the spinout must
balance the cost and risk of developing the prod
uct within the market against expected sales and
profit returns. Fortunately, industrial concerns
and financial investors have better resources for
making these estimates.

3. SO, WHAT ARE THE NuMBERS?
This section is a risky one to both write and read.
People often ask for numbers, but the problem is
that there are no typical numbers, because there are
no typical deals; each one is unique. The section
does, however, attempt to provide some guidance
on numbers. Those presented here are all based on
personal experience with U.S. and U.K. institu
tions and all depend on the following:
• the importance of the technology to the fi
nal product
• the type of product
• the uniqueness of the technology and the
final product
• the typical profitability of that type of prod
uct and/or the industrial sector
• whether the IP is the key IP for the com
pany or only a small piece of its holdings
• the strength and breadth of the IP
• whether the IP includes:
- only present patent rights
- additional know-how for which the
research institution can command re
turn (most know-how is in the public
domain)
- a “pipeline” to future technology and
patents from the research institution (a
dangerous precedent if the pipeline is
too wide)
• whether the company will have to license
blocking patents from third parties
• the state of development of the technology
02 | HANDBOOK OF BEST PRACTICES

• how much and how long it will take to de
velop it
• the cost of development in the country in
which the company resides
• the state of the economy—including the
state of the stock market and the investment
climate in both the country of origin and, if
different, the country of the licensee
• the negotiating power of the research insti
tution relative to the company
• the negotiating skill of the research
institution
The amount of equity the university gets will
depend on all of the above variables, as well as on
the extent to which the research institution “in
cubated” the technology and spinout company
before the technology left the institution. For
example, the amount (or percent) of equity will
be lower if the university merely licenses the aca
demic-stage invention to a newly incorporated
company and higher if the university invests in
showing proof of practical concept or in develop
ing a prototype of the final product. The level of
equity will be highest if the university assists in
forming the company itself, devising and writing
the business plan, hiring the management team,
helping the company raise money, and even al
lowing the company to be housed in the labora
tories of the research institution for the compa
ny’s first year or two of life.
With those caveats, the typical ranges are
given in Box 1 for license fees and royalties for a
conventional license, based on U.S. experience,
with the further caveat that some deals fall out
side of these ranges.

4. CONCluSION
The task of evaluating and pricing early-stage
technology is more art than science. (This is
true for negotiation too.) Success requires a
general knowledge of product development,
manufacture, and markets, plus knowledge of
the pricing for comparable technologies (when
the information is available), plus experience.
Technology transfer offices primarily learn
from their own experiences and by studying the
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experiences of similar institutions. If the offices
can attract and retain both talented staff and
commitment from their administration, they
will get better with time.
No deal will be perfect. Some will fail. It is
important to remember, however, that it is far
better to conclude a deal with a company that
will competently develop the product than to
wait for the best deal or to fight interminably for
the best financial terms. Only when the technol
ogy is developed and brought to market will the
public benefit. And that is ultimately why uni
versities and their technology licensing offices are
in business. n

LITA NELSEN, Director, M.I.T. Technology Licensing Office,

Massachusetts Institute of Technology, Five Cambridge
Center, Kendall Square, Room NE25-230, Cambridge,
MA, 02142-1493, U.S.A. lita@mit.edu
1

See also in this Handbook, chapter 1.4 by L Nelsen and
A Krattiger.

2

See also in this Handbook, chapter 13.1 by A Brown and
J Soderstrom.

Box 1: M.I.T.’s license Fees and Royalties
(u.S. dollars)

Conventional license (without equity)
• License Issue Fee: $10,000–$200,000
• Annual license fee (minimum royalties): $20,000–$200,000 (often beginning low and increasing
by year until the amount reaches a plateau)
• Milestones (when present): $0,000–$1,000,000 (the latter when Food and Drug Administration
approval for marketing is gained for a major drug)
• Running Royalties: 0.%–% (the lower range for process improvements or commodity products;
the higher range for noncommodity products and patents with product claims) This may be still
higher for software and for composition of matter patents on drugs.

Based on U.S. and U.K. experience, the following division of equity is typical for a spinout after it has
raised $1 million in investment. It assumes lower license fees and royalties:
Spinout Company Equity Shares After $1 Million of Investment
Venture investor: ........................................................................................ %
Research institution’s share based on IP alone: ................................. %–%
(If) Research institution does extensive incubation: ........................ 10%–1%
Research institution total: ....................................................................... 1%–22%
Employee stock option pool: ................................................................... 20%
Founding entrepreneurial team: ............................................................ 2%–2%
If no incubation was provided by the research institution, then the entrepreneurial team’s share may
be 0%–%.

HANDBOOK OF BEST PRACTICES | 0

CHAPTER 9.2

Technology Valuation: An Introduction
ROBERT H. POTTER, Senior Associate, Agriculture & Biotechnology Strategies, Inc., Canada

ABSTRACT

This chapter explains the basics of the various ways of
estimating value of a new technology, focusing on the
importance of agreeing on the value before finalizing a
technology transfer deal. Indeed, value is simply the ne
gotiated amount arrived at between two parties. Although
there are many ways to place a value on a technology,
most licensing deals focus on royalty amount, since it
spreads the risk between the technology provider and the
developer. The percentage assigned to royalty has to be
negotiated. Several factors will affect royalty value: level
of market demand, the improvement the technology can
bring to the final product, whether or not other invest
ments will be needed to develop the final product, and,
most importantly, the predicted rate of uptake in the
marketplace. Some understanding of these factors, or at
least the procedures used to estimate them, will enhance
one’s ability to negotiate a deal that will both help bring
the technology to market and nurture the relationship be
tween the parties, thus facilitating any future technology
transfer deals.

1. INTRODuCTION
What is value and what are valuation techniques?
Value is what a willing buyer and a willing seller
have agreed upon as the basis for the exchange
of property or, in our case, intellectual property
(IP) rights. The critical point is finding a particu
lar value that is agreeable to both the buyer and
the seller. The first task, and the most difficult
one, is assigning realistic values (that the partners
can agree on) to the various factors in the system.

Simply put, valuation is the process of estimating
a mutually agreed upon value for a product or an
intellectual property that will enable its transfer
from seller to buyer. People use many techniques
to reach this value. A perfect valuation scenario
would be one where both the buyer and seller
walk away each thinking it got the best deal.
Although we may not realize it, we use valu
ation techniques every day. For example, an indi
vidual might not hesitate to pay US$6 for a ham
burger, but would certainly not be willing to pay
US$50 for the burger. This is because we perceive
the value of a burger to be within a limited range.
The benefits we derive from a burger are not ex
pected to cost more than the money we are will
ing to spend; otherwise, one will eat elsewhere.
From the buyer’s point of view, the cost, benefit,
and competing alternatives determine what we
will pay, and, therefore, determine a value. That
value will change depending on where we are,
how hungry we are, and how far the nearest bet
ter alternative is. From the seller’s point of view,
the questions are: How much can I charge for the
burger? What is the demand for my burgers? How
many different alternatives are there? How is my
product distinct and superior to the alternatives?
This chapter provides background knowledge
on technology valuation that is particularly rel
evant to IP rights in agriculture. The chapter aims
to heighten readers’ awareness of the important

Potter RH. 2007. Technology Valuation: An Introduction. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org.
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issues and methods involved in technology valua
tion when negotiating the sale of rights to a new
technology as well as in other circumstances.

2. VAluATION OF
INTEllECTuAl PROPERTy
Much energy has been spent determining meth
ods for valuing intellectual property, technology,
or products. All available approaches require dif
ferent amounts of data and serve different pur
poses (limitations are inherent regardless of the
approach taken). A brief overview of the most
common approaches to technology valuation is
provided in this chapter. More detailed discus
sions are found elsewhere in the Handbook.1
The valuation of intellectual property tends
to be very complex, since the task of valuation
involves determining the present value against a
future technology or product. Various methods
have been developed that use greater or lesser
amounts of economic theory. In the end, as the
value will usually be a negotiated figure, what is
most important is to find a method that both par
ties agree will produce a value they can accept.
The most common method of valuation is a
process of discounted cash flow, which calculates
the present value of future revenues. Present value
reflects the price a purchaser of the intellectual
property is willing to pay now, in order to receive
anticipated cash from future sales of the product.
Different variables and factors can be built into
this, such as the risk of the technology not deliv
ering promised returns, but obviously it is hard to
accurately estimate the future cash flows from in
tellectual property or from an undeveloped, un
tested technology. The closer one comes to a final
product, the more realistic will be the estimate
of future cash flow. Waiting until near the end of
product development to negotiate royalties can,
however, give rise to serious problems in reaching
a negotiated settlement.
Most valuation models rely on market data,
which, at best, can provide only a range of prob
able values. For a revolutionary new product, di
rect market data is often unavailable and proxies
(or existing products on the market) are used as
substitutes. The complexity of valuation arises
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from the challenge of identifying useful, appro
priate proxies. The more appropriate data one
uses, the more accurate the valuation will be.
Furthermore, the individual and specific val
ue of assets will vary widely. Understanding how
these specific values are statistically distributed
will greatly help estimating value, since including
a probability of receiving a specified return aids
decision making. Wherever an individual compo
nent has a range of possible values, knowing the
statistical distribution over this range can make
the overall valuation more accurate and also allow
one to estimate the probability that this value will
actually be achieved.
The following sections identify several valua
tion approaches and provide a short explanation
of each. To illustrate this, each approach is ex
plained with reference to a fictional, ongoing ne
gotiation, between the University of Costa Rica
and Mer Seeds SA de CV, over a commercial-use
license for a root-rot-resistant gene isolated at the
university. The gene has been transferred into a
line of a root crop called mer, which Mer Seeds
intends to cross with their elite breeding lines.
2.1 Cost approach

The cost approach is based on covering costs of
developing a new product. Using this approach,
the University of Costa Rica would seek to charge
a one-time fee to cover all research and possible
patenting costs for isolating the gene and produc
ing the transgenic root-rot-resistant mer. While
this approach is a highly relevant one for pricing
an article produced for sale, the approach is rarely
used to assign a value to a piece of intellectual
property, because the cost to develop something is
not usually related to the value of any intellectual
property it contains. One version of the approach
is to calculate anticipated future costs of develop
ing similar technologies—in effect, using the pro
ceeds from the sale of this technology to pay for
developing the next one. This approach, however,
is highly subjective and difficult to justify.
Still, knowing the cost of development of
a particular technology is often useful and rel
evant when calculating the relative inputs of par
ties into a joint venture. If, instead of licensing
a technology, an institution enters into a joint
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venture to develop a product, initial investments
into the joint venture often control the share
assigned to each party. A university or research
institution may not have adequate financial re
sources to develop a product from a technology,
but the institution could justifiably claim a share
of a joint venture based on the investment in the
project up to that point, as well as the product’s
potential value.
2.2 Income approach

A pure income approach is carried out by discount
ing future anticipated revenues (cash flows) sev
eral years into the future. In our scenario, this ap
proach is used when the University of Costa Rica
asks Mer Seeds SA de CV how much it would
be willing to pay now for a certain return in the
future (for example, US$10 million in 10 years
time). The big drawback to this approach is that
there may be no sales, market, or cost data from
which to predict future revenues. Furthermore,
the method relies heavily on allocation of risk: de
termining what the chances are of a disappointing
return (or even of no return at all) and who should
take this risk, the university or the company? Risk
estimates are crucial for determining whether to
invest in a new technology, but they are too often
based on little more than gut feeling.
2. Market approach

The market approach requires finding a similar or
comparable technology to the one being evaluat
ed. In our scenario, the University of Costa Rica
would look for other root-rot-resistant mer plants
on the market and determine how much farmers
are using and paying for the seed. So, the valua
tion would rely on finding sufficient data about
similar transactions to arrive at an accurate esti
mate of the value of the new product. The inher
ent weakness of this approach is the difficulty of
obtaining data for a truly novel product.
2. Hybrid approaches

The more common approach is to use a hybrid
of income and market methods of valuation.
This combines the benefits of market compara
bility and the business community’s familiarity
with the income approach. In our example, Mer

SA de CV would use its experience with similar
products to estimate what farmers would pay and
how quickly the market for the seed would grow
to produce the estimated income. This method
is usually applicable where there is prior experi
ence and sufficient information. Where products
are being developed in-house (for example, in a
large company that performs all or most of the
research and development), calculating the net
present value of a new product is based on this
hybrid method. Decisions on funding products
are made by estimating a certain minimum net
present value.
2. Royalty rate method

Because royalties give the inventor a return on
sales of the final product, royalties are often used
to share the risk between the inventor and the de
veloper. Parties often use a royalty rate that has
been agreed upon in the past for similar technolo
gies; that rate is then applied to anticipated rev
enue streams. Because of the risk-sharing nature
of this method (if the product does not become a
success, the royalty amount is low), this is a com
mon approach to licensing technology. But the ap
proach does not always result in a valuation of the
technology itself. Indeed, royalty rates are often
determined arbitrarily, with little or no relation to
the added value the technology may give to the
product. For example, in our scenario, if an ini
tial collaborative research agreement between the
University of Costa Rica and Mer Seeds limits the
university to a maximum royalty of 5% of gross
revenues, then, if the technology increases the
value of Mer seed products by more than that, the
university loses. Another problem with arbitrarily
applying royalty rates, in this case, is that if Mer
Seeds were to combine several traits in one variety,
then the company might be unable to afford to
pay 5% royalties to each technology provider if
the combined added value was insufficient.

3. THE PRODuCTION SySTEM
To accurately value a new technology, the existing
production system must be understood in order
to see where the new technology will be applied.
While agricultural systems vary due to climate
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and local soil conditions, data do exist on input
(costs) and output (benefits)—as in any field.
Because of the complex interrelationships among
agricultural markets, competition is hard to es
timate, but data does exist upon which to base
assumptions. As modern agricultural products
rely more and more on biotechnology, a relatively
new field, for which there is little information
and substantial risk that there will be no product
at all, valuation becomes more difficult. To illus
trate the complexities of agricultural systems, we
use an input/output or cost/benefit model based
on the harvest of mer (see Figure 1).
The diagram depicts average returns per
hectare of mer in Latin America. Input costs,
such as for seed, fertilizer, and pesticide, have
been derived by converting to U.S. dollars from
the average costs in Latin America of those items.
Similarly, yield in metric tons (MT) was calcu
lated by taking conservative yield figures and

deducting average post-harvest and pest losses
to arrive at the final yield per hectare for the av
erage mer farmer. Returns are divided between
those from mer that is consumed domestically
(Domestic) and those from mer that is exported
(Export). On the basis of this model, production
costs are US$90 and returns are US$220. A new
product that reduces inputs (pesticides, in this
case, of root-rot-resistant mer) can be calculated
to increase returns by the amount that the pes
ticides cost.

4. VAluING IP RESOuRCES
Sometimes, all of the IP resources of a company
or institution need to be valued. Valuing these re
sources can provide a value for the whole compa
ny, including its intellectual property and physi
cal resources, or it can reveal the input a company
is investing in to developing a product, excluding

Figure 1: Hypothetical Cost/Income Model
for Mer Production in latin America
Mer - Inputs / Production costs

Returns

Export market

Seed

US$160
(2 x US$80)

US$30

yield

Pesticide
US$25

Fertilizer; organic
inputs; standard
cropping practices

10 metric tons

Pests

Domestic market
US$160
(3 x US$20)

Post-harvest losses

US$35
Note: The online version of the Handbook (www.ipHandbook.org) contains a downloadable Microsoft®
Excel spreadsheet, which readers can use for modeling cost/income scenarios.
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the technology that is being negotiated. In our
hyphothetical example, Mer Seeds can point to
the intellectual property that it already owns, for
example, existing mer varieties, to show that the
company is investing significant resources into
developing the new product and also to show that
the gene being obtained from the university will
be worth only a portion of the total added value.
Knowing such figures is relevant for joint venture
negotiations.
One complication in these calculations is the
need to value nonformal intellectual property: the
know-how, experience, and expertise that reside
in the company, and in its employees, and that
may not be protected by patents and trademarks.
Institutions that consider only the value of formal
intellectual property stand to lose from overlook
ing this form of intellectual property.
.1 Excess earnings/residual value

The excess earning/residual value approach places
a valuation on an entire business, rather than a
single technology. The approach is appropriate
only if a company has just one major-platform
technology and its business is based purely on
products related to that technology. Using a pe
riod of five or more years immediately prior to
the valuation date, a percentage return is assigned
to the average annual value of tangible assets used
in a business. This return is deducted from aver
age earnings of the business for the same period,
and the remainder, if any, is considered to be the
amount of the average annual earnings from the
intangible assets of the business. Since this meth
od is based on past data, it is not necessarily useful
for valuing a novel technology, but it may be used
to value a company’s existing technologies. which
will allow for the determination of how much
of an input one side is making in a negotiation.
For example, Mer Seeds could use this method to
value its existing germplasm in order to show that
the varieties coming out of the transgenic project
are just as much due to their germplasm as to the
transgene. The main flaw in this model, however,
is the assumption that excess earnings above and
beyond the return on tangible assets are solely at
tributable to intangible assets. Such thinking can
lead to an error in valuation because it assumes

that the business is maximizing the exploitation
of all of its intellectual property.
.2 Technology factor method

The technology factor method is a modification of
the income or excess earnings approaches that
addresses the shortcomings of these approaches
by directly measuring the contribution of the
technology to the total revenue of the business.
The technology factor method can be used on
one technology at a time to eliminate the limita
tions of the excess earnings method, in which the
whole set of intangibles are valued and lumped
together. The technology factor method might be
applicable to Mer SA de CV if it sold many more
agricultural products than just mer seeds and if
most of these products had a relatively low tech
nology input (for example, if the company dis
tributed many agricultural chemicals produced
by large multinational corporations). In this case,
an overall picture would not give the true worth
of the value of the company’s germplasm.
. Options pricing method

The options pricing method estimates the value of
the technology at the point it is considered to be
successful and then calculates the probability of its
preliminary successes along the path to commer
cialization. In the root-rot-resistant mer example,
basic research has already been done, but there are
still the possibilities that the technology will not
work in the field, that farmers will not be prepared
to buy it, or that a competitor will offer a better
product (such as a very cheap fungicide). It is also
possible that transgenic mer will not be approved
for biosafety or food safety reasons. The probabil
ity of success at each step in the process is very
hard to calculate, but with each step, the value of
the technology effectively rises as the risk of failure
diminishes. To use this model for early estimates
of value, the technology must be well defined and
the statistical analyses of historical data must be
significant enough to allow the appraiser to assign
probabilities to the technology as it proceeds from
one step to the next. This method is applicable
to start-up companies during their initial rounds
of financing, and also for companies developing
high-risk technologies, such as pharmaceuticals.
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. Technology risk/rewards method

The technology risk/rewards method uses the value
of roughly comparable technology-based busi
nesses as a proxy for the value of patents, and
then subtracts from this number the amount of
cash needed to further develop the technology to
a commercial stage. Thus, Mer SA de CV would
first calculate the value the company could gain
from the technology and then look at the invest
ment needed to bring the technology to market.
Using this number, the company would decide
whether to commercialize the product and wheth
er paying the University of Costa Rica could be
afforded. One drawback of this method is the
assumption that the value of technology-based
companies reflects only the value of the technol
ogy, which ignores many other factors.

5. ADOPTION
One very important factor in determining the
market value of a product is how much of the

product is sold or used and at what rate demand
for the product develops and increases. A prod
uct’s success depends not just on the number of
people who try it once, but on the number of re
peat users. This is referred to as the adoption pro
cess, in which a product goes from being new in
the marketplace to being an established product
(or, in some cases, obsolete).
Figure 2 is a generalized adoption curve
for a hypothetical new technology or product.
Importantly, the rate at which a product is taken
up has a great effect on the revenue that goes to
the developer of the product. In this case, as of
ten happens, initial uptake is low, and adoption
grows slowly as people become aware of the prod
uct, try it out, and use it. Early adopters show
the product’s potential value, and gradually other
consumers begin to use it. As more users see the
benefits, the product spreads throughout the
market. When the new product approaches full
market penetration, the rate of uptake slows—
there are always people who are either very late

Number of users

Figure 2: Generalized Adoption Curve For a New Product

uptake Time
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in adopting or will never adopt the product. At
some point other competing products may enter
the market and reduce market share, or newer
technologies may arise that replace the product
completely. The actual curve, therefore, will be
more complex than Figure 2 suggests.
In reality, farmers are likely to be wary of ini
tially investing heavily in an agricultural product,
such as a new seed variety. Some will try it out
on part of their land and, if they feel it is worth
the investment, they might then plant more of the
seed. Other farmers may see this and decide to try
out the seed themselves. Once a certain amount
of the seed is being grown, the adoption rate will
increase. However, there will almost always be
some farmers who will either delay adoption or
not adopt at all, because they prefer traditional
methods, are unwilling to change, or perhaps be
cause their land is of such poor quality that the
increased yield does not cover the increased price.
Calculating the value of a product by mak
ing sales projections (the income approach) must,
therefore, consider not just the total area of land
on which a seed could be used, but also include
a realistic sense of the rate at which the coverage
area will expand to reach the total. Meanwhile, as
other products will also likely become available,
the original product will be unlikely to retain its
area indefinitely.

6. CONCluDING REMARKS
As the discussions above indicate, no universal
method for technology valuation exists. In fact,
different methods will often be used within one
organization. The method chosen depends on the
kind of technology in question and whether one
is a technology buyer or a technology seller. In the
end, however, what most matters is the accuracy
of the estimations and assumptions about whether
a product will be a success and how much people
will pay for it. Estimating the size of the potential
market and the adoption rate for the product are
both important in this process.
Negotiating is a big part of arriving at a value
for your technology, but remember that develop
ing intellectual property into commercial prod
ucts through in-licensing and out-licensing is not
a zero-sum game. Both buyer and seller are look
ing to get something good out of the deal. And
these are the much-sought win-win deals. n
ROBERT H. POTTER,

Senior Associate, Agriculture &
Biotechnology Strategies, Inc., 106 St. John Street, PO Box
475, Merrickville, Ontario, KOG 1N0, Canada. rpotter@
agbios.com
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See, also in this Handbook, chapter 9.3 by R Razgaitis.
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Pricing the Intellectual Property of Early-Stage
Technologies: A Primer of Basic Valuation
Tools and Considerations
RichaRd RaZgaiTis, Senior Advisor, CRA International, Inc., U.S.A.

ABSTRACT

This chapter introduces technology managers to certain
key issues and to six methods of valuation and pricing.
The value of a technology to a buyer (licensee) depends
upon how it is to be commercially employed, taking
into account the cost of development, the time the tech
nology takes to generate returns, the extent of such fi
nancial returns, and the risk involved in the process. At
the time of a licensing/sale transaction of an early-stage
technology many, perhaps all, of such factors need to
be assessed and quantified by making judgments about
how the future will unfold with respect to the technolo
gy being developed. This assessment and forecast assess
ment are the essence of all pro forma business models.
Valuing license rights for early-stage technologies is in
this sense no different than making other future busi
ness forecasts, though the details may differ because the
forecast time horizon may be longer, the uncertainties
may be greater as to the market size and profitability,
the operating performance of the technology as it will be
used in commercial operation may be less well defined,
and other factors. The price paid for a technology trans
ferred between parties is the amount of money (present
and future) and/or the financial value of noncash assets
given in exchange for the transfer of the technology,
which can only occur if both the seller (licensor) and
buyer (licensee) have by some process reached a com
mon, present understanding of value that makes agree
ment possible.

A key consideration in valuing a technology and arriving
at a price is determining what is to be provided or trans
ferred between the parties. This may include exclusive or
nonexclusive rights to specified patents, know-how, and
copyrights (IP [intellectual property] rights), technical
data, rights to future-seller improvements, rights to subli
cense, and the like. The price can consist of any combina
tion of a variety of types of consideration, including run
ning royalties, fixed payments, common stock (equity),
R&D funding, lab equipment, consulting services, grant
backs, or access to other proprietary buyer resources.
Although sometimes used, cost-basis pricing is a poor ba
sis of valuation, because it fails to consider a technology’s
value based on future commercial applications: the market
pays for value to be received, not the cost to create. This
chapter introduces and explains six methods for valuation
and pricing that are based, to one degree or another, on
the market’s expectation of value.
• Method I: The Use of Industry Standards Method
looks at the range of published royalties (and other
forms of payment) from technology licenses with
in an industry category and uses that information
to guide valuation of a technology currently under
consideration.
• Method II: The Rating/Ranking Method looks
at several existing license agreements for similar
technologies, comparing and ranking a technol
ogy currently under consideration against the
existing license agreements in terms of stage of

Razgaitis R. 2007. Pricing the Intellectual Property of Early-Stage Technologies: A Primer of Basic Valuation Tools and
Considerations. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual (Second Edition Part II: Chapter 4).
© R Razgaitis. 2007. All rights reserved. Photocopying and distribution of this chapter through the internet is permitted
provided that: (1) this complete copyright notice is included; (2) no derivative works or changes to this text are made; (3)
the chapter is copied in its entirety as a single, complete stand-alone work and not be combined with any other text, images, graphics, or works; and (4) no compensation is sought or received for any such copies. www.razgaitis.com.
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•

development, scope of IP protection, market size,
profit margins, and other such factors.
Method III: The Rules of Thumb, such as the 25%
Rule (and Other Rules) Method, which appor
tions anticipated profits from the commercial use
of the technology between the seller and buyer.
Method IV: The Use of Discounted Cash-Flow
Analysis with Risk-Adjusted Hurdle Rates Method
seeks to split expected returns but adjusts basic
profit and loss accounting terms to take into ac
count the timing of investments and returns and
the risks borne by both parties. The method intro
duces a discussion of the different possible struc
tures of payments that are possible, as they affect
both timing and risk.
Method V: The Advanced Tools Method applies
statistical methods, such as Monte Carlo simula
tions, to discounted cash-flow models to test the
influence of various value assumptions and license
terms on the possible outcomes of a deal.
Method VI: The Auctions Method allows in
terested parties to bid on the technology, based
upon their own independent efforts at valuing the
technology, thus comparing their respective valua
tions, identifying the highest valuation, and strik
ing a price based on that highest valuation.

pREfACE
Although we will consider each of the valuation
methods one at a time, doing so does not sug
gest that only one method is to be used in any
given valuation, nor does having six methods
mean that all should be used in every situation.
Depending on the circumstances it is likely to be
advantageous to consider more than one method
in any particular valuation. Yet, not all methods
work equally well in all circumstances, and there
is always the practical consideration of the com
mensurate level of valuation analysis appropri
ate to the magnitude of the potential licensing
opportunity.
The context of the valuation and pricing
discussed in this chapter and with the valuation
methods is licensing (sale) generally known as op
portunity licensing, as distinct from licensing in
litigation contexts. In litigation matters there is
normally a very narrow focus on certain claims
of certain patents that have been infringed as of
a particular date with respect to specified prod
ucts and which patents are known to be valid,
enforceable and infringed. On the other hand,
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opportunity licensing of early-stage technology
is normally performed prior to a licensee’s com
mercial use, includes deal elements other than a
narrow enumeration of certain patent claims, and
anticipates the potential future use for a range of
products, applications, and markets.
This chapter is necessarily a short introduc
tion to a complex subject. The author has writ
ten three published books that give a much fuller
treatment of these valuation and pricing matters
than is possible here. Two of the books are cur
rently in print and available from online sources
such as Amazon® and are recommended for those
who are charged with valuation and pricing of
technology.
• Valuation and Pricing of Technology-Based
Intellectual Property, Dr. Richard Razgaitis,
published by John Wiley & Sons, 2003.
• Dealmaking Using Real Options and Monte
Carlo Analysis, Dr. Richard Razgaitis, pub
lished by John Wiley & Sons, 2003.
• Early-Stage Technologies: Valuation and
Pricing, Dr. Richard Razgaitis, published
by John Wiley & Sons, 1999 (now out of
print, and supplanted by the 2003 valua
tion and pricing book).
Finally, the views expressed here, as in my
above writings, are solely those of the author, and
are not intended to represent the views of CRA
International or that of any professional society
of which I am a member or officer.

1. InTRoduCTIon
One of the most interesting and challenging
tasks facing a licensing manager is determining
the value and price of its specific opportunities.
This chapter provides an overview of useful tools
and methods for this purpose and offers general
observations on licensing practices.1 Because each
valuation situation depends on numerous, casespecific factors, such generalizations may not ap
ply universally, so readers are encouraged to be
cautious when drawing parallels or imagining
similarities.
Pricing, of course, is a crucial issue in the
commercialization process. The customer for
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early-stage technologies can be viewed as a valueadded reseller. Resellers will be induced to buy
(license), if and only if they believe that they can
conduct all the value-added activities needed and
sell the result to their customers at a price signifi
cantly greater than what they paid to acquire the
rights.
When selling rights to early-stage technolo
gies, there are (usually) significant uncertainties
facing both the owner of the technologies and the
licensee. These uncertainties include important
issues such as:
• Does the technology really work in a pro
duction setting as opposed to inside a clois
tered laboratory?
• What product development and manufac
turing activities will need to be conduct
ed—and at what cost—to bring the tech
nology to commercial maturity?
• Will there be any commercially valuable
patent protection to bar copycats?
• What product do end users really want
from the technology, and how much will
they be willing to pay?
• What regulatory requirements will need to
be satisfied?
• How much better is this technology than
what is already available?
• Will competitors develop an even better
way of meeting the end user’s needs?
One way to begin to get around the pric
ing issue is to use royalties. The advantage of the
royalty (and equity) concept is that it spreads,
to some degree, these uncertainties and risks be
tween the parties. Under a royalty (or equity) ar
rangement, technologies that ultimately become
wildly successful in the marketplace will return
high financial rewards to both the licensee and
the licensor in some direct proportion to the
degree of commercial sales achieved. This helps
remove some of the anxiety of determining the
right price—but not all of it.
Technologies that lead to highly profitable
outcomes for a licensee typically warrant a higher
royalty rate on behalf of the licensor. Similarly,
smaller returns (with all relevant factors consid
ered) warrant a lower rate. By fixing a royalty rate,

an equity split, or any combination of royalties
and equity, the technology transfer manager is
apportioning the total financial reward between
the creating organization and the commercial
izing organization. That split should depend on
the relative value-creating contributions of both
parties.
Determining a fair royalty depends on a
present understanding of the commercial use
and economic impact of the licensed technol
ogy. From this perspective, it is better, when
feasible, to defer setting the royalty rate to the
time, or closer to the time, of commercial intro
duction. When licensing early-stage technology,
this means that the license or option agreement
would leave the royalty rate unspecified. The par
ties would commit to engage in good-faith nego
tiations on this matter at a later date, preferably
when a projected income statement based on
more robust market and manufacturing projec
tions was available.
But prospective licensees generally look
at this approach with disfavor. They argue that
the royalty rate is an important factor in reach
ing a decision about licensing the technology in
the first place. Further, the licensees argue that
they cannot commit substantial product- and
market-development investments and risk fac
ing a carnivorous licensor seeking unreasonable
compensation at the eleventh hour. And there are
also some good reasons why a technology seller
might not prefer to defer royalty negotiations.
Depending on the final royalty values, the seller
might have elected to pursue a different commer
cialization approach (taking equity in a spinout
or pursuing industry-wide nonexclusive licens
ing) or to find a different licensee willing to pay
more for the opportunity.
Further, if a market window has closed, a
reversion of rights back to the seller because of
an inability to agree on financial terms may be
of little business value. Clearly, it is in the inter
est of both parties to conduct royalty negotia
tions based on accurate projections of a license’s
economic impact. Agreements reached before
the impact is known are more likely to be dis
appointing to either the licensee or licensor. A
disappointed licensor will normally not have any
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recourse as long as the licensee fulfills its end of
the deal. A disappointed licensee, however, can
come back to the licensor and threaten to drop
the license unless it gets some relief from a royalty
rate that the licensee later perceives as too high.
The licensor can decline such a request, but it
could be put in a difficult bargaining position be
cause of the cost, delay, and risk associated with
finding another licensee, and because the term
of years remaining under the patents may have
been reduced significantly while in the hands of
the original licensee. A royalty rate determined
well before commercial introduction can thus be
viewed as a royalty cap by the buyer, regardless
of what is called for in the agreement. Of course,
the buyer cannot count on a seller agreeing to
such a downward renegotiation in royalty rate;
the buyer may face the choice of proceeding to
commercialization under the agreed terms, or
dropping its license and losing its own invest
ment in the technology.
Parties seeking win-win arrangements
should seek ways to make these negotiations as
fair as possible, even while each party is looking
out for its institution’s interests. This requires
as much economic information as possible and
some tools for using that information. Presented
in the sections below are tools and consider
ations in determining such splits of the com
mercial reward. To set the stage, consider the
following excerpt from an actual letter received
by a venture capitalist:
“… we are asking for Forty Million Dollars
($40,000,000), which will provide the capital
needed … . As planned, at the end of the two-year
period, we will have ramped up to 100% with an
expected pre-tax profit of $211,832,258.”2
Now, is this a good deal? Even more impor
tantly, what methodology could be used that
would lead to a fair price for such an opportunity
and form the basis for a rational decision?
Although the general principles in this chap
ter apply to both a licensee (buyer) and a licen
sor (seller), this chapter primarily looks at these
matters from the point of view of the licensor.
The form of an agreement is not detailed in this
chapter; many differing approaches as to royalties
and equity are possible. This topic is sufficiently
1 | HANDBOOK OF BEST PRACTICES

complex to warrant coverage in other chapters in
this Handbook.3

2. GETTInG STARTEd
Prior to delving into this discussion, it is help
ful to review the definitions of two key, related
terms.4
• value: an amount considered to be a suit
able equivalent for something else
• price: the sum of money or goods asked or
given for something
In this chapter, price will mean the quantifi
cation or specification of value. Price should be
the expression, in monetary and other forms of
consideration, of what the technology manager
believes is an appropriate starting point for dis
cussions and ultimately represents a fair exchange
for the institution’s willingness as a licensor to en
ter into a commercial agreement.
This requires that the technology transfer
manager determine, from the outset, what the
institution is willing to provide as its end of the
bargain. Table 1 summarizes ten sources of value,
from the perspective of a licensor of early-stage
technologies.
Item No. 1 is the key source of value pro
vided by the licensor for a typical early-stage
technology agreement—the right to practice the
technology described by the intellectual property
(IP). The licensor may also provide something
within the categories of Item Nos. 2, 3, and 4.
Item No. 5 is usually a left-pocket/right-pocket
grant: if the licensor agrees to pay the patent costs
for the licensee, then the licensee reimburses the
licensor for these costs, dollar for dollar.5
From the perspective of licensors of earlystage technologies, Item Nos. 6, 7, and 8 are
strictly the responsibility of the licensee and are,
thereby, not part of what is granted. Although the
costs associated with these boxes may be small
on average, the risks of a very significant cost as
sociated with them on a given deal are both so
large, and primarily or solely under the control
of the licensee, that it is imprudent for a licensor
to bear them (this is discussed in greater detail in
Section 6.4).
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The last two Items, Nos. 9 and 10, may in
volve the licensor in some way; most often, how
ever, the licensor will grant only a willingness to
assist the licensee in these activities on a cost-re
imbursement basis.
Generally, therefore, the licensor of earlystage technologies is offering Item No. 1 and,
possibly, Item Nos. 2–4. Within each of these
boxes, figuratively speaking, are yet smaller boxes
that further define the contents of the grant. For
example, in Item No. 1 the license may be exclu
sive for all fields and territories for all patents in
the technology package, for a specific application,

for a specific territory, for a specific term (such
as five years, after which time the licensor can
license others), or exclusive but for one other li
censee (a limited exclusivity, sometimes referred
to as a second-source approach), and so on in a
limitless array of possibilities and combinations.
Each of these options will have a different eco
nomic value; accordingly, each should bear a dif
ferent price. Such issues are sometimes referred to
as aspects of value (see Section 6.2).
As the licensor, a technology transfer man
ager needs to determine what boxes (and contents
thereof ) the institution is offering as its package.

Table 1: Ten Sources of Value Relating to IP (Intellectual Property) Rights
1. Rights to practice the
technology (patents,
trade secrets, copyrights,
trademarks)

• IP rights included
• Field/territory
• Degree of exclusivity
• Duration

2. Commercial data

Production drawings, material balances,
statements, training or technical assistance

3. Future improvements

From licensor, from licensee, from other licensees, rights
to, payment(s) for

4. Right to sublicense

Conditions for, split of fees, improvements/grant backs

5. Patent expenses

Maintenance costs, patent prosecution, foreign filing

6. Defense of patents

Oppositions, interferences, declaratory judgment actions,
claims of ownership

7. Infringement issues

Studies and opinions, freedom to practice, suits against
infringers, suits by third parties

8. General indemnity

Product liability, ownership issues

9. Quality control

Testing, laboratory services, trademark policing

10. Regulatory approval

National regulatory agencies and listings such as the FDA,a
and EPA,b and TSCAc

operating

a U.S. Food and Drug Administration
b U.S. Environmental Protection Agency
c Toxic Substances Control Act
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It is a very good practice to document the con
tents of the package in some detail for internal
purposes, and perhaps in a more succinct fashion
for initial discussions with prospective licensees.
For example, part of a licensing package could
include product prototypes or customized test or
development fixtures, as well as data unpublished
or not yet published that provides additional in
formation on potential applications, costs, or ar
eas of potential improvement.
Similarly, the technology professional should
document in detail what the institution is seeking
from the licensee as fair exchange. Some items to
consider in determining this exchange are:
• royalties (often termed running royalties)
• other cash payments (an upfront cash
payment, progress payments, or annual
minimums)
• common stock or partnership interests (as
partial or total offset for royalties)
• R&D funding at the institution to advance
the technology or other R&D objectives
• lab equipment
• consulting agreement(s)
• improvements to inventions (so-called
grant backs)
• access to proprietary and/or technical data
related to the invention
There is a long list of sources of consider
ation that the institution may wish to seek from
the licensee. By thinking through these items
and writing down those that are desirable from
the institution’s point of view, the technology
transfer manager can develop a rational frame
work for expectations. From a negotiating per
spective, following this process can prevent the
institution from being perceived as a nibbler:
that is, an organization that is always thinking
of something more that it should get for the
deal.

. THE ConTExT of pRICInG
The seller’s pricing expresses belief about value.
Such belief arises from considering the innate eco
nomic benefit associated with the use of the tech
nology being offered, the competitive alternatives
1 | HANDBOOK OF BEST PRACTICES

available to a prospective buyer, and an overall
negotiation strategy.
As mentioned earlier, there are an unlimited
number of combinations that could be agreed to
by the licensor and licensee. It is impractical to
price all these combinations and offer a price list.
Instead, a price is needed for what is considered
to be a basic deal that is of interest to the insti
tution and that the technology manager believes
will be of interest to a licensee.
In the process of discussing an opportunity
with prospective licensees, a licensing profes
sional will learn that there are different items that
each licensee wants and different values that each
licensee places on what it has to grant (surprising
ly, not all companies view money the same way;
there can be a big difference between funding
R&D and upfront cash, or between upfront cash
and royalties, and so on). As new information is
learned, the technology transfer manager should
be prepared to reenter the pricing methodology
and reconsider assumptions and elections. The
technology transfer manager will also learn about
the competitive alternatives that prospective li
censees have use of the institution’s technology.
At the same time, the manager will analyze the
institution’s alternatives should the licensee say
no.
In a free market, all participants can decide
what they think a product is worth and com
municate this to others. From this process, the
technology transfer manager should be able to
learn relevant facts that may cause the price to be
reassessed. It should be remembered that partici
pants in a free market do not consider themselves
compelled to communicate what is good or un
dervalued about what the institution has to offer.
In most instances, a technology transfer manager
will only hear (or primarily hear) the bad news
related to a product; some of it may be true, and
some may even be relevant.
Negotiating strategy is also important.
Although this subject is outside the scope of this
chapter, two pricing negotiation-strategy poles il
lustrate the significance of negotiating strategy:
• fixed-price seller: The seller has made a best
effort at determining a value that repre
sents what it believes is a fair value to both
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parties. This price is its bottom line, and it
offers the product to all prospective buyers
as a here-it-is, here-is-what-it-costs, take-it
or-leave-it proposition.
• price maximizing seller: The seller seeks to
identify only those prospective buyers who
express interest in the opportunity, which
is initially priced at or near the maximum
reasonably conceivable value because it is
expected to be adjusted downward, per
haps substantially, due to the back and
forth of what are likely to be extensive
negotiations.
There is, of course, a continuum of perspec
tives between these polar positions. The fixed
price approach (as an idealization), has the ap
peal of deal simplicity and speed, but may have
as its result (a) no buyers and therefore no deal
or (b) a deal with a buyer who would have been
readily willing to pay more had it just been asked.
The price-maximizing approach is really about a
seller offering some flexibility on price and deal
elements to attract potential buyers to engage in
a negotiation that leads to mutual learning. In
some respects this second approach could be bet
ter described as the deal-probability-maximizing
approach because it offers an adjustability of pric
ing and deal elements not available in the fixedprice approach. However, the initial pricing of
this second approach has to be within a range that
buyers can conceivably find reasonable; otherwise
buyers can be dissuaded from even initiating due
diligence. The most important point to remember
is that pricing is a process, not a one-time event.

. CoST AS A BASIS foR pRICE
Cost is a very poor basis for pricing, although it
is sometimes used. To get a sense of using cost of
development as the deal price, consider the fol
lowing: suppose an institution and its sponsors
have invested $10 million in a particular tech
nology that at long last has been determined not
to work well enough to be used commercially.
What are the chances of going out into the world
of commerce and saying: Have I got a bargain.
Because this technology doesn’t really work, we

are not going to ask for any profit. It is yours for
only the $10 million we have sunk into it. The
market will not value what the institution paid
to develop the technology, not because it is un
sympathetic to the institution’s investment (and
plight), but because what is important to the
market (the buyer) is the value of the product,
not the costs of development. If the product does
not work, it has no value. What the institution
has invested in its development is gone.
Consider the other extreme: An individual
buys a lottery ticket for $1. It turns out to be
the sole winning ticket in a $10-million lottery.
Now, someone shows up and says: I’ll give you
$2 for your winning ticket, which will double
your money. Is this a good deal? Again, the cost
of the lottery ticket is irrelevant in this example.
Rather, its worth after selection is what some will
ing party would pay to gain the benefits of owner
ship. For all the losing tickets together, no ratio
nal buyer would pay even a dime. For the one
winning ticket, in this example, a rational buyer
would offer millions of dollars, but not more than
$10 million.
In the world of manufactured-commodity
goods, costs and price are often closely related.
Historically, pricing in such circumstances was
determined by multiplying the costs of manufac
ture by an industry-standard multiplier. A typical
historic multiplier was simply the factor 2, so the
price would be double the cost of manufacture.6
But in the case of high-cerebral content
products, such as intellectual property, cost is
an inappropriate basis. If Picasso was alive and
you approached him to buy a painting, would
you ask: What did it cost you to make this paint
ing? Consider another example. The late Sammy
Cahn received (it is believed) approximately
US$40,000 for granting the producers of the
movie, Die Hard II, the right to play his song
“Let it Snow” in the movie’s opening scenes to set
the mood for the holiday season. Cahn had sold
rights to “Let It Snow” many times. Cahn did
not write any new music for the movie; he prob
ably did not even provide the producers a copy
of the sheet music. So what did the producers get
for their $40,000? They bought merely the right
to use something already existing. How was the
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$40,000 determined? That is what the two parties
dealing at arm’s length said it was worth, not an
amount based on a person-hours of labor calcula
tion as Cahn’s appropriate value for the rights to
use the song.
The market pays for value, not cost. In re
tail software sales, the actual cost of the CD, the
manual (if not on the CD), and the packaging
is typically less than 10% of the price. Why are
software companies seeking and able to sell their
products for more than 10 times their costs? The
answer again is that it is value, not cost, that the
market buys.
Cost, however, does come into play when
considering a prospective licensee’s alternatives
to entering into an agreement. A prospective li
censee could seek to develop its own technology
by inventing around the institution’s protection
to accomplish the same purpose. If the prospec
tive licensee was convinced that it could do so in
a very short period of time with a parity outcome
for, say, $1 million, then the licensee would rea
sonably determine that the institution’s technol
ogy was not worth much over $1 million, which
is what its costs would be to get what the institu
tion has without buying what the institution is
selling.7
When it comes to cost, it is the costs for the
prospective licensee that are considered. Whether
the seller’s costs for developing the technology
were $10 or $10 million is basically irrelevant.
Another important, usually misunderstood,
point is how to determine the seller’s costs. In
the lottery ticket example, the costs are easily
known—it is printed on the ticket. But in the
case of technology development, such costs are
very difficult to estimate. Consider the variety
and range of questions to be answered: Have we
collected all the direct costs back to the very be
ginning of the development? Do we even know
how to define the beginning? Did we include the
value of all the contributions made to the proj
ect by products, services, insights, intellectual
property, and so on, that were contributed at no
recorded cost to the project? Have we excluded
costs associated with development efforts that are
not being offered to prospective licensees? Have
we deducted “bad judgement” costs (which no
20 | HANDBOOK OF BEST PRACTICES

reasonable R&D program should have spent)?
Or should such “misspent” costs be recognized as
a natural part of R&D? When parties talk about
the seller’s costs, they are usually talking about a
number residing in some seller cost account used
to track certain kinds of investments, and not the
result of a carefully considered analysis of all the
activities and value invested by the seller.

. pRICInG METHodS
If cost is not a good way to determine price,
what is? Sections 5.1–5.6 of this chapter consider
methodologies for answering this question. These
methodologies include:
• Method I: The Use of Industry Standards
• Method II: The Rating/Ranking Method
• Method III: Rules of Thumb, such as the
25% Rule (and Other Rules)
• Method IV: Use of Discounted Cash-Flow
Analysis with Risk-Adjusted Hurdle Rates
• Method V: Advanced Tools
• Method VI: Auctions
The goal of these following discussions is to
develop tools and thinking. Producing an “an
swer,” to the question posed at the beginning of
this section is not the goal of this discussion, be
cause the world of technology rights makes it im
possible to determine a price in the abstract.
.1

The Use of Industry Standards Method

Having dismissed cost as a basis for pricing, the
next most logical approach is to use industry
standards; the reason for this is that such an ap
proach serves decision makers well in many other
areas of experience.
Suppose you want to rent office space. The
coin of that realm is commonly expressed as dol
lars per square foot per year (DSFY). Ranges for
DSFY in the United States are from about US$1
to more than US$50. However, when consider
ation is restricted to a particular city and a region
within that city (downtown/prime, downtown/
periphery, outer belt, suburbs, inner-city ware
house district, and so on), the DSFY range will
shrink remarkably, say to US$6 to $12. Then,
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when one further specifies level of amenities
(Bigelow®carpets versus linoleum), and what is
included in the rate (utilities, janitorial services,
parking, security, partitioned office layout versus
open and bare) the range narrows even further,
say US$10.25 to $11. So it is with many other
goods and services, from haircuts to paper clips.
Why can’t this approach work for rights to
early-stage technology? The problem is primar
ily the absence of a track record for comparable
products bought and sold under known (or
knowable) terms. In the office space example,
there are many properties, many buyers (lessees),
and many sellers (lessors). This results in many
transactions of relatively standardizable terms
agreed to by parties that had numerous alterna
tives to entering into the agreement, which were
considered and evaluated before signing. It is the
tangibility of what is purchased, the frequency
of purchases, and the public knowledge of the
purchase that makes it possible to apply industry
standards.
In the case of early-stage technology licens
ing, it is often unclear what products can or will
be ultimately introduced. The number of similar
transactions on which to determine price are too
few, and frequently it is impossible (or difficult)
to know what price other licensees/licensors have
paid in similar deals. Nonetheless, there does exist
some public and private data on early-stage-tech
nology licensing and in many instances some
thing useful can be learned from it.
One example of published financial data for
licensing agreements is that obtained by survey
ing. Among the more famous examples are tables
published based upon transactions between a
Japanese company and a non-Japanese company.
Prior to liberalization of Japanese foreign ex
change regulations in the 1980s, foreign parties
licensing technology to Japanese parties were re
quired to receive government approval of licens
ing terms. The Japanese government published
annual statistics related to licensing. A typical
table is shown in Table 2. In some respects, this
table is more complete than most since it includes
upfront payments and minimum royalties. As is
typical of such tables, there is a frequency of oc
currence entry for selected royalty-rate ranges for

each of several categories of technology licensed.
The best way to assess how useful such a table
might be is to think about how its existence would
lead a technology transfer manager to reach some
decision about the price of something.
Consider the pricing of a medical device such
as a blood glucose monitor. Reviewing Table 2,
the closest category is probably electrical, but is
this really what was meant by electrical? What
does this table reflect for upfront payments? Half
of the agreements contained a provision for up
front payments, and half did not.9 Now what?
What guidance does this table give about whether
to have such a payment and its amount? What
is the modal (most common) value for running
royalties? None! Now what? Should the royalty
be priced at zero? The percentage of cases the roy
alty was negotiated within the shown ranges can
also be determined using Table 2, but where does
the institution’s product fit? Finally, look at the
minimums row. What can a technology transfer
manager do with this information?
The problem is actually even worse. The
agreements that comprise the table each includ
ed a whole panoply of exchanges, only some of
which were summarized in Table 2. How can a
technology transfer manager shrink all of these
different considerations down to just one num
ber, a royalty rate, and compare the institution’s
opportunity with these published outcomes?
Further, there can be instances of royalty base
ambiguity. Staying with the hypothetical medi
cal-device example and our bold assumption that
“electrical” data may have some relevant teaching,
we can envision instances where the entire device
being sold is covered by the licensed subject mat
ter, whereas in other cases the license could be
about a limited feature or function within a much
more extensive device. In such cases, how was the
royalty-rate data used by the parties? Did they
agree in both of these cases to use the selling price
of the complete medical device, or did they in the
second instance agree to use as the royalty base
some smaller amount than the full selling price
of the device because of the limited application
to a single feature or function? There is no way
to tell from the table. There are also other con
cerns about this table. It is limited to technology
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transferred into Japan in the early/mid-1970s.
And what relevance would these rates have for li
censing technology to be used in the U.S.?
A more recent industry standard survey is
available, which also offers more distinguishing
categories.10 One of the tables is shown in Table
3—does it provide the technology office manager
more useful information?
Again, use the test. How would this data
help a technology transfer manager make a deci
sion? Consider the categories of pharmaceuticals,
general manufacturing, and other. Each royaltyrange category has an entry for each of these.
Unfortunately, all that can be discerned is that

most royalties are in the range of 0%–10% and
that pharmaceuticals are generally higher than
manufacturing. One wonders about the category
of telecommunications. Does this mean that
all royalties for this industry fall in the range of
10%–15%? (No, as it turns out: there was only
one survey respondent.) The paper from which
Table 2 has been prepared contains a lot of good
information, but a technology transfer manager
should recognize its limitations as a guide for set
ting a royalty.
None of this discussion is intended to dis
parage the efforts of those gathering and pub
lishing this data. Determining effective ways of

Table 2: use of Industry Standards to Determine Royalties

(Data set obtained from review of all agreements filed in Japan)
Industry Type
Terms of
Payment

Classification
of Technology

Initial payment

Required
Not required

Chemical

Metal

Machinery

Electrical

Others

100
65

54
37

223
187

119
119

231
220

5

6

16

32

28

2% > x < 5%

42

24

119

55

126

5% > x < 8%

12

8

112

24

119

7

4

24

11

17

Others

48

28

80

54

69

None

51

21

59

62

92

38
127

19
72

116
294

35
203

186
265

165

91

410

238

451

No fee, royalty

16

4

11

2

15

Total

181

95

421

240

466

< 2%

Running
royalties

Minimum
payment
Subtotal

> 8%

Required
Not required

Source: Science & Technology Agency8
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valuing (pricing) technology is extremely diffi
cult, and this author cherishes every scrap of in
formation found. Everyone’s efforts to extricate
and publish anything that might help technolo
gy professionals in this valuation process are ap
plauded. The goal here is simply to caution the
reader about the limitations of using industry
standards for setting royalties and other license
considerations.
Let us now consider, as examples, other
sources of financial information about license
agreements. The references that follow should not

be taken as recommended norms or standards,
but illustrations of information that can be found
by investigation.
Lita Nelsen of M.I.T. has published a table
of standards that is an example of more useful
data than the above broad Japanese license agree
ments. The table below represents a narrower
class of licensors (M.I.T. and similar universities)
and provides a narrower distinction of categories
as well as a narrower range of typical royalties. A
recast version of data she has published is shown
in Table 4.

Table 3: A Recent Royalty Data Set Obtained by Survey
(licensing-out royalty rates by industry royalty rate category)

Primary
Industry

0%–2%

Aerospace

2%–5%

5%–10%

40.0

55.0

10%–
15%

15%–
20%

20%–
25%

Over
25%

5.0

Automotive

35.0

45.0

20.0

Chemical

18.0

57.4

23.9

0.5

Computer

42.5

57.5

Electronics

50.0

45.0

5.0

Energy

50.0

15.0

10.0

0.1

25.0

Food/Consumer

12.5

62.5

25.0

General Manufacturing

21.3

51.5

20.3

2.6

0.8

0.8

G o v e r n m e n t /
University

7.9

38.9

36.4

16.2

0.4

0.6

Healthcare Equipment

10.0

10.0

80.0

1.3

20.7

67.0

8.7

1.3

0.7

0.3

0.9

0.9

0.9

Pharmaceuticals
Telecommunications
Other

2.6

100.0
11.2

41.2

28.7

16.2
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Clearly Nelsen’s data covers wide ranges in
royalty rates, from 0.1% to 20%, a factor of 200.
Even within one category, the range between the
high and low ends can be a factor of five or more.
Further, it is likely that there exist “outliers” from
such ranges that M.I.T. would license at rates be
low the bottom end of the range and perhaps, for
major breakthroughs and extensive IP portfolios,
may expect values above the top of the range. The
data illustrates another trend that appears in other
examples: those products and industries with tra
ditionally high operating margins (profits), such
as pharmaceuticals and software tend to exhibit
higher royalty rates compared with, say, the ma
terials industry.
Other authors have published tables of roy
alties for the purpose of establishing reasonable
expectations of both licensors and licensees. Table
5 is a table published by Corey and Kahn for the
medical industry.12
The table’s context is well defined (early-stage
technologies out of research labs), the categories
are comparatively precise (diagnostics in vivo),
and it includes guidelines on up fronts and mini
mums. However, note that there is an important
economic difference between the ends of the roy
alty ranges given: 1% versus 3% or 2% versus
10%, and so on. Unless the technology transfer
manager understands where the institution’s op
portunity fits in the range identified, it is difficult
to know where to begin. Further, not every oppor
tunity falls within even these broad ranges. Some
opportunities will have only negligible value; oth
ers could be unusually valuable opportunities.
Tom Kiley has published another medical
industry table that deals with exclusivity granted
(Table 6).14
Kiley appears to suggest that for nonexclusive
rights, the royalty should be about half of the ex
clusive royalty. (See section 6.3.2 for more on the
50% rule.) According to Kiley, inventions in sup
port of a pharmaceutical (drug) warrant higher
royalties (7%–15%, as his generalization) than
drug delivery, diagnostic and therapeutic mono
clonal antibodies (2%–7%), perhaps reflecting
another two-to-one ratio.
Published price lists are another source of
industry standards for pricing. Sometimes a
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company simply announces its royalties. One ex
ample, shown in Table 7, was published by one
licensor for nonexclusive licenses for its LCD dis
play patent.
Another example of such published rates
is, or was, IBM’s licensing terms. In the 1980s
and early 1990s, IBM established a licensing
practice—essentially a price list—that offered to
license essentially all of its 34,000 patents world
wide for a 1% royalty each for computer uses (pat
ents only, nonexclusive only), up to a maximum
of 5% for all 34,000.17 This practice does not
establish 1% as a minimum per patent royalty;
rather it reflects IBM’s practice at one time that
a licensee can choose any one from IBM’s massive
portfolio for a rate of 1%, any two for 2%, and so
on. Further, because IBM does not make public
its license agreements it is unknown what pay
ment structure or amount was finally agreed to
with licensees.
The main point about the LCD and IBM
examples is that such published lists can lead toexpectations and, to the degree that the opportu
nity the technology transfer manager is pricing
fits any published examples, this may influence
the thinking of prospective licensees. In some
cases, such proposed pricing can create a widely
accepted norm in the respective industry, mak
ing it difficult for the seller to price above such a
norm if the subject matter is perceived to be in a
similar category. Licensees, like licensors, look to
this method of industry standards (or norms or
comparables). However, they may look to a dif
ferent population of examples such as their own
internal catalog of extensive deals that they have
completed in the past to establish their expecta
tions for financial terms.
Yet another source of industry standards
are court determinations of reasonable royalties
awarded in patent infringement lawsuits. Table 8
offers a summary from a paper by Mike Carpenter
who analyzed a series of judgments.18
The main limitations of such data are that
the result is very specific to the litigated sub
ject. In addition, the maturity state of the tech
nology is normally far beyond what may be
considered as early-stage technology. Further,
adjudicated reasonable royalty rates are almost
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Table 4: Example Table of Royalties Developed by Experience
by a university licensing Office11
Product

Royalty (%)

Materials processes

1–4

Medical equipment/devices

3–5

Software

5–15

Semiconductors

1–2

Pharmaceuticals

8–10
12–20

Diagnostics

Biotechnology

Comments
0.1%–1% for commodities; 0.2%–2% for processes

Chip design
Composition of materials
With clinical testing

4–5

New entity

2–4

New method/old entity

0.25–1.5
1–2

Processa/nonexclusive
Processa/exclusive

a Expression systems, cell lines, growth media/conditions

Table 5: Royalty Rates for the Medical Industry13
Technology/Industry
Reagents/process

Earned
Royalty (%)

upfront Payments
(in uS$)

Minimum Payments
(in uS$)

1–3

Patent costs

2,000–10,000

2–10

Patent costs

2,000–10,000

Diagnostics in vitro

2–6

5,000–20,000

2,000–60,000

Diagnostics in vivo

3–8

5,000–20,000

2,000–60,000

Therapeutics

4–12

20,000–150,000

20,000–150,000

Medical instrumentation

4–10

5,000–150,000

5,000–20,000
(yr. 1)
10,000–25,000
(beyond yr. 1)

Reagents/kits
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always unrepresentative of arm’s-length rates, as
they represent royalties for patents known to be
valid and infringed—conditions not typical of
early-stage technologies. This litigation-particular
outcome example is also quite dated, but dated
ness is a factor here in all of the prior examples
as well, and is innate to any historical collection
of data.20 Still, a court case usually contains a
wealth of information about how such rates were
determined, and of course, the information is in
the public record. Einhorn has published a much
more current summary of reasonable royalty de
terminations by a court.21 One can also search
LEXIS® for even more current data. The key is

to find a comparable technology, stage of devel
opment, market impact, and so on. When some
thing comparable exists and is published, this can
be very helpful.
The most valuable tool for determining in
dustry standards for this method are published
agreements for similar technologies licensed by
similar institutions. As Ashley Stevens explains,
publicly-traded companies will file license agree
ments that may have a significant economic im
pact on the value of the company with the U.S.
Securities and Exchange Commission (SEC).22
The Internet now enables very effective searching
of disclosures made by publicly-traded companies.

Table 6: Proposed Standard Royalties15
Exclusive (%)

Nonexclusive (%)

Development rDNAa drug

7–10

3–4

Approvable rDNAa drug

12–15

5–8

Therapeutic mAbb

5–7

3–4

Diagnostic mAbb

3–4

1–2

Drug delivery component

2–3

0.5–2

a Recombinant DNA
b Monoclonal antibodies

Table 7: Price list for an lCD Display Patent16
Vehicles
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0.125%

VCRs, and so on

2%

Meters, gauges, and so on

3%

Telephones, and so on

4%

Calculators, and so on

5%
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Several organizations offer, as a service, summa
ries of categories of such filings and copies of spe
cific agreements. An example, taken from a talk
by Mark Edwards, is shown in Figure 1.23
These data are unusual in that they show many
of the forms of upfront consideration received by
universities for having licensed their biotechnol
ogy. Underneath such summaries, however, are
specific agreements now numbering in the thou
sands, copies of which can be found with some
research. It is from such published agreements
that one can gain a better understanding of what
was agreed to, at least once, by two parties for
something similar to what is being offered.24
One example of such a specific agreement is
the license between the University of Houston
(UH) and DuPont for the so-called 1-2-3 super
conductors developed by Professor Wu of UH.
The State of Texas required that this agreement
be placed in the public domain. The agreement
details the payments DuPont agreed to make to
gain rights to UH’s superconductor technology:
US$1.5 million in cash upon execution of the
agreement, an additional US$1.5 million upon
issuance of the U.S. patent, and a third US$1.5
million upon the second anniversary of the U.S.

patent. The agreement has many other interest
ing details, and it would be wise to study this
agreement and learn as much as possible about its
background and current status.
To sum up, using this industry standards
method of setting prices has both positive and
negative aspects:
Positive aspects of the industry-standards
method include:
• The values used as the basis are based on the
market.
• No calculations are required (beyond per
haps taking averages and medians or other
statistical methods).
• One has some confidence of being in the
range of some believed-to-be comparable
reference points.
Potential negative aspects include:
• Published information is inevitably dated,
and such datedness could have a mate
rial effect on the present value of a similar
deal.
• The segmentation provided by surveys is
normally too coarse (electrical, mechanical,
telecommunications, and so on).

Table 8: Other Tables of Royalty Rates Based on litigation Outcomes19
Product

Royalty (%)

Date

Citation

Rotary wing aircraft

2

1976

192 USPQ 612

Sleeping bag

5

1967

156 USPQ 403

Digital data transmitter

7.5

1978

200 USPQ 481

Oscilloscope

10

1977

193 USPQ 385

Computerized teaching aid

12

1978

199 USPQ 178

Toilet paper perforator

20

1977

195 USPQ 125

100a

1977

196 USPQ 129

Airline baggage cart
a of profit
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Figure 1: Royalty and Other IP Revenue Data Based
on SEC-Filed and SEC Agreements

Average Pre-Commission Payments: university/Biotechnology licenses

400

350

341

300

$ (in thousands)

250

200

190

152

150

100

50

0

92

31

Upfront
Fees (23)

Advance
Royalties
(23)

Milestone
Fees (4)

Total
Payments
(33)

R&D Payments
(45) Recombinant
Capital

Source: Recombinant Capital (Mark Edwards). AUTM presentation 1993.
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• The values published normally do not provide sufficient information to determine
what IP rights were provided, or to deter
mine their significance or their strength.
• The royalty basis (or base) is not always explicitly defined.
• The connection of the license to the size
and margins of the buyer’s market oppor
tunity is not explicitly known.
• A wide range of royalties is reported for
each classification, with no clear means of
discerning why some opportunities were
higher valued and some lower.
• Often no information on upfront payments, minimums, or due-diligence provisions is available, all of which can be im
portant components of value.
• The licenses often contain other provisions
that directly affect the total value of the
deal and are reflected in the royalty rate.
• One cannot uncover a historical agreement
for exactly the same technology as that of
current interest, between comparable parties, at a comparable stage of development.
So one is commonly performing some interpretation of available data to apply to
one’s present situation.

The industry standard method works best
when one deals in one technology/industry seg
ment, especially when there are a significant
number of deals involving multiple buyers and
competitive sellers, much as in the real-estate
rental market discussed above. The examples giv
en here are not intended to provide representative
technology values but to illustrate some of data
sources that exist.
In summary, price is a very tricky idea. It oc
curs “between the ears” of the technology transfer
manager, as well as between the ears of prospec
tive licensees. As you can see, it is affected by all
the other things that affect a person’s judgment.
For those who doubt this, an experiment has
been published that illustrates this point.25 Two
groups of students were asked to review identical
notebooks containing descriptions of seven consumer products. They were each asked to respond
to each product by specifying what they would
be willing to pay for the item. A summary of the
findings is shown in Table 9.
Everything was identical in the two settings
(A and B), except for one small thing. In setting
B, there were Mastercard® logos left lying on the
table. Even though all the participants understood
that they were not buying the items in the book,

Table 9: Price is a Tricky Idea: What Would you Be Willing to Pay?26
Consumer products book

Mean in setting A

Mean in setting B

(B-A)/A

Dress 1

$27.77

$41.50

49%

Dress 2

$21.09

$33.91

61%

Tent

$69.95

$77.73

11%

$13.91

$20.64

48%

Lamp

$28.36

$40.41

42%

Electric typewriter

$131.45

$165.36

26%

Chess set

$35.29

$43.15

22%

Men’s sweater
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and there was no discussion as to how such items
could or should be paid for, the mere presence
of the logos influenced the group B students
significantly.
The point of relating this experiment is that
everything about the technology transfer manager,
the institution, the inventors, and so on, are po
tential influences on what a licensee will conclude
is a fair price.
Consider these two different settings for the
same invention. In setting A, the prospective
licensee goes to Nowheresville, has to drive four
hours because there is no air service, steps in
cow dung as he gets out of his car, meets the
inventor who has no front teeth and exhibits
an annoying habit of scratching his underarms,
and discusses the invention in the Greasy Spoon
Cafe. In setting B, the prospective licensee goes
to Mostfamousuniversity, where he is intro
duced to the distinguished inventor (who has
previously won a Nobel Prize) at the exclusive
faculty club and a well-known, well-respected,
high-ranking public official stops buy and says
hello during lunch.
Remember, in this thought experiment the
institution is selling the same invention in both
settings. Even though the prospective licensee is
not a student and is not buying consumer prod
ucts as in the example above, the principles are
the same. The licensee will likely be influenced
by the setting and circumstances, which may be
completely unrelated to the underlying value of
the opportunity.
In the first act of a wonderful play by Arthur
Miller called The Price, the owner of a house full
of furniture is frustrated when the dealer he has
invited to bid on all of it delays giving him a
price. Instead, the dealer spends a lot of time
understanding the context of the sale (and learns
that the building is about to be demolished and
that the seller has no time or patience to sell the
items piece by piece). He intermittently (and
politely) points out certain blemishes in objects
that would otherwise have been perceived as
very valuable. When the seller finally demands
to hear the price, the very old man who plays
the buyer simply says, “Because the price of used
furniture is nothing but a viewpoint, if you don’t
0 | HANDBOOK OF BEST PRACTICES

understand the viewpoint, it is impossible to un
derstand the price.” The view from the buyer’s
position always affects the price he is willing to
pay.
One other point needs to be made about
price. It is often the lever used in negotiations.
Often each party to a negotiation uses price as
a lever to get other things. There is a wonderful
ancient saying on how buyers tend to negotiate,
“Bad, bad says the buyer, but then he goes his
way, then he boasts.”
.2 The rating/ranking method

This method applies the elements of any defini
tion: the specification of a genus plus the distinc
tion of a differentiator.
First, the technology transfer manager
must find the genus (or family) for the in
stitution’s technology that he or she is seek
ing to price. Places to look include the pub
lished agreements discussed earlier, friends in
the network of the Association of University
Technology Managers (AUTM) and the
Licensing Executives Society (LES), consul
tants, and the institution’s files of negotiated
deals. Ideally, a technology transfer manager
should find at least one or possibly two or
three comparable deals from such a search.
Second, this method uses some form of rat
ing table to score (differentiate) the deal that
is now being priced based on the known price
of the comparable deal(s). To do this, a tech
nology transfer manager must select a list of
relevant factors. Tom Arnold and Tim Headley
published a useful, extensive list of 100 possible
factors in an article in Les Nouvelles.27 One hun
dred factors, however, are far too many to evalu
ate, which is perhaps why the most well-known
enumeration is the Georgia Pacific factors, so
called because the factors were annunciated in a
lawsuit involving the Georgia Pacific company
and have since been widely cited with respect to
litigation matters. The results of a survey pub
lished by LES asked respondents which of the
primary Georgia Pacific factors they used to as
sess an opportunity when either licensing in or
licensing out. Table 10 gives a summary of these
findings.
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Other approaches may use only three or four
factors to simplify the analysis, such as (1) com
prehensiveness of the IP protection, (2) the stage
of development (or, conversely, the magnitude of
licensee investment) to bring the technology to
the market, (3) the size and value of the market
that is expected to be won by the licensee, and
(4) the sustainability of the innovation wrought
by the subject technology in view of competitive
alternatives both present and anticipated.
Once one has chosen the key factors, the
technology transfer manager, or preferably a
commercial assessment team, scores the subject
opportunity compared to the reference agree
ment found above for each factor selected on
some scale. This can be done by employing a 1
to 5 scale, with a 3 as being indistinguishable to
the comparable agreements, 4 meaning the sub
ject opportunity is better (more valuable) with

regard to this particular factor, 5 meaning much
better, and so on. It is usually a good idea to also
include a weighting factor so that each consider
ation is not treated equally. This is illustrated in
Table 11.
The result is a weight-averaged score.
Anything greater than 3.0 would suggest that the
subject opportunity is better than the examples
being considered as a standard, anything less than
3.0 suggests it is worse. If a technology transfer
manager has two or three standards available, it
may be possible to use this method to bracket the
opportunity.
Although this method is straightforward,
there are some important limitations. What is a
true comparable? Each agreement is a snapshot
in time, no two technologies are really identi
cal, the market is almost never the same, and
the negotiators and organizations will likely be

Table 10: Example of Georgia Pacific Factors used in Rating/Ranking28
Importance of Factor

licensing Ina

licensing Outa

1. Nature of protection

4.3

4.2

2. Utility over old methods

4.2

4.2

3. Scope of exclusivity

4.1

4.1

4. Licensee’s anticipated profits

3.0

3.4

5. Commercial success

3.7

3.4

6. Territory restrictions

3.7

3.5

7. Comparable license rates

3.6

3.7

8. Duration of protection

3.3

3.1

9. Licensors’ anticipated profits

2.6

3.1

10. Commercial relationship

2.6

3.6

11. Tag-along sales

2.1

2.1

a A ranking of 5 corresponds to most important; 1 to least important.
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different. In addition, there are many tradeoffs
and exchanges in every agreement; a technology
transfer manager cannot simply compare one
single aspect, such as a royalty rate, and look
at it without considering what else was in the
agreement. What about the differentiating fac
tors selected? Does a technology transfer man
ager really know what the important ones are for
this opportunity? What does a 4 really mean in
economic terms? Finally, what does a technolo
gy transfer manager do with the result? Suppose
the technology transfer manager determines
that the institution’s opportunity scores a 3.8

compared to the standard. Now what? Does the
technology transfer manager set expectations for
the royalty at 27% better than the standard, as
determined by ((3.8–3.0)/3.0)? Is the up front
now 127 instead of 100? Are the minimums
64 instead of 50? Does the diligence require
ment provide that the licensee must be on the
market in 31 months instead of 40 months? Is
the premium on late payments 3.8% instead of
3%? There are no simple answers to any of these
questions. Still, performing this ranking against
multiple standards and thinking through the re
sults generally allows one to better understand

Table 11: Method II: The Rating/Ranking Method
Factors

Score (1 to 5)

x Weighting Factor

= Weighted Score

Stage of
development

Scope of IP
protection

Market
attractiveness

Sustainability of
protection

Profit margins

Etc.

Average
Weighted Score
Compared to 3.0
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the helpfulness of this rating/ranking method in
a specific circumstance.
The approach also yields at least two other
benefits. First, it prepares the technology transfer
manager for marketing, negotiating, and sharpen
ing his or her thinking about what the important
economic factors are relating to the opportunity.
It gives the manager a greater self-awareness. A
second benefit is that it provides a way of dialogu
ing with the internal stakeholders and beneficially
incorporating some of their insights.
The rating/ranking method can also be
used for selecting a commercialization path.
When developing a commercialization strategy,
there are countless possibilities: exclusive versus
nonexclusive licenses, licensing versus equity in
a new start-up, going with a company in indus
try A as the exclusive licensee or in industry B,
commitment to the industry leader versus a small
company who seeks to upset the industry, and so
on. The rating/ranking method can help a man
ager sort out the advantages and disadvantages of
each of the alternatives. It can also be used with
respect to different potential licensees/partners by
taking into account the particular benefit(s) of
the technology to such licensee; the method can
help a seller differentiate among multiple poten
tial candidates to identify those who would ap
pear to have the most to gain from the license and
would therefore be the likeliest to enter an agree
ment and possibly pay the most. These and other
criteria can help a technology transfer manager
decide upon the best commercialization path.
. Rules of thumb, such as the 25%
rule (and other rules)
..1

The 25% rule

One of the most widely cited tools of valuation is
the 25% rule. It has various manifestations, but
when most managers invoke it they usually mean
either of the following:
1. The royalty in dollars should be one fourth
of the savings in dollars to the licensee by
the use of the license subject matter.
2. The royalty in percent of the net sales price
should be one fourth of the profit, before
taxes, enjoyed by the licensee as a result of

selling products incorporating the licensed
subject matter.
Although this looks simple, it is not. One of
the key issues is the degree to which the licensed
subject matter accomplishes the savings or pro
duces the profit. For example, an invention incor
porated into a process may produce a savings of
$1 a unit. However, when one examines in detail
how such savings are attained, it may be that sev
eral other technologies developed and possessed
by the licensee need to be exploited in order to
realize the full $1. In such a case, does the licen
sor deserve 25 cents, or should the savings be
discounted in some way before the one-fourth
fraction is computed? The issue seems to hinge
on whether the invention opens the door to an
otherwise locked room called: I can save you $1,
or whether the invention is a link in a multilink
chain that together combine to save $1.29
In the second (profit) manifestation of the
rule, things get even more complicated. Although
net sales is generally a straightforward term to ap
ply, profit before tax is subject to many interpre
tations. Normally, the royalty rate is applied to
the royalty basis defined by net sales as follows:
net sales price is the gross invoice price charged
minus allowances for returns, and minus cash and
other discounts granted, charges for packaging
and shipping, and sales and excise taxes.30
For the purposes of this rule, there is no
comparable generally accepted definition of profit
before tax. Indeed, one of the basic problems is
determining what an appropriate income state
ment should look like. Typically, they have the
following categories:
Gross sales
Less: returns/allowances
=
net sales
Less: cost of goods sold (COGS)31
=
gross margin (or gross profit)
Less: overheads (or G&A, for general
and administrative)
Less: sales (or sales and distribution)
Less: other
Less: R&D
=
Profit before tax (or EBIT, earnings
before interest and tax)
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The trouble usually starts below the grossmargin calculation. What overheads should be
attributable to this opportunity? Should all the
overhead costs currently being experienced by
the licensee be included in the calculation, even
though including these may reward the licensee’s
inefficiencies? Will the cost-of-sales allocation,
which is across many products now being sold,
overcharge the appropriate sales allocation for the
subject opportunity? What is “other,” and why is it
being used to draw down the profitably before the
application of the royalty? And finally, what con
stitutes R&D, and should it draw down profits as
calculated for determining a reasonable royalty?
Underneath these questions is the difficulty
of obtaining reasonable estimates for each of the
numbers. Annual reports from companies that
sell products like the one the institution is licens
ing are good places to start. Table 12 shows sum
maries of two large materials companies, one U.S.
company and one European company, based on
their income statements published in annual re
ports. Although the numbers reflected in Table
12 represent real data, for the purposes of this il
lustration, the company names have been noted
as U.S. Co. and Europe Co., respectively.
As discussed earlier, one of the issues in ap
plying the 25% rule is where to apply it. If it is
applied to the EBIT line ($18,352,000, in the
United States company example), it is asserted that
the deductions above that line (COGS, SD&A,
and R&D) are appropriate for determining the
true profitability associated with the commercial
ization of the new opportunity being licensed.
Consider whether it is appropriate to subtract
R&D from available profit. If it is not subtracted,
we would get, by this rule, one fourth of 12%
(11+1) or a 3% royalty. This is a lot better for the
licensor, since it is 12 times the 0.25% one gets by
using what remains after R&D is subtracted. But
should R&D be included in the subtraction? The
argument for including it is that R&D is a neces
sary business expense for the enterprise; without
such investments, the licensee would not have the
high-value, competitive products it needs to sus
tain its operations, and, by implication, would be
unable to successfully commercialize the subject
opportunity.
 | HANDBOOK OF BEST PRACTICES

On the other hand, these expenses are in
vestments for future payoffs to the company for
which the licensor may not enjoy the benefits.
Suppose the U.S. company had elected, in the
year reported, to increase its R&D investment by
$18,351,000 to pursue an antigravity invention.
This would have left the grand sum of $1,000
on the EBIT line, corresponding to one-ten
thousandth of a percentage point (of sales). Why
should a licensor’s fair share of profits depend on
the company’s management pushing an R&D
project to develop an antigravity material or, for
that matter, any other product?
Above or below the EBIT line are even more
subjective costs. If they are associated with the
company’s core operations, they may be appro
priate. But what if they are associated with buying
that new hunting lodge in Montana? Or buying
up Brazilian rain forests? What about restructur
ing, which may be synonymous for the present
cost of past folly? Again the same kinds of argu
ments exist on both sides. And again, what about
that favorite term in accounting statements: “oth
er.” Other than what?
If the licensor agrees that all of the expenses
shown are appropriate allocations against earn
ings, it leads in this particular year to a negative
number. Now what? Does the institution pay the
licensee a royalty to commercialize the institution’s
product? The point of this discussion is that each
cost below the sales line should be analyzed in the
context of the subject technology to determine if
the EBIT percentage shown reasonably predicts
the licensee’s profitability in the present case. If
not, adjustments to such costs should be made to
correct the base on which the rule is applied.
The second example in Table 12 (European
Co.) presents other problems. For competitive
reasons, many companies conceal details in their
statements. They may also use different terminol
ogy. In Europe, sales is normally called turnover,
interest can be finance charges, and so on. This
example shows a gain from investments.32 Should
the licensor receive the benefit of a higher royalty
because the Europe-based company made money
in one year on a good investment? Probably not.
But if the company had lost money on invest
ments, wouldn’t the licensee argue that such loss
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should be subtracted as an appropriate business
expense? So, what about the gain?
Another way to obtain income statements
is to use Ibbotson and Associates33 and Robert
Morris Associates (RMA) publications.34 RMA,
for example, annually publishes income state
ments of categories of companies by Standard
Industrial Classification (SIC) code. Continuing
with our two materials company examples, Table

13 shows the data available from the 1991 edition
for SIC #2395.
In the first two columns are shown summa
ries for 11 smaller companies and 17 larger com
panies, based on assets. The right three columns
provide three years of data for all of the compa
nies in the database. Even when focusing on just
the operating profit row, this gives five choices on
which to apply the one-fourth rule: 4.1%, 4.7%,

Table 12: Example Applications of the 25% Rule
Annual Report, 1991
u.S. Co.

Annual Report, 1991
Europe Co.

US$, in
thousands

UK £ in
millions

%

Sales

1,249,512

100

“Turnover”

COGSa

643,357

52

Other Inc.

Gross margin

606,155

48

“S,D,&A”

447,607

36

R&D
EBITb

140,196
18,352

11
1

Interest

8,090

Restructuring

3,697

Other

9,674

EBTc

(3,109)

454.0

%
100

2.2
456.2

“Operating costs”

405.0

89

EBIT

51.2

11

“Investments”

(1.4)

“Finance charges”

EBT

(0.25)

8.7

43.9

10

Now what? 2.5%?

Now what? 0.25%?
(0.06%)?
a Cost of goods sold (all “direct” costs of making the product)
b Earnings before interest and taxes
c Earnings before tax
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7.8%, 8.4%, and 10.4%. How does a technology
transfer manager choose? Taking an average yields
about 1.5% as the royalty. Is this fair? Unlikely.
The root problem is getting good numbers
for the profitability associated with the subject
opportunity. A prospective licensee will almost
surely make such a calculation. Yet a licensor will
find it very difficult to get access to such infor
mation. The problem with published numbers
of business enterprises—such as annual reports,
10Ks, RMA publications, Ibbotson, and other
sources—is that the numbers are “smeared” over
many different products, each with widely vary
ing profitability. And once a product has been
introduced, a company is inclined to keep it in
the marketplace as long as it contributes to over
head, meaning it at least covers its cost of goods
sold (COGS). In short, dogs in the company’s

profit portfolio bring down the returns of the
stars. Basing a valuation on such numbers will
therefore always be a very tricky business. It also
ignores a company’s willingness to pay more for
a new opportunity, such as licensing a particu
lar technology from which new products can be
made. As a technology transfer manager becomes
more experienced in various business sectors, he
or she will better understand the economics of
such variables—especially the company’s interest
in the opportunity of a new technology—allowing
for better valuations (see Method IV: Discounted
Cash-Flow Analysis with Risk-Adjusted Hurdle,
section 5.4).
One possible remedy to these difficulties is to
request that the licensee provide a pro forma (pre
dictive) income statement for the subject oppor
tunity. In many cases, the licensee will refuse on

Table 13: Another Example Application of the 25% Rule35
Minerals and Earths, Ground or Otherwise Treateda (SIC #2395)
11 Companies
$ 500,000–$2 m
Assets

17 Companies
$2 m–$10 m
Assets

100.0

100.0

100.0

100.0

100.0

29.9

21.8

25.4

33.8

32.5

21.5

17.7

20.7

26.0

22.1

[ 8.4

4.1

4.7

7.8

10.4 ]

“Other”

1.2

0.8

1.0

1.8

1.6

“Profit before tax”

7.2

3.3

3.0

5.9

8.7

Net sales
Gross “profit”
“Op-exp”
“Op profit”

Now what?

1.5%?

All
1991

All
1990

All
1989

Average

a Operating without a mine or quarry crushing, grinding, pulverizing, or otherwise preparing
clay, ceramic and refractory minerals; barite, and other miscellaneous minerals, except fuels. Also
includes crushing slag and preparing roofing granules.
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the grounds that such information is trade-secret
information and that providing it, even under
confidentiality terms, is forbidden. In other cases,
the licensee may provide it. If so, it is a virtual
certainty that what will be provided is the lower
range of possible outcomes. Also, such pro forma
statements may have certain cost allocations in
corporated by rule or custom that may be argu
able (either way) for getting to a figure to which
the parties will apply the 25% rule.
Licensors sometimes call the 25% rule the
“one-third rule.” Licensees, on the other hand,
sometimes argue that claiming even one-fourth
of the profit is overreaching, given such issues
as the technology’s early stage of development,
weak patent protection, high market risks,
the extraordinary value of intangible assets to
be applied by the licensee, and so on. Clearly,
the many numerous factors that go into value
(summarized earlier) must always be considered
when applying rules of thumb. Perhaps the high
risk associated with commercializing a specific
opportunity means that only one-tenth is fair.
And if the technology is only a small part of a
very complex whole, with many other patents
and proprietary technologies required of the li
censee and a royalty base on the selling price
of such a complex whole product, then a value
much less than one-tenth can be reasonable.
This last point relates to the always-relevant dis
cussion of the royalty base that is being used
with the royalty rate to determine the royalty
payment. If the licensor’s technology enables
substantially the entire product, then the sell
ing price of the entire product is normally the
base. If the licensor’s technology is only part of
the entire product, then the parties may elect
to still use the selling price of the entire prod
uct, but discount the royalty rate in recognition
of that fact. Returning to the issue of whether
25% is the appropriate apportionment, if the
commercial introduction of a well-developed,
whole technology package for an attractive mar
ket opportunity is certain, then a value higher
than 25% may be appropriate.
Despite these complexities, the 25% rule is
well known and widely cited. One example is a
citation by the court in Gore vs. Internal Medical

Prosthetics where the judge stated, “As a general
rule of thumb, a royalty of 25 percent of net prof
its is used in license negotiations.”36 However, in
the famous case of Polaroid vs. Kodak, the judge
awarded a reasonable royalty that amounted to
slightly more than 60% of the infringer’s antici
pated profits. The “Ten Sources of Value” (Table
1) and the rating/ranking factors must always be
kept in mind, as should the overwhelming sig
nificance of differing risk perceptions of the same
opportunity. If the licensee sees an opportunity
as extraordinarily risky, then 25% of the profits
will appear far too high. If the licensor sees it as
picking the low-hanging fruit of something that
can be readily commercialized by a license, 33%
or more will seem reasonable. So, one should
not take this “rule” suggesting there is a univer
sal agreement that the value of “25%” covers all
situations.
For more information, a summary of the his
tory of the 25% rule is included in William (Bill)
Lee’s paper.37 Our observations relating to the use
of this rule are summarized below:
Positive aspects of the 25% rule method:
• Has a “feel-right” tug in certain circum
stances
• Can be the basis (principle) of early
agreement
• Appropriately tied to profitability
• Widely accepted (at least in the sense that
lots of people have heard of it)
Difficulties with the 25% rule method:

• The lower you go below the top line of an

income statement or model, the more sub
jective (that is, inauditable and arguable) it
gets, for example, what is appropriate over
head? What are appropriate sales costs?
• The calculation, depending on how it is
performed, can have the effect of rewarding
licensee business inefficiency.
• Very difficult to get good income statement
numbers that are not smeared over many
businesses and products.
• The licensed subject matter (normally) rep
resents only a part of the sales price; com
plex considerations are needed to decide
whether to discount or not.
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• There can be significant year-to-year vari

ability in available income statement
numbers.
• No help on upfront fees.
• There is no inherent assessment of the po
tential importance of third party IP and
technology to a licensee’s use of the subject
technology.
One key piece of advice: If you use the 25% (or
one-third) rule, use it only to develop the calcula
tion of the royalty rate to be based on sales—never
permit the royalty to be calculated on an as-you
go basis as a percentage of earnings before tax.
..2 The 50% rule

Duke Leahey has outlined a 50% rule that is re
lated to the 25% rule:38
• At the point of product introduction, about
50% of the total risk of product failure
remains.
• If the inventing organization brings the
technology to the state of product intro
duction, it is entitled to 50% of the total
reward (profit).
• If the commercializing organization partic
ipates in premarket development costs and
risks, it is entitled to more than 50% of the
total reward.
From this perspective, the 25% rule repre
sents a 50:50 participation in premarket risk.
Accordingly, the 50% rule suggests that to deter
mine a fair apportionment of profit one should
assess the extent to which the premarket risks and
costs will have been borne by the licensor and li
censee when the product finally gets marketed.
Unfortunately, this is not easy to do.
When did the invention begin? In most
cases, the inventing organization and individual
inventors endured a long, costly gestation that
was the essential primordial ooze from which the
invention emerged. It is therefore unfair to the
licensor to add a $5,000 patent application and
a $10,000 project that fleshed out a few numbers
and contend such expenditures are equivalent to
the $1 million required cost asserted by a licensee
to bring the technology to the market as the basis
 | HANDBOOK OF BEST PRACTICES

for determining the relative, premarket contribu
tions of licensor and licensee.
A second version of the 50% rule appears
to be applied primarily in the area of software
and reflects the very significant pre- and postcommercial involvement by university and
R&D organizations in certain situations. When
software is commercialized, many activities
can be the responsibility of either the licensee
or licensor. These include: performing all the
bug fixes and compatibility tests of the original
code, developing user interfaces, creating soft
ware manuals, making copies for distribution,
packaging, finding customers, delivering copies,
hot-line help for routine questions, resources for
in-depth questions, new bug fixes, updates and
improvements, product advertising, sales and
distribution, more bug fixes, and so on. In some
instances, the licensee and licensor will divide
these responsibilities so that when credit for
cost/risk of creating the product is ascribed to
the licensor, then the resulting split is 50:50.
But there is no simple way of saying how
such a split in responsibilities warrants 50:50. At
one extreme, for example, the owner/developer
of the software product could do everything re
quired for commercial use, including advertising
and other promotional activities, and elect to hire
marketers purely on a commission basis to assist
in direct sales. (This is commonly necessary when
selling software that costs in excess of several
thousand dollars). In such a case, the marketer
is playing only a limited role in the commercial
process, basically as a manufacturer’s rep and may
be paid a commission, ranging from 10%–20%.
Taking a figure of 15%, this means the revenues
from sales have been effectively split 85:15 taken
as a percentage of sales in this example of a differ
ent rule of thumb.
At the other extreme, the creating organiza
tion can enter a license at an early stage in de
velopment and turn over a hard drive contain
ing code that works but is not yet complete as a
product. In this case, the licensee has to finish the
code; develop all the user-friendly tools; intro
duce the product to the market; perform all the
promotions, sales, and distribution; handle the
customer; and so forth. Here, the licensee may
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agree to pay a royalty in the range of 10%–25%
(or even much less). Taking again a figure of 15%,
this means that the revenues from sales have been
split 15:85.
By using the 50% rule, or a 50:50 split of
revenues, a licensor agrees to perform an addi
tional 35% share more of services than in the
15:85 example (or the commercial partner is
doing an additional 35% share more of ser
vices than in the manufacturer’s rep example
of 85:15). As you can see, it is unhelpful to
rely too heavily on such numbers. Indeed, like
any other type of licensing, once a technology
transfer manager has gone through a significant
number of deals, he or she will be able to recog
nize what deserves a 50:50 split, as well as the
appropriate split for the level of involvement in
particular cases.
. Discounted cash-flow analysis
with hurdle rates

Method III introduced the concept of apportion
ing profit by examining each party’s contributions
and risks incurred in creating such profit. Method
IV is a more sophisticated way of performing such
considerations. This method consists of deter
mining future cash flows, then discounting these
cash flows by accounting for the time over which
those amounts are to be received and by the as
sociated risk of receiving such cash flows. For this
reason, this method is sometimes known as the
discounted cash flow (DCF) method. When all
such cash flows have been discounted, they can
be added to determine net present value (NPV).
The key to this method is the application of the
risk-adjusted hurdle rate (hereafter designated by
k) or the factor based upon perceived risk that is
used to discount the future cash flows and will be
referred to here as the “risk-adjusted hurdle rate”
(RAHR). In effect, k is used to determine how
the profits (or cash) resulting from the commer
cialization of the subject opportunity should be
apportioned.
..1

Defining risk

First, let us consider what is meant by risk. There
are technical risks, market risks, and the infamous
other risks, such as market erosion or the changing

tastes of consumers. What are some technical
risks? Although it may not be obvious, a key
technical risk has to do with whether the technol
ogy works. For many reasons, a lot of inventions
simply do not work. Sometimes the invention
works, but only under very carefully controlled,
glacially slow procedures with tiny quantities in
clean rooms carried out by very experienced sci
entists using technicians with dexterity and intel
ligence that is hard and very costly to duplicate.
If a product needs to be made in high volumes at
low cost, there is a huge risk in taking something
that works in the cleanest of clean-rooms and get
ting it to work in a factory.
In the category of market risk, a competitor
may develop a superior product based on anoth
er technology. Customer requirements can also
change dramatically. Tastes can change, and antic
ipated profit margins can erode or disappear. And
customers, despite all the market assessment, can
simply decide not to like a product. Remember
New Coke? Remember Corfam? Sinclair and
Commodore computers? An appetite-suppress
ing candy with the unfortunate name of Ayds?
Finally, all sorts of external events can sink
an enterprise. Some raw material that the licens
ee needs to use or a product that it plans to sell
can become illegal or so constrained by regula
tion that there is no cost-effective way to use it
or sell it. Other industries can undergo upheaval
to the mortal detriment of a licensee. Remember
the oil embargo? The shortage of DRAM chips?
Nuclear power? A key trade secret could be sto
len. The patent office could deny patentability or
grant broad rights to a blocking patent owned by
a third party.
..2 Developing a risk-reward model

Investors use a risk-reward model to guide their
investment decision making. It is commonly
expressed in some form of a graph such as the
one shown in Figure 2, where increased risk de
mands an increased required rate of return (k),
also known as the hurdle rate. The job of a busi
nessperson is to convert the investments made in
the company into returns that equal or exceed
the rates of return expected by such investors. So
the floor for a businessperson’s expected returns
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is normally the company-specific, average cost of
capital (a combination of debt and equity). What
makes a particular project investment good or
bad at the stage of making the investment is the
perception of whether the returns will be attrac
tive in relation to its risks, the latter of which are
determined by the company’s prescribed rewardrisk relationship.
From the point of view of the prospective
licensee, one of the basic value questions is the
degree of risk that has been eliminated by the
licensor’s R&D and other activities. The greater
the risk reduction, the greater the perceived value
(or, in other words, it is less likely that a discount
will be applied to the perceived potential value of
the license). From the perspective of the licensor
and, particularly, the professor-inventor, this sug
gests that additional R&D will increase both the
likelihood and the economic value of a license.
But this is only true if the licensor’s R&D activi
ties are successfully applied to commercial risk-re
ducing activities. Investment in R&D that is di
rected toward improved scientific understanding

and publication of an invention may or may not
reduce risks associated with commercializing a
product of interest to a licensee.39 Not all motion
is progress. This is yet another reason why costs
are irrelevant in assessing value. Figure 3 summa
rizes the key steps of this method.
First, a determination must be made of the
earnings before interest and tax (EBIT). This is
done in the same fashion (and with the same un
certainties) as with Method III (see Table 12).
Next, a provision is made for a royalty payment
as yet another cost of the licensee. Initially, this
value is simply a guess. Later, it will be adjusted to
make the overall returns attractive to the licensee.
Next, a provision is made for taxes. Throughout
the 1980s and 1990s, a value of 40% was typi
cal for combined state and federal taxes; some
what lower projections are now sometimes made
for the future. This results in earnings after tax
(EAT—an easy acronym to remember).
But the EAT for a project is rarely the
amount of cash it throws off. One reason is that
to calculate earnings, we have subtracted from

Figure 2: Return and Risk

Required rate of return k(percent)

Good investment

Bad investment
Company-specific average cost of capital

7

Risk-free rate of return (T= bills)
3% is the historic figure people require to defer consumption
+ 4% inflation = 7% T bill
Increasing risk
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revenues some non-cash costs such as deprecia
tion. To get a cash figure, we need to make three
additional adjustments to earnings: (1) the total
depreciation expenses deducted from revenues to
reach EBT must be added back since they are not
a current-year cash expense; (2) the current-year
cash investment (such as plant and equipment)
needed to produce the revenues flowing from the
technology must be deducted; and (3) the year
by-year increase needed in networking capital
(current assets, such as cash, receivables, and in
ventory, less current liabilities, such as payables—
all of which tend to increase with increasing sales)
must be subtracted. The result is net cash flow in
current-year dollars for the projected period, nor
mally at least 10 years of sales, or a total of 15 or
more years from the effective date of the license
agreement.
Next, each years’ cash flow is reduced by di
viding each cash flow by the term (1+k)n, where k

is the hurdle (or discount) rate, and n is the year
from now in which the projected cash flow oc
curs.41 In order to perform this calculation, esti
mates must be made for revenues and all relevant
costs and investments year by year. This can be a
formidable exercise to a first-timer, but after the
technology transfer manager has done this a few
times, timidity flees and the manager will find
him- or herself boldly arguing about projected
costs of sales in the year 2020. Table 14 provides
an example calculation taken from Gordon Smith
and Russell Parr.42
In the example shown in Table 14, a com
pany is considering whether to buy a license for
a specialty product to add to an already existing
commodity product. The royalty line showing
12.6% of sales is based upon the sales of the li
censed, specialty product only. The NPV of the
combined net cash is shown as US$19,684. The
12.6% was used because this NPV is identical to

Figure 3: Value: Risk Plus Magnitude and Timing of Future Cash Flows40
1

Sales
(expenses)
(depreciation)
(royalty)

EBT

Taxes
Depreciation
(investment)
(increase in working capital)

EAT

2

3

Discount cash by NPVa =

Embody risk in “k”

Net
cash
flow

$ in year n
(1 + k)n

4

Choose “k”

a Net present value equals “All the future benefits of ownership compressed into a single payment.”
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Table 14: Commodity Corp. Discounted Cash-Flow Analysis
(uS$, in thousands)

%

1991

1992

Commodity sales

100

100,000

105,000

110,250

115,763

121,551

Specialty product sales

100

1,000

5,000

20,000

45,000

60,000

101,000

110,000

130,250

160,763

181,151

Total sales

1993

1994

1995

Cost of commodity sales

68

68,000

71,400

74,970

78,719

82,564

Cost of specialty product
sales

45

450

2,250

9,000

20,250

27,000

68,450

73,650

83,970

98,969

109,654

2,632

2,813

3,051

3,446

3,699

Total cost of sales
Depreciation expense

%

Gross profit

30

29,918

33,537

43,229

58,348

68,198

38

Selling, general and
administrative

24

24,240

26,400

31,260

38,583

43,572

24

126

630

2,520

5,670

7,560

5,552

6,507

9,449

14,095

17,065

2,499

2,928

4,252

6,343

7,679

3,054

3,579

5,197

7,752

9,386

2,632

2,813

3,051

3,446

3,699

5,685

6,392

8,248

11,198

13,085

- Additions to working
capital

1,200

1,800

4,050

6,103

4,158

- Capital expenditures

2,632

3,632

4,763

7,901

5,046

1,853

960

(565)

(2,805)

3,881

- Discount rate

0.9333

0.8115

0.7057

0.6136

4.9718

- Present value

1,730

779

(399)

(1,721)

19,296

Royalty payment at 12.6%
of sales
Operating income

5

Provision for taxes
Net income

3

Depreciation expense
Gross cash flow

6

14

5

7

Less—

- Net cash flow

2

Total net present value (in uS$, in thousands)
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the NPV of not taking a license for the specialty
product. Therefore, a royalty of 12.6% would be
the most the company would pay to gain this ad
ditional product.
The key aspect of the above calculation is
the specification of a value for k. Before delving
into how a value for k might be selected, a bet
ter understanding of what k does to a calculation
is required. Figure 4, which shows a pro forma
net-cash-flow projection for a license, can help us
take our first steps to understanding k.
At time zero, the license agreement is signed.
During each of the first and second years, the li
censee spends $1 million in combined upfront
fees and technology development and project
costs. In the third year, these costs grow to $2
million, and in the fourth year, as scale-up and
production costs are incurred, they grow to $3
million. So, by the end of the fourth year, and
before any sales occur, the licensee has spent $7
million. Although sales begin in the fifth year,
there is still a net investment required of $2 mil
lion and again of $1 million in the sixth year. At
the seventh year, the licensee finally reaches the

stage where the technology does not require an
additional current-year net cash investment. In
this model, the licensee has had to sink a total of
$10 million to get to this point (7+2+1), and in
the seventh year, the project results in a net cash
inflow of $1 million. Note that for most projects,
the amounts of initial investment required are
generally able to be estimated with more certainty
than are the later-arriving profits.
Now, the market for the product is expect
ed to take off and there is a significant growth
in expected cash generated until the product
peaks in the 12th year. Sales begin to decline
in the 15th year, and finally end after the 19th
year when the product is withdrawn from the
market because it is no longer economically
competitive.
Adding all the cash flows above the line,
from the seventh through the 19th years, shows
a cumulative $136 million. Thus, it took a rela
tively certain $10 million investment to get an
expected return of $136 million.43 Putting this
another way, a $10-million investment starting
today and extending over a period of the next six

Figure 4: Example Future Net Cash Flow
$16

Profit pressure
at maturity

$14

Total net cash flow = $126m
Investment required = $10m

$12
$10
$8

Patent expires

Patent issues

$6

1st commercial sales
year

$4
$2
0
($2)
($4)

Exit the business
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18 19 20

Project years

HANDBOOK OF BEST PRACTICES | 

RAZGAITIS

years, will yield a substantial $126 million net
over the next 19 years.44
Figure 4 ignores inflation and all the risks as
sociated with the production of those future cash
flows. In accounting for inflation, a k value of 2%–
8% (depending on our views of the future) might
be used to reduce all the cash flows to the same
basis so that when the return is netted against the
investment the calculation is made using same year
dollars, at time zero. If a k value of 7% is selected,
each of the shown cash flows would then be di
vided by the term 1.07n, where n is 1, 2, 3, and so
on, up to 19 for each year of the projection.
However, in addition to inflation, risk must
also be assessed and accounted for. The licensee’s
expenditures of money are comparatively cer
tain. The returns are not. If the licensee takes
the view that investments and returns should be
discounted by the company’s cost of capital, and
such cost is, say, 15% (which includes the effects
of inflation), then the cash flows of Figure 4 result
in the curve shown in Figure 5.
This shows that the early-year cash amounts
are reduced slightly (the curve and bars are close

in the first and second years). As time progresses,
there is a compound discounting of cash amounts
until the cash contributions calculated by the 15%
discount factor in the 19th year are almost neg
ligible. This is because the mathematics assumes
a compounding of risk with each succeeding
year (in other words, more things can go wrong
as more time progresses). Remember that a k of
15% in this model is more than the presumed
rate of inflation. This is why the term hurdle rate
is used for k. If the projected cash flows cannot be
attractive using 15%, then this investment does
not jump this hurdle and should not be made.
What Figure 5 shows is that, for a k of 15%,
the $126 million of nominal net cash is really
only $17.25 million of time zero (now) cash.
This $17.25 million value is called the net pres
ent value (NPV) at a hurdle of 15%. The NPV
means that, for a risk value of 15%, including in
flation and all the things that can go wrong, the
decision to invest in this opportunity will pro
duce, in time, the equivalent of $17.25 million
of today’s dollars. By definition, this means it is
worth making the investment, unless the licensee

Figure 5: NPV of Net Cash Flow at a Risk hurdle (Discount rate) of 15%
$16
$14
$12
$10
$8
$6
$4
$2
0

NPV (15% of $126 million) ,
is $17.25 million, which corresponds to
the sum of all the values associated
with this curve,
$17.25 million is the
maximum a licensee
would pay for the
right to such future
cash flows if its
perception of risk
corresponds to a
k of 15%.
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has an even better NPV opportunity at the same
or lower level of risk.
Figure 6 shows the impact of various hurdle
rates on the same cash values shown in Figure 5.
The original cash profile shown was for
a hurdle rate of 0% and assessed this opportu
nity at $126 million net in nominal dollars. If
a k value corresponding to a near risk-free alter
native investment opportunity of 7% is selected
over the period, then the opportunity is assessed
at $49 million (again, and always, in today’s dol
lars). When a hurdle rate of 15% is selected, cor
responding to a low but real risk, this is further
reduced to $17 million. Finally, when this oppor
tunity is believed to contain significant technical,
market, and other risks corresponding to a riskadjusted hurdle rate (RAHR) of 30%, the NPV is
reduced to $1.6 million.
The key idea of NPV is that, once the ap
propriate value for k has been selected by the
licensee, then the licensee should be motivated
to acquire rights to any properties that have a
positive value of NPV, provided the company has
sufficient resources to pursue every positive NPV

opportunity. Otherwise, the licensee will select
the most positive opportunities available. In any
case, the licensee will still want to buy the rights
to the opportunity for as little as possible, even
less than the values used in computing the NPV
in the first place: “Business is about paying tens
for fifteens.”45
.. Determining k (the hurdle rate)

Now, how is k determined? The discussion of
Method I noted that established market prices
exist for certain standard kinds of items, such as
office floor-space rentals, and for standard forms
of debt instruments, such as federal securities of
varying maturity. U.S. Treasury securities, having
essentially no “business” risk, have the lowest k
values. For example, as of 13 April 2001, the k
value ranged from 4.33% on two-year treasuries
to 5.16% on ten-year treasuries. Bonds offered
by corporations generally have higher k values,
depending upon the perceived risk as character
ized by various bond-rating agencies. However,
all such rates are for broadly based investments,
not a specific commercialization project, so they

Figure 6: NPV of Net Cash Flow at Various Risk-Hurdle Rates (k)
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are normally believed to be substantially less risky
(because the companies exist, their markets are
known, their competitors positioned, their tech
nology understood, and their businesses typically
are somewhat diversified).
Unfortunately, there is no such table of values
available for technology licenses. As was the case
when contrasting office space rentals and tech
nology commercialization opportunities, the lat
ter do not fall into sufficiently precise categories
with large numbers of published values to permit
standard ks to be established.
Figure 7 illustrates another type of risk con
sideration: business start-up risk. This is based
primarily on a book by Jeff Timmons.46
A number of terms are used to characterize
the stages of development; at times, these terms
can be confusing and contradictory. In general,
for capital sought prior to initial sales, the hurdle
rate required by risk-capital providers is very high,
50%–100% (or even more). Once sales exist and
a market can be characterized, and assuming the
results are favorable, the hurdle rates can decline

dramatically down to 30%–40% (depending
upon assessments of competitive response, mar
ket saturation, cost of expansion, and so on). The
hurdle rates used for genuine start-up situations
are usually far higher than those used by an exist
ing company, and they reflect the increased risks
associated with all the activities needed to create a
business ex nihilo.
So, what is a reasonable way to categorize
hurdle rates? There is no simple answer to this
question. However, to provide some insight the
broad generalizations of Box 1 are offered for five
categories of risk.47
Most licensing situations with existing
companies will fall into Categories II and III,
corresponding to hurdle rates in the range of
25%–40%. Start-up situations or companies
contemplating a spinout structure normally re
quire hurdle rates in excess of 40%, even to 50%
or higher. However, as was discussed in connec
tion with the 25% Rule, every licensing opportu
nity has case-specific factors that affect both value
and, our present concern, risk. Just because an

Figure 7: Hurdle Rates for Start-ups
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invention relates to an existing manufacturing ca
pability with a known technology area, a poten
tial licensee may see the risk associated with such
specific invention as warranting a RAHR higher,
or lower, than given in the Box below.
Figure 8 applies these five risk categories to
our original cash flow example of Figure 4.
If this opportunity corresponds to Category
III, the NPV ranges from a negative $800,000
(for a k of 40%) to a positive $1.6 million (30%).
So, what originally looked like a simple decision
of making a total investment of $10 million to
net a total of $126 million is actually a close call.
If the risk of this opportunity corresponds to a
hurdle of 40%, this investment cannot be justified
because the NPV is negative. Recall that, when
this model was created, (an unstated) upfront
payment and progress payments were assumed
by the licensee to the licensor, as were continu
ing royalties that reduced the cash flows to those
shown. Both were part of the $10 million invest
ment. From the point of view of the licensee, this
negative NPV should be a stimulus to reconsider
all such IP payments to see if the negative NPV
can be made positive.
.. Reducing risk/enhancing value

In any event, there are at least two other possibili
ties for reducing IP payments. First, the perceived

risk may be reduced by working with prospective
licensees who are either already commercially ap
plying technology similar to the subject opportu
nity or selling like or similar products. The point
here is that companies perceive risk differently
depending upon their technology base and their
existing customers. If, by this redirecting of mar
keting activity, a different prospective licensee’s
assessment of risk is now 30%, then there is the
potential to gain as much as an additional $1.6
million beyond those payments embedded in
the cash-flow calculation. That is a very dramatic
increase in value. Furthermore, the likelihood of
getting the royalties is increased because it is more
likely that such a licensee will succeed (all other
things being equal—and they never are).
A second approach to dealing with negative
NPV outcomes is to consider what R&D and/or
market development activities can reduce the risk.
The real technical risk of some key aspect of the
technology may be known by the inventors to be
much less than that perceived by prospective buy
ers. A carefully directed, internally funded R&D
program tackling commercial objectives can sig
nificantly reduce such risk. Of course, it is always
possible that such results will go the other way.
The key idea is to spend small amounts of money
on critical, commercially relevant experiments—
and not just gather ever-more publishable data

Box 1: What Is Reasonable k?
Unfortunately, the answer is: whatever the market says it is.
What does the market seem to be saying?
I. Low risk (assuredly fits into an existing manufacturing line and market) 10% to 20%; if required
to maintain base product life, then k could be much lower, or even discarded
II. New product (existing manufacturing capability, known technology) 25% to 35%
III. New product and technology (still in existing business) 30% to 40%
IV. New business, product ready for sale (no R&D required) 40% to 50%
V. New business, seed funding, R&D stage 50% to 70% (or more)
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Figure 8: Who Are Prospective licensees
and What Should They Be Willing to Pay?
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Applied to our previous
net-cash-flow model, what would
an investor conclude?

Category

k

NPV

RF........................... 7% ............................ $49m
I............................... 10%–20%............... $33–$8m
II. ............................ 25%–35% ............... $4.2–$0.1m
III> ......................... 30%–40%.............. $1.6– $(0.7)m

Yes
For a “New Product” category
(k=30%):
≤$1.6m
Barely, Yes

IV............................ 40%–50%.............. $(0.7) – $(1.4)m
V. ............................ >50%....................... <$(1.4)m
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sets. Some have described this process as doing
the last experiment first. In general, it is a very
good idea.
Another tool in such a risk-reduction ap
proach is leveraging government funding. It can
be argued that government funding should be
used to reduce the risk of significant commer
cial opportunities so that the private sector can
apply it to create high-valued companies and
jobs. Commercial funding necessarily has some
relatively immediate market application and in
troduction. However, there are other sources of
“research” funding sometimes available that push
forward certain knowledge frontiers that could
have as a consequence the development of know
how that supports the subsequent commercial
development needed for a specific licensing
opportunity.
In addition to reducing risk, one can work
to directly enhance value. One tool to accom
plish the latter is to form partnering relationships
with other R&D organizations that, by pooling
technology resources and market awareness, can
sometimes significantly increase the NPV per
ceived by prospective licensees. Even when the
NPV is already positive and a prospective licensee
is interested in negotiating rights, remember that
a licensor always has alternatives. For example,
the technology could be pushed closer to mar
ket either by internal investment or by partnering
with another R&D organization to increase the
value. The technology transfer manager should
make such investment decisions by calculating
the prospective increase in value discounted by
the risk of success.
This risk-adjusted hurdle rate approach can
be used for exclusive and nonexclusive licenses,
as well as for licenses by field (or product) and
territory. In each case, the cash-flow projections
need to reflect the anticipated commercial out
come given the structure of the agreement. For
example, if the licensing strategy is to have two
competing licensees in all fields and territories,
then the magnitude of the total sales attainable
by each licensee is probably less than if there
were to be one exclusive licensee. However, the
gross margins, or profitability, may remain large,
since each licensee will not face a large number

of competitors. The net result is likely to be that
each licensee will pay less royalty, but together
they could (and should be if such an approach is
considered) pay more total royalties.48 More de
tails on DCF models are provided in the Wileypublished book by this author.49
.. Possible payment structures

Running royalty structures. There are many pos
sible royalty structures. Because the royalty rate
depends upon the economic value associated
with specific products, if there are multiple prod
ucts, then a separate royalty could be established
for each product or product area within a single
agreement. There is also justification for build
ing up a royalty rate based upon the measure of
IP protection obtained. For example, a licensee
might pay a royalty of 3% on the basic patent
and 1% for the use of the two other patents in
the package, or 1% for the use of the unpublished
technical information and an additional 3% for
the patents, and so forth. Of course, this should
only be considered if it relates to an economic
benefit (lower k, higher margins, and so on).
Many licensees ask for a declining royalty rate
with increasing sales, a so-called staircase or wedding-cake royalty structure. One example would
be a royalty of 5% on the first $1 million in sales,
3% for the next $9 million, and 1% for all sales
above $10 million, based on annual sales. The un
derlying theory of this approach appears to be an
economy-of-scale argument similar to bulk pur
chasing. If a company buys one box of paper clips,
it might conclude that $5 is reasonable; if it buys
1,000 boxes it may expect to pay only $3 each;
and if it commits to buying trainloads per year, it
may expect to pay only $1 each. Companies com
monly leverage volume purchases when they buy,
and apply this same kind of thinking when they
sell. However, there is no economy-of-scale prin
ciple for IP rights. The licensor’s costs of provid
ing the grant to the licensee are not relevant, nor
do they decline based on sales volume, as would
the costs of a paper-clip supplier. In fact, based
upon an economic-return model, it can be argued
that the profitability to the licensee increases with
increasing sales, and so, the royalty rate should
actually go up with increasing sales. For practical
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reasons, the parties may elect to simply compro
mise and keep the royalty rate fixed regardless of
sales volume.
Developing a staircase royalty structure based
on cumulative sales or on years from first com
mercial use may have a rational economic basis.
Ordinarily, after the initial introduction, the prof
itability of a product climbs to a peak and then,
as the product matures, pricing pressures tend to
squeeze margins. A royalty structure that attempts
to model this profile makes sense, providing the
rate during the high-profit years has been set to
correspond with economic benefits. For practical
reasons, parties frequently elect a single rate over
the life of the patents that balances all these fac
tors. Regardless of the approach, the rate agreed
to tends to act as a cap for the reasons discussed
in the introduction to this chapter. The licensor
does not have a vehicle for increasing the rate,
and the licensee can come back to the licensor
and threaten to drop the license because of less
than-anticipated margins unless it gets a reduc
tion in the rate.
Licensees sometimes propose capping the to
tal economic return to the licensor. This may be
expressed as some multiple of the licensor’s costs
(You shouldn’t expect to get more than ten times
what you’ve invested in this!) or simply as some
statement of moral principle ($10 million should
be more than enough, after all you are a public,
not-for-profit institution!). This is nonsense. A
licensor who is the rightful owner of a portfolio
of technologies has a stewardship responsibility
to return value to the institution for the transfer
of such rights. Furthermore, all portfolios exhibit
many losers, a few moderate successes, and only
a few agreements that perform really well. If the
licensor agrees to caps on the total return of all
agreements in the portfolio, then the portfolio
will produce only losers and moderate returns.
Without the occasional big win (at a fair royalty
rate), the portfolio will not produce a fair overall
return.
What about the approach of a one-time, paidup license—that is, setting a higher licensing fee
with a zero running royalty? Some licensees push
hard for this approach—and not always from a
pure heart. There are several common arguments
0 | HANDBOOK OF BEST PRACTICES

in favor of the approach: (1) it eliminates the ad
ministrative burdens (quarterly or annual reports
and checks) for both the licensor and licensee and
(2) basing royalties on sales may divulge highly
sensitive licensee business information, which is
against company policy or wishes. Recall the ear
lier discussion about setting the values of future
income streams in well-defined situations such as
office rent. When a stream of cash payments is
well defined and the risk is low or at least well
understood, then two parties can readily agree
on the conversion value of the future stream into
one present payment (which is really just the
NPV of the future stream). However, for earlystage technologies, estimates of the range of pos
sible dollar returns from royalties can vary over
several orders of magnitude. This is precisely why
a royalty rate so effectively deals with such un
certainties. When either the licensee or licensor
seeks to reduce such uncertainties to a one-time
lump sum, there is greater risk involved in mak
ing the conversion. One possible motivation for a
prospective licensee is simply to see if the license
can be acquired cheaply. Every agreement has as
sociated with it a range of expected outcomes. If
a licensee can acquire the license by the one-time
payment of the NPV associated with the most
conservative outcome, then it is in the licensee’s
interest to do so.
Rest assured, a licensee is unlikely to agree
to an NPV associated with the most optimistic
outcome. It should be recognized, however, that
sustaining ongoing agreements is both a business
cost and a risk. An ongoing payment arrangement
could possibly lead to a dispute or even litigation.
And there may be situations where the licensor’s
cash needs are such that the institution is willing
to forgo the returns associated with more opti
mistic possible projections. If this becomes the
licensor’s practice, however, the overall returns on
the licensor’s portfolio of technologies will be re
duced because the licensor will not experience the
rare but important higher-than-projected returns
from an exceptional license.
Having said all this, sometimes such an ar
rangement can be in the interests of both parties
(beyond the simple example given above). The
licensor may wish to take advantage of the high
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opportunity value associated with a paid license
so that the funds can be used to move further and
faster other technology opportunities that will
lead to even more substantial returns. Or perhaps
the licensees are cash-rich from a current highoutcome year and are simply willing to make a
fair and substantial payment to own and control
an opportunity because of its perceived strategic
importance. Overall, in those cases where the fu
ture use and value of an opportunity appears to
be reasonably well-bounded, then an NPV calcu
lation can be made that is fair to both parties.
Upfront payments. Upfront payments take
many possible forms. As discussed earlier, the
extreme case is a one-time payment in lieu of
running royalties.50 A series of payments can also
be made, either by calendar (such as annual pay
ments) or by progress (such as upon filing an IND
[Investigational New Drug application, a filing
with the U.S. Food and Drug Administration],
upon first commercial sale or other milestones) in
conjunction with or instead of royalties. Or the
licensee can commit to R&D to fund certain ac
tivities at the licensor’s laboratories.
All of these are basically down payments on
the NPV opportunity as calculated earlier, and
the purpose of any down payment is the same. It
combines a form of diligence and commitment,
and provides an early return for the original in
vestor, the licensor. In university-industry licens
ing, the upfront payment will commonly at least
exceed the licensee’s payment of all the licensor’s
costs in filing and obtaining a patent or patents
incurred to date. If the license corresponded to
an NPV of $1.6 million as in the previous ex
ample, and the patent costs were $5,000, such an
upfront commitment covering only the licensor’s
costs would be cheap—too cheap.
For well-established transactions such as
buying a house or a car, a down payment of 10%,
more or less, is common, although for highly
motivated sales of, say, certain out-of-popularity
automobiles, might be happy with “no money
down” deals. For highly speculative opportuni
ties, such as a license to new technology, 10%
may be on the high side. Consider in the pre
vious example, that the $1.6 million NPV was
computed on the basis of a single, time zero, cash

payment of $100,000 and then royalties on sales.
Such a figure would then correspond to a down
payment of a little more than 6%. This might be
quite reasonable. Some negotiators use, as a rule
of thumb, one year of projected mature-earned
royalties as an appropriate down payment; this is
approximately 5%–10% of the NPV.
Minimums. Another form of diligence is
the minimum cash payment. Also, agreeing
upon such payments increases the likelihood
that both parties are looking at the opportunity
from similar perspectives. Generally, exclusive li
censes contain minimums. Nonexclusive licenses
may or may not include minimums. The rule of
thumb appears to be an annual payment in the
amount of one-fourth to one-half the annual
projected reasonable royalty based on sales esti
mates. Again, the higher the risk and uncertainty
of such sales estimates, the lower the minimum
royalty, and vice versa.
It is important to realize that the licensee
still has significant negotiating leverage on the
minimums. If they end up being too high, and
it is now five years into the agreement, the li
censee can exert a lot of influence on the licensor
by threatening to drop the license if the mini
mums are not reduced in line with the actual
sales (assuming the licensee has been diligent in
developing the technology and the market). In
addition, getting back a five-year-old technology
may make it difficult for a licensor to find an
other party interested in licensing the product.
As discussed earlier, the wish, or threat, for bet
ter terms, of a licensee in a licensee-initiated ne
gotiation, puts in jeopardy the licensee’s invest
ment in the technology (any upfront payments,
milestones, annual royalties, and of course its
own R&D and market development). So a li
censee would have to take a dramatic step to ful
fill such a threat and drop its license should the
licensor not agree.
Equity consideration. A full treatment of
this subject is beyond the scope of this chapter.
However, much of what has been discussed above
regarding NPV calculations using discounted
cash-flow analysis and hurdle rates applies. The
reader is referred to the author’s Wiley-published
books for more information.
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.. Summary

Summary observations and valuation principles
based on Method IV are given in Box 2 and Box 3.
. Advanced tools

Once a DCF model has been established, it is
possible to extend such analysis by application of
quite complex mathematical modeling tools and
gain a better understanding of their economic
impact.
The basic tool is sometimes called probabilis
tic modeling and, most commonly, Monte Carlo
analysis. The complexity of such models used to
require mainframe or minicomputers, but at least
two such products now run on personal comput
ers. 51
This tool works by replacing certain cells in a
spreadsheet with a probabilistic value rather than
a single number as was done in Method IV. Then
the model is run over and over again, hundreds
of times, to develop a distribution of outcomes.
It is much like running the company 1,000 times
(or more) and comparing the outcomes. Under
the DCF approach, each outcome is the same.
However, under a Monte Carlo method, each of
the 1,000 runs would produce somewhat differ
ent values for those cells that were selected for
treatment in this manner. It may sound more
complicated, but in many ways it is simpler. In
fact, Monte Carlo methods are particularly useful
when modeling a start up situation.
Below is an example taken from one of the
companies that offers a PC product.52 This con
siders a fictitious drug, ClearView, which may be
a cure for nearsightedness. The key assumptions
are shown in Figure 9.
In this illustration, the impact on profitabil
ity will be examined through the probabilistic in
vestigation of five assumptions. These are shown
in Figure 10.
First, consider the testing costs. The origi
nal model assumed the testing costs would be
$4 million. Assume there is an equal probability
that the costs will range between $3 million and
$5 million but will never be less than $3 million
and never more than $5 million. This is shown as
the uniform distribution at the top left of Figure
10A.
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Next, reconsider the estimate for the num
ber of patients cured: 25 out of 100. Now assume
a binomial distribution, a commonly occurring
natural distribution, with a mean of 25 as shown
in Figure 10B.
Now, adjust the assumption for the market
ing costs from simply $16 million to the triangu
lar distribution shown in Figure 10C. The most
probable outcome is shown as $16 million, and
the minimum and maximum are $12 million and
$18 million.
Similarly, the growth rate of the market and
the market penetration single values are replaced
by the distributions shown in Figure 10D and
Figure 10E.
Every simple-value cell in a spreadsheet can
be replaced by any of the available probability
distributions. As a technology transfer manager
gains experience using this tool, it becomes in
creasingly clear which cells to treat in this man
ner and which probability distribution makes the
most sense. There never is a right answer. In fact,
one of the great powers of this methodology is
that the model can be run over and over again
with changing assumptions to better understand
the key assumptions that should be investigated
in more detail to reduce overall uncertainty. The
result of the Monte Carlo simulation is shown in
Figure 11.
This outcome shows what happened when
this business venture was run 998 times. The
financial outcome ranged from the worst case,
when all things broke the wrong way (the high
est marketing cost, the fewest number of cured
patients, and so on), with a loss of $14.9 million,
to the most-favorable outcome (when everything
went right) of a net gain of $51.9 million. Half
the time, the net gain was less than $9.8 million,
and half the time it was more. The big spike to the
left on the graph of Figure 11 reflects the severe
loss that occurs because the cure rate was so low
that U.S. Food and Drug Administration (FDA)
approval was never obtained.
Another advanced method of increasing im
portance is the use of real options (as opposed to
financial options). Indeed, an increasing number
of books explore the use of real options in busi
ness decision making. Their potential application
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Box 2: Summary Observations
1. Value is dependent on risk—the risk-adjusted hurdle rate (for the same magnitude and timing
of future net cash flows).
2. There is no one right risk model.
3. Price is determined by what a buyer will give for the rights to such cash flows.
4. As a licensor’s price aspirations correspond to low (optimistic) values of RAHR, the likelihood of
finding such a buyer is reduced (which translates to increased time and resources required to
find such a buyer).
5. There is no one right price (providing No. 2 is true).
6. The longer the period of such future cash flows, the wider the risk limits and the greater the
uncertainty in price aspiration.
7. For cash streams that meet certain standard categories, such as home mortgages, there are wellestablished markets that significantly reduce the scatter on risk and price. No such market exists
for early-stage technologies.
8. Net-cash-flow models require more work and are subject to significant assumptions about
operations and the future (but the licensee is using them to analyze the opportunity and so
should the licensor).

Box 3: DCF Valuation Principles
1. Value calculations may have wide limits because of the range of estimates of the magnitude,
timing, and risk of future net cash flows.
2. Value is given by a down payment (option/license fee) and a future royalty, which may, in the
end, be used to determine the one-time, upfront payment for a fully paid-up license.
3. The down payment for a running royalty license should (normally) be a small fraction of the
total estimated value based on one or the other of the following:
-

approximating the higher risk bound (but, nonzero)

-

5%–10% of the total NPV (best estimate basis)

4. A fair royalty can only be negotiated when reasonable estimates can be made of future net
cash flows.
5. The royalty should be uncapped.
6. Royalty scales dependent on total sales, if used, should be based on value not on a quantity
discount model.
7. Royalties based on figures below the top line (sales) put the licensor at risk for inefficiency/
ineffectiveness of the licensee, which has the effect of double accounting for risk.
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to early, high-risk technologies can be useful
because real options do not punish substantial
but distant future outcomes by high and com
pounded risk-adjusted hurdle rates. The DCF
approach in particular can calculate an almost
negligible value to a $1 billion opportunity that
occurs, say, 10 years in the future with substan
tial average risk. Real options can be used to take
such risk apart by valuing an opportunity stage
by stage, risk by risk, as decisions are reached
and investments made. An introduction to such
methods is given in the author’s Wiley-pub
lished books and, in particular, another 2003
Wiley book by the author: Dealmaking: Business
Negotiations Using Monte Carlo and Real Options
Analysis. These resources give a more comprehen
sive treatment of Monte Carlo and real option

methods and negotiation planning and strategy.
The 2003 Valuation and Pricing of TechnologyBased IP also gives a more extensive discussion
of various forms of deal structures and financial
payments.
. Auctions

This analysis of methods and tools began by con
sidering the use of industry standards. In a sense,
by considering options it ends there as well. An
auction is simply a formalized way of obtain
ing bids from competitive potential buyers. As a
method, it dates from antiquity and is the preva
lent form of commodity transactions, ranging
from the New York Stock Exchange to commod
ity markets to estate and sheriff sales caused by
owner bankruptcies.

Figure 9: Sample Monte Carlo Method—Basic Assumptions
Fictitious new drug, ClearView, for correcting nearsightedness

Costs (in millions):
Development cost of ClearView to date....................................$10,000
Testing costs ......................................................................................... $4,000
Marketing costs................................................................................. $16,000
Total costs............................................................................................$30,000
Drug test (sample of 100 patients)
Patients cured ........................................................................................... .0.25
FDA approved if 20 or more patients cured
(1 approved, 0= rejected)
Market study
Persons in U.S. with nearsightedness today.............................. 40,000
Growth rate of nearsightedness ..................................................... 1.00%
Persons with nearsightedness after one year........................... 40,400
Gross profit on dosages sold
Market penetration..............................................................................8.00%
Profit per customer in dollars ......................................................... $12.00
Gross profit, if approved ..................................................................$38,784
Net profit ...........................................................................................($14,000)
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Figure 10: Specific Monte Carlo Assumptions for ClearView Example
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Its use in technology licensing contexts,
however, has been comparatively rare because of
various structural difficulties. One of the most
significant barriers is the need for any prospec
tive buyer to perform extensive due diligence
and analysis. Imagine the contrast between be
ing on the floor of an exchange and being of
fered 100 shares of IBM at $100 share or 100
bushels of corn at $3 per bushel. No investiga
tion is needed to determine exactly what is being
sold or whether there is a market for it. Contrast
this with a vice president of an electronics firm
receiving a letter from a university or institute
offering to license or sell a portfolio of patents
relating to a new approach for making a bluegreen laser. For the VP to have any rational idea

as to his or her potential interest, he or she will
have to substantially invest in learning how this
offered technology differs from its own or other
published literature, the stage of development,
the key benefits, the scope of the intellectual
property, and so on.
Another barrier to the use of auctions is that
the mosaic of the licensing deal is typically much
more complicated than a simple cash payment, as
in the case of IBM shares or bushels of corn. An
upfront payment or payments is to be expected,
but so might royalties, additional R&D invest
ments at the discovery institution, and many
other deal features. These aspects are not as eas
ily communicated by bidders or compared by
sellers.

Figure 10 (continued)
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Nonetheless, auctions for intellectual prop
erty do occur. Perhaps the most common occur
rence is in the context of a shutdown or bankrupt
cy proceeding, where the investors are seeking to
recoup some of the investment and the alterna
tive of continuing as a standalone company no
longer exists. All the parties understand that the
court has ordered a process, and there will be a
sale to the highest bidder.
A famous university example of opportunity
licensing is associated with a fat gene discovered
at Rockefeller University. According to a Business
Week article.53 Rockefeller University and a then
recently started biotechnology company initiated
discussions; the invention, which has the promise

to “cure” obesity by a gene, attracted significant
interest by other companies, which led to other,
parallel discussions. However, when a large num
ber of companies expressed interest (reportedly
more than a dozen), all of them were invited to
bid on the opportunity. On 28 February 1995,
Rockefeller announced that Amgen had won by
agreeing to pay a US$20 million signing fee plus
unspecified royalties. According to Rockefeller’s
vice president for academic affairs, “Amgen pur
chased a scientific concept”: a pretty valuable sci
entific concept.
The very high-perceived potential value of
the Rockefeller gene gave the institution enor
mous bargaining power (some might argue that

Figure 11: Simulation Output (Forecast) for ClearView
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it created a feeding frenzy). In most licensing
circumstances, the seller/licensor is simply not
going to be able to attract a sufficient number of
simultaneous bidders. This is because the cost of
the due diligence, coupled with the reduced like
lihood of being the successful acquirer, will en
courage already busy companies to do something
else with their precious time and energy. Some
additional examples of successful and unsuc
cessful auctions are included in the earlier-cited
author’s Wiley books.

. ConCLuSIonS
This chapter started with a letter requesting mon
ey for an investment. It will close with another
one (again, one actually received by a venture
capitalist):54
“Hello, How are you doing? My work is nec
essary for the survival of life of the planet. I need
money. Minimum investment $100,000. Profit
25%. Thank you.”
This letter has all the basic elements of a good
marketing instrument: friendly beginning, state
ment of mission, expression of need, identifica
tion of benefit, friendly close. Now you have the
tools to decide whether this is a good deal.
Finally, for those of you whose mind has
wandered reading all these pages and looking at
all these figures and perhaps now find yourself
completely lost, I understand that, you the reader,
were hoping that by this time I would lead you
to the number. OK, here it is: 3.14156. It is the
best this author can do. Use it with great caution.
That is it. That is all you need to know. Happy
pricing. n
RichaRd RaZgaiTis, Senior Advisor, CRA International,

Inc., P.O. Box 65, Milford, NJ, 08848, U.S.A. richard@
razgaitis.com
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electrical, it appears that two agreements had no
payments at all. So more than half of the agreements
had no upfront fee!

A

10 McGavock DM, et al. 1992. Factors Affecting Royalty
Rates. les Nouvelles June 1992. p. 107.The data presented
was obtained from the voluntary response to a mailed
survey. The authors caution that the number of replies
may not be statistically significant. Also, given the
nature of voluntary replies, there is no assurance that
the survey is not biased.
11 Nelsen L. 1989. University Patents. Presented at the
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1989 AUTM Annual Meeting. These rates were not
determined by a scientific study; rather, they are typical
ranges estimated by Lita Nelsen, Director, Technology
Licensing Office, M.I.T, based on extensive experience
in this area.
12 Adapted from article published by Corey G and E
Kahn. 1991. How to Negotiate Reasonable Royalty
Rates for Licensing Novel Biomedical Products. Genetic
Engineering News July–August 1991. p.4. A related
article by the same authors was published in 1990 as
Biomedical Royalty Rates: Some Approaches. Licensing
Economics Review December 1990. p. 13.
13 Adapted from Corey and Kahn (supra note 2).
14 Kiley T. 1990. IPH Newsbrief April 1990.
15 Ibid.
16 Source: Communication from the seller.
17 Private communication, Emmett Murtha, November
1993.
18 Mike Carpenter presented at workshop given at the
1979 LES Annual Meeting.
19 Ibid.; See also the list of reasonable royalty
determinations in Einhorn: Royalty Patent Licensing
Transactions vol. I, sec 303, pp. 3–11ff; or search DIALOG.

later, with inflation or increasing costs of electricity or
a particular raw material, the savings could be $8 in
the currency of that tenth year. The agreement should
normally have some provision for the calculation of
royalty to similarly inflate in dollars so that, as in this
example, it would yield $2 in the tenth year.
30 This particular form of the definition is adapted from
an article by Sommer EM. 1993. Patent and Technology
License Agreements Explained. The Licensing Journal,
August 1993. p. 3ff. This article and other similar
sources also deal with an important but complicated
issue of transfer pricing: that is, when a licensee sells
or transfers the product made by the practice of the
technology to another division or a subsidiary of the
licensee.
31 All the materials, labor, electricity, and all other variable
costs attributable to the manufacture of the product
sold.
32 Because this is a gain in a part of the statement
where reductions are applied, it is shown as a negative
number; minus a minus means a plus, and so forth.
33 Ibbotson and Associates, Chicago, Ill. www.ibbotson.
com.
34 Robert Morris Associates, Philadelphia, Penn.

20 There is a widely held perception that royalties
determined or negotiated before the mid-1980s,
when the Court of Appeals for the Federal Circuit was
established, are lower than rates established since.

35 Data from RMA Annual Statement Studies, 1991.
published by Robert Morris Assoc.; Philadelphia, Penn.

21 See Einhorn, supra note 19.

37 Lee Jr. W. 1992. Determining Reasonable Royalty. les
Nouvelles, September 1992. p. 24.

22 Stevens A. 2000. Finding Comparable Licensing Terms.
AUTM Technology Transfer Practice Manual. Part VII,
Chapter 5. AUTM: Northbrook.
23 Edwards, M. Workshop presented at the AUTM 1993
Annual Meeting. Since these data were published by
Mark Edwards there has been an enormous increase in
the number of such transactions, especially in the “life
sciences/health” area. Examples of such additional
data are available at www.recap.com.
24 For more discussion on obtaining copies of comparable
agreements see Stevens AJ. 2002. Finding Comparable
Licensing Terms. AUTM Technology Transfer Practice
Manual, Second Edition. part X, chap. 3.
25 Feinber RA. 1982. APA Proceedings. Division of Consumer
Psychology. p. 28.
26 Ibid.
27 Arnold T and T Headley. 1997. 100 Factors. les Nouvelles,
March 1987. p. 31.
28 Degnan SA and C Horton. 1997. A Survey of Licensed
Royalties. les Nouvelles, June 1997. pp. 91–96. Reprinted
with permission from les Nouvelles.
29 When using a savings approach, the technology
transfer manager should build in some inflation factor
to avoid collecting 25 cents a unit over a 15-year period
when inflation eats into the real value of the royalty.
Remember, the $1 savings is $1 in the currency of the year
that the royalty is calculated (in this example).Ten years

36 W.L. Gore and Associates v. International Medical
Prosthetics, 16 USPQ Second. p. 1257.

38 Duke Leahey has included this point in various
talks. The version here was the subject of a private
communication in 1993.
39 This is part of a long, impassioned argument between
business and science. Science argues that it is unwise
to develop and apply technology that is not completely
understood. Business says: If we took that view, we
would still be sitting on a rock and arguing about the
Pythagorean Theorem—so, let’s get on with it.
40 Smith and Parr. 1989. Valuation of IP & Intangible
Assets. Wiley. p. 125. See also, Razgaitis, Valuation
and Pricing of Technology-Based Intellectual Property
(supra note 1); see also, numerous papers and books by
Gordon Smith and Russ Parr on DCF methods and ways
of separating intangible and tangible values.
41 Some people prefer to use a mid-year convention: that
is, the costs and revenues occur on average on one day,
halfway through the year. For this convention, it should
be 1/2, 3/2, 5/2, and so on, which can be generalized by
using a discount factor of (1+k)(2n-1)/2.
42 Smith G and R Parr. 1990. Royalty Rate Analysis
Techniques. Licensing Economics Review November
1990. p. 9ff; also published in the 1991 Supplement to
the Razgaitis’ Valuation of Intellectual Property and
Intangible Assets (supra note 1). Smith G and R Parr have
written extensively on this subject. Their organization
publishes the journal Licensing Economics Review,

HANDBOOK OF BEST PRACTICES | 

RAZGAITIS

which frequently includes articles on the application
of this method, as well as other news and information
on valuation, pricing, and other IP matters.
43 This model assumes that the licensor received upfront and minimum payments as part of the $10
million investment by the licensee and a reasonable
royalty throughout all the period that the product
was in commerce, so that the $126 million cash flow
to the licensee was net of all the licensee’s expenses,
including royalty.
44 Also assumed in this model is that there is no net
residual value or cost after the product is withdrawn
from the market and the business is exited.
45 A quote heard during a talk by Ray Rogers, finance
professor at the University of Michigan Business
School.
46 The summary incorporates some of the terms and
values by Timmons. (See Timmons JA. 1990. New
Venture Creation).
47 Paul Purcell of Battelle, and others, have provided
valuable initial insights to negotiating and valuation
contexts.
48 Earlier in this chapter, Kiley (see supra note 15) proposed
nonexclusive royalties as being approximately onehalf the royalties paid under an exclusive license. The
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economic rationale for such a differentiation would
need to derive from comparing the NPVs of two DCF
scenarios—one as an exclusive license and one as a
nonexclusive license. Although it seems obvious that
the nonexclusive licensee royalty should be less, it is
difficult to generalize what a fair difference should be.
49 Razgaitis R. 1999. Early-Stage Technologies: Valuation
and Pricing. John Wiley and Sons. Razgaitis R. 2003.
Valuation and Pricing of Technology-Based Intellectual
Property. John Wiley and Sons.
50 However, this author generally recommends that a
licensor of early-stage technology not sell out for a
one-time, upfront payment. Exceptions to this rule, as
to most rules, can be warranted, as discussed in the
text.
51 The two products currently available for personal
computers are Crystal Ball®, sold by Decisioneering
of Denver, Colo., (800/289-2550) and @ Risk®, sold by
Palisades, New York (607/277-8000). Both require
the use of a spreadsheet program such as Microsoft
Excel®.
52 Crystal Ball, sold by Decisioneering of Denver, Colo.
53 Business Week, 20 March, 1995.
54 See supra note 2.
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Valuation of Bioprospecting Samples: Approaches,
Calculations, and Implications for Policy-Makers
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ABSTRACT

In this chapter, the revenue consequences of varying col
lection fees and royalties with regard to germplasm pros
pecting contracts are demonstrated. Principal factors are
the uncertainty of finding marketable products and the
value of these products. Negotiation factors are finding
a good balance between collection (initial) fees as op
posed to royalty (delayed) payments. Emphasizing col
lection fees reduces total payments except when national
interest rates are very high. Reducing the risk of failure
through in-country screening, including the use of indig
enous knowledge, is a potentially valuable activity. Issues
for contract negotiators are outlined and the implications
for biodiversity conservation discussed. Conceptually, the
highest valuation approach, royalties, will most encour
age conservation, but as the future is typically heavily dis
counted, collection payments may get more attention and
be most effective. Policy considerations for national gov
ernments, nongovernmental organization (NGOs), and
development agencies are reviewed and it is concluded
that grants/loans and training/equipment for in-country
screening should be given a high priority as a potentially
viable activity in the long term.
It should be noted that the figures and calculations
in this chapter are merely for illustration. The valuation
of samples, and by extension a country’s biodiversity, is
a negotiation and will depend on many factors, includ
ing alternative investment options by a company, alterna
tive technologies that could be used for lead compounds,

interest rates, and a range of risk factors, such as the polit
ical situation in a given country surrounding the national
debate on bioprospecting. The latter point is a key factor:
valuation is always a calculation that has important politi
cal consequences. Another complicating factor is the need
for confidentiality with which a country and company
will hold its overall business estimates. Neither a com
pany nor a country will be likely to share their valuation
basis purely for negotiation purposes and because neither
want to tip off other entities about the opportunity. It is
therefore concluded that, from a practical perspective, the
proper valuation is the one that (1) provides the country
with compensation and other benefits such that it does
not feel taken advantage of and can withstand criticism
from its constituents and (2) provides the licensee (typi
cally a company) with a reasonable cost of obtaining the
crucial raw or semifinished goods it requires as an input
to its business.

1. InTRoduCTIon
Since the adoption of the Convention on
Biological Diversity (CBD) in 1992, the le
gal status of traditional knowledge is in the fo
cus of international debate. Concurrent with
CBD, Merck & Co. and INBio, the National
Biodiversity Institute of Costa Rica, made a deal,

Note: While we have been careful in pointing out throughout this chapter that the monetary figures used in
the examples are illustrative, it is important to urge that these figures not be used in actual negotiations. In the
authors’ opinion, one of the main reasons for the overall low level of interest in bioprospecting deals is that ex
pectations based on the market potential for a blockbuster drug may scuttle a deal on samples to be used for an
industrial application with a much lower market potential.
Lesser WH and A Krattiger. 2007. Valuation of Bioprospecting Samples: Approaches, Calculations, and Implications for
Policy-Makers. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org.
© 2007. WH Lesser and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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which was widely publicized, for the payment of
fees and royalties for germplasm collected inside
Costa Rican conservation areas. Importantly, the
agreement was renewed in 1994, 1996, and 1998
in similar terms and by 2004 has led to the filing
of more than 27 patents based on the collabora
tion. Studies to determine the potential use of a
limited number of extracts of plants, insects, and
environmental samples have been completed, and
the agreement has given INBio access to technol
ogy, teams, and training. It marked the first of a
series of deals made by INBio (Table 1).
Such collection activities, so-called bio
prospecting, have received considerable attention
in the literature and have precipitated discussions
on payments for collected samples and chemical
extracts from samples. But the subject is gener
ally treated in generalities, focusing on research
needs, basic rights, and moral obligations. CBD
itself is famous for broad language with multiple
interpretations possible. On the subject of pay
ments, CBD proposes “sharing in a fair and eq
uitable way the results of research and development
and the benefits arising from commercial and other
utilization of genetic resources … upon mutually
agreed terms” (Article 15(7)). There is no attempt
to identify appropriate payment approaches or a
system for valuing germplasm for specific uses.
Even a full decade after the entering into force
of CBD, the topic still receives attention, and
15 years since its passing has not been resolved.
Evidently, there cannot be resolution on actual
terms and payments, since these will be a func
tion of market conditions, alternative technolo
gies (such as recombinatorial chemistry, to name
one), and other factors. We hope to shed light
on the approaches that could be used to calculate
royalty rates and collection fees.
The purpose of this chapter is also the pro
vision of information on the revenue conse
quences of alternative payment arrangements
for collected germplasm. We do not attempt
to present actual market values for the mate
rial, although approximate figures are used for
illustrative purposes. Commonly, germplasm
rich countries charge for samples in the form
of a fixed initial payment (collection fee), a de
layed payment based on sales of the resultant
2 | HANDBOOK OF BEST PRACTICES

commercial product (a percent royalty, that is, a
form of sharing of benefits), or combination of
the two. Here it is demonstrated that when the
likelihood of finding a commercializable prod
uct is small (the risk of failure great), empha
sizing initial payments can be done only at the
expense of a significant reduction in the royalty
rate and, hence, in the expected overall rev
enues. The importance of the failure risk is such
that reducing it through preliminary in-coun
try screening can improve the revenue prospects
greatly. Whether that is a viable approach de
pends on in-country skills, facilities and costs,
which are not evaluated here. Use of indigenous
knowledge of plants is another means of reduc
ing the failure rate and can add value to the
samples that might be used in determining an
appropriate payment to indigenous groups for
sharing their knowledge.
The examples used herein apply to pharmaceu
tical prospecting for medicinal products, the basis
of the Merck/INBio agreement. Pharmaceuticals
are typically high-value products so the revenue
is potentially greatest. The approach developed
here, however, is general and can be used as well
for other products, such as crop varieties and cos
metics. The variable likelihood of finding useful
germplasm and values with respect to the resul
tant products could lead to somewhat different
conclusions. For example, the long standing (but
possibly evolving) practice of placing plant vari
eties in publicly accessible germplasm collections
limits the market value of that material.
This chapter does not attempt to identify a
specific market value for germplasm. Most efforts
to do so, thus far, date back well over a decade and
have been conceptually general or relevant only
to specific examples from developed countries. It
is, nevertheless, well established that biodiversity
provides two types of values. These are:
1. direct value
- consumptive-use value (that which
derives from such activities
as sport fishing, subsistence hunting,
gathering)
- productive-use value (that which derives
from such activities as logging)
2. indirect values
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Table 1: Main Collaborative Research Agreements
Signed by INBio from 1991 to 2002
Industrial or
academic partner

Natural resources
accessed/Objectives

Field of primary
application

Research
activities in
Costa Rica

Cornell University

INBio’s capacity
building

Chemical prospecting

1990-1992

Merck & Co.

Plants, insects,
micro-organisms

Human health and
veterinary

1991-1999

British Technology Group

DMDP, compound
with nematocidal
activity*

Agriculture

1992-present

ECOS

Lonchocarpus felipei,
source of DMDP*

Agriculture

1993-present

Cornell University and NIH

Insects

Human health

1993-1999

Bristol Myers & Squibb

Insects

Human health

1994-1998

Givaudan Roure

Plants

Fragrances and
essences

1995-1998

University of Massachusetts

Plants and insects

Insecticidal
components

1995-1998

Diversa

DNA from bacteria

Enzymes of industrial
applications

1995-present

INDENA SPA

Plants*

Human health

1996-present

Phytera Inc.

Plants

Human health

1998-2000

Strathclyde University

Plants

Human health

1997-2000

Eli Lilly

Plants

1999-2000

Akkadix Corporation

Bacteria

Human health and
agriculture

Nematocidal proteins

1999-2001

Follajes Ticos

Plants

Ornamental
applications

2000-present

La Gavilana S.A.

Trichoderma spp*

Ecological control of
pathogens of Vanilla

2000-present

Laboratorios Lisan S.A.

None*

Production of
standardized
phytopharmaceuticals

2000-present

Bouganvillea S.A.

None*

Production of
standardized
biopesticide

2000-present

Agrobiot S.A.

Plants*

Ornamental
applications

2000-present

(Continued on Next Page)
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Table 1 (continued)

Research
activities in
Costa Rica

Industrial or
academic partner

Natural resources
accessed/Objectives

Field of primary
application

Guelph University

Plants*

Agriculture and
conservation purposes

2000-present

Florida Ice & Farm

None*

Technical and scientific
support

2001-present

ChagasSpace Program

Plants, fungi*

Chagas disease

2001-present

SACRO

Plants*

Ornamental
applications

2002-

* These agreements include a significant component of technical and scientific support from INBio.
Source: Cabrera Medaglia 2004. 1

- nonconsumptive-use value (that which
derives from such activities as tourism)
- option value (that which derives from
the delaying of destructive use
until the use and value are better
understood)
- existence value (bequest value; that
which derives from leaving
a resource for consumption by future
generations)
Valuation is complicated because, with the
exception of productive-use value, none of these
forms of use involves a marketed product from
which value can be ascertained directly. Rather,
indirect measures, such as travel expenditures,
are used or, in cases of option and existence val
ues, quite esoteric measures, the interpretation
of which is not fully clear. Yet valuation is im
portant because it indicates a potential economic
justification for preservation or, more precisely,
in the case of germplasm prospecting, for sub
stituting sustainable use for destructive uses like
logging.
Further complicating valuation is the discus
sion of appropriateness of adding opportunity
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cost, the value option foregone when another
mutually exclusive use is selected (an opportunity
cost of clear cutting is germplasm prospecting,
for example). Opportunity costs are sometimes
calculated (companies making mutually exclusive
investment choices do this routinely) but, tradi
tionally, never are subtracted from the value of
the selected use as it is sometimes argued they
should be. Conceptually, there is no reason to
limit opportunity cost to a single alternative use
where many likely exist, nor is there a reason in
direct benefits (for instance, those derived from
logging open land for farming or grazing) should
not be added to the use value. There is the further
issue of discount rate for future income—the re
duction akin to an interest rate—in the value of
delayed consumption compared to present con
sumption. Typically, private (personal and corpo
rate) discount rates are greater than social rates,
although the determination of the social rate is
open to different interpretations. Yet, as anyone
who has paid off a loan over a ten- or 20-year pe
riod recognizes, small changes in the interest rate
have major implications on the outcome. Indeed,
the use of opportunity cost is a complex matter
yet to be resolved.
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2. pRICInG CHoICES
The Merck/INBio agreement of the early 1990s
utilized a combination of the two principal pay
ment alternatives: collection fees and royalties.
Merck paid to INBio a fee of US$1.1 million and
an undisclosed royalty rate for resulting product
sales. A collection payment can be (and in the
Merck/INBio case was) paid in total, or in part,
in services, such as providing training to national
scientists in screening procedures, or as equip
ment. The purpose here is to demonstrate how

total revenues are affected by an emphasis on ini
tial, as opposed to delayed, payments.
Delayed (royalty) payments are preferred by
the contracting company, which, for the pur
poses of this article, we shall assume is a mul
tinational pharmaceutical company. Delaying
payments means the company has no interest
costs, which are required if payments are made
before the product is marketed and revenues flow.
Pharmaceutical products can take up to 12 years
to bring to the market in the United States, so the

Table 2: Estimates of Variables for the Base Agreement
Per-sample basis

Item

Value used in
calculations

Range

Comments/Reference

Collection fee

US$50

50–200

Figures are intended to cover actual
costs (packaging, transport and
related costs) but not return a profit

Royalty payment

5%

1%–5%

Royalty of gross sales

Developing-country
interesta

15%

10%–25%

Discount rate used by developing
countries with hard currency
shortages (a likely minimum figure)

Corporate interest rate

7%

5%–9%

Corporate interest rate charged to
and by major corporations; lower
than developing country rate
because of better credit rating and
more efficient credit markets in
developed countries

Product value

US $500
million

100 million– Total worldwide sales once
1 billion +
developed and over the life span
of the product. Below an expected
market of US$100 million, returns
generally do not cover development
and regulatory costs

Development delay

10 years

10–12 years

–

Hit rate

1:12,000

1:6,000–
1:30,000

Frequency with which collected
material will result in a marketable
product

a

This figure represents interest on a hard currency loan such as one denominated in dollars.
It does not reflect the occasionally very high rates - up to and exceeding 100% - for local currency
loans during inflationary periods.
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interest cost could be considerable. As important,
making initial payments shifts the risk of failure to
the company, which will have expended the col
lection and screening costs as well as development
charges. With a successful product found in only
one of some 12,000 tries and average product de
velopment costs of US$230 million including the
costs of failures, the risks are indeed large. Because
of these risk and interest factors, along with tight
budgets and scarce foreign exchange, contracting
countries prefer initial payments to subsequent and
uncertain royalties. However, the contracting com
panies will seek compensation in the form of lower
overall payments for accepting additional risk. Here
we explore how much that compensation is likely
to be.
For the purposes of this article a base agree
ment is computed on a per-sample basis (in U.S.
dollars). This agreement is intended to represent
the outcome of careful negotiations, with both
sides reaching a minimal acceptable position from
which they are unwilling to move without conces
sions from the other party.

Table 2 shows the estimates of the variables
required for a bioprospecting agreement. As we
are developing different variations, we call this the
“base” agreement.
From Table 2, the expected return per sample
collected can be computed as shown in Table 3
(figures are rounded for convenience). Total value
for a 12,000-sample contract is also included.
Of course, most samples would pay $50 with,
on average, the 1/12,000 paying off $25 million.
In other words:
5% royalty of $500 million = $25 million
This is a general average with the likelihood of
a hit2 having a wide latitude. Thus, countries select
ing this approach would be operating in a “boom
or bust” mode. The collection fee covers costs so
that no real revenue comes in until and unless a hit
is scored. No attempt was made here to determine
the range (frequency distribution) with regard to
the estimated 1/12,000 hit figure. The present value

Table 3: Computing Expected Return for the Base Agreement
Per-sample basis
Return

Full contract
12,000 samples

_

50

0.6 million

[1]

2000

25.0 million

[2]

500

6.0 million

550

6.6 million

Item

Calculations

Equation

Collection fee

_

Royalty fee paid
in year 10

5% x $500 million x
2,000

Present value of
a
royalty fee

(1 + i)n

Total present
expected value

50 + 500

1

12,000

b

a Where i=15% (developing-country interest level) and n=10 years (development delay).
b Refers to numbered equations in text.
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Figure 1: Present and Future Value of Contract as a Function
of Product Value and Royalty Rate
Present
value of
sample
(uS$)

Present
value of
Contract
(uS$Million)

1,000

12.5

800

10.0

600

7.5

400

5.0

200

2.5

Future
value of
contract
(uS$Million)
50
40

royalty rate
5%

30

3%

20

1%

10

0

0
200

400

600

800

1,000

Product value (uS$ Million)
Note: Collection fees of $50 per sample are included in the calculations. Other variables are 15% developing
country interest rates, 10 years development delay, and 1/12,000 hit rate.

of the $25 million figure is only $6 million because
of the high interest rate used (15%) and the tenyear delay involved. Figure 1 gives an indication of
how these values are affected by royalty rates and
product value.

. EMpHASIzInG CoLLECTIon fEES
ovER RoyALTIES
What would be the ramifications of shifting fees
forward, emphasizing current collection payments
at the expense of longer term royalties? Suppose
for our example the collection fee was increased by
$150, to $200 per sample. What would change?
We shall assume that the basic revenue situation
remains unchanged and that only the schedule is
altered. Since there are just two payment param
eters (collection fee and royalty rate), increasing
one necessitates reducing the other.
The point about raising collection fees neces
sitating a reduction in the royalty rate has sev
eral components. First, there is a direct transfer
of dollars. Second, the company, which, in this

example, is making payments today instead of
ten years in the future, will add an implicit in
terest charge (technically, a discount) to those
payments. The third component, and the most
complex to calculate, is the change in the risk
undertaken by the company. Under the base
agreement, the selling country accepts most of
the risk; if no marketable product is forthcom
ing no royalty payments are made. The 1/12,000
hit-rate figure used here is an average and an ap
proximation. It is possible that 12,000 samples
will yield no marketable products or ones with
low values. Shifting royalty payments to collec
tion fees means, in effect, that some of the royalty
has been “prepaid” so that the failure of a product
to materialize is a loss for the company. That is,
the company is taking on an additional risk of a
loss. In this regard, the contracting company will
act like a banker, and indeed like any private cor
poration, which is a risk/reward managing entity,
by demanding to be compensated financially for
accepting additional risk. That required compen
sation can be estimated.
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Raising the collection fee by $150 would increase the expected costs for the company by $1.8
million. In other words:
$150 for 12,000=$1.8 million
Moreover, the payments would be made today as opposed to 10 years hence so that the company
would have total (including interest) costs of $3.5 million, that is:
From Table 3, Equation [2]:

$1.8 million x (1+ 7%)10 = $3.5 million

The company is then willing to pay only $21.5 million (25 - 3.5) in royalties (from Table 3) so that
the effective royalty rate becomes:
Equation [3]:

5%
x%
=
$25 million
$21.5 million

x = 107.5
25

= 4.3%

But the company accepts additional risk ($1.8 million worth) and will want to be compensated.
The amount can be computed using the following the equation:
Equation [4]:
size of risk change =

change in payment
payment

=

$3.5
$21.5 / (1.07)10 + $0.6

=

3.5 = 30%
11.5

Thus the company is willing to offer a royalty rate 30% lower, that is:
Equation [5]:

4.3% x 0.3 = 1.3%

The new royalty rate is now 3.0%, that is:
Equation [6], from [3]:

4.3% - 1.3% = 3.0%

This is a reduction of 40% of the original value. The new present value of the expected payment
per sample can now be computed as:
Equation [7] (from Table 3, Equations [1] and [2]):
$200 collection fee + 3.0% x $500 million x

$1,250 = $500
1/12,000
, or $200 +
10
4.045
(1.15)

Hence, the country is giving up $50 ($550 - $500) or 9% per sample to ensure timeliness of the
payment.
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Table 4: Impact of Country Interest Rate on Total Expected
Present Values under Different Interest Rates

Interest Rate

10%

15%

20%

25%

Collection fee

50

50

50

50

Present value of royalty fee

775

495

325

215

Total expected present value/sample

825

545

375

265

Collection fee

200

200

200

200

465

300

195

130

665

500

395

330

-160

-45

+20

+65

a

Present value royalty fee

b

Total expected present value/sample
c

Country loss/gain

a

$2,000/(1+i)10 from Table 3, equation [2] (results rounded)

b

$1,250/(1+i)10 from Table 3, equation [2] (results rounded)

c

Total expected value/sample for $200 collection fee - total expected value/sample for $50 collection fee.

An important insight can be derived from
this example. The penalty for the germplasm
providing country declines as its interest rate
increases, or more correctly, as the gap between
its interest rate and the corporate rate of the
contracting company (7% in this example) in
creases. This penalty is shown in Table 4 where,
using the figures described above, the penalty
declines to zero at a country rate near 20 per
cent; at higher rates the country is actually bet
ter off. The company is borrowing money at a
preferential rate and lending it to the country at
the same rate, plus risk premium. This approach
might be an efficient way for the selling country
to finance itself, but several additional factors
must be considered.
First, the contracting company must be
agreeable to such an arrangement (not all will
be). Second, a 15% figure is quite a high discount

rate and involves a significant discounting of the
future. Note that the country is paying the com
pany 7%, along with discounting the future by
15% for a total discounting of 22%, which re
duces any future royalty payment by a factor of 7
that is (from Table 4, Equation [2]):
$25 million / (1 + 0.22) 10 or 25/7.3
Third and finally, the country is effectively
borrowing against the future; should a hit come,
less additional revenue will be collected. While
that may be undesirable for future generations,
this approach does increase the awareness of the
value of germplasm resources. Referring again
to the Merck/INBio agreement, the more than
US$1 million collection fee (a rather insignificant
amount) received all the public attention while
the level of the royalty figure has never been made
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public and potentially could represent a much
greater figure.
It should be noted that it is very difficult to
come up with an appropriate discount rate with
out knowing specific country circumstances. It
may also not be an objective figure. The concept
of personal discount rate, that is, what the per
son on the other side of the table has internalized
about risk, as well as political and economic in
stability and immediate need for money could all
play major roles in the choice between collection
payments and royalties.

. pAyMEnT foR SCREEnInG
One of the emphases on germplasm prospecting
in the CBD, and elsewhere, is the performance
of the maximum number of services in country
(value added) as opposed to the export of raw
germplasm materials. That emphasis not only
increases payments but also enhances national
scientific expertise while moving away from de
pendency on commodity-type exports. Here we
examine the revenue ramifications of such an
approach. No attempt is made to determine the
practicality of such a step that depends on the
country of origin having adequately trained staff
and adequate facilities to be able to complete
screenings in an accurate, timely, and cost-effi
cient manner. Screening near the source of ori
gin has some advantages due to the cost of pack
aging and transport and the volatility of some
compounds. On the other hand, some screening
procedures are technically complex or, for infec
tious diseases, involve high standards for isola
tion facilities. Those screenings would not be fea

sible away from a major company’s laboratories,
at least for the present.
The development of a marketable pharma
ceutical product passes through several stages
beginning with a primary screening and, if suc
cessful, progressing through secondary screening
(including isolation and preliminary toxicologi
cal evaluations) and proceeding to the several
stages of drug development. For purposes here,
assume in-country collection with primary
screening costs of $200 per sample. Prescreened
samples in this example have a 1/3,000 chance
of being a hit (four times the unscreened rate)
because the least promising samples have been
eliminated. The rate depends on several factors,
including the stringency of the screens. This rate
presumes relatively nonstringent tests that would
be most appropriate for a range of developing
countries.
Of course, screening does not change the
underlying probability of finding a commer
cializable product. Screening merely increases
the value of the retained samples, because they
have a higher probability of viability than the
collected samples. There is a cost for this: every
retained sample represents four screened sam
ples, so the per-sample-retained cost is $800.
It is assumed the country will collect the outof-pocket costs, or $200 per sample, but be
cause these represent actual costs, the country
does not make a profit as in the earlier second
example. Payments can be computed follow
ing the royalty-rate calculation method shown
earlier, using the hit rate of 1/3,000 and a col
lection and screening fee of $800 (figures are
rounded):

Equation [8] (from Table 3, Equations [1] and [2]):
Present value of royalty:
5.0% x $500 million x

1/3,000
(1 + i)n

= 5.0% x

$167,000 = $2,100
4.04

Total expected value per sample: $800 + $2,100 = $2,900
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The total expected value per sample is now
more than five times the base payment.
It should be noted that both the royalty rate
and the risk factor remain unchanged. The ad
ditional “collection” fees are merely a transfer of
expenses from the company’s in-house screening
cost to the developing country, and this does
not change the basic value of the contract. The
calculations assume, however, that the quality
of cost screening in the developing country is
identical to that of the company. If the qual
ity in the developing country is inferior, the
value of the screenings is questionable, and the
pharmaceutical company is likely to reject this
option. Especially in the case of false negative
results (improperly rejecting a potentially viable
compound), inaccurate or inconsistent results
must be repeated. If the total cost of screening
in developing countries is less than that of the
pharmaceutical company (a plausible situation
due to lower wages and shipping costs), then
the selling country can take the difference as
profit. For the example just mentioned, imagine
further that a screening by the pharmaceutical
company costs $150, while in the country of
origin it is $100. Total costs including the $50
collection fee are then $200 versus $150. The
company should, in theory, be willing to pay the
full $200 cost to the developing country, which
would yield it a “profit” of $50 per sample ($200
payment - $150 costs). As discussed in the pre
ceding example neither the royalty rate nor the
risk factor would change.
Now, however, imagine the costs are re
versed, $100 for the pharmaceutical company
and $150 for the selling country. This could hap
pen for a number of reasons, such as a high cost
of maintaining specialized equipment or simple
inexperience and/or inefficiency. If the country
still covered costs by negotiating a $200 collec
tion plus screening fee, the company would treat
$50 of it ($200 payment - $150 costs) as a higher
fee, along the lines of the second example. Rather
than repeating those calculations, note that the
fee increase here is one-third ($50/$150) of the
amount shown in the second example. The roy
alty-rate reduction would likewise be one-third of
that amount, or:

From Equation [6]: 0.33x(5%-3.0%)=0.66
This gives a final rate of:
Equation [9]: 5%-0.66=4.34%
While the amount is not huge, it represents
a penalty and would likely not represent a viable
option in the long term.
These calculations, of course, are only illus
trations and say nothing about the practicality of
screening in-country. Actual cost and result fig
ures will be required for such computations. The
exercise does suggest that economical in-country
screening is a potentially valuable value-added
activity. Screenings in countries, following this
strategy must, as noted, be less costly than con
tracting-company screenings, and less accurate.
Indeed, to the extent screening in-country is less
expensive due to lower salary levels, savings on
shipping costs, and other factors, all parties may
benefit. However, countries must invest in train
ing and equipment/infrastructure before offering
this service. Several sources of funds are possible,
including the use of collection fees (as is provided
to a small degree in the Merck/INBio agreement)
or through a grant or loan from a bilateral or
multilateral agency.

. IndIGEnouS knoWLEdGE
Indigenous knowledge of plants can be an alter
native to preliminary screening. Plants that can
be identified as free from insect damage, for ex
ample, likely contain potent alkaloids, called the
most important group of medical chemicals. If
plants identified by indigenous peoples as having
particular attributes are collected, the probability
of a hit is increased. Here, for simplicity, we will
assume the increase is to 1/6,000. Some argue
that the success of screening could double or tri
ple if information based on traditional knowledge
was utilized. Further, it is assumed that the cost
of a single specimen collection is $100 because of
the additional difficulty of finding selected plants.
Payments are then (again rounded):
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Collection fee: $100
Equation [10] (from Table 3, Equations [1] and [2]):
Present value of royalties = 5% x $500 million x 1/6,000
4.04

= 5% x

$8,330 = $1000
4.04

The royalty level in this example is the same as the base situation because:
$50 x 12,000 = $100 x 6,000
So there is no change in the timing of payments. Similarly, the risk factor is unchanged:
Total expected value per sample: $100 + $1,000 = $1,100 (double the base level of $550)
Again, while only hypothetical, this example does indicate the potential value of indigenous
knowledge, at least for plants (it is less indicative for microbes and insects with which indigenous
cultures are typically less familiar). The additional amount of $500 per sample (Equation [11]), can be
paid to indigenous groups for the value of their knowledge, but a suitable transfer mechanism must
be developed.
Equation [11] (from Table 3, Equation [2]):
$1,100 - $100 collection fee - $500 present value of royalty = $500

. ConCLuSIonS
The negotiating of terms for germplasm collec
tion is a complex matter, made more so by the
absence of a generally accepted value of the ma
terial in its raw form. This article is directed to
a related issue: how any payments should be di
vided between current (collection) fees and future
royalties. The two are different because of the
ramifications of who accepts the risk of finding a
usable product and the capital cost/value of sales
to be made ten or more years into the future. The
examples shown here suggest, but do not guar
antee, that increasing collection rates is costly in
terms of overall expected payments. However, for
countries short on foreign exchange and, hence,
with high interest rates, raising collection fees is
2 | HANDBOOK OF BEST PRACTICES

an economical means of “borrowing” from the
contracting company. Seemingly more favorable
is in-country screening, but costs, feasibility, and
acceptability of results must be considered care
fully before choosing this option. Utilizing in
digenous knowledge is, according to the example
used here, also remunerative along with the pros
pect of providing equity payments to numerous
groups otherwise far removed from market sys
tems. However, to be utilized by companies, in
digenous knowledge must be less costly than mass
screening.
Overall, the aggregate payments for collected
germplasm, given the current state of knowledge,
appear limited. Similarly, the payments to indige
nous groups will likely be fairly modest compared
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to the needs of those groups. These issues make
careful valuation and contractual negotiation all
the more critical.
Negotiators need to consider, at least, two
additional factors, which have not been discussed
here. First is the granting of exclusivity for the
samples. Companies, of course, will be hesitant
to invest in a product when the possibility exists
of a competitor bringing the technology to mar
ket first or obtaining the patent. Therefore, com
panies will seek exclusivity. Countries, however,
will wish to find additional markets; certainly, the
possibility of multiple products from the samples
is there. Thus, countries will opt against exclu
sivity. As a compromise, countries should (1)
charge more for granting exclusivity and (2) set
a time limit (it is four years in the Merck/INBio
agreement).
Second, negotiators must evaluate their level
of trust in the opposite party. One way to consid
er contracts is as a means of reducing the need for
trust by specifying obligations in a way that can
be adjudicated. However, it is not feasible to spec
ify all aspects, so some level of trust is required.
With germplasm prospecting perhaps the most
critical issue is identifying whether the material
used in developing a product was derived directly
or indirectly from a sample provided under the
agreement. Unscreened samples, with the myriad
compounds they could provide, and the numer
ous analogs to them, will be virtually impossible
to track thoroughly. Preliminarily screened sam
ples are described in more detail and hence easier
to track, but documenting a claim in court could
still be difficult and expensive. Thus, considerable
trust in the integrity of the contracting compa
ny would seem to be critical, but perhaps some
checks should be included in the agreement.
In a broader context, this analysis suggests
several policy considerations for national govern
ments, nongovernmental organizations (NGOs),
and international donors, such as foundations
and bilateral and multilateral agencies. These
considerations involve both the allocation of pay
ments between collection fees and royalties and
in-country screening. If the examples used herein

are substantiated at all by actual cost figures, incountry screening is attractive financially as well
as for its effects on development and skills im
provement. However, considerable investment
will be required before such efforts are possible.
With adequate in-country funds lacking, inter
national donors should seriously consider loans
or grants for training and equipment purchases
since in-country screening will be economically
rewarding in the long term. Unlike numerous
potential projects, there appears to be a ready
market for the product, a preliminary-screening
service. More, broader conclusions from INBio
on their experiences are given in Box 1.
The allocation of funds between collection
fees and royalties can affect conservation incen
tives. While a thorough treatment of that issue is
outside of the scope of this article, it does warrant
mentioning. Conceptually, the highest valuation
approach—payment of royalties—will encourage
conservation the most in the long term. However,
people typically discount the future heavily so that
up-front (collection fee) payments may get more
attention and, in the long run, do most to encour
age conservation. This is a matter of perception
and not of business or economics, which needs
exploration through other methodologies. n
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A hit rate is the number of expected lead compounds
divided by the number of samples to be screened to
obtain the given lead compounds.
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Box 1: lessons learned from a Decade of Bioprospecting Partnerships
at INBio in Costa Rica
A. There must be a clear institutional policy for the criteria demanded in prospecting contract
negotiations. For INBio, these include the transfer of technology, royalties, limited quantity
and time access, limited exclusiveness, no negative impacts on biodiversity, and direct
payment for conservation. This policy has led to the stipulation of minimum requirements
for initiating negotiations, and these requirements have meant rejecting some requests (e.g.,
very low royalties, unwillingness to grant training, etc.). This institutional policy also provides
greater transparency and certainty for future negotiations. These same policies must also be
taken into consideration when local communities and indigenous peoples, such as the Kuna’s
in Panama, adopt legal outlines in the contractual arrangements entered into by them. They
should include other relevant ideas, such as those related to the impossibility of patenting
certain elements, licensing instead of a complete transfer, etc.
B. The existence of national scientific capabilities, and consequently the possibilities of adding
value to biodiversity elements, increases the negotiating strengths and benefit sharing
stipulated in contract agreements. As we previously mentioned, the need to grant an
aggregated value to material, extracts, etc., is crucial if one wishes to be more that just a simple
genetic resource provider. In this regard, the development of important human, technical, and
infrastructure capacities through laboratories, equipment, etc., together with the institution’s
prestige, have permitted better negotiation conditions.
The existence of relevant traditional knowledge for operations, which INBio has not yet
experienced, implies greater scientific capacity and, consequently, should lead to better
compensation conditions.
C. knowledge of operational norms and of the changes and transformations taking place in the
business sector, as well as the scientific and technological innovations that underlie these
transformations, helps to define access and benefit-sharing mechanisms. It is essential to
know how different markets operate and what access and benefit-sharing practices already
exist in these markets.These vary from sector to sector: the market dynamics for nutraceuticals,
ornamental plants, crop protection, cosmetics, and pharmaceuticals are complex and different.
This knowledge is needed to correctly negotiate royalties and other payment terms. How can
we otherwise know if a percentage is low or high? It is also crucial to be informed about the
operational aspects of these markets. When INBio began negotiating new compensation
forms, such as advance payments or payments on reaching predefined milestones, with Eli
Lilly and Akkaddix, it was vitally important to know the approximate amounts the industry
was likely to pay in order to negotiate appropriately. Otherwise, one will likely request terms
that are completely off the market or accept terms that are inadequate.
d. Internal capacity for negotiations, which includes adequate legal and counseling skills about
the main aspects of commercial and environmental law. The Institute now recognizes that
negotiations involve a scientific aspect (of crucial importance to define key areas of interest
such as a product, etc.), a commercial aspect, a negotiation aspect, and the respective legal
aspects. These latter are composed not only of national trade law but also international
environment law, conflict resolution, and intellectual property. For these reasons, creating
interdisciplinary teams is crucial. At the same time, the need for such a team is one of the
most important criticisms of the contractual mechanisms. Solutions such as facilitators or
others that pretend to “level the negotiation power” have been proposed by several authors.
Unfortunately, until appropriate multilateral mechanisms exist, benefit sharing and
contractual systems must go hand in hand. The absence of an interdisciplinary team keeps
one of the parties at a disadvantage, particularly given the enormous legal and negotiation
capabilities of pharmaceutical companies.
(Continued on Next Page)
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Box 1 (continued)

E. Innovative and creative ideas for obtaining compensation. An ample spectrum of potential
benefits exists. In the past, interesting benefit-sharing formulas were developed through
appropriate negotiations. Such formulas included, for example, fees for visiting gene banks,
collecting material, etc. The contractual path fortunately permits parties to adapt themselves
to the unique situation of each concrete case and to proceed from there to stipulate new
clauses and dispositions.
f. understanding in such key subjects as: intellectual property rights; the importance of
warranties for legality; clauses on ways to estimate benefits (net, gross, etc.); requirements
and restrictions on third-party transference of material (including subsidiaries, etc.) and the
obligations of such parties; precise definitions of key terms that condition and outline other
important obligations (products,extracts,material,chemical entity,etc.);precise determination
of property and ownership (IPR and others) of the research results, joint relationships, etc.;
confidentiality clauses in the agreements and how to balance them in relation to the need for
transparency in the agreement; termination of obligations and the definition of the survivor
of some obligations and rights (e.g., royalty, confidentiality, etc.); conflict resolutions.
As sub-clause D makes very clear, negotiated agreements are complex. For example, the
outcomes that give rise to benefit sharing, such as royalties, will depend on the nature of the
definitions for “product,” “extract,” “entity,” etc. A more comprehensive definition will lead to
a better position. Further examples of aspects that must be specified include delimiting the
areas or sectors where samples can be used, the net sales, and what is possible to exclude
from them. In addition, the procedures and rights in the case of joint and individual inventions
are of interest (preference and acquisition rights, etc.), as are the conditions for the transfer of
material to third parties (under the same terms as the main agreement? need for consent or
information? transference to third parties so that certain services can be performed? etc.).
G. proactive focus according to institutional policies. There is no need to remain inactive while
waiting for companies to knock on the door to negotiate. An active approach to negotiations
based on the institution’s own policy for understanding national and local requirements has
produced important benefits. INBio’s Business Development Office and its highly qualified
expert staff, the attendance of seminars and activities with industry, the distribution or
sharing of information and material, and direct contacts, all of these empower an institution
to deal with challenges. The current policy is based on the idea that it is not enough to wait to
be contacted or to be available at the behest of a company; instead, one should possess and
maintain one’s own approach.
H. understanding national and local needs in terms of technology, training, and joint research.
International strategic alliances must be struck. Even when an institution or community
possesses adequate resources to face a concrete demand, knowing the national situation and
the strategic needs will permit it to reach better agreements and fulfill a mission that goes
beyond merely satisfying the institution’s interests. It will permit the prospecting to benefit
society as a whole and demonstrate that it is possible to improve quality of life.
I. Macro policies and legal, institutional, and political support. For prospecting to succeed,
so-called macro policies have to exist; that is to say, there must be clear rules about the
“bioprospecting framework,” which requires biodiversity inventories, information systems,
business development, and technology access. One reason for Costa Rica’s success is that
institutions not only have experience in negotiation but also in setting policies and actions in
this area overall.This includes,for example,a current biodiversity inventory rated as “successful”
(Continued on Next Page)
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Box 1 (continued)

that enables us to know what we possess. It is the first step in the quest to use this resource
intelligently. Our relevant experience also includes a National Conservation Area System
that assures the availability of resources, the possibility of future supplies and provisions,
mechanisms that contribute to the conservation of biodiversity as part of the contractual
systems, etc. At the same time, the possibility of possessing adequate instruments to manage
information, systems of land and property ownership, etc., contribute jointly with the existing
scientific capacity to create a favorable environment for bioprospecting and to make possible
the negotiation and attraction of joint enterprises. To this should be added other elements,
such as the existence of trustworthy partners, which is one of the most relevant aspects in
joint undertakings.
Lastly, one crucial topic is the constant denouncement of the business community because
of the uncertainty caused by the new access rules (mainly in terms of who is the competent
authority, the steps to be taken, how to secure prior informed consent, etc.). The emergence
of these new regimes, together with the fact that the intention is to essentially control
genetic information, its flow, supply, and reception—a topic where little national, regional,
and international experience exists—has caused concern because of the possibility of
contravening legal provisions. This has led to the establishment, as a policy, of the inclusion of
clauses related to the need to fulfill local regulations, to demonstrate the contracting parties’
right to fulfill their obligations pursuant to national laws, to present the appropriate permits
and licenses, etc. In some cases, this topic has generated important discussions and analyses in
negotiations. At an international level, various bio-prospecting agreements around the world
are the target of complaints, claims, and lawsuits precisely due to the lack of legal certainty.
This has created problems and discrepancies that hinder activities and joint ventures. A few
examples would be complaints about the Agreement between Diversa and the Autonomous
University of Mexico (which is still being litigated); or the deal between this company and
Yellowstone National Park; or criticisms of the agreement between the Venezuelan Ministry
of the Environment and the Federal University of Zurich.

Source: Reproduced with permission from Cabrera Medaglia J. 2004. Bioprospecting Partnerships
in Practice: A Decade of Experiences at INBio in Costa Rica. IP Strategy Today No. 11 (2004): pp. 27–40.
www.bioDevelopments.org/ip.
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Patents and Patenting:
Balancing Protection
with the Public Domain

CHAPTER 10.1

Defensive Publishing and the Public Domain
saRa boeTTigeR, Senior Advisor, PIPRA and Chief Economist, M-Cam, Inc., U.S.A.
cecilia chi-haM, Director, Biotechnology Resources, PIPRA, U.S.A.

ABSTRACT

IP (intellectual property) rights can reward innovators and
encourage investment in developing new products and
services. However, the exclusionary power of IP rights can
sometimes have negative effects, making technologies less
accessible and, thereby, potentially impeding innovation.
To make informed decisions about how to balance ac
cess and protection requires an understanding of both the
traditional IP rights system (patents, copyrights, trade
marks, and trade secrets) and alternative mechanisms for
preserving access to technologies. This chapter provides
a brief introduction to the public domain and defensive
publishing and examines issues concerning the choice be
hind the choice of whether to publicly disclose or to pat
ent an innovation. Discussing the strategic use of defen
sive publishing in IP management, the chapter considers
both the utility of defensive publishing and its limitations
for supporting broad innovation. After an examination of
the public domain and how it relates to other open-ac
cess concepts, such as open source and the commons, the
chapter focuses on the practical considerations involved
when using public-domain technologies and defensive
publishing to manage intellectual property.

1. InTRoduCTIon
A well-functioning innovation system strikes a
balance between protecting technologies and pre
serving access to them. IP (intellectual property)
rights can provide incentives that reward innova
tors and encourage investment in the develop
ment of new products and services. However,
the exclusionary power of IP rights can also have

negative effects. For instance, when research tools
or enabling technologies are patented and not
available for licensing, the creative and collabora
tive process of innovation can potentially be im
peded. To ensure the balance between access and
protection requires an understanding of both the
traditional IP rights system (patents, copyrights,
trademarks, and trade secrets) and alternative
concepts, such as defensive publishing, public
domain, and open source.
Debates about IP policy and the need to seek
a socially optimal balance between IP rights and
the public domain are important for the pursuit
of vibrant national and international innovation
systems. This chapter’s focus, however, is narrow
er. Rather than examining how policies regard
ing the public domain might support innovation,
we look instead at how, given current IP laws, IP
management practitioners can best use the public
domain to support particular goals.
The term public domain describes a body of
work that is freely available, legally unprotected,
and not subject to individual ownership. Public
domain implies the absence of individual IP rights.
This definition exemplifies the language associat
ed with the public domain and what remains after
all the boundaries of IP rights have been staked.
Likewise, we commonly refer to a technology
falling into the public domain, as if there were
never a conscious decision to place something in

Boettiger S and C Chi-Ham. 2007. Defensive Publishing and the Public Domain. In Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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the public domain; instead, the public domain
encompasses the residuals of the processes of the
IP rights system. This chapter, however, does not
view the public domain as simply a default for
technologies that are not claimed via IP rights.
Instead, the chapter aims to promote a broader
appreciation of the public domain as a valu
able resource. The authors seek to facilitate the
discerning use of the public domain as a tool
(among a set of tools that include traditional IP
rights and related licensing mechanisms) of pru
dent IP management.
Section 2 provides background that illus
trates the importance of the public domain and
how it has changed in recent decades. Section
3 briefly introduces two other open-access con
cepts—the commons and open source—in order
to distinguish three alternatives from one other
and defines their relation to the IP rights system.
Section 4 uses a narrower, legalistic definition of
the public domain to discuss the practical impli
cations surrounding public domain technologies.
That section reviews the patent-law concepts nec
essary for understanding both the construction
of a successful defensive publication, how to as
certain whether a technology is, in a legal sense,
part of the public domain. Section 5 introduces
the practice of defensive publishing, examining
how best to place innovations into the public do
main. Section 6 considers potential strategies for
the IP manager choosing between patenting and
defensive publishing. Section 7 outlines practi
cal issues confronted by users of public domain
technologies.

2. InnovATIon And THE puBLIC doMAIn
“There is no area in which public concern about in
tellectual property and the public domain has been
greater than in scientific and technical research.
Whether it is the controversy over the patenting of,
and access to, the humane genome or pluripotent
stem cell lines, the appropriate role of intellectual
property in university research, or the use of ethno
botany and traditional herbal knowledge in phar
maceutical patenting, the coexistence of science and
property rights has been a fairly constant concern
over the last 15 years.” –James Boyle1
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In recent decades, many authors have exam
ined how innovation systems have been changing
in response to the expanding system of IP rights.
As IP rights have become stronger, broader, and
more far-reaching, many technologies that might
previously have been freely accessible in the pub
lic domain are now proprietarily owned. This
phenomenon has been particularly noticeable in
the fields of health and agriculture.
In 1980, a landmark U.S. Supreme Court
decision (Diamond v. Chakrabarty)2 set the stage
for a burgeoning biotechnology industry and an
exponential rise in the number of life-science pat
ents. Allowing for the patenting of human-made
microorganisms, the decision clarified the Court’s
position that patentability did not depend on the
distinction between living and inanimate things,
but instead between inventions made by “man”
and those that exist naturally. Among other influ
ences to increased patenting during this period,
the Bayh-Dole Act of 1980 has played a role. It
set up new rules for the interface between aca
demia, in which publications are the currency of
the trade, and the commercialization of universi
ty research through patenting and licensing.3 The
rise in the patenting of life-science technologies
and the corresponding reduction in the number
of technologies remaining in the public domain
has been most remarkable in developed countries.
Still, in many developing countries, patenting re
mains sparse.4 Indeed, despite the strengthening
of IP rights policies worldwide through TRIPS
(the Agreement on Trade-Related Aspects of
Intellectual Property Rights) and TRIPS-plus, in
ternational disparities in patenting behavior are
likely to persist. Understanding these differences
can be important for understanding how best to
use the public domain.
Substantial differences in patenting behavior
can also be found between the public and private
sectors within a country. Public sector patenting
behavior and the use of the public domain may
be influenced by culture (for example, the landgrant universities in the United States, the cen
ters of the Consultative Group on International
Agricultural Research, (CGIAR), and many other
public sector agricultural research institutions
worldwide have a strong history of contributions
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to the public domain), a lack of resources relative
to the private sector, and institutional structures
that often are designed to accommodate differ
ent goals. Although there clearly are exceptions,
public sector institutions and individual research
ers are generally at a disadvantage when it comes
to strategically employing the patent system to
achieve their research and development goals. In
these instances, the public domain can be a cru
cial resource.
This chapter does not consider whether the
shift in the relative strength of the public domain
in the life sciences is disadvantageous, and, if so,
to whom. Such complex issues have been consid
ered widely in the literature on IP policy. Instead,
the chapter focuses on how to use the public do
main to achieve individual IP management goals.
Whether research and development goals in
volve decisions about how to access technologies,
how to preserve widespread access to newly de
veloped technologies, or how to ensure that inno
vations continue along the research and develop
ment path toward commercialization unimpeded
by IP issues, a solid understanding of the public
domain is paramount. It is essential to know how
the public domain interfaces with the IP rights
system in order to know when and how to use it.

. dEfInInG opEn-ACCESS ConCEpTS
In this section we compare the concept of pub
lic domain with two other concepts: open source
and the commons. These three terms all relate to
open-access alternatives to the traditional IP
rights system, but they are very different from one
another.
.1 Public domain

In its usage to date, the term public domain is elas
tic and inexact. A definition can be but one of many
definitions, each surely a function of perspective and
agenda ... 5
Defining the term public domain as the ab
sence of individual property rights creates two
mutually exclusive sets of technology: one that is
protected by some form (any form) of IP rights
and another that has no IP rights. Thus, in patent
law, a technology is considered to be in the public

domain if one can make, use, offer for sale, sell, or
import the invention without infringing an active
patent and if there are no other types of IP rights
that lay claim to the invention. Technologies in
the public domain can be used with impunity be
cause, by definition, there is an absence of owner
ship and therefore free access. This description of
the public domain as a distinct set of technologies
with a defined boundary, though, is misleading.
In fact, the boundary between the two sets can
be difficult to discern, can vary from country to
country, and is continually shifting. It is no sim
ple task to ascertain whether or not a technology
is in the public domain.
.2 Open source

Like the public domain, open source is character
ized by free accessibility. However, with regard to
open-source technology, free access derives from
a different source. Free access in the public do
main is defined by an absence of ownership, but
free access in open source is dependent upon the
presence of IP rights that enable the use of opensource licenses.
The concept of open source has its origins
in computer software. Once computer code has
been fixed in a tangible means of expression, it is
automatically the subject of copyright protec
tion. This copyright protection allows the owner
to license the code. A typical (non-open source)
license might, for example, contain terms that
restrict the use of the licensed product or stipu
late fees to be paid. But the terms of an open
source license are seen as an unusual reversal of
typical licensing terms (so unusual the license is
sometimes called copyleft). By signing an opensource license, the licensee agrees to ensure that
the software will remain available for public use,
modification, and redistribution; the licensee
is then in breach if he or she privately appro
priates the technology and restricts its public
availability.
Such legal protection from private appropri
ation has been used to generate a self-defending
commons of software code that is collaboratively
added to and improved upon. A technology li
censed under an open-source license, therefore,
cannot be in the public domain; otherwise there
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would be no license and no way of enforcing the
commons.
Several versions of open-source licenses are
commonly used, and they vary in the restrictive
ness of their terms. For instance, there may be a
provision that any code that is combined with
the licensed code will fall under the ambit of the
open-source license. Therefore the entire body of
code can only be licensed under the same opensource license terms—it cannot be privately ap
propriated. This viral quality limits the utility of
the open-source license in certain commercial
contexts but increases the potential for growth
of the protected commons of code. Other ver
sions of open-source licenses are less viral and
have been tailored to different business needs.
In the fields of health and agriculture, open
source has been most easily adopted in areas with
similar technology characteristics (for example,
genomics). Attempts to apply the open-source
model to nondigital technology sectors6 encoun
ter a range of difficulties. Patent law, not copy
right law, protects technologies in these sectors of
the life sciences. Applying open-source licensing
mechanisms in patent law has its own set of le
gal challenges. Also, there are differences related
to the innovation processes of non-digital tech
nologies. The amounts of time, capital, and risk
involved in, for instance, the production process
of pharmaceuticals, are vastly different from the
production process in software production. In
addition, some technologies simply lend them
selves less easily to the type of collaborative in
novation structures that successful open-source
models are based upon. Still, the tenets of open
source resonate among communities of innova
tors in a wide range of technology sectors. The
search for new applications of the open-source
model is surely a worthwhile pursuit.
. The Commons

The term commons has been used widely in vari
ety of contexts; its meaning, as applied to IP, is
less clear cut than those of either public domain
or open source. Outside the field of intellectual
property, the commons frequently refers to a com
monly managed resource (for example, an ejido
in Mexico describing commonly managed lands).
2 | HANDBOOK OF BEST PRACTICES

The collective-management concept translates,
albeit loosely, into the term’s use in reference to
intellectual property.
In addition to describing the management of
a body of intellectual property, the term commons
has also been used in reference to characteristics
of ownership and access.7 Whether a commons is
defined by lack of private ownership, open access,
or collective management seems to vary according
to the context in which it appears and to the au
thor’s own interpretation of the word. Depending
on the choice of definition, commons can apply
to the public domain and to open source.

. REvIEW of RELATEd LEGAL ConCEpTS
Before discussing the use of the public domain
in greater detail, this section briefly reviews the
relevant sections of patent law. The legal back
ground presented here is important for defen
sive publishing, that is, intentionally placing a
technology in the public domain through pub
lication and thereby preventing future patenting.
In addition, understanding these legal concepts
will make clearer the discussion in Section 7 on
how to ascertain whether technologies are truly
in the public domain. Much of this material will
be familiar to the reader who has read in this
Handbook the chapters on freedom to operate
(FTO)8 and on various aspects of patenting and
patenting strategies.9
.1 Patentability requirements and their
importance in defensive publishing

Defensive publishing seeks to preclude future
patenting in a technology area by making it
impossible for a potential patentee to satisfy one
or more of the statutory patentability require
ments.10 A solid understanding of patentability
requirements allows for greater success in de
fensive publishing. In particular, the patent-law
concepts of novelty, nonobviousness, and enable
ment are key.
.1.1

Prior art and the patent
application process

In order to meet patentability standards, the
claimed invention must satisfy the statutory
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requirements of utility,11 novelty,12 and nonobvi
ousness,13 the latter two of which involve an eval
uation of prior art. In addition, the patent must
be sufficiently described and enabled in the patent
application.14 If the patent examiner assesses the
prior art and deems that the claimed invention is
either not new, or is obvious, the patent may be
denied, or the claims may need to be narrowed in
order to account for the documented prior art. It
should be noted that the term prior art encom
passes both nonpatented and patented prior art.
(This chapter does not consider the latter.)
Citations of prior art can be added by either
the applicant or the examiner.15 U.S. patent law
does not require the patent applicant to search for
prior art (that duty falls to the patent examiner).
However, if the applicant or inventor is aware of
prior art, it must be included. The duty to dis
close exists under the requirement that appli
cants act in “candor and good faith” when deal
ing with the U.S. Patent and Trademark Office
(PTO) during the patent-prosecution process.
A breach of this duty can be considered inequi
table conduct and may result in the patent be
ing unenforceable, but there is nothing to pre
vent intentional ignorance of prior art on behalf
of the applicant. In fact, since 2001, when the
PTO began to record which citations were added
have ree
by the examiner, 40% of U.S. patents have
sulted from applications in which the applicant
has listed no prior art at all.16
It is unclear how thoroughly examiners
search for prior art. Patents, both domestic and
international, are a kind of prior art that allows
for relatively easy and expeditious searching.
Defensive publishing, however, depends on the
ability of patent examiners to find publications
in nonpatent prior art searches. Sampat17 discusses
the difficulties patent examiners face in searching
for nonpatent prior art and notes the growing con
cern that these various constraints on effective prior
art searching are increasingly binding, and that the
PTO is issuing more and more “low quality” pat
ents, [that is,] patents that would not have been is
sued had the examiner considered the entire universe
of relevant prior art.
So for those seeking to practice defensive
publishing, the skills of crafting a good defensive

publication must be matched with attention to its
prominence in search engines that patent exam
iners may be more likely to use. Perhaps more im
portantly, diligent attention should also be paid
to newly published patent applications in the
field of interest. As these applications are issued,
evidence suggests that the author of a defensive
publication may need to make the publication
known to the patent examiner in order to be con
sidered as prior art and, therefore, limit the claims
of the proposed patent. If defensive publications
are brought to light after a patent issues, recourse
through patent invalidation is possible but may
be prohibitively expensive. There are provisions
within U.S. patent law for the submission of pri
or art during a patent’s application process, and
this window of opportunity should be strategi
cally utilized.18
.1.2 Novelty and nonobviousness

An invention is ineligible for patent protection
if it is either not new or obvious in light of ex
isting prior art. The novelty and nonobviousness
requirements for patentability define the param
eters within which defensive publishing can be
implemented. The parameters define how public
ly disclosed inventions, as prior art, can be used
to support future patentability rejections.
Disclosure of an invention, and the accom
panying bar from future patentability due to lack
of novelty, is not limited to publications in print
ed form. An invention can become ineligible for
patenting through any public knowledge of the
invention, or though its being used or offered for
sale. However, it is important to note that U.S.
law limits the use of nonprinted evidence in sup
port of a lack of novelty rejection to that which
originates within the United States. If the inten
tion is to use evidence from other countries to
support a rejection on lack of novelty grounds,
the evidence must be either a patent or a printed
publication.19 The section of U.S. patent law rel
evant to novelty and defensive publishing says
that a patent application can be rejected on the
basis of lack of novelty if “the invention was …
patented or described in a printed publication in
this or a foreign country, before the invention thereof
by the applicant for patent, or … more than one
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year prior to the date of the application for patent
in the United States.”20 In most other countries,
the one-year grace period does not exist; public
disclosure of an invention immediately bars pat
entability in those countries.
In addition to understanding the timing
of disclosures, a successful defensive publishing
strategy should consider the meaning of the words
printed and publication. For example, is a docu
ment posted on the Internet considered printed,
such that the document constitutes prior art and
works to reduce future patenting? Sections 5.1–
5.4 discuss best practices in regard to the content
of defensively published documents, as well as
their date and mode of publication.
The nonobvious requirement in U.S. law
states that if the existing prior art is such that a
person who is skilled in the art would not have
difficulty coming up with the invention, the in
vention is not patentable: “… if the differences
between the subject matter sought to be patented
and the prior art are such that the subject matter
as a whole would have been obvious at the time the
invention was made to a person having ordinary
skill in the art to which said subject matter pertains.
Patentability shall not be negatived by the manner
in which the invention was made.”21
In comparison to the novelty requirement,
the patentability requirement of nonobviousness
gives a broader range of possibilities for defensive
publishing to prevent future patenting. The key
difference is that in order to support a rejection
under the novelty requirement, the printed pub
lication must include each and every limitation
of the claimed invention, either explicitly or im
plicitly. A rejection under the nonobvious require
ment, however, only requires that the content of
the prior art publication can be modified in an
obvious way to arrive at the claimed invention.
In addition, the patent examiner can use combi
nations of prior art to support a nonobviousness
rejection, so even disclosures in defensive publish
ing that are partially complete may still create dif
ficulties for those wishing to patent in the field.
.1. Enablement

Careful defensive publishing anticipates how best
to support a patent examiner’s rejections under
 | HANDBOOK OF BEST PRACTICES

the two patentability requirements described
above (novelty and nonobviousness). In order to
support rejections under the novelty requirement,
the publication, or nonpatent prior art, must be
enabled. If the reference is supporting a rejection
on grounds of nonobviousness, enablement may
not be as critical a factor; a nonenabling publica
tion can still be used to support a rejection on
grounds of nonobviousness.22 This section con
siders enablement for an author constructing a
defensive publication.
Although the legal definitions vary somewhat
depending on the country in question, in general
the enablement requirement is meant to ensure
that the document contains enough detail for a
person skilled in the art to be able to make and
use the invention after reading the document. A
key question is whether it is clear that the public
possessed the invention prior to the date the pat
ent applicant claims to have invented it. While
the burden of proof of enablement for prior art
falls to the patent applicant, who must provide
facts supporting a purported lack of enablement
(this presumption of enablement in prior art is no
different for a nonpatent publication than for a
patent), it is still worthwhile considering enable
ment in a defensive publication.
When plants are the claimed inventions that
a defensive publication is seeking to protect from
patentability, enablement may require that some
one of ordinary skill be able to reproduce the
plant. Descriptions of the plant variety, however
detailed, may be insufficient. In one case, a ref
erence describing a rose was found not enabled,
despite explicit detail and evidence that the au
thor was in possession of the rose.23 In this case
the court ruled that, without information on the
grafting process, reproduction of the rose was im
possible. In other cases, supporting documenta
tion may be necessary to indicate that seeds were
publicly available within the time frame necessary
to bar patenting.
.2 Overlapping claims and dominant patents

What are the legal concepts used to ascertain
whether a technology is in the public domain
and therefore freely available? This question is
relevant to both scientists and IP managers who
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are considering what technologies to choose for
a project. These pesrons must proceed with cau
tion, because the use of a technology in a publi
cation, or the decision to in-license a technology
under an active patent, may go only part way to
providing the right to practice the technology or
pursue a certain research project.
A common misunderstanding in this area
stems from a belief that patent claims define
mutually exclusive areas of technology. In reality,
the patent claims overlap each other: the use of
one technology can infringe claims in more than
one patent. While the issuance of a patent gives
the patentee the right to exclude others from
practicing the invention, it does not imply that
the patentee can practice the invention without,
perhaps, infringing existing patents. When the
rights to existing patents are needed to practice
a technology, those patents are considered domi
nant patents.
The existance of broad, pioneering patents
illustrate how dominant patents can affect the
rights to use downstream innovations. For ex
ample, Monsanto’s claim to the plant transforma
tion method using Agrobacterium means that all
patents in which the claims specifically depend
on this transformation method are blocked by a
previous patent. U.S. Patent No. 6,369,298 is a
patent assigned to Pioneer Hi-Bred International,
Inc. (now a subsidiary of DuPont) for transfor
mation of sorghum. In this case, the claimed
technology depends on the Agrobacterium trans
formation method. A third party intending to
practice this technology would likely not only
need a license for U.S. 6,369,298 but also for
Monsanto’s Agrobacterium transformation domi
nant patent(s).24
Pioneering patents like the one described
above are relatively uncommon, but overlapping
claims and dominant patents exist in all areas of
patented technology. Understanding the overlap
ping nature of patent claims is crucial for those
who intend to utilize the public domain, because
using a technology that appears to be in the pub
lic domain may involve infringing one or more
patents.
The case study of the E8 fruit promoter pro
vides another example (see the timeline in Figure 1

of the chapter by Fenton et al. 25) An initial search
delivers the documents detailed in this figure: sev
eral scientific papers and a group of patents. Once
the documents are arranged chronologically, we
can see that the E8 promoter’s DNA sequence
was disclosed early in our chronology in two
scientific publications. But ascertaining whether
the E8 promoter is still in the public domain and
therefore available freely involves further investi
gation. Years after the initial publications, several
patents were issued that claimed variations on the
sequence and the right to use of the original E8
promoter sequence when combined with partic
ular genes. Therefore, while the original sequence
itself remains in the public domain, when using
the sequence care must be taken to avoid infring
ing subsequent patent claims.
Published scientific literature, trade journals,
conference proceedings, abandoned patents,26
and expired patents are all good sources for find
ing public domain technologies. In the case of
expired and abandoned patents, the boundaries
of the forfeited IP rights have been clearly de
fined by the claims of the patent: the previous
owner of the patent no longer has the legal right
to exclude someone from using what is set out
in the claims of the patent. But these two areas
are especially prone to overlapping claims from
other patents that may still be active and affect
the freedom to use the technology. Companies
often file multiple patents in a technology space,
or there may be multiple patents in one family
that arose from an initial application. Just be
cause a patent has expired and entered the public
domain does not mean the technology is avail
able for use.
When seeking to identify whether a technol
ogy is in the public domain, one must be cau
tious because of overlapping claims. Armed with
this knowledge, research into a potential public
domain technology begins with publicly available
patent databases.27 These databases provide a great
deal of information about the boundaries of the
public domain. Nonetheless, it can be difficult to
understand the interplay between the published
scientific literature and patents, as illustrated in
the E8 case study. PIPRA offers technical assis
tance in this regard, analyzing technologies used
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in public sector agricultural research to ascertain
with greater accuracy the boundaries of the pub
lic domain.28

. WHEn To uSE dEfEnSIvE puBLISHInG:
THE CHoICE BETWEEn pATEnTInG
And puBLISHInG
Deciding whether to patent or publish is a stra
tegic decision that must take into account a
host of variables: the mission of the institution
(and/or the funding agency) involved, the goals
of the individual project, the financial resources
available to spend on IP protection, the nature
of the technology, the functionality of the court
system in the countries where the technology will
be used, and the strategies being employed by
other institutions producing similar technologies.
Moreover, defensive publishing and patenting
inventions each has its limitations and benefits.
Other strategies, such as trade secrecy, trademark
protection, and bailment29 need to be considered
as options when formulating an IP management
strategy.
Defensive publishing is often associated with
promoting access, but there are instances where,
perhaps counter-intuitively, defensive publish
ing may not be the most appropriate choice for
getting widespread access to either an end-prod
uct or a newly developed technology. There are
instances, however, where patenting has limita
tions and defensive publishing may be the better
choice.
.1

Can defensive publishing promote access?

Many institutions and/or sponsors, particularly
in the fields of health and agriculture, place a
high priority on promoting widespread access
to developed technologies. Indeed, publishing
continues to play a critical role in universities
and at other public sector research institutions.
Recent changes in the worldwide use of patent
ing discussed above, however, are forcing these
institutions to reassess whether this IP manage
ment strategy is the best way to support their
goals. This section focuses on promoting access
and highlights some instances where the choice
to patent a technology may be key to achieving
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the goals of promoting access, primarily by pro
viding important leverage.
.1.1

Will the technology need private-sector
resources for further development and
distribution?

IP rights provide private economic incentives that
can sometimes be critical to research, develop
ment, and distribution processes. As an example,
consider the investment needed to bring a drug
from discovery through to delivery. Although
an accurate estimate of the true cost of drug de
velopment is the subject of a lively debate, it is
inarguably hundreds of millions of dollars.30 In
most cases it is unreasonable to expect the public
sector to take on the levels of investment and risk
involved in drug development. A parallel example
can be seen in agriculture, where regulatory clear
ance may be needed for a new product, or seed
distribution networks may need to be engaged.
It is important, therefore, to assess early whether
private capital is likely to be necessary, at some
point, for research, development, regulatory clear
ance, manufacturing, and distribution. IP rights
can facilitate the private sector’s engagement by
providing critical assets for bargaining (for exam
ple, in product development partnerships).
.1.2

Are there benefits to be gained
from segmenting the market?

One benefit of choosing to patent, rather than
publish, is that patenting provides an opportu
nity to segment the market of technology users
or licensees. An IP manager may require differ
ent licensing terms, for instance, depending on
whether the technology will be used commer
cially or for humanitarian purposes. Alternatively,
the license might contain terms to segment the
market geographically or by fields of use. An
exclusive license may be implemented, for ex
ample, to limit the technology’s use to one major
crop, reserving all other uses of the technology
for widely accessible and nonexclusive licens
ing. Using such an approach, income generation
and access may be complementary goals for the
IP provider. Or the rights to a technology in, for
instance, developed country markets may be ex
changed for contractual obligations to deliver the
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product to developing countries for a reasonable
price. Choosing to protect the technology with
IP rights instead of defensive publishing may pro
vide bargaining leverage that ultimately achieves
the institution’s goals.
.1.

Is the technology a research tool
(enabling technology)?

A body of evidence indicates that the patenting
and access restrictions (through exclusive licens
ing, for example) of enabling technologies can
limit the progress of innovation in health and
agriculture.31 Indeed, the existence and effects of
patent thicket– or anticommons-dynamics are
now fairly well accepted. The task of this section,
however, is not to consider the policy question of
whether research tools should be patentable, but
to examine the choice between patenting (nota
bly in the examples given here with widespread
nonexclusive licensing) and defensive publishing
for the IP manager whose goal is to promote ac
cess in a context where research tools, and im
provements to them, are widely patented. In
other words, how can IP management preserve
the right to use an enabling technology?
As a first example, consider plant transfor
mation that confers a new trait. Access to several
complementary enabling technologies is required
to produce a product. A vector that includes a
promoter, selectable marker, a backbone, and a
gene of interest must be used, as well as a trans
formation method and germplasm. Lack of access
to any one technology may delay research and de
velopment or, in some cases, altogether prevent
the progress of the project.
In such a case, the complementary nature
of the technologies implies that the decision to
patent may confer bargaining leverage. If an IP
manager chooses not to patent an enabling tech
nology, for example, a novel selection system with
wide applicability in plant transformation, the
ability to control the technology’s applications is
lost. Research projects where the selection system
would otherwise have been the limiting factor
(where all other technologies are owned or acces
sible) could progress, without impediment, if the
technology were to be published. Alternatively, if
the IP manager chooses to patent, the essential

nature of the technology may place the owner in
a position to demand a wide range of contractual
obligations in exchange for the use of the selec
tion system. BiOS, for example, operates on this
principle by providing patented enabling tech
nologies under licensing terms that support the
organizations open-access goals.32
A second scenario concerns improvement
patents. Here, as in the previous example, suppose
the IP manager chooses not to patent the novel se
lection system. Improvements to the technology
are subsequently invented and patented, restrict
ing the uses of the original technology. Had the
IP manager patented the technology, the value of
the subsequent improvement patents would de
pend on access to the underlying dominant pat
ent (see Section 4.2 on dominant patents). The
E8 case study provides a concrete example where,
had the original sequence been patented instead
of published, the use of some of the downstream
patents would depend on Agritope, Inc. or
Epitope, Inc. licensing the original patent. For
technologies that do not lend themselves to sub
sequent restrictions from improvement patents,
this is not a concern. Mouse models are an ex
ample of this type of technology. The majority of
mouse models used in research, for instance, are
licensed and not patented.
.2 Using defensive publishing as a tool
in an IP management strategy

Clearly, the common perception that publishing
inherently promotes access may require recon
sideration. Still, what are the merits of defen
sive publishing for supporting a wide variety of
IP management goals? And how does it high
light the limitations of using patents to protect
innovations?
.2.1

The costs of maintaining
a patent portfolio

Patent portfolios are costly to develop and main
tain. Moreover, they sometimes require a lengthy
maturation period before reaching a point
where they return income. Unless a licensee is
found who will underwrite the cost before the
prosecution process starts, the initial investment
in the cost of prosecuting patents can be large,
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particularly where protection is sought in mul
tiple countries. Even where licensees are already in
place, it can be many years before a license gener
ates a positive cash flow. In examining U.S. uni
versity technology transfer offices (TTOs), Heher
notes that 40%–50% operate at a net loss and
that profitability often depends on income aris
ing from one or more blockbuster patents.33 In a
cross-country comparison of TTOs, he finds that
“the first and foremost requirement for success from
technology transfer is a well-funded high quality re
search system as the benefits from commercialisation
of research are directly proportional to the magnitude
of the investment in research.”34 While direct and
indirect economic impacts provide broad benefits
from building an institutional patent portfolio
and TTO, the investment is long term and high
risk. If resources are particularly constrained, the
decision to expend money on patenting deserves
careful consideration. Less expensive alternatives
to patenting may support IP management goals
and allow more resources to be directed toward
research.
.2.2 Transaction costs of licensing

The transaction costs of negotiating licenses are
substantial and may need to be accounted for
in the decision to patent. For instance, if the
IP management goal is to promote access to a
technology, and the choice is either defensive
publishing or nonexclusive licensing, the costs of
negotiating multiple nonexclusive licenses, or de
vising licensing language to segment the market
of technology users suitably, may outweigh the
benefits. Transaction costs can be somewhat re
duced in take-it-or-leave-it nonexclusive licenses,
but these tend to be rare.
.2. Enforcement considerations:
costs and legal Infrastructure

The costs (and feasibility) of enforcing the patent
may also need to be considered. Because a pat
ent confers exclusionary rights, it may be worth
less without the ability to enforce those rights.
Enforcement may require litigation against infring
ers or using the patent to invalidate subsequent
blocking patents. In either case, patent litigation
is a game for players with deep pockets. Average
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costs for patent litigation in the United States
exceed $2 million dollars per case. Any decision
to patent must include an assessment of whether
the patentee can afford to enforce the patent. In
addition to the expense, the maturity or efficacy
of the patent law system in the countries likely to
be involved should be considered. If the technol
ogy lends itself to bailment, for example, more
control over the use of technologies may be
found through contract law, particularly in
countries where the patent system is not well
developed.
.2. Defensive publishing as an
active strategy

Defensive publishing is most effective as an active
strategy. This is a different use of publishing than
that found in many research institutions today.
The use of defensive publishing requires carefully
constructed disclosures with the greatest possible
public exposure and diligent worldwide monitor
ing of new patent applications as they arise in a
particular technology field. When a patent appli
cation appears for which the defensive publication
has the potential to force a narrowing of the claims
or a total rejection, the appropriate channels must
be used to alert the patent office of the published
prior art.
.2. Using defensive publishing in
combination with patenting

One of the strongest roles defensive publishing
can play is when it is used, not as a substitute for
patenting, but in conjunction with it. As an ex
ample, consider a strategy where an IP manager
patents a core technology and then defensively
publishes the surrounding, related innovations,
thereby reducing the likelihood that others will
be able to obtain dominant patents. Obtaining
patents on improvements to a core technology as
they are discovered may be a poor use of limited
resources. In addition to improvements, new uses
of the core technology may be discovered as re
search and development progress. But defensive
ly publishing these improvements and alternative
uses will inexpensively and effectively contribute
to preserving the right to a wide field of applica
tions for the core technology.
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. Preserving access: ten questions to consider

For the IP manager deciding on a strategy for pre
serving public access, considering the following
questions should be helpful:
• What are the IP management goals of the
institution or inventor?
• Will the technology need the engagement
of private-sector resources for further devel
opment and distribution?
• Are there benefits to be gained from seg
menting the market?
• Is the technology a research tool (enabling
technology)?
• Do the benefits of patenting and licensing
outweigh the costs?
• How and where might the patent be
enforced?
• Are there other viable options for protec
tion—trade secrecy, bailment, trademarks,
and so forth?
• In which territories/countries is the tech
nology likely to be used?
• Can the technology be licensed without
patenting?
• Can defensive publishing be used in con
junction with traditional forms of IP
protection?

. uSInG puBLIC doMAIn TECHnoLoGIES
Public domain technologies are valuable inputs
to research. Indeed, they are a crucial but com
monly underutilized resource for researchers.
Using research tools or enabling technologies in
the public domain reduces transaction costs and
mitigates future potential IP impediments in the
research and development process.
In developed countries, many of the standard
inputs of science in the fields of health and agri
culture have been patented. Scientists, however,
continue to use these tools because they have a
well-known history, including known levels of
efficiency and documented use in specific crops.
The use of patented research tools, on the other
hand, can open the institution to infringement
liability and/or create problems in later stages
of commercialization. While the maximum use
of public domain technologies may be desirable

at the outset of a research project, using betterknown tools (which are often proprietary) may be
important in the initial proof of concept stages of
research. In this case, it is worthwhile to identify
whether public domain technologies are available
for substitution at a later stage.
The identification and promotion of substi
tute technologies from the public domain is one
of PIPRA’s important contributions to the field
of agriculture. PIPRA’s mandate is to assist pub
lic sector researchers worldwide in overcoming IP
impediments to the research, development, and
distribution of staple crops for developing coun
tries and minor crops in developed countries.
Because the commercial market for these crops
is too small to attract private-sector investment,
the public sector primarily pursues research and
development with respect to such crops—often
without the resources to successfully address IP
issues. Public domain technologies are therefore
a critical resource for developing these orphan
crops.
As PIPRA’s library of technical and legal in
formation on public domain and patented, but
accessible-enabling technologies (including freedom-to-operate opinions from attorneys) in agri
culture grows, so does the demand for knowledge
of what technologies are in the public domain and
how they might be employed in place of currently
used patented technologies. Some practical con
siderations for researchers and IP managers with
regard to identifying public-domain technologies
are laid out below.
.1 Patent databases provide
only part of the picture

As the E8 case study illustrates, an investigation
must begin with a search through both the pub
lished scientific literature and patent databases. It
is both the comparison of the content and the
timing of the publication of each contributing
document that will determine whether the tech
nology in question is in the public domain and
its limitations for use. A simple patent search
may mislead by returning a bewildering number
of related patents. But a comparison of these pat
ents with the published literature can reveal that,
for instance, the core technology is in the public
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domain and that the patent thicket is made up
of improvements, and other patents, limiting
the utility of the original technology. If this is
the case, knowledge of these limitations may be
critical in designing a research plan that invents
around existing patents and maximizes the use of
the public domain technology.
Sequence comparisons may provide another
critical piece of information for the researcher
seeking to use a public domain technology. As an
example, PIPRA’s analysis of the Soybean Heat
Shock Promoter found that changing the se
quence by one nucleotide allowed researchers to
avoid infringing the issued patents.35 It should be
noted, however, that this case is somewhat anom
alous. The determination by PIPRA’s attorneys
that altering a single nucleotide avoided existing
patents was reached by carefully considering both
prior art and patents. Generalizations cannot
be made, because it is only through examining
how both sets of specific documents interact that
FTO can be evaluated. However, the example il
lustrates how critical the use of sequence analy
sis tools such as BLAST can be when analyzing
patents. In general, careful attention to the prior
art and the use of homology measures in patent
claims may be necessary to identify the specific
public domain sequence.
.2 The landscape is continually changing

The boundary of the public domain changes
as new patents are issued. Periodic updates of
the analysis are necessary to check for recent
ly issued patents that may restrict the use of
the original technology. Searches can be hindered
because patent applications remain unpub
lished—and therefore invisible in patent search
engines—for many months after their initial fil
ing dates.
. Geographical considerations

Finding out what is in the public domain is
made even more complex by the territorial
nature of patents. The analysis for the E8 case
study considered only the situation in the
United States; any other country would re
quire collecting a different set of documents.
Nonetheless, because the boundaries of the
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public domain are more expansive in some
countries than in others, opportunities may ex
ist to design research strategies that take advan
tage of these differences.
For example, the territorial limits of patents
have led to suggestions that developing-country
research institutions should use technologies that
are not patented domestically but are patented in
more-developed countries. Legally, a researcher
using a technology in a country where no pat
ent has been filed is not infringing. However, an
obvious constraint surfaces when the product of
the research is destined for export into a country
where there is patent protection. In this case, de
spite the lack of patent protection domestically, it
may be necessary to investigate the patent land
scapes of export markets.
There are still further considerations. In or
der to use a technology that resides in the public
domain domestically, but is patented elsewhere,
a researcher may require the transfer of materials
or know-how from the patentee. These often in
volve material transfer agreements (MTAs) with
restrictive terms and reach-through obligations
that may hinder research and interfere with broad
access for researchers in developed and develop
ing countries alike. Even where no patent rights
are found, this situation may involve negotiating
agreements (such as nonasserts) with the technol
ogy owner. In addition, even when large compa
nies as patentees are not concerned with infringe
ment issues or losing market share, the companies
may be concerned about liability and stewardship
issues. Finally, developing country research insti
tutions, or the organizations that sponsor their
research, may attach considerable value to the
building of relationships with the company that
has patented the technology. Therefore, despite
the lack of patent protection and the legal free
dom to use a technology, there may still be im
portant reasons to negotiate a license.

. THE MECHAnICS of
dEfEnSIvE puBLISHInG
This last section focuses on the mechanics of de
fensive publishing: how to best ensure that a dis
closure precludes downstream patenting by others.
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Elements to consider in drafting a successful de
fensive publication include: content, language of
choice, publication venue, and publication date.
The following sections elaborate on best practices
in defensive publishing.
.1

Content

The goal of defensive publishing is to prevent pat
enting in a particular technology area. Therefore,
constructing a disclosure specifically designed to
create evidence to prevent patentability will in
crease the likelihood that fewer patents will issue
in this technology space. The disclosure should
be as complete and detailed as possible. Where
relevant, a publication should include descrip
tions of all parts of the experiment, experimental
conditions, diagrams, formulas, procedures, se
quences, materials, and methodologies. We indi
cated earlier that enablement of the publication
may be important; a defensive publication should
include evidence illustrating possession of the in
vention and enable a person skilled in the art to
make and/or use the invention.
.1.1

Consider disclosing the potential
for combining technologies

In addition to a thorough description, defensive
publishing should include potential combinations
of the target technology with other technologies.
This is true even for combinations for which the
author may not have detailed documentation.
As the case study of E8 revealed, the inclusion
of additional combinations can expand the use
of the document to support future nonobvious
ness rejections. Publishing the sequence of the E8
plant promoter did not prevent the issuance of
future patents claiming the use of the promoter
combined with particular genes. If the authors of
the original publication had ended their paper
by articulating the likely success of the sequence
for promoting the expression of broad classes
of genes, there may have been stronger grounds
for rejecting subsequent patents. To extend this
point, a defensive publication may be even stron
ger if it anticipates not only the promoter-gene
combination, but also its potential use in entire
systems, such as the transformation method, se
lectable marker systems, and other elements of a

plant transformation vector, as well as its use in
particular crops.
Whether the inclusion of certain language
in a publication will prevent future patenting in
this case is uncertain, and it should be noted that
the combination of prior art references in support
of a rejection on nonobviousness grounds comes
with several caveats. A successful rejection of a
claimed invention due to obviousness must show,
not only that someone skilled in the art would
have been able to combine the prior art refer
ences, but that they would have been motivated to
do so. Second, there must be a reasonable expec
tation of success for the purported combination.
Third, the references taken together must teach or
suggest all the elements of the claimed invention.
When drafting the content of a defensive publica
tion, it is impossible to anticipate all the possible
combinations of the author’s technology with
that belonging to others, but by using language
that acknowledges the caveats above, the author
can broaden the subject matter of the disclosure
as much as possible.
.1.2

Consider disclosing potential
alternative applications

As with potential combinations, it may be worth
while to include alternative applications of the
technology, even if they are not documented in
detail. If the technology is a product, the author
may want to consider including the current prod
uct, potential uses of the product, and derivative
products. While defensive publication can place
a product technology in the public domain, pro
cesses developed later using that product can still
be patented. By anticipating potential applica
tions, the author of the defensive publication
may contribute to an obviousness-type rejection
in the future. If the technology disclosed is a pro
cess, the author might consider including details
of products derived from the process. These con
siderations anticipate the patentability of product
and process patents. As an example of product
and process patents, consider the famous CohenBoyer technology. This was not one patent, but
three: (1) a process patent for the construction of
molecular chimeras, (2) a product patent for pro
teins made using recombinant eukaryote DNA,
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and (3) a product patent for proteins made using
recombinant prokaryote DNA.36
.1. Consider disclosing related alternatives

One way to design around a defensive publica
tion (or a patent) is to alter, even minimally, the
structure of the technology. TGo anticipate this,
defensive publication can indicate how the tech
nology may be altered while still maintaining
the original disclosed functions and characteris
tics. This follows common practice in drafting
patent claims. For instance, a sequence may be
published that includes a percentage homology
within which the function of the technology re
mains the same. In addition, it may be useful to
include homologies across different species.
.1.

Consider depositing biological materials

For some inventions involving biological mate
rial, we have established that a written description
is insufficient to convey the technology in such a
way that a person skilled in the art can practice it.
For such inventions, the patent system has come
to depend on the deposit of biological materials in
recognized, publicly accessible culture collections
worldwide. As a rule of thumb, if the biological
material can be made, or isolated, without undue
experimentation, or if the material is otherwise
known and readily available, it is not necessary
to deposit material. In many cases, however, a
defensive publication will be stronger if biologi
cal materials are deposited (the deposit accession
number should be referenced, where relevant, in
the publication and sequence information given).
Patent deposits worldwide have been regu
lated since 1980 when the Budapest Treaty on
the International Recognition of the Deposit
of Microorganisms for the Purposes of Patent
Procedure came into force.37 The World
Intellectual Property Organization38 provides
an updated list of the countries that have rati
fied the Treaty and the collections that are rec
ognized as international depositary authorities
(IDAs).39
.2 Choice of language

The choice of language (that is, English, or other)
in a defensive publication can also be important.
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The publication language may need to be, for
example, one spoken in the countries in which
the patent will be barred. It may be important,
however, to write at least the abstract and title in
English to maximize the chances that this partic
ular disclosure will be brought to the attention of
the patent offices in the United States and Europe
during prior art searches. Still, given the limita
tions of nonpatent prior art searching in patent
offices, the best post-publication strategy is to
monitor the published application in the technol
ogy field and alert the relevant patent office to the
defense publication.
. Where to publish

As noted previously, U.S. law uses the words
“printed publication” in its novelty require
ment. U.S. courts have adopted a broad defini
tion of the word printed, to include documents
stored on electronic media, and on microfilm.40
Documents posted on the Internet may therefore
be used to satisfy the printed aspect of the novelty
requirement.
The word publication has also been fairly
broadly interpreted to mean any printed docu
ment that is freely available to the public. Peerreviewed publications are only one option for
defensive publication, and their constraints on
content may leave the author with a less than
complete defense. Printed materials presented at
trade shows, conferences, seminars, or on Web
sites are all considered to satisfy the definition of
publication. Indeed, major corporations have used
this kind of defensive publishing as part of their
IP management strategy for many decades. IBM
provides perhaps the best-known example of the
use of a technical journal for defensive publish
ing. The success of that strategy is illustrated by
a 2002 search of the U.S. patent database by Bill
Barrett that found almost 10,000 patent citings
of IBM’s Technical Disclosure Bulletin.41 By pub
lishing technical disclosures without the content
restrictions of peer-reviewed publications, IBM
wields an inexpensive, flexible tool that comple
ments its overall patenting strategy.
A number of companies specialize in pub
lishing nonpatent prior art. The Web site IP.com,
for example, provides expertise in defensive
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publishing and offers a search engine to make it
easy for a patent examiner to navigate through
the site’s library of disclosures.42 Disclosing an
invention through such a company will increase
the likelihood that a patent examiner will see it.
The companies, however, may charge hundreds
of dollars for such a disclosure. Another method
of disclosure is the use of the statutory invention
registration procedure, whereby the PTO allows
for the registration of an invention that is unex
amined. This method, too, can be expensive. The
most cost-effective way to defensively publish is to
publish for free on the Internet (but dating mate
rial published on the Internet can be problematic;
see next section). If the Internet is used to publish
defensively, there may be a greater need to moni
tor recently published patent applications in the
field of interest.
. Timing and date stamping

The date of a defensive publication is a critical
piece of information that must be documented
and discernible by the patent office. It helps the
patent examiner to determine whether the publi
cation brings into doubt the patentability of the
subject matter. The dating of material published
on a Web site can be a difficult matter: many
documents on the Web are date stamped on the
date of access, not the date of posting. Obviously,
this practice can cause problems for a party those
attempting to preclude future patenting in a
technology area by using the Internet for defen
sive publishing. Fortunately, there are solutions.
Many companies now offer digital time stamping
(DTS) or digital notary services. This technology
has become accepted legal proof that the con
tents of a publication existed at a particular point
in time and has not changed since that time.43
Another readily accessible method of establishing
the date of an Internet publication is to scan a
document that includes a date and a signature,
and post the pdf on the Web.

. ConCLuSIon
This chapter has examined how IP managers and
researchers can use the public domain and defen
sive publishing to their advantage. A strategic IP

management plan begins by identifying the in
puts and enabling technologies used in research.
A strategic IP plan also clearly articulates the in
tended use of the technologies that are produced.
Once this framework is established, IP manage
ment tools can be used effectively to support the
project’s goals.
The public domain is a valuable resource
for early-stage thinking about a project’s re
search tools. The above practical considerations
will hopefully assist in effectively incorporating
public-domain technologies into an IP manage
ment plan, thus reducing the need to in-license
technologies and freeing up resources for more
research. Moreover, when managing the prod
ucts of a research project, one tool to consider
alongside more traditional IP rights is defensive
publishing, or placing a technology in the public
domain. When considering defensive publishing,
however, IP managers should keep in mind both
its utility and its limitations. n
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Provisional Patent Applications:
Advantages and Limitations
RICHARd L. CRUZ, Intellectual Property Attorney, DLA Piper US LLP, U.S.A.

ABSTRACT

In the United States, provisional patent applications can
provide an additional year of patent protection, for a to
tal of 21 years from the initial filing date. With such an
extension, a provisional application provides parity with
foreign applicants who, pursuant to the Paris Convention,
may file for a U.S. patent within 12 months of the foreign
filing. Provisional applications have both advantages and
disadvantages, so proper management is essential. The ad
vantages include the preservation of a priority date imme
diately after an invention is conceived, a one-year delay
for further developing the invention, an extra year of pat
ent protection, and constructive reduction to practice of
the invention. In addition, provisional applications pro
vide an inexpensive way to avoid possible statutory bars
and preserve absolute novelty for foreign filing purposes.
They also enable the use of the phrase “Patent Pending” to
mark products embodying the invention. The disadvan
tages include a possible increased overall cost of obtaining
a patent, potential loss of trade secrets, and a false sense
of security. An inventor must also file a nonprovisional
application within one year, and the subject matter of a
nonprovisional application is limited to subject matter in
the provisional application.

1. INTRODuCTION
Beginning in 1995, inventors were able to file
provisional patent applications in the United
States. This informal type of patent application
establishes a priority filing date and provides in
ventors one additional year to prepare and file a
formal utility patent application.

Provisional patent applications were estab
lished in the United States to place domestic in
ventors on an equal footing with foreign inventors.
Before the advent of U.S. provisional applications,
foreign (Paris Convention signatory) applicants
could claim the benefit of a foreign priority date,
yet have their U.S. patent term measured from a
later U.S. filing date. Foreign inventors were thus
granted a term of patent protection that could
last for 21 years. U.S. applicants, on the other
hand, were disadvantaged: their patent term was
measured from their initial U.S. filing date and
limited to 20 years. Effective June 8, 1995, do
mestic applicants were given the opportunity to
file provisional applications, thereby establishing
U.S. priority dates that would not count against
any resulting U.S. patent term. Allowing for U.S.
patent protection that lasts 21 years from an ini
tial filing date, this change in policy established
parity between U.S. and foreign inventors.
As an informal application, a provisional pat
ent application does not require all the formal
elements of a utility patent application. For ex
ample, provisional applications are not required
to include formal claims, a declaration of inven
torship, or drawings, all of which are required for
utility applications. Instead, all that is required is
a written description of an invention and a cov
ersheet that, among other things, identifies the
document as a provisional patent application.

Cruz RL. 2007. Provisional Patent Applications: Advantages and Limitations. In Intellectual Property Management in Health
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K.,
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. RL Cruz. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.

HANDBOOK OF BEST PRACTICES | 

CRuZ

Unlike utility patent applications, provi
sional patent applications are not substantively
examined by a U.S. Patent and Trademark Office
(PTO) examiner. Instead, they are reviewed by
the application division of the PTO to ensure
that the minimum filing requirements have been
met. As a result, the legal cost of preparing provi
sional applications is relatively low compared to
utility applications. Similarly, since the PTO does
not have to perform a prior art search or analyze
provisional patent applications, the cost of filing
these applications is also quite inexpensive when
compared to utility applications.
Aside from costs, several other factors should
be considered when determining whether or not
to file a provisional patent application. A few of
their advantages and limitations associated with
provisional applications are outlined below.

period that the invention is not commercially fea
sible, he or she can avoid the substantially higher
costs of pursuing a utility application.

2. ADVANTAGES OF A PROVISIONAl
APPlICATION

An invention is said to be reduced to practice
when an inventor converts the inventive idea into
something that is operable and capable of being
reproduced by others. Filing a provisional ap
plication has the effect of constructively reducing
an invention to practice, insofaras the invention
is adequately described so as to enable a person
skilled in the art to reproduce it. By filing a provi
sional application, a legal presumption is created
that the invention was reduced to practice, albeit
constructively, at least as early as the filing date
of the provisional application. This presumption
may be very advantageous to an inventor, partic
ularly if another inventor claims to have invented
the same invention first.
In the United States, an inventor is entitled to
a patent if he or she is the first to invent a particu
lar invention. If a dispute arises over who actually
invented the invention first, establishing a reduc
tion to practice date may be paramount to deter
mining which inventor is entitled to the patent.
In such disputes, the inventor who establishes the
earlier reduction to practice date (for example, by
filing the earlier provisional application) will be
presumed to be the first to invent. The challeng
ing inventor, i.e., the inventor not deemed the
first to invent, may only overcome this presump
tion by forwarding evidence that establishes that

2.1 Preserve a priority date

Because they have fewer formal requirements,
provisional applications are simpler and generally
less expensive to prepare and file. A provisional
application may therefore be used to quickly and
inexpensively obtain an official filing date for an
invention immediately after the invention has
been conceived. An official filing date provides
unequivocal proof that an invention was con
ceived at least as early as its filing date.
2.2 A useful one year delay

Once a provisional application is filed, an inventor
has up to one full year to file a formal utility ap
plication. This one-year delay enables an inventor
to further develop his or her invention, assess the
invention’s commercial potential, and seek finan
cial support for further developing and/or patent
ing the invention. In addition, the one-year delay
enables an inventor defer the bulk of the costs
associated with preparing and filing a utility pat
ent application until he or she is confident that
the invention is commercially viable, and/or until
he or she is able to secure financial support for the
invention. If the inventor determines during this
 | HANDBOOK OF BEST PRACTICES

2. An extra year of patent protection

An issued patent gives an inventor the right to
exclude others from using, selling, and/or of
fering to sell the patented invention for twenty
years. This twenty-year patent term is calculated
from the filing date of the inventor’s utility pat
ent application. The one-year delay between the
filing of a provisional application and the filing
of a utility application does not count against the
twenty-year patent term. As such, filing a provi
sional application provides up to an extra year of
patent protection, effectively extending the pat
ent term to 21 years.
2. Constructively reduce an invention
to practice
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he or she (the challenging inventor) is entitled to
an earlier reduction to practice date. Thus, filing
a provisional application not only establishes an
early reduction to practice date, but it also shifts
the burden to any challenging inventor to prove
that she or he invented the invention first.
2. Preserve a non-U.S. priority date

Most countries outside of the U.S. award patents
on a first to file basis. That is, an inventor will be
entitled to a patent if he or she is the first to file an
application for a particular invention, regardless
of whether another inventor was the first to actu
ally reduce the invention to practice. As a result,
many foreign inventors (and U.S. inventors seek
ing international patent protection) seek to file
patent applications in non-U.S. countries as soon
as possible in order to preserve their foreign prior
ity date. It should be noted that under U.S. law,
establishing a foreign priority date does not neces
sarily guarantee a specified period of time for filing
in the United States. Still, as members of the Paris
Convention, patent applicants in Convention
member-nations have up to 12 months to apply
for patent protection in the United States in order
to preserve an international priority date.
2. Avoid statutory bars

Pursuant to 35 U.S.C. § 102(b), if an invention is
published anywhere in the world more than one
year before a U.S. patent application for that in
vention is filed, the publication will act as a statu
tory bar to obtaining a U.S. patent. This statutory
bar is not limited to publications provided by an
invention’s first inventor. If, for example, a second
inventor independently conceives and publishes
the invention more than one year before the first
inventor files in the United States, the second in
ventor’s publication will bar the first inventor from
ever obtaining a U.S. patent on that invention.
To illustrate, suppose inventor X, a German
inventor, invents a novel widget on January 1,
2005, and accordingly files a German patent ap
plication describing the widget in April 2005.
Independently, a French inventor, inventor Y,
conceives of the same widget and publishes it on
March 1, 2005 in a French publication. Under
U.S. law, the German inventor may rely on his or

her earlier invention date to predate the French
publication date. However, if the German inven
tor waits until after March 1, 2006 to file a U.S.
application, the French publication will be deemed
prior art under 35 U.S.C. § 102(b) and will bar the
German inventor from obtaining a U.S. patent.
To avoid this 102(b) U.S. statutory bar, the
German inventor could file a U.S. utility pat
ent application concurrently with, or even after,
filing his or her German application. Pursuant
to the Paris Convention, the German inventor
would still have a period of one year after filing
the German patent application to file a U.S. pat
ent application. However, the utility patent appli
cation option could be quite costly, particularly
since the German application would have to be
translated into English and include U.S.-style
claims, drawings, and other formalities.
As an alternative, if the German inventor was
not prepared to incur such an expense, or if he or
she preferred to further develop the widget be
fore committing to the high costs of filing in the
United States, he or she could simply file a U.S.
provisional application. Since provisional applica
tions are not required to be written in English or
to include claims, drawings, or other formalities,
the German inventor could simply file a copy of
his or her German application in German as a
U.S. provisional application. In this manner, the
German inventor could preserve a U.S. filing date
and avoid a § 102(b) statutory bar, all at a very
reasonable cost.
2. Preserve absolute novelty for foreign filings

Most countries outside of the U.S. require abso
lute novelty, which means that, as a prerequisite to
receiving patent protection, a patent application
must be filed before any public disclosure of that
invention. In these absolute novelty countries, any
public disclosure of an invention prior to filing an
application for patent acts as a bar to patentabil
ity. As such, it is imperative for inventors seek
ing foreign patent protection to preserve absolute
novelty worldwide. Provisional applications may
provide an easy, cost effective way to preserve ab
solute novelty; however, this must be approached
with caution, as adequate disclosure is required.
There is still a general lack of consensus about
HANDBOOK OF BEST PRACTICES | 
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how courts in various foreign jurisdictions will
regard a U.S. provisional application as a basis for
priority. Even so, if an inventor wished to pub
licly disclose an invention as part of a presenta
tion, the inventor could preserve absolute novelty
by filing a copy of all of the presentation and
handout materials as a provisional application. In
this manner, the inventor could both preserve a
U.S. filing date and preserve absolute novelty in
Paris Convention nations, or in nations that have
acceded to the WTO (as the TRIPS Agreement
[Trade-Related Aspects of Intellectual Property
Rights]) incorporates the Paris Convention). This
includes the majority of the world’s nations.
2. Patent pending

Once a provisional application is filed, an inventor
is permitted to apply the phrase “Patent Pending”
to products embodying the invention. Use of this
phrase indicates to the public that the marked
product or products is or are believed to be inven
tive and that any and all available patent rights
in the invention are being pursued. Application
of the phrase also enables the immediate com
mercial promotion of an invention with less risk
of having the invention copied and/or stolen. In
addition, a “Patent Pending” notice gives official
notice to competitors and potential infringers,
which may be particularly useful in establishing
a patent infringement claim once the invention
is formally patented. It should be noted that the
phrase “Patent Pending” does not give rise to en
forceable patent rights. It is only after a patent is
issued that enforceable patent rights attach.

3. lIMITATIONS OF A PROVISIONAl
APPlICATION
Aside from the many advantages described above,
there are several limitations and disadvantages as
sociated with filing provisional applications.
.1 Increased overall cost

Although provisional applications are typically
less expensive to prepare and file than utility pat
ent applications, there are costs associated with
the same. Filing a provisional application first,
and then filing a corresponding utility application
00 | HANDBOOK OF BEST PRACTICES

will always increase the overall cost of obtaining
a patent. This is especially true when multiple
provisional applications are filed to cover various
aspects of an invention.
.2 Disclosure of invention

Although provisional applications do not have all
of the formal requirements of utility patent appli
cations, provisional applications must nonetheless
meet the disclosure and enablement requirements
of utility patent applications. That is, provisional
applications must include a complete, adequate
disclosure of an invention, a disclosure of the best
mode of the invention, and any drawings nec
essary for understanding and/or recreating the
described invention. If a provisional application
cannot adequately support the entirety of a cor
responding utility application, then only those
aspects that are adequately supported in the pro
visional application will be entitled to the provi
sional application’s priority date. All other aspects
of the utility application will have a priority date
corresponding to the filing date of the utility ap
plication. In this regard, preparing a provisional
application to fully support a later filed utility ap
plication may be as time consuming and as costly
as preparing a utility application.
. Potential loss of trade secrets

Another concern relating to provisional applica
tions is the potential lose of trade secrets. As ex
plained above, although provisional applications
do not have all of the formal requirements of
utility patent applications, they must nonetheless
adequately disclose and enable inventions. In at
tempting to satisfy these requirements, inventors
may disclose too much information, including in
formation they might later wish to retain as a trade
secret. Once a provisional application is filed, all
information disclosed will be incorporated into a
later filed corresponding utility application. When
the utility application becomes a patent, the entire
provisional application will become public, and
any potential trade secrets it contains may be lost.
. One-year filing deadline

Once a provisional application is filed, an in
ventor must file a utility application claiming

CHAPTER 10.2

priority to the provisional application within one
year. Failure to file a utility application within the
one-year period will result in the provisional ap
plication automatically being abandoned, which
may prevent the inventor from ever patenting the
invention.
. False sense of security

Filing a provisional application may give an in
ventor a false sense of security. Although filing a
patent application does provide some protections,
it does not provide any enforceable patent rights.
Furthermore, provisional applications never ma
ture into patents. If an inventor falsely believes he
or she is adequately protected by a provisional ap
plication, he or she may delay filing a utility ap
plication. And if an inventor fails to file a utility
application during the one-year period, the pro
visional application will automatically be aban
doned thereby preventing the inventor from ever
patenting the invention.
. Other potential limitations

There are other limitations to filing provisional
patent applications. For example, since filing a
provisional application delays the filing of a util
ity patent application, any patent that may ulti
mately issue may also be delayed. Depending on
the inventor’s (or patent owner’s) patent strategy,
such a delay may not be desirable.
It is important to note that both provisional
and utility patent applications trigger the time line
for filing applications under the Patent Cooperation
Treaty (PCT) and the Paris Convention. Since in
ternational patent applications must be filed within
one year of a U.S. filing, the high costs of inter
national filing will be incurred within one year of
filing a provisional application.

Provisional applications may not be amend
ed. If certain aspects of an invention are devel
oped or changed after a provisional application
has been filed, an inventor will be required to file
another application to reflect these developments
or changes.
Similarly, if an inventor accidentally discloses
secret information in a provisional application,
the inventor will be precluded from going back
and amending the provisional application to re
move the secret information. In this scenario, the
inventor would have the option of abandoning
the provisional application and possibly hav
ing the option of filing another provisional ap
plication that excludes the secret materials. This
would, however, reset the priority date.

4. CONCluSION
Provisional applications provide numerous ad
vantages for both domestic and foreign inventors,
which is why they are widely used and are often
integral to successful patent strategies. There are
also, however, certain risks and limitations associ
ated with provisional applications, so filing provi
sional applications may not always be desirable or
appropriate. Accordingly, before deciding wheth
er to file a provisional application, care must be
taken to properly assess:
• the nature of the invention(s)
• the particular needs of the inventor
(or company)
• the inventor’s (or company’s) overall
patent strategy n
RICHARd L. CRUZ, Intellectual Property Attorney, DLA Piper
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CHAPTER 10.3

Designing Patent Applications
for Possible Field-of-Use Licensing
aRne M. olson, Director, Olson & Hierl, Ltd., U.S.A

ABSTRACT

Patent applications should be organized and drafted with
a long-term objective that carefully considers the multiple
possibilities, and opportunities, of field-of-use licensing.
This is particularly the case in the agricultural, pharmaceu
tical, biochemical, and chemical disciplines, as inventions
can have multiple applications that are sometimes impos
sible to foresee. Technology managers must, therefore, fo
cus strategically, not only on the basic idea of an invention
but broadly, in order to consider the various ways such an
invention might be put into more widespread and more
profitable use. Therefore, the more details, examples and
alternatives that are thought through and then disclosed in
the patent application, the greater the opportunity for fu
ture divisional or continuation applications, as well as fu
ture claims that can be exclusively (field-of-use) licensed.
By making all of the institution’s licenses, in effect, field
of-use licenses, the technology manager retains the ability
to take a possible future use and license it to someone else,
maximizing the benefits of the inventions and generating
higher royalties for the institution.

1. InTRoduCTIon
The life of a technology transfer administrator is
not an easy one. With tight budgets, the more that
a university can make from its licensing program,
the better. One of the great benefits of field-of-use
licensing is that it allows a licensor to license the
same patent or related patents to different parties

in different fields, thereby maximizing the in
come stream from patent royalties. For example,
part of a biotechnology invention could be used
to make diagnostic tests for a disease, while an
other part of the same invention could be used to
prepare pharmaceuticals to treat the disease. One
company may have expertise in the sale and dis
tribution of diagnostics while another company
has all the resources to get U.S. Food and Drug
Administration (FDA) approval for human phar
maceuticals. Either of these companies could be
licensed to cover both areas, but maximum sales
and royalties would be obtained by having each
company sell in its area of expertise. This chapter
focuses on specific examples of field-of-use licens
ing and discusses how a manager can aid in the
development of well-written patent applications
that support this licensing approach.
It might be useful to consider making ev
ery license a field-of-use license. Even though a
particular invention suggests a single use that ap
pears to perfectly fit a potential licensee, there is
simply no way of knowing what other uses may
develop over the life of a patent. A piece of con
trol technology developed solely for automobile
manufacturing may turn out to be useful for op
erating a rocket system developed several years
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thereafter. Rather than simply licensing such a
patent exclusively to a particular automaker, an
inventor should consider licensing the patent to
a particular automaker in the field of automobile
manufacturing. When a particular field of use is
properly licensed, other fields of use developed in
the future would remain the property of the uni
versity for later exploitation.

2. THE vALuE of A quALITy AppLICATIon
There are some basic concepts that can apply to
all patent applications, not just those that are ap
propriate for a potential field-of-use license. First,
it is important to have a well-written patent ap
plication. Far too many technology managers
look at the cost of preparing and filing a patent
application as opposed to the total cost of obtain
ing a patent. It is not the cost of filing the applica
tion that counts, but the total cost of getting the
patent. Although cost alone is not a determining
factor of a well-written application, a frugally pre
pared patent application may contain mistakes or
omissions and/or may not be sufficiently thought
out to provide broad coverage or ideas for pos
sible future expansion into other opportunities.
These initial oversights could lead to expensive
amendments, the necessity of filing continua
tion applications, and even continuation-in-part
applications to rewrite the application and thus,
raising the overall cost of the application.
2.1 The patent application as a sales document

One benefit of a properly written patent applica
tion is that it provides a far more useful sales doc
ument than one that is poorly prepared. Often, a
particularly new and valuable development does
not yet have a licensee. Thus, a well-written pat
ent application is important for convincing a po
tential licensee that the invention is worth licens
ing. Both the potential licensee and the patent
examiner need to be confident of the value of the
invention, but for different reasons. The patent
examiner will look for “statutory” value—wheth
er the invention sought to be patented is novel,
useful, and non-obvious to one skilled in that
art. The potential licensee, in addition to statu
tory value, may seek value based on the potential
0 | HANDBOOK OF BEST PRACTICES

commercial or humanitarian value of an inven
tion. An application that is poorly constructed
and includes typographical errors or scientific in
consistencies will make a negative impression on
a potential licensee and on a patent examiner.
2.2 Allow for future coverage

A well-written application will reflect consider
ations of possible areas of future coverage, de
scribing not only the basic idea developed in the
lab, but also peripheral ideas and extrapolations.
Including such information supports broad and
valuable coverage in a patent. It suggests areas for
future development that can be covered in more
detail in continuation applications. Specifically, if
these future ideas are at least sketched out in an
application’s specification (that is, are adequately
disclosed in the original application), there can
be a basis upon which to reach back to the earli
est filing (priority) date for subsequent claims and
related amendments disclosed in the original par
ent application. Thus, the institution would have
the benefit of a filing date that will avoid what
otherwise would be prior art.
Coming up with alternative uses of an inven
tion, or other ideas for development, should be a
collaborative effort between the patent attorneys,
the technology managers, and the inventors.
Recognizing that managers often prefer to mini
mize direct contact between inventors and the at
torneys in order to keep costs down, this is one
instance where direct communication can prove
to be particularly useful and valuable, as even the
best patent attorney cannot think of all of the al
ternative uses of an invention or all the modifica
tions or possible future uses of an invention.
Such contact between the inventor and the
attorney is critical for developing examples of ad
aptations or permutations needed to provide for
future field-of-use licensing. Prior to this com
munication, the technology manager may wish
to encourage the inventor to describe addition
al alternatives or other possible future uses and
simply forward these descriptions to the patent
attorney. This exercise could begin the creative
thought process—the “what if ” thinking—need
ed to come up with other possible future uses.
The more the inventor engages in this type of
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thinking, the less time it will take for the patent
attorney to consider and describe the potential of
the invention. A monetary savings can sometimes
be realized as well since it will take less time for
the patent attorney to prepare the application.
2. Retain control over the patent application

All too often, a university will turn over the writ
ing of the patent application and the control of
the patent prosecution to the licensee. This creates
an inherent conflict of interest and a potential for
future litigation. (The conflict arises because a li
censee may prefer relatively narrow patent protec
tion to minimize the amount of royalties it might
have to pay in the future.) In patent prosecution,
decisions need to be made as to what level of pro
tection to seek. Relatively narrow patent claims
can often be obtained without too much diffi
culty and expense. Broad coverage, however, may
be far more important for a university because it
would allow for future licensing and would cover
more products to be sold by the licensee. While
broad coverage may have been originally sought
to cover a licensee’s future developments, if, dur
ing patent prosecution, the claims are narrowed
so that the licensee’s future developments are out
side of those patent claims, the university could
lose significant royalties.
Specific to a potential field-of-use licensing
situation, the patent application will have disclo
sures and possibly claims to uses of the invention
that are outside a particular licensee’s interest.
That licensee would, of course, have no incentive
to spend any time or money expanding on the
concepts outside of its own interests.
Where the university controls the patent
prosecution, it has the ability to determine the
breadth of the patent protection it wishes to seek
and whether to dedicate resources to expand the
patent coverage into other fields of use. When
preparing the patent application, one should
think of all possible uses of the invention, not
just those of a present licensee. These do not have
to be worked into all of the claims, but the dis
closures should appear in the patent application.
At some future time, should another potential li
censee show interest in that area, a continuation
(or possibly, a continuation-in-part) application

can be filed, expanding on that particular aspect
of the basic concept. Thus, the institution has the
benefit of the earlier filing date, and a new ap
plication can expand on and claim the particular
new development.
While the university should retain control
over the patent application, it is still possible for
the license agreement to have the licensee pay for
the prosecution of the patent application. In the
case of two licensees for the same patent, the pat
ent expenses can be divided equally between the
two licensees. This also is discussed in greater de
tail in the preceding chapter.
. STRuCTuRInG THE

pATEnT AppLICATIon
In structuring the patent application, it is best to
incorporate as many alternatives as possible for
future expansion. Doing so can have two direct
effects: (1) the application will support broader
claims than might otherwise be possible—this can
be particularly important in the biotechnology
and chemical areas, where it is often necessary to
give more than a simple example to support broad
claims in the patent application—and, (2) having
ideas for future uses in the application allows for
continuation applications to these developments.
This is a version of the “throw in the kitchen sink”
approach. It is difficult to predict what will have
future value, and it may not be worth having
claims for ideas for potential uses in the applica
tion, but it is worth having at least a sentence or
paragraph about a possible alternative. Two or
three pages of a patent application can include a
great many of these “sleeper” inventions that can
remain dormant and be brought to life when they
are found to have a particular value.
This is not a new idea. The 1876 Alexander
Graham Bell patent titled Telegraphy describes
Bell’s invention as a multiple telegraph using
different frequencies of sound to simultaneous
ly transmit several telegraph messages over the
same wire. A reference is made toward the end
of the patent that the invention can be used to
transmit sounds and, if certain modifications are
made, even the human voice. The value of this
last extrapolation can be seen by the number
HANDBOOK OF BEST PRACTICES | 0
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of infringement lawsuits referred to as “The
Telephone Cases.”
The claims of the patent application can also
be structured for field-of-use licensing. There can
be broad claims to the general overall concept
that are licensed to more than one party on a
field-of-use basis; there can also be narrow claims
directed to specific fields of use that are licensed
only to a particular licensee. The narrow claims
can be written to define the field of use, for ex
ample, the use of the invention as a diagnostic
for a particular disease in farm animals; another
narrow claim could define the use as a similar di
agnostic for humans. Future continuation or di
visional applications could have claims directed
to other specific fields of use.
The approach described here has the benefit
of providing specific claims or specific patents that
can be exclusively licensed to a particular licensee.
Generally, licensees prefer to have an exclusive li
cense, even if it is only for a specific claim or a spe
cific patent. In addition, defining specific narrow
claims for different licensees can provide a mecha
nism for allocating the reimbursement cost of
prosecuting the patent applications as well as for
determining which licensee will be responsible for
or involved with suing a potential infringer. For
example, the license agreements can be structured
such that if a patent claim exclusively licensed to a
particular licensee is infringed, then that licensee
is required to take part in the infringement liti
gation. If different claims exclusively licensed to
separate licensees are infringed, then both licens
ees would be involved in the litigation. The idea is
that if each licensee’s exclusive “turf ” is invaded,
they would want to be involved. Separate patents
for exclusive licensing to different licensees can
arise as a result of restriction requirements. This
issue is discussed in more detail below.
.1 Biotechnology example

One of the wonders of biotechnology is the discov
ery that genetic information can be used to code
for proteins or parts of proteins. For example, it
has been found that relatively short lengths of
polypeptides can be used to form vaccines. Prior
to this discovery, vaccines had been made from
proteins obtained from dead or weakened viruses.
0 | HANDBOOK OF BEST PRACTICES

By way of a fictional example, a scientist has
discovered the gene coding for one of the envelope
proteins of “RBS” virus. Suppose the RBS virus
has only recently begun to infect the human pop
ulation and some of its potential effects include
a revival of a previously conquered illness. The
scientist has also discovered that a 20-amino acid
residue polypeptide which is named “Merkin” and
which can serve as a vaccine against the dreaded
RBS. In addition, the scientist has found that
when the Merkin polypeptide is injected into
animals, the animals exhibit an immune response
and begin producing harvestable antibodies that
react with RBS virus in a sample. The scientist has
also recently successfully created a monoclonal cell
line that produces antibodies to RBS.
These anti-Merkin antibodies are particularly
valuable because they have a high affinity for the
RBS virus and, at least in the lab, protect precious
bodily fluids from infection. Therefore, a possible
use of the antibodies would be to create a direct
treatment for an RBS virus infection: the anti
body would be collected and then injected into
the patient as a form of treatment.
Another use for the Merkin polypeptide is
in an assay to detect the presence of anti-RBS
antibodies in human blood serum. It was found
that using the antibody as a means to detect RBS
was not successful because the RBS virus does
not generally appear in a high concentration
in blood. However, when the Merkin polypep
tide was used, it reacted with antibodies in the
patient’s blood and other precious bodily fluids
to indicate whether there had been antibodies
produced to fight the RBS virus, now present in
the blood. One type of HIV assay system works
similarly. It does not detect the presence of HIV
itself, but rather it detects the presence of HIV
antibodies in the patient’s blood. The success of
the test depends on the assumption that if HIV
antibodies are in the patient’s blood, the patient
has been exposed to or infected by HIV.
Thus, it appears as though the Merkin poly
peptide has at least two immediate uses. The first
is as part of an assay system to check for an RBS
virus infection, and the second is for future de
velopment as a vaccine. The antibodies that have
been developed appear to have possible uses for a

CHAPTER 10.

future assay as well as possible future therapeutic
value.
A potential licensee, Assay Specialists, Inc.
(ASI) has shown particular interest in the use of
the Merkin polypeptide for conducting diagnos
tic assays. ASI is a large company that has a great
deal of experience in assays of this type, although
it has little to no experience in therapeutic treat
ments and vaccines. Another company, Vaccinia,
has indicated an interest in possibly developing a
vaccine and therapeutic treatment. At this point,
Vaccinia’s interest is lukewarm, because prelimi
nary studies of using a vaccine on animals are still
being conducted.
Based on this, therefore, a properly prepared
patent application could cover the following
inventions:
1. The gene used to make the envelope
protein.
2. The purified envelope protein.
3. The part of the gene that codes for the
Merkin polypeptide.
4. The Merkin polypeptide.
5. A vaccine based on the Merkin
polypeptide.
6. Antibodies to the Merkin polypeptide.
7. The monoclonal cell line.
8. Diagnostic products based on the Merkin
polypeptide or its antibodies.
9. A therapeutic treatment based on the
antibodies.
10. A cure for the recurring illness.
A field-of-use license can be granted now to
ASI directed to diagnostic products. This would
be a non-exclusive but field-of-use license to the
claims directed to the Merkin polypeptide gen
erally (4) and an exclusive license (meaning that
ASI will be the only licensee) for those claims that
are specifically directed to the use of the Merkin
polypeptide for diagnostics (8). There can also be
a non-exclusive license for the use of the part of
the gene that codes for the Merkin polypeptide
(3) so that ASI can also make the polypeptide,
using DNA cloning techniques. This results in a
licensee signed up in the initial stages and pro
vides a source of revenue to support the patent
application(s) and further research.

As matters progress and Vaccinia becomes
more interested, a non-exclusive but field-of-use
license can be granted to Vaccinia on (3) and (4).
Vaccinia would be the only licensee for the vac
cine based on Merkin (5). At some future date,
if there is a revival of the previously conquered
illness in epidemic proportions, there may be an
other potential licensee and, therefore, justifica
tion for a divisional patent application directed to
a cure for the recurring illness (10).
.2 Chemical example

Dr. Lovejoy has discovered a highly toxic com
pound that he has named oxymoronic acid. This
compound is very useful in treating certain men
tal disorders. The only known source of oxymo
ronic acid is certain mutant desert bushes that
grow only in the area surrounding nuclear test
sites. The elimination of open air testing of nu
clear weapons, however, has put great restrictions
on the number of mutant plants available. All at
tempts to cultivate oxymoronic-producing plants
have thus far been unsuccessful, but Dr. Lovejoy
has recently found a way of synthesizing a pre
cursor of oxymoronic acid that he has named
protomoronic acid that can be manipulated to
form oxymoronic acid. Through this synthesis
scheme, it is possible to produce oxymoronic
acid in the quantities needed for medical treat
ment purposes.
Through encouragement by the technology
manager and the patent attorney, Dr. Lovejoy
has worked out alternative synthesis schemes for
other possible precursors of oxymoronic acid, one
of which is called “AP.” While these schemes have
not been fully tested, they appear to provide oth
er ways of making oxymoronic acid synthetically
and thus may prove to have value in the future.
A patent application is prepared having claims in
the following areas:
1. Oxymoronic acid in a purified form as a
pharmaceutical.
2. The precursor, protomoronic acid.
3. Various alternative precursors, including
AP.
4. The methods of making oxymoronic acid
using the various precursors.
5. A rat poison based on oxymoronic acid.
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The last category listed above was a gratu
itous discovery when one of Dr. Lovejoy’s gradu
ate students, who had a laboratory in a less than
desirable location, dropped some oxymoronic
acid on the floor and it was sampled by one of the
visiting rodents. It was discovered that it made an
extremely effective rat poison.
Because this discovery was fortuitously made
and was not considered to have any immediate
commercial value, the idea of using oxymoronic
acid as a rat poison was put in as a sentence or
two in the patent application. This did not cost
anything, but it left open the possibility of future
options. Some years later, while one of the patent
applications was still pending, a major pesticide
company came to the university asking for a li
cense to further develop this rat poison. Because
a divisional application was still pending, it was
possible to file a continuation (or a continuation-in-part) application having claims directed
to the use of oxymoronic acid as a rat poison and
thereby grant the pesticide company an exclusive
license in the field of using oxymoronic acid as a
rat poison. In such a case, the graduate student
could likely be a co-inventor (as opposed to the
rat who actually made the discovery but did not
live to tell about it).
An exclusive field-of-use license in the medi
cal area was granted for (1), the pharmaceutical,
above. Later it was found that AP had particular
usefulness as an adhesive and was licensed to a
bumper sticker company because no exclusive li
cense had been granted for (3) above.

one, or possibly more, divisional patent applica
tions are carved out of the original parent patent
application.
The typical reaction to this is annoyance.
After all, what has been filed as one patent appli
cation will now be split up into four and perhaps
as many as ten parts. However, one should not
necessarily complain, as there might be a silver
lining in this gray cloud. This situation, albeit
initially annoying, can often be done relatively
simply, and present new opportunities.
Since the U.S. Patent and Trademark Office
has taken the position that there are separate in
ventions in the patent application, these inven
tions can be prosecuted as separate applications.
Thus, one can continue to prosecute the claims
directed to the diagnostics until those are allowed.
The diagnostic patent issues, and that patent can
be exclusively licensed to ASI. Meanwhile, a se
ries of other patents may be obtained from the
same core invention (the parent application) via a
series of divisional patent applications arising out
of the restriction requirement. Each patent can
be directed to a different field of use and licensed
separately. Furthermore, depending on the cir
cumstances of each application, there might be
opportunities for patent term extensions due to
delays in the patent office, certain administrative
proceedings (for example, successful appeals), or
for regulated medical products to compensate for
regulatory delays. Thus, a restriction requirement,
when strategically managed, can become an un
expected series of opportunities.

. RESTRICTIon REquIREMEnTS
AS oppoRTunITIES
It is quite likely that a patent examiner review
ing a patent application directed to the above ex
amples would take the position that there is more
than one invention present in a given application
(in some jurisdictions referred to a lack of unity
of invention). For example, the examiner may
say that the gene is one invention, the polypep
tide is a second invention, the diagnostics are a
third invention, the vaccine is a fourth invention,
etc. When this is the case, the patent application
is “restricted” to only one invention, and then

. ConCLuSIon
The main point presented in this chapter is to
encourage creative thinking when preparing pat
ent applications. The technology manager should
focus not only on the basic idea, but should also
encourage inventors to think broadly regarding
all the various ways their invention might be put
into use. When the patent application is filed,
there is no way of knowing every possible use of
the invention. Thus, the more invention ideas
that can be put into the patent application, the
more support there is for future divisional or con
tinuation applications, or future claims that can

0 | HANDBOOK OF BEST PRACTICES

CHAPTER 10.

be exclusively licensed. By making all of the in
stitution’s licenses, in effect, field-of-use licenses,
the technology manager has retained the ability
to take one of these possible future uses and li
cense it to someone else, maximizing the benefits
of the inventions and generating higher royalties
for the institution. n
aRne M. olson, Director, Olson & Hierl Ltd., 20 North

Wacker Drive, 36th Floor, Chicago, IL, 60606, U.S.A.
aolson@olsonhierl.com
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Patenting Strategies: Building an IP Fortress
JOHN dOddS, Founder, Dodds & Associates, U.S.A.

ABSTRACT

A comprehensive intellectual property (IP) portfolio can
be of substantial value to both private and public sector
entities. Patents are a key element of IP portfolios and
must be managed according to the mission, objectives,
and motivations of the organization that owns them.
Large companies can afford an offensive patent strategy,
but small companies may not have the resources for this.
Therefore, it is extremely important for private sector
entities, especially small- and middle-sized companies,
to design and implement an effective and cost-efficient
strategy for patent management. For public sector enti
ties, patent strategies will focus on advancing social wel
fare, and the mission of the institution will therefore drive
objectives. A key factor to consider is the method of IP
protection: patent, trademark, copyright, or trade secret.
The costs of maintaining each of these IP categories are
different. Although research institutes and companies
will likely wish to reduce costs as much as possible, key
technologies still need to be protected properly. A com
pany can reduce costs by focusing the patent protection
on those geographic areas where it has business. A uni
versity can reduce costs by selectively prosecuting patent
applications with broad claim structures, strategically li
censing technologies, and enforcing patent rights if and
when necessary. To build a strong basis of protection,
several forms of IP may be used for the same invention
or improvement.

1. INTRODuCTION
Historically, a patent was a grant made by a sover
eign that would allow for the monopoly of a par
ticular industry, service, or product. Over time,
the concept has been refined and now stipulates

a contract or compact between the government
and the inventor/creator. In return for the right
to exclude others from the practice of the inven
tion, the government requests that the inventor
fully disclose the enablement of the invention.
Additionally, the monopoly is now limited by
time and is only applicable in the territory under
the jurisdiction of the government that granted
the patent.
In the United States, a patent is a fundamen
tal right provided in Article I, Section 8 of the
Constitution. Congress is empowered to “promote
the progress of science and useful arts by securing for
limited times to authors and inventors the exclusive
right to their respective writings and discoveries.”
In exchange for a right to exclude others from
making, using, or selling the potential invention,
the inventor must provide a complete and accu
rate public description of the invention and the
best mode of practicing it. This disclosure of in
formation by the inventor allows others to invent
further, thus pushing technology forward for the
benefit of society.
Congress has given the U.S. Patent and
Trademark Office (PTO) the authority to grant
an inventor the right to exclude all others from
exploiting the invention in the United States for
a period of 20 years, or for design patents, up to
14 years, from the date of filing a patent applica
tion with the PTO. This right to exclude makes a
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U.S.A. Available online at www.ipHandbook.org.
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patent a negative right, since a patent holder may
only exclude others from using, manufacturing,
copying, or selling his or her invention.
Patents are territorial. For example, a U.S.
patent generally has no force in other countries,
just as a patent granted outside the United States
has no force in the United States. However, prod
ucts sold in the United States, even if they are
made outside the patent domain, may infringe a
U.S. patent. Procedures for filing, regulations for
patentability, and patent terms vary considerably
from country to country.
The United States is the only country in the
world that awards its patents using a first-to-in
vent approach; all other countries have a first-to
file approach. The first-to-invent approach has led
to the development of patent interference prac
tice, a quasi-litigation conducted within the PTO
to determine the issue of priority, or who made
the invention first.
Another important difference between the
U.S. system and the system adopted in many oth
er countries, for example European countries, is
the one-year grace period awarded in the United
States. This means that an invention is patentable
if it has not been published or otherwise brought
into public awareness earlier than one year from
filing the patent application.
Patents are relatively complex documents to
prepare and submit, and the time and expense
in obtaining such protection can be substantial.
Given the legal complexity and the costs in
volved, it is important for the inventor to develop
a coherent strategy with which to approach the
patenting process.

2. DEFINITIONS
• design patent. A drawing or depiction of
an original plan or conception for a novel
pattern, model, shape, or configuration to
be used in the manufacturing, textile, or
fine arts, and chiefly of a decorative or or
namental character. Design patents are is
sued for a period of 14 years.
• monopoly. A privilege or peculiar advan
tage vested in one or more persons or com
panies, consisting of the exclusive right or
12 | HANDBOOK OF BEST PRACTICES

•

•

•

•

•

power to carry on a particular business or
trade, to manufacture a particular article,
or to control the sale of the whole supply
of a particular commodity. Monopoly is a
form of market structure in which one or
only a few firms dominate the total sales of
a product or service.
nonprovisional patent application. A
patent that is filed with the PTO includes a
written document that comprises a specifi
cation (including a description and at least
one claim), an oath or declaration, and,
when necessary, one or more drawings.
patent. A grant or right to exclude others
from making, using, selling, or offering to
sell one’s invention and a right to license
others to sell, make, use, or offer to sell that
invention.
plant patent. A patent granted to an in
ventor who has invented or discovered and
asexually reproduced a distinct and new va
riety of plant. (Plant patents are not issued
for tuber-propagated plants or for plants
found in an uncultivated state.) Plant pat
ents are issued for 20 years.
plant variety protection. Protection for
sexually reproduced (by seeds) or tuberpropagated plants. Registration of Plant
Varieties is administered by the U.S.
Department of Agriculture.
provisional patent application. An inex
pensive first patent application that allows
filing without a formal patent claim. It
provides means to establish an early filing
date. Provisional patent applications expire
12 months after filing. Before this, the in
ventor has to file a nonprovisional patent
application in order to protect his or her
invention.

3. TyPES OF PATENTS
There are three types of patents:
1. A design patent protects a new, original,
and ornamental design for an article of
manufacture.
2. A plant patent protects a new and distinct,
asexually reproduced variety of plant.
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Tuber propagated plants are excluded from
plant patents.
3. A utility patent is granted for any new and
useful process, machine, manufacture, or
composition of matter or for any new or
useful improvement thereof. Most impor
tantly, the invention has to be useful. A
utility patent is the type of patent most
people are familiar with. An application for
a utility patent can be of either the provi
sional or nonprovisional type.
.1 Design patents

A design patent protects the look of an article.
In order to be patentable, the design or the look
has to be original. One cannot, for example, get
a design patent for a vase that is in the shape
of Mickey Mouse, as this image is already pat
ented and not original. A design patent might
be granted, however, to a vase having a different
mouse-shape.
A design patent application should include
the following elements:
• title of the design
• brief description of the nature and intend
ed use of the article in which the design is
embodied
• drawings or photographs
• description of the drawings or photographs
• a single claim
• an oath or declaration
A design patent may have only one claim that
covers the whole design. The following shows an
example of a typical claim: “The ornamental de
sign for a vase as shown (and described).”
It is possible to file a utility patent for a new
and original way an article is functioning and also
file a design patent for the original design of the
same article.
.2 Plant patents

A plant patent may be granted on an entire plant
if it is a new and distinct variety and it is asexu
ally propagated. Asexually propagated plants are
those that are reproduced by means other than
from seeds, such as by the rooting of cuttings,
by layering, budding, grafting, or inarching.

However, tuber-propagated plants are excluded
from plant patents.
An application for a plant patent consists of
the following elements:
• title, which must include the name of the
claimed plant. The following shows an ex
ample of the form of a typical title: Birch
tree named “Renci.”
• specification, which includes a description
and one claim
• one or more drawings or photographs
• an oath or declaration
The specification should include a complete
detailed description of the plant. Characteristics
that distinguish the claimed plant from related,
known varieties should be described comprehen
sively. The specification should also include the
origin or parentage of the plant variety and must
point out where and how the variety has been
asexually reproduced. If the plant variety origi
nated as a newly found seedling, the specification
must fully describe the conditions under which
the seedling was found growing.
A plant patent is granted on the entire plant.
Therefore, only one claim is permitted. The fol
lowing is an example of a typical plant patent
claim: “A new and distinct cultivar of a birch tree
named ‘Renci,’ as illustrated and described.”
The drawing must disclose all the distinctive
characteristics of the plant capable of visual rep
resentation. When color is a distinguishing char
acteristic of the new variety, the drawing must be
in color. As an alternative, a photograph may ac
company the application.
If the plant is a newly found plant, the oath
or declaration must also state that the plant was
found in a cultivated area.
. Utility patents

A utility patent can be issued for any new and
useful process, machine, manufacture, or compo
sition of matter. In order to be patentable, the
invention has to be new, useful, and nonobvious.
A patent cannot be obtained for pure ideas or
theories, no matter how useful the theory might
be. In addition to plant patents, utility patents
can be issued for some types of plants, for examHANDBOOK OF BEST PRACTICES | 1
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ple, transgenic plants. This is because a transgenic
plant, if new and useful, may be regarded as a
composition of matter or manufacture.
An application for a utility patent requires
the same elements as are required for a design
patent application.
..1

Nonprovisional application

A nonprovisional (utility) patent application has
to include the following parts:
• title
• specification, which includes a description
and at least one claim
• one or more drawings
• an oath or declaration
The description should be written in such a
way that any person skilled in the field to which
the invention pertains can make and use the
invention.
In a nonprovisional patent application, there
must be at least one claim. The scope of the
protection of the patent is defined based on the
claims. Whether a patent will be granted is also
largely decided by the choice of the claim. The
optimal claim is one that is wide enough to cover
as much as possible without overlapping anything
that was already known.
..2 Provisional application

A provisional patent application is a lower cost,
initial patent application that does not have to
include any claims, oaths, or declarations. A pro
visional patent application has a pendency of 12
months from the date of its filing. A provisional
patent application cannot mature to an issued
patent, but it gives the inventor an early filing
date and use of the term patent pending. In order
to benefit from the early filing date of the pro
visional application, a nonprovisional patent ap
plication has to be filed before the end of the 12
months pendency of the provisional application.

4. PATENT HARMONIzATION
A patent is valid and effective only in the country
in which it is issued. Trade, however, is global, and
thus it is important to have patent protection in
1 | HANDBOOK OF BEST PRACTICES

more than one country. But because every coun
try has its own laws and regulations for patenting,
obtaining protection in multiple locations is rare
ly simple or cheap. To ameliorate this situation, a
great deal of effort has been spent, for more than
100 years, to try to harmonize patentability stan
dards across countries.
The Patent Cooperation Treaty (PCT) is an
international treaty harmonizing patent appli
cation procedures across 117 countries. PCT is
administered by the World Intellectual Property
Organization (WIPO). With one PCT patent
application, an inventor can get a filing date in
all member countries. Eighteen months after the
filing, the applicant has to decide in which of the
member countries he or she actually wants and
needs to have a patent. The benefit of a PCT ap
plication is that there is no need to file separately
in all countries, as the whole procedure can be
accomplished in one application. Moreover, the
PCT system gives the inventor 18 months time to
shop around before deciding in which countries a
patent would be most useful.
All PCT applications will be published 18
months from the filing, if not abandoned be
fore that. This practice is generally in line with,
although not precisely analogous to, that of the
U.S. PTO. In the United States, the inventor may
require a U.S. patent application not to be pub
lished before issuance if the application is filed
only in the United States. Nevertheless, the in
vention may still be the subject of a PCT applica
tion, with similar delay in publication, providing
certain provisions are met. Specifically, pursuant
to Article 64(3)(b) of the PCT, which articulates
the U.S. Reservation, publication can be simi
larly delayed. According to this article, if only
the United States is designated, the international
publication is postponed until after the issuance
of the U.S. patent. Article 64(3)(b) of the PCT is
therefore not inconsistent with the U.S. rule.

5. REGIONAl PATENTS
The creation of regional patent offices has
helped to harmonize patent applications in dif
ferent parts of the world. The European Patent
Office (EPO) is the regional patent office serving
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countries that are members of European Patent
Convention (EPC). By filing a single application
in one of the three official languages of the EPC
(English, French, German), it is possible to ob
tain a patent in any or all of the 24 contracting
countries. European patent applications can also
be extended to some eastern European countries
that are not parties to the contract. If a patent is
granted by the EPO, then that patent must still
be taken to each individual country and validated
there.
Currently, there is major movement toward
developing a community patent for the European
Union. Once issued, a community patent would
be enforced in all E.U.-counties without any vali
dation requirement. Community patents would,
however, require a centralized patent court sys
tem, with specialized courts and a centralized ap
peal court.
Another effort at harmonizing patent ap
plications involves participation by counties of
the former Soviet Union in the Eurasian Patent
Convention. By filing one application in Russian,
a Eurasian patent may be granted in one or all
of the contracting countries. Likewise, African
countries in which English is spoken have estab
lished the African Regional Intellectual Property
Organization (ARIPO); African countries in
which French is spoken have established the
Organisation Africaine de la Propriete Intellectualle,
or OAPI.

6. FEES
The fees charged by the U.S. PTO include filing
fees, publication fees, issuing fees, and mainte
nance fees. Updated information of the fees is
available at the PTO’s Web site.1
Maintenance fees on utility patents must be
paid at 3½, 7½, and 11½ years after the date of
issue of the patent, or it will expire. Once a patent
expires, the invention is in the public domain and
anyone may use it without authorization from the
patent holder.
The PTO gives a 50% reduction in most of
the fees for organizations designated as “small
entities.” Independent inventors, not-for-profit

organizations, universities, and some small busi
nesses will qualify as small entities.

7. APPEAlS, INTERFERENCE, AND
OTHER PROCEDuRES
The applicant can appeal the decision by a pat
ent examiner to reject a patent application. In the
United States, the Board of Appeals within the
PTO hears the cases. If the applicant is dissatis
fied with the decision of the Board of Appeals, he
or she may appeal to the Court of Appeals for the
Federal Court.
A unique form of patent dispute is a prior
ity dispute between two or more inventors claim
ing to be the first to have developed an inven
tion. These disputes are known as interference
proceedings.
Two types of post-issuance procedures are
available in the United States. If someone believes
there is a priority dispute that was not considered
when the patent application was examined, that
individual can ask for a reexamination of the pat
ent. Anyone, including the patentee, can ask for
reexamination. Often times, individuals accused
of infringement use the reexamination procedure
to question the validity of the patent. If the PTO
finds the patent invalid in the reexamination
process, there can be no grounds for claiming
infringement. Reexamination procedures can be
either ex parte or inter partes. In the ex parte reex
amination process, the third party, even if it was
the requester, does not have a right to participate
in the proceeding after filing the request, nor does
the third party have a right to appeal the deci
sion. The inter partes reexamination procedure
was created in 1999 and can be applied only to
patents issued on or after November 1999. Inter
partes reexamination gives the third party a right
to provide comments and present arguments
during the procedure and a right to appeal to the
Patent Office’s Board of Appeals.
The second type of post-issuance procedure is
a reissue. Only the patentee can seek a reissue and
only in the case of an error being made without
deceptive intent, in the claims or in disclosure of
the original application. If the patentee seeks to
broaden the original claims, the reissue has to be
HANDBOOK OF BEST PRACTICES | 1
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filed no later than two years from the issuance of
the patent. However, if the patentee seeks to nar
row the claims, a reissue can be filed at any time.
The PTO charges fees for each of these pro
cedures, with reexamination fees being the high
est. In addition to these fees, attorney fees will
have be paid by the applicant. Attorney fees will
probably be significantly higher than PTO fees.

8. OTHER NONPATENT INTEllECTuAl
PROPERTy ElEMENTS
Intellectual property (IP), sometimes also called
“intangible property,” is any product of the hu
man mind or intellect. Thus, IP can be almost
anything, including a technical invention or an
improvement of an earlier invention. It can also be
a unique name or logo, design, method, software,
database, domain name, or piece of writing.
The broad area of IP is subdivided into dif
ferent legal classes that are protected by different
means. Patents are not the only way to protect
IP. Trademarks, copyrights, and trade secrets are
used as well, and very often they form an impor
tant part of an overall IP strategy.
.1

Trademarks

A trademark is a word, phrase, symbol, design,
or combination of these that distinguishes the
source of one’s goods or services from those of
another. A trademark can be valid only when it is
used on or in connection with goods or services
in commerce. A trademark provides protection to
the owner of the mark by ensuring the exclusive
right to use it to identify goods or services or to
authorize another to use it in return for payment.
Trademark protection keeps others from applying
similar marks to inferior or different products or
services.
Rights to a federally registered trademark can
last indefinitely if the owner continues to use the
mark on, or in connection with, the goods and/or
services stipulated in the registration, as long as
the owner renews the mark with the PTO every
ten years.
There are various types of marks that can be
registered with the PTO. In addition to laying out
the provisions for trademarks and service marks,
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the Trademark Act provides for registration of
collective marks, membership marks, and certi
fication marks. A domain name, such as yahoo.
com, can qualify as a trademark or service mark if
it is used in connection with a Web site that offers
goods or services to the public.
The basis for filing a trademark can be either
actual use or intent to use. If the applicant files a
trademark based on intent to use, she or he has
to swear to a bona fide intent to use the mark
in connection with the proposed products or ser
vices. If the mark is not actually used within 30
months of registering the mark, the registration,
as related to that specific class,2 would be consid
ered abandoned.
.2 Geographical indications

A geographical indication is a sign used on goods
that have a specific geographical origin and pos
sess qualities or a reputation that rely on that place
of origin. Geographical indications are defined in
the TRIPS Agreement (Trade-Related Aspects of
Intellectual Property Rights) as a type of IP. The
World Trade Organization (WTO) provides legal
means for interested parties to prevent the use of
a geographical indication that indicates or sug
gests that a good originates in a geographical area
other than its true place of origin. Geographical
indications cannot mislead the public as to the
true geographical origin of the good, nor can they
constitute an act of unfair competition.
Most commonly, a geographical indication
includes the name of the place of origin of the
good. Agricultural products typically have quali
ties that derive from their place of production
and are influenced by specific local factors, such
as climate and soil. Examples of geographical in
dications are Idaho for potatoes or Roquefort for a
type of French cheese.
Whether a sign functions as a geographical
indication is a matter of national law and con
sumer perception. The TRIPS Agreement does
not require that a WTO member extend protec
tion to a geographical indication if that geograph
ical indication is the generic name of the good in
that member country. Therefore, the word “cham
pagne” is not registrable as a geographical indica
tion in the United States because champagne is
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a generic term in the United States meaning any
light-colored wine with bubbles.
The United States offers robust protection
for geographical indications, generally by regis
tering the good with a certification mark, which
is a type of trademark.
. Trade secrets

Trade secrets are an important and widely used
business asset in the United States. Both large and
small businesses rely on trade secret protection,
often without even realizing it. It has been esti
mated that 90% of inventions are protected by
trade secrets.
There are various kinds of trade secrets. The
most famous example of a trade secret is the
formula of Coca Cola, which has been kept se
cret for over 100 years. In addition to chemical
formulas or processing methods, trade secrets
can consist of software, accounting records, cus
tomer lists, and plant designs, among others.
Although trade secrets may overlap with patent
able subject matter, they go well beyond that.
Even failed experiments can qualify as trade se
crets; knowledge that a method does not work,
in some cases, can give an individual or business
a huge competitive edge.
The generally accepted definition of a trade
secret appears in the 1939 Restatement of Torts.
The subject matter of a trade secret must be secret;
as such, matters of public or general knowledge in
an industry cannot be appropriated by anyone as
a secret. Information that is completely disclosed
by the goods that one markets cannot be consid
ered a trade secret. By definition, a trade secret is
known only to those in the particular business in
which it is used.
. Copyrights

A copyright is a type of IP protection for authors
of original works. A copyright protects an original
work and allows the author an exclusive right to:
• reproduce the work exclusively
• prepare derivative works
• distribute copies or records by sale, lease, or
other type of ownership transfer
• perform the work publicly
• display the work

In the Copyright Act there is, however, a
fair-use exception that states that the use of an
author’s original creation is authorized for the
purposes of criticism, comment, news reporting,
teaching, scholarship, or research. Fair use takes
into consideration the purpose and character of
the use, the nature of the copyrighted work, the
amount and substance of the portion used in re
lation to copyrighted work as a whole, and the
effect of the use upon the potential market.
Generally the categories of works that are
protected are:
• literary works
• musical works, including words accompa
nying music
• dramatic works
• pantomimes and choreographic works
• pictorial graphic and sculptural works
• motion pictures and other audiovisual
works
• sound recordings
• architectural works
The work has to be original and in a fixed
medium. This means that the work has to be an
independent creation of the author and it must
exhibit some creativity. Being in a fixed medium
means that the creation is in a tangible form: A
short story is written down, a song is recorded,
and so on. A pure idea or concept cannot be
copyrighted without description or illustration.

9. ASSEMBlING A STRATEGy
The development of a coherent IP strategy in
volves an analysis of three types of IP: self-de
veloped, incoming, and outgoing. In order to
develop a strategy to manage IP, an organization
generally conducts a freedom-to-operate study
or IP audit. Such an analysis inspects all patents,
trademarks, copyrights, contracts, material trans
fer agreements, know-how, and anything else
that could be part of the intellectual capital of an
organization.
The first step in developing an IP strategy
is to document the technologies that already
exist in the organization, plus the technologies
in development. The existing technology could
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consist of trade secrets, know-how, patents, or
combinations thereof. The most critical elements
of the technologies are placed in a database. The
database could, for example, contain the follow
ing elements: issued patents, filing and expira
tion dates of the patents, abstracts of technolo
gies, first claims of patents, current and future
potential of IP, existence of licenses, and so on.
Each project of the company can be similarly
documented. Data of issued and applied patents
in each project should be documented; valuable
trade secret and contracts should likewise be
documented.
When all the IP is documented in a database,
consideration should be given to the merits of the
documented technologies. Questions to be asked
are, for example:
• What stage is the technology in?
• What is the novelty of the technology?
• Is the technology in use?
• Are outside licenses needed to develop the
technology further?
• Does a competitive technology exist?
• Is the technology commercially launched?
• Are capital requirements needed to launch
the technology?
• Are there environmental or regulatory is
sues related to the technology?
Depending on the organization, the answers
to the above questions will have varying impor
tance. For example, a university technology trans
fer office might not care too much if the stage of
the technology is at a pilot level or whether the
patent has been issued. For an organization bas
ing its business on in-house developed technol
ogy, however, these issues are crucial.
Patenting is expensive. Therefore, it is impor
tant, especially for a small organization, to criti
cally assess which technologies it needs to patent
and where. Even if an invention is patentable, it
might not always be the best solution to patent it.
If, for example, an invention is difficult to reverse
engineer, or if it would be easy to invent around a
patented technology, then keeping the invention
as a trade secret might be more beneficial. Also,
patenting might not be an effective tool if it would
be difficult to ensure that no one is infringing on
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the patent. If an organization developed a patent
able method for transforming a plant species, for
example, it would be very difficult to ensure that
no one was infringing on that method, and thus
patenting would be largely ineffective.
The organization should also analyze where
it will need the protection. There might not be a
need to keep a patent valid all over the world if
the technology is used only in the United States,
or if the only prospective market is in Germany.
In these cases, it would be advisable to apply for
patents only in the relevant countries.
It is also important to get accurate knowl
edge of the IP rights of competitors in your field.
Knowing the IP rights of other organizations in
your field will help you identify where your or
ganization has a distinct competitive advantage,
and will enable you to identify and eliminate
costs of any out-of-date IP. By knowing your
own IP, you can identify under-utilized IP that
could potentially be sold or licensed out; know
ing other people’s IP could help you to avoid
costly infringements suits. Finally, knowing your
IP gives you a road map to create a successful
R&D strategy.
Finally, an organization can choose an offen
sive or a defensive patent strategy. This depends
a great deal on the size of the company, but also
on the demands of the particular industry within
which the company operates.
.1

Offensive patent strategy

An offensive patent strategy is designed to build
barriers to block competitors from gaining entry
to your proprietary technologies. Using an offen
sive patent strategy means filing patents as soon
as is practicably possible. Filing a large number
of patent applications and later maintaining the
issued patents is expensive; on the other hand, an
offensive patent strategy may derive large licens
ing incomes.
Given the expense, an offensive patent strat
egy is often available only to large organizations,
since small companies generally cannot afford the
costs of filing and maintaining patents. Beyond
size, an offensive patent strategy is more impor
tant for companies operating in very competitive
fields.
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.2 Defensive patent strategy

Using a defensive patent strategy, a company files
patents primarily to ensure that innovations can
be practically used. With a defensive strategy, fil
ing and maintenance fees will be small, but the
company will not gain royalties from licensing
patents out.
In addition to these two strategies (offensive
and defensive) an organization can adopt some
thing in between, depending on the field and the
type of the technology it uses. A defensive patent
strategy can be combined with a strong tradesecret portfolio, or a large number of in-licensed
technologies. An offensive patent strategy can be
used to demonstrate innovations to industries
and markets.
. Public and private sector strategies
compared

The public and private sectors by and large have
different missions, objectives, and motivations.
These, in turn, drive the overall patent strategies
that each employs.
Private sector organizations, primarily cor
porations, are profit oriented and must aggres
sively respond to the pressures imposed by the
marketplace and shareholders who expect returns
on their investments. Therefore, the private sector
will use defensive and offensive patenting strate
gies, often obtaining numerous patents contain
ing narrowly drafted claims. In this way, a series of
painstakingly prosecuted patent portfolios is stra
tegically used to build proprietary fortifications.
The private sector organization can thereby stake
out its territory, protect its interests, and secure
its profits. In the expanding world marketplace,
this strategy is becoming more and more com
mon; the use of foreign filing and patent families
confirms the global strategic perspective of multi
national companies.
The public sector, on the other hand, has
the very different mission of serving the greater
public good. Additionally, for much of the pub
lic sector, the perspective is primarily local: either
national, or possibly regional. Patenting strategies
will focus on more broadly drafted claims that
will encompass a technology, or, more often, a
key process, method, or technique (for example, a

technique of genetic transformation). These types
of patents, when strategically licensed, will en
able effective development, broad dissemination,
and maximum social usefulness of a technological
advance. This is precisely in line with the public
sector mission of providing for humanitarian in
terests and the welfare of the general public, in
contrast to the much more limited mission of the
private sector.

10. THE IP FORTRESS
Building a strong base for IP protection will make
it difficult for other people and companies to in
fringe upon protected rights. One way to secure
IP protection is to cover IP with various types of
IP rights.
Imagine that the IP of a particular U.S.
company is a novel paintbrush. The company
can obtain a utility patent in the United States
covering the novel paintbrush. If the company
has business in Europe, it might be wise to file
a PCT as well. It might be beneficial to write a
claim, also, for painting with the paintbrush. By
doing so, the company would ensure that both
people manufacturing the brush, and each small
or large painting using the brush, would be guilty
of infringement if they were not first granted a li
cense to use the brush in any manner they saw fit.
When the company holding the patent improves
the tool, it can always file a new patent covering
the improvement (continuation-in-part applica
tion). Additionally, the design of the paintbrush
might be protected by a design patent. Finally,
the company might have a unique name for the
tool that could be trademarked.
Building such a fortress around the invention
makes it difficult for others to use the invention
without getting a license. Depending on the pol
icy of the organization and the type of the inven
tion, the organization can then grant either exclu
sive or nonexclusive licenses to use the product.
There are several ways to protect IP, but one
should always remember that protecting IP is ex
pensive. Therefore, an organization needs to think
carefully about its competitors, likely infringers,
and the geographical area where the invention is to
be marketed. Sometimes keeping an invention as a
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trade secret might be the cheapest way to protect
it. Sometimes patenting, even if more expensive,
might give better protection. Finding the best way
to build and protect an IP portfolio requires imagi
nation, in addition to a thorough knowledge of the
company and its product lines.

11. SuMMARy AND CONCluSIONS
A comprehensive IP portfolio can be of substan
tial value to both private and public sector enti
ties. For both sectors, patents are a key element of
an IP portfolio. Large companies can afford an of
fensive patent strategy, but small companies may
not have recourses for this. Therefore, especially
for small- and middle-sized companies, planning
and lateral thinking about how to put in place
an effective and cost efficient strategy is extremely
important. IP can be protected through patents,
trademarks, copyrights, and trade secrets. The
costs of maintaining each of these IP categories
are different. A company can reduce costs by lim
iting patent protection to those geographic areas
where it has business. But even when a company
wishes to reduce costs as much as possible, im
portant technologies need to be protected prop
erly. A strong protection may be built by using
several forms of IP for the same invention or im
provement.3 n
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CHAPTER 10.5

Cost-Conscious Strategies for Patent Application Filings
oRen livne, Associate Director, Licensing, Office of Technology & Industry Alliances,

University of California, Santa Barbara, U.S.A.

ABSTRACT

Timing and cost are two key factors involved in patentfiling decisions. This chapter explores mechanisms for de
laying the high costs of filing a patent application as long
as possible, so that additional information on an inven
tion and evidence of its worthiness can be gathered. The
efforts to minimize up-front costs are balanced against the
potential need to secure viable patent rights at some point
in the future. This chapter begins by walking through the
stages of the publication process—from prior to submis
sion, to after publication—and suggests cost-conscious
patent-filing strategies that are possible at each stage. The
focus is on delaying significant costs until the value of
the invention is more certain. The chapter concludes with
additional points to consider when making patent-filing
decisions.

1. InTRoduCTIon
With university inventions, research is often early
stage and an invention’s worthiness can be uncer
tain from both a scientific and market perspec
tive. At the same time there is a drive to publish
that forces early patenting decisions. Companies
have some extra leeway with respect to delaying
publication, but are pushed by competitors and
a need to demonstrate technical capabilities and,
as a result, often face patenting decisions well in
advance of a clearly defined product line. Both
universities and companies must therefore make
decisions on inventions that represent only pos
sibilities—an invention that might end up in a

product, an invention for which additional re
search may demonstrate some significant result, or
an invention that may be licensed in the future.1
The cost-minimizing approach recommended in
this chapter is intended for such inventions with
questionable or uncertain value. The approach is
not recommend for a blockbuster drug or an in
vention that represents the core of a company’s
products.

2. dECISIonS, dECISIonS
2.1 No publications planned

When the inventors plan no publications and
there are no other reasons (such as concerns over
competing groups) to secure a priority date, a
company or university can enjoy the luxury of
time. There is no need to do anything on the pat
ent side so long as the invention will not be sup
pressed, concealed, or abandoned. Technical re
search and market evaluation may continue until
the invention’s value is determined. Then a patent
application may be filed, if appropriate.
2.2 Publication planned for a future date

If there is significant time before publication sub
mission, technical research and market evalua
tion may continue in the hopes that additional
information will be gathered that can support

Livne O. 2007. Cost-Conscious Strategies for Patent Application Filings. In Intellectual Property Management in Health and
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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the patent filing decision. Often publication sub
missions are delayed, providing additional time
for evaluation. When submission becomes more
definite, the steps in the following section may be
followed.
2. Publication submission

Submission of a publication is not necessarily a
dire situation. Not all submissions are considered
publications. Usually submissions will be main
tained in confidence until the publication date (it
is advisable to note “CONFIDENTIAL” on the
manuscript). If that is the case, several additional
months are gained for technical research and mar
ket evaluation (again, assuming there are no other
reasons to secure an earlier priority date). If the
submission will not be maintained in confidence
and is considered a publication, then a patent ap
plication may need to be filed prior to submission
(see section 2.4).
2. Publication imminent

When publication is imminent, an application
needs to be filed only if foreign (non-U.S.) patent
rights are desired. If foreign patent rights are not
desired, the U.S. patent-application filing does
not need to occur until a year after publication.
In this case, the steps in section 2.5 “Publication”
can be followed (assuming there are no other rea
sons to secure an earlier priority date).
If foreign patent rights are desired, an ap
plication must be filed prior to publication (only
a few countries in addition to the United States
have grace periods).2 Figure 1 details the steps
that may be taken (see the left-hand “YES” side
of the Figure).
There are two main options to choose from.
A U.S. provisional application can be filed.
Alternatively, if the invention’s value is more cer
tain or it has the potential to generate significant
revenues, a nonprovisional U.S. application can
be filed. By avoiding the provisional stage for
more certain inventions, the total patenting cost
can be reduced.
2..1 Nonprovisional U.S. application

If the nonprovisional application filing route is tak
en,3 attorney costs can be reduced by providing a
22 | HANDBOOK OF BEST PRACTICES

single cohesive document containing all data and
information relating to the invention. If possible,
this document can be drafted by the inventors
and then reviewed by the invention manager. The
invention manager can discuss the description
with the inventors and work to add any missing
information, alternative methods, compositions
or devices, and additional breadth to the descrip
tion. The attorney will then have a more-solid
starting point from which to draft the applica
tion. Depending on the nature of the invention,
costs may be kept below US$10,000.4
Once the nonprovisional U.S. application is
filed, there is one year during which foreign rights
can still be pursued (assuming no prior publica
tion has taken place). If foreign patent rights are
no longer desired, no action needs to be taken. If
foreign rights are still desired, one of the two fol
lowing filing approaches can be employed prior
to one year from the initial filing:
1. File a Patent Cooperation Treaty (PCT)
application claiming all or specific na
tions. Filing a PCT application provides
30 months from the earliest priority date
(filing date of the nonprovisional applica
tion) before which national-stage patent fil
ings need to occur. Most countries are now
members of the PCT (with the Republic of
China [Chinese Taipei] one notable excep
tion), so the PCT application is a valuable
interim step for maintaining worldwide
patent protection.
The PCT route will reduce initial costs
significantly, but total costs will be higher
(by the amount of the PCT filing). If the
specific countries or regions of interest
are not yet known, this is a good route
to take (the PCT filing may designate all
member nations). Since the U.S. applica
tion was already drafted, PCT costs will
be limited to governmental fees, and a
small amount for attorney time (currently
a total of less than US$4,000 for all na
tions). The U.S. Patent and Trademark
Office (PTO) and the World Intellectual
Property Organization (WIPO) have ex
tensive Web sites with helpful information
on PCT filings.5

File one:
1. PCT application
2. Full U.S. and PCT applications
3. specific-country application

yES

Prior to 1 year
from filing: are foreign
still desired?

File provisional.

NO

Will a full U.S.
application definitely
be filed?

yES

Must file application
prior to publication.

yES

Are foreign patent
rights potentially
desired?

NO

NO

File full U.S. application.

yES

Is priority of
provisional needed?

yES

Is U.S. filing
still desired?

File PCT or file in
specific countries.

yES

Prior to 1 yr from
filing: are foreign still
desired?

File full U.S.
application.

NO

NO

NO

Refile provisional.

Abandon provisional.

No action needed.

NO

File full U.S. application.

yES

Prior to 1 yr from
2nd filing: is U.S. still
desired?

Abandon provisional.

NO

Is full U.S. filing
still desired?

Will a full U.S.
application definitely
be filed?

yES

Prior to 1 yr from
Publication: is a patent
still desired?

Have until 1 yr from
publication to file.

NO

yES

File provisional.

yES

NO

Abandon provisional.

File full U.S. application.

File full U.S. application.

No action needed.

Figure 1: Decision Chart for a low-Cost Patent-Filing Approach with Invention Details about to be Published
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2. File national-phase applications in spe
cific countries or regions of interest. If the
desired countries or regions of interest are
already known, patent applications may be
filed directly in those countries. The cost
per country is significant, including transla
tion costs, governmental fees, and attorney
time. This route is typically reserved for in
ventions whose potential has already been
demonstrated or whose value, if proven,
will be very significant.
2..2 Provisional patent applications

If the provisional-application filing route is taken,
attorney costs can be reduced also by providing a
single cohesive document containing all data and
information relating to the invention. Like the
nonprovisional application discussed above, this
can be drafted by the inventors and then reviewed
by the invention manager. The invention man
ager can discuss the description with the inven
tors and work to add any missing information,
alternative approaches, and additional breadth to
the description.
This description can then be filed “as is,” with
out claims, at minimal cost (roughly US$300,
including attorney time) or, with some sample
claims, for a little more. This is a somewhat risky
approach, as the attorney will not have reviewed
the description to ensure that it provides the in
formation necessary to support desired claims. If
it is very uncertain whether or not foreign rights
are desired and the added provisional year is likely
to provide that information, this may be an ap
propriate approach. If foreign rights are very like
ly of interest or the invention has strong potential
in foreign markets, it may be preferable to pro
vide the attorney with the single reviewed docu
ment and ask that an additional review be con
ducted and claims added (a total cost of roughly
US$1,500–US$2,500, depending on the nature
of the invention).
2..2.1

Foreign rights desired

Once the provisional U.S. application is filed,
there is one year during which foreign rights
can still be pursued. If foreign rights are de
sired, one of the three following approaches can
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be employed up until one year after the initial
filing:
1. File a PCT application claiming all or
specific nations. Filing a PCT application
provides 30 months from the priority date
(filing date of the provisional application)
before which national-stage patent filings
need to occur. Most countries are now
members of the PCT (with the Republic
of China one notable exception) so the
PCT application is a valuable interim
step for maintaining worldwide patent
protection.
The PCT route provides the lowest up
front costs, but total costs will be higher
than the combined costs of filings directly
in a few specific countries or regions of in
terest. If the specific countries or regions of
interest are not yet known, a PCT filing is
a good route to take (it may designate all
member nations). The cost of converting
a previously filed provisional application
into a full PCT filing can vary significantly
depending on how strong the provisional
filing was and whether any new informa
tion needs to be incorporated (depending
on the nature of the invention, costs may
be kept below US$10,000)
2. File a PCT application claiming all or spe
cific nations and file a separate nonprovi
sional U.S. application. Filing a U.S. patent
application in addition to the PCT at this
stage has certain benefits. The U.S. patent
application will likely issue sooner. Also, it
is possible that the PTO will issue an of
fice action in time to help with the decision
on whether or not to go national-phase in
other countries. There will be added costs
for filing the additional U.S. application,
primarily in the form of government fees
(roughly US$1,500 to US$2,500 for the
filing fee, plus minimal attorney time). If
an office action is issued on the U.S. ap
plication, there will be additional costs for
drafting and filing the response (roughly
US$3,000, depending on the nature of the
office action).
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3. File applications in specific countries. If
the desired countries or regions of interest
are already known, patent applications may
be filed directly in those countries. The cost
per country is significant, including trans
lation costs, government fees, and attorney
time. This route is typically reserved for in
ventions whose potential has already been
demonstrated or whose value, if proven,
will be very significant.
2..2.2 Foreign rights not desired

If foreign rights are not desired but U.S. rights
still are, a full U.S. application must be filed with
in one year of the provisional U.S. filing if the
priority date of the provisional is needed.
If priority to the provisional is not needed
(for example, if there are no concerns about com
peting groups), then a full U.S. application does
not need to be filed. The provisional application
can be refiled within one year of the earliest pub
lication—the cost would be minimal since all the
paper work would already be in place (roughly
US$300 if an attorney is used). Using this strat
egy, a company or university would have a year
to decide if foreign patent rights were worthwhile
(the first provisional) and an additional year to
see if a full U.S. patent is desired (the second pro
visional). If a full U.S. patent is desired, the ap
plication must be filed within one year from the
filing of the second provisional application.
2. Publication

If enabling details of the invention have already
been published, then non-U.S. rights are gener
ally not attainable.6 The right hand, “NO,” side
of Figure 1 outlines the steps that may be taken
in such cases. A U.S. patent application does not
need to be filed until one year from the publi
cation. During this time additional research and
market analysis can occur.
If, toward the end of the one-year time pe
riod, the invention’s value becomes more certain,
a nonprovisional U.S. patent application may be
filed.
If the value of the invention is still uncertain
but it continues to have potential, a provisional

U.S. application may be filed, providing an ad
ditional year for evaluation. Filing a provisional
application would raise the total costs somewhat,
but can dramatically reduce the initial costs. If
the evaluation proved positive and a U.S. patent
is desired, a nonprovisional application must be
filed by one year from the provisional filing date.

. ConCLuSIonS
This chapter offers ideas for delaying the upfront
cost of patent filings in a manner that allows pat
ent rights to be secured in the future. Below are
some important points to consider when employ
ing these strategies:
• Before applying the strategies described in
this paper, please consult with an attorney
to confirm they are appropriate for your
specific circumstances.
• There are risks associated with delaying
a patent filing. There may be prior art of
which you were unaware. Sometimes a
paper will be published online prior to
print, or a journal will be mailed before
its cover date, or conference proceedings
sent to attendees prior to the conference.
Other groups may publish before you have
a chance to file. Foreign countries (and pos
sibly soon, the United States) have a first
to-file system, so delay may result in other
groups securing patent rights before you
have an opportunity to do so.
• Consider what information will be gained
before the next patenting-decision point.
If, for example, it will take three years of
research to confirm whether an invention
is viable, filing a provisional application is
not likely to be worthwhile: going straight
to a nonprovisional filing will reduce the
total costs. On the other hand, if only six
months are needed to confirm the value
of an invention, a provisional application
might be preferable.
• Delaying filings through provisional appli
cations and the other approaches discussed
in this paper makes sense only if some ap
plications are abandoned at future decision
points. The main benefit of the delay is that
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it allows additional time for research and
market evaluation so the strong inventions
can be separated from the weak. If a patent
filing is definitely going to occur, adding
the provisional application will increase the
total costs.
• Evaluate whether or not foreign (non-U.S.)
patent rights are truly desired. Significant
flexibility is gained if foreign patent rights
are not needed.
• Remember, attorney costs can be reduced
by providing a single cohesive document
containing all data and information relating
to the invention, enhanced by the inven
tion manager who could add any missing
information, alternative methods, compo
sitions or devices, and additional breadth to
the description. n
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ABSTRACT

When approaching the international production, mar
keting, distribution, and sales of a patented product or
process, several key factors must be carefully identified
and evaluated. These factors include business and legal is
sues. Business issues include market location, market size,
presence (or absence) of competitors, emerging markets
as opportunities, life cycle of the product, and taxes. Legal
issues include the presence (or absence) of trade secrets in
the patent application, the status of patent applications
in foreign countries, the level of patent protection (both
law and enforcement) in foreign countries, and statutes,
such as novelty requirements, in prospective foreign mar
kets. Having considered a full range of business and legal
factors, options for international patent protection can
then be evaluated and appropriately selected, according
to the business goals and financial resources of the orga
nization. Options include national, regional, and interna
tional patent applications, each having its own advantages
and disadvantages. This overall strategy can be effectively
employed to maximize either business or humanitarian
objectives.

1. BASICS of InTERnATIonAL
fILInG STRATEGIES
You have a researcher who has developed an excit
ing invention, and you have already decided to
file a patent application in the United States. Now
you need to decide if you should also file patent
applications abroad, and if so, where. The cost of

filing patent applications in every country in the
world can add up quickly, as there are about 200
countries where some degree of patent rights are
available. Therefore, you will need to be selective
as to where you will file patent applications.
Many factors need to be considered when de
ciding where to file foreign patent applications.
Some factors relate to the business development
or marketing of the invention, and other factors
relate to the legal status of the invention. For ex
ample, will the invention be considered “novel”
in the countries where you want to file? Do the
countries permit patenting the type of technol
ogy your inventor has developed? Some countries
do not offer patent protection for computer soft
ware, for instance. Another factor to consider is
whether you will be able to enforce your patent
once you receive it. The degree of judicial respect
that patents are given in different countries varies
considerably. Some countries have laws that al
low a party to obtain a patent but have almost no
enforcement mechanisms. International treaties
such as the North American Free Trade Agreement
(NAFTA) and the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS)
should help to make enforcement easier and rem
edies for infringement more adequate.

Viksnins AS and AM McCrackin. 2007. A Guide to International Patent Protection. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM
Technology Transfer Practice Manual Second Edition (Part IV: Chapter 2.2).
© 2007. AS Viksnins and AM McCrackin. Sharing the Art of IP Management: Photocopying and distribution through the
Internet for noncommercial purposes is permitted and encouraged.
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Specifically, here are some of the business and
legal questions to consider when planning a foreign patent filing strategy:
• How big is the market for your inven
tion in a particular country? If the market
for the invention is a relatively small one,
it may not be worth the expense of filing
an application in that particular country.
A benchmark that some companies use is
US$5 million in revenue per year for the
invention.
• How big is the market for your invention
in a particular region? Many inventions are
region-specific. For example, if your inven
tion is a transgenic blueberry plant, you
likely do not need to consider filing in the
region of Equatorial Africa, since blueberry
plants do not grow there. Also, it may be
that a patented product has a major market
in a handful of countries and only a minor amount of interest elsewhere. Further,
covering the major markets may provide an
advantage in economies of scale. If most
of your potential customers are in coun
tries where you have patent protection,
you may have such strong manufacturing
and cost advantages that you do not need
to have patent coverage in less-important
countries.
• Where are the major manufacturing cen
ters for you and for your competitors?
Certain regions of the world are centers
of manufacturing for different industries.
For example, the Far East economies of
Singapore, Hong Kong, Korea, Indonesia,
Thailand, the Republic of China, China
(People’s Republic of China), and Japan are
important manufacturing countries for the
computer and semiconductor industries.
• Where are the emerging markets?
Developing countries may be strengthening
their patent laws and therefore make patents
more valuable in the near future. For ex
ample, China has recently revised its patent
laws and should be considered for certain
inventions. There are still many problems in
enforcing patents in China, but in the long
run, the size of the market could make up
2 | HANDBOOK OF BEST PRACTICES
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for the short-term difficulties. As another
example, Vietnam’s recent accession to the
World Trade Organization (WTO) will ne
cessitate tangible progress towards TRIPS
provisions implementation.1 An important
aspect of this will be strengthening patent
laws and their enforcement.
Would a defensive patent be valuable? It
can be worthwhile filing in a particular
country, even if a market is small, if you
know that a major competitor is doing
business or has a manufacturing plant in
that country. You can possibly get the com
petitor to license the new technology from
you or at least prevent the competitor from
commercializing your invention in that
country.
Do you have limited time? Some technolo
gies only have a life span of a few years, and
you can expect to get income from licens
ing fees only in the early years of a patent.
Other technologies are in development for
a long period of time and are only economi
cally valuable in the last years of the patent.
It can take ten years to get a Japanese patent
application issued. Even though you might
be able to successfully sue an infringer and
get retroactive royalties back to your filing
date, by then the competitor will already be
in the market. Also, you often cannot get
a restraining order to make the competitor
stop infringing until after the patent has actually issued.
Do you have limited funds to spend on
foreign patent protection? It may be more
worthwhile to carefully pick just a few
countries and spend all your money on
getting well-prosecuted, broad patents in
those countries rather than getting nar
row patents in a lot of countries. Another
strategy would be to concentrate all your
efforts on the key features of your technol
ogy that competitors will need in order to
be competitive.
What is the status of a patent application
in the foreign country of interest? In some
countries, such as Japan, published applica
tions are respected almost as though they

CHAPTER 10.

•

•

•

•

were already-issued patents and can provide
licensing opportunities. This local custom
can make an unissued patent application
valuable even if the national patent office
has a reputation for letting patent applica
tions pend for a long time.
Would your invention be considered novel
in your country of interest? Most countries
require that an invention be undisclosed, or
novel, as of the effective filing date of the ap
plication. Novelty requirements vary con
siderably from country to country. Some
countries require absolute novelty (which, in
practical terms, means that a patent appli
cation must be filed before any public dis
closure), while other countries give inven
tors or applicants grace periods, following
disclosure, for filing patent applications.
Where are your competitors filing their
patent applications? Place of filing can
be indicative of future business plans. You
may want to file in the same countries your
competitors are filing in, even if you do not
initially plan to manufacture or sell your
invention in those countries.
Are there trade secrets in your applica
tion? Most foreign applications (and most
U.S. patent applications filed on or after 29
November 2000) are published about 18
months after their priority date. The inven
tion may be of more value when kept as a
trade secret for a potentially unlimited time
than when disclosed in a patent, which has
a limited life span.
Can holders of patent rights realize tax ad
vantages in foreign countries? Patents can be
bundled with a technology transfer license to
transfer the situs of taxation, allowing expa
triation of funds with less tax impact.

2. opTIonS foR fILInG InTERnATIonAL
pATEnT AppLICATIonS
2.1 Overview

Once a decision has been made to file a patent ap
plication, there are three choices for filing in a for
eign country: (1) file directly in the patent office

of the country of interest, (2) file in a regional
patent office, or (3) file using the procedures set
forth in the Patent Cooperation Treaty (PCT).2
These filing options are discussed below. Unlike
in the United States, applications in most other
countries are filed in the name of the assignee(s),
not the inventor(s).
2.1.1

National applications

Prior to 1 June 1978, directly filing a patent ap
plication in a foreign country’s patent office was
the primary way to obtain foreign patent protec
tion. Applicants often would rely on the rights
granted under the Paris Union Convention (that
is, for member nations of the Paris Convention)
for a right of priority.3 This right of priority al
lows a resident of a country that is a member of
the Paris Convention to first file a patent applica
tion in any member country, and then, within 12
months of the original filing date, to file patent
applications for the same invention in any of the
other member countries. By treaty, the later ap
plications receive effective filing dates that are the
same as the original filing date. In other words,
they would be treated as though they had been
filed on the same day as the first application,
so long as they were filed within the 12-month
period.
Applicants who file a subsequent applica
tion in a country that is a member of the Paris
Convention will not be given the priority of
their original application. If possible, applicants
should consider filing any applications in non
member countries on the same day as their first
Paris Convention application.
It should be noted that even though the
Republic of China is not a member of the Paris
Convention, patent applications filed in the
United States may have priority over applica
tions filed in the Republic of China because of
a bilateral agreement between the two countries
(effective 10 April 1996). The priority period is
12 months for inventions and new utility model
applications; the period is six months for new de
sign applications. Various requirements must be
met in order for priority to be granted. For ex
ample, priority must be claimed on the filing date
of the application filed in the Republic of China,
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the applicant of that country’s application must
be the same as the applicant on the U.S. applica
tion, and the invention disclosed in the Republic
of China application must be the same as that of
the corresponding U.S. application.
A major disadvantage of filing directly in
individual countries is that such a strategy can
be very expensive, as applicants must pay the
individual national government filing fees, pat
ent attorney fees, foreign associate fees, and
potential translation costs early in the patent
program.
2.1.2

Regional applications

A potential alternative to filing directly in each
country of interest is to file in a regional patent
office. These patent offices have come into exis
tence through international treaties. Examples of
regional patent offices are the European Patent
Office (EPO),4 the African Regional Industrial
Property Organization (ARIPO),5 the African
Intellectual Property Organization (OAPI),6 and
the Eurasian Patent Convention (EA).7
Often, the EPO is the most commercially im
portant of the regional patent offices, so its proce
dures will be discussed in more detail. Use of the
EPO allows for a uniform procedural system for
filing a patent application in member European
countries. The cost of filing a patent application
in the EPO is about US$10,000. This figure
includes the EPO filing fees, the U.S. attorney
fees, and the fees charged by the EPO associate.
The EPO does not allow U.S. patent attorneys
to communicate directly with it, so a European
patent attorney, or agent qualified to practice in
the EPO, must be hired for certain aspects of the
filing and prosecution process.
The application is reviewed by an EPO exam
iner based on the investigation of the prior art in
light of the claims. The examiner must consider
a PCT Chapter II examination report, if appli
cable. (The PCT procedure is discussed in further
detail below). The EPO issues an official action
statement. The U.S. patent attorneys respond to
the official action through their European asso
ciates. After successful examination, the applica
tion is granted as a European patent. It should
be noted that interim protection can be available
0 | HANDBOOK OF BEST PRACTICES

during pendency by filing a translation of claims
in each designated country.
An applicant, however, does not gain any en
forceable patent rights until the European patent
is registered, or “validated,” in each of the coun
tries in which protection is sought. Registration
can be expensive because in addition to govern
ment issue fees and translation fees, further fees
for the European associate and local agents in
each country will be incurred. Once the European
patent is validated, annual maintenance fees, or
annuities, will be due periodically in each of the
countries. Maintenance fees vary considerably
from country to country. For example, annui
ties in the United Kingdom and France can total
about US$7,000, whereas in Germany they can
total about US$18,000, over the life of the pat
ent. Of course, these are estimates and are subject
to change.
2.1.

PCT applications

The Patent Cooperation Treaty (PCT) is an in
ternational agreement that provides a unified and
simplified procedure for filing multiple foreign
patent applications via a single initial applica
tion. Most industrialized countries are members
of the PCT, including many countries that are
also members of different regional patent offices.
Please note that this list is constantly changing
as new countries join the PCT. All PCT mem
ber countries are bound by the Paris Convention;
however, not all Paris Convention member states
are PCT member countries.8 If you have ques
tions as to whether certain countries are PCT
member countries, you may check the most re
cent PCT newsletter, on the Web, or contact the
PCT Help Desk.9
PCT Rule 4.10 enables applicants to claim
priority of an earlier-filed application in, or for, a
member country of the WTO10 that is not party
to the Paris Convention.
The procedures set forth in the PCT allow
applicants to obtain and/or preserve the prior
ity date of the first-filed application in any of the
PCT member countries, including the United
States. An applicant files a copy of the applica
tion in a PCT office and pays the PCT filing fee.
This filing of the patent application may be the
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first time it has been filed anywhere, or it can be
an application that claims priority over an earlierfiled application, so long as it is filed within 12
months of the initial filing date.
Along with a copy of the application, the
applicant files a PCT request. When the request
is filed, the presumption is that the applicant
would like to designate all available countries or
regional offices, thereby reserving the right to, at a
later time, file national (or regional) applications
claiming priority to the first-filed application. In
Box No. V of the PCT request form, it is stated
that “The filing of this request constitutes, under
Rule 4.9(a), the designation of all Contracting
States [emphasis added] bound by the PCT on the
international filing date, for the grant of every kind
of protection available, and, where applicable, for
the grant of both regional and national patents.” In
other words, priority to the first-filed application
is automatic and all-inclusive, with all possible
designations. The PCT request form, however,
provides for the “de-designation” of Germany,
Korea, Russia, and Japan (for example, if applica
tions have already been filed in these countries).
It is critical to keep in mind that if patent protec
tion is desired in a non-PCT country, an appli
cant must file directly in that country.
When filing an international application that
relies on the Paris Convention one-year grace pe
riod for a priority date, the time period for filing
the foreign application is calculated from the date
of the first-filed national application. For most
U.S. applicants, the first-filed national applica
tion is a regular nonprovisional U.S. application.
It is important to note, however, that if a U.S.
provisional application is filed as the first-filed ap
plication, the one-year grace period begins with
the filing of this provisional application and not
with the filing of the “conversion” regular nonprovisional U.S. application that claims priority
over the provisional application. Thus, if a provi
sional application is filed, the conversion date for
the nonprovisional U.S. application and the Paris
Convention bar date for the filing of internation
al applications fall on the same day. Therefore, the
international application and the U.S. regular ap
plication need to be filed on the same date. The
applicant does not get an additional year beyond

the regular U.S. application in which to file its
international applications.
Prosecution of a PCT application has two
parts. Chapter I involves the initial processing
of the application, a search of the prior art, and
publication of the application and search results.
Chapter II involves an optional international pre
liminary examination. (Figures 1 and 2)
Once an applicant decides to file a PCT ap
plication, the applicant enters Chapter I by filing
a PCT office request, a copy of the application, and
the PCT filing fee. Application in most countries
is made in the name of the owner of the invention,
not of the inventor, as in the United States. The
PCT filing of the patent application may be the
first filing, or a PCT application that claims pri
ority to an earlier-filed application can be filed, so
long as it is filed within 12 months of the priority
date. Either the U.S. Patent and Trademark Office
(PTO) or the International Bureau of the World
Intellectual Property Organization (WIPO) can
act as PCT receiving offices for applications on
inventions by applicants who are either nationals
or residents of the United States. Either the PTO
or the European Patent Office can be designated
as the searching authority.
The application is then reviewed by an au
thorized examiner, and a prior art search is per
formed. The examiner reviews patents and pub
lications from around the world and lists those
that are determined to be relevant prior art, with
respect to the claims of the application. Within
16 months of the priority date, a preliminary
search report is issued. The applicant then has an
opportunity to amend the claims in the applica
tion. After 18 months from the priority date, the
application is published.
Under previous PCT procedure, within 19
months of the priority date, applicants were re
quired to choose to enter PCT Chapter II, enter
the national stage (that is, file the application in
at least some of the countries or regional offices
designated), or abandon the application. If the
applicant decided to enter PCT Chapter II, the
filing of a demand for a preliminary examination
was required and a Chapter II filing fee would
be assessed. However, the Article 22(1) time limit
for filing national-stage applications without the
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need to file a demand has been changed from 20
or 21 months to 30 or 31 months. This change
went into force on 1 April 2002. Applicants
should recognize, however, that some PCT mem
ber countries maintain reservations regarding this
new timing rule and should remain cautious.11
Applicants may file a preliminary amendment
with the demand. When that has been done, the
PCT examiner prepares a written opinion that
should be received by the applicant within 22
months of the priority date. The applicant has an
opportunity to amend the claims and respond to
the examiner’s opinion during the period between
22 and 28 months following the priority date. A
final PCT international preliminary examination
report is published approximately 28 months
from the priority date. PCT Chapter II is closed
at 30 or 31 months from the priority date.
Normally, just before the 30- or 31-month
mark, the applicant again must decide whether to
file applications in at least some of the designated
countries, or regional offices, or to abandon the
application. The applicant can choose to file the
application in some or all of the countries origi
nally designated. The applicant, however, cannot
add to the list of countries originally designated.
Because the PCT application does not, in itself,
result in the granting of any national patent
rights, the applicant must initiate the national
stage in each of the national offices where patent
protection is desired. At this point, the applicant,
via a local attorney or agent, files a copy of the
international application, a translation of the ap
plication (if necessary), the national fee, and any
other documentation required by the national of
fice. The remainder of the prosecution is similar
to that discussed above, when an application is
filed directly in a national office. The national
offices, however, do give deference to the PCT
international preliminary examination report and
may not conduct a further search.
It should be noted that it is possible at any
time during the PCT process to file one or more
national-stage applications. It is not necessary to
wait until the end of Chapter I or Chapter II to
file a national or a regional application.
For U.S. applicants using the PCT procedure
and wanting to select the EPO to perform the
2 | HANDBOOK OF BEST PRACTICES

prior art search, the EPO has limited the categories
it will search and/or examine. The EPO will not
search or examine applications in the areas of busi
ness methods and related inventions. “[T]he EPO
is no longer a competent [International Preliminary
Examining Authority], within the meaning of PCT
Article 32(3), for international applications filed by
U.S. residents or nationals in the [U.S. Patent and
Trademark Office] or [International Bureau] as a
Receiving Office where the corresponding demand is
filed with the EPO on or after 01 March 2002, and
where the application contains one or more claims
directed to the fields of business methods.”12
In the 1990s, the EPO had indicated that
it would search inventions in the area of tele
communications, but would not examine these
applications. This meant that U.S. applicants
needed to have all telecommunications inven
tions examined by the U.S. Patent Office, even
if the EPO had performed the search. The EPO,
however, resumed its competence as an interna
tional preliminary examining authority, effective
1 July 2004, for demands filed by U.S. residents
or nationals on or after 1 July 2004, for interna
tional applications filed by nationals or residents
of the United States, where the application con
tains one or more claims relating to the field of
telecommunications.13
Similarly, in the field of biotechnology, al
though the EPO had earlier announced that it
would neither search nor examine applications
in that area, and that such applications were re
quired to designate the U.S. Patent Office as the
searching and examining authority, the EPO re
sumed its competence as an international search
ing authority and international preliminary ex
amining authority, effective 1 January 2004, for
international applications filed by nationals or
residents of the United States, where the applica
tion contains one or more claims relating to the
field of biotechnology.14
2.2 Advantages and disadvantages
of different application strategies
2.2.1

Direct national filings

If an applicant has only a small number of coun
tries where she or he wants to file and chooses to
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actively pursue prosecution in only those coun
tries, the applicant can avoid the costs associ
ated with the intermediate steps of filing in the
PCT or regional patent office prior to filing na
tionally. Some countries conduct no, or limited,
examination.
Disadvantages to direct national filing are
that (1) each application will be independently
examined (no deference given to a prior favorable
review in a different country), and (2) govern
ment filing fees and translation costs will be due
early in the patenting process.
2.2.2 Direct regional filings

With direct regional filings, applicants may be
able to avoid some translation costs (for example,
the Eurasian Patent Convention requires applica
tions to be filed in Russian, but no translations
into different languages will be required by the
various countries after grant of a Eurasian pat
ent). Another advantage to direct filings is that
substantive examination of the regional patent in
each of the designated countries is no longer nec
essary. This makes direct regional filing especially
cost-effective if protection is desired in a number
of member countries, since the single regional
examination replaces national examinations per
formed by each member country.
If obtaining protection in only a few member
countries is desired, it may be less expensive to file
applications in each country individually, thus
avoiding costs associated with the intermediate
steps of first filing in the regional patent office.
2.2. PCT filings

PCT filings preserve future foreign patent rights
and permit an applicant to delay national entry
into PCT member countries for up to 30 or 31
months from the priority date. This delay period
may provide opportunities for further market
analysis, obtaining a licensee or business partner
for the invention, and obtaining a preliminary ex
amination report regarding the issues of novelty,
inventive step, and industrial applicability of the
claimed invention.
Ultimately, the same costs for national fil
ing or registration (and possible further national
prosecution), patent attorney fees, local associate

fees, and translation costs, if appropriate, will be
incurred just as they would if the national stage
was entered directly. Also, the additional inter
mediate costs associated with the filing and pros
ecution of the PCT application will be incurred.
Further, the countries of interest must be mem
bers of the PCT.

. poSSIBLE InTERnATIonAL
fILInG pLAnS
The selected international filing strategy will de
pend on the potential importance of the inven
tion and other business and legal considerations.
The following are examples of filing strategies in a
variety of circumstances.
.1 Invention has immediate international
market potential

1. File application in the United States; expe
dite obtaining a foreign filing license from
the U.S. Patent Office.
2. After receipt of a foreign filing license, file
in countries of interest that are not mem
bers of the Paris Convention.
3. File a PCT application designating all PCT
countries within three months after the
U.S. filing.
4. Within 12 months after the U.S. filing date,
pay designation fees for desired countries,
and proceed with the PCT prosecution.
5. Within 12 months after the U.S. filing date,
file national applications in non-PCT coun
tries that are Paris Convention countries.

.2 Invention has international, but not global,
market potential

1. If it is known ahead of time which coun
tries have market potential, one could:
a. File a PCT application designating coun
tries of interest, including the United
States. If filing in any Paris Convention
nonmember countries is desired, obtain a
foreign filing license, and file applications
upon receipt of the foreign filing license.
b. Within 12 months after the PCT filing
date, pay designation fees, and proceed
with the PCT prosecution.
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c. Within 12 months after the PCT filing
date, file national applications in nonPCT countries that are Paris Convention
countries.
2. If it is not known which countries may
be of interest at the initial filing date, one
could:
a. File a U.S. application (and obtain a
foreign filing license if interested in any
countries that are not members of the
Paris Convention).
b. Within 12 months after the U.S. filing
date, file a PCT application designat
ing EPO, Japan, Canada, and any other
PCT countries of possible interest.
c. Within 12 months after the U.S. filing
date, file national applications in nonPCT countries that are Paris Convention
countries.
. Applicant is interested only
in NAFTA countries

1. File a U.S. application.
2. Within a one-year grace period, file an ap
plication in Canada and Mexico. (File in
Canada within one year from any disclo
sure by the inventor.)

. Bars to patentability in foreign countries

Most countries require that an invention be “new
or novel” in order for the inventor or applicant
to obtain a patent for the invention. The defi
nition of novelty varies considerably among the
different countries of the world. Some countries
have a requirement of absolute novelty, that is,
the invention cannot have been described orally
or in writing, anywhere in the world, or have
been sold, used, and so forth, prior to the filing
or priority date. Other countries have a require
ment of relative novelty. For example, relative
novelty can mean that the invention must not be
known in the particular country or described in
a written document anywhere in the world (but
foreign oral disclosures may not destroy novelty).
Also, a country might give inventors or appli
cants a grace period in which to file their patent
application after they, or a third party, disclose
the invention.
 | HANDBOOK OF BEST PRACTICES

Under Chapter II of the PCT, a claim not
disclosed by prior art is considered to be novel.
The relevant prior art is anything made available
to the public, anywhere in the world, by means of
a written disclosure, drawings, or other illustra
tions, prior to the relevant date (filing date of the
first-filed patent application or the filing date of
the PCT application).
The European Patent Convention (EPC) has
a more-restrictive view of what is new. Under the
EPC, an invention is considered to be new if it
does not form a part of the state of the art. The
state of the art includes everything made avail
able to the public by means of written or oral
description, by use, or in any other way, before
the effective date of filing of the European pat
ent application or a patent application from
which the European application claims priority.
Additionally, the content of European patent
applications that were filed prior to the priority
application, but published after the priority date,
are also part of the prior art for novelty purposes.
There are many variations as to what consti
tutes novelty in a particular country, and these
national definitions can change. Therefore, it is
highly advisable to inquire of a local patent at
torney or agent as to the current novelty require
ments for a given country.

. ConCLuSIonS
When properly managed, international patent
protection can afford many strategic and eco
nomic advantages for an organization, as it seeks
to optimize value in its inventions. However,
implementation of such a patent-portfolio-man
agement strategy requires careful planning, co
herent organization, and a thorough knowledge
of an invention’s potential. For example, critical
considerations include market potential (both
in terms of monetary and geographical factors),
the presence or absence of competitors, and the
overall patent protection regime (in terms of laws
and enforcement) in the various nations or re
gions where the invention might be used, sold,
produced, or marketed. Having carefully weighed
these considerations, options for patent protec
tion can then be evaluated. For example, patent
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applications can be filed within national (for ex
ample the U.S. Patent Office), regional (for ex
ample, the EPO), or international systems (for
example the PCT), each with advantages and
disadvantages, depending on the objectives and
resources of the organization. Whatever course
is taken, coherent planning is essential, and a
thorough knowledge of all relevant parameters is
fundamental. Finally, it is important to remem
ber that such an overall strategy can be effectively
employed to maximize either business or human
itarian objectives. n
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Figure 1: Overview of International Patent-Protection Procedures
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CHAPTER 10.7

Filing International Patent Applications
under the Patent Cooperation Treaty (PCT):
Strategies for Delaying Costs and Maximizing
the Value of Your Intellectual Property Worldwide
anne M. schneideRMan, Registered Patent Attorney, Law Offices of Anne M. Schneiderman, Ph.D., U.S.A.

ABSTRACT

Obtaining international patent protection for an inven
tion can present a significant financial commitment for an
early-stage company, entrepreneurial venture or not-for
profit organization with a limited budget for intellectual
property management. This chapter examines the use of
patent application filings under the Patent Cooperation
Treaty (PCT) to delay, consolidate, or minimize the costs
of patenting overseas. Using the PCT to file internation
ally enables a patent applicant to delay, generally for up
to 30 months after the first (priority) filing date, strategic
decisions about the countries in which to pursue patent
protection. The delay offers a significant advantage, since
it allows the applicant more time in which to evaluate
commercial demand for the invention, the likelihood of
its success in overseas marketplaces, and the likelihood of
obtaining a patent grant in a particular country, prior to
filing national-phase patent applications in the countries
in which patent protection is sought.

1. InTRoduCTIon
Obtaining international patent protection for an
invention can present a significant financial com
mitment, especially for small or early-stage com
panies, entrepreneurial ventures, not-for-profit
organizations (such as universities and charitable
organizations), and independent inventors. Such
entities usually have to conserve their financial re
sources while striving to build, maintain, protect,
and expand their intellectual property (IP). The cost
of procuring a national or regional patent, from the

initial drafting of the application through prosecu
tion of the patent application, allowance, issuance,
and post-issuance maintenance of the patent, can
easily run from US$30,000 to US$50,000 in legal
and patent-office fees. Should patent protection
for an invention be sought in more than one coun
try, the costs of international patent procurement
can multiply accordingly. Since the costs associated
with obtaining patent protection are so significant,
IP protection strategies that delay, consolidate, or
minimize costs are advantageous.
The Patent Cooperation Treaty (PCT) is an
important IP protection tool that can be used to
confront the financial challenges associated with
international patent protection. By facilitating
the filing in any number of PCT member coun
tries of parallel patent applications, a PCT patent
application offers a valuable means of managing,
delaying, or consolidating the costs of interna
tional patent protection for a given invention.
The PCT can buy time to strategically evaluate
the overall potential value of an invention, that is,
provide time within which to make an informed
decision as to how to best proceed.1
The challenge of managing the costs of pro
tecting IP so that the IP becomes a commercial
asset—and not a financial liability—is one that is
faced universally by technology managers. An en
terprise that has developed (or acquired) IP must

Schneiderman AM. 2007. Filing International Patent Applications under the Patent Cooperation Treaty (PCT): Strategies for
Delaying Costs and Maximizing the Value of Your Intellectual Property Worldwide. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. AM Schneiderman. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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decide at the outset whether that IP is worth
protecting with a patent. The costs and benefits
of patent protection must be carefully analyzed.
Although a discussion of such a cost-benefit
analysis is beyond the scope of this chapter, it is
worth noting here that a granted patent generally
“protects” the subject IP only to the extent that it
confers to the patent owner the right to enforce
the patent, that is, to exclude others from making
the invention, using it, importing it, and so forth.
In conducting a cost-benefit analysis, an enter
prise may decide that the total expected value of
a particular piece of IP simply does not merit the
expense of obtaining a patent and enforcing the
rights the patent confers.
The patent applicant (or IP owner) must de
termine the merits of the invention, the commer
cial demand for the product or process provided
by the invention, the likelihood of its success in
the marketplace, and whether protection should
be sought in a particular country.2 The applicant
must also determine, preferably with the advice
of a patent attorney, patent agent, or other profes
sional with expertise in patent law, the likelihood
that the patent application would succeed in the
patent office of a particular country or region and
whether that national patent office would decide
that the invention meets its requirements for pat
entability and, thereby, grant a patent.
Ideally, these analyses are conducted prior to
selecting specific countries in which to file pat
ent applications. Thus, any strategy that extends
the time limit for filing a patent application in a
country, while preserving the priority (first filing)
date for the application, potentially gives the pat
ent owner more time for analysis and decisionmaking before making the financial commitment
to seek patent protection abroad.
For patent owners and other entities with
a proprietary interest in the subject matter to be
patented, but without large budgets for patent
portfolio development (for example, not-for-profit
organizations, universities, regional technology in
cubators, and agricultural cooperatives), extending
the time limit for filing a patent application can
provide a much-needed opportunity to stimulate
investment and technology transfer. The extended
time period afforded by filing an international
2 | HANDBOOK OF BEST PRACTICES

PCT application, as described below, is increas
ingly recognized by developing countries as an
opportunity to publicly promulgate an invention
with “patent pending” status, to identify and nego
tiate with potential corporate sponsors, investors,
licensees, and others involved in technology devel
opment and commercialization and to stimulate
further domestic inventive and related technologi
cal activities.

2. AppRoACHES To InTERnATIonAL
pATEnT pRoTECTIon
There are three basic approaches to procuring in
ternational patent protection on an invention.3
The first approach, and the most expensive, is
to file (usually on the same day) separate patent
applications in the national patent office of each
country or region4 in which protection is sought.5
The drawback of this approach is that legal and
filing fees for each country begin to accrue as
soon as the application is filed.
The second approach for filing internation
ally is to file a patent application in accordance
with the Paris Convention for the Protection of
Industrial Property.6 Taking this route, the ap
plicant files a patent application in a single Paris
Convention member country7 (usually required
to be the country of residence of at least one of
the inventors), which establishes a first or priority
filing date for the application. The applicant can
then delay filing in other Paris Convention coun
tries for up to 12 months after the priority filing
date. Member countries of the Paris Convention
agree to recognize the priority date of a patent
application filed in one member country and
to give the benefit of that priority date to cor
responding applications in all member countries.
This approach delays the costs associated with
international patent procurement for one year.
Procurement costs initially accrue in the coun
try of first filing, and then, up to one year later,
the costs associated with filing applications in the
other Paris Convention countries begin to accrue
(Figure 1).
The third and least-expensive approach,
which is the primary focus of this chapter, is to
file a single “international” application under the
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auspices of the PCT. Of the three approaches, fil
ing a PCT patent application is, financially and
strategically, the most advantageous for manag
ing, delaying, or consolidating the costs of inter
national patent procurement. Filing a PCT pat
ent application allows the applicant to delay, for
up to 18 months after the filing the application
or in most cases, for up to 30 months after the
filing of the first (priority) application, strategic
decisions about which countries to pursue patent
protection in. The delay provides a significant ad
vantage, since it allows the applicant more time
to evaluate the commercial strength and viabil
ity of the invention prior to filing national-phase
patent applications in the countries in which pat
ent protection is sought.

. THE pATEnT CoopERATIon
TREATy (pCT)
The Patent Cooperation Treaty (PCT) is a coop
erative agreement entered into by more than 130
countries (called PCT contracting states) with
the purpose of bringing international conformity

to the filing and preliminary evaluation of patent
applications,8 both simplifying and making more
economical the process of seeking patent protec
tion in other countries. An applicant does not ap
ply for an “international” patent by filing an ap
plication under the PCT. The World Intellectual
Property Organization (WIPO), which adminis
ters the processing of PCT applications, does not
grant international patents. Instead, the PCT fil
ing process produces a single patent application
that has been vetted for compliance with filing
formalities and that has undergone a preliminary
search and evaluation. This single application can
then be transmitted to the national patent offices
of as many PCT member countries as the appli
cant chooses, for filing as a national-phase appli
cation in that country. The PCT thus streamlines
and consolidates the process of seeking patent
protection in more than one country into a single
series of steps and a single set of preliminary re
quirements (see Section 4).
Filing international applications with the
PCT is becoming increasingly popular. In January
2005, the one millionth PCT application was

Figure 1: Traditional Filing Route under Paris Convention
Month: 0

12

File first
local application

File
applications
abroad

Local first-filed patent application followed within 12 months by multiple foreign
applications claiming priority under the Paris Convention:
• multiple formality requirements
• multiple searches

• multiple publications

• multiple examinations and prosecutions of applications
• translations and fees required at 12 months

Some rationalization because of regional arrangements: ARIPO, EAPO, EPO, and OAPI†
†

African Regional Intellectual Property Organization, European Patent Office, Eurasian Patent
Organization, Organisation Africaine de la Propriété Intellectuelle.
Source: Courtesy TDR Patents: T. David Reed LLC.
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filed, with the doubling time for numbers of ap
plications filed having gone from 22 years (for the
first half million applications) to just 4 years (for
the next half million applications).9

will be obliged to file a separate patent application
(usually on the same day) in the national patent
office of each country or region in which protec
tion is sought (Section 2, first approach, above).

.1 Non-PCT member countries

.2 Costs associated with filing
a PCT patent application

More than one hundred countries, however, are
not members of the PCT, including a number
of countries in Asia (for example, Cambodia,
Nepal, Pakistan, Thailand), South America (for
example, Bolivia, Chile, Guyana, Paraguay, Peru,
Suriname, Uruguay, Venezuela), Central America
(for example, Panama), the Middle East (for
example, Iran, Iraq, Jordan, Kuwait, Lebanon,
Saudi Arabia, Yemen), and Africa (for example,
Ethiopia, Rwanda, Somalia). To obtain patent
protection in nonmember countries, a patent
application must generally be filed directly with
the national (or regional) patent office.10 Since
patent protection involves complex questions of
law, the applicant is well-advised to consult with
patent counsel familiar with local patent law, in
ternational Paris Convention patent practice, and
international PCT patent practice before filing a
patent application, especially if applicants are ei
ther residents of non-PCT contracting states or
inventions were made in non-PCT contracting
states. For example, if all of the applicants on a
patent application are residents or nationals of
non-PCT countries, then an application filed
with the PCT is generally denied an international
PCT filing date.
In general, if the application is first filed in
a country that is not a member of the PCT but
is a member of the Paris Convention,11 then the
applicant will be ineligible to file a PCT appli
cation but may choose to file additional applica
tions in the national patent offices of other Paris
Convention member countries within 12 months
of the filing (priority) date of the first application
(Section 2, second approach, above).
If the application is first filed in a country
that is not a member of the PCT or the Paris
Convention, then the applicant will be ineligible
to file a PCT application, or an application under
the Paris Convention in Paris Convention mem
ber countries, within 12 months of the filing (pri
ority) date of the first application. The applicant
 | HANDBOOK OF BEST PRACTICES

Filing a PCT patent application entails paying a
single set of filing fees, as opposed to multiple filing
fees for each country in which patent protection
is sought. Currently, PCT filing fees are approxi
mately US$1100 for filing an application (with a
fee reduction for filing electronically online or via
other electronic media), from US$200 to US$2100
for a search of prior art publications (depending on
which international searching authority performs
the search), and a nominal transmittal fee (around
US$300) charged by the PCT receiving office. The
applicant can also elect to file a demand (request)
for international preliminary examination of the
application, which entails an additional fee of ap
proximately US$600 to US$750.
. PCT filing consolidates and
delays patent prosecution costs

Filing a patent application under the PCT con
solidates or eliminates the duplication of costs
associated with multiple filings in multiple coun
tries and enables the applicant to submit a single
patent application in a single language and in a
format that conforms to the requirements of all
the national patent (or regional) offices of PCT
contracting states. The added burden and expense
of translating the application and of filing it in a
particular format for a particular national patent
office is thus avoided.
During the international phase of its pendency,
a PCT application undergoes a preliminary evalua
tion that comprises an international search for prior
art publications, a written opinion and a prelimi
nary report on patentability, and optionally, a pre
liminary examination and a second, more detailed,
report on patentability. The applicant can then
choose to transmit the uniform application and ac
companying evaluation documents to the national
patent offices of as many PCT contracting states as
desired, in which the application enters the national
phase of the patent procurement process.

CHAPTER 10.

By far, the most expensive aspect of interna
tional patent procurement is the national-phase
cost, which includes the fees paid to each national
patent office for entrance into the national phase
and during the patent prosecution process, the
legal fees of local attorneys or agents to obtain a
national patent, and the fees to the national pat
ent office to maintain the granted patent in force.
Filing under the PCT enables costs associated
with the national phase to be deferred, in most
cases for up to 30 months from the priority (first
filing) date, while an international patent-protec
tion strategy is formulated and decisions are made
about which countries to seek protection in.
. The role of WIPO in the
Patent Cooperation Treaty

WIPO, an international organization based in
Geneva, Switzerland, is the administrative body
that oversees the filing of international applica
tions under the PCT. The International Bureau
of WIPO administers the international phase of
the PCT application process, prior to entrance
into the national phase of countries in which
patent protection is sought. WIPO receives and
stores PCT applications, along with their associ
ated files of patent search and examination doc
uments and correspondence. WIPO examines
each application for its adherence to filing for
malities (such as the required format for the pat
ent application, accompanying administrative
filing papers, and fees paid). Based on this initial
examination, the applicant may be required to
correct any formal defects to bring the applica
tion into conformity with the PCT format ac
cepted by patent offices in the member states.
The carrying out of these procedures reduces the
costs of patent procurement at an early stage.
Formalities defects in the PCT application that
are identified during the international phase can
be rectified before the application reaches the
national patent offices and enters the national
phase of the patent examination and procure
ment process. Thus, separate formalities rejec
tions by national patent offices in which patent
protection is sought can be avoided.
WIPO is responsible for publishing PCT
applications12 and accompanying information

about them, which can be accessed worldwide
via the Internet at the WIPO Web site. WIPO
oversees translation of portions of the PCT ap
plication and associated documents into English
or French, also available on the Internet, and can
provide the national patent offices of contracting
states with application documents.

. opTIonS And STEpS foR
fILInG undER THE pCT
.1 Alternative 1: File an international
PCT application that complies
with PCT formality requirements
and pay one set of fees.

An international patent application can be filed
under the PCT if at least one of the inventors of
the invention is a resident of a PCT contract
ing state. Applicants can generally file an in
ternational PCT application with the national
patent office of their country of residence, with
the national office acting as a receiving office for
the PCT. Under some circumstances, the PCT
application can be filed directly with WIPO in
Geneva.
The WIPO Web site provides detailed guides
to PCT filing requirements,13 as well as a guide to
PCT time limits14 and a PCT time-limit calcu
lator15 to assist applicants in computation of es
sential time limits for filing applications and for
submissions of other required documents. Time
limits under the PCT are measured from the
priority date of the application (Figure 2). The
priority date is defined in PCT Article 2(xi) as
follows:
(xi) “priority date,” for the purposes of computing
time limits, means:
(a) where the international application con
tains a priority claim under Article 8 [of
the PCT], the filing date of the application
whose priority is so claimed;
(b) where the international application con
tains several priority claims under Article
8, the filing date of the earliest application
whose priority is so claimed;
(c) where the international application does
not contain any priority claim under
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Figure 2: PCT Time limits
Chapter I
20

(months)

Chapter 1

0
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application

30

International
publication
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File PCT
International
application search report and
ISA written
opinion issued

Enter
national
phase

19/22
File demand
International
preliminary
examination

30
28

Issuance
of IPRP
Chapter II
Chapter II
Time limits for international PCT applications filed on or after 1 January 2004.
• “Month 0” corresponds to the priority date, the date of earliest filing of a local, regional or
national application. An international PCT application claiming priority to the priority date
must be filed prior to the expiration of 12 months from the priority date.
• Approximately 16 months after the priority date, the international search report and the
written opinion are issued by the international searching authority (ISA).
• Approximately 18 months after the priority date, the application is published.

• In countries that have not withdrawn their notifications of the incompatibility of the time limit
under PCT Article 22(1) with applicable national law, a demand for international preliminary
examination should be filed prior to the expiration of 19 months from the priority date, if the
applicant wishes to postpone entry into the national phase. Otherwise, a demand may be filed
for up to three months from the date of transmittal of the international search report and
written opinion of the ISA, or 22 months from the priority date, whichever expires later.

• The international preliminary report on patentability (Chapter II) is issued by the international
preliminary examining authority (IPEA), approximately 28 months from the priority date.
Unless an international preliminary examination report is established under Chapter II, the
International Bureau of WIPO issues a report on behalf of the ISA that has the same contents
as the written opinion. This report, the international preliminary report on patentability
(Chapter I), is communicated to each designated national-phase office not before the
expiration of 30 months from the priority date.

• The national phase usually must be entered prior to the expiration of 30 months from the
priority date. Some countries make provisions for entering the national phase later than the
PCT 30-month time limit (see endnote 15). As with all deadlines mentioned in this chapter, the
PCT articles, rules, applicant’s guides, and the PCT time-limit calculator should be consulted,
and deadlines should be confirmed by a qualified patent attorney or agent.

• For all designated states to which new Article 22(1) of the PCT does not yet apply, the applicant
must decide whether to file demand by 19 months or to enter national phase by 20 months.
As of 26 June 2006, these countries maintain reservations to the new Article 22(1) timing:
Switzerland, Lithuania, Sweden, Tanzania, and Uganda.
Source: Modified after the U.S. Patent and Trademark Office.17
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Article 8, the international filing date of
such application[.]16
The time limits are based on the earliest pri
ority date of the PCT application and include:
• time limit for submission of the priority
document on which the priority date of the
PCT application is based
• earliest potential date for international
publication of the PCT application, which
is usually 18 months after the priority date
• time limit for a demand for international
preliminary examination
• time limit for entry of the application into
the national/regional phase
.2 Alternative 2: File a national
application first and then a PCT application
within 12 months

Once a PCT application is filed, the applicant
has up to 18 months to delay before deciding
to enter the national phase and file national
applications in one or more PCT contracting
states (Figure 2). To delay even further the time
between the first filing (priority) date of an ap
plication and entry into the national phase, the
applicant has the option of filing a national ap
plication first, and then, up to 12 months lat
er, filing a PCT application claiming priority
to the national application. Laws of individual
PCT contracting states generally require that if
an applicant desires to file a patent application
and the invention was made in a particular state,
then either a national patent application must be
filed in that state (and generally, a foreign filing
license obtained) before the application is filed as
a national application in other states, or an inter
national PCT application must be filed directly
with a PCT receiving office.
During the 12-month period following the
filing of the priority application, the applicant
can choose to file one or more additional national
applications, as new refinements or embodiments
of the invention are developed. A PCT applica
tion must be filed no later than 12 months after
the filing date of the first application, however, to
claim benefit of that earliest application’s priority
date.

The PCT application, however, can incor
porate the disclosures of, and claim priority to,
all the national applications directed to that
invention that were filed during the previous
12-month period. The disclosure and claims of
the PCT application may therefore differ from
those of the priority application(s) preceding it
in the patent family.18 The PCT application can
also include new disclosure pertaining to the in
vention (for example, a description of new em
bodiments of the invention) or new claims that
were not set forth in any of the priority applica
tions. However, to obtain benefit of an earlier
priority date, a new claim included in the PCT
application must be supported by the disclosure
of the priority application filed on that date.
After filing the PCT application, the appli
cant has, as described above, up to 18 months
to delay before deciding to enter the national
phase and to file national-phase applications in
separate PCT member countries. Hence, the ap
plicant can delay for 12 months plus 18 months,
or in most cases up to 30 months, after the filing
of the initial priority application before entering
the national phase in a desired PCT contracting
state.19 In the meantime, the applicant can use
this delay to advantage, and take the time to eval
uate the merits of seeking protection in specific
countries and to delay the assessment and accrual
of patent prosecution fees in multiple countries.
Hence, with this approach:
• A national patent application is filed in the
patent office of a PCT contracting state
(member country), establishing the priority
(first filing) date. This national application is
sometimes referred to the priority application.
• Within 12 months after the priority date,
a PCT application is filed and enters the
international phase.
• Within 18 months of PCT filing, or within
30 months of the priority date, the PCT
application enters the national phase of se
lected PCT member countries.20
. Designating countries in which
to file a national-phase application

When a PCT application is filed, all contract
ing states that are bound by the PCT to the
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international filing date are designated, by de
fault, as potential venues for filing subsequent
national-phase applications.21 Before the expira
tion of the 30-month time limit after the priority
date, the applicant can select a specific subset of
the designated states for actual filing of nationalphase applications with national patent offices.
The transmittal to, and filing of, the international
PCT application with the national patent office
of a contracting state is known as entering the na
tional phase of international patent prosecution
(Figure 2). By filing under the PCT just before
the expiration of the 30-month time limit, the
applicant delays examination of the application
for patentability by a national patent office signif
icantly past the point at which national examina
tion would normally occur had application been
filed directly with the national patent office.
The prosecution phase of a national-phase
patent application can become very expensive.
It can take several years of interaction between
the patent attorney and the patent examiner dur
ing the examination proceedings and cost tens of
thousands of dollars (US$) in attorney costs and
national-patent-office prosecution fees, before
patent claims are possibly allowed and the appli
cation issues as a patent. If patent prosecution is
undertaken in more than one country, then the
costs of obtaining patent protection multiply ac
cordingly. Thus, one of the chief advantages of
filing under the PCT is the permitted delay of up
to 30 months after the priority date to enter the
national phase.
. PCT international search
report and written opinion

Prior to publication of the PCT application 18
months after the priority date, and during the
international phase, a PCT international search
ing authority (ISA) conducts a search of the in
ternational technical literature to identify patent
publications, technical publications, and other
prior art references that are material to patentability of the claimed invention. Current ISA’s
are the European Patent Office and the nation
al patent offices of Australia, Austria, Canada,
China, Finland, Japan, the Republic of Korea,
the Russian Federation, Spain, Sweden and the
 | HANDBOOK OF BEST PRACTICES

United States. The ISA conducts the search ac
cording to search standards set by the PCT and
compiles an international search report contain
ing a list of references that are deemed material
to patentability. For each reference, the search re
port states the patentability criteria (for example,
novelty, nonobviousness or inventive step, and
industrial applicability) for which the reference
is considered material. The ISA issues a written
opinion that accompanies the search report and
that states whether the invention appears to be
patentable based on the results of the search.
The international search report and the writ
ten opinion provide the applicant with an early
indication of the likelihood of success in obtain
ing a patent based on the claims as filed. This
early indication is another significant advantage
of filing under the PCT. In view of the search re
port and the written opinion, the patent claims
can be amended by the applicant to better dis
tinguish the invention from the prior art before
the application enters the national phase. Thus,
the possibility of having the same claims rejected
by multiple national patent offices for the same
(or similar) reasons can be minimized or avoided.
The added legal and administrative expense of fil
ing separate claim amendments in each national
patent office can also be avoided.
Another distinct advantage is that the ap
plicant may submit to WIPO informal written
comments addressing, and possibly rebutting, the
reasoning and conclusions set forth in the writ
ten opinion. This enables the applicant to begin
creation of a prosecution record for the applica
tion that sets forth reasons for patentability of the
claims, and that accompanies the application as it
enters the national phase in each country and is
examined by each national patent office.
The applicant (as explained in Section 4.5)
also has the option to file a demand and to pay
for an international preliminary examination
(a Chapter II examination), which is a more de
tailed evaluation of the patentability of the claims
that results in the issuance of an international
preliminary report on patentability (IPRP
Chapter II). The time limit for filing a demand
is three months from the date of transmittal of
the international search report and the written
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opinion, or 22 months from the priority date,
whichever comes last.22
If the applicant does not file a demand for
international preliminary examination, the ISA’s
written opinion will be subsequently converted
into an international preliminary report on pat
entability (IPRP Chapter I), which is sent, along
with the applicant’s informal comments respond
ing to the written opinion, to each of the patent
offices selected for national-phase entry, not be
fore the expiration of 30 months from the prior
ity date.
Thus, when the national phase is entered in
each country, each national-phase patent applica
tion is accompanied by the same search and in
ternational preliminary report(s) on patentability
(a Chapter I report, and optionally, a Chapter II
report, depending on whether international pre
liminary examination has been elected or not).
This significantly reduces the search and exami
nation effort required for each separate national
patent office.
. International preliminary examination

If an applicant requests and pays the additional
fee for international preliminary examination,
then a second, more-detailed evaluation of the
patentability of the claims is conducted by a PCT
examiner associated with one of the internation
al preliminary examining authorities (IPEAs),
which are the same as the international search
ing authorities (ISAs) described above. A demand
(request) for international preliminary examina
tion may be made at any time prior to (a) three
months from the date of transmittal to the ap
plicant of the international search report and the
written opinion or (b) 22 months from the earli
est priority date (whichever is later).
The international preliminary examination
provides a formal opportunity for the applicant to
respond to the reasoning and conclusions of the
PCT examiner, as set forth in the written report
or the international preliminary report on patentability (Chapter I), regarding patentability of the
claims, and to set forth on the record amended
claims and arguments for patentability. The inter
national preliminary examination concludes with
the issuance, by the PCT examiner, of a second or

international preliminary report on patentability
(Chapter II), which is transmitted to the national
patent offices. The international preliminary re
port on patentability (Chapter II) will be issued
by the IPEA, in general, at around 28 months
from the priority date (see Figure 2).
This creation of a formal-patent prosecution
record prior to national-phase entry further re
duces the duplication of efforts of each separate
national office in performing a separate prelimi
nary examination and the expense incurred by
the applicant in responding to the results of each
such national examination. The international pre
liminary report on patentability (Chapter II) ac
companies the patent application as it enters the
national phase, which can further reduce the du
plication of examination efforts in each national
patent office. It also can serve to consolidate and
focus the prosecution strategy for the application
and avoid the duplication of efforts by patent at
torneys or agents prosecuting the application in
each country.
Although national patent offices have no le
gal obligation to consider the reasoning and con
clusions of the international preliminary reports
on patentability (Chapters I and II), they will
frequently do so. Thus, international preliminary
examination is a means to reduce the effort ex
pended on separate examination of the same ap
plication in various national patent offices, and
hence to reduce the applicant’s legal fees associ
ated with separate examinations. For example,
examiners in several national patent offices may
have the same basis for objection to (or rejection
of ) the same group of claims in the application,
and the applicant may choose to submit similar
arguments to each examiner to overcome the ob
jection. The examiner in each country, however,
may respond very differently to these arguments,
taking into account the differences in national or
regional patent law. Thus, although a nationalphase application may elicit similar objections in
the initial office actions issued by examiners in
different national or regional patent offices, there
may be much less conformity in the subsequent
prosecution history of the application as the ap
plication progresses through the various patent
offices. In patent offices of countries that have less
HANDBOOK OF BEST PRACTICES | 
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capacity or resources for patent examination, how
ever, patent examiners may rely on IPRPs more
extensively. Thus, the IPRPs can have a greater
influence on the patent claims that eventually are
granted in those countries, thus promoting some
similarity or uniformity in the claims granted in
various countries.
Furthermore, the PCT examiner who is
sues the written report or the international pre
liminary report on patentability (Chapter I),
and who performs the optional international
preliminary examination and issues the moredetailed international preliminary report on
patentability (Chapter II), may be the same per
son and be assigned to examine the application
during the national phase. For example, the ex
aminer who examines a PCT application sub
mitted to the U.S. receiving office may be the
same person who examines the corresponding
application filed with the United States Patent
and Trademark Office (PTO). This also avoids
duplication of efforts and can result in a more
thorough and informed evaluation by the pat
ent examiner, who has previous experience with
the application during the international phase.
. National-phase entry

National-phase entry of a PCT application re
quires, by the end of the 30th month after the
first priority date of the application, that the
applicant selects the PCT contracting states in
which to file a national phase application, files an
application with each national-patent office, pays
the associated national filing fees, and, under cer
tain circumstances, furnishes a translation of the
application.23
An advantage of filing a national-phase ap
plication, as opposed to filing a national appli
cation directly with a patent office, is that the
applicant can use information acquired during
the PCT international phase to strengthen the
application upon entry into the national phase.
The applicant can use information derived from
the written opinion and the international pre
liminary report(s) on patentability to plan which
claims to amend or eliminate prior to entry into
the national phase. In countries that charge fil
ing surcharges for claims in excess of a prescribed
0 | HANDBOOK OF BEST PRACTICES

number, such surcharges can be reduced or
avoided.24 For example, the United States charg
es significant surcharges for independent claims
in excess of three or total claims in excess of 20
in an application. Under the PCT, there is no
claim limit or charge for excess claims. Hence, an
applicant planning a subsequent U.S. nationalphase entry can choose to include a large number
of contemplated claims in the PCT application
and then consider the results of the PCT evalua
tion from the international phase and amend or
eliminate claims accordingly.

. SuMMARy And ConCLuSIonS
Filing a patent application under the PCT en
ables the applicant to delay strategic decisions
about where to pursue patent protection by:
• consolidating patent prosecution costs: single-application format, language, and set of
fees
• providing the applicant with preliminary
feedback regarding patentability of the
invention
• providing the applicant with the opportu
nity to present arguments for patentability,
to amend claims, and to strengthen the ap
plication prior to filing with national pat
ent offices
• enabling the applicant to delay filing the
application in individual national patent
offices for up to 30 months after the first
(priority) filing date
• delaying prosecution costs of filing applica
tions in multiple countries
• streamlining the process of filing applica
tions in multiple countries
Delaying international patent prosecution
provides more time to determine:
• the value of IP to applicant or owner
• the strength of commercial demand abroad
• which claims in a patent application are
likely to be patentable
• which countries are most attractive for pur
suing patent protection
• the likelihood of obtaining a patent grant
in target countries. n
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and the PCT Time Limit Calculator (available online at
www.wipo.int) should be consulted in determining
time limits and the deadlines confirmed by a qualified
patent attorney or agent.
20 If the country in which the national (priority)
application was filed is also selected as a country into
which the PCT application enters the national phase,
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that country.
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wishes to postpone entry into the national phase in
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Filing and Defending Patents in Different Jurisdictions
Ronald yin, Partner, DLA Piper US LLP, U.S.A.
sean cunninghaM, Partner, DLA Piper US LLP, U.S.A.

ABSTRACT

In order to build an effective patent portfolio, an organi
zation must (1) understand the dynamics of the interna
tional patent landscape: how to establish foreign prior
ity, where to file patent applications, and the advantages
and disadvantages of pursuing various filing options; (2)
determine in which countries and/or jurisdictions the
organization should seek patent protection based on its
objectives (whether commercial or humanitarian access);
and (3) anticipate the possibility of litigation and know
what its options for litigation are.

1. InTRoduCTIon
In February 2006, the U.S. Patent and Trademark
Office (PTO) issued its seven millionth patent. It
took 75 years for the PTO to issue its one-mil
lionth patent (in the year 1911), but in less than
a tenth of that time the office issued its last mil
lion.1 Inventors in the United States and abroad
are seeking to obtain patents at a pace unparal
leled in history, and revenue from patent licens
ing is at an all-time high.
A company must ask itself several key ques
tions before assembling a patent portfolio (or
portfolios). What do we plan to do with our pat
ents once we have them? Do we intend to assert
our patents offensively (that is, with the aim of pro
tecting market share), either as part of a licensing
strategy or in litigation if companies are unwill
ing to license? Or do we plan to use our patents

defensively, as leverage in licensing negotiations
or in order to ward off litigation by others? If a
portfolio is to be used offensively, where are our
potential targets located and/or doing the most
business? If a portfolio is to be primarily defensive,
in what location is our company most at risk from
licensing approaches or litigation offensives?

2. ovERvIEW of pATEnTInG pRoCEduRES
To obtain a patent for an invention, the inven
tor (often called the applicant) must file an ap
plication for a patent at one or more national or
regional patent offices. Once the necessary docu
ments are filed and any fees paid, the patent office
will examine the patent and decide whether or
not to grant the applicant patent rights for the
claimed invention. A patent’s first application
date is commonly called its “priority date.”
In most instances, an applicant will file a pat
ent application in a national patent office in the
country where he or she is located (such as the U.S.
Patent Office [PTO], the Japanese Patent Office
[JPO] or the European Patent Office [EPO]), in
order to protect the invention for domestic mar
kets; later, he or she can file patent applications
in other countries or file an international applica
tion under the Patent Cooperation Treaty (PCT)
procedure (see Section 3) in order to protect the
invention in foreign markets. Importantly, patent
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rights awarded by a patent office protect the inven
tion only within the jurisdiction of that particular
patent office, and not in other parts of the world.

. ovERvIEW of THE pARIS
ConvEnTIon TREATy
The Paris Convention, formally known as the
Paris Convention for the Protection of Industrial
Property, established the system of priority rights
that is now internationally accepted. The United
States and 171 other countries are signatories to
the Paris Convention Treaty, and the signatories
are sometimes collectively referred to as the “Paris
Union.”2
Under the Paris Convention Treaty, if an in
ventor files a patent or trademark application in
another Paris Convention member nation with
in 12 months of the priority date, he or she is
granted the right of priority: in other words, his
or her patent or trademark application will take
precedence over that of any identical patent or
trademark application filed in the second country.

Therefore, an inventor will not lose patent rights
even if it takes him or her a long time to transfer
the application to another country and have it
translated into that country’s language. Since the
Paris Convention Treaty is reciprocal (in other
words, country A must accord to the inventors of
country B the same right of priority as country B
accords to the inventors of country A), no mem
ber has an advantage over any other.
Not every country is a member of the Paris
Union. However, some countries that are not sig
natories of the Paris Convention Treaty, such as
Thailand, have entered into bilateral treaties with
the United States that grant inventors rights simi
lar to the right of priority.

. fILInG A pATEnT AppLICATIon In
dIffEREnT TERRIToRIES
Significant differences exist between patent offic
es. Table 1 provides the main differences between
the three major patent offices, and the following
text describes them in more detail.

Table 1: Significant Differences between the Three Main Patent Offices3
Issue

EPO

JPO

u.S. PTO

Status of successful
patent applicant

First to file

First to file

First to invent

Patent duration

20 years

20 years

20 years

Application language

English, French, or
German

Japanese

English

Area in which the
patent is valid

Designated EPCa
member and extension
countries

Japan

United States

Request for
re-examination
of the patent

Yes, within 6 months

Yes, within 3 years

No provision

Time of publication of
application

18 months
from priority date

18 months from
priority date

18 months from
priority date4

a European patent convention
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.1 Filing with the U.S. Patent and Trademark
Office

When an application is filed at the U.S. Patent
Office [PTO], it is assigned to a patent examiner.
On the date 18 months from the priority date,
the application is published (that is, information
about the application is made available to the
general public). It is possible for an applicant to
request that the application not be published, but
this request will be considered only if a patent for
the invention has not been, and will not be, filed
in a foreign country. The patent examiner search
es through U.S. and foreign patent documents
and published patent applications dated prior to
the priority date in order to determine whether
or not the claimed invention fulfills the require
ments of being new, useful, and nonobvious.
If a patent application is rejected, the ap
plicant is notified in writing and given the op
portunity to challenge the rejection. At any time
during the lifetime of a patent, any person may
file a request for the PTO to conduct a second
examination of any claim of the patent on the
basis of prior art patents or printed publications.
In order to keep the patent in force (that is, to
keep the invention protected by the patent), the
applicant must pay maintenance fees within cer
tain time periods.
In the calendar year 2005, the PTO granted
a total of 157,740 patents: 143,806 utility pat
ents, 12,950 design patents, 716 plant patents,
245 reissue patents, and 23 statutory invention
registrations.5 The total number of patents issued
in 2005 was 13% less than the number issued in
2004 and 8.7% less than the number issued in
2000; the number of utility patent grants issued
in 2005 was 12.5% less than the number issued
in 2004 and 10.4% less than the number issued
in 2000.6
In 2005, U.S.-resident inventors were grant
ed 52.4% of all U.S. patents—a half-percent in
crease over 2004—and foreign-resident inventors
were granted the remaining 47.6%.7
.2 Filing with the JPO

The patent application process of the JPO is simi
lar to that of U.S. PTO, although there are some
important differences. Patent applications filed

with the JPO are not automatically examined by
patent examiners. Instead, the applicant has to
file a request for examination within three years
(reduced from seven years in 2001) of the appli
cation date. If the applicant fails to file a request
for examination within the time limit, the appli
cation is withdrawn. All applications pending ex
amination are published in an official Patent and
Utility Model Gazette 18 months after the prior
ity date. If the patent examination process does
not turn up any reasons for refusal, the patent is
granted and published in the gazette. After the
patent is granted, anyone can request an appeal
examination of the patent on the basis of lacking
novelty or an inventive step (obviousness).8
. Filing with the EPO

By filing a single patent application with the EPO
in one of the three official languages (English,
French, or German), an applicant can obtain the
patent rights to an invention in one or more coun
tries that are signatories of the European Patent
Convention Treaty (EPC Treaty). Currently, 31
countries have signed the treaty, and five addi
tional countries are covered by an extension agree
ment. At the time of filing, the applicant has to
specify the EPC countries and “extension” coun
tries in which he or she wishes to seek protection.
If the applicant pays designation fees for seven
countries, then the patent will automatically be
granted in all EPC member states. Consequently,
each patent application to the EPO is usually a
bundle of patents, one for each country in which
the applicant is seeking protection.
There are three different ways to file EPO
patent applications:
1. Direct filing with the EPO; filing date be
comes the priority date
2. National patent application extended to
the EPO application within 12 months of
the priority date, that is, the EPO applica
tion is filed after first application
3. International application filed under EPC
Treaty
Once an application is filed with the EPO,
it is subjected to a two-phase examination proce
dure. First, the patent examiner will search for priHANDBOOK OF BEST PRACTICES | 
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or art relevant to the invention; this search report,
along with the patent application, is published 18
months after the priority date. The applicant then
has six months to file a request for a further ex
amination. If he or she files such a request, the
EPO will conduct a substantive examination to
decide whether or not to grant the patent. If the
applicant does not file a request within that time
period, the application is deemed to have with
drawn. Within nine months of a successful EPO
patent grant, anyone can file an opposition to the
patent.9
In 2002, more than 110,000 patent appli
cations were filed at the EPO. This represented
an 84% increase from 1991. In 2002, residents
of the European Union were granted the largest
share of EPO patent applications (44.7%), a share
that far exceeded that of U.S. residents (27.3%)
and Japanese residents (17.4%). The share of bio
technology patents filed with the EPO grew by
8.3% a year between 1991 and 2002, while total
EPO patent applications grew by 5.7%. In 2002,
more than 5,800 biotechnology patents were
filed at the EPO, with 39.9% coming from the
United States, 34.5% from the European Union,
and 14% from Japan. The proportion of residents
of European Union being granted EPO patents is
consistent with the proportion of U.S. residents
being granted U.S. patents, suggesting that, over
all, U.S. residents and E.U. residents must “share”
their home market with residents from other ju
risdictions. However, the growth of biotech pat
ents has exceeded the growth of nonbiotech pat
ents, and U.S. residents have filed proportionally
more patents in this area than E.U. residents, sug
gesting the lead U.S. residents have in this area of
technology.
. Filing international applications
under the PCT

On January 24, 1978, the United States became
a signatory to a multijurisdiction treaty, the PCT.
The PCT allows an applicant to seek patent rights
in a large number of countries by filing a single
international application with a single patent of
fice. The PCT is not a single patent filing effec
tive in many jurisdictions. Instead, an applicant
who files a PCT application is allowed to prolong
 | HANDBOOK OF BEST PRACTICES

his or her right to file patent applications in the
national or regional jurisdictions designated in
the PCT application for up to 30 months from
the priority date.
During the 1990s, the average annual growth
rate for PCT filings was 17%. More recently,
the growth rate has slowed, but there were still
135,602 PCT applications filed in 2005, a 10.6%
increase over the previous year and a more than
45% increase over the number of applications
filed in 2000 (93,237). These figures demonstrate
the increasing importance of PCT filings.

. A GLoBAL pATEnT-fILInG pRoGRAM
For several reasons, a global patent-filing program
can quickly become prohibitively expensive if it is
not managed properly. Patents are only enforce
able within certain geographical regions. Patent
prosecution (that is, the process of obtaining the
patent) can be costly and time consuming. In
many countries, the applicant must pay regular
post-issuance fees (“maintenance fees” or “annui
ties”) in order to keep the patent in force. Finally,
patent applications must be filed before the in
vention is disclosed—in other words, when its
commercial merits are uncertain. Global patent
filing is a high-stakes gamble.
Nevertheless, the risk can be reduced some
what by considering the following questions:
• Does the invention have global market po
tential? If the invention has only regional
application, then it does not merit global
patents.
• Will the invention still be useful 15 or
20 years from the date of filing? In many
countries, the typical lifespan of a patent is
15 to 20 years from the date of filing. If
the invention will quickly become obso
lete, then a global filing program may not
be economical. Furthermore, it often takes
two to three years from the date of filing for
a patent to issue. Until a patent is issued,
the invention will not have any enforceable
legal protection. In that case, it may not be
worth applying for patent protection at all:
it may be more cost-effective to cash in on
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the advantages of being the first to bring
the invention to market.
• Are the rights accorded to the patent owner
separable? That is, has the owner the right
to exclude another from selling the inven
tion or the right to exclude another from
manufacturing the invention? Countries
can be divided into two categories: those
where the invention can be manufactured
and those where the invention can be sold.
Of course, some of these countries may
overlap. Nevertheless, it is not necessary to
file patent applications in both countries
where the invention can be made and in
countries where the invention can be sold.
Protection in only the countries where the
invention can be sold effectively controls
the world. Even though a would-be in
fringer/competitor can make the product
in a country not protected by any patent,
the product cannot be sold in other coun
tries. Furthermore, during the time a pat
ent offers protection, capital markets and
labor markets change—thus changing the
situs of manufacturing over the life of an
issued patent. In general, therefore, filing
patent applications in the countries where
the invention can be sold offers sufficient
protection.
• Is it necessary to file for patent protection
in every country in which the invention
might be marketed? This may not be neces
sary. If patents are filed in 80%–90% of the
countries where the invention can be mar
keted, no competitor could capture more
than 10%–20% of the worldwide market.
If the cost of producing the product can
be brought low enough, there may be no
would-be competitors at all.

. LITIGATIon ConSIdERATIonS
Patents often lead to litigation, both at home and
abroad. This is not, however, all bad. Patents can
be used prospectively—by threatening or initiat
ing litigation to help preserve market share. Patent
rights can, of course, be used by a company to
protect itself from other companies that would

accuse it of patent infringement. Parties seeking
to initiate patent litigation in the United States
can do so in various federal district courts or be
fore the U.S. International Trade Commission
(ITC).
.1 Filing in a federal district court

When filing a patent lawsuit in a federal district
court in the United States, a litigant must first
identify which courts would be proper venues.
Then it must consider which of the permissible
district courts would best suit its litigation goals.
.1.1

Finding the proper venue for litigation10

For a court to be a proper venue for patent litiga
tion, the court must have jurisdiction with regard
to the subject matter of the dispute and the per
sons or entities involved. Jurisdiction is the power
of a court to adjudicate a dispute.
A corporation is considered to “reside” in any
judicial district in which it is subject to personal
jurisdiction at the time an action is commenced.11
According to the U.S. Court of Appeals for the
Federal Circuit, personal jurisdiction exists in a
patent infringement case in which a defendant de
liberately places infringing products in the stream
of commerce with the expectation of exploiting
business in the forum state. Accordingly, an action
for patent infringement may be brought against a
corporation in any district where the corporation
is subject to personal jurisdiction at the time the
suit is commenced. An action for patent infringe
ment may be brought in any judicial district
where the defendant resides.12
U.S. district courts that hear patent litigation
cases are located in various states. Each district
court in a state (the forum state), may properly
exercise personal jurisdiction over a party outside
the forum state if: (1) the party is amenable to
service of process under the long-arm statute of
the forum state; and (2) the party’s activities in
the forum state satisfy the minimum contacts re
quirement of the Due Process Clause.13 With re
gard to the first requirement of long-arm statute,
various states have enacted legislation permitting
its courts (including the federal district courts in
that state) to exercise personal jurisdiction over
nonresidents of the forum state, under certain
HANDBOOK OF BEST PRACTICES | 
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conditions. As for the second requirement of due
process, the Supreme Court of the United States
has decided that the Constitution permits a non
resident of a forum state to be subject to the ju
risdiction of the courts in the forum state, if the
nonresident had certain minimum activities with
the forum state, thereby satisfying due process.
Because several state long-arm statutes, includ
ing those of Texas and California, are coextensive
with the Due Process Clause, the questions of
personal jurisdiction often collapse into a consti
tutional due process inquiry.
Even if a court is chosen for litigation pro
ceedings, the case will not necessarily be held in
that court. Patentee plaintiffs are often subject
to venue challenges in the form of (1) a motion
to dismiss for lack of personal jurisdiction,14 (2)
a motion to dismiss for forum non conveniens,
which is to say, the forum is inconvenient for wit
nesses, experts, documents, and so forth, or (3) a
motion to transfer to an alternate venue. When
the original venue is improper, and not merely
inconvenient, the defendant can file a motion to
dismiss for improper venue. If a plaintiff files a
lawsuit in a district of proper venue that is incon
venient for the defendant or the witnesses, and
if there is a more convenient federal court where
the lawsuit could have been brought, the defen
dant may file a motion to transfer venue under 28
U.S.C. § 1404(a). When the more convenient fo
rum is abroad, the defendant can file a motion to
dismiss for forum non conveniens.15 A defendant
should request a transfer of venue in a separate
motion filed either at or near the time the defen
dant files its answer.
.1.2

Evaluating the proper venues

Next, the patent applicant must decide which
federal district courts and divisions are most fa
vorable. This decision will likely depend on the
average time to resolution, the cost of litigation,
and the likelihood of litigation success. Other fac
tors, such as potential for a retaliatory suit, may
also need to be taken into account, but they are
not within the scope of this article.
Time to resolution is a critically important
consideration. Some district courts are known
for prompt resolution; others are not. Some are
 | HANDBOOK OF BEST PRACTICES

known for being especially fast and are familiarly
known as “rocket dockets”: the Eastern District
of Texas, the Eastern District of Virginia, and
others who have adopted specific local patent
rules that require expedited disclosures and trial
time lines.
Federal Court Management Statistics for
200516 reveal that the median time from filing to
trial in civil cases during the twelve-month period
ending September 30, 2005, was approximately
22.5 months. During this period, an estimated
253,273 civil cases came before federal courts,
of which approximately 12,184 were classified as
intellectual property cases involving copyrights,
patents, and/or trademarks (Table 2).
Rocket dockets may become more com
mon. In September 2006, the U.S. House of
Representatives passed a bill to create a pilot
program designed to encourage and develop
the expertise of district judges in patent cases.
Should the bill become law, it would establish
a ten-year pilot program in at least five federal
district courts and grant US$5 million each year
to educate judges and hire additional staff with
expertise in patent matters. The five courts will be
chosen from the 15 district courts with the larg
est number of patent cases in the previous year
and only those that (1) are authorized to have at
least ten district judges and (2) have at least three
judges who have requested to hear patent cases.
According to a study recently performed by the
law firm of Fulbright & Jaworski LLP, if the pilot
program were to become law this year, the five
participating district courts would likely be cho
sen from among the following fourteen candidate
districts:17
• Central District of California
• Southern District of New York
• Northern District of California
• District of New Jersey
• Southern District of California
• District of Massachusetts
• Middle District of Florida
• Eastern District of Michigan
• Southern District of Florida
• Eastern District of Pennsylvania
• Northern District of Georgia
• Northern District of Texas
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• Northern District of Illinois
• Southern District of Texas
The cost of litigation (see Table 3) should also
be considered by plaintiffs when choosing where
to initiate patent litigation. According to a 2005
study of the American Intellectual Property Trial
Lawyers Association, the location of patent litiga
tion can greatly influence litigation costs.18
Finally, although the likelihood of success
is difficult to predict, George Mason University
School of Law Professor Kimberly A. Moore
says that “choice of forum plays a critical role in

the outcome of patent litigation.”19 Ms. Moore
conducted an empirical analysis of the ten most
frequently selected district courts for patent litiga
tion between 1983 and 1999. She concludes that,
overall, patentees won 58% of all patent suits but
that the win rate varies by region (Table 4).
.2 Filing in the U.S. ITC

Although federal district courts are the custom
ary venues for patent litigation, plaintiffs can also
file a complaint in the U.S. ITC under certain
circumstances. Under the Tariff Act of 1930 (19

Table 2: Median Time from Filing to Trial
for Civil Cases in 2005 in 20 Districts20
District court

Months from filing to trial

Number of IP cases

Eastern District of Virginia

9.4

182

Western District of Wisconsin

11.3

51

District of Maine21

13.0

17

Southern District of Texas

15.3

366

Eastern District of Texas

15.9

193

Southern District of Florida

16.7

332

Middle District of Florida

20.0

280

Eastern District of Wisconsin

20.3

76

Central District of California

20.5

1427

Northern District of Texas

20.7

279

Eastern District of Pennsylvania

20.8

1005

Southern District of New York

22.0

876

Eastern District of Michigan

22.0

208

District of Minnesota

23.0

201

District of Delaware

23.5

149

Southern District of California

25.4

162

Northern District of Georgia

27.0

273

Northern District of Illinois

27.0

462

Northern District of California

28.0

467

District of Massachusetts

31.0

221

HANDBOOK OF BEST PRACTICES | 

YIN & CuNNINGHAM

U.S.C. § 1337), the ITC conducts investiga
tions into allegations of certain unfair practices
in import trade, including patent infringement,
via the importation of infringing products. In
2003, the ITC initiated 18 patent investigations;
in 2004, it initiated 28; and in the first half of
2005, it initiated 21.
Plaintiffs are required to provide more evi
dence to the ITC than they are to federal courts.
In patent cases, for example, the Commission re
quires the following documents in order to initi
ate a “Section 1337 investigation”: claim charts
that purport to show infringement, copies of li
cense agreements pertaining to each asserted pat
ent, copies of certified prosecution histories for
each asserted patent, and copies of the technical

references cited in the prosecution histories for
each asserted patent.22
After a complaint is filed with the Commission,
the Office of Unfair Import Investigations (OUII)
examines the complaint and determines whether
or not to initiate a Section 1337 investigation,
usually within 30 calendar days of the filing of the
complaint. In the event the Commission opts to
institute such an investigation, the Commission
serves all respondents named in the investiga
tion, as well as the U.S. embassy for the coun
try in which they are located, with a copy of the
complaint and a notice of investigation. A notice
of investigation is also published in the Federal
Register. The OUII only rarely decides not to ini
tiate an investigation.23

Table 3: All-Inclusive Cost of Patent litigation in 2005
Geographic region

Average cost of patent
litigation for cases valued
from uS$1 to uS$25 million
(in uS$)

Average cost of patent
litigation for cases valued
above uS$25 million
(in uS$)

Boston

2,638,889

4,107,143

New York City

3,667,308

6,190,000

Philadelphia

3,287,500

4,712,500

3,167,742

6,947,917

Other East

2,468,750

3,076,923

Metro Southeast

3,285,294

9,440,909

Other Southeast

1,662,500

3,342,857

Chicago

2,133,000

4,404,412

Minneapolis-St. Paul

1,567,500

3,688,889

Other Central

1,686,098

3,258,571

Texas

2,847,826

4,993,750

Los Angeles

3,015,000

4,866,667

San Francisco

2,823,529

7,985,714

Other West

2,279,630

5,283,333

Washington, DC
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Once an investigation is instituted, the
Commission assigns an investigative attorney from
the OUII to function as an independent litigant rep
resenting the public interest in the investigation.
A Section 1337 investigation is conducted in
accordance with procedural rules unique to the
ITC, although these rules have some similarities
with the Federal Rules of Civil Procedure. The
Federal Rules of Civil Procedure are the rules
by which litigation is conducted before all U.S.
District Courts. However, for example, during a
Section 1337 Investigation, it is the administra
tive law judge who issues subpoenas24 with nation
wide jurisdiction. Another important distinction
is timing. Typically, a Section 1337 investigation
moves quickly, with quick deadlines for discovery
responses and briefing (usually ten days, rather
than 30 days) and statutory target dates that re
quire completion of the Commission’s proceed
ings “at the earliest practical time.” This often
occurs within 15 months, depending on the com
plexity of the case. As a result, parties initiating

ITC investigations can reasonably expect a trial
within nine or ten months from filing.
A Section 1337 investigation often leads to
a formal evidentiary hearing before the presiding
administrative law judge. At the conclusion of this
hearing, the administrative law judge issues an
initial determination that serves as an initial deci
sion of the merits of the case. The initial determi
nation may then be subject to a review by the full
Commission of the ITC (if the parties so choose)
before it becomes the final determination of the
ITC Commission. The initial determination often
issues at least three months prior to the 15-month
target date for the investigation’s completion. At
the request of one of the parties for a review of
the initial determination, the Commission may
review and adopt, modify, or reverse the initial de
termination or it may decide not to review it at all.
If the Commission declines to review the initial
determination, it becomes the final determination
of the Commission by default.25

Table 4: Win Rate Distribution Among
Some Prolific District Courts (1983-1999)
District court

Patentee wins
(percent of total cases)

Infringer wins
(percent of total cases)

Northern District of California

68

32

District of Minnesota

67

33

Central District of California

63

37

Southern District of New York

63

37

Southern District of Florida

63

37

District of New Jersey

61

39

Eastern District of Virginia

58

42

Northern District of Illinois

48

52

District of Delaware

46

54

District of Massachusetts

30

70

Source: The Federal Judiciary26
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In the event that the Commission determines
that Section 1337 has been violated, the commis
sion may issue a cease-and-desist order, directing
the violating parties to cease their illegal activities,
as well as one of two types of exclusion orders: gen
eral (applying to all infringing articles, regardless
of source) or limited (applying to those infringing
articles imported by a respondent to the investiga
tion) barring certain products from entry into the
United States.27 The Commission cannot assess
monetary damages. The Commission’s exclusion
orders are enforced by the U.S. Customs Service,
although the Commission enforces its own cease
and-desist orders.
The president has 60 days to review
Commission orders before they become effec
tive. During this period, infringing articles may
enter the United States if the importer posts a
bond with the Customs Service for an amount
determined by the Commission. Similarly, activi
ties prohibited by a Commission cease-and-desist
order may also continue during the Presidential
review period if the respondent posts a bond with
the Customs Service. Appeals of Commission
orders pursuant to Section 1337 investigations
are heard by the U.S. Court of Appeals for the
Federal Circuit.
There are advantages and disadvantages to
using the International Trade Commission as a
forum for patent litigation (see Table 5). Perhaps
the greatest advantage is that the win rate of
plaintiffs in ITC investigations is approximate
ly 70%, as opposed to 58% in federal district
courts.

. ConCLuSIonS
A global patent filing program is an essential
component of an integrated system of IP man
agement. It maximizes value and protects the
integrity of an organization’s patent portfolio.
Such a program requires knowledge, organiza
tion, and planning. The dynamics of the interna
tional patent landscape must be understood (for
example, issues relating to establishing foreign
priority, where to file patent applications, and
the advantages and disadvantages of the various
filing options). Organizational efforts will focus
2 | HANDBOOK OF BEST PRACTICES

on arranging the patent portfolio to achieve stra
tegic global objectives (for example, determining
in which countries and/or jurisdictions to seek
patent protection according to (in the case of pri
vate sector) commercial objectives, or, (in the case
of the public sector) humanitarian access objec
tives. Planning requires foresight. For example,
one must anticipate the possibility of litigation
and know what the venue options are based on
the cost, speed, and likelihood of success in liti
gation. With such a comprehensive program in
place, both public and private sector organiza
tions will be positioned to anticipate, manage,
and overcome the uncertainties and challenges
that characterize the international technology
marketplace in agricultural and health innova
tions. n
Ronald yin,
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PTO Press Release (February 14, 2006) titled United
States Patent and Trademark Office Issues 7 Millionth
Patent.

2

For a current listing of members of the Paris Union:
www.wipo.int/treaties/en/ShowResults.jsp?lang=
en&treaty_id=2.

3

A patent application filed with the EPO may be
submitted in the official language of any EPC member
state (including the extension states), but a translation
must be submitted in one of the three official EPO
languages (English, French, or German) within three
months of filing the application and no more than
13 months after the earliest requested priority date.
The date of application is the actual filing date. If a
request for priority is also filed, that is, the application
was initially filed in a foreign jurisdiction, then the
“requested priority date” is the priority date that the
applicant requests the EPC application be accorded. A
patent application filed with the JPO must be written
in Japanese, but the specification, claims, drawings,
and abstract can be written in English, as long as a
Japanese translation of the English documents is
filed within two months of the initial filing date. It
is possible to file a patent with the U.S. Patent Office
in any language, as long as an English translation is
submitted within two months.

4

The application for an invention that has not and
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will not be patented in foreign countries will not be
published if the applicant so requests.
5 A Statutory Invention Registration is authorized by law:35
U.S.C. § 157. It permits a party to publish an invention, but
without all theattributesofapatent,that is,thepublished
invention can be used defensively, as a publication, but
not offensively to assert infringement against others.
6

U.S. Patent and Trademark Office. 2006. Calendar Years
1790 to the Present. Table of Annual U.S. Patent Activity
Since 1790. www.uspto.gov/web/offices/ac/ido/oeip/taf/
h_counts.pdf.
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U.S. Patent and Trademark Office. 8 February 2006.
Patent Trends Calendar Year 2005.

8 OECD. 2005. Compendium of Patent Statistics.
Organisation for Economic Co-Operation and
Development: Paris. p. 55.
9

OECD. 2005. Compendium of Patent Statistics.
Organisation for Economic Co-Operation and
Development: Paris. pp. 55–56.

10 Subject matter jurisdiction (that is, the power of
the district court to hear the subject matter of the
controversy) is not an issue for patent cases because

Table 5: Advantages and Disadvantages to Initiating ITC Investigations
Advantages

Disadvantages

Broad injunctive remedies exclude
importations or order infringing parties to
cease and desist from particular activities.

Section 1337 refers only to imported goods;
ITC does not award monetary damages.
(However, filing a case with the ITC does not
prohibit one from filing a parallel case in
federal court.)

Investigations are usually completed in 15
months or less, faster than most district
courts.

The discovery and motion practice is fast,
permitting little time to search for prior
art that might invalidate a patent or other
evidence to render a patent unenforceable.
Responses are often due within 10 calendar
days. Furthermore, because in an ITC
investigation the OUII is another party,
discovery and response briefing are served/
filed not only by the opposing party, but also
by the OUII.

Broad (in rem) jurisdiction means jurisdiction
is derived from the imported articles, as
opposed to the presence of particular parties
or acts in and around Washington, DC. Thus,
goods of a downstream importer who is not
named in the ITC, and who normally might
not be subject to the jurisdiction of the
courts (such as a foreign resident), may be
excluded.

The domestic industry requirement mandates
that the complainant demonstrate that:
• there exists a domestic industry protected
by the patent right that the plaintiff seeks
to enforce
• the defendant has performed an unfair act
• the defendant’s act has a detrimental effect
or tendency (above and beyond mere legal
infringement).

No counter-claims are permitted.

The plaintiff must provide detailed factual
allegations for each element of each claim.

The trier of fact is an administrative law
judge with experience in patent lawsuits.

There is no possible recourse to trial by jury.

The administrative law judges are rotated on
a regular basis. Thus, assignment of a case to
an administrative judge might be predicted.

In recent months, the rotation of judges has
become less predictable
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federal courts have exclusive jurisdiction over patent
issues. See 28 U.S.C. § 1338. However, if the litigation
involves other claims, those other claims might be
permissible in federal court.
11 28 U.S.C. § 1391(c).
12 See 28 U.S.C. § 1400(b).
13 See Hildebrand v. Steck Mfg. Co., Inc., 279 F.3d 1351, 1354
(Fed. Cir. 2002).
14 Unlike challenges to subject matter jurisdiction, the
defense of lack of personal jurisdiction must be raised
at the outset of litigation or else the defense is deemed
waived. See Fed. R. Civ. P. 12.
15 Quackenbush v. Allstate Ins. Co. (517 U.S. 706, 722
[1996]).
16 www.uscourts.gov/fcmstat/index.html.
17 Anonymous. 2006. Patent Rocket Dockets? House
Approves Bill for Pilot Program to Enhance Patent
Expertise in Certain Federal District Courts.
Fulbright & Jaworski LLP Client Alert (October
2006).
www.fulbright.com/images/publications/
FulbrightClientAlertPatentRocketDockets1.pdf.
18 American Intellectual Property Lawyers Association.
2005. AIPLA Report of the Economic Survey 2005. pp.
109–10.
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889.
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20 The median time was calculated using the date a case
was filed and the date the trial began. In the case of
reopened cases that resulted in a second completed
trial, the median time was calculated using the
original filing date and the date the second trial was
completed.
21 Statistics for the District of Maine were not available
for 2005. These statistics are for 2004.
22 See Rule 210.12(c–g), 19 C.F.R. § 210.12(c–g).
23 See U.S. International Trade Commission. 2004. Section
1337 Investigation: Answers to Frequently Asked
Questions. Publication No. 3708. p. 21.
24 See Rule 210.32, 19 C.F.R. § 1337. Investigation: Answers
to Frequently Asked Questions 210.32.The Federal Rules
of Civil Procedure limit the scope of any subpoena to
command a person within 100 miles where the court
sits if the rules of state statute permit issuance of state
-wide subpoena.
25 Ibid.
26 See supra note 21 at page 916.
27 The remedy of an exclusion order has become a more
powerful tool (and threat) after eBay v. MercExchange
(126 S.Ct. 1837 [U.S. 2006]). In the wake of the eBay
decision, patent owners can no longer assume that
injunctions will issue if infringement is found in a case
brought in federal district court.
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ABSTRACT

All biotechnology and pharmaceutical products must be
approved by both the U.S. Patent and Trademark Office
(PTO) and the U.S. Food and Drug Administration
(FDA). To maximize the impact of a product’s market
exclusivity, the time spent on getting approval should
be minimized. This chapter discusses how the interplay
between PTO and FDA applications affect the patent
approval process, and by extension the patent term, and
how these impact the commercial life of a product.

1. InTRoduCTIon
The goals of the public and private sectors of
the drug industry are often different. The public
sector’s main goal is to provide drugs to the public
for the lowest possible price, while the private
sector is most interested in achieving the greatest
possible profit. Many private company tactics are
employed for maximizing revenue are important
to understand as they can also help the public
sector to achieve its goals. For example, price
discrimination—the practice of selling health
products at different prices to different customers
in various markets—is commonly used by private
corporations to increase their profit margins. This
practice, however, can also be used by nonprofit
organizations: if they were to sell their products to

developed countries at higher prices—or to license
them to manufacturers in developed countries—
the organizations would be better able to subsidize
drug prices in poorer countries.
There are other ways that companies can
maximize their revenue. For instance, companies
in the biotechnology and pharmaceutical area
must apply for approval from the U.S. Patent and
Trademark Office (PTO) and Food and Drug
Administration (FDA). Both of these applications
are necessary: the PTO approves patents that pro
tect a company’s inventions, and FDA approval
of a product is necessary before a new product
can be marketed. These approval processes are
lengthy, and companies should minimize the time
spent on the process as part of a profit-maximiz
ing strategy. This chapter outlines various ways to
extend a patent’s effective life through the strate
gic management of these approval processes.

2. pTo And fdA AppRovAL pRoCESSES
2.1 Patent applications

The PTO grants patents to inventions that are novel,
useful, and nonobvious.1 The novelty requirement

Fernandez DS, J Huie and J Hsu. 2007. The Interface of Patents with the Regulatory Drug Approval Process and How Resulting Interplay Can Affect Market Entry. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available
online at www.ipHandbook.org.
Editors Note: This chapter is included in this Handbook to show the important interface of patents and the regulatory
drug approval process and how this interplay affects market entry. It is not intended as an endorsement of effective patent life extensions to delay the market entry of generic drugs.
© 2007. DS Fernandez, J Huie and J Hsu. Sharing the Art of IP Management: Photocopying and distribution through the
Internet for noncommercial purposes is permitted and encouraged.
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prevents anyone from patenting an invention
that is already available to the public. The useful
ness, or utility, requirement states that one skilled
in the art must be able to utilize the invention
in a manner that provides immediate benefit to
the public. The obviousness requirement prevents
applicants from patenting products or processes
that are insignificant modifications of already ex
isting products or processes.
The inventor of a patented invention has
the right to exclude others from making, using,
offering for sale, or selling the invention in the
United States or in U.S. territories or possessions.
A limited 20-year monopoly2 is granted to the
inventor in exchange for public disclosure of the
invention.3 In the United States, the average time
between filing of the application and approval of
the patent is 3 ½ years, while the average time for
a biotechnology patent is nearly 4 ½ years.
2.2 Discovery phase and preclinical studies

Simply put, in the discovery phase of research, sci
entists identify specific chemical or biochemical
entities that are worth testing further. Next, pre
clinical studies are undertaken comprising in vi
tro studies and animal testing, pharmacodynamic
responses, metabolic profiling, cellular receptor
interaction, and/or physiology that is generally
analogous to humans. Preclinical studies take
an average of five years, but the precise length of
time depends on the complexity of the study and
the success achieved by initial research.
2. FDA approval process

The FDA approval process usually requires ten to
12 years and US$100 to US$500 million. The
process is accomplished in two phases: clinical tri
als and new drug application (NDA) approval.
The FDA approval process begins when a
manufacturer requests permission, by submitting
an investigational new drug (IND) application,
to begin human testing. The IND application
must provide preclinical data of high quality to
justify the testing of the drug in humans. Once
the IND application is filed, the manufacturer
must allow the FDA 30 days to review the pro
spective study before clinical trials can begin.
IND applications must be re-filed annually until
 | HANDBOOK OF BEST PRACTICES

clinical testing is completed. Approximately
85% of all drugs for which IND applications
are filed are subjected to clinical trials.
The next stage is Phase I clinical trials, which
use human subjects. Phase I trials focus on es
tablishing a drug’s safety profile and examining
how the drug is absorbed, distributed in the body,
metabolized, and finally excreted. Phase I trials
usually do not use more than 100 healthy volun
teers, and the trials last, on average, from one to
three years.
If the drug successfully passes Phase I, it is
submitted to Phase II trials, which evaluate dos
age, broad efficacy and additional safety. In this
phase, volunteers who suffer from the targeted
disease are given the drug. Phase II lasts two
years, on average.
Phase III trials attempt to verify the effec
tiveness of the drug with double-blind studies
that involve at least 1,000 patients. (A doubleblind study is a stringent way of conducting clin
ical trials whereby subjective bias is eliminated
by neither doctors/nurses nor patients knowing
whether they administer/receive a placebo or ex
perimental drug.) This phase continues to build
the drug’s safety profile by monitoring any side
effects that result from long-term use of the drug.
This phase lasts, on average, between three and
four years.
If the drug successfully passes the first three
phases of clinical trials, researchers can then file
a new drug application (NDA) that includes the
drug’s proposed labeling. A team of physicians,
statisticians, chemists, pharmacologists, and oth
er scientists at the Center for Drug Evaluation
and Research review the company’s NDA by ex
amining the preclinical and clinical reports and
using risk-benefit analysis to determine whether
or not the product’s beneficial effects outweigh
its possible harmful effects. Approval of an NDA
can take from two months to several years, but,
on average, approval is granted within two years.
Once the NDA is approved, the innovating
company is allowed to distribute and market the
drug.
Once the drug is distributed in the public
market, it is considered to be in Phase IV trials.
The manufacturer must continue to monitor and
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Figure 1: Timeline for Patent/Product Approval
and Profit-Maximizing Options
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evaluate the drug’s safety during routine use (see
Figure 1 for a timeline of the above process).
2. Filing PTO and FDA applications

The “effective life” of a patent is defined as the pe
riod of time between a product’s introduction to
the market and the patent’s expiration date. The
manufacturer of a product with a long effective
life will enjoy extended market exclusivity and
thereby recover research and development costs.
When the patent expires, the manufacturer will
be at a real disadvantage: on average, generic drug
companies capture 57.6% of the market for drugs
with expired patents. Obviously, the faster the
drug is approved and thus comes to market, the
longer the marketing period and thus the genera
tion of revenues and profits.
Preclinical studies are the rate-limiting step
in the FDA approval process because clinical tri
als cannot begin until there is sufficient data to
justify human testing. Therefore, as many pre
clinical studies should be performed as early as
possible and preferably before a patent applica
tion is filed, as the results of such studies also help
support claims for the utility of an invention.
There are several reasons why innovating
companies should file patents for their products
before seeking FDA approval for them. In the
first place, the PTO has lower safety standards
than the FDA;4 although a patent application
must demonstrate that a drug has a “sufficient
probability” of safety in humans, the applicant
is not required to provide any clinical evidence
of its safety.5
Next, patents are important IP (intellectual
property) safeguards. If an innovating company
were to begin the FDA process before filing a
PTO application, another company could patent
the invention before them. The innovating com
pany would either have to license the biophar
maceutical from the other company (losing royal
ties, market exclusivity, and company value in the
process) or abandon the FDA process altogether
and forfeit millions spent in research and devel
opment.6 Even if another company does not pat
ent the product, the innovating company must
be careful not to disclose the invention, otherwise
the innovating company would have one year to
 | HANDBOOK OF BEST PRACTICES

file the patent before the patent enters the public
domain (internationally, the patent application
must be filed before disclosure).
There are two other reasons to file patents
before beginning an FDA application: (1) FDA
approval is accelerated for patented compounds,
and (2) patents attract the notice of potential in
vestors who can provide the capital to fund FDA
clinical trials. Ideally, preclinical studies should
end before, or concurrently with, patent issuance,
and FDA clinical trials should begin immediately
thereafter. But before clinical trials can begin, the
manufacturer must turn over several documents
justifying the conduct of the trial, verifying the
quality of the data produced, and demonstrating
the compliance of the investigator with all regula
tory requirements. These documents include: sci
entific journal publications, in vitro and animal
data, trial subject information, financial analysis,
and laboratory protocol. The FDA must review
and approve these documents before clinical trials
can begin. As mentioned above, the filing of the
patent should be done first, or the drug manufac
turer runs the risk of missing the one-year dead
line for establishing priority of invention.
Once the FDA has approved the drug for
U.S. consumers, the innovating company will
enjoy market exclusivity for the patent’s effective
life. A strategically written patent will effectively
and efficiently protect against product infringe
ment by other companies. The innovating com
pany should take pains to develop brand recogni
tion and build consumer reliance on its products
in order to retain the largest possible market share
once the patent term ends.

. ExTEndInG A pATEnT TERM
Once the patent term ends, the innovating com
pany need not lose its market exclusivity imme
diately. Various tactics can be used to extend a
patent term and delay generic market entry.
Assuming a patent satisfies certain basic
criteria,7 the PTO will grant patent extensions
when its approval process takes longer than
three years. If, for example, a patent took four
years to issue, the patent term may be extended
by an additional year.8
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Two laws also allow for patent terms to be
extended: the Drug Price Competition and
Patent Term Restoration Act of 1984 (also known
as the Hatch-Waxman Act) and the Generic
Animal Drug and Patent Term Restoration Act
of 1988. Title II of the Hatch-Waxman Act (the
“patent term restoration” or “extension” clause)
gives certain patent holders the opportunity to
extend patent terms for human drug products,
including antibiotics and biologics, medical
devices, food additives, and color additives.
The Generic Animal Drug and Patent Term
Restoration Act provides a similar opportunity
to holders of patents for animal drug products
(excluding those derived from recombinant
DNA technology). These laws were designed
to stimulate innovation by domestic drug
companies. Both acts allow a patent term to be
extended by up to five years. However, the total
effective patent life cannot exceed 14 years from
the date of FDA approval.9
In order for an innovating company to
obtain a patent term extension, certain criteria
must be met:
1. The patent has not expired.
2. The patent has not previously been
extended.
3. The patent owner or its agent submits the
application.
4. The product has been subjected to a regu
latory review period with the FDA or the
U.S. Department of Agriculture (USDA)
before its commercial marketing or use.
5. The permission for commercial marketing
or use represents the first permitted com
mercial marketing or use of the product
for which the regulatory review occurred
(see below). For products produced using
recombinant DNA technology, excluding
animal drug products, the product must be
the first produced using that technology.
6. The patent restoration application must be
submitted within 60 days of the product’s
initial FDA approval.10
The regulatory review period is composed of
a testing phase and an approval phase. The testing
phase is the period between the effective date of

an investigational product exemption (for exam
ple, an IND application) and the initial submis
sion of a marketing application (for example, an
NDA). The approval phase is the period between
the submission and the approval of the marketing
application.11 The PTO calculates the length of
the extension by considering both the lengths of
the aforementioned testing and approval phases.
It is important to note that the PTO does not
consider times the applicant did not exercise due
diligence12 during the regulatory review period.
After the innovating company’s patent term
expires, generic companies may enter the mar
ket with generic drug equivalents. Whereas the
initial FDA approval process may have taken
ten to 12 years, the Hatch-Waxman Act allows
generic companies to use the abbreviated new
drug approval (ANDA) process to gain approval
for generic equivalents within six months. There
are three requirements for filing an ANDA
application:
1. The company must show that the proposed
generic drug is the same as, or bioequiva
lent to, an FDA-approved drug.
2. The company must certify that a patent
protected the approved drug.
3. The company must not use a production
method that has been patented by the in
novating company (a so-called production
method patent).
Because of the third stipulation, it is wise
to file the drug production method patent a few
years after filing the original patent (generally
focusing on the composition of the drug). This
will ensure that even when the drug composition
enters the public domain, the production meth
od will continue to be protected. This strategy is
even more effective for biopharmaceuticals than
for traditional chemical pharmaceuticals because
it is so difficult to create production methods us
ing complex microbiological systems.
Another strategy is known as the metabolite13
defense involves filing patents for useful drug me
tabolites in years subsequent to the filing date of
the main patent. Once the generic version of the
drug is marketed, the innovating company can
bring a patent infringement claim against the
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generic company, since the company will inevi
tably be manufacturing infringing products via
its customers’ metabolic processes.14 While the
effectiveness in court of the metabolite defense
may be debatable,15 litigation can delay market
entry of generics.
Finally, an innovating company can file a
citizen petition with the FDA, citing safety concerns
regarding a generic biopharmaceutical. Although
the majority of citizen petitions are eventually
rejected by the FDA or withdrawn by innovating
companies, filing such a petition can delay generic
market entry for six months or more.

. ACCELERATInG MARkET EnTRy
There are essentially five ways in which compa
nies may accelerate the introduction to market of
a new drug:
• PTO special status: The PTO awards spe
cial status to certain biotechnology inven
tions, processing them ahead of all others.
To qualify for a special status the company
must be a small entity (a company with
fewer than 50 employees) or a nonprofit
organization. The petition must state that
the patent applicant’s technology will be
significantly impaired if a patent examina
tion is delayed.
• FDA well-characterized status: The FDA
can designate a biopharmaceutical as a well
characterized biotechnology product if its
identity, purity, potency, and quality can be
substantially determined and controlled.
As long as the manufacturer is able to pro
duce the same product, the manufacturing
technologies of a well-characterized phar
maceutical can be altered without having to
repeat clinical trials. If a company develops
a well-characterized biotechnology product,
it can begin FDA clinical trials immediately
and improve the manufacturing process at
a later date.
• FDA expanded access exception: This excep
tion allows manufacturers to market the
product before completing clinical trials
(before completing the approval process).
Expanded access is available for a very
0 | HANDBOOK OF BEST PRACTICES

limited number of new drugs that are pend
ing final FDA approval. This program al
lows drugs to be used and marketed before
the FDA approval process is completed. The
manufacturer must apply for a drug to be
made available through an expanded access
program. To acquire such status, the com
pany must provide sufficient evidence that
the drug will be effective against a given dis
ease and that the drug has not been linked
to unreasonable health risks. The provision
is somewhat uncommon because the FDA
generally allows expanded access only if
there are no other satisfactory treatments
available for the given disease.
• FDA accelerated approval process: The FDA
may accelerate approval of a biopharma
ceutical if adequate and well-controlled
clinical trials indicate that it will provide
considerable therapeutic benefit over exist
ing therapies, particularly in cases of serious
or life-threatening diseases.

. ConCLuSIon
The PTO and FDA approval processes are expen
sive and time-consuming. By the time a drug can
be marketed to the public, part of its patent term
will have already expired. In order to maximize
profits, FDA processing time should be mini
mized as far as possible. In addition, patent terms
can sometimes be extended, and various strategies
can be used to prevent generic companies from
taking too much of market share. Nonprofit orga
nizations in particular may benefit from the strate
gies outlined in this chapter, especially if they are
used in conjunction with price discrimination. n
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1

35 U.S.C. § 102; 35 U.S.C. § 103.

2

On December 8, 1994, President Clinton signed the
Uruguay Round Agreements Act into U.S. law. The
Uruguay Round Agreements Act gives all patents that
were in force or filed as of 8 June, 1995 an effective term
of 17 years from the date the patent was granted or
20 years from the date of the first filing of the patent
application. All patents filed after 8 June, 1995 have a
patent expiration date of 20 years from the date of the
first filing of the patent application.

3

Nelson v. Bowler 626 F.2d 853 Cust. & Pat. App., 1980
(C.C.P.A. 1980), “Knowledge of the pharmacological
activity of any compound is obviously beneficial to
the public. It is inherently faster and easier to combat
illnesses and alleviate symptoms when the medical
profession is armed with an arsenal of chemicals having
known pharmacological activities. Since it is crucial
to provide researchers with an incentive to disclose
pharmacological activities in as many compounds as
possible, we conclude that adequate proof of any such
activity constitutes a showing of practical utility.”

4

35 § U.S.C. 102; 35 U.S.C. 103.

5

See In re Hartop, 311 F.2d 249 (C.C.P.A. 1962).

6

The Federal Circuit recognized such concerns of
pharmaceutical companies in In re Brana, 51 F.3d
1560 (Fed. Cir. 1995): “FDA approval, however, is not a
prerequisite for finding a compound useful within the
meaning of the patent laws. . . . Usefulness in patent
law, and in particular in the context of pharmaceutical
inventions, necessarily includes the expectation of
further research and development.The stage at which an
invention in this field becomes useful is well before it is
ready to be administered to humans.Were we to require
Phase II testing in order to prove utility, the associated
costs would prevent many companies from obtaining
patent protection on promising new inventions, thereby
eliminating an incentive to pursue, through research
and development, potential cures in many crucial areas
such as the treatment of cancer.”

7

8

35 U.S.C. § 155; 35 U.S.C. § 156.

9

If the patent was issued before 24 September, 1984
and the product’s regulatory review period began
before that date, then the limit is two years. For animal
drug products whose regulatory review periods began
before 16 November, 1988 the limit is three years. In
all cases, the total patent life for the product cannot
exceed 14 years from the product’s approval date.

10 The FDA defines product approval as the date the FDA
sends a letter notifying the marketing applicant that
(1) the FDA approved the marketing application, (2) the
product development protocol was completed, or (3)
the listing of used food or color additives. The 60-day
term begins on the day after approval; the PTO must
receive the application for patent extension on the
60th day (or the next business day after the 60th day
if this day falls on a weekday or holiday).
11 The FDA has 30 days by law to determine the regulatory
review period for a product. After this period, there
is a 60-day comment period during which parties
can request revisions to the regulatory review period
determination. The end of the 60-day comment period
marks the end of the regulatory-review period stage.
12 Due diligence is defined as “that degree of attention,
continuous directed effort, and timeliness as may
reasonably be expected from,and are ordinarily exercised
by, a person during a regulatory review period.” 35 U.S.C.
§ 156(d)(3).
13 Metabolites are the metabolized derivatives of a drug.
14 In Hoechst-Roussel Pharms., Inc. v. Lehman, 109 F.3d 759
(Fed. Cir. 1997), the court “recognized that a person may
infringe a claim to a metabolite if the person ingests a
compound that metabolizes to form the metabolite.”
See also Zenith Labs., Inc. v. Bristol-Meyers Squibb Co., 19
F.3d 1418 (Fed. Cir. 1994) (stating that a compound claim
could cover a compound formed upon ingestion).
15 In Schering Corporation v. Geneva Pharmaceuticals,
Inc., 339 F.3d 1373 (Fed. Cir. 2003), a Federal Circuit
panel recognized that patent protection is available
for metabolites of known drugs: “[A] patentee may
obtain patent protection for an inherently anticipated
compound through proper claiming.”

21 C.F.R. Part 60.
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Deposit of Biological Materials in
Support of a U.S. Patent Application
dENNIS J. HARNEy, Attorney, Sonnenschein Nath & Rosenthal LLP, U.S.A.
TIMOTHy B. MCBRIdE, Attorney, Senniger Powers, U.S.A.

ABSTRACT

The deposit of biological material in support of a U.S.
patent application is a mechanism by which an applicant
can cure what might otherwise be potentially fatal defects
in a patent application and even an issued patent. A bio
logical deposit can, in some cases, satisfy the requirements
of enablement, written description, and best mode, and
potentially broaden the scope of claims in the event of
litigation. This chapter briefly explores the relationship
between biological deposits and patentability require
ments, what can be deposited, where and when a deposit
can be made, and who has access to the deposit.

1. WHAT DOES A DEPOSIT ACCOMPlISH?
Referencing deposited biological material in the
specification of a U.S. patent application provides
the advantage of the deposited material being in
corporated into that patent’s disclosure.3 As part
of the disclosure, the deposited material may be
employed to augment or correct deficiencies in
the specification of the application, specifically,
as to enablement, written description, and best
mode requirements.
1.1

Deposit and the enablement requirement

While not always required, a deposit of biologi
cal material is one way to satisfy the enablement
requirement of 35 U.S.C. § 112. The specifica
tion of a patent must enable a person skilled in
the art to make and use the invention claimed,
aided only by his or her ordinary skill and the

state of the art.4 The enablement requirement is
typically accomplished through a written descrip
tion of the invention within the specification. But
inventions not easily or reasonably described by
the written word alone may be “described in sur
rogate form by a deposit that is incorporated by refer
ence into the specification.”5 By providing access to
biological material that is difficult to describe, an
applicant enables the public to make and use the
claimed invention.
A deposit of biological material also can re
duce the amount of disclosure required in the
application to enable the claimed invention. For
example, in In Ex parte C, by describing the pa
rental varieties and the selection process in con
junction with a seed deposit, applicants success
fully enabled a novel variety of soybean plant,
seeds from the plant, and a method of producing
seeds by self-pollination.6 Notably, the Board of
Patent Appeals and Interferences (BPAI) did not
require an exacting description of breeding, selec
tion, and testing since the invention, a disease-re
sistant soybean plant, was placed in deposit.
A deposit of biological material may enable
more than just the species so deposited. For exam
ple, in Ajinomoto v. Archer-Daniels-Midland, the
Federal Circuit held that a method for producing
an amino acid from a genetically engineered bac
terium was enabled, despite the fact that only one
altered strain of bacteria that produced threonine

Harney DJ and TB McBride. 2007. Deposit of Biological Materials in Support of a U.S. Patent Application. In Intellectual
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. DJ Harney1 and TB McBride2. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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was disclosed and deposited.7 However, the BPAI
was not quite so generous in several previous
cases. For example, in Ex parte Hata, the BPAI
affirmed the rejection of claims directed to treat
ment of infectious disease by administering spe
cific strains of Lactobacillus on the grounds that
the select strains deposited were narrower than
the broader class of all strains and that undue ex
perimentation would be required to locate new
microorganisms covered by the claim.8
1.2 Deposit and the written description
requirement

While not always required, a deposit of biologi
cal material is one way of satisfying the written
description requirement of 35 U.S.C. § 112.
This requirement is met if the specification de
scribes the claimed invention in sufficient detail,
such that one skilled in the art would reasonably
conclude that the applicant was in possession of
the claimed invention at the time of filing. This
can be achieved by describing the invention with
all its limitations using such descriptive means
as words, structures, figures, diagrams, and for
mulas that fully set forth the claimed invention.9
Put simply, the specification must describe the
invention such that it is distinguishable.
Until 2002, it was somewhat uncertain
whether a deposit of a biological sample could
satisfy the written description requirement. But
in that year, the Federal Circuit, in Enzo v. GenProbe, held that deposit of a biological sample
in a public repository could fulfill the require
ment.10 The specification of the Enzo patent
provided a functional description (hybridization
characteristics) and referenced a biological de
posit, but disclosed no sequences or structural
descriptions of any of the claimed nucleic ac
ids. Thus, under Enzo, a reference to a deposit
coupled with a functional description meets the
written description requirement so long as a
known correlation exists between the described
function and a deposited or described structure.
The generic scope of claims supported would
be that which a person of skill would deem the
patentee to possess based upon the disclosure,
which includes information obtainable from the
deposits.11
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The information obtainable from deposits in
support of a patent can potentially broaden inter
pretation of the claims. For example, in Schering
v. Amgen, the patent owner could have used de
posited biological material to show that the claims
to leukocyte interferon encompassed the subtype
IFN-alpha14, despite that the specification dis
closed only two other subtypes.12 In Schering, the
patent owner provided evidence that the deposit
coded for IFN-alpha14, but only to the appellate
court and not to the trial court. The court held
that, although a deposit could satisfy the enable
ment requirement, the deposit must be part of
the record before it is used to provide support
for a particular claim construction. Because the
patent owners in Schering presented the evidence
too late, the deposit could not influence claim
construction. However, the lesson remains that
deposited biological material incorporated into
the disclosure may be used to support a claim
interpretation more broadly than that explicitly
disclosed in the specification.
1. Deposit and the best mode requirement

A deposit of biological material may also satisfy
the best mode requirement under 35 U.S.C. § 112,
¶ 1,13 but a deposit is not strictly necessary.14 The
best mode of carrying out an invention must be
disclosed in sufficient detail at the time of filing
the application to allow one of ordinary skill to
practice it. To satisfy the best mode requirement,
there must be no concealment of a mode of prac
tice known by the inventor at the time of filing to
be better than that disclosed.15
In Amgen v. Chugai Pharmaceutical, the de
fendants argued that, in the field of living materi
als, a biological deposit should be required so that
the public has access to exactly what the patent
applicant contemplates as the best mode.16 The
Federal Circuit held that a deposit was not neces
sary where the best mode of preparing a cell line
necessary to practice the invention was disclosed
and enabled in the specification.17
Similarly, in Scripps v. Genetech, where a
patent specification described the process for
producing, screening, and evaluating mono
clonal antibodies, the Federal Circuit held that
applicants had not concealed the best mode for
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practicing the invention of protein purification
using antibodies, despite not having deposited
successfully isolated antibodies.18 In Scripps, the
court specifically rejected the argument that the
“laborious nature of the process of screening the
monoclonal antibodies” required deposit of the an
tibodies representing the best mode.

2. WHAT CAN BE DEPOSITED?
Biological material eligible for deposit are those
materials capable of direct or indirect self-replica
tion.19 Representative examples include bacteria,
fungi, yeast, algae, protozoa, eukaryotic cells, cell
lines, hybridomas, plasmids, viruses, plant tissue
cells, lichens, and seeds. Furthermore, the deposit
rules provide that viruses, vectors, cell organelles,
and other nonliving material existing in, and re
producible from, a living cell may be deposited
by means of a deposit of the host cell capable of
reproducing the nonliving material.
Generally, for each deposit, the specification
of the patent must contain the accession number
for the deposit, the date of the deposit, a descrip
tion of the deposited biological material sufficient
to specifically identify it and to permit examina
tion, and the name and address of the deposi
tory.20
3. IS A DEPOSIT REQuIRED?
The biological deposit “requirement” is not a re
quirement per se. Rather, the deposit rules pro
vide a mechanism by which an applicant can
overcome what would otherwise be a deficiency
in the patent application. It is important to note
that a biological deposit may be referenced in a
specification even when not required. Moreover,
referencing a biological deposit in the specifica
tion does not give rise to a presumption that the
deposit was necessary under 35 U.S.C. § 112.
A biological deposit may be necessary where
biological material is required to practice an
invention and “words alone cannot sufficiently
describe how to make and use the invention in a
reproducible manner.”21 For example, a deposit
could be required where an invention cannot
be practiced without access to an organism only

obtainable from nature.22 In the words of the
Federal Circuit:
When an invention relates to new biological
material, the material may not be reproducible even
when detailed procedures and complete taxonomic
description are included in the specification. It is
then a condition of the patent grant that physical
samples of such materials be deposited and made
available to the public, under procedures established
by the [U.S. Patent and Trademark Office] and in
ternational treaty.23
Even so, if “words alone cannot sufficiently de
scribe” the invention such that a biological deposit
would normally be required, such a deposit would
still not be necessary if the biological material nec
essary to the invention is (1) known and readily
available to the public or (2) derived from readily
available starting materials through routine screen
ing that does not require undue experimentation.24
.1 Known and readily available

Biological material need not be deposited unless
access to the material is required under 35 U.S.C.
§ 112 and the material is not otherwise known
and not readily available to the public. Indica
tions that biological material is known and avail
able include:
• commercial availability
• references to biological material in printed
publications
• declarations of accessibility by those work
ing in the field
• evidence of predictable isolation techniques
• an existing deposit
Thus a patentee may forgo a deposit in favor
of assuming an obligation to make the necessary
biological material publicly available.
While the U.S. Patent and Trademark Office
(PTO) will accept a showing of current availabil
ity, the patentee takes the risk that the biologi
cal material will cease to be known and readily
available.25 The rules do not provide for post-is
suance original deposits. But the PTO will accept
a replacement deposit when a patent owner has
diligently provided the replacement deposit after
receiving notification that the depository can no
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longer furnish samples of the original deposit, or
that the deposit has become contaminated or lost
its capability to function.26 Failure to diligently
make a replacement deposit will preclude grant of
a certificate of correction.27 A replacement depos
it subsequently made will not be recognized by
the PTO, and a request for a certificate of correc
tion, even if made promptly thereafter, will not
be granted.28 Furthermore, the failure to make a
replacement deposit where a deposit is considered
to be necessary to satisfy the requirements of 35
U.S.C. § 112, will cause a patent involved in a
reissue or reexamination proceeding to be treated
by the PTO as if no deposit had been made.29
As such, unavailability of biological material
necessary to practice the invention is a defect that
cannot be cured after the grant of a patent and
can result in unenforceability. This risk is reflect
ed in advice from the PTO:
[Where] an applicant for patent has any doubt
as to whether access to a biological material specifi
cally identified in the specification is necessary to
satisfy 35 U.S.C. § 112 or whether such a mate
rial, while currently freely available, may become
unavailable in the future, the applicant would be
well-advised to make a deposit thereof before any
patent issues.30
.2 Derived without undue experimentation

If only starting materials are readily available,
the specification must provide sufficient guid
ance on making or isolating the biological ma
terial necessary to the invention without undue
experimentation, or else a deposit of the material
will be required.31 Undue experimentation is de
cided under a standard of reasonableness; it is not
merely a quantitative determination. Generally,
there is no undue experimentation where timeconsuming experiments are merely routine, such
as a reliable screening test performed on a large
number of samples.32

4. WHEN CAN BIOlOGICAl MATERIAl
BE DEPOSITED?
Under current U.S. patent laws and practice, bio
logical material may be deposited at any time pri
or to the issue of the patent the deposit supports.
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This includes deposits made during the pendency
of the application. But deposit after application
can seriously compromise international rights.
In the United States, biological material spe
cifically identified in the patent application may
be deposited during the pendency of the applica
tion (i.e., before issuance of the application as a
patent).33 A reference to a deposit in the specifica
tion provides a basis for making a deposit after
the filing date of the application. The applicant
must merely provide a corroborating statement
that the deposited biological material is that spe
cifically identified in the application as filed. If
the requirements are met, the post-filing addition
to the application of a deposit date and accession
number at an independent depository will not be
considered new matter prohibited by 35 U.S.C.
§ 132.34
As such, a U.S. patent applicant could pri
vately deposit a biological sample on or before the
patent application date, identify the deposited
material in the disclosure, and then later trans
fer the sample to a recognized public depository
and add the depository data at any time prior to
the issuance of the patent. Such a private deposit
may be in the inventor’s own laboratory or in the
laboratory of a colleague, so long as the PTO has
access to the samples during pendency and the
samples are transferred to a public depository be
fore the patent issues.
For example, in In re Lundak, the inventor
deposited a biological sample necessary to his in
vention in the laboratory of a colleague.35 After
filing a patent application that identified the pri
vately held sample, the inventor transferred the
sample to the American Type Culture Collection
(ATCC) and amended his application with the
accession number and deposit date. The Federal
Circuit held that for the purposes of 35 U.S.C.
§ 112, it was “not material whether a [biologi
cal] sample … resided in the [inventor’s] hands or
the hands of an independent depository as of filing
date.” 36
As another example, in In re Argoudelis, Ar
goudelis deposited biological material with a
depository prior to filing the patent application
but restricted access to the deposit during the
pendency to persons authorized by the patent
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applicant.37 The court found the deposit met the
requirements of 35 U.S.C. § 112 despite the re
striction on public access, because access would
be unrestricted after patent issuance.38 Similarly,
in Feldman v. Aunstrup, Aunstrup deposited bio
logical samples at a recognized depository in the
Netherlands before his filing date, but restricted
deposit availability to his designees.39 These re
strictions were removed before the patent issued.
The court found the deposit sufficient because the
PTO could access the deposit through Aunstrup
during application pendency, and the public was
assured access upon issuance.40
To the contrary, many foreign jurisdictions
require a deposit to be made before the filing date
of the priority application to obtain foreign prior
ity rights. For example, an applicant who deposits
biological material after filing a U.S. provisional
application but before filing a PCT application
will be unable to benefit from the U.S. provision
al application priority date to the extent it is de
pendent on the deposit. As such, to fully preserve
foreign rights, an applicant should make any de
posit of biological samples before the priority ap
plication is filed.41
Examples of jurisdictions that require de
posits to be made before the filing date of the
priority application include Australia, Canada,
China, and the European countries that are
members of the European Patent Organization
(as established by the European Patent Conven
tion). While certain of these jurisdictions pro
vide means of correcting for a late deposit, such
remedies often require that (1) the failure to de
posit be the result of an error in judgment or an
omission that led to the failure to deposit (such
error not being the failure to deposit itself and
not including intentional delay, for example, for
strategic or financial reasons) or (2) the applicant
be able to declare that, although a deposit was
not made, the biological sample was nevertheless
available to the public on the filing date of the
application. Because the successful use of such
remedies is not a foregone conclusion, it is high
ly encouraged that any deposit be made prior to
the filing of an application that may be called to
serve as a priority document for an international
application.

Again, while a post-filing, pre-issuance de
posit is sufficient for the purposes of a U.S. patent
application, this approach may not fully preserve
foreign patent rights.

5. WHERE IS BIOlOGICAl
MATERIAl DEPOSITED?
A U.S. applicant may deposit biological mate
rials in any of the 35 International Depositary
Authorities (IDA) recognized by the World In
tellectual Property Organization (WIPO) un
der the Budapest Treaty.42 Signatory countries
(64, as of 2006),43 including the United States,
are required to recognize a biological deposit
made in any depository institution approved by
WIPO, no matter the location. Under the Buda
pest Treaty, storage time is required to be at least
30 years, and after the applicant has made the
deposit, it cannot be reclaimed. Furthermore,
the depository has a duty of secrecy concerning
the fact of a deposit and the nature of the depos
ited material.
Only two of the 37 IDAs recognized by
WIPO are in the United States—the American
Type Culture Collection (ATCC) in Manassas,
Virginia, and the Agricultural Research Service
Culture Collection (NRRL, acronym based on
former name) in Peoria, Illinois. But as of 1999,
these two U.S. depositories held 51.6% (or 20,461
deposits) of the world‘s total patent-related bio
logical deposits.44 As an example of applicable
fees, the ATCC charges US$2,500 for a patentrelated deposit. This fee includes viability testing,
a deposit certificate, 30 years of storage, release
of samples according to deposit rules, quarterly
informing report of distribution of released mate
rials, and regulatory compliance reviews.45
A recent report from the U.S. Government
Accounting Office (GAO) compiled empirical
data regarding the deposit practice in the United
States.46 The GAO reported that about 0.6% of
U.S. patents (308 out of 52,841) granted during
the final three months of 1999 were supported by
biological deposits in the two IDAs in the United
States. Of these, only 53 patents (about 0.1%)
were supported by biological deposits of seeds.
The ATCC, one of only four IDAs accepting seed
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deposits, estimated that less than 8% of its total
deposits were for seeds.
An applicant should also maintain his or her
own samples of the biological material during the
term of deposit. As discussed above, unavailability
of biological material necessary to practicing the
invention is a defect that cannot be cured after
the grant of a patent and can result in unenforce
ability. The applicant’s practice of maintaining his
or her own samples for the duration of the pat
ent protects against any circumstances wherein
samples would no longer be available from the
depository.

6. WHO IS ENTITlED TO SAMPlES OF
DEPOSITED BIOlOGICAl MATERIAl?
During pendency of an application, a deposit in
corporated into a patent application specification
need not be available to the public, but must be
available to the PTO.47
After issuance of a patent, deposited biologi
cal material that is incorporated into the specifi
cation by accession number must be freely avail
able to the public.48 That is to say, all restrictions
on availability of the deposit to the public must
be irrevocably removed upon granting of the pat
ent, unless the request is not made according to
proper procedures. As a small measure of protec
tion, a depositor can contract with the depository
to require that samples of a deposited biological
material will only be furnished if the request is in
a dated writing that contains the name and ad
dress of the requesting party and the accession
number of the deposit, and the depositor is noti
fied in writing of such a request.49
The deposit of biological material in a rec
ognized depository is not a grant of a license,
either express or implied, to infringe the pat
ent. Furthermore, the release of deposited ma
terial from the depository to others does not
grant them a license, either express or implied,
to infringe the patent. The ATCC, for example,
provides a standard disclaimer in its catalogs,
reference guides, and to recipients of cultures:
“This material is cited in a United States and/or
other Patent and may not be used to infringe the
patent claims.” 50 Regardless, a depositor should
 | HANDBOOK OF BEST PRACTICES

supplement this disclaimer with a letter tailored
to each notification of request for samples, mak
ing it clear there is no implied or express license
covering the biological materials received from
the depository.
The number of samples estimated to have
been released worldwide to legally entitled par
ties in 1999 was estimated at 7,400. In that
year, the ATCC released about 7,000 samples,
or 95% of the worldwide total. In comparison,
NRRL (the other recognized U.S. depository)
released 123 samples, European IDAs released
190 samples, and a Japanese IDA released 63
samples.
In its recent report to Congress, the GAO
was unable to identify a single documented case
in which a person or organization had gained
access to a biological deposit and then used it
to infringe the underlying patent.51 This lack of
findings was based on court cases, representatives
from the biotechnology industry, and officials
from PTO, ATCC, NRRL, and WIPO.

7. CONCluSION
The rules governing biological deposits in sup
port of a patent application provide a means of
curing potentially fatal patent defects, as well as
flexibility in the preparation of the application.
As discussed above, a biological deposit can in
some cases satisfy the requirements of enable
ment, written description, and best mode, and
potentially broaden the scope of claims in the
event of litigation. A deposit will usually be nec
essary only when words fail to explain how to
make and use the invention, but an applicant
may reference a deposit even when not required.
While a deposit can be made at any time dur
ing pendency of a U.S. application, those seeking
foreign rights are advised to deposit before the fil
ing of any priority application. A U.S. applicant
can deposit in any of the 35 IDAs recognized by
WIPO, with two of these in the United States
The public will have free access to biological ma
terials deposited in support of an issued patent,
but the patent owner is somewhat protected by
receiving information regarding who receives
such deposits. n
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CHAPTER 10.11

Protecting New Plant Varieties through PVP: Practical
Suggestions from a Plant Breeder for Plant Breeders
williaM d. paRdee, Professor Emeritus, Department of Plant Breeding and Genetics, Cornell University, U.S.A.

ABSTRACT

A plant variety protection (PVP) certificate preserves a
plant variety owner’s exclusive rights to sell, reproduce,
import, and export a plant variety and its seed. In ad
dition, a PVP certificate prevents others from claiming
PVP or utility patent rights. This chapter walks the reader
through the process of applying for a PVP certificate and
describes other ways to prevent the unauthorized use or
sale of protected plant varieties.

1. InTRoduCTIon
A plant variety protection (PVP) certificate pre
serves a plant variety owner’s exclusive rights to
sell, reproduce, import, and export the plant vari
ety and its seed; In addition, a PVP certificate can
also prevent others from claiming PVP or utility
patent rights. The duration of a PVP certificate
is 20 years (25 years for a tree or vine). A PVP
certificate can, when combined with licensing,
develop future funds for a breeding program. It
also can preserve the financial and other interests
of participants in a program, who may have pro
vided upfront funds.
To be eligible for PVP, a variety must be:
• new and distinct from other varieties
(novel)
• genetically uniform
• stable through successive generations

This chapter discusses the rules governing the
U.S. PVP application procedure, which is admin
istered by the U.S. Department of Agriculture
(USDA).1 The U.S. PVP Act is very similar to the
provisions developed by the Convention of the
International Union for the Protection of New
Plant Varieties (UPOV), which have been, or are
being, adopted in many nations around the world.
Of course, anyone considering applying for a PVP
certificate must thoroughly familiarize him- or
herself with local laws and application procedures.
The U.S. PVP Office (PVPO) considers a
variety to be new, and therefore eligible for PVP
certification, only if propagating or harvested ma
terial of the variety has not been sold, or other
wise disposed of to other persons, for the purpose
of exploiting the variety for more than one year,
in the United States, or four years outside of the
United States.

2. THE CounTdoWn To
pvp CERTIfICATIon
The breeder should be the person to complete the
PVP certificate application because only he or she
will possess the required information and be able
to answer follow-up questions from the examin
ers. It is important to maintain good breeding
records, because they are invaluable in case of an
infringement challenge.
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2.1 Two years in advance

Obtain from the U.S. PVPO the instructions for
application as well as the proper (species-specific)
Exhibit C form (see Section 3.4 below for more
details). Start conducting any tests that will be
required to fill out Exhibit C (such as those for
disease and pest resistance); such tests may take
one or two years to complete.
2.2 One year in advance

Verify that the crop variety is worth protecting
and that the potential returns on the sale of the
crop justify the expense of the PVP certificate.
The plant breeder should consult with his or her
seed project leader (if he or she works for a na
tional research center or a university) or his or her
supervisor or sales manager (if he or she works
in the private sector). The decision of whether or
not to apply for a PVP certificate and subsequent
commercialization must be driven by objective
analysis, not emotion. It is easy to form an emo
tional attachment to a project that has required
a great deal of time, effort, or money. Seek ad
vice and suggestions from seed growers, advisory
committees, company sales representatives, and,
most critically, the farmers who will ultimately be
growing the crops.
The following questions are important to
consider:
• Is it likely that royalties or other returns on
the variety will repay the cost of PVP cer
tificate application?
• Does the variety have sufficient advantages
over standard varieties? Is it likely to attract
the interest of seed companies, seed grow
ers, and (most importantly) farmers?
• How large are the new variety’s seed vol
umes likely to become?
• How broad will the variety’s geographical
area of adaptation be?
• How large will the variety’s potential market be?
• Do any seed companies or seed growers
have a particular interest in the variety?
Depending on the answers to these questions,
you will want to consider whether the variety is
appropriate for general release (that is, release to
all interested companies or growers) or exclusive/
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limited release (that is, to one or a limited group
of companies and/or growers). PVP is most use
ful when the release is exclusive.
If there were several contributors to the breed
ing project, you would need to decide whether
or not to pursue an application for a joint PVP
certificate with them. Consider the following
questions:
• What entities (companies, associations,
and so on) contributed to the development
of the new variety?
• Do these entities wish to seek a license for
the new variety?
• Will these entities help to cover the ap
plication costs for a PVP certificate and
certification?
• Do these entities have first refusal rights for
licensing?

. pREpARInG THE pvp
CERTIfICATE AppLICATIon
The U.S. PVPO provides detailed instructions for
how to fill out and submit application forms for PVP
certification. All documents can be accessed online.2
.1 General application requirements
and procedure

A PVP application consists of:
1) A completed and signed Form S&T-470
(Application for Plant Variety Protection
Certificate). The applicant must provide
his or her name, address, and representa
tive, and the variety’s genus, species, and
variety name (a temporary variety name
will suffice until the PVP certificate is is
sued). The proposed variety name or ex
perimental number must be cleared with
the Seed Regulatory and Testing Branch of
the USDA.3
2) the following “exhibits,” all of which will
be discussed in detail in the following
sections:
• Exhibit A: Breeding History, consisting of
the variety’s genealogy, the methods used to
develop the variety, a statement of the level
of variability in any variety characteristics, a
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•

•
•
•

•

statement of genetic stability, and the type
and frequency of variants
Exhibit B: Statement of Distinctness
Guidelines, stating how the variety may be
distinguished from all other varieties in the
same crop
Exhibit C: Objective Description of Variety,
a crop-specific form
Exhibit D: Optional Supporting Information
Exhibit E: Statement of the Basis of
Ownership, stating who owns the variety
and verifying that the applicant is eligible
to file for PVP in the United States
Exhibit F: Declaration Regarding Deposit,
stating that the applicant will submit a cer
tain amount of propagation material to a
seed depository

Included with the forms must be a check
drawn on a U.S. bank (as of 6 October 2006, the
fee for filing and examination was US$4,382),
payable to “Treasury of the United States.” Since
fees are subject to change periodically, always
check current schedules at the U.S. PVPO Web
site.4 Issue fees will also be charged when the cer
tificate is issued.
The U.S. PVPO office maintains databases
of known varieties of most U.S. crops (includ
ing those originating in the United States and in
some foreign countries). The PVP examiner will
compare the information given in the application
with the database for that crop. The examiner
may request additional data if he or she finds one
or more varieties in the database with essentially
similar descriptions (which often happens). Please
note that if all other traits seem similar to another
variety, then DNA profiling may be useful, at the
discretion of the PVP examiner.
Remember, that the U.S. PVPO does not
conduct actual field/greenhouse evaluation (socalled growing out) or other tests on varieties that
are described in PVP applications. The applicant
must provide all data. Diligence in this regard will
be well worth the effort.
.2 Exhibit A: Breeding History
.2.1

Parentage and breeding methods

Exhibit A describes a number of different aspects
of the variety’s breeding history. First, it describes
the pedigree of the new variety, including both
the parents used in each cross and the source and
pedigree of each parent. The PVP office specifies
that:
Obtaining intellectual property rights requires
disclosure. As part of this disclosure the applicant is
to provide the public with information about his/her
invention in exchange for protection of the variety.
For Plant Variety Protection, this includes a full dis
closure of the parentage and breeding methodology
in the Exhibit A, Origin and Breeding History. This
information would specify the plant material the ap
plicant started from, i.e., the parentage. All material
in the parentage must be traceable back to varieties,
lines, or clones, etc. that are publicly known or a
matter of common knowledge.5
Exhibit A also describes the breeding meth
ods used in creating the new variety, including
any specific selection criteria that were used. Keep
it simple to avoid confusing the examiner. There
is no need to say why certain selections were car
ried out, merely what was accomplished and when
it took place.
.2.2 Uniformity and stability

This statement declares that the variety has been
observed to be uniform and stable for all char
acteristics over a certain number of generations.
The words “uniform” and “stable” must be used
in the statement.
The statement specifies the number of cycles
of seed reproduction through which the variety
has remained unchanged for all distinguishing
characteristics. It is likely that stability dates from
when you initiated increase of the line that be
came this variety. Remember that variation is ac
ceptable, as long as it is predictable and the vari
ants are describable and commercially acceptable.
Many modern varieties include a low level of one
or more variants.
A variant is a predictable phenotype that dif
fers in one or more ways from the main pheno
type of the variety. The applicant must identify
the variant as typical of the variety and provide
data on the percentage and frequency distribuHANDBOOK OF BEST PRACTICES | 

PARDEE

tion of variant plants. It is permissible to have
more than one variant, so long as each one is
accounted for. However, the total frequency of all
variants in the population cannot exceed 5%; a
variety that is composed of more than 5% vari
ants will be deemed a mixture (and thus not eli
gible for PVP).
An off-type is a phenotype that is not speci
fied as an expected variant. If you find that you
cannot remove a certain phenotype from your
variety, consider describing it as a variant. If you
do not describe it as a variant, the variant will be
considered an off-type by certification inspectors
or seed analysts.
. Exhibit B: Statement of Distinctness

In order to demonstrate distinctiveness, the vari
ety must be shown to be distinct in one or more
traits from either:
(1) the variety that is most similar to it
(2) several similar varieties
(3) all other varieties of the species
When measuring quantitative traits, describe
your statistical design and provide statistical ref
erences such as F values, least significant differ
ences (LSD’s), standard deviations (SD’s), range,
or other references, that may indicate the degree
of variability in the tests; this provides an indica
tion of just how distinct the variety really is, that
is, if it can be distinguished from similar variet
ies. Include data taken from at least two locations
(preferably from two different states) or over two
years, but do not pool data across years or loca
tions. The more data, the better. Sources of data
may include trials at state agricultural colleges,
cooperative tests performed by breeders in several
states, or industry tests. However, be aware that
the PVP office also has access to results from most
of these tests and will likely use these to evalu
ate the distinctiveness of your variety. For many
crops, the PVP office requests that several stan
dard varieties be included in comparative tests
against the variety submitted in the PVP applica
tion in order to provide a point of reference to
evaluate distinctness.
The U.S. PVP application instructions indi
cate that:
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• Differences in quantitative characters such
as plant size, seed size, and maturity, that
are not obvious and detectable without a
direct comparison, must be supported by
evidence provided by the applicant. The
evidence must be given as numerical data
obtained from at least two trials.
• Distinction based on differences in color
needs to be referenced with a standard
such as the Royal Horticultural Society
Colour Chart or the Munsell Book of
Color, unless dramatic (i.e., red versus
green). Color chart measurements must
be conducted in two or more localities or
growing seasons.6
It is sometimes helpful to submit photos to
demonstrate color differences.
Distinctions in disease reaction between the
new variety and other varieties must be support
ed with data or results from at least two trials
conducted in two or more localities or growing
seasons, unless the distinction is dramatic (for
example, other varieties are highly susceptible
to disease, while the new variety is disease-resis
tant). Remember to include the following: the
disease reaction to the causal agent or organ
ism; the causal agent or source of the disease (if
it has been demonstrated or identified); and the
race, strain, or pathotype of the disease, where
appropriate.
It is important to note that yield is not ac
cepted by the PVP office as a basis for distinct
ness because it is not a sufficiently stable trait.
Yields depend largely on environmental factors.
. Exhibit C: Objective Description of Variety

As in Exhibit B, numerical data must be provided
to support certain elements of the variety descrip
tion: performance characteristics, pest resistance,
quality, or other traits. Data should be gathered in
at least two locations or over two years. Describe
the statistical methods used, plus coefficient of
variance (CV), SD, LSD, range, or other esti
mates of test variability.
..1 Essentially derived varieties
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An essentially derived variety is usually developed
when one or a few genes or traits are added to
a preexisting variety, resulting in a phenotypic
change or changes. The change may be cosmetic
(for example, a change in flower color) or eco
nomic (for example, the addition of a value-add
ed, genetically engineered trait, such as an insectresistance gene, into an existing variety).
The U.S. PVPO will approve an essentially
derived variety if it shows one or more distinguish
ing characteristics and if the original variety has a
PVP certificate issued after 1994. The U.S. PVPO
will not protect an essentially derived variety if the
original variety was not protected, or was protected
only with pre-1994 criteria. PVP protection may
not protect the owner of the variety from infringe
ment liability if the original variety’s germplasm
comprises the majority of the essentially derived va
riety. For that reason, it is sensible to make arrange
ments to compensate the owner of the original va
riety for the use of the germplasm. At the time of
this writing, there was no absolute rule regarding
which varieties are essentially derived and which
are not, though seed committees and organizations
are working to develop criteria. Disagreements
must be worked out between variety owners, or if
this is not successful, by the courts.
. Exhibit D: Optional Supporting
Information

Exhibit D is required for wheat (milling and bak
ing quality must be described), but it is optional
for other crops. This exhibit describes quality fac
tors of the crop and/or offers other information
pertaining to variety uniqueness that is not in
cluded in the other exhibits.
. Exhibit E: Statement of Ownership

Exhibit E is a statement of who developed the
variety, who owns it, and who or what entity,
if any, has rights to it. A single paragraph will
suffice.
. Exhibit F: Declaration Regarding Deposit

In Exhibit F, the applicant declares that he or
she has included with the application a “voucher
sample” of at least 3,000 untreated, viable seeds
capable of propagating the application variety

(minimum germination rate 85%). In the case of
vegetative and clonal crops, the applicant declares
that he or she will deposit a viable cell culture in a
public depository, where it will be maintained for
the duration of the certificate.
The U.S. PVPO may use a small subsample
of the submitted seed (no more than 25 seeds)
in the process of examining the application. The
rest of the seed sample will be deposited by the
U.S. PVPO in the National Seed Depository
Laboratory (NSDL) at Fort Collins, Colorado.
The NSDL keeps PVP seeds separate from their
normal collections and only the applicant and the
U.S. PVPO will have access to the seed for the
duration of the certificate. These deposited seeds
will be used in case of an identity challenge. The
NSDL will return any remaining seed to the ap
plicant after the PVP certificate has expired or is
no longer in force.

. oTHER ConSIdERATIonS
.1 Critical dates to keep in mind

1. Date of first sale. You must apply for a PVP
certificate within one year after the date of
the first commercial sale of seed or planting
stock of your variety. (Sales of experimental
seed for further testing only are exempt.)
You have four years from the date of the
first commercial sale (six years for a tree
or vine) to apply for a PVP certificate for
foreign varieties. Keep evidence of the date
of first sale in the form of an invoice or
receipt.
2. Date application is received in the U.S.
PVPO. The date the original application
was received is considered to be the date
of application, though requests for addi
tional information may take months or
years to satisfy. The variety can be sold
while a PVP certificate is being sought
for it.

.2 When to apply

Apply for PVP certificate as soon as you decide to
protect the variety and can assemble the necessary
information (which should be before the date of
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first sale). The amount of time it takes to get a
PVP certificate application approved is highly
variable. It depends on the current workload at
the U.S. PVPO and can be lengthened by re
quests for additional information. Figure on at
least a year or possibly two years.
. After filing

Be prepared to respond to questions and re
quests from the PVP examiner; few applications
are accepted as originally submitted. Some of
these questions may be answerable with exist
ing data; for others, more data may need to be
collected.

. fuRTHER pRoTECTIon
foR pLAnT vARIETIES
Although a PVP certificate gives you or your
agent the sole right to sell the plant variety in
question and protects the variety name from
infringement, it is sensible to take additional
precautions:
• Control all breeder seed that you or your
organization grow, harvest, and maintain.
• Control all foundation seed production by
producing it only within your organization
or granting tight licenses or contracts to
trusted seed producers.
• Control who gets foundation seed, through
licenses or sales, with tight contracts.
.1

Enforce protection

Stay alert for unauthorized sales of your PVP
seed: such things as advertisements in local news
papers are giveaways of illegal activity. Tell any in
dividuals, companies, or other organizations that
sell or distribute your variety to be alert to illegal
sales and to notify you immediately if they detect
them.
It is important to realize that the unauthor
ized seller may very well not realize that the va
riety is protected. Notify the offender that he or
she is selling a PVP-protected variety. A warning
is often sufficient to stop the problem. If the of
fender persists in making illegal sales, threaten
to cut him or her off from future releases. Sue
only as a last resort, and consider whether a court
 | HANDBOOK OF BEST PRACTICES

battle is worth the cost in money and public
relations.
.2 Bag-tag warning

Before the PVP certificate is awarded, label all
seed containers of the variety as follows:
Unauthorized Propagation Prohibited
U.S. Variety Protection PVPA 1994
Applied For
After the PVP certificate is awarded, label
seed containers as follows:
U.S. Protected Variety PVPA 1994
Unauthorized Sales for Reproductive
Purposes Prohibited

. Brown-bag sales

Under the farmer exemption, farmers are permit
ted to grow and save enough seed of a PVP va
riety to plant their own acreage.7 If they decide
not to plant the seed, they are allowed to sell it.
However, some farmers produce and sell large
volumes of seed, far more than they would be
able to plant on their own farms. In the United
States, this practice is unfortunately common in
the Midwest and South, particularly with soy
beans, cotton, and peanuts. Because the illegal
seed is often sold in unmarked brown bags, this
practice is popularly called “brown bagging.” A
recent Supreme Court decision that upholds the
rights of PVP certificate owners may discourage,
but will not stop, brown-bag sales.
Title V of the U.S. Federal Seed Act makes it
unlawful to sell uncertified seed of a PVP variety
by the variety name. Many state seed laws include
similar provisos. On page one of the PVP appli
cation, you can state your intention to also apply
for Title V protection. Of course, brown bagging
can still occur even if Title V is in force. In such
cases, you will need to seek help from the appro
priate state, federal, or state seed-law enforcement
agency. Seed-law enforcers can issue orders that
prohibit offenders from further action, and may
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issue a stop-sales order or fines to a persistent
offender.

6. ConCLuSIon
Assembling and submitting a PVP application for
your variety can be either a nearly unbearable ag
gravation or a very easy task. It all depends on
how organized, diligent, and proactive you are.
The key elements are to plan well ahead, keep
careful records, know what you need to do, know
when you need to do it, and know what the PVP
offices needs (not less and not more) to process
your application. From a practical standpoint,
this means keeping good breeding records, being
familiar with the PVP Web site, knowing what
the forms and exhibit schedules are, and keeping
track of time. If you are organized, the application
process will likely go smoothly. And remember,
after your PVP certificate is issued, be diligent
and watch for infringers. PVP can provide your
variety, and your breeding program or business,
with a foundation for realizing returns on your
investments, which can then be used to develop

the next round of improved varieties from your
breeding program, for which you will then seek
PVP. n
williaM d paRdee, Professor Emeritus, Department of Plant

Breeding and Genetics, Emerson Hall, Cornell University,
Ithaca, NY, 14853, U.S.A. wdp5@cornell.edu

1

Pursuant to the PVP Act of 1970, 7 U.S.C. § 2321–2583.

2

www.ams.usda.gov/science/pvpo/apply.htm.

3

They may be contacted at: U.S. Department of
Agriculture, Agricultural Marketing Service, Livestock
and Seed Programs, Seed Regulatory and Testing
Branch, 801 Summit Crossing, Place, Suite C, Gastonia,
North Carolina, 28054-2193 (Phone: 704-810-8870).
www.ams.usda.gov/lsg/seed.htm.

4

See supra note 2.

5

www.ams.usda.gov/science/PVPO/Forms/Guidelines
A.htm.

6

www.ams.usda.gov/Science/PVPO/Forms/Guidelines
B.htm.

7

McCarthy JT, RE Schechter and DJ Franklyn. 2004.
McCarthy’s Desk Encyclopedia of Intellectual Property,
Third Edition. The Bureau of National Affairs, Inc.:
Washington, DC.
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